"eudract_number","title","protocol_country_code","double_blind","single_blind","open","design","randomised","crossover","parallel_group","controlled","arms","active_comparator","placebo","open_gs","single_blind_gs","double_blind_gs","randomised_gs","crossover_gs","parallel_group_gs","arms_gs","controlled_gs","arms_probab0","arms_probab1","arms_probab2","arms_orig","open_probab0","open_probab1","open_orig","double_blind_probab0","double_blind_probab1","double_blind_orig","single_blind_probab0","single_blind_probab1","single_blind_orig","controlled_probab0","controlled_probab1","controlled_orig","parallel_group_probab0","parallel_group_probab1","parallel_group_orig","crossover_probab0","crossover_probab1","crossover_orig","randomised_probab0","randomised_probab1","randomised_orig"
"2004-000232-91","GvHD prophylaxis with ATG-Fresenius S in allogenic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxies with cyclosporine A and Methotrexate with additional pretransplant ATG-Fresenius S","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","","","Yes","No","No","Yes","No","Yes","2+","Yes",3.6649309705233127e-44,1.1757839445222206e-05,0.9999882421605573,"-1",9.304179240456753e-12,0.9999999999907062,"Yes",0.9999999999945146,5.495858241277321e-12,"No",0.9999999999999432,6.066004275741559e-14,"No",1.0258231382845644e-12,0.9999999999989768,"Yes",0.9667726341538881,0.03322736584610897,"",0.9999642870769161,3.571292306998046e-05,"",0.26585157383062824,0.7341484261693714,"Yes"
"2004-000232-91","EICH Profilaxis con ATeGe-FRESENIUS en trasplante alogénico de progenitores hematopoyéticos procedente de donantes no emparentados","FI","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","Yes","No","Yes","2+","Yes",9.104918645280841e-07,0.9990566493475787,0.0009424401605629412,"-1",2.7333266163174374e-07,0.9999997266673352,"Information not present in EudraCT",0.9999998661308586,1.338691476807274e-07,"Information not present in EudraCT",0.9998813733966782,0.00011862660331678765,"Information not present in EudraCT",0.9084530247371702,0.091546975262835,"Yes",0.998473700356292,0.001526299643712919,"",0.9999995057418772,4.942581291770347e-07,"",0.999972536478241,2.7463521761527946e-05,"Yes"
"2004-000232-91","GvHD prophylaxis with ATG-Fresenius S in allogenic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxies with cyclosporine A and Methotrexate with additional pretransplant ATG-Fresenius S","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","","","Yes","No","No","Yes","No","Yes","2+","Yes",3.6649309705233127e-44,1.1757839445222206e-05,0.9999882421605573,"-1",9.304179240456753e-12,0.9999999999907062,"Yes",0.9999999999945146,5.495858241277321e-12,"No",0.9999999999999432,6.066004275741559e-14,"No",1.0258231382845644e-12,0.9999999999989768,"Yes",0.9667726341538881,0.03322736584610897,"",0.9999642870769161,3.571292306998046e-05,"",0.26585157383062824,0.7341484261693714,"Yes"
"2004-001307-35","A prospective open label randomised parallel group comparative pilot study to study the efficacy and safety of highly purified Menotrophin versus recombinant FSH (Follitropin alfa) administered subcutaneously to subfertile female patients undergoing IVF using antagonist downregulation.","GB","No","Yes","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1942265115329675e-39,1.4752223383578858e-06,0.9999985247776604,"-1",0.049504256650345135,0.9504957433496556,"Yes",0.9999800681424376,1.993185755401773e-05,"No",5.505912450113971e-05,0.9999449408755026,"No",3.716492110552958e-08,0.9999999628350914,"Yes",0.004460160005545696,0.9955398399944416,"No",0.999999999809461,1.9054336570598931e-10,"No",2.947714182650856e-07,0.9999997052285758,"Yes"
"2004-002203-32","A Multicenter Open-Label Randomized Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.26248169951226e-71,3.826508688000732e-08,0.999999961734887,"-1",6.783674472988408e-08,0.9999999321632368,"Yes",0.9999999119554029,8.804460770036404e-08,"No",1.0,1.2430332226150153e-21,"No",6.100504053857438e-05,0.9999389949594504,"Yes",0.9999559675100554,4.4032489947156726e-05,"No",1.0,1.9994921957616996e-14,"No",1.5754422687506255e-08,0.9999999842455625,"Yes"
"2004-002203-32","A Multicenter Open-Label Randomized Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.26248169951226e-71,3.826508688000732e-08,0.999999961734887,"-1",6.783674472988408e-08,0.9999999321632368,"Yes",0.9999999119554029,8.804460770036404e-08,"No",1.0,1.2430332226150153e-21,"No",6.100504053857438e-05,0.9999389949594504,"Yes",0.9999559675100554,4.4032489947156726e-05,"No",1.0,1.9994921957616996e-14,"No",1.5754422687506255e-08,0.9999999842455625,"Yes"
"2004-002203-32","A Multicenter Open-Label Randomized Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.26248169951226e-71,3.826508688000732e-08,0.999999961734887,"-1",6.783674472988408e-08,0.9999999321632368,"Yes",0.9999999119554029,8.804460770036404e-08,"No",1.0,1.2430332226150153e-21,"No",6.100504053857438e-05,0.9999389949594504,"Yes",0.9999559675100554,4.4032489947156726e-05,"No",1.0,1.9994921957616996e-14,"No",1.5754422687506255e-08,0.9999999842455625,"Yes"
"2004-002203-32","A Multicenter Open-Label Randomized Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.26248169951226e-71,3.826508688000732e-08,0.999999961734887,"-1",6.783674472988408e-08,0.9999999321632368,"Yes",0.9999999119554029,8.804460770036404e-08,"No",1.0,1.2430332226150153e-21,"No",6.100504053857438e-05,0.9999389949594504,"Yes",0.9999559675100554,4.4032489947156726e-05,"No",1.0,1.9994921957616996e-14,"No",1.5754422687506255e-08,0.9999999842455625,"Yes"
"2004-002203-32","A Multicenter Open-Label Randomized Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.26248169951226e-71,3.826508688000732e-08,0.999999961734887,"-1",6.783674472988408e-08,0.9999999321632368,"Yes",0.9999999119554029,8.804460770036404e-08,"No",1.0,1.2430332226150153e-21,"No",6.100504053857438e-05,0.9999389949594504,"Yes",0.9999559675100554,4.4032489947156726e-05,"No",1.0,1.9994921957616996e-14,"No",1.5754422687506255e-08,0.9999999842455625,"Yes"
"2004-002203-32","A Multicenter Open-Label Randomized Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.26248169951226e-71,3.826508688000732e-08,0.999999961734887,"-1",6.783674472988408e-08,0.9999999321632368,"Yes",0.9999999119554029,8.804460770036404e-08,"No",1.0,1.2430332226150153e-21,"No",6.100504053857438e-05,0.9999389949594504,"Yes",0.9999559675100554,4.4032489947156726e-05,"No",1.0,1.9994921957616996e-14,"No",1.5754422687506255e-08,0.9999999842455625,"Yes"
"2005-000454-73","A multicenter randomized double-blind placebo-controlled 3-arm study of the efficacy and safety of 2 doses of lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects with low- or intermediate-1-risk myelodyplastic syndromes (MDS) associated with a deletion (del) 5q[31] cytogenetic abnormality.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","Yes","No","2+","Yes",4.581574916905656e-67,3.324275936635211e-12,0.9999999999966747,"2+",0.9999999196174973,8.038250472511525e-08,"No",2.516151085361024e-07,0.9999997483848835,"Yes",1.0,2.3706454586838732e-23,"No",9.779138505602598e-13,0.9999999999990337,"Yes",0.0001621993651487893,0.9998378006348628,"Yes",0.9999999919842822,8.015728615451567e-09,"No",4.4068821596507095e-11,0.9999999999559179,"Yes"
"2005-000454-73","A multicenter randomized double-blind placebo-controlled 3-arm study of the efficacy and safety of 2 doses of lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects with low- or intermediate-1-risk myelodyplastic syndromes (MDS) associated with a deletion (del) 5q[31] cytogenetic abnormality.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","Yes","No","2+","Yes",4.581574916905656e-67,3.324275936635211e-12,0.9999999999966747,"2+",0.9999999196174973,8.038250472511525e-08,"No",2.516151085361024e-07,0.9999997483848835,"Yes",1.0,2.3706454586838732e-23,"No",9.779138505602598e-13,0.9999999999990337,"Yes",0.0001621993651487893,0.9998378006348628,"Yes",0.9999999919842822,8.015728615451567e-09,"No",4.4068821596507095e-11,0.9999999999559179,"Yes"
"2005-000454-73","A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBOCONTROLLED 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","Yes","No","2+","Yes",9.647065760021772e-63,1.5026713674660076e-11,0.9999999999849934,"2+",0.9999994312715811,5.687284048623468e-07,"No",8.534224013614965e-07,0.9999991465776025,"Yes",1.0,1.632220194346433e-26,"No",3.182607698000967e-12,0.9999999999968168,"Yes",0.00014441396403308066,0.9998555860359568,"Yes",0.9999999998939871,1.0602536516913239e-10,"No",9.723633041609071e-11,0.9999999999027409,"Yes"
"2005-000454-73","A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBOCONTROLLED 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","Yes","No","2+","Yes",9.647065760021772e-63,1.5026713674660076e-11,0.9999999999849934,"2+",0.9999994312715811,5.687284048623468e-07,"No",8.534224013614965e-07,0.9999991465776025,"Yes",1.0,1.632220194346433e-26,"No",3.182607698000967e-12,0.9999999999968168,"Yes",0.00014441396403308066,0.9998555860359568,"Yes",0.9999999998939871,1.0602536516913239e-10,"No",9.723633041609071e-11,0.9999999999027409,"Yes"
"2005-000454-73","A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBOCONTROLLED 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","Yes","No","2+","Yes",9.647065760021772e-63,1.5026713674660076e-11,0.9999999999849934,"2+",0.9999994312715811,5.687284048623468e-07,"No",8.534224013614965e-07,0.9999991465776025,"Yes",1.0,1.632220194346433e-26,"No",3.182607698000967e-12,0.9999999999968168,"Yes",0.00014441396403308066,0.9998555860359568,"Yes",0.9999999998939871,1.0602536516913239e-10,"No",9.723633041609071e-11,0.9999999999027409,"Yes"
"2005-000454-73","A multicenter randomized double-blind placebo-controlled 3-arm study of the efficacy and safety of 2 doses of lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects with low- or intermediate-1-risk myelodyplastic syndromes (MDS) associated with a deletion (del) 5q[31] cytogenetic abnormality.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","Yes","No","2+","Yes",4.581574916905656e-67,3.324275936635211e-12,0.9999999999966747,"2+",0.9999999196174973,8.038250472511525e-08,"No",2.516151085361024e-07,0.9999997483848835,"Yes",1.0,2.3706454586838732e-23,"No",9.779138505602598e-13,0.9999999999990337,"Yes",0.0001621993651487893,0.9998378006348628,"Yes",0.9999999919842822,8.015728615451567e-09,"No",4.4068821596507095e-11,0.9999999999559179,"Yes"
"2005-001678-28","A randomized explorative double-blind double-dummy multi-center parallel group study to assess sustainable efficacy of once daily vardenafil (10 mg) for 12 and 24 weeks versus vardenafil PRN in men with mild or mild to moderate erectile dysfunction","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.2430547996128605e-60,1.066510014820691e-14,1.0,"-1",1.0,1.6065539878412996e-15,"No",2.598749349069583e-14,0.9999999999999717,"Yes",0.9999999999989768,1.0292755408372532e-12,"No",4.951824465990419e-15,1.0,"Yes",4.518234477611271e-06,0.9999954817655275,"Yes",0.9999996103160433,3.896839614050433e-07,"No",1.700863262564764e-14,0.9999999999999717,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors ","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.6588828761781155e-76,1.200642615364106e-06,0.9999987993573815,"-1",0.20829449834357547,0.7917055016564125,"No",0.9383069331544784,0.061693066845521186,"Yes",1.0,2.53178070701412e-22,"No",0.001266403228661578,0.9987335967713472,"Yes",0.9995792862487923,0.00042071375120073564,"Yes",0.9999999999663771,3.3615378422350954e-11,"No",3.1701667787923625e-05,0.9999682983322046,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors.Estudio fase III multicéntrico aleatorizado doble ciego controlado con placebo de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa con o sin quimioterapia adyuvante en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo.","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.715478125947668e-143,9.173827222177954e-13,0.9999999999990905,"-1",0.04976797434177328,0.950232025658192,"No",0.9943321458082734,0.005667854191720499,"Yes",1.0,3.5022737196497937e-46,"No",1.4106995598027269e-06,0.9999985893004183,"Yes",0.9999992569822699,7.43017721075153e-07,"Yes",1.0,3.038877577687019e-39,"No",1.736568352716224e-10,0.9999999998263434,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors ","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.6588828761781155e-76,1.200642615364106e-06,0.9999987993573815,"-1",0.20829449834357547,0.7917055016564125,"No",0.9383069331544784,0.061693066845521186,"Yes",1.0,2.53178070701412e-22,"No",0.001266403228661578,0.9987335967713472,"Yes",0.9995792862487923,0.00042071375120073564,"Yes",0.9999999999663771,3.3615378422350954e-11,"No",3.1701667787923625e-05,0.9999682983322046,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors.Estudio fase III multicéntrico aleatorizado doble ciego controlado con placebo de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa con o sin quimioterapia adyuvante en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo.","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.715478125947668e-143,9.173827222177954e-13,0.9999999999990905,"-1",0.04976797434177328,0.950232025658192,"No",0.9943321458082734,0.005667854191720499,"Yes",1.0,3.5022737196497937e-46,"No",1.4106995598027269e-06,0.9999985893004183,"Yes",0.9999992569822699,7.43017721075153e-07,"Yes",1.0,3.038877577687019e-39,"No",1.736568352716224e-10,0.9999999998263434,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors ","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.6588828761781155e-76,1.200642615364106e-06,0.9999987993573815,"-1",0.20829449834357547,0.7917055016564125,"No",0.9383069331544784,0.061693066845521186,"Yes",1.0,2.53178070701412e-22,"No",0.001266403228661578,0.9987335967713472,"Yes",0.9995792862487923,0.00042071375120073564,"Yes",0.9999999999663771,3.3615378422350954e-11,"No",3.1701667787923625e-05,0.9999682983322046,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors ","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.6588828761781155e-76,1.200642615364106e-06,0.9999987993573815,"-1",0.20829449834357547,0.7917055016564125,"No",0.9383069331544784,0.061693066845521186,"Yes",1.0,2.53178070701412e-22,"No",0.001266403228661578,0.9987335967713472,"Yes",0.9995792862487923,0.00042071375120073564,"Yes",0.9999999999663771,3.3615378422350954e-11,"No",3.1701667787923625e-05,0.9999682983322046,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors ","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.6588828761781155e-76,1.200642615364106e-06,0.9999987993573815,"-1",0.20829449834357547,0.7917055016564125,"No",0.9383069331544784,0.061693066845521186,"Yes",1.0,2.53178070701412e-22,"No",0.001266403228661578,0.9987335967713472,"Yes",0.9995792862487923,0.00042071375120073564,"Yes",0.9999999999663771,3.3615378422350954e-11,"No",3.1701667787923625e-05,0.9999682983322046,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors ","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.6588828761781155e-76,1.200642615364106e-06,0.9999987993573815,"-1",0.20829449834357547,0.7917055016564125,"No",0.9383069331544784,0.061693066845521186,"Yes",1.0,2.53178070701412e-22,"No",0.001266403228661578,0.9987335967713472,"Yes",0.9995792862487923,0.00042071375120073564,"Yes",0.9999999999663771,3.3615378422350954e-11,"No",3.1701667787923625e-05,0.9999682983322046,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors.Estudio fase III multicéntrico aleatorizado doble ciego controlado con placebo de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa con o sin quimioterapia adyuvante en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo.","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.715478125947668e-143,9.173827222177954e-13,0.9999999999990905,"-1",0.04976797434177328,0.950232025658192,"No",0.9943321458082734,0.005667854191720499,"Yes",1.0,3.5022737196497937e-46,"No",1.4106995598027269e-06,0.9999985893004183,"Yes",0.9999992569822699,7.43017721075153e-07,"Yes",1.0,3.038877577687019e-39,"No",1.736568352716224e-10,0.9999999998263434,"Yes"
"2005-001747-29","A Multi-center Randomized Double-blind Placebo-controlled Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors.Estudio fase III multicéntrico aleatorizado doble ciego controlado con placebo de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa con o sin quimioterapia adyuvante en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo.","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.715478125947668e-143,9.173827222177954e-13,0.9999999999990905,"-1",0.04976797434177328,0.950232025658192,"No",0.9943321458082734,0.005667854191720499,"Yes",1.0,3.5022737196497937e-46,"No",1.4106995598027269e-06,0.9999985893004183,"Yes",0.9999992569822699,7.43017721075153e-07,"Yes",1.0,3.038877577687019e-39,"No",1.736568352716224e-10,0.9999999998263434,"Yes"
"2005-002524-34","An open label non comparative phase III study of the Raf Kinase Inhibitor BAY 43-9006 as a subsequent to first line therapy in patients with advanced renal cell carcinoma.","DK","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",8.81402833269218e-37,0.5824576423878853,0.4175423576121165,"-1",1.0807096480241527e-07,0.9999998919290422,"Information not present in EudraCT",0.9999998036578199,1.9634218762009942e-07,"Information not present in EudraCT",0.9999999999953388,4.651993435148116e-12,"Information not present in EudraCT",0.9770780225222938,0.02292197747770797,"No",0.9991379217053921,0.0008620782946086937,"No",0.9975474017013192,0.002452598298683544,"No",0.8891635176964644,0.11083648230353654,"No"
"2005-002524-34","An Open Label Non Comparative Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma","SE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",8.81402833269218e-37,0.5824576423878853,0.4175423576121165,"-1",1.0807096480241527e-07,0.9999998919290422,"Information not present in EudraCT",0.9999998036578199,1.9634218762009942e-07,"Information not present in EudraCT",0.9999999999953388,4.651993435148116e-12,"Information not present in EudraCT",0.9770780225222938,0.02292197747770797,"No",0.9991379217053921,0.0008620782946086937,"No",0.9975474017013192,0.002452598298683544,"No",0.8891635176964644,0.11083648230353654,"No"
"2005-002524-34","An open label non comparative phase III study of the Raf Kinase Inhibitor BAY 43-9006 as a subsequent to first line therapy in patients with advanced renal cell carcinoma.","AT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",8.81402833269218e-37,0.5824576423878853,0.4175423576121165,"-1",1.0807096480241527e-07,0.9999998919290422,"Information not present in EudraCT",0.9999998036578199,1.9634218762009942e-07,"Information not present in EudraCT",0.9999999999953388,4.651993435148116e-12,"Information not present in EudraCT",0.9770780225222938,0.02292197747770797,"No",0.9991379217053921,0.0008620782946086937,"No",0.9975474017013192,0.002452598298683544,"No",0.8891635176964644,0.11083648230353654,"No"
"2005-002524-34","An Open Label Non Comparative Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma","ES","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",8.81402833269218e-37,0.5824576423878853,0.4175423576121165,"-1",1.0807096480241527e-07,0.9999998919290422,"Information not present in EudraCT",0.9999998036578199,1.9634218762009942e-07,"Information not present in EudraCT",0.9999999999953388,4.651993435148116e-12,"Information not present in EudraCT",0.9770780225222938,0.02292197747770797,"No",0.9991379217053921,0.0008620782946086937,"No",0.9975474017013192,0.002452598298683544,"No",0.8891635176964644,0.11083648230353654,"No"
"2005-002524-34","An Open Label Non Comparative Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma","DE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",8.81402833269218e-37,0.5824576423878853,0.4175423576121165,"-1",1.0807096480241527e-07,0.9999998919290422,"Information not present in EudraCT",0.9999998036578199,1.9634218762009942e-07,"Information not present in EudraCT",0.9999999999953388,4.651993435148116e-12,"Information not present in EudraCT",0.9770780225222938,0.02292197747770797,"No",0.9991379217053921,0.0008620782946086937,"No",0.9975474017013192,0.002452598298683544,"No",0.8891635176964644,0.11083648230353654,"No"
"2005-002524-34","An open label non comparative phase III study of the Raf Kinase Inhibitor BAY 43-9006 as a subsequent to first line therapy in patients with advanced renal cell carcinoma.","PT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",8.81402833269218e-37,0.5824576423878853,0.4175423576121165,"-1",1.0807096480241527e-07,0.9999998919290422,"Information not present in EudraCT",0.9999998036578199,1.9634218762009942e-07,"Information not present in EudraCT",0.9999999999953388,4.651993435148116e-12,"Information not present in EudraCT",0.9770780225222938,0.02292197747770797,"No",0.9991379217053921,0.0008620782946086937,"No",0.9975474017013192,0.002452598298683544,"No",0.8891635176964644,0.11083648230353654,"No"
"2005-002524-34","An Open Label Non Comparative Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell CarcinomaEstudio en fase III abierto no comparativo del inhibidor de la Raf-kinasa BAY 43-9006 como tratamiento posterior a la terapia de primera línea en pacientes con carcinoma de células renales avanzado","BE","No","No","Yes","","No","No","No","No","2+","","","Yes","No","No","No","No","No","1","No",6.6032711184592084e-65,0.3868839965143045,0.6131160034856811,"-1",1.3881271148105217e-13,0.9999999999998864,"Information not present in EudraCT",0.9999999999996021,3.898772732036043e-13,"Information not present in EudraCT",1.0,1.2592015335450708e-25,"Information not present in EudraCT",0.9980402098907819,0.0019597901092314267,"No",0.9999941491709087,5.850829113848124e-06,"No",1.0,1.43443606362521e-14,"No",0.6988568950118556,0.30114310498813773,"No"
"2005-002618-40","HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas supratentorial PNETs) and ependymomas in children and adolescentsParts of the study:P-HIT-REZ 2005 - a non-randomised trial for the treatment of relapsed PNETs E-HIT-REZ 2005: Phase II study: oral therapy with temozolomide - a nonrandomised trial for the treatment of relapsed ependymomas Phase II study - intraventricular therapy with etoposide in neoplastic meningitis","DE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","No","Yes","No","2+","No",1.01003863526847e-72,0.9999875220571856,1.2477942789107115e-05,"2+",8.149347459781808e-16,1.0,"Yes",1.0,7.281206448906098e-16,"No",1.0,5.172794249648387e-20,"No",0.9999982787435363,1.7212564736509782e-06,"Yes",0.9995480852840217,0.00045191471596629817,"No",1.0,2.0219717351299325e-17,"No",0.999953333379352,4.6666620654777894e-05,"No"
"2005-002796-32","A randomized double-blind placebo-controlled multi-center parallel group study to assess the efficacy of vardenafil in the treatment of symtomatic Benign Prostatic Hyperplasia","DE","Yes","Yes","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9371188096132028e-33,6.515510783694883e-12,0.9999999999934914,"-1",0.9999999998854179,1.1458816560132718e-10,"No",1.1020144825438166e-06,0.9999988979855166,"Yes",0.009130003452323485,0.9908699965476768,"No",1.0844247292976257e-11,0.9999999999891571,"Yes",7.275363448952195e-07,0.9999992724636488,"Yes",0.9999999261532962,7.384670808872812e-08,"No",8.963595402177714e-11,0.999999999910358,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","CZ","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"Information not present in EudraCT",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"Information not present in EudraCT",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","MT","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"Information not present in EudraCT",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"Information not present in EudraCT",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","AT","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"Information not present in EudraCT",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"Information not present in EudraCT",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","SK","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"Information not present in EudraCT",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"Information not present in EudraCT",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"No",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"No",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","BE","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"Information not present in EudraCT",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"Information not present in EudraCT",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"No",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"No",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","GB","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"Information not present in EudraCT",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"Information not present in EudraCT",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","DE","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"Information not present in EudraCT",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"Information not present in EudraCT",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","LV","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"Information not present in EudraCT",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"Information not present in EudraCT",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003440-66","A Randomised Double-blind Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil Leucovorin and Oxaliplatin (FOLFOX) to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer","HU","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",8.083488377920205e-57,2.7711843572375686e-12,0.9999999999972431,"-1",0.13170004432842278,0.8682999556715798,"Information not present in EudraCT",0.9031945592013129,0.0968054407987005,"Yes",1.0,4.1539101098255846e-20,"Information not present in EudraCT",3.749672061765971e-08,0.999999962503268,"Yes",0.6567653114589669,0.34323468854102246,"Yes",0.9999999995654605,4.34543530186474e-10,"",1.1959923640529691e-11,0.9999999999880346,"Yes"
"2005-003484-23","Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cisplatin to standard RCT (70.2 Gy) with 5-Fluorouracil/Cisplatin","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.515351958972824e-64,1.6326855742131365e-09,0.999999998367315,"2+",2.0364488677631337e-08,0.9999999796355044,"Yes",0.9999999853407645,1.465923472333516e-08,"No",0.9999999999999147,7.201354665082127e-14,"No",0.00013158184502356295,0.999868418154989,"Yes",0.999362903649501,0.0006370963504896068,"Yes",1.0,8.078809199133024e-20,"No",1.25587675506508e-06,0.9999987441232392,"Yes"
"2005-003593-16","A phase II double-blind placebo-controleed randomised study to assess the efficacy and safety of docetaxel (Taxotere)/ prednisolone/ ZD6474 vs. docetaxel/ prednisolone/ placebo in patients with hormone refractory prostate cancer (HRPC)","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","1","Yes",2.3139181343323658e-48,2.086636835843466e-12,0.9999999999979252,"-1",0.9999999847658787,1.5234108866443515e-08,"No",6.23555688817778e-08,0.99999993764442,"Yes",1.0,3.4342786434818803e-16,"No",1.628546665220892e-09,0.9999999983714646,"Yes",0.2875533951518362,0.712446604848168,"Yes",0.9997849427987046,0.00021505720129944022,"No",4.106731823493464e-09,0.999999995893262,"Yes"
"2005-003593-16","A phase II double-blind placebo-controleed randomised study to assess the efficacy and safety of docetaxel (Taxotere)/ prednisolone/ ZD6474 vs. docetaxel/ prednisolone/ placebo in patients with hormone refractory prostate cancer (HRPC)","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","1","Yes",2.3139181343323658e-48,2.086636835843466e-12,0.9999999999979252,"-1",0.9999999847658787,1.5234108866443515e-08,"No",6.23555688817778e-08,0.99999993764442,"Yes",1.0,3.4342786434818803e-16,"No",1.628546665220892e-09,0.9999999983714646,"Yes",0.2875533951518362,0.712446604848168,"Yes",0.9997849427987046,0.00021505720129944022,"No",4.106731823493464e-09,0.999999995893262,"Yes"
"2005-003593-16","A phase II double-blind placebo-controleed randomised study to assess the efficacy and safety of docetaxel (Taxotere)/ prednisolone/ ZD6474 vs. docetaxel/ prednisolone/ placebo in patients with hormone refractory prostate cancer (HRPC)","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","1","Yes",2.3139181343323658e-48,2.086636835843466e-12,0.9999999999979252,"-1",0.9999999847658787,1.5234108866443515e-08,"No",6.23555688817778e-08,0.99999993764442,"Yes",1.0,3.4342786434818803e-16,"No",1.628546665220892e-09,0.9999999983714646,"Yes",0.2875533951518362,0.712446604848168,"Yes",0.9997849427987046,0.00021505720129944022,"No",4.106731823493464e-09,0.999999995893262,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy","FI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy","GR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy","SK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004094-25","A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.550990128820077e-49,0.0020097285316617226,0.9979902714683333,"-1",0.000448827000604104,0.9995511729994054,"Yes",0.999353063855094,0.0006469361449006614,"No",0.9999999999936336,6.3683301512939264e-12,"No",0.00231035872474343,0.9976896412752517,"Yes",0.08403672914781411,0.9159632708521749,"Yes",0.9999999999990905,9.081909725704875e-13,"No",0.009534444886373854,0.9904655551136322,"Yes"
"2005-004944-30","An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection (Hematide™) in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease","DE","No","No","Yes","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",5.327384693262139e-23,0.025226653542709084,0.974773346457294,"1",0.004434612430478981,0.9955653875695176,"Yes",0.994077240028822,0.005922759971178844,"No",0.9999999995151398,4.848652273425531e-10,"No",0.05371750746468242,0.9462824925353165,"No",0.4278955185881068,0.5721044814118951,"No",0.9996883427300847,0.0003116572699087708,"No",0.6018980506052016,0.3981019493947976,"No"
"2005-005077-29","An International Phase II Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1986190393029527e-55,2.208499586748804e-10,0.9999999997791633,"2+",0.9999999240968152,7.590318087539915e-08,"No",2.287753981275424e-07,0.999999771224592,"Yes",0.9999999999985221,1.4805087238284327e-12,"No",4.2137709915580775e-10,0.9999999995786197,"Yes",0.00027740629210820645,0.9997225937078986,"Yes",0.999999259735564,7.402644315877929e-07,"No",6.73749034806575e-10,0.9999999993262635,"Yes"
"2005-005077-29","An International Phase II Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1986190393029527e-55,2.208499586748804e-10,0.9999999997791633,"2+",0.9999999240968152,7.590318087539915e-08,"No",2.287753981275424e-07,0.999999771224592,"Yes",0.9999999999985221,1.4805087238284327e-12,"No",4.2137709915580775e-10,0.9999999995786197,"Yes",0.00027740629210820645,0.9997225937078986,"Yes",0.999999259735564,7.402644315877929e-07,"No",6.73749034806575e-10,0.9999999993262635,"Yes"
"2005-005077-29","An International Phase III Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.204274790753489e-55,4.748918250340365e-11,0.9999999999525073,"2+",0.9999999661405361,3.3859453873987006e-08,"No",1.0626509422236424e-07,0.9999998937349005,"Yes",0.9999999999973568,2.641443581180854e-12,"No",5.985963507555643e-11,0.999999999940144,"Yes",0.00012682141214152213,0.9998731785878718,"Yes",0.9999991958722597,8.041277353230374e-07,"No",9.138111540404099e-11,0.9999999999086242,"Yes"
"2005-005077-29","An International Phase III Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.204274790753489e-55,4.748918250340365e-11,0.9999999999525073,"2+",0.9999999661405361,3.3859453873987006e-08,"No",1.0626509422236424e-07,0.9999998937349005,"Yes",0.9999999999973568,2.641443581180854e-12,"No",5.985963507555643e-11,0.999999999940144,"Yes",0.00012682141214152213,0.9998731785878718,"Yes",0.9999991958722597,8.041277353230374e-07,"No",9.138111540404099e-11,0.9999999999086242,"Yes"
"2005-005077-29","An International Phase II Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1986190393029527e-55,2.208499586748804e-10,0.9999999997791633,"2+",0.9999999240968152,7.590318087539915e-08,"No",2.287753981275424e-07,0.999999771224592,"Yes",0.9999999999985221,1.4805087238284327e-12,"No",4.2137709915580775e-10,0.9999999995786197,"Yes",0.00027740629210820645,0.9997225937078986,"Yes",0.999999259735564,7.402644315877929e-07,"No",6.73749034806575e-10,0.9999999993262635,"Yes"
"2005-005077-29","An International Phase III Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.204274790753489e-55,4.748918250340365e-11,0.9999999999525073,"2+",0.9999999661405361,3.3859453873987006e-08,"No",1.0626509422236424e-07,0.9999998937349005,"Yes",0.9999999999973568,2.641443581180854e-12,"No",5.985963507555643e-11,0.999999999940144,"Yes",0.00012682141214152213,0.9998731785878718,"Yes",0.9999991958722597,8.041277353230374e-07,"No",9.138111540404099e-11,0.9999999999086242,"Yes"
"2005-005077-29","An International Phase II Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1986190393029527e-55,2.208499586748804e-10,0.9999999997791633,"2+",0.9999999240968152,7.590318087539915e-08,"No",2.287753981275424e-07,0.999999771224592,"Yes",0.9999999999985221,1.4805087238284327e-12,"No",4.2137709915580775e-10,0.9999999995786197,"Yes",0.00027740629210820645,0.9997225937078986,"Yes",0.999999259735564,7.402644315877929e-07,"No",6.73749034806575e-10,0.9999999993262635,"Yes"
"2005-005077-29","An International Phase III Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.204274790753489e-55,4.748918250340365e-11,0.9999999999525073,"2+",0.9999999661405361,3.3859453873987006e-08,"No",1.0626509422236424e-07,0.9999998937349005,"Yes",0.9999999999973568,2.641443581180854e-12,"No",5.985963507555643e-11,0.999999999940144,"Yes",0.00012682141214152213,0.9998731785878718,"Yes",0.9999991958722597,8.041277353230374e-07,"No",9.138111540404099e-11,0.9999999999086242,"Yes"
"2005-005077-29","An International Phase II Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1986190393029527e-55,2.208499586748804e-10,0.9999999997791633,"2+",0.9999999240968152,7.590318087539915e-08,"No",2.287753981275424e-07,0.999999771224592,"Yes",0.9999999999985221,1.4805087238284327e-12,"No",4.2137709915580775e-10,0.9999999995786197,"Yes",0.00027740629210820645,0.9997225937078986,"Yes",0.999999259735564,7.402644315877929e-07,"No",6.73749034806575e-10,0.9999999993262635,"Yes"
"2005-005077-29","An International Phase III Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.204274790753489e-55,4.748918250340365e-11,0.9999999999525073,"2+",0.9999999661405361,3.3859453873987006e-08,"No",1.0626509422236424e-07,0.9999998937349005,"Yes",0.9999999999973568,2.641443581180854e-12,"No",5.985963507555643e-11,0.999999999940144,"Yes",0.00012682141214152213,0.9998731785878718,"Yes",0.9999991958722597,8.041277353230374e-07,"No",9.138111540404099e-11,0.9999999999086242,"Yes"
"2005-005077-29","An International Phase III Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.204274790753489e-55,4.748918250340365e-11,0.9999999999525073,"2+",0.9999999661405361,3.3859453873987006e-08,"No",1.0626509422236424e-07,0.9999998937349005,"Yes",0.9999999999973568,2.641443581180854e-12,"No",5.985963507555643e-11,0.999999999940144,"Yes",0.00012682141214152213,0.9998731785878718,"Yes",0.9999991958722597,8.041277353230374e-07,"No",9.138111540404099e-11,0.9999999999086242,"Yes"
"2005-005077-29","An International Phase II Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1986190393029527e-55,2.208499586748804e-10,0.9999999997791633,"2+",0.9999999240968152,7.590318087539915e-08,"No",2.287753981275424e-07,0.999999771224592,"Yes",0.9999999999985221,1.4805087238284327e-12,"No",4.2137709915580775e-10,0.9999999995786197,"Yes",0.00027740629210820645,0.9997225937078986,"Yes",0.999999259735564,7.402644315877929e-07,"No",6.73749034806575e-10,0.9999999993262635,"Yes"
"2005-005077-29","An International Phase II Randomized Double-Blinded Placebo-Controlled Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1986190393029527e-55,2.208499586748804e-10,0.9999999997791633,"2+",0.9999999240968152,7.590318087539915e-08,"No",2.287753981275424e-07,0.999999771224592,"Yes",0.9999999999985221,1.4805087238284327e-12,"No",4.2137709915580775e-10,0.9999999995786197,"Yes",0.00027740629210820645,0.9997225937078986,"Yes",0.999999259735564,7.402644315877929e-07,"No",6.73749034806575e-10,0.9999999993262635,"Yes"
"2005-005217-38","Randomised Study Comparing 4 and 6 Cycles of Chemotherapy with CHOP (Cyclophosphamide Doxorubicin Vincristine and Prednisone) at 21-day Intervals both with 6 Cycles of Immunotherapy with the Monoclonal anti-CD20 Antibody Rituximab  in Patients with Aggressive CD20-positive B-Cell Lyphoma  Aged 18 to 60 Years with no Risk Faktor (Age-adjusted IPI=0) and  no Bulky Disease (Diameter <75cm)","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.9055509709918693e-76,1.1931741336074488e-06,0.9999988068258587,"-1",1.895486317662629e-12,0.9999999999981242,"Yes",0.9999999999997727,2.551883195345077e-13,"No",1.0,1.5373877010183978e-26,"No",6.119371523075831e-05,0.999938806284764,"Yes",0.24529778790246629,0.7547022120975396,"No",1.0,1.470539682103088e-33,"No",1.5136098235569775e-06,0.9999984863901632,"Yes"
"2005-005217-38","Randomised Study Comparing 4 and 6 Cycles of Chemotherapy with CHOP (Cyclophosphamide Doxorubicin Vincristine and Prednisone) at 21-day Intervals both with 6 Cycles of Immunotherapy with the Monoclonal anti-CD20 Antibody Rituximab  in Patients with Aggressive CD20-positive B-Cell Lyphoma  Aged 18 to 60 Years with no Risk Faktor (Age-adjusted IPI=0) and  no Bulky Disease (Diameter <75cm)","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.9055509709918693e-76,1.1931741336074488e-06,0.9999988068258587,"-1",1.895486317662629e-12,0.9999999999981242,"Yes",0.9999999999997727,2.551883195345077e-13,"No",1.0,1.5373877010183978e-26,"No",6.119371523075831e-05,0.999938806284764,"Yes",0.24529778790246629,0.7547022120975396,"No",1.0,1.470539682103088e-33,"No",1.5136098235569775e-06,0.9999984863901632,"Yes"
"2005-005377-29","International Consortium on  Low Grade Glioma  - ICLGG of the International Society of Pediatric Oncology - SIOPCooperative multicenter Study for Children and Adolescents with  Low Grade Glioma SIOP - LGG 2003","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","Yes","2+","No",1.4514708164465017e-26,8.052947395835168e-06,0.9999919470526168,"-1",3.768611080207015e-09,0.9999999962313951,"Yes",0.9999999996755093,3.2449028737236414e-10,"No",0.9999052708733798,9.472912660631873e-05,"No",0.04173504564582515,0.9582649543541794,"No",0.8730186444763304,0.12698135552367235,"",0.9999999996465192,3.534856666179206e-10,"",0.053975076746008016,0.9460249232540051,"Yes"
"2005-005377-29","SIOP-LGG 2004Cooperative multicenter Study for Children and Adolescents with Low Grade Gliome","IE","No","No","Yes","","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","Yes","2+","No",3.3116747224554783e-13,0.03150741183673372,0.96849258816293,"-1",0.00011516368250790486,0.9998848363174869,"Information not present in EudraCT",0.9998765666649626,0.00012343333503111222,"Information not present in EudraCT",0.9965058456721033,0.0034941543278946383,"Information not present in EudraCT",0.013294934136662865,0.9867050658633322,"No",0.8350920802986499,0.16490791970134483,"",0.9995742455011175,0.0004257544988792074,"",0.03522158335536242,0.9647784166446423,"Yes"
"2005-005377-29","International Consortium on  Low Grade Glioma  - ICLGG of the International Society of Pediatric Oncology - SIOPCooperative multicenter Study for Children and Adolescents with  Low Grade Glioma SIOP - LGG 2003","NO","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","Yes","2+","No",1.4514708164465017e-26,8.052947395835168e-06,0.9999919470526168,"-1",3.768611080207015e-09,0.9999999962313951,"Yes",0.9999999996755093,3.2449028737236414e-10,"No",0.9999052708733798,9.472912660631873e-05,"No",0.04173504564582515,0.9582649543541794,"No",0.8730186444763304,0.12698135552367235,"",0.9999999996465192,3.534856666179206e-10,"",0.053975076746008016,0.9460249232540051,"Yes"
"2006-000284-28","Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion","DE","No","Yes","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","Yes","No","1","Yes",1.7844334787184523e-18,0.17705767099049952,0.8229423290094912,"-1",0.20889041384733803,0.7911095861526597,"No",0.9440683093631167,0.05593169063688717,"Yes",0.43537501483694685,0.5646249851630478,"No",0.012252169795050413,0.9877478302049436,"Yes",0.8320746477011853,0.16792535229880384,"No",0.9992112323472482,0.0007887676527619886,"Yes",0.43289855505002967,0.5671014449499748,"Yes"
"2006-000720-13","Double-blind randomised placebo-controlled multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.853019571488867e-47,1.1978049312102223e-10,0.9999999998802309,"2+",0.9999999999959358,4.0734608735658275e-12,"No",1.7099231240684617e-11,0.9999999999828901,"Yes",0.999999940919567,5.908042352408613e-08,"No",1.1969933495531492e-09,0.9999999988030197,"Yes",0.009955197623105495,0.9900448023769073,"Yes",0.9984847918775824,0.001515208122425529,"No",8.659262742510336e-09,0.9999999913407295,"Yes"
"2006-000720-13","Double-blind randomised placebo-controlled multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.853019571488867e-47,1.1978049312102223e-10,0.9999999998802309,"2+",0.9999999999959358,4.0734608735658275e-12,"No",1.7099231240684617e-11,0.9999999999828901,"Yes",0.999999940919567,5.908042352408613e-08,"No",1.1969933495531492e-09,0.9999999988030197,"Yes",0.009955197623105495,0.9900448023769073,"Yes",0.9984847918775824,0.001515208122425529,"No",8.659262742510336e-09,0.9999999913407295,"Yes"
"2006-000720-13","Double-blind randomised placebo-controlled multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.853019571488867e-47,1.1978049312102223e-10,0.9999999998802309,"2+",0.9999999999959358,4.0734608735658275e-12,"No",1.7099231240684617e-11,0.9999999999828901,"Yes",0.999999940919567,5.908042352408613e-08,"No",1.1969933495531492e-09,0.9999999988030197,"Yes",0.009955197623105495,0.9900448023769073,"Yes",0.9984847918775824,0.001515208122425529,"No",8.659262742510336e-09,0.9999999913407295,"Yes"
"2006-000720-13","Double-blind randomised placebo-controlled multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.853019571488867e-47,1.1978049312102223e-10,0.9999999998802309,"2+",0.9999999999959358,4.0734608735658275e-12,"No",1.7099231240684617e-11,0.9999999999828901,"Yes",0.999999940919567,5.908042352408613e-08,"No",1.1969933495531492e-09,0.9999999988030197,"Yes",0.009955197623105495,0.9900448023769073,"Yes",0.9984847918775824,0.001515208122425529,"No",8.659262742510336e-09,0.9999999913407295,"Yes"
"2006-001228-37","A randomized double blind parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners’ sexual quality of life. PARTNER II","BE","Yes","No","No","","Yes","No","Yes","Yes","2+","","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.319096856244812e-38,5.871088008167112e-09,0.9999999941288992,"-1",0.9999999995504539,4.495359051354117e-10,"Information not present in EudraCT",1.8812192030826403e-09,0.999999998118767,"Yes",0.9999999991433698,8.566341191943977e-10,"Information not present in EudraCT",3.571794748909724e-09,0.9999999964282155,"Yes",0.04329318957456993,0.9567068104254398,"Yes",0.9999964110538883,3.5889461053813164e-06,"",1.3179080820346034e-08,0.9999999868209103,"Yes"
"2006-001228-37","A randomized double blind parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners’ sexual quality of life. PARTNER II","DE","Yes","No","No","","Yes","No","Yes","Yes","2+","","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.319096856244812e-38,5.871088008167112e-09,0.9999999941288992,"-1",0.9999999995504539,4.495359051354117e-10,"Information not present in EudraCT",1.8812192030826403e-09,0.999999998118767,"Yes",0.9999999991433698,8.566341191943977e-10,"Information not present in EudraCT",3.571794748909724e-09,0.9999999964282155,"Yes",0.04329318957456993,0.9567068104254398,"Yes",0.9999964110538883,3.5889461053813164e-06,"",1.3179080820346034e-08,0.9999999868209103,"Yes"
"2006-001228-37","A randomized double blind parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners’ sexual quality of life. PARTNER II","ES","Yes","No","No","","Yes","No","Yes","Yes","2+","","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.319096856244812e-38,5.871088008167112e-09,0.9999999941288992,"-1",0.9999999995504539,4.495359051354117e-10,"Information not present in EudraCT",1.8812192030826403e-09,0.999999998118767,"Yes",0.9999999991433698,8.566341191943977e-10,"Information not present in EudraCT",3.571794748909724e-09,0.9999999964282155,"Yes",0.04329318957456993,0.9567068104254398,"Yes",0.9999964110538883,3.5889461053813164e-06,"",1.3179080820346034e-08,0.9999999868209103,"Yes"
"2006-001228-37","A randomized double blind parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners’ sexual quality of life. PARTNER II","NL","Yes","No","No","","Yes","No","Yes","Yes","2+","","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.319096856244812e-38,5.871088008167112e-09,0.9999999941288992,"-1",0.9999999995504539,4.495359051354117e-10,"Information not present in EudraCT",1.8812192030826403e-09,0.999999998118767,"Yes",0.9999999991433698,8.566341191943977e-10,"Information not present in EudraCT",3.571794748909724e-09,0.9999999964282155,"Yes",0.04329318957456993,0.9567068104254398,"Yes",0.9999964110538883,3.5889461053813164e-06,"",1.3179080820346034e-08,0.9999999868209103,"Yes"
"2006-001671-38","A Phase 2 Multicenter Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC)","AT","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.0316606418989325e-39,0.337454507044727,0.6625454929552815,"-1",0.0005020678939815282,0.9994979321060201,"Yes",0.9988898667402012,0.001110133259798336,"No",0.9999999999996589,3.4069090814857515e-13,"No",0.8636597917549215,0.13634020824508472,"Yes",0.8567473172165878,0.14325268278341327,"Yes",0.9999989390344923,1.0609654957948995e-06,"No",0.9708737292864711,0.029126270713517085,"Yes"
"2006-001671-38","Estudio Fase 2 abierto multicéntrico de CNTO 328 (Anticuerpo Monoclonal Anti-IL-6) en combinación con mitoxantrona versus mitoxantrona en sujetos con Cáncer de Próstata Metastásico Hormono-Resistente (CPHR)","DE","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.453013155969082e-37,0.3204035189990966,0.6795964810009154,"-1",0.00013503447406774003,0.9998649655259226,"Yes",0.999792150883333,0.0002078491166534101,"No",0.9999999999999432,4.6318681245069936e-14,"No",0.7564473048546002,0.2435526951454035,"Yes",0.9604936308043039,0.03950636919570871,"Yes",0.9999999999214992,7.850297393855793e-11,"No",0.9959003706805057,0.0040996293194892975,"Yes"
"2006-001671-38","Estudio Fase 2 abierto multicéntrico de CNTO 328 (Anticuerpo Monoclonal Anti-IL-6) en combinación con mitoxantrona versus mitoxantrona en sujetos con Cáncer de Próstata Metastásico Hormono-Resistente (CPHR)","GB","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.453013155969082e-37,0.3204035189990966,0.6795964810009154,"-1",0.00013503447406774003,0.9998649655259226,"Yes",0.999792150883333,0.0002078491166534101,"No",0.9999999999999432,4.6318681245069936e-14,"No",0.7564473048546002,0.2435526951454035,"Yes",0.9604936308043039,0.03950636919570871,"Yes",0.9999999999214992,7.850297393855793e-11,"No",0.9959003706805057,0.0040996293194892975,"Yes"
"2006-001671-38","Estudio Fase 2 abierto multicéntrico de CNTO 328 (Anticuerpo Monoclonal Anti-IL-6) en combinación con mitoxantrona versus mitoxantrona en sujetos con Cáncer de Próstata Metastásico Hormono-Resistente (CPHR)","FR","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.453013155969082e-37,0.3204035189990966,0.6795964810009154,"-1",0.00013503447406774003,0.9998649655259226,"Yes",0.999792150883333,0.0002078491166534101,"No",0.9999999999999432,4.6318681245069936e-14,"No",0.7564473048546002,0.2435526951454035,"Yes",0.9604936308043039,0.03950636919570871,"Yes",0.9999999999214992,7.850297393855793e-11,"No",0.9959003706805057,0.0040996293194892975,"Yes"
"2006-001671-38","A Phase 2 Multicenter Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC)","ES","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.0316606418989325e-39,0.337454507044727,0.6625454929552815,"-1",0.0005020678939815282,0.9994979321060201,"Yes",0.9988898667402012,0.001110133259798336,"No",0.9999999999996589,3.4069090814857515e-13,"No",0.8636597917549215,0.13634020824508472,"Yes",0.8567473172165878,0.14325268278341327,"Yes",0.9999989390344923,1.0609654957948995e-06,"No",0.9708737292864711,0.029126270713517085,"Yes"
"2006-001671-38","Estudio Fase 2 abierto multicéntrico de CNTO 328 (Anticuerpo Monoclonal Anti-IL-6) en combinación con mitoxantrona versus mitoxantrona en sujetos con Cáncer de Próstata Metastásico Hormono-Resistente (CPHR)","BE","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.453013155969082e-37,0.3204035189990966,0.6795964810009154,"-1",0.00013503447406774003,0.9998649655259226,"Yes",0.999792150883333,0.0002078491166534101,"No",0.9999999999999432,4.6318681245069936e-14,"No",0.7564473048546002,0.2435526951454035,"Yes",0.9604936308043039,0.03950636919570871,"Yes",0.9999999999214992,7.850297393855793e-11,"No",0.9959003706805057,0.0040996293194892975,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","IE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-001865-41","A Phase III Multicentre Randomised Double-Blind Placebo-Controlled 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.552017951023937e-77,2.466948690048605e-13,0.9999999999997442,"-1",0.9998001474511927,0.00019985254881016258,"No",0.001175982404746264,0.998824017595252,"Yes",1.0,9.945913565850005e-22,"No",2.0321068850356586e-12,0.9999999999979822,"Yes",4.981456995690155e-05,0.9999501854300464,"Yes",1.0,1.4732554168773168e-19,"No",5.151486330152497e-11,0.9999999999484714,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate (3 mg 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms (LUTS) associated with begnin prostatic hyperplasia (BPH) -  [SATURN]","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.137640939286612e-107,2.315511324733661e-22,1.0,"-1",1.0,1.7730494728058427e-21,"No",2.6103228445671685e-18,1.0,"Yes",0.9999999612666678,3.8733324952177275e-08,"No",8.260566129509276e-18,1.0,"Yes",1.844826001150316e-08,0.9999999815517528,"Yes",1.0,7.349112855248326e-20,"No",2.3072835403384177e-22,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate  3 mg 6 mg and 9 mg  in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy  3 mg 6 mg and 9 mg  and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms  LUTS  associated with benign prostatic hyperplasia  BPH ","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6269961264590994e-107,4.005192715985559e-23,1.0,"-1",1.0,2.0787519984664615e-22,"No",6.088467190275543e-18,1.0,"Yes",0.9999976778837226,2.3221163046918197e-06,"No",9.93226121565389e-19,1.0,"Yes",2.5309477192612496e-09,0.9999999974690468,"Yes",1.0,9.486327785228895e-21,"No",2.764593403048924e-23,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate (3 mg 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms (LUTS) associated with begnin prostatic hyperplasia (BPH) -  [SATURN]","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.137640939286612e-107,2.315511324733661e-22,1.0,"-1",1.0,1.7730494728058427e-21,"No",2.6103228445671685e-18,1.0,"Yes",0.9999999612666678,3.8733324952177275e-08,"No",8.260566129509276e-18,1.0,"Yes",1.844826001150316e-08,0.9999999815517528,"Yes",1.0,7.349112855248326e-20,"No",2.3072835403384177e-22,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate (3 mg 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms (LUTS) associated with begnin prostatic hyperplasia (BPH) -  [SATURN]","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.137640939286612e-107,2.315511324733661e-22,1.0,"-1",1.0,1.7730494728058427e-21,"No",2.6103228445671685e-18,1.0,"Yes",0.9999999612666678,3.8733324952177275e-08,"No",8.260566129509276e-18,1.0,"Yes",1.844826001150316e-08,0.9999999815517528,"Yes",1.0,7.349112855248326e-20,"No",2.3072835403384177e-22,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate  3 mg 6 mg and 9 mg  in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy  3 mg 6 mg and 9 mg  and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms  LUTS  associated with benign prostatic hyperplasia  BPH ","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6269961264590994e-107,4.005192715985559e-23,1.0,"-1",1.0,2.0787519984664615e-22,"No",6.088467190275543e-18,1.0,"Yes",0.9999976778837226,2.3221163046918197e-06,"No",9.93226121565389e-19,1.0,"Yes",2.5309477192612496e-09,0.9999999974690468,"Yes",1.0,9.486327785228895e-21,"No",2.764593403048924e-23,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate (3 mg 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms ","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.651645935287106e-103,2.0657181362719011e-19,1.0,"-1",1.0,2.571924760861816e-19,"No",4.726917384459877e-18,1.0,"Yes",0.9999999991111395,8.888341548345205e-10,"No",4.330090512491732e-14,0.9999999999999432,"Yes",1.300275511328952e-05,0.9999869972448996,"Yes",1.0,5.963885481881161e-16,"No",1.1392769083517808e-18,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate (3 mg 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms (LUTS) associated with begnin prostatic hyperplasia (BPH) -  [SATURN]","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.137640939286612e-107,2.315511324733661e-22,1.0,"-1",1.0,1.7730494728058427e-21,"No",2.6103228445671685e-18,1.0,"Yes",0.9999999612666678,3.8733324952177275e-08,"No",8.260566129509276e-18,1.0,"Yes",1.844826001150316e-08,0.9999999815517528,"Yes",1.0,7.349112855248326e-20,"No",2.3072835403384177e-22,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate  3 mg 6 mg and 9 mg  in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy  3 mg 6 mg and 9 mg  and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms  LUTS  associated with benign prostatic hyperplasia  BPH ","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6269961264590994e-107,4.005192715985559e-23,1.0,"-1",1.0,2.0787519984664615e-22,"No",6.088467190275543e-18,1.0,"Yes",0.9999976778837226,2.3221163046918197e-06,"No",9.93226121565389e-19,1.0,"Yes",2.5309477192612496e-09,0.9999999974690468,"Yes",1.0,9.486327785228895e-21,"No",2.764593403048924e-23,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate (3 mg 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms ","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.651645935287106e-103,2.0657181362719011e-19,1.0,"-1",1.0,2.571924760861816e-19,"No",4.726917384459877e-18,1.0,"Yes",0.9999999991111395,8.888341548345205e-10,"No",4.330090512491732e-14,0.9999999999999432,"Yes",1.300275511328952e-05,0.9999869972448996,"Yes",1.0,5.963885481881161e-16,"No",1.1392769083517808e-18,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate (3 mg 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms ","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.651645935287106e-103,2.0657181362719011e-19,1.0,"-1",1.0,2.571924760861816e-19,"No",4.726917384459877e-18,1.0,"Yes",0.9999999991111395,8.888341548345205e-10,"No",4.330090512491732e-14,0.9999999999999432,"Yes",1.300275511328952e-05,0.9999869972448996,"Yes",1.0,5.963885481881161e-16,"No",1.1392769083517808e-18,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate  3 mg 6 mg and 9 mg  in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy  3 mg 6 mg and 9 mg  and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms  LUTS  associated with benign prostatic hyperplasia  BPH ","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6269961264590994e-107,4.005192715985559e-23,1.0,"-1",1.0,2.0787519984664615e-22,"No",6.088467190275543e-18,1.0,"Yes",0.9999976778837226,2.3221163046918197e-06,"No",9.93226121565389e-19,1.0,"Yes",2.5309477192612496e-09,0.9999999974690468,"Yes",1.0,9.486327785228895e-21,"No",2.764593403048924e-23,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate  3 mg 6 mg and 9 mg  in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy  3 mg 6 mg and 9 mg  and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms  LUTS  associated with benign prostatic hyperplasia  BPH ","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6269961264590994e-107,4.005192715985559e-23,1.0,"-1",1.0,2.0787519984664615e-22,"No",6.088467190275543e-18,1.0,"Yes",0.9999976778837226,2.3221163046918197e-06,"No",9.93226121565389e-19,1.0,"Yes",2.5309477192612496e-09,0.9999999974690468,"Yes",1.0,9.486327785228895e-21,"No",2.764593403048924e-23,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate (3 mg 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms ","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.651645935287106e-103,2.0657181362719011e-19,1.0,"-1",1.0,2.571924760861816e-19,"No",4.726917384459877e-18,1.0,"Yes",0.9999999991111395,8.888341548345205e-10,"No",4.330090512491732e-14,0.9999999999999432,"Yes",1.300275511328952e-05,0.9999869972448996,"Yes",1.0,5.963885481881161e-16,"No",1.1392769083517808e-18,1.0,"Yes"
"2006-002072-18","A randomized double-blind parallel group placebo controlled multi center dose ranging study of solifenacin succinate (3 mg 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms ","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.651645935287106e-103,2.0657181362719011e-19,1.0,"-1",1.0,2.571924760861816e-19,"No",4.726917384459877e-18,1.0,"Yes",0.9999999991111395,8.888341548345205e-10,"No",4.330090512491732e-14,0.9999999999999432,"Yes",1.300275511328952e-05,0.9999869972448996,"Yes",1.0,5.963885481881161e-16,"No",1.1392769083517808e-18,1.0,"Yes"
"2006-004532-73","A MULTICENTER SINGLE-ARM OPEN-LABEL EXPANDED ACCESS PROGRAM FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED SUBJECTS WITH MULTIPLE MYELOMA","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.743942538660254e-30,0.9999976040546839,2.3959453145509484e-06,"-1",6.8972428739044e-10,0.9999999993102762,"Yes",0.9999999998396589,1.6034132867832024e-10,"No",0.9999999999999147,8.322780073043147e-14,"No",0.9999994185053097,5.814946899720804e-07,"No",0.9998320127563166,0.0001679872436897705,"No",0.9999998901212227,1.0987877133150109e-07,"No",0.9999983427740294,1.6572259774154954e-06,"No"
"2006-004633-15","A randomized double-blind parallel group prospective pilot study to assess the effect of vardenafil on clinical outcome and on procedure duration after green light laser-ablation of the prostate gland for therapy of benign prostate hypertrophy (BPH)","DE","Yes","Yes","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.959925331329103e-44,4.253862479940696e-10,0.9999999995746123,"-1",0.9999987373475975,1.262652412627538e-06,"No",0.0012703420632881254,0.9987296579367005,"Yes",0.410991175362152,0.5890088246378428,"No",1.1367101060788891e-11,0.9999999999886313,"Yes",5.286525742918555e-05,0.9999471347425766,"Yes",0.9999999999995737,4.260776852336414e-13,"No",4.919587760525007e-10,0.9999999995080486,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.837524404362395e-51,2.4767699030830792e-08,0.9999999752322996,"-1",0.9982886356027744,0.0017113643972365357,"No",0.003973795340357531,0.9960262046596379,"Yes",1.0,9.922963688738632e-17,"No",7.328694172021142e-07,0.9999992671305747,"Yes",0.039601009993226195,0.9603989900067802,"Yes",0.999999906450431,9.354958251709634e-08,"No",2.5003792003721085e-08,0.9999999749962004,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.837524404362395e-51,2.4767699030830792e-08,0.9999999752322996,"-1",0.9982886356027744,0.0017113643972365357,"No",0.003973795340357531,0.9960262046596379,"Yes",1.0,9.922963688738632e-17,"No",7.328694172021142e-07,0.9999992671305747,"Yes",0.039601009993226195,0.9603989900067802,"Yes",0.999999906450431,9.354958251709634e-08,"No",2.5003792003721085e-08,0.9999999749962004,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer------------------------------------------------------------------------------------------------------Estudio multicéntrico aleatorizado doble ciego para comparar la eficacia de aflibercept frente a placebo administrado cada 3 semanas en pacientes con cáncer de próstata metastásico hormonorresistente tratados con docetaxel/prednisona","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.479779218479872e-96,7.641451158238109e-17,1.0,"-1",0.9999960901220941,3.909877883623046e-06,"No",2.188626036142857e-05,0.9999781137396135,"Yes",1.0,3.6318189853019396e-36,"No",4.681760077515095e-14,0.9999999999999432,"Yes",0.0036611077606697614,0.9963388922393245,"Yes",1.0,2.213205554122632e-19,"No",5.0451210813352394e-15,1.0,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.837524404362395e-51,2.4767699030830792e-08,0.9999999752322996,"-1",0.9982886356027744,0.0017113643972365357,"No",0.003973795340357531,0.9960262046596379,"Yes",1.0,9.922963688738632e-17,"No",7.328694172021142e-07,0.9999992671305747,"Yes",0.039601009993226195,0.9603989900067802,"Yes",0.999999906450431,9.354958251709634e-08,"No",2.5003792003721085e-08,0.9999999749962004,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer------------------------------------------------------------------------------------------------------Estudio multicéntrico aleatorizado doble ciego para comparar la eficacia de aflibercept frente a placebo administrado cada 3 semanas en pacientes con cáncer de próstata metastásico hormonorresistente tratados con docetaxel/prednisona","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.479779218479872e-96,7.641451158238109e-17,1.0,"-1",0.9999960901220941,3.909877883623046e-06,"No",2.188626036142857e-05,0.9999781137396135,"Yes",1.0,3.6318189853019396e-36,"No",4.681760077515095e-14,0.9999999999999432,"Yes",0.0036611077606697614,0.9963388922393245,"Yes",1.0,2.213205554122632e-19,"No",5.0451210813352394e-15,1.0,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer------------------------------------------------------------------------------------------------------Estudio multicéntrico aleatorizado doble ciego para comparar la eficacia de aflibercept frente a placebo administrado cada 3 semanas en pacientes con cáncer de próstata metastásico hormonorresistente tratados con docetaxel/prednisona","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.479779218479872e-96,7.641451158238109e-17,1.0,"-1",0.9999960901220941,3.909877883623046e-06,"No",2.188626036142857e-05,0.9999781137396135,"Yes",1.0,3.6318189853019396e-36,"No",4.681760077515095e-14,0.9999999999999432,"Yes",0.0036611077606697614,0.9963388922393245,"Yes",1.0,2.213205554122632e-19,"No",5.0451210813352394e-15,1.0,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer------------------------------------------------------------------------------------------------------Estudio multicéntrico aleatorizado doble ciego para comparar la eficacia de aflibercept frente a placebo administrado cada 3 semanas en pacientes con cáncer de próstata metastásico hormonorresistente tratados con docetaxel/prednisona","EE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.479779218479872e-96,7.641451158238109e-17,1.0,"-1",0.9999960901220941,3.909877883623046e-06,"No",2.188626036142857e-05,0.9999781137396135,"Yes",1.0,3.6318189853019396e-36,"No",4.681760077515095e-14,0.9999999999999432,"Yes",0.0036611077606697614,0.9963388922393245,"Yes",1.0,2.213205554122632e-19,"No",5.0451210813352394e-15,1.0,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.837524404362395e-51,2.4767699030830792e-08,0.9999999752322996,"-1",0.9982886356027744,0.0017113643972365357,"No",0.003973795340357531,0.9960262046596379,"Yes",1.0,9.922963688738632e-17,"No",7.328694172021142e-07,0.9999992671305747,"Yes",0.039601009993226195,0.9603989900067802,"Yes",0.999999906450431,9.354958251709634e-08,"No",2.5003792003721085e-08,0.9999999749962004,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer------------------------------------------------------------------------------------------------------Estudio multicéntrico aleatorizado doble ciego para comparar la eficacia de aflibercept frente a placebo administrado cada 3 semanas en pacientes con cáncer de próstata metastásico hormonorresistente tratados con docetaxel/prednisona","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.479779218479872e-96,7.641451158238109e-17,1.0,"-1",0.9999960901220941,3.909877883623046e-06,"No",2.188626036142857e-05,0.9999781137396135,"Yes",1.0,3.6318189853019396e-36,"No",4.681760077515095e-14,0.9999999999999432,"Yes",0.0036611077606697614,0.9963388922393245,"Yes",1.0,2.213205554122632e-19,"No",5.0451210813352394e-15,1.0,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer------------------------------------------------------------------------------------------------------Estudio multicéntrico aleatorizado doble ciego para comparar la eficacia de aflibercept frente a placebo administrado cada 3 semanas en pacientes con cáncer de próstata metastásico hormonorresistente tratados con docetaxel/prednisona","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.479779218479872e-96,7.641451158238109e-17,1.0,"-1",0.9999960901220941,3.909877883623046e-06,"No",2.188626036142857e-05,0.9999781137396135,"Yes",1.0,3.6318189853019396e-36,"No",4.681760077515095e-14,0.9999999999999432,"Yes",0.0036611077606697614,0.9963388922393245,"Yes",1.0,2.213205554122632e-19,"No",5.0451210813352394e-15,1.0,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.837524404362395e-51,2.4767699030830792e-08,0.9999999752322996,"-1",0.9982886356027744,0.0017113643972365357,"No",0.003973795340357531,0.9960262046596379,"Yes",1.0,9.922963688738632e-17,"No",7.328694172021142e-07,0.9999992671305747,"Yes",0.039601009993226195,0.9603989900067802,"Yes",0.999999906450431,9.354958251709634e-08,"No",2.5003792003721085e-08,0.9999999749962004,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.837524404362395e-51,2.4767699030830792e-08,0.9999999752322996,"-1",0.9982886356027744,0.0017113643972365357,"No",0.003973795340357531,0.9960262046596379,"Yes",1.0,9.922963688738632e-17,"No",7.328694172021142e-07,0.9999992671305747,"Yes",0.039601009993226195,0.9603989900067802,"Yes",0.999999906450431,9.354958251709634e-08,"No",2.5003792003721085e-08,0.9999999749962004,"Yes"
"2006-004756-20","A Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.837524404362395e-51,2.4767699030830792e-08,0.9999999752322996,"-1",0.9982886356027744,0.0017113643972365357,"No",0.003973795340357531,0.9960262046596379,"Yes",1.0,9.922963688738632e-17,"No",7.328694172021142e-07,0.9999992671305747,"Yes",0.039601009993226195,0.9603989900067802,"Yes",0.999999906450431,9.354958251709634e-08,"No",2.5003792003721085e-08,0.9999999749962004,"Yes"
"2006-005145-11","Randomized double-blind placebo-controlled parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity). ","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1744537428381976e-48,2.428725620608436e-12,0.9999999999975842,"-1",0.9999999999948272,5.1658521892544625e-12,"No",3.5450939593088096e-11,0.9999999999645582,"Yes",0.9999999998817942,1.181976541058208e-10,"No",4.1619503669795806e-11,0.9999999999583907,"Yes",8.581838683182004e-07,0.9999991418161459,"Yes",0.9999986560041457,1.3439958610858526e-06,"No",1.0744728091080231e-11,0.9999999999892567,"Yes"
"2006-005145-11","Estudio aleatorizado doble ciego controlado con placebo de grupos paralelos con una dosis de 10 mg de vardenafilo dos veces al día para evaluar el efecto en la prueba urodinámica en pacientes con vejiga hiperactiva (hiperactividad del detrusor)Randomized double-blind placebo-controlled parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity). ","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.08899346280686e-96,7.557853873164923e-22,1.0,"-1",1.0,4.868430215451918e-20,"No",6.742489348745719e-18,1.0,"Yes",1.0,8.336042427085124e-17,"No",5.820621030221492e-21,1.0,"Yes",2.8598420304010662e-11,0.9999999999714079,"Yes",0.9999999999999432,7.558018331481859e-14,"No",1.5881505995739734e-19,1.0,"Yes"
"2006-005145-11","Randomized double-blind placebo-controlled parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity). ","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1744537428381976e-48,2.428725620608436e-12,0.9999999999975842,"-1",0.9999999999948272,5.1658521892544625e-12,"No",3.5450939593088096e-11,0.9999999999645582,"Yes",0.9999999998817942,1.181976541058208e-10,"No",4.1619503669795806e-11,0.9999999999583907,"Yes",8.581838683182004e-07,0.9999991418161459,"Yes",0.9999986560041457,1.3439958610858526e-06,"No",1.0744728091080231e-11,0.9999999999892567,"Yes"
"2006-005145-11","Estudio aleatorizado doble ciego controlado con placebo de grupos paralelos con una dosis de 10 mg de vardenafilo dos veces al día para evaluar el efecto en la prueba urodinámica en pacientes con vejiga hiperactiva (hiperactividad del detrusor)Randomized double-blind placebo-controlled parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity). ","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.08899346280686e-96,7.557853873164923e-22,1.0,"-1",1.0,4.868430215451918e-20,"No",6.742489348745719e-18,1.0,"Yes",1.0,8.336042427085124e-17,"No",5.820621030221492e-21,1.0,"Yes",2.8598420304010662e-11,0.9999999999714079,"Yes",0.9999999999999432,7.558018331481859e-14,"No",1.5881505995739734e-19,1.0,"Yes"
"2006-005145-11","Randomized double-blind placebo-controlled parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity). ","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1744537428381976e-48,2.428725620608436e-12,0.9999999999975842,"-1",0.9999999999948272,5.1658521892544625e-12,"No",3.5450939593088096e-11,0.9999999999645582,"Yes",0.9999999998817942,1.181976541058208e-10,"No",4.1619503669795806e-11,0.9999999999583907,"Yes",8.581838683182004e-07,0.9999991418161459,"Yes",0.9999986560041457,1.3439958610858526e-06,"No",1.0744728091080231e-11,0.9999999999892567,"Yes"
"2006-005145-11","Estudio aleatorizado doble ciego controlado con placebo de grupos paralelos con una dosis de 10 mg de vardenafilo dos veces al día para evaluar el efecto en la prueba urodinámica en pacientes con vejiga hiperactiva (hiperactividad del detrusor)Randomized double-blind placebo-controlled parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity). ","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.08899346280686e-96,7.557853873164923e-22,1.0,"-1",1.0,4.868430215451918e-20,"No",6.742489348745719e-18,1.0,"Yes",1.0,8.336042427085124e-17,"No",5.820621030221492e-21,1.0,"Yes",2.8598420304010662e-11,0.9999999999714079,"Yes",0.9999999999999432,7.558018331481859e-14,"No",1.5881505995739734e-19,1.0,"Yes"
"2006-005145-11","Estudio aleatorizado doble ciego controlado con placebo de grupos paralelos con una dosis de 10 mg de vardenafilo dos veces al día para evaluar el efecto en la prueba urodinámica en pacientes con vejiga hiperactiva (hiperactividad del detrusor)Randomized double-blind placebo-controlled parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity). ","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.08899346280686e-96,7.557853873164923e-22,1.0,"-1",1.0,4.868430215451918e-20,"No",6.742489348745719e-18,1.0,"Yes",1.0,8.336042427085124e-17,"No",5.820621030221492e-21,1.0,"Yes",2.8598420304010662e-11,0.9999999999714079,"Yes",0.9999999999999432,7.558018331481859e-14,"No",1.5881505995739734e-19,1.0,"Yes"
"2006-005145-11","Randomized double-blind placebo-controlled parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity). ","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1744537428381976e-48,2.428725620608436e-12,0.9999999999975842,"-1",0.9999999999948272,5.1658521892544625e-12,"No",3.5450939593088096e-11,0.9999999999645582,"Yes",0.9999999998817942,1.181976541058208e-10,"No",4.1619503669795806e-11,0.9999999999583907,"Yes",8.581838683182004e-07,0.9999991418161459,"Yes",0.9999986560041457,1.3439958610858526e-06,"No",1.0744728091080231e-11,0.9999999999892567,"Yes"
"2006-005751-16","An open label dose escalation safety and tolerability trial of the combination of s.c. recombinant human IL-21 (rIL-21) and sunitinib (phase 1) followed by an open label stratified randomized 2-arm trial of rIL-21 plus sunitinib versus sunitinib alone (phase 2a) in subjects with stage IV renal cell carcinoma. Trial Phase: 1/2a","DK","No","No","Yes","ok","No","No","No","Yes","1","Yes","No","Yes","No","No","No","No","No","2+","No",2.017629830062224e-88,0.9987282352991778,0.0012717647008477972,"-1",7.138534916277689e-14,0.9999999999999432,"Yes",0.9999999999999432,7.556313865733367e-14,"No",1.0,8.121626407280565e-18,"No",0.005071468525939105,0.994928531474067,"Yes",0.9990112559301286,0.0009887440698925249,"Yes",0.999999987524575,1.247543749769084e-08,"No",0.9998390688688206,0.00016093113118128186,"Yes"
"2006-005751-16","An open label dose escalation safety and tolerability trial of the combination of s.c. recombinant human IL-21 (rIL-21) and sunitinib (phase 1) followed by an open label stratified randomized 2-arm trial of rIL-21 plus sunitinib versus sunitinib alone (phase 2a) in subjects with stage IV renal cell carcinoma. Trial Phase: 1/2a","DE","No","No","Yes","ok","No","No","No","Yes","1","Yes","No","Yes","No","No","No","No","No","2+","No",2.017629830062224e-88,0.9987282352991778,0.0012717647008477972,"-1",7.138534916277689e-14,0.9999999999999432,"Yes",0.9999999999999432,7.556313865733367e-14,"No",1.0,8.121626407280565e-18,"No",0.005071468525939105,0.994928531474067,"Yes",0.9990112559301286,0.0009887440698925249,"Yes",0.999999987524575,1.247543749769084e-08,"No",0.9998390688688206,0.00016093113118128186,"Yes"
"2006-005751-16","An open label dose escalation safety and tolerability trial of the combination of s.c. recombinant human IL-21 (rIL-21) and sunitinib (phase 1) followed by an open label stratified randomized 2-arm trial of rIL-21 plus sunitinib versus sunitinib alone (phase 2a) in subjects with stage IV renal cell carcinoma. Trial Phase: 1/2a","NL","No","No","Yes","ok","No","No","No","Yes","1","Yes","No","Yes","No","No","No","No","No","2+","No",2.017629830062224e-88,0.9987282352991778,0.0012717647008477972,"-1",7.138534916277689e-14,0.9999999999999432,"Yes",0.9999999999999432,7.556313865733367e-14,"No",1.0,8.121626407280565e-18,"No",0.005071468525939105,0.994928531474067,"Yes",0.9990112559301286,0.0009887440698925249,"Yes",0.999999987524575,1.247543749769084e-08,"No",0.9998390688688206,0.00016093113118128186,"Yes"
"2006-005766-39","A Randomized Double-blind Multicenter Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Subjects With Metastatic Hormone Refractory prostate Cancer","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.005254287696173e-52,1.1942436676799436e-05,0.9999880575633157,"-1",0.9852150412944476,0.014784958705540793,"No",0.02279696524403858,0.9772030347559503,"Yes",1.0,3.6466373995447116e-17,"No",0.0010392485730180293,0.9989607514269941,"Yes",0.9243598469657208,0.07564015303428562,"Yes",0.9999998822334887,1.1776650073791134e-07,"No",0.018574397825209647,0.9814256021747818,"Yes"
"2006-005766-39","A Randomized Double-blind Multicenter Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Subjects With Metastatic Hormone Refractory prostate Cancer","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.005254287696173e-52,1.1942436676799436e-05,0.9999880575633157,"-1",0.9852150412944476,0.014784958705540793,"No",0.02279696524403858,0.9772030347559503,"Yes",1.0,3.6466373995447116e-17,"No",0.0010392485730180293,0.9989607514269941,"Yes",0.9243598469657208,0.07564015303428562,"Yes",0.9999998822334887,1.1776650073791134e-07,"No",0.018574397825209647,0.9814256021747818,"Yes"
"2006-005766-39","A Randomized Double-blind Multicenter Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Subjects With Metastatic Hormone Refractory prostate Cancer","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.005254287696173e-52,1.1942436676799436e-05,0.9999880575633157,"-1",0.9852150412944476,0.014784958705540793,"No",0.02279696524403858,0.9772030347559503,"Yes",1.0,3.6466373995447116e-17,"No",0.0010392485730180293,0.9989607514269941,"Yes",0.9243598469657208,0.07564015303428562,"Yes",0.9999998822334887,1.1776650073791134e-07,"No",0.018574397825209647,0.9814256021747818,"Yes"
"2006-005766-39","A Randomized Double-blind Multicenter Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Subjects With Metastatic Hormone Refractory prostate Cancer","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.005254287696173e-52,1.1942436676799436e-05,0.9999880575633157,"-1",0.9852150412944476,0.014784958705540793,"No",0.02279696524403858,0.9772030347559503,"Yes",1.0,3.6466373995447116e-17,"No",0.0010392485730180293,0.9989607514269941,"Yes",0.9243598469657208,0.07564015303428562,"Yes",0.9999998822334887,1.1776650073791134e-07,"No",0.018574397825209647,0.9814256021747818,"Yes"
"2006-005766-39","A Randomized Double-blind Multicenter Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Subjects With Metastatic Hormone Refractory prostate Cancer","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.005254287696173e-52,1.1942436676799436e-05,0.9999880575633157,"-1",0.9852150412944476,0.014784958705540793,"No",0.02279696524403858,0.9772030347559503,"Yes",1.0,3.6466373995447116e-17,"No",0.0010392485730180293,0.9989607514269941,"Yes",0.9243598469657208,0.07564015303428562,"Yes",0.9999998822334887,1.1776650073791134e-07,"No",0.018574397825209647,0.9814256021747818,"Yes"
"2006-005834-19","A phase III trials program exploring the integration of Bevacizumab Everolimus (RAD001) and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3571092539188125e-29,0.018398226921756865,0.981601773078231,"-1",5.303901991098754e-10,0.9999999994696226,"Yes",0.9999999997993143,2.0067215056772952e-10,"No",0.9999999999999432,6.920241900825254e-14,"No",0.29743146401155346,0.7025685359884482,"Yes",0.8817057420729362,0.11829425792705414,"Yes",0.9999999999940884,5.919351379089085e-12,"No",0.2270158249009952,0.7729841750990047,"Yes"
"2006-006188-22","A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed non high-risk acute promyelocytic leukemia","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5314138821322614e-48,2.8097729693295365e-12,0.9999999999971863,"2+",2.1051908950208598e-14,0.9999999999999717,"Yes",0.9999999999999432,5.1315747663586756e-14,"No",1.0,3.948687259900704e-16,"No",1.6645835957072362e-12,0.9999999999983232,"Yes",7.560849737368334e-08,0.9999999243914914,"Yes",1.0,4.0871115711683086e-16,"No",7.11564299392225e-13,0.9999999999992895,"Yes"
"2006-006188-22","A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed non high-risk acute promyelocytic leukemia","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5314138821322614e-48,2.8097729693295365e-12,0.9999999999971863,"2+",2.1051908950208598e-14,0.9999999999999717,"Yes",0.9999999999999432,5.1315747663586756e-14,"No",1.0,3.948687259900704e-16,"No",1.6645835957072362e-12,0.9999999999983232,"Yes",7.560849737368334e-08,0.9999999243914914,"Yes",1.0,4.0871115711683086e-16,"No",7.11564299392225e-13,0.9999999999992895,"Yes"
"2006-006188-22","A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed non high-risk acute promyelocytic leukemia","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5314138821322614e-48,2.8097729693295365e-12,0.9999999999971863,"2+",2.1051908950208598e-14,0.9999999999999717,"Yes",0.9999999999999432,5.1315747663586756e-14,"No",1.0,3.948687259900704e-16,"No",1.6645835957072362e-12,0.9999999999983232,"Yes",7.560849737368334e-08,0.9999999243914914,"Yes",1.0,4.0871115711683086e-16,"No",7.11564299392225e-13,0.9999999999992895,"Yes"
"2006-006370-25","Phase 2 randomised open label multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.Estudio de fase 2 aleatorizado abierto multicéntrico de IMA901 intradérmico más FEC-GM con o sin pretratamiento de ciclofosfamida en dosis bajas en pacientes con carcinoma de células renales avanzado con enfermedad medible.","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.291381560924545e-78,3.988546474106121e-05,0.9999601145352495,"-1",4.1607660551645265e-13,0.9999999999996021,"Yes",0.9999999999985789,1.4228890985444708e-12,"No",1.0,6.23799652462656e-26,"No",0.00010588816310238029,0.9998941118368762,"No",0.9652582814012428,0.03474171859878295,"Yes",1.0,2.6493146071026147e-17,"No",4.702854163980526e-06,0.9999952971458324,"Yes"
"2006-006370-25","Phase 2 randomised open label multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.65813191091677e-41,0.005158995364929007,0.9948410046350781,"-1",3.488628975959915e-07,0.9999996511371064,"Yes",0.999999366674844,6.33325158490154e-07,"No",0.9999999999975557,2.439472733779341e-12,"No",0.014886925468277818,0.9851130745317342,"No",0.9630784552852343,0.03692154471477789,"Yes",0.9997121346811949,0.0002878653188132059,"No",0.004214755518872087,0.9957852444811164,"Yes"
"2006-006370-25","Phase 2 randomised open label multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.65813191091677e-41,0.005158995364929007,0.9948410046350781,"-1",3.488628975959915e-07,0.9999996511371064,"Yes",0.999999366674844,6.33325158490154e-07,"No",0.9999999999975557,2.439472733779341e-12,"No",0.014886925468277818,0.9851130745317342,"No",0.9630784552852343,0.03692154471477789,"Yes",0.9997121346811949,0.0002878653188132059,"No",0.004214755518872087,0.9957852444811164,"Yes"
"2006-006370-25","Phase 2 randomised open label multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease","BG","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.65813191091677e-41,0.005158995364929007,0.9948410046350781,"-1",3.488628975959915e-07,0.9999996511371064,"Yes",0.999999366674844,6.33325158490154e-07,"No",0.9999999999975557,2.439472733779341e-12,"No",0.014886925468277818,0.9851130745317342,"No",0.9630784552852343,0.03692154471477789,"Yes",0.9997121346811949,0.0002878653188132059,"No",0.004214755518872087,0.9957852444811164,"Yes"
"2006-006370-25","Phase 2 randomised open label multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.Estudio de fase 2 aleatorizado abierto multicéntrico de IMA901 intradérmico más FEC-GM con o sin pretratamiento de ciclofosfamida en dosis bajas en pacientes con carcinoma de células renales avanzado con enfermedad medible.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.291381560924545e-78,3.988546474106121e-05,0.9999601145352495,"-1",4.1607660551645265e-13,0.9999999999996021,"Yes",0.9999999999985789,1.4228890985444708e-12,"No",1.0,6.23799652462656e-26,"No",0.00010588816310238029,0.9998941118368762,"No",0.9652582814012428,0.03474171859878295,"Yes",1.0,2.6493146071026147e-17,"No",4.702854163980526e-06,0.9999952971458324,"Yes"
"2006-006370-25","Phase 2 randomised open label multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.Estudio de fase 2 aleatorizado abierto multicéntrico de IMA901 intradérmico más FEC-GM con o sin pretratamiento de ciclofosfamida en dosis bajas en pacientes con carcinoma de células renales avanzado con enfermedad medible.","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.291381560924545e-78,3.988546474106121e-05,0.9999601145352495,"-1",4.1607660551645265e-13,0.9999999999996021,"Yes",0.9999999999985789,1.4228890985444708e-12,"No",1.0,6.23799652462656e-26,"No",0.00010588816310238029,0.9998941118368762,"No",0.9652582814012428,0.03474171859878295,"Yes",1.0,2.6493146071026147e-17,"No",4.702854163980526e-06,0.9999952971458324,"Yes"
"2006-006370-25","Phase 2 randomised open label multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.Estudio de fase 2 aleatorizado abierto multicéntrico de IMA901 intradérmico más FEC-GM con o sin pretratamiento de ciclofosfamida en dosis bajas en pacientes con carcinoma de células renales avanzado con enfermedad medible.","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.291381560924545e-78,3.988546474106121e-05,0.9999601145352495,"-1",4.1607660551645265e-13,0.9999999999996021,"Yes",0.9999999999985789,1.4228890985444708e-12,"No",1.0,6.23799652462656e-26,"No",0.00010588816310238029,0.9998941118368762,"No",0.9652582814012428,0.03474171859878295,"Yes",1.0,2.6493146071026147e-17,"No",4.702854163980526e-06,0.9999952971458324,"Yes"
"2006-006404-11","INTRAMYOCARDIAL TRANSPLANTATION OF BONE MARROW STEM CELLS FOR IMPROVEMENT OF POST-INFARCT MYOCARDIAL REGENERATION IN ADDITION TO CABG SURGERY: a controlled prospective randomized double blinded multicenter trialIntramyokardiale Transplantation von Knochenmark-Stammzellen zur Verbesserung der myokardialen Regeneration nach Infarkt in Ergänzung zur Bypass-Operation","DE","No","Yes","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.7328938385878575e-48,1.8652023906495796e-10,0.9999999998134969,"2+",0.09242220154477213,0.9075777984552059,"No",0.9993598852969998,0.0006401147030078567,"Yes",0.001976176474796983,0.9980238235252026,"No",2.0552909502648675e-10,0.9999999997944542,"Yes",0.9999929571438488,7.042856139205568e-06,"Yes",0.998639596672027,0.0013604033279670461,"No",1.7922419434695576e-08,0.9999999820775545,"Yes"
"2006-006538-16","AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT ","ES","No","No","Yes","ok","No","No","No","Yes","1","","","Yes","No","No","No","No","No","1","No",3.8455214463112966e-25,0.999999995506471,4.493522859690084e-09,"-1",1.8159604989196758e-10,0.9999999998184137,"Yes",0.9999999999147349,8.525416814520657e-11,"No",1.0,1.2208322602390652e-14,"No",0.004078834835321574,0.9959211651646653,"No",0.9999870424171814,1.2957582827969538e-05,"No",0.9999997007748953,2.992251119784634e-07,"No",0.999999989285783,1.0714214345437327e-08,"No"
"2006-006538-16","AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT ","BG","No","No","Yes","ok","No","No","No","Yes","1","","","Yes","No","No","No","No","No","1","No",3.8455214463112966e-25,0.999999995506471,4.493522859690084e-09,"-1",1.8159604989196758e-10,0.9999999998184137,"Yes",0.9999999999147349,8.525416814520657e-11,"No",1.0,1.2208322602390652e-14,"No",0.004078834835321574,0.9959211651646653,"No",0.9999870424171814,1.2957582827969538e-05,"No",0.9999997007748953,2.992251119784634e-07,"No",0.999999989285783,1.0714214345437327e-08,"No"
"2006-006538-16","AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT ","FR","No","No","Yes","","No","No","No","Yes","1","","","Yes","No","No","No","No","No","1","No",3.8455214463112966e-25,0.999999995506471,4.493522859690084e-09,"-1",1.8159604989196758e-10,0.9999999998184137,"Information not present in EudraCT",0.9999999999147349,8.525416814520657e-11,"Information not present in EudraCT",1.0,1.2208322602390652e-14,"Information not present in EudraCT",0.004078834835321574,0.9959211651646653,"No",0.9999870424171814,1.2957582827969538e-05,"No",0.9999997007748953,2.992251119784634e-07,"No",0.999999989285783,1.0714214345437327e-08,"No"
"2006-006538-16","AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT ","DK","No","No","Yes","ok","No","No","No","Yes","1","","","Yes","No","No","No","No","No","1","No",3.8455214463112966e-25,0.999999995506471,4.493522859690084e-09,"-1",1.8159604989196758e-10,0.9999999998184137,"Yes",0.9999999999147349,8.525416814520657e-11,"No",1.0,1.2208322602390652e-14,"No",0.004078834835321574,0.9959211651646653,"No",0.9999870424171814,1.2957582827969538e-05,"No",0.9999997007748953,2.992251119784634e-07,"No",0.999999989285783,1.0714214345437327e-08,"No"
"2006-006538-16","AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT ","NL","No","No","Yes","ok","No","No","No","Yes","1","","","Yes","No","No","No","No","No","1","No",3.8455214463112966e-25,0.999999995506471,4.493522859690084e-09,"-1",1.8159604989196758e-10,0.9999999998184137,"Yes",0.9999999999147349,8.525416814520657e-11,"No",1.0,1.2208322602390652e-14,"No",0.004078834835321574,0.9959211651646653,"No",0.9999870424171814,1.2957582827969538e-05,"No",0.9999997007748953,2.992251119784634e-07,"No",0.999999989285783,1.0714214345437327e-08,"No"
"2006-006852-37","A phase III randomized double-blind study of induction(daunorubicin/cytarabine)and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.867389473167501e-61,5.036023321817151e-11,0.9999999999496367,"2+",0.9999364946991972,6.350530079762717e-05,"No",0.00014252351184675268,0.9998574764881647,"Yes",1.0,2.3521228674175764e-21,"No",4.099488176665109e-14,0.9999999999999717,"Yes",0.9998197131247891,0.00018028687521064909,"Yes",1.0,1.3264740402571842e-25,"No",3.3035231988078487e-09,0.999999996696488,"Yes"
"2006-006852-37","A phase III randomized double-blind study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy + midostaurin (PKC 412) (IND # 101261) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.342776545097392e-61,4.585744206587773e-11,0.9999999999541558,"2+",0.9999429744623972,5.702553759623196e-05,"No",0.0001279821576242879,0.9998720178423814,"Yes",1.0,2.1296052825809247e-21,"No",3.706215114019945e-14,0.9999999999999717,"Yes",0.9762783524200238,0.02372164757998012,"Yes",1.0,1.2008268522790883e-25,"No",2.986061739183233e-09,0.99999999701393,"Yes"
"2006-006852-37","A phase III randomized double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)Randomizované dvojito slepé klinické skúšanie fázy III indukčnej chemoterapie (daunorubicín/cytarabín) a konsolidačnej chemoterapie (vysoké dávky cytarabínu) kombinovanej s podávaním lieku midostaurín (PKC412) alebo placeba u novodiagnostikovaných pacientov s akútnou myeloidnou leukémiou (AML) s prítomnou mutáciou FLT3 ktorí majú menej ako 60 rokov ","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.426588494795073e-104,1.5596831493625146e-24,1.0,"2+",0.9999999999988632,1.1452902461388328e-12,"No",2.575745268585739e-13,0.9999999999997727,"Yes",1.0,3.6455588839665636e-55,"No",1.0998783306030366e-34,1.0,"Yes",0.9999996897563987,3.1024358645393945e-07,"Yes",1.0,2.673008291505957e-60,"No",1.9029358713588413e-24,1.0,"Yes"
"2006-006852-37","A phase III randomized double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)Randomizované dvojito slepé klinické skúšanie fázy III indukčnej chemoterapie (daunorubicín/cytarabín) a konsolidačnej chemoterapie (vysoké dávky cytarabínu) kombinovanej s podávaním lieku midostaurín (PKC412) alebo placeba u novodiagnostikovaných pacientov s akútnou myeloidnou leukémiou (AML) s prítomnou mutáciou FLT3 ktorí majú menej ako 60 rokov ","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.426588494795073e-104,1.5596831493625146e-24,1.0,"2+",0.9999999999988632,1.1452902461388328e-12,"No",2.575745268585739e-13,0.9999999999997727,"Yes",1.0,3.6455588839665636e-55,"No",1.0998783306030366e-34,1.0,"Yes",0.9999996897563987,3.1024358645393945e-07,"Yes",1.0,2.673008291505957e-60,"No",1.9029358713588413e-24,1.0,"Yes"
"2006-006852-37","A phase III randomized double-blind study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy + midostaurin (PKC 412) (IND # 101261) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)","SK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.342776545097392e-61,4.585744206587773e-11,0.9999999999541558,"2+",0.9999429744623972,5.702553759623196e-05,"No",0.0001279821576242879,0.9998720178423814,"Yes",1.0,2.1296052825809247e-21,"No",3.706215114019945e-14,0.9999999999999717,"Yes",0.9762783524200238,0.02372164757998012,"Yes",1.0,1.2008268522790883e-25,"No",2.986061739183233e-09,0.99999999701393,"Yes"
"2006-006852-37","A phase III randomized double-blind study of induction(daunorubicin/cytarabine)and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.867389473167501e-61,5.036023321817151e-11,0.9999999999496367,"2+",0.9999364946991972,6.350530079762717e-05,"No",0.00014252351184675268,0.9998574764881647,"Yes",1.0,2.3521228674175764e-21,"No",4.099488176665109e-14,0.9999999999999717,"Yes",0.9998197131247891,0.00018028687521064909,"Yes",1.0,1.3264740402571842e-25,"No",3.3035231988078487e-09,0.999999996696488,"Yes"
"2006-006852-37","A phase III randomized double-blind study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy + midostaurin (PKC 412) (IND # 101261) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.342776545097392e-61,4.585744206587773e-11,0.9999999999541558,"2+",0.9999429744623972,5.702553759623196e-05,"No",0.0001279821576242879,0.9998720178423814,"Yes",1.0,2.1296052825809247e-21,"No",3.706215114019945e-14,0.9999999999999717,"Yes",0.9762783524200238,0.02372164757998012,"Yes",1.0,1.2008268522790883e-25,"No",2.986061739183233e-09,0.99999999701393,"Yes"
"2006-006852-37","Estudio de fase III aleatorizado y doble ciego de la quimioterapia de inducción (daunorubicina/citarabina) y consolidación (citarabina en dosis altas) + midostaurina (PKC412) (ind nº 101261) o placebo en pacientes menores de 60 años diagnosticados de novo de leucemia mieloide aguda (LMA) con mutación en FLT3","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.890745645577432e-52,1.1965515829649376e-06,0.9999988034483973,"2+",0.938254641852188,0.06174535814780737,"No",0.09136592121569416,0.9086340787843126,"Yes",1.0,4.3678941558402135e-21,"No",1.622990600219673e-11,0.9999999999837428,"Yes",0.9654209341853696,0.034579065814603495,"Yes",1.0,1.3064177224717639e-29,"No",3.5396893455872024e-09,0.9999999964603036,"Yes"
"2006-006852-37","Estudio de fase III aleatorizado y doble ciego de la quimioterapia de inducción (daunorubicina/citarabina) y consolidación (citarabina en dosis altas) + midostaurina (PKC412) (ind nº 101261) o placebo en pacientes menores de 60 años diagnosticados de novo de leucemia mieloide aguda (LMA) con mutación en FLT3","FR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.890745645577432e-52,1.1965515829649376e-06,0.9999988034483973,"2+",0.938254641852188,0.06174535814780737,"No",0.09136592121569416,0.9086340787843126,"Yes",1.0,4.3678941558402135e-21,"No",1.622990600219673e-11,0.9999999999837428,"Yes",0.9654209341853696,0.034579065814603495,"Yes",1.0,1.3064177224717639e-29,"No",3.5396893455872024e-09,0.9999999964603036,"Yes"
"2006-006852-37","Estudio de fase III aleatorizado y doble ciego de la quimioterapia de inducción (daunorubicina/citarabina) y consolidación (citarabina en dosis altas) + midostaurina (PKC412) (ind nº 101261) o placebo en pacientes menores de 60 años diagnosticados de novo de leucemia mieloide aguda (LMA) con mutación en FLT3","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.890745645577432e-52,1.1965515829649376e-06,0.9999988034483973,"2+",0.938254641852188,0.06174535814780737,"No",0.09136592121569416,0.9086340787843126,"Yes",1.0,4.3678941558402135e-21,"No",1.622990600219673e-11,0.9999999999837428,"Yes",0.9654209341853696,0.034579065814603495,"Yes",1.0,1.3064177224717639e-29,"No",3.5396893455872024e-09,0.9999999964603036,"Yes"
"2006-006852-37","A phase III randomized double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)Randomizované dvojito slepé klinické skúšanie fázy III indukčnej chemoterapie (daunorubicín/cytarabín) a konsolidačnej chemoterapie (vysoké dávky cytarabínu) kombinovanej s podávaním lieku midostaurín (PKC412) alebo placeba u novodiagnostikovaných pacientov s akútnou myeloidnou leukémiou (AML) s prítomnou mutáciou FLT3 ktorí majú menej ako 60 rokov ","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.426588494795073e-104,1.5596831493625146e-24,1.0,"2+",0.9999999999988632,1.1452902461388328e-12,"No",2.575745268585739e-13,0.9999999999997727,"Yes",1.0,3.6455588839665636e-55,"No",1.0998783306030366e-34,1.0,"Yes",0.9999996897563987,3.1024358645393945e-07,"Yes",1.0,2.673008291505957e-60,"No",1.9029358713588413e-24,1.0,"Yes"
"2006-006913-34","An Open-Label Multi-Centre Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy","DE","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.5601833848574974e-31,0.9059035051527307,0.09409649484726704,"-1",2.674424586663758e-07,0.9999997325575481,"Information not present in EudraCT",0.999999764660344,2.353396597142022e-07,"Information not present in EudraCT",0.9999995168130087,4.831869889836015e-07,"Information not present in EudraCT",0.9995927942924725,0.0004072057075417243,"No",0.9917469057021534,0.008253094297842383,"No",0.9999999935400582,6.4599457107621604e-09,"No",0.993634088718443,0.006365911281545313,"No"
"2006-006913-34","An Open-Label Multi-Centre Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy","NL","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.5601833848574974e-31,0.9059035051527307,0.09409649484726704,"-1",2.674424586663758e-07,0.9999997325575481,"Information not present in EudraCT",0.999999764660344,2.353396597142022e-07,"Information not present in EudraCT",0.9999995168130087,4.831869889836015e-07,"Information not present in EudraCT",0.9995927942924725,0.0004072057075417243,"No",0.9917469057021534,0.008253094297842383,"No",0.9999999935400582,6.4599457107621604e-09,"No",0.993634088718443,0.006365911281545313,"No"
"2006-006913-34","An Open-Label Multi-Centre Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy","HU","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.5601833848574974e-31,0.9059035051527307,0.09409649484726704,"-1",2.674424586663758e-07,0.9999997325575481,"Information not present in EudraCT",0.999999764660344,2.353396597142022e-07,"Information not present in EudraCT",0.9999995168130087,4.831869889836015e-07,"Information not present in EudraCT",0.9995927942924725,0.0004072057075417243,"No",0.9917469057021534,0.008253094297842383,"No",0.9999999935400582,6.4599457107621604e-09,"No",0.993634088718443,0.006365911281545313,"No"
"2006-006913-34","An Open-Label Multi-Centre Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy","GB","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.5601833848574974e-31,0.9059035051527307,0.09409649484726704,"-1",2.674424586663758e-07,0.9999997325575481,"Information not present in EudraCT",0.999999764660344,2.353396597142022e-07,"Information not present in EudraCT",0.9999995168130087,4.831869889836015e-07,"Information not present in EudraCT",0.9995927942924725,0.0004072057075417243,"No",0.9917469057021534,0.008253094297842383,"No",0.9999999935400582,6.4599457107621604e-09,"No",0.993634088718443,0.006365911281545313,"No"
"2006-007021-32","Multi-center open-label prospective randomized parallel group long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose regimen","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.893512100445624e-45,3.7808062272533388e-06,0.9999962191937605,"-1",3.662099283217036e-10,0.9999999996337864,"Yes",0.9999999997077681,2.922332104550367e-10,"No",0.99999995456247,4.543752347599997e-08,"No",2.183654449248878e-06,0.9999978163455377,"Yes",8.430472975830748e-06,0.9999915695270356,"Yes",0.9999999999999432,4.465812865011225e-14,"No",7.6326506217816e-06,0.9999923673493891,"Yes"
"2007-000180-13","OPTIMA: A Randomized Open-label 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.9982612804964086e-27,0.0009395859632271666,0.9990604140367687,"-1",0.00018551770672403195,0.9998144822932883,"Yes",0.999712113751478,0.00028788624853266456,"No",0.9999999995733903,4.265967650289184e-10,"No",0.0013334212921733125,0.9986665787078339,"Yes",0.677166351847528,0.32283364815248544,"Yes",0.9999999998179021,1.8208767718619193e-10,"No",0.007062841863554591,0.9929371581364461,"Yes"
"2007-000180-13","OPTIMA: A Randomized Open-label 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.158299414678399e-28,0.002413772782246418,0.9975862272177597,"-1",0.00012003682050066302,0.9998799631795025,"Yes",0.9998062146403186,0.0001937853596701799,"No",0.9999999997600639,2.399355573661036e-10,"No",0.0027739689654156566,0.9972260310345971,"Yes",0.7616110652407394,0.23838893475924647,"Yes",0.9999999999967883,3.2006577266462475e-12,"No",0.013220076122219822,0.9867799238777898,"Yes"
"2007-000180-13","OPTIMA: A Randomized Open-label 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.9982612804964086e-27,0.0009395859632271666,0.9990604140367687,"-1",0.00018551770672403195,0.9998144822932883,"Yes",0.999712113751478,0.00028788624853266456,"No",0.9999999995733903,4.265967650289184e-10,"No",0.0013334212921733125,0.9986665787078339,"Yes",0.677166351847528,0.32283364815248544,"Yes",0.9999999998179021,1.8208767718619193e-10,"No",0.007062841863554591,0.9929371581364461,"Yes"
"2007-000180-13","OPTIMA: A Randomized Open-label 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.158299414678399e-28,0.002413772782246418,0.9975862272177597,"-1",0.00012003682050066302,0.9998799631795025,"Yes",0.9998062146403186,0.0001937853596701799,"No",0.9999999997600639,2.399355573661036e-10,"No",0.0027739689654156566,0.9972260310345971,"Yes",0.7616110652407394,0.23838893475924647,"Yes",0.9999999999967883,3.2006577266462475e-12,"No",0.013220076122219822,0.9867799238777898,"Yes"
"2007-000180-13","OPTIMA: A Randomized Open-label 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept","BG","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.9982612804964086e-27,0.0009395859632271666,0.9990604140367687,"-1",0.00018551770672403195,0.9998144822932883,"Yes",0.999712113751478,0.00028788624853266456,"No",0.9999999995733903,4.265967650289184e-10,"No",0.0013334212921733125,0.9986665787078339,"Yes",0.677166351847528,0.32283364815248544,"Yes",0.9999999998179021,1.8208767718619193e-10,"No",0.007062841863554591,0.9929371581364461,"Yes"
"2007-000180-13","OPTIMA: A Randomized Open-label 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.9982612804964086e-27,0.0009395859632271666,0.9990604140367687,"-1",0.00018551770672403195,0.9998144822932883,"Yes",0.999712113751478,0.00028788624853266456,"No",0.9999999995733903,4.265967650289184e-10,"No",0.0013334212921733125,0.9986665787078339,"Yes",0.677166351847528,0.32283364815248544,"Yes",0.9999999998179021,1.8208767718619193e-10,"No",0.007062841863554591,0.9929371581364461,"Yes"
"2007-000281-21","Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter Gene of MGMT Enzyme– a Multicenter Open-label Uncontrolled Phase II Study","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.1465267414338172e-37,0.9964343764892757,0.0035656235107248595,"-1",5.58937427437788e-09,0.9999999944106152,"Yes",0.9999999882826957,1.1717306367805275e-08,"No",0.9999999999998864,1.1719511164928692e-13,"No",0.7530119711712006,0.24698802882880747,"No",0.9962761759078615,0.0037238240921349574,"No",0.9999999999989768,1.0095215903951516e-12,"No",0.9976496468965779,0.002350353103417155,"No"
"2007-000323-17","A Randomized Open Label Multicenter Phase III 2-Arm Study of Androgen Deprivation with Leuprolide +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3808116146945528e-38,0.0007778601779577692,0.9992221398220471,"-1",0.005825375659973371,0.9941746243400221,"Yes",0.9868889352624503,0.013111064737544725,"No",1.0,2.6932314294688977e-17,"No",0.002006817883975501,0.9979931821160208,"Yes",0.8624793675320181,0.13752063246799487,"Yes",0.99999999999784,2.1552379891100954e-12,"No",7.531767363018532e-05,0.9999246823263696,"Yes"
"2007-000323-17","A Randomized Open Label Multicenter Phase III 2-Arm Study of Androgen Deprivation with Leuprolide +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3808116146945528e-38,0.0007778601779577692,0.9992221398220471,"-1",0.005825375659973371,0.9941746243400221,"Yes",0.9868889352624503,0.013111064737544725,"No",1.0,2.6932314294688977e-17,"No",0.002006817883975501,0.9979931821160208,"Yes",0.8624793675320181,0.13752063246799487,"Yes",0.99999999999784,2.1552379891100954e-12,"No",7.531767363018532e-05,0.9999246823263696,"Yes"
"2007-000323-17","A Randomized Open Label Multicenter Phase III 2-Arm Study of Androgen Deprivation with Leuprolide +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3808116146945528e-38,0.0007778601779577692,0.9992221398220471,"-1",0.005825375659973371,0.9941746243400221,"Yes",0.9868889352624503,0.013111064737544725,"No",1.0,2.6932314294688977e-17,"No",0.002006817883975501,0.9979931821160208,"Yes",0.8624793675320181,0.13752063246799487,"Yes",0.99999999999784,2.1552379891100954e-12,"No",7.531767363018532e-05,0.9999246823263696,"Yes"
"2007-000323-17","A Randomized Open Label Multicenter Phase III 2-Arm Study of Androgen Deprivation with Leuprolide +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3808116146945528e-38,0.0007778601779577692,0.9992221398220471,"-1",0.005825375659973371,0.9941746243400221,"Yes",0.9868889352624503,0.013111064737544725,"No",1.0,2.6932314294688977e-17,"No",0.002006817883975501,0.9979931821160208,"Yes",0.8624793675320181,0.13752063246799487,"Yes",0.99999999999784,2.1552379891100954e-12,"No",7.531767363018532e-05,0.9999246823263696,"Yes"
"2007-000323-17","A Randomized Open Label Multicenter Phase III 2-Arm Study of Androgen Deprivation with Leuprolide +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy","LT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3808116146945528e-38,0.0007778601779577692,0.9992221398220471,"-1",0.005825375659973371,0.9941746243400221,"Yes",0.9868889352624503,0.013111064737544725,"No",1.0,2.6932314294688977e-17,"No",0.002006817883975501,0.9979931821160208,"Yes",0.8624793675320181,0.13752063246799487,"Yes",0.99999999999784,2.1552379891100954e-12,"No",7.531767363018532e-05,0.9999246823263696,"Yes"
"2007-000323-17","A Randomized Open Label Multicenter Phase III 2-Arm Study of Androgen Deprivation with Leuprolide +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3808116146945528e-38,0.0007778601779577692,0.9992221398220471,"-1",0.005825375659973371,0.9941746243400221,"Yes",0.9868889352624503,0.013111064737544725,"No",1.0,2.6932314294688977e-17,"No",0.002006817883975501,0.9979931821160208,"Yes",0.8624793675320181,0.13752063246799487,"Yes",0.99999999999784,2.1552379891100954e-12,"No",7.531767363018532e-05,0.9999246823263696,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","FR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung CancerKettősvak randomizált placebóval ellenőrzött III. fázisú vizsgálat az adjuváns kezelésként alkalmazott recMAGE-A3 + AS15 antigén-specifikus tumorellenes immunterápia hatékonyságának értékelésére olyan betegekben akiknek rezekálható MAGE-A3-antigén pozitív nem kissejtes tüdőkarcinómájuk van","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.236809271463055e-85,1.5685052461241518e-13,0.9999999999998295,"2+",0.999999999569809,4.3018562151920753e-10,"No",3.1019911785006258e-09,0.9999999968979979,"Yes",1.0,5.576928412768471e-22,"No",8.614217923430716e-14,0.9999999999998864,"Yes",0.9909621931867914,0.009037806813232178,"Yes",1.0,1.7590571063372343e-28,"No",6.537381058785141e-13,0.9999999999993748,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung CancerKettősvak randomizált placebóval ellenőrzött III. fázisú vizsgálat az adjuváns kezelésként alkalmazott recMAGE-A3 + AS15 antigén-specifikus tumorellenes immunterápia hatékonyságának értékelésére olyan betegekben akiknek rezekálható MAGE-A3-antigén pozitív nem kissejtes tüdőkarcinómájuk van","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.236809271463055e-85,1.5685052461241518e-13,0.9999999999998295,"2+",0.999999999569809,4.3018562151920753e-10,"No",3.1019911785006258e-09,0.9999999968979979,"Yes",1.0,5.576928412768471e-22,"No",8.614217923430716e-14,0.9999999999998864,"Yes",0.9909621931867914,0.009037806813232178,"Yes",1.0,1.7590571063372343e-28,"No",6.537381058785141e-13,0.9999999999993748,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung CancerKettősvak randomizált placebóval ellenőrzött III. fázisú vizsgálat az adjuváns kezelésként alkalmazott recMAGE-A3 + AS15 antigén-specifikus tumorellenes immunterápia hatékonyságának értékelésére olyan betegekben akiknek rezekálható MAGE-A3-antigén pozitív nem kissejtes tüdőkarcinómájuk van","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.236809271463055e-85,1.5685052461241518e-13,0.9999999999998295,"2+",0.999999999569809,4.3018562151920753e-10,"No",3.1019911785006258e-09,0.9999999968979979,"Yes",1.0,5.576928412768471e-22,"No",8.614217923430716e-14,0.9999999999998864,"Yes",0.9909621931867914,0.009037806813232178,"Yes",1.0,1.7590571063372343e-28,"No",6.537381058785141e-13,0.9999999999993748,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","LV","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung CancerKettősvak randomizált placebóval ellenőrzött III. fázisú vizsgálat az adjuváns kezelésként alkalmazott recMAGE-A3 + AS15 antigén-specifikus tumorellenes immunterápia hatékonyságának értékelésére olyan betegekben akiknek rezekálható MAGE-A3-antigén pozitív nem kissejtes tüdőkarcinómájuk van","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.236809271463055e-85,1.5685052461241518e-13,0.9999999999998295,"2+",0.999999999569809,4.3018562151920753e-10,"No",3.1019911785006258e-09,0.9999999968979979,"Yes",1.0,5.576928412768471e-22,"No",8.614217923430716e-14,0.9999999999998864,"Yes",0.9909621931867914,0.009037806813232178,"Yes",1.0,1.7590571063372343e-28,"No",6.537381058785141e-13,0.9999999999993748,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung CancerKettősvak randomizált placebóval ellenőrzött III. fázisú vizsgálat az adjuváns kezelésként alkalmazott recMAGE-A3 + AS15 antigén-specifikus tumorellenes immunterápia hatékonyságának értékelésére olyan betegekben akiknek rezekálható MAGE-A3-antigén pozitív nem kissejtes tüdőkarcinómájuk van","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.236809271463055e-85,1.5685052461241518e-13,0.9999999999998295,"2+",0.999999999569809,4.3018562151920753e-10,"No",3.1019911785006258e-09,0.9999999968979979,"Yes",1.0,5.576928412768471e-22,"No",8.614217923430716e-14,0.9999999999998864,"Yes",0.9909621931867914,0.009037806813232178,"Yes",1.0,1.7590571063372343e-28,"No",6.537381058785141e-13,0.9999999999993748,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","FI","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung CancerKettősvak randomizált placebóval ellenőrzött III. fázisú vizsgálat az adjuváns kezelésként alkalmazott recMAGE-A3 + AS15 antigén-specifikus tumorellenes immunterápia hatékonyságának értékelésére olyan betegekben akiknek rezekálható MAGE-A3-antigén pozitív nem kissejtes tüdőkarcinómájuk van","EE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.236809271463055e-85,1.5685052461241518e-13,0.9999999999998295,"2+",0.999999999569809,4.3018562151920753e-10,"No",3.1019911785006258e-09,0.9999999968979979,"Yes",1.0,5.576928412768471e-22,"No",8.614217923430716e-14,0.9999999999998864,"Yes",0.9909621931867914,0.009037806813232178,"Yes",1.0,1.7590571063372343e-28,"No",6.537381058785141e-13,0.9999999999993748,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung CancerKettősvak randomizált placebóval ellenőrzött III. fázisú vizsgálat az adjuváns kezelésként alkalmazott recMAGE-A3 + AS15 antigén-specifikus tumorellenes immunterápia hatékonyságának értékelésére olyan betegekben akiknek rezekálható MAGE-A3-antigén pozitív nem kissejtes tüdőkarcinómájuk van","IE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.236809271463055e-85,1.5685052461241518e-13,0.9999999999998295,"2+",0.999999999569809,4.3018562151920753e-10,"No",3.1019911785006258e-09,0.9999999968979979,"Yes",1.0,5.576928412768471e-22,"No",8.614217923430716e-14,0.9999999999998864,"Yes",0.9909621931867914,0.009037806813232178,"Yes",1.0,1.7590571063372343e-28,"No",6.537381058785141e-13,0.9999999999993748,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","SI","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","GR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001283-73","A double-blind randomized placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5418159649044313e-59,1.0803694072075534e-09,0.999999998919634,"2+",0.999995040869085,4.959130908806653e-06,"No",3.5474847748893945e-05,0.9999645251522415,"Yes",0.9999999999999432,4.74746124563152e-14,"No",2.711190037406411e-07,0.999999728881002,"Yes",0.9964746465331108,0.0035253534668833126,"Yes",0.99999998174863,1.8251365089079867e-08,"No",1.6716230360785854e-07,0.9999998328377016,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo y tratamiento activo para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactiva. A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.775759564560931e-132,9.59573727070761e-31,1.0,"-1",1.0,2.841893325761799e-25,"No",1.384295722654581e-23,1.0,"Yes",1.0,2.4584172695133037e-21,"No",6.439973323393092e-25,1.0,"Yes",1.393898950080531e-13,0.9999999999998864,"Yes",1.0,1.0153971185655856e-15,"No",2.069316609501194e-27,1.0,"Yes"
"2007-001451-19","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo y tratamiento activo para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactiva. A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.775759564560931e-132,9.59573727070761e-31,1.0,"-1",1.0,2.841893325761799e-25,"No",1.384295722654581e-23,1.0,"Yes",1.0,2.4584172695133037e-21,"No",6.439973323393092e-25,1.0,"Yes",1.393898950080531e-13,0.9999999999998864,"Yes",1.0,1.0153971185655856e-15,"No",2.069316609501194e-27,1.0,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","IE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo y tratamiento activo para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactiva. A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.775759564560931e-132,9.59573727070761e-31,1.0,"-1",1.0,2.841893325761799e-25,"No",1.384295722654581e-23,1.0,"Yes",1.0,2.4584172695133037e-21,"No",6.439973323393092e-25,1.0,"Yes",1.393898950080531e-13,0.9999999999998864,"Yes",1.0,1.0153971185655856e-15,"No",2.069316609501194e-27,1.0,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo y tratamiento activo para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactiva. A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","IS","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.775759564560931e-132,9.59573727070761e-31,1.0,"-1",1.0,2.841893325761799e-25,"No",1.384295722654581e-23,1.0,"Yes",1.0,2.4584172695133037e-21,"No",6.439973323393092e-25,1.0,"Yes",1.393898950080531e-13,0.9999999999998864,"Yes",1.0,1.0153971185655856e-15,"No",2.069316609501194e-27,1.0,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo y tratamiento activo para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactiva. A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.775759564560931e-132,9.59573727070761e-31,1.0,"-1",1.0,2.841893325761799e-25,"No",1.384295722654581e-23,1.0,"Yes",1.0,2.4584172695133037e-21,"No",6.439973323393092e-25,1.0,"Yes",1.393898950080531e-13,0.9999999999998864,"Yes",1.0,1.0153971185655856e-15,"No",2.069316609501194e-27,1.0,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo y tratamiento activo para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactiva. A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.775759564560931e-132,9.59573727070761e-31,1.0,"-1",1.0,2.841893325761799e-25,"No",1.384295722654581e-23,1.0,"Yes",1.0,2.4584172695133037e-21,"No",6.439973323393092e-25,1.0,"Yes",1.393898950080531e-13,0.9999999999998864,"Yes",1.0,1.0153971185655856e-15,"No",2.069316609501194e-27,1.0,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2129491783042938e-55,4.519602037746176e-15,1.0,"-1",1.0,2.762201479715469e-15,"No",1.6556392969815576e-14,0.9999999999999717,"Yes",0.9999999999675708,3.2423295630210793e-11,"No",1.3208674436140428e-12,0.9999999999986926,"Yes",7.205850972309557e-07,0.9999992794149118,"Yes",0.9999995308638994,4.691361109656159e-07,"No",8.048304204417463e-14,0.9999999999999147,"Yes"
"2007-001451-19","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo y tratamiento activo para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactiva. A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.775759564560931e-132,9.59573727070761e-31,1.0,"-1",1.0,2.841893325761799e-25,"No",1.384295722654581e-23,1.0,"Yes",1.0,2.4584172695133037e-21,"No",6.439973323393092e-25,1.0,"Yes",1.393898950080531e-13,0.9999999999998864,"Yes",1.0,1.0153971185655856e-15,"No",2.069316609501194e-27,1.0,"Yes"
"2007-001451-19","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo y tratamiento activo para evaluar la eficacia y seguridad del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactiva. A Randomized Double-blind Parallel Group Placebo and Active Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.775759564560931e-132,9.59573727070761e-31,1.0,"-1",1.0,2.841893325761799e-25,"No",1.384295722654581e-23,1.0,"Yes",1.0,2.4584172695133037e-21,"No",6.439973323393092e-25,1.0,"Yes",1.393898950080531e-13,0.9999999999998864,"Yes",1.0,1.0153971185655856e-15,"No",2.069316609501194e-27,1.0,"Yes"
"2007-001452-39","Estudio multicéntrico aleatorizado doble-ciego de grupos paralelos controlado con tratamiento activo para evaluar la seguridad y eficacia a largo plazo del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactivaA Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symtpoms of Overactive Bladder","IS","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.918217063979448e-120,1.9967580238002807e-23,1.0,"-1",1.0,1.47952084556504e-19,"No",1.9945464206395334e-18,1.0,"Yes",1.0,4.716389777386079e-22,"No",4.037723499497432e-18,1.0,"Yes",4.6011334523399055e-11,0.9999999999540137,"Yes",1.0,4.566573998763965e-18,"No",2.733015483747387e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive BladderA Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","IE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.4676305759268695e-100,2.4341710386113304e-23,1.0,"-1",1.0,1.5265299458212901e-24,"No",1.6462478908946733e-23,1.0,"Yes",1.0,5.282632693836163e-21,"No",1.816768686259377e-18,1.0,"Yes",1.6137072095628733e-10,0.9999999998386215,"Yes",0.999999999999261,7.315369101946614e-13,"No",1.1040735373142456e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive BladderA Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.4676305759268695e-100,2.4341710386113304e-23,1.0,"-1",1.0,1.5265299458212901e-24,"No",1.6462478908946733e-23,1.0,"Yes",1.0,5.282632693836163e-21,"No",1.816768686259377e-18,1.0,"Yes",1.6137072095628733e-10,0.9999999998386215,"Yes",0.999999999999261,7.315369101946614e-13,"No",1.1040735373142456e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.562759054503884e-49,2.7496176870098656e-12,0.9999999999972431,"-1",0.9999999999992326,7.673787847958165e-13,"No",2.5951099931611363e-12,0.9999999999974137,"Yes",0.9999999999598401,4.0146222628591506e-11,"No",8.978725249280065e-10,0.9999999991021298,"Yes",7.087546899655686e-06,0.9999929124531013,"Yes",0.9999999629187933,3.708120845958857e-08,"No",5.718509405878691e-11,0.9999999999428155,"Yes"
"2007-001452-39","Estudio multicéntrico aleatorizado doble-ciego de grupos paralelos controlado con tratamiento activo para evaluar la seguridad y eficacia a largo plazo del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactivaA Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symtpoms of Overactive Bladder","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.918217063979448e-120,1.9967580238002807e-23,1.0,"-1",1.0,1.47952084556504e-19,"No",1.9945464206395334e-18,1.0,"Yes",1.0,4.716389777386079e-22,"No",4.037723499497432e-18,1.0,"Yes",4.6011334523399055e-11,0.9999999999540137,"Yes",1.0,4.566573998763965e-18,"No",2.733015483747387e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive BladderA Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.4676305759268695e-100,2.4341710386113304e-23,1.0,"-1",1.0,1.5265299458212901e-24,"No",1.6462478908946733e-23,1.0,"Yes",1.0,5.282632693836163e-21,"No",1.816768686259377e-18,1.0,"Yes",1.6137072095628733e-10,0.9999999998386215,"Yes",0.999999999999261,7.315369101946614e-13,"No",1.1040735373142456e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.562759054503884e-49,2.7496176870098656e-12,0.9999999999972431,"-1",0.9999999999992326,7.673787847958165e-13,"No",2.5951099931611363e-12,0.9999999999974137,"Yes",0.9999999999598401,4.0146222628591506e-11,"No",8.978725249280065e-10,0.9999999991021298,"Yes",7.087546899655686e-06,0.9999929124531013,"Yes",0.9999999629187933,3.708120845958857e-08,"No",5.718509405878691e-11,0.9999999999428155,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive BladderA Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.4676305759268695e-100,2.4341710386113304e-23,1.0,"-1",1.0,1.5265299458212901e-24,"No",1.6462478908946733e-23,1.0,"Yes",1.0,5.282632693836163e-21,"No",1.816768686259377e-18,1.0,"Yes",1.6137072095628733e-10,0.9999999998386215,"Yes",0.999999999999261,7.315369101946614e-13,"No",1.1040735373142456e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive BladderA Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.4676305759268695e-100,2.4341710386113304e-23,1.0,"-1",1.0,1.5265299458212901e-24,"No",1.6462478908946733e-23,1.0,"Yes",1.0,5.282632693836163e-21,"No",1.816768686259377e-18,1.0,"Yes",1.6137072095628733e-10,0.9999999998386215,"Yes",0.999999999999261,7.315369101946614e-13,"No",1.1040735373142456e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive BladderA Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.4676305759268695e-100,2.4341710386113304e-23,1.0,"-1",1.0,1.5265299458212901e-24,"No",1.6462478908946733e-23,1.0,"Yes",1.0,5.282632693836163e-21,"No",1.816768686259377e-18,1.0,"Yes",1.6137072095628733e-10,0.9999999998386215,"Yes",0.999999999999261,7.315369101946614e-13,"No",1.1040735373142456e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.562759054503884e-49,2.7496176870098656e-12,0.9999999999972431,"-1",0.9999999999992326,7.673787847958165e-13,"No",2.5951099931611363e-12,0.9999999999974137,"Yes",0.9999999999598401,4.0146222628591506e-11,"No",8.978725249280065e-10,0.9999999991021298,"Yes",7.087546899655686e-06,0.9999929124531013,"Yes",0.9999999629187933,3.708120845958857e-08,"No",5.718509405878691e-11,0.9999999999428155,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive BladderA Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.4676305759268695e-100,2.4341710386113304e-23,1.0,"-1",1.0,1.5265299458212901e-24,"No",1.6462478908946733e-23,1.0,"Yes",1.0,5.282632693836163e-21,"No",1.816768686259377e-18,1.0,"Yes",1.6137072095628733e-10,0.9999999998386215,"Yes",0.999999999999261,7.315369101946614e-13,"No",1.1040735373142456e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.562759054503884e-49,2.7496176870098656e-12,0.9999999999972431,"-1",0.9999999999992326,7.673787847958165e-13,"No",2.5951099931611363e-12,0.9999999999974137,"Yes",0.9999999999598401,4.0146222628591506e-11,"No",8.978725249280065e-10,0.9999999991021298,"Yes",7.087546899655686e-06,0.9999929124531013,"Yes",0.9999999629187933,3.708120845958857e-08,"No",5.718509405878691e-11,0.9999999999428155,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.562759054503884e-49,2.7496176870098656e-12,0.9999999999972431,"-1",0.9999999999992326,7.673787847958165e-13,"No",2.5951099931611363e-12,0.9999999999974137,"Yes",0.9999999999598401,4.0146222628591506e-11,"No",8.978725249280065e-10,0.9999999991021298,"Yes",7.087546899655686e-06,0.9999929124531013,"Yes",0.9999999629187933,3.708120845958857e-08,"No",5.718509405878691e-11,0.9999999999428155,"Yes"
"2007-001452-39","Estudio multicéntrico aleatorizado doble-ciego de grupos paralelos controlado con tratamiento activo para evaluar la seguridad y eficacia a largo plazo del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactivaA Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symtpoms of Overactive Bladder","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.918217063979448e-120,1.9967580238002807e-23,1.0,"-1",1.0,1.47952084556504e-19,"No",1.9945464206395334e-18,1.0,"Yes",1.0,4.716389777386079e-22,"No",4.037723499497432e-18,1.0,"Yes",4.6011334523399055e-11,0.9999999999540137,"Yes",1.0,4.566573998763965e-18,"No",2.733015483747387e-20,1.0,"Yes"
"2007-001452-39","Estudio multicéntrico aleatorizado doble-ciego de grupos paralelos controlado con tratamiento activo para evaluar la seguridad y eficacia a largo plazo del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactivaA Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symtpoms of Overactive Bladder","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.918217063979448e-120,1.9967580238002807e-23,1.0,"-1",1.0,1.47952084556504e-19,"No",1.9945464206395334e-18,1.0,"Yes",1.0,4.716389777386079e-22,"No",4.037723499497432e-18,1.0,"Yes",4.6011334523399055e-11,0.9999999999540137,"Yes",1.0,4.566573998763965e-18,"No",2.733015483747387e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive BladderA Randomized Double-Blind Parallel Group Active Controlled Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.4676305759268695e-100,2.4341710386113304e-23,1.0,"-1",1.0,1.5265299458212901e-24,"No",1.6462478908946733e-23,1.0,"Yes",1.0,5.282632693836163e-21,"No",1.816768686259377e-18,1.0,"Yes",1.6137072095628733e-10,0.9999999998386215,"Yes",0.999999999999261,7.315369101946614e-13,"No",1.1040735373142456e-20,1.0,"Yes"
"2007-001452-39","Estudio multicéntrico aleatorizado doble-ciego de grupos paralelos controlado con tratamiento activo para evaluar la seguridad y eficacia a largo plazo del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactivaA Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symtpoms of Overactive Bladder","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.918217063979448e-120,1.9967580238002807e-23,1.0,"-1",1.0,1.47952084556504e-19,"No",1.9945464206395334e-18,1.0,"Yes",1.0,4.716389777386079e-22,"No",4.037723499497432e-18,1.0,"Yes",4.6011334523399055e-11,0.9999999999540137,"Yes",1.0,4.566573998763965e-18,"No",2.733015483747387e-20,1.0,"Yes"
"2007-001452-39","Estudio multicéntrico aleatorizado doble-ciego de grupos paralelos controlado con tratamiento activo para evaluar la seguridad y eficacia a largo plazo del agonista beta-3 YM178 (50 mg una vez al día y 100 mg una vez al día) en pacientes con síntomas de vejiga hiperactivaA Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symtpoms of Overactive Bladder","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.918217063979448e-120,1.9967580238002807e-23,1.0,"-1",1.0,1.47952084556504e-19,"No",1.9945464206395334e-18,1.0,"Yes",1.0,4.716389777386079e-22,"No",4.037723499497432e-18,1.0,"Yes",4.6011334523399055e-11,0.9999999999540137,"Yes",1.0,4.566573998763965e-18,"No",2.733015483747387e-20,1.0,"Yes"
"2007-001452-39","A Randomized Double-Blind Parallel Group Active Controlled Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.562759054503884e-49,2.7496176870098656e-12,0.9999999999972431,"-1",0.9999999999992326,7.673787847958165e-13,"No",2.5951099931611363e-12,0.9999999999974137,"Yes",0.9999999999598401,4.0146222628591506e-11,"No",8.978725249280065e-10,0.9999999991021298,"Yes",7.087546899655686e-06,0.9999929124531013,"Yes",0.9999999629187933,3.708120845958857e-08,"No",5.718509405878691e-11,0.9999999999428155,"Yes"
"2007-001478-10","CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children adolescents and young adults","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.766999612838086e-37,7.553875801148683e-10,0.9999999992446079,"2+",7.110960789616985e-09,0.9999999928890305,"Yes",0.9999999897643762,1.0235631132360266e-08,"No",0.999999999998181,1.8191739497721425e-12,"No",1.0929723236174916e-07,0.9999998907027592,"Yes",0.9942401669121933,0.005759833087813246,"Yes",0.9999999991487698,8.512442306131086e-10,"No",5.049699828643796e-10,0.9999999994950315,"Yes"
"2007-001478-10","CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children adolescents and young adults","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.766999612838086e-37,7.553875801148683e-10,0.9999999992446079,"2+",7.110960789616985e-09,0.9999999928890305,"Yes",0.9999999897643762,1.0235631132360266e-08,"No",0.999999999998181,1.8191739497721425e-12,"No",1.0929723236174916e-07,0.9999998907027592,"Yes",0.9942401669121933,0.005759833087813246,"Yes",0.9999999991487698,8.512442306131086e-10,"No",5.049699828643796e-10,0.9999999994950315,"Yes"
"2007-001478-10","CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children adolescents and young adults","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.766999612838086e-37,7.553875801148683e-10,0.9999999992446079,"2+",7.110960789616985e-09,0.9999999928890305,"Yes",0.9999999897643762,1.0235631132360266e-08,"No",0.999999999998181,1.8191739497721425e-12,"No",1.0929723236174916e-07,0.9999998907027592,"Yes",0.9942401669121933,0.005759833087813246,"Yes",0.9999999991487698,8.512442306131086e-10,"No",5.049699828643796e-10,0.9999999994950315,"Yes"
"2007-001478-10","CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children adolescents and young adults","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.766999612838086e-37,7.553875801148683e-10,0.9999999992446079,"2+",7.110960789616985e-09,0.9999999928890305,"Yes",0.9999999897643762,1.0235631132360266e-08,"No",0.999999999998181,1.8191739497721425e-12,"No",1.0929723236174916e-07,0.9999998907027592,"Yes",0.9942401669121933,0.005759833087813246,"Yes",0.9999999991487698,8.512442306131086e-10,"No",5.049699828643796e-10,0.9999999994950315,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.043123035020798e-53,5.305609164789199e-10,0.999999999469452,"-1",0.9999999915048933,8.495104253603505e-09,"No",8.033895650868856e-08,0.9999999196610394,"Yes",0.9999994325731526,5.674268384274192e-07,"No",1.1962398630770533e-09,0.9999999988037587,"Yes",0.03257238261698464,0.9674276173830241,"Yes",0.9711368215400461,0.028863178459950883,"No",4.698993369609551e-10,0.9999999995301039,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy andSafety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistantProstate Cancer and Bone Metastasis who are Pain Free or MildlySymptomatic","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.113006823142251e-48,6.677612886297784e-10,0.9999999993322319,"-1",0.9999999910002374,8.99976472644453e-09,"No",9.307489370765406e-08,0.999999906925102,"Yes",0.9999957184573275,4.281542666987119e-06,"No",2.7198356830020156e-09,0.9999999972801704,"Yes",0.028552763078554373,0.9714472369214495,"Yes",0.9959150574966085,0.0040849425033979,"No",1.422491611824609e-09,0.9999999985775077,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy andSafety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistantProstate Cancer and Bone Metastasis who are Pain Free or MildlySymptomatic","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.113006823142251e-48,6.677612886297784e-10,0.9999999993322319,"-1",0.9999999910002374,8.99976472644453e-09,"No",9.307489370765406e-08,0.999999906925102,"Yes",0.9999957184573275,4.281542666987119e-06,"No",2.7198356830020156e-09,0.9999999972801704,"Yes",0.028552763078554373,0.9714472369214495,"Yes",0.9959150574966085,0.0040849425033979,"No",1.422491611824609e-09,0.9999999985775077,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy andSafety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistantProstate Cancer and Bone Metastasis who are Pain Free or MildlySymptomatic","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.113006823142251e-48,6.677612886297784e-10,0.9999999993322319,"-1",0.9999999910002374,8.99976472644453e-09,"No",9.307489370765406e-08,0.999999906925102,"Yes",0.9999957184573275,4.281542666987119e-06,"No",2.7198356830020156e-09,0.9999999972801704,"Yes",0.028552763078554373,0.9714472369214495,"Yes",0.9959150574966085,0.0040849425033979,"No",1.422491611824609e-09,0.9999999985775077,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy andSafety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistantProstate Cancer and Bone Metastasis who are Pain Free or MildlySymptomatic","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.113006823142251e-48,6.677612886297784e-10,0.9999999993322319,"-1",0.9999999910002374,8.99976472644453e-09,"No",9.307489370765406e-08,0.999999906925102,"Yes",0.9999957184573275,4.281542666987119e-06,"No",2.7198356830020156e-09,0.9999999972801704,"Yes",0.028552763078554373,0.9714472369214495,"Yes",0.9959150574966085,0.0040849425033979,"No",1.422491611824609e-09,0.9999999985775077,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy andSafety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistantProstate Cancer and Bone Metastasis who are Pain Free or MildlySymptomatic","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.113006823142251e-48,6.677612886297784e-10,0.9999999993322319,"-1",0.9999999910002374,8.99976472644453e-09,"No",9.307489370765406e-08,0.999999906925102,"Yes",0.9999957184573275,4.281542666987119e-06,"No",2.7198356830020156e-09,0.9999999972801704,"Yes",0.028552763078554373,0.9714472369214495,"Yes",0.9959150574966085,0.0040849425033979,"No",1.422491611824609e-09,0.9999999985775077,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.043123035020798e-53,5.305609164789199e-10,0.999999999469452,"-1",0.9999999915048933,8.495104253603505e-09,"No",8.033895650868856e-08,0.9999999196610394,"Yes",0.9999994325731526,5.674268384274192e-07,"No",1.1962398630770533e-09,0.9999999988037587,"Yes",0.03257238261698464,0.9674276173830241,"Yes",0.9711368215400461,0.028863178459950883,"No",4.698993369609551e-10,0.9999999995301039,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.043123035020798e-53,5.305609164789199e-10,0.999999999469452,"-1",0.9999999915048933,8.495104253603505e-09,"No",8.033895650868856e-08,0.9999999196610394,"Yes",0.9999994325731526,5.674268384274192e-07,"No",1.1962398630770533e-09,0.9999999988037587,"Yes",0.03257238261698464,0.9674276173830241,"Yes",0.9711368215400461,0.028863178459950883,"No",4.698993369609551e-10,0.9999999995301039,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy andSafety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistantProstate Cancer and Bone Metastasis who are Pain Free or MildlySymptomatic","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.113006823142251e-48,6.677612886297784e-10,0.9999999993322319,"-1",0.9999999910002374,8.99976472644453e-09,"No",9.307489370765406e-08,0.999999906925102,"Yes",0.9999957184573275,4.281542666987119e-06,"No",2.7198356830020156e-09,0.9999999972801704,"Yes",0.028552763078554373,0.9714472369214495,"Yes",0.9959150574966085,0.0040849425033979,"No",1.422491611824609e-09,0.9999999985775077,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.043123035020798e-53,5.305609164789199e-10,0.999999999469452,"-1",0.9999999915048933,8.495104253603505e-09,"No",8.033895650868856e-08,0.9999999196610394,"Yes",0.9999994325731526,5.674268384274192e-07,"No",1.1962398630770533e-09,0.9999999988037587,"Yes",0.03257238261698464,0.9674276173830241,"Yes",0.9711368215400461,0.028863178459950883,"No",4.698993369609551e-10,0.9999999995301039,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy andSafety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistantProstate Cancer and Bone Metastasis who are Pain Free or MildlySymptomatic","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.113006823142251e-48,6.677612886297784e-10,0.9999999993322319,"-1",0.9999999910002374,8.99976472644453e-09,"No",9.307489370765406e-08,0.999999906925102,"Yes",0.9999957184573275,4.281542666987119e-06,"No",2.7198356830020156e-09,0.9999999972801704,"Yes",0.028552763078554373,0.9714472369214495,"Yes",0.9959150574966085,0.0040849425033979,"No",1.422491611824609e-09,0.9999999985775077,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy andSafety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistantProstate Cancer and Bone Metastasis who are Pain Free or MildlySymptomatic","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.113006823142251e-48,6.677612886297784e-10,0.9999999993322319,"-1",0.9999999910002374,8.99976472644453e-09,"No",9.307489370765406e-08,0.999999906925102,"Yes",0.9999957184573275,4.281542666987119e-06,"No",2.7198356830020156e-09,0.9999999972801704,"Yes",0.028552763078554373,0.9714472369214495,"Yes",0.9959150574966085,0.0040849425033979,"No",1.422491611824609e-09,0.9999999985775077,"Yes"
"2007-003227-20","A Phase III Randomised Double-blind Study to Assess the Efficacy andSafety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistantProstate Cancer and Bone Metastasis who are Pain Free or MildlySymptomatic","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.113006823142251e-48,6.677612886297784e-10,0.9999999993322319,"-1",0.9999999910002374,8.99976472644453e-09,"No",9.307489370765406e-08,0.999999906925102,"Yes",0.9999957184573275,4.281542666987119e-06,"No",2.7198356830020156e-09,0.9999999972801704,"Yes",0.028552763078554373,0.9714472369214495,"Yes",0.9959150574966085,0.0040849425033979,"No",1.422491611824609e-09,0.9999999985775077,"Yes"
"2007-003710-34","EFFECT OF BROMOCRIPTINE ON LEFT VENTRICULAR FUNCTION IN WOMEN WITH PERIPARTUM CARDIOMYOPATHY ","DE","Yes","Yes","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1268114907715946e-11,2.0107683641927786e-05,0.9999798922950934,"2+",0.9994195572961247,0.0005804427038773755,"Yes",0.0012706760417680303,0.9987293239582313,"No",0.2739811694059469,0.7260188305940548,"No",0.0001882434840976904,0.9998117565159057,"Yes",0.08313114449987433,0.9168688555001286,"Yes",0.9987286305083511,0.0012713694916476814,"No",0.000383849641689112,0.9996161503583088,"Yes"
"2007-003793-26","Estudio de fase 3b aleatorizado y abierto de bevacizumab (Avastin®) + temsirolimus (Torisel®) frente a bevacizumab (Avastin®) + interferón alfa (Roferon®) como tratamiento de primera línea en pacientes con carcinoma de células renales avanzadoPhase 3b Randomized Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus(Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-LineTreatment in Subjects With Advanced Renal Cell Carcinoma","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.673743355226699e-66,6.414511383145616e-11,0.9999999999358806,"-1",4.889685826333356e-10,0.999999999511033,"Yes",0.9999999984748911,1.5251083291144408e-09,"No",1.0,2.0407150058058612e-38,"No",9.842389796504181e-12,0.9999999999901661,"Yes",0.0028297467425107536,0.9971702532574992,"Yes",1.0,2.528720731362121e-35,"No",2.6044175822567354e-13,0.9999999999997159,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab + Temsirolimusvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma","SK","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.171544888498196e-28,0.5904998320616527,0.409500167938351,"-1",3.069538742023516e-06,0.9999969304612579,"Yes",0.9999953792524001,4.620747599204519e-06,"No",1.0,5.61709754710415e-16,"No",0.9183350330660854,0.08166496693391594,"Yes",0.8237086939206567,0.17629130607933763,"Yes",0.9999999994761738,5.23822054036806e-10,"No",0.5203476777035062,0.4796523222964893,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab + Temsirolimusvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects WithAdvanced Renal Cell Carcinoma","ES","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.8189516975983076e-25,0.19383045021347614,0.8061695497865288,"-1",3.656597787044309e-05,0.9999634340221227,"Yes",0.9999447429712487,5.525702875627718e-05,"No",1.0,5.759962247885549e-15,"No",0.535196673655158,0.46480332634484534,"Yes",0.4495013649573978,0.5504986350425963,"Yes",0.9999999998107256,1.8928129113213486e-10,"No",0.11084294255449989,0.8891570574454942,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab + Temsirolimusvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects WithAdvanced Renal Cell Carcinoma","BE","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.8189516975983076e-25,0.19383045021347614,0.8061695497865288,"-1",3.656597787044309e-05,0.9999634340221227,"Yes",0.9999447429712487,5.525702875627718e-05,"No",1.0,5.759962247885549e-15,"No",0.535196673655158,0.46480332634484534,"Yes",0.4495013649573978,0.5504986350425963,"Yes",0.9999999998107256,1.8928129113213486e-10,"No",0.11084294255449989,0.8891570574454942,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab + Temsirolimusvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects WithAdvanced Renal Cell Carcinoma","NL","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.8189516975983076e-25,0.19383045021347614,0.8061695497865288,"-1",3.656597787044309e-05,0.9999634340221227,"Yes",0.9999447429712487,5.525702875627718e-05,"No",1.0,5.759962247885549e-15,"No",0.535196673655158,0.46480332634484534,"Yes",0.4495013649573978,0.5504986350425963,"Yes",0.9999999998107256,1.8928129113213486e-10,"No",0.11084294255449989,0.8891570574454942,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab (Avastin) + Temsirolimus (Torisel) vs. Bevacizumab (Avastin) + Interferon-alfa (Roferon) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.204978802489377e-33,2.1159948608813593e-05,0.9999788400513949,"-1",1.0262179035564957e-05,0.9999897378209734,"Yes",0.9999785990076016,2.1400992405237403e-05,"No",1.0,1.3932628697430793e-20,"No",3.424323747139313e-05,0.9999657567625223,"Yes",0.09770311115817466,0.9022968888418293,"Yes",0.9999999999999432,5.352466576000806e-14,"No",3.5268616475866702e-06,0.9999964731383622,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab + Temsirolimusvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma","IT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.171544888498196e-28,0.5904998320616527,0.409500167938351,"-1",3.069538742023516e-06,0.9999969304612579,"Yes",0.9999953792524001,4.620747599204519e-06,"No",1.0,5.61709754710415e-16,"No",0.9183350330660854,0.08166496693391594,"Yes",0.8237086939206567,0.17629130607933763,"Yes",0.9999999994761738,5.23822054036806e-10,"No",0.5203476777035062,0.4796523222964893,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus(Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-LineTreatment in Subjects With Advanced Renal Cell Carcinoma","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0072648281328405e-31,8.998959063858894e-06,0.9999910010409294,"-1",1.1487918332010498e-05,0.9999885120816628,"Yes",0.9999765355032396,2.3464496763908726e-05,"No",1.0,7.939591998623876e-20,"No",7.031030368698665e-06,0.9999929689696411,"Yes",0.20388205892091446,0.7961179410790953,"Yes",0.9999999999999432,5.119796982103503e-14,"No",8.375599718320802e-07,0.9999991624400293,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab (Avastin) + Temsirolimus (Torisel) vs. Bevacizumab (Avastin) + Interferon-alfa (Roferon) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.204978802489377e-33,2.1159948608813593e-05,0.9999788400513949,"-1",1.0262179035564957e-05,0.9999897378209734,"Yes",0.9999785990076016,2.1400992405237403e-05,"No",1.0,1.3932628697430793e-20,"No",3.424323747139313e-05,0.9999657567625223,"Yes",0.09770311115817466,0.9022968888418293,"Yes",0.9999999999999432,5.352466576000806e-14,"No",3.5268616475866702e-06,0.9999964731383622,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab + Temsirolimusvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma","DE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.171544888498196e-28,0.5904998320616527,0.409500167938351,"-1",3.069538742023516e-06,0.9999969304612579,"Yes",0.9999953792524001,4.620747599204519e-06,"No",1.0,5.61709754710415e-16,"No",0.9183350330660854,0.08166496693391594,"Yes",0.8237086939206567,0.17629130607933763,"Yes",0.9999999994761738,5.23822054036806e-10,"No",0.5203476777035062,0.4796523222964893,"Yes"
"2007-003793-26","Phase 3b Randomized Open-Label Study of Bevacizumab (Avastin) + Temsirolimus (Torisel) vs. Bevacizumab (Avastin) + Interferon-alfa (Roferon) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.204978802489377e-33,2.1159948608813593e-05,0.9999788400513949,"-1",1.0262179035564957e-05,0.9999897378209734,"Yes",0.9999785990076016,2.1400992405237403e-05,"No",1.0,1.3932628697430793e-20,"No",3.424323747139313e-05,0.9999657567625223,"Yes",0.09770311115817466,0.9022968888418293,"Yes",0.9999999999999432,5.352466576000806e-14,"No",3.5268616475866702e-06,0.9999964731383622,"Yes"
"2007-004126-24","A placebo controlled randomized 12-week dose-ranging double-blind study versus placebo using tolterodine as a study calibrator to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.757457122588325e-50,1.2851155029282382e-16,1.0,"-1",1.0,1.0986108921130219e-16,"No",1.0964492992805015e-15,1.0,"Yes",0.9999999992364508,7.635579484675846e-10,"No",2.7034700448254845e-12,0.9999999999972999,"Yes",5.835656376200167e-08,0.9999999416434395,"Yes",0.9999999999999717,4.054868528506595e-14,"No",1.6831735547425448e-15,1.0,"Yes"
"2007-004126-24","A placebo controlled randomized 12-week dose-ranging double-blind study versus placebo using tolterodine as a study calibrator to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.757457122588325e-50,1.2851155029282382e-16,1.0,"-1",1.0,1.0986108921130219e-16,"No",1.0964492992805015e-15,1.0,"Yes",0.9999999992364508,7.635579484675846e-10,"No",2.7034700448254845e-12,0.9999999999972999,"Yes",5.835656376200167e-08,0.9999999416434395,"Yes",0.9999999999999717,4.054868528506595e-14,"No",1.6831735547425448e-15,1.0,"Yes"
"2007-004126-24","A placebo controlled randomized 12-week dose-ranging double-blind study versus placebo using tolterodine as a study calibrator to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.757457122588325e-50,1.2851155029282382e-16,1.0,"-1",1.0,1.0986108921130219e-16,"No",1.0964492992805015e-15,1.0,"Yes",0.9999999992364508,7.635579484675846e-10,"No",2.7034700448254845e-12,0.9999999999972999,"Yes",5.835656376200167e-08,0.9999999416434395,"Yes",0.9999999999999717,4.054868528506595e-14,"No",1.6831735547425448e-15,1.0,"Yes"
"2007-004126-24","A placebo controlled randomized 12-week dose-ranging double-blind study versus placebo using tolterodine as a study calibrator to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.757457122588325e-50,1.2851155029282382e-16,1.0,"-1",1.0,1.0986108921130219e-16,"No",1.0964492992805015e-15,1.0,"Yes",0.9999999992364508,7.635579484675846e-10,"No",2.7034700448254845e-12,0.9999999999972999,"Yes",5.835656376200167e-08,0.9999999416434395,"Yes",0.9999999999999717,4.054868528506595e-14,"No",1.6831735547425448e-15,1.0,"Yes"
"2007-004126-24","A placebo controlled randomized 12-week dose-ranging double-blind study versus placebo using tolterodine as a study calibrator to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.757457122588325e-50,1.2851155029282382e-16,1.0,"-1",1.0,1.0986108921130219e-16,"No",1.0964492992805015e-15,1.0,"Yes",0.9999999992364508,7.635579484675846e-10,"No",2.7034700448254845e-12,0.9999999999972999,"Yes",5.835656376200167e-08,0.9999999416434395,"Yes",0.9999999999999717,4.054868528506595e-14,"No",1.6831735547425448e-15,1.0,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","SK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004344-78","Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter open-label controlled Phase III study testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy followed by temozolomide maintenance therapy) versus standard treatment alone.","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.873317417000512e-47,2.50662339602316e-06,0.9999974933765979,"-1",5.01685219707548e-12,0.9999999999949694,"Yes",0.9999999999923261,7.66785336342999e-12,"No",1.0,4.625935935355833e-18,"No",1.3476025777206392e-09,0.9999999986523848,"Yes",0.028102162315240625,0.9718978376847551,"Yes",1.0,5.3611227351522435e-21,"No",9.389337220398747e-06,0.9999906106627899,"Yes"
"2007-004517-34","Allogeneic stem cell transplantation for children adolescents and young adults with relapsed or refractory AMLMulti Center Therapy Concept","DE","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",7.077323411725696e-31,0.9971521607044823,0.002847839295515668,"2+",6.385293016509462e-05,0.999936147069842,"Yes",0.9999525050507199,4.7494949285121115e-05,"No",0.9999983205121517,1.679487854523886e-06,"No",0.9988896562878039,0.0011103437122026024,"Yes",0.9964938776394403,0.0035061223605548017,"Yes",0.10706438067527378,0.8929356193247292,"No",0.9997184590457336,0.00028154095426177294,"No"
"2007-004517-34","Allogeneic stem cell transplantation for children adolescents and young adults with relapsed or refractory AMLMulti Center Therapy Concept","CZ","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",7.077323411725696e-31,0.9971521607044823,0.002847839295515668,"2+",6.385293016509462e-05,0.999936147069842,"Yes",0.9999525050507199,4.7494949285121115e-05,"No",0.9999983205121517,1.679487854523886e-06,"No",0.9988896562878039,0.0011103437122026024,"Yes",0.9964938776394403,0.0035061223605548017,"Yes",0.10706438067527378,0.8929356193247292,"No",0.9997184590457336,0.00028154095426177294,"No"
"2007-004517-34","Allogeneic stem cell transplantation for children adolescents and young adults with relapsed or refractory AML","AT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.4599610101477844e-25,0.9986471779477021,0.0013528220522963717,"2+",2.7606493480006477e-06,0.9999972393506503,"Yes",0.9999977542580532,2.2457419488415836e-06,"No",0.9999969731345624,3.026865444114246e-06,"No",0.9988326523995603,0.0011673476004450886,"Yes",0.9987160681142888,0.0012839318857090186,"Yes",0.9633631903476316,0.036636809652371434,"No",0.999933595618072,6.640438192709993e-05,"No"
"2007-004803-36","Sperimentazione multicentrica randomizzata di fase III in doppio cieco per la valutazione dellefficacia e della sicurezza del BIBF 1120 orale associato a terapia standard con docetaxel rispetto al placebo associato a terapia standard con docetaxel nei pazienti affetti da cancro del polmone a cellule non piccole in stadio IIIB/IV o recidivo dopo il fallimento della chemioterapia di prima linea","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3062697067636155e-91,0.00013096205806614506,0.9998690379419201,"-1",5.487266533390645e-09,0.9999999945127344,"Yes",0.9999999884849445,1.1515058168357868e-08,"No",1.0,4.6967896826378505e-32,"No",0.010746118782253075,0.9892538812177243,"Yes",0.9875488471688091,0.012451152831172369,"Yes",1.0,1.0883201212968289e-26,"No",0.01993814938531461,0.9800618506146767,"Yes"
"2007-004803-36","Sperimentazione multicentrica randomizzata di fase III in doppio cieco per la valutazione dellefficacia e della sicurezza del BIBF 1120 orale associato a terapia standard con docetaxel rispetto al placebo associato a terapia standard con docetaxel nei pazienti affetti da cancro del polmone a cellule non piccole in stadio IIIB/IV o recidivo dopo il fallimento della chemioterapia di prima linea","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3062697067636155e-91,0.00013096205806614506,0.9998690379419201,"-1",5.487266533390645e-09,0.9999999945127344,"No",0.9999999884849445,1.1515058168357868e-08,"Yes",1.0,4.6967896826378505e-32,"No",0.010746118782253075,0.9892538812177243,"Yes",0.9875488471688091,0.012451152831172369,"Yes",1.0,1.0883201212968289e-26,"No",0.01993814938531461,0.9800618506146767,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy","BG","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2676881379946765e-88,6.114842887781237e-13,0.9999999999993748,"-1",0.5435547801681598,0.4564452198318331,"No",0.6569627005358373,0.343037299464159,"Yes",1.0,3.7138066650201474e-21,"No",4.81945249879924e-08,0.9999999518054791,"Yes",0.15524349205543606,0.84475650794456,"Yes",0.9999999999988917,1.1139773334500528e-12,"No",5.113512301054688e-10,0.9999999994886367,"Yes"
"2007-004803-36","Sperimentazione multicentrica randomizzata di fase III in doppio cieco per la valutazione dellefficacia e della sicurezza del BIBF 1120 orale associato a terapia standard con docetaxel rispetto al placebo associato a terapia standard con docetaxel nei pazienti affetti da cancro del polmone a cellule non piccole in stadio IIIB/IV o recidivo dopo il fallimento della chemioterapia di prima linea","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3062697067636155e-91,0.00013096205806614506,0.9998690379419201,"-1",5.487266533390645e-09,0.9999999945127344,"No",0.9999999884849445,1.1515058168357868e-08,"Yes",1.0,4.6967896826378505e-32,"No",0.010746118782253075,0.9892538812177243,"Yes",0.9875488471688091,0.012451152831172369,"Yes",1.0,1.0883201212968289e-26,"No",0.01993814938531461,0.9800618506146767,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate theefficacy and safety of oral BIBF 1120 plus standard docetaxel therapycompared to placebo plus standard docetaxel therapy in patients withstage IIIB/IV or recurrent non small cell lung cancer after failure of firstline chemotherapy.Estudio en Fase III multicéntrico randomizado doble-ciego  para investigar la eficacia y seguridad de la administración oral de BIBF 1120 junto con Docetaxel como terapia estándar comparado con placebo junto con Docetaxel como terapia estándar en pacientes con cáncer de pulmón no microcítico en estadío IIIB/IV o recurrente después del fracaso de la quimioterapia de primera línea.","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.568162255075783e-159,1.2830358980416494e-21,1.0,"-1",1.3148751517522788e-06,0.99999868512482,"No",0.9999999018001566,9.819985972199323e-08,"Yes",1.0,4.755858823867753e-45,"No",6.74807582792804e-09,0.9999999932518905,"Yes",0.998493907453373,0.0015060925466830984,"Yes",1.0,3.230233735834325e-45,"No",5.218786007524758e-15,1.0,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy","BE","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2676881379946765e-88,6.114842887781237e-13,0.9999999999993748,"-1",0.5435547801681598,0.4564452198318331,"No",0.6569627005358373,0.343037299464159,"Yes",1.0,3.7138066650201474e-21,"No",4.81945249879924e-08,0.9999999518054791,"Yes",0.15524349205543606,0.84475650794456,"Yes",0.9999999999988917,1.1139773334500528e-12,"No",5.113512301054688e-10,0.9999999994886367,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate theefficacy and safety of oral BIBF 1120 plus standard docetaxel therapycompared to placebo plus standard docetaxel therapy in patients withstage IIIB/IV or recurrent non small cell lung cancer after failure of firstline chemotherapy.Estudio en Fase III multicéntrico randomizado doble-ciego  para investigar la eficacia y seguridad de la administración oral de BIBF 1120 junto con Docetaxel como terapia estándar comparado con placebo junto con Docetaxel como terapia estándar en pacientes con cáncer de pulmón no microcítico en estadío IIIB/IV o recurrente después del fracaso de la quimioterapia de primera línea.","PT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.568162255075783e-159,1.2830358980416494e-21,1.0,"-1",1.3148751517522788e-06,0.99999868512482,"No",0.9999999018001566,9.819985972199323e-08,"Yes",1.0,4.755858823867753e-45,"No",6.74807582792804e-09,0.9999999932518905,"Yes",0.998493907453373,0.0015060925466830984,"Yes",1.0,3.230233735834325e-45,"No",5.218786007524758e-15,1.0,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate theefficacy and safety of oral BIBF 1120 plus standard docetaxel therapycompared to placebo plus standard docetaxel therapy in patients withstage IIIB/IV or recurrent non small cell lung cancer after failure of firstline chemotherapy.Estudio en Fase III multicéntrico randomizado doble-ciego  para investigar la eficacia y seguridad de la administración oral de BIBF 1120 junto con Docetaxel como terapia estándar comparado con placebo junto con Docetaxel como terapia estándar en pacientes con cáncer de pulmón no microcítico en estadío IIIB/IV o recurrente después del fracaso de la quimioterapia de primera línea.","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.568162255075783e-159,1.2830358980416494e-21,1.0,"-1",1.3148751517522788e-06,0.99999868512482,"Yes",0.9999999018001566,9.819985972199323e-08,"No",1.0,4.755858823867753e-45,"No",6.74807582792804e-09,0.9999999932518905,"Yes",0.998493907453373,0.0015060925466830984,"Yes",1.0,3.230233735834325e-45,"No",5.218786007524758e-15,1.0,"Yes"
"2007-004803-36","Sperimentazione multicentrica randomizzata di fase III in doppio cieco per la valutazione dellefficacia e della sicurezza del BIBF 1120 orale associato a terapia standard con docetaxel rispetto al placebo associato a terapia standard con docetaxel nei pazienti affetti da cancro del polmone a cellule non piccole in stadio IIIB/IV o recidivo dopo il fallimento della chemioterapia di prima linea","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3062697067636155e-91,0.00013096205806614506,0.9998690379419201,"-1",5.487266533390645e-09,0.9999999945127344,"No",0.9999999884849445,1.1515058168357868e-08,"Yes",1.0,4.6967896826378505e-32,"No",0.010746118782253075,0.9892538812177243,"Yes",0.9875488471688091,0.012451152831172369,"Yes",1.0,1.0883201212968289e-26,"No",0.01993814938531461,0.9800618506146767,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients withstage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.5432258049168784e-86,8.06171419099493e-12,0.9999999999919282,"-1",0.1792656412803325,0.820734358719661,"No",0.9093197959508399,0.0906802040491695,"Yes",1.0,2.372117428869106e-21,"No",4.3769259490472683e-07,0.999999562307419,"Yes",0.6196023678601698,0.3803976321398194,"Yes",0.9999999999986642,1.3471584573047038e-12,"No",5.362955608700148e-09,0.9999999946370509,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate theefficacy and safety of oral BIBF 1120 plus standard docetaxel therapycompared to placebo plus standard docetaxel therapy in patients withstage IIIB/IV or recurrent non small cell lung cancer after failure of firstline chemotherapy.Estudio en Fase III multicéntrico randomizado doble-ciego  para investigar la eficacia y seguridad de la administración oral de BIBF 1120 junto con Docetaxel como terapia estándar comparado con placebo junto con Docetaxel como terapia estándar en pacientes con cáncer de pulmón no microcítico en estadío IIIB/IV o recurrente después del fracaso de la quimioterapia de primera línea.","LT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.568162255075783e-159,1.2830358980416494e-21,1.0,"-1",1.3148751517522788e-06,0.99999868512482,"No",0.9999999018001566,9.819985972199323e-08,"Yes",1.0,4.755858823867753e-45,"No",6.74807582792804e-09,0.9999999932518905,"Yes",0.998493907453373,0.0015060925466830984,"Yes",1.0,3.230233735834325e-45,"No",5.218786007524758e-15,1.0,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients withstage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.5432258049168784e-86,8.06171419099493e-12,0.9999999999919282,"-1",0.1792656412803325,0.820734358719661,"No",0.9093197959508399,0.0906802040491695,"Yes",1.0,2.372117428869106e-21,"No",4.3769259490472683e-07,0.999999562307419,"Yes",0.6196023678601698,0.3803976321398194,"Yes",0.9999999999986642,1.3471584573047038e-12,"No",5.362955608700148e-09,0.9999999946370509,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy","ES","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2676881379946765e-88,6.114842887781237e-13,0.9999999999993748,"-1",0.5435547801681598,0.4564452198318331,"No",0.6569627005358373,0.343037299464159,"Yes",1.0,3.7138066650201474e-21,"No",4.81945249879924e-08,0.9999999518054791,"Yes",0.15524349205543606,0.84475650794456,"Yes",0.9999999999988917,1.1139773334500528e-12,"No",5.113512301054688e-10,0.9999999994886367,"Yes"
"2007-004803-36","Multicentre randomised double-blind Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy","GR","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2676881379946765e-88,6.114842887781237e-13,0.9999999999993748,"-1",0.5435547801681598,0.4564452198318331,"No",0.6569627005358373,0.343037299464159,"Yes",1.0,3.7138066650201474e-21,"No",4.81945249879924e-08,0.9999999518054791,"Yes",0.15524349205543606,0.84475650794456,"Yes",0.9999999999988917,1.1139773334500528e-12,"No",5.113512301054688e-10,0.9999999994886367,"Yes"
"2007-005017-19","Open-label multi-center randomized two stage adaptive design study of the combination of bevacizumab with standard chemotherapy in minor patients with metastatic rhabdomyosarcoma non-rhabdomyosarcoma soft-tissue sarcoma or Ewing’s sarcoma/soft-tissue primitive neuroectodermal tumors.","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6611130240807995e-45,3.357744191962167e-12,0.9999999999966463,"-1",1.7365502124651606e-11,0.9999999999826343,"Yes",0.9999999999689635,3.104052729588711e-11,"No",1.0,2.2250383183415216e-15,"No",6.611107400072623e-07,0.9999993388892588,"Yes",0.999921452405932,7.854759405457096e-05,"Yes",0.9999331826939436,6.681730604389797e-05,"No",3.903428841351591e-09,0.9999999960965625,"Yes"
"2007-005017-19","Open-label multi-center randomized two stage adaptive design study of the combination of bevacizumab with standard chemotherapy in minor patients with metastatic rhabdomyosarcoma non-rhabdomyosarcoma soft-tissue sarcoma or Ewing’s sarcoma/soft-tissue primitive neuroectodermal tumors.","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6611130240807995e-45,3.357744191962167e-12,0.9999999999966463,"-1",1.7365502124651606e-11,0.9999999999826343,"Yes",0.9999999999689635,3.104052729588711e-11,"No",1.0,2.2250383183415216e-15,"No",6.611107400072623e-07,0.9999993388892588,"Yes",0.999921452405932,7.854759405457096e-05,"Yes",0.9999331826939436,6.681730604389797e-05,"No",3.903428841351591e-09,0.9999999960965625,"Yes"
"2007-005017-19","Open-label multi-center randomized phase II study evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma.","Outside EU/EEA","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3346132144722497e-42,5.585529396039805e-08,0.9999999441447204,"-1",1.1538628492298079e-08,0.9999999884613829,"Yes",0.9999999856240437,1.4375968540204693e-08,"No",0.9999999999998864,1.1158759204887494e-13,"No",9.54076026755005e-07,0.9999990459239716,"Yes",0.9910878924637674,0.008912107536242204,"Yes",0.9999975894584232,2.410541562879611e-06,"No",1.2546017953592023e-07,0.9999998745398181,"Yes"
"2007-005017-19","Open-label multi-center randomized two stage adaptive design study of the combination of bevacizumab with standard chemotherapy in minor patients with metastatic rhabdomyosarcoma non-rhabdomyosarcoma soft-tissue sarcoma or Ewing’s sarcoma/soft-tissue primitive neuroectodermal tumors.","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6611130240807995e-45,3.357744191962167e-12,0.9999999999966463,"-1",1.7365502124651606e-11,0.9999999999826343,"Yes",0.9999999999689635,3.104052729588711e-11,"No",1.0,2.2250383183415216e-15,"No",6.611107400072623e-07,0.9999993388892588,"Yes",0.999921452405932,7.854759405457096e-05,"Yes",0.9999331826939436,6.681730604389797e-05,"No",3.903428841351591e-09,0.9999999960965625,"Yes"
"2007-005017-19","Open-label multi-center randomized phase II study evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma.","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3346132144722497e-42,5.585529396039805e-08,0.9999999441447204,"-1",1.1538628492298079e-08,0.9999999884613829,"Yes",0.9999999856240437,1.4375968540204693e-08,"No",0.9999999999998864,1.1158759204887494e-13,"No",9.54076026755005e-07,0.9999990459239716,"Yes",0.9910878924637674,0.008912107536242204,"Yes",0.9999975894584232,2.410541562879611e-06,"No",1.2546017953592023e-07,0.9999998745398181,"Yes"
"2007-005017-19","Open-label multi-center randomized two stage adaptive design study of the combination of bevacizumab with standard chemotherapy in minor patients with metastatic rhabdomyosarcoma non-rhabdomyosarcoma soft-tissue sarcoma or Ewing’s sarcoma/soft-tissue primitive neuroectodermal tumors.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6611130240807995e-45,3.357744191962167e-12,0.9999999999966463,"-1",1.7365502124651606e-11,0.9999999999826343,"Yes",0.9999999999689635,3.104052729588711e-11,"No",1.0,2.2250383183415216e-15,"No",6.611107400072623e-07,0.9999993388892588,"Yes",0.999921452405932,7.854759405457096e-05,"Yes",0.9999331826939436,6.681730604389797e-05,"No",3.903428841351591e-09,0.9999999960965625,"Yes"
"2007-005017-19","Open-label multi-center randomized two stage adaptive design study of the combination of bevacizumab with standard chemotherapy in minor patients with metastatic rhabdomyosarcoma non-rhabdomyosarcoma soft-tissue sarcoma or Ewing’s sarcoma/soft-tissue primitive neuroectodermal tumors.","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6611130240807995e-45,3.357744191962167e-12,0.9999999999966463,"-1",1.7365502124651606e-11,0.9999999999826343,"Yes",0.9999999999689635,3.104052729588711e-11,"No",1.0,2.2250383183415216e-15,"No",6.611107400072623e-07,0.9999993388892588,"Yes",0.999921452405932,7.854759405457096e-05,"Yes",0.9999331826939436,6.681730604389797e-05,"No",3.903428841351591e-09,0.9999999960965625,"Yes"
"2007-005017-19","Open-label multi-center randomized two stage adaptive design study of the combination of bevacizumab with standard chemotherapy in minor patients with metastatic rhabdomyosarcoma non-rhabdomyosarcoma soft-tissue sarcoma or Ewing’s sarcoma/soft-tissue primitive neuroectodermal tumors.","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6611130240807995e-45,3.357744191962167e-12,0.9999999999966463,"-1",1.7365502124651606e-11,0.9999999999826343,"Yes",0.9999999999689635,3.104052729588711e-11,"No",1.0,2.2250383183415216e-15,"No",6.611107400072623e-07,0.9999993388892588,"Yes",0.999921452405932,7.854759405457096e-05,"Yes",0.9999331826939436,6.681730604389797e-05,"No",3.903428841351591e-09,0.9999999960965625,"Yes"
"2007-005017-19","Open-label multi-center randomized two stage adaptive design study of the combination of bevacizumab with standard chemotherapy in minor patients with metastatic rhabdomyosarcoma non-rhabdomyosarcoma soft-tissue sarcoma or Ewing’s sarcoma/soft-tissue primitive neuroectodermal tumors.","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6611130240807995e-45,3.357744191962167e-12,0.9999999999966463,"-1",1.7365502124651606e-11,0.9999999999826343,"Yes",0.9999999999689635,3.104052729588711e-11,"No",1.0,2.2250383183415216e-15,"No",6.611107400072623e-07,0.9999993388892588,"Yes",0.999921452405932,7.854759405457096e-05,"Yes",0.9999331826939436,6.681730604389797e-05,"No",3.903428841351591e-09,0.9999999960965625,"Yes"
"2007-005017-19","Open-label multi-center randomized phase II study evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma.","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3346132144722497e-42,5.585529396039805e-08,0.9999999441447204,"-1",1.1538628492298079e-08,0.9999999884613829,"Yes",0.9999999856240437,1.4375968540204693e-08,"No",0.9999999999998864,1.1158759204887494e-13,"No",9.54076026755005e-07,0.9999990459239716,"Yes",0.9910878924637674,0.008912107536242204,"Yes",0.9999975894584232,2.410541562879611e-06,"No",1.2546017953592023e-07,0.9999998745398181,"Yes"
"2007-005129-31","A randomized controlled open-label multi-centre parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs.","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.675084393992225e-46,1.0867686542663507e-11,0.9999999999891429,"-1",0.9995154869804863,0.0004845130195154477,"Yes",0.0012613422770854517,0.9987386577229105,"No",0.9999999986778789,1.3221333188351638e-09,"No",5.2235038810695015e-12,0.9999999999947704,"Yes",6.486480777212348e-07,0.9999993513519144,"Yes",0.9999999851261522,1.4873838956198217e-08,"No",4.305922617873667e-10,0.9999999995694111,"Yes"
"2007-005129-31","A randomized controlled open-label multi-centre parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs.","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.675084393992225e-46,1.0867686542663507e-11,0.9999999999891429,"-1",0.9995154869804863,0.0004845130195154477,"Yes",0.0012613422770854517,0.9987386577229105,"No",0.9999999986778789,1.3221333188351638e-09,"No",5.2235038810695015e-12,0.9999999999947704,"Yes",6.486480777212348e-07,0.9999993513519144,"Yes",0.9999999851261522,1.4873838956198217e-08,"No",4.305922617873667e-10,0.9999999995694111,"Yes"
"2007-005129-31","A randomized controlled open-label multi-centre parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.675084393992225e-46,1.0867686542663507e-11,0.9999999999891429,"-1",0.9995154869804863,0.0004845130195154477,"Yes",0.0012613422770854517,0.9987386577229105,"No",0.9999999986778789,1.3221333188351638e-09,"No",5.2235038810695015e-12,0.9999999999947704,"Yes",6.486480777212348e-07,0.9999993513519144,"Yes",0.9999999851261522,1.4873838956198217e-08,"No",4.305922617873667e-10,0.9999999995694111,"Yes"
"2007-005129-31","A randomized controlled open-label multi-centre parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.675084393992225e-46,1.0867686542663507e-11,0.9999999999891429,"-1",0.9995154869804863,0.0004845130195154477,"Yes",0.0012613422770854517,0.9987386577229105,"No",0.9999999986778789,1.3221333188351638e-09,"No",5.2235038810695015e-12,0.9999999999947704,"Yes",6.486480777212348e-07,0.9999993513519144,"Yes",0.9999999851261522,1.4873838956198217e-08,"No",4.305922617873667e-10,0.9999999995694111,"Yes"
"2007-005129-31","A randomized controlled open-label multi-centre parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.675084393992225e-46,1.0867686542663507e-11,0.9999999999891429,"-1",0.9995154869804863,0.0004845130195154477,"Yes",0.0012613422770854517,0.9987386577229105,"No",0.9999999986778789,1.3221333188351638e-09,"No",5.2235038810695015e-12,0.9999999999947704,"Yes",6.486480777212348e-07,0.9999993513519144,"Yes",0.9999999851261522,1.4873838956198217e-08,"No",4.305922617873667e-10,0.9999999995694111,"Yes"
"2007-005129-31","A randomized controlled open-label multi-centre parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.675084393992225e-46,1.0867686542663507e-11,0.9999999999891429,"-1",0.9995154869804863,0.0004845130195154477,"Yes",0.0012613422770854517,0.9987386577229105,"No",0.9999999986778789,1.3221333188351638e-09,"No",5.2235038810695015e-12,0.9999999999947704,"Yes",6.486480777212348e-07,0.9999993513519144,"Yes",0.9999999851261522,1.4873838956198217e-08,"No",4.305922617873667e-10,0.9999999995694111,"Yes"
"2007-005129-31","A randomized controlled open-label multi-centre parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs.","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.675084393992225e-46,1.0867686542663507e-11,0.9999999999891429,"-1",0.9995154869804863,0.0004845130195154477,"Yes",0.0012613422770854517,0.9987386577229105,"No",0.9999999986778789,1.3221333188351638e-09,"No",5.2235038810695015e-12,0.9999999999947704,"Yes",6.486480777212348e-07,0.9999993513519144,"Yes",0.9999999851261522,1.4873838956198217e-08,"No",4.305922617873667e-10,0.9999999995694111,"Yes"
"2007-005129-31","A randomized controlled open-label multi-centre parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.675084393992225e-46,1.0867686542663507e-11,0.9999999999891429,"-1",0.9995154869804863,0.0004845130195154477,"Yes",0.0012613422770854517,0.9987386577229105,"No",0.9999999986778789,1.3221333188351638e-09,"No",5.2235038810695015e-12,0.9999999999947704,"Yes",6.486480777212348e-07,0.9999993513519144,"Yes",0.9999999851261522,1.4873838956198217e-08,"No",4.305922617873667e-10,0.9999999995694111,"Yes"
"2007-005129-31","A randomized controlled open-label multi-centre parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA® or reference ESAs.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.675084393992225e-46,1.0867686542663507e-11,0.9999999999891429,"-1",0.9995154869804863,0.0004845130195154477,"Yes",0.0012613422770854517,0.9987386577229105,"No",0.9999999986778789,1.3221333188351638e-09,"No",5.2235038810695015e-12,0.9999999999947704,"Yes",6.486480777212348e-07,0.9999993513519144,"Yes",0.9999999851261522,1.4873838956198217e-08,"No",4.305922617873667e-10,0.9999999995694111,"Yes"
"2007-005365-35","Multicenter parallel controlled randimized single-blind clinical evaluation of new low sodium peritoneal dialysis solution on patients with hypertension treated with continuous ambulatory or automated peritoneal dialysis","SE","No","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",1.7960866477718377e-44,1.0342138580036417e-08,0.9999999896578516,"2+",0.9109236360858017,0.08907636391420783,"No",0.7562396763894755,0.24376032361053127,"No",0.7755572174923593,0.22444278250765148,"Yes",1.239267617291862e-07,0.999999876073226,"Yes",0.0012804144126081123,0.9987195855874048,"Yes",0.7266991295241585,0.27330087047584883,"No",1.9427926698463734e-06,0.9999980572073185,"Yes"
"2007-005365-35","Multicenter parallel controlled randomized single blind clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension treated with  continuous ambulatory or automated peritoneal dialysis. Multizentrische parallele kontrollierte randomisierte einfach verblindete klinische Prüfung einer neuen Lösung für die Peritonealdialyse mit niedrigem Natriumgehalt an Patienten mit Bluthochdruck die mit kontinuierlicher ambulanter oder automatisierter Peritonealdialyse behandelt werden  ","GB","No","Yes","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",8.219830391518725e-72,3.822053666677622e-14,0.9999999999999432,"2+",0.4205362786741428,0.5794637213258361,"No",0.9999895431151815,1.045688481444614e-05,"No",0.0007220134930816316,0.9992779865069281,"Yes",5.410568923198909e-14,0.9999999999999432,"Yes",0.9996606346365507,0.0003393653634679394,"Yes",1.7272765689295158e-05,0.9999827272343016,"No",2.2137446665254e-11,0.999999999977888,"Yes"
"2007-005365-35","Multicentric parallel controlled randomized single blind clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension treated with  continous ambulatory or automated peritoneal dialysis. ","DK","No","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",1.3753035395195496e-44,4.894441333283653e-09,0.9999999951055544,"2+",0.9315097733151685,0.06849022668481893,"No",0.690969188661555,0.3090308113384516,"No",0.7108266751693645,0.2891733248306359,"Yes",6.333859759247444e-08,0.9999999366613984,"Yes",0.001213556185100249,0.998786443814901,"Yes",0.500000517532595,0.49999948246739884,"No",4.246762190215143e-07,0.999999575323789,"Yes"
"2007-005365-35","Multicentric parallel controlled randomized single blind clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension treated with  continous ambulatory or automated peritoneal dialysis. ","DE","No","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",1.3753035395195496e-44,4.894441333283653e-09,0.9999999951055544,"2+",0.9315097733151685,0.06849022668481893,"No",0.690969188661555,0.3090308113384516,"No",0.7108266751693645,0.2891733248306359,"Yes",6.333859759247444e-08,0.9999999366613984,"Yes",0.001213556185100249,0.998786443814901,"Yes",0.500000517532595,0.49999948246739884,"No",4.246762190215143e-07,0.999999575323789,"Yes"
"2007-005365-35","Multicenter parallel controlled randimized single-blind clinical evaluation of new low sodium peritoneal dialysis solution on patients with hypertension treated with continuous ambulatory or automated peritoneal dialysis","FR","No","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",1.7960866477718377e-44,1.0342138580036417e-08,0.9999999896578516,"2+",0.9109236360858017,0.08907636391420783,"No",0.7562396763894755,0.24376032361053127,"No",0.7755572174923593,0.22444278250765148,"Yes",1.239267617291862e-07,0.999999876073226,"Yes",0.0012804144126081123,0.9987195855874048,"Yes",0.7266991295241585,0.27330087047584883,"No",1.9427926698463734e-06,0.9999980572073185,"Yes"
"2007-005376-13","A MULTICENTER FOUR ARM RANDOMIZED OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))","SE","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.902326483264779e-30,0.03330860128761171,0.9666913987123762,"-1",4.915385185115928e-09,0.9999999950846076,"Yes",0.9999999922499684,7.750019302783601e-09,"No",0.9999999999258762,7.413007327548435e-11,"No",0.5425404931445356,0.4574595068554558,"Yes",0.03662906003667049,0.9633709399633429,"Yes",0.9999999749330474,2.5066955828656307e-08,"No",0.24231166530213472,0.7576883346978757,"Yes"
"2007-005376-13","Estudio clínico multicéntrico aleatorizado y abierto con cuatro ramas de tratamiento para investigar la dosis óptima de una pauta inmunosupresora basada en Prograf® / Advagraf® en pacientes trasplantados renales. Protocolo del estudio fase IIIb de Advagraf® (FK506E (MR4))","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6619116300289225e-38,0.016485168000070622,0.983514831999919,"-1",6.509539445769826e-12,0.9999999999934914,"Yes",0.9999999999915019,8.499327748707027e-12,"No",0.9999999999999432,6.14909836677822e-14,"No",0.0021869726984076027,0.9978130273015892,"Yes",0.0009788771260038683,0.9990211228740065,"Yes",0.9999999999999147,9.246720444665986e-14,"No",0.006983386323572264,0.9930166136764333,"Yes"
"2007-005376-13","A MULTICENTER FOUR ARM RANDOMIZED OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))","PT","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.902326483264779e-30,0.03330860128761171,0.9666913987123762,"-1",4.915385185115928e-09,0.9999999950846076,"Yes",0.9999999922499684,7.750019302783601e-09,"No",0.9999999999258762,7.413007327548435e-11,"No",0.5425404931445356,0.4574595068554558,"Yes",0.03662906003667049,0.9633709399633429,"Yes",0.9999999749330474,2.5066955828656307e-08,"No",0.24231166530213472,0.7576883346978757,"Yes"
"2007-005376-13","A MULTICENTER FOUR ARM RANDOMIZED OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))","SK","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.902326483264779e-30,0.03330860128761171,0.9666913987123762,"-1",4.915385185115928e-09,0.9999999950846076,"Yes",0.9999999922499684,7.750019302783601e-09,"No",0.9999999999258762,7.413007327548435e-11,"No",0.5425404931445356,0.4574595068554558,"Yes",0.03662906003667049,0.9633709399633429,"Yes",0.9999999749330474,2.5066955828656307e-08,"No",0.24231166530213472,0.7576883346978757,"Yes"
"2007-005376-13","Estudio clínico multicéntrico aleatorizado y abierto con cuatro ramas de tratamiento para investigar la dosis óptima de una pauta inmunosupresora basada en Prograf® / Advagraf® en pacientes trasplantados renales. Protocolo del estudio fase IIIb de Advagraf® (FK506E (MR4))","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6619116300289225e-38,0.016485168000070622,0.983514831999919,"-1",6.509539445769826e-12,0.9999999999934914,"Yes",0.9999999999915019,8.499327748707027e-12,"No",0.9999999999999432,6.14909836677822e-14,"No",0.0021869726984076027,0.9978130273015892,"Yes",0.0009788771260038683,0.9990211228740065,"Yes",0.9999999999999147,9.246720444665986e-14,"No",0.006983386323572264,0.9930166136764333,"Yes"
"2007-005376-13","A MULTICENTER FOUR ARM RANDOMIZED OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))","CZ","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.902326483264779e-30,0.03330860128761171,0.9666913987123762,"-1",4.915385185115928e-09,0.9999999950846076,"Yes",0.9999999922499684,7.750019302783601e-09,"No",0.9999999999258762,7.413007327548435e-11,"No",0.5425404931445356,0.4574595068554558,"Yes",0.03662906003667049,0.9633709399633429,"Yes",0.9999999749330474,2.5066955828656307e-08,"No",0.24231166530213472,0.7576883346978757,"Yes"
"2007-005376-13","Estudio clínico multicéntrico aleatorizado y abierto con cuatro ramas de tratamiento para investigar la dosis óptima de una pauta inmunosupresora basada en Prograf® / Advagraf® en pacientes trasplantados renales. Protocolo del estudio fase IIIb de Advagraf® (FK506E (MR4))","GR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6619116300289225e-38,0.016485168000070622,0.983514831999919,"-1",6.509539445769826e-12,0.9999999999934914,"Yes",0.9999999999915019,8.499327748707027e-12,"No",0.9999999999999432,6.14909836677822e-14,"No",0.0021869726984076027,0.9978130273015892,"Yes",0.0009788771260038683,0.9990211228740065,"Yes",0.9999999999999147,9.246720444665986e-14,"No",0.006983386323572264,0.9930166136764333,"Yes"
"2007-005376-13","A MULTICENTER FOUR ARM RANDOMIZED OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))","DE","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.902326483264779e-30,0.03330860128761171,0.9666913987123762,"-1",4.915385185115928e-09,0.9999999950846076,"Yes",0.9999999922499684,7.750019302783601e-09,"No",0.9999999999258762,7.413007327548435e-11,"No",0.5425404931445356,0.4574595068554558,"Yes",0.03662906003667049,0.9633709399633429,"Yes",0.9999999749330474,2.5066955828656307e-08,"No",0.24231166530213472,0.7576883346978757,"Yes"
"2007-005376-13","A MULTICENTER FOUR ARM RANDOMIZED OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))","FR","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.902326483264779e-30,0.03330860128761171,0.9666913987123762,"-1",4.915385185115928e-09,0.9999999950846076,"Yes",0.9999999922499684,7.750019302783601e-09,"No",0.9999999999258762,7.413007327548435e-11,"No",0.5425404931445356,0.4574595068554558,"Yes",0.03662906003667049,0.9633709399633429,"Yes",0.9999999749330474,2.5066955828656307e-08,"No",0.24231166530213472,0.7576883346978757,"Yes"
"2007-005376-13","Estudio clínico multicéntrico aleatorizado y abierto con cuatro ramas de tratamiento para investigar la dosis óptima de una pauta inmunosupresora basada en Prograf® / Advagraf® en pacientes trasplantados renales. Protocolo del estudio fase IIIb de Advagraf® (FK506E (MR4))","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6619116300289225e-38,0.016485168000070622,0.983514831999919,"-1",6.509539445769826e-12,0.9999999999934914,"Yes",0.9999999999915019,8.499327748707027e-12,"No",0.9999999999999432,6.14909836677822e-14,"No",0.0021869726984076027,0.9978130273015892,"Yes",0.0009788771260038683,0.9990211228740065,"Yes",0.9999999999999147,9.246720444665986e-14,"No",0.006983386323572264,0.9930166136764333,"Yes"
"2007-005376-13","Estudio clínico multicéntrico aleatorizado y abierto con cuatro ramas de tratamiento para investigar la dosis óptima de una pauta inmunosupresora basada en Prograf® / Advagraf® en pacientes trasplantados renales. Protocolo del estudio fase IIIb de Advagraf® (FK506E (MR4))","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6619116300289225e-38,0.016485168000070622,0.983514831999919,"-1",6.509539445769826e-12,0.9999999999934914,"Yes",0.9999999999915019,8.499327748707027e-12,"No",0.9999999999999432,6.14909836677822e-14,"No",0.0021869726984076027,0.9978130273015892,"Yes",0.0009788771260038683,0.9990211228740065,"Yes",0.9999999999999147,9.246720444665986e-14,"No",0.006983386323572264,0.9930166136764333,"Yes"
"2007-005376-13","A MULTICENTER FOUR ARM RANDOMIZED OPEN LABEL  CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A  PROGRAF-/ ADVAGRAF-BASED   IMMUNOSUPPRESSIVE  REGIMEN IN KIDNEY TRANSPLANT SUBJECTS.  Protocol for Phase IIIb Study of Advagraf (FK506E (MR4))","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3066306152022075e-36,0.008148580071132294,0.991851419928863,"-1",1.8299370724324723e-12,0.999999999998181,"Yes",0.9999999999969305,3.056070589068619e-12,"No",0.9999999999999432,4.8483931717530276e-14,"No",0.13313527872887423,0.8668647212711144,"Yes",0.002766186254222486,0.9972338137457811,"Yes",0.9999999999758417,2.4156287772641056e-11,"No",0.07514738581267011,0.924852614187319,"Yes"
"2007-005376-13","A MULTICENTER FOUR ARM RANDOMIZED OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))","AT","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.902326483264779e-30,0.03330860128761171,0.9666913987123762,"-1",4.915385185115928e-09,0.9999999950846076,"Yes",0.9999999922499684,7.750019302783601e-09,"No",0.9999999999258762,7.413007327548435e-11,"No",0.5425404931445356,0.4574595068554558,"Yes",0.03662906003667049,0.9633709399633429,"Yes",0.9999999749330474,2.5066955828656307e-08,"No",0.24231166530213472,0.7576883346978757,"Yes"
"2007-005376-13","A MULTICENTER FOUR ARM RANDOMIZED OPEN LABEL  CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A  PROGRAF-/ ADVAGRAF-BASED   IMMUNOSUPPRESSIVE  REGIMEN IN KIDNEY TRANSPLANT SUBJECTS.  Protocol for Phase IIIb Study of Advagraf (FK506E (MR4))","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3066306152022075e-36,0.008148580071132294,0.991851419928863,"-1",1.8299370724324723e-12,0.999999999998181,"Yes",0.9999999999969305,3.056070589068619e-12,"No",0.9999999999999432,4.8483931717530276e-14,"No",0.13313527872887423,0.8668647212711144,"Yes",0.002766186254222486,0.9972338137457811,"Yes",0.9999999999758417,2.4156287772641056e-11,"No",0.07514738581267011,0.924852614187319,"Yes"
"2007-005376-13","Estudio clínico multicéntrico aleatorizado y abierto con cuatro ramas de tratamiento para investigar la dosis óptima de una pauta inmunosupresora basada en Prograf® / Advagraf® en pacientes trasplantados renales. Protocolo del estudio fase IIIb de Advagraf® (FK506E (MR4))","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6619116300289225e-38,0.016485168000070622,0.983514831999919,"-1",6.509539445769826e-12,0.9999999999934914,"Yes",0.9999999999915019,8.499327748707027e-12,"No",0.9999999999999432,6.14909836677822e-14,"No",0.0021869726984076027,0.9978130273015892,"Yes",0.0009788771260038683,0.9990211228740065,"Yes",0.9999999999999147,9.246720444665986e-14,"No",0.006983386323572264,0.9930166136764333,"Yes"
"2007-005684-10","An open Phase I/IIa trial to investigate the maximum tolerated dose safety efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatment","ES","No","No","Yes","ok","No","No","No","Yes","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.7999955450794686e-39,0.9306283991816758,0.069371600818329,"-1",0.000262522434025571,0.9997374775659867,"Yes",0.9997755939835408,0.00022440601646136945,"No",1.0,4.8616092758463314e-17,"No",0.1407142940566794,0.8592857059433344,"Yes",0.9451811065855119,0.05481889341447842,"Yes",0.9999999999354543,6.454897558556789e-11,"No",0.7582810427523787,0.24171895724762088,"Yes"
"2007-005684-10","An open Phase I/IIa trial to investigate the maximum tolerated dose safety efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatment","DE","No","No","Yes","ok","No","No","No","Yes","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.7999955450794686e-39,0.9306283991816758,0.069371600818329,"-1",0.000262522434025571,0.9997374775659867,"Yes",0.9997755939835408,0.00022440601646136945,"No",1.0,4.8616092758463314e-17,"No",0.1407142940566794,0.8592857059433344,"Yes",0.9451811065855119,0.05481889341447842,"Yes",0.9999999999354543,6.454897558556789e-11,"No",0.7582810427523787,0.24171895724762088,"Yes"
"2007-005684-10","An open Phase I/IIa trial to investigate the maximum tolerated dose safety efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatment","AT","No","No","Yes","ok","No","No","No","Yes","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.7999955450794686e-39,0.9306283991816758,0.069371600818329,"-1",0.000262522434025571,0.9997374775659867,"Yes",0.9997755939835408,0.00022440601646136945,"No",1.0,4.8616092758463314e-17,"No",0.1407142940566794,0.8592857059433344,"Yes",0.9451811065855119,0.05481889341447842,"Yes",0.9999999999354543,6.454897558556789e-11,"No",0.7582810427523787,0.24171895724762088,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006195-11","A double-blind randomised multiple dose Phase III multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9216614338674293e-41,1.4294750151186767e-06,0.9999985705249784,"-1",0.9999195207962823,8.047920371566693e-05,"No",0.0002280476685214779,0.9997719523314788,"Yes",0.9999996320657198,3.6793428182047535e-07,"No",1.4174822399110167e-05,0.9999858251775963,"Yes",0.20521294836792223,0.794787051632082,"Yes",0.9909488297554884,0.009051170244509537,"No",2.3146958386391245e-06,0.999997685304159,"Yes"
"2007-006263-68","RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT SAFETY AND EFFICACY OF SIX MONTHS DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTING – ISAR-SAFE","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.955224203298338e-52,2.7406131986702588e-18,1.0,"2+",0.18893279224782916,0.8110672077521838,"No",0.9906422566431473,0.009357743356861313,"Yes",0.9999984643441305,1.5356558581946413e-06,"No",6.361043081426778e-17,1.0,"Yes",1.4811591276224638e-08,0.9999999851883957,"Yes",0.9999999999476189,5.236733151095186e-11,"No",2.212954304810664e-17,1.0,"Yes"
"2007-006263-68","RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT SAFETY AND EFFICACY OF SIX MONTHS DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTING – ISAR-SAFE","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.955224203298338e-52,2.7406131986702588e-18,1.0,"2+",0.18893279224782916,0.8110672077521838,"No",0.9906422566431473,0.009357743356861313,"Yes",0.9999984643441305,1.5356558581946413e-06,"No",6.361043081426778e-17,1.0,"Yes",1.4811591276224638e-08,0.9999999851883957,"Yes",0.9999999999476189,5.236733151095186e-11,"No",2.212954304810664e-17,1.0,"Yes"
"2007-006263-68","RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT SAFETY AND EFFICACY OF SIX MONTHS DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTING – ISAR-SAFE","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.955224203298338e-52,2.7406131986702588e-18,1.0,"2+",0.18893279224782916,0.8110672077521838,"No",0.9906422566431473,0.009357743356861313,"Yes",0.9999984643441305,1.5356558581946413e-06,"No",6.361043081426778e-17,1.0,"Yes",1.4811591276224638e-08,0.9999999851883957,"Yes",0.9999999999476189,5.236733151095186e-11,"No",2.212954304810664e-17,1.0,"Yes"
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN®)in combination with low-dose interferon as first-line treatment ofnephrectomised patients with metastatic clear cell renal cell carcinoma","PT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.9635684165467102e-44,0.9715431977294752,0.02845680227051897,"-1",8.062267213828706e-08,0.9999999193773339,"Information not present in EudraCT",0.9999998970504915,1.0294950343045548e-07,"Information not present in EudraCT",1.0,1.529181803612512e-17,"Information not present in EudraCT",0.9869656030883263,0.013034396911683196,"No",0.9913620283680148,0.008637971631983356,"",0.9999999996461213,3.5386470902479397e-10,"",0.9346269111576968,0.06537308884229152,""
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of  nephrectomised patients with metastatic clear cell renal cell carcinoma","GB","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4079516190904446e-44,0.9210076474872674,0.07899235251273808,"-1",3.11597012982031e-07,0.9999996884029858,"Information not present in EudraCT",0.9999995696567584,4.303432385450122e-07,"Information not present in EudraCT",1.0,3.846877266374949e-18,"Information not present in EudraCT",0.9500624510404659,0.049937548959533305,"No",0.972026433771267,0.02797356622872973,"",0.9999999999055547,9.443964292185737e-11,"",0.7818937814138283,0.21810621858616888,""
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcinoma","FI","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4079516190904446e-44,0.9210076474872674,0.07899235251273808,"-1",3.11597012982031e-07,0.9999996884029858,"Information not present in EudraCT",0.9999995696567584,4.303432385450122e-07,"Information not present in EudraCT",1.0,3.846877266374949e-18,"Information not present in EudraCT",0.9500624510404659,0.049937548959533305,"No",0.972026433771267,0.02797356622872973,"",0.9999999999055547,9.443964292185737e-11,"",0.7818937814138283,0.21810621858616888,""
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of  nephrectomised patients with metastatic clear cell renal cell carcinoma","EE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4079516190904446e-44,0.9210076474872674,0.07899235251273808,"-1",3.11597012982031e-07,0.9999996884029858,"Information not present in EudraCT",0.9999995696567584,4.303432385450122e-07,"Information not present in EudraCT",1.0,3.846877266374949e-18,"Information not present in EudraCT",0.9500624510404659,0.049937548959533305,"No",0.972026433771267,0.02797356622872973,"",0.9999999999055547,9.443964292185737e-11,"",0.7818937814138283,0.21810621858616888,""
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcinoma","NL","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4079516190904446e-44,0.9210076474872674,0.07899235251273808,"-1",3.11597012982031e-07,0.9999996884029858,"Information not present in EudraCT",0.9999995696567584,4.303432385450122e-07,"Information not present in EudraCT",1.0,3.846877266374949e-18,"Information not present in EudraCT",0.9500624510404659,0.049937548959533305,"No",0.972026433771267,0.02797356622872973,"",0.9999999999055547,9.443964292185737e-11,"",0.7818937814138283,0.21810621858616888,""
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of  nephrectomised patients with metastatic clear cell renal cell carcinoma","CZ","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4079516190904446e-44,0.9210076474872674,0.07899235251273808,"-1",3.11597012982031e-07,0.9999996884029858,"Information not present in EudraCT",0.9999995696567584,4.303432385450122e-07,"Information not present in EudraCT",1.0,3.846877266374949e-18,"Information not present in EudraCT",0.9500624510404659,0.049937548959533305,"No",0.972026433771267,0.02797356622872973,"",0.9999999999055547,9.443964292185737e-11,"",0.7818937814138283,0.21810621858616888,""
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of  nephrectomised patients with metastatic clear cell renal cell carcinoma","SE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4079516190904446e-44,0.9210076474872674,0.07899235251273808,"-1",3.11597012982031e-07,0.9999996884029858,"Information not present in EudraCT",0.9999995696567584,4.303432385450122e-07,"Information not present in EudraCT",1.0,3.846877266374949e-18,"Information not present in EudraCT",0.9500624510404659,0.049937548959533305,"No",0.972026433771267,0.02797356622872973,"",0.9999999999055547,9.443964292185737e-11,"",0.7818937814138283,0.21810621858616888,""
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of  nephrectomised patients with metastatic clear cell renal cell carcinoma","GR","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4079516190904446e-44,0.9210076474872674,0.07899235251273808,"-1",3.11597012982031e-07,0.9999996884029858,"Information not present in EudraCT",0.9999995696567584,4.303432385450122e-07,"Information not present in EudraCT",1.0,3.846877266374949e-18,"Information not present in EudraCT",0.9500624510404659,0.049937548959533305,"No",0.972026433771267,0.02797356622872973,"",0.9999999999055547,9.443964292185737e-11,"",0.7818937814138283,0.21810621858616888,""
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcinoma","DE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4079516190904446e-44,0.9210076474872674,0.07899235251273808,"-1",3.11597012982031e-07,0.9999996884029858,"Information not present in EudraCT",0.9999995696567584,4.303432385450122e-07,"Information not present in EudraCT",1.0,3.846877266374949e-18,"Information not present in EudraCT",0.9500624510404659,0.049937548959533305,"No",0.972026433771267,0.02797356622872973,"",0.9999999999055547,9.443964292185737e-11,"",0.7818937814138283,0.21810621858616888,""
"2007-006611-23","Open-label single-arm phase II study of bevacizumab (AVASTIN®)in combination with low-dose interferon as first-line treatment ofnephrectomised patients with metastatic clear cell renal cell carcinoma","LT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.9635684165467102e-44,0.9715431977294752,0.02845680227051897,"-1",8.062267213828706e-08,0.9999999193773339,"Information not present in EudraCT",0.9999998970504915,1.0294950343045548e-07,"Information not present in EudraCT",1.0,1.529181803612512e-17,"Information not present in EudraCT",0.9869656030883263,0.013034396911683196,"No",0.9913620283680148,0.008637971631983356,"",0.9999999996461213,3.5386470902479397e-10,"",0.9346269111576968,0.06537308884229152,""
"2007-007847-28","A multicenter randomized two-armed open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected monosomy 3 uveal melanoma","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.064154692214641e-41,0.004343721030710268,0.9956562789692966,"2+",1.5950644329614715e-11,0.9999999999840554,"Yes",0.9999999999906777,9.31093064539074e-12,"No",0.9999999999799911,2.001137866223281e-11,"No",0.05620153101847639,0.9437984689815188,"Yes",0.9993575645558584,0.0006424354441452689,"Yes",0.999999996995797,3.0041919268170254e-09,"No",7.993953614012318e-05,0.9999200604638605,"Yes"
"2008-000077-38","Estudio de fase II aleatorizado abierto y multicéntrico que compara el tratamiento con bevacizumab más RAD001 frente a interferón alfa-2a más bevacizumab en el tratamiento de primera línea de pacientes con carcinoma renal metastásico de células clarasA randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.46984943160078e-99,5.180427334882877e-05,0.9999481957266732,"-1",2.8136751255315125e-15,1.0,"Yes",1.0,6.9214032916647476e-15,"No",1.0,3.58186103017804e-37,"No",0.030464195650674295,0.9695358043493238,"Yes",0.9566595198513644,0.04334048014863911,"Yes",1.0,1.2192450237746621e-34,"No",3.649017044877623e-05,0.9999635098295454,"Yes"
"2008-000077-38","A randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney.","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0737174765693056e-50,0.015151756114046367,0.9848482438859674,"-1",8.563681199226908e-08,0.9999999143631764,"Yes",0.9999998434275436,1.565724618063896e-07,"No",1.0,4.422682990886286e-19,"No",0.19762243812404315,0.8023775618759557,"Yes",0.8222641916685609,0.17773580833143068,"Yes",0.9999999999982094,1.7995140456757651e-12,"No",0.03142059302238851,0.9685794069776156,"Yes"
"2008-000077-38","A randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0737174765693056e-50,0.015151756114046367,0.9848482438859674,"-1",8.563681199226908e-08,0.9999999143631764,"Yes",0.9999998434275436,1.565724618063896e-07,"No",1.0,4.422682990886286e-19,"No",0.19762243812404315,0.8023775618759557,"Yes",0.8222641916685609,0.17773580833143068,"Yes",0.9999999999982094,1.7995140456757651e-12,"No",0.03142059302238851,0.9685794069776156,"Yes"
"2008-000077-38","A randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-  2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.234135333018609e-53,0.002700159888067792,0.9972998401119353,"-1",7.818193621181634e-08,0.9999999218180764,"Yes",0.9999998544880775,1.4551193019495016e-07,"No",1.0,3.339849932295604e-19,"No",0.05348823496030054,0.9465117650397067,"Yes",0.7523527170761043,0.24764728292388916,"Yes",0.9999999999990052,9.970665011218745e-13,"No",0.00708423130707639,0.9929157686929136,"Yes"
"2008-000077-38","A randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney.","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0737174765693056e-50,0.015151756114046367,0.9848482438859674,"-1",8.563681199226908e-08,0.9999999143631764,"Yes",0.9999998434275436,1.565724618063896e-07,"No",1.0,4.422682990886286e-19,"No",0.19762243812404315,0.8023775618759557,"Yes",0.8222641916685609,0.17773580833143068,"Yes",0.9999999999982094,1.7995140456757651e-12,"No",0.03142059302238851,0.9685794069776156,"Yes"
"2008-000077-38","A randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney.","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0737174765693056e-50,0.015151756114046367,0.9848482438859674,"-1",8.563681199226908e-08,0.9999999143631764,"Yes",0.9999998434275436,1.565724618063896e-07,"No",1.0,4.422682990886286e-19,"No",0.19762243812404315,0.8023775618759557,"Yes",0.8222641916685609,0.17773580833143068,"Yes",0.9999999999982094,1.7995140456757651e-12,"No",0.03142059302238851,0.9685794069776156,"Yes"
"2008-000077-38","A randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0737174765693056e-50,0.015151756114046367,0.9848482438859674,"-1",8.563681199226908e-08,0.9999999143631764,"Yes",0.9999998434275436,1.565724618063896e-07,"No",1.0,4.422682990886286e-19,"No",0.19762243812404315,0.8023775618759557,"Yes",0.8222641916685609,0.17773580833143068,"Yes",0.9999999999982094,1.7995140456757651e-12,"No",0.03142059302238851,0.9685794069776156,"Yes"
"2008-000077-38","Estudio de fase II aleatorizado abierto y multicéntrico que compara el tratamiento con bevacizumab más RAD001 frente a interferón alfa-2a más bevacizumab en el tratamiento de primera línea de pacientes con carcinoma renal metastásico de células clarasA randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.46984943160078e-99,5.180427334882877e-05,0.9999481957266732,"-1",2.8136751255315125e-15,1.0,"Yes",1.0,6.9214032916647476e-15,"No",1.0,3.58186103017804e-37,"No",0.030464195650674295,0.9695358043493238,"Yes",0.9566595198513644,0.04334048014863911,"Yes",1.0,1.2192450237746621e-34,"No",3.649017044877623e-05,0.9999635098295454,"Yes"
"2008-000077-38","Estudio de fase II aleatorizado abierto y multicéntrico que compara el tratamiento con bevacizumab más RAD001 frente a interferón alfa-2a más bevacizumab en el tratamiento de primera línea de pacientes con carcinoma renal metastásico de células clarasA randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.46984943160078e-99,5.180427334882877e-05,0.9999481957266732,"-1",2.8136751255315125e-15,1.0,"Yes",1.0,6.9214032916647476e-15,"No",1.0,3.58186103017804e-37,"No",0.030464195650674295,0.9695358043493238,"Yes",0.9566595198513644,0.04334048014863911,"Yes",1.0,1.2192450237746621e-34,"No",3.649017044877623e-05,0.9999635098295454,"Yes"
"2008-000077-38","A randomized open label multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0737174765693056e-50,0.015151756114046367,0.9848482438859674,"-1",8.563681199226908e-08,0.9999999143631764,"Yes",0.9999998434275436,1.565724618063896e-07,"No",1.0,4.422682990886286e-19,"No",0.19762243812404315,0.8023775618759557,"Yes",0.8222641916685609,0.17773580833143068,"Yes",0.9999999999982094,1.7995140456757651e-12,"No",0.03142059302238851,0.9685794069776156,"Yes"
"2008-000107-28","A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)","GB","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.625366607628513e-33,0.8459489611189591,0.1540510388810345,"-1",0.013603510682923326,0.9863964893170774,"Information not present in EudraCT",0.9738509362202915,0.026149063779707528,"Information not present in EudraCT",1.0,2.266232950999172e-17,"Information not present in EudraCT",0.8771699924349738,0.12283000756502564,"No",0.9783567979691611,0.021643202030836726,"No",0.9994979722480628,0.0005020277519390498,"No",0.7704866510501777,0.2295133489498239,"No"
"2008-000107-28","A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)","FR","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.625366607628513e-33,0.8459489611189591,0.1540510388810345,"-1",0.013603510682923326,0.9863964893170774,"Information not present in EudraCT",0.9738509362202915,0.026149063779707528,"Information not present in EudraCT",1.0,2.266232950999172e-17,"Information not present in EudraCT",0.8771699924349738,0.12283000756502564,"No",0.9783567979691611,0.021643202030836726,"No",0.9994979722480628,0.0005020277519390498,"No",0.7704866510501777,0.2295133489498239,"No"
"2008-000498-40","A randomized double-blind placebo-controlled multicenter  phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximabchemotherapy","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.188614650196034e-71,3.0888747384413823e-06,0.9999969111252611,"-1",0.9874053176293021,0.012594682370703764,"No",0.20565627660117916,0.794343723398832,"Yes",1.0,1.2571389428993882e-22,"No",7.781368941220431e-05,0.9999221863105757,"Yes",0.912611241205665,0.08738875879432215,"Yes",1.0,1.5138104489916993e-16,"No",1.0041894945044766e-05,0.9999899581050614,"Yes"
"2008-000498-40","A randomized double-blind placebo-controlled multicenter  phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximabchemotherapy","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.188614650196034e-71,3.0888747384413823e-06,0.9999969111252611,"-1",0.9874053176293021,0.012594682370703764,"No",0.20565627660117916,0.794343723398832,"Yes",1.0,1.2571389428993882e-22,"No",7.781368941220431e-05,0.9999221863105757,"Yes",0.912611241205665,0.08738875879432215,"Yes",1.0,1.5138104489916993e-16,"No",1.0041894945044766e-05,0.9999899581050614,"Yes"
"2008-000498-40","A randomized double-blind placebo-controlled multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyRandomizované dvojitě zaslepené placebem kontrolované multicentrické klinické hodnocení fáze III u pacientů s difúzním velkobuněčným lymfomem z B buněk (DLBCL) se špatným prognostickým skóre kterým bude po dosažení kompletní léčebné odpovědi po chemoterapii první linie s rituximabem podávána adjuvantní terapie přípravkem RAD001 nebo placebem","SK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.181786676813841e-136,1.813965337024827e-21,1.0,"-1",0.9999996925593468,3.0744069109388246e-07,"No",2.7285845460531713e-06,0.9999972714154802,"Yes",1.0,5.597341501783314e-66,"No",5.0843233991409724e-20,1.0,"Yes",0.990674292847098,0.009325707152924252,"Yes",1.0,6.590898743297817e-46,"No",1.032595244631331e-16,1.0,"Yes"
"2008-000498-40","A randomized double-blind placebo-controlled multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyRandomizované dvojitě zaslepené placebem kontrolované multicentrické klinické hodnocení fáze III u pacientů s difúzním velkobuněčným lymfomem z B buněk (DLBCL) se špatným prognostickým skóre kterým bude po dosažení kompletní léčebné odpovědi po chemoterapii první linie s rituximabem podávána adjuvantní terapie přípravkem RAD001 nebo placebem","GR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.181786676813841e-136,1.813965337024827e-21,1.0,"-1",0.9999996925593468,3.0744069109388246e-07,"No",2.7285845460531713e-06,0.9999972714154802,"Yes",1.0,5.597341501783314e-66,"No",5.0843233991409724e-20,1.0,"Yes",0.990674292847098,0.009325707152924252,"Yes",1.0,6.590898743297817e-46,"No",1.032595244631331e-16,1.0,"Yes"
"2008-000498-40","A randomized double-blind placebo-controlled multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyRandomizované dvojitě zaslepené placebem kontrolované multicentrické klinické hodnocení fáze III u pacientů s difúzním velkobuněčným lymfomem z B buněk (DLBCL) se špatným prognostickým skóre kterým bude po dosažení kompletní léčebné odpovědi po chemoterapii první linie s rituximabem podávána adjuvantní terapie přípravkem RAD001 nebo placebem","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.181786676813841e-136,1.813965337024827e-21,1.0,"-1",0.9999996925593468,3.0744069109388246e-07,"No",2.7285845460531713e-06,0.9999972714154802,"Yes",1.0,5.597341501783314e-66,"No",5.0843233991409724e-20,1.0,"Yes",0.990674292847098,0.009325707152924252,"Yes",1.0,6.590898743297817e-46,"No",1.032595244631331e-16,1.0,"Yes"
"2008-000498-40","A randomized double-blind placebo-controlled multicenter  phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximabchemotherapy","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.188614650196034e-71,3.0888747384413823e-06,0.9999969111252611,"-1",0.9874053176293021,0.012594682370703764,"No",0.20565627660117916,0.794343723398832,"Yes",1.0,1.2571389428993882e-22,"No",7.781368941220431e-05,0.9999221863105757,"Yes",0.912611241205665,0.08738875879432215,"Yes",1.0,1.5138104489916993e-16,"No",1.0041894945044766e-05,0.9999899581050614,"Yes"
"2008-000498-40","A randomized double-blind placebo-controlled multicenter  phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximabchemotherapy","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.188614650196034e-71,3.0888747384413823e-06,0.9999969111252611,"-1",0.9874053176293021,0.012594682370703764,"No",0.20565627660117916,0.794343723398832,"Yes",1.0,1.2571389428993882e-22,"No",7.781368941220431e-05,0.9999221863105757,"Yes",0.912611241205665,0.08738875879432215,"Yes",1.0,1.5138104489916993e-16,"No",1.0041894945044766e-05,0.9999899581050614,"Yes"
"2008-000498-40","A randomized double-blind placebo-controlled multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy","IT","No","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.783681229922735e-76,7.630301257942453e-07,0.9999992369698772,"-1",0.9053423839942599,0.09465761600573303,"No",0.6654259938188334,0.3345740061811794,"Yes",1.0,5.924947986436957e-26,"No",2.7161403863337e-05,0.9999728385961285,"Yes",0.908115003777077,0.09188499622291497,"Yes",1.0,7.909978370773572e-20,"No",3.4735629778574853e-06,0.9999965264370093,"Yes"
"2008-000536-40","Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose double-blind raNdomized multi-center Trial - POTENT I","DE","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.21816219766819e-50,1.6966609110593226e-09,0.9999999983033376,"-1",0.9999999962518303,3.74818353532926e-09,"No",1.5233013213851324e-08,0.9999999847669871,"Yes",0.9999999998305215,1.6948753352228982e-10,"No",2.7405457977004175e-09,0.9999999972594652,"Yes",0.0019476331203948716,0.9980523668796071,"Yes",0.06803549613235992,0.9319645038676384,"No",2.0502229297114664e-08,0.9999999794977728,"Yes"
"2008-000536-40","Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose double-blind raNdomized multi-center Trial - POTENT I","FR","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.21816219766819e-50,1.6966609110593226e-09,0.9999999983033376,"-1",0.9999999962518303,3.74818353532926e-09,"No",1.5233013213851324e-08,0.9999999847669871,"Yes",0.9999999998305215,1.6948753352228982e-10,"No",2.7405457977004175e-09,0.9999999972594652,"Yes",0.0019476331203948716,0.9980523668796071,"Yes",0.06803549613235992,0.9319645038676384,"No",2.0502229297114664e-08,0.9999999794977728,"Yes"
"2008-000536-40","Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose double-blind raNdomized multi-center Trial - POTENT I","BE","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.21816219766819e-50,1.6966609110593226e-09,0.9999999983033376,"-1",0.9999999962518303,3.74818353532926e-09,"No",1.5233013213851324e-08,0.9999999847669871,"Yes",0.9999999998305215,1.6948753352228982e-10,"No",2.7405457977004175e-09,0.9999999972594652,"Yes",0.0019476331203948716,0.9980523668796071,"Yes",0.06803549613235992,0.9319645038676384,"No",2.0502229297114664e-08,0.9999999794977728,"Yes"
"2008-000536-40","Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose double-blind raNdomized multi-center Trial - POTENT I","ES","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.21816219766819e-50,1.6966609110593226e-09,0.9999999983033376,"-1",0.9999999962518303,3.74818353532926e-09,"No",1.5233013213851324e-08,0.9999999847669871,"Yes",0.9999999998305215,1.6948753352228982e-10,"No",2.7405457977004175e-09,0.9999999972594652,"Yes",0.0019476331203948716,0.9980523668796071,"Yes",0.06803549613235992,0.9319645038676384,"No",2.0502229297114664e-08,0.9999999794977728,"Yes"
"2008-000536-40","Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose double-blind raNdomized multi-center Trial - POTENT I","NL","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.21816219766819e-50,1.6966609110593226e-09,0.9999999983033376,"-1",0.9999999962518303,3.74818353532926e-09,"No",1.5233013213851324e-08,0.9999999847669871,"Yes",0.9999999998305215,1.6948753352228982e-10,"No",2.7405457977004175e-09,0.9999999972594652,"Yes",0.0019476331203948716,0.9980523668796071,"Yes",0.06803549613235992,0.9319645038676384,"No",2.0502229297114664e-08,0.9999999794977728,"Yes"
"2008-000615-15","Open-label randomized controlled Phase I/IIstudy of cilengitide to evaluate the safety andefficacy of the combination of different regimensof cilengitide added to cisplatin 5-FU andcetuximab in subjects with recurrent/metastaticsquamous cell cancer of the head and neck(�ADVANTAGE�)","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.77524461741123e-38,5.483405801492804e-07,0.9999994516594283,"2+",5.626156503975426e-08,0.999999943738432,"Yes",0.999999896290893,1.0370909382336886e-07,"No",1.0,8.209913299905274e-15,"No",0.00017908814607406708,0.9998209118539276,"Yes",0.053815297714870106,0.9461847022851393,"Yes",1.0,1.3216468361822012e-15,"No",1.071480779908412e-05,0.9999892851922062,"Yes"
"2008-000615-15","Open-label randomized controlled Phase I/IIstudy of cilengitide to evaluate the safety andefficacy of the combination of different regimensof cilengitide added to cisplatin 5-FU andcetuximab in subjects with recurrent/metastaticsquamous cell cancer of the head and neck(�ADVANTAGE�)","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.77524461741123e-38,5.483405801492804e-07,0.9999994516594283,"2+",5.626156503975426e-08,0.999999943738432,"Yes",0.999999896290893,1.0370909382336886e-07,"No",1.0,8.209913299905274e-15,"No",0.00017908814607406708,0.9998209118539276,"Yes",0.053815297714870106,0.9461847022851393,"Yes",1.0,1.3216468361822012e-15,"No",1.071480779908412e-05,0.9999892851922062,"Yes"
"2008-000615-15","Open-label randomized controlled Phase I/IIstudy of cilengitide to evaluate the safety andefficacy of the combination of different regimensof cilengitide added to cisplatin 5-FU andcetuximab in subjects with recurrent/metastaticsquamous cell cancer of the head and neck(�ADVANTAGE�)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.77524461741123e-38,5.483405801492804e-07,0.9999994516594283,"2+",5.626156503975426e-08,0.999999943738432,"Yes",0.999999896290893,1.0370909382336886e-07,"No",1.0,8.209913299905274e-15,"No",0.00017908814607406708,0.9998209118539276,"Yes",0.053815297714870106,0.9461847022851393,"Yes",1.0,1.3216468361822012e-15,"No",1.071480779908412e-05,0.9999892851922062,"Yes"
"2008-000615-15","Open-label randomized controlled Phase I/IIstudy of cilengitide to evaluate the safety andefficacy of the combination of different regimensof cilengitide added to cisplatin 5-FU andcetuximab in subjects with recurrent/metastaticsquamous cell cancer of the head and neck(�ADVANTAGE�)","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.77524461741123e-38,5.483405801492804e-07,0.9999994516594283,"2+",5.626156503975426e-08,0.999999943738432,"Yes",0.999999896290893,1.0370909382336886e-07,"No",1.0,8.209913299905274e-15,"No",0.00017908814607406708,0.9998209118539276,"Yes",0.053815297714870106,0.9461847022851393,"Yes",1.0,1.3216468361822012e-15,"No",1.071480779908412e-05,0.9999892851922062,"Yes"
"2008-000615-15","Open-label randomized controlled Phase I/IIstudy of cilengitide to evaluate the safety andefficacy of the combination of different regimensof cilengitide added to cisplatin 5-FU andcetuximab in subjects with recurrent/metastaticsquamous cell cancer of the head and neck(�ADVANTAGE�)","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.77524461741123e-38,5.483405801492804e-07,0.9999994516594283,"2+",5.626156503975426e-08,0.999999943738432,"Yes",0.999999896290893,1.0370909382336886e-07,"No",1.0,8.209913299905274e-15,"No",0.00017908814607406708,0.9998209118539276,"Yes",0.053815297714870106,0.9461847022851393,"Yes",1.0,1.3216468361822012e-15,"No",1.071480779908412e-05,0.9999892851922062,"Yes"
"2008-000615-15","Open-label randomized controlled Phase I/II study of cilengitide to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin 5-FU and cetuximab in subjects with recurrent/metastatic squamous cell cancer of the head and neck.","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.635909632114424e-48,3.4520365631318063e-06,0.9999965479634239,"2+",4.285760487076941e-10,0.9999999995714292,"Yes",0.9999999991019309,8.980810321207879e-10,"No",1.0,1.739141864504141e-19,"No",0.008823970646251247,0.9911760293537386,"Yes",0.13820681311069188,0.8617931868893035,"Yes",1.0,1.4303019252126067e-19,"No",9.055125683148386e-05,0.999909448743164,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate CancerRevised Protocol 03 incorporating Administrative Letter(s) 02 andAmendment(s) 05+Protocol Amendment 01 (v1.0 date 20-Jun-2008)","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.757697217971011e-71,4.724836354833051e-13,0.9999999999995453,"2+",0.9997953052183671,0.00020469478163879604,"No",0.0022186675454216624,0.9977813324545766,"Yes",1.0,8.501820299391409e-21,"No",2.209712538079016e-12,0.9999999999977832,"Yes",1.7755309954001343e-09,0.9999999982244958,"Yes",1.0,4.205895695222185e-18,"No",3.3545408055093124e-14,0.9999999999999432,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer.Revised Protocol 03 incorporating Administrative Letter(s) 02 andAmendment(s) 05+ Protocol Amendment 01 (v1.0 date 20-Jun-2008)","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.858413467331489e-75,5.263234477611964e-13,0.9999999999994884,"2+",0.9992759874698555,0.0007240125301560254,"No",0.007629985855524268,0.992370014144504,"Yes",1.0,8.181182939185186e-22,"No",4.841302021819859e-12,0.9999999999951684,"Yes",5.781359241053698e-10,0.9999999994218456,"Yes",1.0,3.1704767997174547e-20,"No",2.7628697912923377e-14,1.0,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined withDasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer+Protocol Amendment 01 (v1.0 date 20-Jun-2008)","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.987416978228117e-57,1.269515273501817e-11,0.9999999999872956,"2+",0.999804605212425,0.0001953947875771283,"No",0.0020726075972669665,0.9979273924027401,"Yes",1.0,5.018121886447463e-16,"No",2.544071202692327e-10,0.9999999997455973,"Yes",1.6830065371716347e-05,0.9999831699346391,"Yes",0.9999999999993463,6.489547905484688e-13,"No",1.1003964004302097e-11,0.9999999999890009,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.426251610425295e-44,1.0468733336386494e-07,0.9999998953126605,"2+",0.9963746499320911,0.003625350067908947,"No",0.010415893140586913,0.9895841068594124,"Yes",0.9999999999994884,5.149836277391926e-13,"No",2.0022827104755558e-05,0.9999799771729,"Yes",0.29704603377189015,0.702953966228106,"Yes",0.9999972870311207,2.7129688849880325e-06,"No",6.717877374656486e-07,0.9999993282122671,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate CancerRevised Protocol 03 incorporating Administrative Letter(s) 02 andAmendment(s) 05+Protocol Amendment 01 (v1.0 date 20-Jun-2008)","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.757697217971011e-71,4.724836354833051e-13,0.9999999999995453,"2+",0.9997953052183671,0.00020469478163879604,"No",0.0022186675454216624,0.9977813324545766,"Yes",1.0,8.501820299391409e-21,"No",2.209712538079016e-12,0.9999999999977832,"Yes",1.7755309954001343e-09,0.9999999982244958,"Yes",1.0,4.205895695222185e-18,"No",3.3545408055093124e-14,0.9999999999999432,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.426251610425295e-44,1.0468733336386494e-07,0.9999998953126605,"2+",0.9963746499320911,0.003625350067908947,"No",0.010415893140586913,0.9895841068594124,"Yes",0.9999999999994884,5.149836277391926e-13,"No",2.0022827104755558e-05,0.9999799771729,"Yes",0.29704603377189015,0.702953966228106,"Yes",0.9999972870311207,2.7129688849880325e-06,"No",6.717877374656486e-07,0.9999993282122671,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined withDasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer","IE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.26650438041161e-44,6.355003265066053e-08,0.9999999364499693,"2+",0.9992833290053152,0.0007166709946898246,"No",0.002238870444231614,0.9977611295557672,"Yes",0.9999999999898534,1.0147756662487493e-11,"No",7.734360233006462e-06,0.9999922656397723,"Yes",0.2533615957084178,0.7466384042915873,"Yes",0.9999495293191786,5.047068082480834e-05,"No",5.49358110480656e-07,0.999999450641889,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer.Revised Protocol 03 incorporating Administrative Letter(s) 02 andAmendment(s) 05+ Protocol Amendment 01 (v1.0 date 20-Jun-2008)","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.858413467331489e-75,5.263234477611964e-13,0.9999999999994884,"2+",0.9992759874698555,0.0007240125301560254,"No",0.007629985855524268,0.992370014144504,"Yes",1.0,8.181182939185186e-22,"No",4.841302021819859e-12,0.9999999999951684,"Yes",5.781359241053698e-10,0.9999999994218456,"Yes",1.0,3.1704767997174547e-20,"No",2.7628697912923377e-14,1.0,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing DocetaxelCombined with Dasatinib to Docetaxel Combined with Placebo inCastration-Resistant Prostate CancerRevised Protocol 03 incorporating Administrative Letter(s) 02 andAmendment(s) 05+ Protocol Amendment 01 (v1.0 date 20-Jun-2008)","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3657181229393236e-65,5.166510413315963e-13,0.9999999999994884,"2+",0.9999889728971191,1.1027102894674761e-05,"No",0.00014440222769896593,0.9998555977723141,"Yes",1.0,2.8105617223780805e-16,"No",9.187012723816446e-13,0.9999999999990905,"Yes",6.013288947771268e-10,0.9999999993986819,"Yes",1.0,1.0783816120468845e-16,"No",4.9927684242276774e-14,0.9999999999999432,"Yes"
"2008-000701-11","A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate CancerRevised Protocol 03 incorporating Administrative Letter(s) 02 andAmendment(s) 05+ Protocol Amendment 01 (v1.0 date 20-Jun-2008)","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.757697217971011e-71,4.724836354833051e-13,0.9999999999995453,"2+",0.9997953052183671,0.00020469478163879604,"No",0.0022186675454216624,0.9977813324545766,"Yes",1.0,8.501820299391409e-21,"No",2.209712538079016e-12,0.9999999999977832,"Yes",1.7755309954001343e-09,0.9999999982244958,"Yes",1.0,4.205895695222185e-18,"No",3.3545408055093124e-14,0.9999999999999432,"Yes"
"2008-000879-26","(REASON) double-blind Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.","GB","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.736093095864283e-27,9.731816568311164e-07,0.9999990268183485,"-1",0.9999996732138322,3.267861632373325e-07,"No",4.53620011082449e-06,0.9999954637998911,"Yes",0.998165644510154,0.0018343554898468612,"No",1.0919347392343155e-07,0.9999998908065268,"Yes",0.014839292732488872,0.9851607072675066,"Yes",0.003287368353260263,0.996712631646745,"No",1.8917237885309712e-06,0.9999981082762149,"Yes"
"2008-000879-26","Double-blind randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of Sagopilone-induced peripheral Neuropathy","DE","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.273960649771427e-27,4.342559073543156e-07,0.9999995657440996,"-1",0.9999999346729163,6.532707782352583e-08,"No",3.60752105859659e-07,0.9999996392478975,"Yes",0.9998225815740224,0.00017741842598299133,"No",4.3459295895569786e-07,0.9999995654070467,"Yes",0.017970154074232848,0.9820298459257735,"Yes",0.024644765900399136,0.9753552340995943,"No",1.0341684445179844e-06,0.9999989658315603,"Yes"
"2008-000879-26","(REASON) double-blind Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.","NL","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.736093095864283e-27,9.731816568311164e-07,0.9999990268183485,"-1",0.9999996732138322,3.267861632373325e-07,"No",4.53620011082449e-06,0.9999954637998911,"Yes",0.998165644510154,0.0018343554898468612,"No",1.0919347392343155e-07,0.9999998908065268,"Yes",0.014839292732488872,0.9851607072675066,"Yes",0.003287368353260263,0.996712631646745,"No",1.8917237885309712e-06,0.9999981082762149,"Yes"
"2008-000879-26","(REASON) double-blind Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.","BE","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.736093095864283e-27,9.731816568311164e-07,0.9999990268183485,"-1",0.9999996732138322,3.267861632373325e-07,"No",4.53620011082449e-06,0.9999954637998911,"Yes",0.998165644510154,0.0018343554898468612,"No",1.0919347392343155e-07,0.9999998908065268,"Yes",0.014839292732488872,0.9851607072675066,"Yes",0.003287368353260263,0.996712631646745,"No",1.8917237885309712e-06,0.9999981082762149,"Yes"
"2008-000879-26","(REASON) double-blind Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.","ES","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.736093095864283e-27,9.731816568311164e-07,0.9999990268183485,"-1",0.9999996732138322,3.267861632373325e-07,"No",4.53620011082449e-06,0.9999954637998911,"Yes",0.998165644510154,0.0018343554898468612,"No",1.0919347392343155e-07,0.9999998908065268,"Yes",0.014839292732488872,0.9851607072675066,"Yes",0.003287368353260263,0.996712631646745,"No",1.8917237885309712e-06,0.9999981082762149,"Yes"
"2008-000879-26","Double-blind randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of Sagopilone-induced peripheral Neuropathy","FR","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.273960649771427e-27,4.342559073543156e-07,0.9999995657440996,"-1",0.9999999346729163,6.532707782352583e-08,"No",3.60752105859659e-07,0.9999996392478975,"Yes",0.9998225815740224,0.00017741842598299133,"No",4.3459295895569786e-07,0.9999995654070467,"Yes",0.017970154074232848,0.9820298459257735,"Yes",0.024644765900399136,0.9753552340995943,"No",1.0341684445179844e-06,0.9999989658315603,"Yes"
"2008-000879-26","Double-blind randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of Sagopilone-induced peripheral Neuropathy","IT","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.273960649771427e-27,4.342559073543156e-07,0.9999995657440996,"-1",0.9999999346729163,6.532707782352583e-08,"No",3.60752105859659e-07,0.9999996392478975,"Yes",0.9998225815740224,0.00017741842598299133,"No",4.3459295895569786e-07,0.9999995654070467,"Yes",0.017970154074232848,0.9820298459257735,"Yes",0.024644765900399136,0.9753552340995943,"No",1.0341684445179844e-06,0.9999989658315603,"Yes"
"2008-001211-37","A randomized double-blind parallel group placebo controlled multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.188068333619286e-81,1.423904804383237e-20,1.0,"-1",1.0,1.2286249217963933e-19,"No",3.865627548438139e-15,1.0,"Yes",0.9999934627907069,6.5372092829073276e-06,"No",1.9556441042106067e-18,1.0,"Yes",3.817903925173348e-10,0.9999999996181828,"Yes",0.9999999999949978,5.017155974971107e-12,"No",6.014232615213188e-20,1.0,"Yes"
"2008-001211-37","A randomized double-blind parallel group placebo controlled multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.188068333619286e-81,1.423904804383237e-20,1.0,"-1",1.0,1.2286249217963933e-19,"No",3.865627548438139e-15,1.0,"Yes",0.9999934627907069,6.5372092829073276e-06,"No",1.9556441042106067e-18,1.0,"Yes",3.817903925173348e-10,0.9999999996181828,"Yes",0.9999999999949978,5.017155974971107e-12,"No",6.014232615213188e-20,1.0,"Yes"
"2008-001211-37","A randomized double-blind parallel group placebo controlled multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.188068333619286e-81,1.423904804383237e-20,1.0,"-1",1.0,1.2286249217963933e-19,"No",3.865627548438139e-15,1.0,"Yes",0.9999934627907069,6.5372092829073276e-06,"No",1.9556441042106067e-18,1.0,"Yes",3.817903925173348e-10,0.9999999996181828,"Yes",0.9999999999949978,5.017155974971107e-12,"No",6.014232615213188e-20,1.0,"Yes"
"2008-001211-37","A randomized double-blind parallel group placebo controlled multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.188068333619286e-81,1.423904804383237e-20,1.0,"-1",1.0,1.2286249217963933e-19,"No",3.865627548438139e-15,1.0,"Yes",0.9999934627907069,6.5372092829073276e-06,"No",1.9556441042106067e-18,1.0,"Yes",3.817903925173348e-10,0.9999999996181828,"Yes",0.9999999999949978,5.017155974971107e-12,"No",6.014232615213188e-20,1.0,"Yes"
"2008-001211-37","A randomized double-blind parallel group placebo controlled multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.188068333619286e-81,1.423904804383237e-20,1.0,"-1",1.0,1.2286249217963933e-19,"No",3.865627548438139e-15,1.0,"Yes",0.9999934627907069,6.5372092829073276e-06,"No",1.9556441042106067e-18,1.0,"Yes",3.817903925173348e-10,0.9999999996181828,"Yes",0.9999999999949978,5.017155974971107e-12,"No",6.014232615213188e-20,1.0,"Yes"
"2008-001211-37","A randomized double-blind parallel group placebo controlled multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.188068333619286e-81,1.423904804383237e-20,1.0,"-1",1.0,1.2286249217963933e-19,"No",3.865627548438139e-15,1.0,"Yes",0.9999934627907069,6.5372092829073276e-06,"No",1.9556441042106067e-18,1.0,"Yes",3.817903925173348e-10,0.9999999996181828,"Yes",0.9999999999949978,5.017155974971107e-12,"No",6.014232615213188e-20,1.0,"Yes"
"2008-001211-37","A randomized double-blind parallel group placebo controlled multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.188068333619286e-81,1.423904804383237e-20,1.0,"-1",1.0,1.2286249217963933e-19,"No",3.865627548438139e-15,1.0,"Yes",0.9999934627907069,6.5372092829073276e-06,"No",1.9556441042106067e-18,1.0,"Yes",3.817903925173348e-10,0.9999999996181828,"Yes",0.9999999999949978,5.017155974971107e-12,"No",6.014232615213188e-20,1.0,"Yes"
"2008-001211-37","A randomized double-blind parallel group placebo controlled multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.188068333619286e-81,1.423904804383237e-20,1.0,"-1",1.0,1.2286249217963933e-19,"No",3.865627548438139e-15,1.0,"Yes",0.9999934627907069,6.5372092829073276e-06,"No",1.9556441042106067e-18,1.0,"Yes",3.817903925173348e-10,0.9999999996181828,"Yes",0.9999999999949978,5.017155974971107e-12,"No",6.014232615213188e-20,1.0,"Yes"
"2008-001211-37","A randomized double-blind parallel group placebo controlled multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.188068333619286e-81,1.423904804383237e-20,1.0,"-1",1.0,1.2286249217963933e-19,"No",3.865627548438139e-15,1.0,"Yes",0.9999934627907069,6.5372092829073276e-06,"No",1.9556441042106067e-18,1.0,"Yes",3.817903925173348e-10,0.9999999996181828,"Yes",0.9999999999949978,5.017155974971107e-12,"No",6.014232615213188e-20,1.0,"Yes"
"2008-001212-20","An open-label long term multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component ","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.2214578322204321e-43,5.164779483212538e-08,0.9999999483521846,"-1",0.9999998840828607,1.1591712044976329e-07,"Yes",0.0004961723830484803,0.9995038276169691,"No",0.999980514249266,1.9485750740223714e-05,"No",2.559107564324761e-06,0.9999974408924349,"No",0.0002342450436387359,0.9997657549563725,"No",0.999999996837687,3.1622958385821978e-09,"No",1.477726407269153e-08,0.9999999852227576,"No"
"2008-001252-52","A multicenter randomized double-blind placebo controlled efficacy and safety trial of intravenous zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.3618351729573356e-43,1.1844048920611594e-12,0.9999999999988205,"1",0.9999999999979252,2.0736898065993876e-12,"No",1.3466856319509098e-11,0.9999999999865281,"Yes",0.9999999994489032,5.510996388653091e-10,"No",1.80540795353635e-11,0.9999999999819522,"Yes",0.0038495675371258563,0.9961504324628746,"No",0.9999242581624062,7.574183759315943e-05,"No",5.8890518327825874e-12,0.9999999999941168,"Yes"
"2008-001252-52","A multicenter randomized double-blind placebo controlled efficacy and safety trial of intravenous zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids","Outside EU/EEA","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.3618351729573356e-43,1.1844048920611594e-12,0.9999999999988205,"1",0.9999999999979252,2.0736898065993876e-12,"No",1.3466856319509098e-11,0.9999999999865281,"Yes",0.9999999994489032,5.510996388653091e-10,"No",1.80540795353635e-11,0.9999999999819522,"Yes",0.0038495675371258563,0.9961504324628746,"No",0.9999242581624062,7.574183759315943e-05,"No",5.8890518327825874e-12,0.9999999999941168,"Yes"
"2008-001252-52","A multicenter randomized double-blind placebo controlled efficacy and safety trial  of intravenous (i.v.) zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids for chronic inflammatory conditions.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2040748898955864e-51,4.092563097264493e-13,0.9999999999996021,"1",0.999999999999801,1.872215583440099e-13,"No",1.4571723101707532e-12,0.9999999999985506,"Yes",0.9999999997780834,2.219155735639938e-10,"No",4.921433062587218e-13,0.9999999999995168,"Yes",0.0021274390963258935,0.9978725609036653,"No",0.9997010389218713,0.0002989610781347418,"No",1.1478028346054853e-12,0.9999999999988632,"Yes"
"2008-001252-52","A multicenter randomized double-blind placebo controlled efficacy and safety trial  of intravenous (i.v.) zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids for chronic inflammatory conditions.","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2040748898955864e-51,4.092563097264493e-13,0.9999999999996021,"1",0.999999999999801,1.872215583440099e-13,"No",1.4571723101707532e-12,0.9999999999985506,"Yes",0.9999999997780834,2.219155735639938e-10,"No",4.921433062587218e-13,0.9999999999995168,"Yes",0.0021274390963258935,0.9978725609036653,"No",0.9997010389218713,0.0002989610781347418,"No",1.1478028346054853e-12,0.9999999999988632,"Yes"
"2008-001252-52","A multicenter randomized double-blind placebo controlled efficacy and safety trial  of intravenous (i.v.) zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids for chronic inflammatory conditions.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2040748898955864e-51,4.092563097264493e-13,0.9999999999996021,"1",0.999999999999801,1.872215583440099e-13,"No",1.4571723101707532e-12,0.9999999999985506,"Yes",0.9999999997780834,2.219155735639938e-10,"No",4.921433062587218e-13,0.9999999999995168,"Yes",0.0021274390963258935,0.9978725609036653,"No",0.9997010389218713,0.0002989610781347418,"No",1.1478028346054853e-12,0.9999999999988632,"Yes"
"2008-001252-52","A multicenter randomized double-blind placebo controlled efficacy and safety trial  of intravenous (i.v.) zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids for chronic inflammatory conditions.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2040748898955864e-51,4.092563097264493e-13,0.9999999999996021,"1",0.999999999999801,1.872215583440099e-13,"No",1.4571723101707532e-12,0.9999999999985506,"Yes",0.9999999997780834,2.219155735639938e-10,"No",4.921433062587218e-13,0.9999999999995168,"Yes",0.0021274390963258935,0.9978725609036653,"No",0.9997010389218713,0.0002989610781347418,"No",1.1478028346054853e-12,0.9999999999988632,"Yes"
"2008-001252-52","A multicenter randomized double-blind placebo controlled efficacy and safety trial  of intravenous (i.v.) zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids for chronic inflammatory conditions.","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2040748898955864e-51,4.092563097264493e-13,0.9999999999996021,"1",0.999999999999801,1.872215583440099e-13,"No",1.4571723101707532e-12,0.9999999999985506,"Yes",0.9999999997780834,2.219155735639938e-10,"No",4.921433062587218e-13,0.9999999999995168,"Yes",0.0021274390963258935,0.9978725609036653,"No",0.9997010389218713,0.0002989610781347418,"No",1.1478028346054853e-12,0.9999999999988632,"Yes"
"2008-001252-52","A multicenter randomized double-blind placebo controlled efficacy and safety trial of intravenous zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.3618351729573356e-43,1.1844048920611594e-12,0.9999999999988205,"1",0.9999999999979252,2.0736898065993876e-12,"No",1.3466856319509098e-11,0.9999999999865281,"Yes",0.9999999994489032,5.510996388653091e-10,"No",1.80540795353635e-11,0.9999999999819522,"Yes",0.0038495675371258563,0.9961504324628746,"No",0.9999242581624062,7.574183759315943e-05,"No",5.8890518327825874e-12,0.9999999999941168,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL  CELL CANCER: AXIS TRIALAXITINIB (AG 013736) COME TRATTAMENTO DI SECONDA LINEA PER L'ADENOCARCINOMA RENALE METASTATICO (AXIS)","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.286069908163469e-37,4.994438100121069e-07,0.9999995005561968,"2+",8.054784032101998e-08,0.9999999194521683,"Yes",0.9999998860067544,1.1399325418307923e-07,"No",1.0,2.1473864011064028e-20,"No",0.0008205954030497834,0.9991794045969533,"Yes",0.06407310111854926,0.9359268988814443,"Yes",0.9999999997758664,2.2414457297082706e-10,"No",1.9428984918860137e-07,0.9999998057101511,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIAL","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.212832770229496e-19,0.005137652596799477,0.9948623474032042,"2+",0.00044034897123662137,0.9995596510287638,"Yes",0.9995728266301249,0.0004271733698799601,"No",0.9999999455877331,5.4412270438988666e-08,"No",0.1566723775992621,0.8433276224007402,"Yes",0.5283617996260249,0.4716382003739728,"Yes",0.9986631194810994,0.0013368805188993106,"No",0.0016153780490028163,0.998384621950993,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIAL","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.212832770229496e-19,0.005137652596799477,0.9948623474032042,"2+",0.00044034897123662137,0.9995596510287638,"Yes",0.9995728266301249,0.0004271733698799601,"No",0.9999999455877331,5.4412270438988666e-08,"No",0.1566723775992621,0.8433276224007402,"Yes",0.5283617996260249,0.4716382003739728,"Yes",0.9986631194810994,0.0013368805188993106,"No",0.0016153780490028163,0.998384621950993,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIAL","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.212832770229496e-19,0.005137652596799477,0.9948623474032042,"2+",0.00044034897123662137,0.9995596510287638,"Yes",0.9995728266301249,0.0004271733698799601,"No",0.9999999455877331,5.4412270438988666e-08,"No",0.1566723775992621,0.8433276224007402,"Yes",0.5283617996260249,0.4716382003739728,"Yes",0.9986631194810994,0.0013368805188993106,"No",0.0016153780490028163,0.998384621950993,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIAL","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.212832770229496e-19,0.005137652596799477,0.9948623474032042,"2+",0.00044034897123662137,0.9995596510287638,"Yes",0.9995728266301249,0.0004271733698799601,"No",0.9999999455877331,5.4412270438988666e-08,"No",0.1566723775992621,0.8433276224007402,"Yes",0.5283617996260249,0.4716382003739728,"Yes",0.9986631194810994,0.0013368805188993106,"No",0.0016153780490028163,0.998384621950993,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL  CELL CANCER: AXIS TRIALAXITINIB (AG 013736) COME TRATTAMENTO DI SECONDA LINEA PER L'ADENOCARCINOMA RENALE METASTATICO (AXIS)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.286069908163469e-37,4.994438100121069e-07,0.9999995005561968,"2+",8.054784032101998e-08,0.9999999194521683,"Yes",0.9999998860067544,1.1399325418307923e-07,"No",1.0,2.1473864011064028e-20,"No",0.0008205954030497834,0.9991794045969533,"Yes",0.06407310111854926,0.9359268988814443,"Yes",0.9999999997758664,2.2414457297082706e-10,"No",1.9428984918860137e-07,0.9999998057101511,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIALAxitinib (AG 013736) como tratamiento de segunda línea del cáncer de células renales metastático: Ensayo Axis","IE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.080250836279285e-34,5.944148340023344e-06,0.9999940558516467,"2+",1.2113798832737306e-08,0.9999999878862128,"Yes",0.9999999880537019,1.1946304314373204e-08,"No",1.0,1.3238595196116852e-16,"No",0.02291407762471929,0.9770859223752705,"Yes",0.8579149151037961,0.142085084896217,"Yes",0.9999999996886402,3.1136179013645307e-10,"No",3.875925280230785e-06,0.9999961240747065,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIALAxitinib (AG 013736) como tratamiento de segunda línea del cáncer de células renales metastático: Ensayo Axis","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.080250836279285e-34,5.944148340023344e-06,0.9999940558516467,"2+",1.2113798832737306e-08,0.9999999878862128,"Yes",0.9999999880537019,1.1946304314373204e-08,"No",1.0,1.3238595196116852e-16,"No",0.02291407762471929,0.9770859223752705,"Yes",0.8579149151037961,0.142085084896217,"Yes",0.9999999996886402,3.1136179013645307e-10,"No",3.875925280230785e-06,0.9999961240747065,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIAL","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.212832770229496e-19,0.005137652596799477,0.9948623474032042,"2+",0.00044034897123662137,0.9995596510287638,"Yes",0.9995728266301249,0.0004271733698799601,"No",0.9999999455877331,5.4412270438988666e-08,"No",0.1566723775992621,0.8433276224007402,"Yes",0.5283617996260249,0.4716382003739728,"Yes",0.9986631194810994,0.0013368805188993106,"No",0.0016153780490028163,0.998384621950993,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIAL","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.212832770229496e-19,0.005137652596799477,0.9948623474032042,"2+",0.00044034897123662137,0.9995596510287638,"Yes",0.9995728266301249,0.0004271733698799601,"No",0.9999999455877331,5.4412270438988666e-08,"No",0.1566723775992621,0.8433276224007402,"Yes",0.5283617996260249,0.4716382003739728,"Yes",0.9986631194810994,0.0013368805188993106,"No",0.0016153780490028163,0.998384621950993,"Yes"
"2008-001451-21","AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIAL","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.212832770229496e-19,0.005137652596799477,0.9948623474032042,"2+",0.00044034897123662137,0.9995596510287638,"Yes",0.9995728266301249,0.0004271733698799601,"No",0.9999999455877331,5.4412270438988666e-08,"No",0.1566723775992621,0.8433276224007402,"Yes",0.5283617996260249,0.4716382003739728,"Yes",0.9986631194810994,0.0013368805188993106,"No",0.0016153780490028163,0.998384621950993,"Yes"
"2008-001674-32","NordiNet International Outcome Study (NordiNet IOS)","FI","Yes","No","No","","No","No","Yes","Yes","2+","","","No","No","Yes","No","No","No","1","No",0.00012367865226825702,0.45393372424520134,0.5459425971025321,"-1",0.6783434287231406,0.3216565712768586,"Information not present in EudraCT",0.31501184834051477,0.6849881516594852,"Information not present in EudraCT",0.9913407922133932,0.008659207786607852,"Information not present in EudraCT",0.38363531907776666,0.6163646809222338,"No",0.33799156662107416,0.6620084333789265,"",0.6497020109165377,0.350297989083462,"",0.5069640516799658,0.4930359483200332,""
"2008-001755-22","STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDOMIZED STUDY","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.0451766222383695e-43,0.00010410693530475313,0.9998958930646841,"-1",3.319250577688601e-05,0.9999668074942175,"Yes",0.9999557944108519,4.420558915359131e-05,"No",0.9999999999999432,6.13217879966793e-14,"No",0.005652474161277633,0.9943475258387212,"Yes",0.940585934563496,0.05941406543650526,"No",0.9999999999557759,4.42375092402904e-11,"No",3.087405367306259e-06,0.9999969125946305,"Yes"
"2008-001755-22","STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDOMIZED STUDY","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.0451766222383695e-43,0.00010410693530475313,0.9998958930646841,"-1",3.319250577688601e-05,0.9999668074942175,"Yes",0.9999557944108519,4.420558915359131e-05,"No",0.9999999999999432,6.13217879966793e-14,"No",0.005652474161277633,0.9943475258387212,"Yes",0.940585934563496,0.05941406543650526,"No",0.9999999999557759,4.42375092402904e-11,"No",3.087405367306259e-06,0.9999969125946305,"Yes"
"2008-001755-22","STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDOMIZED STUDY","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.0451766222383695e-43,0.00010410693530475313,0.9998958930646841,"-1",3.319250577688601e-05,0.9999668074942175,"Yes",0.9999557944108519,4.420558915359131e-05,"No",0.9999999999999432,6.13217879966793e-14,"No",0.005652474161277633,0.9943475258387212,"Yes",0.940585934563496,0.05941406543650526,"No",0.9999999999557759,4.42375092402904e-11,"No",3.087405367306259e-06,0.9999969125946305,"Yes"
"2008-001849-26","Multicentre open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach gastroesophageal junction or distal esophagus. ","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.7632127883998775e-34,5.243435376250703e-07,0.9999994756564615,"-1",1.2290462777016536e-06,0.9999987709537258,"Yes",0.9999993343594666,6.656405347585266e-07,"No",0.9999999999999432,5.002899485447998e-14,"No",4.394042808620805e-06,0.9999956059571862,"Yes",0.6570464063594105,0.34295359364060185,"No",0.9999999999999432,5.677269810688583e-14,"No",4.606439066825231e-06,0.9999953935609454,"No"
"2008-002140-41","Double-blind placebo controlled randomized study of vardenafil to determine efficacy on Erectile Dysfunction (ED) in men with ED and Metabolic Syndrome (ED-METABOLIC)","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.41422428157443e-32,1.6203925193079959e-09,0.9999999983796216,"-1",0.9999999987606715,1.2393230224292084e-09,"No",6.7777402981301966e-09,0.9999999932222466,"Yes",0.9999985709107742,1.4290892226443603e-06,"No",4.592019124026552e-10,0.9999999995407906,"Yes",0.0009354757887306125,0.9990645242112632,"Yes",0.9964334848710512,0.003566515128944704,"No",1.1752272132831387e-07,0.9999998824772901,"Yes"
"2008-002226-11","Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.404648915815777e-16,8.379630398896823e-06,0.9999916203696003,"2+",0.9991778812085473,0.0008221187914553013,"No",0.0010670582222225195,0.9989329417777758,"Yes",0.9904166619760078,0.00958333802398874,"No",5.584046340412825e-06,0.9999944159536598,"Yes",0.004463414820480865,0.9955365851795206,"Yes",0.8403626957818703,0.15963730421813166,"No",2.797787221137775e-05,0.9999720221277852,"Yes"
"2008-002356-18","Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.III. fázisú klinikai vizsgálat a treoszulfán-alapú kondicionáló kezelés és a buszulfán-alapú csökkentett intenzitású kondicionálás (RIC) összehasonlítására allogén hematopoietikus őssejt-transzplantáció előtt AML-ben és MDS-ben szenvedő betegeken akik nem alkalmasak hagyományos kondicionáló kezelésre","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.266962055025892e-79,0.2813219275961293,0.718678072403843,"-1",1.68318626294861e-18,1.0,"Yes",1.0,6.969013700436515e-19,"No",1.0,2.378128496020095e-25,"No",0.0008884959239160029,0.9991115040760745,"Yes",0.999999935241933,6.475804126117653e-08,"Yes",1.0,5.429694041613224e-30,"No",0.00018639198060566465,0.9998136080193708,"Yes"
"2008-002356-18","Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.Klinische Phase III Studie zum Vergleich von Treosulfan-basierter Konditionierungstherapie mit Busulfan-basierter intensitätsreduzierter Konditionierung (RIC) vor allogener hämatopoetischer Stamzelltransplantation bei Patienten mit AML oder MDS die für eine Standard-Konditionierungsbehandlung nicht in Frage kommen.","FI","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3791478218107991e-93,0.9999995836351175,4.1636486565725725e-07,"-1",1.3215911461647954e-29,1.0,"Yes",1.0,1.7107743405801397e-29,"No",1.0,1.237654841431581e-25,"No",0.9990287739035456,0.0009712260964602794,"Yes",1.0,1.603823189581427e-14,"Yes",1.0,1.4068877738770818e-30,"No",0.9999948243942993,5.175605679063062e-06,"Yes"
"2008-002356-18","Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.","HU","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0664946770234253e-53,0.9958424945644707,0.004157505435540739,"-1",8.699117143092495e-18,1.0,"Yes",1.0,1.5303275651285735e-17,"No",1.0,2.4260841152563923e-20,"No",0.8939268634558072,0.10607313654419723,"Yes",0.9999919280400392,8.07195995388609e-06,"Yes",1.0,1.5707396115026448e-20,"No",0.7899905857711471,0.21000941422886135,"Yes"
"2008-002356-18","Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.","DE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0664946770234253e-53,0.9958424945644707,0.004157505435540739,"-1",8.699117143092495e-18,1.0,"Yes",1.0,1.5303275651285735e-17,"No",1.0,2.4260841152563923e-20,"No",0.8939268634558072,0.10607313654419723,"Yes",0.9999919280400392,8.07195995388609e-06,"Yes",1.0,1.5707396115026448e-20,"No",0.7899905857711471,0.21000941422886135,"Yes"
"2008-002356-18","Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.","IT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0664946770234253e-53,0.9958424945644707,0.004157505435540739,"-1",8.699117143092495e-18,1.0,"Yes",1.0,1.5303275651285735e-17,"No",1.0,2.4260841152563923e-20,"No",0.8939268634558072,0.10607313654419723,"Yes",0.9999919280400392,8.07195995388609e-06,"Yes",1.0,1.5707396115026448e-20,"No",0.7899905857711471,0.21000941422886135,"Yes"
"2008-002356-18","Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.III. fázisú klinikai vizsgálat a treoszulfán-alapú kondicionáló kezelés és a buszulfán-alapú csökkentett intenzitású kondicionálás (RIC) összehasonlítására allogén hematopoietikus őssejt-transzplantáció előtt AML-ben és MDS-ben szenvedő betegeken akik nem alkalmasak hagyományos kondicionáló kezelésre","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.266962055025892e-79,0.2813219275961293,0.718678072403843,"-1",1.68318626294861e-18,1.0,"Yes",1.0,6.969013700436515e-19,"No",1.0,2.378128496020095e-25,"No",0.0008884959239160029,0.9991115040760745,"Yes",0.999999935241933,6.475804126117653e-08,"Yes",1.0,5.429694041613224e-30,"No",0.00018639198060566465,0.9998136080193708,"Yes"
"2008-003003-31","Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter open-label Phase II study ","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.734745583398581e-37,5.0904862577598926e-05,0.9999490951374318,"-1",1.7410107095762607e-11,0.9999999999825775,"Yes",0.9999999999622275,3.777691623277281e-11,"No",0.9999999999999717,1.4863635096817525e-14,"No",6.544094332268096e-06,0.9999934559056781,"Yes",0.9321038469644545,0.06789615303555928,"No",1.0,1.413867546693469e-16,"No",3.2991522589989725e-05,0.9999670084774116,"Yes"
"2008-003003-31","Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter open-label Phase II study ","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.734745583398581e-37,5.0904862577598926e-05,0.9999490951374318,"-1",1.7410107095762607e-11,0.9999999999825775,"Yes",0.9999999999622275,3.777691623277281e-11,"No",0.9999999999999717,1.4863635096817525e-14,"No",6.544094332268096e-06,0.9999934559056781,"Yes",0.9321038469644545,0.06789615303555928,"No",1.0,1.413867546693469e-16,"No",3.2991522589989725e-05,0.9999670084774116,"Yes"
"2008-003003-31","Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter open-label Phase II study ","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.734745583398581e-37,5.0904862577598926e-05,0.9999490951374318,"-1",1.7410107095762607e-11,0.9999999999825775,"Yes",0.9999999999622275,3.777691623277281e-11,"No",0.9999999999999717,1.4863635096817525e-14,"No",6.544094332268096e-06,0.9999934559056781,"Yes",0.9321038469644545,0.06789615303555928,"No",1.0,1.413867546693469e-16,"No",3.2991522589989725e-05,0.9999670084774116,"Yes"
"2008-003003-31","Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter open-label Phase II study ","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.734745583398581e-37,5.0904862577598926e-05,0.9999490951374318,"-1",1.7410107095762607e-11,0.9999999999825775,"Yes",0.9999999999622275,3.777691623277281e-11,"No",0.9999999999999717,1.4863635096817525e-14,"No",6.544094332268096e-06,0.9999934559056781,"Yes",0.9321038469644545,0.06789615303555928,"No",1.0,1.413867546693469e-16,"No",3.2991522589989725e-05,0.9999670084774116,"Yes"
"2008-003003-31","Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter open-label Phase II study ","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.734745583398581e-37,5.0904862577598926e-05,0.9999490951374318,"-1",1.7410107095762607e-11,0.9999999999825775,"Yes",0.9999999999622275,3.777691623277281e-11,"No",0.9999999999999717,1.4863635096817525e-14,"No",6.544094332268096e-06,0.9999934559056781,"Yes",0.9321038469644545,0.06789615303555928,"No",1.0,1.413867546693469e-16,"No",3.2991522589989725e-05,0.9999670084774116,"Yes"
"2008-003003-31","Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter open-label Phase II study ","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.734745583398581e-37,5.0904862577598926e-05,0.9999490951374318,"-1",1.7410107095762607e-11,0.9999999999825775,"Yes",0.9999999999622275,3.777691623277281e-11,"No",0.9999999999999717,1.4863635096817525e-14,"No",6.544094332268096e-06,0.9999934559056781,"Yes",0.9321038469644545,0.06789615303555928,"No",1.0,1.413867546693469e-16,"No",3.2991522589989725e-05,0.9999670084774116,"Yes"
"2008-003003-31","Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter open-label Phase II study ","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.734745583398581e-37,5.0904862577598926e-05,0.9999490951374318,"-1",1.7410107095762607e-11,0.9999999999825775,"Yes",0.9999999999622275,3.777691623277281e-11,"No",0.9999999999999717,1.4863635096817525e-14,"No",6.544094332268096e-06,0.9999934559056781,"Yes",0.9321038469644545,0.06789615303555928,"No",1.0,1.413867546693469e-16,"No",3.2991522589989725e-05,0.9999670084774116,"Yes"
"2008-003003-31","Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter open-label Phase II study ","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.734745583398581e-37,5.0904862577598926e-05,0.9999490951374318,"-1",1.7410107095762607e-11,0.9999999999825775,"Yes",0.9999999999622275,3.777691623277281e-11,"No",0.9999999999999717,1.4863635096817525e-14,"No",6.544094332268096e-06,0.9999934559056781,"Yes",0.9321038469644545,0.06789615303555928,"No",1.0,1.413867546693469e-16,"No",3.2991522589989725e-05,0.9999670084774116,"Yes"
"2008-003174-18","Open-labeled randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated carcinoma of unknown primary (CUP)","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9186076205656924e-31,0.08125060771768593,0.9187493922823216,"-1",3.0816390633510044e-08,0.99999996918362,"Yes",0.9999999462317548,5.3768235137648136e-08,"No",0.9999999999998579,1.3687369571932013e-13,"No",0.23392784032385264,0.7660721596761341,"Yes",0.9825578772405413,0.017442122759449112,"Yes",0.9999996256736514,3.7432635625637523e-07,"No",0.04260916531811504,0.9573908346818834,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Revised Protocol 06 incorporating Protocol Amendments 04 09 11 12 14 and 15+ Biomarker Amendment 06 (version 1.0 dated 16-Nov-09) - Site Specific + Serum Biomarker Amendment 13 (Version 1.0 dated 18-Mar-11) - Site Specific ","NL","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6894376405117222e-102,4.5550060429113006e-12,0.9999999999954525,"2+",0.6042759997134941,0.3957240002865168,"No",0.8115551923008119,0.18844480769921362,"Yes",1.0,2.0449381060023355e-44,"No",1.6776362660200422e-10,0.9999999998322552,"Yes",1.1009856327303206e-14,1.0,"Yes",1.0,1.4443315788362762e-43,"No",9.314277392692416e-11,0.9999999999068336,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Ensayo fase 3 aleatorizado doble ciego y comparativo de ipilimumab frente a placebo después de radioterapia en sujetos con cáncer de próstata avanzado y resistente a maniobras de castración previamente tratado con docetaxel","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.442685745365402e-91,1.5422726239657433e-12,0.9999999999984652,"2+",0.86606419129468,0.1339358087053217,"No",0.24420224478298155,0.7557977552170188,"Yes",1.0,1.1040189896398254e-38,"No",1.049057121166907e-08,0.9999999895094335,"Yes",0.5752292286734141,0.4247707713265843,"Yes",1.0,5.572626933498673e-18,"No",1.3597283623586027e-10,0.9999999998640305,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Revised Protocol 06 incorporating Protocol Amendments 04 09 11 12 14 and 15+ Pharmacogenetics Blood Sample Amendment 01 (version 2.0 dated 23-Feb-09) - Site Specific+ Biomarker Amendment 06 (version 1.0 dated 16-Nov-09) - Site Specific + Serum Biomarker Amendemnt 13 (Version 1.0 dated 18-Mar-11)- Site SpecificRandomizovaná dvojitě zaslepená studie fáze III porovnávající ipilimumab s placebem u pacientů po radioterapii s kastračně rezistentním nádorem prostaty kteří obdrželi předchozí léčbu docetaxelem.Revidovaný protokol č. 6 zahrnující Dodatky k protokolu č. 4 9 11 12 14 a 15+ Dodatek č. 1 pro farmakogenetický výzkum vzorků krve (verze 2.0 datovaná 23. 2. 2009) – specifický dle centra + Dodatek č. 6 pro výzkum biomarkerů (verze 1.0 datovaná 16. 11. 2009) - specifický dle centra + Dodatek č. 13 pro výzkum biomarkerů z krevního séra (verze 1.0 datovaná 18. 3. 2011) - specifický dle centra","IE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6608557048733004e-247,3.4089337009737354e-45,1.0,"2+",0.9999999999990905,9.456977681721116e-13,"No",6.933015872742423e-11,0.999999999930651,"Yes",1.0,1.6972026287870227e-124,"No",6.849051807217109e-49,1.0,"Yes",7.4114047747367e-44,1.0,"Yes",1.0,1.2954692355201057e-102,"No",1.497180400959527e-44,1.0,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Revised Protocol 06 incorporating Protocol Amendments 04 09 11 12 14 and 15+ Biomarker Amendment 06 (version 1.0 dated 16-Nov-09) - Site Specific + Serum Biomarker Amendment 13 (Version 1.0 dated 18-Mar-11) - Site Specific ","IT","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6894376405117222e-102,4.5550060429113006e-12,0.9999999999954525,"2+",0.6042759997134941,0.3957240002865168,"No",0.8115551923008119,0.18844480769921362,"Yes",1.0,2.0449381060023355e-44,"No",1.6776362660200422e-10,0.9999999998322552,"Yes",1.1009856327303206e-14,1.0,"Yes",1.0,1.4443315788362762e-43,"No",9.314277392692416e-11,0.9999999999068336,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Revised Protocol 06 incorporating Protocol Amendments 04 09 11 12 14 and 15+Pharmacogenetics Blood Sample Amendment 01 (version 2.0 dated 23-Feb-09) - Site Specific+ Serum Biomarker Amendemnt 13 (Version 1.0 dated 18-Mar-11)- SiteSpecific","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2557752573633755e-106,1.5224477316848178e-14,1.0,"2+",0.9571297283928912,0.042870271607124213,"No",0.36967508045008934,0.6303249195499169,"Yes",1.0,3.589283077054397e-43,"No",9.002965525866923e-15,1.0,"Yes",6.2543711021792816e-15,1.0,"Yes",1.0,3.498900221401673e-39,"No",1.642879640218258e-13,0.9999999999998295,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Revised Protocol 06 incorporating Protocol Amendments 04 09 11 12 14 and 15+ Pharmacogenetics Blood Sample Amendment 01 (version 2.0 dated 23-Feb-09) - Site Specific+ Biomarker Amendment 06 (version 1.0 dated 16-Nov-09) - Site Specific + Serum Biomarker Amendemnt 13 (Version 1.0 dated 18-Mar-11)- Site SpecificRandomizovaná dvojitě zaslepená studie fáze III porovnávající ipilimumab s placebem u pacientů po radioterapii s kastračně rezistentním nádorem prostaty kteří obdrželi předchozí léčbu docetaxelem.Revidovaný protokol č. 6 zahrnující Dodatky k protokolu č. 4 9 11 12 14 a 15+ Dodatek č. 1 pro farmakogenetický výzkum vzorků krve (verze 2.0 datovaná 23. 2. 2009) – specifický dle centra + Dodatek č. 6 pro výzkum biomarkerů (verze 1.0 datovaná 16. 11. 2009) - specifický dle centra + Dodatek č. 13 pro výzkum biomarkerů z krevního séra (verze 1.0 datovaná 18. 3. 2011) - specifický dle centra","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6608557048733004e-247,3.4089337009737354e-45,1.0,"2+",0.9999999999990905,9.456977681721116e-13,"No",6.933015872742423e-11,0.999999999930651,"Yes",1.0,1.6972026287870227e-124,"No",6.849051807217109e-49,1.0,"Yes",7.4114047747367e-44,1.0,"Yes",1.0,1.2954692355201057e-102,"No",1.497180400959527e-44,1.0,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Revised Protocol 06 incorporating Protocol Amendments 04 09 11 12 14 and 15+ Pharmacogenetics Blood Sample Amendment 01 (version 2.0 dated 23-Feb-09) - Site Specific+ Biomarker Amendment 06 (version 1.0 dated 16-Nov-09) - Site Specific + Serum Biomarker Amendemnt 13 (Version 1.0 dated 18-Mar-11)- Site SpecificRandomizovaná dvojitě zaslepená studie fáze III porovnávající ipilimumab s placebem u pacientů po radioterapii s kastračně rezistentním nádorem prostaty kteří obdrželi předchozí léčbu docetaxelem.Revidovaný protokol č. 6 zahrnující Dodatky k protokolu č. 4 9 11 12 14 a 15+ Dodatek č. 1 pro farmakogenetický výzkum vzorků krve (verze 2.0 datovaná 23. 2. 2009) – specifický dle centra + Dodatek č. 6 pro výzkum biomarkerů (verze 1.0 datovaná 16. 11. 2009) - specifický dle centra + Dodatek č. 13 pro výzkum biomarkerů z krevního séra (verze 1.0 datovaná 18. 3. 2011) - specifický dle centra","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6608557048733004e-247,3.4089337009737354e-45,1.0,"2+",0.9999999999990905,9.456977681721116e-13,"No",6.933015872742423e-11,0.999999999930651,"Yes",1.0,1.6972026287870227e-124,"No",6.849051807217109e-49,1.0,"Yes",7.4114047747367e-44,1.0,"Yes",1.0,1.2954692355201057e-102,"No",1.497180400959527e-44,1.0,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.7644578077068788e-42,1.4432331938632763e-06,0.9999985567668018,"2+",0.7594686571646345,0.24053134283536284,"No",0.3290817005735102,0.6709182994264841,"Yes",1.0,5.270066202893287e-16,"No",0.00020316420187356898,0.9997968357981232,"Yes",0.6419613099816847,0.35803869001830835,"Yes",0.9999999869319681,1.3068037910292392e-08,"No",1.5489945385923415e-05,0.9999845100546192,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Revised Protocol 06 incorporating Protocol Amendments 04 09 11 12 14 and 15+Pharmacogenetics Blood Sample Amendment 01 (version 2.0 dated 23-Feb-09) - Site Specific+ Serum Biomarker Amendemnt 13 (Version 1.0 dated 18-Mar-11)- SiteSpecific","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2557752573633755e-106,1.5224477316848178e-14,1.0,"2+",0.9571297283928912,0.042870271607124213,"No",0.36967508045008934,0.6303249195499169,"Yes",1.0,3.589283077054397e-43,"No",9.002965525866923e-15,1.0,"Yes",6.2543711021792816e-15,1.0,"Yes",1.0,3.498900221401673e-39,"No",1.642879640218258e-13,0.9999999999998295,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Revised Protocol 06 incorporating Protocol Amendments 04 09 11 12 14 and 15+ Pharmacogenetics Blood Sample Amendment 01 (version 2.0 dated 23-Feb-09) - Site Specific+ Biomarker Amendment 06 (version 1.0 dated 16-Nov-09) - Site Specific + Serum Biomarker Amendemnt 13 (Version 1.0 dated 18-Mar-11)- Site SpecificRandomizovaná dvojitě zaslepená studie fáze III porovnávající ipilimumab s placebem u pacientů po radioterapii s kastračně rezistentním nádorem prostaty kteří obdrželi předchozí léčbu docetaxelem.Revidovaný protokol č. 6 zahrnující Dodatky k protokolu č. 4 9 11 12 14 a 15+ Dodatek č. 1 pro farmakogenetický výzkum vzorků krve (verze 2.0 datovaná 23. 2. 2009) – specifický dle centra + Dodatek č. 6 pro výzkum biomarkerů (verze 1.0 datovaná 16. 11. 2009) - specifický dle centra + Dodatek č. 13 pro výzkum biomarkerů z krevního séra (verze 1.0 datovaná 18. 3. 2011) - specifický dle centra","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6608557048733004e-247,3.4089337009737354e-45,1.0,"2+",0.9999999999990905,9.456977681721116e-13,"No",6.933015872742423e-11,0.999999999930651,"Yes",1.0,1.6972026287870227e-124,"No",6.849051807217109e-49,1.0,"Yes",7.4114047747367e-44,1.0,"Yes",1.0,1.2954692355201057e-102,"No",1.497180400959527e-44,1.0,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.","DK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.7644578077068788e-42,1.4432331938632763e-06,0.9999985567668018,"2+",0.7594686571646345,0.24053134283536284,"No",0.3290817005735102,0.6709182994264841,"Yes",1.0,5.270066202893287e-16,"No",0.00020316420187356898,0.9997968357981232,"Yes",0.6419613099816847,0.35803869001830835,"Yes",0.9999999869319681,1.3068037910292392e-08,"No",1.5489945385923415e-05,0.9999845100546192,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Ensayo fase 3 aleatorizado doble ciego y comparativo de ipilimumab frente a placebo después de radioterapia en sujetos con cáncer de próstata avanzado y resistente a maniobras de castración previamente tratado con docetaxel","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.442685745365402e-91,1.5422726239657433e-12,0.9999999999984652,"2+",0.86606419129468,0.1339358087053217,"No",0.24420224478298155,0.7557977552170188,"Yes",1.0,1.1040189896398254e-38,"No",1.049057121166907e-08,0.9999999895094335,"Yes",0.5752292286734141,0.4247707713265843,"Yes",1.0,5.572626933498673e-18,"No",1.3597283623586027e-10,0.9999999998640305,"Yes"
"2008-003314-97","A Randomized Double-Blind Phase 3 Trial Comparing Ipilimumab vs. PlaceboFollowing Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.Ensayo fase 3 aleatorizado doble ciego y comparativo de ipilimumab frente a placebo después de radioterapia en sujetos con cáncer de próstata avanzado y resistente a maniobras de castración previamente tratado con docetaxel","GR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.442685745365402e-91,1.5422726239657433e-12,0.9999999999984652,"2+",0.86606419129468,0.1339358087053217,"No",0.24420224478298155,0.7557977552170188,"Yes",1.0,1.1040189896398254e-38,"No",1.049057121166907e-08,0.9999999895094335,"Yes",0.5752292286734141,0.4247707713265843,"Yes",1.0,5.572626933498673e-18,"No",1.3597283623586027e-10,0.9999999998640305,"Yes"
"2008-003617-27","An open phase I/IIa trial to investigate the maximum tolerated dose safetypharmacokinetics and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemia","BE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.522170709725377e-31,0.8044241492371352,0.19557585076285489,"-1",0.00013752057422313204,0.999862479425767,"Yes",0.9998290619539324,0.000170938046065246,"No",0.999999999958419,4.157565031243175e-11,"No",0.8768592066232123,0.12314079337678162,"Yes",0.9890930485948151,0.010906951405173735,"Yes",0.9999999985489296,1.451069041283319e-09,"No",0.9946178713178414,0.005382128682147417,"Yes"
"2008-003617-27","An open phase I/IIa trial to investigate the maximum tolerated dose safetypharmacokinetics and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemia","AT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.522170709725377e-31,0.8044241492371352,0.19557585076285489,"-1",0.00013752057422313204,0.999862479425767,"Yes",0.9998290619539324,0.000170938046065246,"No",0.999999999958419,4.157565031243175e-11,"No",0.8768592066232123,0.12314079337678162,"Yes",0.9890930485948151,0.010906951405173735,"Yes",0.9999999985489296,1.451069041283319e-09,"No",0.9946178713178414,0.005382128682147417,"Yes"
"2008-003617-27","An open phase I/IIa trial to investigate the maximum tolerated dose safetypharmacokinetics and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemia","DE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.522170709725377e-31,0.8044241492371352,0.19557585076285489,"-1",0.00013752057422313204,0.999862479425767,"Yes",0.9998290619539324,0.000170938046065246,"No",0.999999999958419,4.157565031243175e-11,"No",0.8768592066232123,0.12314079337678162,"Yes",0.9890930485948151,0.010906951405173735,"Yes",0.9999999985489296,1.451069041283319e-09,"No",0.9946178713178414,0.005382128682147417,"Yes"
"2008-003800-73","A phase III multicentre randomised double-blind placebo controlled clinical trial to investigate the efficacy and safety of 10 or 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant (LT) patients","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1535038129918186e-69,2.256156093426797e-15,1.0,"-1",0.9999999999939178,6.076374171409648e-12,"No",1.4889612810600126e-09,0.9999999985110435,"Yes",0.999999999966775,3.3220128125058534e-11,"No",8.401291548010014e-16,1.0,"Yes",1.7944476347455198e-06,0.9999982055523631,"Yes",0.9999999999511716,4.883520683141959e-11,"No",2.1477146629970899e-13,0.9999999999997727,"Yes"
"2008-003800-73","A phase II multicentre randomised double-blind placebo controlled clinical trial to investigate the efficacy and safety of 10 or 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant (LT) patients","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.582964149677595e-69,1.0492325911233235e-14,1.0,"-1",0.9999999999863861,1.3621488075482207e-11,"No",3.2055469720386957e-09,0.9999999967944576,"Yes",0.9999999999813838,1.8619625210590933e-11,"No",5.914021791937219e-15,1.0,"Yes",3.925717083963412e-06,0.999996074282908,"Yes",0.9999999999550369,4.495674347487623e-11,"No",1.5835007875281239e-12,0.9999999999984084,"Yes"
"2008-003800-73","A phase II multicentre randomised double-blind placebo controlled clinical trial to investigate the efficacy and safety of 10 or 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant (LT) patients","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.582964149677595e-69,1.0492325911233235e-14,1.0,"-1",0.9999999999863861,1.3621488075482207e-11,"No",3.2055469720386957e-09,0.9999999967944576,"Yes",0.9999999999813838,1.8619625210590933e-11,"No",5.914021791937219e-15,1.0,"Yes",3.925717083963412e-06,0.999996074282908,"Yes",0.9999999999550369,4.495674347487623e-11,"No",1.5835007875281239e-12,0.9999999999984084,"Yes"
"2008-003800-73","A phase III multicentre randomised double-blind placebo controlled clinical trial to investigate the efficacy and safety of 10 or 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant (LT) patients","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1535038129918186e-69,2.256156093426797e-15,1.0,"-1",0.9999999999939178,6.076374171409648e-12,"No",1.4889612810600126e-09,0.9999999985110435,"Yes",0.999999999966775,3.3220128125058534e-11,"No",8.401291548010014e-16,1.0,"Yes",1.7944476347455198e-06,0.9999982055523631,"Yes",0.9999999999511716,4.883520683141959e-11,"No",2.1477146629970899e-13,0.9999999999997727,"Yes"
"2008-003800-73","A phase II multicentre randomised double-blind placebo controlled clinical trial to investigate the efficacy and safety of 10 or 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant (LT) patients","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.582964149677595e-69,1.0492325911233235e-14,1.0,"-1",0.9999999999863861,1.3621488075482207e-11,"No",3.2055469720386957e-09,0.9999999967944576,"Yes",0.9999999999813838,1.8619625210590933e-11,"No",5.914021791937219e-15,1.0,"Yes",3.925717083963412e-06,0.999996074282908,"Yes",0.9999999999550369,4.495674347487623e-11,"No",1.5835007875281239e-12,0.9999999999984084,"Yes"
"2008-003800-73","A phase III multicentre randomised double-blind placebo controlled clinical trial to investigate the efficacy and safety of 10 or 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant (LT) patients","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1535038129918186e-69,2.256156093426797e-15,1.0,"-1",0.9999999999939178,6.076374171409648e-12,"No",1.4889612810600126e-09,0.9999999985110435,"Yes",0.999999999966775,3.3220128125058534e-11,"No",8.401291548010014e-16,1.0,"Yes",1.7944476347455198e-06,0.9999982055523631,"Yes",0.9999999999511716,4.883520683141959e-11,"No",2.1477146629970899e-13,0.9999999999997727,"Yes"
"2008-003995-23","An investigational randomized phase II-(III) study on epirubicin plus cyclophospamide (or CMF) vs nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","","Yes","No","No","Yes","No","Yes","2+","Yes",8.437905637462346e-54,3.16332530100222e-09,0.9999999968366639,"-1",0.00011032537202920039,0.9998896746279612,"Yes",0.9997723610175276,0.00022763898246444707,"No",1.0,6.168388662109217e-15,"No",2.2009636746672752e-05,0.9999779903632545,"Yes",0.4467182526011372,0.5532817473988667,"Yes",0.999999999890605,1.0938700895168374e-10,"No",1.8465957073024088e-07,0.9999998153404193,"Yes"
"2008-003997-17","A randomized phase III study to determine the efficacy of a taxane and bevacizumab with or without capecitabine as first line chemotherapy in patients with metastatic breast cancer","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6920471923396972e-34,0.00360028108865653,0.9963997189113469,"-1",0.0015193852346692778,0.9984806147653241,"Yes",0.9974997889939657,0.0025002110060406324,"No",0.9999999999945857,5.415021045160761e-12,"No",0.04494838864626408,0.9550516113537381,"Yes",0.3268026692906779,0.6731973307093282,"Yes",0.9999999114292462,8.857074979689285e-08,"No",0.005342314062132906,0.9946576859378699,"Yes"
"2008-004338-26","Ensayo clínico abierto aleatorizado de grupos paralelos que compara degarelix frente a bloqueo androgénico combinado (goserelina + bicalutamida) en términos de reducción de la puntuación en la escala internacional de síntomas prostáticos (IPSS) en pacientes con síntomas del tracto urinario inferior (LUTS) asociados a cáncer de próstata localmente avanzadoA randomised parallel-arm open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide) in terms of reduction in International Prostate Symptom Score (IPSS) in patients with lower urinary tract symptoms (LUTS) secondary to locally advanced prostate cancer","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.05329986880142e-90,2.3363423232591355e-19,1.0,"-1",9.71406613241921e-07,0.9999990285933962,"Yes",0.9999999999681677,3.1832410660889046e-11,"No",0.9999999999834017,1.6581416856125752e-11,"No",1.6602494163438254e-16,1.0,"Yes",0.009555648950955554,0.9904443510491008,"Yes",1.0,3.832324551316798e-31,"No",8.137290527652115e-22,1.0,"Yes"
"2008-004338-26","A randomised parallel-arm open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide) in terms of reduction in International Prostate Symptom Score (IPSS) in patients with lower urinary tract symptoms (LUTS) secondary to locally advanced prostate cancer","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.317169086997907e-53,2.2535933927662452e-10,0.9999999997746158,"-1",0.0002464473683384186,0.9997535526316588,"Yes",0.9998766318173571,0.00012336818262439735,"No",1.0,1.4400527403493326e-14,"No",5.405296175953962e-07,0.9999994594703918,"Yes",0.9964888428948524,0.003511157105126725,"Yes",1.0,2.3813493643001837e-14,"No",7.783924467337656e-12,0.9999999999922125,"Yes"
"2008-004338-26","Ensayo clínico abierto aleatorizado de grupos paralelos que compara degarelix frente a bloqueo androgénico combinado (goserelina + bicalutamida) en términos de reducción de la puntuación en la escala internacional de síntomas prostáticos (IPSS) en pacientes con síntomas del tracto urinario inferior (LUTS) asociados a cáncer de próstata localmente avanzadoA randomised parallel-arm open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide) in terms of reduction in International Prostate Symptom Score (IPSS) in patients with lower urinary tract symptoms (LUTS) secondary to locally advanced prostate cancer","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.05329986880142e-90,2.3363423232591355e-19,1.0,"-1",9.71406613241921e-07,0.9999990285933962,"Yes",0.9999999999681677,3.1832410660889046e-11,"No",0.9999999999834017,1.6581416856125752e-11,"No",1.6602494163438254e-16,1.0,"Yes",0.009555648950955554,0.9904443510491008,"Yes",1.0,3.832324551316798e-31,"No",8.137290527652115e-22,1.0,"Yes"
"2008-004496-22","Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to severe renal impairment for the development of nephrogenic systemic fibrosis (NSF) based on diagnostically specific clinical and histopathologic information","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",4.963173857769589e-46,0.10490558009356098,0.8950944199064349,"-1",0.004599686661334908,0.9954003133386623,"Yes",0.9993115887256625,0.0006884112743343947,"No",0.999924536218791,7.54637812180653e-05,"No",0.06576837146348397,0.9342316285365221,"No",0.9626249117006477,0.03737508829935097,"No",0.6319761886341991,0.36802381136581025,"No",0.32304214509716084,0.6769578549028429,"No"
"2008-004496-22","Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to severe renal impairment for the development of nephrogenic systemic fibrosis (NSF) based on diagnostically specific clinical and histopathologic information","AT","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",4.963173857769589e-46,0.10490558009356098,0.8950944199064349,"-1",0.004599686661334908,0.9954003133386623,"Information not present in EudraCT",0.9993115887256625,0.0006884112743343947,"Information not present in EudraCT",0.999924536218791,7.54637812180653e-05,"Information not present in EudraCT",0.06576837146348397,0.9342316285365221,"No",0.9626249117006477,0.03737508829935097,"No",0.6319761886341991,0.36802381136581025,"No",0.32304214509716084,0.6769578549028429,"No"
"2008-004496-22","Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to severe renal impairment for the development of nephrogenic systemic fibrosis (NSF) based on diagnostically specific clinical and histopathologic information","FR","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",4.963173857769589e-46,0.10490558009356098,0.8950944199064349,"-1",0.004599686661334908,0.9954003133386623,"Information not present in EudraCT",0.9993115887256625,0.0006884112743343947,"Information not present in EudraCT",0.999924536218791,7.54637812180653e-05,"Information not present in EudraCT",0.06576837146348397,0.9342316285365221,"No",0.9626249117006477,0.03737508829935097,"No",0.6319761886341991,0.36802381136581025,"No",0.32304214509716084,0.6769578549028429,"No"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","AT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","SE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).Randomizované otevřené multicentrické klinické hodnocení fáze III hodnotící účinnost a bezpečnost přípravku nilotinib oproti přípravku imatinib u dospělých pacientů s diagnózou neoperabilního nebo metastatického gastrointestinálního stromálního tumoru (GIST).","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",3.6822241082061096e-84,5.87380206492181e-10,0.999999999412637,"-1",1.7013793856442398e-10,0.9999999998298678,"Yes",0.9999999998719319,1.280541776559338e-10,"No",1.0,5.2404994393514736e-30,"No",0.0005103031327466086,0.999489696867265,"Yes",0.989341102205741,0.010658897794257032,"Yes",1.0,7.259547792326193e-16,"No",2.5947295812811452e-08,0.9999999740526849,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).Randomizované otevřené multicentrické klinické hodnocení fáze III hodnotící účinnost a bezpečnost přípravku nilotinib oproti přípravku imatinib u dospělých pacientů s diagnózou neoperabilního nebo metastatického gastrointestinálního stromálního tumoru (GIST).","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",3.6822241082061096e-84,5.87380206492181e-10,0.999999999412637,"-1",1.7013793856442398e-10,0.9999999998298678,"Yes",0.9999999998719319,1.280541776559338e-10,"No",1.0,5.2404994393514736e-30,"No",0.0005103031327466086,0.999489696867265,"Yes",0.989341102205741,0.010658897794257032,"Yes",1.0,7.259547792326193e-16,"No",2.5947295812811452e-08,0.9999999740526849,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","HU","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","GB","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","FR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","DK","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).Randomizované otevřené multicentrické klinické hodnocení fáze III hodnotící účinnost a bezpečnost přípravku nilotinib oproti přípravku imatinib u dospělých pacientů s diagnózou neoperabilního nebo metastatického gastrointestinálního stromálního tumoru (GIST).","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",3.6822241082061096e-84,5.87380206492181e-10,0.999999999412637,"-1",1.7013793856442398e-10,0.9999999998298678,"Yes",0.9999999998719319,1.280541776559338e-10,"No",1.0,5.2404994393514736e-30,"No",0.0005103031327466086,0.999489696867265,"Yes",0.989341102205741,0.010658897794257032,"Yes",1.0,7.259547792326193e-16,"No",2.5947295812811452e-08,0.9999999740526849,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).Randomizované otevřené multicentrické klinické hodnocení fáze III hodnotící účinnost a bezpečnost přípravku nilotinib oproti přípravku imatinib u dospělých pacientů s diagnózou neoperabilního nebo metastatického gastrointestinálního stromálního tumoru (GIST).","BG","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",3.6822241082061096e-84,5.87380206492181e-10,0.999999999412637,"-1",1.7013793856442398e-10,0.9999999998298678,"Yes",0.9999999998719319,1.280541776559338e-10,"No",1.0,5.2404994393514736e-30,"No",0.0005103031327466086,0.999489696867265,"Yes",0.989341102205741,0.010658897794257032,"Yes",1.0,7.259547792326193e-16,"No",2.5947295812811452e-08,0.9999999740526849,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-004758-34","A randomized open-label multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).","SK","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","Yes","No","2+","Yes",1.8246411384197817e-39,0.0028191648254349,0.9971808351745625,"-1",4.397041037047647e-09,0.9999999956029627,"Yes",0.9999999923650763,7.63492018434415e-09,"No",0.9999999999998295,1.7435336772831985e-13,"No",0.9376894369965465,0.062310563003460724,"Yes",0.9863757493559318,0.013624250644081577,"Yes",0.9405942980045614,0.05940570199544419,"No",0.008957112361364372,0.9910428876386216,"Yes"
"2008-005011-18","A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4725327268895994e-41,0.001942195114527567,0.9980578048854765,"-1",3.7794650186824223e-08,0.9999999622053516,"Yes",0.9999999009365915,9.906340344473277e-08,"No",1.0,2.4204612520418523e-21,"No",1.3767467755365313e-05,0.9999862325322372,"Yes",0.2897527903974091,0.7102472096025928,"Yes",0.9999854334763771,1.4566523621083132e-05,"No",0.001565782648553737,0.9984342173514391,"Yes"
"2008-005011-18","A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4725327268895994e-41,0.001942195114527567,0.9980578048854765,"-1",3.7794650186824223e-08,0.9999999622053516,"Yes",0.9999999009365915,9.906340344473277e-08,"No",1.0,2.4204612520418523e-21,"No",1.3767467755365313e-05,0.9999862325322372,"Yes",0.2897527903974091,0.7102472096025928,"Yes",0.9999854334763771,1.4566523621083132e-05,"No",0.001565782648553737,0.9984342173514391,"Yes"
"2008-005011-18","A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4725327268895994e-41,0.001942195114527567,0.9980578048854765,"-1",3.7794650186824223e-08,0.9999999622053516,"Yes",0.9999999009365915,9.906340344473277e-08,"No",1.0,2.4204612520418523e-21,"No",1.3767467755365313e-05,0.9999862325322372,"Yes",0.2897527903974091,0.7102472096025928,"Yes",0.9999854334763771,1.4566523621083132e-05,"No",0.001565782648553737,0.9984342173514391,"Yes"
"2008-005056-24","A Phase II randomized double-blind placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC). ","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9896249696206812e-44,4.708941188302962e-12,0.999999999995282,"-1",0.999997626688244,2.3733117421332906e-06,"No",1.6399475359100773e-05,0.9999836005246534,"Yes",0.9999999999999432,5.1539623223739026e-14,"No",5.54716050239965e-10,0.9999999994452793,"Yes",0.07948347563797373,0.920516524362024,"Yes",0.9999984874148495,1.5125851623267655e-06,"No",4.2025531661923104e-10,0.9999999995797424,"Yes"
"2008-005056-24","A Phase II randomized double-blind placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC).Ensayo Fase II aleatorizado doble ciego controlado con placebo de sorafenib en combinación con quimioembolización transarterial (TACE) realizada mediante la asociación de doxorubicina y microesferas como tratamiento para el Carcinoma Hepatocelular en estadío intermedio.","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.3913283390831736e-81,6.778074663617493e-20,1.0,"-1",0.9999999261028193,7.3897194543208e-08,"No",2.7231001829253516e-06,0.999997276899832,"Yes",1.0,5.600786915615462e-24,"No",2.4692011369263325e-16,1.0,"Yes",0.7708188696220937,0.22918113037793425,"Yes",1.0,8.902911896373927e-16,"No",1.2733001123149684e-16,1.0,"Yes"
"2008-005056-24","A Phase II randomized double-blind placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC). ","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9896249696206812e-44,4.708941188302962e-12,0.999999999995282,"-1",0.999997626688244,2.3733117421332906e-06,"No",1.6399475359100773e-05,0.9999836005246534,"Yes",0.9999999999999432,5.1539623223739026e-14,"No",5.54716050239965e-10,0.9999999994452793,"Yes",0.07948347563797373,0.920516524362024,"Yes",0.9999984874148495,1.5125851623267655e-06,"No",4.2025531661923104e-10,0.9999999995797424,"Yes"
"2008-005056-24","A Phase II randomized double-blind placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC). ","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9896249696206812e-44,4.708941188302962e-12,0.999999999995282,"-1",0.999997626688244,2.3733117421332906e-06,"No",1.6399475359100773e-05,0.9999836005246534,"Yes",0.9999999999999432,5.1539623223739026e-14,"No",5.54716050239965e-10,0.9999999994452793,"Yes",0.07948347563797373,0.920516524362024,"Yes",0.9999984874148495,1.5125851623267655e-06,"No",4.2025531661923104e-10,0.9999999995797424,"Yes"
"2008-005056-24","A Phase II randomized double-blind placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC).Ensayo Fase II aleatorizado doble ciego controlado con placebo de sorafenib en combinación con quimioembolización transarterial (TACE) realizada mediante la asociación de doxorubicina y microesferas como tratamiento para el Carcinoma Hepatocelular en estadío intermedio.","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.3913283390831736e-81,6.778074663617493e-20,1.0,"-1",0.9999999261028193,7.3897194543208e-08,"No",2.7231001829253516e-06,0.999997276899832,"Yes",1.0,5.600786915615462e-24,"No",2.4692011369263325e-16,1.0,"Yes",0.7708188696220937,0.22918113037793425,"Yes",1.0,8.902911896373927e-16,"No",1.2733001123149684e-16,1.0,"Yes"
"2008-005056-24","A Phase II randomized double-blind placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC). ","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9896249696206812e-44,4.708941188302962e-12,0.999999999995282,"-1",0.999997626688244,2.3733117421332906e-06,"No",1.6399475359100773e-05,0.9999836005246534,"Yes",0.9999999999999432,5.1539623223739026e-14,"No",5.54716050239965e-10,0.9999999994452793,"Yes",0.07948347563797373,0.920516524362024,"Yes",0.9999984874148495,1.5125851623267655e-06,"No",4.2025531661923104e-10,0.9999999995797424,"Yes"
"2008-005084-34","A randomized double-blind multi-center phase III study of Brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to Sorafenib:the BRISK PS Sudy.","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0586220115018304e-54,8.189136458306253e-17,1.0,"-1",0.9999964937614799,3.5062385266936533e-06,"No",5.930275991385506e-06,0.9999940697240017,"Yes",1.0,3.987535698236365e-24,"No",9.398881799346967e-15,1.0,"Yes",0.002198719702979319,0.9978012802970174,"Yes",1.0,1.4662585430372675e-17,"No",1.1979253624134433e-16,1.0,"Yes"
"2008-005084-34","A randomized double-blind multi-center phase III study of Brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to Sorafenib:the BRISK PS Sudy.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0586220115018304e-54,8.189136458306253e-17,1.0,"-1",0.9999964937614799,3.5062385266936533e-06,"No",5.930275991385506e-06,0.9999940697240017,"Yes",1.0,3.987535698236365e-24,"No",9.398881799346967e-15,1.0,"Yes",0.002198719702979319,0.9978012802970174,"Yes",1.0,1.4662585430372675e-17,"No",1.1979253624134433e-16,1.0,"Yes"
"2008-005084-34","A Randomized Double-blind Multi-center Phase III Study of Brivanib plus BestSupportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK PS Study.Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (v1.0 dated 12-Sep-2008)///  Estudio fase III aleatorizado doble ciego multicéntrico de brivanib más mejor tratamiento de soporte (BSC) frente a placebo más BSC en sujetos con carcinoma hepatocelular (CHC) avanzado con fracaso o intolerancia a sorafenib: estudio BRISK PSEnmienda número 01 - sobre muestras de sangre para farmacogenética - Específica de centro","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.7806431759331e-125,9.017041263895916e-33,1.0,"-1",0.9999999684490609,3.155089909467067e-08,"No",1.5831322772691147e-07,0.9999998416867709,"Yes",1.0,1.8494220047249522e-52,"No",3.3799239165681564e-31,1.0,"Yes",3.787081767337669e-10,0.9999999996213091,"Yes",1.0,4.3274898245391754e-54,"No",1.0327120534476177e-33,1.0,"Yes"
"2008-005084-34","A Randomized Double-blind Multi-center Phase III Study of Brivanib plus BestSupportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK PS Study.Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (v1.0 dated 12-Sep-2008)///  Estudio fase III aleatorizado doble ciego multicéntrico de brivanib más mejor tratamiento de soporte (BSC) frente a placebo más BSC en sujetos con carcinoma hepatocelular (CHC) avanzado con fracaso o intolerancia a sorafenib: estudio BRISK PSEnmienda número 01 - sobre muestras de sangre para farmacogenética - Específica de centro","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.7806431759331e-125,9.017041263895916e-33,1.0,"-1",0.9999999684490609,3.155089909467067e-08,"No",1.5831322772691147e-07,0.9999998416867709,"Yes",1.0,1.8494220047249522e-52,"No",3.3799239165681564e-31,1.0,"Yes",3.787081767337669e-10,0.9999999996213091,"Yes",1.0,4.3274898245391754e-54,"No",1.0327120534476177e-33,1.0,"Yes"
"2008-005084-34","A randomized double-blind multi-center phase III study of Brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to Sorafenib:the BRISK PS Sudy.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0586220115018304e-54,8.189136458306253e-17,1.0,"-1",0.9999964937614799,3.5062385266936533e-06,"No",5.930275991385506e-06,0.9999940697240017,"Yes",1.0,3.987535698236365e-24,"No",9.398881799346967e-15,1.0,"Yes",0.002198719702979319,0.9978012802970174,"Yes",1.0,1.4662585430372675e-17,"No",1.1979253624134433e-16,1.0,"Yes"
"2008-005084-34","A randomized double-blind multi-center phase III study of Brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to Sorafenib:the BRISK PS Sudy.","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0586220115018304e-54,8.189136458306253e-17,1.0,"-1",0.9999964937614799,3.5062385266936533e-06,"No",5.930275991385506e-06,0.9999940697240017,"Yes",1.0,3.987535698236365e-24,"No",9.398881799346967e-15,1.0,"Yes",0.002198719702979319,0.9978012802970174,"Yes",1.0,1.4662585430372675e-17,"No",1.1979253624134433e-16,1.0,"Yes"
"2008-005084-34","A Randomized Double-blind Multi-center Phase III Study of Brivanib plus BestSupportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK Study","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0329547039846417e-50,1.808836716618037e-14,0.9999999999999717,"-1",0.9999825438932441,1.7456106766331934e-05,"No",3.389767582550443e-05,0.9999661023241744,"Yes",1.0,2.2588062448086887e-19,"No",3.101361184094771e-13,0.9999999999996874,"Yes",0.009257999977596418,0.9907420000223939,"Yes",1.0,1.1282327582354165e-15,"No",4.382110480097804e-14,0.9999999999999432,"Yes"
"2008-005215-17","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo para evaluar el efecto global de Solifenacina 5mg y 10 mg sobre el espesor de la pared vesical y el factor de crecimiento nervioso urinario en mujeres con vejiga hiperactiva y diagnóstico de hiperactividad del detrusor.A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity. A double-blind randomized placebo-controlled parallel group multicentre study","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0560859236096564e-105,8.380020235652801e-26,1.0,"-1",1.0,4.239039406740522e-18,"No",9.83472501280124e-15,1.0,"Yes",1.0,3.190329786296141e-22,"No",3.936176483715451e-27,1.0,"Yes",1.4090111635634623e-08,0.9999999859098808,"Yes",1.0,3.0310419721442283e-24,"No",4.462257809586616e-25,1.0,"Yes"
"2008-005215-17","A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind randomized placebo-controlled parallel group multicentre study","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1053845931325434e-52,8.865644995363394e-15,1.0,"-1",0.9999999999994601,5.367938029578066e-13,"No",2.008383374749399e-11,0.9999999999799059,"Yes",1.0,4.299250458982686e-15,"No",9.675455557844062e-17,1.0,"Yes",3.2926285912436416e-05,0.9999670737140838,"Yes",0.9999999999972715,2.7232032826419846e-12,"No",1.643371553231254e-15,1.0,"Yes"
"2008-005215-17","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo para evaluar el efecto global de Solifenacina 5mg y 10 mg sobre el espesor de la pared vesical y el factor de crecimiento nervioso urinario en mujeres con vejiga hiperactiva y diagnóstico de hiperactividad del detrusor.A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity. A double-blind randomized placebo-controlled parallel group multicentre study","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0560859236096564e-105,8.380020235652801e-26,1.0,"-1",1.0,4.239039406740522e-18,"No",9.83472501280124e-15,1.0,"Yes",1.0,3.190329786296141e-22,"No",3.936176483715451e-27,1.0,"Yes",1.4090111635634623e-08,0.9999999859098808,"Yes",1.0,3.0310419721442283e-24,"No",4.462257809586616e-25,1.0,"Yes"
"2008-005215-17","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo para evaluar el efecto global de Solifenacina 5mg y 10 mg sobre el espesor de la pared vesical y el factor de crecimiento nervioso urinario en mujeres con vejiga hiperactiva y diagnóstico de hiperactividad del detrusor.A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity. A double-blind randomized placebo-controlled parallel group multicentre study","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0560859236096564e-105,8.380020235652801e-26,1.0,"-1",1.0,4.239039406740522e-18,"No",9.83472501280124e-15,1.0,"Yes",1.0,3.190329786296141e-22,"No",3.936176483715451e-27,1.0,"Yes",1.4090111635634623e-08,0.9999999859098808,"Yes",1.0,3.0310419721442283e-24,"No",4.462257809586616e-25,1.0,"Yes"
"2008-005215-17","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo para evaluar el efecto global de Solifenacina 5mg y 10 mg sobre el espesor de la pared vesical y el factor de crecimiento nervioso urinario en mujeres con vejiga hiperactiva y diagnóstico de hiperactividad del detrusor.A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity. A double-blind randomized placebo-controlled parallel group multicentre study","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0560859236096564e-105,8.380020235652801e-26,1.0,"-1",1.0,4.239039406740522e-18,"No",9.83472501280124e-15,1.0,"Yes",1.0,3.190329786296141e-22,"No",3.936176483715451e-27,1.0,"Yes",1.4090111635634623e-08,0.9999999859098808,"Yes",1.0,3.0310419721442283e-24,"No",4.462257809586616e-25,1.0,"Yes"
"2008-005215-17","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo para evaluar el efecto global de Solifenacina 5mg y 10 mg sobre el espesor de la pared vesical y el factor de crecimiento nervioso urinario en mujeres con vejiga hiperactiva y diagnóstico de hiperactividad del detrusor.A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity. A double-blind randomized placebo-controlled parallel group multicentre study","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0560859236096564e-105,8.380020235652801e-26,1.0,"-1",1.0,4.239039406740522e-18,"No",9.83472501280124e-15,1.0,"Yes",1.0,3.190329786296141e-22,"No",3.936176483715451e-27,1.0,"Yes",1.4090111635634623e-08,0.9999999859098808,"Yes",1.0,3.0310419721442283e-24,"No",4.462257809586616e-25,1.0,"Yes"
"2008-005215-17","A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind randomized placebo-controlled parallel group multicentre study","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1053845931325434e-52,8.865644995363394e-15,1.0,"-1",0.9999999999994601,5.367938029578066e-13,"No",2.008383374749399e-11,0.9999999999799059,"Yes",1.0,4.299250458982686e-15,"No",9.675455557844062e-17,1.0,"Yes",3.2926285912436416e-05,0.9999670737140838,"Yes",0.9999999999972715,2.7232032826419846e-12,"No",1.643371553231254e-15,1.0,"Yes"
"2008-005215-17","A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind randomized placebo-controlled parallel group multicentre study","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1053845931325434e-52,8.865644995363394e-15,1.0,"-1",0.9999999999994601,5.367938029578066e-13,"No",2.008383374749399e-11,0.9999999999799059,"Yes",1.0,4.299250458982686e-15,"No",9.675455557844062e-17,1.0,"Yes",3.2926285912436416e-05,0.9999670737140838,"Yes",0.9999999999972715,2.7232032826419846e-12,"No",1.643371553231254e-15,1.0,"Yes"
"2008-005215-17","A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind randomized placebo-controlled parallel group multicentre study","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1053845931325434e-52,8.865644995363394e-15,1.0,"-1",0.9999999999994601,5.367938029578066e-13,"No",2.008383374749399e-11,0.9999999999799059,"Yes",1.0,4.299250458982686e-15,"No",9.675455557844062e-17,1.0,"Yes",3.2926285912436416e-05,0.9999670737140838,"Yes",0.9999999999972715,2.7232032826419846e-12,"No",1.643371553231254e-15,1.0,"Yes"
"2008-005215-17","Estudio multicéntrico aleatorizado doble ciego de grupos paralelos controlado con placebo para evaluar el efecto global de Solifenacina 5mg y 10 mg sobre el espesor de la pared vesical y el factor de crecimiento nervioso urinario en mujeres con vejiga hiperactiva y diagnóstico de hiperactividad del detrusor.A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity. A double-blind randomized placebo-controlled parallel group multicentre study","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0560859236096564e-105,8.380020235652801e-26,1.0,"-1",1.0,4.239039406740522e-18,"No",9.83472501280124e-15,1.0,"Yes",1.0,3.190329786296141e-22,"No",3.936176483715451e-27,1.0,"Yes",1.4090111635634623e-08,0.9999999859098808,"Yes",1.0,3.0310419721442283e-24,"No",4.462257809586616e-25,1.0,"Yes"
"2008-005215-17","A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind randomized placebo-controlled parallel group multicentre study","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1053845931325434e-52,8.865644995363394e-15,1.0,"-1",0.9999999999994601,5.367938029578066e-13,"No",2.008383374749399e-11,0.9999999999799059,"Yes",1.0,4.299250458982686e-15,"No",9.675455557844062e-17,1.0,"Yes",3.2926285912436416e-05,0.9999670737140838,"Yes",0.9999999999972715,2.7232032826419846e-12,"No",1.643371553231254e-15,1.0,"Yes"
"2008-005215-17","A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A double-blind randomized placebo-controlled parallel group multicentre study","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1053845931325434e-52,8.865644995363394e-15,1.0,"-1",0.9999999999994601,5.367938029578066e-13,"No",2.008383374749399e-11,0.9999999999799059,"Yes",1.0,4.299250458982686e-15,"No",9.675455557844062e-17,1.0,"Yes",3.2926285912436416e-05,0.9999670737140838,"Yes",0.9999999999972715,2.7232032826419846e-12,"No",1.643371553231254e-15,1.0,"Yes"
"2008-005232-33","A randomised parallel arm open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide) in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1877090037769e-52,1.5003653292977388e-10,0.9999999998499902,"-1",9.94850289785497e-08,0.9999999005149839,"Yes",0.9999998178393124,1.8216070637368635e-07,"No",1.0,2.6995776540914154e-21,"No",1.0487113162211126e-06,0.9999989512886984,"Yes",0.995449775959155,0.004550224040854166,"Yes",0.9999999999999432,5.2746700999648455e-14,"No",1.6753817355440165e-11,0.9999999999832312,"Yes"
"2008-005232-33","A randomised parallel arm open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide) in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1877090037769e-52,1.5003653292977388e-10,0.9999999998499902,"-1",9.94850289785497e-08,0.9999999005149839,"Yes",0.9999998178393124,1.8216070637368635e-07,"No",1.0,2.6995776540914154e-21,"No",1.0487113162211126e-06,0.9999989512886984,"Yes",0.995449775959155,0.004550224040854166,"Yes",0.9999999999999432,5.2746700999648455e-14,"No",1.6753817355440165e-11,0.9999999999832312,"Yes"
"2008-005232-33","A randomised parallel arm open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide) in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1877090037769e-52,1.5003653292977388e-10,0.9999999998499902,"-1",9.94850289785497e-08,0.9999999005149839,"Yes",0.9999998178393124,1.8216070637368635e-07,"No",1.0,2.6995776540914154e-21,"No",1.0487113162211126e-06,0.9999989512886984,"Yes",0.995449775959155,0.004550224040854166,"Yes",0.9999999999999432,5.2746700999648455e-14,"No",1.6753817355440165e-11,0.9999999999832312,"Yes"
"2008-005232-33","A randomised parallel arm open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide) in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1877090037769e-52,1.5003653292977388e-10,0.9999999998499902,"-1",9.94850289785497e-08,0.9999999005149839,"Yes",0.9999998178393124,1.8216070637368635e-07,"No",1.0,2.6995776540914154e-21,"No",1.0487113162211126e-06,0.9999989512886984,"Yes",0.995449775959155,0.004550224040854166,"Yes",0.9999999999999432,5.2746700999648455e-14,"No",1.6753817355440165e-11,0.9999999999832312,"Yes"
"2008-005232-33","A randomised parallel arm open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide) in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1877090037769e-52,1.5003653292977388e-10,0.9999999998499902,"-1",9.94850289785497e-08,0.9999999005149839,"Yes",0.9999998178393124,1.8216070637368635e-07,"No",1.0,2.6995776540914154e-21,"No",1.0487113162211126e-06,0.9999989512886984,"Yes",0.995449775959155,0.004550224040854166,"Yes",0.9999999999999432,5.2746700999648455e-14,"No",1.6753817355440165e-11,0.9999999999832312,"Yes"
"2008-005232-33","A randomised parallel arm open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide) in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1877090037769e-52,1.5003653292977388e-10,0.9999999998499902,"-1",9.94850289785497e-08,0.9999999005149839,"Yes",0.9999998178393124,1.8216070637368635e-07,"No",1.0,2.6995776540914154e-21,"No",1.0487113162211126e-06,0.9999989512886984,"Yes",0.995449775959155,0.004550224040854166,"Yes",0.9999999999999432,5.2746700999648455e-14,"No",1.6753817355440165e-11,0.9999999999832312,"Yes"
"2008-005276-27","An Open-Label Multi-Centre Randomised Parallel-Arm One-Year Trial Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.9223954354572834e-43,6.549559015677857e-07,0.9999993450440896,"-1",5.181259389320652e-06,0.9999948187405969,"Yes",0.9999950137587175,4.986241279651044e-06,"No",0.999999999902002,9.799721342799304e-11,"No",0.00020066433113051765,0.9997993356688767,"Yes",0.72664259497836,0.2733574050216299,"Yes",0.9999999999982094,1.798453158433346e-12,"No",1.924838102440252e-06,0.9999980751619029,"Yes"
"2008-005276-27","An Open-Label Multi-Centre Randomised Parallel-Arm One-Year Trial Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.9223954354572834e-43,6.549559015677857e-07,0.9999993450440896,"-1",5.181259389320652e-06,0.9999948187405969,"Yes",0.9999950137587175,4.986241279651044e-06,"No",0.999999999902002,9.799721342799304e-11,"No",0.00020066433113051765,0.9997993356688767,"Yes",0.72664259497836,0.2733574050216299,"Yes",0.9999999999982094,1.798453158433346e-12,"No",1.924838102440252e-06,0.9999980751619029,"Yes"
"2008-005276-27","An Open-Label Multi-Centre Randomised Parallel-Arm One-Year Trial Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.9223954354572834e-43,6.549559015677857e-07,0.9999993450440896,"-1",5.181259389320652e-06,0.9999948187405969,"Yes",0.9999950137587175,4.986241279651044e-06,"No",0.999999999902002,9.799721342799304e-11,"No",0.00020066433113051765,0.9997993356688767,"Yes",0.72664259497836,0.2733574050216299,"Yes",0.9999999999982094,1.798453158433346e-12,"No",1.924838102440252e-06,0.9999980751619029,"Yes"
"2008-005276-27","An Open-Label Multi-Centre Randomised Parallel-Arm One-Year Trial Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.9223954354572834e-43,6.549559015677857e-07,0.9999993450440896,"-1",5.181259389320652e-06,0.9999948187405969,"Yes",0.9999950137587175,4.986241279651044e-06,"No",0.999999999902002,9.799721342799304e-11,"No",0.00020066433113051765,0.9997993356688767,"Yes",0.72664259497836,0.2733574050216299,"Yes",0.9999999999982094,1.798453158433346e-12,"No",1.924838102440252e-06,0.9999980751619029,"Yes"
"2008-005276-27","An Open-Label Multi-Centre Randomised Parallel-Arm One-Year Trial Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.9223954354572834e-43,6.549559015677857e-07,0.9999993450440896,"-1",5.181259389320652e-06,0.9999948187405969,"Yes",0.9999950137587175,4.986241279651044e-06,"No",0.999999999902002,9.799721342799304e-11,"No",0.00020066433113051765,0.9997993356688767,"Yes",0.72664259497836,0.2733574050216299,"Yes",0.9999999999982094,1.798453158433346e-12,"No",1.924838102440252e-06,0.9999980751619029,"Yes"
"2008-005276-27","An Open-Label Multi-Centre Randomised Parallel-Arm One-Year Trial Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.9223954354572834e-43,6.549559015677857e-07,0.9999993450440896,"-1",5.181259389320652e-06,0.9999948187405969,"Yes",0.9999950137587175,4.986241279651044e-06,"No",0.999999999902002,9.799721342799304e-11,"No",0.00020066433113051765,0.9997993356688767,"Yes",0.72664259497836,0.2733574050216299,"Yes",0.9999999999982094,1.798453158433346e-12,"No",1.924838102440252e-06,0.9999980751619029,"Yes"
"2008-005276-27","An Open-Label Multi-Centre Randomised Parallel-Arm One-Year Trial Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.9223954354572834e-43,6.549559015677857e-07,0.9999993450440896,"-1",5.181259389320652e-06,0.9999948187405969,"Yes",0.9999950137587175,4.986241279651044e-06,"No",0.999999999902002,9.799721342799304e-11,"No",0.00020066433113051765,0.9997993356688767,"Yes",0.72664259497836,0.2733574050216299,"Yes",0.9999999999982094,1.798453158433346e-12,"No",1.924838102440252e-06,0.9999980751619029,"Yes"
"2008-006021-14","A Phase III  randomized placebo controlled double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.776489267412794e-53,1.580115837166344e-14,0.9999999999999717,"-1",0.9999989589449588,1.0410550504517433e-06,"No",4.645010696286899e-06,0.9999953549893114,"Yes",1.0,4.014753795183656e-16,"No",2.320584537957591e-12,0.9999999999976694,"Yes",0.009823824271822547,0.9901761757281662,"Yes",0.9999999968124486,3.187556312415552e-09,"No",1.336116851361927e-12,0.9999999999986642,"Yes"
"2008-006021-14","A Phase III  randomized placebo controlled double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)","GR","Yes","No","No","","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.776489267412794e-53,1.580115837166344e-14,0.9999999999999717,"-1",0.9999989589449588,1.0410550504517433e-06,"Information not present in EudraCT",4.645010696286899e-06,0.9999953549893114,"Yes",1.0,4.014753795183656e-16,"Information not present in EudraCT",2.320584537957591e-12,0.9999999999976694,"Yes",0.009823824271822547,0.9901761757281662,"Yes",0.9999999968124486,3.187556312415552e-09,"No",1.336116851361927e-12,0.9999999999986642,"Yes"
"2008-006021-14","A Phase III  randomized placebo controlled double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.776489267412794e-53,1.580115837166344e-14,0.9999999999999717,"-1",0.9999989589449588,1.0410550504517433e-06,"No",4.645010696286899e-06,0.9999953549893114,"Yes",1.0,4.014753795183656e-16,"No",2.320584537957591e-12,0.9999999999976694,"Yes",0.009823824271822547,0.9901761757281662,"Yes",0.9999999968124486,3.187556312415552e-09,"No",1.336116851361927e-12,0.9999999999986642,"Yes"
"2008-006021-14","A Phase III  randomized placebo controlled double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)","FR","Yes","No","No","","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.776489267412794e-53,1.580115837166344e-14,0.9999999999999717,"-1",0.9999989589449588,1.0410550504517433e-06,"Information not present in EudraCT",4.645010696286899e-06,0.9999953549893114,"Yes",1.0,4.014753795183656e-16,"Information not present in EudraCT",2.320584537957591e-12,0.9999999999976694,"Yes",0.009823824271822547,0.9901761757281662,"Yes",0.9999999968124486,3.187556312415552e-09,"No",1.336116851361927e-12,0.9999999999986642,"Yes"
"2008-006021-14","A Phase III  randomized placebo controlled double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.776489267412794e-53,1.580115837166344e-14,0.9999999999999717,"-1",0.9999989589449588,1.0410550504517433e-06,"No",4.645010696286899e-06,0.9999953549893114,"Yes",1.0,4.014753795183656e-16,"No",2.320584537957591e-12,0.9999999999976694,"Yes",0.009823824271822547,0.9901761757281662,"Yes",0.9999999968124486,3.187556312415552e-09,"No",1.336116851361927e-12,0.9999999999986642,"Yes"
"2008-006021-14","A Phase III  randomized placebo controlled double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.776489267412794e-53,1.580115837166344e-14,0.9999999999999717,"-1",0.9999989589449588,1.0410550504517433e-06,"No",4.645010696286899e-06,0.9999953549893114,"Yes",1.0,4.014753795183656e-16,"No",2.320584537957591e-12,0.9999999999976694,"Yes",0.009823824271822547,0.9901761757281662,"Yes",0.9999999968124486,3.187556312415552e-09,"No",1.336116851361927e-12,0.9999999999986642,"Yes"
"2008-006021-14","A Phase III  randomized placebo controlled double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.776489267412794e-53,1.580115837166344e-14,0.9999999999999717,"-1",0.9999989589449588,1.0410550504517433e-06,"No",4.645010696286899e-06,0.9999953549893114,"Yes",1.0,4.014753795183656e-16,"No",2.320584537957591e-12,0.9999999999976694,"Yes",0.009823824271822547,0.9901761757281662,"Yes",0.9999999968124486,3.187556312415552e-09,"No",1.336116851361927e-12,0.9999999999986642,"Yes"
"2008-006021-14","A Phase III  randomized placebo controlled double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.776489267412794e-53,1.580115837166344e-14,0.9999999999999717,"-1",0.9999989589449588,1.0410550504517433e-06,"No",4.645010696286899e-06,0.9999953549893114,"Yes",1.0,4.014753795183656e-16,"No",2.320584537957591e-12,0.9999999999976694,"Yes",0.009823824271822547,0.9901761757281662,"Yes",0.9999999968124486,3.187556312415552e-09,"No",1.336116851361927e-12,0.9999999999986642,"Yes"
"2008-006021-14","A Phase III  randomized placebo controlled double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)","DE","Yes","No","No","","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.776489267412794e-53,1.580115837166344e-14,0.9999999999999717,"-1",0.9999989589449588,1.0410550504517433e-06,"Information not present in EudraCT",4.645010696286899e-06,0.9999953549893114,"Yes",1.0,4.014753795183656e-16,"Information not present in EudraCT",2.320584537957591e-12,0.9999999999976694,"Yes",0.009823824271822547,0.9901761757281662,"Yes",0.9999999968124486,3.187556312415552e-09,"No",1.336116851361927e-12,0.9999999999986642,"Yes"
"2008-006181-28","A single arm multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer","FR","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.9946520715517647e-33,0.9957544411372107,0.004245558862786064,"-1",0.0011230573686008426,0.9988769426314061,"Information not present in EudraCT",0.998937644525376,0.0010623554746204075,"Information not present in EudraCT",0.9999995909311521,4.090688447959256e-07,"Information not present in EudraCT",0.9990795029437385,0.0009204970562637375,"No",0.956803500006107,0.04319649999389929,"",0.9995290496654441,0.00047095033455113087,"",0.998220404080721,0.0017795959192803833,""
"2008-006181-28","A single arm multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer","ES","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.9946520715517647e-33,0.9957544411372107,0.004245558862786064,"-1",0.0011230573686008426,0.9988769426314061,"Information not present in EudraCT",0.998937644525376,0.0010623554746204075,"Information not present in EudraCT",0.9999995909311521,4.090688447959256e-07,"Information not present in EudraCT",0.9990795029437385,0.0009204970562637375,"No",0.956803500006107,0.04319649999389929,"",0.9995290496654441,0.00047095033455113087,"",0.998220404080721,0.0017795959192803833,""
"2008-006181-28","A single arm multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer","GB","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.9946520715517647e-33,0.9957544411372107,0.004245558862786064,"-1",0.0011230573686008426,0.9988769426314061,"Information not present in EudraCT",0.998937644525376,0.0010623554746204075,"Information not present in EudraCT",0.9999995909311521,4.090688447959256e-07,"Information not present in EudraCT",0.9990795029437385,0.0009204970562637375,"No",0.956803500006107,0.04319649999389929,"",0.9995290496654441,0.00047095033455113087,"",0.998220404080721,0.0017795959192803833,""
"2008-006181-28","RAPTOR: Estudio de fase II de RAD001 multicéntrico con un solo grupo como monoterapia para el tratamiento  del carcinoma papilar avanzado de células renales","BE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.7262986021430455e-30,0.9999529894269967,4.701057300364439e-05,"-1",1.6836101141310106e-05,0.999983163898865,"Information not present in EudraCT",0.9999825567981376,1.7443201867456144e-05,"Information not present in EudraCT",0.9999999994450378,5.549654250381411e-10,"Information not present in EudraCT",0.9999697580539563,3.0241946040446635e-05,"No",0.9951519800799288,0.004848019920078059,"",0.9999999821681345,1.783185324429139e-08,"",0.999977769017064,2.2230982940288685e-05,""
"2008-006181-28","RAPTOR: Estudio de fase II de RAD001 multicéntrico con un solo grupo como monoterapia para el tratamiento  del carcinoma papilar avanzado de células renales","DE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.7262986021430455e-30,0.9999529894269967,4.701057300364439e-05,"-1",1.6836101141310106e-05,0.999983163898865,"Information not present in EudraCT",0.9999825567981376,1.7443201867456144e-05,"Information not present in EudraCT",0.9999999994450378,5.549654250381411e-10,"Information not present in EudraCT",0.9999697580539563,3.0241946040446635e-05,"No",0.9951519800799288,0.004848019920078059,"",0.9999999821681345,1.783185324429139e-08,"",0.999977769017064,2.2230982940288685e-05,""
"2008-006300-27","Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -","NL","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",4.8876440927057636e-33,0.9994218058037577,0.0005781941962368631,"-1",1.216781012466223e-05,0.9999878321898775,"Information not present in EudraCT",0.9999894617952434,1.053820475745569e-05,"Information not present in EudraCT",0.9999999980293667,1.9706306287533643e-09,"Information not present in EudraCT",0.9991174183220851,0.0008825816779170728,"No",0.994153568596035,0.005846431403961738,"",0.9999990797656977,9.202343031669377e-07,"",0.9997036638865412,0.0002963361134517436,""
"2008-006300-27","Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -","DE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",4.8876440927057636e-33,0.9994218058037577,0.0005781941962368631,"-1",1.216781012466223e-05,0.9999878321898775,"Information not present in EudraCT",0.9999894617952434,1.053820475745569e-05,"Information not present in EudraCT",0.9999999980293667,1.9706306287533643e-09,"Information not present in EudraCT",0.9991174183220851,0.0008825816779170728,"No",0.994153568596035,0.005846431403961738,"",0.9999990797656977,9.202343031669377e-07,"",0.9997036638865412,0.0002963361134517436,""
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment (START)","FI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment (START) ","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment(START) ","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment(START) ","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment (START) ","EE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment (START)","GR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment (START)","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment (START)","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Momento Estratégico para el Inicio de la Terapia AntiretroviralStrategic Timing of AntiRetroviral Treatment (START)","PT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.000972766035845473,0.007053407509044956,0.991973826455111,"-1",0.13270776245282023,0.8672922375471734,"Yes",0.8879666501076257,0.11203334989237837,"No",0.9999738255119777,2.6174488015595424e-05,"No",0.004863701711103734,0.9951362982889022,"Yes",0.7105316938897955,0.2894683061102026,"Yes",0.9999996273767506,3.7262325580710134e-07,"No",0.005367124474841344,0.994632875525152,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment(START) ","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment (START) ","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Momento Estratégico para el Inicio de la Terapia AntiretroviralStrategic Timing of AntiRetroviral Treatment (START)","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.000972766035845473,0.007053407509044956,0.991973826455111,"-1",0.13270776245282023,0.8672922375471734,"Yes",0.8879666501076257,0.11203334989237837,"No",0.9999738255119777,2.6174488015595424e-05,"No",0.004863701711103734,0.9951362982889022,"Yes",0.7105316938897955,0.2894683061102026,"Yes",0.9999996273767506,3.7262325580710134e-07,"No",0.005367124474841344,0.994632875525152,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment (START) ","NO","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006439-12","Strategic Timing of AntiRetroviral Treatment (START) ","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",0.020148828580827883,0.004956371369065689,0.974894800050106,"-1",0.20633264997884052,0.7936673500211565,"Yes",0.8265689381983101,0.17343106180168746,"No",0.9983660171869642,0.0016339828130350882,"No",0.0041868009164584006,0.9958131990835384,"Yes",0.2042838467098139,0.795716153290187,"Yes",0.9999153564588452,8.464354115313651e-05,"No",0.005362692706858363,0.994637307293139,"Yes"
"2008-006801-17","A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) ","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.158885199619187e-56,0.10584867267818389,0.8941513273218139,"2+",2.8698861845709013e-07,0.9999997130113755,"Yes",0.9999994089806463,5.910193619171618e-07,"No",1.0,8.565367139989789e-23,"No",0.8058683609945549,0.19413163900543615,"Yes",0.8428049631986263,0.15719503680137262,"Yes",0.9999999506247276,4.937526182220828e-08,"Yes",0.17354202034360167,0.8264579796564092,"Yes"
"2008-006801-17","A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) ","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.158885199619187e-56,0.10584867267818389,0.8941513273218139,"2+",2.8698861845709013e-07,0.9999997130113755,"Yes",0.9999994089806463,5.910193619171618e-07,"No",1.0,8.565367139989789e-23,"No",0.8058683609945549,0.19413163900543615,"Yes",0.8428049631986263,0.15719503680137262,"Yes",0.9999999506247276,4.937526182220828e-08,"Yes",0.17354202034360167,0.8264579796564092,"Yes"
"2008-006801-17","Estudio de fase II multicéntrico aleatorizado para comparar la combinación de trastuzumab y capecitabina con o sin pertuzumab en pacientes con cáncer de mama metastático positivo para HER2 que hayan progresado tras una línea de tratamiento basado en trastuzumab en el contexto metastásico (PHEREXA).A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA)","NL","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.805579315850271e-112,0.24114058274296363,0.758859417257056,"2+",4.3732593991354434e-16,1.0,"Yes",1.0,1.7679376589033756e-15,"No",1.0,1.2589548158761821e-48,"No",0.9994734830266484,0.0005265169733798759,"Yes",0.9777381136176552,0.022261886382360915,"Yes",1.0,4.242045054021703e-23,"Yes",0.8232462595308203,0.17675374046919698,"Yes"
"2008-006801-17","Estudio de fase II multicéntrico aleatorizado para comparar la combinación de trastuzumab y capecitabina con o sin pertuzumab en pacientes con cáncer de mama metastático positivo para HER2 que hayan progresado tras una línea de tratamiento basado en trastuzumab en el contexto metastásico (PHEREXA).A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA)","FR","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.805579315850271e-112,0.24114058274296363,0.758859417257056,"2+",4.3732593991354434e-16,1.0,"Yes",1.0,1.7679376589033756e-15,"No",1.0,1.2589548158761821e-48,"No",0.9994734830266484,0.0005265169733798759,"Yes",0.9777381136176552,0.022261886382360915,"Yes",1.0,4.242045054021703e-23,"Yes",0.8232462595308203,0.17675374046919698,"Yes"
"2008-006801-17","A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) ","EE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.158885199619187e-56,0.10584867267818389,0.8941513273218139,"2+",2.8698861845709013e-07,0.9999997130113755,"Yes",0.9999994089806463,5.910193619171618e-07,"No",1.0,8.565367139989789e-23,"No",0.8058683609945549,0.19413163900543615,"Yes",0.8428049631986263,0.15719503680137262,"Yes",0.9999999506247276,4.937526182220828e-08,"Yes",0.17354202034360167,0.8264579796564092,"Yes"
"2008-006801-17","A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) ","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.158885199619187e-56,0.10584867267818389,0.8941513273218139,"2+",2.8698861845709013e-07,0.9999997130113755,"Yes",0.9999994089806463,5.910193619171618e-07,"No",1.0,8.565367139989789e-23,"No",0.8058683609945549,0.19413163900543615,"Yes",0.8428049631986263,0.15719503680137262,"Yes",0.9999999506247276,4.937526182220828e-08,"Yes",0.17354202034360167,0.8264579796564092,"Yes"
"2008-006801-17","Estudio de fase II multicéntrico aleatorizado para comparar la combinación de trastuzumab y capecitabina con o sin pertuzumab en pacientes con cáncer de mama metastático positivo para HER2 que hayan progresado tras una línea de tratamiento basado en trastuzumab en el contexto metastásico (PHEREXA).A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA)","BE","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.805579315850271e-112,0.24114058274296363,0.758859417257056,"2+",4.3732593991354434e-16,1.0,"Yes",1.0,1.7679376589033756e-15,"No",1.0,1.2589548158761821e-48,"No",0.9994734830266484,0.0005265169733798759,"Yes",0.9777381136176552,0.022261886382360915,"Yes",1.0,4.242045054021703e-23,"Yes",0.8232462595308203,0.17675374046919698,"Yes"
"2008-006801-17","A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) ","GB","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.158885199619187e-56,0.10584867267818389,0.8941513273218139,"2+",2.8698861845709013e-07,0.9999997130113755,"Yes",0.9999994089806463,5.910193619171618e-07,"No",1.0,8.565367139989789e-23,"No",0.8058683609945549,0.19413163900543615,"Yes",0.8428049631986263,0.15719503680137262,"Yes",0.9999999506247276,4.937526182220828e-08,"Yes",0.17354202034360167,0.8264579796564092,"Yes"
"2008-006801-17","A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) ","AT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.158885199619187e-56,0.10584867267818389,0.8941513273218139,"2+",2.8698861845709013e-07,0.9999997130113755,"Yes",0.9999994089806463,5.910193619171618e-07,"No",1.0,8.565367139989789e-23,"No",0.8058683609945549,0.19413163900543615,"Yes",0.8428049631986263,0.15719503680137262,"Yes",0.9999999506247276,4.937526182220828e-08,"Yes",0.17354202034360167,0.8264579796564092,"Yes"
"2008-006801-17","A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) ","HU","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.158885199619187e-56,0.10584867267818389,0.8941513273218139,"2+",2.8698861845709013e-07,0.9999997130113755,"Yes",0.9999994089806463,5.910193619171618e-07,"No",1.0,8.565367139989789e-23,"No",0.8058683609945549,0.19413163900543615,"Yes",0.8428049631986263,0.15719503680137262,"Yes",0.9999999506247276,4.937526182220828e-08,"Yes",0.17354202034360167,0.8264579796564092,"Yes"
"2008-006801-17","A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA) ","IT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.158885199619187e-56,0.10584867267818389,0.8941513273218139,"2+",2.8698861845709013e-07,0.9999997130113755,"Yes",0.9999994089806463,5.910193619171618e-07,"No",1.0,8.565367139989789e-23,"No",0.8058683609945549,0.19413163900543615,"Yes",0.8428049631986263,0.15719503680137262,"Yes",0.9999999506247276,4.937526182220828e-08,"Yes",0.17354202034360167,0.8264579796564092,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","GR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","FR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","PT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","PL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","SK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","DK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","FI","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006831-10","Multicenter randomised double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1370425837954368e-58,5.445248410007646e-12,0.999999999994543,"-1",0.9996539004208365,0.0003460995791653519,"No",0.0011415809356780748,0.9988584190643238,"Yes",0.9999999999994884,5.057113172542459e-13,"No",2.126970739757821e-08,0.9999999787303014,"Yes",0.5704191324151594,0.4295808675848446,"Yes",0.9999509222229058,4.9077777085755306e-05,"No",1.97793186283654e-09,0.9999999980220764,"Yes"
"2008-006871-60","Dose-intensified Rechallenge with Temozolomide One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1643856110470192e-27,0.008530636690014652,0.9914693633099906,"-1",0.3159414441505737,0.684058555849428,"Yes",0.6335138987437455,0.3664861012562523,"No",0.9999984721235811,1.527876419128898e-06,"No",0.011720489147753484,0.9882795108522483,"Yes",0.0516331074135553,0.9483668925864505,"Yes",0.9999999988597494,1.1402466897105906e-09,"No",0.0031757359856117275,0.9968242640143905,"Yes"
"2008-006871-60","Dose-intensified Rechallenge with Temozolomide One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1643856110470192e-27,0.008530636690014652,0.9914693633099906,"-1",0.3159414441505737,0.684058555849428,"Yes",0.6335138987437455,0.3664861012562523,"No",0.9999984721235811,1.527876419128898e-06,"No",0.011720489147753484,0.9882795108522483,"Yes",0.0516331074135553,0.9483668925864505,"Yes",0.9999999988597494,1.1402466897105906e-09,"No",0.0031757359856117275,0.9968242640143905,"Yes"
"2008-006954-17","AN OPEN-LABEL MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) ","AT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2113610839064634e-33,0.9999498547719499,5.0145228057214425e-05,"-1",1.4401791812648153e-05,0.99998559820818,"Yes",0.9999852272934002,1.4772706586953735e-05,"No",0.9999999851154656,1.4884529641705114e-08,"No",0.9998978421694026,0.00010215783060629872,"Yes",0.9988972800735011,0.00110271992650066,"No",0.9999329162492193,6.708375079247221e-05,"No",0.9999748621565597,2.513784342985793e-05,"No"
"2008-006954-17","AN OPEN-LABEL MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) ","ES","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2113610839064634e-33,0.9999498547719499,5.0145228057214425e-05,"-1",1.4401791812648153e-05,0.99998559820818,"Yes",0.9999852272934002,1.4772706586953735e-05,"No",0.9999999851154656,1.4884529641705114e-08,"No",0.9998978421694026,0.00010215783060629872,"Yes",0.9988972800735011,0.00110271992650066,"No",0.9999329162492193,6.708375079247221e-05,"No",0.9999748621565597,2.513784342985793e-05,"No"
"2008-006954-17","AN OPEN-LABEL MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)","NL","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2113610839064634e-33,0.9999498547719499,5.0145228057214425e-05,"-1",1.4401791812648153e-05,0.99998559820818,"Yes",0.9999852272934002,1.4772706586953735e-05,"No",0.9999999851154656,1.4884529641705114e-08,"No",0.9998978421694026,0.00010215783060629872,"Yes",0.9988972800735011,0.00110271992650066,"No",0.9999329162492193,6.708375079247221e-05,"No",0.9999748621565597,2.513784342985793e-05,"No"
"2008-006954-17","AN OPEN-LABEL MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) ","SE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2113610839064634e-33,0.9999498547719499,5.0145228057214425e-05,"-1",1.4401791812648153e-05,0.99998559820818,"Yes",0.9999852272934002,1.4772706586953735e-05,"No",0.9999999851154656,1.4884529641705114e-08,"No",0.9998978421694026,0.00010215783060629872,"Yes",0.9988972800735011,0.00110271992650066,"No",0.9999329162492193,6.708375079247221e-05,"No",0.9999748621565597,2.513784342985793e-05,"No"
"2008-006954-17","AN OPEN-LABEL MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)","GB","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2113610839064634e-33,0.9999498547719499,5.0145228057214425e-05,"-1",1.4401791812648153e-05,0.99998559820818,"Yes",0.9999852272934002,1.4772706586953735e-05,"No",0.9999999851154656,1.4884529641705114e-08,"No",0.9998978421694026,0.00010215783060629872,"Yes",0.9988972800735011,0.00110271992650066,"No",0.9999329162492193,6.708375079247221e-05,"No",0.9999748621565597,2.513784342985793e-05,"No"
"2008-006954-17","AN OPEN-LABEL MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)","FR","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2113610839064634e-33,0.9999498547719499,5.0145228057214425e-05,"-1",1.4401791812648153e-05,0.99998559820818,"Yes",0.9999852272934002,1.4772706586953735e-05,"No",0.9999999851154656,1.4884529641705114e-08,"No",0.9998978421694026,0.00010215783060629872,"Yes",0.9988972800735011,0.00110271992650066,"No",0.9999329162492193,6.708375079247221e-05,"No",0.9999748621565597,2.513784342985793e-05,"No"
"2008-006954-17","AN OPEN-LABEL MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)","DE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2113610839064634e-33,0.9999498547719499,5.0145228057214425e-05,"-1",1.4401791812648153e-05,0.99998559820818,"Yes",0.9999852272934002,1.4772706586953735e-05,"No",0.9999999851154656,1.4884529641705114e-08,"No",0.9998978421694026,0.00010215783060629872,"Yes",0.9988972800735011,0.00110271992650066,"No",0.9999329162492193,6.708375079247221e-05,"No",0.9999748621565597,2.513784342985793e-05,"No"
"2008-007008-27","Open label study of bevacizumab maintenance therapy (AVASTIN) with or without pemetrexed after a first line treatment chemotherapy with bevacizumab-cisplatin-pemetrexed in patients with advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)","NL","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","Yes","No","Yes","2+","Yes",4.3862172122837313e-51,1.2083791806709894e-06,0.9999987916208309,"-1",9.203183505114792e-10,0.9999999990796766,"Information not present in EudraCT",0.9999999965016003,3.4983986159298275e-09,"Information not present in EudraCT",1.0,2.66942374474827e-34,"Information not present in EudraCT",0.05762672321934019,0.9423732767806617,"No",0.9840210386274955,0.015978961372495402,"",1.0,4.950842486734434e-20,"",5.539616618009534e-07,0.9999994460383278,""
"2008-007008-27","Open label study of bevacizumab maintenance therapy (AVASTIN) with or without pemetrexed after a first line treatment chemotherapy with bevacizumab-cisplatin-pemetrexed in patients with advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)","ES","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","Yes","No","Yes","2+","Yes",4.3862172122837313e-51,1.2083791806709894e-06,0.9999987916208309,"-1",9.203183505114792e-10,0.9999999990796766,"Information not present in EudraCT",0.9999999965016003,3.4983986159298275e-09,"Information not present in EudraCT",1.0,2.66942374474827e-34,"Information not present in EudraCT",0.05762672321934019,0.9423732767806617,"No",0.9840210386274955,0.015978961372495402,"",1.0,4.950842486734434e-20,"",5.539616618009534e-07,0.9999994460383278,""
"2008-007008-27","Open label study of bevacizumab maintenance therapy (AVASTIN) with or without pemetrexed after a first line treatment chemotherapy with bevacizumab-cisplatin-pemetrexed in patients with advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)","SE","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","Yes","No","Yes","2+","Yes",4.3862172122837313e-51,1.2083791806709894e-06,0.9999987916208309,"-1",9.203183505114792e-10,0.9999999990796766,"Information not present in EudraCT",0.9999999965016003,3.4983986159298275e-09,"Information not present in EudraCT",1.0,2.66942374474827e-34,"Information not present in EudraCT",0.05762672321934019,0.9423732767806617,"No",0.9840210386274955,0.015978961372495402,"",1.0,4.950842486734434e-20,"",5.539616618009534e-07,0.9999994460383278,""
"2008-007008-27","Estudio abierto de terapia de mantenimiento con bevacizumab (AVASTIN) con o sin pemetrexed tras una quimioterapia de primera línea con bevacizumab-cisplatino-pemetrexed en pacientes con cáncer de pulmón no microcítico (NSCLC) no escamoso avanzado metastásico o recurrente Open label study of bevacizumab maintenance therapy (AVASTIN) with or without pemetrexed after a first line treatment chemotherapy with bevacizumab-cisplatin-pemetrexed in patients with advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)","DE","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","Yes","No","Yes","2+","Yes",2.758802538954602e-99,3.807630459919704e-14,0.9999999999999432,"-1",1.832984599523928e-17,1.0,"Information not present in EudraCT",1.0,1.8861100478863398e-16,"Information not present in EudraCT",1.0,5.874266061071593e-65,"Information not present in EudraCT",1.7808617465959456e-06,0.999998219138257,"No",0.9993448640211992,0.0006551359788079961,"",1.0,5.20104920473411e-53,"",1.2541946939034574e-14,1.0,""
"2008-007008-27","Estudio abierto de terapia de mantenimiento con bevacizumab (AVASTIN) con o sin pemetrexed tras una quimioterapia de primera línea con bevacizumab-cisplatino-pemetrexed en pacientes con cáncer de pulmón no microcítico (NSCLC) no escamoso avanzado metastásico o recurrente Open label study of bevacizumab maintenance therapy (AVASTIN) with or without pemetrexed after a first line treatment chemotherapy with bevacizumab-cisplatin-pemetrexed in patients with advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)","GR","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","Yes","No","Yes","2+","Yes",2.758802538954602e-99,3.807630459919704e-14,0.9999999999999432,"-1",1.832984599523928e-17,1.0,"Information not present in EudraCT",1.0,1.8861100478863398e-16,"Information not present in EudraCT",1.0,5.874266061071593e-65,"Information not present in EudraCT",1.7808617465959456e-06,0.999998219138257,"No",0.9993448640211992,0.0006551359788079961,"",1.0,5.20104920473411e-53,"",1.2541946939034574e-14,1.0,""
"2008-007008-27","Open label study of bevacizumab maintenance therapy (AVASTIN®) with or without pemetrexed after a first line treatment chemotherapy with bevacizumab-cisplatin-pemetrexed in patients with advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","","","Yes","No","No","Yes","No","Yes","2+","Yes",4.3862172122837313e-51,1.2083791806709894e-06,0.9999987916208309,"-1",9.203183505114792e-10,0.9999999990796766,"Yes",0.9999999965016003,3.4983986159298275e-09,"No",1.0,2.66942374474827e-34,"No",0.05762672321934019,0.9423732767806617,"No",0.9840210386274955,0.015978961372495402,"",1.0,4.950842486734434e-20,"",5.539616618009534e-07,0.9999994460383278,""
"2008-007087-42","A Phase III Randomized Double-Blind Parallel Group Placebo Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1984446167959725e-59,1.315757148454577e-14,1.0,"-1",1.0,5.211169969215474e-15,"No",2.7528236667634652e-14,0.9999999999999717,"Yes",0.9999999999950546,4.932036855261523e-12,"No",3.0886759255513197e-12,0.9999999999969021,"Yes",1.836189431349414e-06,0.9999981638105827,"Yes",0.9999996036060499,3.963939452403373e-07,"No",1.515694089074897e-13,0.9999999999998579,"Yes"
"2008-007087-42","A Phase III Randomized Double-Blind Parallel Group Placebo Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1984446167959725e-59,1.315757148454577e-14,1.0,"-1",1.0,5.211169969215474e-15,"No",2.7528236667634652e-14,0.9999999999999717,"Yes",0.9999999999950546,4.932036855261523e-12,"No",3.0886759255513197e-12,0.9999999999969021,"Yes",1.836189431349414e-06,0.9999981638105827,"Yes",0.9999996036060499,3.963939452403373e-07,"No",1.515694089074897e-13,0.9999999999998579,"Yes"
"2008-007087-42","A Phase III Randomized Double-Blind Parallel Group Placebo Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1984446167959725e-59,1.315757148454577e-14,1.0,"-1",1.0,5.211169969215474e-15,"No",2.7528236667634652e-14,0.9999999999999717,"Yes",0.9999999999950546,4.932036855261523e-12,"No",3.0886759255513197e-12,0.9999999999969021,"Yes",1.836189431349414e-06,0.9999981638105827,"Yes",0.9999996036060499,3.963939452403373e-07,"No",1.515694089074897e-13,0.9999999999998579,"Yes"
"2008-007087-42","A Phase III Randomized Double-Blind Parallel Group Placebo Controlled Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1984446167959725e-59,1.315757148454577e-14,1.0,"-1",1.0,5.211169969215474e-15,"No",2.7528236667634652e-14,0.9999999999999717,"Yes",0.9999999999950546,4.932036855261523e-12,"No",3.0886759255513197e-12,0.9999999999969021,"Yes",1.836189431349414e-06,0.9999981638105827,"Yes",0.9999996036060499,3.963939452403373e-07,"No",1.515694089074897e-13,0.9999999999998579,"Yes"
"2008-007609-36","Prospektiv randomisierte multizentrische Phase II-Studie zur Metastasenresektion von Lungenfiliae (poor-prognosis) beim klarzelligen Nierenzellkarzinom +/- adjuvante Sunitinibtherapie über 1 Jahr - SMAT","DE","No","No","Yes","ok","No","No","No","No","1","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.091006642322811e-23,0.6045540250117512,0.3954459749882427,"-1",0.0032845686686679555,0.9967154313313413,"No",0.9995176912854753,0.00048230871453131186,"Yes",0.9866889355715331,0.013311064428473369,"No",0.8699450162298341,0.1300549837701633,"Yes",0.9798494476454528,0.020150552354543723,"Yes",0.9999735969591681,2.640304083794234e-05,"No",0.769448350769343,0.2305516492306611,"Yes"
"2008-007645-31","Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie- PRIMAIN-Studie -","DE","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",6.794402152858788e-22,0.2719078021180495,0.728092197881942,"-1",0.010165706616405515,0.9898342933835891,"Information not present in EudraCT",0.990421745886806,0.009578254113186383,"Information not present in EudraCT",0.9998547285620638,0.0001452714379342767,"Information not present in EudraCT",0.008542692134668819,0.99145730786534,"No",0.7306975065981532,0.26930249340183315,"",0.9999999501712593,4.9828734196974074e-08,"",0.09591293740753756,0.9040870625924521,""
"2008-007969-23","Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.66973020348308e-57,0.029478442333270134,0.9705215576667141,"-1",7.113471072155087e-06,0.9999928865289347,"No",0.9999858705616065,1.4129438405339753e-05,"Yes",1.0,5.4879240706075245e-21,"No",0.3392817603492399,0.6607182396507782,"Yes",0.9627216680246025,0.03727833197540265,"Yes",1.0,1.0059843214753763e-16,"No",0.16380136202031334,0.836198637979699,"Yes"
"2008-007969-23","A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.114022379320236e-23,0.04766791580671264,0.9523320841932931,"-1",0.0643785812774348,0.9356214187225695,"No",0.9023532118617091,0.09764678813828416,"Yes",0.999999999993193,6.807984477018595e-12,"No",0.1165141490534305,0.88348585094657,"Yes",0.5133800301823053,0.4866199698176958,"Yes",0.9999983610255259,1.6389744750826636e-06,"No",0.05603465170249477,0.9439653482975001,"Yes"
"2008-007969-23","A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.114022379320236e-23,0.04766791580671264,0.9523320841932931,"-1",0.0643785812774348,0.9356214187225695,"No",0.9023532118617091,0.09764678813828416,"Yes",0.999999999993193,6.807984477018595e-12,"No",0.1165141490534305,0.88348585094657,"Yes",0.5133800301823053,0.4866199698176958,"Yes",0.9999983610255259,1.6389744750826636e-06,"No",0.05603465170249477,0.9439653482975001,"Yes"
"2008-007969-23","Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.66973020348308e-57,0.029478442333270134,0.9705215576667141,"-1",7.113471072155087e-06,0.9999928865289347,"No",0.9999858705616065,1.4129438405339753e-05,"Yes",1.0,5.4879240706075245e-21,"No",0.3392817603492399,0.6607182396507782,"Yes",0.9627216680246025,0.03727833197540265,"Yes",1.0,1.0059843214753763e-16,"No",0.16380136202031334,0.836198637979699,"Yes"
"2008-007969-23","Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.66973020348308e-57,0.029478442333270134,0.9705215576667141,"-1",7.113471072155087e-06,0.9999928865289347,"No",0.9999858705616065,1.4129438405339753e-05,"Yes",1.0,5.4879240706075245e-21,"No",0.3392817603492399,0.6607182396507782,"Yes",0.9627216680246025,0.03727833197540265,"Yes",1.0,1.0059843214753763e-16,"No",0.16380136202031334,0.836198637979699,"Yes"
"2008-007969-23","A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.114022379320236e-23,0.04766791580671264,0.9523320841932931,"-1",0.0643785812774348,0.9356214187225695,"No",0.9023532118617091,0.09764678813828416,"Yes",0.999999999993193,6.807984477018595e-12,"No",0.1165141490534305,0.88348585094657,"Yes",0.5133800301823053,0.4866199698176958,"Yes",0.9999983610255259,1.6389744750826636e-06,"No",0.05603465170249477,0.9439653482975001,"Yes"
"2008-007969-23","Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.66973020348308e-57,0.029478442333270134,0.9705215576667141,"-1",7.113471072155087e-06,0.9999928865289347,"No",0.9999858705616065,1.4129438405339753e-05,"Yes",1.0,5.4879240706075245e-21,"No",0.3392817603492399,0.6607182396507782,"Yes",0.9627216680246025,0.03727833197540265,"Yes",1.0,1.0059843214753763e-16,"No",0.16380136202031334,0.836198637979699,"Yes"
"2008-007969-23","A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.114022379320236e-23,0.04766791580671264,0.9523320841932931,"-1",0.0643785812774348,0.9356214187225695,"No",0.9023532118617091,0.09764678813828416,"Yes",0.999999999993193,6.807984477018595e-12,"No",0.1165141490534305,0.88348585094657,"Yes",0.5133800301823053,0.4866199698176958,"Yes",0.9999983610255259,1.6389744750826636e-06,"No",0.05603465170249477,0.9439653482975001,"Yes"
"2008-007969-23","Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.66973020348308e-57,0.029478442333270134,0.9705215576667141,"-1",7.113471072155087e-06,0.9999928865289347,"No",0.9999858705616065,1.4129438405339753e-05,"Yes",1.0,5.4879240706075245e-21,"No",0.3392817603492399,0.6607182396507782,"Yes",0.9627216680246025,0.03727833197540265,"Yes",1.0,1.0059843214753763e-16,"No",0.16380136202031334,0.836198637979699,"Yes"
"2008-007969-23","A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.114022379320236e-23,0.04766791580671264,0.9523320841932931,"-1",0.0643785812774348,0.9356214187225695,"No",0.9023532118617091,0.09764678813828416,"Yes",0.999999999993193,6.807984477018595e-12,"No",0.1165141490534305,0.88348585094657,"Yes",0.5133800301823053,0.4866199698176958,"Yes",0.9999983610255259,1.6389744750826636e-06,"No",0.05603465170249477,0.9439653482975001,"Yes"
"2008-007969-23","A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.114022379320236e-23,0.04766791580671264,0.9523320841932931,"-1",0.0643785812774348,0.9356214187225695,"No",0.9023532118617091,0.09764678813828416,"Yes",0.999999999993193,6.807984477018595e-12,"No",0.1165141490534305,0.88348585094657,"Yes",0.5133800301823053,0.4866199698176958,"Yes",0.9999983610255259,1.6389744750826636e-06,"No",0.05603465170249477,0.9439653482975001,"Yes"
"2008-007969-23","A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.114022379320236e-23,0.04766791580671264,0.9523320841932931,"-1",0.0643785812774348,0.9356214187225695,"No",0.9023532118617091,0.09764678813828416,"Yes",0.999999999993193,6.807984477018595e-12,"No",0.1165141490534305,0.88348585094657,"Yes",0.5133800301823053,0.4866199698176958,"Yes",0.9999983610255259,1.6389744750826636e-06,"No",0.05603465170249477,0.9439653482975001,"Yes"
"2008-008004-41","A Phase 3 Randomized Double-blind Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","","","No","No","Yes","Yes","No","Yes","2+","Yes",7.1043725593855e-51,4.988267197758313e-09,0.9999999950117343,"2+",0.999997478230366,2.521769628861966e-06,"No",6.035608184715815e-06,0.9999939643918158,"Yes",1.0,5.031173464170153e-17,"No",1.728676937361676e-08,0.9999999827132344,"No",0.17863934406093623,0.8213606559390605,"No",0.9998755272199185,0.0001244727800889364,"No",1.6773699583517872e-08,0.9999999832263031,"No"
"2008-008004-41","A Phase 3 Randomized Double-blind Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisolone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","","","No","No","Yes","Yes","No","Yes","2+","Yes",3.7637275001551607e-50,3.9990476559819294e-10,0.9999999996001065,"2+",0.9999997135835896,2.864164223499288e-07,"No",6.8551174051321e-07,0.9999993144882714,"Yes",1.0,2.802639560583189e-16,"No",1.0569464586793805e-08,0.9999999894305348,"No",0.08483792206826535,0.9151620779317438,"No",0.9992780937451073,0.0007219062548831054,"No",2.0811904341377102e-08,0.9999999791880898,"No"
"2008-008004-41","A Phase 3 Randomized Double-blind Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisolone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","","","No","No","Yes","Yes","No","Yes","2+","Yes",3.7637275001551607e-50,3.9990476559819294e-10,0.9999999996001065,"2+",0.9999997135835896,2.864164223499288e-07,"No",6.8551174051321e-07,0.9999993144882714,"Yes",1.0,2.802639560583189e-16,"No",1.0569464586793805e-08,0.9999999894305348,"No",0.08483792206826535,0.9151620779317438,"No",0.9992780937451073,0.0007219062548831054,"No",2.0811904341377102e-08,0.9999999791880898,"No"
"2008-008004-41","A Phase 3 Randomized Double-blind Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisolone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","","","No","No","Yes","Yes","No","Yes","2+","Yes",3.7637275001551607e-50,3.9990476559819294e-10,0.9999999996001065,"2+",0.9999997135835896,2.864164223499288e-07,"No",6.8551174051321e-07,0.9999993144882714,"Yes",1.0,2.802639560583189e-16,"No",1.0569464586793805e-08,0.9999999894305348,"No",0.08483792206826535,0.9151620779317438,"No",0.9992780937451073,0.0007219062548831054,"No",2.0811904341377102e-08,0.9999999791880898,"No"
"2008-008198-73","An open label uncontrolled multicentre multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR) through the use of TH9402 and light treatment in an ex vivo process in atients receiving a CD34-selected peripheral blood stem cell graft from a related halpoidentical donor.","NL","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",7.886453391642537e-39,0.9999999247205011,7.527948483527132e-08,"-1",6.147964782773116e-15,1.0,"Information not present in EudraCT",1.0,9.051550097178633e-15,"Information not present in EudraCT",1.0,1.7473345148540685e-15,"Information not present in EudraCT",0.9980211825996224,0.0019788174004044135,"Yes",0.9999999751031513,2.489682271825374e-08,"Yes",0.9999997887369088,2.1126308099657881e-07,"No",0.9999998492146575,1.5078534941752645e-07,"No"
"2008-008198-73","An open-label uncontrolled multicenter multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR) through the use of TH9402 and light treatment in an ex vivo process in patients receiving a CD34-selected peripheral blood stem cell graft from a related haploidentical donor.","GB","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.0813015945336347e-44,0.9999999695203888,3.047960869886546e-08,"-1",3.446385399807148e-17,1.0,"Yes",1.0,5.743900154014113e-17,"No",1.0,3.2209188349843904e-17,"No",0.9993604921821075,0.000639507817897256,"Yes",0.999999980908058,1.9091962035660187e-08,"Yes",0.9999999880336078,1.196639256484688e-08,"No",0.9999995161710479,4.838289726894919e-07,"No"
"2008-008198-73","An open-label uncontrolled multicenter multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR) through the use of TH9402 and light treatment in an ex vivo process in patients receiving a CD34-selected peripheral blood stem cell graft from a related haploidentical donor.","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.0813015945336347e-44,0.9999999695203888,3.047960869886546e-08,"-1",3.446385399807148e-17,1.0,"Yes",1.0,5.743900154014113e-17,"No",1.0,3.2209188349843904e-17,"No",0.9993604921821075,0.000639507817897256,"Yes",0.999999980908058,1.9091962035660187e-08,"Yes",0.9999999880336078,1.196639256484688e-08,"No",0.9999995161710479,4.838289726894919e-07,"No"
"2008-008198-73","An open label uncontrolled multicentre multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR) through the use of TH9402 and light treatment in an ex vivo process in atients receiving a CD34-selected peripheral blood stem cell graft from a related halpoidentical donor.","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",7.886453391642537e-39,0.9999999247205011,7.527948483527132e-08,"-1",6.147964782773116e-15,1.0,"Yes",1.0,9.051550097178633e-15,"No",1.0,1.7473345148540685e-15,"No",0.9980211825996224,0.0019788174004044135,"Yes",0.9999999751031513,2.489682271825374e-08,"Yes",0.9999997887369088,2.1126308099657881e-07,"No",0.9999998492146575,1.5078534941752645e-07,"No"
"2009-010143-13","Prospective randomized phase-II trial with Temsirolimus versus Sunitinib in previously untreated patients with advanced or metastatic non-clear cell renal carcinoma","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.133765953070584e-46,0.08441172089456418,0.915588279105437,"-1",1.3023299742980761e-07,0.9999998697670037,"Yes",0.999999760647356,2.393526433579545e-07,"No",1.0,1.2364303096608666e-16,"No",0.003143469252753976,0.9968565307472411,"Yes",0.3906658356130301,0.6093341643869671,"No",0.9999589667456595,4.10332543393265e-05,"No",0.026273341725065173,0.9737266582749405,"Yes"
"2009-010403-84","A one year open label multicenter trial of LBH589 alone or in combination with ESA in red blood cell transfusion-dependent LOW and INT-1 MDS patients being either refractory to ESA or with a low probability of response  – the GErman PAnobinostat low Risk MDS trial","DE","No","No","Yes","ok","Yes","No","No","No","1","No","No","Yes","No","No","No","No","No","2+","No",4.587597854823723e-48,0.879442946767139,0.1205570532328544,"-1",9.504998462544735e-09,0.9999999904950131,"Yes",0.999999977790225,2.2209761820811075e-08,"No",1.0,1.6250616729352757e-19,"No",0.9963074719812912,0.003692528018721435,"Yes",0.9342233611517965,0.06577663884820366,"Yes",0.9999999999970441,2.9638947316664147e-12,"No",0.4787282643895296,0.521271735610471,"Yes"
"2009-010760-42","A proof-of-concept Phase II study to evaluate  efficacy safety and pharmacokinetics of 4SC-201  and the treatment combination of Sorafenib plus  4SC-201 in patients with hepatocellular carcinoma  exhibiting progressive disease under Sorafenib  treatmentStudio di fase II di prova di concetto per la valutazione dell'efficacia la sicurezza e la farmacocinetica di 4SC-201 e della combinazione terapeutica di Sorafenib piu' DSC-201 in pazienti affetti da carcinoma epatocellulare che dimostrano patologia progressiva con trattamento a base di Sorafenib","DE","No","No","Yes","","No","No","Yes","No","2+","","","Yes","No","No","No","No","Yes","2+","No",8.973614178749883e-101,0.09291789161395955,0.9070821083860151,"-1",8.781402592704828e-07,0.9999991218597178,"Information not present in EudraCT",0.9999976702178939,2.3297820814548374e-06,"Information not present in EudraCT",1.0,6.992368704992636e-35,"Information not present in EudraCT",0.9754123937608006,0.02458760623917816,"No",0.008477667977198131,0.9915223320227835,"",1.0,1.357554872457078e-16,"",0.9865002108379157,0.01349978916208199,""
"2009-011056-21","An open-label multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed  by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.225849971258804e-49,0.044597819228997956,0.9554021807709934,"-1",9.171046528582594e-10,0.9999999990828883,"Yes",0.9999999968829628,3.1170300444749587e-09,"No",1.0,1.7344067829177277e-25,"No",0.00016492927792939184,0.9998350707220824,"Yes",0.6160004852455637,0.3839995147544303,"No",0.9999999843841751,1.561581634688572e-08,"Yes",0.3138469185427173,0.6861530814572835,"Yes"
"2009-011056-21","An open-label multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma","ES","No","No","Yes","","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.225849971258804e-49,0.044597819228997956,0.9554021807709934,"-1",9.171046528582594e-10,0.9999999990828883,"Information not present in EudraCT",0.9999999968829628,3.1170300444749587e-09,"Information not present in EudraCT",1.0,1.7344067829177277e-25,"Information not present in EudraCT",0.00016492927792939184,0.9998350707220824,"Yes",0.6160004852455637,0.3839995147544303,"No",0.9999999843841751,1.561581634688572e-08,"Yes",0.3138469185427173,0.6861530814572835,"Yes"
"2009-011056-21","Estudio fase II multicéntrico abierto para comparar la eficacia y seguridad de RAD001 en primera línea seguido de sunitinib en segunda línea frente a sunitinib en primera línea seguido de RAD001 en segunda línea en el tratamiento de pacientes con carcinoma de células renales metastásico","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.1567122968033664e-48,2.03188838676602e-06,0.999997968111604,"-1",1.0063737122271055e-11,0.9999999999899387,"Yes",0.999999999977888,2.2118448652960494e-11,"No",1.0,3.379608000679636e-27,"No",1.5417074180033628e-05,0.9999845829258182,"Yes",0.3581906548440971,0.6418093451558831,"No",1.0,2.648594590420817e-30,"Yes",0.013066534712915454,0.9869334652870967,"Yes"
"2009-011056-21","An open-label multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed  by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.225849971258804e-49,0.044597819228997956,0.9554021807709934,"-1",9.171046528582594e-10,0.9999999990828883,"Yes",0.9999999968829628,3.1170300444749587e-09,"No",1.0,1.7344067829177277e-25,"No",0.00016492927792939184,0.9998350707220824,"Yes",0.6160004852455637,0.3839995147544303,"No",0.9999999843841751,1.561581634688572e-08,"Yes",0.3138469185427173,0.6861530814572835,"Yes"
"2009-011056-21","An open-label multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinomaEt åbent fase II multicenterforsøg der har til formål at sammenligne virkningen af og sikkerheden ved RAD001 som førstelinjebehandling efterfulgt af andenlinje sunitinib over for sunitinib som førstelinjebehandling efterfulgt af andenlinje RAD001 til behandling af patienter med metastatisk renalcellekarcinom","FR","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0382783346975725e-79,0.053849220337144385,0.9461507796628584,"-1",6.730213405557753e-16,1.0,"Yes",1.0,3.3497895753045345e-16,"No",1.0,2.2164037477294853e-26,"No",9.296874114205755e-05,0.9999070312588849,"Yes",0.9999994880521005,5.119478924404221e-07,"No",0.999082946286311,0.0009170537137163751,"Yes",0.6588473248887469,0.34115267511126063,"Yes"
"2009-011056-21","An open-label multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinomaEt åbent fase II multicenterforsøg der har til formål at sammenligne virkningen af og sikkerheden ved RAD001 som førstelinjebehandling efterfulgt af andenlinje sunitinib over for sunitinib som førstelinjebehandling efterfulgt af andenlinje RAD001 til behandling af patienter med metastatisk renalcellekarcinom","DE","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0382783346975725e-79,0.053849220337144385,0.9461507796628584,"-1",6.730213405557753e-16,1.0,"Yes",1.0,3.3497895753045345e-16,"No",1.0,2.2164037477294853e-26,"No",9.296874114205755e-05,0.9999070312588849,"Yes",0.9999994880521005,5.119478924404221e-07,"No",0.999082946286311,0.0009170537137163751,"Yes",0.6588473248887469,0.34115267511126063,"Yes"
"2009-011252-22","Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.518936660110796e-36,5.335710525794018e-05,0.9999466428947528,"-1",0.004947204507327191,0.9950527954926637,"Yes",0.9925961846197011,0.007403815380297345,"No",0.999999964064586,3.593542115499607e-08,"No",6.602164858159759e-06,0.9999933978351357,"Yes",0.017502982802691813,0.982497017197303,"Yes",0.9999999999719478,2.8047194243926776e-11,"No",0.001516169548460389,0.9984838304515374,"Yes"
"2009-011454-17","Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia - A European paediatric oncology off-patent medicines consortium protocol.","DE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.2692698837090905e-32,0.9690246019861161,0.03097539801389121,"-1",7.382855339872938e-06,0.9999926171446673,"Information not present in EudraCT",0.9999996504465444,3.495534652919465e-07,"Information not present in EudraCT",0.9999748289039393,2.5171096072750616e-05,"Information not present in EudraCT",0.9986869893449433,0.0013130106550613971,"No",0.9999791854678741,2.081453213285098e-05,"",0.9999999196454075,8.035458872968579e-08,"",0.9994540320673357,0.0005459679326604789,""
"2009-011454-17","Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia - A European paediatric oncology off-patent medicines consortium protocol.","FR","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.2692698837090905e-32,0.9690246019861161,0.03097539801389121,"-1",7.382855339872938e-06,0.9999926171446673,"Information not present in EudraCT",0.9999996504465444,3.495534652919465e-07,"Information not present in EudraCT",0.9999748289039393,2.5171096072750616e-05,"Information not present in EudraCT",0.9986869893449433,0.0013130106550613971,"No",0.9999791854678741,2.081453213285098e-05,"",0.9999999196454075,8.035458872968579e-08,"",0.9994540320673357,0.0005459679326604789,""
"2009-011454-17","Etude pharmacocinétique de la doxorubicine en fonction de l'âge chez des enfants atteints de tumeurs ou leucémies.","GB","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.1236178291190917e-17,0.9974593084371155,0.0025406915628902586,"-1",1.5319451583839408e-06,0.9999984680548348,"Information not present in EudraCT",0.9999991890065892,8.109934109768957e-07,"Information not present in EudraCT",0.9999001776381838,9.982236181580543e-05,"Information not present in EudraCT",0.9998928287191893,0.00010717128081491124,"No",0.9994445378670038,0.0005554621330025693,"",0.9856627943116681,0.014337205688328294,"",0.9997113290647246,0.0002886709352754533,""
"2009-011902-41","Split-dose TPF-Induction chemotherapy before Surgery of Oropharyngeal and cavity of the mouth Cancer","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",4.057761845716598e-15,0.01704343568948571,0.9829565643105121,"-1",0.44342639893539487,0.5565736010646033,"Yes",0.8306370536540859,0.16936294634591392,"No",0.663114974192559,0.3368850258074418,"No",0.0005290144603628838,0.9994709855396338,"Yes",0.9727062024119107,0.027293797588087528,"No",0.9999898369406586,1.0163059346376514e-05,"No",0.0005799848302365958,0.9994200151697594,"No"
"2009-011925-14","A multicentre open label phase I/randomised phase II study to evaluatesafety pharmacokinetics and efficacy of BIBF 1120 in comparison withSorafenib for advanced hepatocellular carcinoma patients","HU","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.5700522901561135e-30,0.029102892437592547,0.9708971075624024,"2+",1.0851639632234426e-05,0.9999891483603744,"Yes",0.9999860880154012,1.3911984597135666e-05,"No",0.9999999940267515,5.973253708917486e-09,"No",0.9120685664881294,0.08793143351186376,"Yes",0.9823328149998465,0.017667185000155034,"Yes",0.9998518241258488,0.00014817587414506402,"No",0.8029089552935983,0.19709104470640257,"Yes"
"2009-011925-14","A multicentre open label phase I/randomised phase II study to evaluatesafety pharmacokinetics and efficacy of BIBF 1120 in comparison withSorafenib for advanced hepatocellular carcinoma patients","SK","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.5700522901561135e-30,0.029102892437592547,0.9708971075624024,"2+",1.0851639632234426e-05,0.9999891483603744,"Yes",0.9999860880154012,1.3911984597135666e-05,"No",0.9999999940267515,5.973253708917486e-09,"No",0.9120685664881294,0.08793143351186376,"Yes",0.9823328149998465,0.017667185000155034,"Yes",0.9998518241258488,0.00014817587414506402,"No",0.8029089552935983,0.19709104470640257,"Yes"
"2009-011925-14","A multicentre open label phase I/randomised phase II study to evaluatesafety pharmacokinetics and efficacy of BIBF 1120 in comparison withSorafenib for advanced hepatocellular carcinoma patients","NL","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.5700522901561135e-30,0.029102892437592547,0.9708971075624024,"2+",1.0851639632234426e-05,0.9999891483603744,"Yes",0.9999860880154012,1.3911984597135666e-05,"No",0.9999999940267515,5.973253708917486e-09,"No",0.9120685664881294,0.08793143351186376,"Yes",0.9823328149998465,0.017667185000155034,"Yes",0.9998518241258488,0.00014817587414506402,"No",0.8029089552935983,0.19709104470640257,"Yes"
"2009-011925-14","A multicenter open label phase I / II study to evaluate safety pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients. ","GB","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.359869877779174e-31,0.12220853636593618,0.8777914636340582,"2+",3.8385374617024995e-06,0.9999961614625394,"Yes",0.9999932854244565,6.714575536964784e-06,"No",0.9999999999971153,2.8795288475447503e-12,"No",0.9953255950933079,0.0046744049066863,"Yes",0.9830015375993395,0.016998462400655914,"Yes",0.9999953752963865,4.6247036153835535e-06,"No",0.9734495778761493,0.026550422123845733,"Yes"
"2009-011925-14","A multicentre open label phase I/randomised phase II study to evaluatesafety pharmacokinetics and efficacy of BIBF 1120 in comparison withSorafenib for advanced hepatocellular carcinoma patients","AT","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.5700522901561135e-30,0.029102892437592547,0.9708971075624024,"2+",1.0851639632234426e-05,0.9999891483603744,"Yes",0.9999860880154012,1.3911984597135666e-05,"No",0.9999999940267515,5.973253708917486e-09,"No",0.9120685664881294,0.08793143351186376,"Yes",0.9823328149998465,0.017667185000155034,"Yes",0.9998518241258488,0.00014817587414506402,"No",0.8029089552935983,0.19709104470640257,"Yes"
"2009-011925-14","A multicenter open label phase I / II study to evaluate safety pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients. ","DE","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.359869877779174e-31,0.12220853636593618,0.8777914636340582,"2+",3.8385374617024995e-06,0.9999961614625394,"Yes",0.9999932854244565,6.714575536964784e-06,"No",0.9999999999971153,2.8795288475447503e-12,"No",0.9953255950933079,0.0046744049066863,"Yes",0.9830015375993395,0.016998462400655914,"Yes",0.9999953752963865,4.6247036153835535e-06,"No",0.9734495778761493,0.026550422123845733,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012007-25","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1606801119370045e-43,6.290777117500651e-08,0.9999999370922288,"-1",0.9999701264189049,2.987358109511991e-05,"No",8.287346585601857e-05,0.9999171265341434,"Yes",0.9999999999978257,2.176889885907847e-12,"No",9.867650977735983e-07,0.9999990132349021,"Yes",0.07891442894265516,0.9210855710573418,"Yes",0.9999991720965243,8.279034792395835e-07,"No",2.8834835783535536e-07,0.9999997116516387,"Yes"
"2009-012432-32","Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa and with or without Rituximab followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.945006576454696e-68,1.3490982143837352e-06,0.9999986509017736,"-1",9.195987704149625e-10,0.9999999990803872,"Yes",0.9999999987773834,1.2226138290704536e-09,"No",1.0,1.488613690344643e-16,"No",3.964378086459451e-06,0.9999960356219187,"Yes",0.9990577127520879,0.0009422872479023193,"No",0.9999999999998864,9.47998462912126e-14,"No",0.004396561285214032,0.9956034387148043,"Yes"
"2009-012432-32","Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa and with or without Rituximab followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma.","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.945006576454696e-68,1.3490982143837352e-06,0.9999986509017736,"-1",9.195987704149625e-10,0.9999999990803872,"Yes",0.9999999987773834,1.2226138290704536e-09,"No",1.0,1.488613690344643e-16,"No",3.964378086459451e-06,0.9999960356219187,"Yes",0.9990577127520879,0.0009422872479023193,"No",0.9999999999998864,9.47998462912126e-14,"No",0.004396561285214032,0.9956034387148043,"Yes"
"2009-012432-32","Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa and with or without Rituximab followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma.","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.945006576454696e-68,1.3490982143837352e-06,0.9999986509017736,"-1",9.195987704149625e-10,0.9999999990803872,"Yes",0.9999999987773834,1.2226138290704536e-09,"No",1.0,1.488613690344643e-16,"No",3.964378086459451e-06,0.9999960356219187,"Yes",0.9990577127520879,0.0009422872479023193,"No",0.9999999999998864,9.47998462912126e-14,"No",0.004396561285214032,0.9956034387148043,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in Patients with Relapsing-Remitting Multiple Sclerosis","SI","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon β-1a) in Patients with Relapsing Remitting Multiple Sclerosis ","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon β-1a) in Patients with Relapsing Remitting Multiple Sclerosis ","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon β-1a) in Patients with Relapsing Remitting Multiple Sclerosis ","FI","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in Patients with Relapsing-Remitting Multiple Sclerosis","IE","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in Patients with Relapsing-Remitting Multiple Sclerosis","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in Patients with Relapsing-Remitting Multiple Sclerosis","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon β-1a) in Patients with Relapsing Remitting Multiple Sclerosis ","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon β-1a) in Patients with Relapsing Remitting Multiple Sclerosis ","DK","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon β-1a) in Patients with Relapsing Remitting Multiple Sclerosis ","FR","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon β-1a) in Patients with Relapsing Remitting Multiple Sclerosis ","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon β-1a) in Patients with Relapsing Remitting Multiple Sclerosis ","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-012500-11","Multicenter Double-blind Randomized Parallel-group Monotherapy Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in Patients with Relapsing-Remitting Multiple Sclerosis","GR","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.5632740374837945e-52,2.5421690363947108e-11,0.999999999974591,"2+",0.9999876493900641,1.235060993757527e-05,"No",2.1356599267215255e-05,0.9999786434007373,"Yes",0.9999999999997159,2.859016260691878e-13,"No",0.007265833695322293,0.9927341663046673,"Yes",0.9522343416525153,0.0477656583474833,"Yes",1.0,2.976016800429671e-17,"No",0.014710813182385287,0.9852891868176148,"Yes"
"2009-013174-41","AFFIRM: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.148668559086647e-55,3.239703617174838e-07,0.9999996760296269,"-1",0.9999715346046073,2.8465395388651374e-05,"No",6.62697717846556e-05,0.9999337302282275,"Yes",1.0,1.5738880629446819e-15,"No",1.1586215573640859e-06,0.9999988413784313,"Yes",0.0408428789272043,0.9591571210727952,"Yes",0.9999987140364253,1.2859635820815478e-06,"No",1.062147338737077e-06,0.999998937852662,"Yes"
"2009-013174-41","AFFIRM:  Estudio multinacional fase 3 aleatorizado doble ciego controlado con placebo para evaluar la eficacia y la seguridad del MDV3100 oral en pacientes con cáncer de próstata en progresión resistente a la castración previamente tratados con quimioterapia con docetaxel.AFFIRM: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3895045790461278e-107,3.9656523383220335e-14,0.9999999999999432,"-1",0.9999999666072773,3.339271418791368e-08,"No",1.5151426904083825e-07,0.9999998484857544,"Yes",1.0,3.8145722565159095e-34,"No",2.987018091138783e-12,0.9999999999969873,"Yes",0.0021896613032609167,0.9978103386967215,"Yes",1.0,5.9867510913317476e-18,"No",2.2129800891722306e-12,0.9999999999977832,"Yes"
"2009-013174-41","AFFIRM: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.148668559086647e-55,3.239703617174838e-07,0.9999996760296269,"-1",0.9999715346046073,2.8465395388651374e-05,"No",6.62697717846556e-05,0.9999337302282275,"Yes",1.0,1.5738880629446819e-15,"No",1.1586215573640859e-06,0.9999988413784313,"Yes",0.0408428789272043,0.9591571210727952,"Yes",0.9999987140364253,1.2859635820815478e-06,"No",1.062147338737077e-06,0.999998937852662,"Yes"
"2009-013174-41","AFFIRM: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.148668559086647e-55,3.239703617174838e-07,0.9999996760296269,"-1",0.9999715346046073,2.8465395388651374e-05,"No",6.62697717846556e-05,0.9999337302282275,"Yes",1.0,1.5738880629446819e-15,"No",1.1586215573640859e-06,0.9999988413784313,"Yes",0.0408428789272043,0.9591571210727952,"Yes",0.9999987140364253,1.2859635820815478e-06,"No",1.062147338737077e-06,0.999998937852662,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","NL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","GR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","IT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","BE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","FR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","AT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-013435-38","An Open-label Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)","DK","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5006365529489362e-26,0.029545849922148416,0.9704541500778461,"-1",0.0004520180210052405,0.9995479819789954,"Yes",0.9993360323954993,0.0006639676044958906,"No",0.9999999999998437,1.559220774575498e-13,"No",0.5403090238396819,0.4596909761603215,"Yes",0.9217622791841966,0.0782377208157998,"No",0.9999999935282774,6.4717253036369635e-09,"No",0.06284504756930061,0.9371549524306931,"Yes"
"2009-015114-22","A randomized controlled single-blind proof- of- concept-study to investigate the protective effects of early treatment with C.E.R.A. in patients with chronic kidney disease on renal disease progression (PRIMAVERA-Study)","DE","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","Yes","No","Yes","No","Yes","2+","Yes",3.778645636115443e-49,1.63818550631801e-05,0.9999836181449434,"2+",0.9992905501960372,0.0007094498039490769,"No",0.003720438004898145,0.996279561995103,"No",0.9999991351485608,8.648514512192271e-07,"Yes",4.4325996656159844e-05,0.9999556740033325,"Yes",0.3987921972747298,0.6012078027252643,"Yes",0.0059696769337888944,0.9940303230661992,"No",0.0017628631508521358,0.9982371368491445,"Yes"
"2009-015119-42","An open-label randomised multicentre phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.647879970768732e-57,4.048009534473231e-05,0.9999595199046498,"-1",1.051725978109893e-12,0.9999999999989484,"Yes",0.9999999999973852,2.60100266921613e-12,"No",1.0,3.07009530968454e-20,"No",0.23965458797139008,0.7603454120286084,"Yes",0.9395161955136515,0.0604838044863615,"Yes",0.9999999999387796,6.122721900549767e-11,"No",0.0012529126327140325,0.9987470873672796,"Yes"
"2009-015407-47","Estudio de fase II aleatorizado abierto multicéntrico de comparación de AUY922 con docetaxel o irinotecán en pacientes adultos con cáncer gástrico avanzado y en progresión tras una línea de quimioterapia","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",9.28953061812496e-45,2.6463056982370046e-05,0.9999735369430286,"-1",5.971986829407478e-08,0.9999999402801355,"Yes",0.9999999171679724,8.283201379391157e-08,"No",0.9999999999999717,3.946928002369235e-14,"No",0.0011395377784884564,0.9988604622215123,"Yes",0.9538961695428976,0.046103830457112645,"No",1.0,1.0081759524152321e-16,"No",1.7622630021971572e-06,0.9999982377369928,"Yes"
"2009-015407-47","A randomized open-label multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer who have progressed after one line of chemotherapy","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",9.392694535893925e-42,0.0013618180673215222,0.9986381819326674,"-1",4.892777614525969e-08,0.9999999510722274,"Yes",0.999999910390987,8.960900663940834e-08,"No",1.0,2.6962930465298475e-15,"No",0.08232558454698832,0.9176744154529981,"Yes",0.9808030646825221,0.019196935317472998,"No",0.9999999769538025,2.304619505078077e-08,"No",0.02895134957690253,0.97104865042309,"Yes"
"2009-015407-47","Estudio de fase II aleatorizado abierto multicéntrico de comparación de AUY922 con docetaxel o irinotecán en pacientes adultos con cáncer gástrico avanzado y en progresión tras una línea de quimioterapia","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",9.28953061812496e-45,2.6463056982370046e-05,0.9999735369430286,"-1",5.971986829407478e-08,0.9999999402801355,"Yes",0.9999999171679724,8.283201379391157e-08,"No",0.9999999999999717,3.946928002369235e-14,"No",0.0011395377784884564,0.9988604622215123,"Yes",0.9538961695428976,0.046103830457112645,"No",1.0,1.0081759524152321e-16,"No",1.7622630021971572e-06,0.9999982377369928,"Yes"
"2009-015407-47","A randomized open-label multi-center phase II study to compare AUY922 with docetaxel or irinotecan in  adult patients with advanced gastric cancer who have progressed after one line of chemotherapy.","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",9.392694535893925e-42,0.0013618180673215222,0.9986381819326674,"-1",4.892777614525969e-08,0.9999999510722274,"Yes",0.999999910390987,8.960900663940834e-08,"No",1.0,2.6962930465298475e-15,"No",0.08232558454698832,0.9176744154529981,"Yes",0.9808030646825221,0.019196935317472998,"No",0.9999999769538025,2.304619505078077e-08,"No",0.02895134957690253,0.97104865042309,"Yes"
"2009-015407-47","A randomized open-label multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer who have progressed after one line of chemotherapy","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",9.392694535893925e-42,0.0013618180673215222,0.9986381819326674,"-1",4.892777614525969e-08,0.9999999510722274,"Yes",0.999999910390987,8.960900663940834e-08,"No",1.0,2.6962930465298475e-15,"No",0.08232558454698832,0.9176744154529981,"Yes",0.9808030646825221,0.019196935317472998,"No",0.9999999769538025,2.304619505078077e-08,"No",0.02895134957690253,0.97104865042309,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","NL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","BE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","HU","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","SK","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","An open-label randomized multi-center Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.217968698589135e-48,0.025285430929442725,0.9747145690705689,"-1",2.980828432019656e-07,0.9999997019171635,"Yes",0.99999938386434,6.161356620595654e-07,"No",1.0,1.5574715980629008e-17,"No",0.15844758679614074,0.8415524132038507,"Yes",0.6059899344216635,0.3940100655783329,"Yes",0.9999999983022292,1.6977571852884442e-09,"No",0.011679349769786853,0.9883206502302032,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","NO","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","IT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","AT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","An open-label randomized multi-center Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.217968698589135e-48,0.025285430929442725,0.9747145690705689,"-1",2.980828432019656e-07,0.9999997019171635,"Yes",0.99999938386434,6.161356620595654e-07,"No",1.0,1.5574715980629008e-17,"No",0.15844758679614074,0.8415524132038507,"Yes",0.6059899344216635,0.3940100655783329,"Yes",0.9999999983022292,1.6977571852884442e-09,"No",0.011679349769786853,0.9883206502302032,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","GB","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","Estudio fase III multicéntrico abierto y aleatorizado para comparar la seguridad y la eficacia de TKI258 frente a sorafenib en pacientes con cáncer de células renales metastásico después del fallo a terapias antiangiogénicas (inhibidor de mTOR y con diana en el VEGF)","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.624962774655323e-48,0.047195008894857775,0.9528049911051366,"-1",1.080325851350941e-06,0.9999989196741562,"Yes",0.9999987346648188,1.2653351816338566e-06,"No",1.0,6.297155720001269e-16,"No",0.9129299268439749,0.08707007315602062,"Yes",0.9883249943904575,0.011675005609555261,"Yes",0.9999999999996874,3.248972164026286e-13,"No",0.21335823591896352,0.7866417640810253,"Yes"
"2009-015459-25","An open-label randomized multi-center Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.217968698589135e-48,0.025285430929442725,0.9747145690705689,"-1",2.980828432019656e-07,0.9999997019171635,"Yes",0.99999938386434,6.161356620595654e-07,"No",1.0,1.5574715980629008e-17,"No",0.15844758679614074,0.8415524132038507,"Yes",0.6059899344216635,0.3940100655783329,"Yes",0.9999999983022292,1.6977571852884442e-09,"No",0.011679349769786853,0.9883206502302032,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW  2992 and vinorelbine versus trastuzumab and vinorelbine in patients  with metastatic HER2-overexpressing breast cancer failing one prior  trastuzumab treatment","SI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 Estudio de Fase III aleatorizado abierto de BIBW 2992 combinado con vinorelbina versus trastuzumab combinado con vinorelbina en pacientes con cáncer de mama metastásico con sobreexpresión del HER2 que fracasaron a un tratamiento previo con trastuzumabLUX-Breast 1 An open label randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.4676624477132404e-87,1.1383148333551516e-05,0.9999886168516681,"2+",3.0470568397513763e-28,1.0,"Yes",1.0,2.3333606155557866e-27,"No",1.0,1.942365088951794e-43,"No",0.00017274667597119491,0.9998272533240474,"Yes",0.9999998110469229,1.889530596909076e-07,"Yes",1.0,3.3447702320990586e-21,"No",3.5194790541308077e-06,0.9999964805209604,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW  2992 and vinorelbine versus trastuzumab and vinorelbine in patients  with metastatic HER2-overexpressing breast cancer failing one prior  trastuzumab treatment","NO","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 Estudio de Fase III aleatorizado abierto de BIBW 2992 combinado con vinorelbina versus trastuzumab combinado con vinorelbina en pacientes con cáncer de mama metastásico con sobreexpresión del HER2 que fracasaron a un tratamiento previo con trastuzumabLUX-Breast 1 An open label randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.4676624477132404e-87,1.1383148333551516e-05,0.9999886168516681,"2+",3.0470568397513763e-28,1.0,"Yes",1.0,2.3333606155557866e-27,"No",1.0,1.942365088951794e-43,"No",0.00017274667597119491,0.9998272533240474,"Yes",0.9999998110469229,1.889530596909076e-07,"Yes",1.0,3.3447702320990586e-21,"No",3.5194790541308077e-06,0.9999964805209604,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW  2992 and vinorelbine versus trastuzumab and vinorelbine in patients  with metastatic HER2-overexpressing breast cancer failing one prior  trastuzumab treatment","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW  2992 and vinorelbine versus trastuzumab and vinorelbine in patients  with metastatic HER2-overexpressing breast cancer failing one prior  trastuzumab treatment","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 Estudio de Fase III aleatorizado abierto de BIBW 2992 combinado con vinorelbina versus trastuzumab combinado con vinorelbina en pacientes con cáncer de mama metastásico con sobreexpresión del HER2 que fracasaron a un tratamiento previo con trastuzumabLUX-Breast 1 An open label randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.4676624477132404e-87,1.1383148333551516e-05,0.9999886168516681,"2+",3.0470568397513763e-28,1.0,"Yes",1.0,2.3333606155557866e-27,"No",1.0,1.942365088951794e-43,"No",0.00017274667597119491,0.9998272533240474,"Yes",0.9999998110469229,1.889530596909076e-07,"Yes",1.0,3.3447702320990586e-21,"No",3.5194790541308077e-06,0.9999964805209604,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW  2992 and vinorelbine versus trastuzumab and vinorelbine in patients  with metastatic HER2-overexpressing breast cancer failing one prior  trastuzumab treatment","LV","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW  2992 and vinorelbine versus trastuzumab and vinorelbine in patients  with metastatic HER2-overexpressing breast cancer failing one prior  trastuzumab treatment","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW  2992 and vinorelbine versus trastuzumab and vinorelbine in patients  with metastatic HER2-overexpressing breast cancer failing one prior  trastuzumab treatment","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 An open label randomised phase III trial of BIBW  2992 and vinorelbine versus trastuzumab and vinorelbine in patients  with metastatic HER2-overexpressing breast cancer failing one prior  trastuzumab treatment","IE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0004852747084111e-44,0.0029666133463722467,0.9970333866536355,"2+",7.989479096666076e-17,1.0,"Yes",1.0,2.2090710236869968e-16,"No",1.0,5.5892694176641e-22,"No",0.05828451006658432,0.9417154899334271,"Yes",0.9997877358640561,0.00021226413593153164,"Yes",0.9999999998325961,1.673993268156046e-10,"No",0.00047972035627160363,0.999520279643733,"Yes"
"2009-015476-98","LUX-Breast 1 Estudio de Fase III aleatorizado abierto de BIBW 2992 combinado con vinorelbina versus trastuzumab combinado con vinorelbina en pacientes con cáncer de mama metastásico con sobreexpresión del HER2 que fracasaron a un tratamiento previo con trastuzumabLUX-Breast 1 An open label randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment","PT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.4676624477132404e-87,1.1383148333551516e-05,0.9999886168516681,"2+",3.0470568397513763e-28,1.0,"Yes",1.0,2.3333606155557866e-27,"No",1.0,1.942365088951794e-43,"No",0.00017274667597119491,0.9998272533240474,"Yes",0.9999998110469229,1.889530596909076e-07,"Yes",1.0,3.3447702320990586e-21,"No",3.5194790541308077e-06,0.9999964805209604,"Yes"
"2009-015476-98","LUX-Breast 1 Estudio de Fase III aleatorizado abierto de BIBW 2992 combinado con vinorelbina versus trastuzumab combinado con vinorelbina en pacientes con cáncer de mama metastásico con sobreexpresión del HER2 que fracasaron a un tratamiento previo con trastuzumabLUX-Breast 1 An open label randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment","LT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.4676624477132404e-87,1.1383148333551516e-05,0.9999886168516681,"2+",3.0470568397513763e-28,1.0,"Yes",1.0,2.3333606155557866e-27,"No",1.0,1.942365088951794e-43,"No",0.00017274667597119491,0.9998272533240474,"Yes",0.9999998110469229,1.889530596909076e-07,"Yes",1.0,3.3447702320990586e-21,"No",3.5194790541308077e-06,0.9999964805209604,"Yes"
"2009-016047-19","An Open-Label Multicenter Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination with Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.1926286437056967e-55,5.2497810131858566e-05,0.9999475021898581,"2+",2.3535392582355397e-11,0.9999999999764668,"Yes",0.9999999999354543,6.455914610429979e-11,"No",1.0,7.915904784186462e-24,"No",0.8082365471618468,0.19176345283814028,"Yes",0.9452587625929493,0.05474123740705926,"No",0.9999999999991475,8.442417034742615e-13,"No",0.00031166821563994484,0.9996883317843603,"Yes"
"2009-016047-19","An Open-Label Multicenter Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination with Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.1926286437056967e-55,5.2497810131858566e-05,0.9999475021898581,"2+",2.3535392582355397e-11,0.9999999999764668,"Yes",0.9999999999354543,6.455914610429979e-11,"No",1.0,7.915904784186462e-24,"No",0.8082365471618468,0.19176345283814028,"Yes",0.9452587625929493,0.05474123740705926,"No",0.9999999999991475,8.442417034742615e-13,"No",0.00031166821563994484,0.9996883317843603,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate CancerRevised Protocol Number 03 incorporating Amendment 08+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 3.0 dated 11-Jan-10)+ Immune Monitoring Amendment 04 (version 1.0 dated 18-Mar-11)-Site SpecificRandomizovaná dvojitě zaslepená studie fáze III porovnávající účinnost ipilimumabu s placebem u pacientů s asymptomatickým nebo mírně symptomatickým metastazujícím kastračně rezistentním nádorem prostaty kteří neobdrželi předchozí léčbu chemoterapií.Revidovaný protokol č. 03 zahrnující Dodatky č. 8+ Dodatek č. 1 pro farmakogenetický výzkum vzorků krve – specifický dle centra (verze 3.0 datovaná 11. 1. 2010)+ Dodatek č. 4 pro sledování imunity (verze 1.0 datovaná 18. 3. 2011) - specifický dle centra","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.505222185214024e-200,2.8410104503852867e-40,1.0,"-1",1.0,1.974712750535168e-16,"No",3.675872449894475e-14,1.0,"Yes",1.0,5.342886825475033e-77,"No",1.729535881854633e-41,1.0,"Yes",3.300452501391401e-31,1.0,"Yes",1.0,1.9882758822407628e-72,"No",1.9738274655384895e-42,1.0,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Na�ve Castration Resistant Prostate Cancer.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5776772121350217e-52,9.460648223106499e-11,0.9999999999053842,"-1",0.9999976673848813,2.3326151323348306e-06,"No",9.761392679991674e-06,0.9999902386073325,"Yes",0.9999999999976126,2.3892855597409702e-12,"No",6.07756878349551e-10,0.9999999993922302,"Yes",0.10985136414182364,0.8901486358581858,"Yes",0.9999980996523314,1.9003476617064471e-06,"No",7.177280080753947e-10,0.9999999992822667,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate CancerRevised Protocol Number 03 incorporating Amendment 08+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 3.0 dated 11-Jan-10)+ Immune Monitoring Amendment 04 (version 1.0 dated 18-Mar-11)-Site Specific+ Protocol Amendment 07 - Site Specific (version 1.0 dated 02-Jan-14)","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.333444831389719e-126,4.63507326898956e-16,1.0,"-1",0.999797445570349,0.00020255442968697515,"No",0.019764813758309546,0.9802351862416339,"Yes",1.0,9.61155601837944e-33,"No",1.533934498333734e-14,1.0,"Yes",1.0974287565982193e-19,1.0,"Yes",1.0,1.8857545721761013e-46,"No",3.4117541225724655e-19,1.0,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Na�ve Castration Resistant Prostate Cancer.","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5776772121350217e-52,9.460648223106499e-11,0.9999999999053842,"-1",0.9999976673848813,2.3326151323348306e-06,"No",9.761392679991674e-06,0.9999902386073325,"Yes",0.9999999999976126,2.3892855597409702e-12,"No",6.07756878349551e-10,0.9999999993922302,"Yes",0.10985136414182364,0.8901486358581858,"Yes",0.9999980996523314,1.9003476617064471e-06,"No",7.177280080753947e-10,0.9999999992822667,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate CancerRevised Protocol Number 03 incorporating Amendment 08+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 3.0 dated 11-Jan-10)+ Immune Monitoring Amendment 04 (version 1.0 dated 18-Mar-11)-Site Specific+ Protocol Amendment 07 - Site Specific (version 1.0 dated 02-Jan-14)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.333444831389719e-126,4.63507326898956e-16,1.0,"-1",0.999797445570349,0.00020255442968697515,"No",0.019764813758309546,0.9802351862416339,"Yes",1.0,9.61155601837944e-33,"No",1.533934498333734e-14,1.0,"Yes",1.0974287565982193e-19,1.0,"Yes",1.0,1.8857545721761013e-46,"No",3.4117541225724655e-19,1.0,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate CancerRevised Protocol Number 03 incorporating Amendment 08+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 3.0 dated 11-Jan-10)+ Immune Monitoring Amendment 04 (version 1.0 dated 18-Mar-11)-Site Specific+ Protocol Amendment 07 - Site Specific (version 1.0 dated 02-Jan-14)","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.333444831389719e-126,4.63507326898956e-16,1.0,"-1",0.999797445570349,0.00020255442968697515,"No",0.019764813758309546,0.9802351862416339,"Yes",1.0,9.61155601837944e-33,"No",1.533934498333734e-14,1.0,"Yes",1.0974287565982193e-19,1.0,"Yes",1.0,1.8857545721761013e-46,"No",3.4117541225724655e-19,1.0,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Na�ve Castration Resistant Prostate Cancer.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5776772121350217e-52,9.460648223106499e-11,0.9999999999053842,"-1",0.9999976673848813,2.3326151323348306e-06,"No",9.761392679991674e-06,0.9999902386073325,"Yes",0.9999999999976126,2.3892855597409702e-12,"No",6.07756878349551e-10,0.9999999993922302,"Yes",0.10985136414182364,0.8901486358581858,"Yes",0.9999980996523314,1.9003476617064471e-06,"No",7.177280080753947e-10,0.9999999992822667,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate CancerRevised Protocol Number 03 incorporating Amendment 08+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 3.0 dated 11-Jan-10)+ Immune Monitoring Amendment 04 (version 1.0 dated 18-Mar-11)-Site SpecificRandomizovaná dvojitě zaslepená studie fáze III porovnávající účinnost ipilimumabu s placebem u pacientů s asymptomatickým nebo mírně symptomatickým metastazujícím kastračně rezistentním nádorem prostaty kteří neobdrželi předchozí léčbu chemoterapií.Revidovaný protokol č. 03 zahrnující Dodatky č. 8+ Dodatek č. 1 pro farmakogenetický výzkum vzorků krve – specifický dle centra (verze 3.0 datovaná 11. 1. 2010)+ Dodatek č. 4 pro sledování imunity (verze 1.0 datovaná 18. 3. 2011) - specifický dle centra","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.505222185214024e-200,2.8410104503852867e-40,1.0,"-1",1.0,1.974712750535168e-16,"No",3.675872449894475e-14,1.0,"Yes",1.0,5.342886825475033e-77,"No",1.729535881854633e-41,1.0,"Yes",3.300452501391401e-31,1.0,"Yes",1.0,1.9882758822407628e-72,"No",1.9738274655384895e-42,1.0,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate CancerRevised Protocol Number 03 incorporating Amendment 08+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 3.0 dated 11-Jan-10)+ Immune Monitoring Amendment 04 (version 1.0 dated 18-Mar-11)-Site Specific+ Protocol Amendment 07 - Site Specific (version 1.0 dated 02-Jan-14)","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.333444831389719e-126,4.63507326898956e-16,1.0,"-1",0.999797445570349,0.00020255442968697515,"No",0.019764813758309546,0.9802351862416339,"Yes",1.0,9.61155601837944e-33,"No",1.533934498333734e-14,1.0,"Yes",1.0974287565982193e-19,1.0,"Yes",1.0,1.8857545721761013e-46,"No",3.4117541225724655e-19,1.0,"Yes"
"2009-016217-23","Randomized Double-Blind Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate CancerRevised Protocol Number 03 incorporating Amendment 08+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 3.0 dated 11-Jan-10)+ Immune Monitoring Amendment 04 (version 1.0 dated 18-Mar-11)-Site SpecificRandomizovaná dvojitě zaslepená studie fáze III porovnávající účinnost ipilimumabu s placebem u pacientů s asymptomatickým nebo mírně symptomatickým metastazujícím kastračně rezistentním nádorem prostaty kteří neobdrželi předchozí léčbu chemoterapií.Revidovaný protokol č. 03 zahrnující Dodatky č. 8+ Dodatek č. 1 pro farmakogenetický výzkum vzorků krve – specifický dle centra (verze 3.0 datovaná 11. 1. 2010)+ Dodatek č. 4 pro sledování imunity (verze 1.0 datovaná 18. 3. 2011) - specifický dle centra","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.505222185214024e-200,2.8410104503852867e-40,1.0,"-1",1.0,1.974712750535168e-16,"No",3.675872449894475e-14,1.0,"Yes",1.0,5.342886825475033e-77,"No",1.729535881854633e-41,1.0,"Yes",3.300452501391401e-31,1.0,"Yes",1.0,1.9882758822407628e-72,"No",1.9738274655384895e-42,1.0,"Yes"
"2009-016584-10","Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial","HU","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","No","2+","Yes",1.4151837012343336e-27,0.8883672180408189,0.11163278195917922,"2+",2.0979349618640472e-06,0.9999979020650451,"Yes",0.9999980950305298,1.9049694739337317e-06,"No",0.9999994250473582,5.74952646220324e-07,"No",0.7787938733077614,0.2212061266922427,"Yes",0.9819460628483915,0.01805393715161491,"Yes",0.999925382043865,7.461795613102916e-05,"No",0.9471773785581621,0.05282262144184099,"Yes"
"2009-016584-10","Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial","AT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","No","2+","Yes",1.4151837012343336e-27,0.8883672180408189,0.11163278195917922,"2+",2.0979349618640472e-06,0.9999979020650451,"Yes",0.9999980950305298,1.9049694739337317e-06,"No",0.9999994250473582,5.74952646220324e-07,"No",0.7787938733077614,0.2212061266922427,"Yes",0.9819460628483915,0.01805393715161491,"Yes",0.999925382043865,7.461795613102916e-05,"No",0.9471773785581621,0.05282262144184099,"Yes"
"2009-016584-10","Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","No","2+","Yes",1.4151837012343336e-27,0.8883672180408189,0.11163278195917922,"2+",2.0979349618640472e-06,0.9999979020650451,"Yes",0.9999980950305298,1.9049694739337317e-06,"No",0.9999994250473582,5.74952646220324e-07,"No",0.7787938733077614,0.2212061266922427,"Yes",0.9819460628483915,0.01805393715161491,"Yes",0.999925382043865,7.461795613102916e-05,"No",0.9471773785581621,0.05282262144184099,"Yes"
"2009-017374-20","Probiotic Saccharomyces boulardii for the prevention of antibiotic-associateddiarrhoea – randomised double-blind placebo-controlled trialSaccharomyces boulardii zur Prävention der Antibiotika-assoziierten Diarrhö – randomisierte doppelblinde Placebo-kontrollierte Studie","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.396622373354555e-36,7.58919517687016e-12,0.9999999999924114,"2+",0.999999999757705,2.422889278458664e-10,"No",2.6512061034629693e-09,0.9999999973487946,"Yes",0.9999895781394853,1.0421860515539412e-05,"No",1.5147794916073833e-11,0.9999999999848512,"Yes",0.4596044782103798,0.5403955217896186,"Yes",0.6918876900776284,0.30811230992237937,"No",1.6731977552052159e-09,0.999999998326814,"Yes"
"2009-017432-40","A Phase 2 Randomized Double-blind Placebo-controlled Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy (IMPACT Study)","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2132977255558238e-65,1.2612646581455984e-08,0.999999987387355,"2+",0.9999628610858761,3.7138914113394384e-05,"No",0.00011358251777876809,0.9998864174822238,"Yes",0.9999999999664624,3.355172011852058e-11,"No",4.8297649318278444e-08,0.9999999517023367,"Yes",0.6777304137762704,0.32226958622373786,"Yes",0.9999999401166538,5.988334618662558e-08,"No",4.877952157322601e-08,0.999999951220475,"Yes"
"2009-017432-40","A Phase 2 Randomized Double-blind Placebo-controlled Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy (IMPACT Study)","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2132977255558238e-65,1.2612646581455984e-08,0.999999987387355,"2+",0.9999628610858761,3.7138914113394384e-05,"No",0.00011358251777876809,0.9998864174822238,"Yes",0.9999999999664624,3.355172011852058e-11,"No",4.8297649318278444e-08,0.9999999517023367,"Yes",0.6777304137762704,0.32226958622373786,"Yes",0.9999999401166538,5.988334618662558e-08,"No",4.877952157322601e-08,0.999999951220475,"Yes"
"2009-017432-40","A Phase 2 Randomized Double-blind Placebo-controlled Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy (IMPACT Study)","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2132977255558238e-65,1.2612646581455984e-08,0.999999987387355,"2+",0.9999628610858761,3.7138914113394384e-05,"No",0.00011358251777876809,0.9998864174822238,"Yes",0.9999999999664624,3.355172011852058e-11,"No",4.8297649318278444e-08,0.9999999517023367,"Yes",0.6777304137762704,0.32226958622373786,"Yes",0.9999999401166538,5.988334618662558e-08,"No",4.877952157322601e-08,0.999999951220475,"Yes"
"2009-017432-40","A Phase 2 Randomized Double-blind Placebo-controlled Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy (IMPACT Study)","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2132977255558238e-65,1.2612646581455984e-08,0.999999987387355,"2+",0.9999628610858761,3.7138914113394384e-05,"No",0.00011358251777876809,0.9998864174822238,"Yes",0.9999999999664624,3.355172011852058e-11,"No",4.8297649318278444e-08,0.9999999517023367,"Yes",0.6777304137762704,0.32226958622373786,"Yes",0.9999999401166538,5.988334618662558e-08,"No",4.877952157322601e-08,0.999999951220475,"Yes"
"2009-017485-23","TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (Treat CTC trial)","AT","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1998418141794397e-23,0.12920840725913385,0.870791592740873,"-1",3.5568120893489396e-06,0.9999964431879124,"Yes",0.9999942160945501,5.7839054556548325e-06,"No",0.9999999969328145,3.0671817780218003e-09,"No",0.9996574162440052,0.00034258375600176096,"No",0.9996659164907788,0.00033408350922136136,"No",0.9847843928768858,0.015215607123116152,"No",0.026249065065230382,0.9737509349347688,"Yes"
"2009-017485-23","TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (Treat CTC trial)","GR","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1998418141794397e-23,0.12920840725913385,0.870791592740873,"-1",3.5568120893489396e-06,0.9999964431879124,"Yes",0.9999942160945501,5.7839054556548325e-06,"No",0.9999999969328145,3.0671817780218003e-09,"No",0.9996574162440052,0.00034258375600176096,"No",0.9996659164907788,0.00033408350922136136,"No",0.9847843928768858,0.015215607123116152,"No",0.026249065065230382,0.9737509349347688,"Yes"
"2009-017485-23","TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (Treat CTC trial)","FR","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1998418141794397e-23,0.12920840725913385,0.870791592740873,"-1",3.5568120893489396e-06,0.9999964431879124,"Yes",0.9999942160945501,5.7839054556548325e-06,"No",0.9999999969328145,3.0671817780218003e-09,"No",0.9996574162440052,0.00034258375600176096,"No",0.9996659164907788,0.00033408350922136136,"No",0.9847843928768858,0.015215607123116152,"No",0.026249065065230382,0.9737509349347688,"Yes"
"2009-017485-23","TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (Treat CTC trial)","DE","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1998418141794397e-23,0.12920840725913385,0.870791592740873,"-1",3.5568120893489396e-06,0.9999964431879124,"Yes",0.9999942160945501,5.7839054556548325e-06,"No",0.9999999969328145,3.0671817780218003e-09,"No",0.9996574162440052,0.00034258375600176096,"No",0.9996659164907788,0.00033408350922136136,"No",0.9847843928768858,0.015215607123116152,"No",0.026249065065230382,0.9737509349347688,"Yes"
"2009-017485-23","TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (Treat CTC trial)","GB","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1998418141794397e-23,0.12920840725913385,0.870791592740873,"-1",3.5568120893489396e-06,0.9999964431879124,"Yes",0.9999942160945501,5.7839054556548325e-06,"No",0.9999999969328145,3.0671817780218003e-09,"No",0.9996574162440052,0.00034258375600176096,"No",0.9996659164907788,0.00033408350922136136,"No",0.9847843928768858,0.015215607123116152,"No",0.026249065065230382,0.9737509349347688,"Yes"
"2009-017485-23","TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (Treat CTC trial)","BE","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1998418141794397e-23,0.12920840725913385,0.870791592740873,"-1",3.5568120893489396e-06,0.9999964431879124,"Yes",0.9999942160945501,5.7839054556548325e-06,"No",0.9999999969328145,3.0671817780218003e-09,"No",0.9996574162440052,0.00034258375600176096,"No",0.9996659164907788,0.00033408350922136136,"No",0.9847843928768858,0.015215607123116152,"No",0.026249065065230382,0.9737509349347688,"Yes"
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","DK","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Yes",1.0,1.0255965240678137e-15,"No",1.0,8.104975676565942e-16,"No",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","SE","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Yes",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","LT","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Yes",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","ES","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","SI","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","CZ","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","EE","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","PT","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Yes",1.0,1.0255965240678137e-15,"No",1.0,8.104975676565942e-16,"No",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Yes",1.0,1.0255965240678137e-15,"No",1.0,8.104975676565942e-16,"No",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","LV","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","BG","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","NL","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","SK","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","GB","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017775-19","A Phase IIIb multicentre open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase","FI","No","No","Yes","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",3.4547682249286014e-32,0.02726843646907038,0.9727315635309387,"-1",4.662688370081254e-16,1.0,"Information not present in EudraCT",1.0,1.0255965240678137e-15,"Information not present in EudraCT",1.0,8.104975676565942e-16,"Information not present in EudraCT",0.3624830474455391,0.6375169525544561,"No",0.9989365034462068,0.001063496553785399,"",0.9999999999995453,4.569782115300859e-13,"",0.09800528681220314,0.9019947131877999,""
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube CancerΜία Φάσης 3 Τυχαιοποιημένη Διπλά Τυφλή Μελέτη της Πεγκυλιωμένης Λιποσωμικής Δοξορουβικίνης (PLD) σε Συνδυασμό με AMG 386 ή Εικονικό Φάρμακο σε Γυναίκες με Υποτροπιάζοντα Μερικώς Ευαίσθητο ή Ανθεκτικό στην Πλατίνη Επιθηλιακό Καρκίνο των Ωοθηκών Πρωτοπαθή Καρκίνο του Περιτοναίου ή Καρκίνο των Σαλπίγγων","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.81659268915351e-59,1.0239264118764426e-16,1.0,"-1",0.9999999458799793,5.412002074016613e-08,"No",1.873521782544725e-07,0.9999998126478323,"Yes",1.0,5.544915407367322e-23,"No",2.4079202823107424e-09,0.9999999975920844,"Yes",0.0018144471658680767,0.9981855528341371,"Yes",1.0,2.2606764864871594e-27,"No",2.495165394398638e-15,1.0,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.669760035227521e-56,8.212142141369334e-14,0.9999999999999147,"-1",0.9999635459912137,3.645400877755522e-05,"No",0.00015859189778494564,0.9998414081022055,"Yes",1.0,5.034844366520673e-18,"No",2.393528365681032e-08,0.9999999760647146,"Yes",0.04306636856359237,0.9569336314364144,"Yes",1.0,1.5640663627490979e-22,"No",1.964850068783417e-12,0.999999999998039,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.669760035227521e-56,8.212142141369334e-14,0.9999999999999147,"-1",0.9999635459912137,3.645400877755522e-05,"No",0.00015859189778494564,0.9998414081022055,"Yes",1.0,5.034844366520673e-18,"No",2.393528365681032e-08,0.9999999760647146,"Yes",0.04306636856359237,0.9569336314364144,"Yes",1.0,1.5640663627490979e-22,"No",1.964850068783417e-12,0.999999999998039,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube CancerΜία Φάσης 3 Τυχαιοποιημένη Διπλά Τυφλή Μελέτη της Πεγκυλιωμένης Λιποσωμικής Δοξορουβικίνης (PLD) σε Συνδυασμό με AMG 386 ή Εικονικό Φάρμακο σε Γυναίκες με Υποτροπιάζοντα Μερικώς Ευαίσθητο ή Ανθεκτικό στην Πλατίνη Επιθηλιακό Καρκίνο των Ωοθηκών Πρωτοπαθή Καρκίνο του Περιτοναίου ή Καρκίνο των Σαλπίγγων","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.81659268915351e-59,1.0239264118764426e-16,1.0,"-1",0.9999999458799793,5.412002074016613e-08,"No",1.873521782544725e-07,0.9999998126478323,"Yes",1.0,5.544915407367322e-23,"No",2.4079202823107424e-09,0.9999999975920844,"Yes",0.0018144471658680767,0.9981855528341371,"Yes",1.0,2.2606764864871594e-27,"No",2.495165394398638e-15,1.0,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube CancerΜία Φάσης 3 Τυχαιοποιημένη Διπλά Τυφλή Μελέτη της Πεγκυλιωμένης Λιποσωμικής Δοξορουβικίνης (PLD) σε Συνδυασμό με AMG 386 ή Εικονικό Φάρμακο σε Γυναίκες με Υποτροπιάζοντα Μερικώς Ευαίσθητο ή Ανθεκτικό στην Πλατίνη Επιθηλιακό Καρκίνο των Ωοθηκών Πρωτοπαθή Καρκίνο του Περιτοναίου ή Καρκίνο των Σαλπίγγων","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.81659268915351e-59,1.0239264118764426e-16,1.0,"-1",0.9999999458799793,5.412002074016613e-08,"No",1.873521782544725e-07,0.9999998126478323,"Yes",1.0,5.544915407367322e-23,"No",2.4079202823107424e-09,0.9999999975920844,"Yes",0.0018144471658680767,0.9981855528341371,"Yes",1.0,2.2606764864871594e-27,"No",2.495165394398638e-15,1.0,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.669760035227521e-56,8.212142141369334e-14,0.9999999999999147,"-1",0.9999635459912137,3.645400877755522e-05,"No",0.00015859189778494564,0.9998414081022055,"Yes",1.0,5.034844366520673e-18,"No",2.393528365681032e-08,0.9999999760647146,"Yes",0.04306636856359237,0.9569336314364144,"Yes",1.0,1.5640663627490979e-22,"No",1.964850068783417e-12,0.999999999998039,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube CancerΜία Φάσης 3 Τυχαιοποιημένη Διπλά Τυφλή Μελέτη της Πεγκυλιωμένης Λιποσωμικής Δοξορουβικίνης (PLD) σε Συνδυασμό με AMG 386 ή Εικονικό Φάρμακο σε Γυναίκες με Υποτροπιάζοντα Μερικώς Ευαίσθητο ή Ανθεκτικό στην Πλατίνη Επιθηλιακό Καρκίνο των Ωοθηκών Πρωτοπαθή Καρκίνο του Περιτοναίου ή Καρκίνο των Σαλπίγγων","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.81659268915351e-59,1.0239264118764426e-16,1.0,"-1",0.9999999458799793,5.412002074016613e-08,"No",1.873521782544725e-07,0.9999998126478323,"Yes",1.0,5.544915407367322e-23,"No",2.4079202823107424e-09,0.9999999975920844,"Yes",0.0018144471658680767,0.9981855528341371,"Yes",1.0,2.2606764864871594e-27,"No",2.495165394398638e-15,1.0,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.669760035227521e-56,8.212142141369334e-14,0.9999999999999147,"-1",0.9999635459912137,3.645400877755522e-05,"No",0.00015859189778494564,0.9998414081022055,"Yes",1.0,5.034844366520673e-18,"No",2.393528365681032e-08,0.9999999760647146,"Yes",0.04306636856359237,0.9569336314364144,"Yes",1.0,1.5640663627490979e-22,"No",1.964850068783417e-12,0.999999999998039,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.669760035227521e-56,8.212142141369334e-14,0.9999999999999147,"-1",0.9999635459912137,3.645400877755522e-05,"No",0.00015859189778494564,0.9998414081022055,"Yes",1.0,5.034844366520673e-18,"No",2.393528365681032e-08,0.9999999760647146,"Yes",0.04306636856359237,0.9569336314364144,"Yes",1.0,1.5640663627490979e-22,"No",1.964850068783417e-12,0.999999999998039,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.669760035227521e-56,8.212142141369334e-14,0.9999999999999147,"-1",0.9999635459912137,3.645400877755522e-05,"No",0.00015859189778494564,0.9998414081022055,"Yes",1.0,5.034844366520673e-18,"No",2.393528365681032e-08,0.9999999760647146,"Yes",0.04306636856359237,0.9569336314364144,"Yes",1.0,1.5640663627490979e-22,"No",1.964850068783417e-12,0.999999999998039,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.669760035227521e-56,8.212142141369334e-14,0.9999999999999147,"-1",0.9999635459912137,3.645400877755522e-05,"No",0.00015859189778494564,0.9998414081022055,"Yes",1.0,5.034844366520673e-18,"No",2.393528365681032e-08,0.9999999760647146,"Yes",0.04306636856359237,0.9569336314364144,"Yes",1.0,1.5640663627490979e-22,"No",1.964850068783417e-12,0.999999999998039,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.669760035227521e-56,8.212142141369334e-14,0.9999999999999147,"-1",0.9999635459912137,3.645400877755522e-05,"No",0.00015859189778494564,0.9998414081022055,"Yes",1.0,5.034844366520673e-18,"No",2.393528365681032e-08,0.9999999760647146,"Yes",0.04306636856359237,0.9569336314364144,"Yes",1.0,1.5640663627490979e-22,"No",1.964850068783417e-12,0.999999999998039,"Yes"
"2009-017946-30","A Phase 3 Randomized Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal or Fallopian Tube CancerΜία Φάσης 3 Τυχαιοποιημένη Διπλά Τυφλή Μελέτη της Πεγκυλιωμένης Λιποσωμικής Δοξορουβικίνης (PLD) σε Συνδυασμό με AMG 386 ή Εικονικό Φάρμακο σε Γυναίκες με Υποτροπιάζοντα Μερικώς Ευαίσθητο ή Ανθεκτικό στην Πλατίνη Επιθηλιακό Καρκίνο των Ωοθηκών Πρωτοπαθή Καρκίνο του Περιτοναίου ή Καρκίνο των Σαλπίγγων","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.81659268915351e-59,1.0239264118764426e-16,1.0,"-1",0.9999999458799793,5.412002074016613e-08,"No",1.873521782544725e-07,0.9999998126478323,"Yes",1.0,5.544915407367322e-23,"No",2.4079202823107424e-09,0.9999999975920844,"Yes",0.0018144471658680767,0.9981855528341371,"Yes",1.0,2.2606764864871594e-27,"No",2.495165394398638e-15,1.0,"Yes"
"2009-018015-11","A Randomized Phase 2 Study of Human Anti-PDGRFα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CRPC) Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.986343784934149e-59,4.593431228252081e-05,0.9999540656877163,"2+",7.541634137744486e-05,0.9999245836586335,"Yes",0.9998702920453365,0.00012970795466899106,"No",1.0,1.1200800470340507e-21,"No",0.009202702224241119,0.9907972977757652,"Yes",0.13887134280354876,0.8611286571964495,"Yes",0.9999999999993463,6.496126521485311e-13,"No",8.835072674055717e-05,0.9999116492732604,"Yes"
"2009-018015-11","A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CRPC) Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.Randomizovaná studie fáze 2 porovnávající humánní monoklonální protilátku anti-PDGFRα (IMC-3G3) v kombinaci s mitoxantronem a prednisonem a mitoxantron a prednison u metastatického karcinomu prostaty refrakterního na kastraci (CRPC) po progresi choroby nebo intoleranci chemoterapie docetaxelem.","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3133824918033666e-98,3.23688854155692e-11,0.9999999999676561,"2+",9.875744021320302e-06,0.9999901242559811,"Yes",0.9999281897919468,7.181020802566567e-05,"No",1.0,4.896003121105051e-43,"No",1.0619339740933939e-08,0.9999999893806831,"Yes",0.019889719792317642,0.9801102802077071,"Yes",1.0,8.519789178317253e-32,"No",4.47606019784266e-11,0.9999999999552643,"Yes"
"2009-018015-11","A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CRPC) Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.Randomizovaná studie fáze 2 porovnávající humánní monoklonální protilátku anti-PDGFRα (IMC-3G3) v kombinaci s mitoxantronem a prednisonem a mitoxantron a prednison u metastatického karcinomu prostaty refrakterního na kastraci (CRPC) po progresi choroby nebo intoleranci chemoterapie docetaxelem.","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3133824918033666e-98,3.23688854155692e-11,0.9999999999676561,"2+",9.875744021320302e-06,0.9999901242559811,"Yes",0.9999281897919468,7.181020802566567e-05,"No",1.0,4.896003121105051e-43,"No",1.0619339740933939e-08,0.9999999893806831,"Yes",0.019889719792317642,0.9801102802077071,"Yes",1.0,8.519789178317253e-32,"No",4.47606019784266e-11,0.9999999999552643,"Yes"
"2009-018015-11","A Randomized Phase 2 Study of Human Anti-PDGRFα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CRPC) Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.986343784934149e-59,4.593431228252081e-05,0.9999540656877163,"2+",7.541634137744486e-05,0.9999245836586335,"Yes",0.9998702920453365,0.00012970795466899106,"No",1.0,1.1200800470340507e-21,"No",0.009202702224241119,0.9907972977757652,"Yes",0.13887134280354876,0.8611286571964495,"Yes",0.9999999999993463,6.496126521485311e-13,"No",8.835072674055717e-05,0.9999116492732604,"Yes"
"2009-018015-11","A Randomized Phase 2 Study of Human Anti-PDGRFα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CRPC) Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.986343784934149e-59,4.593431228252081e-05,0.9999540656877163,"2+",7.541634137744486e-05,0.9999245836586335,"Yes",0.9998702920453365,0.00012970795466899106,"No",1.0,1.1200800470340507e-21,"No",0.009202702224241119,0.9907972977757652,"Yes",0.13887134280354876,0.8611286571964495,"Yes",0.9999999999993463,6.496126521485311e-13,"No",8.835072674055717e-05,0.9999116492732604,"Yes"
"2009-018015-11","A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CRPC) Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy.Randomizovaná studie fáze 2 porovnávající humánní monoklonální protilátku anti-PDGFRα (IMC-3G3) v kombinaci s mitoxantronem a prednisonem a mitoxantron a prednison u metastatického karcinomu prostaty refrakterního na kastraci (CRPC) po progresi choroby nebo intoleranci chemoterapie docetaxelem.","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3133824918033666e-98,3.23688854155692e-11,0.9999999999676561,"2+",9.875744021320302e-06,0.9999901242559811,"Yes",0.9999281897919468,7.181020802566567e-05,"No",1.0,4.896003121105051e-43,"No",1.0619339740933939e-08,0.9999999893806831,"Yes",0.019889719792317642,0.9801102802077071,"Yes",1.0,8.519789178317253e-32,"No",4.47606019784266e-11,0.9999999999552643,"Yes"
"2009-018072-33","Prospective Trial for the diagnosis and treatment of children adolescents and young adults with Intracranial Germ Cell Tumours","IT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","2+","No",2.6748448908223602e-20,0.9931768751062157,0.006823124893779936,"-1",4.421489218439205e-05,0.9999557851078145,"Yes",0.999953034583589,4.6965416415109075e-05,"No",0.9999856155384375,1.4384461566119702e-05,"No",0.9934899421159731,0.006510057884022359,"No",0.9834827694424828,0.016517230557520926,"No",0.9990971137851576,0.0009028862148457259,"No",0.9972726351501621,0.0027273648498418305,"No"
"2010-018370-21","Phase I/II study with Temsirolimus versus no add-on in patients with castration resistant prostate cancer (CRPC) receiving first-line Docetaxel chemotherapy CESAR Study in Prostrate Cancer with Temsirolimus added to standard Docetaxel therapy (CEPTAS)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","No","No","No","1","No",9.288438555883342e-47,0.0002339940205983043,0.9997660059794042,"-1",8.090424001883001e-08,0.99999991909576,"Yes",0.9999997970255585,2.029744449569771e-07,"No",1.0,1.512164910013398e-17,"No",0.0012213240446440363,0.9987786759553664,"Yes",0.0027703825507991134,0.9972296174491901,"No",0.9999999999995168,4.712612134174506e-13,"No",3.050893430190159e-05,0.9999694910656858,"Yes"
"2010-018534-44","A Phase II multi-centre randomised double-blind placebo-controlled parallel group study to investigate the efficacy safety and tolerability of Cogane™ (PYM50028) a novel orally active neurotrophic factor inducer in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1816155893322534e-68,4.20053009980957e-12,0.9999999999957936,"2+",0.9999999999995168,4.897250592859729e-13,"No",2.0902230786779872e-12,0.9999999999978968,"Yes",1.0,4.07531282712941e-15,"No",8.151539048580425e-11,0.9999999999184865,"Yes",5.725532808797553e-06,0.9999942744672042,"Yes",0.9803197663833552,0.01968023361663109,"No",4.3571587909489155e-10,0.9999999995642952,"Yes"
"2010-018534-44","A Phase II multi-centre randomised double-blind placebo-controlled parallel group study to investigate the efficacy safety and tolerability of Cogane™ (PYM50028) a novel orally active neurotrophic factor inducer in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1816155893322534e-68,4.20053009980957e-12,0.9999999999957936,"2+",0.9999999999995168,4.897250592859729e-13,"No",2.0902230786779872e-12,0.9999999999978968,"Yes",1.0,4.07531282712941e-15,"No",8.151539048580425e-11,0.9999999999184865,"Yes",5.725532808797553e-06,0.9999942744672042,"Yes",0.9803197663833552,0.01968023361663109,"No",4.3571587909489155e-10,0.9999999995642952,"Yes"
"2010-018534-44","A Phase II multi-centre randomised double-blind placebo-controlled parallel group study to investigate the efficacy safety and tolerability of Cogane™ (PYM50028) a novel orally active neurotrophic factor inducer in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeksII. fázisú multicentrikus randomizált kettős-vak placebo-kontrollált párhuzamos csoportos vizsgálat a Cogane™ (PYM50028) – egy új orálisan aktív neurotrop faktort indukáló készítmény - hatékonyságának biztonságosságának és tolerálhatóságának vizsgálatára korai stádiumú Parkinson-kórban szenvedő férfi és nő vizsgálati alanyokon 28 hetes kezelés során a készítményt naponta egyszer alkalmazva","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.738846905340073e-113,1.053564053183885e-25,1.0,"2+",1.0,3.6830432892467524e-26,"No",1.4020307876528683e-24,1.0,"Yes",1.0,3.9717167874231555e-30,"No",2.5122830908886363e-28,1.0,"Yes",5.265286327453389e-16,1.0,"Yes",1.0,2.2752667649832272e-17,"No",6.090439634952197e-25,1.0,"Yes"
"2010-018534-44","A Phase II multi-centre randomised double-blind placebo-controlled parallel group study to investigate the efficacy safety and tolerability of Cogane™ (PYM50028) a novel orally active neurotrophic factor inducer in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1816155893322534e-68,4.20053009980957e-12,0.9999999999957936,"2+",0.9999999999995168,4.897250592859729e-13,"No",2.0902230786779872e-12,0.9999999999978968,"Yes",1.0,4.07531282712941e-15,"No",8.151539048580425e-11,0.9999999999184865,"Yes",5.725532808797553e-06,0.9999942744672042,"Yes",0.9803197663833552,0.01968023361663109,"No",4.3571587909489155e-10,0.9999999995642952,"Yes"
"2010-019287-37","A Phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy and safety of two r-hFSH formulations (AFOLIA vs Gonal-f®) in women for assisted reproductive treatment","DE","No","Yes","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",5.036081931978414e-38,9.860670360640158e-12,0.9999999999901378,"-1",0.8811249396466273,0.11887506035337359,"No",0.9999987435285724,1.2564714248876487e-06,"No",1.878750867842059e-08,0.9999999812124829,"Yes",8.090416427523023e-13,0.9999999999992043,"Yes",1.1501307473310432e-06,0.9999988498692651,"Yes",0.9999999997307328,2.69258695799914e-10,"No",4.9459511980173565e-12,0.9999999999950546,"Yes"
"2010-019287-37","Un estudio multicéntrico de fase III realizado con un grupo paralelo aleatorizado y enmascaramiento para los evaluadores para comparar la eficacia y seguridad de dos formulaciones r-hFSH (AFOLIA frente a Gonal-f®) en mujeres para el tratamiento de reproducción asistida.               A phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy adn safety of two r-hFSH formulations (AFOLIA and Gonal-f®) in women for assisted reproductive treatment","GB","No","Yes","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",6.064620769346946e-74,1.9670433062275713e-16,1.0,"-1",0.06822513588923158,0.9317748641107787,"No",1.0,4.235531492649024e-16,"No",9.631941326607339e-18,1.0,"Yes",1.913358740367031e-18,1.0,"Yes",1.5769676492301686e-10,0.9999999998423165,"Yes",1.0,5.070311017860201e-27,"No",9.887809912575345e-16,1.0,"Yes"
"2010-019287-37","A phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy adn safety of two r-hFSH formulations (AFOLIA and Gonal-f®) in women for assisted reproductive treatment","DK","No","Yes","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",1.2816829362034004e-35,7.478842412538594e-11,0.9999999999252226,"-1",0.9304691226320286,0.06953087736798143,"No",0.9999977592725978,2.240727411080435e-06,"No",1.7611354619148436e-08,0.9999999823886585,"Yes",6.622621354510141e-12,0.9999999999933779,"Yes",1.105036239748303e-06,0.9999988949637522,"Yes",0.9999999999121201,8.788727995228833e-11,"No",3.7364126911867846e-11,0.9999999999626255,"Yes"
"2010-019287-37","A Phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy and safety of two r-hFSH formulations (AFOLIA vs Gonal-f®) in women for assisted reproductive treatment","ES","No","Yes","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",5.036081931978414e-38,9.860670360640158e-12,0.9999999999901378,"-1",0.8811249396466273,0.11887506035337359,"No",0.9999987435285724,1.2564714248876487e-06,"No",1.878750867842059e-08,0.9999999812124829,"Yes",8.090416427523023e-13,0.9999999999992043,"Yes",1.1501307473310432e-06,0.9999988498692651,"Yes",0.9999999997307328,2.69258695799914e-10,"No",4.9459511980173565e-12,0.9999999999950546,"Yes"
"2010-019287-37","Un estudio multicéntrico de fase III realizado con un grupo paralelo aleatorizado y enmascaramiento para los evaluadores para comparar la eficacia y seguridad de dos formulaciones r-hFSH (AFOLIA frente a Gonal-f®) en mujeres para el tratamiento de reproducción asistida.               A phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy adn safety of two r-hFSH formulations (AFOLIA and Gonal-f®) in women for assisted reproductive treatment","AT","No","Yes","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",6.064620769346946e-74,1.9670433062275713e-16,1.0,"-1",0.06822513588923158,0.9317748641107787,"No",1.0,4.235531492649024e-16,"No",9.631941326607339e-18,1.0,"Yes",1.913358740367031e-18,1.0,"Yes",1.5769676492301686e-10,0.9999999998423165,"Yes",1.0,5.070311017860201e-27,"No",9.887809912575345e-16,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.898383992199295e-60,1.1674860710225176e-18,1.0,"-1",0.9999963891745373,3.6108254722520294e-06,"No",5.9722668350882766e-06,0.9999940277331655,"Yes",1.0,1.2447975408466258e-26,"No",1.0208078132533741e-14,1.0,"Yes",1.4444063770716773e-05,0.9999855559362434,"Yes",1.0,8.869704466391059e-16,"No",1.604772051946698e-17,1.0,"Yes"
"2010-019318-26","Estudio de fase 3 multicéntrico aleatorizado doble ciego del Ramucirumab (IMC-1121B) y el mejor tratamiento de soporte (BSC) frente a placebo más el BSC como tratamiento de segunda línea en pacientes con carcinoma hepatocelular tras el tratamiento de primera línea con sorafenib.//A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.023238852780606e-115,1.1720492180889304e-34,1.0,"-1",0.9999999944065509,5.593443670601496e-09,"No",1.6046652205228112e-08,0.9999999839533305,"Yes",1.0,3.2650590931271504e-49,"No",3.084392982285203e-29,1.0,"Yes",6.219732892646491e-10,0.9999999993780193,"Yes",1.0,4.232298883936101e-44,"No",4.3162401470444316e-33,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With SorafenibTöbb központban végzett randomizált kettős vak 3-as fázisú vizsgálat az első vonalbeli sorafenib kezelést követően második vonalbeli kezelésként alkalmazott ramucirumab (IMC-1121B) gyógyszerkészítmény és a legjobb szupportív kezelés illetve a placebo és a legjobb szupportív kezelés összehasonlítására hepatocelluláris karcinómában szenvedő betegeknél","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0494329583641448e-104,1.866871728332041e-29,1.0,"-1",0.9999999998664749,1.3354653025726151e-10,"No",1.5886062894981822e-08,0.9999999841139131,"Yes",1.0,4.4474232224103e-39,"No",1.714714098903534e-26,1.0,"Yes",8.049640691691843e-07,0.9999991950359516,"Yes",1.0,9.736238952792304e-25,"No",3.882530964136056e-29,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With SorafenibRandomizovaná multicentrická dvojitě zaslepená studie fáze III hodnotící léčivý přípravek ramucirumab (IMC-1121B) s nejlepší podpůrnou léčbou (BSC- Best Supportive Care) v porovnání s placebem a BSC v léčbě druhé linie u pacientů s hepatocelulárním karcinomem kteří podstoupili  léčbu první linie sorafenibem.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.235707003756214e-122,6.163911560354412e-41,1.0,"-1",0.9999999999967031,3.2509736055145816e-12,"No",9.91645827768661e-13,0.9999999999989768,"Yes",1.0,7.526950910548447e-71,"No",1.2335763813324077e-35,1.0,"Yes",4.092102087447043e-11,0.9999999999590728,"Yes",1.0,1.7167097498803096e-42,"No",1.8667655188644006e-38,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.898383992199295e-60,1.1674860710225176e-18,1.0,"-1",0.9999963891745373,3.6108254722520294e-06,"No",5.9722668350882766e-06,0.9999940277331655,"Yes",1.0,1.2447975408466258e-26,"No",1.0208078132533741e-14,1.0,"Yes",1.4444063770716773e-05,0.9999855559362434,"Yes",1.0,8.869704466391059e-16,"No",1.604772051946698e-17,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.898383992199295e-60,1.1674860710225176e-18,1.0,"-1",0.9999963891745373,3.6108254722520294e-06,"No",5.9722668350882766e-06,0.9999940277331655,"Yes",1.0,1.2447975408466258e-26,"No",1.0208078132533741e-14,1.0,"Yes",1.4444063770716773e-05,0.9999855559362434,"Yes",1.0,8.869704466391059e-16,"No",1.604772051946698e-17,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With SorafenibRandomizovaná multicentrická dvojitě zaslepená studie fáze III hodnotící léčivý přípravek ramucirumab (IMC-1121B) s nejlepší podpůrnou léčbou (BSC- Best Supportive Care) v porovnání s placebem a BSC v léčbě druhé linie u pacientů s hepatocelulárním karcinomem kteří podstoupili  léčbu první linie sorafenibem.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.235707003756214e-122,6.163911560354412e-41,1.0,"-1",0.9999999999967031,3.2509736055145816e-12,"No",9.91645827768661e-13,0.9999999999989768,"Yes",1.0,7.526950910548447e-71,"No",1.2335763813324077e-35,1.0,"Yes",4.092102087447043e-11,0.9999999999590728,"Yes",1.0,1.7167097498803096e-42,"No",1.8667655188644006e-38,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With SorafenibTöbb központban végzett randomizált kettős vak 3-as fázisú vizsgálat az első vonalbeli sorafenib kezelést követően második vonalbeli kezelésként alkalmazott ramucirumab (IMC-1121B) gyógyszerkészítmény és a legjobb szupportív kezelés illetve a placebo és a legjobb szupportív kezelés összehasonlítására hepatocelluláris karcinómában szenvedő betegeknél","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0494329583641448e-104,1.866871728332041e-29,1.0,"-1",0.9999999998664749,1.3354653025726151e-10,"No",1.5886062894981822e-08,0.9999999841139131,"Yes",1.0,4.4474232224103e-39,"No",1.714714098903534e-26,1.0,"Yes",8.049640691691843e-07,0.9999991950359516,"Yes",1.0,9.736238952792304e-25,"No",3.882530964136056e-29,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With SorafenibTöbb központban végzett randomizált kettős vak 3-as fázisú vizsgálat az első vonalbeli sorafenib kezelést követően második vonalbeli kezelésként alkalmazott ramucirumab (IMC-1121B) gyógyszerkészítmény és a legjobb szupportív kezelés illetve a placebo és a legjobb szupportív kezelés összehasonlítására hepatocelluláris karcinómában szenvedő betegeknél","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0494329583641448e-104,1.866871728332041e-29,1.0,"-1",0.9999999998664749,1.3354653025726151e-10,"No",1.5886062894981822e-08,0.9999999841139131,"Yes",1.0,4.4474232224103e-39,"No",1.714714098903534e-26,1.0,"Yes",8.049640691691843e-07,0.9999991950359516,"Yes",1.0,9.736238952792304e-25,"No",3.882530964136056e-29,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With SorafenibRandomizovaná multicentrická dvojitě zaslepená studie fáze III hodnotící léčivý přípravek ramucirumab (IMC-1121B) s nejlepší podpůrnou léčbou (BSC- Best Supportive Care) v porovnání s placebem a BSC v léčbě druhé linie u pacientů s hepatocelulárním karcinomem kteří podstoupili  léčbu první linie sorafenibem.","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.235707003756214e-122,6.163911560354412e-41,1.0,"-1",0.9999999999967031,3.2509736055145816e-12,"No",9.91645827768661e-13,0.9999999999989768,"Yes",1.0,7.526950910548447e-71,"No",1.2335763813324077e-35,1.0,"Yes",4.092102087447043e-11,0.9999999999590728,"Yes",1.0,1.7167097498803096e-42,"No",1.8667655188644006e-38,1.0,"Yes"
"2010-019318-26","Estudio de fase 3 multicéntrico aleatorizado doble ciego del Ramucirumab (IMC-1121B) y el mejor tratamiento de soporte (BSC) frente a placebo más el BSC como tratamiento de segunda línea en pacientes con carcinoma hepatocelular tras el tratamiento de primera línea con sorafenib.//A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.023238852780606e-115,1.1720492180889304e-34,1.0,"-1",0.9999999944065509,5.593443670601496e-09,"No",1.6046652205228112e-08,0.9999999839533305,"Yes",1.0,3.2650590931271504e-49,"No",3.084392982285203e-29,1.0,"Yes",6.219732892646491e-10,0.9999999993780193,"Yes",1.0,4.232298883936101e-44,"No",4.3162401470444316e-33,1.0,"Yes"
"2010-019318-26","Estudio de fase 3 multicéntrico aleatorizado doble ciego del Ramucirumab (IMC-1121B) y el mejor tratamiento de soporte (BSC) frente a placebo más el BSC como tratamiento de segunda línea en pacientes con carcinoma hepatocelular tras el tratamiento de primera línea con sorafenib.//A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib","NO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.023238852780606e-115,1.1720492180889304e-34,1.0,"-1",0.9999999944065509,5.593443670601496e-09,"No",1.6046652205228112e-08,0.9999999839533305,"Yes",1.0,3.2650590931271504e-49,"No",3.084392982285203e-29,1.0,"Yes",6.219732892646491e-10,0.9999999993780193,"Yes",1.0,4.232298883936101e-44,"No",4.3162401470444316e-33,1.0,"Yes"
"2010-019318-26","A Multicenter Randomized Double-Blind Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With SorafenibTöbb központban végzett randomizált kettős vak 3-as fázisú vizsgálat az első vonalbeli sorafenib kezelést követően második vonalbeli kezelésként alkalmazott ramucirumab (IMC-1121B) gyógyszerkészítmény és a legjobb szupportív kezelés illetve a placebo és a legjobb szupportív kezelés összehasonlítására hepatocelluláris karcinómában szenvedő betegeknél","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0494329583641448e-104,1.866871728332041e-29,1.0,"-1",0.9999999998664749,1.3354653025726151e-10,"No",1.5886062894981822e-08,0.9999999841139131,"Yes",1.0,4.4474232224103e-39,"No",1.714714098903534e-26,1.0,"Yes",8.049640691691843e-07,0.9999991950359516,"Yes",1.0,9.736238952792304e-25,"No",3.882530964136056e-29,1.0,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens Alone in Paediatric Patients Aged 1 to <18 Years with Solid Tumours Eligible for Autologous Transplants","Outside EU/EEA","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.151110771667435e-63,0.034605434331140314,0.9653945656688807,"2+",7.0980305156765085e-12,0.9999999999928947,"Yes",0.9999999999990337,9.718156064817278e-13,"No",0.9999999999998864,1.0737710969453877e-13,"No",0.9910498900333228,0.008950109966654803,"Yes",0.9999288979814043,7.110201860231588e-05,"Yes",1.0,3.8016466807696055e-19,"No",0.14821971588890798,0.8517802841110906,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens Alone in Paediatric Patients Aged 1 to <18 Years with Solid Tumours Eligible for Autologous Transplants","NL","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.151110771667435e-63,0.034605434331140314,0.9653945656688807,"2+",7.0980305156765085e-12,0.9999999999928947,"Yes",0.9999999999990337,9.718156064817278e-13,"No",0.9999999999998864,1.0737710969453877e-13,"No",0.9910498900333228,0.008950109966654803,"Yes",0.9999288979814043,7.110201860231588e-05,"Yes",1.0,3.8016466807696055e-19,"No",0.14821971588890798,0.8517802841110906,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens Alone in Paediatric Patients Aged 2 to <18 Years with Solid Tumours Eligible for Autologous TransplantsEstudio combinado de fase 1/2 de búsqueda de dosis y comparativo abierto aleatorizado para evaluar la eficacia y seguridad de plerixafor junto con regímenes estándar para la movilización de células madre hematopoyéticas a sangre periférica y posterior recolección por aféresis frente a solo regímenes estándar para la movilización en pacientes pediátricos de 2 a <18 años con tumores sólidos que reúnen los requisitos para trasplantes autólogos","GB","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.8841116792039626e-124,0.9971030690204207,0.002896930979597368,"2+",6.88932052469003e-26,1.0,"Yes",1.0,3.314456712575097e-26,"No",1.0,1.3739675225519119e-27,"No",0.9999999999799911,2.0053035205094853e-11,"Yes",0.9999999999765805,2.3436019931580704e-11,"Yes",1.0,2.392565449778333e-50,"No",0.9999991073473785,8.92652652365784e-07,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens Alone in Paediatric Patients Aged 2 to <18 Years with Solid Tumours Eligible for Autologous TransplantsEstudio combinado de fase 1/2 de búsqueda de dosis y comparativo abierto aleatorizado para evaluar la eficacia y seguridad de plerixafor junto con regímenes estándar para la movilización de células madre hematopoyéticas a sangre periférica y posterior recolección por aféresis frente a solo regímenes estándar para la movilización en pacientes pediátricos de 2 a <18 años con tumores sólidos que reúnen los requisitos para trasplantes autólogos","IT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.8841116792039626e-124,0.9971030690204207,0.002896930979597368,"2+",6.88932052469003e-26,1.0,"Yes",1.0,3.314456712575097e-26,"No",1.0,1.3739675225519119e-27,"No",0.9999999999799911,2.0053035205094853e-11,"Yes",0.9999999999765805,2.3436019931580704e-11,"Yes",1.0,2.392565449778333e-50,"No",0.9999991073473785,8.92652652365784e-07,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy  and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells  into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens  Alone in Paediatric Patients Aged 2 to < 18 Years with Solid Tumours Eligible for Autologous Transplants","DK","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.852113221373258e-63,0.02464776428997136,0.9753522357100043,"2+",8.72408653288158e-12,0.999999999991303,"Yes",0.9999999999988064,1.19429820940558e-12,"No",0.9999999999998864,1.2207836570452343e-13,"No",0.9901802958428843,0.009819704157128671,"Yes",0.9999213458935746,7.865410639798002e-05,"Yes",1.0,2.871560380475346e-19,"No",0.12442130603154905,0.8755786939684749,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens Alone in Paediatric Patients Aged 1 to <18 Years with Solid Tumours Eligible for Autologous Transplants","PL","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.151110771667435e-63,0.034605434331140314,0.9653945656688807,"2+",7.0980305156765085e-12,0.9999999999928947,"Yes",0.9999999999990337,9.718156064817278e-13,"No",0.9999999999998864,1.0737710969453877e-13,"No",0.9910498900333228,0.008950109966654803,"Yes",0.9999288979814043,7.110201860231588e-05,"Yes",1.0,3.8016466807696055e-19,"No",0.14821971588890798,0.8517802841110906,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy  and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells  into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens  Alone in Paediatric Patients Aged 2 to < 18 Years with Solid Tumours Eligible for Autologous Transplants","BE","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.852113221373258e-63,0.02464776428997136,0.9753522357100043,"2+",8.72408653288158e-12,0.999999999991303,"Yes",0.9999999999988064,1.19429820940558e-12,"No",0.9999999999998864,1.2207836570452343e-13,"No",0.9901802958428843,0.009819704157128671,"Yes",0.9999213458935746,7.865410639798002e-05,"Yes",1.0,2.871560380475346e-19,"No",0.12442130603154905,0.8755786939684749,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens Alone in Paediatric Patients Aged 1 to <18 Years with Solid Tumours Eligible for Autologous Transplants","CZ","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.151110771667435e-63,0.034605434331140314,0.9653945656688807,"2+",7.0980305156765085e-12,0.9999999999928947,"Yes",0.9999999999990337,9.718156064817278e-13,"No",0.9999999999998864,1.0737710969453877e-13,"No",0.9910498900333228,0.008950109966654803,"Yes",0.9999288979814043,7.110201860231588e-05,"Yes",1.0,3.8016466807696055e-19,"No",0.14821971588890798,0.8517802841110906,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens Alone in Paediatric Patients Aged 1 to <18 Years with Solid Tumours Eligible for Autologous Transplants","ES","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.151110771667435e-63,0.034605434331140314,0.9653945656688807,"2+",7.0980305156765085e-12,0.9999999999928947,"Yes",0.9999999999990337,9.718156064817278e-13,"No",0.9999999999998864,1.0737710969453877e-13,"No",0.9910498900333228,0.008950109966654803,"Yes",0.9999288979814043,7.110201860231588e-05,"Yes",1.0,3.8016466807696055e-19,"No",0.14821971588890798,0.8517802841110906,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy  and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells  into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens  Alone in Paediatric Patients Aged 2 to < 18 Years with Solid Tumours Eligible for Autologous Transplants","DE","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.852113221373258e-63,0.02464776428997136,0.9753522357100043,"2+",8.72408653288158e-12,0.999999999991303,"Yes",0.9999999999988064,1.19429820940558e-12,"No",0.9999999999998864,1.2207836570452343e-13,"No",0.9901802958428843,0.009819704157128671,"Yes",0.9999213458935746,7.865410639798002e-05,"Yes",1.0,2.871560380475346e-19,"No",0.12442130603154905,0.8755786939684749,"Yes"
"2010-019340-40","A Phase 1/2 Combined Dose Ranging and Randomised Open-label Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood and Subsequent Collection by Apheresis Versus Standard Mobilisation Regimens Alone in Paediatric Patients Aged 1 to <18 Years with Solid Tumours Eligible for Autologous Transplants","HU","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.151110771667435e-63,0.034605434331140314,0.9653945656688807,"2+",7.0980305156765085e-12,0.9999999999928947,"Yes",0.9999999999990337,9.718156064817278e-13,"No",0.9999999999998864,1.0737710969453877e-13,"No",0.9910498900333228,0.008950109966654803,"Yes",0.9999288979814043,7.110201860231588e-05,"Yes",1.0,3.8016466807696055e-19,"No",0.14821971588890798,0.8517802841110906,"Yes"
"2010-019347-18","Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1246519073686632e-59,3.1439653164207975e-07,0.9999996856034767,"-1",3.809800072515336e-06,0.9999961901999185,"Yes",0.9999890158548947,1.0984145096949589e-05,"No",1.0,2.1312572199975914e-21,"No",0.001870019780404357,0.9981299802195901,"Yes",0.9985889583326922,0.001411041667307791,"No",1.0,2.6831303124487875e-22,"No",9.03125565394415e-06,0.9999909687443531,"Yes"
"2010-019439-37","A Phase 3 Prospective Randomized Double-blind Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 years with Moderate to Severe Chronic Kidney Disease.  Estudio en fase 3 prospectivo multicéntrico aleatorizado doble ciego y controlado con placebo para evaluar la farmacocinéticala seguridad y la eficacia de paricalcitol cápsulas en cuanto a la reducción de la concentración sérica de hormona paratiroidea intacta en niños y adolescentes de entre 10 y 16 años connefropatía crónica moderada o grave.","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.0802552216153425e-121,2.1300586284063328e-11,0.9999999999787407,"2+",1.0,1.1198042128362906e-15,"No",8.438922518620224e-14,0.9999999999998864,"Yes",1.0,2.060328427846154e-23,"No",5.2262519131513475e-12,0.9999999999947704,"Yes",0.9760433354393828,0.02395666456062379,"No",1.0,8.02478727549269e-16,"No",1.7166479828158813e-08,0.9999999828335151,"Yes"
"2010-019632-12","A phase II multicentre open prospective randomised parallel-group pharmacodynamic equivalence study on intramuscular versus subcutaneous applications of Triptorelin pamoate (Pamorelin® LA 11.25 mg) in patients with advanced prostate cancer","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.262331549702407e-43,3.988307621863469e-06,0.9999960116923841,"2+",0.25188706655510196,0.7481129334449027,"Yes",0.9645028603677012,0.03549713963228677,"No",0.9997958521857286,0.00020414781426103857,"No",5.9365647043978775e-06,0.9999940634353096,"Yes",0.007344724413520913,0.9926552755864735,"Yes",0.9999827546419345,1.7245358067275068e-05,"No",5.255592896508475e-06,0.9999947444071018,"Yes"
"2010-019748-38","Hautveränderungen bei Patienten mit Kopf- und Halstumor unter kombinierter RadioImmuno-(chemo)-therapie mit Erbitux®","DE","No","No","Yes","ok","No","No","No","No","2+","No","No","Yes","No","No","No","No","No","2+","No",4.192434623112536e-14,0.47092134711327027,0.529078652886695,"-1",0.00023335029914080884,0.9997666497008634,"Yes",0.9998461248123224,0.0001538751876740589,"No",0.8082534932156272,0.19174650678437408,"No",0.9360354057454386,0.06396459425455644,"No",0.9885573754474474,0.011442624552547435,"No",0.8434485373171523,0.15655146268284664,"No",0.5861202393449967,0.41387976065500687,"No"
"2010-020122-18","A prospective randomized double-blind double-dummy placebo- and active controlled multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.54752522987348e-56,1.501882775832654e-13,0.9999999999998579,"-1",0.9999999999999147,9.677301080241573e-14,"No",1.4847912676659005e-12,0.9999999999985221,"Yes",0.9999999999849934,1.5005883766506104e-11,"No",1.473708899454764e-14,0.9999999999999717,"Yes",0.00011518462062848774,0.9998848153793801,"Yes",0.9999999034382985,9.656170351956576e-08,"No",1.0929927296615942e-13,0.9999999999998864,"Yes"
"2010-020122-18","A prospective randomized double-blind double-dummy placebo- and active controlled multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.54752522987348e-56,1.501882775832654e-13,0.9999999999998579,"-1",0.9999999999999147,9.677301080241573e-14,"No",1.4847912676659005e-12,0.9999999999985221,"Yes",0.9999999999849934,1.5005883766506104e-11,"No",1.473708899454764e-14,0.9999999999999717,"Yes",0.00011518462062848774,0.9998848153793801,"Yes",0.9999999034382985,9.656170351956576e-08,"No",1.0929927296615942e-13,0.9999999999998864,"Yes"
"2010-020122-18","A prospective randomized double-blind double-dummy placebo- and active controlled multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.54752522987348e-56,1.501882775832654e-13,0.9999999999998579,"-1",0.9999999999999147,9.677301080241573e-14,"No",1.4847912676659005e-12,0.9999999999985221,"Yes",0.9999999999849934,1.5005883766506104e-11,"No",1.473708899454764e-14,0.9999999999999717,"Yes",0.00011518462062848774,0.9998848153793801,"Yes",0.9999999034382985,9.656170351956576e-08,"No",1.0929927296615942e-13,0.9999999999998864,"Yes"
"2010-020122-18","A prospective randomized double-blind double-dummy placebo- and active controlled multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.54752522987348e-56,1.501882775832654e-13,0.9999999999998579,"-1",0.9999999999999147,9.677301080241573e-14,"No",1.4847912676659005e-12,0.9999999999985221,"Yes",0.9999999999849934,1.5005883766506104e-11,"No",1.473708899454764e-14,0.9999999999999717,"Yes",0.00011518462062848774,0.9998848153793801,"Yes",0.9999999034382985,9.656170351956576e-08,"No",1.0929927296615942e-13,0.9999999999998864,"Yes"
"2010-020122-18","A prospective randomized double-blind double-dummy placebo- and active controlled multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.54752522987348e-56,1.501882775832654e-13,0.9999999999998579,"-1",0.9999999999999147,9.677301080241573e-14,"No",1.4847912676659005e-12,0.9999999999985221,"Yes",0.9999999999849934,1.5005883766506104e-11,"No",1.473708899454764e-14,0.9999999999999717,"Yes",0.00011518462062848774,0.9998848153793801,"Yes",0.9999999034382985,9.656170351956576e-08,"No",1.0929927296615942e-13,0.9999999999998864,"Yes"
"2010-020122-18","A prospective randomized double-blind double-dummy placebo- and active controlled multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.54752522987348e-56,1.501882775832654e-13,0.9999999999998579,"-1",0.9999999999999147,9.677301080241573e-14,"No",1.4847912676659005e-12,0.9999999999985221,"Yes",0.9999999999849934,1.5005883766506104e-11,"No",1.473708899454764e-14,0.9999999999999717,"Yes",0.00011518462062848774,0.9998848153793801,"Yes",0.9999999034382985,9.656170351956576e-08,"No",1.0929927296615942e-13,0.9999999999998864,"Yes"
"2010-020122-18","A prospective randomized double-blind double-dummy placebo- and active controlled multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.54752522987348e-56,1.501882775832654e-13,0.9999999999998579,"-1",0.9999999999999147,9.677301080241573e-14,"No",1.4847912676659005e-12,0.9999999999985221,"Yes",0.9999999999849934,1.5005883766506104e-11,"No",1.473708899454764e-14,0.9999999999999717,"Yes",0.00011518462062848774,0.9998848153793801,"Yes",0.9999999034382985,9.656170351956576e-08,"No",1.0929927296615942e-13,0.9999999999998864,"Yes"
"2010-020386-24","Phase II multicenter randomized adaptive double-blind placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.226001655298344e-48,4.549711739174709e-08,0.9999999545028839,"-1",0.9999999973834549,2.616549040227039e-09,"No",1.1398162034069383e-08,0.999999988601843,"Yes",0.9999940520586075,5.947941388704602e-06,"No",1.8965619803554353e-06,0.999998103438025,"Yes",0.023450385679504086,0.9765496143204981,"Yes",0.999999991751139,8.248861288052832e-09,"No",1.636720771978939e-05,0.9999836327922863,"Yes"
"2010-020386-24","Phase II multicenter randomized adaptive double-blind placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.226001655298344e-48,4.549711739174709e-08,0.9999999545028839,"-1",0.9999999973834549,2.616549040227039e-09,"No",1.1398162034069383e-08,0.999999988601843,"Yes",0.9999940520586075,5.947941388704602e-06,"No",1.8965619803554353e-06,0.999998103438025,"Yes",0.023450385679504086,0.9765496143204981,"Yes",0.999999991751139,8.248861288052832e-09,"No",1.636720771978939e-05,0.9999836327922863,"Yes"
"2010-020386-24","Phase IImulticenterrandomizedadaptivedouble-blindplacebo controlled study to assess safety and efficacy of olexosime (TRO19622)in 3-25 year old Spinal Muscular Atrophy (SMA) patients","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8851723154851288e-26,0.09416959541624109,0.9058304045837573,"-1",0.999836928438076,0.00016307156192792155,"No",0.00015516748320689973,0.999844832516799,"Yes",0.9996836507283764,0.00031634927163013625,"No",0.06065203191545929,0.9393479680845457,"Yes",0.24037662943015844,0.7596233705698473,"Yes",0.9999997423269255,2.5767307040267456e-07,"No",0.07187645018687483,0.9281235498131265,"Yes"
"2010-020386-24","Phase II multicenter randomized adaptive double-blind placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.226001655298344e-48,4.549711739174709e-08,0.9999999545028839,"-1",0.9999999973834549,2.616549040227039e-09,"No",1.1398162034069383e-08,0.999999988601843,"Yes",0.9999940520586075,5.947941388704602e-06,"No",1.8965619803554353e-06,0.999998103438025,"Yes",0.023450385679504086,0.9765496143204981,"Yes",0.999999991751139,8.248861288052832e-09,"No",1.636720771978939e-05,0.9999836327922863,"Yes"
"2010-020386-24","Phase II multicenter randomized adaptive double-blind placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.226001655298344e-48,4.549711739174709e-08,0.9999999545028839,"-1",0.9999999973834549,2.616549040227039e-09,"No",1.1398162034069383e-08,0.999999988601843,"Yes",0.9999940520586075,5.947941388704602e-06,"No",1.8965619803554353e-06,0.999998103438025,"Yes",0.023450385679504086,0.9765496143204981,"Yes",0.999999991751139,8.248861288052832e-09,"No",1.636720771978939e-05,0.9999836327922863,"Yes"
"2010-020386-24","Phase IImulticenterrandomizedadaptivedouble-blindplacebo controlled study to assess safety and efficacy of olexosime (TRO19622)in 3-25 year old Spinal Muscular Atrophy (SMA) patients","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8851723154851288e-26,0.09416959541624109,0.9058304045837573,"-1",0.999836928438076,0.00016307156192792155,"No",0.00015516748320689973,0.999844832516799,"Yes",0.9996836507283764,0.00031634927163013625,"No",0.06065203191545929,0.9393479680845457,"Yes",0.24037662943015844,0.7596233705698473,"Yes",0.9999997423269255,2.5767307040267456e-07,"No",0.07187645018687483,0.9281235498131265,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder","NO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020601-32","A Randomized Double-Blind Factorial Parallel-Group Active and Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.213463511642308e-55,4.789365627077784e-15,1.0,"2+",1.0,9.732166180109045e-15,"No",2.858054361574875e-14,0.9999999999999717,"Yes",1.0,8.088741808781061e-18,"No",7.176392044358646e-15,1.0,"Yes",0.0015980835330479696,0.9984019164669411,"Yes",1.0,2.426645855750858e-18,"No",1.443224596852433e-12,0.9999999999985506,"Yes"
"2010-020814-27","Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase IIIstrategy study of the EORTC Infectious Diseases and Leukemia Groups","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.483448976463774e-42,0.9995307773749401,0.0004692226250571433,"2+",1.9564104898398136e-14,0.9999999999999717,"Yes",1.0,8.185833809817126e-15,"No",1.0,3.4744717859350987e-15,"No",0.9991863533910073,0.0008136466089979658,"Yes",0.9997225320384777,0.00027746796152846134,"No",0.99999999906467,9.353169917670845e-10,"No",0.9997499807166031,0.0002500192834019959,"Yes"
"2010-020814-27","Empirical versus pre-emptive antifungal therapy of patients withhaematological malignanciesEmpirical versus pre-emptive (diagnosticdriven)antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase IIIstrategy study of the EORTC Infectious Diseases and Leukemia Groups.","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.9386462690915594e-51,0.999571129020177,0.00042887097982458776,"2+",5.178475086100103e-16,1.0,"Yes",1.0,1.901062575727956e-16,"No",0.9999999999999432,4.473026829947819e-14,"No",0.9998986211257379,0.00010137887426002652,"Yes",0.9999948024768412,5.197523145652732e-06,"No",0.99999997107733,2.8922667474435082e-08,"No",0.999791899732117,0.00020810026788285461,"Yes"
"2010-020814-27","Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.944178461300814e-45,0.9543450989565672,0.04565490104343431,"2+",1.5183073335566406e-15,1.0,"Yes",1.0,6.183331810300883e-16,"No",1.0,2.1503384107235997e-15,"No",0.9893006980282456,0.01069930197175817,"Yes",0.9995977508183315,0.0004022491816702281,"No",0.9999999996247483,3.752486158287238e-10,"No",0.9923872552852436,0.007612744714748293,"Yes"
"2010-020814-27","Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups","CZ","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.944178461300814e-45,0.9543450989565672,0.04565490104343431,"2+",1.5183073335566406e-15,1.0,"Yes",1.0,6.183331810300883e-16,"No",1.0,2.1503384107235997e-15,"No",0.9893006980282456,0.01069930197175817,"Yes",0.9995977508183315,0.0004022491816702281,"No",0.9999999996247483,3.752486158287238e-10,"No",0.9923872552852436,0.007612744714748293,"Yes"
"2010-020814-27","Empirical versus pre-emptive antifungal therapy of patients withhaematological malignanciesEmpirical versus pre-emptive (diagnosticdriven)antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase IIIstrategy study of the EORTC Infectious Diseases and Leukemia Groups.","SK","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.9386462690915594e-51,0.999571129020177,0.00042887097982458776,"2+",5.178475086100103e-16,1.0,"Yes",1.0,1.901062575727956e-16,"No",0.9999999999999432,4.473026829947819e-14,"No",0.9998986211257379,0.00010137887426002652,"Yes",0.9999948024768412,5.197523145652732e-06,"No",0.99999997107733,2.8922667474435082e-08,"No",0.999791899732117,0.00020810026788285461,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-020821-41","PREVAIL: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6936216931715877e-53,5.986741240977959e-09,0.9999999940132512,"2+",0.9999717149412334,2.828505875811341e-05,"No",7.376643747446437e-05,0.9999262335625294,"Yes",0.9999999999819806,1.8006931735274436e-11,"No",5.952021837008203e-08,0.9999999404797695,"Yes",0.07980829749311671,0.9201917025068764,"Yes",0.9999999967806731,3.2193297031463264e-09,"No",3.5614947434330435e-08,0.9999999643850408,"Yes"
"2010-021113-23","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 infected subjects who relapsed after previous interferon-based therapy","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.612115256490326e-67,8.793543016218071e-07,0.9999991206456856,"-1",0.9999831342217713,1.6865778216097394e-05,"No",9.951157985877809e-05,0.9999004884201423,"Yes",1.0,7.198085078957801e-19,"No",1.738929029282934e-07,0.9999998261071009,"Yes",0.9697948893014322,0.030205110698562375,"Yes",1.0,7.501615368009686e-15,"No",6.519230823849168e-06,0.9999934807691682,"Yes"
"2010-021113-23","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 infected subjects who relapsed after previous interferon-based therapy","PL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.612115256490326e-67,8.793543016218071e-07,0.9999991206456856,"-1",0.9999831342217713,1.6865778216097394e-05,"No",9.951157985877809e-05,0.9999004884201423,"Yes",1.0,7.198085078957801e-19,"No",1.738929029282934e-07,0.9999998261071009,"Yes",0.9697948893014322,0.030205110698562375,"Yes",1.0,7.501615368009686e-15,"No",6.519230823849168e-06,0.9999934807691682,"Yes"
"2010-021113-23","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 infected subjects who relapsed after previous interferon-based therapy","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.612115256490326e-67,8.793543016218071e-07,0.9999991206456856,"-1",0.9999831342217713,1.6865778216097394e-05,"No",9.951157985877809e-05,0.9999004884201423,"Yes",1.0,7.198085078957801e-19,"No",1.738929029282934e-07,0.9999998261071009,"Yes",0.9697948893014322,0.030205110698562375,"Yes",1.0,7.501615368009686e-15,"No",6.519230823849168e-06,0.9999934807691682,"Yes"
"2010-021113-23","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 infected subjects who relapsed after previous interferon-based therapy","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.612115256490326e-67,8.793543016218071e-07,0.9999991206456856,"-1",0.9999831342217713,1.6865778216097394e-05,"No",9.951157985877809e-05,0.9999004884201423,"Yes",1.0,7.198085078957801e-19,"No",1.738929029282934e-07,0.9999998261071009,"Yes",0.9697948893014322,0.030205110698562375,"Yes",1.0,7.501615368009686e-15,"No",6.519230823849168e-06,0.9999934807691682,"Yes"
"2010-021113-23","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 infected subjects who relapsed after previous interferon-based therapy","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.612115256490326e-67,8.793543016218071e-07,0.9999991206456856,"-1",0.9999831342217713,1.6865778216097394e-05,"No",9.951157985877809e-05,0.9999004884201423,"Yes",1.0,7.198085078957801e-19,"No",1.738929029282934e-07,0.9999998261071009,"Yes",0.9697948893014322,0.030205110698562375,"Yes",1.0,7.501615368009686e-15,"No",6.519230823849168e-06,0.9999934807691682,"Yes"
"2010-021113-23","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 infected subjects who relapsed after previous interferon-based therapy","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.612115256490326e-67,8.793543016218071e-07,0.9999991206456856,"-1",0.9999831342217713,1.6865778216097394e-05,"No",9.951157985877809e-05,0.9999004884201423,"Yes",1.0,7.198085078957801e-19,"No",1.738929029282934e-07,0.9999998261071009,"Yes",0.9697948893014322,0.030205110698562375,"Yes",1.0,7.501615368009686e-15,"No",6.519230823849168e-06,0.9999934807691682,"Yes"
"2010-021113-23","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 infected subjects who relapsed after previous interferon-based therapy","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.612115256490326e-67,8.793543016218071e-07,0.9999991206456856,"-1",0.9999831342217713,1.6865778216097394e-05,"No",9.951157985877809e-05,0.9999004884201423,"Yes",1.0,7.198085078957801e-19,"No",1.738929029282934e-07,0.9999998261071009,"Yes",0.9697948893014322,0.030205110698562375,"Yes",1.0,7.501615368009686e-15,"No",6.519230823849168e-06,0.9999934807691682,"Yes"
"2010-021174-11","Estudio en fase III aleatorizado doble ciego y controlado con placebo para investigar la eficacia la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de un régimen de tratamiento que incluye peginterferón alfa-2a  (Pegasys®) y ribavirina (Copegus®) o peginterferón alfa-2b (PegIntron®) y ribavirina (Rebetol®) en sujetos infectados por el virus de la hepatitis C genotipo 1 no tratados previamente.A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon alfa-2b  (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve genotype 1 hepatitis C-infected subjects.","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.7288925706278184e-154,6.640688647269313e-11,0.9999999999336069,"2+",0.9999999999047304,9.52369563504546e-11,"No",3.2973470213518184e-08,0.9999999670264975,"Yes",1.0,4.347849775838507e-46,"No",3.249658833028692e-13,0.9999999999996589,"Yes",0.9994910962483331,0.0005089037516674146,"Yes",1.0,2.5575201005314877e-45,"No",2.050904513514464e-09,0.9999999979490896,"Yes"
"2010-021174-11","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon α-2b (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve genotype 1 hepatitis C-infected subjects.","BG","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8164532821527294e-64,4.314664373457523e-07,0.9999995685335613,"2+",0.9999984945146956,1.5054853184451244e-06,"No",4.868510263873279e-06,0.9999951314897254,"Yes",1.0,3.9532785863999934e-24,"No",1.0722675069544856e-07,0.9999998927732521,"Yes",0.9464387868800189,0.05356121311998937,"Yes",1.0,1.0035028703117323e-19,"No",2.554225953649159e-06,0.9999974457740499,"Yes"
"2010-021174-11","Estudio en fase III aleatorizado doble ciego y controlado con placebo para investigar la eficacia la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de un régimen de tratamiento que incluye peginterferón alfa-2a  (Pegasys®) y ribavirina (Copegus®) o peginterferón alfa-2b (PegIntron®) y ribavirina (Rebetol®) en sujetos infectados por el virus de la hepatitis C genotipo 1 no tratados previamente.A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon alfa-2b  (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve genotype 1 hepatitis C-infected subjects.","PL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.7288925706278184e-154,6.640688647269313e-11,0.9999999999336069,"2+",0.9999999999047304,9.52369563504546e-11,"No",3.2973470213518184e-08,0.9999999670264975,"Yes",1.0,4.347849775838507e-46,"No",3.249658833028692e-13,0.9999999999996589,"Yes",0.9994910962483331,0.0005089037516674146,"Yes",1.0,2.5575201005314877e-45,"No",2.050904513514464e-09,0.9999999979490896,"Yes"
"2010-021174-11","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon α-2b (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve genotype 1 hepatitis C-infected subjects.","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8164532821527294e-64,4.314664373457523e-07,0.9999995685335613,"2+",0.9999984945146956,1.5054853184451244e-06,"No",4.868510263873279e-06,0.9999951314897254,"Yes",1.0,3.9532785863999934e-24,"No",1.0722675069544856e-07,0.9999998927732521,"Yes",0.9464387868800189,0.05356121311998937,"Yes",1.0,1.0035028703117323e-19,"No",2.554225953649159e-06,0.9999974457740499,"Yes"
"2010-021174-11","Estudio en fase III aleatorizado doble ciego y controlado con placebo para investigar la eficacia la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de un régimen de tratamiento que incluye peginterferón alfa-2a  (Pegasys®) y ribavirina (Copegus®) o peginterferón alfa-2b (PegIntron®) y ribavirina (Rebetol®) en sujetos infectados por el virus de la hepatitis C genotipo 1 no tratados previamente.A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon alfa-2b  (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve genotype 1 hepatitis C-infected subjects.","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.7288925706278184e-154,6.640688647269313e-11,0.9999999999336069,"2+",0.9999999999047304,9.52369563504546e-11,"No",3.2973470213518184e-08,0.9999999670264975,"Yes",1.0,4.347849775838507e-46,"No",3.249658833028692e-13,0.9999999999996589,"Yes",0.9994910962483331,0.0005089037516674146,"Yes",1.0,2.5575201005314877e-45,"No",2.050904513514464e-09,0.9999999979490896,"Yes"
"2010-021174-11","A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon α-2b (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve genotype 1 hepatitis C-infected subjects.","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8164532821527294e-64,4.314664373457523e-07,0.9999995685335613,"2+",0.9999984945146956,1.5054853184451244e-06,"No",4.868510263873279e-06,0.9999951314897254,"Yes",1.0,3.9532785863999934e-24,"No",1.0722675069544856e-07,0.9999998927732521,"Yes",0.9464387868800189,0.05356121311998937,"Yes",1.0,1.0035028703117323e-19,"No",2.554225953649159e-06,0.9999974457740499,"Yes"
"2010-021174-11","Estudio en fase III aleatorizado doble ciego y controlado con placebo para investigar la eficacia la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de un régimen de tratamiento que incluye peginterferón alfa-2a  (Pegasys®) y ribavirina (Copegus®) o peginterferón alfa-2b (PegIntron®) y ribavirina (Rebetol®) en sujetos infectados por el virus de la hepatitis C genotipo 1 no tratados previamente.A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon alfa-2b  (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve genotype 1 hepatitis C-infected subjects.","PT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.7288925706278184e-154,6.640688647269313e-11,0.9999999999336069,"2+",0.9999999999047304,9.52369563504546e-11,"No",3.2973470213518184e-08,0.9999999670264975,"Yes",1.0,4.347849775838507e-46,"No",3.249658833028692e-13,0.9999999999996589,"Yes",0.9994910962483331,0.0005089037516674146,"Yes",1.0,2.5575201005314877e-45,"No",2.050904513514464e-09,0.9999999979490896,"Yes"
"2010-021174-11","Estudio en fase III aleatorizado doble ciego y controlado con placebo para investigar la eficacia la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de un régimen de tratamiento que incluye peginterferón alfa-2a  (Pegasys®) y ribavirina (Copegus®) o peginterferón alfa-2b (PegIntron®) y ribavirina (Rebetol®) en sujetos infectados por el virus de la hepatitis C genotipo 1 no tratados previamente.A Phase III randomized double-blind placebo-controlled study to investigate the efficacy safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon alfa-2b  (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve genotype 1 hepatitis C-infected subjects.","SK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.7288925706278184e-154,6.640688647269313e-11,0.9999999999336069,"2+",0.9999999999047304,9.52369563504546e-11,"No",3.2973470213518184e-08,0.9999999670264975,"Yes",1.0,4.347849775838507e-46,"No",3.249658833028692e-13,0.9999999999996589,"Yes",0.9994910962483331,0.0005089037516674146,"Yes",1.0,2.5575201005314877e-45,"No",2.050904513514464e-09,0.9999999979490896,"Yes"
"2010-021287-16","A phase 2 open-label single-arm efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer","CZ","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.519757001099619e-25,0.9979930779318619,0.0020069220681394064,"-1",5.217296971748568e-05,0.9999478270302811,"Yes",0.9999559333918646,4.406660813542285e-05,"No",0.999977129588667,2.2870411334738724e-05,"No",0.9996310994843941,0.0003689005156061656,"No",0.9859269882842834,0.014073011715716772,"No",0.978550937174079,0.021449062825915077,"No",0.9963471640928704,0.0036528359071336725,"No"
"2010-021287-16","A phase 2 open-label single-arm efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.519757001099619e-25,0.9979930779318619,0.0020069220681394064,"-1",5.217296971748568e-05,0.9999478270302811,"Yes",0.9999559333918646,4.406660813542285e-05,"No",0.999977129588667,2.2870411334738724e-05,"No",0.9996310994843941,0.0003689005156061656,"No",0.9859269882842834,0.014073011715716772,"No",0.978550937174079,0.021449062825915077,"No",0.9963471640928704,0.0036528359071336725,"No"
"2010-021370-11","An open label single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy.","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",7.207597152680207e-37,0.99941840806665,0.0005815919333529382,"1",2.3721717495662537e-07,0.9999997627828205,"Yes",0.9999997275443578,2.724556359010942e-07,"No",0.9999999999999005,9.344294993484157e-14,"No",0.999074642402125,0.000925357597871138,"No",0.953876470050138,0.04612352994986296,"No",0.9999991999543812,8.000456183324412e-07,"No",0.9975721645908554,0.002427835409142005,"No"
"2010-021434-55","An Open-label Multi-Centre Extension Trial Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.1845445118386624e-36,0.000776253056589726,0.9992237469434018,"-1",2.672909326375989e-07,0.9999997327090642,"Yes",0.9999997698640452,2.3013596667727947e-07,"No",0.9999999979436609,2.05634039432667e-09,"No",0.003943077864664617,0.996056922135348,"Yes",0.9991656307078954,0.0008343692920956657,"Yes",0.999999999997499,2.5104561478077214e-12,"No",0.00023903996644995316,0.9997609600335576,"No"
"2010-021434-55","An Open-label Multi-Centre Extension Trial Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.1845445118386624e-36,0.000776253056589726,0.9992237469434018,"-1",2.672909326375989e-07,0.9999997327090642,"Yes",0.9999997698640452,2.3013596667727947e-07,"No",0.9999999979436609,2.05634039432667e-09,"No",0.003943077864664617,0.996056922135348,"Yes",0.9991656307078954,0.0008343692920956657,"Yes",0.999999999997499,2.5104561478077214e-12,"No",0.00023903996644995316,0.9997609600335576,"No"
"2010-021434-55","An Open-label Multi-Centre Extension Trial Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.1845445118386624e-36,0.000776253056589726,0.9992237469434018,"-1",2.672909326375989e-07,0.9999997327090642,"Yes",0.9999997698640452,2.3013596667727947e-07,"No",0.9999999979436609,2.05634039432667e-09,"No",0.003943077864664617,0.996056922135348,"Yes",0.9991656307078954,0.0008343692920956657,"Yes",0.999999999997499,2.5104561478077214e-12,"No",0.00023903996644995316,0.9997609600335576,"No"
"2010-021434-55","An Open-label Multi-Centre Extension Trial Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.1845445118386624e-36,0.000776253056589726,0.9992237469434018,"-1",2.672909326375989e-07,0.9999997327090642,"Yes",0.9999997698640452,2.3013596667727947e-07,"No",0.9999999979436609,2.05634039432667e-09,"No",0.003943077864664617,0.996056922135348,"Yes",0.9991656307078954,0.0008343692920956657,"Yes",0.999999999997499,2.5104561478077214e-12,"No",0.00023903996644995316,0.9997609600335576,"No"
"2010-021434-55","An Open-label Multi-Centre Extension Trial Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.1845445118386624e-36,0.000776253056589726,0.9992237469434018,"-1",2.672909326375989e-07,0.9999997327090642,"Yes",0.9999997698640452,2.3013596667727947e-07,"No",0.9999999979436609,2.05634039432667e-09,"No",0.003943077864664617,0.996056922135348,"Yes",0.9991656307078954,0.0008343692920956657,"Yes",0.999999999997499,2.5104561478077214e-12,"No",0.00023903996644995316,0.9997609600335576,"No"
"2010-021434-55","An Open-label Multi-Centre Extension Trial Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.1845445118386624e-36,0.000776253056589726,0.9992237469434018,"-1",2.672909326375989e-07,0.9999997327090642,"Yes",0.9999997698640452,2.3013596667727947e-07,"No",0.9999999979436609,2.05634039432667e-09,"No",0.003943077864664617,0.996056922135348,"Yes",0.9991656307078954,0.0008343692920956657,"Yes",0.999999999997499,2.5104561478077214e-12,"No",0.00023903996644995316,0.9997609600335576,"No"
"2010-021434-55","An Open-label Multi-Centre Extension Trial Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.1845445118386624e-36,0.000776253056589726,0.9992237469434018,"-1",2.672909326375989e-07,0.9999997327090642,"Yes",0.9999997698640452,2.3013596667727947e-07,"No",0.9999999979436609,2.05634039432667e-09,"No",0.003943077864664617,0.996056922135348,"Yes",0.9991656307078954,0.0008343692920956657,"Yes",0.999999999997499,2.5104561478077214e-12,"No",0.00023903996644995316,0.9997609600335576,"No"
"2010-021821-10","Open Randomized Mono-centre Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous In-fusion of Human Bone-Marrow Derived Autologous CD34-Negative Mesenchymal Stem Cell for the Treatment of Critical Limb Ischemia in Patients with Advanced Peripheral Arterial Occlusive Disease Subsequent to Percutaneous Transluminal Angioplasty   ","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.9346986530251965e-66,0.0014080316719205196,0.9985919683280767,"2+",3.049695794456349e-06,0.9999969503041831,"Yes",0.9999963375492478,3.66245073169575e-06,"No",1.0,9.436322003942708e-15,"No",0.023420857351575713,0.9765791426484155,"Yes",0.9898037146205968,0.010196285379413516,"Yes",0.9999999999997727,2.262470797847454e-13,"No",0.002482185699883188,0.9975178143001299,"Yes"
"2010-021868-15","A Randomized Double-Blind Phase II Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.258582049541357e-30,2.8497623623796256e-06,0.9999971502376431,"2+",0.9957335204743032,0.00426647952569465,"No",0.007205141200256225,0.992794858799748,"Yes",0.9999999995170867,4.82908934785445e-10,"No",0.000496598488898479,0.9995034015111025,"Yes",0.8152930558553325,0.18470694414466787,"Yes",0.9885769646650977,0.011423035334905265,"No",1.0119896053493948e-05,0.9999898801039442,"Yes"
"2010-021868-15","A Randomized Double-Blind Phase II Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.258582049541357e-30,2.8497623623796256e-06,0.9999971502376431,"2+",0.9957335204743032,0.00426647952569465,"No",0.007205141200256225,0.992794858799748,"Yes",0.9999999995170867,4.82908934785445e-10,"No",0.000496598488898479,0.9995034015111025,"Yes",0.8152930558553325,0.18470694414466787,"Yes",0.9885769646650977,0.011423035334905265,"No",1.0119896053493948e-05,0.9999898801039442,"Yes"
"2010-021868-15","A Randomized Double-Blind Phase II Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.258582049541357e-30,2.8497623623796256e-06,0.9999971502376431,"2+",0.9957335204743032,0.00426647952569465,"No",0.007205141200256225,0.992794858799748,"Yes",0.9999999995170867,4.82908934785445e-10,"No",0.000496598488898479,0.9995034015111025,"Yes",0.8152930558553325,0.18470694414466787,"Yes",0.9885769646650977,0.011423035334905265,"No",1.0119896053493948e-05,0.9999898801039442,"Yes"
"2010-022064-12","Randomized Open Label Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with ChemotherapyStudio multicentrico randomizzato in aperto di Cabazitaxel alla dose di 25 mg/m² e 20 mg/m² in associazione a Prednisone ogni 3 settimane in confronto a Docetaxel/Prednisone in pazienti affetti da carcinoma prostatico metastatico resistente alla castrazione non precedentemente trattati con chemioterapia.","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.551552723807742e-121,0.00011292378642570643,0.9998870762135711,"-1",4.772859413269488e-13,0.9999999999995453,"Yes",0.9999999999985789,1.434319837785914e-12,"No",1.0,9.731668355332826e-45,"No",0.00234356125984411,0.9976564387401635,"Yes",0.018840035323998153,0.9811599646760075,"Yes",1.0,5.371441382643723e-18,"No",5.927370253476694e-06,0.9999940726297633,"Yes"
"2010-022064-12","Randomized Open Label Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with ChemotherapyStudio multicentrico randomizzato in aperto di Cabazitaxel alla dose di 25 mg/m² e 20 mg/m² in associazione a Prednisone ogni 3 settimane in confronto a Docetaxel/Prednisone in pazienti affetti da carcinoma prostatico metastatico resistente alla castrazione non precedentemente trattati con chemioterapia.","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.551552723807742e-121,0.00011292378642570643,0.9998870762135711,"-1",4.772859413269488e-13,0.9999999999995453,"Yes",0.9999999999985789,1.434319837785914e-12,"No",1.0,9.731668355332826e-45,"No",0.00234356125984411,0.9976564387401635,"Yes",0.018840035323998153,0.9811599646760075,"Yes",1.0,5.371441382643723e-18,"No",5.927370253476694e-06,0.9999940726297633,"Yes"
"2010-022064-12","Randomized Open Label Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with Chemotherapy","SE","No","No","Yes","ok","Yes","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6523467922277355e-58,0.5706293888162716,0.4293706111837281,"-1",4.810226103406075e-07,0.9999995189773777,"Yes",0.999999280611607,7.193883858234889e-07,"No",1.0,2.337384778050337e-19,"No",0.968678056869687,0.031321943130325165,"Yes",0.9348461971297114,0.06515380287028394,"Yes",0.9993426281888871,0.0006573718111077328,"No",0.17024906845472637,0.8297509315452728,"Yes"
"2010-022064-12","Randomized Open Label Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with ChemotherapyStudio multicentrico randomizzato in aperto di Cabazitaxel alla dose di 25 mg/m² e 20 mg/m² in associazione a Prednisone ogni 3 settimane in confronto a Docetaxel/Prednisone in pazienti affetti da carcinoma prostatico metastatico resistente alla castrazione non precedentemente trattati con chemioterapia.","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.551552723807742e-121,0.00011292378642570643,0.9998870762135711,"-1",4.772859413269488e-13,0.9999999999995453,"Yes",0.9999999999985789,1.434319837785914e-12,"No",1.0,9.731668355332826e-45,"No",0.00234356125984411,0.9976564387401635,"Yes",0.018840035323998153,0.9811599646760075,"Yes",1.0,5.371441382643723e-18,"No",5.927370253476694e-06,0.9999940726297633,"Yes"
"2010-022064-12","Randomized Open Label Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with ChemotherapyStudio multicentrico randomizzato in aperto di Cabazitaxel alla dose di 25 mg/m² e 20 mg/m² in associazione a Prednisone ogni 3 settimane in confronto a Docetaxel/Prednisone in pazienti affetti da carcinoma prostatico metastatico resistente alla castrazione non precedentemente trattati con chemioterapia.","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.551552723807742e-121,0.00011292378642570643,0.9998870762135711,"-1",4.772859413269488e-13,0.9999999999995453,"Yes",0.9999999999985789,1.434319837785914e-12,"No",1.0,9.731668355332826e-45,"No",0.00234356125984411,0.9976564387401635,"Yes",0.018840035323998153,0.9811599646760075,"Yes",1.0,5.371441382643723e-18,"No",5.927370253476694e-06,0.9999940726297633,"Yes"
"2010-022064-12","Randomized Open Label Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with Chemotherapy","FI","No","No","Yes","ok","Yes","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6523467922277355e-58,0.5706293888162716,0.4293706111837281,"-1",4.810226103406075e-07,0.9999995189773777,"Yes",0.999999280611607,7.193883858234889e-07,"No",1.0,2.337384778050337e-19,"No",0.968678056869687,0.031321943130325165,"Yes",0.9348461971297114,0.06515380287028394,"Yes",0.9993426281888871,0.0006573718111077328,"No",0.17024906845472637,0.8297509315452728,"Yes"
"2010-022064-12","Randomized Open Label Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with Chemotherapy","PL","No","No","Yes","ok","Yes","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6523467922277355e-58,0.5706293888162716,0.4293706111837281,"-1",4.810226103406075e-07,0.9999995189773777,"Yes",0.999999280611607,7.193883858234889e-07,"No",1.0,2.337384778050337e-19,"No",0.968678056869687,0.031321943130325165,"Yes",0.9348461971297114,0.06515380287028394,"Yes",0.9993426281888871,0.0006573718111077328,"No",0.17024906845472637,0.8297509315452728,"Yes"
"2010-022064-12","Randomized Open Label Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with Chemotherapy","ES","No","No","Yes","ok","Yes","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6523467922277355e-58,0.5706293888162716,0.4293706111837281,"-1",4.810226103406075e-07,0.9999995189773777,"Yes",0.999999280611607,7.193883858234889e-07,"No",1.0,2.337384778050337e-19,"No",0.968678056869687,0.031321943130325165,"Yes",0.9348461971297114,0.06515380287028394,"Yes",0.9993426281888871,0.0006573718111077328,"No",0.17024906845472637,0.8297509315452728,"Yes"
"2010-022064-12","Randomized Open Label Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with Chemotherapy","IT","No","No","Yes","ok","Yes","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6523467922277355e-58,0.5706293888162716,0.4293706111837281,"-1",4.810226103406075e-07,0.9999995189773777,"Yes",0.999999280611607,7.193883858234889e-07,"No",1.0,2.337384778050337e-19,"No",0.968678056869687,0.031321943130325165,"Yes",0.9348461971297114,0.06515380287028394,"Yes",0.9993426281888871,0.0006573718111077328,"No",0.17024906845472637,0.8297509315452728,"Yes"
"2010-022163-35","Randomized Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m²and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment ofMetastatic Castration Resistant Prostate Cancer Previously Treated With aDocetaxel-Containing Regimen","ES","No","No","Yes","ok","Yes","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.104500071793174e-49,0.6330924780864966,0.3669075219135131,"-1",2.127954013231451e-06,0.9999978720459997,"Yes",0.9999975198350403,2.4801649736439376e-06,"No",1.0,4.7510732283049536e-15,"No",0.8659254668486058,0.13407453315138543,"Yes",0.6976484791819824,0.30235152081802674,"Yes",0.9523803562755062,0.04761964372449957,"No",0.1538518341928673,0.8461481658071295,"Yes"
"2010-022163-35","Randomized Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen","NL","No","No","Yes","ok","Yes","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4960937361262396e-54,0.6785425289144907,0.3214574710855005,"-1",3.7030446768037935e-07,0.9999996296955207,"Yes",0.9999996164700801,3.8352990913799457e-07,"No",1.0,6.13282897678328e-18,"No",0.9307091024900869,0.06929089750990168,"Yes",0.8406098276238615,0.15939017237614472,"Yes",0.9897602805533123,0.010239719446679214,"No",0.13117147270336013,0.8688285272966405,"Yes"
"2010-022163-35","Randomized Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen","PL","No","No","Yes","ok","Yes","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4960937361262396e-54,0.6785425289144907,0.3214574710855005,"-1",3.7030446768037935e-07,0.9999996296955207,"Yes",0.9999996164700801,3.8352990913799457e-07,"No",1.0,6.13282897678328e-18,"No",0.9307091024900869,0.06929089750990168,"Yes",0.8406098276238615,0.15939017237614472,"Yes",0.9897602805533123,0.010239719446679214,"No",0.13117147270336013,0.8688285272966405,"Yes"
"2010-022163-35","Randomized Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m²and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment ofMetastatic Castration Resistant Prostate Cancer Previously Treated With aDocetaxel-Containing Regimen","FR","No","No","Yes","ok","Yes","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.104500071793174e-49,0.6330924780864966,0.3669075219135131,"-1",2.127954013231451e-06,0.9999978720459997,"Yes",0.9999975198350403,2.4801649736439376e-06,"No",1.0,4.7510732283049536e-15,"No",0.8659254668486058,0.13407453315138543,"Yes",0.6976484791819824,0.30235152081802674,"Yes",0.9523803562755062,0.04761964372449957,"No",0.1538518341928673,0.8461481658071295,"Yes"
"2010-022163-35","Randomized Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m²and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment ofMetastatic Castration Resistant Prostate Cancer Previously Treated With aDocetaxel-Containing Regimen","HU","No","No","Yes","ok","Yes","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.104500071793174e-49,0.6330924780864966,0.3669075219135131,"-1",2.127954013231451e-06,0.9999978720459997,"Yes",0.9999975198350403,2.4801649736439376e-06,"No",1.0,4.7510732283049536e-15,"No",0.8659254668486058,0.13407453315138543,"Yes",0.6976484791819824,0.30235152081802674,"Yes",0.9523803562755062,0.04761964372449957,"No",0.1538518341928673,0.8461481658071295,"Yes"
"2010-022163-35","Randomized Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen","GB","No","No","Yes","ok","Yes","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4960937361262396e-54,0.6785425289144907,0.3214574710855005,"-1",3.7030446768037935e-07,0.9999996296955207,"Yes",0.9999996164700801,3.8352990913799457e-07,"No",1.0,6.13282897678328e-18,"No",0.9307091024900869,0.06929089750990168,"Yes",0.8406098276238615,0.15939017237614472,"Yes",0.9897602805533123,0.010239719446679214,"No",0.13117147270336013,0.8688285272966405,"Yes"
"2010-022163-35","Randomized Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen","BE","No","No","Yes","ok","Yes","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4960937361262396e-54,0.6785425289144907,0.3214574710855005,"-1",3.7030446768037935e-07,0.9999996296955207,"Yes",0.9999996164700801,3.8352990913799457e-07,"No",1.0,6.13282897678328e-18,"No",0.9307091024900869,0.06929089750990168,"Yes",0.8406098276238615,0.15939017237614472,"Yes",0.9897602805533123,0.010239719446679214,"No",0.13117147270336013,0.8688285272966405,"Yes"
"2010-022163-35","Estudio aleatorizado abierto y multicéntrico de comparación de cabazitaxel a dosis de 20 mg/m2 y 25 mg/m2 administrado cada 3 semanas en combinación con prednisona para el tratamiento del cáncer de próstata metastásico resistente a la castración tratado previamente con un régimen a base de docetaxel_______________________Randomized Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m²and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment ofMetastatic Castration Resistant Prostate Cancer Previously Treated With aDocetaxel-Containing Regimen","DE","No","No","Yes","ok","Yes","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.810124242889952e-100,0.5021409060670566,0.49785909393296884,"-1",2.1739507817148134e-11,0.9999999999782858,"Yes",0.9999999999832312,1.6751642878740268e-11,"No",1.0,3.345648068998571e-33,"No",0.7743898147553819,0.2256101852445981,"Yes",0.7912203057703731,0.20877969422960127,"Yes",0.9999999999992043,7.736647321083402e-13,"No",0.0006436752500798863,0.9993563247499408,"Yes"
"2010-022388-37","Treatment of patients with MDS or AML with an impending hematological relapse with Azacitidin (Vidaza)Behandlung des drohenden hämatologischen Rezidivs von Patienten mit MDS oder AML mit Azacitidin (Vidaza®)","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.583920104741182e-27,0.8994229125613096,0.10057708743869853,"1",4.8703862698212396e-12,0.9999999999951399,"Yes",0.9999999999940599,5.950711593694506e-12,"No",0.9999999998063346,1.9367027700606397e-10,"No",0.5392486109205081,0.46075138907948926,"No",0.9999950367328941,4.9632671200899555e-06,"No",1.0,2.6312879289332153e-16,"No",0.9999999998209432,1.7905781661535163e-10,"No"
"2010-022459-45","A randomized controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7383383364727417e-46,0.002215669078740201,0.9977843309212553,"-1",0.002469489461622945,0.9975305105383772,"Yes",0.9972837154527496,0.0027162845472478597,"No",0.999999999922352,7.765475443885584e-11,"No",3.636600162877749e-05,0.9999636339983763,"Yes",0.2816226085250938,0.7183773914749132,"Yes",0.9999896770834534,1.0322916550329442e-05,"No",0.004434416025499185,0.9955655839744948,"Yes"
"2010-022459-45","A randomized controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7383383364727417e-46,0.002215669078740201,0.9977843309212553,"-1",0.002469489461622945,0.9975305105383772,"Yes",0.9972837154527496,0.0027162845472478597,"No",0.999999999922352,7.765475443885584e-11,"No",3.636600162877749e-05,0.9999636339983763,"Yes",0.2816226085250938,0.7183773914749132,"Yes",0.9999896770834534,1.0322916550329442e-05,"No",0.004434416025499185,0.9955655839744948,"Yes"
"2010-022459-45","A randomized controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7383383364727417e-46,0.002215669078740201,0.9977843309212553,"-1",0.002469489461622945,0.9975305105383772,"Yes",0.9972837154527496,0.0027162845472478597,"No",0.999999999922352,7.765475443885584e-11,"No",3.636600162877749e-05,0.9999636339983763,"Yes",0.2816226085250938,0.7183773914749132,"Yes",0.9999896770834534,1.0322916550329442e-05,"No",0.004434416025499185,0.9955655839744948,"Yes"
"2010-022459-45","A randomized controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7383383364727417e-46,0.002215669078740201,0.9977843309212553,"-1",0.002469489461622945,0.9975305105383772,"Yes",0.9972837154527496,0.0027162845472478597,"No",0.999999999922352,7.765475443885584e-11,"No",3.636600162877749e-05,0.9999636339983763,"Yes",0.2816226085250938,0.7183773914749132,"Yes",0.9999896770834534,1.0322916550329442e-05,"No",0.004434416025499185,0.9955655839744948,"Yes"
"2010-022459-45","A randomized controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7383383364727417e-46,0.002215669078740201,0.9977843309212553,"-1",0.002469489461622945,0.9975305105383772,"Yes",0.9972837154527496,0.0027162845472478597,"No",0.999999999922352,7.765475443885584e-11,"No",3.636600162877749e-05,0.9999636339983763,"Yes",0.2816226085250938,0.7183773914749132,"Yes",0.9999896770834534,1.0322916550329442e-05,"No",0.004434416025499185,0.9955655839744948,"Yes"
"2010-022579-68","COR-1 an anti-ß1 receptor antibody cyclopeptide in heart failure: a phase II multicentre randomised double-blind and placebo-controlled study with parallel groups","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.703986537471322e-48,3.4972809246228834e-09,0.999999996502723,"2+",0.9999999925092738,7.490721525621367e-09,"No",5.135337184598924e-08,0.9999999486466336,"Yes",0.9993901249440211,0.0006098750559748042,"No",2.5952207307301898e-09,0.9999999974047854,"Yes",0.001623218132537321,0.9983767818674609,"Yes",0.9998508499640762,0.00014915003591692419,"No",1.0926989366136171e-08,0.9999999890730039,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy3. fázisú randomizált kettős vak placebo kontrollált párhuzamos csoportokon zajló több központban végzett vizsgálat az ustekinumab indukciós kezelés biztonságosságának és hatékonyságának meghatározására közepesen vagy kifejezetten aktív Crohn-betegségben szenvedők körében akiknél a korábbi TNF antagonista kezelés sikertelennek vagy tolerálhatatlannak bizonyult","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5259643986220652e-109,2.0836928380224235e-27,1.0,"2+",1.0,5.879942971244838e-29,"No",4.8285274445022654e-26,1.0,"Yes",1.0,4.3008004728542446e-33,"No",1.551865602003239e-29,1.0,"Yes",8.32477406204702e-15,1.0,"Yes",1.0,6.018064046745672e-25,"No",2.4669248357491034e-24,1.0,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy3. fázisú randomizált kettős vak placebo kontrollált párhuzamos csoportokon zajló több központban végzett vizsgálat az ustekinumab indukciós kezelés biztonságosságának és hatékonyságának meghatározására közepesen vagy kifejezetten aktív Crohn-betegségben szenvedők körében akiknél a korábbi TNF antagonista kezelés sikertelennek vagy tolerálhatatlannak bizonyult","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5259643986220652e-109,2.0836928380224235e-27,1.0,"2+",1.0,5.879942971244838e-29,"No",4.8285274445022654e-26,1.0,"Yes",1.0,4.3008004728542446e-33,"No",1.551865602003239e-29,1.0,"Yes",8.32477406204702e-15,1.0,"Yes",1.0,6.018064046745672e-25,"No",2.4669248357491034e-24,1.0,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy3. fázisú randomizált kettős vak placebo kontrollált párhuzamos csoportokon zajló több központban végzett vizsgálat az ustekinumab indukciós kezelés biztonságosságának és hatékonyságának meghatározására közepesen vagy kifejezetten aktív Crohn-betegségben szenvedők körében akiknél a korábbi TNF antagonista kezelés sikertelennek vagy tolerálhatatlannak bizonyult","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5259643986220652e-109,2.0836928380224235e-27,1.0,"2+",1.0,5.879942971244838e-29,"No",4.8285274445022654e-26,1.0,"Yes",1.0,4.3008004728542446e-33,"No",1.551865602003239e-29,1.0,"Yes",8.32477406204702e-15,1.0,"Yes",1.0,6.018064046745672e-25,"No",2.4669248357491034e-24,1.0,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.755677699298484e-65,1.0805034677837986e-12,0.99999999999892,"2+",0.9999999999999147,8.573753016031828e-14,"No",2.9300851509539956e-13,0.9999999999997159,"Yes",1.0,2.6170062129555403e-18,"No",5.172552099417976e-11,0.9999999999482725,"Yes",1.0973780741201986e-05,0.9999890262192689,"Yes",1.0,5.345913054757179e-16,"No",3.6756732093576324e-11,0.9999999999632507,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.755677699298484e-65,1.0805034677837986e-12,0.99999999999892,"2+",0.9999999999999147,8.573753016031828e-14,"No",2.9300851509539956e-13,0.9999999999997159,"Yes",1.0,2.6170062129555403e-18,"No",5.172552099417976e-11,0.9999999999482725,"Yes",1.0973780741201986e-05,0.9999890262192689,"Yes",1.0,5.345913054757179e-16,"No",3.6756732093576324e-11,0.9999999999632507,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy","IS","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.755677699298484e-65,1.0805034677837986e-12,0.99999999999892,"2+",0.9999999999999147,8.573753016031828e-14,"No",2.9300851509539956e-13,0.9999999999997159,"Yes",1.0,2.6170062129555403e-18,"No",5.172552099417976e-11,0.9999999999482725,"Yes",1.0973780741201986e-05,0.9999890262192689,"Yes",1.0,5.345913054757179e-16,"No",3.6756732093576324e-11,0.9999999999632507,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.755677699298484e-65,1.0805034677837986e-12,0.99999999999892,"2+",0.9999999999999147,8.573753016031828e-14,"No",2.9300851509539956e-13,0.9999999999997159,"Yes",1.0,2.6170062129555403e-18,"No",5.172552099417976e-11,0.9999999999482725,"Yes",1.0973780741201986e-05,0.9999890262192689,"Yes",1.0,5.345913054757179e-16,"No",3.6756732093576324e-11,0.9999999999632507,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy3. fázisú randomizált kettős vak placebo kontrollált párhuzamos csoportokon zajló több központban végzett vizsgálat az ustekinumab indukciós kezelés biztonságosságának és hatékonyságának meghatározására közepesen vagy kifejezetten aktív Crohn-betegségben szenvedők körében akiknél a korábbi TNF antagonista kezelés sikertelennek vagy tolerálhatatlannak bizonyult","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5259643986220652e-109,2.0836928380224235e-27,1.0,"2+",1.0,5.879942971244838e-29,"No",4.8285274445022654e-26,1.0,"Yes",1.0,4.3008004728542446e-33,"No",1.551865602003239e-29,1.0,"Yes",8.32477406204702e-15,1.0,"Yes",1.0,6.018064046745672e-25,"No",2.4669248357491034e-24,1.0,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy","IE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.755677699298484e-65,1.0805034677837986e-12,0.99999999999892,"2+",0.9999999999999147,8.573753016031828e-14,"No",2.9300851509539956e-13,0.9999999999997159,"Yes",1.0,2.6170062129555403e-18,"No",5.172552099417976e-11,0.9999999999482725,"Yes",1.0973780741201986e-05,0.9999890262192689,"Yes",1.0,5.345913054757179e-16,"No",3.6756732093576324e-11,0.9999999999632507,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy3. fázisú randomizált kettős vak placebo kontrollált párhuzamos csoportokon zajló több központban végzett vizsgálat az ustekinumab indukciós kezelés biztonságosságának és hatékonyságának meghatározására közepesen vagy kifejezetten aktív Crohn-betegségben szenvedők körében akiknél a korábbi TNF antagonista kezelés sikertelennek vagy tolerálhatatlannak bizonyult","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5259643986220652e-109,2.0836928380224235e-27,1.0,"2+",1.0,5.879942971244838e-29,"No",4.8285274445022654e-26,1.0,"Yes",1.0,4.3008004728542446e-33,"No",1.551865602003239e-29,1.0,"Yes",8.32477406204702e-15,1.0,"Yes",1.0,6.018064046745672e-25,"No",2.4669248357491034e-24,1.0,"Yes"
"2010-022758-18","A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.755677699298484e-65,1.0805034677837986e-12,0.99999999999892,"2+",0.9999999999999147,8.573753016031828e-14,"No",2.9300851509539956e-13,0.9999999999997159,"Yes",1.0,2.6170062129555403e-18,"No",5.172552099417976e-11,0.9999999999482725,"Yes",1.0973780741201986e-05,0.9999890262192689,"Yes",1.0,5.345913054757179e-16,"No",3.6756732093576324e-11,0.9999999999632507,"Yes"
"2010-022872-30","A multicenter randomized double-blind parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.33982043493574e-50,5.1979392291228575e-14,0.9999999999999432,"2+",0.9999999999953673,4.619847017042478e-12,"No",2.0444099380122686e-10,0.9999999997955628,"Yes",0.9999991356067467,8.643932541150325e-07,"No",1.6053817015863851e-12,0.9999999999984084,"Yes",1.1369610161825832e-09,0.9999999988630465,"Yes",1.0,5.477795152663214e-16,"No",3.587863492381277e-13,0.9999999999996306,"Yes"
"2010-022872-30","A multicenter randomized double-blind parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.33982043493574e-50,5.1979392291228575e-14,0.9999999999999432,"2+",0.9999999999953673,4.619847017042478e-12,"No",2.0444099380122686e-10,0.9999999997955628,"Yes",0.9999991356067467,8.643932541150325e-07,"No",1.6053817015863851e-12,0.9999999999984084,"Yes",1.1369610161825832e-09,0.9999999988630465,"Yes",1.0,5.477795152663214e-16,"No",3.587863492381277e-13,0.9999999999996306,"Yes"
"2010-022872-30","A multicenter randomized double-blind parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.33982043493574e-50,5.1979392291228575e-14,0.9999999999999432,"2+",0.9999999999953673,4.619847017042478e-12,"No",2.0444099380122686e-10,0.9999999997955628,"Yes",0.9999991356067467,8.643932541150325e-07,"No",1.6053817015863851e-12,0.9999999999984084,"Yes",1.1369610161825832e-09,0.9999999988630465,"Yes",1.0,5.477795152663214e-16,"No",3.587863492381277e-13,0.9999999999996306,"Yes"
"2010-022872-30","A multicenter randomized double-blind parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.33982043493574e-50,5.1979392291228575e-14,0.9999999999999432,"2+",0.9999999999953673,4.619847017042478e-12,"No",2.0444099380122686e-10,0.9999999997955628,"Yes",0.9999991356067467,8.643932541150325e-07,"No",1.6053817015863851e-12,0.9999999999984084,"Yes",1.1369610161825832e-09,0.9999999988630465,"Yes",1.0,5.477795152663214e-16,"No",3.587863492381277e-13,0.9999999999996306,"Yes"
"2010-022872-30","A multicenter randomized double-blind parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.33982043493574e-50,5.1979392291228575e-14,0.9999999999999432,"2+",0.9999999999953673,4.619847017042478e-12,"No",2.0444099380122686e-10,0.9999999997955628,"Yes",0.9999991356067467,8.643932541150325e-07,"No",1.6053817015863851e-12,0.9999999999984084,"Yes",1.1369610161825832e-09,0.9999999988630465,"Yes",1.0,5.477795152663214e-16,"No",3.587863492381277e-13,0.9999999999996306,"Yes"
"2010-022872-30","A multicenter randomized double-blind parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.33982043493574e-50,5.1979392291228575e-14,0.9999999999999432,"2+",0.9999999999953673,4.619847017042478e-12,"No",2.0444099380122686e-10,0.9999999997955628,"Yes",0.9999991356067467,8.643932541150325e-07,"No",1.6053817015863851e-12,0.9999999999984084,"Yes",1.1369610161825832e-09,0.9999999988630465,"Yes",1.0,5.477795152663214e-16,"No",3.587863492381277e-13,0.9999999999996306,"Yes"
"2010-022872-30","A multicenter randomized double-blind parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.","EE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.33982043493574e-50,5.1979392291228575e-14,0.9999999999999432,"2+",0.9999999999953673,4.619847017042478e-12,"No",2.0444099380122686e-10,0.9999999997955628,"Yes",0.9999991356067467,8.643932541150325e-07,"No",1.6053817015863851e-12,0.9999999999984084,"Yes",1.1369610161825832e-09,0.9999999988630465,"Yes",1.0,5.477795152663214e-16,"No",3.587863492381277e-13,0.9999999999996306,"Yes"
"2010-022872-30","A multicenter randomized double-blind parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.33982043493574e-50,5.1979392291228575e-14,0.9999999999999432,"2+",0.9999999999953673,4.619847017042478e-12,"No",2.0444099380122686e-10,0.9999999997955628,"Yes",0.9999991356067467,8.643932541150325e-07,"No",1.6053817015863851e-12,0.9999999999984084,"Yes",1.1369610161825832e-09,0.9999999988630465,"Yes",1.0,5.477795152663214e-16,"No",3.587863492381277e-13,0.9999999999996306,"Yes"
"2010-022923-31","A multicenter double-blind placebo controlled randomized pilot trial to assess the efficacy of pre-hospital administration of Fibrinogen Concentrate (FGTW) in trauma patients presumed to bleed (FI in TIC)Eine multizentrische doppelblinde placebokontrollierte Pilotstudie zur Untersuchung der Wirksamkeit von präklinisch verabreichtem Fibrinogenkonzentrat (FGTW) in Traumapatienten mit Blutungsverdacht (FI in TIC)","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.111329932812825e-58,8.628905664212226e-12,0.9999999999913598,"2+",0.9999999999998864,1.1851511748916313e-13,"No",5.462575991492364e-12,0.999999999994543,"Yes",0.9999935381735716,6.4618264145241525e-06,"No",1.488146254324013e-13,0.9999999999998295,"Yes",0.9972555209115401,0.0027444790884689086,"Yes",0.7697766182677429,0.2302233817322564,"No",7.415502147970146e-09,0.9999999925844919,"Yes"
"2010-022923-31","A multicenter double-blind placebo controlled randomized pilot trial to assess the efficacy of pre-hospital administration of Fibrinogen Concentrate (FGTW) in trauma patients presumed to bleed (FI in TIC)Eine multizentrische doppelblinde placebokontrollierte Pilotstudie zur Untersuchung der Wirksamkeit von präklinisch verabreichtem Fibrinogenkonzentrat (FGTW) in Traumapatienten mit Blutungsverdacht (FI in TIC)","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.111329932812825e-58,8.628905664212226e-12,0.9999999999913598,"2+",0.9999999999998864,1.1851511748916313e-13,"No",5.462575991492364e-12,0.999999999994543,"Yes",0.9999935381735716,6.4618264145241525e-06,"No",1.488146254324013e-13,0.9999999999998295,"Yes",0.9972555209115401,0.0027444790884689086,"Yes",0.7697766182677429,0.2302233817322564,"No",7.415502147970146e-09,0.9999999925844919,"Yes"
"2010-022923-31","A multicenter double-blind placebo controlled randomized pilot trial to assess the efficacy of pre-hospital administration of Fibrinogen Concentrate (FGTW) in trauma patients presumed to bleed (FI in TIC)Eine multizentrische doppelblinde placebokontrollierte Pilotstudie zur Untersuchung der Wirksamkeit von präklinisch verabreichtem Fibrinogenkonzentrat (FGTW) in Traumapatienten mit Blutungsverdacht (FI in TIC)","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.111329932812825e-58,8.628905664212226e-12,0.9999999999913598,"2+",0.9999999999998864,1.1851511748916313e-13,"No",5.462575991492364e-12,0.999999999994543,"Yes",0.9999935381735716,6.4618264145241525e-06,"No",1.488146254324013e-13,0.9999999999998295,"Yes",0.9972555209115401,0.0027444790884689086,"Yes",0.7697766182677429,0.2302233817322564,"No",7.415502147970146e-09,0.9999999925844919,"Yes"
"2010-023409-37","Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 Mutation","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.0925349359138286e-40,0.00013495002360414452,0.9998650499763949,"2+",9.176411896210802e-07,0.9999990823588069,"Yes",0.9999981848893913,1.815110596337138e-06,"No",1.0,9.6854414411269e-18,"No",3.0639642507333018e-06,0.9999969360357612,"Yes",0.0792056756860012,0.9207943243139864,"Yes",0.9999999936512723,6.348738096032146e-09,"No",0.0001482629688617945,0.9998517370311516,"Yes"
"2010-023409-37","Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 Mutation","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.0925349359138286e-40,0.00013495002360414452,0.9998650499763949,"2+",9.176411896210802e-07,0.9999990823588069,"Yes",0.9999981848893913,1.815110596337138e-06,"No",1.0,9.6854414411269e-18,"No",3.0639642507333018e-06,0.9999969360357612,"Yes",0.0792056756860012,0.9207943243139864,"Yes",0.9999999936512723,6.348738096032146e-09,"No",0.0001482629688617945,0.9998517370311516,"Yes"
"2010-023427-18","Definitive radiochemotherapy with 5-FU / cisplatin plus/minuscetuximab in unresectable locally advanced esophageal cancer:a phase II study","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.394954164143098e-28,0.00036864900057889145,0.9996313509994229,"2+",0.0024225510158600175,0.9975774489841467,"Yes",0.9983178960285569,0.0016821039714414127,"No",0.9999999999617444,3.825670435477676e-11,"No",0.001769713120548383,0.9982302868794554,"Yes",0.9570516347630954,0.04294836523690892,"Yes",0.9999995284217935,4.7157820790054933e-07,"No",0.0017732028481191855,0.9982267971518789,"No"
"2010-023526-21","An open-label multicenter study of RO5185426 in patients with metastatic melanoma","HU","No","No","Yes","","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",2.079454504836955e-12,0.6840272546938999,0.3159727453040218,"1",0.0010462309285513016,0.9989537690714523,"Information not present in EudraCT",0.9985795483844543,0.0014204516155452258,"Information not present in EudraCT",0.9999999609619231,3.903807821721036e-08,"Information not present in EudraCT",0.8505523153922093,0.1494476846077917,"No",0.3423481245785345,0.6576518754214636,"No",0.9720261831632179,0.027973816836785376,"No",0.652454391153374,0.3475456088466263,"No"
"2010-023526-21","An open-label multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma","SK","No","No","Yes","","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",9.092573920603151e-15,0.7579986973171652,0.24200130268282932,"1",0.0024738408736339882,0.9975261591263683,"Information not present in EudraCT",0.9968496647010138,0.0031503352989897004,"Information not present in EudraCT",0.9999999484501472,5.154985442603599e-08,"Information not present in EudraCT",0.8796968713222226,0.12030312867777784,"No",0.29315658145106577,0.7068434185489347,"No",0.9830707796110282,0.01692922038897328,"No",0.7380152999718979,0.26198470002810365,"No"
"2010-023526-21","An open-label multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma","SI","No","No","Yes","","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",9.092573920603151e-15,0.7579986973171652,0.24200130268282932,"1",0.0024738408736339882,0.9975261591263683,"Information not present in EudraCT",0.9968496647010138,0.0031503352989897004,"Information not present in EudraCT",0.9999999484501472,5.154985442603599e-08,"Information not present in EudraCT",0.8796968713222226,0.12030312867777784,"No",0.29315658145106577,0.7068434185489347,"No",0.9830707796110282,0.01692922038897328,"No",0.7380152999718979,0.26198470002810365,"No"
"2010-023526-21","An open-label multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma","NL","No","No","Yes","","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",9.092573920603151e-15,0.7579986973171652,0.24200130268282932,"1",0.0024738408736339882,0.9975261591263683,"Information not present in EudraCT",0.9968496647010138,0.0031503352989897004,"Information not present in EudraCT",0.9999999484501472,5.154985442603599e-08,"Information not present in EudraCT",0.8796968713222226,0.12030312867777784,"No",0.29315658145106577,0.7068434185489347,"No",0.9830707796110282,0.01692922038897328,"No",0.7380152999718979,0.26198470002810365,"No"
"2010-023526-21","An open-label multicenter expanded access study of RO5185426 in patients with metastatic melanoma","GR","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",9.601699767495073e-16,0.9981250485175975,0.0018749514824018068,"1",4.2169186211102895e-05,0.9999578308137846,"Information not present in EudraCT",0.9999330029941772,6.699700581870645e-05,"Information not present in EudraCT",0.9999999999333085,6.668502890951169e-11,"Information not present in EudraCT",0.9990012071630154,0.0009987928369853858,"No",0.9391732913386914,0.0608267086613056,"No",0.9999448624906296,5.5137509365236815e-05,"No",0.9963124859964506,0.00368751400354763,"No"
"2010-023526-21","An open-label multicenter expanded access study of RO5185426 in patients with metastatic melanoma","ES","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",9.601699767495073e-16,0.9981250485175975,0.0018749514824018068,"1",4.2169186211102895e-05,0.9999578308137846,"Information not present in EudraCT",0.9999330029941772,6.699700581870645e-05,"Information not present in EudraCT",0.9999999999333085,6.668502890951169e-11,"Information not present in EudraCT",0.9990012071630154,0.0009987928369853858,"No",0.9391732913386914,0.0608267086613056,"No",0.9999448624906296,5.5137509365236815e-05,"No",0.9963124859964506,0.00368751400354763,"No"
"2010-023526-21","An open-label multicenter expanded access study of RO5185426 in patients with metastatic melanoma.","AT","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",9.601699767495073e-16,0.9981250485175975,0.0018749514824018068,"1",4.2169186211102895e-05,0.9999578308137846,"Information not present in EudraCT",0.9999330029941772,6.699700581870645e-05,"Information not present in EudraCT",0.9999999999333085,6.668502890951169e-11,"Information not present in EudraCT",0.9990012071630154,0.0009987928369853858,"No",0.9391732913386914,0.0608267086613056,"No",0.9999448624906296,5.5137509365236815e-05,"No",0.9963124859964506,0.00368751400354763,"No"
"2010-023744-33","Duchenne muscular dystrophy: double-blind randomized trial to find optimum steroid regimen.Distrofia muscolare di Duchenne: studio in doppio cieco randomizzato per trovare il regime ottimale di steroidi.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.712881764843553e-43,8.026488776684898e-12,0.9999999999919852,"-1",0.9999974330525538,2.566947454667447e-06,"No",1.1009965273766753e-05,0.9999889900347378,"Yes",0.9999999999993748,6.201601202094595e-13,"No",3.209704328082756e-08,0.9999999679029662,"Yes",9.045792021232902e-06,0.9999909542079739,"Yes",0.9999999999998864,1.094046376266445e-13,"No",3.787981121969954e-08,0.9999999621202001,"Yes"
"2010-023744-33","Duchenne muscular dystrophy: double-blind randomized trial to find optimum steroid regimen.Distrofia muscolare di Duchenne: studio in doppio cieco randomizzato per trovare il regime ottimale di steroidi.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.712881764843553e-43,8.026488776684898e-12,0.9999999999919852,"-1",0.9999974330525538,2.566947454667447e-06,"No",1.1009965273766753e-05,0.9999889900347378,"Yes",0.9999999999993748,6.201601202094595e-13,"No",3.209704328082756e-08,0.9999999679029662,"Yes",9.045792021232902e-06,0.9999909542079739,"Yes",0.9999999999998864,1.094046376266445e-13,"No",3.787981121969954e-08,0.9999999621202001,"Yes"
"2010-023775-25","A Phase II Randomized Double-blind Placebo-controlled Parallel group Adaptive combined Proof of Concept and Dose-Finding study to investigate Efficacy Safety Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPSEstudio de fase II aleatorizado doble ciego controlado con placebo en grupos paralelos con un diseño adaptativo combinando prueba de concepto y búsqueda de dosis para evaluar la eficacia seguridad farmacodinámica y farmacocinética de ASP3652 en el tratamiento de la prostatitis crónica/síndrome de dolor pélvico crónico","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.377768048089278e-100,2.797166442890534e-29,1.0,"-1",1.0,3.2287163997541735e-25,"No",2.1051265995372362e-23,1.0,"Yes",1.0,1.1990858048393971e-20,"No",8.039162407509022e-26,1.0,"Yes",2.510428470411034e-12,0.999999999997499,"Yes",1.0,3.7120991311116016e-22,"No",4.22617194862152e-23,1.0,"Yes"
"2010-023775-25","A Phase II Randomized Double-blind Placebo-controlled Parallel group Adaptive combined Proof of Concept and Dose-Finding study to investigate Efficacy Safety Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPSEstudio de fase II aleatorizado doble ciego controlado con placebo en grupos paralelos con un diseño adaptativo combinando prueba de concepto y búsqueda de dosis para evaluar la eficacia seguridad farmacodinámica y farmacocinética de ASP3652 en el tratamiento de la prostatitis crónica/síndrome de dolor pélvico crónico","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.377768048089278e-100,2.797166442890534e-29,1.0,"-1",1.0,3.2287163997541735e-25,"No",2.1051265995372362e-23,1.0,"Yes",1.0,1.1990858048393971e-20,"No",8.039162407509022e-26,1.0,"Yes",2.510428470411034e-12,0.999999999997499,"Yes",1.0,3.7120991311116016e-22,"No",4.22617194862152e-23,1.0,"Yes"
"2010-023775-25","A Phase II Randomized Double-blind Placebo-controlled Parallel group Adaptive combined Proof of Concept and Dose-Finding study to investigate Efficacy Safety Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPSEstudio de fase II aleatorizado doble ciego controlado con placebo en grupos paralelos con un diseño adaptativo combinando prueba de concepto y búsqueda de dosis para evaluar la eficacia seguridad farmacodinámica y farmacocinética de ASP3652 en el tratamiento de la prostatitis crónica/síndrome de dolor pélvico crónico","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.377768048089278e-100,2.797166442890534e-29,1.0,"-1",1.0,3.2287163997541735e-25,"No",2.1051265995372362e-23,1.0,"Yes",1.0,1.1990858048393971e-20,"No",8.039162407509022e-26,1.0,"Yes",2.510428470411034e-12,0.999999999997499,"Yes",1.0,3.7120991311116016e-22,"No",4.22617194862152e-23,1.0,"Yes"
"2010-023775-25","A Phase II Randomized Double-blind Placebo-controlled Parallel group Adaptive combined Proof of Concept and Dose-Finding study to investigate Efficacy Safety Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPSEstudio de fase II aleatorizado doble ciego controlado con placebo en grupos paralelos con un diseño adaptativo combinando prueba de concepto y búsqueda de dosis para evaluar la eficacia seguridad farmacodinámica y farmacocinética de ASP3652 en el tratamiento de la prostatitis crónica/síndrome de dolor pélvico crónico","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.377768048089278e-100,2.797166442890534e-29,1.0,"-1",1.0,3.2287163997541735e-25,"No",2.1051265995372362e-23,1.0,"Yes",1.0,1.1990858048393971e-20,"No",8.039162407509022e-26,1.0,"Yes",2.510428470411034e-12,0.999999999997499,"Yes",1.0,3.7120991311116016e-22,"No",4.22617194862152e-23,1.0,"Yes"
"2010-023775-25","A Phase II Randomized Double-blind Placebo-controlled Parallel group Adaptive combined Proof of Concept and Dose-Finding study to investigate Efficacy Safety Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPS","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.796040889496863e-51,1.4999963915963133e-13,0.9999999999998579,"-1",0.9999999999843396,1.567107480487339e-11,"No",1.2429933661406273e-10,0.9999999998757119,"Yes",0.9999990992627168,9.007372835574081e-07,"No",2.873924971220033e-10,0.9999999997125998,"Yes",6.3051818344869e-06,0.9999936948181695,"Yes",0.9999999990779997,9.220005573515553e-10,"No",6.207118447637104e-09,0.9999999937928693,"Yes"
"2010-023775-25","A Phase II Randomized Double-blind Placebo-controlled Parallel group Adaptive combined Proof of Concept and Dose-Finding study to investigate Efficacy Safety Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPS","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.796040889496863e-51,1.4999963915963133e-13,0.9999999999998579,"-1",0.9999999999843396,1.567107480487339e-11,"No",1.2429933661406273e-10,0.9999999998757119,"Yes",0.9999990992627168,9.007372835574081e-07,"No",2.873924971220033e-10,0.9999999997125998,"Yes",6.3051818344869e-06,0.9999936948181695,"Yes",0.9999999990779997,9.220005573515553e-10,"No",6.207118447637104e-09,0.9999999937928693,"Yes"
"2010-023775-25","A Phase II Randomized Double-blind Placebo-controlled Parallel group Adaptive combined Proof of Concept and Dose-Finding study to investigate Efficacy Safety Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of CP/CPPSEstudio de fase II aleatorizado doble ciego controlado con placebo en grupos paralelos con un diseño adaptativo combinando prueba de concepto y búsqueda de dosis para evaluar la eficacia seguridad farmacodinámica y farmacocinética de ASP3652 en el tratamiento de la prostatitis crónica/síndrome de dolor pélvico crónico","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.377768048089278e-100,2.797166442890534e-29,1.0,"-1",1.0,3.2287163997541735e-25,"No",2.1051265995372362e-23,1.0,"Yes",1.0,1.1990858048393971e-20,"No",8.039162407509022e-26,1.0,"Yes",2.510428470411034e-12,0.999999999997499,"Yes",1.0,3.7120991311116016e-22,"No",4.22617194862152e-23,1.0,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMPARED  WITH RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY GA101 OR RITUXIMAB  MAINTENANCE THERAPY IN RESPONDERS","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.595198729437449e-69,0.00019034794584880173,0.999809652054153,"2+",3.193451226886082e-14,0.9999999999999717,"Yes",0.9999999999999717,2.968437765678251e-14,"No",1.0,5.948110757136731e-31,"No",2.391728950980042e-07,0.999999760827109,"Yes",0.048237117644923735,0.9517628823550837,"Yes",1.0,7.623301785246425e-23,"No",6.389570037229632e-05,0.9999361042996209,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABELRANDOMIZED STUDY IN PREVIOUSLYUNTREATED PATIENTS WITH ADVANCEDINDOLENT NON-HODGKIN'S LYMPHOMAEVALUATING THE BENEFIT OF GA101(RO5072759) PLUS CHEMOTHERAPYCOMPARED WITH RITUXIMAB PLUSCHEMOTHERAPY FOLLOWED BY GA101 ORRITUXIMAB MAINTENANCE THERAPY INRESPONDERS","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.430954506928061e-38,0.025458055775481152,0.9745419442245069,"2+",1.980648409135186e-10,0.9999999998019291,"Yes",0.9999999996379074,3.620895474335723e-10,"No",1.0,7.74173152659386e-15,"No",3.0020298813517597e-05,0.9999699797011976,"Yes",0.022408488849689268,0.9775915111502977,"Yes",0.9999999999996874,3.168984464802543e-13,"No",0.010455136369613333,0.9895448636303817,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABELRANDOMIZED STUDY IN PREVIOUSLYUNTREATED PATIENTS WITH ADVANCEDINDOLENT NON-HODGKIN'S LYMPHOMAEVALUATING THE BENEFIT OF GA101(RO5072759) PLUS CHEMOTHERAPYCOMPARED WITH RITUXIMAB PLUSCHEMOTHERAPY FOLLOWED BY GA101 ORRITUXIMAB MAINTENANCE THERAPY INRESPONDERS","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.430954506928061e-38,0.025458055775481152,0.9745419442245069,"2+",1.980648409135186e-10,0.9999999998019291,"Yes",0.9999999996379074,3.620895474335723e-10,"No",1.0,7.74173152659386e-15,"No",3.0020298813517597e-05,0.9999699797011976,"Yes",0.022408488849689268,0.9775915111502977,"Yes",0.9999999999996874,3.168984464802543e-13,"No",0.010455136369613333,0.9895448636303817,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMPARED WITH RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY GA101 OR RITUXIMAB MAINTENANCE THERAPY IN RESPONDERSFáze III multicentrická odslepená randomizovaná studie u dříve neléčených pacientů s pokročilým indolentním non-Hodgkinským lymfomem hodnotící prospěch GA101 (RO5072759) s chemoterapií v porovnání s Rituximabem s chemoterapií následovaná udržovací léčbou GA101 nebo Rituximabem u pacientů s odpovědí na léčbu.","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.569960799355544e-134,1.4180262493894678e-16,1.0,"2+",8.190308577083428e-23,1.0,"Yes",1.0,6.482014965915833e-22,"No",1.0,2.8721440576898754e-71,"No",1.7722661514169537e-20,1.0,"Yes",1.0413939955038e-06,0.9999989586060304,"Yes",1.0,2.079816307655787e-47,"No",1.6732224664933033e-14,1.0,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMPARED WITH RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY GA101 OR RITUXIMAB MAINTENANCE THERAPY IN RESPONDERSFáze III multicentrická odslepená randomizovaná studie u dříve neléčených pacientů s pokročilým indolentním non-Hodgkinským lymfomem hodnotící prospěch GA101 (RO5072759) s chemoterapií v porovnání s Rituximabem s chemoterapií následovaná udržovací léčbou GA101 nebo Rituximabem u pacientů s odpovědí na léčbu.","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.569960799355544e-134,1.4180262493894678e-16,1.0,"2+",8.190308577083428e-23,1.0,"Yes",1.0,6.482014965915833e-22,"No",1.0,2.8721440576898754e-71,"No",1.7722661514169537e-20,1.0,"Yes",1.0413939955038e-06,0.9999989586060304,"Yes",1.0,2.079816307655787e-47,"No",1.6732224664933033e-14,1.0,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMPARED WITH RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY GA101 OR RITUXIMAB MAINTENANCE THERAPY IN RESPONDERSFáze III multicentrická odslepená randomizovaná studie u dříve neléčených pacientů s pokročilým indolentním non-Hodgkinským lymfomem hodnotící prospěch GA101 (RO5072759) s chemoterapií v porovnání s Rituximabem s chemoterapií následovaná udržovací léčbou GA101 nebo Rituximabem u pacientů s odpovědí na léčbu.","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.569960799355544e-134,1.4180262493894678e-16,1.0,"2+",8.190308577083428e-23,1.0,"Yes",1.0,6.482014965915833e-22,"No",1.0,2.8721440576898754e-71,"No",1.7722661514169537e-20,1.0,"Yes",1.0413939955038e-06,0.9999989586060304,"Yes",1.0,2.079816307655787e-47,"No",1.6732224664933033e-14,1.0,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMPARED WITH RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY GA101 OR RITUXIMAB MAINTENANCE THERAPY IN RESPONDERSFáze III multicentrická odslepená randomizovaná studie u dříve neléčených pacientů s pokročilým indolentním non-Hodgkinským lymfomem hodnotící prospěch GA101 (RO5072759) s chemoterapií v porovnání s Rituximabem s chemoterapií následovaná udržovací léčbou GA101 nebo Rituximabem u pacientů s odpovědí na léčbu.","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.569960799355544e-134,1.4180262493894678e-16,1.0,"2+",8.190308577083428e-23,1.0,"Yes",1.0,6.482014965915833e-22,"No",1.0,2.8721440576898754e-71,"No",1.7722661514169537e-20,1.0,"Yes",1.0413939955038e-06,0.9999989586060304,"Yes",1.0,2.079816307655787e-47,"No",1.6732224664933033e-14,1.0,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABELRANDOMIZED STUDY IN PREVIOUSLYUNTREATED PATIENTS WITH ADVANCEDINDOLENT NON-HODGKIN'S LYMPHOMAEVALUATING THE BENEFIT OF GA101(RO5072759) PLUS CHEMOTHERAPYCOMPARED WITH RITUXIMAB PLUSCHEMOTHERAPY FOLLOWED BY GA101 ORRITUXIMAB MAINTENANCE THERAPY INRESPONDERS","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.430954506928061e-38,0.025458055775481152,0.9745419442245069,"2+",1.980648409135186e-10,0.9999999998019291,"Yes",0.9999999996379074,3.620895474335723e-10,"No",1.0,7.74173152659386e-15,"No",3.0020298813517597e-05,0.9999699797011976,"Yes",0.022408488849689268,0.9775915111502977,"Yes",0.9999999999996874,3.168984464802543e-13,"No",0.010455136369613333,0.9895448636303817,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABELRANDOMIZED STUDY IN PREVIOUSLYUNTREATED PATIENTS WITH ADVANCEDINDOLENT NON-HODGKIN'S LYMPHOMAEVALUATING THE BENEFIT OF GA101(RO5072759) PLUS CHEMOTHERAPYCOMPARED WITH RITUXIMAB PLUSCHEMOTHERAPY FOLLOWED BY GA101 ORRITUXIMAB MAINTENANCE THERAPY INRESPONDERSSTUDIO DI FASE III MULTICENTRICO IN APERTO RANDOMIZZATO IN PAZIENTI AFFETTI DA LINFOMA NON-HODGKIN INDOLENTE AVANZATO NON TRATTATO IN PRECEDENZA PER VALUTARE L`EFFICACIA DI GA101 (RO5072759) PIU' CHEMIOTERAPIA RISPETTO A RITUXIMAB PIU' CHEMIOTERAPIA E SUCCESSIVA TERAPIA DI MANTENIMENTO CON GA101 O RITUXIMAB NEI PAZIENTI IN RISPOSTA","FI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.002775248781996e-112,0.001253991595461407,0.9987460084045557,"2+",6.0799326588512e-27,1.0,"Yes",1.0,5.085065479172988e-26,"No",1.0,1.2518594884243005e-49,"No",5.111694368654256e-09,0.9999999948882988,"Yes",1.8792011125710357e-06,0.9999981207988675,"Yes",1.0,8.649137380423649e-49,"No",0.00033963851987821916,0.9996603614801058,"Yes"
"2010-024132-41","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMPARED  WITH RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY GA101 OR RITUXIMAB  MAINTENANCE THERAPY IN RESPONDERS","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.595198729437449e-69,0.00019034794584880173,0.999809652054153,"2+",3.193451226886082e-14,0.9999999999999717,"Yes",0.9999999999999717,2.968437765678251e-14,"No",1.0,5.948110757136731e-31,"No",2.391728950980042e-07,0.999999760827109,"Yes",0.048237117644923735,0.9517628823550837,"Yes",1.0,7.623301785246425e-23,"No",6.389570037229632e-05,0.9999361042996209,"Yes"
"2010-024262-22","Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy.Optimalizace léčby pacientů  s nově diagnostikovanou Ph/BCR-ABL pozitivní chronickou myeloidní leukémií (CML) v chronické fázi srovnávající nilotinib versus nilonitib a interferon alfa v indukční léčbě a nilotinib versus interferon alfa v udržovací terapii.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.098662379185848e-95,1.974208415553396e-16,1.0,"2+",1.0560666285563414e-29,1.0,"Yes",1.0,5.270276549174258e-29,"No",1.0,3.476286927093631e-56,"No",1.2718902274687335e-12,0.9999999999987494,"Yes",0.9999416894611912,5.831053879256479e-05,"Yes",1.0,6.7319291439859905e-56,"No",3.811249339419546e-08,0.9999999618875116,"Yes"
"2010-024262-22","Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy.Optimalizace léčby pacientů  s nově diagnostikovanou Ph/BCR-ABL pozitivní chronickou myeloidní leukémií (CML) v chronické fázi srovnávající nilotinib versus nilonitib a interferon alfa v indukční léčbě a nilotinib versus interferon alfa v udržovací terapii.","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.098662379185848e-95,1.974208415553396e-16,1.0,"2+",1.0560666285563414e-29,1.0,"Yes",1.0,5.270276549174258e-29,"No",1.0,3.476286927093631e-56,"No",1.2718902274687335e-12,0.9999999999987494,"Yes",0.9999416894611912,5.831053879256479e-05,"Yes",1.0,6.7319291439859905e-56,"No",3.811249339419546e-08,0.9999999618875116,"Yes"
"2010-024300-10","Early prospective therapy trial to delay renal failure in children with Alport syndrome.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7208453546294673e-20,0.04498392516510163,0.9550160748349033,"2+",0.9520116122905886,0.04798838770941665,"No",0.047780133030535826,0.9522198669694579,"Yes",0.9780059967089182,0.021994003291081466,"No",0.014193705895314929,0.9858062941046836,"Yes",0.07238289984212905,0.9276171001578721,"Yes",0.8691272275784039,0.13087277242159645,"No",0.01126731935768778,0.9887326806423148,"Yes"
"2010-024311-13","A Multicenter Double-Blind Placebo Controlled Randomized 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults with Phenylketonuria","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.752505922209863e-48,5.422873154452376e-07,0.9999994577126806,"2+",0.9999428085359294,5.719146406620998e-05,"No",0.0011466527324262004,0.9988533472675798,"Yes",0.9846349858298119,0.015365014170189144,"No",3.005262205222851e-06,0.9999969947377959,"Yes",0.06384975101162892,0.9361502489883692,"Yes",0.9699347606866201,0.030065239313384923,"No",2.8194048953923534e-05,0.9999718059510448,"Yes"
"2010-024311-13","A Multicenter Double-Blind Placebo Controlled Randomized 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults with Phenylketonuria","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.752505922209863e-48,5.422873154452376e-07,0.9999994577126806,"2+",0.9999428085359294,5.719146406620998e-05,"No",0.0011466527324262004,0.9988533472675798,"Yes",0.9846349858298119,0.015365014170189144,"No",3.005262205222851e-06,0.9999969947377959,"Yes",0.06384975101162892,0.9361502489883692,"Yes",0.9699347606866201,0.030065239313384923,"No",2.8194048953923534e-05,0.9999718059510448,"Yes"
"2010-024311-13","A Multicenter Double-Blind Placebo Controlled Randomized 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults with Phenylketonuria","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.752505922209863e-48,5.422873154452376e-07,0.9999994577126806,"2+",0.9999428085359294,5.719146406620998e-05,"No",0.0011466527324262004,0.9988533472675798,"Yes",0.9846349858298119,0.015365014170189144,"No",3.005262205222851e-06,0.9999969947377959,"Yes",0.06384975101162892,0.9361502489883692,"Yes",0.9699347606866201,0.030065239313384923,"No",2.8194048953923534e-05,0.9999718059510448,"Yes"
"2010-024311-13","A Multicenter Double-Blind Placebo Controlled Randomized 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults with Phenylketonuria","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.752505922209863e-48,5.422873154452376e-07,0.9999994577126806,"2+",0.9999428085359294,5.719146406620998e-05,"No",0.0011466527324262004,0.9988533472675798,"Yes",0.9846349858298119,0.015365014170189144,"No",3.005262205222851e-06,0.9999969947377959,"Yes",0.06384975101162892,0.9361502489883692,"Yes",0.9699347606866201,0.030065239313384923,"No",2.8194048953923534e-05,0.9999718059510448,"Yes"
"2010-024311-13","A Multicenter Double-Blind Placebo Controlled Randomized 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults with Phenylketonuria","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.752505922209863e-48,5.422873154452376e-07,0.9999994577126806,"2+",0.9999428085359294,5.719146406620998e-05,"No",0.0011466527324262004,0.9988533472675798,"Yes",0.9846349858298119,0.015365014170189144,"No",3.005262205222851e-06,0.9999969947377959,"Yes",0.06384975101162892,0.9361502489883692,"Yes",0.9699347606866201,0.030065239313384923,"No",2.8194048953923534e-05,0.9999718059510448,"Yes"
"2010-024332-42","A randomized double-blind placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg 1.0 mg 1.5 mg 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP)Studio di Fase II  randomizzato in doppio cieco controllato verso placebo per valutare l’efficacia e la sicurezza di Riociguat (0.5 mg 1 mg 1.5 mg 2 mg or 2.5 mg TID) in pazienti con ipertensione arteriosa polmonare associata a polmoniti interstiziali idiopatiche (IIP)","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.883630225108512e-163,1.2762847200034885e-06,0.9999987237152554,"2+",1.0,3.368999736582584e-15,"No",5.06944006998897e-14,0.9999999999999432,"Yes",1.0,5.0808525441920335e-24,"No",1.914509493736466e-07,0.9999998085490531,"Yes",0.021579352594356442,0.9784206474056629,"No",0.9999999637901744,3.620981163887439e-08,"No",1.2738307828717605e-07,0.9999998726169192,"Yes"
"2010-024332-42","A randomized double-blind placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg 1.0 mg 1.5 mg 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP)Estudio de fase II aleatorizado doble ciego controlado con placebo para investigar la eficacia y la seguridad de Riociguat (05 mg 10 mg 15 mg 20 mg y 25 mg tres veces al día) en pacientes con hipertensión pulmonar sintomática asociada a neumonía intersticial idiopática (NII).","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4199729647532372e-154,3.779374653430661e-12,0.9999999999962484,"2+",1.0,1.3958862305335728e-20,"No",3.836410694699543e-18,1.0,"Yes",1.0,6.416967554805838e-23,"No",3.160494932938678e-11,0.9999999999683951,"Yes",0.10437938975792624,0.8956206102421215,"No",0.9999999999994316,5.407564679740256e-13,"No",6.466497501100821e-13,0.9999999999993748,"Yes"
"2010-024332-42","A randomized double-blind placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg 1.0 mg 1.5 mg 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP)","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.61938916078352e-83,3.2897747804509e-05,0.9999671022522071,"2+",0.9999999999244551,7.555749021242982e-11,"No",8.614871361545864e-10,0.9999999991385096,"Yes",0.999999867824508,1.3217549324524705e-07,"No",1.4082138019855343e-05,0.9999859178619681,"Yes",0.18065446389810855,0.8193455361018954,"No",0.7655998532030933,0.23440014679691912,"No",2.0930841096434733e-05,0.9999790691588899,"Yes"
"2010-024332-42","A randomized double-blind placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg 1.0 mg 1.5 mg 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP)Estudio de fase II aleatorizado doble ciego controlado con placebo para investigar la eficacia y la seguridad de Riociguat (05 mg 10 mg 15 mg 20 mg y 25 mg tres veces al día) en pacientes con hipertensión pulmonar sintomática asociada a neumonía intersticial idiopática (NII).","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4199729647532372e-154,3.779374653430661e-12,0.9999999999962484,"2+",1.0,1.3958862305335728e-20,"No",3.836410694699543e-18,1.0,"Yes",1.0,6.416967554805838e-23,"No",3.160494932938678e-11,0.9999999999683951,"Yes",0.10437938975792624,0.8956206102421215,"No",0.9999999999994316,5.407564679740256e-13,"No",6.466497501100821e-13,0.9999999999993748,"Yes"
"2010-024332-42","A randomized double-blind placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg 1.0 mg 1.5 mg 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP)Estudio de fase II aleatorizado doble ciego controlado con placebo para investigar la eficacia y la seguridad de Riociguat (05 mg 10 mg 15 mg 20 mg y 25 mg tres veces al día) en pacientes con hipertensión pulmonar sintomática asociada a neumonía intersticial idiopática (NII).","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4199729647532372e-154,3.779374653430661e-12,0.9999999999962484,"2+",1.0,1.3958862305335728e-20,"No",3.836410694699543e-18,1.0,"Yes",1.0,6.416967554805838e-23,"No",3.160494932938678e-11,0.9999999999683951,"Yes",0.10437938975792624,0.8956206102421215,"No",0.9999999999994316,5.407564679740256e-13,"No",6.466497501100821e-13,0.9999999999993748,"Yes"
"2010-024332-42","A randomized double-blind placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg 1.0 mg 1.5 mg 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP)Estudio de fase II aleatorizado doble ciego controlado con placebo para investigar la eficacia y la seguridad de Riociguat (05 mg 10 mg 15 mg 20 mg y 25 mg tres veces al día) en pacientes con hipertensión pulmonar sintomática asociada a neumonía intersticial idiopática (NII).","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4199729647532372e-154,3.779374653430661e-12,0.9999999999962484,"2+",1.0,1.3958862305335728e-20,"No",3.836410694699543e-18,1.0,"Yes",1.0,6.416967554805838e-23,"No",3.160494932938678e-11,0.9999999999683951,"Yes",0.10437938975792624,0.8956206102421215,"No",0.9999999999994316,5.407564679740256e-13,"No",6.466497501100821e-13,0.9999999999993748,"Yes"
"2010-024332-42","A randomized double-blind placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg 1.0 mg 1.5 mg 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP)Studio di Fase II  randomizzato in doppio cieco controllato verso placebo per valutare l’efficacia e la sicurezza di Riociguat (0.5 mg 1 mg 1.5 mg 2 mg or 2.5 mg TID) in pazienti con ipertensione arteriosa polmonare associata a polmoniti interstiziali idiopatiche (IIP)","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.883630225108512e-163,1.2762847200034885e-06,0.9999987237152554,"2+",1.0,3.368999736582584e-15,"No",5.06944006998897e-14,0.9999999999999432,"Yes",1.0,5.0808525441920335e-24,"No",1.914509493736466e-07,0.9999998085490531,"Yes",0.021579352594356442,0.9784206474056629,"No",0.9999999637901744,3.620981163887439e-08,"No",1.2738307828717605e-07,0.9999998726169192,"Yes"
"2010-024332-42","A randomized double-blind placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg 1.0 mg 1.5 mg 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP)Studio di Fase II  randomizzato in doppio cieco controllato verso placebo per valutare l’efficacia e la sicurezza di Riociguat (0.5 mg 1 mg 1.5 mg 2 mg or 2.5 mg TID) in pazienti con ipertensione arteriosa polmonare associata a polmoniti interstiziali idiopatiche (IIP)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.883630225108512e-163,1.2762847200034885e-06,0.9999987237152554,"2+",1.0,3.368999736582584e-15,"No",5.06944006998897e-14,0.9999999999999432,"Yes",1.0,5.0808525441920335e-24,"No",1.914509493736466e-07,0.9999998085490531,"Yes",0.021579352594356442,0.9784206474056629,"No",0.9999999637901744,3.620981163887439e-08,"No",1.2738307828717605e-07,0.9999998726169192,"Yes"
"2010-024355-85","Ensayo de fase II aleatorizado doble ciego controlado con placebo para evaluar la seguridad y la eficacia de ASCI recMAGE-A3 + AS15 en pacientes con cáncer de vejiga músculo-invasivo positivo para MAGE-A3 tras cistectomía","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.190451113895763e-39,3.1285016613901787e-07,0.9999996871498446,"2+",0.9982279977920809,0.001772002207925615,"No",0.004862153827328868,0.9951378461726673,"Yes",0.9999999986401917,1.3598119083379966e-09,"No",9.84555442504704e-07,0.9999990154445599,"Yes",0.2389465939676589,0.7610534060323475,"Yes",0.9999999971446699,2.855340643261496e-09,"No",2.3557942512673397e-06,0.9999976442057525,"Yes"
"2010-024355-85","Ensayo de fase II aleatorizado doble ciego controlado con placebo para evaluar la seguridad y la eficacia de ASCI recMAGE-A3 + AS15 en pacientes con cáncer de vejiga músculo-invasivo positivo para MAGE-A3 tras cistectomía","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.190451113895763e-39,3.1285016613901787e-07,0.9999996871498446,"2+",0.9982279977920809,0.001772002207925615,"No",0.004862153827328868,0.9951378461726673,"Yes",0.9999999986401917,1.3598119083379966e-09,"No",9.84555442504704e-07,0.9999990154445599,"Yes",0.2389465939676589,0.7610534060323475,"Yes",0.9999999971446699,2.855340643261496e-09,"No",2.3557942512673397e-06,0.9999976442057525,"Yes"
"2010-024355-85","Ensayo de fase II aleatorizado doble ciego controlado con placebo para evaluar la seguridad y la eficacia de ASCI recMAGE-A3 + AS15 en pacientes con cáncer de vejiga músculo-invasivo positivo para MAGE-A3 tras cistectomía","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.190451113895763e-39,3.1285016613901787e-07,0.9999996871498446,"2+",0.9982279977920809,0.001772002207925615,"No",0.004862153827328868,0.9951378461726673,"Yes",0.9999999986401917,1.3598119083379966e-09,"No",9.84555442504704e-07,0.9999990154445599,"Yes",0.2389465939676589,0.7610534060323475,"Yes",0.9999999971446699,2.855340643261496e-09,"No",2.3557942512673397e-06,0.9999976442057525,"Yes"
"2010-024355-85","A randomized double blind placebo controlled phase II trial to evaluate  the safety and efficacy of recMAGE-A3 + AS15 ASCI in patients with  MAGE-A3 positive muscle invasive bladder cancer after cystectomyStudio di fase II randomizzato in doppio cieco controllato verso placebo volto a valutare la sicurezza e l'efficacia del prodotto immunoterapico antitumorale antigene-specifico (ASCI)recMAGE-A3 + AS15 in pazienti con carcinoma vescicale muscolo-invasivo MAGE-A3 positivo dopo cistectomia","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6410023966278268e-89,6.446887199756058e-12,0.9999999999935767,"2+",0.9999999997910437,2.089426101124321e-10,"No",8.91408282228433e-10,0.9999999991085815,"Yes",1.0,4.227466934756223e-20,"No",2.2528708928977497e-12,0.9999999999977264,"Yes",0.3953616579796674,0.6046383420203095,"Yes",0.9999999989825028,1.017493201370592e-09,"No",3.454682996399888e-11,0.9999999999654392,"Yes"
"2010-024355-85","Ensayo de fase II aleatorizado doble ciego controlado con placebo para evaluar la seguridad y la eficacia de ASCI recMAGE-A3 + AS15 en pacientes con cáncer de vejiga músculo-invasivo positivo para MAGE-A3 tras cistectomía","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.190451113895763e-39,3.1285016613901787e-07,0.9999996871498446,"2+",0.9982279977920809,0.001772002207925615,"No",0.004862153827328868,0.9951378461726673,"Yes",0.9999999986401917,1.3598119083379966e-09,"No",9.84555442504704e-07,0.9999990154445599,"Yes",0.2389465939676589,0.7610534060323475,"Yes",0.9999999971446699,2.855340643261496e-09,"No",2.3557942512673397e-06,0.9999976442057525,"Yes"
"2010-024379-15","Pazopanib with 5-Flourouracil Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer a randomized Phase II study.- The PaFLO study.Pazopanib mit 5-FU Leukovorin und Oxaliplatin als Erstlinientherapie bei fortgeschrittenem Magenkarzinom eine randomisierte Phase-II-Studie. – Die PaFLO-Studie.","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2525180775759925e-57,0.0050948731549859605,0.9949051268450039,"2+",1.6742049986797765e-06,0.9999983257949996,"Yes",0.9999964773164524,3.522683543266577e-06,"No",1.0,1.0342836902452204e-19,"No",0.8765185896528004,0.12348141034720589,"Yes",0.9999250386736083,7.496132638025273e-05,"Yes",0.9999241144971807,7.588550282294357e-05,"No",0.23982843280721688,0.7601715671927882,"Yes"
"2010-024473-39","An open-label multicenter expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)","AT","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.052319255402408e-31,0.9999745226634557,2.5477336535465812e-05,"1",2.7716571863651394e-10,0.9999999997228316,"Yes",0.9999999993673043,6.326956591591563e-10,"No",1.0,3.6772026208951655e-22,"No",0.9999845338603598,1.546613964578523e-05,"No",1.0,8.329281241210207e-15,"No",5.146914507859854e-13,0.9999999999994884,"No",0.9991651878093387,0.0008348121906686013,"No"
"2010-024473-39","An open-label multicenter expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)","PT","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.052319255402408e-31,0.9999745226634557,2.5477336535465812e-05,"1",2.7716571863651394e-10,0.9999999997228316,"Yes",0.9999999993673043,6.326956591591563e-10,"No",1.0,3.6772026208951655e-22,"No",0.9999845338603598,1.546613964578523e-05,"No",1.0,8.329281241210207e-15,"No",5.146914507859854e-13,0.9999999999994884,"No",0.9991651878093387,0.0008348121906686013,"No"
"2010-024473-39","An open-label multicenter expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)","SK","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.052319255402408e-31,0.9999745226634557,2.5477336535465812e-05,"1",2.7716571863651394e-10,0.9999999997228316,"Yes",0.9999999993673043,6.326956591591563e-10,"No",1.0,3.6772026208951655e-22,"No",0.9999845338603598,1.546613964578523e-05,"No",1.0,8.329281241210207e-15,"No",5.146914507859854e-13,0.9999999999994884,"No",0.9991651878093387,0.0008348121906686013,"No"
"2010-024473-39","Ensayo clínico abierto multicéntrico de acceso expandido de INC424 en pacientes con mielofibrosis primaria (PMF) o mielofibrosis secundaria a policitemia (PPV MF) o mielofibrosis secundaria a trombocitemia esencial (PET-MF)","BE","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.9116406458958085e-25,0.9982628195979446,0.0017371804020508128,"1",9.36159914074835e-06,0.9999906384008677,"Yes",0.9999774330679044,2.2566932097447678e-05,"No",1.0,1.2255657605965873e-14,"No",0.9304273729612268,0.06957262703878418,"No",0.9999999999996306,3.6509398498377165e-13,"No",0.00964755028999184,0.9903524497100177,"No",0.9787645500993103,0.021235449900677047,"No"
"2010-024473-39","An open-label multicenter expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)","IE","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.052319255402408e-31,0.9999745226634557,2.5477336535465812e-05,"1",2.7716571863651394e-10,0.9999999997228316,"Yes",0.9999999993673043,6.326956591591563e-10,"No",1.0,3.6772026208951655e-22,"No",0.9999845338603598,1.546613964578523e-05,"No",1.0,8.329281241210207e-15,"No",5.146914507859854e-13,0.9999999999994884,"No",0.9991651878093387,0.0008348121906686013,"No"
"2010-024473-39","An open-label multicenter expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)","DE","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.052319255402408e-31,0.9999745226634557,2.5477336535465812e-05,"1",2.7716571863651394e-10,0.9999999997228316,"Yes",0.9999999993673043,6.326956591591563e-10,"No",1.0,3.6772026208951655e-22,"No",0.9999845338603598,1.546613964578523e-05,"No",1.0,8.329281241210207e-15,"No",5.146914507859854e-13,0.9999999999994884,"No",0.9991651878093387,0.0008348121906686013,"No"
"2010-024473-39","Ensayo clínico abierto multicéntrico de acceso expandido de INC424 en pacientes con mielofibrosis primaria (PMF) o mielofibrosis secundaria a policitemia (PPV MF) o mielofibrosis secundaria a trombocitemia esencial (PET-MF)","PL","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.9116406458958085e-25,0.9982628195979446,0.0017371804020508128,"1",9.36159914074835e-06,0.9999906384008677,"Yes",0.9999774330679044,2.2566932097447678e-05,"No",1.0,1.2255657605965873e-14,"No",0.9304273729612268,0.06957262703878418,"No",0.9999999999996306,3.6509398498377165e-13,"No",0.00964755028999184,0.9903524497100177,"No",0.9787645500993103,0.021235449900677047,"No"
"2010-024473-39","Ensayo clínico abierto multicéntrico de acceso expandido de INC424 en pacientes con mielofibrosis primaria (PMF) o mielofibrosis secundaria a policitemia (PPV MF) o mielofibrosis secundaria a trombocitemia esencial (PET-MF)","IT","No","No","Yes","","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.9116406458958085e-25,0.9982628195979446,0.0017371804020508128,"1",9.36159914074835e-06,0.9999906384008677,"Information not present in EudraCT",0.9999774330679044,2.2566932097447678e-05,"Information not present in EudraCT",1.0,1.2255657605965873e-14,"Information not present in EudraCT",0.9304273729612268,0.06957262703878418,"No",0.9999999999996306,3.6509398498377165e-13,"No",0.00964755028999184,0.9903524497100177,"No",0.9787645500993103,0.021235449900677047,"No"
"2010-024473-39","An open-label multicenter expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)","GR","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.052319255402408e-31,0.9999745226634557,2.5477336535465812e-05,"1",2.7716571863651394e-10,0.9999999997228316,"Yes",0.9999999993673043,6.326956591591563e-10,"No",1.0,3.6772026208951655e-22,"No",0.9999845338603598,1.546613964578523e-05,"No",1.0,8.329281241210207e-15,"No",5.146914507859854e-13,0.9999999999994884,"No",0.9991651878093387,0.0008348121906686013,"No"
"2010-024473-39","Ensayo clínico abierto multicéntrico de acceso expandido de INC424 en pacientes con mielofibrosis primaria (PMF) o mielofibrosis secundaria a policitemia (PPV MF) o mielofibrosis secundaria a trombocitemia esencial (PET-MF)","HU","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.9116406458958085e-25,0.9982628195979446,0.0017371804020508128,"1",9.36159914074835e-06,0.9999906384008677,"Yes",0.9999774330679044,2.2566932097447678e-05,"No",1.0,1.2255657605965873e-14,"No",0.9304273729612268,0.06957262703878418,"No",0.9999999999996306,3.6509398498377165e-13,"No",0.00964755028999184,0.9903524497100177,"No",0.9787645500993103,0.021235449900677047,"No"
"2010-024473-39","Ensayo clínico abierto multicéntrico de acceso expandido de INC424 en pacientes con mielofibrosis primaria (PMF) o mielofibrosis secundaria a policitemia (PPV MF) o mielofibrosis secundaria a trombocitemia esencial (PET-MF)","ES","No","No","Yes","","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.9116406458958085e-25,0.9982628195979446,0.0017371804020508128,"1",9.36159914074835e-06,0.9999906384008677,"Information not present in EudraCT",0.9999774330679044,2.2566932097447678e-05,"Information not present in EudraCT",1.0,1.2255657605965873e-14,"Information not present in EudraCT",0.9304273729612268,0.06957262703878418,"No",0.9999999999996306,3.6509398498377165e-13,"No",0.00964755028999184,0.9903524497100177,"No",0.9787645500993103,0.021235449900677047,"No"
"2010-024473-39","An open-label multicenter expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)","CZ","No","No","Yes","ok","No","Yes","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.052319255402408e-31,0.9999745226634557,2.5477336535465812e-05,"1",2.7716571863651394e-10,0.9999999997228316,"Yes",0.9999999993673043,6.326956591591563e-10,"No",1.0,3.6772026208951655e-22,"No",0.9999845338603598,1.546613964578523e-05,"No",1.0,8.329281241210207e-15,"No",5.146914507859854e-13,0.9999999999994884,"No",0.9991651878093387,0.0008348121906686013,"No"
"2011-000152-42","An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren 15% gel and Differin 0.1 % gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females","DE","Yes","Yes","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",1.6026725753742816e-34,8.658657793296714e-12,0.9999999999913314,"2+",0.9999965858947933,3.414105217564856e-06,"No",0.00042835295507743593,0.9995716470449284,"No",0.427976942625021,0.5720230573749921,"Yes",3.2682823751287624e-09,0.9999999967317309,"Yes",5.955250118634041e-06,0.9999940447498804,"Yes",1.0,9.489854790892745e-15,"No",2.4726748308464812e-08,0.9999999752732552,"Yes"
"2011-000281-35","A Multicenter Randomized Double-Mask Placebo-Controlled Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon versus Placebo in Totally Blind Subjects with N24HSWD followed by an OLE Phase","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0665250812637484e-44,1.9632247954344946e-10,0.999999999803677,"2+",0.9999999989859704,1.0140236123818057e-09,"No",7.078657435067505e-09,0.999999992921346,"Yes",0.9999999008286317,9.91713755553043e-08,"No",2.113698849043208e-09,0.9999999978863059,"Yes",0.0015624676073430627,0.9984375323926606,"Yes",0.9999984085871902,1.5914128114512296e-06,"No",2.165125265900135e-07,0.999999783487477,"Yes"
"2011-000391-34","LUX-Head & Neck 1 A randomised open-label phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapyLUX-Head & Neck 1Estudio aleatorizado abierto de fase III para evaluar la eficacia y seguridad de afatinib oral (BIBW 2992) frente a metotrexato intravenoso en pacientes con carcinoma de células escamosas de cabeza y cuello recurrente y/o metastásico que hayan mostrado progresión tras terapia con platino","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.583784458581332e-114,4.271986356945331e-11,0.9999999999572539,"2+",6.752160766853042e-22,1.0,"Yes",1.0,3.137861117152071e-21,"No",1.0,3.8654735938078354e-44,"No",2.7993738011297757e-09,0.9999999972005754,"Yes",0.9999727906909058,2.7209309066442764e-05,"Yes",1.0,1.577854198860286e-49,"No",6.356711231612186e-09,0.9999999936433143,"Yes"
"2011-000391-34","LUX-Head & Neck 1A randomised open-label phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.77718756829245e-57,7.275956122084839e-08,0.9999999272404265,"2+",1.860564876971795e-12,0.9999999999981526,"Yes",0.9999999999964473,3.5431086342953996e-12,"No",1.0,4.1161458796044575e-23,"No",0.0001265966259445858,0.9998734033740558,"Yes",0.9879040279794882,0.012095972020500952,"Yes",1.0,7.45817678088586e-25,"No",2.443469090557917e-06,0.999997556530901,"Yes"
"2011-000391-34","LUX-Head & Neck 1A randomised open-label phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.77718756829245e-57,7.275956122084839e-08,0.9999999272404265,"2+",1.860564876971795e-12,0.9999999999981526,"Yes",0.9999999999964473,3.5431086342953996e-12,"No",1.0,4.1161458796044575e-23,"No",0.0001265966259445858,0.9998734033740558,"Yes",0.9879040279794882,0.012095972020500952,"Yes",1.0,7.45817678088586e-25,"No",2.443469090557917e-06,0.999997556530901,"Yes"
"2011-000391-34","A randomised open-label phase III study to evaluate the efficacy and  safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in  patients with recurrent and/or metastatic head and neck squamous cell  carcinoma who have progressed after platinum-based therapyStudio randomizzato in aperto di fase III per valutare l'efficacia e la sicurezza di afatinib (BIBW 2992) somministrazione orale verso metotressato somministrazione endovenosa in pazienti con carcinoma a cellule squamose del testa-collo ricorrente/metastatico che sono in progressione dopo terapia a base di platino.","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.809585796600986e-108,1.701219274487178e-10,0.9999999998299245,"2+",3.025044662877861e-22,1.0,"Yes",1.0,1.0561674115512453e-21,"No",1.0,3.673510384370411e-41,"No",5.711636720300503e-10,0.9999999994288374,"Yes",0.9976727939979295,0.0023272060020157748,"Yes",1.0,1.7920108640790163e-35,"No",2.168302950351417e-09,0.9999999978316509,"Yes"
"2011-000391-34","A randomised open-label phase III study to evaluate the efficacy and  safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in  patients with recurrent and/or metastatic head and neck squamous cell  carcinoma who have progressed after platinum-based therapyStudio randomizzato in aperto di fase III per valutare l'efficacia e la sicurezza di afatinib (BIBW 2992) somministrazione orale verso metotressato somministrazione endovenosa in pazienti con carcinoma a cellule squamose del testa-collo ricorrente/metastatico che sono in progressione dopo terapia a base di platino.","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.809585796600986e-108,1.701219274487178e-10,0.9999999998299245,"2+",3.025044662877861e-22,1.0,"Yes",1.0,1.0561674115512453e-21,"No",1.0,3.673510384370411e-41,"No",5.711636720300503e-10,0.9999999994288374,"Yes",0.9976727939979295,0.0023272060020157748,"Yes",1.0,1.7920108640790163e-35,"No",2.168302950351417e-09,0.9999999978316509,"Yes"
"2011-000391-34","LUX-Head & Neck 1 A randomised open-label phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapyLUX-Head & Neck 1Estudio aleatorizado abierto de fase III para evaluar la eficacia y seguridad de afatinib oral (BIBW 2992) frente a metotrexato intravenoso en pacientes con carcinoma de células escamosas de cabeza y cuello recurrente y/o metastásico que hayan mostrado progresión tras terapia con platino","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.583784458581332e-114,4.271986356945331e-11,0.9999999999572539,"2+",6.752160766853042e-22,1.0,"Yes",1.0,3.137861117152071e-21,"No",1.0,3.8654735938078354e-44,"No",2.7993738011297757e-09,0.9999999972005754,"Yes",0.9999727906909058,2.7209309066442764e-05,"Yes",1.0,1.577854198860286e-49,"No",6.356711231612186e-09,0.9999999936433143,"Yes"
"2011-000391-34","A randomised open-label phase III study to evaluate the efficacy and  safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in  patients with recurrent and/or metastatic head and neck squamous cell  carcinoma who have progressed after platinum-based therapyStudio randomizzato in aperto di fase III per valutare l'efficacia e la sicurezza di afatinib (BIBW 2992) somministrazione orale verso metotressato somministrazione endovenosa in pazienti con carcinoma a cellule squamose del testa-collo ricorrente/metastatico che sono in progressione dopo terapia a base di platino.","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.809585796600986e-108,1.701219274487178e-10,0.9999999998299245,"2+",3.025044662877861e-22,1.0,"Yes",1.0,1.0561674115512453e-21,"No",1.0,3.673510384370411e-41,"No",5.711636720300503e-10,0.9999999994288374,"Yes",0.9976727939979295,0.0023272060020157748,"Yes",1.0,1.7920108640790163e-35,"No",2.168302950351417e-09,0.9999999978316509,"Yes"
"2011-000391-34","A randomised open-label phase III study to evaluate the efficacy and  safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in  patients with recurrent and/or metastatic head and neck squamous cell  carcinoma who have progressed after platinum-based therapyStudio randomizzato in aperto di fase III per valutare l'efficacia e la sicurezza di afatinib (BIBW 2992) somministrazione orale verso metotressato somministrazione endovenosa in pazienti con carcinoma a cellule squamose del testa-collo ricorrente/metastatico che sono in progressione dopo terapia a base di platino.","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.809585796600986e-108,1.701219274487178e-10,0.9999999998299245,"2+",3.025044662877861e-22,1.0,"Yes",1.0,1.0561674115512453e-21,"No",1.0,3.673510384370411e-41,"No",5.711636720300503e-10,0.9999999994288374,"Yes",0.9976727939979295,0.0023272060020157748,"Yes",1.0,1.7920108640790163e-35,"No",2.168302950351417e-09,0.9999999978316509,"Yes"
"2011-000391-34","LUX-Head & Neck 1A randomised open-label phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.77718756829245e-57,7.275956122084839e-08,0.9999999272404265,"2+",1.860564876971795e-12,0.9999999999981526,"Yes",0.9999999999964473,3.5431086342953996e-12,"No",1.0,4.1161458796044575e-23,"No",0.0001265966259445858,0.9998734033740558,"Yes",0.9879040279794882,0.012095972020500952,"Yes",1.0,7.45817678088586e-25,"No",2.443469090557917e-06,0.999997556530901,"Yes"
"2011-000391-34","A randomised open-label phase III study to evaluate the efficacy and  safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in  patients with recurrent and/or metastatic head and neck squamous cell  carcinoma who have progressed after platinum-based therapyStudio randomizzato in aperto di fase III per valutare l'efficacia e la sicurezza di afatinib (BIBW 2992) somministrazione orale verso metotressato somministrazione endovenosa in pazienti con carcinoma a cellule squamose del testa-collo ricorrente/metastatico che sono in progressione dopo terapia a base di platino.","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.809585796600986e-108,1.701219274487178e-10,0.9999999998299245,"2+",3.025044662877861e-22,1.0,"Yes",1.0,1.0561674115512453e-21,"No",1.0,3.673510384370411e-41,"No",5.711636720300503e-10,0.9999999994288374,"Yes",0.9976727939979295,0.0023272060020157748,"Yes",1.0,1.7920108640790163e-35,"No",2.168302950351417e-09,0.9999999978316509,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinomaLUXHead & Neck 2 Estudio aleatorizado doble ciego controlado con placebo en fase III para evaluar la eficacia y la seguridad de afatinib (BIBW 2992) como terapia adyuvante tras quimio-radioterapia en pacientes no sometidos a resección primaria con carcinoma de células escamosas de cabeza y cuello con estadio III IVa o IVb locorregionalmente avanzado.","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.3768525271044694e-135,4.2899509183300045e-25,1.0,"2+",3.6555364646468375e-10,0.9999999996344968,"No",0.999999999932129,6.788731739011983e-11,"Yes",1.0,5.402257819488233e-42,"No",2.656414192071928e-22,1.0,"Yes",0.9997256062599688,0.00027439374004983814,"Yes",1.0,3.013725465712727e-44,"No",1.3187045291807056e-23,1.0,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma ","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.584947688519336e-67,1.6102049333014509e-12,0.9999999999984084,"2+",1.175060924613324e-06,0.9999988249390496,"No",0.9999994350104549,5.649895178735366e-07,"Yes",1.0,6.639283381288472e-22,"No",5.170574489277051e-10,0.9999999994829524,"Yes",0.9993020939030621,0.0006979060969364429,"Yes",1.0,4.1133196332489784e-20,"No",2.732197831581843e-12,0.9999999999972715,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma ","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.584947688519336e-67,1.6102049333014509e-12,0.9999999999984084,"2+",1.175060924613324e-06,0.9999988249390496,"No",0.9999994350104549,5.649895178735366e-07,"Yes",1.0,6.639283381288472e-22,"No",5.170574489277051e-10,0.9999999994829524,"Yes",0.9993020939030621,0.0006979060969364429,"Yes",1.0,4.1133196332489784e-20,"No",2.732197831581843e-12,0.9999999999972715,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinomaLUXHead & Neck 2 Estudio aleatorizado doble ciego controlado con placebo en fase III para evaluar la eficacia y la seguridad de afatinib (BIBW 2992) como terapia adyuvante tras quimio-radioterapia en pacientes no sometidos a resección primaria con carcinoma de células escamosas de cabeza y cuello con estadio III IVa o IVb locorregionalmente avanzado.","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.3768525271044694e-135,4.2899509183300045e-25,1.0,"2+",3.6555364646468375e-10,0.9999999996344968,"No",0.999999999932129,6.788731739011983e-11,"Yes",1.0,5.402257819488233e-42,"No",2.656414192071928e-22,1.0,"Yes",0.9997256062599688,0.00027439374004983814,"Yes",1.0,3.013725465712727e-44,"No",1.3187045291807056e-23,1.0,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinomaLUXHead & Neck 2 Estudio aleatorizado doble ciego controlado con placebo en fase III para evaluar la eficacia y la seguridad de afatinib (BIBW 2992) como terapia adyuvante tras quimio-radioterapia en pacientes no sometidos a resección primaria con carcinoma de células escamosas de cabeza y cuello con estadio III IVa o IVb locorregionalmente avanzado.","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.3768525271044694e-135,4.2899509183300045e-25,1.0,"2+",3.6555364646468375e-10,0.9999999996344968,"No",0.999999999932129,6.788731739011983e-11,"Yes",1.0,5.402257819488233e-42,"No",2.656414192071928e-22,1.0,"Yes",0.9997256062599688,0.00027439374004983814,"Yes",1.0,3.013725465712727e-44,"No",1.3187045291807056e-23,1.0,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients withstage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0585733007940037e-65,3.2043619652972274e-11,0.9999999999679404,"2+",1.2063607279814498e-07,0.999999879363948,"No",0.9999999346768527,6.532313972513878e-08,"Yes",1.0,1.2000321594844159e-23,"No",3.946857436665032e-09,0.9999999960531342,"Yes",0.9999711835036086,2.8816496399552428e-05,"Yes",1.0,1.4908197812621708e-21,"No",1.3794675818946365e-11,0.999999999986187,"Yes"
"2011-000392-14","LUX-Head & Neck 2A randomised double-blind placebo-controlled phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III IVa or IVb loco-regionally advanced head and neck squamous cell carcinomaLUXHead & Neck 2 Estudio aleatorizado doble ciego controlado con placebo en fase III para evaluar la eficacia y la seguridad de afatinib (BIBW 2992) como terapia adyuvante tras quimio-radioterapia en pacientes no sometidos a resección primaria con carcinoma de células escamosas de cabeza y cuello con estadio III IVa o IVb locorregionalmente avanzado.","PT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.3768525271044694e-135,4.2899509183300045e-25,1.0,"2+",3.6555364646468375e-10,0.9999999996344968,"No",0.999999999932129,6.788731739011983e-11,"Yes",1.0,5.402257819488233e-42,"No",2.656414192071928e-22,1.0,"Yes",0.9997256062599688,0.00027439374004983814,"Yes",1.0,3.013725465712727e-44,"No",1.3187045291807056e-23,1.0,"Yes"
"2011-000440-22","MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI","DK","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",5.3511232895889296e-17,0.8063529098769946,0.19364709012300865,"1",0.00013990271677662294,0.9998600972832302,"Yes",0.9998366029063871,0.00016339709361670466,"No",0.9999997789652287,2.2103476797494016e-07,"No",0.20384990597543493,0.7961500940245594,"No",0.9895685653810726,0.010431434618931425,"No",0.999999995255621,4.744384861336517e-09,"No",0.37283254147272094,0.6271674585272808,"No"
"2011-000440-22","Multicenter prospective trial estimating the persistence of molecular remission in chronic myeloid leukemia after stopping TKIMultizentrische Studie zur Abschätzung der Fortdauer der molekularen Remission beiChronischer Myeloischer Leukämie (CML) nach dem Absetzen vonTyrosinkinaseinhibitoren (TKI)","PT","No","No","Yes","ok","No","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",8.867851137707209e-35,0.7820351750252766,0.21796482497471292,"1",1.0558176585751083e-09,0.9999999989441903,"Yes",0.9999999992598135,7.401778807658462e-10,"No",1.0,7.645419194836709e-15,"No",0.12060676326477539,0.879393236735225,"No",0.9999880588603534,1.1941139653369337e-05,"No",0.9999999999998864,1.2588302267427868e-13,"No",0.8742478211148185,0.12575217888518356,"No"
"2011-000440-22","MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI","ES","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",5.3511232895889296e-17,0.8063529098769946,0.19364709012300865,"1",0.00013990271677662294,0.9998600972832302,"Yes",0.9998366029063871,0.00016339709361670466,"No",0.9999997789652287,2.2103476797494016e-07,"No",0.20384990597543493,0.7961500940245594,"No",0.9895685653810726,0.010431434618931425,"No",0.999999995255621,4.744384861336517e-09,"No",0.37283254147272094,0.6271674585272808,"No"
"2011-000440-22","MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKIEnsayo clínico multicéntrico para estimar la persistencia de la remisión molecular tras interrumpir el tratamiento con inhibidores tirosina cinasa en la leucemia mieloide crónica","NO","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",6.931684966180015e-30,0.8914268006887107,0.10857319931128802,"1",6.316571356941479e-08,0.9999999368342876,"Yes",0.9999999173306299,8.266936849128165e-08,"No",1.0,8.240809266137523e-15,"No",0.0005639049872711292,0.9994360950127165,"No",0.9997059801101815,0.00029401988981043385,"No",1.0,7.959263971791141e-20,"No",0.0012473138004199357,0.9987526861995882,"No"
"2011-000440-22","MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI","FI","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",5.3511232895889296e-17,0.8063529098769946,0.19364709012300865,"1",0.00013990271677662294,0.9998600972832302,"Yes",0.9998366029063871,0.00016339709361670466,"No",0.9999997789652287,2.2103476797494016e-07,"No",0.20384990597543493,0.7961500940245594,"No",0.9895685653810726,0.010431434618931425,"No",0.999999995255621,4.744384861336517e-09,"No",0.37283254147272094,0.6271674585272808,"No"
"2011-000440-22","MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI","SE","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",5.3511232895889296e-17,0.8063529098769946,0.19364709012300865,"1",0.00013990271677662294,0.9998600972832302,"Yes",0.9998366029063871,0.00016339709361670466,"No",0.9999997789652287,2.2103476797494016e-07,"No",0.20384990597543493,0.7961500940245594,"No",0.9895685653810726,0.010431434618931425,"No",0.999999995255621,4.744384861336517e-09,"No",0.37283254147272094,0.6271674585272808,"No"
"2011-000440-22","MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKIEnsayo clínico multicéntrico para estimar la persistencia de la remisión molecular tras interrumpir el tratamiento con inhibidores tirosina cinasa en la leucemia mieloide crónica","CZ","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",6.931684966180015e-30,0.8914268006887107,0.10857319931128802,"1",6.316571356941479e-08,0.9999999368342876,"Yes",0.9999999173306299,8.266936849128165e-08,"No",1.0,8.240809266137523e-15,"No",0.0005639049872711292,0.9994360950127165,"No",0.9997059801101815,0.00029401988981043385,"No",1.0,7.959263971791141e-20,"No",0.0012473138004199357,0.9987526861995882,"No"
"2011-000440-22","Multicenter prospective trial estimating the persistence of molecular remission in chronic myeloid leukemia after stopping TKIMultizentrische Studie zur Abschätzung der Fortdauer der molekularen Remission beiChronischer Myeloischer Leukämie (CML) nach dem Absetzen vonTyrosinkinaseinhibitoren (TKI)","AT","No","No","Yes","ok","No","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",8.867851137707209e-35,0.7820351750252766,0.21796482497471292,"1",1.0558176585751083e-09,0.9999999989441903,"Yes",0.9999999992598135,7.401778807658462e-10,"No",1.0,7.645419194836709e-15,"No",0.12060676326477539,0.879393236735225,"No",0.9999880588603534,1.1941139653369337e-05,"No",0.9999999999998864,1.2588302267427868e-13,"No",0.8742478211148185,0.12575217888518356,"No"
"2011-000493-56","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF GDC-0980 VERSUS EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE PROGRESSED ON OR FOLLOWING VEGF-TARGETED THERAPY","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5485709667553478e-39,0.005407984215987721,0.9945920157840066,"2+",4.467392950616302e-06,0.9999955326070478,"Yes",0.9999916290117811,8.370988212412716e-06,"No",1.0,2.7618461034677117e-16,"No",0.050535935954462555,0.9494640640455271,"Yes",0.9902119244797232,0.009788075520267038,"Yes",0.9999999992868142,7.131808760853781e-10,"No",0.0033659904163061117,0.9966340095836964,"Yes"
"2011-000493-56","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF GDC-0980 VERSUS EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE PROGRESSED ON OR FOLLOWING VEGF-TARGETED THERAPY","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5485709667553478e-39,0.005407984215987721,0.9945920157840066,"2+",4.467392950616302e-06,0.9999955326070478,"Yes",0.9999916290117811,8.370988212412716e-06,"No",1.0,2.7618461034677117e-16,"No",0.050535935954462555,0.9494640640455271,"Yes",0.9902119244797232,0.009788075520267038,"Yes",0.9999999992868142,7.131808760853781e-10,"No",0.0033659904163061117,0.9966340095836964,"Yes"
"2011-000493-56","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF GDC-0980 VERSUS EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE PROGRESSED ON OR FOLLOWING VEGF-TARGETED THERAPYESTUDIO DE FASE II ABIERTO RANDOMIZADO DE GDC-0980 FRENTE A EVEROLIMUS EN PACIENTES CON CARCINOMA DE CÉLULAS RENALES METASTÁSICO QUE HAN MANIFESTADO PROGRESIÓN DE LA ENFERMEDAD DURANTE O DESPUÉS DE UN TRATAMIENTO DIRIGIDO CONTRA VEGF","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.765773370939383e-75,1.254663394141961e-06,0.9999987453365888,"2+",2.495275825972155e-10,0.9999999997504574,"Yes",0.9999999993764278,6.236000230946736e-10,"No",1.0,7.481605295532286e-36,"No",0.0025054354731719524,0.9974945645268153,"Yes",0.9998804124163388,0.00011958758367361551,"Yes",1.0,2.7540149162435687e-26,"No",3.5154074147831927e-07,0.9999996484592707,"Yes"
"2011-000756-42","A phase 2 multicentre single arm pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid.Pilotstudie der Phase 2 multizentrisch bei einzelnen Gruppen zur Beurteilung der Wirksamkeit und der Sicherheit von DF2156A 150 mg zweimal täglich oral verabreicht bei Patentien die an einem bullösen Pemphigoid in der aktiven Phase leiden","IT","Yes","No","No","","No","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",6.423387893307458e-80,0.3561891268902578,0.6438108731097205,"-1",0.999451424332167,0.000548575667818638,"Information not present in EudraCT",0.0020154477392865418,0.9979845522607189,"Information not present in EudraCT",0.9999999947467587,5.253260936808154e-09,"Information not present in EudraCT",0.08282063811832295,0.9171793618816909,"No",0.008628533101908337,0.9913714668981098,"No",0.99999917698045,8.230195595509642e-07,"No",0.5932924251708559,0.4067075748291166,"No"
"2011-001015-32","A multi-centre open-label randomised twoarm Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian fallopian tube or peritoneal cancer.","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.745187218348406e-50,2.2809336451134717e-07,0.9999997719066277,"2+",1.5591664676291674e-05,0.9999844083353283,"Yes",0.9999862152048397,1.3784795151946845e-05,"No",0.9999999999996306,3.639619322959852e-13,"No",5.625004188714123e-05,0.9999437499581049,"Yes",0.25842708956152205,0.7415729104384804,"Yes",0.9999999997830002,2.1698878766564544e-10,"No",6.350411833755009e-06,0.9999936495881757,"Yes"
"2011-001015-32","A multi-centre open-label randomised twoarm Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian fallopian tube or peritoneal cancer.","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.745187218348406e-50,2.2809336451134717e-07,0.9999997719066277,"2+",1.5591664676291674e-05,0.9999844083353283,"Yes",0.9999862152048397,1.3784795151946845e-05,"No",0.9999999999996306,3.639619322959852e-13,"No",5.625004188714123e-05,0.9999437499581049,"Yes",0.25842708956152205,0.7415729104384804,"Yes",0.9999999997830002,2.1698878766564544e-10,"No",6.350411833755009e-06,0.9999936495881757,"Yes"
"2011-001015-32","A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian fallopian tube or peritoneal cancer.","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.519394573759402e-49,1.943903517300075e-08,0.9999999805609721,"2+",0.0025445995430787654,0.9974554004569158,"Yes",0.9979582140669432,0.002041785933045571,"No",0.9999999999516831,4.831323447780264e-11,"No",3.85851552972096e-06,0.999996141484471,"Yes",0.13393503159197895,0.8660649684080258,"Yes",0.9999999998340741,1.6593752991054533e-10,"No",4.918606303601396e-07,0.9999995081393609,"Yes"
"2011-001015-32","A multi-centre open-label randomised twoarm Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian fallopian tube or peritoneal cancer.","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.745187218348406e-50,2.2809336451134717e-07,0.9999997719066277,"2+",1.5591664676291674e-05,0.9999844083353283,"Yes",0.9999862152048397,1.3784795151946845e-05,"No",0.9999999999996306,3.639619322959852e-13,"No",5.625004188714123e-05,0.9999437499581049,"Yes",0.25842708956152205,0.7415729104384804,"Yes",0.9999999997830002,2.1698878766564544e-10,"No",6.350411833755009e-06,0.9999936495881757,"Yes"
"2011-001015-32","A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian fallopian tube or peritoneal cancer.","FI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.519394573759402e-49,1.943903517300075e-08,0.9999999805609721,"2+",0.0025445995430787654,0.9974554004569158,"Yes",0.9979582140669432,0.002041785933045571,"No",0.9999999999516831,4.831323447780264e-11,"No",3.85851552972096e-06,0.999996141484471,"Yes",0.13393503159197895,0.8660649684080258,"Yes",0.9999999998340741,1.6593752991054533e-10,"No",4.918606303601396e-07,0.9999995081393609,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects","DE","No","No","Yes","ok","No","No","Yes","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.93865649174147e-25,0.625675646584252,0.3743243534157426,"2+",0.30951473953618175,0.690485260463817,"Yes",0.6364264093580441,0.36357359064196176,"No",0.9999999999997016,2.927054095587858e-13,"No",0.4757609429856215,0.5242390570143747,"Yes",0.4847488462361509,0.5152511537638553,"Yes",0.9999999999297842,7.022291235117072e-11,"No",0.9903211259130779,0.009678874086919958,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC SubjectsKlinické hodnocení bezpečnosti a účinnosti fáze 3 krátkodobé léčby přípravkem Boceprevir/Peg/riba u pacientů s chronickou infekcí HCV genotypu 1 IL28B CC","HU","Yes","No","No","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1219712141259946e-58,0.00035811997327983916,0.9996418800267343,"2+",0.9017316643636297,0.09826833563635774,"Yes",0.10920014413584962,0.8907998558641385,"No",1.0,1.2679132080019635e-24,"No",0.0002069435751790419,0.9997930564248249,"Yes",0.06274064361896287,0.937259356381025,"Yes",1.0,4.677382466424043e-21,"No",0.7448650950608698,0.25513490493914154,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects","PT","No","No","Yes","ok","No","No","Yes","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.93865649174147e-25,0.625675646584252,0.3743243534157426,"2+",0.30951473953618175,0.690485260463817,"Yes",0.6364264093580441,0.36357359064196176,"No",0.9999999999997016,2.927054095587858e-13,"No",0.4757609429856215,0.5242390570143747,"Yes",0.4847488462361509,0.5152511537638553,"Yes",0.9999999999297842,7.022291235117072e-11,"No",0.9903211259130779,0.009678874086919958,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC SubjectsKlinické hodnocení bezpečnosti a účinnosti fáze 3 krátkodobé léčby přípravkem Boceprevir/Peg/riba u pacientů s chronickou infekcí HCV genotypu 1 IL28B CC","EE","Yes","No","No","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1219712141259946e-58,0.00035811997327983916,0.9996418800267343,"2+",0.9017316643636297,0.09826833563635774,"Yes",0.10920014413584962,0.8907998558641385,"No",1.0,1.2679132080019635e-24,"No",0.0002069435751790419,0.9997930564248249,"Yes",0.06274064361896287,0.937259356381025,"Yes",1.0,4.677382466424043e-21,"No",0.7448650950608698,0.25513490493914154,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects","GB","No","No","Yes","ok","No","No","Yes","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.93865649174147e-25,0.625675646584252,0.3743243534157426,"2+",0.30951473953618175,0.690485260463817,"Yes",0.6364264093580441,0.36357359064196176,"No",0.9999999999997016,2.927054095587858e-13,"No",0.4757609429856215,0.5242390570143747,"Yes",0.4847488462361509,0.5152511537638553,"Yes",0.9999999999297842,7.022291235117072e-11,"No",0.9903211259130779,0.009678874086919958,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC SubjectsKlinické hodnocení bezpečnosti a účinnosti fáze 3 krátkodobé léčby přípravkem Boceprevir/Peg/riba u pacientů s chronickou infekcí HCV genotypu 1 IL28B CC","BE","Yes","No","No","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1219712141259946e-58,0.00035811997327983916,0.9996418800267343,"2+",0.9017316643636297,0.09826833563635774,"Yes",0.10920014413584962,0.8907998558641385,"No",1.0,1.2679132080019635e-24,"No",0.0002069435751790419,0.9997930564248249,"Yes",0.06274064361896287,0.937259356381025,"Yes",1.0,4.677382466424043e-21,"No",0.7448650950608698,0.25513490493914154,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC SubjectsKlinické hodnocení bezpečnosti a účinnosti fáze 3 krátkodobé léčby přípravkem Boceprevir/Peg/riba u pacientů s chronickou infekcí HCV genotypu 1 IL28B CC","LT","Yes","No","No","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1219712141259946e-58,0.00035811997327983916,0.9996418800267343,"2+",0.9017316643636297,0.09826833563635774,"Yes",0.10920014413584962,0.8907998558641385,"No",1.0,1.2679132080019635e-24,"No",0.0002069435751790419,0.9997930564248249,"Yes",0.06274064361896287,0.937259356381025,"Yes",1.0,4.677382466424043e-21,"No",0.7448650950608698,0.25513490493914154,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects","AT","No","No","Yes","ok","No","No","Yes","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.93865649174147e-25,0.625675646584252,0.3743243534157426,"2+",0.30951473953618175,0.690485260463817,"Yes",0.6364264093580441,0.36357359064196176,"No",0.9999999999997016,2.927054095587858e-13,"No",0.4757609429856215,0.5242390570143747,"Yes",0.4847488462361509,0.5152511537638553,"Yes",0.9999999999297842,7.022291235117072e-11,"No",0.9903211259130779,0.009678874086919958,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC SubjectsKlinické hodnocení bezpečnosti a účinnosti fáze 3 krátkodobé léčby přípravkem Boceprevir/Peg/riba u pacientů s chronickou infekcí HCV genotypu 1 IL28B CC","CZ","Yes","No","No","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1219712141259946e-58,0.00035811997327983916,0.9996418800267343,"2+",0.9017316643636297,0.09826833563635774,"Yes",0.10920014413584962,0.8907998558641385,"No",1.0,1.2679132080019635e-24,"No",0.0002069435751790419,0.9997930564248249,"Yes",0.06274064361896287,0.937259356381025,"Yes",1.0,4.677382466424043e-21,"No",0.7448650950608698,0.25513490493914154,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC SubjectsKlinické hodnocení bezpečnosti a účinnosti fáze 3 krátkodobé léčby přípravkem Boceprevir/Peg/riba u pacientů s chronickou infekcí HCV genotypu 1 IL28B CC","PL","Yes","No","No","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1219712141259946e-58,0.00035811997327983916,0.9996418800267343,"2+",0.9017316643636297,0.09826833563635774,"Yes",0.10920014413584962,0.8907998558641385,"No",1.0,1.2679132080019635e-24,"No",0.0002069435751790419,0.9997930564248249,"Yes",0.06274064361896287,0.937259356381025,"Yes",1.0,4.677382466424043e-21,"No",0.7448650950608698,0.25513490493914154,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects","SE","No","No","Yes","ok","No","No","Yes","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.93865649174147e-25,0.625675646584252,0.3743243534157426,"2+",0.30951473953618175,0.690485260463817,"Yes",0.6364264093580441,0.36357359064196176,"No",0.9999999999997016,2.927054095587858e-13,"No",0.4757609429856215,0.5242390570143747,"Yes",0.4847488462361509,0.5152511537638553,"Yes",0.9999999999297842,7.022291235117072e-11,"No",0.9903211259130779,0.009678874086919958,"Yes"
"2011-001345-32","A Phase 3 Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects","ES","No","No","Yes","ok","No","No","Yes","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.93865649174147e-25,0.625675646584252,0.3743243534157426,"2+",0.30951473953618175,0.690485260463817,"Yes",0.6364264093580441,0.36357359064196176,"No",0.9999999999997016,2.927054095587858e-13,"No",0.4757609429856215,0.5242390570143747,"Yes",0.4847488462361509,0.5152511537638553,"Yes",0.9999999999297842,7.022291235117072e-11,"No",0.9903211259130779,0.009678874086919958,"Yes"
"2011-001539-21","A 2-arm prospective randomized controlled open-label 12 month Phase III trial to evaluate the efficacy of Everolimus in combination with a centre specific standard immunosuppressive regimen consisting of CNI MPA and steroids versus a  standard triple immunosuppressive regimen in lung transplant recipients","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.952363720282115e-66,1.8162199250312887e-09,0.9999999981837675,"2+",1.0250194930940274e-11,0.9999999999897398,"Yes",0.9999999999859597,1.404843256475863e-11,"No",1.0,9.565392307620881e-17,"No",1.7301312896703195e-07,0.9999998269868663,"Yes",3.472210904157261e-05,0.9999652778909669,"Yes",1.0,5.4093172361624975e-17,"No",3.1353920126783976e-08,0.9999999686460802,"Yes"
"2011-001988-52","Phase II clinical trial exploring the activity of crizotinib in patients with advanced solid tumors induced by causal alterations of specific receptors (ALK and MET/HGF receptor tyrosine kinases) expressed by cancer sells.Sperimentazione clinica di fase 2 su vari tumori per la valutazione di crizotinib (PF-02341066) in pazienti con tumori in stadio avanzato indotti da alterazioni causali di ALK e/o MET (CREATE)","IT","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",3.6701999189171164e-80,0.9929553312184423,0.007044668781569181,"1",4.7295742756808734e-18,1.0,"Information not present in EudraCT",1.0,1.420797731805277e-17,"Information not present in EudraCT",1.0,2.0597116237338847e-29,"Information not present in EudraCT",1.0,2.2902016687547824e-16,"No",0.9999998729931089,1.2700690280936537e-07,"No",1.0,7.832655173959443e-30,"No",0.9999999999979536,2.0696831194896417e-12,"No"
"2011-001988-52","Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.","PL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",4.230314864694135e-30,0.7159848958317786,0.2840151041682237,"1",2.730817407819004e-07,0.9999997269182561,"Yes",0.9999997128315798,2.8716841784320846e-07,"No",0.9999999999920135,7.975164245767627e-12,"No",0.9999649638096038,3.503619038762444e-05,"No",0.999962840917756,3.715908225011239e-05,"No",0.999999996669999,3.329998289467034e-09,"No",0.9996409463566974,0.0003590536433107177,"No"
"2011-001988-52","Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",4.230314864694135e-30,0.7159848958317786,0.2840151041682237,"1",2.730817407819004e-07,0.9999997269182561,"Yes",0.9999997128315798,2.8716841784320846e-07,"No",0.9999999999920135,7.975164245767627e-12,"No",0.9999649638096038,3.503619038762444e-05,"No",0.999962840917756,3.715908225011239e-05,"No",0.999999996669999,3.329998289467034e-09,"No",0.9996409463566974,0.0003590536433107177,"No"
"2011-001988-52","Phase II clinical trial exploring the activity of crizotinib in patients with advanced solid tumors induced by causal alterations of specific receptors (ALK and MET/HGF receptor tyrosine kinases) expressed by cancer sells.Sperimentazione clinica di fase 2 su vari tumori per la valutazione di crizotinib (PF-02341066) in pazienti con tumori in stadio avanzato indotti da alterazioni causali di ALK e/o MET (CREATE)","GB","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",3.6701999189171164e-80,0.9929553312184423,0.007044668781569181,"1",4.7295742756808734e-18,1.0,"Yes",1.0,1.420797731805277e-17,"No",1.0,2.0597116237338847e-29,"No",1.0,2.2902016687547824e-16,"No",0.9999998729931089,1.2700690280936537e-07,"No",1.0,7.832655173959443e-30,"No",0.9999999999979536,2.0696831194896417e-12,"No"
"2011-001988-52","Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.","SI","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",4.230314864694135e-30,0.7159848958317786,0.2840151041682237,"1",2.730817407819004e-07,0.9999997269182561,"Yes",0.9999997128315798,2.8716841784320846e-07,"No",0.9999999999920135,7.975164245767627e-12,"No",0.9999649638096038,3.503619038762444e-05,"No",0.999962840917756,3.715908225011239e-05,"No",0.999999996669999,3.329998289467034e-09,"No",0.9996409463566974,0.0003590536433107177,"No"
"2011-001988-52","Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",4.230314864694135e-30,0.7159848958317786,0.2840151041682237,"1",2.730817407819004e-07,0.9999997269182561,"Yes",0.9999997128315798,2.8716841784320846e-07,"No",0.9999999999920135,7.975164245767627e-12,"No",0.9999649638096038,3.503619038762444e-05,"No",0.999962840917756,3.715908225011239e-05,"No",0.999999996669999,3.329998289467034e-09,"No",0.9996409463566974,0.0003590536433107177,"No"
"2011-001988-52","Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",4.230314864694135e-30,0.7159848958317786,0.2840151041682237,"1",2.730817407819004e-07,0.9999997269182561,"Yes",0.9999997128315798,2.8716841784320846e-07,"No",0.9999999999920135,7.975164245767627e-12,"No",0.9999649638096038,3.503619038762444e-05,"No",0.999962840917756,3.715908225011239e-05,"No",0.999999996669999,3.329998289467034e-09,"No",0.9996409463566974,0.0003590536433107177,"No"
"2011-001988-52","Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.","SK","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",4.230314864694135e-30,0.7159848958317786,0.2840151041682237,"1",2.730817407819004e-07,0.9999997269182561,"Yes",0.9999997128315798,2.8716841784320846e-07,"No",0.9999999999920135,7.975164245767627e-12,"No",0.9999649638096038,3.503619038762444e-05,"No",0.999962840917756,3.715908225011239e-05,"No",0.999999996669999,3.329998289467034e-09,"No",0.9996409463566974,0.0003590536433107177,"No"
"2011-002159-32","A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy Safety and Tolerability of BIIB023 in Subjects With Lupus Nephritis","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2287584451103478e-29,1.0354040004556092e-09,0.9999999989645971,"2+",0.9999999999404423,5.955363091735949e-11,"No",2.431239406342708e-10,0.9999999997568807,"Yes",0.9999999793919161,2.0608081848589735e-08,"No",2.746810622071968e-05,0.9999725318937747,"Yes",8.957201089007748e-05,0.9999104279891098,"Yes",0.9996940585545956,0.0003059414454070135,"No",0.00021850071288210176,0.999781499287121,"Yes"
"2011-002159-32","A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy Safety and Tolerability of BIIB023 in Subjects With Lupus Nephritis","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2287584451103478e-29,1.0354040004556092e-09,0.9999999989645971,"2+",0.9999999999404423,5.955363091735949e-11,"No",2.431239406342708e-10,0.9999999997568807,"Yes",0.9999999793919161,2.0608081848589735e-08,"No",2.746810622071968e-05,0.9999725318937747,"Yes",8.957201089007748e-05,0.9999104279891098,"Yes",0.9996940585545956,0.0003059414454070135,"No",0.00021850071288210176,0.999781499287121,"Yes"
"2011-002159-32","A Multicenter Randomized Double-Blind Placebo-Controlled Study to  Evaluate the Efficacy Safety and Tolerability of BIIB023 in Subjects With  Lupus NephritisStudio multicentrico randomizzato in doppio-cieco controllato con placebo per valutare l'efficacia la sicurezza e la tollerabilitÃÂÃÂ¯ ÃÂÃÂ½  di BIIB023 in soggetti affetti da nefrite lupica","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.63338876851297e-64,5.650046779500985e-13,0.9999999999994316,"2+",1.0,2.8916749323134736e-16,"No",2.0047994630046074e-15,1.0,"Yes",0.9999999999998579,1.2947844094377827e-13,"No",4.9704682640923936e-08,0.9999999502953201,"Yes",2.349710047551397e-07,0.9999997650290019,"Yes",0.9999967754794715,3.224520541987467e-06,"No",1.884447746723995e-06,0.9999981155522583,"Yes"
"2011-002159-32","A Multicenter Randomized Double-Blind Placebo-Controlled Study to  Evaluate the Efficacy Safety and Tolerability of BIIB023 in Subjects With  Lupus NephritisStudio multicentrico randomizzato in doppio-cieco controllato con placebo per valutare l'efficacia la sicurezza e la tollerabilitÃÂÃÂ¯ ÃÂÃÂ½  di BIIB023 in soggetti affetti da nefrite lupica","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.63338876851297e-64,5.650046779500985e-13,0.9999999999994316,"2+",1.0,2.8916749323134736e-16,"No",2.0047994630046074e-15,1.0,"Yes",0.9999999999998579,1.2947844094377827e-13,"No",4.9704682640923936e-08,0.9999999502953201,"Yes",2.349710047551397e-07,0.9999997650290019,"Yes",0.9999967754794715,3.224520541987467e-06,"No",1.884447746723995e-06,0.9999981155522583,"Yes"
"2011-002159-32","A Multicenter Randomized Double-Blind Placebo-Controlled Study to  Evaluate the Efficacy Safety and Tolerability of BIIB023 in Subjects With  Lupus NephritisStudio multicentrico randomizzato in doppio-cieco controllato con placebo per valutare l'efficacia la sicurezza e la tollerabilitÃÂÃÂ¯ ÃÂÃÂ½  di BIIB023 in soggetti affetti da nefrite lupica","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.63338876851297e-64,5.650046779500985e-13,0.9999999999994316,"2+",1.0,2.8916749323134736e-16,"No",2.0047994630046074e-15,1.0,"Yes",0.9999999999998579,1.2947844094377827e-13,"No",4.9704682640923936e-08,0.9999999502953201,"Yes",2.349710047551397e-07,0.9999997650290019,"Yes",0.9999967754794715,3.224520541987467e-06,"No",1.884447746723995e-06,0.9999981155522583,"Yes"
"2011-002159-32","A Multicenter Randomized Double-Blind Placebo-Controlled Study to  Evaluate the Efficacy Safety and Tolerability of BIIB023 in Subjects With  Lupus NephritisStudio multicentrico randomizzato in doppio-cieco controllato con placebo per valutare l'efficacia la sicurezza e la tollerabilitÃÂÃÂ¯ ÃÂÃÂ½  di BIIB023 in soggetti affetti da nefrite lupica","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.63338876851297e-64,5.650046779500985e-13,0.9999999999994316,"2+",1.0,2.8916749323134736e-16,"No",2.0047994630046074e-15,1.0,"Yes",0.9999999999998579,1.2947844094377827e-13,"No",4.9704682640923936e-08,0.9999999502953201,"Yes",2.349710047551397e-07,0.9999997650290019,"Yes",0.9999967754794715,3.224520541987467e-06,"No",1.884447746723995e-06,0.9999981155522583,"Yes"
"2011-002159-32","A Multicenter Randomized Double-Blind Placebo-Controlled Study to  Evaluate the Efficacy Safety and Tolerability of BIIB023 in Subjects With  Lupus NephritisStudio multicentrico randomizzato in doppio-cieco controllato con placebo per valutare l'efficacia la sicurezza e la tollerabilitÃÂÃÂ¯ ÃÂÃÂ½  di BIIB023 in soggetti affetti da nefrite lupica","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.63338876851297e-64,5.650046779500985e-13,0.9999999999994316,"2+",1.0,2.8916749323134736e-16,"No",2.0047994630046074e-15,1.0,"Yes",0.9999999999998579,1.2947844094377827e-13,"No",4.9704682640923936e-08,0.9999999502953201,"Yes",2.349710047551397e-07,0.9999997650290019,"Yes",0.9999967754794715,3.224520541987467e-06,"No",1.884447746723995e-06,0.9999981155522583,"Yes"
"2011-002184-17","A two part double-blind randomized placebo-controlled and open-label study to investigate the efficacy safety and tolerability of eltrombopag a thrombopoietin receptor agonist in pediatric patients with previously treated chronic immune (idiopathic) thrombocytopenic purpura (ITP).Dvoudílné dvojitě zaslepené randomizované placebem kontrolované a otevřené  multicentrické hodnocení ke zjištění účinnosti bezpečnosti a snášenlivosti eltrombopagu agonisty trombopoetinového receptoru u dříve léčených dětských pacientů s  chronickou idiopatickou trombocytopenií (ITP).","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.028767576631588e-83,3.3734548401189344e-21,1.0,"2+",1.0,1.0848924847421282e-14,"No",1.0626655492602485e-12,0.99999999999892,"Yes",1.0,2.3619955056673506e-34,"No",1.2222886292018959e-15,1.0,"Yes",0.9996385330140533,0.00036146698594316615,"No",1.0,4.719343903158716e-20,"No",2.365426948977403e-10,0.9999999997634745,"Yes"
"2011-002184-17","A two part double-blind randomized placebo-controlled and open-label study to investigate the efficacy safety and tolerability of eltrombopag a thrombopoietin receptor agonist in pediatric patients with previously treated chronic immune (idiopathic) thrombocytopenic purpura (ITP).Dvoudílné dvojitě zaslepené randomizované placebem kontrolované a otevřené  multicentrické hodnocení ke zjištění účinnosti bezpečnosti a snášenlivosti eltrombopagu agonisty trombopoetinového receptoru u dříve léčených dětských pacientů s  chronickou idiopatickou trombocytopenií (ITP).","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.028767576631588e-83,3.3734548401189344e-21,1.0,"2+",1.0,1.0848924847421282e-14,"No",1.0626655492602485e-12,0.99999999999892,"Yes",1.0,2.3619955056673506e-34,"No",1.2222886292018959e-15,1.0,"Yes",0.9996385330140533,0.00036146698594316615,"No",1.0,4.719343903158716e-20,"No",2.365426948977403e-10,0.9999999997634745,"Yes"
"2011-002257-61","An open label multicenter phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) ","IT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.46581419800524e-37,0.9998874720398876,0.00011252796010702268,"1",6.351482136549324e-08,0.9999999364851838,"Information not present in EudraCT",0.9999999061129943,9.388699931547603e-08,"Information not present in EudraCT",0.999999999998181,1.8150271438795822e-12,"Information not present in EudraCT",0.9999961045789392,3.89542106554143e-06,"No",0.9992533009374903,0.0007466990625057856,"",0.9998563008822156,0.00014369911778198356,"",0.9999944212473797,5.578752616807593e-06,""
"2011-002271-42","Sofortige versus bedarfsangepasste Antibiotikatherapie beim unkomplizierten Harnwegsinfekt – eine vergleichende Effektivitätsstudie in hausärztlichen Praxen","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.511768345243499e-05,0.03109868107758919,0.9688862012389543,"2+",0.3945148165648322,0.6054851834351707,"No",0.504773663732862,0.495226336267141,"Yes",0.9980213973258274,0.0019786026741731052,"No",0.007220969778838908,0.9927790302211578,"Yes",0.3915894864821021,0.6084105135179005,"Yes",0.9971843662233453,0.002815633776655281,"No",0.0053065250318354296,0.9946934749681658,"Yes"
"2011-002329-23","A 2-Week Randomized Placebo-Controlled Fixed Dose Period Followed by a 6-Month Single-Arm Open-Label Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients with Chronic Kidney Disease","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",8.771753133818269e-58,2.0038430871799723e-05,0.9999799615691256,"2+",0.0828839819768473,0.917116018023154,"Yes",0.9638818662789613,0.03611813372105026,"No",0.9999997741602129,2.2583978288369398e-07,"No",7.062551383568814e-06,0.9999929374486242,"Yes",0.010399736241870678,0.9896002637581431,"Yes",0.6482218962668498,0.3517781037331387,"No",5.540488494337699e-05,0.9999445951150606,"Yes"
"2011-002329-23","A 2-Week Randomized Placebo-Controlled Fixed Dose Period Followed by a 6-Month Single-Arm Open-Label Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients with Chronic Kidney Disease","LT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",8.771753133818269e-58,2.0038430871799723e-05,0.9999799615691256,"2+",0.0828839819768473,0.917116018023154,"Yes",0.9638818662789613,0.03611813372105026,"No",0.9999997741602129,2.2583978288369398e-07,"No",7.062551383568814e-06,0.9999929374486242,"Yes",0.010399736241870678,0.9896002637581431,"Yes",0.6482218962668498,0.3517781037331387,"No",5.540488494337699e-05,0.9999445951150606,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.861893935217719e-58,3.094443374622857e-05,0.9999690555662507,"2+",3.196876472242114e-11,0.9999999999680257,"Yes",0.9999999998928502,1.0713660718184935e-10,"No",1.0,1.8697624600234952e-26,"No",0.0044960895844448285,0.9955039104155676,"Yes",0.9040053673509335,0.09599463264907089,"Yes",0.9999999998858584,1.141312877358862e-10,"No",3.176000403364851e-05,0.9999682399959675,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapyLUX-Lung 8: Ensayo clínico de fase III abierto aleatorizado de afatinib versus erlotinib en pacientes con carcinoma escamoso de pulmón como segunda línea de tratamiento tras quimioterapia basada en platino en primera línea","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.772016002230126e-99,2.166871767550959e-10,0.999999999783313,"2+",1.4148821117310972e-19,1.0,"Yes",1.0,9.122503641119011e-19,"No",1.0,4.84416653700993e-44,"No",8.333295360821302e-07,0.9999991666704835,"Yes",0.8610286120573785,0.13897138794260455,"Yes",1.0,1.9327083416626679e-32,"No",1.3921142490183574e-09,0.9999999986079047,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapyLUX-Lung 8: Ensayo clínico de fase III abierto aleatorizado de afatinib versus erlotinib en pacientes con carcinoma escamoso de pulmón como segunda línea de tratamiento tras quimioterapia basada en platino en primera línea","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.772016002230126e-99,2.166871767550959e-10,0.999999999783313,"2+",1.4148821117310972e-19,1.0,"Yes",1.0,9.122503641119011e-19,"No",1.0,4.84416653700993e-44,"No",8.333295360821302e-07,0.9999991666704835,"Yes",0.8610286120573785,0.13897138794260455,"Yes",1.0,1.9327083416626679e-32,"No",1.3921142490183574e-09,0.9999999986079047,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapyLUX-Lung 8: Ensayo clínico de fase III abierto aleatorizado de afatinib versus erlotinib en pacientes con carcinoma escamoso de pulmón como segunda línea de tratamiento tras quimioterapia basada en platino en primera línea","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.772016002230126e-99,2.166871767550959e-10,0.999999999783313,"2+",1.4148821117310972e-19,1.0,"Yes",1.0,9.122503641119011e-19,"No",1.0,4.84416653700993e-44,"No",8.333295360821302e-07,0.9999991666704835,"Yes",0.8610286120573785,0.13897138794260455,"Yes",1.0,1.9327083416626679e-32,"No",1.3921142490183574e-09,0.9999999986079047,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapyLUX-Lung 8: Ensayo clínico de fase III abierto aleatorizado de afatinib versus erlotinib en pacientes con carcinoma escamoso de pulmón como segunda línea de tratamiento tras quimioterapia basada en platino en primera línea","IE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.772016002230126e-99,2.166871767550959e-10,0.999999999783313,"2+",1.4148821117310972e-19,1.0,"Yes",1.0,9.122503641119011e-19,"No",1.0,4.84416653700993e-44,"No",8.333295360821302e-07,0.9999991666704835,"Yes",0.8610286120573785,0.13897138794260455,"Yes",1.0,1.9327083416626679e-32,"No",1.3921142490183574e-09,0.9999999986079047,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapyLUX-Lung 8: Ensayo clínico de fase III abierto aleatorizado de afatinib versus erlotinib en pacientes con carcinoma escamoso de pulmón como segunda línea de tratamiento tras quimioterapia basada en platino en primera línea","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.772016002230126e-99,2.166871767550959e-10,0.999999999783313,"2+",1.4148821117310972e-19,1.0,"Yes",1.0,9.122503641119011e-19,"No",1.0,4.84416653700993e-44,"No",8.333295360821302e-07,0.9999991666704835,"Yes",0.8610286120573785,0.13897138794260455,"Yes",1.0,1.9327083416626679e-32,"No",1.3921142490183574e-09,0.9999999986079047,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.861893935217719e-58,3.094443374622857e-05,0.9999690555662507,"2+",3.196876472242114e-11,0.9999999999680257,"Yes",0.9999999998928502,1.0713660718184935e-10,"No",1.0,1.8697624600234952e-26,"No",0.0044960895844448285,0.9955039104155676,"Yes",0.9040053673509335,0.09599463264907089,"Yes",0.9999999998858584,1.141312877358862e-10,"No",3.176000403364851e-05,0.9999682399959675,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.861893935217719e-58,3.094443374622857e-05,0.9999690555662507,"2+",3.196876472242114e-11,0.9999999999680257,"Yes",0.9999999998928502,1.0713660718184935e-10,"No",1.0,1.8697624600234952e-26,"No",0.0044960895844448285,0.9955039104155676,"Yes",0.9040053673509335,0.09599463264907089,"Yes",0.9999999998858584,1.141312877358862e-10,"No",3.176000403364851e-05,0.9999682399959675,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapyLUX-Lung 8: Ensayo clínico de fase III abierto aleatorizado de afatinib versus erlotinib en pacientes con carcinoma escamoso de pulmón como segunda línea de tratamiento tras quimioterapia basada en platino en primera línea","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.772016002230126e-99,2.166871767550959e-10,0.999999999783313,"2+",1.4148821117310972e-19,1.0,"Yes",1.0,9.122503641119011e-19,"No",1.0,4.84416653700993e-44,"No",8.333295360821302e-07,0.9999991666704835,"Yes",0.8610286120573785,0.13897138794260455,"Yes",1.0,1.9327083416626679e-32,"No",1.3921142490183574e-09,0.9999999986079047,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapyLUX-Lung 8: Ensayo clínico de fase III abierto aleatorizado de afatinib versus erlotinib en pacientes con carcinoma escamoso de pulmón como segunda línea de tratamiento tras quimioterapia basada en platino en primera línea","PT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.772016002230126e-99,2.166871767550959e-10,0.999999999783313,"2+",1.4148821117310972e-19,1.0,"Yes",1.0,9.122503641119011e-19,"No",1.0,4.84416653700993e-44,"No",8.333295360821302e-07,0.9999991666704835,"Yes",0.8610286120573785,0.13897138794260455,"Yes",1.0,1.9327083416626679e-32,"No",1.3921142490183574e-09,0.9999999986079047,"Yes"
"2011-002380-24","LUX-Lung 8: A randomized open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.861893935217719e-58,3.094443374622857e-05,0.9999690555662507,"2+",3.196876472242114e-11,0.9999999999680257,"Yes",0.9999999998928502,1.0713660718184935e-10,"No",1.0,1.8697624600234952e-26,"No",0.0044960895844448285,0.9955039104155676,"Yes",0.9040053673509335,0.09599463264907089,"Yes",0.9999999998858584,1.141312877358862e-10,"No",3.176000403364851e-05,0.9999682399959675,"Yes"
"2011-002669-40","A Phase 2 Multi-center Randomized Double-blindPlacebo-controlled Clinical Trial to Evaluate theSafety and Efficacy of ALD518 in the Reduction ofOral Mucositis in Subjects With Head and NeckCancer Receiving Concomitant Chemotherapy andRadiotherapy","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0854660989095505e-42,3.183450872849452e-06,0.9999968165491364,"2+",0.9999085633295504,9.14366704481359e-05,"No",7.112387575455658e-05,0.9999288761242484,"Yes",0.9999999986222862,1.3777273399395173e-09,"No",5.218449501348977e-05,0.999947815504984,"Yes",0.13889788841216427,0.8611021115878318,"Yes",0.9999999997955911,2.0442115672767373e-10,"No",1.432369638002525e-05,0.9999856763036062,"Yes"
"2011-002669-40","A Phase 2 Multi-center Randomized Double-blindPlacebo-controlled Clinical Trial to Evaluate theSafety and Efficacy of ALD518 in the Reduction ofOral Mucositis in Subjects With Head and NeckCancer Receiving Concomitant Chemotherapy andRadiotherapy","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0854660989095505e-42,3.183450872849452e-06,0.9999968165491364,"2+",0.9999085633295504,9.14366704481359e-05,"No",7.112387575455658e-05,0.9999288761242484,"Yes",0.9999999986222862,1.3777273399395173e-09,"No",5.218449501348977e-05,0.999947815504984,"Yes",0.13889788841216427,0.8611021115878318,"Yes",0.9999999997955911,2.0442115672767373e-10,"No",1.432369638002525e-05,0.9999856763036062,"Yes"
"2011-002669-40","A Phase 2 Multi-center Randomized Double-blindPlacebo-controlled Clinical Trial to Evaluate theSafety and Efficacy of ALD518 in the Reduction ofOral Mucositis in Subjects With Head and NeckCancer Receiving Concomitant Chemotherapy andRadiotherapy","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0854660989095505e-42,3.183450872849452e-06,0.9999968165491364,"2+",0.9999085633295504,9.14366704481359e-05,"No",7.112387575455658e-05,0.9999288761242484,"Yes",0.9999999986222862,1.3777273399395173e-09,"No",5.218449501348977e-05,0.999947815504984,"Yes",0.13889788841216427,0.8611021115878318,"Yes",0.9999999997955911,2.0442115672767373e-10,"No",1.432369638002525e-05,0.9999856763036062,"Yes"
"2011-002715-28","A PHASE II RANDOMIZED DOUBLE-BLINDMULTICENTER ACTIVE-CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH TELAPREVIR AND PEGASYS/COPEGUS COMPARED WITH TELAPREVIR ANDPEGASYS/COPEGUS IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 VIRUS INFECTION WHO WERE PRIOR NULL RESPONDERS TO TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN.STUDIO DI FASE II RANDOMIZZATO IN DOPPIO CIECO MULTICENTRICO CONTROLLATO CON FARMACO ATTIVO A GRUPPI PARALLELI PER LA VALUTAZIONE DELLA RISPOSTA VIROLOGICA SOSTENUTA AL PROFARMACO DELL` INIBITORE DELLA POLIMERASI DI HCV RO5024048 IN COMBINAZIONE CON TELAPREVIR E PEGASYS/COPEGUS RISPETTO A TELAPREVIR E PEGASYS/COPEGUS IN PAZIENTI CON INFEZIONE DA EPATITE C CRONICA DI GENOTIPO 1 CHE HANNO RIPORTATO UNA RISPOSTA NULLA (NULL RESPONDERS) AL TRATTAMENTO PRECEDENTE CON INTERFERONE PEGILATO/RIBAVIRINA.","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.198728340579566e-173,8.358402194669594e-12,0.9999999999915872,"2+",0.011257327578887595,0.9887426724211492,"No",0.9654715931559502,0.03452840684401004,"Yes",1.0,3.227500133626373e-68,"No",3.210332030520515e-14,1.0,"Yes",2.411259773694633e-06,0.9999975887402083,"Yes",1.0,6.230739288214825e-74,"No",2.36401688401915e-11,0.9999999999763532,"Yes"
"2011-002715-28","A PHASE II RANDOMIZED DOUBLE-BLINDMULTICENTER ACTIVE-CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH TELAPREVIR AND PEGASYS/COPEGUS COMPARED WITH TELAPREVIR ANDPEGASYS/COPEGUS IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 VIRUS INFECTION WHO WERE PRIOR NULL RESPONDERS TO TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN.STUDIO DI FASE II RANDOMIZZATO IN DOPPIO CIECO MULTICENTRICO CONTROLLATO CON FARMACO ATTIVO A GRUPPI PARALLELI PER LA VALUTAZIONE DELLA RISPOSTA VIROLOGICA SOSTENUTA AL PROFARMACO DELL` INIBITORE DELLA POLIMERASI DI HCV RO5024048 IN COMBINAZIONE CON TELAPREVIR E PEGASYS/COPEGUS RISPETTO A TELAPREVIR E PEGASYS/COPEGUS IN PAZIENTI CON INFEZIONE DA EPATITE C CRONICA DI GENOTIPO 1 CHE HANNO RIPORTATO UNA RISPOSTA NULLA (NULL RESPONDERS) AL TRATTAMENTO PRECEDENTE CON INTERFERONE PEGILATO/RIBAVIRINA.","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.198728340579566e-173,8.358402194669594e-12,0.9999999999915872,"2+",0.011257327578887595,0.9887426724211492,"No",0.9654715931559502,0.03452840684401004,"Yes",1.0,3.227500133626373e-68,"No",3.210332030520515e-14,1.0,"Yes",2.411259773694633e-06,0.9999975887402083,"Yes",1.0,6.230739288214825e-74,"No",2.36401688401915e-11,0.9999999999763532,"Yes"
"2011-002715-28","A PHASE II RANDOMIZED DOUBLE-BLINDMULTICENTER ACTIVE-CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH TELAPREVIR AND PEGASYS/COPEGUS COMPARED WITH TELAPREVIR ANDPEGASYS/COPEGUS IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 VIRUS INFECTION WHO WERE PRIOR NULL RESPONDERS TO TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN.STUDIO DI FASE II RANDOMIZZATO IN DOPPIO CIECO MULTICENTRICO CONTROLLATO CON FARMACO ATTIVO A GRUPPI PARALLELI PER LA VALUTAZIONE DELLA RISPOSTA VIROLOGICA SOSTENUTA AL PROFARMACO DELL` INIBITORE DELLA POLIMERASI DI HCV RO5024048 IN COMBINAZIONE CON TELAPREVIR E PEGASYS/COPEGUS RISPETTO A TELAPREVIR E PEGASYS/COPEGUS IN PAZIENTI CON INFEZIONE DA EPATITE C CRONICA DI GENOTIPO 1 CHE HANNO RIPORTATO UNA RISPOSTA NULLA (NULL RESPONDERS) AL TRATTAMENTO PRECEDENTE CON INTERFERONE PEGILATO/RIBAVIRINA.","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.198728340579566e-173,8.358402194669594e-12,0.9999999999915872,"2+",0.011257327578887595,0.9887426724211492,"No",0.9654715931559502,0.03452840684401004,"Yes",1.0,3.227500133626373e-68,"No",3.210332030520515e-14,1.0,"Yes",2.411259773694633e-06,0.9999975887402083,"Yes",1.0,6.230739288214825e-74,"No",2.36401688401915e-11,0.9999999999763532,"Yes"
"2011-002715-28","A PHASE II RANDOMIZED DOUBLE-BLINDMULTICENTER ACTIVE-CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH TELAPREVIR AND PEGASYS/COPEGUS COMPARED WITH TELAPREVIR ANDPEGASYS/COPEGUS IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 VIRUS INFECTION WHO WERE PRIOR NULL RESPONDERS TO TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN.STUDIO DI FASE II RANDOMIZZATO IN DOPPIO CIECO MULTICENTRICO CONTROLLATO CON FARMACO ATTIVO A GRUPPI PARALLELI PER LA VALUTAZIONE DELLA RISPOSTA VIROLOGICA SOSTENUTA AL PROFARMACO DELL` INIBITORE DELLA POLIMERASI DI HCV RO5024048 IN COMBINAZIONE CON TELAPREVIR E PEGASYS/COPEGUS RISPETTO A TELAPREVIR E PEGASYS/COPEGUS IN PAZIENTI CON INFEZIONE DA EPATITE C CRONICA DI GENOTIPO 1 CHE HANNO RIPORTATO UNA RISPOSTA NULLA (NULL RESPONDERS) AL TRATTAMENTO PRECEDENTE CON INTERFERONE PEGILATO/RIBAVIRINA.","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.198728340579566e-173,8.358402194669594e-12,0.9999999999915872,"2+",0.011257327578887595,0.9887426724211492,"No",0.9654715931559502,0.03452840684401004,"Yes",1.0,3.227500133626373e-68,"No",3.210332030520515e-14,1.0,"Yes",2.411259773694633e-06,0.9999975887402083,"Yes",1.0,6.230739288214825e-74,"No",2.36401688401915e-11,0.9999999999763532,"Yes"
"2011-002843-92","Multicentre randomised controlled open-label study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses  of Doxorubicin TransdrugTM (DT) (20 mg/m² or 30 mg/m²) to those of best standard of care (BSC) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib - ReLive StudyEstudio abierto controlado aleatorizado y multicéntrico que compara la eficacia y la seguridad de infusiones intravenosas lentas repetidas de 2 dosis de doxorrubicina Transdrug (DT) (20 mg/m2 o 30 mg/m2) con las del mejor tratamiento de referencia (MTR) en pacientes con carcinoma hepatocelular avanzado (CHC) tras fracaso o intolerancia a sorafenib. Estudio ReLive","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.1494367504246586e-116,6.2772581484728394e-09,0.9999999937227814,"2+",1.2358929327603406e-09,0.9999999987641105,"Yes",0.9999999997271516,2.7282648000136724e-10,"No",1.0,2.0065232802046857e-31,"No",1.2258294353527489e-05,0.9999877417056816,"Yes",0.9965105147442579,0.0034894852557047864,"Yes",1.0,4.979029151509088e-25,"No",1.998087450254346e-08,0.9999999800190837,"Yes"
"2011-002843-92","Multicentre randomised controlled open-label study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses  of Doxorubicin TransdrugTM (DT) (20 mg/m² or 30 mg/m²) to those of best standard of care (BSC) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib - ReLive StudyEstudio abierto controlado aleatorizado y multicéntrico que compara la eficacia y la seguridad de infusiones intravenosas lentas repetidas de 2 dosis de doxorrubicina Transdrug (DT) (20 mg/m2 o 30 mg/m2) con las del mejor tratamiento de referencia (MTR) en pacientes con carcinoma hepatocelular avanzado (CHC) tras fracaso o intolerancia a sorafenib. Estudio ReLive","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.1494367504246586e-116,6.2772581484728394e-09,0.9999999937227814,"2+",1.2358929327603406e-09,0.9999999987641105,"Yes",0.9999999997271516,2.7282648000136724e-10,"No",1.0,2.0065232802046857e-31,"No",1.2258294353527489e-05,0.9999877417056816,"Yes",0.9965105147442579,0.0034894852557047864,"Yes",1.0,4.979029151509088e-25,"No",1.998087450254346e-08,0.9999999800190837,"Yes"
"2011-002843-92","Multicentre randomised controlled open-label study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses  of Doxorubicin TransdrugTM (DT) (20 mg/m² or 30 mg/m²) to those of best standard of care (BSC) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib - ReLive StudyEstudio abierto controlado aleatorizado y multicéntrico que compara la eficacia y la seguridad de infusiones intravenosas lentas repetidas de 2 dosis de doxorrubicina Transdrug (DT) (20 mg/m2 o 30 mg/m2) con las del mejor tratamiento de referencia (MTR) en pacientes con carcinoma hepatocelular avanzado (CHC) tras fracaso o intolerancia a sorafenib. Estudio ReLive","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.1494367504246586e-116,6.2772581484728394e-09,0.9999999937227814,"2+",1.2358929327603406e-09,0.9999999987641105,"Yes",0.9999999997271516,2.7282648000136724e-10,"No",1.0,2.0065232802046857e-31,"No",1.2258294353527489e-05,0.9999877417056816,"Yes",0.9965105147442579,0.0034894852557047864,"Yes",1.0,4.979029151509088e-25,"No",1.998087450254346e-08,0.9999999800190837,"Yes"
"2011-002843-92","Multicentre randomised controlled open-label study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses  of Doxorubicin Transdrug™ (DT) (20 mg/m² or 30 mg/m²) to those of best standard of care (BSC) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib - ReLive Study","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.1437752984887134e-54,4.186058390554344e-09,0.9999999958139371,"2+",0.025570296400626087,0.9744297035993873,"Yes",0.9877504541213926,0.012249545878633885,"No",1.0,5.0971316977463674e-18,"No",4.125288225494769e-06,0.9999958747117542,"Yes",0.5223004893106786,0.4776995106893159,"Yes",0.9999999835857241,1.6414258976457944e-08,"No",2.094833960012722e-08,0.9999999790516656,"Yes"
"2011-002843-92","Multicentre randomised controlled open-label study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses  of Doxorubicin Transdrug™ (DT) (20 mg/m² or 30 mg/m²) to those of best standard of care (BSC) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib - ReLive Study","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.1437752984887134e-54,4.186058390554344e-09,0.9999999958139371,"2+",0.025570296400626087,0.9744297035993873,"Yes",0.9877504541213926,0.012249545878633885,"No",1.0,5.0971316977463674e-18,"No",4.125288225494769e-06,0.9999958747117542,"Yes",0.5223004893106786,0.4776995106893159,"Yes",0.9999999835857241,1.6414258976457944e-08,"No",2.094833960012722e-08,0.9999999790516656,"Yes"
"2011-002843-92","Multicentre randomised controlled open-label study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses  of Doxorubicin Transdrug™ (DT) (20 mg/m² or 30 mg/m²) to those of best standard of care (BSC) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib - ReLive Study","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.1437752984887134e-54,4.186058390554344e-09,0.9999999958139371,"2+",0.025570296400626087,0.9744297035993873,"Yes",0.9877504541213926,0.012249545878633885,"No",1.0,5.0971316977463674e-18,"No",4.125288225494769e-06,0.9999958747117542,"Yes",0.5223004893106786,0.4776995106893159,"Yes",0.9999999835857241,1.6414258976457944e-08,"No",2.094833960012722e-08,0.9999999790516656,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.2672659589936657e-51,6.744388619839105e-13,0.9999999999993179,"2+",0.9924835526123806,0.007516447387629631,"No",0.01328923661255591,0.9867107633874339,"Yes",1.0,1.7645485987928965e-22,"No",7.520379982209853e-10,0.9999999992479617,"Yes",0.0012945692415541146,0.9987054307584327,"Yes",0.9999999996154543,3.845560450745413e-10,"No",3.558685356211745e-11,0.999999999964416,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origineen gerandomiseerde dubbelblinde multicentrum fase 3 studie naar everolimus (RAD001) met maximaal ondersteunende therapie in vergelijking met placebo met maximaal ondersteunende therapie plus in patiënten met gevorderde NET afkomstig uit GI of long.","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.302299610057418e-85,1.6804319992815904e-14,1.0,"2+",0.19867820009408824,0.8013217999059339,"No",0.9371184807733092,0.06288151922668746,"Yes",1.0,7.047619914710117e-28,"No",1.3605342276295642e-11,0.9999999999864144,"Yes",0.621721326513408,0.37827867348659183,"Yes",0.9999999999729425,2.7081345360249974e-11,"No",7.455862720014092e-10,0.9999999992544417,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.2672659589936657e-51,6.744388619839105e-13,0.9999999999993179,"2+",0.9924835526123806,0.007516447387629631,"No",0.01328923661255591,0.9867107633874339,"Yes",1.0,1.7645485987928965e-22,"No",7.520379982209853e-10,0.9999999992479617,"Yes",0.0012945692415541146,0.9987054307584327,"Yes",0.9999999996154543,3.845560450745413e-10,"No",3.558685356211745e-11,0.999999999964416,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung originEstudio fase III aleatorizado doble ciego multicéntrico de everolimus (RAD001) más el mejor tratamiento de soporte frente al mejor tratamiento de soporte en el tratamiento de pacientes con NET avanzados de origen GI o pulmonar-RADIANT-4","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1249812377312008e-89,5.484114324643425e-22,1.0,"2+",0.9974787193436819,0.0025212806563340525,"No",0.007303923549173787,0.9926960764508158,"Yes",1.0,1.3640411309354335e-36,"No",1.9816302543113584e-18,1.0,"Yes",3.2411882640605615e-05,0.9999675881173722,"Yes",1.0,3.4778453443387734e-25,"No",5.153504905427616e-19,1.0,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung originEstudio fase III aleatorizado doble ciego multicéntrico de everolimus (RAD001) más el mejor tratamiento de soporte frente al mejor tratamiento de soporte en el tratamiento de pacientes con NET avanzados de origen GI o pulmonar-RADIANT-4","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1249812377312008e-89,5.484114324643425e-22,1.0,"2+",0.9974787193436819,0.0025212806563340525,"No",0.007303923549173787,0.9926960764508158,"Yes",1.0,1.3640411309354335e-36,"No",1.9816302543113584e-18,1.0,"Yes",3.2411882640605615e-05,0.9999675881173722,"Yes",1.0,3.4778453443387734e-25,"No",5.153504905427616e-19,1.0,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origineen gerandomiseerde dubbelblinde multicentrum fase 3 studie naar everolimus (RAD001) met maximaal ondersteunende therapie in vergelijking met placebo met maximaal ondersteunende therapie plus in patiënten met gevorderde NET afkomstig uit GI of long.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.302299610057418e-85,1.6804319992815904e-14,1.0,"2+",0.19867820009408824,0.8013217999059339,"No",0.9371184807733092,0.06288151922668746,"Yes",1.0,7.047619914710117e-28,"No",1.3605342276295642e-11,0.9999999999864144,"Yes",0.621721326513408,0.37827867348659183,"Yes",0.9999999999729425,2.7081345360249974e-11,"No",7.455862720014092e-10,0.9999999992544417,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origineen gerandomiseerde dubbelblinde multicentrum fase 3 studie naar everolimus (RAD001) met maximaal ondersteunende therapie in vergelijking met placebo met maximaal ondersteunende therapie plus in patiënten met gevorderde NET afkomstig uit GI of long.","NO","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.302299610057418e-85,1.6804319992815904e-14,1.0,"2+",0.19867820009408824,0.8013217999059339,"No",0.9371184807733092,0.06288151922668746,"Yes",1.0,7.047619914710117e-28,"No",1.3605342276295642e-11,0.9999999999864144,"Yes",0.621721326513408,0.37827867348659183,"Yes",0.9999999999729425,2.7081345360249974e-11,"No",7.455862720014092e-10,0.9999999992544417,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung originEstudio fase III aleatorizado doble ciego multicéntrico de everolimus (RAD001) más el mejor tratamiento de soporte frente al mejor tratamiento de soporte en el tratamiento de pacientes con NET avanzados de origen GI o pulmonar-RADIANT-4","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1249812377312008e-89,5.484114324643425e-22,1.0,"2+",0.9974787193436819,0.0025212806563340525,"No",0.007303923549173787,0.9926960764508158,"Yes",1.0,1.3640411309354335e-36,"No",1.9816302543113584e-18,1.0,"Yes",3.2411882640605615e-05,0.9999675881173722,"Yes",1.0,3.4778453443387734e-25,"No",5.153504905427616e-19,1.0,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.2672659589936657e-51,6.744388619839105e-13,0.9999999999993179,"2+",0.9924835526123806,0.007516447387629631,"No",0.01328923661255591,0.9867107633874339,"Yes",1.0,1.7645485987928965e-22,"No",7.520379982209853e-10,0.9999999992479617,"Yes",0.0012945692415541146,0.9987054307584327,"Yes",0.9999999996154543,3.845560450745413e-10,"No",3.558685356211745e-11,0.999999999964416,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung originEstudio fase III aleatorizado doble ciego multicéntrico de everolimus (RAD001) más el mejor tratamiento de soporte frente al mejor tratamiento de soporte en el tratamiento de pacientes con NET avanzados de origen GI o pulmonar-RADIANT-4","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1249812377312008e-89,5.484114324643425e-22,1.0,"2+",0.9974787193436819,0.0025212806563340525,"No",0.007303923549173787,0.9926960764508158,"Yes",1.0,1.3640411309354335e-36,"No",1.9816302543113584e-18,1.0,"Yes",3.2411882640605615e-05,0.9999675881173722,"Yes",1.0,3.4778453443387734e-25,"No",5.153504905427616e-19,1.0,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of  everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung originStudio di Fase III multicentrico randomizzato in doppio cieco per confrontare everolimus (RAD001) associato alla miglior terapia di supporto verso placebo associato alla  miglior terapia di supporto per il trattamento di pazienti con NET in stadio avanzato di origine gastrointestinale o polmonare","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4172928590405291e-114,1.9274985183793908e-20,1.0,"2+",0.9950039679837668,0.00499603201621042,"No",0.004289959636264171,0.9957100403637327,"Yes",1.0,3.060338304051778e-48,"No",9.272609961159141e-18,1.0,"Yes",6.763644545454975e-08,0.999999932363553,"Yes",1.0,4.1650943050251564e-30,"No",2.3492723803250114e-17,1.0,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of  everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung originStudio di Fase III multicentrico randomizzato in doppio cieco per confrontare everolimus (RAD001) associato alla miglior terapia di supporto verso placebo associato alla  miglior terapia di supporto per il trattamento di pazienti con NET in stadio avanzato di origine gastrointestinale o polmonare","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4172928590405291e-114,1.9274985183793908e-20,1.0,"2+",0.9950039679837668,0.00499603201621042,"No",0.004289959636264171,0.9957100403637327,"Yes",1.0,3.060338304051778e-48,"No",9.272609961159141e-18,1.0,"Yes",6.763644545454975e-08,0.999999932363553,"Yes",1.0,4.1650943050251564e-30,"No",2.3492723803250114e-17,1.0,"Yes"
"2011-002887-26","A randomized double-blind multicenter Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origineen gerandomiseerde dubbelblinde multicentrum fase 3 studie naar everolimus (RAD001) met maximaal ondersteunende therapie in vergelijking met placebo met maximaal ondersteunende therapie plus in patiënten met gevorderde NET afkomstig uit GI of long.","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.302299610057418e-85,1.6804319992815904e-14,1.0,"2+",0.19867820009408824,0.8013217999059339,"No",0.9371184807733092,0.06288151922668746,"Yes",1.0,7.047619914710117e-28,"No",1.3605342276295642e-11,0.9999999999864144,"Yes",0.621721326513408,0.37827867348659183,"Yes",0.9999999999729425,2.7081345360249974e-11,"No",7.455862720014092e-10,0.9999999992544417,"Yes"
"2011-003130-14","A placebo-controlled double-blind randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.244074899362029e-38,1.1406307253417216e-06,0.9999988593692817,"2+",0.9999998566698839,1.4333011817749404e-07,"No",7.405942024813223e-07,0.9999992594058015,"Yes",0.9999999998117489,1.882477222103935e-10,"No",1.728015612755987e-06,0.9999982719843823,"Yes",0.009710263585243725,0.9902897364147575,"No",0.9998951221097635,0.0001048778902340739,"No",1.5391266451016665e-05,0.9999846087335549,"Yes"
"2011-003130-14","A placebo-controlled double-blind randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.244074899362029e-38,1.1406307253417216e-06,0.9999988593692817,"2+",0.9999998566698839,1.4333011817749404e-07,"No",7.405942024813223e-07,0.9999992594058015,"Yes",0.9999999998117489,1.882477222103935e-10,"No",1.728015612755987e-06,0.9999982719843823,"Yes",0.009710263585243725,0.9902897364147575,"No",0.9998951221097635,0.0001048778902340739,"No",1.5391266451016665e-05,0.9999846087335549,"Yes"
"2011-003130-14","A placebo-controlled double-blind randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.244074899362029e-38,1.1406307253417216e-06,0.9999988593692817,"2+",0.9999998566698839,1.4333011817749404e-07,"No",7.405942024813223e-07,0.9999992594058015,"Yes",0.9999999998117489,1.882477222103935e-10,"No",1.728015612755987e-06,0.9999982719843823,"Yes",0.009710263585243725,0.9902897364147575,"No",0.9998951221097635,0.0001048778902340739,"No",1.5391266451016665e-05,0.9999846087335549,"Yes"
"2011-003130-14","A placebo-controlled double-blind randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.244074899362029e-38,1.1406307253417216e-06,0.9999988593692817,"2+",0.9999998566698839,1.4333011817749404e-07,"No",7.405942024813223e-07,0.9999992594058015,"Yes",0.9999999998117489,1.882477222103935e-10,"No",1.728015612755987e-06,0.9999982719843823,"Yes",0.009710263585243725,0.9902897364147575,"No",0.9998951221097635,0.0001048778902340739,"No",1.5391266451016665e-05,0.9999846087335549,"Yes"
"2011-003130-14","A placebo-controlled double-blind randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.244074899362029e-38,1.1406307253417216e-06,0.9999988593692817,"2+",0.9999998566698839,1.4333011817749404e-07,"No",7.405942024813223e-07,0.9999992594058015,"Yes",0.9999999998117489,1.882477222103935e-10,"No",1.728015612755987e-06,0.9999982719843823,"Yes",0.009710263585243725,0.9902897364147575,"No",0.9998951221097635,0.0001048778902340739,"No",1.5391266451016665e-05,0.9999846087335549,"Yes"
"2011-003130-14","A placebo-controlled double-blind randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.244074899362029e-38,1.1406307253417216e-06,0.9999988593692817,"2+",0.9999998566698839,1.4333011817749404e-07,"No",7.405942024813223e-07,0.9999992594058015,"Yes",0.9999999998117489,1.882477222103935e-10,"No",1.728015612755987e-06,0.9999982719843823,"Yes",0.009710263585243725,0.9902897364147575,"No",0.9998951221097635,0.0001048778902340739,"No",1.5391266451016665e-05,0.9999846087335549,"Yes"
"2011-003168-63","Phase-II study evaluating midostaurin in induction consolidation andmaintenance therapy also after allogeneic blood stem cell transplantationin patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication AMLSG 16-10Phase II Studie zu Midostaurin in der Induktions- Konsolidierungs- undErhaltungstherapie sowie nach allogener Blutstammzelltransplantation bei Patienten mit neu diagnostizierter akuter myeloischer Leukämie undNachweis einer internen Tandemduplikation des FLT3-Gens","DE","No","No","Yes","ok","No","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.365953163426757e-64,0.00020245438199948762,0.9997975456179783,"1",3.6414514185129653e-07,0.9999996358548724,"Yes",0.999998187911381,1.8120886068068278e-06,"No",1.0,8.872744087632645e-29,"No",1.2275885840177587e-06,0.9999987724114167,"No",0.9999998266156505,1.733843461485921e-07,"No",1.0,2.9569545376553846e-22,"No",0.8419222253637051,0.15807777463631462,"No"
"2011-003179-12","Mineralocorticoid Receptor antagonists in End stage reNal DiseAse ","DE","No","No","Yes","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.256133479792889e-13,0.002814809733571974,0.9971851902655046,"2+",0.2517626598058492,0.7482373401941539,"No",0.7434933382615699,0.2565066617384303,"Yes",0.9971100488497682,0.002889951150233315,"No",0.0014807035946411786,0.9985192964053606,"Yes",0.17736342260120538,0.822636577398796,"Yes",0.035279164129818595,0.9647208358701846,"No",0.005546620872096275,0.9944533791279029,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","PT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.374423229136875e-47,0.6925160990898968,0.3074839009101109,"2+",5.7207638849990314e-11,0.9999999999427871,"Yes",0.9999999999931504,6.842001520655562e-12,"No",1.0,2.0620470819241812e-16,"No",0.9948232158432958,0.005176784156701837,"Yes",0.9999297779914806,7.02220085314055e-05,"Yes",0.9999999999957369,4.252851311404594e-12,"No",0.9998915283122334,0.00010847168775440957,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","DK","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.374423229136875e-47,0.6925160990898968,0.3074839009101109,"2+",5.7207638849990314e-11,0.9999999999427871,"Yes",0.9999999999931504,6.842001520655562e-12,"No",1.0,2.0620470819241812e-16,"No",0.9948232158432958,0.005176784156701837,"Yes",0.9999297779914806,7.02220085314055e-05,"Yes",0.9999999999957369,4.252851311404594e-12,"No",0.9998915283122334,0.00010847168775440957,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator?s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaEnsayo multicéntrico internacional de fase 3 de dos grupos aleatorizado y abierto de alisertib (MLN8237) o la elección del investigador (agente único seleccionado) en pacientes con linfoma de células T periféricas recidivante o resistente al tratamiento","GB","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.110364510900986e-93,0.9741400794956457,0.02585992050435894,"2+",1.9877870413374127e-16,1.0,"Yes",1.0,1.8290477156267562e-19,"No",1.0,4.7399997100494686e-17,"No",0.9794261579032324,0.020573842096757847,"Yes",0.999998009309528,1.9906904475775105e-06,"Yes",1.0,1.3754229085163245e-23,"No",0.9999936305058477,6.369494125219843e-06,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","CZ","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.374423229136875e-47,0.6925160990898968,0.3074839009101109,"2+",5.7207638849990314e-11,0.9999999999427871,"Yes",0.9999999999931504,6.842001520655562e-12,"No",1.0,2.0620470819241812e-16,"No",0.9948232158432958,0.005176784156701837,"Yes",0.9999297779914806,7.02220085314055e-05,"Yes",0.9999999999957369,4.252851311404594e-12,"No",0.9998915283122334,0.00010847168775440957,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator?s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaEnsayo multicéntrico internacional de fase 3 de dos grupos aleatorizado y abierto de alisertib (MLN8237) o la elección del investigador (agente único seleccionado) en pacientes con linfoma de células T periféricas recidivante o resistente al tratamiento","NL","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.110364510900986e-93,0.9741400794956457,0.02585992050435894,"2+",1.9877870413374127e-16,1.0,"Yes",1.0,1.8290477156267562e-19,"No",1.0,4.7399997100494686e-17,"No",0.9794261579032324,0.020573842096757847,"Yes",0.999998009309528,1.9906904475775105e-06,"Yes",1.0,1.3754229085163245e-23,"No",0.9999936305058477,6.369494125219843e-06,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","DE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.374423229136875e-47,0.6925160990898968,0.3074839009101109,"2+",5.7207638849990314e-11,0.9999999999427871,"Yes",0.9999999999931504,6.842001520655562e-12,"No",1.0,2.0620470819241812e-16,"No",0.9948232158432958,0.005176784156701837,"Yes",0.9999297779914806,7.02220085314055e-05,"Yes",0.9999999999957369,4.252851311404594e-12,"No",0.9998915283122334,0.00010847168775440957,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator?s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaEnsayo multicéntrico internacional de fase 3 de dos grupos aleatorizado y abierto de alisertib (MLN8237) o la elección del investigador (agente único seleccionado) en pacientes con linfoma de células T periféricas recidivante o resistente al tratamiento","HU","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.110364510900986e-93,0.9741400794956457,0.02585992050435894,"2+",1.9877870413374127e-16,1.0,"Yes",1.0,1.8290477156267562e-19,"No",1.0,4.7399997100494686e-17,"No",0.9794261579032324,0.020573842096757847,"Yes",0.999998009309528,1.9906904475775105e-06,"Yes",1.0,1.3754229085163245e-23,"No",0.9999936305058477,6.369494125219843e-06,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","SE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.374423229136875e-47,0.6925160990898968,0.3074839009101109,"2+",5.7207638849990314e-11,0.9999999999427871,"Yes",0.9999999999931504,6.842001520655562e-12,"No",1.0,2.0620470819241812e-16,"No",0.9948232158432958,0.005176784156701837,"Yes",0.9999297779914806,7.02220085314055e-05,"Yes",0.9999999999957369,4.252851311404594e-12,"No",0.9998915283122334,0.00010847168775440957,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator?s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaEnsayo multicéntrico internacional de fase 3 de dos grupos aleatorizado y abierto de alisertib (MLN8237) o la elección del investigador (agente único seleccionado) en pacientes con linfoma de células T periféricas recidivante o resistente al tratamiento","IT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.110364510900986e-93,0.9741400794956457,0.02585992050435894,"2+",1.9877870413374127e-16,1.0,"Yes",1.0,1.8290477156267562e-19,"No",1.0,4.7399997100494686e-17,"No",0.9794261579032324,0.020573842096757847,"Yes",0.999998009309528,1.9906904475775105e-06,"Yes",1.0,1.3754229085163245e-23,"No",0.9999936305058477,6.369494125219843e-06,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","BE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.374423229136875e-47,0.6925160990898968,0.3074839009101109,"2+",5.7207638849990314e-11,0.9999999999427871,"Yes",0.9999999999931504,6.842001520655562e-12,"No",1.0,2.0620470819241812e-16,"No",0.9948232158432958,0.005176784156701837,"Yes",0.9999297779914806,7.02220085314055e-05,"Yes",0.9999999999957369,4.252851311404594e-12,"No",0.9998915283122334,0.00010847168775440957,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","AT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.374423229136875e-47,0.6925160990898968,0.3074839009101109,"2+",5.7207638849990314e-11,0.9999999999427871,"Yes",0.9999999999931504,6.842001520655562e-12,"No",1.0,2.0620470819241812e-16,"No",0.9948232158432958,0.005176784156701837,"Yes",0.9999297779914806,7.02220085314055e-05,"Yes",0.9999999999957369,4.252851311404594e-12,"No",0.9998915283122334,0.00010847168775440957,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","ES","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.374423229136875e-47,0.6925160990898968,0.3074839009101109,"2+",5.7207638849990314e-11,0.9999999999427871,"Yes",0.9999999999931504,6.842001520655562e-12,"No",1.0,2.0620470819241812e-16,"No",0.9948232158432958,0.005176784156701837,"Yes",0.9999297779914806,7.02220085314055e-05,"Yes",0.9999999999957369,4.252851311404594e-12,"No",0.9998915283122334,0.00010847168775440957,"Yes"
"2011-003545-18","A Phase 3 Randomized Two-Arm Open-Label Multicenter International Trial of Alisertib (MLN8237) or Investigator?s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaEnsayo multicéntrico internacional de fase 3 de dos grupos aleatorizado y abierto de alisertib (MLN8237) o la elección del investigador (agente único seleccionado) en pacientes con linfoma de células T periféricas recidivante o resistente al tratamiento","BG","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.110364510900986e-93,0.9741400794956457,0.02585992050435894,"2+",1.9877870413374127e-16,1.0,"Yes",1.0,1.8290477156267562e-19,"No",1.0,4.7399997100494686e-17,"No",0.9794261579032324,0.020573842096757847,"Yes",0.999998009309528,1.9906904475775105e-06,"Yes",1.0,1.3754229085163245e-23,"No",0.9999936305058477,6.369494125219843e-06,"Yes"
"2011-004062-15","Prospective open label randomized phase II trial to assess a multimodal molecular targeted therapy in children adolescent and young adults with relapsed or refractory high risk neuroblastomaProspektive randomisierte open-label Phase II-Studie zur Untersuchung der Wirksamkeit einer multimodalen molekular basierten Therapie bei Kindern Jugendlichen und jungen Erwachsenen mit rezidiviertem oder therapierefraktärem Neuroblastom ","AT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",5.5329084599584e-75,0.9999734306467497,2.65693532783393e-05,"2+",2.6412516612110634e-16,1.0,"Yes",1.0,1.1350540807107957e-16,"No",0.9999999999402577,5.972443515361577e-11,"No",0.9999978844366734,2.115563323599173e-06,"Yes",0.9999999928569993,7.143004713422993e-09,"Yes",0.9999999999906208,9.350882017329478e-12,"No",0.999999985390673,1.460935150129332e-08,"Yes"
"2011-004062-15","Prospective open label randomized phase II trial to assess a multimodal molecular targeted therapy in children adolescent and young adults with relapsed or refractory high risk neuroblastomaProspektive randomisierte open-label Phase II-Studie zur Untersuchung der Wirksamkeit einer multimodalen molekular basierten Therapie bei Kindern Jugendlichen und jungen Erwachsenen mit rezidiviertem oder therapierefraktärem Neuroblastom","DE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",5.5329084599584e-75,0.9999734306467497,2.65693532783393e-05,"2+",2.6412516612110634e-16,1.0,"Yes",1.0,1.1350540807107957e-16,"No",0.9999999999402577,5.972443515361577e-11,"No",0.9999978844366734,2.115563323599173e-06,"Yes",0.9999999928569993,7.143004713422993e-09,"Yes",0.9999999999906208,9.350882017329478e-12,"No",0.999999985390673,1.460935150129332e-08,"Yes"
"2011-004237-14","A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-CRevised Protocol 02 incorporating protocol amendment 03 (version 1.0 dated 22-Jan-13).+ Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated23-Nov-11)","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5199386763524396e-77,1.8653064683129166e-05,0.9999813469353014,"2+",0.03592392152219571,0.9640760784777788,"Yes",0.992116147749916,0.00788385225007914,"No",1.0,8.312666216744673e-28,"No",4.732746604227077e-06,0.9999952672533836,"Yes",5.556494240855702e-12,0.9999999999944293,"Yes",1.0,1.9025963788015642e-34,"No",1.0895040815863765e-06,0.999998910495915,"Yes"
"2011-004237-14","A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-CRevised Protocol 02 incorporating protocol amendment 03 (version 1.0 dated 22-Jan-13).+ Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated 23-Nov-11)+ Administrative Letter 01 Site Specific dated 27-Mar-2012 ","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3748338946048442e-91,2.006440153305248e-09,0.9999999979935411,"2+",0.0030310565365067304,0.9969689434634724,"Yes",0.9990209580404865,0.0009790419595026017,"No",1.0,2.107303124654234e-40,"No",2.2561533743673723e-10,0.9999999997743886,"Yes",3.6677132720339885e-18,1.0,"Yes",1.0,3.866970237634456e-46,"No",5.207853134985834e-11,0.9999999999479314,"Yes"
"2011-004237-14","A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-CRevised Protocol 02 incorporating protocol amendment 03 (version 1.0 dated 22-Jan-13).+ Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated 23-Nov-11)+ Administrative Letter 01 Site Specific dated 27-Mar-2012 ","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3748338946048442e-91,2.006440153305248e-09,0.9999999979935411,"2+",0.0030310565365067304,0.9969689434634724,"Yes",0.9990209580404865,0.0009790419595026017,"No",1.0,2.107303124654234e-40,"No",2.2561533743673723e-10,0.9999999997743886,"Yes",3.6677132720339885e-18,1.0,"Yes",1.0,3.866970237634456e-46,"No",5.207853134985834e-11,0.9999999999479314,"Yes"
"2011-004237-14","A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-CRevised Protocol 02 incorporating protocol amendment 03 (version 1.0 dated 22-Jan-13).+ Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated 23-Nov-11)+ Administrative Letter 01 Site Specific dated 27-Mar-2012 ","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3748338946048442e-91,2.006440153305248e-09,0.9999999979935411,"2+",0.0030310565365067304,0.9969689434634724,"Yes",0.9990209580404865,0.0009790419595026017,"No",1.0,2.107303124654234e-40,"No",2.2561533743673723e-10,0.9999999997743886,"Yes",3.6677132720339885e-18,1.0,"Yes",1.0,3.866970237634456e-46,"No",5.207853134985834e-11,0.9999999999479314,"Yes"
"2011-004237-14","A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-CRevised Protocol 02 incorporating protocol amendment 03 (version 1.0 dated 22-Jan-13).+ Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated23-Nov-11)","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5199386763524396e-77,1.8653064683129166e-05,0.9999813469353014,"2+",0.03592392152219571,0.9640760784777788,"Yes",0.992116147749916,0.00788385225007914,"No",1.0,8.312666216744673e-28,"No",4.732746604227077e-06,0.9999952672533836,"Yes",5.556494240855702e-12,0.9999999999944293,"Yes",1.0,1.9025963788015642e-34,"No",1.0895040815863765e-06,0.999998910495915,"Yes"
"2011-004237-14","A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-CRevised Protocol 02 incorporating protocol amendment 03 (version 1.0 dated 22-Jan-13).+ Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated23-Nov-11)","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5199386763524396e-77,1.8653064683129166e-05,0.9999813469353014,"2+",0.03592392152219571,0.9640760784777788,"Yes",0.992116147749916,0.00788385225007914,"No",1.0,8.312666216744673e-28,"No",4.732746604227077e-06,0.9999952672533836,"Yes",5.556494240855702e-12,0.9999999999944293,"Yes",1.0,1.9025963788015642e-34,"No",1.0895040815863765e-06,0.999998910495915,"Yes"
"2011-004301-24","The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial","IT","No","No","Yes","","Yes","No","Yes","Yes","2+","","","Yes","No","No","No","No","No","1","No",8.089965022359715e-18,0.004082306662118247,0.9959176933378798,"-1",0.025070060646376464,0.9749299393536182,"Information not present in EudraCT",0.9892033874407126,0.010796612559290117,"Information not present in EudraCT",0.999935047468531,6.495253147066638e-05,"Information not present in EudraCT",0.004645835999639314,0.9953541640003646,"No",0.4927194729797246,0.5072805270202716,"",0.9999995720338354,4.2796616320217956e-07,"",0.1397104503911478,0.860289549608847,""
"2011-004301-24","The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial","DE","No","No","Yes","","Yes","No","Yes","Yes","2+","","","Yes","No","No","No","No","No","1","No",8.089965022359715e-18,0.004082306662118247,0.9959176933378798,"-1",0.025070060646376464,0.9749299393536182,"Information not present in EudraCT",0.9892033874407126,0.010796612559290117,"Information not present in EudraCT",0.999935047468531,6.495253147066638e-05,"Information not present in EudraCT",0.004645835999639314,0.9953541640003646,"No",0.4927194729797246,0.5072805270202716,"",0.9999995720338354,4.2796616320217956e-07,"",0.1397104503911478,0.860289549608847,""
"2011-004301-24","The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial","FR","No","No","Yes","","Yes","No","Yes","Yes","2+","","","Yes","No","No","No","No","No","1","No",8.089965022359715e-18,0.004082306662118247,0.9959176933378798,"-1",0.025070060646376464,0.9749299393536182,"Information not present in EudraCT",0.9892033874407126,0.010796612559290117,"Information not present in EudraCT",0.999935047468531,6.495253147066638e-05,"Information not present in EudraCT",0.004645835999639314,0.9953541640003646,"No",0.4927194729797246,0.5072805270202716,"",0.9999995720338354,4.2796616320217956e-07,"",0.1397104503911478,0.860289549608847,""
"2011-004396-36","Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2)","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5536376782691857e-43,0.0002567640553884788,0.9997432359446164,"2+",5.7292842129444036e-08,0.9999999427071503,"Yes",0.9999998546718238,1.4532818700710333e-07,"No",1.0,5.459457422550791e-20,"No",0.048804716096856444,0.9511952839031466,"Yes",0.8514462391768934,0.14855376082310173,"Yes",0.9999925700447297,7.429955260018797e-06,"No",0.011070808290703903,0.9889291917092872,"Yes"
"2011-004396-36","Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2)","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5536376782691857e-43,0.0002567640553884788,0.9997432359446164,"2+",5.7292842129444036e-08,0.9999999427071503,"Yes",0.9999998546718238,1.4532818700710333e-07,"No",1.0,5.459457422550791e-20,"No",0.048804716096856444,0.9511952839031466,"Yes",0.8514462391768934,0.14855376082310173,"Yes",0.9999925700447297,7.429955260018797e-06,"No",0.011070808290703903,0.9889291917092872,"Yes"
"2011-004396-36","Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2)","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5536376782691857e-43,0.0002567640553884788,0.9997432359446164,"2+",5.7292842129444036e-08,0.9999999427071503,"Yes",0.9999998546718238,1.4532818700710333e-07,"No",1.0,5.459457422550791e-20,"No",0.048804716096856444,0.9511952839031466,"Yes",0.8514462391768934,0.14855376082310173,"Yes",0.9999925700447297,7.429955260018797e-06,"No",0.011070808290703903,0.9889291917092872,"Yes"
"2011-004593-29","Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.6489282793676114e-19,0.5059908118090952,0.49400918819090595,"1",8.700978464757461e-05,0.9999129902153481,"Yes",0.999907543532253,9.24564677432644e-05,"No",0.9962513984182417,0.0037486015817604044,"No",0.6817779835322642,0.3182220164677379,"No",0.8900561058569822,0.10994389414301434,"No",0.9999810933968996,1.89066031026095e-05,"No",0.7008703017603246,0.2991296982396774,"No"
"2011-004618-40","An Open-label Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving DialysisStudio in aperto e a braccio singolo per la valutazione della sicurezza e della tollerabilità di Cinacalcet HCI in aggiunta alle terapie standard in soggetti pediatrici di età compresa tra 28 giorni e 6 anni con malattia renale cronica e iperparatiroidismo sottoposti a dialisi","IT","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.2204126992760729e-90,0.9999956217780898,4.378221908585859e-06,"-1",2.8419673764485556e-10,0.9999999997157829,"Yes",0.9999999999647571,3.524972252217909e-11,"No",1.0,2.4740510468856558e-18,"No",0.9967994812127331,0.0032005187872194267,"No",0.1398640387922625,0.8601359612077044,"No",1.0,4.986992290312389e-26,"No",0.9999969650839955,3.0349159871171756e-06,"No"
"2011-004618-40","An Open-label Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis","PL","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",3.122907509741321e-38,0.988819023986945,0.011180976013067693,"-1",0.002382957594860389,0.9976170424051349,"Yes",0.9986827293426185,0.0013172706573714645,"No",0.9999999976788275,2.3211641029120967e-09,"No",0.9825796684743693,0.01742033152562584,"No",0.3679297705969472,0.632070229403043,"No",0.9999995771791859,4.228208265905266e-07,"No",0.9982372244344518,0.0017627755655556863,"No"
"2011-004618-40","An Open-label Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving DialysisStudio in aperto e a braccio singolo per la valutazione della sicurezza e della tollerabilità di Cinacalcet HCI in aggiunta alle terapie standard in soggetti pediatrici di età compresa tra 28 giorni e 6 anni con malattia renale cronica e iperparatiroidismo sottoposti a dialisi","BE","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.2204126992760729e-90,0.9999956217780898,4.378221908585859e-06,"-1",2.8419673764485556e-10,0.9999999997157829,"Yes",0.9999999999647571,3.524972252217909e-11,"No",1.0,2.4740510468856558e-18,"No",0.9967994812127331,0.0032005187872194267,"No",0.1398640387922625,0.8601359612077044,"No",1.0,4.986992290312389e-26,"No",0.9999969650839955,3.0349159871171756e-06,"No"
"2011-004618-40","An Open-label Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis","CZ","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",3.122907509741321e-38,0.988819023986945,0.011180976013067693,"-1",0.002382957594860389,0.9976170424051349,"Yes",0.9986827293426185,0.0013172706573714645,"No",0.9999999976788275,2.3211641029120967e-09,"No",0.9825796684743693,0.01742033152562584,"No",0.3679297705969472,0.632070229403043,"No",0.9999995771791859,4.228208265905266e-07,"No",0.9982372244344518,0.0017627755655556863,"No"
"2011-004618-40","An Open-label Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving DialysisStudio in aperto e a braccio singolo per la valutazione della sicurezza e della tollerabilità di Cinacalcet HCI in aggiunta alle terapie standard in soggetti pediatrici di età compresa tra 28 giorni e 6 anni con malattia renale cronica e iperparatiroidismo sottoposti a dialisi","HU","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.2204126992760729e-90,0.9999956217780898,4.378221908585859e-06,"-1",2.8419673764485556e-10,0.9999999997157829,"Yes",0.9999999999647571,3.524972252217909e-11,"No",1.0,2.4740510468856558e-18,"No",0.9967994812127331,0.0032005187872194267,"No",0.1398640387922625,0.8601359612077044,"No",1.0,4.986992290312389e-26,"No",0.9999969650839955,3.0349159871171756e-06,"No"
"2011-004618-40","An Open-label Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving DialysisStudio in aperto e a braccio singolo per la valutazione della sicurezza e della tollerabilità di Cinacalcet HCI in aggiunta alle terapie standard in soggetti pediatrici di età compresa tra 28 giorni e 6 anni con malattia renale cronica e iperparatiroidismo sottoposti a dialisi","SK","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.2204126992760729e-90,0.9999956217780898,4.378221908585859e-06,"-1",2.8419673764485556e-10,0.9999999997157829,"Yes",0.9999999999647571,3.524972252217909e-11,"No",1.0,2.4740510468856558e-18,"No",0.9967994812127331,0.0032005187872194267,"No",0.1398640387922625,0.8601359612077044,"No",1.0,4.986992290312389e-26,"No",0.9999969650839955,3.0349159871171756e-06,"No"
"2011-004618-40","An Open-label Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving DialysisStudio in aperto e a braccio singolo per la valutazione della sicurezza e della tollerabilità di Cinacalcet HCI in aggiunta alle terapie standard in soggetti pediatrici di età compresa tra 28 giorni e 6 anni con malattia renale cronica e iperparatiroidismo sottoposti a dialisi","Outside EU/EEA","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.2204126992760729e-90,0.9999956217780898,4.378221908585859e-06,"-1",2.8419673764485556e-10,0.9999999997157829,"Yes",0.9999999999647571,3.524972252217909e-11,"No",1.0,2.4740510468856558e-18,"No",0.9967994812127331,0.0032005187872194267,"No",0.1398640387922625,0.8601359612077044,"No",1.0,4.986992290312389e-26,"No",0.9999969650839955,3.0349159871171756e-06,"No"
"2011-004868-30","AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR) AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR) OR TP53 MUTATION AND REGISTRY FOR MB OCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION","AT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.068759763919555e-46,0.9999864246532894,1.357534672407666e-05,"2+",2.280946159435263e-11,0.9999999999772058,"Yes",0.9999999999432704,5.670298626838288e-11,"No",1.0,9.298192701465639e-21,"No",0.9988992353001173,0.0011007646999015108,"Yes",0.9999999529389367,4.7061039203227096e-08,"Yes",0.9999999972991419,2.70086762589522e-09,"No",0.9994353206583237,0.0005646793416967524,"Yes"
"2011-004868-30","AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO  5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR)AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO  5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR)","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.085087677867589e-85,0.15207172767492488,0.8479282723250723,"2+",2.5346219150576126e-07,0.9999997465377854,"Yes",0.9999995870775535,4.129224569589e-07,"No",1.0,2.5440851154147334e-23,"No",1.359821207296192e-07,0.9999998640178753,"Yes",0.9994223997426358,0.0005776002573585076,"Yes",1.0,1.4829625552110453e-14,"No",5.985172304940086e-07,0.999999401482748,"Yes"
"2011-004868-30","AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR)Kansainvälinen prospektiivinen tutkimus kliinisen standardiriskin medulloblastoman hoidosta yli 3-5 –vuotiailla lapsilla joiden kasvaimella on matalan riskin biologiset ominaisuudet (PNET5 MB – LR) tai keskiriskin biologiset ominaisuudet (PNET5 MB – SR)","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.780352878397894e-52,0.0015332909617855395,0.9984667090382029,"2+",0.05519707013760023,0.9448029298623752,"Yes",0.9193342418007949,0.08066575819918603,"No",1.0,8.17976141447999e-16,"No",1.2019801036052386e-07,0.9999998798019833,"Yes",0.9472574326710552,0.05274256732895558,"Yes",0.9999999997341433,2.6586657900152124e-10,"No",6.669668432896955e-07,0.99999933303314,"Yes"
"2011-004868-30","AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR)Kansainvälinen prospektiivinen tutkimus kliinisen standardiriskin medulloblastoman hoidosta yli 3-5 –vuotiailla lapsilla joiden kasvaimella on matalan riskin biologiset ominaisuudet (PNET5 MB – LR) tai keskiriskin biologiset ominaisuudet (PNET5 MB – SR)","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.780352878397894e-52,0.0015332909617855395,0.9984667090382029,"2+",0.05519707013760023,0.9448029298623752,"Yes",0.9193342418007949,0.08066575819918603,"No",1.0,8.17976141447999e-16,"No",1.2019801036052386e-07,0.9999998798019833,"Yes",0.9472574326710552,0.05274256732895558,"Yes",0.9999999997341433,2.6586657900152124e-10,"No",6.669668432896955e-07,0.99999933303314,"Yes"
"2011-004868-30","AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO  5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR)AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO  5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR)","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.085087677867589e-85,0.15207172767492488,0.8479282723250723,"2+",2.5346219150576126e-07,0.9999997465377854,"Yes",0.9999995870775535,4.129224569589e-07,"No",1.0,2.5440851154147334e-23,"No",1.359821207296192e-07,0.9999998640178753,"Yes",0.9994223997426358,0.0005776002573585076,"Yes",1.0,1.4829625552110453e-14,"No",5.985172304940086e-07,0.999999401482748,"Yes"
"2011-005018-13","Ingenol Mebutate Gel 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp","DE","No","Yes","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3976102487345953e-13,2.755267562939316e-07,0.9999997244731087,"2+",5.1482110424495154e-06,0.9999948517889626,"No",0.9999999398488929,6.015110334823262e-08,"Yes",0.0027168178402604175,0.997283182159733,"No",5.863935871395748e-07,0.9999994136064189,"Yes",0.013049545600762137,0.9869504543992427,"Yes",0.9999638556341283,3.614436587757913e-05,"No",0.0033379053128799185,0.9966620946871131,"Yes"
"2011-005238-21","12 month multi-center open-label prospective randomized parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican® based regimen either in combination with Cyclosporin A or Tacrolimus","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.7828449561846656e-49,1.6126599716334748e-06,0.9999983873400354,"2+",2.0076541681651525e-09,0.9999999979923473,"Yes",0.9999999975736672,2.426319344266408e-09,"No",0.9999999985712122,1.4288004133573514e-09,"No",9.190861595504979e-06,0.9999908091384117,"Yes",8.295241688839086e-05,0.9999170475831064,"Yes",1.0,8.274251201678518e-15,"No",5.879667332154543e-06,0.9999941203326778,"Yes"
"2011-005238-21","12 month multi-center open-label prospective randomized parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican® based regimen either in combination with Cyclosporin A or Tacrolimus","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.7828449561846656e-49,1.6126599716334748e-06,0.9999983873400354,"2+",2.0076541681651525e-09,0.9999999979923473,"Yes",0.9999999975736672,2.426319344266408e-09,"No",0.9999999985712122,1.4288004133573514e-09,"No",9.190861595504979e-06,0.9999908091384117,"Yes",8.295241688839086e-05,0.9999170475831064,"Yes",1.0,8.274251201678518e-15,"No",5.879667332154543e-06,0.9999941203326778,"Yes"
"2011-005243-28","A Phase 3bMulticenter Open-label Abiraterone Acetate Long-term Access Study","SE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.969457811144013e-08,0.9999774584895768,2.2511815845370535e-05,"1",2.5738633315813176e-05,0.9999742613666847,"Yes",0.9999639591639004,3.604083610168768e-05,"No",0.9999999869597148,1.3040285884656979e-08,"No",0.9999728199636037,2.7180036394625687e-05,"No",0.9967800514943651,0.003219948505636055,"No",0.9997422852375302,0.00025771476246867905,"No",0.9999735156561084,2.6484343891955005e-05,"No"
"2011-005296-16","Capecitabine and bevacizumab with radiotherapy after 3-6 months chemotherapy for patients with oligometastatic colorectal cancer (OLGA trial)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.7530707518963207e-27,0.0075651724406107426,0.9924348275593886,"1",0.004577429705565015,0.9954225702944287,"Yes",0.9952565182689949,0.004743481731002085,"No",0.9999999581319949,4.1868006049635135e-08,"No",0.040473887615468475,0.95952611238453,"No",0.3150137973226819,0.6849862026773196,"No",0.9999992361215893,7.638784112153679e-07,"No",0.009531622181398136,0.9904683778185976,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer [SafeHer study]Nerandomizovaná prospektivní dvoukohortová multicentrickámezinárodní otevřená studie fáze III k posouzení bezpečnosti asistovaného a samo-aplikovaného subkutánního podání trastuzumabu jako terapie u pacientů s operabilním HER2 pozitivním časným karcinomem prsu [SafeHer Studie]","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",6.444950595850573e-88,0.002225249514392171,0.9977747504856009,"2+",5.297307726357733e-09,0.9999999947027051,"Yes",0.9999999920628398,7.937144586672416e-09,"No",1.0,6.53100127814806e-37,"No",0.958453637017359,0.04154636298263135,"Yes",0.993977443225393,0.006022556774591365,"Yes",1.0,4.01015175285816e-25,"No",0.011462099838978203,0.9885379001610465,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer [SafeHer study]","GB","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",8.011007021475938e-53,0.8042998863477933,0.19570011365220277,"2+",2.2104466704041058e-07,0.9999997789553238,"Yes",0.9999999140900437,8.590995388374655e-08,"No",0.9999999999998295,1.634981908885493e-13,"No",0.9995022698514101,0.0004977301485912886,"Yes",0.9914502031861887,0.008549796813801849,"Yes",0.99999996970729,3.029271546855612e-08,"No",0.6726812116782938,0.3273187883216996,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer [SafeHer study]Nerandomizovaná prospektivní dvoukohortová multicentrickámezinárodní otevřená studie fáze III k posouzení bezpečnosti asistovaného a samo-aplikovaného subkutánního podání trastuzumabu jako terapie u pacientů s operabilním HER2 pozitivním časným karcinomem prsu [SafeHer Studie]","PT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",6.444950595850573e-88,0.002225249514392171,0.9977747504856009,"2+",5.297307726357733e-09,0.9999999947027051,"Yes",0.9999999920628398,7.937144586672416e-09,"No",1.0,6.53100127814806e-37,"No",0.958453637017359,0.04154636298263135,"Yes",0.993977443225393,0.006022556774591365,"Yes",1.0,4.01015175285816e-25,"No",0.011462099838978203,0.9885379001610465,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer [SafeHer study]ESTUDIO FASE III PROSPECTIVO NO RANDOMIZADO Y ABIERTO DE DOS COHORTES MULTICENTRICO Y  MULTINACIONAL PARA ASEGURAR LA SEGURIDAD DE ADMINISTRACIÓN ASISTIDA O AUTOADMINISTRACIÓN DE TRASTUZUMAB SUBCUTÁNEO COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON CARCINOMA DE MAMA PRECOZ OPERABLE HER-2 + [SafeHer Study]","BG","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.4234827135887273e-97,0.07211149882220633,0.9278885011777779,"2+",1.6896038710313465e-13,0.9999999999998295,"Yes",1.0,4.4299555263486e-15,"No",1.0,1.6263065236979095e-21,"No",0.99999887782639,1.1221735865737313e-06,"Yes",0.9978580053006582,0.0021419946993285234,"Yes",1.0,2.7202635759779416e-22,"No",0.008986940025238255,0.9910130599747603,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centremultinational open label study to assess the safety of assisted- and selfadministeredsubcutaneous trastuzumab as therapy in patients withoperable Her2-positive early breast cancer [SafeHer study]Prospektivna nerandomizirana multicetrična mednarodna odprta raziskava faze III z dvema kohortama za oceno varnosti asistiranega injiciranja in samoinjiciranja subkutanega trastuzumaba kot zdravljenja pri bolnicah z operabilnim zgodnjim HER2-pozitivnim rakom dojke","GR","No","No","Yes","ok","Yes","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",1.1950392331649656e-67,0.9836024401416759,0.01639755985834863,"2+",7.401203689018702e-07,0.9999992598796336,"Yes",0.9999993791823494,6.208176304992572e-07,"No",1.0,4.319580720264116e-28,"No",0.9865661020147019,0.01343389798529948,"Yes",0.9999710817561439,2.8918243849500705e-05,"Yes",1.0,1.9025871481860616e-17,"No",0.28871033971398774,0.7112896602860204,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer [SafeHer study]","DE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",8.011007021475938e-53,0.8042998863477933,0.19570011365220277,"2+",2.2104466704041058e-07,0.9999997789553238,"Yes",0.9999999140900437,8.590995388374655e-08,"No",0.9999999999998295,1.634981908885493e-13,"No",0.9995022698514101,0.0004977301485912886,"Yes",0.9914502031861887,0.008549796813801849,"Yes",0.99999996970729,3.029271546855612e-08,"No",0.6726812116782938,0.3273187883216996,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centremultinational open label study to assess the safety of assisted- and selfadministered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer [SafeHer study]","IE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",2.1210793005151803e-43,0.8651472872529596,0.1348527127470385,"2+",5.10364490134919e-07,0.9999994896355016,"Yes",0.9999998097960553,1.9020394649353665e-07,"No",0.9999999999975273,2.472162486325775e-12,"No",0.9981486179031454,0.0018513820968623451,"Yes",0.9913268209501076,0.00867317904987935,"Yes",0.9999998698998894,1.3010011754567978e-07,"No",0.8004460769707734,0.19955392302923253,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer [SafeHer study]ESTUDIO FASE III PROSPECTIVO NO RANDOMIZADO Y ABIERTO DE DOS COHORTES MULTICENTRICO Y  MULTINACIONAL PARA ASEGURAR LA SEGURIDAD DE ADMINISTRACIÓN ASISTIDA O AUTOADMINISTRACIÓN DE TRASTUZUMAB SUBCUTÁNEO COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON CARCINOMA DE MAMA PRECOZ OPERABLE HER-2 + [SafeHer Study]","FI","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.4234827135887273e-97,0.07211149882220633,0.9278885011777779,"2+",1.6896038710313465e-13,0.9999999999998295,"Yes",1.0,4.4299555263486e-15,"No",1.0,1.6263065236979095e-21,"No",0.99999887782639,1.1221735865737313e-06,"Yes",0.9978580053006582,0.0021419946993285234,"Yes",1.0,2.7202635759779416e-22,"No",0.008986940025238255,0.9910130599747603,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer [SafeHer study]ESTUDIO FASE III PROSPECTIVO NO RANDOMIZADO Y ABIERTO DE DOS COHORTES MULTICENTRICO Y  MULTINACIONAL PARA ASEGURAR LA SEGURIDAD DE ADMINISTRACIÓN ASISTIDA O AUTOADMINISTRACIÓN DE TRASTUZUMAB SUBCUTÁNEO COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON CARCINOMA DE MAMA PRECOZ OPERABLE HER-2 + [SafeHer Study]","IT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.4234827135887273e-97,0.07211149882220633,0.9278885011777779,"2+",1.6896038710313465e-13,0.9999999999998295,"Yes",1.0,4.4299555263486e-15,"No",1.0,1.6263065236979095e-21,"No",0.99999887782639,1.1221735865737313e-06,"Yes",0.9978580053006582,0.0021419946993285234,"Yes",1.0,2.7202635759779416e-22,"No",0.008986940025238255,0.9910130599747603,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centremultinational open label study to assess the safety of assisted- and selfadministeredsubcutaneous trastuzumab as therapy in patients withoperable Her2-positive early breast cancer [SafeHer study]Prospektivna nerandomizirana multicetrična mednarodna odprta raziskava faze III z dvema kohortama za oceno varnosti asistiranega injiciranja in samoinjiciranja subkutanega trastuzumaba kot zdravljenja pri bolnicah z operabilnim zgodnjim HER2-pozitivnim rakom dojke","HU","No","No","Yes","ok","Yes","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",1.1950392331649656e-67,0.9836024401416759,0.01639755985834863,"2+",7.401203689018702e-07,0.9999992598796336,"Yes",0.9999993791823494,6.208176304992572e-07,"No",1.0,4.319580720264116e-28,"No",0.9865661020147019,0.01343389798529948,"Yes",0.9999710817561439,2.8918243849500705e-05,"Yes",1.0,1.9025871481860616e-17,"No",0.28871033971398774,0.7112896602860204,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centremultinational open label study to assess the safety of assisted- and selfadministered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer [SafeHer study]","CZ","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",2.1210793005151803e-43,0.8651472872529596,0.1348527127470385,"2+",5.10364490134919e-07,0.9999994896355016,"Yes",0.9999998097960553,1.9020394649353665e-07,"No",0.9999999999975273,2.472162486325775e-12,"No",0.9981486179031454,0.0018513820968623451,"Yes",0.9913268209501076,0.00867317904987935,"Yes",0.9999998698998894,1.3010011754567978e-07,"No",0.8004460769707734,0.19955392302923253,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer [SafeHer study]Nerandomizovaná prospektivní dvoukohortová multicentrickámezinárodní otevřená studie fáze III k posouzení bezpečnosti asistovaného a samo-aplikovaného subkutánního podání trastuzumabu jako terapie u pacientů s operabilním HER2 pozitivním časným karcinomem prsu [SafeHer Studie]","SI","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",6.444950595850573e-88,0.002225249514392171,0.9977747504856009,"2+",5.297307726357733e-09,0.9999999947027051,"Yes",0.9999999920628398,7.937144586672416e-09,"No",1.0,6.53100127814806e-37,"No",0.958453637017359,0.04154636298263135,"Yes",0.993977443225393,0.006022556774591365,"Yes",1.0,4.01015175285816e-25,"No",0.011462099838978203,0.9885379001610465,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centremultinational open label study to assess the safety of assisted- and selfadministeredsubcutaneous trastuzumab as therapy in patients withoperable Her2-positive early breast cancer [SafeHer study]Prospektivna nerandomizirana multicetrična mednarodna odprta raziskava faze III z dvema kohortama za oceno varnosti asistiranega injiciranja in samoinjiciranja subkutanega trastuzumaba kot zdravljenja pri bolnicah z operabilnim zgodnjim HER2-pozitivnim rakom dojke","PL","No","No","Yes","ok","Yes","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",1.1950392331649656e-67,0.9836024401416759,0.01639755985834863,"2+",7.401203689018702e-07,0.9999992598796336,"Yes",0.9999993791823494,6.208176304992572e-07,"No",1.0,4.319580720264116e-28,"No",0.9865661020147019,0.01343389798529948,"Yes",0.9999710817561439,2.8918243849500705e-05,"Yes",1.0,1.9025871481860616e-17,"No",0.28871033971398774,0.7112896602860204,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer [SafeHer study]","LT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",8.011007021475938e-53,0.8042998863477933,0.19570011365220277,"2+",2.2104466704041058e-07,0.9999997789553238,"Yes",0.9999999140900437,8.590995388374655e-08,"No",0.9999999999998295,1.634981908885493e-13,"No",0.9995022698514101,0.0004977301485912886,"Yes",0.9914502031861887,0.008549796813801849,"Yes",0.99999996970729,3.029271546855612e-08,"No",0.6726812116782938,0.3273187883216996,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centremultinational open label study to assess the safety of assisted- and selfadministered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer [SafeHer study]","FR","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",2.1210793005151803e-43,0.8651472872529596,0.1348527127470385,"2+",5.10364490134919e-07,0.9999994896355016,"Yes",0.9999998097960553,1.9020394649353665e-07,"No",0.9999999999975273,2.472162486325775e-12,"No",0.9981486179031454,0.0018513820968623451,"Yes",0.9913268209501076,0.00867317904987935,"Yes",0.9999998698998894,1.3010011754567978e-07,"No",0.8004460769707734,0.19955392302923253,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer [SafeHer study]Nerandomizovaná prospektivní dvoukohortová multicentrickámezinárodní otevřená studie fáze III k posouzení bezpečnosti asistovaného a samo-aplikovaného subkutánního podání trastuzumabu jako terapie u pacientů s operabilním HER2 pozitivním časným karcinomem prsu [SafeHer Studie]","SK","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",6.444950595850573e-88,0.002225249514392171,0.9977747504856009,"2+",5.297307726357733e-09,0.9999999947027051,"Yes",0.9999999920628398,7.937144586672416e-09,"No",1.0,6.53100127814806e-37,"No",0.958453637017359,0.04154636298263135,"Yes",0.993977443225393,0.006022556774591365,"Yes",1.0,4.01015175285816e-25,"No",0.011462099838978203,0.9885379001610465,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patients with operable Her2-positive early breast cancer [SafeHer study]","SE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","No","No","Yes","2+","No",1.7582138406690046e-51,0.9635416358991203,0.0364583641008855,"2+",4.481668280763276e-07,0.9999995518331711,"Yes",0.9999998291039423,1.7089605947368327e-07,"No",0.999999999999801,1.9352057659920624e-13,"No",0.9992052676928248,0.000794732307175484,"Yes",0.9858672410903571,0.014132758909654264,"Yes",0.9999996246180979,3.7538188846403084e-07,"No",0.9149094311100863,0.08509056888991091,"No"
"2011-005328-17","A phase III prospective two-cohort non-randomized multi-centre multinational open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer [SafeHer study]ESTUDIO FASE III PROSPECTIVO NO RANDOMIZADO Y ABIERTO DE DOS COHORTES MULTICENTRICO Y  MULTINACIONAL PARA ASEGURAR LA SEGURIDAD DE ADMINISTRACIÓN ASISTIDA O AUTOADMINISTRACIÓN DE TRASTUZUMAB SUBCUTÁNEO COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON CARCINOMA DE MAMA PRECOZ OPERABLE HER-2 + [SafeHer Study]","NL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",4.4234827135887273e-97,0.07211149882220633,0.9278885011777779,"2+",1.6896038710313465e-13,0.9999999999998295,"Yes",1.0,4.4299555263486e-15,"No",1.0,1.6263065236979095e-21,"No",0.99999887782639,1.1221735865737313e-06,"Yes",0.9978580053006582,0.0021419946993285234,"Yes",1.0,2.7202635759779416e-22,"No",0.008986940025238255,0.9910130599747603,"No"
"2011-005422-21","A Phase 3 Open-Label Study with Asunaprevir and Daclatasvir Plus  Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for  Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b  Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4 InfectionStudio di Fase 3 in Aperto con Asunaprevir e Daclatasvir piÃ¹ Peginterferone Alfa-2a (Pegasys) e  Ribavirina (Copegus) (P/R) (QUAD) nei soggetti affetti da epatite cronica C di Genotipo 1 o 4 che Non Rispondono o Rispondono In Modo Parziale (âNull/Partial Respondersâ)  a Peginterferone Alfa 2a o Alfa 2b e Ribavirina","NL","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4721714637684205e-137,0.9999997939852605,2.060147018864264e-07,"-1",2.4755354879023224e-09,0.9999999975244692,"Information not present in EudraCT",0.9999999969900274,3.009936019414373e-09,"Information not present in EudraCT",1.0,1.1756205356193125e-49,"Information not present in EudraCT",0.999620939320817,0.0003790606791939679,"No",0.9938703286554937,0.006129671344483955,"",1.0,5.425423504829112e-45,"",0.9999998815072857,1.1849276360021509e-07,""
"2011-005422-21","A Phase 3 Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4 Infection+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 13-Mar-12)Revised Protocol 02 incorporating Protocol Amendment 03","ES","No","No","Yes","","Yes","No","Yes","Yes","2+","","","Yes","No","No","No","No","No","1","No",1.2958040078412103e-92,0.4404948019803481,0.5595051980196531,"-1",0.001088723235724244,0.9989112767642921,"Information not present in EudraCT",0.9995328851437504,0.0004671148562559457,"Information not present in EudraCT",1.0,6.352972908964554e-39,"Information not present in EudraCT",0.0012664469757524745,0.9987335530242477,"No",5.773275277881334e-08,0.9999999422672675,"",1.0,3.520890163049275e-44,"",0.0033473385572747685,0.996652661442708,""
"2011-005422-21","A Phase 3 Open-Label Study with Asunaprevir and Daclatasvir Plus  Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for  Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b  Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4 InfectionStudio di Fase 3 in Aperto con Asunaprevir e Daclatasvir piÃ¹ Peginterferone Alfa-2a (Pegasys) e  Ribavirina (Copegus) (P/R) (QUAD) nei soggetti affetti da epatite cronica C di Genotipo 1 o 4 che Non Rispondono o Rispondono In Modo Parziale (âNull/Partial Respondersâ)  a Peginterferone Alfa 2a o Alfa 2b e Ribavirina","SE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4721714637684205e-137,0.9999997939852605,2.060147018864264e-07,"-1",2.4755354879023224e-09,0.9999999975244692,"Information not present in EudraCT",0.9999999969900274,3.009936019414373e-09,"Information not present in EudraCT",1.0,1.1756205356193125e-49,"Information not present in EudraCT",0.999620939320817,0.0003790606791939679,"No",0.9938703286554937,0.006129671344483955,"",1.0,5.425423504829112e-45,"",0.9999998815072857,1.1849276360021509e-07,""
"2011-005422-21","A Phase 3 Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4 Infection+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 13-Mar-12)Revised Protocol 02 incorporating Protocol Amendment 03","DE","No","No","Yes","","Yes","No","Yes","Yes","2+","","","Yes","No","No","No","No","No","1","No",1.2958040078412103e-92,0.4404948019803481,0.5595051980196531,"-1",0.001088723235724244,0.9989112767642921,"Information not present in EudraCT",0.9995328851437504,0.0004671148562559457,"Information not present in EudraCT",1.0,6.352972908964554e-39,"Information not present in EudraCT",0.0012664469757524745,0.9987335530242477,"No",5.773275277881334e-08,0.9999999422672675,"",1.0,3.520890163049275e-44,"",0.0033473385572747685,0.996652661442708,""
"2011-005422-21","A Phase 3 Open-Label Study with Asunaprevir and Daclatasvir Plus  Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for  Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b  Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4 InfectionStudio di Fase 3 in Aperto con Asunaprevir e Daclatasvir piÃ¹ Peginterferone Alfa-2a (Pegasys) e  Ribavirina (Copegus) (P/R) (QUAD) nei soggetti affetti da epatite cronica C di Genotipo 1 o 4 che Non Rispondono o Rispondono In Modo Parziale (âNull/Partial Respondersâ)  a Peginterferone Alfa 2a o Alfa 2b e Ribavirina","IT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",3.4721714637684205e-137,0.9999997939852605,2.060147018864264e-07,"-1",2.4755354879023224e-09,0.9999999975244692,"Information not present in EudraCT",0.9999999969900274,3.009936019414373e-09,"Information not present in EudraCT",1.0,1.1756205356193125e-49,"Information not present in EudraCT",0.999620939320817,0.0003790606791939679,"No",0.9938703286554937,0.006129671344483955,"",1.0,5.425423504829112e-45,"",0.9999998815072857,1.1849276360021509e-07,""
"2011-005422-21","A Phase 3 Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4 Infection+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 13-Mar-12)Revised Protocol 02 incorporating Protocol Amendment 03","DK","No","No","Yes","","Yes","No","Yes","Yes","2+","","","Yes","No","No","No","No","No","1","No",1.2958040078412103e-92,0.4404948019803481,0.5595051980196531,"-1",0.001088723235724244,0.9989112767642921,"Information not present in EudraCT",0.9995328851437504,0.0004671148562559457,"Information not present in EudraCT",1.0,6.352972908964554e-39,"Information not present in EudraCT",0.0012664469757524745,0.9987335530242477,"No",5.773275277881334e-08,0.9999999422672675,"",1.0,3.520890163049275e-44,"",0.0033473385572747685,0.996652661442708,""
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.393578585796026e-37,0.00013378044865471484,0.9998662195513391,"2+",4.2526392492534447e-14,0.9999999999999717,"Yes",0.9999999999999717,3.4472577709416447e-14,"No",1.0,9.266245302524072e-17,"No",0.12689768999804574,0.8731023100019669,"Yes",0.8742313904003375,0.12576860959965222,"No",0.9999999986116564,1.3883402378298086e-09,"No",0.044821166714044354,0.9551788332859495,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.393578585796026e-37,0.00013378044865471484,0.9998662195513391,"2+",4.2526392492534447e-14,0.9999999999999717,"Yes",0.9999999999999717,3.4472577709416447e-14,"No",1.0,9.266245302524072e-17,"No",0.12689768999804574,0.8731023100019669,"Yes",0.8742313904003375,0.12576860959965222,"No",0.9999999986116564,1.3883402378298086e-09,"No",0.044821166714044354,0.9551788332859495,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator?s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)Estudio en Fase 3 abierto y aleatorizado de ozogamicina de inotuzumab comparado con un fármaco definido elegido por el investigador en pacientes adultos con leucemia linfoblástica aguda (LLA) positiva al CD22 recidivante o refractaria","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.3516914678142754e-74,8.554375984206191e-06,0.9999914456240435,"2+",1.2558827008255533e-23,1.0,"Yes",1.0,1.196378384327075e-24,"No",1.0,8.99919331166456e-22,"No",0.00019548139392284625,0.9998045186060663,"Yes",0.3475574566546199,0.6524425433453618,"No",1.0,2.563442641488501e-28,"No",4.321085870662656e-05,0.999956789141285,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator?s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)Estudio en Fase 3 abierto y aleatorizado de ozogamicina de inotuzumab comparado con un fármaco definido elegido por el investigador en pacientes adultos con leucemia linfoblástica aguda (LLA) positiva al CD22 recidivante o refractaria","SK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.3516914678142754e-74,8.554375984206191e-06,0.9999914456240435,"2+",1.2558827008255533e-23,1.0,"Yes",1.0,1.196378384327075e-24,"No",1.0,8.99919331166456e-22,"No",0.00019548139392284625,0.9998045186060663,"Yes",0.3475574566546199,0.6524425433453618,"No",1.0,2.563442641488501e-28,"No",4.321085870662656e-05,0.999956789141285,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator?s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)Estudio en Fase 3 abierto y aleatorizado de ozogamicina de inotuzumab comparado con un fármaco definido elegido por el investigador en pacientes adultos con leucemia linfoblástica aguda (LLA) positiva al CD22 recidivante o refractaria","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.3516914678142754e-74,8.554375984206191e-06,0.9999914456240435,"2+",1.2558827008255533e-23,1.0,"Yes",1.0,1.196378384327075e-24,"No",1.0,8.99919331166456e-22,"No",0.00019548139392284625,0.9998045186060663,"Yes",0.3475574566546199,0.6524425433453618,"No",1.0,2.563442641488501e-28,"No",4.321085870662656e-05,0.999956789141285,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator?s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)Estudio en Fase 3 abierto y aleatorizado de ozogamicina de inotuzumab comparado con un fármaco definido elegido por el investigador en pacientes adultos con leucemia linfoblástica aguda (LLA) positiva al CD22 recidivante o refractaria","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.3516914678142754e-74,8.554375984206191e-06,0.9999914456240435,"2+",1.2558827008255533e-23,1.0,"Yes",1.0,1.196378384327075e-24,"No",1.0,8.99919331166456e-22,"No",0.00019548139392284625,0.9998045186060663,"Yes",0.3475574566546199,0.6524425433453618,"No",1.0,2.563442641488501e-28,"No",4.321085870662656e-05,0.999956789141285,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator?s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)Estudio en Fase 3 abierto y aleatorizado de ozogamicina de inotuzumab comparado con un fármaco definido elegido por el investigador en pacientes adultos con leucemia linfoblástica aguda (LLA) positiva al CD22 recidivante o refractaria","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.3516914678142754e-74,8.554375984206191e-06,0.9999914456240435,"2+",1.2558827008255533e-23,1.0,"Yes",1.0,1.196378384327075e-24,"No",1.0,8.99919331166456e-22,"No",0.00019548139392284625,0.9998045186060663,"Yes",0.3475574566546199,0.6524425433453618,"No",1.0,2.563442641488501e-28,"No",4.321085870662656e-05,0.999956789141285,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.393578585796026e-37,0.00013378044865471484,0.9998662195513391,"2+",4.2526392492534447e-14,0.9999999999999717,"Yes",0.9999999999999717,3.4472577709416447e-14,"No",1.0,9.266245302524072e-17,"No",0.12689768999804574,0.8731023100019669,"Yes",0.8742313904003375,0.12576860959965222,"No",0.9999999986116564,1.3883402378298086e-09,"No",0.044821166714044354,0.9551788332859495,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.393578585796026e-37,0.00013378044865471484,0.9998662195513391,"2+",4.2526392492534447e-14,0.9999999999999717,"Yes",0.9999999999999717,3.4472577709416447e-14,"No",1.0,9.266245302524072e-17,"No",0.12689768999804574,0.8731023100019669,"Yes",0.8742313904003375,0.12576860959965222,"No",0.9999999986116564,1.3883402378298086e-09,"No",0.044821166714044354,0.9551788332859495,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.393578585796026e-37,0.00013378044865471484,0.9998662195513391,"2+",4.2526392492534447e-14,0.9999999999999717,"Yes",0.9999999999999717,3.4472577709416447e-14,"No",1.0,9.266245302524072e-17,"No",0.12689768999804574,0.8731023100019669,"Yes",0.8742313904003375,0.12576860959965222,"No",0.9999999986116564,1.3883402378298086e-09,"No",0.044821166714044354,0.9551788332859495,"Yes"
"2011-005491-41","An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator?s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)Estudio en Fase 3 abierto y aleatorizado de ozogamicina de inotuzumab comparado con un fármaco definido elegido por el investigador en pacientes adultos con leucemia linfoblástica aguda (LLA) positiva al CD22 recidivante o refractaria","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.3516914678142754e-74,8.554375984206191e-06,0.9999914456240435,"2+",1.2558827008255533e-23,1.0,"Yes",1.0,1.196378384327075e-24,"No",1.0,8.99919331166456e-22,"No",0.00019548139392284625,0.9998045186060663,"Yes",0.3475574566546199,0.6524425433453618,"No",1.0,2.563442641488501e-28,"No",4.321085870662656e-05,0.999956789141285,"Yes"
"2011-005539-22","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLATINUM BASED CHEMOTHERAPYESTUDIO ABIERTO Y ALEATORIZADO DE FASE II DE MEHD7945A FRENTE A CETUXIMAB EN PACIENTES CON CARCINOMA  DE CÉLULAS ESCAMOSAS RECIDIVANTE O METASTÁSICO DE CABEZA Y CUELLO CON PROGRESIÓN DE LA ENFERMEDAD DURANTE O DESPUÉS DE QUIMIOTERAPIA CON PLATINO","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.2727279617165067e-88,0.0034049714202821837,0.9965950285797374,"2+",6.24993421918819e-20,1.0,"Yes",1.0,4.1632640217066305e-19,"No",1.0,2.548504924173733e-41,"No",0.38757357333815917,0.612426426661822,"Yes",0.9975731823373943,0.0024268176626226065,"Yes",1.0,1.106227529536841e-34,"Yes",0.0008698597734121334,0.9991301402266084,"Yes"
"2011-005539-22","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLATINUM BASED CHEMOTHERAPYESTUDIO ABIERTO Y ALEATORIZADO DE FASE II DE MEHD7945A FRENTE A CETUXIMAB EN PACIENTES CON CARCINOMA  DE CÉLULAS ESCAMOSAS RECIDIVANTE O METASTÁSICO DE CABEZA Y CUELLO CON PROGRESIÓN DE LA ENFERMEDAD DURANTE O DESPUÉS DE QUIMIOTERAPIA CON PLATINO","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.2727279617165067e-88,0.0034049714202821837,0.9965950285797374,"2+",6.24993421918819e-20,1.0,"Yes",1.0,4.1632640217066305e-19,"No",1.0,2.548504924173733e-41,"No",0.38757357333815917,0.612426426661822,"Yes",0.9975731823373943,0.0024268176626226065,"Yes",1.0,1.106227529536841e-34,"Yes",0.0008698597734121334,0.9991301402266084,"Yes"
"2011-005539-22","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLATINUM BASED CHEMOTHERAPY ","BG","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4846015829886267e-44,0.02193126011046547,0.978068739889523,"2+",4.097325081929031e-11,0.9999999999590159,"Yes",0.9999999998919122,1.0809617124766116e-10,"No",1.0,5.768289040218918e-20,"No",0.7084816572515212,0.291518342748473,"Yes",0.9513399911642266,0.04866000883576521,"Yes",1.0,2.894284985873712e-16,"Yes",0.028869635295822538,0.9711303647041675,"Yes"
"2011-005539-22","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLATINUM BASED CHEMOTHERAPY ","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4846015829886267e-44,0.02193126011046547,0.978068739889523,"2+",4.097325081929031e-11,0.9999999999590159,"Yes",0.9999999998919122,1.0809617124766116e-10,"No",1.0,5.768289040218918e-20,"No",0.7084816572515212,0.291518342748473,"Yes",0.9513399911642266,0.04866000883576521,"Yes",1.0,2.894284985873712e-16,"Yes",0.028869635295822538,0.9711303647041675,"Yes"
"2011-005539-22","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLATINUM BASED CHEMOTHERAPY ","HU","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4846015829886267e-44,0.02193126011046547,0.978068739889523,"2+",4.097325081929031e-11,0.9999999999590159,"Yes",0.9999999998919122,1.0809617124766116e-10,"No",1.0,5.768289040218918e-20,"No",0.7084816572515212,0.291518342748473,"Yes",0.9513399911642266,0.04866000883576521,"Yes",1.0,2.894284985873712e-16,"Yes",0.028869635295822538,0.9711303647041675,"Yes"
"2011-005539-22","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLATINUM BASED CHEMOTHERAPY ","IT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4846015829886267e-44,0.02193126011046547,0.978068739889523,"2+",4.097325081929031e-11,0.9999999999590159,"Yes",0.9999999998919122,1.0809617124766116e-10,"No",1.0,5.768289040218918e-20,"No",0.7084816572515212,0.291518342748473,"Yes",0.9513399911642266,0.04866000883576521,"Yes",1.0,2.894284985873712e-16,"Yes",0.028869635295822538,0.9711303647041675,"Yes"
"2011-005539-22","A PHASE II OPEN-LABEL RANDOMIZED STUDY OF MEHD7945A VERSUS  CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS  CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED  DURING OR FOLLOWING PLATINUM BASED CHEMOTHERAPYSTUDIO DI FASE II IN APERTO CON MEHD7945A RANDOMIZZATO VERSO CETUXIMAB IN PAZIENTI CON TUMORE TESTA/COLLO RICORRENTE/METASTATICO A CELLULE SQUAMOSE PROGREDITO DURANTE O DOPO CHEMIOTERAPIA A BASE DI PLATINO","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.6950035400486955e-79,4.3309763253470126e-06,0.9999956690236895,"2+",3.006122107592712e-22,1.0,"Yes",1.0,3.1681269647157825e-21,"No",1.0,3.2994942671523805e-42,"No",0.00016447922323897443,0.9998355207767674,"Yes",0.7577498473006619,0.24225015269931477,"Yes",1.0,3.806917492382584e-31,"Yes",1.2747547847248737e-07,0.9999998725245487,"Yes"
"2011-005722-21","A Phase III Randomized Multicenter Double-Blind Double Dummy Parallel Group Comparative Study to Determine the Efficacy Safety and Tolerability of Ceftazidime-Avibactam (CAZ-AVI formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections Including Acute Pyelonephritis With a Gram Negative Pathogen in Hospitalized Adults","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.935545328022696e-76,1.8242548853953113e-24,1.0,"2+",1.0,3.496558732984889e-23,"No",2.4800328399975816e-20,1.0,"Yes",1.0,8.5283423595878985e-16,"No",5.791739573510352e-23,1.0,"Yes",1.7125120517962186e-11,0.9999999999828901,"Yes",1.0,3.142826772936255e-26,"No",6.464506493714006e-23,1.0,"Yes"
"2011-005722-21","A Phase III Randomized Multicenter Double-Blind Double Dummy  Parallel Group Comparative Study to Determine the Efficacy Safety and  Tolerability of Ceftazidime-Avibactam (CAZ-AVI formerly CAZ104) Versus  Doripenem Followed by Appropriate Oral Therapy in the Treatment of  Complicated Urinary Tract Infections Including Acute Pyelonephritis With  a Gram Negative Pathogen in Hospitalized Adults.Studio comparativo di fase III randomizzato multicentrico in doppio cieco doppio mascheramento a gruppi paralleli progettato per determinare l'efficacia la sicurezza e la tollerabilita' di ceftazidima avibactam (CAZ-AVI gia' CAZ104) rispetto a doripenem seguito da appropriata terapia orale nel trattamento delle infezioni complicate delle vie urinarie tra cui pielonefrite acuta con agente patogeno gram-negativo in adulti ospedalizzati.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0113971627309851e-146,2.8969886945648095e-37,1.0,"2+",1.0,4.059690980545833e-32,"No",1.6431011161877708e-29,1.0,"Yes",1.0,2.9621451291973338e-43,"No",2.148545531560653e-36,1.0,"Yes",5.207128364814933e-20,1.0,"Yes",1.0,7.957306361645444e-58,"No",1.98991705677106e-38,1.0,"Yes"
"2011-005722-21","A Phase III Randomized Multicenter Double-Blind Double Dummy Parallel Group Comparative Study to Determine the Efficacy Safety and Tolerability of Ceftazidime-Avibactam (CAZ-AVI formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections Including Acute Pyelonephritis With a Gram Negative Pathogen in Hospitalized AdultsRandomizované multicentrické dvojitě zaslepené dvojitě maskované komparativní klinické hodnocení fáze III s paralelními skupinami zjišťující účinnost bezpečnost a snášenlivost ceftazidimu-avibactamu (CAZ-AVI dříve CAZ104) oproti doripenemu následovaným vhodnou perorální léčbou v léčbě komplikovaných infekcí močového ústrojí včetně akutní pyelonefritidy s gramnegativním patogenem u hospitalizovaných dospělých","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.5520969586900278e-133,2.166690337303548e-49,1.0,"2+",1.0,1.2519685321052816e-43,"No",1.0561368947678697e-40,1.0,"Yes",1.0,2.1810452585660676e-49,"No",2.3371438118669696e-50,1.0,"Yes",1.8454029257824352e-24,1.0,"Yes",1.0,7.741925874112498e-64,"No",2.9644467226763358e-46,1.0,"Yes"
"2011-005722-21","A Phase III Randomized Multicenter Double-Blind Double Dummy Parallel Group Comparative Study to Determine the Efficacy Safety and Tolerability of Ceftazidime-Avibactam (CAZ-AVI formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections Including Acute Pyelonephritis With a Gram Negative Pathogen in Hospitalized Adults","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.935545328022696e-76,1.8242548853953113e-24,1.0,"2+",1.0,3.496558732984889e-23,"No",2.4800328399975816e-20,1.0,"Yes",1.0,8.5283423595878985e-16,"No",5.791739573510352e-23,1.0,"Yes",1.7125120517962186e-11,0.9999999999828901,"Yes",1.0,3.142826772936255e-26,"No",6.464506493714006e-23,1.0,"Yes"
"2011-005722-21","A Phase III Randomized Multicenter Double-Blind Double Dummy Parallel Group Comparative Study to Determine the Efficacy Safety and Tolerability of Ceftazidime-Avibactam (CAZ-AVI formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections Including Acute Pyelonephritis With a Gram Negative Pathogen in Hospitalized Adults","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.935545328022696e-76,1.8242548853953113e-24,1.0,"2+",1.0,3.496558732984889e-23,"No",2.4800328399975816e-20,1.0,"Yes",1.0,8.5283423595878985e-16,"No",5.791739573510352e-23,1.0,"Yes",1.7125120517962186e-11,0.9999999999828901,"Yes",1.0,3.142826772936255e-26,"No",6.464506493714006e-23,1.0,"Yes"
"2011-005722-21","A Phase III Randomized Multicenter Double-Blind Double Dummy  Parallel Group Comparative Study to Determine the Efficacy Safety and  Tolerability of Ceftazidime-Avibactam (CAZ-AVI formerly CAZ104) Versus  Doripenem Followed by Appropriate Oral Therapy in the Treatment of  Complicated Urinary Tract Infections Including Acute Pyelonephritis With  a Gram Negative Pathogen in Hospitalized Adults.Studio comparativo di fase III randomizzato multicentrico in doppio cieco doppio mascheramento a gruppi paralleli progettato per determinare l'efficacia la sicurezza e la tollerabilita' di ceftazidima avibactam (CAZ-AVI gia' CAZ104) rispetto a doripenem seguito da appropriata terapia orale nel trattamento delle infezioni complicate delle vie urinarie tra cui pielonefrite acuta con agente patogeno gram-negativo in adulti ospedalizzati.","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0113971627309851e-146,2.8969886945648095e-37,1.0,"2+",1.0,4.059690980545833e-32,"No",1.6431011161877708e-29,1.0,"Yes",1.0,2.9621451291973338e-43,"No",2.148545531560653e-36,1.0,"Yes",5.207128364814933e-20,1.0,"Yes",1.0,7.957306361645444e-58,"No",1.98991705677106e-38,1.0,"Yes"
"2011-005722-21","A Phase III Randomized Multicenter Double-Blind Double Dummy  Parallel Group Comparative Study to Determine the Efficacy Safety and  Tolerability of Ceftazidime-Avibactam (CAZ-AVI formerly CAZ104) Versus  Doripenem Followed by Appropriate Oral Therapy in the Treatment of  Complicated Urinary Tract Infections Including Acute Pyelonephritis With  a Gram Negative Pathogen in Hospitalized Adults.Studio comparativo di fase III randomizzato multicentrico in doppio cieco doppio mascheramento a gruppi paralleli progettato per determinare l'efficacia la sicurezza e la tollerabilita' di ceftazidima avibactam (CAZ-AVI gia' CAZ104) rispetto a doripenem seguito da appropriata terapia orale nel trattamento delle infezioni complicate delle vie urinarie tra cui pielonefrite acuta con agente patogeno gram-negativo in adulti ospedalizzati.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0113971627309851e-146,2.8969886945648095e-37,1.0,"2+",1.0,4.059690980545833e-32,"No",1.6431011161877708e-29,1.0,"Yes",1.0,2.9621451291973338e-43,"No",2.148545531560653e-36,1.0,"Yes",5.207128364814933e-20,1.0,"Yes",1.0,7.957306361645444e-58,"No",1.98991705677106e-38,1.0,"Yes"
"2011-005722-21","A Phase III Randomized Multicenter Double-Blind Double Dummy  Parallel Group Comparative Study to Determine the Efficacy Safety and  Tolerability of Ceftazidime-Avibactam (CAZ-AVI formerly CAZ104) Versus  Doripenem Followed by Appropriate Oral Therapy in the Treatment of  Complicated Urinary Tract Infections Including Acute Pyelonephritis With  a Gram Negative Pathogen in Hospitalized Adults.Studio comparativo di fase III randomizzato multicentrico in doppio cieco doppio mascheramento a gruppi paralleli progettato per determinare l'efficacia la sicurezza e la tollerabilita' di ceftazidima avibactam (CAZ-AVI gia' CAZ104) rispetto a doripenem seguito da appropriata terapia orale nel trattamento delle infezioni complicate delle vie urinarie tra cui pielonefrite acuta con agente patogeno gram-negativo in adulti ospedalizzati.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0113971627309851e-146,2.8969886945648095e-37,1.0,"2+",1.0,4.059690980545833e-32,"No",1.6431011161877708e-29,1.0,"Yes",1.0,2.9621451291973338e-43,"No",2.148545531560653e-36,1.0,"Yes",5.207128364814933e-20,1.0,"Yes",1.0,7.957306361645444e-58,"No",1.98991705677106e-38,1.0,"Yes"
"2011-005975-17","A two-part randomized Phase II double-blind multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expressionESTUDIO DE FASE II MULTICÉNTRICO DOBLE CIEGO RANDOMIZADO EN DOS PARTES PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE PERTUZUMAB EN COMBINACIÓN CON QUIMIOTERAPIA ESTÁNDAR FRENTE A PLACEBO MÁS QUIMIOTERAPIA ESTÁNDAR EN MUJERES CON CÁNCER EPITELIAL DE OVARIO RECURRENTE RESISTENTE A PLATINO CON EXPRESIÓN BAJA DE HER3 EN ARNm","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.249101468176302e-119,3.4724570586651465e-16,1.0,"2+",0.2346067419233926,0.7653932580766033,"No",0.9580958973237418,0.041904102676231396,"Yes",1.0,6.438765977545363e-28,"No",3.6218578458522446e-10,0.9999999996377938,"Yes",0.06599988420957063,0.9340001157904138,"Yes",1.0,2.388271782999962e-37,"No",5.036436561355494e-14,0.9999999999999432,"Yes"
"2011-005975-17","A two-part randomized Phase III double-blind multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.3145975335635195e-67,7.762756166128282e-10,0.9999999992237179,"2+",0.4292503132588672,0.5707496867411256,"No",0.7715453452396321,0.22845465476037777,"Yes",1.0,1.846765679209894e-15,"No",1.3669855259897418e-07,0.9999998633014494,"Yes",0.24768885284659645,0.7523111471534032,"Yes",0.9999999999984368,1.564828108297118e-12,"No",1.7541975009944085e-08,0.9999999824580359,"Yes"
"2011-005975-17","A two-part randomized Phase II double-blind multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expressionESTUDIO DE FASE II MULTICÉNTRICO DOBLE CIEGO RANDOMIZADO EN DOS PARTES PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE PERTUZUMAB EN COMBINACIÓN CON QUIMIOTERAPIA ESTÁNDAR FRENTE A PLACEBO MÁS QUIMIOTERAPIA ESTÁNDAR EN MUJERES CON CÁNCER EPITELIAL DE OVARIO RECURRENTE RESISTENTE A PLATINO CON EXPRESIÓN BAJA DE HER3 EN ARNm","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.249101468176302e-119,3.4724570586651465e-16,1.0,"2+",0.2346067419233926,0.7653932580766033,"No",0.9580958973237418,0.041904102676231396,"Yes",1.0,6.438765977545363e-28,"No",3.6218578458522446e-10,0.9999999996377938,"Yes",0.06599988420957063,0.9340001157904138,"Yes",1.0,2.388271782999962e-37,"No",5.036436561355494e-14,0.9999999999999432,"Yes"
"2011-005975-17","A two-part randomized Phase III double-blind multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.3145975335635195e-67,7.762756166128282e-10,0.9999999992237179,"2+",0.4292503132588672,0.5707496867411256,"No",0.7715453452396321,0.22845465476037777,"Yes",1.0,1.846765679209894e-15,"No",1.3669855259897418e-07,0.9999998633014494,"Yes",0.24768885284659645,0.7523111471534032,"Yes",0.9999999999984368,1.564828108297118e-12,"No",1.7541975009944085e-08,0.9999999824580359,"Yes"
"2011-005975-17","A two-part randomized Phase II double-blind multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expressionESTUDIO DE FASE II MULTICÉNTRICO DOBLE CIEGO RANDOMIZADO EN DOS PARTES PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE PERTUZUMAB EN COMBINACIÓN CON QUIMIOTERAPIA ESTÁNDAR FRENTE A PLACEBO MÁS QUIMIOTERAPIA ESTÁNDAR EN MUJERES CON CÁNCER EPITELIAL DE OVARIO RECURRENTE RESISTENTE A PLATINO CON EXPRESIÓN BAJA DE HER3 EN ARNm","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.249101468176302e-119,3.4724570586651465e-16,1.0,"2+",0.2346067419233926,0.7653932580766033,"No",0.9580958973237418,0.041904102676231396,"Yes",1.0,6.438765977545363e-28,"No",3.6218578458522446e-10,0.9999999996377938,"Yes",0.06599988420957063,0.9340001157904138,"Yes",1.0,2.388271782999962e-37,"No",5.036436561355494e-14,0.9999999999999432,"Yes"
"2011-005975-17","A two-part randomized Phase III double-blind multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.3145975335635195e-67,7.762756166128282e-10,0.9999999992237179,"2+",0.4292503132588672,0.5707496867411256,"No",0.7715453452396321,0.22845465476037777,"Yes",1.0,1.846765679209894e-15,"No",1.3669855259897418e-07,0.9999998633014494,"Yes",0.24768885284659645,0.7523111471534032,"Yes",0.9999999999984368,1.564828108297118e-12,"No",1.7541975009944085e-08,0.9999999824580359,"Yes"
"2011-005975-17","A two-part randomized Phase III double-blind multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.3145975335635195e-67,7.762756166128282e-10,0.9999999992237179,"2+",0.4292503132588672,0.5707496867411256,"No",0.7715453452396321,0.22845465476037777,"Yes",1.0,1.846765679209894e-15,"No",1.3669855259897418e-07,0.9999998633014494,"Yes",0.24768885284659645,0.7523111471534032,"Yes",0.9999999999984368,1.564828108297118e-12,"No",1.7541975009944085e-08,0.9999999824580359,"Yes"
"2011-005975-17","A two-part randomized Phase III double-blind multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.3145975335635195e-67,7.762756166128282e-10,0.9999999992237179,"2+",0.4292503132588672,0.5707496867411256,"No",0.7715453452396321,0.22845465476037777,"Yes",1.0,1.846765679209894e-15,"No",1.3669855259897418e-07,0.9999998633014494,"Yes",0.24768885284659645,0.7523111471534032,"Yes",0.9999999999984368,1.564828108297118e-12,"No",1.7541975009944085e-08,0.9999999824580359,"Yes"
"2011-005991-40","A 6 Week Randomized Multicenter Double-blind Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension With or Without Chronic Kidney Disease Followed by a 20 Week OpenlabelTitration PhaseEstudio de 6 semanas aleatorizado multicéntrico doble ciego y con doble simulación para evaluar la respuesta a la dosis de valsartán en términos de reducción de la presión arterial en niños de 1 a 5 años con hipertensión con o sin enfermedad renal crónica seguido de una fase abierta de ajuste de la dosis de 20 semanas.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0839370439403056e-132,2.175854136226313e-19,1.0,"2+",1.0,1.1473941678586892e-21,"No",2.4850315160119788e-19,1.0,"Yes",1.0,5.044243100587123e-27,"No",2.6510968896293887e-19,1.0,"Yes",1.5196422024031966e-07,0.9999998480357819,"Yes",1.0,1.6350542123195803e-15,"No",2.60876790691613e-18,1.0,"Yes"
"2011-005991-40","A 6 Week Randomized Multicenter Double-blind Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension With or Without Chronic Kidney Disease Followed by a 20 Week OpenlabelTitration PhaseEstudio de 6 semanas aleatorizado multicéntrico doble ciego y con doble simulación para evaluar la respuesta a la dosis de valsartán en términos de reducción de la presión arterial en niños de 1 a 5 años con hipertensión con o sin enfermedad renal crónica seguido de una fase abierta de ajuste de la dosis de 20 semanas.","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0839370439403056e-132,2.175854136226313e-19,1.0,"2+",1.0,1.1473941678586892e-21,"No",2.4850315160119788e-19,1.0,"Yes",1.0,5.044243100587123e-27,"No",2.6510968896293887e-19,1.0,"Yes",1.5196422024031966e-07,0.9999998480357819,"Yes",1.0,1.6350542123195803e-15,"No",2.60876790691613e-18,1.0,"Yes"
"2011-005991-40","A 6 Week Randomized Multicenter Double-blind Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension With or Without Chronic Kidney Disease Followed by a 20 Week OpenlabelTitration Phase","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.000103652195657e-72,2.8333893747991857e-12,0.9999999999971579,"2+",0.9999999999998579,1.4951105000124e-13,"No",2.9151078909795947e-12,0.9999999999970726,"Yes",0.9999999975348431,2.4651530587099724e-09,"No",9.176702289318536e-13,0.9999999999990905,"Yes",0.00023469125756862944,0.9997653087424397,"Yes",0.9101232910171538,0.08987670898283272,"No",6.371798973650457e-11,0.9999999999362786,"Yes"
"2011-005991-40","A 6 Week Randomized Multicenter Double-blind Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension With or Without Chronic Kidney Disease Followed by a 20 Week OpenlabelTitration PhaseEstudio de 6 semanas aleatorizado multicéntrico doble ciego y con doble simulación para evaluar la respuesta a la dosis de valsartán en términos de reducción de la presión arterial en niños de 1 a 5 años con hipertensión con o sin enfermedad renal crónica seguido de una fase abierta de ajuste de la dosis de 20 semanas.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0839370439403056e-132,2.175854136226313e-19,1.0,"2+",1.0,1.1473941678586892e-21,"No",2.4850315160119788e-19,1.0,"Yes",1.0,5.044243100587123e-27,"No",2.6510968896293887e-19,1.0,"Yes",1.5196422024031966e-07,0.9999998480357819,"Yes",1.0,1.6350542123195803e-15,"No",2.60876790691613e-18,1.0,"Yes"
"2011-005991-40","A 6 Week Randomized Multicenter Double-blind Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension With or Without Chronic Kidney Disease Followed by a 20 Week OpenlabelTitration PhaseEstudio de 6 semanas aleatorizado multicéntrico doble ciego y con doble simulación para evaluar la respuesta a la dosis de valsartán en términos de reducción de la presión arterial en niños de 1 a 5 años con hipertensión con o sin enfermedad renal crónica seguido de una fase abierta de ajuste de la dosis de 20 semanas.","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0839370439403056e-132,2.175854136226313e-19,1.0,"2+",1.0,1.1473941678586892e-21,"No",2.4850315160119788e-19,1.0,"Yes",1.0,5.044243100587123e-27,"No",2.6510968896293887e-19,1.0,"Yes",1.5196422024031966e-07,0.9999998480357819,"Yes",1.0,1.6350542123195803e-15,"No",2.60876790691613e-18,1.0,"Yes"
"2011-005991-40","A 6 Week Randomized Multicenter Double-blind Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension With or Without Chronic Kidney Disease Followed by a 20 Week OpenlabelTitration Phase","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.000103652195657e-72,2.8333893747991857e-12,0.9999999999971579,"2+",0.9999999999998579,1.4951105000124e-13,"No",2.9151078909795947e-12,0.9999999999970726,"Yes",0.9999999975348431,2.4651530587099724e-09,"No",9.176702289318536e-13,0.9999999999990905,"Yes",0.00023469125756862944,0.9997653087424397,"Yes",0.9101232910171538,0.08987670898283272,"No",6.371798973650457e-11,0.9999999999362786,"Yes"
"2011-005991-40","A 6 Week Randomized Multicenter Double-blind Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension With or Without Chronic Kidney Disease Followed by a 20 Week OpenlabelTitration PhaseEstudio de 6 semanas aleatorizado multicéntrico doble ciego y con doble simulación para evaluar la respuesta a la dosis de valsartán en términos de reducción de la presión arterial en niños de 1 a 5 años con hipertensión con o sin enfermedad renal crónica seguido de una fase abierta de ajuste de la dosis de 20 semanas.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.0839370439403056e-132,2.175854136226313e-19,1.0,"2+",1.0,1.1473941678586892e-21,"No",2.4850315160119788e-19,1.0,"Yes",1.0,5.044243100587123e-27,"No",2.6510968896293887e-19,1.0,"Yes",1.5196422024031966e-07,0.9999998480357819,"Yes",1.0,1.6350542123195803e-15,"No",2.60876790691613e-18,1.0,"Yes"
"2011-005991-40","A 6 Week Randomized Multicenter Double-blind Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension With or Without Chronic Kidney Disease Followed by a 20 Week OpenlabelTitration Phase","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.000103652195657e-72,2.8333893747991857e-12,0.9999999999971579,"2+",0.9999999999998579,1.4951105000124e-13,"No",2.9151078909795947e-12,0.9999999999970726,"Yes",0.9999999975348431,2.4651530587099724e-09,"No",9.176702289318536e-13,0.9999999999990905,"Yes",0.00023469125756862944,0.9997653087424397,"Yes",0.9101232910171538,0.08987670898283272,"No",6.371798973650457e-11,0.9999999999362786,"Yes"
"2011-006041-14","A Multi-Dose Double-Blind Double-Dummy Active Control Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7015116361938783e-46,1.5592359845424252e-15,1.0,"2+",0.9999999999998579,1.5097669245747454e-13,"No",3.6711280875538605e-12,0.9999999999963337,"Yes",0.9999873833616091,1.2616638381935585e-05,"No",1.1100533804523437e-12,0.9999999999988917,"Yes",3.299027283448351e-05,0.9999670097271581,"Yes",0.9999965974331154,3.4025668936794885e-06,"No",2.441153550560908e-13,0.9999999999997442,"Yes"
"2011-006250-90","Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).Randomisierte doppelblinde Placebo-kontrollierte Phase II-Studie zur Bewertung von Wirksamkeit und Sicherheit einer Behandlung mit Sorafenib bei Patienten mit medullärem Schilddrüsenkarzinom (SUMMIT) ","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.65591790357175e-82,2.019098121183976e-12,0.9999999999979536,"2+",0.9999999953748785,4.625099525606508e-09,"No",6.715268125549281e-08,0.9999999328472905,"Yes",0.9999999999844817,1.5523295629356353e-11,"No",4.2337300860249673e-10,0.9999999995766302,"Yes",0.1691957575991357,0.8308042424008919,"Yes",0.9999997257809049,2.7421912124700557e-07,"Yes",2.4432491622980076e-09,0.9999999975567563,"Yes"
"2011-006250-90","Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).Randomisierte doppelblinde Placebo-kontrollierte Phase II-Studie zur Bewertung von Wirksamkeit und Sicherheit einer Behandlung mit Sorafenib bei Patienten mit medullärem Schilddrüsenkarzinom (SUMMIT)","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.65591790357175e-82,2.019098121183976e-12,0.9999999999979536,"2+",0.9999999953748785,4.625099525606508e-09,"No",6.715268125549281e-08,0.9999999328472905,"Yes",0.9999999999844817,1.5523295629356353e-11,"No",4.2337300860249673e-10,0.9999999995766302,"Yes",0.1691957575991357,0.8308042424008919,"Yes",0.9999997257809049,2.7421912124700557e-07,"Yes",2.4432491622980076e-09,0.9999999975567563,"Yes"
"2012-000066-37","Double-blind randomized placebo-controlled study on efficacy safety and tolerability of ancrod in patients with sudden sensorineural hearing lossDvojitě zaslepená randomizovaná placebem kontrolovaná studie účinnosti bezpečnosti a snášenlivosti přípravku ancrod u pacientů s náhlou sensorineurální ztrátou sluchu","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.440591329671448e-52,1.313984132906949e-18,1.0,"2+",1.0,2.195266471981344e-16,"No",8.583154587827898e-16,1.0,"Yes",1.0,5.942136071618591e-18,"No",8.2274454323268e-18,1.0,"Yes",8.909599580825873e-05,0.9999109040041891,"Yes",0.9999999944072898,5.5927204412183605e-09,"No",7.384675036900154e-15,1.0,"Yes"
"2012-000066-37","Double-blind randomized placebo-controlled study on efficacy safety and tolerability of ancrod in patients with sudden sensorineural hearing lossDoppelblinde randomisierte plazebokontrollierte Studie zur Wirksamkeit Sicherheit und Verträglichkeit von Ancrod bei Patienten mit plötzlichem sensorineuralem Hörverlust (Hörsturz).","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.777998389750583e-45,2.2128565905758128e-08,0.9999999778714258,"2+",0.9999999953661814,4.6338093538486695e-09,"No",4.470219701931507e-08,0.9999999552977964,"Yes",0.9831030055466199,0.016896994453382205,"No",2.6180475150975026e-08,0.9999999738195133,"Yes",0.21533144056183703,0.7846685594381532,"Yes",0.9976402745354721,0.002359725464537465,"No",9.403295873430421e-07,0.9999990596704026,"Yes"
"2012-000072-42","A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.066817397386199e-31,2.7906790660264003e-05,0.9999720932093469,"2+",4.827235954800397e-07,0.9999995172764102,"Yes",0.9999994255486458,5.744513599601102e-07,"No",0.999999999999261,7.329893454897866e-13,"No",2.8156378396473812e-05,0.9999718436216093,"Yes",0.28531330168225955,0.7146866983177405,"No",0.999999999999119,8.782571663485028e-13,"No",1.1103254359991915e-05,0.9999888967456435,"Yes"
"2012-000072-42","A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.066817397386199e-31,2.7906790660264003e-05,0.9999720932093469,"2+",4.827235954800397e-07,0.9999995172764102,"Yes",0.9999994255486458,5.744513599601102e-07,"No",0.999999999999261,7.329893454897866e-13,"No",2.8156378396473812e-05,0.9999718436216093,"Yes",0.28531330168225955,0.7146866983177405,"No",0.999999999999119,8.782571663485028e-13,"No",1.1103254359991915e-05,0.9999888967456435,"Yes"
"2012-000072-42","A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.066817397386199e-31,2.7906790660264003e-05,0.9999720932093469,"2+",4.827235954800397e-07,0.9999995172764102,"Yes",0.9999994255486458,5.744513599601102e-07,"No",0.999999999999261,7.329893454897866e-13,"No",2.8156378396473812e-05,0.9999718436216093,"Yes",0.28531330168225955,0.7146866983177405,"No",0.999999999999119,8.782571663485028e-13,"No",1.1103254359991915e-05,0.9999888967456435,"Yes"
"2012-000072-42","A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.066817397386199e-31,2.7906790660264003e-05,0.9999720932093469,"2+",4.827235954800397e-07,0.9999995172764102,"Yes",0.9999994255486458,5.744513599601102e-07,"No",0.999999999999261,7.329893454897866e-13,"No",2.8156378396473812e-05,0.9999718436216093,"Yes",0.28531330168225955,0.7146866983177405,"No",0.999999999999119,8.782571663485028e-13,"No",1.1103254359991915e-05,0.9999888967456435,"Yes"
"2012-000072-42","A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.066817397386199e-31,2.7906790660264003e-05,0.9999720932093469,"2+",4.827235954800397e-07,0.9999995172764102,"Yes",0.9999994255486458,5.744513599601102e-07,"No",0.999999999999261,7.329893454897866e-13,"No",2.8156378396473812e-05,0.9999718436216093,"Yes",0.28531330168225955,0.7146866983177405,"No",0.999999999999119,8.782571663485028e-13,"No",1.1103254359991915e-05,0.9999888967456435,"Yes"
"2012-000072-42","A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.066817397386199e-31,2.7906790660264003e-05,0.9999720932093469,"2+",4.827235954800397e-07,0.9999995172764102,"Yes",0.9999994255486458,5.744513599601102e-07,"No",0.999999999999261,7.329893454897866e-13,"No",2.8156378396473812e-05,0.9999718436216093,"Yes",0.28531330168225955,0.7146866983177405,"No",0.999999999999119,8.782571663485028e-13,"No",1.1103254359991915e-05,0.9999888967456435,"Yes"
"2012-000072-42","A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.066817397386199e-31,2.7906790660264003e-05,0.9999720932093469,"2+",4.827235954800397e-07,0.9999995172764102,"Yes",0.9999994255486458,5.744513599601102e-07,"No",0.999999999999261,7.329893454897866e-13,"No",2.8156378396473812e-05,0.9999718436216093,"Yes",0.28531330168225955,0.7146866983177405,"No",0.999999999999119,8.782571663485028e-13,"No",1.1103254359991915e-05,0.9999888967456435,"Yes"
"2012-000072-42","A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.066817397386199e-31,2.7906790660264003e-05,0.9999720932093469,"2+",4.827235954800397e-07,0.9999995172764102,"Yes",0.9999994255486458,5.744513599601102e-07,"No",0.999999999999261,7.329893454897866e-13,"No",2.8156378396473812e-05,0.9999718436216093,"Yes",0.28531330168225955,0.7146866983177405,"No",0.999999999999119,8.782571663485028e-13,"No",1.1103254359991915e-05,0.9999888967456435,"Yes"
"2012-000072-42","A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.066817397386199e-31,2.7906790660264003e-05,0.9999720932093469,"2+",4.827235954800397e-07,0.9999995172764102,"Yes",0.9999994255486458,5.744513599601102e-07,"No",0.999999999999261,7.329893454897866e-13,"No",2.8156378396473812e-05,0.9999718436216093,"Yes",0.28531330168225955,0.7146866983177405,"No",0.999999999999119,8.782571663485028e-13,"No",1.1103254359991915e-05,0.9999888967456435,"Yes"
"2012-000075-16","Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis","DK","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","No","No","No","1","No",1.404158504505359e-21,0.42010000164463324,0.5798999983553699,"1",0.13110256654978697,0.8688974334502167,"Yes",0.7784146466258346,0.221585353374162,"No",0.9999999999034089,9.659781727825373e-11,"No",0.6702524497417772,0.32974755025822267,"No",0.6419992171747709,0.35800078282523,"No",0.9999968976312579,3.102368742126478e-06,"No",0.14272940163771689,0.8572705983622781,"No"
"2012-000075-16","Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone MetastasisPodávání chloridu radnatého s 223Ra (Alpharadin) u karcinomu prostaty rezistentního vůči kastraci (hormonálně refrakterního) s metastázami v kostech","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.2336480048182242e-35,0.00017830869399555413,0.9998216913059904,"1",0.01694043290339792,0.9830595670965998,"Yes",0.936834594922716,0.06316540507727568,"No",1.0,6.643259165132672e-19,"No",5.18638968496387e-06,0.9999948136103061,"No",0.39263864930201525,0.6073613506979874,"No",0.9999999999994884,5.037063437785208e-13,"No",0.0005151508432012355,0.9994848491568064,"No"
"2012-000075-16","Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-  Refractory) Prostate Cancer Patients with Bone MetastasisCloruro di radio-223 (Alpharadin) nei pazienti affetti da tumore alla prostata resistente alla castrazione  (ormonerefrattario) con metastasi ossee","GB","No","No","Yes","ok","Yes","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",5.420243080270651e-40,0.7377352468045224,0.2622647531954708,"1",5.235147953810491e-06,0.9999947648520375,"Yes",0.9999832806809849,1.6719319008306594e-05,"No",1.0,3.293550070646993e-18,"No",0.5644563083672389,0.4355436916327657,"No",0.21807235500080543,0.7819276449992084,"No",0.9999999999998579,1.417997705683975e-13,"No",0.36788995389425727,0.6321100461057472,"No"
"2012-000075-16","Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone MetastasisPodávání chloridu radnatého s 223Ra (Alpharadin) u karcinomu prostaty rezistentního vůči kastraci (hormonálně refrakterního) s metastázami v kostech","NO","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.2336480048182242e-35,0.00017830869399555413,0.9998216913059904,"1",0.01694043290339792,0.9830595670965998,"Yes",0.936834594922716,0.06316540507727568,"No",1.0,6.643259165132672e-19,"No",5.18638968496387e-06,0.9999948136103061,"No",0.39263864930201525,0.6073613506979874,"No",0.9999999999994884,5.037063437785208e-13,"No",0.0005151508432012355,0.9994848491568064,"No"
"2012-000075-16","Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-  Refractory) Prostate Cancer Patients with Bone MetastasisCloruro di radio-223 (Alpharadin) nei pazienti affetti da tumore alla prostata resistente alla castrazione  (ormonerefrattario) con metastasi ossee","DE","No","No","Yes","ok","Yes","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",5.420243080270651e-40,0.7377352468045224,0.2622647531954708,"1",5.235147953810491e-06,0.9999947648520375,"Yes",0.9999832806809849,1.6719319008306594e-05,"No",1.0,3.293550070646993e-18,"No",0.5644563083672389,0.4355436916327657,"No",0.21807235500080543,0.7819276449992084,"No",0.9999999999998579,1.417997705683975e-13,"No",0.36788995389425727,0.6321100461057472,"No"
"2012-000075-16","Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-  Refractory) Prostate Cancer Patients with Bone MetastasisCloruro di radio-223 (Alpharadin) nei pazienti affetti da tumore alla prostata resistente alla castrazione  (ormonerefrattario) con metastasi ossee","IE","No","No","Yes","ok","Yes","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",5.420243080270651e-40,0.7377352468045224,0.2622647531954708,"1",5.235147953810491e-06,0.9999947648520375,"Yes",0.9999832806809849,1.6719319008306594e-05,"No",1.0,3.293550070646993e-18,"No",0.5644563083672389,0.4355436916327657,"No",0.21807235500080543,0.7819276449992084,"No",0.9999999999998579,1.417997705683975e-13,"No",0.36788995389425727,0.6321100461057472,"No"
"2012-000075-16","Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone MetastasisPodávání chloridu radnatého s 223Ra (Alpharadin) u karcinomu prostaty rezistentního vůči kastraci (hormonálně refrakterního) s metastázami v kostech","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.2336480048182242e-35,0.00017830869399555413,0.9998216913059904,"1",0.01694043290339792,0.9830595670965998,"Yes",0.936834594922716,0.06316540507727568,"No",1.0,6.643259165132672e-19,"No",5.18638968496387e-06,0.9999948136103061,"No",0.39263864930201525,0.6073613506979874,"No",0.9999999999994884,5.037063437785208e-13,"No",0.0005151508432012355,0.9994848491568064,"No"
"2012-000075-16","Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis","CZ","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","No","No","No","1","No",1.404158504505359e-21,0.42010000164463324,0.5798999983553699,"1",0.13110256654978697,0.8688974334502167,"Yes",0.7784146466258346,0.221585353374162,"No",0.9999999999034089,9.659781727825373e-11,"No",0.6702524497417772,0.32974755025822267,"No",0.6419992171747709,0.35800078282523,"No",0.9999968976312579,3.102368742126478e-06,"No",0.14272940163771689,0.8572705983622781,"No"
"2012-000075-16","Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone MetastasisPodávání chloridu radnatého s 223Ra (Alpharadin) u karcinomu prostaty rezistentního vůči kastraci (hormonálně refrakterního) s metastázami v kostech","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.2336480048182242e-35,0.00017830869399555413,0.9998216913059904,"1",0.01694043290339792,0.9830595670965998,"Yes",0.936834594922716,0.06316540507727568,"No",1.0,6.643259165132672e-19,"No",5.18638968496387e-06,0.9999948136103061,"No",0.39263864930201525,0.6073613506979874,"No",0.9999999999994884,5.037063437785208e-13,"No",0.0005151508432012355,0.9994848491568064,"No"
"2012-000075-16","Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis","AT","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","No","No","No","1","No",1.404158504505359e-21,0.42010000164463324,0.5798999983553699,"1",0.13110256654978697,0.8688974334502167,"Yes",0.7784146466258346,0.221585353374162,"No",0.9999999999034089,9.659781727825373e-11,"No",0.6702524497417772,0.32974755025822267,"No",0.6419992171747709,0.35800078282523,"No",0.9999968976312579,3.102368742126478e-06,"No",0.14272940163771689,0.8572705983622781,"No"
"2012-000075-16","Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-  Refractory) Prostate Cancer Patients with Bone MetastasisCloruro di radio-223 (Alpharadin) nei pazienti affetti da tumore alla prostata resistente alla castrazione  (ormonerefrattario) con metastasi ossee","FI","No","No","Yes","ok","Yes","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",5.420243080270651e-40,0.7377352468045224,0.2622647531954708,"1",5.235147953810491e-06,0.9999947648520375,"Yes",0.9999832806809849,1.6719319008306594e-05,"No",1.0,3.293550070646993e-18,"No",0.5644563083672389,0.4355436916327657,"No",0.21807235500080543,0.7819276449992084,"No",0.9999999999998579,1.417997705683975e-13,"No",0.36788995389425727,0.6321100461057472,"No"
"2012-000075-16","Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-  Refractory) Prostate Cancer Patients with Bone MetastasisCloruro di radio-223 (Alpharadin) nei pazienti affetti da tumore alla prostata resistente alla castrazione  (ormonerefrattario) con metastasi ossee","NL","No","No","Yes","ok","Yes","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",5.420243080270651e-40,0.7377352468045224,0.2622647531954708,"1",5.235147953810491e-06,0.9999947648520375,"Yes",0.9999832806809849,1.6719319008306594e-05,"No",1.0,3.293550070646993e-18,"No",0.5644563083672389,0.4355436916327657,"No",0.21807235500080543,0.7819276449992084,"No",0.9999999999998579,1.417997705683975e-13,"No",0.36788995389425727,0.6321100461057472,"No"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0032002949410927e-58,4.611949259429749e-17,1.0,"2+",0.99999974395232,2.5604769277105606e-07,"No",1.1758031666665021e-06,0.9999988241968459,"Yes",1.0,2.85587013982381e-18,"No",3.5948036572611855e-15,1.0,"Yes",0.008787377686652114,0.9912126223133589,"Yes",0.9999999999971294,2.879479498831946e-12,"No",1.4872413864773192e-16,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.Studio di fase III in doppio cieco randomizzato con nintedanib in aggiunta alle migliori terapie di supporto (BSC) controllato verso placebo più BSC in pazienti con carcinoma del colon retto refrattario alle terapie standard.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8811525102252253e-110,6.156844783715424e-28,1.0,"2+",0.9999999999965326,3.4842090710009033e-12,"No",3.250643345304099e-11,0.9999999999674856,"Yes",1.0,1.0348340619190208e-39,"No",2.8102815296631007e-30,1.0,"Yes",1.8686360154252193e-05,0.9999813136398336,"Yes",1.0,5.886478154702164e-32,"No",3.4568199931659164e-27,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.Studio di fase III in doppio cieco randomizzato con nintedanib in aggiunta alle migliori terapie di supporto (BSC) controllato verso placebo più BSC in pazienti con carcinoma del colon retto refrattario alle terapie standard.","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8811525102252253e-110,6.156844783715424e-28,1.0,"2+",0.9999999999965326,3.4842090710009033e-12,"No",3.250643345304099e-11,0.9999999999674856,"Yes",1.0,1.0348340619190208e-39,"No",2.8102815296631007e-30,1.0,"Yes",1.8686360154252193e-05,0.9999813136398336,"Yes",1.0,5.886478154702164e-32,"No",3.4568199931659164e-27,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0032002949410927e-58,4.611949259429749e-17,1.0,"2+",0.99999974395232,2.5604769277105606e-07,"No",1.1758031666665021e-06,0.9999988241968459,"Yes",1.0,2.85587013982381e-18,"No",3.5948036572611855e-15,1.0,"Yes",0.008787377686652114,0.9912126223133589,"Yes",0.9999999999971294,2.879479498831946e-12,"No",1.4872413864773192e-16,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.","LU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0032002949410927e-58,4.611949259429749e-17,1.0,"2+",0.99999974395232,2.5604769277105606e-07,"No",1.1758031666665021e-06,0.9999988241968459,"Yes",1.0,2.85587013982381e-18,"No",3.5948036572611855e-15,1.0,"Yes",0.008787377686652114,0.9912126223133589,"Yes",0.9999999999971294,2.879479498831946e-12,"No",1.4872413864773192e-16,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0032002949410927e-58,4.611949259429749e-17,1.0,"2+",0.99999974395232,2.5604769277105606e-07,"No",1.1758031666665021e-06,0.9999988241968459,"Yes",1.0,2.85587013982381e-18,"No",3.5948036572611855e-15,1.0,"Yes",0.008787377686652114,0.9912126223133589,"Yes",0.9999999999971294,2.879479498831946e-12,"No",1.4872413864773192e-16,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0032002949410927e-58,4.611949259429749e-17,1.0,"2+",0.99999974395232,2.5604769277105606e-07,"No",1.1758031666665021e-06,0.9999988241968459,"Yes",1.0,2.85587013982381e-18,"No",3.5948036572611855e-15,1.0,"Yes",0.008787377686652114,0.9912126223133589,"Yes",0.9999999999971294,2.879479498831946e-12,"No",1.4872413864773192e-16,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.Studio di fase III in doppio cieco randomizzato con nintedanib in aggiunta alle migliori terapie di supporto (BSC) controllato verso placebo più BSC in pazienti con carcinoma del colon retto refrattario alle terapie standard.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8811525102252253e-110,6.156844783715424e-28,1.0,"2+",0.9999999999965326,3.4842090710009033e-12,"No",3.250643345304099e-11,0.9999999999674856,"Yes",1.0,1.0348340619190208e-39,"No",2.8102815296631007e-30,1.0,"Yes",1.8686360154252193e-05,0.9999813136398336,"Yes",1.0,5.886478154702164e-32,"No",3.4568199931659164e-27,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0032002949410927e-58,4.611949259429749e-17,1.0,"2+",0.99999974395232,2.5604769277105606e-07,"No",1.1758031666665021e-06,0.9999988241968459,"Yes",1.0,2.85587013982381e-18,"No",3.5948036572611855e-15,1.0,"Yes",0.008787377686652114,0.9912126223133589,"Yes",0.9999999999971294,2.879479498831946e-12,"No",1.4872413864773192e-16,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0032002949410927e-58,4.611949259429749e-17,1.0,"2+",0.99999974395232,2.5604769277105606e-07,"No",1.1758031666665021e-06,0.9999988241968459,"Yes",1.0,2.85587013982381e-18,"No",3.5948036572611855e-15,1.0,"Yes",0.008787377686652114,0.9912126223133589,"Yes",0.9999999999971294,2.879479498831946e-12,"No",1.4872413864773192e-16,1.0,"Yes"
"2012-000095-42","A double-blind randomised placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0032002949410927e-58,4.611949259429749e-17,1.0,"2+",0.99999974395232,2.5604769277105606e-07,"No",1.1758031666665021e-06,0.9999988241968459,"Yes",1.0,2.85587013982381e-18,"No",3.5948036572611855e-15,1.0,"Yes",0.008787377686652114,0.9912126223133589,"Yes",0.9999999999971294,2.879479498831946e-12,"No",1.4872413864773192e-16,1.0,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.4586212784969345e-36,2.3903661583687222e-05,0.9999760963384169,"2+",2.64526486104934e-10,0.9999999997354792,"Yes",0.9999999996114894,3.885105238770282e-10,"No",0.9999999999997016,2.930840339603711e-13,"No",0.41832509032676085,0.5816749096732328,"Yes",0.9212576570267053,0.07874234297329713,"Yes",0.9937150016958379,0.00628499830415946,"No",0.0002254287274607892,0.9997745712725403,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2106563864991805e-35,2.385153301417284e-05,0.9999761484669926,"2+",2.487500664484231e-10,0.9999999997512532,"Yes",0.9999999996301199,3.698865119923258e-10,"No",0.9999999999996733,3.2964231165734127e-13,"No",0.3141558577554865,0.685844142244509,"Yes",0.9420090268170859,0.05799097318291077,"Yes",0.9692938906674177,0.030706109332583907,"No",0.00028191378831097933,0.9997180862116883,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple MyelomaEstudio de fase 3 aleatorizado y abierto de carfilzomib y dexametasona en comparación con bortezomib y dexametasona en pacientes con mieloma múltiple en recidiva","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.342298082833168e-68,1.5655201646975495e-09,0.9999999984344755,"2+",7.024519733219455e-18,1.0,"Yes",1.0,1.1476269968491195e-17,"No",1.0,5.2831310095602723e-20,"No",0.5603623843992332,0.43963761560076725,"Yes",0.9922739295072802,0.007726070492731971,"Yes",0.999999969784057,3.021594853481584e-08,"No",1.720266834101524e-09,0.9999999982797193,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2106563864991805e-35,2.385153301417284e-05,0.9999761484669926,"2+",2.487500664484231e-10,0.9999999997512532,"Yes",0.9999999996301199,3.698865119923258e-10,"No",0.9999999999996733,3.2964231165734127e-13,"No",0.3141558577554865,0.685844142244509,"Yes",0.9420090268170859,0.05799097318291077,"Yes",0.9692938906674177,0.030706109332583907,"No",0.00028191378831097933,0.9997180862116883,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2106563864991805e-35,2.385153301417284e-05,0.9999761484669926,"2+",2.487500664484231e-10,0.9999999997512532,"Yes",0.9999999996301199,3.698865119923258e-10,"No",0.9999999999996733,3.2964231165734127e-13,"No",0.3141558577554865,0.685844142244509,"Yes",0.9420090268170859,0.05799097318291077,"Yes",0.9692938906674177,0.030706109332583907,"No",0.00028191378831097933,0.9997180862116883,"Yes"
"2012-000128-16","Study of Carfilzomib Plus Dexamethasone versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple MyelomaStudio di Fase 3 randomizzato in aperto di carfilzomib piu' desametasone rispetto a bortezomib piu' desametasone in pazienti con mieloma multiplo recidivante","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.252002162777958e-57,4.155442845116685e-10,0.9999999995844462,"2+",1.5574870314603626e-18,1.0,"Yes",1.0,4.2071878734796745e-18,"No",1.0,4.5186190605927274e-24,"No",0.03861835709072329,0.9613816429092752,"Yes",0.05965442479516381,0.9403455752048357,"Yes",1.0,4.13143536166641e-17,"No",3.5620966511214217e-07,0.9999996437903245,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2106563864991805e-35,2.385153301417284e-05,0.9999761484669926,"2+",2.487500664484231e-10,0.9999999997512532,"Yes",0.9999999996301199,3.698865119923258e-10,"No",0.9999999999996733,3.2964231165734127e-13,"No",0.3141558577554865,0.685844142244509,"Yes",0.9420090268170859,0.05799097318291077,"Yes",0.9692938906674177,0.030706109332583907,"No",0.00028191378831097933,0.9997180862116883,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2106563864991805e-35,2.385153301417284e-05,0.9999761484669926,"2+",2.487500664484231e-10,0.9999999997512532,"Yes",0.9999999996301199,3.698865119923258e-10,"No",0.9999999999996733,3.2964231165734127e-13,"No",0.3141558577554865,0.685844142244509,"Yes",0.9420090268170859,0.05799097318291077,"Yes",0.9692938906674177,0.030706109332583907,"No",0.00028191378831097933,0.9997180862116883,"Yes"
"2012-000128-16","Study of Carfilzomib Plus Dexamethasone versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple MyelomaStudio di Fase 3 randomizzato in aperto di carfilzomib piu' desametasone rispetto a bortezomib piu' desametasone in pazienti con mieloma multiplo recidivante","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.252002162777958e-57,4.155442845116685e-10,0.9999999995844462,"2+",1.5574870314603626e-18,1.0,"Yes",1.0,4.2071878734796745e-18,"No",1.0,4.5186190605927274e-24,"No",0.03861835709072329,0.9613816429092752,"Yes",0.05965442479516381,0.9403455752048357,"Yes",1.0,4.13143536166641e-17,"No",3.5620966511214217e-07,0.9999996437903245,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple MyelomaEstudio de fase 3 aleatorizado y abierto de carfilzomib y dexametasona en comparación con bortezomib y dexametasona en pacientes con mieloma múltiple en recidiva","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.342298082833168e-68,1.5655201646975495e-09,0.9999999984344755,"2+",7.024519733219455e-18,1.0,"Yes",1.0,1.1476269968491195e-17,"No",1.0,5.2831310095602723e-20,"No",0.5603623843992332,0.43963761560076725,"Yes",0.9922739295072802,0.007726070492731971,"Yes",0.999999969784057,3.021594853481584e-08,"No",1.720266834101524e-09,0.9999999982797193,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2106563864991805e-35,2.385153301417284e-05,0.9999761484669926,"2+",2.487500664484231e-10,0.9999999997512532,"Yes",0.9999999996301199,3.698865119923258e-10,"No",0.9999999999996733,3.2964231165734127e-13,"No",0.3141558577554865,0.685844142244509,"Yes",0.9420090268170859,0.05799097318291077,"Yes",0.9692938906674177,0.030706109332583907,"No",0.00028191378831097933,0.9997180862116883,"Yes"
"2012-000128-16","A Randomized Open-label Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma","BG","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2106563864991805e-35,2.385153301417284e-05,0.9999761484669926,"2+",2.487500664484231e-10,0.9999999997512532,"Yes",0.9999999996301199,3.698865119923258e-10,"No",0.9999999999996733,3.2964231165734127e-13,"No",0.3141558577554865,0.685844142244509,"Yes",0.9420090268170859,0.05799097318291077,"Yes",0.9692938906674177,0.030706109332583907,"No",0.00028191378831097933,0.9997180862116883,"Yes"
"2012-000171-17","A Three Part Open-Label Study to Assess the Pharmacokinetics of Lanthanum Carbonate compare the Efficacy Safety and Tolerability of 8 weeks treatment with Lanthanum Carbonate and Calcium Carbonate using a Crossover design and Investigate the  Efficacy and Safety of 8 months of Treatment with Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents aged 10 years to <18 years with Chronic Kidney Disease on Dialysis.","CZ","No","No","Yes","ok","Yes","Yes","Yes","Yes","2+","Yes","No","Yes","No","No","No","Yes","No","2+","No",6.079651799762417e-50,6.419341989184037e-06,0.9999935806580124,"1",3.413123609523743e-06,0.9999965868763906,"Yes",0.9999988337227117,1.166277290423805e-06,"No",0.9999999996279598,3.7204065081337036e-10,"No",3.2319540151691485e-06,0.9999967680459964,"Yes",0.07697215473844318,0.9230278452615621,"No",4.452342731315523e-08,0.999999955476569,"Yes",7.801272666139504e-05,0.9999219872733351,"No"
"2012-000171-17","A Three Part Open-Label Study to Assess the Pharmacokinetics of Lanthanum Carbonate compare the Efficacy Safety and Tolerability of 8 weeks treatment with Lanthanum Carbonate and Calcium Carbonate using a Crossover design and Investigate the  Efficacy and Safety of 8 months of Treatment with Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents aged 10 years to <18 years with Chronic Kidney Disease on Dialysis.","HU","No","No","Yes","ok","Yes","Yes","Yes","Yes","2+","Yes","No","Yes","No","No","No","Yes","No","2+","No",6.079651799762417e-50,6.419341989184037e-06,0.9999935806580124,"1",3.413123609523743e-06,0.9999965868763906,"Yes",0.9999988337227117,1.166277290423805e-06,"No",0.9999999996279598,3.7204065081337036e-10,"No",3.2319540151691485e-06,0.9999967680459964,"Yes",0.07697215473844318,0.9230278452615621,"No",4.452342731315523e-08,0.999999955476569,"Yes",7.801272666139504e-05,0.9999219872733351,"No"
"2012-000171-17","A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate Compare the Efficacy Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate using a Crossover design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 years to <18 Years With Chronic Kidney Disease on Dialysis","RO","No","No","Yes","ok","Yes","Yes","Yes","Yes","2+","Yes","No","Yes","No","No","No","Yes","No","2+","No",3.1046620586679943e-53,2.881782407996043e-06,0.9999971182176096,"1",4.372135436646602e-06,0.9999956278645723,"Yes",0.9999985158849185,1.4841150618751659e-06,"No",0.9999999996370548,3.629210986307923e-10,"No",1.4744196135648968e-06,0.9999985255804019,"Yes",0.06725547746315336,0.9327445225368485,"No",4.234160125866121e-08,0.9999999576584183,"Yes",4.187242834698836e-05,0.9999581275716664,"No"
"2012-000171-17","A Three Part Open-Label Study to Assess the Pharmacokinetics of Lanthanum Carbonate compare the Efficacy Safety and Tolerability of 8 weeks treatment with Lanthanum Carbonate and Calcium Carbonate using a Crossover design and Investigate the  Efficacy and Safety of 8 months of Treatment with Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents aged 10 years to <18 years with Chronic Kidney Disease on Dialysis.","PL","No","No","Yes","ok","Yes","Yes","Yes","Yes","2+","Yes","No","Yes","No","No","No","Yes","No","2+","No",6.079651799762417e-50,6.419341989184037e-06,0.9999935806580124,"1",3.413123609523743e-06,0.9999965868763906,"Yes",0.9999988337227117,1.166277290423805e-06,"No",0.9999999996279598,3.7204065081337036e-10,"No",3.2319540151691485e-06,0.9999967680459964,"Yes",0.07697215473844318,0.9230278452615621,"No",4.452342731315523e-08,0.999999955476569,"Yes",7.801272666139504e-05,0.9999219872733351,"No"
"2012-000171-17","A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate Compare the Efficacy Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate using a Crossover design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 years to <18 Years With Chronic Kidney Disease on Dialysis","DE","No","No","Yes","ok","Yes","Yes","Yes","Yes","2+","Yes","No","Yes","No","No","No","Yes","No","2+","No",3.1046620586679943e-53,2.881782407996043e-06,0.9999971182176096,"1",4.372135436646602e-06,0.9999956278645723,"Yes",0.9999985158849185,1.4841150618751659e-06,"No",0.9999999996370548,3.629210986307923e-10,"No",1.4744196135648968e-06,0.9999985255804019,"Yes",0.06725547746315336,0.9327445225368485,"No",4.234160125866121e-08,0.9999999576584183,"Yes",4.187242834698836e-05,0.9999581275716664,"No"
"2012-000171-17","A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate Compare the Efficacy Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate using a Crossover design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 years to <18 Years With Chronic Kidney Disease on Dialysis","Outside EU/EEA","No","No","Yes","ok","Yes","Yes","Yes","Yes","2+","Yes","No","Yes","No","No","No","Yes","No","2+","No",3.1046620586679943e-53,2.881782407996043e-06,0.9999971182176096,"1",4.372135436646602e-06,0.9999956278645723,"Yes",0.9999985158849185,1.4841150618751659e-06,"No",0.9999999996370548,3.629210986307923e-10,"No",1.4744196135648968e-06,0.9999985255804019,"Yes",0.06725547746315336,0.9327445225368485,"No",4.234160125866121e-08,0.9999999576584183,"Yes",4.187242834698836e-05,0.9999581275716664,"No"
"2012-000414-11","Multicenter placebo-controlled long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.562671193258507e-22,9.845280447387512e-07,0.9999990154719585,"2+",0.9999997587526658,2.4124733494410227e-07,"No",4.936308320955994e-07,0.9999995063691725,"Yes",0.9999928002647754,7.199735220220327e-06,"No",3.9943055098213255e-08,0.9999999600569405,"Yes",0.0004296216799282268,0.9995703783200673,"Yes",0.9999999860567642,1.3943235675902125e-08,"No",5.539594133231465e-05,0.9999446040586639,"Yes"
"2012-000414-11","Multicenter placebo-controlled long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.562671193258507e-22,9.845280447387512e-07,0.9999990154719585,"2+",0.9999997587526658,2.4124733494410227e-07,"No",4.936308320955994e-07,0.9999995063691725,"Yes",0.9999928002647754,7.199735220220327e-06,"No",3.9943055098213255e-08,0.9999999600569405,"Yes",0.0004296216799282268,0.9995703783200673,"Yes",0.9999999860567642,1.3943235675902125e-08,"No",5.539594133231465e-05,0.9999446040586639,"Yes"
"2012-000414-11","Multicenter placebo-controlled long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.562671193258507e-22,9.845280447387512e-07,0.9999990154719585,"2+",0.9999997587526658,2.4124733494410227e-07,"No",4.936308320955994e-07,0.9999995063691725,"Yes",0.9999928002647754,7.199735220220327e-06,"No",3.9943055098213255e-08,0.9999999600569405,"Yes",0.0004296216799282268,0.9995703783200673,"Yes",0.9999999860567642,1.3943235675902125e-08,"No",5.539594133231465e-05,0.9999446040586639,"Yes"
"2012-000414-11","Multicenter placebo-controlled long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.562671193258507e-22,9.845280447387512e-07,0.9999990154719585,"2+",0.9999997587526658,2.4124733494410227e-07,"No",4.936308320955994e-07,0.9999995063691725,"Yes",0.9999928002647754,7.199735220220327e-06,"No",3.9943055098213255e-08,0.9999999600569405,"Yes",0.0004296216799282268,0.9995703783200673,"Yes",0.9999999860567642,1.3943235675902125e-08,"No",5.539594133231465e-05,0.9999446040586639,"Yes"
"2012-000414-11","Multicenter placebo-controlled long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.562671193258507e-22,9.845280447387512e-07,0.9999990154719585,"2+",0.9999997587526658,2.4124733494410227e-07,"No",4.936308320955994e-07,0.9999995063691725,"Yes",0.9999928002647754,7.199735220220327e-06,"No",3.9943055098213255e-08,0.9999999600569405,"Yes",0.0004296216799282268,0.9995703783200673,"Yes",0.9999999860567642,1.3943235675902125e-08,"No",5.539594133231465e-05,0.9999446040586639,"Yes"
"2012-000414-11","Multicenter placebo-controlled long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.562671193258507e-22,9.845280447387512e-07,0.9999990154719585,"2+",0.9999997587526658,2.4124733494410227e-07,"No",4.936308320955994e-07,0.9999995063691725,"Yes",0.9999928002647754,7.199735220220327e-06,"No",3.9943055098213255e-08,0.9999999600569405,"Yes",0.0004296216799282268,0.9995703783200673,"Yes",0.9999999860567642,1.3943235675902125e-08,"No",5.539594133231465e-05,0.9999446040586639,"Yes"
"2012-000442-35","PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32 A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.854772211974555e-15,0.0008513023508965454,0.9991486976490936,"2+",0.998517227944394,0.0014827720556119621,"No",0.0023865947857210105,0.997613405214285,"Yes",0.9999923585605115,7.641439486901224e-06,"No",0.0005218478424256684,0.999478152157577,"Yes",0.05185886665990851,0.9481411333400953,"Yes",0.999999999912717,8.72820194518479e-11,"No",0.18915727346751982,0.8108427265324759,"Yes"
"2012-000442-35","PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32 A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.854772211974555e-15,0.0008513023508965454,0.9991486976490936,"2+",0.998517227944394,0.0014827720556119621,"No",0.0023865947857210105,0.997613405214285,"Yes",0.9999923585605115,7.641439486901224e-06,"No",0.0005218478424256684,0.999478152157577,"Yes",0.05185886665990851,0.9481411333400953,"Yes",0.999999999912717,8.72820194518479e-11,"No",0.18915727346751982,0.8108427265324759,"Yes"
"2012-000442-35","PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32 A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.854772211974555e-15,0.0008513023508965454,0.9991486976490936,"2+",0.998517227944394,0.0014827720556119621,"No",0.0023865947857210105,0.997613405214285,"Yes",0.9999923585605115,7.641439486901224e-06,"No",0.0005218478424256684,0.999478152157577,"Yes",0.05185886665990851,0.9481411333400953,"Yes",0.999999999912717,8.72820194518479e-11,"No",0.18915727346751982,0.8108427265324759,"Yes"
"2012-000442-35","PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32 A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY","SI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.854772211974555e-15,0.0008513023508965454,0.9991486976490936,"2+",0.998517227944394,0.0014827720556119621,"No",0.0023865947857210105,0.997613405214285,"Yes",0.9999923585605115,7.641439486901224e-06,"No",0.0005218478424256684,0.999478152157577,"Yes",0.05185886665990851,0.9481411333400953,"Yes",0.999999999912717,8.72820194518479e-11,"No",0.18915727346751982,0.8108427265324759,"Yes"
"2012-000442-35","PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32 A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.854772211974555e-15,0.0008513023508965454,0.9991486976490936,"2+",0.998517227944394,0.0014827720556119621,"No",0.0023865947857210105,0.997613405214285,"Yes",0.9999923585605115,7.641439486901224e-06,"No",0.0005218478424256684,0.999478152157577,"Yes",0.05185886665990851,0.9481411333400953,"Yes",0.999999999912717,8.72820194518479e-11,"No",0.18915727346751982,0.8108427265324759,"Yes"
"2012-000442-35","PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32 A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.854772211974555e-15,0.0008513023508965454,0.9991486976490936,"2+",0.998517227944394,0.0014827720556119621,"No",0.0023865947857210105,0.997613405214285,"Yes",0.9999923585605115,7.641439486901224e-06,"No",0.0005218478424256684,0.999478152157577,"Yes",0.05185886665990851,0.9481411333400953,"Yes",0.999999999912717,8.72820194518479e-11,"No",0.18915727346751982,0.8108427265324759,"Yes"
"2012-000452-34","Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuriaProteomická predikce a inhibice systému renin angiotensin aldosteron kprevenci časné diabetické nefropatie u pacientů s diabetem typu 2 anormoalbuminurií","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.158923254614931e-39,9.436785537262439e-10,0.9999999990563141,"2+",0.9999394300283324,6.056997167953667e-05,"No",3.3307209550427356e-05,0.9999666927904424,"Yes",1.0,6.444072749445092e-15,"No",3.1231899912560785e-10,0.999999999687674,"Yes",0.00039297864104212806,0.9996070213589459,"No",0.9895789145240685,0.010421085475936523,"No",4.4735318283659105e-15,1.0,"Yes"
"2012-000452-34","Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuriaProteomická predikce a inhibice systému renin angiotensin aldosteron kprevenci časné diabetické nefropatie u pacientů s diabetem typu 2 anormoalbuminurií","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.158923254614931e-39,9.436785537262439e-10,0.9999999990563141,"2+",0.9999394300283324,6.056997167953667e-05,"No",3.3307209550427356e-05,0.9999666927904424,"Yes",1.0,6.444072749445092e-15,"No",3.1231899912560785e-10,0.999999999687674,"Yes",0.00039297864104212806,0.9996070213589459,"No",0.9895789145240685,0.010421085475936523,"No",4.4735318283659105e-15,1.0,"Yes"
"2012-000452-34","Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuriaProteomická predikce a inhibice systému renin angiotensin aldosteron kprevenci časné diabetické nefropatie u pacientů s diabetem typu 2 anormoalbuminurií","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.158923254614931e-39,9.436785537262439e-10,0.9999999990563141,"2+",0.9999394300283324,6.056997167953667e-05,"No",3.3307209550427356e-05,0.9999666927904424,"Yes",1.0,6.444072749445092e-15,"No",3.1231899912560785e-10,0.999999999687674,"Yes",0.00039297864104212806,0.9996070213589459,"No",0.9895789145240685,0.010421085475936523,"No",4.4735318283659105e-15,1.0,"Yes"
"2012-000452-34","Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuriaProteomická predikce a inhibice systému renin angiotensin aldosteron kprevenci časné diabetické nefropatie u pacientů s diabetem typu 2 anormoalbuminurií","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.158923254614931e-39,9.436785537262439e-10,0.9999999990563141,"2+",0.9999394300283324,6.056997167953667e-05,"No",3.3307209550427356e-05,0.9999666927904424,"Yes",1.0,6.444072749445092e-15,"No",3.1231899912560785e-10,0.999999999687674,"Yes",0.00039297864104212806,0.9996070213589459,"No",0.9895789145240685,0.010421085475936523,"No",4.4735318283659105e-15,1.0,"Yes"
"2012-000452-34","Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuriaProteomická predikce a inhibice systému renin angiotensin aldosteron kprevenci časné diabetické nefropatie u pacientů s diabetem typu 2 anormoalbuminurií","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.158923254614931e-39,9.436785537262439e-10,0.9999999990563141,"2+",0.9999394300283324,6.056997167953667e-05,"No",3.3307209550427356e-05,0.9999666927904424,"Yes",1.0,6.444072749445092e-15,"No",3.1231899912560785e-10,0.999999999687674,"Yes",0.00039297864104212806,0.9996070213589459,"No",0.9895789145240685,0.010421085475936523,"No",4.4735318283659105e-15,1.0,"Yes"
"2012-000452-34","Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuriaProteomická predikce a inhibice systému renin angiotensin aldosteron kprevenci časné diabetické nefropatie u pacientů s diabetem typu 2 anormoalbuminurií","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.158923254614931e-39,9.436785537262439e-10,0.9999999990563141,"2+",0.9999394300283324,6.056997167953667e-05,"No",3.3307209550427356e-05,0.9999666927904424,"Yes",1.0,6.444072749445092e-15,"No",3.1231899912560785e-10,0.999999999687674,"Yes",0.00039297864104212806,0.9996070213589459,"No",0.9895789145240685,0.010421085475936523,"No",4.4735318283659105e-15,1.0,"Yes"
"2012-000452-34","Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuriaProteomická predikce a inhibice systému renin angiotensin aldosteron kprevenci časné diabetické nefropatie u pacientů s diabetem typu 2 anormoalbuminurií","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.158923254614931e-39,9.436785537262439e-10,0.9999999990563141,"2+",0.9999394300283324,6.056997167953667e-05,"No",3.3307209550427356e-05,0.9999666927904424,"Yes",1.0,6.444072749445092e-15,"No",3.1231899912560785e-10,0.999999999687674,"Yes",0.00039297864104212806,0.9996070213589459,"No",0.9895789145240685,0.010421085475936523,"No",4.4735318283659105e-15,1.0,"Yes"
"2012-000452-34","Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuriaProteomická predikce a inhibice systému renin angiotensin aldosteron kprevenci časné diabetické nefropatie u pacientů s diabetem typu 2 anormoalbuminurií","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.158923254614931e-39,9.436785537262439e-10,0.9999999990563141,"2+",0.9999394300283324,6.056997167953667e-05,"No",3.3307209550427356e-05,0.9999666927904424,"Yes",1.0,6.444072749445092e-15,"No",3.1231899912560785e-10,0.999999999687674,"Yes",0.00039297864104212806,0.9996070213589459,"No",0.9895789145240685,0.010421085475936523,"No",4.4735318283659105e-15,1.0,"Yes"
"2012-000566-38","A randomized Phase III factorial design of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","No","2+","Yes",3.8083624031923113e-32,1.298563992834705e-07,0.9999998701436055,"2+",0.01034390378300244,0.9896560962169948,"Yes",0.992200242584522,0.007799757415483047,"No",0.9999999999286899,7.131079919819149e-11,"No",9.027105234458265e-06,0.9999909728947664,"Yes",0.9258269904568452,0.07417300954315532,"Yes",0.9999999965136085,3.486397939309113e-09,"No",2.2306250021478633e-07,0.9999997769374965,"Yes"
"2012-000566-38","A randomized Phase III factorial design of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse.","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","No","2+","Yes",3.8083624031923113e-32,1.298563992834705e-07,0.9999998701436055,"2+",0.01034390378300244,0.9896560962169948,"Yes",0.992200242584522,0.007799757415483047,"No",0.9999999999286899,7.131079919819149e-11,"No",9.027105234458265e-06,0.9999909728947664,"Yes",0.9258269904568452,0.07417300954315532,"Yes",0.9999999965136085,3.486397939309113e-09,"No",2.2306250021478633e-07,0.9999997769374965,"Yes"
"2012-000566-38","A randomized Phase III factorial design of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","No","2+","Yes",3.8083624031923113e-32,1.298563992834705e-07,0.9999998701436055,"2+",0.01034390378300244,0.9896560962169948,"Yes",0.992200242584522,0.007799757415483047,"No",0.9999999999286899,7.131079919819149e-11,"No",9.027105234458265e-06,0.9999909728947664,"Yes",0.9258269904568452,0.07417300954315532,"Yes",0.9999999965136085,3.486397939309113e-09,"No",2.2306250021478633e-07,0.9999997769374965,"Yes"
"2012-000620-17","High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trialRandomisierte kontrollierte offene multizentrische Phase III Studie mit 2 parallelen Armen - Hochdosis Chemotherapie und autologe Stammzelltransplantation oder konventionelle Chemotherapie zur Konsolidierung bei primären ZNS-Lymphomen","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1126594615451733e-64,0.9457704791468864,0.05422952085310851,"2+",1.2825029852568556e-10,0.9999999998717612,"Yes",0.9999999998759677,1.2401999681041968e-10,"No",0.9999999999998864,1.0177213240095799e-13,"No",0.9988476939988439,0.0011523060011351326,"Yes",0.9999861486025251,1.3851397453244246e-05,"No",0.9999999999997727,2.5107143102017407e-13,"No",0.9998193764766279,0.00018062352335677972,"Yes"
"2012-000620-17","High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trialRandomisierte kontrollierte offene multizentrische Phase III Studie mit 2 parallelen Armen - Hochdosis Chemotherapie und autologe Stammzelltransplantation oder konventionelle Chemotherapie zur Konsolidierung bei primären ZNS-Lymphomen","DK","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1126594615451733e-64,0.9457704791468864,0.05422952085310851,"2+",1.2825029852568556e-10,0.9999999998717612,"Yes",0.9999999998759677,1.2401999681041968e-10,"No",0.9999999999998864,1.0177213240095799e-13,"No",0.9988476939988439,0.0011523060011351326,"Yes",0.9999861486025251,1.3851397453244246e-05,"No",0.9999999999997727,2.5107143102017407e-13,"No",0.9998193764766279,0.00018062352335677972,"Yes"
"2012-000726-21","An Open-Label Randomized Multicenter Phase III Study of Ceftazidime Avibactam (CAZ-AVI formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens","IT","No","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.140632098330147e-32,4.963118411331882e-09,0.9999999950368875,"2+",0.992205225066631,0.007794774933360993,"Yes",0.7147413398619408,0.2852586601380602,"No",0.999999999994742,5.2699980437494505e-12,"No",3.85666200966546e-09,0.9999999961433447,"Yes",0.12119099594661174,0.8788090040533967,"Yes",0.9999999999959358,4.0679712418791305e-12,"No",1.724751827728453e-10,0.9999999998275371,"Yes"
"2012-000726-21","An Open-Label Randomized Multicenter Phase III Study of Ceftazidime Avibactam (CAZ-AVI) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens","BG","No","No","No","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3431351449963528e-31,5.7013614970258876e-08,0.9999999429863936,"2+",0.8769653339662598,0.1230346660337321,"Yes",0.979755366600399,0.020244633399592513,"No",0.9999999999120918,8.790372941553014e-11,"No",6.552721026585063e-08,0.9999999344727848,"Yes",0.6778990022711491,0.3221009977288391,"Yes",0.9999999999359376,6.405910162610235e-11,"No",2.942671266108306e-09,0.99999999705733,"Yes"
"2012-000726-21","An Open-Label Randomized Multicenter Phase III Study of Ceftazidime Avibactam (CAZ-AVI formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens","BE","No","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.140632098330147e-32,4.963118411331882e-09,0.9999999950368875,"2+",0.992205225066631,0.007794774933360993,"Yes",0.7147413398619408,0.2852586601380602,"No",0.999999999994742,5.2699980437494505e-12,"No",3.85666200966546e-09,0.9999999961433447,"Yes",0.12119099594661174,0.8788090040533967,"Yes",0.9999999999959358,4.0679712418791305e-12,"No",1.724751827728453e-10,0.9999999998275371,"Yes"
"2012-000726-21","An Open-Label Randomized Multicenter Phase III Study of Ceftazidime Avibactam (CAZ-AVI formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative PathogensEstudio de fase III abierto aleatorizado multicéntrico de ceftazidima-avibactam (CAZ-AVI antes CAZ104) y la mejor terapia disponible para el tratamiento de infecciones causadas por patógenos gramnegativos resistentes a ceftazidima","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.009085929012785e-54,2.781917030293623e-17,1.0,"2+",0.9994702975284382,0.0005297024715356376,"Yes",0.164243494271242,0.8357565057287833,"No",1.0,1.649011942148973e-23,"No",9.740484502310555e-19,1.0,"Yes",4.715595693895465e-06,0.9999952844043264,"Yes",1.0,7.926176031226801e-28,"No",5.31547807298445e-19,1.0,"Yes"
"2012-000726-21","An Open-Label Randomized Multicenter Phase III Study of Ceftazidime Avibactam (CAZ-AVI) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative PathogensOtevřená randomizovaná multicentrická studie fáze III kombinace ceftazidimu a avibactamu (CAZ-AVI) a nejlepší dostupné léčby infekcí způsobených gramnegativními patogeny rezistentními vůči ceftazidimu.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3691902947921826e-51,1.0495451773300177e-17,1.0,"2+",0.999998667217973,1.33278203003993e-06,"Yes",0.0046669248653726505,0.9953330751346,"No",1.0,1.0408220273222982e-19,"No",4.7765388732411214e-18,1.0,"Yes",3.5157958879774945e-06,0.9999964842041168,"Yes",1.0,3.3979783374757316e-20,"No",8.72552589410399e-20,1.0,"Yes"
"2012-000726-21","An Open-Label Randomized Multicenter Phase III Study of Ceftazidime Avibactam (CAZ-AVI formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative PathogensEstudio de fase III abierto aleatorizado multicéntrico de ceftazidima-avibactam (CAZ-AVI antes CAZ104) y la mejor terapia disponible para el tratamiento de infecciones causadas por patógenos gramnegativos resistentes a ceftazidima","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.009085929012785e-54,2.781917030293623e-17,1.0,"2+",0.9994702975284382,0.0005297024715356376,"Yes",0.164243494271242,0.8357565057287833,"No",1.0,1.649011942148973e-23,"No",9.740484502310555e-19,1.0,"Yes",4.715595693895465e-06,0.9999952844043264,"Yes",1.0,7.926176031226801e-28,"No",5.31547807298445e-19,1.0,"Yes"
"2012-000726-21","An Open-Label Randomized Multicenter Phase III Study of Ceftazidime Avibactam (CAZ-AVI formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative PathogensEstudio de fase III abierto aleatorizado multicéntrico de ceftazidima-avibactam (CAZ-AVI antes CAZ104) y la mejor terapia disponible para el tratamiento de infecciones causadas por patógenos gramnegativos resistentes a ceftazidima","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.009085929012785e-54,2.781917030293623e-17,1.0,"2+",0.9994702975284382,0.0005297024715356376,"Yes",0.164243494271242,0.8357565057287833,"No",1.0,1.649011942148973e-23,"No",9.740484502310555e-19,1.0,"Yes",4.715595693895465e-06,0.9999952844043264,"Yes",1.0,7.926176031226801e-28,"No",5.31547807298445e-19,1.0,"Yes"
"2012-000726-21","An Open-Label Randomized Multicenter Phase III Study of Ceftazidime Avibactam (CAZ-AVI formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens","GR","No","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.140632098330147e-32,4.963118411331882e-09,0.9999999950368875,"2+",0.992205225066631,0.007794774933360993,"Yes",0.7147413398619408,0.2852586601380602,"No",0.999999999994742,5.2699980437494505e-12,"No",3.85666200966546e-09,0.9999999961433447,"Yes",0.12119099594661174,0.8788090040533967,"Yes",0.9999999999959358,4.0679712418791305e-12,"No",1.724751827728453e-10,0.9999999998275371,"Yes"
"2012-000726-21","An Open-Label Randomized Multicenter Phase III Study of Ceftazidime Avibactam (CAZ-AVI formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens","HU","No","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.140632098330147e-32,4.963118411331882e-09,0.9999999950368875,"2+",0.992205225066631,0.007794774933360993,"Yes",0.7147413398619408,0.2852586601380602,"No",0.999999999994742,5.2699980437494505e-12,"No",3.85666200966546e-09,0.9999999961433447,"Yes",0.12119099594661174,0.8788090040533967,"Yes",0.9999999999959358,4.0679712418791305e-12,"No",1.724751827728453e-10,0.9999999998275371,"Yes"
"2012-000975-18","Open-label Randomized Parallel-Group Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects with Nonalcoholic Steatohepatitis (NASH) and non-treated matched healthy volunteers as control group","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.165127149689122e-42,2.5302086060808263e-05,0.9999746979139454,"2+",0.9452836645608952,0.05471633543909435,"Yes",0.12986717684747495,0.8701328231525376,"No",0.9999999920695474,7.930443091227245e-09,"No",6.903563178604153e-05,0.999930964368212,"Yes",0.0014848111662488397,0.9985151888337414,"Yes",0.9999999922081316,7.791867263486283e-09,"No",0.018204164948852332,0.9817958350511361,"Yes"
"2012-001534-34","A multi-center intra-patient dose escalation phase II study to evaluate the preliminary efficacy safety and pharmacokinetics of pasireotide (SOM230) subcutaneous (s.c.) followed by pasireotide LAR in patients with dumping syndrome","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.355274842797385e-44,0.9999082615340157,9.17384659749215e-05,"-1",0.0002756531644783335,0.9997243468355096,"Yes",0.9997049916829752,0.0002950083170297409,"No",0.999999999699412,3.005795140882703e-10,"No",0.9999748205392429,2.5179460758921764e-05,"No",0.9942265675319104,0.005773432468088586,"No",0.9959024963126328,0.004097503687374111,"No",0.9999829294813329,1.7070518665043268e-05,"No"
"2012-001534-34","A multi-center intra-patient dose escalation phase II study to evaluate the preliminary efficacy safety and pharmacokinetics of pasireotide (SOM230) subcutaneous (s.c.) followed by pasireotide LAR in patients with dumping syndrome","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.355274842797385e-44,0.9999082615340157,9.17384659749215e-05,"-1",0.0002756531644783335,0.9997243468355096,"Yes",0.9997049916829752,0.0002950083170297409,"No",0.999999999699412,3.005795140882703e-10,"No",0.9999748205392429,2.5179460758921764e-05,"No",0.9942265675319104,0.005773432468088586,"No",0.9959024963126328,0.004097503687374111,"No",0.9999829294813329,1.7070518665043268e-05,"No"
"2012-001592-37","Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter Randomised Double-blind Parallel-group Placebo-Controlled Study.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.113081652997581e-45,4.908747778903023e-12,0.999999999995083,"2+",0.9999999999850361,1.4966591369083127e-11,"No",2.7993047452220154e-10,0.9999999997200746,"Yes",0.9440227738778965,0.05597722612210486,"No",1.6339220623353905e-13,0.9999999999998437,"Yes",0.00026464024906629836,0.9997353597509342,"Yes",0.9999969743504394,3.0256495535657917e-06,"No",1.6946555616237713e-11,0.9999999999830466,"Yes"
"2012-001592-37","Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter Randomised Double-blind Parallel-group Placebo-Controlled Study.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.113081652997581e-45,4.908747778903023e-12,0.999999999995083,"2+",0.9999999999850361,1.4966591369083127e-11,"No",2.7993047452220154e-10,0.9999999997200746,"Yes",0.9440227738778965,0.05597722612210486,"No",1.6339220623353905e-13,0.9999999999998437,"Yes",0.00026464024906629836,0.9997353597509342,"Yes",0.9999969743504394,3.0256495535657917e-06,"No",1.6946555616237713e-11,0.9999999999830466,"Yes"
"2012-001592-37","Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter Randomised Double-blind Parallel-group Placebo-Controlled Study.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.113081652997581e-45,4.908747778903023e-12,0.999999999995083,"2+",0.9999999999850361,1.4966591369083127e-11,"No",2.7993047452220154e-10,0.9999999997200746,"Yes",0.9440227738778965,0.05597722612210486,"No",1.6339220623353905e-13,0.9999999999998437,"Yes",0.00026464024906629836,0.9997353597509342,"Yes",0.9999969743504394,3.0256495535657917e-06,"No",1.6946555616237713e-11,0.9999999999830466,"Yes"
"2012-001592-37","Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter Randomised Double-blind Parallel-group Placebo-Controlled Study.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.113081652997581e-45,4.908747778903023e-12,0.999999999995083,"2+",0.9999999999850361,1.4966591369083127e-11,"No",2.7993047452220154e-10,0.9999999997200746,"Yes",0.9440227738778965,0.05597722612210486,"No",1.6339220623353905e-13,0.9999999999998437,"Yes",0.00026464024906629836,0.9997353597509342,"Yes",0.9999969743504394,3.0256495535657917e-06,"No",1.6946555616237713e-11,0.9999999999830466,"Yes"
"2012-001592-37","Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter Randomised Double-blind Parallel-group Placebo-Controlled Study.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.113081652997581e-45,4.908747778903023e-12,0.999999999995083,"2+",0.9999999999850361,1.4966591369083127e-11,"No",2.7993047452220154e-10,0.9999999997200746,"Yes",0.9440227738778965,0.05597722612210486,"No",1.6339220623353905e-13,0.9999999999998437,"Yes",0.00026464024906629836,0.9997353597509342,"Yes",0.9999969743504394,3.0256495535657917e-06,"No",1.6946555616237713e-11,0.9999999999830466,"Yes"
"2012-001592-37","Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter Randomised Double-blind Parallel-group Placebo-Controlled Study.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.113081652997581e-45,4.908747778903023e-12,0.999999999995083,"2+",0.9999999999850361,1.4966591369083127e-11,"No",2.7993047452220154e-10,0.9999999997200746,"Yes",0.9440227738778965,0.05597722612210486,"No",1.6339220623353905e-13,0.9999999999998437,"Yes",0.00026464024906629836,0.9997353597509342,"Yes",0.9999969743504394,3.0256495535657917e-06,"No",1.6946555616237713e-11,0.9999999999830466,"Yes"
"2012-001592-37","Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter Randomised Double-blind Parallel-group Placebo-Controlled Study.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.113081652997581e-45,4.908747778903023e-12,0.999999999995083,"2+",0.9999999999850361,1.4966591369083127e-11,"No",2.7993047452220154e-10,0.9999999997200746,"Yes",0.9440227738778965,0.05597722612210486,"No",1.6339220623353905e-13,0.9999999999998437,"Yes",0.00026464024906629836,0.9997353597509342,"Yes",0.9999969743504394,3.0256495535657917e-06,"No",1.6946555616237713e-11,0.9999999999830466,"Yes"
"2012-001592-37","Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter Randomised Double-blind Parallel-group Placebo-Controlled Study.","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.113081652997581e-45,4.908747778903023e-12,0.999999999995083,"2+",0.9999999999850361,1.4966591369083127e-11,"No",2.7993047452220154e-10,0.9999999997200746,"Yes",0.9440227738778965,0.05597722612210486,"No",1.6339220623353905e-13,0.9999999999998437,"Yes",0.00026464024906629836,0.9997353597509342,"Yes",0.9999969743504394,3.0256495535657917e-06,"No",1.6946555616237713e-11,0.9999999999830466,"Yes"
"2012-001815-21","A Multicenter Prospective Randomized Open-label Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa","PT","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.452733220886659e-24,0.6470536825557588,0.3529463174442362,"2+",0.07783557477598076,0.9221644252240077,"Yes",0.9300747294031869,0.06992527059681691,"No",0.9999999993915765,6.084132494213299e-10,"No",0.22172336932916278,0.7782766306708278,"Yes",0.948188352930526,0.051811647069471056,"No",0.998414955321939,0.0015850446780729434,"No",0.1264777793061429,0.8735222206938432,"Yes"
"2012-001815-21","A Multicenter Prospective Randomized Open-label Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis BullosaEstudio multicéntrico prospectivo aleatorizado abierto de control intraindividual sobre la eficacia y seguridad de ABH001 para el tratamiento deheridas cutáneas crónicas estancadas asociadas con la epidermólisis bullosa generalizada","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.067883389270149e-35,0.41714053641335014,0.5828594635866633,"2+",0.04069227305073506,0.959307726949257,"Yes",0.9979292040484637,0.002070795951509534,"No",0.9999999848666337,1.5133357642763963e-08,"No",0.017605123838339554,0.9823948761616661,"Yes",0.999999834515179,1.6548479806150117e-07,"No",0.9999999847856886,1.5214293002872574e-08,"No",0.011771422035278915,0.988228577964725,"Yes"
"2012-001815-21","A Multicenter Prospective Randomized Open-label Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa","ES","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.452733220886659e-24,0.6470536825557588,0.3529463174442362,"2+",0.07783557477598076,0.9221644252240077,"Yes",0.9300747294031869,0.06992527059681691,"No",0.9999999993915765,6.084132494213299e-10,"No",0.22172336932916278,0.7782766306708278,"Yes",0.948188352930526,0.051811647069471056,"No",0.998414955321939,0.0015850446780729434,"No",0.1264777793061429,0.8735222206938432,"Yes"
"2012-001815-21","A Multicenter Prospective Randomized Open-label Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis BullosaEstudio multicéntrico prospectivo aleatorizado abierto de control intraindividual sobre la eficacia y seguridad de ABH001 para el tratamiento deheridas cutáneas crónicas estancadas asociadas con la epidermólisis bullosa generalizada","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.067883389270149e-35,0.41714053641335014,0.5828594635866633,"2+",0.04069227305073506,0.959307726949257,"Yes",0.9979292040484637,0.002070795951509534,"No",0.9999999848666337,1.5133357642763963e-08,"No",0.017605123838339554,0.9823948761616661,"Yes",0.999999834515179,1.6548479806150117e-07,"No",0.9999999847856886,1.5214293002872574e-08,"No",0.011771422035278915,0.988228577964725,"Yes"
"2012-001834-33","A Phase 3 Randomized Double-blind Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.951894264481253e-52,3.0140027166568946e-07,0.9999996985997257,"2+",0.44881918192737785,0.5511808180726084,"No",0.588929344349726,0.4110706556502743,"Yes",1.0,6.809341346381246e-21,"No",9.829494440281727e-07,0.9999990170505555,"Yes",0.05455656788341367,0.9454434321165844,"Yes",0.9999999901274067,9.872590130845995e-09,"Yes",2.8152726953503e-07,0.9999997184727191,"Yes"
"2012-001834-33","A Phase 3 Randomized Double-blind Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100Estudio de fase 3 aleatorizado doble ciego y controlado de Cabozantinib (XL184) en comparación con prednisona en pacientes con cáncer de próstata metastásico resistente a la castración que han recibido previamente docetaxel y abiraterona o MDV3100","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0053482915195817e-102,1.428260832984594e-15,1.0,"2+",0.12232788084657029,0.8776721191534437,"No",0.86515349314716,0.13484650685284646,"Yes",1.0,5.654022302677084e-44,"No",2.646909149710075e-14,1.0,"Yes",0.0005230054320177449,0.9994769945679849,"Yes",1.0,4.4347607263653887e-26,"Yes",5.179266183489066e-16,1.0,"Yes"
"2012-001834-33","A Phase 3 Randomized Double-blind Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100Estudio de fase 3 aleatorizado doble ciego y controlado de Cabozantinib (XL184) en comparación con prednisona en pacientes con cáncer de próstata metastásico resistente a la castración que han recibido previamente docetaxel y abiraterona o MDV3100","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0053482915195817e-102,1.428260832984594e-15,1.0,"2+",0.12232788084657029,0.8776721191534437,"No",0.86515349314716,0.13484650685284646,"Yes",1.0,5.654022302677084e-44,"No",2.646909149710075e-14,1.0,"Yes",0.0005230054320177449,0.9994769945679849,"Yes",1.0,4.4347607263653887e-26,"Yes",5.179266183489066e-16,1.0,"Yes"
"2012-001834-33","A Phase 3 Randomized Double-blind Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100Estudio de fase 3 aleatorizado doble ciego y controlado de Cabozantinib (XL184) en comparación con prednisona en pacientes con cáncer de próstata metastásico resistente a la castración que han recibido previamente docetaxel y abiraterona o MDV3100","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0053482915195817e-102,1.428260832984594e-15,1.0,"2+",0.12232788084657029,0.8776721191534437,"No",0.86515349314716,0.13484650685284646,"Yes",1.0,5.654022302677084e-44,"No",2.646909149710075e-14,1.0,"Yes",0.0005230054320177449,0.9994769945679849,"Yes",1.0,4.4347607263653887e-26,"Yes",5.179266183489066e-16,1.0,"Yes"
"2012-001834-33","A Phase 3 Randomized Double-blind Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100Estudio de fase 3 aleatorizado doble ciego y controlado de Cabozantinib (XL184) en comparación con prednisona en pacientes con cáncer de próstata metastásico resistente a la castración que han recibido previamente docetaxel y abiraterona o MDV3100","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0053482915195817e-102,1.428260832984594e-15,1.0,"2+",0.12232788084657029,0.8776721191534437,"No",0.86515349314716,0.13484650685284646,"Yes",1.0,5.654022302677084e-44,"No",2.646909149710075e-14,1.0,"Yes",0.0005230054320177449,0.9994769945679849,"Yes",1.0,4.4347607263653887e-26,"Yes",5.179266183489066e-16,1.0,"Yes"
"2012-001834-33","A Phase 3 Randomized Double-blind Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.951894264481253e-52,3.0140027166568946e-07,0.9999996985997257,"2+",0.44881918192737785,0.5511808180726084,"No",0.588929344349726,0.4110706556502743,"Yes",1.0,6.809341346381246e-21,"No",9.829494440281727e-07,0.9999990170505555,"Yes",0.05455656788341367,0.9454434321165844,"Yes",0.9999999901274067,9.872590130845995e-09,"Yes",2.8152726953503e-07,0.9999997184727191,"Yes"
"2012-001834-33","A Phase 3 Randomized Double-blind Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100Estudio de fase 3 aleatorizado doble ciego y controlado de Cabozantinib (XL184) en comparación con prednisona en pacientes con cáncer de próstata metastásico resistente a la castración que han recibido previamente docetaxel y abiraterona o MDV3100","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0053482915195817e-102,1.428260832984594e-15,1.0,"2+",0.12232788084657029,0.8776721191534437,"No",0.86515349314716,0.13484650685284646,"Yes",1.0,5.654022302677084e-44,"No",2.646909149710075e-14,1.0,"Yes",0.0005230054320177449,0.9994769945679849,"Yes",1.0,4.4347607263653887e-26,"Yes",5.179266183489066e-16,1.0,"Yes"
"2012-001834-33","A Phase 3 Randomized Double-blind Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100Estudio de fase 3 aleatorizado doble ciego y controlado de Cabozantinib (XL184) en comparación con prednisona en pacientes con cáncer de próstata metastásico resistente a la castración que han recibido previamente docetaxel y abiraterona o MDV3100","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0053482915195817e-102,1.428260832984594e-15,1.0,"2+",0.12232788084657029,0.8776721191534437,"No",0.86515349314716,0.13484650685284646,"Yes",1.0,5.654022302677084e-44,"No",2.646909149710075e-14,1.0,"Yes",0.0005230054320177449,0.9994769945679849,"Yes",1.0,4.4347607263653887e-26,"Yes",5.179266183489066e-16,1.0,"Yes"
"2012-001834-33","A Phase 3 Randomized Double-blind Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.951894264481253e-52,3.0140027166568946e-07,0.9999996985997257,"2+",0.44881918192737785,0.5511808180726084,"No",0.588929344349726,0.4110706556502743,"Yes",1.0,6.809341346381246e-21,"No",9.829494440281727e-07,0.9999990170505555,"Yes",0.05455656788341367,0.9454434321165844,"Yes",0.9999999901274067,9.872590130845995e-09,"Yes",2.8152726953503e-07,0.9999997184727191,"Yes"
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","FI","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","BE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","NO","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","DE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","EE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","PT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","IE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","SE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","GR","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Yes",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","AT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","ES","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","DK","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","SI","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","PL","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","GB","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","SK","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001888-78","A MULTICENTER SINGLE-ARM OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION  WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA","NL","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.826481760592727e-33,0.9989576847603595,0.0010423152396448043,"-1",6.413930960849144e-10,0.9999999993586073,"Information not present in EudraCT",0.9999999994740563,5.25946994171916e-10,"Information not present in EudraCT",0.9999999999644018,3.560332219427138e-11,"Information not present in EudraCT",0.9999700106261875,2.99893738054495e-05,"No",0.9964893932358904,0.0035106067641031188,"",0.9845062722376916,0.01549372776230291,"",0.9999040647074638,9.593529253541245e-05,""
"2012-001923-11","A Multicentre Interventional treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in primary IgA nephropathy patients at risk of developing end-stage renal diseaseStudio Interventistico Multicentrico Randomizzato in doppio Cieco Singolo Gruppo di Assegnazione Controllato vs. Placebo per valutare l'Efficacia e la Sicurezza di due differenti dosi di Nefecon in pazienti con nefropatie primaria da IgA a rischio di sviluppare una malattia renale all'ultimo stadio","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.3171720754620695e-109,6.205375412370939e-20,1.0,"2+",1.0,1.468150423678242e-17,"No",5.740742734005214e-16,1.0,"Yes",1.0,3.3343772493651485e-23,"No",2.658092363754875e-20,1.0,"Yes",0.08405986742197268,0.9159401325780551,"Yes",1.0,8.954848869396371e-20,"No",1.499606065776214e-16,1.0,"Yes"
"2012-001923-11","A Multicentre Interventional Treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal Disease","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",6.646380640522921e-54,1.8605350042161158e-15,1.0,"2+",0.9999999999989484,1.0436763752619626e-12,"No",7.612247452977404e-12,0.9999999999923831,"Yes",0.9999999986272315,1.3727703147363726e-09,"No",4.573432693704826e-15,1.0,"Yes",0.2826310068275336,0.7173689931724704,"Yes",0.9999976496569668,2.350343028346892e-06,"No",7.84908373267926e-14,0.9999999999999147,"Yes"
"2012-001923-11","A Multicentre Interventional Treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal DiseaseEstudio multicéntrico de tratamiento intervencionista aleatorizado doble ciego controlado con placebo para evaluar la eficacia y seguridad de dos dosis diferentes de Nefecon® en pacientes con Nefropatía IgA Primaria en riesgo de desarrollar Enfermedad Renal en Etapa Terminal (ERET).","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",3.775733039088597e-94,3.455412779039001e-26,1.0,"2+",1.0,1.754520297495494e-21,"No",1.5256731890431033e-19,1.0,"Yes",1.0,9.835189651162699e-20,"No",2.0933289005812963e-24,1.0,"Yes",0.9973443038512938,0.0026556961486994294,"Yes",1.0,5.7859147170348325e-21,"No",1.2119408698769622e-20,1.0,"Yes"
"2012-001923-11","A Multicentre Interventional Treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal DiseaseEstudio multicéntrico de tratamiento intervencionista aleatorizado doble ciego controlado con placebo para evaluar la eficacia y seguridad de dos dosis diferentes de Nefecon® en pacientes con Nefropatía IgA Primaria en riesgo de desarrollar Enfermedad Renal en Etapa Terminal (ERET).","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",3.775733039088597e-94,3.455412779039001e-26,1.0,"2+",1.0,1.754520297495494e-21,"No",1.5256731890431033e-19,1.0,"Yes",1.0,9.835189651162699e-20,"No",2.0933289005812963e-24,1.0,"Yes",0.9973443038512938,0.0026556961486994294,"Yes",1.0,5.7859147170348325e-21,"No",1.2119408698769622e-20,1.0,"Yes"
"2012-001923-11","A Multicentre Interventional Treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal DiseaseEstudio multicéntrico de tratamiento intervencionista aleatorizado doble ciego controlado con placebo para evaluar la eficacia y seguridad de dos dosis diferentes de Nefecon® en pacientes con Nefropatía IgA Primaria en riesgo de desarrollar Enfermedad Renal en Etapa Terminal (ERET).","FI","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",3.775733039088597e-94,3.455412779039001e-26,1.0,"2+",1.0,1.754520297495494e-21,"No",1.5256731890431033e-19,1.0,"Yes",1.0,9.835189651162699e-20,"No",2.0933289005812963e-24,1.0,"Yes",0.9973443038512938,0.0026556961486994294,"Yes",1.0,5.7859147170348325e-21,"No",1.2119408698769622e-20,1.0,"Yes"
"2012-001923-11","A Multicentre Interventional Treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal Disease","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",6.646380640522921e-54,1.8605350042161158e-15,1.0,"2+",0.9999999999989484,1.0436763752619626e-12,"No",7.612247452977404e-12,0.9999999999923831,"Yes",0.9999999986272315,1.3727703147363726e-09,"No",4.573432693704826e-15,1.0,"Yes",0.2826310068275336,0.7173689931724704,"Yes",0.9999976496569668,2.350343028346892e-06,"No",7.84908373267926e-14,0.9999999999999147,"Yes"
"2012-001923-11","A Multicentre Interventional treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in primary IgA nephropathy patients at risk of developing end-stage renal diseaseStudio Interventistico Multicentrico Randomizzato in doppio Cieco Singolo Gruppo di Assegnazione Controllato vs. Placebo per valutare l'Efficacia e la Sicurezza di due differenti dosi di Nefecon in pazienti con nefropatie primaria da IgA a rischio di sviluppare una malattia renale all'ultimo stadio","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.3171720754620695e-109,6.205375412370939e-20,1.0,"2+",1.0,1.468150423678242e-17,"No",5.740742734005214e-16,1.0,"Yes",1.0,3.3343772493651485e-23,"No",2.658092363754875e-20,1.0,"Yes",0.08405986742197268,0.9159401325780551,"Yes",1.0,8.954848869396371e-20,"No",1.499606065776214e-16,1.0,"Yes"
"2012-001923-11","A Multicentre Interventional Treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal DiseaseMulticentrické intervenční randomizované dvojitě zaslepené placebem kontrolované klinické hodnocení se zařazováním do jedné skupiny ke stanovení účinnosti a bezpečnosti dvou různých dávek přípravku Nefecon® u pacientů s primární IgA nefropatií s rizikem rozvoje konečného stádia onemocnění ledvin","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.4543902040548137e-101,1.6062740636594253e-34,1.0,"2+",1.0,1.256270452515711e-29,"No",4.586303067698696e-29,1.0,"Yes",1.0,1.051911889060075e-42,"No",1.9880843232954164e-34,1.0,"Yes",0.9467953493296871,0.053204650670315504,"Yes",1.0,3.338325103636892e-32,"No",8.402735287038659e-31,1.0,"Yes"
"2012-001923-11","A Multicentre Interventional Treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal DiseaseMulticentrické intervenční randomizované dvojitě zaslepené placebem kontrolované klinické hodnocení se zařazováním do jedné skupiny ke stanovení účinnosti a bezpečnosti dvou různých dávek přípravku Nefecon® u pacientů s primární IgA nefropatií s rizikem rozvoje konečného stádia onemocnění ledvin","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.4543902040548137e-101,1.6062740636594253e-34,1.0,"2+",1.0,1.256270452515711e-29,"No",4.586303067698696e-29,1.0,"Yes",1.0,1.051911889060075e-42,"No",1.9880843232954164e-34,1.0,"Yes",0.9467953493296871,0.053204650670315504,"Yes",1.0,3.338325103636892e-32,"No",8.402735287038659e-31,1.0,"Yes"
"2012-001923-11","A Multicentre Interventional Treatment Randomised Double-Blind Single Group Assignment Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal DiseaseEstudio multicéntrico de tratamiento intervencionista aleatorizado doble ciego controlado con placebo para evaluar la eficacia y seguridad de dos dosis diferentes de Nefecon® en pacientes con Nefropatía IgA Primaria en riesgo de desarrollar Enfermedad Renal en Etapa Terminal (ERET).","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",3.775733039088597e-94,3.455412779039001e-26,1.0,"2+",1.0,1.754520297495494e-21,"No",1.5256731890431033e-19,1.0,"Yes",1.0,9.835189651162699e-20,"No",2.0933289005812963e-24,1.0,"Yes",0.9973443038512938,0.0026556961486994294,"Yes",1.0,5.7859147170348325e-21,"No",1.2119408698769622e-20,1.0,"Yes"
"2012-002011-26","A randomized double-blind multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0544262934254634e-43,4.4978717646342414e-10,0.9999999995502264,"2+",0.999999999954241,4.5767424194402327e-11,"No",3.521140688377575e-10,0.9999999996478834,"Yes",0.999999999997641,2.3711922055305063e-12,"No",2.6342389692727696e-12,0.9999999999973568,"Yes",4.454247721306988e-07,0.9999995545752396,"Yes",0.9999999999982094,1.7812246554789465e-12,"No",6.358524731756223e-10,0.9999999993641496,"Yes"
"2012-002011-26","A randomized double-blind multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0544262934254634e-43,4.4978717646342414e-10,0.9999999995502264,"2+",0.999999999954241,4.5767424194402327e-11,"No",3.521140688377575e-10,0.9999999996478834,"Yes",0.999999999997641,2.3711922055305063e-12,"No",2.6342389692727696e-12,0.9999999999973568,"Yes",4.454247721306988e-07,0.9999995545752396,"Yes",0.9999999999982094,1.7812246554789465e-12,"No",6.358524731756223e-10,0.9999999993641496,"Yes"
"2012-002011-26","A randomized double-blind multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0544262934254634e-43,4.4978717646342414e-10,0.9999999995502264,"2+",0.999999999954241,4.5767424194402327e-11,"No",3.521140688377575e-10,0.9999999996478834,"Yes",0.999999999997641,2.3711922055305063e-12,"No",2.6342389692727696e-12,0.9999999999973568,"Yes",4.454247721306988e-07,0.9999995545752396,"Yes",0.9999999999982094,1.7812246554789465e-12,"No",6.358524731756223e-10,0.9999999993641496,"Yes"
"2012-002011-26","A randomized double-blind multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0544262934254634e-43,4.4978717646342414e-10,0.9999999995502264,"2+",0.999999999954241,4.5767424194402327e-11,"No",3.521140688377575e-10,0.9999999996478834,"Yes",0.999999999997641,2.3711922055305063e-12,"No",2.6342389692727696e-12,0.9999999999973568,"Yes",4.454247721306988e-07,0.9999995545752396,"Yes",0.9999999999982094,1.7812246554789465e-12,"No",6.358524731756223e-10,0.9999999993641496,"Yes"
"2012-002011-26","A randomized double-blind multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasisRandomizované dvojitě zaslepené multicentrické klinické hodnocení kterémá prokázat rovnocennou účinnost a porovnat bezpečnost a imunogenitubiosimilar etanerceptu (GP2015) a Enbrelu® u pacientů se střednězávažnou až závažnou chronickou ložiskovou psoriázou","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.431192397206782e-73,9.094762434079055e-20,1.0,"2+",1.0,5.081676127529983e-19,"No",2.277579047578515e-18,1.0,"Yes",1.0,1.8396722462970135e-28,"No",8.845808414222969e-23,1.0,"Yes",2.4733516895592213e-09,0.9999999975266292,"Yes",1.0,8.247542403213671e-26,"No",1.47721883302904e-16,1.0,"Yes"
"2012-002011-26","A randomized double-blind multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasisRandomizované dvojitě zaslepené multicentrické klinické hodnocení kterémá prokázat rovnocennou účinnost a porovnat bezpečnost a imunogenitubiosimilar etanerceptu (GP2015) a Enbrelu® u pacientů se střednězávažnou až závažnou chronickou ložiskovou psoriázou","EE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.431192397206782e-73,9.094762434079055e-20,1.0,"2+",1.0,5.081676127529983e-19,"No",2.277579047578515e-18,1.0,"Yes",1.0,1.8396722462970135e-28,"No",8.845808414222969e-23,1.0,"Yes",2.4733516895592213e-09,0.9999999975266292,"Yes",1.0,8.247542403213671e-26,"No",1.47721883302904e-16,1.0,"Yes"
"2012-002011-26","A randomized double-blind multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0544262934254634e-43,4.4978717646342414e-10,0.9999999995502264,"2+",0.999999999954241,4.5767424194402327e-11,"No",3.521140688377575e-10,0.9999999996478834,"Yes",0.999999999997641,2.3711922055305063e-12,"No",2.6342389692727696e-12,0.9999999999973568,"Yes",4.454247721306988e-07,0.9999995545752396,"Yes",0.9999999999982094,1.7812246554789465e-12,"No",6.358524731756223e-10,0.9999999993641496,"Yes"
"2012-002011-26","A randomized double-blind multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0544262934254634e-43,4.4978717646342414e-10,0.9999999995502264,"2+",0.999999999954241,4.5767424194402327e-11,"No",3.521140688377575e-10,0.9999999996478834,"Yes",0.999999999997641,2.3711922055305063e-12,"No",2.6342389692727696e-12,0.9999999999973568,"Yes",4.454247721306988e-07,0.9999995545752396,"Yes",0.9999999999982094,1.7812246554789465e-12,"No",6.358524731756223e-10,0.9999999993641496,"Yes"
"2012-002047-26","FDC116115: A prospective study of sexual function in sexually active men treated for BPH","NL","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.351859112581755e-13,0.13786126091164982,0.862138739087612,"2+",0.9866863890837895,0.013313610916206304,"No",0.010987297755622438,0.9890127022443803,"Yes",0.9999746366520764,2.5363347927289976e-05,"No",0.04480131083696208,0.9551986891630436,"Yes",0.23599743658895134,0.7640025634110418,"Yes",0.20477309471265479,0.7952269052873454,"No",0.050242240144689844,0.9497577598553096,"Yes"
"2012-002047-26","FDC116115: A prospective study of sexual function in sexually active men treated for BPH","GR","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.351859112581755e-13,0.13786126091164982,0.862138739087612,"2+",0.9866863890837895,0.013313610916206304,"No",0.010987297755622438,0.9890127022443803,"Yes",0.9999746366520764,2.5363347927289976e-05,"No",0.04480131083696208,0.9551986891630436,"Yes",0.23599743658895134,0.7640025634110418,"Yes",0.20477309471265479,0.7952269052873454,"No",0.050242240144689844,0.9497577598553096,"Yes"
"2012-002047-26","FDC116115: A prospective study of sexual function in sexually active men treated for BPHEstudio prospectivo de la función sexual en hombres sexualmente activos tratados para la HBP.","DE","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.919283878348599e-16,0.44359162085303927,0.5564083791469727,"2+",0.9159516804482017,0.08404831955179201,"No",0.06817916774761965,0.9318208322523733,"Yes",0.9999998076372848,1.923627172254112e-07,"No",0.08266585474713141,0.9173341452528717,"Yes",0.8795258619095062,0.12047413809048031,"Yes",0.004035029073581827,0.9959649709264174,"No",0.13296380191912593,0.8670361980808722,"Yes"
"2012-002047-26","FDC116115: A prospective study of sexual function in sexually active men treated for BPHEstudio prospectivo de la función sexual en hombres sexualmente activos tratados para la HBP.","ES","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.919283878348599e-16,0.44359162085303927,0.5564083791469727,"2+",0.9159516804482017,0.08404831955179201,"No",0.06817916774761965,0.9318208322523733,"Yes",0.9999998076372848,1.923627172254112e-07,"No",0.08266585474713141,0.9173341452528717,"Yes",0.8795258619095062,0.12047413809048031,"Yes",0.004035029073581827,0.9959649709264174,"No",0.13296380191912593,0.8670361980808722,"Yes"
"2012-002047-26","FDC116115: A prospective study of sexual function in sexually active men treated for BPHEstudio prospectivo de la función sexual en hombres sexualmente activos tratados para la HBP.","HU","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.919283878348599e-16,0.44359162085303927,0.5564083791469727,"2+",0.9159516804482017,0.08404831955179201,"No",0.06817916774761965,0.9318208322523733,"Yes",0.9999998076372848,1.923627172254112e-07,"No",0.08266585474713141,0.9173341452528717,"Yes",0.8795258619095062,0.12047413809048031,"Yes",0.004035029073581827,0.9959649709264174,"No",0.13296380191912593,0.8670361980808722,"Yes"
"2012-002215-26","A Double-Blind Double-Dummy Randomized Two-arm Multicenter Study Comparing the Efficacy Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Intravaginal Micronized Progesterone Capsules 600 mg daily for Luteal Support in In-Vitro Fertilization ","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.018602394397676e-48,1.5512444034072465e-14,0.9999999999999717,"2+",0.9999999994813606,5.186529307241973e-10,"No",2.6583370784092125e-09,0.9999999973416608,"Yes",1.0,1.783020981947167e-16,"No",1.6440712215886876e-13,0.9999999999998295,"Yes",0.00014520772295641154,0.999854792277038,"Yes",0.9999998946071627,1.0539283981591863e-07,"No",3.375490865230254e-14,0.9999999999999717,"Yes"
"2012-002215-26","A Double-Blind Double-Dummy Randomized Two-arm Multicenter Study Comparing the Efficacy Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Intravaginal Micronized Progesterone Capsules 600 mg daily for Luteal Support in In-Vitro Fertilization ","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.018602394397676e-48,1.5512444034072465e-14,0.9999999999999717,"2+",0.9999999994813606,5.186529307241973e-10,"No",2.6583370784092125e-09,0.9999999973416608,"Yes",1.0,1.783020981947167e-16,"No",1.6440712215886876e-13,0.9999999999998295,"Yes",0.00014520772295641154,0.999854792277038,"Yes",0.9999998946071627,1.0539283981591863e-07,"No",3.375490865230254e-14,0.9999999999999717,"Yes"
"2012-002215-26","A Double-Blind Double-Dummy Randomized Two-arm Multicenter Study Comparing the Efficacy Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Intravaginal Micronized Progesterone Capsules 600 mg daily for Luteal Support in In-Vitro Fertilization ","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.018602394397676e-48,1.5512444034072465e-14,0.9999999999999717,"2+",0.9999999994813606,5.186529307241973e-10,"No",2.6583370784092125e-09,0.9999999973416608,"Yes",1.0,1.783020981947167e-16,"No",1.6440712215886876e-13,0.9999999999998295,"Yes",0.00014520772295641154,0.999854792277038,"Yes",0.9999998946071627,1.0539283981591863e-07,"No",3.375490865230254e-14,0.9999999999999717,"Yes"
"2012-002215-26","A Double-Blind Double-Dummy Randomized Two-arm Multicenter Study Comparing the Efficacy Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Intravaginal Micronized Progesterone Capsules 600 mg daily for Luteal Support in In-Vitro Fertilization ","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.018602394397676e-48,1.5512444034072465e-14,0.9999999999999717,"2+",0.9999999994813606,5.186529307241973e-10,"No",2.6583370784092125e-09,0.9999999973416608,"Yes",1.0,1.783020981947167e-16,"No",1.6440712215886876e-13,0.9999999999998295,"Yes",0.00014520772295641154,0.999854792277038,"Yes",0.9999998946071627,1.0539283981591863e-07,"No",3.375490865230254e-14,0.9999999999999717,"Yes"
"2012-002250-23","Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancerEstudio de fase Ib de búsqueda de dosis de acetato de abiraterona más BEZ235 o BKM120 en pacientes con cáncer de próstata resistente a la castración","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","No","No","Yes","2+","No",1.2963785133144907e-52,0.00010663063158828468,0.9998933693684077,"2+",7.109919801057857e-07,0.9999992890080277,"Yes",0.9999975927753708,2.4072246199372865e-06,"No",1.0,4.707016085763853e-26,"No",0.00039383924486636427,0.9996061607551274,"Yes",0.9999901646522112,9.835347802059663e-06,"No",1.0,1.0220039111856613e-21,"No",0.0016713316342486968,0.9983286683657495,"No"
"2012-002340-24","A Phase IIb Partially-Blinded Randomized Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics Safety and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Emetogenic Chemotherapy Subtitle: Open-Label Cohort to Further Evaluate the Pharmacokinetics /Pharmacodynamics Safety and Tolerability of Fosaprepitant in Pediatric Patients Birth to <12 Years Old","Outside EU/EEA","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0390614830975626e-75,1.3191452848606735e-12,0.9999999999986926,"2+",0.9999973873707996,2.6126292247260215e-06,"Yes",1.6410378546652473e-05,0.9999835896214687,"No",0.999999999989484,1.054087013555985e-11,"No",1.7719926276457365e-12,0.999999999998238,"Yes",2.508252225324759e-09,0.9999999974917274,"Yes",1.0,9.117320744739452e-18,"No",3.35499772861529e-11,0.9999999999664624,"Yes"
"2012-002603-17","A phase IIIb multicenter multinational randomized double-blind placebo controlled parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 mg for 24 weeks in type 2 diabetes patients with micro- or macroalbuminuria (30-3000mg/g creatinine) on top of current treatment with Angiotensin Converting Enzyme inhibitor or Angiotensin Receptor Blocker – MARLINA (Efficacy safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.9197950844266517e-101,4.915209239570715e-27,1.0,"2+",1.0,3.0155248409427954e-20,"No",4.658994821277385e-19,1.0,"Yes",1.0,2.610858023347881e-22,"No",8.270595116704432e-29,1.0,"Yes",2.2149246762735084e-14,1.0,"Yes",0.9999999867305861,1.326943159606441e-08,"No",8.053758021189107e-27,1.0,"Yes"
"2012-002603-17","A phase IIIb multicenter multinational randomized double-blind placebo controlled parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 mg for 24 weeks in type 2 diabetes patients with micro- or macroalbuminuria (30-3000mg/g creatinine) on top of current treatment with Angiotensin Converting Enzyme inhibitor or Angiotensin Receptor Blocker – MARLINA (Efficacy safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin)","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.9197950844266517e-101,4.915209239570715e-27,1.0,"2+",1.0,3.0155248409427954e-20,"No",4.658994821277385e-19,1.0,"Yes",1.0,2.610858023347881e-22,"No",8.270595116704432e-29,1.0,"Yes",2.2149246762735084e-14,1.0,"Yes",0.9999999867305861,1.326943159606441e-08,"No",8.053758021189107e-27,1.0,"Yes"
"2012-002603-17","A phase IIIb multicenter multinational randomized double-blind placebo controlled parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 mg for 24 weeks in type 2 diabetes patients with micro- or macroalbuminuria (30-3000mg/g creatinine) on top of current treatment with Angiotensin Converting Enzyme inhibitor or Angiotensin Receptor Blocker – MARLINA (Efficacy safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin)","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.9197950844266517e-101,4.915209239570715e-27,1.0,"2+",1.0,3.0155248409427954e-20,"No",4.658994821277385e-19,1.0,"Yes",1.0,2.610858023347881e-22,"No",8.270595116704432e-29,1.0,"Yes",2.2149246762735084e-14,1.0,"Yes",0.9999999867305861,1.326943159606441e-08,"No",8.053758021189107e-27,1.0,"Yes"
"2012-002603-17","A phase IIIb multicenter multinational randomized double-blind placebo controlled parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 mg for 24 weeks in type 2 diabetes patients with micro- or macroalbuminuria (30-3000mg/g creatinine) on top of current treatment with Angiotensin Converting Enzyme inhibitor or Angiotensin Receptor Blocker – MARLINA (Efficacy safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin)","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.9197950844266517e-101,4.915209239570715e-27,1.0,"2+",1.0,3.0155248409427954e-20,"No",4.658994821277385e-19,1.0,"Yes",1.0,2.610858023347881e-22,"No",8.270595116704432e-29,1.0,"Yes",2.2149246762735084e-14,1.0,"Yes",0.9999999867305861,1.326943159606441e-08,"No",8.053758021189107e-27,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneEnsayo aleatorizado doble ciego con doble simulación multicéntrico para evaluar la seguridad y eficacia de BAY 94-8862 en pacientes que acuden a urgencias  del hospital debido a un empeoramiento de la insuficiencia cardiaca crónica con disfunción sistólica ventricular izquierda acompañada bien de diabetes mellitus de tipo 2 con o sin enfermedad renal crónica o bien únicamente de enfermedad renal crónica moderada en comparación con eplerenona","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.260050474274372e-151,3.1724604403446265e-40,1.0,"2+",1.0,2.3132195783762724e-28,"No",4.3528434536119756e-27,1.0,"Yes",1.0,8.055886410031282e-41,"No",1.7377797551689938e-42,1.0,"Yes",2.3123261365872845e-15,1.0,"Yes",1.0,1.1053393834068706e-32,"No",1.2854967330903193e-37,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneStudio multicentrico randomizzato in doppio cieco double-dummy per valutare la sicurezza e l’efficacia di BAY 94-8862 rispetto all’eplerenone in soggetti giunti d’urgenza in ospedale a causa del peggioramento dell’insufficienza cardiaca cronica con disfunzione sistolica del ventricolo sinistro con diabete mellito di tipo 2 con o senza nefropatia cronica o con sola nefropatia cronica moderata","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.3630410375460507e-142,1.3142827815439825e-40,1.0,"2+",1.0,2.529671336190554e-25,"No",1.0201661411581576e-23,1.0,"Yes",1.0,9.802961117275449e-36,"No",5.406548162339311e-42,1.0,"Yes",2.603710024210212e-17,1.0,"Yes",1.0,5.906292426273726e-30,"No",1.1269897725020722e-35,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenone","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.280826774026002e-76,1.6959817136208807e-24,1.0,"2+",1.0,1.2219396529932707e-18,"No",3.74050967546167e-17,1.0,"Yes",0.9999999999999432,7.609643660966961e-14,"No",2.7287087684309142e-25,1.0,"Yes",3.938431199447183e-09,0.999999996061547,"Yes",0.9999999980327062,1.9673190928325283e-09,"No",2.199437182602325e-22,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneEnsayo aleatorizado doble ciego con doble simulación multicéntrico para evaluar la seguridad y eficacia de BAY 94-8862 en pacientes que acuden a urgencias  del hospital debido a un empeoramiento de la insuficiencia cardiaca crónica con disfunción sistólica ventricular izquierda acompañada bien de diabetes mellitus de tipo 2 con o sin enfermedad renal crónica o bien únicamente de enfermedad renal crónica moderada en comparación con eplerenona","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.260050474274372e-151,3.1724604403446265e-40,1.0,"2+",1.0,2.3132195783762724e-28,"No",4.3528434536119756e-27,1.0,"Yes",1.0,8.055886410031282e-41,"No",1.7377797551689938e-42,1.0,"Yes",2.3123261365872845e-15,1.0,"Yes",1.0,1.1053393834068706e-32,"No",1.2854967330903193e-37,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneStudio multicentrico randomizzato in doppio cieco double-dummy per valutare la sicurezza e l’efficacia di BAY 94-8862 rispetto all’eplerenone in soggetti giunti d’urgenza in ospedale a causa del peggioramento dell’insufficienza cardiaca cronica con disfunzione sistolica del ventricolo sinistro con diabete mellito di tipo 2 con o senza nefropatia cronica o con sola nefropatia cronica moderata","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.3630410375460507e-142,1.3142827815439825e-40,1.0,"2+",1.0,2.529671336190554e-25,"No",1.0201661411581576e-23,1.0,"Yes",1.0,9.802961117275449e-36,"No",5.406548162339311e-42,1.0,"Yes",2.603710024210212e-17,1.0,"Yes",1.0,5.906292426273726e-30,"No",1.1269897725020722e-35,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneStudio multicentrico randomizzato in doppio cieco double-dummy per valutare la sicurezza e l’efficacia di BAY 94-8862 rispetto all’eplerenone in soggetti giunti d’urgenza in ospedale a causa del peggioramento dell’insufficienza cardiaca cronica con disfunzione sistolica del ventricolo sinistro con diabete mellito di tipo 2 con o senza nefropatia cronica o con sola nefropatia cronica moderata","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.3630410375460507e-142,1.3142827815439825e-40,1.0,"2+",1.0,2.529671336190554e-25,"No",1.0201661411581576e-23,1.0,"Yes",1.0,9.802961117275449e-36,"No",5.406548162339311e-42,1.0,"Yes",2.603710024210212e-17,1.0,"Yes",1.0,5.906292426273726e-30,"No",1.1269897725020722e-35,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenone","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.280826774026002e-76,1.6959817136208807e-24,1.0,"2+",1.0,1.2219396529932707e-18,"No",3.74050967546167e-17,1.0,"Yes",0.9999999999999432,7.609643660966961e-14,"No",2.7287087684309142e-25,1.0,"Yes",3.938431199447183e-09,0.999999996061547,"Yes",0.9999999980327062,1.9673190928325283e-09,"No",2.199437182602325e-22,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneRandomizovaná dvojitězaslepená dvojitě matoucí multicentrická studie s cílem zhodnotit bezpečnost a účinnost látky BAY 94-8862 u subjektů s náhlou hospitalizací kvůli zhoršení chronického srdečního selhání se systolickou dysfunkcí levé komory a buď cukrovkou (DM) typu 2 s chronickým onemocněním ledvin nebo bez něj nebo se samotným středně závažným onemocněním ledvin ve srovnání s eplerenonem.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0579168049634242e-139,6.540342231349873e-44,1.0,"2+",1.0,6.453455491198406e-36,"No",8.614186786694696e-36,1.0,"Yes",1.0,5.9794176757531895e-61,"No",4.4926799761464404e-49,1.0,"Yes",2.6803644086118966e-18,1.0,"Yes",1.0,7.352206667978772e-50,"No",4.3404158632195366e-44,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneRandomizovaná dvojitězaslepená dvojitě matoucí multicentrická studie s cílem zhodnotit bezpečnost a účinnost látky BAY 94-8862 u subjektů s náhlou hospitalizací kvůli zhoršení chronického srdečního selhání se systolickou dysfunkcí levé komory a buď cukrovkou (DM) typu 2 s chronickým onemocněním ledvin nebo bez něj nebo se samotným středně závažným onemocněním ledvin ve srovnání s eplerenonem.","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0579168049634242e-139,6.540342231349873e-44,1.0,"2+",1.0,6.453455491198406e-36,"No",8.614186786694696e-36,1.0,"Yes",1.0,5.9794176757531895e-61,"No",4.4926799761464404e-49,1.0,"Yes",2.6803644086118966e-18,1.0,"Yes",1.0,7.352206667978772e-50,"No",4.3404158632195366e-44,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenone","NO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.280826774026002e-76,1.6959817136208807e-24,1.0,"2+",1.0,1.2219396529932707e-18,"No",3.74050967546167e-17,1.0,"Yes",0.9999999999999432,7.609643660966961e-14,"No",2.7287087684309142e-25,1.0,"Yes",3.938431199447183e-09,0.999999996061547,"Yes",0.9999999980327062,1.9673190928325283e-09,"No",2.199437182602325e-22,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneStudio multicentrico randomizzato in doppio cieco double-dummy per valutare la sicurezza e l’efficacia di BAY 94-8862 rispetto all’eplerenone in soggetti giunti d’urgenza in ospedale a causa del peggioramento dell’insufficienza cardiaca cronica con disfunzione sistolica del ventricolo sinistro con diabete mellito di tipo 2 con o senza nefropatia cronica o con sola nefropatia cronica moderata","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.3630410375460507e-142,1.3142827815439825e-40,1.0,"2+",1.0,2.529671336190554e-25,"No",1.0201661411581576e-23,1.0,"Yes",1.0,9.802961117275449e-36,"No",5.406548162339311e-42,1.0,"Yes",2.603710024210212e-17,1.0,"Yes",1.0,5.906292426273726e-30,"No",1.1269897725020722e-35,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneStudio multicentrico randomizzato in doppio cieco double-dummy per valutare la sicurezza e l’efficacia di BAY 94-8862 rispetto all’eplerenone in soggetti giunti d’urgenza in ospedale a causa del peggioramento dell’insufficienza cardiaca cronica con disfunzione sistolica del ventricolo sinistro con diabete mellito di tipo 2 con o senza nefropatia cronica o con sola nefropatia cronica moderata","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.3630410375460507e-142,1.3142827815439825e-40,1.0,"2+",1.0,2.529671336190554e-25,"No",1.0201661411581576e-23,1.0,"Yes",1.0,9.802961117275449e-36,"No",5.406548162339311e-42,1.0,"Yes",2.603710024210212e-17,1.0,"Yes",1.0,5.906292426273726e-30,"No",1.1269897725020722e-35,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneRandomizovaná dvojitězaslepená dvojitě matoucí multicentrická studie s cílem zhodnotit bezpečnost a účinnost látky BAY 94-8862 u subjektů s náhlou hospitalizací kvůli zhoršení chronického srdečního selhání se systolickou dysfunkcí levé komory a buď cukrovkou (DM) typu 2 s chronickým onemocněním ledvin nebo bez něj nebo se samotným středně závažným onemocněním ledvin ve srovnání s eplerenonem.","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0579168049634242e-139,6.540342231349873e-44,1.0,"2+",1.0,6.453455491198406e-36,"No",8.614186786694696e-36,1.0,"Yes",1.0,5.9794176757531895e-61,"No",4.4926799761464404e-49,1.0,"Yes",2.6803644086118966e-18,1.0,"Yes",1.0,7.352206667978772e-50,"No",4.3404158632195366e-44,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenone","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.280826774026002e-76,1.6959817136208807e-24,1.0,"2+",1.0,1.2219396529932707e-18,"No",3.74050967546167e-17,1.0,"Yes",0.9999999999999432,7.609643660966961e-14,"No",2.7287087684309142e-25,1.0,"Yes",3.938431199447183e-09,0.999999996061547,"Yes",0.9999999980327062,1.9673190928325283e-09,"No",2.199437182602325e-22,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneEnsayo aleatorizado doble ciego con doble simulación multicéntrico para evaluar la seguridad y eficacia de BAY 94-8862 en pacientes que acuden a urgencias  del hospital debido a un empeoramiento de la insuficiencia cardiaca crónica con disfunción sistólica ventricular izquierda acompañada bien de diabetes mellitus de tipo 2 con o sin enfermedad renal crónica o bien únicamente de enfermedad renal crónica moderada en comparación con eplerenona","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.260050474274372e-151,3.1724604403446265e-40,1.0,"2+",1.0,2.3132195783762724e-28,"No",4.3528434536119756e-27,1.0,"Yes",1.0,8.055886410031282e-41,"No",1.7377797551689938e-42,1.0,"Yes",2.3123261365872845e-15,1.0,"Yes",1.0,1.1053393834068706e-32,"No",1.2854967330903193e-37,1.0,"Yes"
"2012-002627-15","A randomized double-blind double-dummy multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone versus eplerenoneRandomizovaná dvojitězaslepená dvojitě matoucí multicentrická studie s cílem zhodnotit bezpečnost a účinnost látky BAY 94-8862 u subjektů s náhlou hospitalizací kvůli zhoršení chronického srdečního selhání se systolickou dysfunkcí levé komory a buď cukrovkou (DM) typu 2 s chronickým onemocněním ledvin nebo bez něj nebo se samotným středně závažným onemocněním ledvin ve srovnání s eplerenonem.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0579168049634242e-139,6.540342231349873e-44,1.0,"2+",1.0,6.453455491198406e-36,"No",8.614186786694696e-36,1.0,"Yes",1.0,5.9794176757531895e-61,"No",4.4926799761464404e-49,1.0,"Yes",2.6803644086118966e-18,1.0,"Yes",1.0,7.352206667978772e-50,"No",4.3404158632195366e-44,1.0,"Yes"
"2012-002751-42","A randomized double-blind placebo-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomasRandomizovaná dvojitě zaslepená placebem kontrolovaná studie fáze 3 zkoumající brentuximab vedotin spolu s chemoterapií  CHP (A-CHP) oproti chemoterapii CHOP v úvodní léčbě pacientů s CD30-pozitivními zralými T- buněčnými lymfomy","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.989048969758091e-90,4.973245539741408e-22,1.0,"2+",0.9945525255650165,0.005447474434978673,"No",0.006336350824405594,0.9936636491756221,"Yes",1.0,3.574595996398908e-45,"No",6.184477532821358e-24,1.0,"Yes",7.660076855036174e-07,0.9999992339923075,"Yes",1.0,6.487155620666794e-35,"No",3.9852520446012925e-19,1.0,"Yes"
"2012-002751-42","A randomized double-blind placebo-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7419099075623147e-45,2.0773804392332325e-09,0.999999997922629,"2+",0.043113028977560454,0.9568869710224496,"No",0.9807135684120502,0.01928643158795199,"Yes",1.0,3.1859326926581256e-18,"No",4.516490130851136e-09,0.9999999954835063,"Yes",0.0696010739691779,0.9303989260308353,"Yes",0.9999999999983517,1.6521842041598908e-12,"No",2.0719838791662434e-08,0.9999999792801477,"Yes"
"2012-002751-42","A randomized double-blind placebo-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomasEstudio de fase III aleatorizado doble ciego y controlado con placebo de brentuximab vedotina y CHP (A+CHP) en comparación con CHOP como tratamiento de primera línea de los linfomas de células T maduras CD30-positivos","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.320608060944104e-90,1.8025311191445867e-20,1.0,"2+",0.002045175568604483,0.9979548244313785,"No",0.9995139471022234,0.0004860528977932972,"Yes",1.0,6.018075427066702e-35,"No",4.568975915818316e-18,1.0,"Yes",0.027116108864835984,0.972883891135152,"Yes",1.0,3.8173557065627165e-29,"No",1.4348961099880285e-18,1.0,"Yes"
"2012-002751-42","A randomized double-blind placebo-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomasEstudio de fase III aleatorizado doble ciego y controlado con placebo de brentuximab vedotina y CHP (A+CHP) en comparación con CHOP como tratamiento de primera línea de los linfomas de células T maduras CD30-positivos","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.320608060944104e-90,1.8025311191445867e-20,1.0,"2+",0.002045175568604483,0.9979548244313785,"No",0.9995139471022234,0.0004860528977932972,"Yes",1.0,6.018075427066702e-35,"No",4.568975915818316e-18,1.0,"Yes",0.027116108864835984,0.972883891135152,"Yes",1.0,3.8173557065627165e-29,"No",1.4348961099880285e-18,1.0,"Yes"
"2012-002751-42","A randomized double-blind placebo-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomasStudio di fase 3 randomizzato in doppio cieco controllato con placebo su brentuximab vedotin e CHP (A+CHP) rispetto a CHOP nel trattamento di prima linea di pazienti con linfomi a cellule T mature CD30-positivi","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3587038985014004e-97,4.5189170746713684e-17,1.0,"2+",3.796222009047131e-06,0.9999962037779689,"No",0.9999983006125833,1.699387417451817e-06,"Yes",1.0,1.2138754455841344e-35,"No",1.2479644362561635e-17,1.0,"Yes",0.0002372015782228581,0.9997627984217748,"Yes",1.0,1.601504111594474e-28,"No",5.4906577624512925e-15,1.0,"Yes"
"2012-002751-42","A randomized double-blind placebo-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomasEstudio de fase III aleatorizado doble ciego y controlado con placebo de brentuximab vedotina y CHP (A+CHP) en comparación con CHOP como tratamiento de primera línea de los linfomas de células T maduras CD30-positivos","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.320608060944104e-90,1.8025311191445867e-20,1.0,"2+",0.002045175568604483,0.9979548244313785,"No",0.9995139471022234,0.0004860528977932972,"Yes",1.0,6.018075427066702e-35,"No",4.568975915818316e-18,1.0,"Yes",0.027116108864835984,0.972883891135152,"Yes",1.0,3.8173557065627165e-29,"No",1.4348961099880285e-18,1.0,"Yes"
"2012-002785-12","A 28-week randomised open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients withschizophrenia","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.74349903087855e-23,5.4362990964258e-05,0.9999456370090396,"2+",0.70544479346801,0.2945552065319915,"Yes",0.2559561826163519,0.7440438173836436,"No",0.9999999861711758,1.3828828402738754e-08,"No",0.0017231576045169655,0.9982768423954871,"Yes",0.06925248400903758,0.9307475159909683,"Yes",0.9999989685774926,1.0314225093950426e-06,"No",0.00022153602357869435,0.9997784639764272,"Yes"
"2012-002785-12","A 28-week randomised open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients withschizophrenia","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.74349903087855e-23,5.4362990964258e-05,0.9999456370090396,"2+",0.70544479346801,0.2945552065319915,"Yes",0.2559561826163519,0.7440438173836436,"No",0.9999999861711758,1.3828828402738754e-08,"No",0.0017231576045169655,0.9982768423954871,"Yes",0.06925248400903758,0.9307475159909683,"Yes",0.9999989685774926,1.0314225093950426e-06,"No",0.00022153602357869435,0.9997784639764272,"Yes"
"2012-002785-12","A 28-week randomised open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients withschizophreniaStudio in aperto randomizzato della durata di 28 settimane per valutare l’efficacia di aripiprazolo somministrato una volta al mese rispetto al paliperidone palmitato in pazienti adulti affetti da schizofrenia","EE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.048156354353279e-64,7.671977712688752e-10,0.9999999992327844,"2+",0.03094725819468962,0.9690527418053062,"Yes",0.9384225277335178,0.061577472266457135,"No",1.0,4.695304995013815e-22,"No",1.8269738272273298e-08,0.9999999817302412,"Yes",0.0012376135321356923,0.9987623864678902,"Yes",1.0,2.4070149534828177e-17,"No",7.567359402565538e-10,0.9999999992432436,"Yes"
"2012-002785-12","A 28-week randomised open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients withschizophrenia","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.74349903087855e-23,5.4362990964258e-05,0.9999456370090396,"2+",0.70544479346801,0.2945552065319915,"Yes",0.2559561826163519,0.7440438173836436,"No",0.9999999861711758,1.3828828402738754e-08,"No",0.0017231576045169655,0.9982768423954871,"Yes",0.06925248400903758,0.9307475159909683,"Yes",0.9999989685774926,1.0314225093950426e-06,"No",0.00022153602357869435,0.9997784639764272,"Yes"
"2012-002785-12","A 28-week randomised open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients withschizophrenia","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.74349903087855e-23,5.4362990964258e-05,0.9999456370090396,"2+",0.70544479346801,0.2945552065319915,"Yes",0.2559561826163519,0.7440438173836436,"No",0.9999999861711758,1.3828828402738754e-08,"No",0.0017231576045169655,0.9982768423954871,"Yes",0.06925248400903758,0.9307475159909683,"Yes",0.9999989685774926,1.0314225093950426e-06,"No",0.00022153602357869435,0.9997784639764272,"Yes"
"2012-002785-12","A 28-week randomised open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients withschizophrenia","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.74349903087855e-23,5.4362990964258e-05,0.9999456370090396,"2+",0.70544479346801,0.2945552065319915,"Yes",0.2559561826163519,0.7440438173836436,"No",0.9999999861711758,1.3828828402738754e-08,"No",0.0017231576045169655,0.9982768423954871,"Yes",0.06925248400903758,0.9307475159909683,"Yes",0.9999989685774926,1.0314225093950426e-06,"No",0.00022153602357869435,0.9997784639764272,"Yes"
"2012-002785-12","A 28-week randomised open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients withschizophreniaStudio in aperto randomizzato della durata di 28 settimane per valutare l’efficacia di aripiprazolo somministrato una volta al mese rispetto al paliperidone palmitato in pazienti adulti affetti da schizofrenia","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.048156354353279e-64,7.671977712688752e-10,0.9999999992327844,"2+",0.03094725819468962,0.9690527418053062,"Yes",0.9384225277335178,0.061577472266457135,"No",1.0,4.695304995013815e-22,"No",1.8269738272273298e-08,0.9999999817302412,"Yes",0.0012376135321356923,0.9987623864678902,"Yes",1.0,2.4070149534828177e-17,"No",7.567359402565538e-10,0.9999999992432436,"Yes"
"2012-002805-23","A Randomized Double-blind Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisEine randomisierte doppelblinde placebokontrollierte Phase-III-Studie zur Beurteilung der Wirksamkeit und Sicherheit von AMG 416 zur Behandlung des sekundären Hyperparathyreoidismus bei Patienten mit chronischer Nierenerkrankung unter Hämodialyse","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2203587756995244e-71,4.0493571003436906e-08,0.9999999595064546,"2+",0.9999999995609415,4.390532699112216e-10,"No",1.267480612454302e-08,0.9999999873251683,"Yes",0.9999999999996021,4.1023498070062803e-13,"No",9.085321469107562e-10,0.9999999990914717,"Yes",0.9996957777690234,0.0003042222309789839,"No",0.9999999994963106,5.036633350188028e-10,"No",4.4846182050212006e-05,0.9999551538179535,"Yes"
"2012-002805-23","A Randomized Double-blind Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisRandomizované dvojitě zaslepené placebem kontrolované klinické hodnocení fáze III hodnotící účinnost a bezpečnost přípravku AMG 416 v léčbě sekundární hyperparatyreózy u hemodialyzovaných pacientů s chronickým onemocněním ledvin","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1826109765579506e-78,3.802749300711778e-18,1.0,"2+",1.0,2.5960793312628046e-22,"No",3.113779164501532e-22,1.0,"Yes",1.0,1.5388268181123105e-35,"No",6.80332456673984e-20,1.0,"Yes",0.9996921072134309,0.00030789278656348507,"No",1.0,3.435632075259302e-27,"No",4.6494991055694e-16,1.0,"Yes"
"2012-002805-23","A Randomized Double-blind Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisEstudio en fase III aleatorizado doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de AMG 416 en el tratamiento del hiperparatiroidismo secundario en pacientes con insuficiencia renal crónica sometidos a hemodiálisis","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.150567353905512e-75,1.4594250004761323e-17,1.0,"2+",1.0,9.354820325562195e-16,"No",1.0129543668050993e-14,1.0,"Yes",1.0,5.33482089551913e-19,"No",1.1593738572874524e-16,1.0,"Yes",0.715096860149148,0.2849031398508706,"No",1.0,4.263781878120835e-19,"No",9.67658551270573e-11,0.9999999999032525,"Yes"
"2012-002805-23","A Randomized Double-blind Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisEine randomisierte doppelblinde placebokontrollierte Phase-III-Studie zur Beurteilung der Wirksamkeit und Sicherheit von AMG 416 zur Behandlung des sekundären Hyperparathyreoidismus bei Patienten mit chronischer Nierenerkrankung unter Hämodialyse","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2203587756995244e-71,4.0493571003436906e-08,0.9999999595064546,"2+",0.9999999995609415,4.390532699112216e-10,"No",1.267480612454302e-08,0.9999999873251683,"Yes",0.9999999999996021,4.1023498070062803e-13,"No",9.085321469107562e-10,0.9999999990914717,"Yes",0.9996957777690234,0.0003042222309789839,"No",0.9999999994963106,5.036633350188028e-10,"No",4.4846182050212006e-05,0.9999551538179535,"Yes"
"2012-002805-23","A Randomized Double-blind Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisRandomizované dvojitě zaslepené placebem kontrolované klinické hodnocení fáze III hodnotící účinnost a bezpečnost přípravku AMG 416 v léčbě sekundární hyperparatyreózy u hemodialyzovaných pacientů s chronickým onemocněním ledvin","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1826109765579506e-78,3.802749300711778e-18,1.0,"2+",1.0,2.5960793312628046e-22,"No",3.113779164501532e-22,1.0,"Yes",1.0,1.5388268181123105e-35,"No",6.80332456673984e-20,1.0,"Yes",0.9996921072134309,0.00030789278656348507,"No",1.0,3.435632075259302e-27,"No",4.6494991055694e-16,1.0,"Yes"
"2012-002805-23","A Randomized Double-blind Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisRandomizované dvojitě zaslepené placebem kontrolované klinické hodnocení fáze III hodnotící účinnost a bezpečnost přípravku AMG 416 v léčbě sekundární hyperparatyreózy u hemodialyzovaných pacientů s chronickým onemocněním ledvin","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1826109765579506e-78,3.802749300711778e-18,1.0,"2+",1.0,2.5960793312628046e-22,"No",3.113779164501532e-22,1.0,"Yes",1.0,1.5388268181123105e-35,"No",6.80332456673984e-20,1.0,"Yes",0.9996921072134309,0.00030789278656348507,"No",1.0,3.435632075259302e-27,"No",4.6494991055694e-16,1.0,"Yes"
"2012-002805-23","A Randomized Double-blind Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisRandomizované dvojitě zaslepené placebem kontrolované klinické hodnocení fáze III hodnotící účinnost a bezpečnost přípravku AMG 416 v léčbě sekundární hyperparatyreózy u hemodialyzovaných pacientů s chronickým onemocněním ledvin","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1826109765579506e-78,3.802749300711778e-18,1.0,"2+",1.0,2.5960793312628046e-22,"No",3.113779164501532e-22,1.0,"Yes",1.0,1.5388268181123105e-35,"No",6.80332456673984e-20,1.0,"Yes",0.9996921072134309,0.00030789278656348507,"No",1.0,3.435632075259302e-27,"No",4.6494991055694e-16,1.0,"Yes"
"2012-002805-23","A Randomized Double-blind Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisRandomizované dvojitě zaslepené placebem kontrolované klinické hodnocení fáze III hodnotící účinnost a bezpečnost přípravku AMG 416 v léčbě sekundární hyperparatyreózy u hemodialyzovaných pacientů s chronickým onemocněním ledvin","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1826109765579506e-78,3.802749300711778e-18,1.0,"2+",1.0,2.5960793312628046e-22,"No",3.113779164501532e-22,1.0,"Yes",1.0,1.5388268181123105e-35,"No",6.80332456673984e-20,1.0,"Yes",0.9996921072134309,0.00030789278656348507,"No",1.0,3.435632075259302e-27,"No",4.6494991055694e-16,1.0,"Yes"
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-termEfficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","PL","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.98008691715407e-20,0.9999895535944974,1.0446405501642833e-05,"1",0.04362160072348082,0.9563783992765258,"Information not present in EudraCT",0.9538674127644592,0.0461325872355357,"Information not present in EudraCT",0.9999999976193266,2.380674725005392e-09,"Information not present in EudraCT",0.9999798308287785,2.0169171215005664e-05,"No",0.9998768034468359,0.00012319655315755384,"No",0.9999989067654277,1.0932345690074307e-06,"",0.9999966086293408,3.3913706627069696e-06,""
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","NL","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",4.821927068786611e-19,0.9999990612687385,9.387312588120635e-07,"1",0.012014070177503805,0.9879859298224996,"Information not present in EudraCT",0.9877713863851573,0.012228613614843604,"Information not present in EudraCT",0.9999999963849718,3.615027321469871e-09,"Information not present in EudraCT",0.9999986583175988,1.3416823985613896e-06,"No",0.9999748531834548,2.5146816545575553e-05,"No",0.9999997513938891,2.4860610920010197e-07,"",0.9999998356648228,1.6433518055641445e-07,""
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","AT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",4.821927068786611e-19,0.9999990612687385,9.387312588120635e-07,"1",0.012014070177503805,0.9879859298224996,"Information not present in EudraCT",0.9877713863851573,0.012228613614843604,"Information not present in EudraCT",0.9999999963849718,3.615027321469871e-09,"Information not present in EudraCT",0.9999986583175988,1.3416823985613896e-06,"No",0.9999748531834548,2.5146816545575553e-05,"No",0.9999997513938891,2.4860610920010197e-07,"",0.9999998356648228,1.6433518055641445e-07,""
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-termEfficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","SE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.98008691715407e-20,0.9999895535944974,1.0446405501642833e-05,"1",0.04362160072348082,0.9563783992765258,"Information not present in EudraCT",0.9538674127644592,0.0461325872355357,"Information not present in EudraCT",0.9999999976193266,2.380674725005392e-09,"Information not present in EudraCT",0.9999798308287785,2.0169171215005664e-05,"No",0.9998768034468359,0.00012319655315755384,"No",0.9999989067654277,1.0932345690074307e-06,"",0.9999966086293408,3.3913706627069696e-06,""
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-termEfficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","GB","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.98008691715407e-20,0.9999895535944974,1.0446405501642833e-05,"1",0.04362160072348082,0.9563783992765258,"Information not present in EudraCT",0.9538674127644592,0.0461325872355357,"Information not present in EudraCT",0.9999999976193266,2.380674725005392e-09,"Information not present in EudraCT",0.9999798308287785,2.0169171215005664e-05,"No",0.9998768034468359,0.00012319655315755384,"No",0.9999989067654277,1.0932345690074307e-06,"",0.9999966086293408,3.3913706627069696e-06,""
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-termEfficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","IT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.98008691715407e-20,0.9999895535944974,1.0446405501642833e-05,"1",0.04362160072348082,0.9563783992765258,"Information not present in EudraCT",0.9538674127644592,0.0461325872355357,"Information not present in EudraCT",0.9999999976193266,2.380674725005392e-09,"Information not present in EudraCT",0.9999798308287785,2.0169171215005664e-05,"No",0.9998768034468359,0.00012319655315755384,"No",0.9999989067654277,1.0932345690074307e-06,"",0.9999966086293408,3.3913706627069696e-06,""
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-termEfficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","CZ","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.98008691715407e-20,0.9999895535944974,1.0446405501642833e-05,"1",0.04362160072348082,0.9563783992765258,"Information not present in EudraCT",0.9538674127644592,0.0461325872355357,"Information not present in EudraCT",0.9999999976193266,2.380674725005392e-09,"Information not present in EudraCT",0.9999798308287785,2.0169171215005664e-05,"No",0.9998768034468359,0.00012319655315755384,"No",0.9999989067654277,1.0932345690074307e-06,"",0.9999966086293408,3.3913706627069696e-06,""
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","ES","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",4.821927068786611e-19,0.9999990612687385,9.387312588120635e-07,"1",0.012014070177503805,0.9879859298224996,"Information not present in EudraCT",0.9877713863851573,0.012228613614843604,"Information not present in EudraCT",0.9999999963849718,3.615027321469871e-09,"Information not present in EudraCT",0.9999986583175988,1.3416823985613896e-06,"No",0.9999748531834548,2.5146816545575553e-05,"No",0.9999997513938891,2.4860610920010197e-07,"",0.9999998356648228,1.6433518055641445e-07,""
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-termEfficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","BE","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.98008691715407e-20,0.9999895535944974,1.0446405501642833e-05,"1",0.04362160072348082,0.9563783992765258,"Information not present in EudraCT",0.9538674127644592,0.0461325872355357,"Information not present in EudraCT",0.9999999976193266,2.380674725005392e-09,"Information not present in EudraCT",0.9999798308287785,2.0169171215005664e-05,"No",0.9998768034468359,0.00012319655315755384,"No",0.9999989067654277,1.0932345690074307e-06,"",0.9999966086293408,3.3913706627069696e-06,""
"2012-002808-41","A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of SecondaryHyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","HU","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",4.821927068786611e-19,0.9999990612687385,9.387312588120635e-07,"1",0.012014070177503805,0.9879859298224996,"Information not present in EudraCT",0.9877713863851573,0.012228613614843604,"Information not present in EudraCT",0.9999999963849718,3.615027321469871e-09,"Information not present in EudraCT",0.9999986583175988,1.3416823985613896e-06,"No",0.9999748531834548,2.5146816545575553e-05,"No",0.9999997513938891,2.4860610920010197e-07,"",0.9999998356648228,1.6433518055641445e-07,""
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyÉtude de phase III randomisée multicentrique en double aveugle et groupes parallèles visant à évaluer l’efficacité et la sécurité d’emploi du DCVAC/PCa par rapport au placebo chez des hommes présentant un cancer de la prostate métastatique résistant à la castration (CPmRC) et admissibles à une chimiothérapie de première intention.","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.2034711320836646e-110,3.412792733529153e-12,0.9999999999965895,"2+",2.3237450079125883e-05,0.9999767625499079,"No",0.9999969478777155,3.0521222946707245e-06,"Yes",1.0,1.0154112536870601e-29,"No",4.953047090228864e-12,0.9999999999950546,"Yes",0.0006655835848180233,0.9993344164151601,"Yes",1.0,6.348638538970248e-19,"No",1.545447577167486e-13,0.9999999999998295,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyÉtude de phase III randomisée multicentrique en double aveugle et groupes parallèles visant à évaluer l’efficacité et la sécurité d’emploi du DCVAC/PCa par rapport au placebo chez des hommes présentant un cancer de la prostate métastatique résistant à la castration (CPmRC) et admissibles à une chimiothérapie de première intention.","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.2034711320836646e-110,3.412792733529153e-12,0.9999999999965895,"2+",2.3237450079125883e-05,0.9999767625499079,"No",0.9999969478777155,3.0521222946707245e-06,"Yes",1.0,1.0154112536870601e-29,"No",4.953047090228864e-12,0.9999999999950546,"Yes",0.0006655835848180233,0.9993344164151601,"Yes",1.0,6.348638538970248e-19,"No",1.545447577167486e-13,0.9999999999998295,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyÉtude de phase III randomisée multicentrique en double aveugle et groupes parallèles visant à évaluer l’efficacité et la sécurité d’emploi du DCVAC/PCa par rapport au placebo chez des hommes présentant un cancer de la prostate métastatique résistant à la castration (CPmRC) et admissibles à une chimiothérapie de première intention.","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.2034711320836646e-110,3.412792733529153e-12,0.9999999999965895,"2+",2.3237450079125883e-05,0.9999767625499079,"No",0.9999969478777155,3.0521222946707245e-06,"Yes",1.0,1.0154112536870601e-29,"No",4.953047090228864e-12,0.9999999999950546,"Yes",0.0006655835848180233,0.9993344164151601,"Yes",1.0,6.348638538970248e-19,"No",1.545447577167486e-13,0.9999999999998295,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyRandomizovaná dvojitě zaslepená multicentrická studie fáze III s paralelními skupinami pacientů určena k vyhodnocení účinnosti a bezpečnosti přípravku DCVAC/PCa v porovnání s placebem u mužů infikovaných k chemoterapii metastatického kiastračně-rezistentního karcinomu prostaty (VIABLE).","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.4479897555476754e-108,1.5264016194522483e-17,1.0,"2+",0.9999988043276503,1.195672332051217e-06,"No",1.440288665351264e-06,0.9999985597113578,"Yes",1.0,2.5574528183268186e-46,"No",6.84469131426527e-21,1.0,"Yes",3.5613142870116433e-06,0.9999964386857165,"Yes",1.0,6.824088248094733e-32,"No",5.6723713980419645e-12,0.9999999999943157,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyRandomizirano dvostruko slijepo multicentrično ispitivanje faze III na usporednim skupinama radi procjene učinkovitosti i sigurnosti lijeka DCVAC/PCa u odnosu na placebo u muškaraca s metastatskim karcinomom prostate rezistentnim na kastraciju koji su pogodni za 1. liniju kemoterapije","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.674851795017164e-101,3.504566739877586e-18,1.0,"2+",0.9999952047704859,4.795229495090013e-06,"No",6.437285439368295e-06,0.9999935627145362,"Yes",1.0,1.0355910553310524e-40,"No",5.1917536536094534e-17,1.0,"Yes",4.339403819235808e-07,0.9999995660595947,"Yes",1.0,2.6217267349776867e-34,"No",1.5352894907929464e-18,1.0,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyÉtude de phase III randomisée multicentrique en double aveugle et groupes parallèles visant à évaluer l’efficacité et la sécurité d’emploi du DCVAC/PCa par rapport au placebo chez des hommes présentant un cancer de la prostate métastatique résistant à la castration (CPmRC) et admissibles à une chimiothérapie de première intention.","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.2034711320836646e-110,3.412792733529153e-12,0.9999999999965895,"2+",2.3237450079125883e-05,0.9999767625499079,"No",0.9999969478777155,3.0521222946707245e-06,"Yes",1.0,1.0154112536870601e-29,"No",4.953047090228864e-12,0.9999999999950546,"Yes",0.0006655835848180233,0.9993344164151601,"Yes",1.0,6.348638538970248e-19,"No",1.545447577167486e-13,0.9999999999998295,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.637933714702923e-58,1.2463983004752234e-07,0.9999998753601822,"2+",0.9401328356709746,0.05986716432903815,"No",0.1454844804434939,0.8545155195565134,"Yes",1.0,5.841736774815161e-17,"No",1.4151426922828951e-06,0.9999985848573156,"Yes",0.0006236457687701084,0.999376354231235,"Yes",0.9999999999979252,2.0675157966318256e-12,"No",3.9468800587791557e-07,0.9999996053120055,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyRandomizovaná dvojitě zaslepená multicentrická studie fáze III s paralelními skupinami pacientů určena k vyhodnocení účinnosti a bezpečnosti přípravku DCVAC/PCa v porovnání s placebem u mužů infikovaných k chemoterapii metastatického kiastračně-rezistentního karcinomu prostaty (VIABLE).","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.4479897555476754e-108,1.5264016194522483e-17,1.0,"2+",0.9999988043276503,1.195672332051217e-06,"No",1.440288665351264e-06,0.9999985597113578,"Yes",1.0,2.5574528183268186e-46,"No",6.84469131426527e-21,1.0,"Yes",3.5613142870116433e-06,0.9999964386857165,"Yes",1.0,6.824088248094733e-32,"No",5.6723713980419645e-12,0.9999999999943157,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy","HR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.637933714702923e-58,1.2463983004752234e-07,0.9999998753601822,"2+",0.9401328356709746,0.05986716432903815,"No",0.1454844804434939,0.8545155195565134,"Yes",1.0,5.841736774815161e-17,"No",1.4151426922828951e-06,0.9999985848573156,"Yes",0.0006236457687701084,0.999376354231235,"Yes",0.9999999999979252,2.0675157966318256e-12,"No",3.9468800587791557e-07,0.9999996053120055,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyRandomizovaná dvojitě zaslepená multicentrická studie fáze III s paralelními skupinami pacientů určena k vyhodnocení účinnosti a bezpečnosti přípravku DCVAC/PCa v porovnání s placebem u mužů infikovaných k chemoterapii metastatického kiastračně-rezistentního karcinomu prostaty (VIABLE).","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.4479897555476754e-108,1.5264016194522483e-17,1.0,"2+",0.9999988043276503,1.195672332051217e-06,"No",1.440288665351264e-06,0.9999985597113578,"Yes",1.0,2.5574528183268186e-46,"No",6.84469131426527e-21,1.0,"Yes",3.5613142870116433e-06,0.9999964386857165,"Yes",1.0,6.824088248094733e-32,"No",5.6723713980419645e-12,0.9999999999943157,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyÉtude de phase III randomisée multicentrique en double aveugle et groupes parallèles visant à évaluer l’efficacité et la sécurité d’emploi du DCVAC/PCa par rapport au placebo chez des hommes présentant un cancer de la prostate métastatique résistant à la castration (CPmRC) et admissibles à une chimiothérapie de première intention.","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.2034711320836646e-110,3.412792733529153e-12,0.9999999999965895,"2+",2.3237450079125883e-05,0.9999767625499079,"No",0.9999969478777155,3.0521222946707245e-06,"Yes",1.0,1.0154112536870601e-29,"No",4.953047090228864e-12,0.9999999999950546,"Yes",0.0006655835848180233,0.9993344164151601,"Yes",1.0,6.348638538970248e-19,"No",1.545447577167486e-13,0.9999999999998295,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyRandomizovaná dvojitě zaslepená multicentrická studie fáze III s paralelními skupinami pacientů určena k vyhodnocení účinnosti a bezpečnosti přípravku DCVAC/PCa v porovnání s placebem u mužů infikovaných k chemoterapii metastatického kiastračně-rezistentního karcinomu prostaty (VIABLE).","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.4479897555476754e-108,1.5264016194522483e-17,1.0,"2+",0.9999988043276503,1.195672332051217e-06,"No",1.440288665351264e-06,0.9999985597113578,"Yes",1.0,2.5574528183268186e-46,"No",6.84469131426527e-21,1.0,"Yes",3.5613142870116433e-06,0.9999964386857165,"Yes",1.0,6.824088248094733e-32,"No",5.6723713980419645e-12,0.9999999999943157,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyÉtude de phase III randomisée multicentrique en double aveugle et groupes parallèles visant à évaluer l’efficacité et la sécurité d’emploi du DCVAC/PCa par rapport au placebo chez des hommes présentant un cancer de la prostate métastatique résistant à la castration (CPmRC) et admissibles à une chimiothérapie de première intention.","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.2034711320836646e-110,3.412792733529153e-12,0.9999999999965895,"2+",2.3237450079125883e-05,0.9999767625499079,"No",0.9999969478777155,3.0521222946707245e-06,"Yes",1.0,1.0154112536870601e-29,"No",4.953047090228864e-12,0.9999999999950546,"Yes",0.0006655835848180233,0.9993344164151601,"Yes",1.0,6.348638538970248e-19,"No",1.545447577167486e-13,0.9999999999998295,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.637933714702923e-58,1.2463983004752234e-07,0.9999998753601822,"2+",0.9401328356709746,0.05986716432903815,"No",0.1454844804434939,0.8545155195565134,"Yes",1.0,5.841736774815161e-17,"No",1.4151426922828951e-06,0.9999985848573156,"Yes",0.0006236457687701084,0.999376354231235,"Yes",0.9999999999979252,2.0675157966318256e-12,"No",3.9468800587791557e-07,0.9999996053120055,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.637933714702923e-58,1.2463983004752234e-07,0.9999998753601822,"2+",0.9401328356709746,0.05986716432903815,"No",0.1454844804434939,0.8545155195565134,"Yes",1.0,5.841736774815161e-17,"No",1.4151426922828951e-06,0.9999985848573156,"Yes",0.0006236457687701084,0.999376354231235,"Yes",0.9999999999979252,2.0675157966318256e-12,"No",3.9468800587791557e-07,0.9999996053120055,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.637933714702923e-58,1.2463983004752234e-07,0.9999998753601822,"2+",0.9401328356709746,0.05986716432903815,"No",0.1454844804434939,0.8545155195565134,"Yes",1.0,5.841736774815161e-17,"No",1.4151426922828951e-06,0.9999985848573156,"Yes",0.0006236457687701084,0.999376354231235,"Yes",0.9999999999979252,2.0675157966318256e-12,"No",3.9468800587791557e-07,0.9999996053120055,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyEstudio fase III aleatorizado doble ciego multicentrico en grupos paralelos para evaluar la eficacia y seguridad de VCD/CPa frente a placebo en hombres con cancer de prostata metastasico resistente a la castracion elegibles para primera linea de quimioterapia","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1298170802622735e-103,2.2806763269825953e-15,1.0,"2+",0.9992719418990532,0.0007280581009690772,"No",0.004114828373011726,0.9958851716269901,"Yes",1.0,4.704124885114889e-33,"No",4.794471063041658e-14,0.9999999999999432,"Yes",1.0143171706180998e-06,0.9999989856828535,"Yes",1.0,1.121729591467285e-31,"No",3.829698113746354e-14,0.9999999999999432,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapyRandomizovaná dvojitě zaslepená multicentrická studie fáze III s paralelními skupinami pacientů určena k vyhodnocení účinnosti a bezpečnosti přípravku DCVAC/PCa v porovnání s placebem u mužů infikovaných k chemoterapii metastatického kiastračně-rezistentního karcinomu prostaty (VIABLE).","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.4479897555476754e-108,1.5264016194522483e-17,1.0,"2+",0.9999988043276503,1.195672332051217e-06,"No",1.440288665351264e-06,0.9999985597113578,"Yes",1.0,2.5574528183268186e-46,"No",6.84469131426527e-21,1.0,"Yes",3.5613142870116433e-06,0.9999964386857165,"Yes",1.0,6.824088248094733e-32,"No",5.6723713980419645e-12,0.9999999999943157,"Yes"
"2012-002814-38","A Randomized Double Blind Multicenter Parallel-group Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.637933714702923e-58,1.2463983004752234e-07,0.9999998753601822,"2+",0.9401328356709746,0.05986716432903815,"No",0.1454844804434939,0.8545155195565134,"Yes",1.0,5.841736774815161e-17,"No",1.4151426922828951e-06,0.9999985848573156,"Yes",0.0006236457687701084,0.999376354231235,"Yes",0.9999999999979252,2.0675157966318256e-12,"No",3.9468800587791557e-07,0.9999996053120055,"Yes"
"2012-002839-28","A long-term randomised double-blind placebo-controlled multinational multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6250318653512636e-39,4.999960059095685e-09,0.999999995000053,"2+",0.9999999813781673,1.862182630175632e-08,"No",7.502170515220291e-08,0.9999999249783003,"Yes",0.9999999988441601,1.1558469703329526e-09,"No",2.3392699288882265e-09,0.999999997660737,"Yes",7.26543107094166e-05,0.9999273456892858,"Yes",0.9999999831910034,1.6808994256600412e-08,"No",1.180709266985772e-07,0.999999881929078,"Yes"
"2012-002839-28","A long-term randomised double-blind placebo-controlled multinational multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6250318653512636e-39,4.999960059095685e-09,0.999999995000053,"2+",0.9999999813781673,1.862182630175632e-08,"No",7.502170515220291e-08,0.9999999249783003,"Yes",0.9999999988441601,1.1558469703329526e-09,"No",2.3392699288882265e-09,0.999999997660737,"Yes",7.26543107094166e-05,0.9999273456892858,"Yes",0.9999999831910034,1.6808994256600412e-08,"No",1.180709266985772e-07,0.999999881929078,"Yes"
"2012-002839-28","A long-term randomised double-blind placebo-controlled multinational multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6250318653512636e-39,4.999960059095685e-09,0.999999995000053,"2+",0.9999999813781673,1.862182630175632e-08,"No",7.502170515220291e-08,0.9999999249783003,"Yes",0.9999999988441601,1.1558469703329526e-09,"No",2.3392699288882265e-09,0.999999997660737,"Yes",7.26543107094166e-05,0.9999273456892858,"Yes",0.9999999831910034,1.6808994256600412e-08,"No",1.180709266985772e-07,0.999999881929078,"Yes"
"2012-002839-28","A long-term randomised double-blind placebo-controlled multinational multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6250318653512636e-39,4.999960059095685e-09,0.999999995000053,"2+",0.9999999813781673,1.862182630175632e-08,"No",7.502170515220291e-08,0.9999999249783003,"Yes",0.9999999988441601,1.1558469703329526e-09,"No",2.3392699288882265e-09,0.999999997660737,"Yes",7.26543107094166e-05,0.9999273456892858,"Yes",0.9999999831910034,1.6808994256600412e-08,"No",1.180709266985772e-07,0.999999881929078,"Yes"
"2012-002839-28","A long-term randomised double-blind placebo-controlled multinational multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6250318653512636e-39,4.999960059095685e-09,0.999999995000053,"2+",0.9999999813781673,1.862182630175632e-08,"No",7.502170515220291e-08,0.9999999249783003,"Yes",0.9999999988441601,1.1558469703329526e-09,"No",2.3392699288882265e-09,0.999999997660737,"Yes",7.26543107094166e-05,0.9999273456892858,"Yes",0.9999999831910034,1.6808994256600412e-08,"No",1.180709266985772e-07,0.999999881929078,"Yes"
"2012-002839-28","A long-term randomised double-blind placebo-controlled multinational multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6250318653512636e-39,4.999960059095685e-09,0.999999995000053,"2+",0.9999999813781673,1.862182630175632e-08,"No",7.502170515220291e-08,0.9999999249783003,"Yes",0.9999999988441601,1.1558469703329526e-09,"No",2.3392699288882265e-09,0.999999997660737,"Yes",7.26543107094166e-05,0.9999273456892858,"Yes",0.9999999831910034,1.6808994256600412e-08,"No",1.180709266985772e-07,0.999999881929078,"Yes"
"2012-002839-28","A long-term randomised double-blind placebo-controlled multinational multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6250318653512636e-39,4.999960059095685e-09,0.999999995000053,"2+",0.9999999813781673,1.862182630175632e-08,"No",7.502170515220291e-08,0.9999999249783003,"Yes",0.9999999988441601,1.1558469703329526e-09,"No",2.3392699288882265e-09,0.999999997660737,"Yes",7.26543107094166e-05,0.9999273456892858,"Yes",0.9999999831910034,1.6808994256600412e-08,"No",1.180709266985772e-07,0.999999881929078,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of ZYTIGA (Abiraterone Acetate) Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-Naive Prostate Cancer (mHNPC)Studio comparativo randomizzato in doppio cieco su ZYTIGA  (abiraterone acetato) piu' prednisone a basso dosaggio piu' terapia androgeno-soppressiva (ADT) rispetto a sola ADT in soggetti con diagnosi recente di carcinoma prostatico metastatico naive al trattamento ormonale (mHNPC) ad alto rischio","BG","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.3792710182957133e-103,1.1305310101121467e-20,1.0,"2+",0.003672570104383078,0.996327429895609,"No",0.9961843109835433,0.0038156890164729625,"Yes",1.0,1.7511166098192123e-37,"No",4.2610889003781e-17,1.0,"Yes",0.31502463549561305,0.6849753645043705,"Yes",1.0,9.549370164793146e-22,"No",9.612435774189541e-20,1.0,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of ZYTIGA (Abiraterone Acetate) Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)Estudio aleatorizado doble-ciego y comparativo de ZYTIGA® (acetato de abiraterona) más dosis bajas de prednisona más terapia de privación de andrógenos (TPA) frente a TPA sola en sujetos con cáncer de próstata metastásico sin tratamiento hormonal previo (CPmSTHP) de nuevo diagnóstico y alto riesgo","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.696502686275724e-107,1.4962330586765432e-20,1.0,"2+",1.8555718296863078e-05,0.9999814442817104,"No",0.9999744918401017,2.550815988856478e-05,"Yes",1.0,1.9531384095797485e-41,"No",1.0287767238493304e-18,1.0,"Yes",0.9950722239906789,0.0049277760093346555,"Yes",1.0,2.800760914542534e-34,"No",7.495164016209493e-20,1.0,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of ZYTIGA (Abiraterone Acetate) Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-Naive Prostate Cancer (mHNPC)Studio comparativo randomizzato in doppio cieco su ZYTIGA  (abiraterone acetato) piu' prednisone a basso dosaggio piu' terapia androgeno-soppressiva (ADT) rispetto a sola ADT in soggetti con diagnosi recente di carcinoma prostatico metastatico naive al trattamento ormonale (mHNPC) ad alto rischio","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.3792710182957133e-103,1.1305310101121467e-20,1.0,"2+",0.003672570104383078,0.996327429895609,"No",0.9961843109835433,0.0038156890164729625,"Yes",1.0,1.7511166098192123e-37,"No",4.2610889003781e-17,1.0,"Yes",0.31502463549561305,0.6849753645043705,"Yes",1.0,9.549370164793146e-22,"No",9.612435774189541e-20,1.0,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of ZYTIGA (Abiraterone Acetate) Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-002940-26","A Randomized Double-blind Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk Metastatic Hormone-naive Prostate Cancer (mHNPC)","PT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1228011383199965e-56,4.467606186773093e-10,0.9999999995532393,"2+",0.048231118967117785,0.9517688810328921,"No",0.953834329471173,0.04616567052881583,"Yes",1.0,3.14699860485715e-18,"No",1.578544616018764e-08,0.9999999842145544,"Yes",0.970883240750996,0.02911675924901623,"Yes",0.9999999998051692,1.948213187806467e-10,"No",1.698242968533338e-09,0.999999998301746,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIBPLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITHUNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMAFÁZE III DVOJITĚ ZASLEPENÁ PLACEBEM KONTROLOVANÁ STUDIEHODNOTÍCÍ VEMURAFENIB V POROVNÁNÍ S VEMURAFENIBEM VKOMBINACI S PŘÍPRAVKEM GDC-0973 U DŘÍVE NELÉČENÝCH PACIENTŮ SPOZITIVNÍ MUTACÍ GENU BRAFV600 S NEODSTRANITELNÝM MÍSTNĚPOKROČILÝM NEBO METASTATICKÝM MELANOMEM","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.942788132848262e-92,2.53229797665076e-16,1.0,"2+",0.999999997785551,2.2144685045071864e-09,"No",3.875414990665542e-09,0.9999999961245863,"Yes",1.0,1.1733397100090481e-46,"No",4.9601899925803944e-17,1.0,"Yes",0.9981588767746395,0.001841123225377006,"Yes",1.0,2.3611216909979698e-20,"No",1.7832083794144477e-14,1.0,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATEDBRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0407751562033182e-53,2.8055429127923425e-06,0.9999971944570937,"2+",0.9961541674845747,0.0038458325154148067,"No",0.010167005444481415,0.9898329945555324,"Yes",1.0,8.338396210778188e-22,"No",6.0147056072270184e-05,0.9999398529439318,"Yes",0.7354954145697281,0.26450458543026906,"Yes",0.9999997408461406,2.5915384857674476e-07,"No",1.4214904987113563e-05,0.9999857850950142,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIBPLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITHUNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMAFÁZE III DVOJITĚ ZASLEPENÁ PLACEBEM KONTROLOVANÁ STUDIEHODNOTÍCÍ VEMURAFENIB V POROVNÁNÍ S VEMURAFENIBEM VKOMBINACI S PŘÍPRAVKEM GDC-0973 U DŘÍVE NELÉČENÝCH PACIENTŮ SPOZITIVNÍ MUTACÍ GENU BRAFV600 S NEODSTRANITELNÝM MÍSTNĚPOKROČILÝM NEBO METASTATICKÝM MELANOMEM","FR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.942788132848262e-92,2.53229797665076e-16,1.0,"2+",0.999999997785551,2.2144685045071864e-09,"No",3.875414990665542e-09,0.9999999961245863,"Yes",1.0,1.1733397100090481e-46,"No",4.9601899925803944e-17,1.0,"Yes",0.9981588767746395,0.001841123225377006,"Yes",1.0,2.3611216909979698e-20,"No",1.7832083794144477e-14,1.0,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIBPLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITHUNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.600504099267348e-50,3.799022667504799e-05,0.9999620097733184,"2+",0.993535183338615,0.006464816661391491,"No",0.017317719295107538,0.9826822807048977,"Yes",1.0,2.239563421421053e-21,"No",0.0008335980209421435,0.9991664019790577,"Yes",0.9451637805309618,0.05483621946903312,"Yes",0.9999988389529538,1.161047048168316e-06,"No",0.00012436520923688507,0.9998756347907607,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIBPLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITHUNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.600504099267348e-50,3.799022667504799e-05,0.9999620097733184,"2+",0.993535183338615,0.006464816661391491,"No",0.017317719295107538,0.9826822807048977,"Yes",1.0,2.239563421421053e-21,"No",0.0008335980209421435,0.9991664019790577,"Yes",0.9451637805309618,0.05483621946903312,"Yes",0.9999988389529538,1.161047048168316e-06,"No",0.00012436520923688507,0.9998756347907607,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATEDBRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0407751562033182e-53,2.8055429127923425e-06,0.9999971944570937,"2+",0.9961541674845747,0.0038458325154148067,"No",0.010167005444481415,0.9898329945555324,"Yes",1.0,8.338396210778188e-22,"No",6.0147056072270184e-05,0.9999398529439318,"Yes",0.7354954145697281,0.26450458543026906,"Yes",0.9999997408461406,2.5915384857674476e-07,"No",1.4214904987113563e-05,0.9999857850950142,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATEDBRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0407751562033182e-53,2.8055429127923425e-06,0.9999971944570937,"2+",0.9961541674845747,0.0038458325154148067,"No",0.010167005444481415,0.9898329945555324,"Yes",1.0,8.338396210778188e-22,"No",6.0147056072270184e-05,0.9999398529439318,"Yes",0.7354954145697281,0.26450458543026906,"Yes",0.9999997408461406,2.5915384857674476e-07,"No",1.4214904987113563e-05,0.9999857850950142,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIBPLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITHUNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.600504099267348e-50,3.799022667504799e-05,0.9999620097733184,"2+",0.993535183338615,0.006464816661391491,"No",0.017317719295107538,0.9826822807048977,"Yes",1.0,2.239563421421053e-21,"No",0.0008335980209421435,0.9991664019790577,"Yes",0.9451637805309618,0.05483621946903312,"Yes",0.9999988389529538,1.161047048168316e-06,"No",0.00012436520923688507,0.9998756347907607,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIBPLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITHUNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMAFÁZE III DVOJITĚ ZASLEPENÁ PLACEBEM KONTROLOVANÁ STUDIEHODNOTÍCÍ VEMURAFENIB V POROVNÁNÍ S VEMURAFENIBEM VKOMBINACI S PŘÍPRAVKEM GDC-0973 U DŘÍVE NELÉČENÝCH PACIENTŮ SPOZITIVNÍ MUTACÍ GENU BRAFV600 S NEODSTRANITELNÝM MÍSTNĚPOKROČILÝM NEBO METASTATICKÝM MELANOMEM","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.942788132848262e-92,2.53229797665076e-16,1.0,"2+",0.999999997785551,2.2144685045071864e-09,"No",3.875414990665542e-09,0.9999999961245863,"Yes",1.0,1.1733397100090481e-46,"No",4.9601899925803944e-17,1.0,"Yes",0.9981588767746395,0.001841123225377006,"Yes",1.0,2.3611216909979698e-20,"No",1.7832083794144477e-14,1.0,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATEDBRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.0407751562033182e-53,2.8055429127923425e-06,0.9999971944570937,"2+",0.9961541674845747,0.0038458325154148067,"No",0.010167005444481415,0.9898329945555324,"Yes",1.0,8.338396210778188e-22,"No",6.0147056072270184e-05,0.9999398529439318,"Yes",0.7354954145697281,0.26450458543026906,"Yes",0.9999997408461406,2.5915384857674476e-07,"No",1.4214904987113563e-05,0.9999857850950142,"Yes"
"2012-003008-11","A PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIBPLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITHUNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMAFÁZE III DVOJITĚ ZASLEPENÁ PLACEBEM KONTROLOVANÁ STUDIEHODNOTÍCÍ VEMURAFENIB V POROVNÁNÍ S VEMURAFENIBEM VKOMBINACI S PŘÍPRAVKEM GDC-0973 U DŘÍVE NELÉČENÝCH PACIENTŮ SPOZITIVNÍ MUTACÍ GENU BRAFV600 S NEODSTRANITELNÝM MÍSTNĚPOKROČILÝM NEBO METASTATICKÝM MELANOMEM","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.942788132848262e-92,2.53229797665076e-16,1.0,"2+",0.999999997785551,2.2144685045071864e-09,"No",3.875414990665542e-09,0.9999999961245863,"Yes",1.0,1.1733397100090481e-46,"No",4.9601899925803944e-17,1.0,"Yes",0.9981588767746395,0.001841123225377006,"Yes",1.0,2.3611216909979698e-20,"No",1.7832083794144477e-14,1.0,"Yes"
"2012-003112-31","Risk of Squamous Cell Carcinoma on Skin Areas Treated with Ingenol Mebutate Gel 0.015% and Imiquimod Cream 5%  ","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.210829967400495e-24,6.60570625888844e-06,0.9999933942937288,"2+",7.144733960092799e-06,0.9999928552660446,"Yes",0.999999874784188,1.252158051784444e-07,"No",0.9756967465892746,0.024303253410728906,"No",1.8530572594963096e-05,0.9999814694274084,"Yes",0.08371666547931382,0.9162833345206848,"Yes",0.9999996955290735,3.044709316548056e-07,"No",8.182635689773028e-06,0.9999918173643011,"Yes"
"2012-003112-31","Risk of Squamous Cell Carcinoma on Skin Areas Treated with Ingenol Mebutate Gel 0.015% and Imiquimod Cream 5%  ","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.210829967400495e-24,6.60570625888844e-06,0.9999933942937288,"2+",7.144733960092799e-06,0.9999928552660446,"Yes",0.999999874784188,1.252158051784444e-07,"No",0.9756967465892746,0.024303253410728906,"No",1.8530572594963096e-05,0.9999814694274084,"Yes",0.08371666547931382,0.9162833345206848,"Yes",0.9999996955290735,3.044709316548056e-07,"No",8.182635689773028e-06,0.9999918173643011,"Yes"
"2012-003112-31","Risk of Squamous Cell Carcinoma on Skin Areas Treated with Ingenol Mebutate Gel 0.015% and Imiquimod Cream 5%  ","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.210829967400495e-24,6.60570625888844e-06,0.9999933942937288,"2+",7.144733960092799e-06,0.9999928552660446,"Yes",0.999999874784188,1.252158051784444e-07,"No",0.9756967465892746,0.024303253410728906,"No",1.8530572594963096e-05,0.9999814694274084,"Yes",0.08371666547931382,0.9162833345206848,"Yes",0.9999996955290735,3.044709316548056e-07,"No",8.182635689773028e-06,0.9999918173643011,"Yes"
"2012-003208-10","A Randomized Double-blind Placebo-controlled Parallel 26 Week Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.99182185798855e-65,4.372455838105421e-17,1.0,"2+",1.0,2.075851302696916e-17,"No",1.7085458921632087e-16,1.0,"Yes",0.9999999999992043,7.844024933903845e-13,"No",7.647110254375423e-17,1.0,"Yes",2.538920729177664e-10,0.9999999997461089,"Yes",0.9999999999999717,3.8199911374430684e-14,"No",4.656409629642313e-16,1.0,"Yes"
"2012-003208-10","A Randomized Double-blind Placebo-controlled Parallel 26 Week Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.99182185798855e-65,4.372455838105421e-17,1.0,"2+",1.0,2.075851302696916e-17,"No",1.7085458921632087e-16,1.0,"Yes",0.9999999999992043,7.844024933903845e-13,"No",7.647110254375423e-17,1.0,"Yes",2.538920729177664e-10,0.9999999997461089,"Yes",0.9999999999999717,3.8199911374430684e-14,"No",4.656409629642313e-16,1.0,"Yes"
"2012-003208-10","A Randomized Double-blind Placebo-controlled Parallel 26 Week Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.99182185798855e-65,4.372455838105421e-17,1.0,"2+",1.0,2.075851302696916e-17,"No",1.7085458921632087e-16,1.0,"Yes",0.9999999999992043,7.844024933903845e-13,"No",7.647110254375423e-17,1.0,"Yes",2.538920729177664e-10,0.9999999997461089,"Yes",0.9999999999999717,3.8199911374430684e-14,"No",4.656409629642313e-16,1.0,"Yes"
"2012-003228-19","A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124 an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist as an Adjunctive Pro-cognitiveTreatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.761125119122404e-54,4.2947546905513923e-07,0.9999995705245296,"2+",0.999999910434188,8.95658013495823e-08,"No",6.916877258370385e-08,0.9999999308312251,"Yes",0.9999999999998295,1.7694832057063544e-13,"No",8.933356365932935e-08,0.9999999106664501,"Yes",9.69503206664558e-07,0.9999990304967963,"Yes",0.9999999999985789,1.4315734718227503e-12,"No",3.0918383330177873e-07,0.9999996908161587,"Yes"
"2012-003228-19","A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124 an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist as an Adjunctive Pro-cognitiveTreatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.761125119122404e-54,4.2947546905513923e-07,0.9999995705245296,"2+",0.999999910434188,8.95658013495823e-08,"No",6.916877258370385e-08,0.9999999308312251,"Yes",0.9999999999998295,1.7694832057063544e-13,"No",8.933356365932935e-08,0.9999999106664501,"Yes",9.69503206664558e-07,0.9999990304967963,"Yes",0.9999999999985789,1.4315734718227503e-12,"No",3.0918383330177873e-07,0.9999996908161587,"Yes"
"2012-003228-19","A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124 an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist as an Adjunctive Pro-cognitiveTreatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.761125119122404e-54,4.2947546905513923e-07,0.9999995705245296,"2+",0.999999910434188,8.95658013495823e-08,"No",6.916877258370385e-08,0.9999999308312251,"Yes",0.9999999999998295,1.7694832057063544e-13,"No",8.933356365932935e-08,0.9999999106664501,"Yes",9.69503206664558e-07,0.9999990304967963,"Yes",0.9999999999985789,1.4315734718227503e-12,"No",3.0918383330177873e-07,0.9999996908161587,"Yes"
"2012-003228-19","A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124 an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist as an Adjunctive Pro-cognitiveTreatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.761125119122404e-54,4.2947546905513923e-07,0.9999995705245296,"2+",0.999999910434188,8.95658013495823e-08,"No",6.916877258370385e-08,0.9999999308312251,"Yes",0.9999999999998295,1.7694832057063544e-13,"No",8.933356365932935e-08,0.9999999106664501,"Yes",9.69503206664558e-07,0.9999990304967963,"Yes",0.9999999999985789,1.4315734718227503e-12,"No",3.0918383330177873e-07,0.9999996908161587,"Yes"
"2012-003228-19","A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124 an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist as an Adjunctive Pro-cognitiveTreatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.761125119122404e-54,4.2947546905513923e-07,0.9999995705245296,"2+",0.999999910434188,8.95658013495823e-08,"No",6.916877258370385e-08,0.9999999308312251,"Yes",0.9999999999998295,1.7694832057063544e-13,"No",8.933356365932935e-08,0.9999999106664501,"Yes",9.69503206664558e-07,0.9999990304967963,"Yes",0.9999999999985789,1.4315734718227503e-12,"No",3.0918383330177873e-07,0.9999996908161587,"Yes"
"2012-003332-23","A phase 2 randomized double-blind placebo-controlled parallel group multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonist (PF-04634817) in adults with Type 2 diabetes and overt nephropathy.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.323937130967613e-65,1.996035633751756e-16,1.0,"2+",0.9999999999987494,1.2447677547349132e-12,"No",4.056188995167686e-12,0.9999999999959358,"Yes",0.9999999999779449,2.2049018171171786e-11,"No",5.975590518321129e-15,1.0,"Yes",4.412940823970112e-07,0.999999558705907,"Yes",0.9999999982780993,1.7219086138925134e-09,"No",5.956292171882045e-15,1.0,"Yes"
"2012-003332-23","A phase 2 randomized double-blind placebo-controlled parallel group multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonist (PF-04634817) in adults with Type 2 diabetes and overt nephropathy.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.323937130967613e-65,1.996035633751756e-16,1.0,"2+",0.9999999999987494,1.2447677547349132e-12,"No",4.056188995167686e-12,0.9999999999959358,"Yes",0.9999999999779449,2.2049018171171786e-11,"No",5.975590518321129e-15,1.0,"Yes",4.412940823970112e-07,0.999999558705907,"Yes",0.9999999982780993,1.7219086138925134e-09,"No",5.956292171882045e-15,1.0,"Yes"
"2012-003332-23","A phase 2 randomized double-blind placebo-controlled parallel group multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonist (PF-04634817) in adults with Type 2 diabetes and overt nephropathy.ESTUDIO DE FASE II MULTICÉNTRICO ALEATORIZADO DOBLE CIEGO CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE LA ADMINISTRACIÓN UNA VEZ AL DÍA DE UN ANTAGONISTA DEL RECEPTOR DE QUIMIOCINAS CCR2/5 (PF-04634817) EN ADULTOS CON DIABETES TIPO 2 Y NEFROPATÍA EVIDENTE","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5450754117923695e-138,6.598879717839098e-32,1.0,"2+",1.0,1.8117115798556873e-22,"No",2.1067372056273164e-21,1.0,"Yes",1.0,2.3375070072817784e-23,"No",1.8798808578117008e-28,1.0,"Yes",7.16130457686522e-13,0.999999999999261,"Yes",1.0,4.366768022031965e-24,"No",5.888221870259251e-27,1.0,"Yes"
"2012-003332-23","A phase 2 randomized double-blind placebo-controlled parallel group multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonist (PF-04634817) in adults with Type 2 diabetes and overt nephropathy.ESTUDIO DE FASE II MULTICÉNTRICO ALEATORIZADO DOBLE CIEGO CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE LA ADMINISTRACIÓN UNA VEZ AL DÍA DE UN ANTAGONISTA DEL RECEPTOR DE QUIMIOCINAS CCR2/5 (PF-04634817) EN ADULTOS CON DIABETES TIPO 2 Y NEFROPATÍA EVIDENTE","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5450754117923695e-138,6.598879717839098e-32,1.0,"2+",1.0,1.8117115798556873e-22,"No",2.1067372056273164e-21,1.0,"Yes",1.0,2.3375070072817784e-23,"No",1.8798808578117008e-28,1.0,"Yes",7.16130457686522e-13,0.999999999999261,"Yes",1.0,4.366768022031965e-24,"No",5.888221870259251e-27,1.0,"Yes"
"2012-003332-23","A phase 2 randomized double-blind placebo-controlled parallel group multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonist (PF-04634817) in adults with Type 2 diabetes and overt nephropathy.ESTUDIO DE FASE II MULTICÉNTRICO ALEATORIZADO DOBLE CIEGO CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE LA ADMINISTRACIÓN UNA VEZ AL DÍA DE UN ANTAGONISTA DEL RECEPTOR DE QUIMIOCINAS CCR2/5 (PF-04634817) EN ADULTOS CON DIABETES TIPO 2 Y NEFROPATÍA EVIDENTE","RO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5450754117923695e-138,6.598879717839098e-32,1.0,"2+",1.0,1.8117115798556873e-22,"No",2.1067372056273164e-21,1.0,"Yes",1.0,2.3375070072817784e-23,"No",1.8798808578117008e-28,1.0,"Yes",7.16130457686522e-13,0.999999999999261,"Yes",1.0,4.366768022031965e-24,"No",5.888221870259251e-27,1.0,"Yes"
"2012-003387-43","A Phase 3 Multicenter Randomized Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection","ES","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.529063783403604e-48,0.0059610796400980885,0.9940389203598995,"2+",0.014609459758426462,0.9853905402415803,"Yes",0.9809486016352545,0.01905139836473191,"No",1.0,4.479307934741074e-16,"No",0.9658139046478509,0.034186095352137534,"Yes",0.6893412683222768,0.31065873167772123,"No",0.9999999998843522,1.1563607535029349e-10,"No",0.2718623195306901,0.728137680469314,"Yes"
"2012-003387-43","A Phase 3 Multicenter Randomized Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection","DE","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.529063783403604e-48,0.0059610796400980885,0.9940389203598995,"2+",0.014609459758426462,0.9853905402415803,"Yes",0.9809486016352545,0.01905139836473191,"No",1.0,4.479307934741074e-16,"No",0.9658139046478509,0.034186095352137534,"Yes",0.6893412683222768,0.31065873167772123,"No",0.9999999998843522,1.1563607535029349e-10,"No",0.2718623195306901,0.728137680469314,"Yes"
"2012-003387-43","A Phase 3 Multicenter Randomized Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection","GB","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.529063783403604e-48,0.0059610796400980885,0.9940389203598995,"2+",0.014609459758426462,0.9853905402415803,"Yes",0.9809486016352545,0.01905139836473191,"No",1.0,4.479307934741074e-16,"No",0.9658139046478509,0.034186095352137534,"Yes",0.6893412683222768,0.31065873167772123,"No",0.9999999998843522,1.1563607535029349e-10,"No",0.2718623195306901,0.728137680469314,"Yes"
"2012-003387-43","A Phase 3 Multicenter Randomized Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection","FR","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.529063783403604e-48,0.0059610796400980885,0.9940389203598995,"2+",0.014609459758426462,0.9853905402415803,"Yes",0.9809486016352545,0.01905139836473191,"No",1.0,4.479307934741074e-16,"No",0.9658139046478509,0.034186095352137534,"Yes",0.6893412683222768,0.31065873167772123,"No",0.9999999998843522,1.1563607535029349e-10,"No",0.2718623195306901,0.728137680469314,"Yes"
"2012-003499-37","Long-term study evaluating the effect of Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.Studio a lungo termine volto alla valutazione dell'effetto di Givinostat in pazienti JAK2V617F positivi affetti da neoplasie mieloproliferative croniche.","DE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.361118976818628e-35,0.997929409223044,0.002070590776967315,"1",4.027878790420683e-06,0.9999959721211955,"Yes",0.9999986490989871,1.3509010210598467e-06,"No",0.9999999999559465,4.402615377725476e-11,"No",0.9836000036491142,0.016399996350885297,"No",0.9133298022703562,0.08667019772966116,"No",0.9999999992711537,7.288481218365511e-10,"No",0.9989744635591139,0.0010255364408727897,"No"
"2012-003499-37","Long-term study evaluating the effect of Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.Studio a lungo termine volto alla valutazione dell'effetto di Givinostat in pazienti JAK2V617F positivi affetti da neoplasie mieloproliferative croniche.","IT","No","No","Yes","","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.361118976818628e-35,0.997929409223044,0.002070590776967315,"1",4.027878790420683e-06,0.9999959721211955,"Yes",0.9999986490989871,1.3509010210598467e-06,"Information not present in EudraCT",0.9999999999559465,4.402615377725476e-11,"Information not present in EudraCT",0.9836000036491142,0.016399996350885297,"No",0.9133298022703562,0.08667019772966116,"No",0.9999999992711537,7.288481218365511e-10,"No",0.9989744635591139,0.0010255364408727897,"No"
"2012-003499-37","Long-term study evaluating the effect of Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.Studio a lungo termine volto alla valutazione dell'effetto di Givinostat in pazienti JAK2V617F positivi affetti da neoplasie mieloproliferative croniche.","PL","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.361118976818628e-35,0.997929409223044,0.002070590776967315,"1",4.027878790420683e-06,0.9999959721211955,"Yes",0.9999986490989871,1.3509010210598467e-06,"No",0.9999999999559465,4.402615377725476e-11,"No",0.9836000036491142,0.016399996350885297,"No",0.9133298022703562,0.08667019772966116,"No",0.9999999992711537,7.288481218365511e-10,"No",0.9989744635591139,0.0010255364408727897,"No"
"2012-003533-41","A Phase III Randomised Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV InfectionStudio clinico di fase III randomizzato parzialmente in doppio cieco e controllato verso placebo di BI 207127 in combinazione con Faldaprevir e Ribavirina in pazienti naive affetti da epatite C cronica genotipo 1","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1204231427894916e-104,4.864834248293073e-16,1.0,"2+",0.9999977132896445,2.2867103393316545e-06,"No",9.261615623610212e-06,0.9999907383843556,"Yes",1.0,1.7209535302918e-34,"No",1.821927516604276e-14,1.0,"Yes",0.023359004396462556,0.9766409956035439,"Yes",1.0,5.444589762166207e-18,"No",6.529705978532344e-15,1.0,"Yes"
"2012-003533-41","A Phase III Randomised Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infection","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.043035506259471e-49,2.782820763666069e-10,0.999999999721723,"2+",0.9996763805607762,0.0003236194392225128,"No",0.001597351559543471,0.9984026484404555,"Yes",0.9999999999999432,4.3921700753095694e-14,"No",2.6557131558742027e-08,0.9999999734428688,"Yes",0.07957143742064847,0.9204285625793552,"Yes",0.9999999947416712,5.258319220163156e-09,"No",1.3193135872164565e-09,0.9999999986806928,"Yes"
"2012-003533-41","A Phase III Randomised Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV InfectionStudio clinico di fase III randomizzato parzialmente in doppio cieco e controllato verso placebo di BI 207127 in combinazione con Faldaprevir e Ribavirina in pazienti naive affetti da epatite C cronica genotipo 1","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1204231427894916e-104,4.864834248293073e-16,1.0,"2+",0.9999977132896445,2.2867103393316545e-06,"No",9.261615623610212e-06,0.9999907383843556,"Yes",1.0,1.7209535302918e-34,"No",1.821927516604276e-14,1.0,"Yes",0.023359004396462556,0.9766409956035439,"Yes",1.0,5.444589762166207e-18,"No",6.529705978532344e-15,1.0,"Yes"
"2012-003533-41","A Phase III Randomised Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV InfectionEnsayo clínico de fase III aleatorizado parcialmente doble ciego y controlado con placebo de BI 207127 en combinación con Faldaprevir y Ribavirina en pacientes con Hepatitis C crónica de genotipo 1 que no han recibido tratamiento previo (naïve)","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8401179095031068e-103,2.5103888538820854e-17,1.0,"2+",0.9999707005398039,2.9299460176436265e-05,"No",0.00018081357182112812,0.9998191864281784,"Yes",1.0,1.3462423289118252e-33,"No",1.0280165346216123e-14,1.0,"Yes",0.09060198533308156,0.9093980146669176,"Yes",1.0,2.0349762728760585e-27,"No",2.495599742411765e-15,1.0,"Yes"
"2012-003533-41","A Phase III Randomised Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV InfectionEnsayo clínico de fase III aleatorizado parcialmente doble ciego y controlado con placebo de BI 207127 en combinación con Faldaprevir y Ribavirina en pacientes con Hepatitis C crónica de genotipo 1 que no han recibido tratamiento previo (naïve)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8401179095031068e-103,2.5103888538820854e-17,1.0,"2+",0.9999707005398039,2.9299460176436265e-05,"No",0.00018081357182112812,0.9998191864281784,"Yes",1.0,1.3462423289118252e-33,"No",1.0280165346216123e-14,1.0,"Yes",0.09060198533308156,0.9093980146669176,"Yes",1.0,2.0349762728760585e-27,"No",2.495599742411765e-15,1.0,"Yes"
"2012-003533-41","A Phase III Randomised Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV InfectionStudio clinico di fase III randomizzato parzialmente in doppio cieco e controllato verso placebo di BI 207127 in combinazione con Faldaprevir e Ribavirina in pazienti naive affetti da epatite C cronica genotipo 1","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1204231427894916e-104,4.864834248293073e-16,1.0,"2+",0.9999977132896445,2.2867103393316545e-06,"No",9.261615623610212e-06,0.9999907383843556,"Yes",1.0,1.7209535302918e-34,"No",1.821927516604276e-14,1.0,"Yes",0.023359004396462556,0.9766409956035439,"Yes",1.0,5.444589762166207e-18,"No",6.529705978532344e-15,1.0,"Yes"
"2012-003533-41","A Phase III Randomised Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV InfectionEnsayo clínico de fase III aleatorizado parcialmente doble ciego y controlado con placebo de BI 207127 en combinación con Faldaprevir y Ribavirina en pacientes con Hepatitis C crónica de genotipo 1 que no han recibido tratamiento previo (naïve)","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8401179095031068e-103,2.5103888538820854e-17,1.0,"2+",0.9999707005398039,2.9299460176436265e-05,"No",0.00018081357182112812,0.9998191864281784,"Yes",1.0,1.3462423289118252e-33,"No",1.0280165346216123e-14,1.0,"Yes",0.09060198533308156,0.9093980146669176,"Yes",1.0,2.0349762728760585e-27,"No",2.495599742411765e-15,1.0,"Yes"
"2012-003533-41","A Phase III Randomised Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV InfectionEnsayo clínico de fase III aleatorizado parcialmente doble ciego y controlado con placebo de BI 207127 en combinación con Faldaprevir y Ribavirina en pacientes con Hepatitis C crónica de genotipo 1 que no han recibido tratamiento previo (naïve)","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8401179095031068e-103,2.5103888538820854e-17,1.0,"2+",0.9999707005398039,2.9299460176436265e-05,"No",0.00018081357182112812,0.9998191864281784,"Yes",1.0,1.3462423289118252e-33,"No",1.0280165346216123e-14,1.0,"Yes",0.09060198533308156,0.9093980146669176,"Yes",1.0,2.0349762728760585e-27,"No",2.495599742411765e-15,1.0,"Yes"
"2012-003533-41","A Phase III Randomised Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV InfectionStudio clinico di fase III randomizzato parzialmente in doppio cieco e controllato verso placebo di BI 207127 in combinazione con Faldaprevir e Ribavirina in pazienti naive affetti da epatite C cronica genotipo 1","IE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.1204231427894916e-104,4.864834248293073e-16,1.0,"2+",0.9999977132896445,2.2867103393316545e-06,"No",9.261615623610212e-06,0.9999907383843556,"Yes",1.0,1.7209535302918e-34,"No",1.821927516604276e-14,1.0,"Yes",0.023359004396462556,0.9766409956035439,"Yes",1.0,5.444589762166207e-18,"No",6.529705978532344e-15,1.0,"Yes"
"2012-003535-27","A phase III randomised partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferonEnsayo clínico de fase III aleatorizado parcialmente doble ciego y controlado con placebo de BI 207127 en combinación con Faldaprevir y Ribavirina en pacientes con Hepatitis C crónica de genotipo 1 que no han recibido tratamiento previo (naïve) incluyendo a pacientes que no sean elegibles para recibir tratamiento con interferon","BE","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.491553596987609e-116,1.2981654916104003e-17,1.0,"2+",0.8240807368459526,0.1759192631540612,"No",0.865539610754968,0.13446038924505163,"Yes",1.0,1.2864305138914647e-38,"No",8.061050644419049e-14,0.9999999999999432,"Yes",0.04171817591370013,0.9582818240863077,"Yes",1.0,2.944383996874508e-37,"No",4.3642738793688405e-18,1.0,"Yes"
"2012-003535-27","A phase III randomised partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.104466095525046e-54,1.346504116463195e-10,0.999999999865338,"2+",0.9956085298169258,0.0043914701830720165,"No",0.12013172330477664,0.8798682766952167,"Yes",1.0,3.619703534658831e-16,"No",7.14136835724383e-10,0.9999999992858761,"Yes",0.1728558737300425,0.827144126269954,"Yes",0.9999999999999432,6.063163695750378e-14,"No",1.3617970222372618e-10,0.9999999998638316,"Yes"
"2012-003535-27","A phase III randomised partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferonΜια Φάσης ΙΙΙ τυχαιοποιημένη μερικά διπλά τυφλή και ελεγχόμενη με εικονικό φάρμακο μελέτη του BI 207127 σε συνδυασμό με Faldaprevir και ριμπαβιρίνη για την χρόνια ηπατίτιδα C γονότυπου 1 σε ευρύ πληθυσμό πρωτοθεραπευόμενων ασθενών που συμπεριλαμβάνει ασθενείς ακατάλληλους να λάβουν πεγκυλιωμένη ιντερφερόνη.","DE","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.6337890727353092e-61,2.490749971597719e-11,0.9999999999751027,"2+",0.5671973712675612,0.43280262873243497,"No",0.9451544931471655,0.05484550685284307,"Yes",1.0,4.1735972191681174e-21,"No",5.4821489543318035e-11,0.9999999999451745,"Yes",0.22160911980656411,0.7783908801934448,"Yes",1.0,4.842930345334004e-16,"No",8.846835989196956e-12,0.999999999991161,"Yes"
"2012-003535-27","A phase III randomised partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferonEnsayo clínico de fase III aleatorizado parcialmente doble ciego y controlado con placebo de BI 207127 en combinación con Faldaprevir y Ribavirina en pacientes con Hepatitis C crónica de genotipo 1 que no han recibido tratamiento previo (naïve) incluyendo a pacientes que no sean elegibles para recibir tratamiento con interferon","GR","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.491553596987609e-116,1.2981654916104003e-17,1.0,"2+",0.8240807368459526,0.1759192631540612,"No",0.865539610754968,0.13446038924505163,"Yes",1.0,1.2864305138914647e-38,"No",8.061050644419049e-14,0.9999999999999432,"Yes",0.04171817591370013,0.9582818240863077,"Yes",1.0,2.944383996874508e-37,"No",4.3642738793688405e-18,1.0,"Yes"
"2012-003535-27","A phase III randomised partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.104466095525046e-54,1.346504116463195e-10,0.999999999865338,"2+",0.9956085298169258,0.0043914701830720165,"No",0.12013172330477664,0.8798682766952167,"Yes",1.0,3.619703534658831e-16,"No",7.14136835724383e-10,0.9999999992858761,"Yes",0.1728558737300425,0.827144126269954,"Yes",0.9999999999999432,6.063163695750378e-14,"No",1.3617970222372618e-10,0.9999999998638316,"Yes"
"2012-003535-27","A phase III randomised partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferonEnsayo clínico de fase III aleatorizado parcialmente doble ciego y controlado con placebo de BI 207127 en combinación con Faldaprevir y Ribavirina en pacientes con Hepatitis C crónica de genotipo 1 que no han recibido tratamiento previo (naïve) incluyendo a pacientes que no sean elegibles para recibir tratamiento con interferon","PT","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.491553596987609e-116,1.2981654916104003e-17,1.0,"2+",0.8240807368459526,0.1759192631540612,"No",0.865539610754968,0.13446038924505163,"Yes",1.0,1.2864305138914647e-38,"No",8.061050644419049e-14,0.9999999999999432,"Yes",0.04171817591370013,0.9582818240863077,"Yes",1.0,2.944383996874508e-37,"No",4.3642738793688405e-18,1.0,"Yes"
"2012-003535-27","A phase III randomised partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.104466095525046e-54,1.346504116463195e-10,0.999999999865338,"2+",0.9956085298169258,0.0043914701830720165,"No",0.12013172330477664,0.8798682766952167,"Yes",1.0,3.619703534658831e-16,"No",7.14136835724383e-10,0.9999999992858761,"Yes",0.1728558737300425,0.827144126269954,"Yes",0.9999999999999432,6.063163695750378e-14,"No",1.3617970222372618e-10,0.9999999998638316,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","PT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0935831239489579e-49,4.7576798125568646e-05,0.9999524232018783,"2+",4.639078934045866e-13,0.9999999999995453,"Yes",0.9999999999986642,1.3261320758771066e-12,"No",1.0,7.218396738650662e-25,"No",0.9672997464694512,0.03270025353055256,"Yes",0.9986718221899964,0.0013281778100163039,"Yes",0.9999999079016718,9.209831470471602e-08,"No",0.08756389486976505,0.912436105130241,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanomaEnsayo NEMO (melanoma NRAS e inhibidor MEK): Estudio aleatorizado de Fase III abierto multicéntrico de dos brazos que compara la eficacia de MEK162 frente a Dacarbazina en pacientes con melanoma avanzado no resecable o metástasico con mutación NRAS positiva","GB","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.695389329495681e-97,5.72974100801187e-11,0.999999999942702,"2+",7.361825066881262e-28,1.0,"Yes",1.0,6.025169602681293e-27,"No",1.0,5.0009373806517904e-48,"No",0.998782702082283,0.001217297917729806,"Yes",0.9999819540416605,1.804595836209446e-05,"Yes",1.0,4.836166960036468e-24,"No",0.0008323615889073611,0.9991676384111159,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","SK","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.85616791123606e-50,6.251535886994093e-05,0.9999374846411264,"2+",2.5924468857372935e-13,0.9999999999997442,"Yes",0.999999999999261,7.388918274989217e-13,"No",1.0,9.714443338633732e-25,"No",0.9747446391875256,0.02525536081248517,"Yes",0.9989979976140793,0.001002002385914783,"Yes",0.9999998513871842,1.4861282199107227e-07,"No",0.11014893721096425,0.8898510627890442,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanomaEnsayo NEMO (melanoma NRAS e inhibidor MEK): Estudio aleatorizado de Fase III abierto multicéntrico de dos brazos que compara la eficacia de MEK162 frente a Dacarbazina en pacientes con melanoma avanzado no resecable o metástasico con mutación NRAS positiva","BE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.695389329495681e-97,5.72974100801187e-11,0.999999999942702,"2+",7.361825066881262e-28,1.0,"Yes",1.0,6.025169602681293e-27,"No",1.0,5.0009373806517904e-48,"No",0.998782702082283,0.001217297917729806,"Yes",0.9999819540416605,1.804595836209446e-05,"Yes",1.0,4.836166960036468e-24,"No",0.0008323615889073611,0.9991676384111159,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanomaEnsayo NEMO (melanoma NRAS e inhibidor MEK): Estudio aleatorizado de Fase III abierto multicéntrico de dos brazos que compara la eficacia de MEK162 frente a Dacarbazina en pacientes con melanoma avanzado no resecable o metástasico con mutación NRAS positiva","IT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.695389329495681e-97,5.72974100801187e-11,0.999999999942702,"2+",7.361825066881262e-28,1.0,"Yes",1.0,6.025169602681293e-27,"No",1.0,5.0009373806517904e-48,"No",0.998782702082283,0.001217297917729806,"Yes",0.9999819540416605,1.804595836209446e-05,"Yes",1.0,4.836166960036468e-24,"No",0.0008323615889073611,0.9991676384111159,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0935831239489579e-49,4.7576798125568646e-05,0.9999524232018783,"2+",4.639078934045866e-13,0.9999999999995453,"Yes",0.9999999999986642,1.3261320758771066e-12,"No",1.0,7.218396738650662e-25,"No",0.9672997464694512,0.03270025353055256,"Yes",0.9986718221899964,0.0013281778100163039,"Yes",0.9999999079016718,9.209831470471602e-08,"No",0.08756389486976505,0.912436105130241,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","PL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0935831239489579e-49,4.7576798125568646e-05,0.9999524232018783,"2+",4.639078934045866e-13,0.9999999999995453,"Yes",0.9999999999986642,1.3261320758771066e-12,"No",1.0,7.218396738650662e-25,"No",0.9672997464694512,0.03270025353055256,"Yes",0.9986718221899964,0.0013281778100163039,"Yes",0.9999999079016718,9.209831470471602e-08,"No",0.08756389486976505,0.912436105130241,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","NL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.85616791123606e-50,6.251535886994093e-05,0.9999374846411264,"2+",2.5924468857372935e-13,0.9999999999997442,"Yes",0.999999999999261,7.388918274989217e-13,"No",1.0,9.714443338633732e-25,"No",0.9747446391875256,0.02525536081248517,"Yes",0.9989979976140793,0.001002002385914783,"Yes",0.9999998513871842,1.4861282199107227e-07,"No",0.11014893721096425,0.8898510627890442,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.85616791123606e-50,6.251535886994093e-05,0.9999374846411264,"2+",2.5924468857372935e-13,0.9999999999997442,"Yes",0.999999999999261,7.388918274989217e-13,"No",1.0,9.714443338633732e-25,"No",0.9747446391875256,0.02525536081248517,"Yes",0.9989979976140793,0.001002002385914783,"Yes",0.9999998513871842,1.4861282199107227e-07,"No",0.11014893721096425,0.8898510627890442,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","AT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0935831239489579e-49,4.7576798125568646e-05,0.9999524232018783,"2+",4.639078934045866e-13,0.9999999999995453,"Yes",0.9999999999986642,1.3261320758771066e-12,"No",1.0,7.218396738650662e-25,"No",0.9672997464694512,0.03270025353055256,"Yes",0.9986718221899964,0.0013281778100163039,"Yes",0.9999999079016718,9.209831470471602e-08,"No",0.08756389486976505,0.912436105130241,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanomaEnsayo NEMO (melanoma NRAS e inhibidor MEK): Estudio aleatorizado de Fase III abierto multicéntrico de dos brazos que compara la eficacia de MEK162 frente a Dacarbazina en pacientes con melanoma avanzado no resecable o metástasico con mutación NRAS positiva","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.695389329495681e-97,5.72974100801187e-11,0.999999999942702,"2+",7.361825066881262e-28,1.0,"Yes",1.0,6.025169602681293e-27,"No",1.0,5.0009373806517904e-48,"No",0.998782702082283,0.001217297917729806,"Yes",0.9999819540416605,1.804595836209446e-05,"Yes",1.0,4.836166960036468e-24,"No",0.0008323615889073611,0.9991676384111159,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","HU","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0935831239489579e-49,4.7576798125568646e-05,0.9999524232018783,"2+",4.639078934045866e-13,0.9999999999995453,"Yes",0.9999999999986642,1.3261320758771066e-12,"No",1.0,7.218396738650662e-25,"No",0.9672997464694512,0.03270025353055256,"Yes",0.9986718221899964,0.0013281778100163039,"Yes",0.9999999079016718,9.209831470471602e-08,"No",0.08756389486976505,0.912436105130241,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","FR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0935831239489579e-49,4.7576798125568646e-05,0.9999524232018783,"2+",4.639078934045866e-13,0.9999999999995453,"Yes",0.9999999999986642,1.3261320758771066e-12,"No",1.0,7.218396738650662e-25,"No",0.9672997464694512,0.03270025353055256,"Yes",0.9986718221899964,0.0013281778100163039,"Yes",0.9999999079016718,9.209831470471602e-08,"No",0.08756389486976505,0.912436105130241,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","GR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.85616791123606e-50,6.251535886994093e-05,0.9999374846411264,"2+",2.5924468857372935e-13,0.9999999999997442,"Yes",0.999999999999261,7.388918274989217e-13,"No",1.0,9.714443338633732e-25,"No",0.9747446391875256,0.02525536081248517,"Yes",0.9989979976140793,0.001002002385914783,"Yes",0.9999998513871842,1.4861282199107227e-07,"No",0.11014893721096425,0.8898510627890442,"Yes"
"2012-003593-51","The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III open label multicenter two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma","SE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0935831239489579e-49,4.7576798125568646e-05,0.9999524232018783,"2+",4.639078934045866e-13,0.9999999999995453,"Yes",0.9999999999986642,1.3261320758771066e-12,"No",1.0,7.218396738650662e-25,"No",0.9672997464694512,0.03270025353055256,"Yes",0.9986718221899964,0.0013281778100163039,"Yes",0.9999999079016718,9.209831470471602e-08,"No",0.08756389486976505,0.912436105130241,"Yes"
"2012-003630-16","A Randomized Parallel Group Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft OperationTiCAB– Ticagrelor in CABG","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1728664725082488e-42,1.1944746090469105e-17,1.0,"2+",0.9999925878320121,7.4121679836225476e-06,"No",0.00026710520665940927,0.9997328947933518,"Yes",0.8745697586391031,0.1254302413609053,"No",4.0342226803880694e-17,1.0,"Yes",3.6070068282280226e-05,0.9999639299317057,"Yes",0.9999987563233848,1.2436766219728341e-06,"No",5.258036936687403e-14,0.9999999999999432,"Yes"
"2012-003630-16","A Randomized Parallel Group Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft OperationTiCAB– Ticagrelor in CABG","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1728664725082488e-42,1.1944746090469105e-17,1.0,"2+",0.9999925878320121,7.4121679836225476e-06,"No",0.00026710520665940927,0.9997328947933518,"Yes",0.8745697586391031,0.1254302413609053,"No",4.0342226803880694e-17,1.0,"Yes",3.6070068282280226e-05,0.9999639299317057,"Yes",0.9999987563233848,1.2436766219728341e-06,"No",5.258036936687403e-14,0.9999999999999432,"Yes"
"2012-003788-23","A Phase 2 Multicenter Randomized Open Label Multiple Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects with End-Stage Kidney Disease on Hemodialysis Switched from Erythropoiesis Stimulating Agents with Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: to Evaluate the Pharmacokinetics Safety Tolerability Efficacy Dosing Regimen and Pharmacodynamics of Sotatercept","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","No","2+","Yes",1.6218811129307308e-89,8.247831778862984e-06,0.999991752168249,"2+",0.029841192918240864,0.9701588070817689,"Yes",0.9783119130572819,0.021688086942696354,"No",0.9999999999990337,9.902699044080658e-13,"No",0.007263465142244957,0.9927365348577658,"Yes",0.12470760786725371,0.8752923921327569,"Yes",1.0,8.830652992890901e-19,"No",0.00981203856576553,0.9901879614342398,"Yes"
"2012-003788-23","A Phase 2 Multicenter Randomized Open Label Multiple Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects with End-Stage Kidney Disease on Hemodialysis Switched from Erythropoiesis Stimulating Agents with Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: to Evaluate the Pharmacokinetics Safety Tolerability Efficacy Dosing Regimen and Pharmacodynamics of Sotatercept","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","No","2+","Yes",1.6218811129307308e-89,8.247831778862984e-06,0.999991752168249,"2+",0.029841192918240864,0.9701588070817689,"Yes",0.9783119130572819,0.021688086942696354,"No",0.9999999999990337,9.902699044080658e-13,"No",0.007263465142244957,0.9927365348577658,"Yes",0.12470760786725371,0.8752923921327569,"Yes",1.0,8.830652992890901e-19,"No",0.00981203856576553,0.9901879614342398,"Yes"
"2012-003788-23","A Phase 2 Multicenter Randomized Open Label Multiple Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects with End-Stage Kidney Disease on Hemodialysis Switched from Erythropoiesis Stimulating Agents with Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: to Evaluate the Pharmacokinetics Safety Tolerability Efficacy Dosing Regimen and Pharmacodynamics of Sotatercept","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","No","2+","Yes",1.6218811129307308e-89,8.247831778862984e-06,0.999991752168249,"2+",0.029841192918240864,0.9701588070817689,"Yes",0.9783119130572819,0.021688086942696354,"No",0.9999999999990337,9.902699044080658e-13,"No",0.007263465142244957,0.9927365348577658,"Yes",0.12470760786725371,0.8752923921327569,"Yes",1.0,8.830652992890901e-19,"No",0.00981203856576553,0.9901879614342398,"Yes"
"2012-003788-23","A Phase 2 Multicenter Randomized Open Label Multiple Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects with End-Stage Kidney Disease on Hemodialysis Switched from Erythropoiesis Stimulating Agents with Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: to Evaluate the Pharmacokinetics Safety Tolerability Efficacy Dosing Regimen and Pharmacodynamics of Sotatercept","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","No","2+","Yes",1.6218811129307308e-89,8.247831778862984e-06,0.999991752168249,"2+",0.029841192918240864,0.9701588070817689,"Yes",0.9783119130572819,0.021688086942696354,"No",0.9999999999990337,9.902699044080658e-13,"No",0.007263465142244957,0.9927365348577658,"Yes",0.12470760786725371,0.8752923921327569,"Yes",1.0,8.830652992890901e-19,"No",0.00981203856576553,0.9901879614342398,"Yes"
"2012-003788-23","A Phase 2 Multicenter Randomized Open Label Multiple Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects with End-Stage Kidney Disease on Hemodialysis Switched from Erythropoiesis Stimulating Agents with Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: to Evaluate the Pharmacokinetics Safety Tolerability Efficacy Dosing Regimen and Pharmacodynamics of Sotatercept","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","No","2+","Yes",1.6218811129307308e-89,8.247831778862984e-06,0.999991752168249,"2+",0.029841192918240864,0.9701588070817689,"Yes",0.9783119130572819,0.021688086942696354,"No",0.9999999999990337,9.902699044080658e-13,"No",0.007263465142244957,0.9927365348577658,"Yes",0.12470760786725371,0.8752923921327569,"Yes",1.0,8.830652992890901e-19,"No",0.00981203856576553,0.9901879614342398,"Yes"
"2012-004027-20","A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) inSubjects with Relapsed/Refractory or Previously Untreated ChronicLymphocytic Leukemia Harboring the 17p Deletion","PL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",7.439162050870159e-31,0.9999998327768791,1.6722311518434302e-07,"1",9.580707749124386e-14,0.9999999999999147,"Yes",0.999999999999801,1.8683528584114416e-13,"No",1.0,1.751676944825478e-23,"No",0.9999999503261292,4.967387570846826e-08,"No",0.9999310476306008,6.895236939305737e-05,"No",0.9999999999999717,3.07787192538569e-14,"No",0.9999998082446282,1.9175537095683558e-07,"No"
"2012-004027-20","A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) inSubjects with Relapsed/Refractory or Previously Untreated ChronicLymphocytic Leukemia Harboring the 17p Deletion","GB","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",7.439162050870159e-31,0.9999998327768791,1.6722311518434302e-07,"1",9.580707749124386e-14,0.9999999999999147,"Yes",0.999999999999801,1.8683528584114416e-13,"No",1.0,1.751676944825478e-23,"No",0.9999999503261292,4.967387570846826e-08,"No",0.9999310476306008,6.895236939305737e-05,"No",0.9999999999999717,3.07787192538569e-14,"No",0.9999998082446282,1.9175537095683558e-07,"No"
"2012-004027-20","A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) inSubjects with Relapsed/Refractory or Previously Untreated ChronicLymphocytic Leukemia Harboring the 17p Deletion","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",7.439162050870159e-31,0.9999998327768791,1.6722311518434302e-07,"1",9.580707749124386e-14,0.9999999999999147,"Yes",0.999999999999801,1.8683528584114416e-13,"No",1.0,1.751676944825478e-23,"No",0.9999999503261292,4.967387570846826e-08,"No",0.9999310476306008,6.895236939305737e-05,"No",0.9999999999999717,3.07787192538569e-14,"No",0.9999998082446282,1.9175537095683558e-07,"No"
"2012-004125-24","A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.Eine prospektive randomisierte klinische Prüfung der Phase III von Carboplatin/Gemcitabin/Bevacizumab vs. Carboplatin/pegyliertes liposomales Doxorubicin/Bevacizumab bei Patientinnen mit platin-sensitivem rezidivierendem Ovarialkarzinom.","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3507760604109258e-82,2.2244583459247052e-11,0.9999999999777742,"2+",1.1115228205849715e-10,0.9999999998888712,"Yes",0.9999999998585737,1.4144557575065283e-10,"No",1.0,1.1391097521024475e-33,"No",5.5632648144603625e-08,0.9999999443673475,"Yes",0.998932515859158,0.0010674841408231219,"No",1.0,6.87830003890124e-23,"No",1.6171669176577746e-11,0.9999999999838565,"Yes"
"2012-004125-24","A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.Eine prospektive randomisierte klinische Prüfung der Phase III von Carboplatin/Gemcitabin/Bevacizumab vs. Carboplatin/pegyliertes liposomales Doxorubicin/Bevacizumab bei Patientinnen mit platin-sensitivem rezidivierendem Ovarialkarzinom.","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3507760604109258e-82,2.2244583459247052e-11,0.9999999999777742,"2+",1.1115228205849715e-10,0.9999999998888712,"Yes",0.9999999998585737,1.4144557575065283e-10,"No",1.0,1.1391097521024475e-33,"No",5.5632648144603625e-08,0.9999999443673475,"Yes",0.998932515859158,0.0010674841408231219,"No",1.0,6.87830003890124e-23,"No",1.6171669176577746e-11,0.9999999999838565,"Yes"
"2012-004125-24","A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.Eine prospektive randomisierte klinische Prüfung der Phase III von Carboplatin/Gemcitabin/Bevacizumab vs. Carboplatin/pegyliertes liposomales Doxorubicin/Bevacizumab bei Patientinnen mit platin-sensitivem rezidivierendem Ovarialkarzinom.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3507760604109258e-82,2.2244583459247052e-11,0.9999999999777742,"2+",1.1115228205849715e-10,0.9999999998888712,"Yes",0.9999999998585737,1.4144557575065283e-10,"No",1.0,1.1391097521024475e-33,"No",5.5632648144603625e-08,0.9999999443673475,"Yes",0.998932515859158,0.0010674841408231219,"No",1.0,6.87830003890124e-23,"No",1.6171669176577746e-11,0.9999999999838565,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2027993075965094e-53,8.011765616739477e-13,0.9999999999992043,"2+",0.9999999994120117,5.879940729888089e-10,"No",2.3280129887220763e-09,0.9999999976719779,"Yes",0.9999999999967031,3.2992880386196635e-12,"No",2.1834282337033907e-12,0.9999999999978115,"Yes",6.001405529043885e-05,0.999939985944709,"No",0.9954925054401791,0.004507494559818871,"No",6.8553881144269666e-12,0.9999999999931504,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyA szájon át különböző dózisokban alkalmazott BAY94-8862 randomizált kettős-vak placebo kontrollált multicentrikus klinikai vizsgálata a biztonságosság és a hatékonyság értékelésére 2. típusú diabéteszben és klinikailag igazolt diabéteszes nefropátiában szenvedő betegeknél","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.532220714476396e-88,2.9218980324174333e-21,1.0,"2+",1.0,6.593734211430366e-22,"No",9.67169372951264e-21,1.0,"Yes",1.0,7.004023343294967e-22,"No",4.795320489729848e-23,1.0,"Yes",7.810805231845639e-14,0.9999999999999432,"No",1.0,6.021949133054639e-16,"No",2.1649760118653448e-21,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyStudio multicentrico randomizzato controllato verso placebo in doppio cieco per valutare la sicurezza e l’efficacia di diverse dosi orali di BAY 94-8862 in soggetti affetti da diabete mellito di tipo 2 con diagnosi clinica di nefropatia diabetica.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.391240447411184e-112,2.2042789617644034e-20,1.0,"2+",1.0,3.9870562634162375e-15,"No",2.776680686688641e-14,1.0,"Yes",1.0,1.6478746996065e-27,"No",3.525258627419762e-21,1.0,"Yes",2.0058613625582165e-10,0.9999999997993996,"No",1.0,4.4718014272567536e-17,"No",1.5604687899958313e-17,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyRandomizovaná dvakrát zaslepená placebem kontrolovaná multicentrická studie s cílem stanovit účinnost a bezpečnost látky BAY 94-8862 u subjektů s cukrovkou typu 2 a klinickou diagnózou diabetické nefropatie","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.041796627617854e-89,1.1963375746257216e-23,1.0,"2+",1.0,3.093839595653803e-20,"No",4.951172469572128e-19,1.0,"Yes",1.0,1.0009089887604663e-29,"No",2.1794434734489755e-24,1.0,"Yes",8.69651155778706e-08,0.9999999130348595,"No",1.0,1.733551799966003e-19,"No",6.430688040953162e-22,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyA szájon át különböző dózisokban alkalmazott BAY94-8862 randomizált kettős-vak placebo kontrollált multicentrikus klinikai vizsgálata a biztonságosság és a hatékonyság értékelésére 2. típusú diabéteszben és klinikailag igazolt diabéteszes nefropátiában szenvedő betegeknél","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.532220714476396e-88,2.9218980324174333e-21,1.0,"2+",1.0,6.593734211430366e-22,"No",9.67169372951264e-21,1.0,"Yes",1.0,7.004023343294967e-22,"No",4.795320489729848e-23,1.0,"Yes",7.810805231845639e-14,0.9999999999999432,"No",1.0,6.021949133054639e-16,"No",2.1649760118653448e-21,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyStudio multicentrico randomizzato controllato verso placebo in doppio cieco per valutare la sicurezza e l’efficacia di diverse dosi orali di BAY 94-8862 in soggetti affetti da diabete mellito di tipo 2 con diagnosi clinica di nefropatia diabetica.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.391240447411184e-112,2.2042789617644034e-20,1.0,"2+",1.0,3.9870562634162375e-15,"No",2.776680686688641e-14,1.0,"Yes",1.0,1.6478746996065e-27,"No",3.525258627419762e-21,1.0,"Yes",2.0058613625582165e-10,0.9999999997993996,"No",1.0,4.4718014272567536e-17,"No",1.5604687899958313e-17,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyRandomizovaná dvakrát zaslepená placebem kontrolovaná multicentrická studie s cílem stanovit účinnost a bezpečnost látky BAY 94-8862 u subjektů s cukrovkou typu 2 a klinickou diagnózou diabetické nefropatie","NO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.041796627617854e-89,1.1963375746257216e-23,1.0,"2+",1.0,3.093839595653803e-20,"No",4.951172469572128e-19,1.0,"Yes",1.0,1.0009089887604663e-29,"No",2.1794434734489755e-24,1.0,"Yes",8.69651155778706e-08,0.9999999130348595,"No",1.0,1.733551799966003e-19,"No",6.430688040953162e-22,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyStudio multicentrico randomizzato controllato verso placebo in doppio cieco per valutare la sicurezza e l’efficacia di diverse dosi orali di BAY 94-8862 in soggetti affetti da diabete mellito di tipo 2 con diagnosi clinica di nefropatia diabetica.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.391240447411184e-112,2.2042789617644034e-20,1.0,"2+",1.0,3.9870562634162375e-15,"No",2.776680686688641e-14,1.0,"Yes",1.0,1.6478746996065e-27,"No",3.525258627419762e-21,1.0,"Yes",2.0058613625582165e-10,0.9999999997993996,"No",1.0,4.4718014272567536e-17,"No",1.5604687899958313e-17,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyA szájon át különböző dózisokban alkalmazott BAY94-8862 randomizált kettős-vak placebo kontrollált multicentrikus klinikai vizsgálata a biztonságosság és a hatékonyság értékelésére 2. típusú diabéteszben és klinikailag igazolt diabéteszes nefropátiában szenvedő betegeknél","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.532220714476396e-88,2.9218980324174333e-21,1.0,"2+",1.0,6.593734211430366e-22,"No",9.67169372951264e-21,1.0,"Yes",1.0,7.004023343294967e-22,"No",4.795320489729848e-23,1.0,"Yes",7.810805231845639e-14,0.9999999999999432,"No",1.0,6.021949133054639e-16,"No",2.1649760118653448e-21,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyA szájon át különböző dózisokban alkalmazott BAY94-8862 randomizált kettős-vak placebo kontrollált multicentrikus klinikai vizsgálata a biztonságosság és a hatékonyság értékelésére 2. típusú diabéteszben és klinikailag igazolt diabéteszes nefropátiában szenvedő betegeknél","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.532220714476396e-88,2.9218980324174333e-21,1.0,"2+",1.0,6.593734211430366e-22,"No",9.67169372951264e-21,1.0,"Yes",1.0,7.004023343294967e-22,"No",4.795320489729848e-23,1.0,"Yes",7.810805231845639e-14,0.9999999999999432,"No",1.0,6.021949133054639e-16,"No",2.1649760118653448e-21,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2027993075965094e-53,8.011765616739477e-13,0.9999999999992043,"2+",0.9999999994120117,5.879940729888089e-10,"No",2.3280129887220763e-09,0.9999999976719779,"Yes",0.9999999999967031,3.2992880386196635e-12,"No",2.1834282337033907e-12,0.9999999999978115,"Yes",6.001405529043885e-05,0.999939985944709,"No",0.9954925054401791,0.004507494559818871,"No",6.8553881144269666e-12,0.9999999999931504,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyStudio multicentrico randomizzato controllato verso placebo in doppio cieco per valutare la sicurezza e l’efficacia di diverse dosi orali di BAY 94-8862 in soggetti affetti da diabete mellito di tipo 2 con diagnosi clinica di nefropatia diabetica.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.391240447411184e-112,2.2042789617644034e-20,1.0,"2+",1.0,3.9870562634162375e-15,"No",2.776680686688641e-14,1.0,"Yes",1.0,1.6478746996065e-27,"No",3.525258627419762e-21,1.0,"Yes",2.0058613625582165e-10,0.9999999997993996,"No",1.0,4.4718014272567536e-17,"No",1.5604687899958313e-17,1.0,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2027993075965094e-53,8.011765616739477e-13,0.9999999999992043,"2+",0.9999999994120117,5.879940729888089e-10,"No",2.3280129887220763e-09,0.9999999976719779,"Yes",0.9999999999967031,3.2992880386196635e-12,"No",2.1834282337033907e-12,0.9999999999978115,"Yes",6.001405529043885e-05,0.999939985944709,"No",0.9954925054401791,0.004507494559818871,"No",6.8553881144269666e-12,0.9999999999931504,"Yes"
"2012-004179-38","A randomized double-blind placebo-controlled multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathyStudio multicentrico randomizzato controllato verso placebo in doppio cieco per valutare la sicurezza e l’efficacia di diverse dosi orali di BAY 94-8862 in soggetti affetti da diabete mellito di tipo 2 con diagnosi clinica di nefropatia diabetica.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.391240447411184e-112,2.2042789617644034e-20,1.0,"2+",1.0,3.9870562634162375e-15,"No",2.776680686688641e-14,1.0,"Yes",1.0,1.6478746996065e-27,"No",3.525258627419762e-21,1.0,"Yes",2.0058613625582165e-10,0.9999999997993996,"No",1.0,4.4718014272567536e-17,"No",1.5604687899958313e-17,1.0,"Yes"
"2012-004331-23","A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic Chemotherapy-Naïve and Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.0753474577035543e-48,7.58773932539744e-09,0.9999999924122563,"2+",0.0012560160314265024,0.9987439839685806,"Yes",0.9988178515880631,0.0011821484119379957,"No",0.999999999999801,1.932521838128596e-13,"No",2.3848489867481796e-06,0.9999976151510185,"Yes",0.06994873013673665,0.9300512698632509,"Yes",0.9999999781034322,2.189656860917897e-08,"No",4.176140676394518e-08,0.9999999582385906,"Yes"
"2012-004331-23","A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic Chemotherapy-Naïve and Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.0753474577035543e-48,7.58773932539744e-09,0.9999999924122563,"2+",0.0012560160314265024,0.9987439839685806,"Yes",0.9988178515880631,0.0011821484119379957,"No",0.999999999999801,1.932521838128596e-13,"No",2.3848489867481796e-06,0.9999976151510185,"Yes",0.06994873013673665,0.9300512698632509,"Yes",0.9999999781034322,2.189656860917897e-08,"No",4.176140676394518e-08,0.9999999582385906,"Yes"
"2012-004331-23","A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic Chemotherapy-Naïve and Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.0753474577035543e-48,7.58773932539744e-09,0.9999999924122563,"2+",0.0012560160314265024,0.9987439839685806,"Yes",0.9988178515880631,0.0011821484119379957,"No",0.999999999999801,1.932521838128596e-13,"No",2.3848489867481796e-06,0.9999976151510185,"Yes",0.06994873013673665,0.9300512698632509,"Yes",0.9999999781034322,2.189656860917897e-08,"No",4.176140676394518e-08,0.9999999582385906,"Yes"
"2012-004331-23","A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic Chemotherapy-Naïve and Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.0753474577035543e-48,7.58773932539744e-09,0.9999999924122563,"2+",0.0012560160314265024,0.9987439839685806,"Yes",0.9988178515880631,0.0011821484119379957,"No",0.999999999999801,1.932521838128596e-13,"No",2.3848489867481796e-06,0.9999976151510185,"Yes",0.06994873013673665,0.9300512698632509,"Yes",0.9999999781034322,2.189656860917897e-08,"No",4.176140676394518e-08,0.9999999582385906,"Yes"
"2012-004331-23","A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic Chemotherapy-Naïve and Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.0753474577035543e-48,7.58773932539744e-09,0.9999999924122563,"2+",0.0012560160314265024,0.9987439839685806,"Yes",0.9988178515880631,0.0011821484119379957,"No",0.999999999999801,1.932521838128596e-13,"No",2.3848489867481796e-06,0.9999976151510185,"Yes",0.06994873013673665,0.9300512698632509,"Yes",0.9999999781034322,2.189656860917897e-08,"No",4.176140676394518e-08,0.9999999582385906,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMARANDOMIZÁLT FÁZIS III VIZSGÁLAT A GANETESPIB DOCETAXEL KOMBINÁCIÓ ÉS A DOCETAXEL ÖNÁLLÓ KEZELÉS ÖSSZEHASONLÍTÁSÁRA ELŐREHALADOTT NEM-KISSEJTES TÜDŐ-ADENOKARCINÓMÁS BETEGEK ESETÉBEN","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1504822695036595e-61,1.20989219659883e-05,0.9999879010780215,"2+",3.7771328941402076e-10,0.9999999996222755,"Yes",0.9999999987442437,1.2557631855977276e-09,"No",1.0,1.6168617445331848e-29,"No",0.0016179599105424582,0.9983820400894537,"Yes",0.9999934500621844,6.549937806555637e-06,"Yes",1.0,1.5660928333154073e-15,"No",0.00014395920277701047,0.9998560407972233,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMARANDOMIZÁLT FÁZIS III VIZSGÁLAT A GANETESPIB DOCETAXEL KOMBINÁCIÓ ÉS A DOCETAXEL ÖNÁLLÓ KEZELÉS ÖSSZEHASONLÍTÁSÁRA ELŐREHALADOTT NEM-KISSEJTES TÜDŐ-ADENOKARCINÓMÁS BETEGEK ESETÉBEN","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1504822695036595e-61,1.20989219659883e-05,0.9999879010780215,"2+",3.7771328941402076e-10,0.9999999996222755,"Yes",0.9999999987442437,1.2557631855977276e-09,"No",1.0,1.6168617445331848e-29,"No",0.0016179599105424582,0.9983820400894537,"Yes",0.9999934500621844,6.549937806555637e-06,"Yes",1.0,1.5660928333154073e-15,"No",0.00014395920277701047,0.9998560407972233,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMARandomizirana študija faze III o zdravilu Ganetespib v kombinaciji z zdravilom Docetaxel v primjerjavi z učinkovitostjo zdravljenja samo z Docetaxelom pri bolnikih z napredovanim nedrobnoceličnim pljučnim adenokarcinomom","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2218815869481146e-68,1.3072252072297847e-07,0.9999998692774824,"2+",1.0176797788389821e-05,0.999989823202213,"Yes",0.9999617965795686,3.8203420427338905e-05,"No",1.0,7.076854326557346e-30,"No",1.1042842107996178e-06,0.9999988957157897,"Yes",0.9983584840690146,0.0016415159309902598,"Yes",0.9999999996080646,3.919420442532097e-10,"No",3.2127415495426555e-06,0.9999967872584415,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMARandomizirana študija faze III o zdravilu Ganetespib v kombinaciji z zdravilom Docetaxel v primjerjavi z učinkovitostjo zdravljenja samo z Docetaxelom pri bolnikih z napredovanim nedrobnoceličnim pljučnim adenokarcinomom","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2218815869481146e-68,1.3072252072297847e-07,0.9999998692774824,"2+",1.0176797788389821e-05,0.999989823202213,"Yes",0.9999617965795686,3.8203420427338905e-05,"No",1.0,7.076854326557346e-30,"No",1.1042842107996178e-06,0.9999988957157897,"Yes",0.9983584840690146,0.0016415159309902598,"Yes",0.9999999996080646,3.919420442532097e-10,"No",3.2127415495426555e-06,0.9999967872584415,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMAEnsayo en fase III aleatorizado de ganetespib en combinación con docetaxel frente a docetaxel solo en pacientes con adenocarcinoma de pulmón no microcítico avanzado","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.879529305060587e-67,4.7196109115653533e-07,0.9999995280388965,"2+",2.9764420579605505e-12,0.9999999999970157,"Yes",0.9999999999908766,9.128242107607619e-12,"No",1.0,5.152726424656375e-32,"No",0.001167520716483286,0.9988324792835286,"Yes",0.9999001943907966,9.980560920906526e-05,"Yes",1.0,6.784568341933521e-16,"No",0.0002742586000652351,0.9997257413999469,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA","SI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.220928640241375e-40,0.00011905058899201322,0.9998809494110105,"2+",1.472326645239722e-05,0.999985276733542,"Yes",0.999973315452877,2.6684547124615613e-05,"No",1.0,2.383280197948128e-17,"No",0.021331143262317123,0.9786688567376826,"Yes",0.9843386529482633,0.015661347051740125,"Yes",0.9999863144435309,1.3685556474844894e-05,"No",0.005377114494915633,0.9946228855050884,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMAEnsayo en fase III aleatorizado de ganetespib en combinación con docetaxel frente a docetaxel solo en pacientes con adenocarcinoma de pulmón no microcítico avanzado","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.879529305060587e-67,4.7196109115653533e-07,0.9999995280388965,"2+",2.9764420579605505e-12,0.9999999999970157,"Yes",0.9999999999908766,9.128242107607619e-12,"No",1.0,5.152726424656375e-32,"No",0.001167520716483286,0.9988324792835286,"Yes",0.9999001943907966,9.980560920906526e-05,"Yes",1.0,6.784568341933521e-16,"No",0.0002742586000652351,0.9997257413999469,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.220928640241375e-40,0.00011905058899201322,0.9998809494110105,"2+",1.472326645239722e-05,0.999985276733542,"Yes",0.999973315452877,2.6684547124615613e-05,"No",1.0,2.383280197948128e-17,"No",0.021331143262317123,0.9786688567376826,"Yes",0.9843386529482633,0.015661347051740125,"Yes",0.9999863144435309,1.3685556474844894e-05,"No",0.005377114494915633,0.9946228855050884,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMARANDOMIZÁLT FÁZIS III VIZSGÁLAT A GANETESPIB DOCETAXEL KOMBINÁCIÓ ÉS A DOCETAXEL ÖNÁLLÓ KEZELÉS ÖSSZEHASONLÍTÁSÁRA ELŐREHALADOTT NEM-KISSEJTES TÜDŐ-ADENOKARCINÓMÁS BETEGEK ESETÉBEN","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1504822695036595e-61,1.20989219659883e-05,0.9999879010780215,"2+",3.7771328941402076e-10,0.9999999996222755,"Yes",0.9999999987442437,1.2557631855977276e-09,"No",1.0,1.6168617445331848e-29,"No",0.0016179599105424582,0.9983820400894537,"Yes",0.9999934500621844,6.549937806555637e-06,"Yes",1.0,1.5660928333154073e-15,"No",0.00014395920277701047,0.9998560407972233,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMARandomizirana študija faze III o zdravilu Ganetespib v kombinaciji z zdravilom Docetaxel v primjerjavi z učinkovitostjo zdravljenja samo z Docetaxelom pri bolnikih z napredovanim nedrobnoceličnim pljučnim adenokarcinomom","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2218815869481146e-68,1.3072252072297847e-07,0.9999998692774824,"2+",1.0176797788389821e-05,0.999989823202213,"Yes",0.9999617965795686,3.8203420427338905e-05,"No",1.0,7.076854326557346e-30,"No",1.1042842107996178e-06,0.9999988957157897,"Yes",0.9983584840690146,0.0016415159309902598,"Yes",0.9999999996080646,3.919420442532097e-10,"No",3.2127415495426555e-06,0.9999967872584415,"Yes"
"2012-004349-34","A RANDOMIZED PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.220928640241375e-40,0.00011905058899201322,0.9998809494110105,"2+",1.472326645239722e-05,0.999985276733542,"Yes",0.999973315452877,2.6684547124615613e-05,"No",1.0,2.383280197948128e-17,"No",0.021331143262317123,0.9786688567376826,"Yes",0.9843386529482633,0.015661347051740125,"Yes",0.9999863144435309,1.3685556474844894e-05,"No",0.005377114494915633,0.9946228855050884,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.","BG","Yes","Yes","No","ok","Yes","No","Yes","No","1","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2248781781027796e-27,0.5682026966264225,0.4317973033735724,"2+",0.9034370301312945,0.09656296986870597,"No",0.435492087267668,0.5645079127323359,"Yes",0.03203866156694792,0.9679613384330483,"No",0.7593315026073674,0.2406684973926316,"Yes",0.2562434776309156,0.7437565223690927,"Yes",0.9127230123396951,0.08727698766031335,"No",0.431199428677524,0.5688005713224785,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.Hodnocení účinnosti a bezpečnosti tapentadolu ve formě perorálního roztoku při léčbě akutní pooperační bolesti vyžadující léčbu opioidy u pediatrických pacientů ve věku od narození do 18 let.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0266850582475197e-58,0.00031121062835409187,0.9996887893716735,"2+",0.9999999816753304,1.8324663645692265e-08,"No",1.1972148827123206e-07,0.9999998802785016,"Yes",0.9999999985818137,1.4181939055533577e-09,"No",3.5688258171257336e-05,0.9999643117418161,"Yes",0.09096001119380553,0.9090399888062193,"Yes",0.9999999999922693,7.718501062961963e-12,"No",7.386091159348367e-05,0.9999261390884084,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.Hodnocení účinnosti a bezpečnosti tapentadolu ve formě perorálního roztoku při léčbě akutní pooperační bolesti vyžadující léčbu opioidy u pediatrických pacientů ve věku od narození do 18 let.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0266850582475197e-58,0.00031121062835409187,0.9996887893716735,"2+",0.9999999816753304,1.8324663645692265e-08,"No",1.1972148827123206e-07,0.9999998802785016,"Yes",0.9999999985818137,1.4181939055533577e-09,"No",3.5688258171257336e-05,0.9999643117418161,"Yes",0.09096001119380553,0.9090399888062193,"Yes",0.9999999999922693,7.718501062961963e-12,"No",7.386091159348367e-05,0.9999261390884084,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.","HR","Yes","Yes","No","ok","Yes","No","Yes","No","1","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2248781781027796e-27,0.5682026966264225,0.4317973033735724,"2+",0.9034370301312945,0.09656296986870597,"No",0.435492087267668,0.5645079127323359,"Yes",0.03203866156694792,0.9679613384330483,"No",0.7593315026073674,0.2406684973926316,"Yes",0.2562434776309156,0.7437565223690927,"Yes",0.9127230123396951,0.08727698766031335,"No",0.431199428677524,0.5688005713224785,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.","GB","Yes","Yes","No","ok","Yes","No","Yes","No","1","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2248781781027796e-27,0.5682026966264225,0.4317973033735724,"2+",0.9034370301312945,0.09656296986870597,"No",0.435492087267668,0.5645079127323359,"Yes",0.03203866156694792,0.9679613384330483,"No",0.7593315026073674,0.2406684973926316,"Yes",0.2562434776309156,0.7437565223690927,"Yes",0.9127230123396951,0.08727698766031335,"No",0.431199428677524,0.5688005713224785,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.","SE","Yes","Yes","No","ok","Yes","No","Yes","No","1","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2248781781027796e-27,0.5682026966264225,0.4317973033735724,"2+",0.9034370301312945,0.09656296986870597,"No",0.435492087267668,0.5645079127323359,"Yes",0.03203866156694792,0.9679613384330483,"No",0.7593315026073674,0.2406684973926316,"Yes",0.2562434776309156,0.7437565223690927,"Yes",0.9127230123396951,0.08727698766031335,"No",0.431199428677524,0.5688005713224785,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.","PL","Yes","Yes","No","ok","Yes","No","Yes","No","1","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.2248781781027796e-27,0.5682026966264225,0.4317973033735724,"2+",0.9034370301312945,0.09656296986870597,"No",0.435492087267668,0.5645079127323359,"Yes",0.03203866156694792,0.9679613384330483,"No",0.7593315026073674,0.2406684973926316,"Yes",0.2562434776309156,0.7437565223690927,"Yes",0.9127230123396951,0.08727698766031335,"No",0.431199428677524,0.5688005713224785,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.Hodnocení účinnosti a bezpečnosti tapentadolu ve formě perorálního roztoku při léčbě akutní pooperační bolesti vyžadující léčbu opioidy u pediatrických pacientů ve věku od narození do 18 let.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0266850582475197e-58,0.00031121062835409187,0.9996887893716735,"2+",0.9999999816753304,1.8324663645692265e-08,"No",1.1972148827123206e-07,0.9999998802785016,"Yes",0.9999999985818137,1.4181939055533577e-09,"No",3.5688258171257336e-05,0.9999643117418161,"Yes",0.09096001119380553,0.9090399888062193,"Yes",0.9999999999922693,7.718501062961963e-12,"No",7.386091159348367e-05,0.9999261390884084,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.Hodnocení účinnosti a bezpečnosti tapentadolu ve formě perorálního roztoku při léčbě akutní pooperační bolesti vyžadující léčbu opioidy u pediatrických pacientů ve věku od narození do 18 let.","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0266850582475197e-58,0.00031121062835409187,0.9996887893716735,"2+",0.9999999816753304,1.8324663645692265e-08,"No",1.1972148827123206e-07,0.9999998802785016,"Yes",0.9999999985818137,1.4181939055533577e-09,"No",3.5688258171257336e-05,0.9999643117418161,"Yes",0.09096001119380553,0.9090399888062193,"Yes",0.9999999999922693,7.718501062961963e-12,"No",7.386091159348367e-05,0.9999261390884084,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.Hodnocení účinnosti a bezpečnosti tapentadolu ve formě perorálního roztoku při léčbě akutní pooperační bolesti vyžadující léčbu opioidy u pediatrických pacientů ve věku od narození do 18 let.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0266850582475197e-58,0.00031121062835409187,0.9996887893716735,"2+",0.9999999816753304,1.8324663645692265e-08,"No",1.1972148827123206e-07,0.9999998802785016,"Yes",0.9999999985818137,1.4181939055533577e-09,"No",3.5688258171257336e-05,0.9999643117418161,"Yes",0.09096001119380553,0.9090399888062193,"Yes",0.9999999999922693,7.718501062961963e-12,"No",7.386091159348367e-05,0.9999261390884084,"Yes"
"2012-004359-35","An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.Hodnocení účinnosti a bezpečnosti tapentadolu ve formě perorálního roztoku při léčbě akutní pooperační bolesti vyžadující léčbu opioidy u pediatrických pacientů ve věku od narození do 18 let.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0266850582475197e-58,0.00031121062835409187,0.9996887893716735,"2+",0.9999999816753304,1.8324663645692265e-08,"No",1.1972148827123206e-07,0.9999998802785016,"Yes",0.9999999985818137,1.4181939055533577e-09,"No",3.5688258171257336e-05,0.9999643117418161,"Yes",0.09096001119380553,0.9090399888062193,"Yes",0.9999999999922693,7.718501062961963e-12,"No",7.386091159348367e-05,0.9999261390884084,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","SK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","HR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","SI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004360-22","An open label trial enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment to evaluate the safety and efficacy of tapentadol PR versus morphine PR followed by an open label extension.","BG","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.9228737272661727e-32,7.99948968441038e-06,0.9999920005103253,"2+",0.006637039606379443,0.9933629603936148,"Yes",0.9988680732828465,0.0011319267171604993,"No",0.999983649908725,1.6350091276911364e-05,"No",3.3959630919860033e-06,0.9999966040369056,"Yes",0.04123559485665767,0.9587644051433558,"Yes",0.8275912510161416,0.1724087489838712,"No",0.051149650054609794,0.9488503499454015,"Yes"
"2012-004877-26","BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age BOTOX® pro léčbu močové inkontinence způsobené neurogenní hyperaktivitou detruzoru u pacientů ve věku 5 až 17 let","BE","Yes","No","No","ok","Yes","No","Yes","No","1","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.700385796761757e-41,0.5036030264702864,0.4963969735296883,"2+",0.9999989495999391,1.0504000447319503e-06,"No",1.2062858484808158e-06,0.9999987937141441,"Yes",1.0,1.1072597448483642e-17,"No",0.9990646168710519,0.0009353831289507201,"No",1.219819894929764e-05,0.9999878018010597,"Yes",0.9999999999888018,1.119225309873394e-11,"No",0.005976282126122548,0.9940237178738806,"Yes"
"2012-004877-26","BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age BOTOX® pro léčbu močové inkontinence způsobené neurogenní hyperaktivitou detruzoru u pacientů ve věku 5 až 17 let","DE","Yes","No","No","ok","Yes","No","Yes","No","1","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.700385796761757e-41,0.5036030264702864,0.4963969735296883,"2+",0.9999989495999391,1.0504000447319503e-06,"No",1.2062858484808158e-06,0.9999987937141441,"Yes",1.0,1.1072597448483642e-17,"No",0.9990646168710519,0.0009353831289507201,"No",1.219819894929764e-05,0.9999878018010597,"Yes",0.9999999999888018,1.119225309873394e-11,"No",0.005976282126122548,0.9940237178738806,"Yes"
"2012-004877-26","BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age BOTOX® pro léčbu močové inkontinence způsobené neurogenní hyperaktivitou detruzoru u pacientů ve věku 5 až 17 let","PL","Yes","No","No","ok","Yes","No","Yes","No","1","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.700385796761757e-41,0.5036030264702864,0.4963969735296883,"2+",0.9999989495999391,1.0504000447319503e-06,"No",1.2062858484808158e-06,0.9999987937141441,"Yes",1.0,1.1072597448483642e-17,"No",0.9990646168710519,0.0009353831289507201,"No",1.219819894929764e-05,0.9999878018010597,"Yes",0.9999999999888018,1.119225309873394e-11,"No",0.005976282126122548,0.9940237178738806,"Yes"
"2012-004877-26","BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age ","IT","Yes","No","No","ok","Yes","No","Yes","No","1","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",9.488569501969069e-20,0.5961576045557616,0.4038423954442317,"2+",0.9950666847793361,0.004933315220668826,"No",0.006539677589092091,0.9934603224109139,"Yes",0.9999998820501971,1.1794980783762374e-07,"No",0.8270551165523233,0.17294488344767525,"No",0.0002693584076404674,0.9997306415923609,"Yes",0.999984699585466,1.53004145282148e-05,"No",0.11756386289214836,0.8824361371078573,"Yes"
"2012-004877-26","BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age ","CZ","Yes","No","No","ok","Yes","No","Yes","No","1","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",9.488569501969069e-20,0.5961576045557616,0.4038423954442317,"2+",0.9950666847793361,0.004933315220668826,"No",0.006539677589092091,0.9934603224109139,"Yes",0.9999998820501971,1.1794980783762374e-07,"No",0.8270551165523233,0.17294488344767525,"No",0.0002693584076404674,0.9997306415923609,"Yes",0.999984699585466,1.53004145282148e-05,"No",0.11756386289214836,0.8824361371078573,"Yes"
"2012-004877-26","BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age ","FR","Yes","No","No","ok","Yes","No","Yes","No","1","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",9.488569501969069e-20,0.5961576045557616,0.4038423954442317,"2+",0.9950666847793361,0.004933315220668826,"No",0.006539677589092091,0.9934603224109139,"Yes",0.9999998820501971,1.1794980783762374e-07,"No",0.8270551165523233,0.17294488344767525,"No",0.0002693584076404674,0.9997306415923609,"Yes",0.999984699585466,1.53004145282148e-05,"No",0.11756386289214836,0.8824361371078573,"Yes"
"2012-004877-26","BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age ","AT","Yes","No","No","ok","Yes","No","Yes","No","1","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",9.488569501969069e-20,0.5961576045557616,0.4038423954442317,"2+",0.9950666847793361,0.004933315220668826,"No",0.006539677589092091,0.9934603224109139,"Yes",0.9999998820501971,1.1794980783762374e-07,"No",0.8270551165523233,0.17294488344767525,"No",0.0002693584076404674,0.9997306415923609,"Yes",0.999984699585466,1.53004145282148e-05,"No",0.11756386289214836,0.8824361371078573,"Yes"
"2012-004898-30","Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of AgeDlouhodobá rozšířená studie přípravku BOTOX® k léčbě močové inkontinence z důvodu hyperaktivity neurogenního detruzoru u pacientů ve věku 5 až 17 let","FR","Yes","No","No","ok","No","No","Yes","No","1","","","No","No","Yes","No","No","Yes","2+","No",6.537905369437734e-47,0.989024399267646,0.010975600732374823,"2+",0.9999076362480334,9.236375197963741e-05,"No",9.458279061095828e-05,0.9999054172093889,"Yes",1.0,8.939196172961477e-17,"No",0.9996366540398238,0.0003633459601551036,"No",0.00011972404162051082,0.9998802759583845,"No",0.9999999999999432,7.38798838033489e-14,"No",0.5028383859474032,0.49716161405257786,"No"
"2012-004898-30","Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of AgeDlouhodobá rozšířená studie přípravku BOTOX® k léčbě močové inkontinence z důvodu hyperaktivity neurogenního detruzoru u pacientů ve věku 5 až 17 let","CZ","Yes","No","No","ok","No","No","Yes","No","1","","","No","No","Yes","No","No","Yes","2+","No",6.537905369437734e-47,0.989024399267646,0.010975600732374823,"2+",0.9999076362480334,9.236375197963741e-05,"No",9.458279061095828e-05,0.9999054172093889,"Yes",1.0,8.939196172961477e-17,"No",0.9996366540398238,0.0003633459601551036,"No",0.00011972404162051082,0.9998802759583845,"No",0.9999999999999432,7.38798838033489e-14,"No",0.5028383859474032,0.49716161405257786,"No"
"2012-004898-30","Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of AgeDlouhodobá rozšířená studie přípravku BOTOX® k léčbě močové inkontinence z důvodu hyperaktivity neurogenního detruzoru u pacientů ve věku 5 až 17 let","PL","Yes","No","No","ok","No","No","Yes","No","1","","","No","No","Yes","No","No","Yes","2+","No",6.537905369437734e-47,0.989024399267646,0.010975600732374823,"2+",0.9999076362480334,9.236375197963741e-05,"No",9.458279061095828e-05,0.9999054172093889,"Yes",1.0,8.939196172961477e-17,"No",0.9996366540398238,0.0003633459601551036,"No",0.00011972404162051082,0.9998802759583845,"No",0.9999999999999432,7.38798838033489e-14,"No",0.5028383859474032,0.49716161405257786,"No"
"2012-004898-30","Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of AgeDlouhodobá rozšířená studie přípravku BOTOX® k léčbě močové inkontinence z důvodu hyperaktivity neurogenního detruzoru u pacientů ve věku 5 až 17 let","BE","Yes","No","No","ok","No","No","Yes","No","1","","","No","No","Yes","No","No","Yes","2+","No",6.537905369437734e-47,0.989024399267646,0.010975600732374823,"2+",0.9999076362480334,9.236375197963741e-05,"No",9.458279061095828e-05,0.9999054172093889,"Yes",1.0,8.939196172961477e-17,"No",0.9996366540398238,0.0003633459601551036,"No",0.00011972404162051082,0.9998802759583845,"No",0.9999999999999432,7.38798838033489e-14,"No",0.5028383859474032,0.49716161405257786,"No"
"2012-004898-30","Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age","DE","Yes","No","No","ok","No","No","Yes","No","1","","","No","No","Yes","No","No","Yes","2+","No",1.544163479819258e-21,0.9974526418248045,0.00254735817519337,"2+",0.95443106800837,0.045568931991627766,"No",0.05181969246100093,0.9481803075390045,"Yes",0.9999999978809485,2.1190533843410552e-09,"No",0.9992268319191595,0.0007731680808389144,"No",0.00426810448039736,0.9957318955195973,"No",0.9999999128636187,8.713637690488194e-08,"No",0.9884309317869238,0.011569068213073413,"No"
"2012-004898-30","Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of AgeDlouhodobá rozšířená studie přípravku BOTOX® k léčbě močové inkontinence z důvodu hyperaktivity neurogenního detruzoru u pacientů ve věku 5 až 17 let","AT","Yes","No","No","ok","No","No","Yes","No","1","","","No","No","Yes","No","No","Yes","2+","No",6.537905369437734e-47,0.989024399267646,0.010975600732374823,"2+",0.9999076362480334,9.236375197963741e-05,"No",9.458279061095828e-05,0.9999054172093889,"Yes",1.0,8.939196172961477e-17,"No",0.9996366540398238,0.0003633459601551036,"No",0.00011972404162051082,0.9998802759583845,"No",0.9999999999999432,7.38798838033489e-14,"No",0.5028383859474032,0.49716161405257786,"No"
"2012-004898-30","Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age","IT","Yes","No","No","ok","No","No","Yes","No","1","","","No","No","Yes","No","No","Yes","2+","No",1.544163479819258e-21,0.9974526418248045,0.00254735817519337,"2+",0.95443106800837,0.045568931991627766,"No",0.05181969246100093,0.9481803075390045,"Yes",0.9999999978809485,2.1190533843410552e-09,"No",0.9992268319191595,0.0007731680808389144,"No",0.00426810448039736,0.9957318955195973,"No",0.9999999128636187,8.713637690488194e-08,"No",0.9884309317869238,0.011569068213073413,"No"
"2012-005078-70","Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)A randomized multidisciplinary multinational AIO/DGAV/DGVS phase III trial.","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5434797996668418e-41,2.779074780593296e-05,0.9999722092521821,"2+",1.564036234847181e-05,0.9999843596376498,"Yes",0.9999837115785079,1.628842150064625e-05,"No",0.9999999957632896,4.236710785950134e-09,"No",8.272254004627293e-05,0.9999172774599656,"No",0.9692677572118226,0.030732242788164103,"No",0.9999999997750706,2.2492986681303586e-10,"No",3.717376030777128e-06,0.9999962826239569,"Yes"
"2012-005078-70","Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)A randomized multidisciplinary multinational AIO/DGAV/DGVS phase III trial.","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5434797996668418e-41,2.779074780593296e-05,0.9999722092521821,"2+",1.564036234847181e-05,0.9999843596376498,"Yes",0.9999837115785079,1.628842150064625e-05,"No",0.9999999957632896,4.236710785950134e-09,"No",8.272254004627293e-05,0.9999172774599656,"No",0.9692677572118226,0.030732242788164103,"No",0.9999999997750706,2.2492986681303586e-10,"No",3.717376030777128e-06,0.9999962826239569,"Yes"
"2012-005078-70","Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)A randomized multidisciplinary multinational AIO/DGAV/DGVS phase III trial.","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5434797996668418e-41,2.779074780593296e-05,0.9999722092521821,"2+",1.564036234847181e-05,0.9999843596376498,"Yes",0.9999837115785079,1.628842150064625e-05,"No",0.9999999957632896,4.236710785950134e-09,"No",8.272254004627293e-05,0.9999172774599656,"No",0.9692677572118226,0.030732242788164103,"No",0.9999999997750706,2.2492986681303586e-10,"No",3.717376030777128e-06,0.9999962826239569,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple MyelomaEnsayo en fase III abierto aleatorizado de carfilzomib melfalán y prednisona frente a bortezomib melfalán y prednisona en pacientes no aptos para trasplante con mieloma múltiple de nuevo diagnóstico","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.8439898484372108e-68,3.1075098994463334e-09,0.999999996892484,"2+",5.298134487097283e-22,1.0,"Yes",1.0,1.3337204882152314e-21,"No",1.0,6.255750048891694e-34,"No",6.31410118446193e-05,0.9999368589881573,"Yes",0.9947917787987262,0.005208221201276511,"Yes",1.0,1.2926854005595963e-25,"No",2.609271164523703e-07,0.9999997390728822,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple MyelomaРандомизирано открито фаза 3 изпитване на Карфилзомиб Мелфалан и Преднизон в сравнение с Бортезомиб Мелфалан и Преднизон при пациенти с новодиагностициран множествен миелом които не са подходящи за трансплантация","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2573990254835854e-40,0.00037295863576712954,0.9996270413642216,"2+",8.433935023311603e-12,0.9999999999915589,"Yes",0.9999999999862723,1.3728735556752007e-11,"No",1.0,1.5114236207282842e-21,"No",0.4585302478505422,0.5414697521494459,"Yes",0.9128138495515599,0.08718615044844998,"Yes",0.9999999999999147,7.6454705408406e-14,"No",0.001534392427255798,0.9984656075727422,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple MyelomaРандомизирано открито фаза 3 изпитване на Карфилзомиб Мелфалан и Преднизон в сравнение с Бортезомиб Мелфалан и Преднизон при пациенти с новодиагностициран множествен миелом които не са подходящи за трансплантация","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2573990254835854e-40,0.00037295863576712954,0.9996270413642216,"2+",8.433935023311603e-12,0.9999999999915589,"Yes",0.9999999999862723,1.3728735556752007e-11,"No",1.0,1.5114236207282842e-21,"No",0.4585302478505422,0.5414697521494459,"Yes",0.9128138495515599,0.08718615044844998,"Yes",0.9999999999999147,7.6454705408406e-14,"No",0.001534392427255798,0.9984656075727422,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple MyelomaРандомизирано открито фаза 3 изпитване на Карфилзомиб Мелфалан и Преднизон в сравнение с Бортезомиб Мелфалан и Преднизон при пациенти с новодиагностициран множествен миелом които не са подходящи за трансплантация","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2573990254835854e-40,0.00037295863576712954,0.9996270413642216,"2+",8.433935023311603e-12,0.9999999999915589,"Yes",0.9999999999862723,1.3728735556752007e-11,"No",1.0,1.5114236207282842e-21,"No",0.4585302478505422,0.5414697521494459,"Yes",0.9128138495515599,0.08718615044844998,"Yes",0.9999999999999147,7.6454705408406e-14,"No",0.001534392427255798,0.9984656075727422,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple MyelomaEnsayo en fase III abierto aleatorizado de carfilzomib melfalán y prednisona frente a bortezomib melfalán y prednisona en pacientes no aptos para trasplante con mieloma múltiple de nuevo diagnóstico","BG","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.8439898484372108e-68,3.1075098994463334e-09,0.999999996892484,"2+",5.298134487097283e-22,1.0,"Yes",1.0,1.3337204882152314e-21,"No",1.0,6.255750048891694e-34,"No",6.31410118446193e-05,0.9999368589881573,"Yes",0.9947917787987262,0.005208221201276511,"Yes",1.0,1.2926854005595963e-25,"No",2.609271164523703e-07,0.9999997390728822,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple MyelomaРандомизирано открито фаза 3 изпитване на Карфилзомиб Мелфалан и Преднизон в сравнение с Бортезомиб Мелфалан и Преднизон при пациенти с новодиагностициран множествен миелом които не са подходящи за трансплантация","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2573990254835854e-40,0.00037295863576712954,0.9996270413642216,"2+",8.433935023311603e-12,0.9999999999915589,"Yes",0.9999999999862723,1.3728735556752007e-11,"No",1.0,1.5114236207282842e-21,"No",0.4585302478505422,0.5414697521494459,"Yes",0.9128138495515599,0.08718615044844998,"Yes",0.9999999999999147,7.6454705408406e-14,"No",0.001534392427255798,0.9984656075727422,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma","NL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.4611622194229304e-37,0.0008304103299550167,0.9991695896700586,"2+",6.5839760822045615e-12,0.9999999999934062,"Yes",0.9999999999891998,1.0788588990412155e-11,"No",1.0,1.5494029684056291e-21,"No",0.6498917220683678,0.35010827793164245,"Yes",0.9237133387297363,0.07628666127027321,"Yes",0.9999999999999147,7.270811882740877e-14,"No",0.002855056017314286,0.9971449439826877,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.4611622194229304e-37,0.0008304103299550167,0.9991695896700586,"2+",6.5839760822045615e-12,0.9999999999934062,"Yes",0.9999999999891998,1.0788588990412155e-11,"No",1.0,1.5494029684056291e-21,"No",0.6498917220683678,0.35010827793164245,"Yes",0.9237133387297363,0.07628666127027321,"Yes",0.9999999999999147,7.270811882740877e-14,"No",0.002855056017314286,0.9971449439826877,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple MyelomaРандомизирано открито фаза 3 изпитване на Карфилзомиб Мелфалан и Преднизон в сравнение с Бортезомиб Мелфалан и Преднизон при пациенти с новодиагностициран множествен миелом които не са подходящи за трансплантация","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2573990254835854e-40,0.00037295863576712954,0.9996270413642216,"2+",8.433935023311603e-12,0.9999999999915589,"Yes",0.9999999999862723,1.3728735556752007e-11,"No",1.0,1.5114236207282842e-21,"No",0.4585302478505422,0.5414697521494459,"Yes",0.9128138495515599,0.08718615044844998,"Yes",0.9999999999999147,7.6454705408406e-14,"No",0.001534392427255798,0.9984656075727422,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple MyelomaРандомизирано открито фаза 3 изпитване на Карфилзомиб Мелфалан и Преднизон в сравнение с Бортезомиб Мелфалан и Преднизон при пациенти с новодиагностициран множествен миелом които не са подходящи за трансплантация","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2573990254835854e-40,0.00037295863576712954,0.9996270413642216,"2+",8.433935023311603e-12,0.9999999999915589,"Yes",0.9999999999862723,1.3728735556752007e-11,"No",1.0,1.5114236207282842e-21,"No",0.4585302478505422,0.5414697521494459,"Yes",0.9128138495515599,0.08718615044844998,"Yes",0.9999999999999147,7.6454705408406e-14,"No",0.001534392427255798,0.9984656075727422,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple MyelomaРандомизирано открито фаза 3 изпитване на Карфилзомиб Мелфалан и Преднизон в сравнение с Бортезомиб Мелфалан и Преднизон при пациенти с новодиагностициран множествен миелом които не са подходящи за трансплантация","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2573990254835854e-40,0.00037295863576712954,0.9996270413642216,"2+",8.433935023311603e-12,0.9999999999915589,"Yes",0.9999999999862723,1.3728735556752007e-11,"No",1.0,1.5114236207282842e-21,"No",0.4585302478505422,0.5414697521494459,"Yes",0.9128138495515599,0.08718615044844998,"Yes",0.9999999999999147,7.6454705408406e-14,"No",0.001534392427255798,0.9984656075727422,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple MyelomaРандомизирано открито фаза 3 изпитване на Карфилзомиб Мелфалан и Преднизон в сравнение с Бортезомиб Мелфалан и Преднизон при пациенти с новодиагностициран множествен миелом които не са подходящи за трансплантация","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2573990254835854e-40,0.00037295863576712954,0.9996270413642216,"2+",8.433935023311603e-12,0.9999999999915589,"Yes",0.9999999999862723,1.3728735556752007e-11,"No",1.0,1.5114236207282842e-21,"No",0.4585302478505422,0.5414697521494459,"Yes",0.9128138495515599,0.08718615044844998,"Yes",0.9999999999999147,7.6454705408406e-14,"No",0.001534392427255798,0.9984656075727422,"Yes"
"2012-005283-97","A Randomized Open-label Phase 3 Study of Carfilzomib Melphalan and Prednisone versus Bortezomib Melphalan and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple MyelomaРандомизирано открито фаза 3 изпитване на Карфилзомиб Мелфалан и Преднизон в сравнение с Бортезомиб Мелфалан и Преднизон при пациенти с новодиагностициран множествен миелом които не са подходящи за трансплантация","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2573990254835854e-40,0.00037295863576712954,0.9996270413642216,"2+",8.433935023311603e-12,0.9999999999915589,"Yes",0.9999999999862723,1.3728735556752007e-11,"No",1.0,1.5114236207282842e-21,"No",0.4585302478505422,0.5414697521494459,"Yes",0.9128138495515599,0.08718615044844998,"Yes",0.9999999999999147,7.6454705408406e-14,"No",0.001534392427255798,0.9984656075727422,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Estudio multicéntrico aleatorizado doble ciego  para evaluar la eficacia y seguridad de añadir mirabegrón a solifenacina en pacientes con vejiga hiperactiva (VH) incontinentes que han recibido solifenacina 4 semanas y requieren un alivio adicional de sus síntomas de vejiga hiperactiva","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.680399729432997e-75,1.4481864813754495e-13,0.9999999999998295,"2+",1.0,1.226525165304362e-15,"No",4.835028199101272e-13,0.9999999999994884,"Yes",1.0,4.0321434022163386e-27,"No",5.578303358620818e-19,1.0,"Yes",3.880310098705207e-06,0.999996119689879,"Yes",1.0,1.7544573372281692e-20,"No",4.6526538873963513e-14,0.9999999999999432,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Randomizované dvojito zaslepené multicentrické klinické skúšanie na zhodnotenie účinnosti a bezpečnosti pridania mirabegronu k solifenacínu u inkontinentných pacientov s hyperaktívnym močovým mechúrom (OAB) ktorí užívali solifenacín počas štyroch týždňov a požadujú ďalšiu úľavu od príznakov OAB.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.8893692774368306e-73,6.550016019639375e-22,1.0,"2+",1.0,3.1160088258421444e-26,"No",2.3905958277482196e-26,1.0,"Yes",1.0,9.815956685985745e-41,"No",2.995619092405698e-28,1.0,"Yes",3.5130856828458576e-11,0.9999999999648708,"Yes",1.0,1.942898160558797e-30,"No",1.531345309554177e-23,1.0,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.","NO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.385667040945799e-35,3.8594604676861416e-08,0.9999999614053942,"2+",0.9999999999514273,4.8572879533669235e-11,"No",1.2954168854686272e-10,0.999999999870454,"Yes",1.0,1.3174843953830084e-16,"No",3.753827195800673e-11,0.9999999999624549,"Yes",0.0006889246107498882,0.9993110753892568,"Yes",0.9999960222579135,3.977742093584945e-06,"No",9.003734999433412e-08,0.9999999099626434,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.385667040945799e-35,3.8594604676861416e-08,0.9999999614053942,"2+",0.9999999999514273,4.8572879533669235e-11,"No",1.2954168854686272e-10,0.999999999870454,"Yes",1.0,1.3174843953830084e-16,"No",3.753827195800673e-11,0.9999999999624549,"Yes",0.0006889246107498882,0.9993110753892568,"Yes",0.9999960222579135,3.977742093584945e-06,"No",9.003734999433412e-08,0.9999999099626434,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Randomizované dvojito zaslepené multicentrické klinické skúšanie na zhodnotenie účinnosti a bezpečnosti pridania mirabegronu k solifenacínu u inkontinentných pacientov s hyperaktívnym močovým mechúrom (OAB) ktorí užívali solifenacín počas štyroch týždňov a požadujú ďalšiu úľavu od príznakov OAB.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.8893692774368306e-73,6.550016019639375e-22,1.0,"2+",1.0,3.1160088258421444e-26,"No",2.3905958277482196e-26,1.0,"Yes",1.0,9.815956685985745e-41,"No",2.995619092405698e-28,1.0,"Yes",3.5130856828458576e-11,0.9999999999648708,"Yes",1.0,1.942898160558797e-30,"No",1.531345309554177e-23,1.0,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.385667040945799e-35,3.8594604676861416e-08,0.9999999614053942,"2+",0.9999999999514273,4.8572879533669235e-11,"No",1.2954168854686272e-10,0.999999999870454,"Yes",1.0,1.3174843953830084e-16,"No",3.753827195800673e-11,0.9999999999624549,"Yes",0.0006889246107498882,0.9993110753892568,"Yes",0.9999960222579135,3.977742093584945e-06,"No",9.003734999433412e-08,0.9999999099626434,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Randomizowane prowadzone metodą podwójnie ślepej próby wieloośrodkowe badanie kliniczne oceniające skuteczność i bezpieczeństwo stosowania mirabegronu z solifencyną u chorych z nietrzymaniem moczu w przebiegu pęcherza nadreaktywnego (OAB) leczonych przez cztery tygodnie solifenacyną i wymagających dodatkowego złagodzenia objawów OAB.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.5445888678858495e-65,1.376588720916104e-21,1.0,"2+",1.0,8.764703200576821e-20,"No",4.3441147125248455e-20,1.0,"Yes",1.0,1.4979118176855778e-44,"No",1.2131492657196075e-24,1.0,"Yes",6.686533185430406e-08,0.9999999331346908,"Yes",1.0,6.4128777961818294e-24,"No",3.223398936246261e-21,1.0,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Een gerandomizeerd dubbelblind multicenter onderzoek ter beoordeling van de werkzaamheid en veiligheid van de toevoeging van Mirabegron aan Solifenacine in incontinente OAB proefpersonen die 4 weken met Solifenacine zijn behandeld en additionele verlichting vragen/wensen voor hun OAB symptomen.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7275072194457432e-66,5.0504163143882264e-17,1.0,"2+",1.0,1.4653565560467656e-19,"No",4.675673184028575e-19,1.0,"Yes",1.0,5.562089562329543e-27,"No",3.7499867325238504e-23,1.0,"Yes",2.1823963054638408e-05,0.9999781760369337,"Yes",1.0,2.335465355108451e-15,"No",2.822109374132799e-15,1.0,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Een gerandomizeerd dubbelblind multicenter onderzoek ter beoordeling van de werkzaamheid en veiligheid van de toevoeging van Mirabegron aan Solifenacine in incontinente OAB proefpersonen die 4 weken met Solifenacine zijn behandeld en additionele verlichting vragen/wensen voor hun OAB symptomen.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7275072194457432e-66,5.0504163143882264e-17,1.0,"2+",1.0,1.4653565560467656e-19,"No",4.675673184028575e-19,1.0,"Yes",1.0,5.562089562329543e-27,"No",3.7499867325238504e-23,1.0,"Yes",2.1823963054638408e-05,0.9999781760369337,"Yes",1.0,2.335465355108451e-15,"No",2.822109374132799e-15,1.0,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Estudio multicéntrico aleatorizado doble ciego  para evaluar la eficacia y seguridad de añadir mirabegrón a solifenacina en pacientes con vejiga hiperactiva (VH) incontinentes que han recibido solifenacina 4 semanas y requieren un alivio adicional de sus síntomas de vejiga hiperactiva","IE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.680399729432997e-75,1.4481864813754495e-13,0.9999999999998295,"2+",1.0,1.226525165304362e-15,"No",4.835028199101272e-13,0.9999999999994884,"Yes",1.0,4.0321434022163386e-27,"No",5.578303358620818e-19,1.0,"Yes",3.880310098705207e-06,0.999996119689879,"Yes",1.0,1.7544573372281692e-20,"No",4.6526538873963513e-14,0.9999999999999432,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Randomizowane prowadzone metodą podwójnie ślepej próby wieloośrodkowe badanie kliniczne oceniające skuteczność i bezpieczeństwo stosowania mirabegronu z solifencyną u chorych z nietrzymaniem moczu w przebiegu pęcherza nadreaktywnego (OAB) leczonych przez cztery tygodnie solifenacyną i wymagających dodatkowego złagodzenia objawów OAB.","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.5445888678858495e-65,1.376588720916104e-21,1.0,"2+",1.0,8.764703200576821e-20,"No",4.3441147125248455e-20,1.0,"Yes",1.0,1.4979118176855778e-44,"No",1.2131492657196075e-24,1.0,"Yes",6.686533185430406e-08,0.9999999331346908,"Yes",1.0,6.4128777961818294e-24,"No",3.223398936246261e-21,1.0,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Estudio multicéntrico aleatorizado doble ciego  para evaluar la eficacia y seguridad de añadir mirabegrón a solifenacina en pacientes con vejiga hiperactiva (VH) incontinentes que han recibido solifenacina 4 semanas y requieren un alivio adicional de sus síntomas de vejiga hiperactiva","SI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.680399729432997e-75,1.4481864813754495e-13,0.9999999999998295,"2+",1.0,1.226525165304362e-15,"No",4.835028199101272e-13,0.9999999999994884,"Yes",1.0,4.0321434022163386e-27,"No",5.578303358620818e-19,1.0,"Yes",3.880310098705207e-06,0.999996119689879,"Yes",1.0,1.7544573372281692e-20,"No",4.6526538873963513e-14,0.9999999999999432,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.385667040945799e-35,3.8594604676861416e-08,0.9999999614053942,"2+",0.9999999999514273,4.8572879533669235e-11,"No",1.2954168854686272e-10,0.999999999870454,"Yes",1.0,1.3174843953830084e-16,"No",3.753827195800673e-11,0.9999999999624549,"Yes",0.0006889246107498882,0.9993110753892568,"Yes",0.9999960222579135,3.977742093584945e-06,"No",9.003734999433412e-08,0.9999999099626434,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.385667040945799e-35,3.8594604676861416e-08,0.9999999614053942,"2+",0.9999999999514273,4.8572879533669235e-11,"No",1.2954168854686272e-10,0.999999999870454,"Yes",1.0,1.3174843953830084e-16,"No",3.753827195800673e-11,0.9999999999624549,"Yes",0.0006889246107498882,0.9993110753892568,"Yes",0.9999960222579135,3.977742093584945e-06,"No",9.003734999433412e-08,0.9999999099626434,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.385667040945799e-35,3.8594604676861416e-08,0.9999999614053942,"2+",0.9999999999514273,4.8572879533669235e-11,"No",1.2954168854686272e-10,0.999999999870454,"Yes",1.0,1.3174843953830084e-16,"No",3.753827195800673e-11,0.9999999999624549,"Yes",0.0006889246107498882,0.9993110753892568,"Yes",0.9999960222579135,3.977742093584945e-06,"No",9.003734999433412e-08,0.9999999099626434,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Randomizowane prowadzone metodą podwójnie ślepej próby wieloośrodkowe badanie kliniczne oceniające skuteczność i bezpieczeństwo stosowania mirabegronu z solifencyną u chorych z nietrzymaniem moczu w przebiegu pęcherza nadreaktywnego (OAB) leczonych przez cztery tygodnie solifenacyną i wymagających dodatkowego złagodzenia objawów OAB.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.5445888678858495e-65,1.376588720916104e-21,1.0,"2+",1.0,8.764703200576821e-20,"No",4.3441147125248455e-20,1.0,"Yes",1.0,1.4979118176855778e-44,"No",1.2131492657196075e-24,1.0,"Yes",6.686533185430406e-08,0.9999999331346908,"Yes",1.0,6.4128777961818294e-24,"No",3.223398936246261e-21,1.0,"Yes"
"2012-005401-41","A Randomized Double-Blind Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms.Randomizované dvojito zaslepené multicentrické klinické skúšanie na zhodnotenie účinnosti a bezpečnosti pridania mirabegronu k solifenacínu u inkontinentných pacientov s hyperaktívnym močovým mechúrom (OAB) ktorí užívali solifenacín počas štyroch týždňov a požadujú ďalšiu úľavu od príznakov OAB.","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.8893692774368306e-73,6.550016019639375e-22,1.0,"2+",1.0,3.1160088258421444e-26,"No",2.3905958277482196e-26,1.0,"Yes",1.0,9.815956685985745e-41,"No",2.995619092405698e-28,1.0,"Yes",3.5130856828458576e-11,0.9999999999648708,"Yes",1.0,1.942898160558797e-30,"No",1.531345309554177e-23,1.0,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate CancerEstudio multinacional de fase  III aleatorizado con doble enmascaramiento y controlado con placebo de la eficacia y la seguridad de la enzalutamida en los pacientes con cáncer de próstata no metastatizante resistente a la castración","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.838517419988392e-76,6.358607842315774e-10,0.9999999993641496,"2+",0.999999998374733,1.6252519889604585e-09,"No",1.2182640899303273e-08,0.9999999878173754,"Yes",1.0,1.4017066305328273e-19,"No",9.34521163334896e-10,0.9999999990654942,"Yes",0.16238271935225548,0.8376172806477201,"Yes",0.9999999999097896,9.021858195847844e-11,"No",1.3858347220962855e-08,0.9999999861416314,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate CancerStudio multinazionale di fase 3 randomizzato in doppio cieco controllato con placebo teso a valutare l'efficacia e la sicurezza dell'enzalutamide in pazienti affetti da cancro della prostata non metastatico resistente alla castrazione","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.307853918387282e-92,1.0874544204679943e-10,0.9999999998912585,"2+",0.9999999801703441,1.9829658686293903e-08,"No",2.320232112081243e-07,0.9999997679767872,"Yes",1.0,1.2605760821473015e-22,"No",6.196928895720172e-11,0.9999999999380407,"Yes",6.912168219341353e-05,0.9999308783177965,"Yes",0.9999999788589096,2.1141094802108646e-08,"No",1.8458678296320263e-10,0.9999999998154294,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8600452293778836e-39,3.871274654238581e-06,0.999996128725347,"2+",0.99999625913218,3.740867822705563e-06,"No",1.271229350528086e-05,0.9999872877064878,"Yes",0.999999996896051,3.1039524385161016e-09,"No",9.469406289180126e-06,0.9999905305937061,"Yes",0.14409344269766994,0.8559065573023253,"Yes",0.9944185118196808,0.00558148818031289,"No",2.2834254445721642e-05,0.9999771657455557,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8600452293778836e-39,3.871274654238581e-06,0.999996128725347,"2+",0.99999625913218,3.740867822705563e-06,"No",1.271229350528086e-05,0.9999872877064878,"Yes",0.999999996896051,3.1039524385161016e-09,"No",9.469406289180126e-06,0.9999905305937061,"Yes",0.14409344269766994,0.8559065573023253,"Yes",0.9944185118196808,0.00558148818031289,"No",2.2834254445721642e-05,0.9999771657455557,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8600452293778836e-39,3.871274654238581e-06,0.999996128725347,"2+",0.99999625913218,3.740867822705563e-06,"No",1.271229350528086e-05,0.9999872877064878,"Yes",0.999999996896051,3.1039524385161016e-09,"No",9.469406289180126e-06,0.9999905305937061,"Yes",0.14409344269766994,0.8559065573023253,"Yes",0.9944185118196808,0.00558148818031289,"No",2.2834254445721642e-05,0.9999771657455557,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate CancerStudio multinazionale di fase 3 randomizzato in doppio cieco controllato con placebo teso a valutare l'efficacia e la sicurezza dell'enzalutamide in pazienti affetti da cancro della prostata non metastatico resistente alla castrazione","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.307853918387282e-92,1.0874544204679943e-10,0.9999999998912585,"2+",0.9999999801703441,1.9829658686293903e-08,"No",2.320232112081243e-07,0.9999997679767872,"Yes",1.0,1.2605760821473015e-22,"No",6.196928895720172e-11,0.9999999999380407,"Yes",6.912168219341353e-05,0.9999308783177965,"Yes",0.9999999788589096,2.1141094802108646e-08,"No",1.8458678296320263e-10,0.9999999998154294,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate CancerStudio multinazionale di fase 3 randomizzato in doppio cieco controllato con placebo teso a valutare l'efficacia e la sicurezza dell'enzalutamide in pazienti affetti da cancro della prostata non metastatico resistente alla castrazione","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.307853918387282e-92,1.0874544204679943e-10,0.9999999998912585,"2+",0.9999999801703441,1.9829658686293903e-08,"No",2.320232112081243e-07,0.9999997679767872,"Yes",1.0,1.2605760821473015e-22,"No",6.196928895720172e-11,0.9999999999380407,"Yes",6.912168219341353e-05,0.9999308783177965,"Yes",0.9999999788589096,2.1141094802108646e-08,"No",1.8458678296320263e-10,0.9999999998154294,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate CancerEstudio multinacional de fase  III aleatorizado con doble enmascaramiento y controlado con placebo de la eficacia y la seguridad de la enzalutamida en los pacientes con cáncer de próstata no metastatizante resistente a la castración","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.838517419988392e-76,6.358607842315774e-10,0.9999999993641496,"2+",0.999999998374733,1.6252519889604585e-09,"No",1.2182640899303273e-08,0.9999999878173754,"Yes",1.0,1.4017066305328273e-19,"No",9.34521163334896e-10,0.9999999990654942,"Yes",0.16238271935225548,0.8376172806477201,"Yes",0.9999999999097896,9.021858195847844e-11,"No",1.3858347220962855e-08,0.9999999861416314,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate CancerStudio multinazionale di fase 3 randomizzato in doppio cieco controllato con placebo teso a valutare l'efficacia e la sicurezza dell'enzalutamide in pazienti affetti da cancro della prostata non metastatico resistente alla castrazione","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.307853918387282e-92,1.0874544204679943e-10,0.9999999998912585,"2+",0.9999999801703441,1.9829658686293903e-08,"No",2.320232112081243e-07,0.9999997679767872,"Yes",1.0,1.2605760821473015e-22,"No",6.196928895720172e-11,0.9999999999380407,"Yes",6.912168219341353e-05,0.9999308783177965,"Yes",0.9999999788589096,2.1141094802108646e-08,"No",1.8458678296320263e-10,0.9999999998154294,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate CancerStudio multinazionale di fase 3 randomizzato in doppio cieco controllato con placebo teso a valutare l'efficacia e la sicurezza dell'enzalutamide in pazienti affetti da cancro della prostata non metastatico resistente alla castrazione","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.307853918387282e-92,1.0874544204679943e-10,0.9999999998912585,"2+",0.9999999801703441,1.9829658686293903e-08,"No",2.320232112081243e-07,0.9999997679767872,"Yes",1.0,1.2605760821473015e-22,"No",6.196928895720172e-11,0.9999999999380407,"Yes",6.912168219341353e-05,0.9999308783177965,"Yes",0.9999999788589096,2.1141094802108646e-08,"No",1.8458678296320263e-10,0.9999999998154294,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate CancerEstudio multinacional de fase  III aleatorizado con doble enmascaramiento y controlado con placebo de la eficacia y la seguridad de la enzalutamida en los pacientes con cáncer de próstata no metastatizante resistente a la castración","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.838517419988392e-76,6.358607842315774e-10,0.9999999993641496,"2+",0.999999998374733,1.6252519889604585e-09,"No",1.2182640899303273e-08,0.9999999878173754,"Yes",1.0,1.4017066305328273e-19,"No",9.34521163334896e-10,0.9999999990654942,"Yes",0.16238271935225548,0.8376172806477201,"Yes",0.9999999999097896,9.021858195847844e-11,"No",1.3858347220962855e-08,0.9999999861416314,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate CancerEstudio multinacional de fase  III aleatorizado con doble enmascaramiento y controlado con placebo de la eficacia y la seguridad de la enzalutamida en los pacientes con cáncer de próstata no metastatizante resistente a la castración","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.838517419988392e-76,6.358607842315774e-10,0.9999999993641496,"2+",0.999999998374733,1.6252519889604585e-09,"No",1.2182640899303273e-08,0.9999999878173754,"Yes",1.0,1.4017066305328273e-19,"No",9.34521163334896e-10,0.9999999990654942,"Yes",0.16238271935225548,0.8376172806477201,"Yes",0.9999999999097896,9.021858195847844e-11,"No",1.3858347220962855e-08,0.9999999861416314,"Yes"
"2012-005665-12","A Multinational Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8600452293778836e-39,3.871274654238581e-06,0.999996128725347,"2+",0.99999625913218,3.740867822705563e-06,"No",1.271229350528086e-05,0.9999872877064878,"Yes",0.999999996896051,3.1039524385161016e-09,"No",9.469406289180126e-06,0.9999905305937061,"Yes",0.14409344269766994,0.8559065573023253,"Yes",0.9944185118196808,0.00558148818031289,"No",2.2834254445721642e-05,0.9999771657455557,"Yes"
"2012-005694-31","Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised Double-Masked Placebo-Controlled Multi-Centre Proof-of-Concept Study","DE","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2469416713036212e-35,3.4349508166400565e-14,0.9999999999999717,"2+",0.9999999999985221,1.4747365813395515e-12,"No",2.9198721906442814e-10,0.9999999997080239,"Yes",0.8213737993555571,0.1786262006444345,"No",1.5208051592031227e-12,0.9999999999984652,"Yes",9.169399004259188e-06,0.9999908306009822,"Yes",0.4467496484452525,0.5532503515547524,"No",4.359441658366375e-12,0.9999999999956515,"Yes"
"2012-005694-31","Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised Double-Masked Placebo-Controlled Multi-Centre Proof-of-Concept Study","PL","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2469416713036212e-35,3.4349508166400565e-14,0.9999999999999717,"2+",0.9999999999985221,1.4747365813395515e-12,"No",2.9198721906442814e-10,0.9999999997080239,"Yes",0.8213737993555571,0.1786262006444345,"No",1.5208051592031227e-12,0.9999999999984652,"Yes",9.169399004259188e-06,0.9999908306009822,"Yes",0.4467496484452525,0.5532503515547524,"No",4.359441658366375e-12,0.9999999999956515,"Yes"
"2012-005694-31","Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised Double-Masked Placebo-Controlled Multi-Centre Proof-of-Concept Study","SE","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2469416713036212e-35,3.4349508166400565e-14,0.9999999999999717,"2+",0.9999999999985221,1.4747365813395515e-12,"No",2.9198721906442814e-10,0.9999999997080239,"Yes",0.8213737993555571,0.1786262006444345,"No",1.5208051592031227e-12,0.9999999999984652,"Yes",9.169399004259188e-06,0.9999908306009822,"Yes",0.4467496484452525,0.5532503515547524,"No",4.359441658366375e-12,0.9999999999956515,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive BladderEstudio aleatorizado doble ciego de grupos paralelos controlado con placebo y con comparador activo y multicéntrico para la evaluación de la eficacia  seguridad y tolerabilidad de combinaciones de succinato de solifenacina y Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en el tratamiento de vejiga hiperactiva","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.0352334075014684e-98,6.50149640984137e-23,1.0,"2+",1.0,2.482646980639667e-20,"No",4.53167001486101e-19,1.0,"Yes",1.0,1.719861588791511e-22,"No",8.4544864115465e-26,1.0,"Yes",1.868802578521388e-08,0.9999999813119873,"Yes",1.0,2.627262604672291e-23,"No",2.2164932136551454e-18,1.0,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive BladderEstudio aleatorizado doble ciego de grupos paralelos controlado con placebo y con comparador activo y multicéntrico para la evaluación de la eficacia  seguridad y tolerabilidad de combinaciones de succinato de solifenacina y Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en el tratamiento de vejiga hiperactiva","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.0352334075014684e-98,6.50149640984137e-23,1.0,"2+",1.0,2.482646980639667e-20,"No",4.53167001486101e-19,1.0,"Yes",1.0,1.719861588791511e-22,"No",8.4544864115465e-26,1.0,"Yes",1.868802578521388e-08,0.9999999813119873,"Yes",1.0,2.627262604672291e-23,"No",2.2164932136551454e-18,1.0,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive BladderEstudio aleatorizado doble ciego de grupos paralelos controlado con placebo y con comparador activo y multicéntrico para la evaluación de la eficacia  seguridad y tolerabilidad de combinaciones de succinato de solifenacina y Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en el tratamiento de vejiga hiperactiva","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.0352334075014684e-98,6.50149640984137e-23,1.0,"2+",1.0,2.482646980639667e-20,"No",4.53167001486101e-19,1.0,"Yes",1.0,1.719861588791511e-22,"No",8.4544864115465e-26,1.0,"Yes",1.868802578521388e-08,0.9999999813119873,"Yes",1.0,2.627262604672291e-23,"No",2.2164932136551454e-18,1.0,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive BladderEstudio aleatorizado doble ciego de grupos paralelos controlado con placebo y con comparador activo y multicéntrico para la evaluación de la eficacia  seguridad y tolerabilidad de combinaciones de succinato de solifenacina y Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en el tratamiento de vejiga hiperactiva","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.0352334075014684e-98,6.50149640984137e-23,1.0,"2+",1.0,2.482646980639667e-20,"No",4.53167001486101e-19,1.0,"Yes",1.0,1.719861588791511e-22,"No",8.4544864115465e-26,1.0,"Yes",1.868802578521388e-08,0.9999999813119873,"Yes",1.0,2.627262604672291e-23,"No",2.2164932136551454e-18,1.0,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive BladderEstudio aleatorizado doble ciego de grupos paralelos controlado con placebo y con comparador activo y multicéntrico para la evaluación de la eficacia  seguridad y tolerabilidad de combinaciones de succinato de solifenacina y Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en el tratamiento de vejiga hiperactiva","SI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.0352334075014684e-98,6.50149640984137e-23,1.0,"2+",1.0,2.482646980639667e-20,"No",4.53167001486101e-19,1.0,"Yes",1.0,1.719861588791511e-22,"No",8.4544864115465e-26,1.0,"Yes",1.868802578521388e-08,0.9999999813119873,"Yes",1.0,2.627262604672291e-23,"No",2.2164932136551454e-18,1.0,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive BladderEstudio aleatorizado doble ciego de grupos paralelos controlado con placebo y con comparador activo y multicéntrico para la evaluación de la eficacia  seguridad y tolerabilidad de combinaciones de succinato de solifenacina y Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en el tratamiento de vejiga hiperactiva","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.0352334075014684e-98,6.50149640984137e-23,1.0,"2+",1.0,2.482646980639667e-20,"No",4.53167001486101e-19,1.0,"Yes",1.0,1.719861588791511e-22,"No",8.4544864115465e-26,1.0,"Yes",1.868802578521388e-08,0.9999999813119873,"Yes",1.0,2.627262604672291e-23,"No",2.2164932136551454e-18,1.0,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","EE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005735-91","A Randomized Double-Blind Parallel-Group Placebo- and Active-Controlled Multi-center Study to Evaluate the Efficacy Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0577570044521716e-51,5.79023211284949e-11,0.9999999999421051,"2+",0.9999999999997727,2.2258385748256863e-13,"No",7.273281320880897e-13,0.999999999999261,"Yes",1.0,2.9981634121624365e-15,"No",1.419899922620713e-11,0.9999999999857893,"Yes",0.001185452772398851,0.9988145472276004,"Yes",1.0,6.106533018124708e-15,"No",2.42374607663452e-09,0.9999999975762535,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder","SI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.859992701423923e-44,1.3891409248949466e-07,0.9999998610859205,"2+",0.9999999999378987,6.210561465604374e-11,"No",1.0927176808146545e-10,0.9999999998907185,"Yes",0.9999999999999147,7.882483112917483e-14,"No",1.0679932420433153e-08,0.9999999893200596,"Yes",0.012211736312081502,0.9877882636879073,"Yes",1.0,1.5009289999571403e-15,"No",1.5125003327316347e-06,0.9999984874996598,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.859992701423923e-44,1.3891409248949466e-07,0.9999998610859205,"2+",0.9999999999378987,6.210561465604374e-11,"No",1.0927176808146545e-10,0.9999999998907185,"Yes",0.9999999999999147,7.882483112917483e-14,"No",1.0679932420433153e-08,0.9999999893200596,"Yes",0.012211736312081502,0.9877882636879073,"Yes",1.0,1.5009289999571403e-15,"No",1.5125003327316347e-06,0.9999984874996598,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive BladderEstudio aleatorizado doble ciego de grupos paralelos control activo y multicéntrico para la evaluación de la seguridad y la eficacia a largo plazo de la combinación de succinato de solifenacina con Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en sujetos con vejiga hiperactiva","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0104971318124135e-84,1.7901664223001504e-13,0.9999999999998295,"2+",1.0,8.394880198511444e-15,"No",3.987583460205091e-14,0.9999999999999432,"Yes",1.0,9.789506377515567e-20,"No",2.448842433621911e-16,1.0,"Yes",5.7225005650205444e-05,0.9999427749943764,"Yes",1.0,1.308188008914634e-23,"No",1.1270693136316154e-11,0.999999999988745,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive BladderRandomizované dvojitě zaslepené multicentrické hodnocení s paralelními skupinami a kontrolou aktivní látkou ke stanovení dlouhodobé bezpečnosti a účinnosti kombinace solifenacin-sukcinátu s přípravkem Mirabegron ve srovnání s monoterapií solifenacin-sukcinátem a přípravkem Mirabegron u osob s hyperaktivním močovým měchýřem","EE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.5099835874402405e-94,2.1770588501648684e-18,1.0,"2+",1.0,1.4003066310838456e-20,"No",7.473438643718958e-21,1.0,"Yes",1.0,3.5145837430147244e-43,"No",2.565612491204108e-27,1.0,"Yes",2.2840255353329073e-06,0.9999977159744667,"Yes",1.0,1.490633533385029e-35,"No",3.045129056144826e-14,0.9999999999999432,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive BladderRandomizované dvojitě zaslepené multicentrické hodnocení s paralelními skupinami a kontrolou aktivní látkou ke stanovení dlouhodobé bezpečnosti a účinnosti kombinace solifenacin-sukcinátu s přípravkem Mirabegron ve srovnání s monoterapií solifenacin-sukcinátem a přípravkem Mirabegron u osob s hyperaktivním močovým měchýřem","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.5099835874402405e-94,2.1770588501648684e-18,1.0,"2+",1.0,1.4003066310838456e-20,"No",7.473438643718958e-21,1.0,"Yes",1.0,3.5145837430147244e-43,"No",2.565612491204108e-27,1.0,"Yes",2.2840255353329073e-06,0.9999977159744667,"Yes",1.0,1.490633533385029e-35,"No",3.045129056144826e-14,0.9999999999999432,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive BladderRandomizované dvojitě zaslepené multicentrické hodnocení s paralelními skupinami a kontrolou aktivní látkou ke stanovení dlouhodobé bezpečnosti a účinnosti kombinace solifenacin-sukcinátu s přípravkem Mirabegron ve srovnání s monoterapií solifenacin-sukcinátem a přípravkem Mirabegron u osob s hyperaktivním močovým měchýřem","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.5099835874402405e-94,2.1770588501648684e-18,1.0,"2+",1.0,1.4003066310838456e-20,"No",7.473438643718958e-21,1.0,"Yes",1.0,3.5145837430147244e-43,"No",2.565612491204108e-27,1.0,"Yes",2.2840255353329073e-06,0.9999977159744667,"Yes",1.0,1.490633533385029e-35,"No",3.045129056144826e-14,0.9999999999999432,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.859992701423923e-44,1.3891409248949466e-07,0.9999998610859205,"2+",0.9999999999378987,6.210561465604374e-11,"No",1.0927176808146545e-10,0.9999999998907185,"Yes",0.9999999999999147,7.882483112917483e-14,"No",1.0679932420433153e-08,0.9999999893200596,"Yes",0.012211736312081502,0.9877882636879073,"Yes",1.0,1.5009289999571403e-15,"No",1.5125003327316347e-06,0.9999984874996598,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive BladderRandomizované dvojitě zaslepené multicentrické hodnocení s paralelními skupinami a kontrolou aktivní látkou ke stanovení dlouhodobé bezpečnosti a účinnosti kombinace solifenacin-sukcinátu s přípravkem Mirabegron ve srovnání s monoterapií solifenacin-sukcinátem a přípravkem Mirabegron u osob s hyperaktivním močovým měchýřem","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.5099835874402405e-94,2.1770588501648684e-18,1.0,"2+",1.0,1.4003066310838456e-20,"No",7.473438643718958e-21,1.0,"Yes",1.0,3.5145837430147244e-43,"No",2.565612491204108e-27,1.0,"Yes",2.2840255353329073e-06,0.9999977159744667,"Yes",1.0,1.490633533385029e-35,"No",3.045129056144826e-14,0.9999999999999432,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive BladderEstudio aleatorizado doble ciego de grupos paralelos control activo y multicéntrico para la evaluación de la seguridad y la eficacia a largo plazo de la combinación de succinato de solifenacina con Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en sujetos con vejiga hiperactiva","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0104971318124135e-84,1.7901664223001504e-13,0.9999999999998295,"2+",1.0,8.394880198511444e-15,"No",3.987583460205091e-14,0.9999999999999432,"Yes",1.0,9.789506377515567e-20,"No",2.448842433621911e-16,1.0,"Yes",5.7225005650205444e-05,0.9999427749943764,"Yes",1.0,1.308188008914634e-23,"No",1.1270693136316154e-11,0.999999999988745,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive BladderRandomizované dvojitě zaslepené multicentrické hodnocení s paralelními skupinami a kontrolou aktivní látkou ke stanovení dlouhodobé bezpečnosti a účinnosti kombinace solifenacin-sukcinátu s přípravkem Mirabegron ve srovnání s monoterapií solifenacin-sukcinátem a přípravkem Mirabegron u osob s hyperaktivním močovým měchýřem","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.5099835874402405e-94,2.1770588501648684e-18,1.0,"2+",1.0,1.4003066310838456e-20,"No",7.473438643718958e-21,1.0,"Yes",1.0,3.5145837430147244e-43,"No",2.565612491204108e-27,1.0,"Yes",2.2840255353329073e-06,0.9999977159744667,"Yes",1.0,1.490633533385029e-35,"No",3.045129056144826e-14,0.9999999999999432,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.859992701423923e-44,1.3891409248949466e-07,0.9999998610859205,"2+",0.9999999999378987,6.210561465604374e-11,"No",1.0927176808146545e-10,0.9999999998907185,"Yes",0.9999999999999147,7.882483112917483e-14,"No",1.0679932420433153e-08,0.9999999893200596,"Yes",0.012211736312081502,0.9877882636879073,"Yes",1.0,1.5009289999571403e-15,"No",1.5125003327316347e-06,0.9999984874996598,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.859992701423923e-44,1.3891409248949466e-07,0.9999998610859205,"2+",0.9999999999378987,6.210561465604374e-11,"No",1.0927176808146545e-10,0.9999999998907185,"Yes",0.9999999999999147,7.882483112917483e-14,"No",1.0679932420433153e-08,0.9999999893200596,"Yes",0.012211736312081502,0.9877882636879073,"Yes",1.0,1.5009289999571403e-15,"No",1.5125003327316347e-06,0.9999984874996598,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive BladderEstudio aleatorizado doble ciego de grupos paralelos control activo y multicéntrico para la evaluación de la seguridad y la eficacia a largo plazo de la combinación de succinato de solifenacina con Mirabegron en comparación con monoterapias de succinato de solifenacina y de Mirabegron en sujetos con vejiga hiperactiva","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.0104971318124135e-84,1.7901664223001504e-13,0.9999999999998295,"2+",1.0,8.394880198511444e-15,"No",3.987583460205091e-14,0.9999999999999432,"Yes",1.0,9.789506377515567e-20,"No",2.448842433621911e-16,1.0,"Yes",5.7225005650205444e-05,0.9999427749943764,"Yes",1.0,1.308188008914634e-23,"No",1.1270693136316154e-11,0.999999999988745,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive BladderRandomizované dvojitě zaslepené multicentrické hodnocení s paralelními skupinami a kontrolou aktivní látkou ke stanovení dlouhodobé bezpečnosti a účinnosti kombinace solifenacin-sukcinátu s přípravkem Mirabegron ve srovnání s monoterapií solifenacin-sukcinátem a přípravkem Mirabegron u osob s hyperaktivním močovým měchýřem","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.5099835874402405e-94,2.1770588501648684e-18,1.0,"2+",1.0,1.4003066310838456e-20,"No",7.473438643718958e-21,1.0,"Yes",1.0,3.5145837430147244e-43,"No",2.565612491204108e-27,1.0,"Yes",2.2840255353329073e-06,0.9999977159744667,"Yes",1.0,1.490633533385029e-35,"No",3.045129056144826e-14,0.9999999999999432,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.859992701423923e-44,1.3891409248949466e-07,0.9999998610859205,"2+",0.9999999999378987,6.210561465604374e-11,"No",1.0927176808146545e-10,0.9999999998907185,"Yes",0.9999999999999147,7.882483112917483e-14,"No",1.0679932420433153e-08,0.9999999893200596,"Yes",0.012211736312081502,0.9877882636879073,"Yes",1.0,1.5009289999571403e-15,"No",1.5125003327316347e-06,0.9999984874996598,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.859992701423923e-44,1.3891409248949466e-07,0.9999998610859205,"2+",0.9999999999378987,6.210561465604374e-11,"No",1.0927176808146545e-10,0.9999999998907185,"Yes",0.9999999999999147,7.882483112917483e-14,"No",1.0679932420433153e-08,0.9999999893200596,"Yes",0.012211736312081502,0.9877882636879073,"Yes",1.0,1.5009289999571403e-15,"No",1.5125003327316347e-06,0.9999984874996598,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.859992701423923e-44,1.3891409248949466e-07,0.9999998610859205,"2+",0.9999999999378987,6.210561465604374e-11,"No",1.0927176808146545e-10,0.9999999998907185,"Yes",0.9999999999999147,7.882483112917483e-14,"No",1.0679932420433153e-08,0.9999999893200596,"Yes",0.012211736312081502,0.9877882636879073,"Yes",1.0,1.5009289999571403e-15,"No",1.5125003327316347e-06,0.9999984874996598,"Yes"
"2012-005736-29","A Randomized Double-Blind Parallel-Group Active-Controlled Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.859992701423923e-44,1.3891409248949466e-07,0.9999998610859205,"2+",0.9999999999378987,6.210561465604374e-11,"No",1.0927176808146545e-10,0.9999999998907185,"Yes",0.9999999999999147,7.882483112917483e-14,"No",1.0679932420433153e-08,0.9999999893200596,"Yes",0.012211736312081502,0.9877882636879073,"Yes",1.0,1.5009289999571403e-15,"No",1.5125003327316347e-06,0.9999984874996598,"Yes"
"2013-000068-27","A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-versus-Host Disease.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",3.201659157824038e-34,0.05845754268721167,0.941542457312778,"-1",0.0007696534209873799,0.9992303465790215,"Yes",0.9992983616456202,0.000701638354379202,"No",0.9999792475777954,2.0752422201314817e-05,"No",0.06901387390362262,0.9309861260963729,"No",0.9579249985179373,0.0420750014820769,"No",0.9885219003811315,0.011478099618864191,"No",0.09295477185704341,0.9070452281429504,"No"
"2013-000068-27","A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-versus-Host Disease.A Fase Ib/IIa multi-center studie ter bepaling van de veiligheid en effectiviteit van een combinatie van anti-CD3 en anti-CD7 ricine A immunotoxins (T-Guard) voor de behandeling van steroïde-resistente acute Graft-versus-Host Disease.","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.5688368645633936e-85,0.0009114165774465119,0.9990885834225656,"-1",1.1056467863637198e-08,0.9999999889435572,"Yes",0.9999999945990795,5.400935714486588e-09,"No",0.9999999980210533,1.9789430499851628e-09,"No",0.0023069042248968444,0.9976930957750832,"No",0.9999990201061705,9.798938257277003e-07,"No",0.9980576959694348,0.0019423040305915817,"No",0.09312840767946585,0.9068715923205288,"No"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in HemodialysisSubjects With Secondary Hyperparathyroidism","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.28245592717039e-43,9.273541533642999e-10,0.9999999990726565,"2+",0.9999999999989768,1.0326743851457557e-12,"No",1.1418474260165395e-11,0.9999999999885745,"Yes",0.999999999994003,5.985546110440736e-12,"No",1.4363621045349514e-08,0.9999999856363787,"Yes",0.3626081494264412,0.637391850573566,"No",0.9999986770360975,1.3229638964641044e-06,"No",6.9705384538229e-07,0.9999993029461663,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7309980513552647e-43,2.5601042578189326e-09,0.9999999974398862,"2+",0.9999999999992043,7.868635231687554e-13,"No",7.995786007550652e-12,0.9999999999920135,"Yes",0.9999999999998579,1.4869461429715576e-13,"No",3.3853708820926035e-08,0.9999999661462773,"Yes",0.5462364741155158,0.45376352588447444,"No",0.9999981248323837,1.875167619814207e-06,"No",2.2207169292879803e-06,0.9999977792830566,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in HemodialysisSubjects With Secondary Hyperparathyroidism","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.28245592717039e-43,9.273541533642999e-10,0.9999999990726565,"2+",0.9999999999989768,1.0326743851457557e-12,"No",1.1418474260165395e-11,0.9999999999885745,"Yes",0.999999999994003,5.985546110440736e-12,"No",1.4363621045349514e-08,0.9999999856363787,"Yes",0.3626081494264412,0.637391850573566,"No",0.9999986770360975,1.3229638964641044e-06,"No",6.9705384538229e-07,0.9999993029461663,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7309980513552647e-43,2.5601042578189326e-09,0.9999999974398862,"2+",0.9999999999992043,7.868635231687554e-13,"No",7.995786007550652e-12,0.9999999999920135,"Yes",0.9999999999998579,1.4869461429715576e-13,"No",3.3853708820926035e-08,0.9999999661462773,"Yes",0.5462364741155158,0.45376352588447444,"No",0.9999981248323837,1.875167619814207e-06,"No",2.2207169292879803e-06,0.9999977792830566,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in HemodialysisSubjects With Secondary Hyperparathyroidism","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.28245592717039e-43,9.273541533642999e-10,0.9999999990726565,"2+",0.9999999999989768,1.0326743851457557e-12,"No",1.1418474260165395e-11,0.9999999999885745,"Yes",0.999999999994003,5.985546110440736e-12,"No",1.4363621045349514e-08,0.9999999856363787,"Yes",0.3626081494264412,0.637391850573566,"No",0.9999986770360975,1.3229638964641044e-06,"No",6.9705384538229e-07,0.9999993029461663,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in HemodialysisSubjects With Secondary Hyperparathyroidism","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.28245592717039e-43,9.273541533642999e-10,0.9999999990726565,"2+",0.9999999999989768,1.0326743851457557e-12,"No",1.1418474260165395e-11,0.9999999999885745,"Yes",0.999999999994003,5.985546110440736e-12,"No",1.4363621045349514e-08,0.9999999856363787,"Yes",0.3626081494264412,0.637391850573566,"No",0.9999986770360975,1.3229638964641044e-06,"No",6.9705384538229e-07,0.9999993029461663,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in HemodialysisSubjects With Secondary Hyperparathyroidism","EE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.28245592717039e-43,9.273541533642999e-10,0.9999999990726565,"2+",0.9999999999989768,1.0326743851457557e-12,"No",1.1418474260165395e-11,0.9999999999885745,"Yes",0.999999999994003,5.985546110440736e-12,"No",1.4363621045349514e-08,0.9999999856363787,"Yes",0.3626081494264412,0.637391850573566,"No",0.9999986770360975,1.3229638964641044e-06,"No",6.9705384538229e-07,0.9999993029461663,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism","DK","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7309980513552647e-43,2.5601042578189326e-09,0.9999999974398862,"2+",0.9999999999992043,7.868635231687554e-13,"No",7.995786007550652e-12,0.9999999999920135,"Yes",0.9999999999998579,1.4869461429715576e-13,"No",3.3853708820926035e-08,0.9999999661462773,"Yes",0.5462364741155158,0.45376352588447444,"No",0.9999981248323837,1.875167619814207e-06,"No",2.2207169292879803e-06,0.9999977792830566,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism","LV","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7309980513552647e-43,2.5601042578189326e-09,0.9999999974398862,"2+",0.9999999999992043,7.868635231687554e-13,"No",7.995786007550652e-12,0.9999999999920135,"Yes",0.9999999999998579,1.4869461429715576e-13,"No",3.3853708820926035e-08,0.9999999661462773,"Yes",0.5462364741155158,0.45376352588447444,"No",0.9999981248323837,1.875167619814207e-06,"No",2.2207169292879803e-06,0.9999977792830566,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism","GR","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7309980513552647e-43,2.5601042578189326e-09,0.9999999974398862,"2+",0.9999999999992043,7.868635231687554e-13,"No",7.995786007550652e-12,0.9999999999920135,"Yes",0.9999999999998579,1.4869461429715576e-13,"No",3.3853708820926035e-08,0.9999999661462773,"Yes",0.5462364741155158,0.45376352588447444,"No",0.9999981248323837,1.875167619814207e-06,"No",2.2207169292879803e-06,0.9999977792830566,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7309980513552647e-43,2.5601042578189326e-09,0.9999999974398862,"2+",0.9999999999992043,7.868635231687554e-13,"No",7.995786007550652e-12,0.9999999999920135,"Yes",0.9999999999998579,1.4869461429715576e-13,"No",3.3853708820926035e-08,0.9999999661462773,"Yes",0.5462364741155158,0.45376352588447444,"No",0.9999981248323837,1.875167619814207e-06,"No",2.2207169292879803e-06,0.9999977792830566,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in HemodialysisSubjects With Secondary Hyperparathyroidism","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.28245592717039e-43,9.273541533642999e-10,0.9999999990726565,"2+",0.9999999999989768,1.0326743851457557e-12,"No",1.1418474260165395e-11,0.9999999999885745,"Yes",0.999999999994003,5.985546110440736e-12,"No",1.4363621045349514e-08,0.9999999856363787,"Yes",0.3626081494264412,0.637391850573566,"No",0.9999986770360975,1.3229638964641044e-06,"No",6.9705384538229e-07,0.9999993029461663,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7309980513552647e-43,2.5601042578189326e-09,0.9999999974398862,"2+",0.9999999999992043,7.868635231687554e-13,"No",7.995786007550652e-12,0.9999999999920135,"Yes",0.9999999999998579,1.4869461429715576e-13,"No",3.3853708820926035e-08,0.9999999661462773,"Yes",0.5462364741155158,0.45376352588447444,"No",0.9999981248323837,1.875167619814207e-06,"No",2.2207169292879803e-06,0.9999977792830566,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.7309980513552647e-43,2.5601042578189326e-09,0.9999999974398862,"2+",0.9999999999992043,7.868635231687554e-13,"No",7.995786007550652e-12,0.9999999999920135,"Yes",0.9999999999998579,1.4869461429715576e-13,"No",3.3853708820926035e-08,0.9999999661462773,"Yes",0.5462364741155158,0.45376352588447444,"No",0.9999981248323837,1.875167619814207e-06,"No",2.2207169292879803e-06,0.9999977792830566,"Yes"
"2013-000192-33","A Multicenter Multiple-dose Two-arm Active-controlled Double-blind Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in HemodialysisSubjects With Secondary Hyperparathyroidism","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.28245592717039e-43,9.273541533642999e-10,0.9999999990726565,"2+",0.9999999999989768,1.0326743851457557e-12,"No",1.1418474260165395e-11,0.9999999999885745,"Yes",0.999999999994003,5.985546110440736e-12,"No",1.4363621045349514e-08,0.9999999856363787,"Yes",0.3626081494264412,0.637391850573566,"No",0.9999986770360975,1.3229638964641044e-06,"No",6.9705384538229e-07,0.9999993029461663,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","IE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","NO","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000277-72","The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational Randomized Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary Fallopian Tube or Primary Peritoneum","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.931349151331335e-52,4.804455461251583e-13,0.9999999999995168,"2+",2.3913819648279623e-12,0.9999999999976126,"Yes",0.9999999999977264,2.285291124679373e-12,"No",0.9999999999988347,1.1663839513621768e-12,"No",2.1818588341023226e-07,0.9999997818141207,"Yes",0.8576020814560376,0.14239791854395326,"No",1.0,5.600184330998962e-15,"No",1.5546121142060056e-06,0.9999984453878744,"Yes"
"2013-000314-38","A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing salivary gland cancer (SGCs)","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0835001935193784e-40,0.00017045912198471565,0.9998295408780151,"2+",6.911868401919559e-06,0.9999930881316019,"Yes",0.9999954359287375,4.564071272416746e-06,"No",0.9999999980576035,1.9423936036764504e-09,"No",0.003110315913552012,0.9968896840864598,"Yes",0.9269739302925117,0.07302606970747987,"Yes",0.9999999999943726,5.623774320909038e-12,"No",0.0022940857897435856,0.997705914210253,"Yes"
"2013-000314-38","A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing salivary gland cancer (SGCs)","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0835001935193784e-40,0.00017045912198471565,0.9998295408780151,"2+",6.911868401919559e-06,0.9999930881316019,"Yes",0.9999954359287375,4.564071272416746e-06,"No",0.9999999980576035,1.9423936036764504e-09,"No",0.003110315913552012,0.9968896840864598,"Yes",0.9269739302925117,0.07302606970747987,"Yes",0.9999999999943726,5.623774320909038e-12,"No",0.0022940857897435856,0.997705914210253,"Yes"
"2013-000314-38","A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing salivary gland cancer (SGCs)","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0835001935193784e-40,0.00017045912198471565,0.9998295408780151,"2+",6.911868401919559e-06,0.9999930881316019,"Yes",0.9999954359287375,4.564071272416746e-06,"No",0.9999999980576035,1.9423936036764504e-09,"No",0.003110315913552012,0.9968896840864598,"Yes",0.9269739302925117,0.07302606970747987,"Yes",0.9999999999943726,5.623774320909038e-12,"No",0.0022940857897435856,0.997705914210253,"Yes"
"2013-000314-38","A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing salivary gland cancer (SGCs)","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0835001935193784e-40,0.00017045912198471565,0.9998295408780151,"2+",6.911868401919559e-06,0.9999930881316019,"Yes",0.9999954359287375,4.564071272416746e-06,"No",0.9999999980576035,1.9423936036764504e-09,"No",0.003110315913552012,0.9968896840864598,"Yes",0.9269739302925117,0.07302606970747987,"Yes",0.9999999999943726,5.623774320909038e-12,"No",0.0022940857897435856,0.997705914210253,"Yes"
"2013-000314-38","A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing salivary gland cancer (SGCs)Eine randomisierte Phase-II-Studie zur Untersuchung der Wirksamkeit und Sicherheit einer Chemotherapie gegenüber einer Androgendeprivationstherapie (ADT) bei Patienten mit rezidivierenden Störungen oder Metastasen in Bezug auf die Androgen-Rezeptoren (AR) aufgrund von Speicheldrüsenkrebs (SGCs).","AT","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.455442720566295e-81,0.09793676393742651,0.9020632360625642,"2+",1.3109206106434437e-10,0.9999999998689191,"Yes",0.9999999999543548,4.564941870170949e-11,"No",0.9999999999309921,6.903484126911023e-11,"No",0.18972695230025127,0.8102730476997315,"Yes",0.9999998376459435,1.6235403899843554e-07,"Yes",0.9999999999973852,2.6398902572387695e-12,"No",0.9717497198739313,0.028250280126041437,"Yes"
"2013-000314-38","A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing salivary gland cancer (SGCs)Eine randomisierte Phase-II-Studie zur Untersuchung der Wirksamkeit und Sicherheit einer Chemotherapie gegenüber einer Androgendeprivationstherapie (ADT) bei Patienten mit rezidivierenden Störungen oder Metastasen in Bezug auf die Androgen-Rezeptoren (AR) aufgrund von Speicheldrüsenkrebs (SGCs).","GB","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.455442720566295e-81,0.09793676393742651,0.9020632360625642,"2+",1.3109206106434437e-10,0.9999999998689191,"Yes",0.9999999999543548,4.564941870170949e-11,"No",0.9999999999309921,6.903484126911023e-11,"No",0.18972695230025127,0.8102730476997315,"Yes",0.9999998376459435,1.6235403899843554e-07,"Yes",0.9999999999973852,2.6398902572387695e-12,"No",0.9717497198739313,0.028250280126041437,"Yes"
"2013-000314-38","A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing salivary gland cancer (SGCs)Eine randomisierte Phase-II-Studie zur Untersuchung der Wirksamkeit und Sicherheit einer Chemotherapie gegenüber einer Androgendeprivationstherapie (ADT) bei Patienten mit rezidivierenden Störungen oder Metastasen in Bezug auf die Androgen-Rezeptoren (AR) aufgrund von Speicheldrüsenkrebs (SGCs).","GR","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.455442720566295e-81,0.09793676393742651,0.9020632360625642,"2+",1.3109206106434437e-10,0.9999999998689191,"Yes",0.9999999999543548,4.564941870170949e-11,"No",0.9999999999309921,6.903484126911023e-11,"No",0.18972695230025127,0.8102730476997315,"Yes",0.9999998376459435,1.6235403899843554e-07,"Yes",0.9999999999973852,2.6398902572387695e-12,"No",0.9717497198739313,0.028250280126041437,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEt multicenter randomiseret fase III forsøg med peroral LDK378 sammenlignet med standard kemoterapi hos hidtil ubehandlede voksne med ALK positiv ikke-skvamøs ikke-småcellet lungekræft stadium IIIB eller IV","PL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.342800705989011e-95,3.838476677087085e-07,0.9999996161523255,"2+",7.446810365401634e-19,1.0,"Yes",1.0,2.311018773577302e-18,"No",1.0,8.094539085915578e-34,"No",0.9999634820644815,3.65179355301398e-05,"Yes",0.9999999935011489,6.49884694640967e-09,"Yes",1.0,2.2381970432492855e-17,"No",5.865795078744164e-07,0.9999994134204842,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancer","IT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2663905129410137e-67,0.5214695667068513,0.47853043329314393,"2+",2.5783162954913313e-11,0.9999999999742215,"Yes",0.9999999999218687,7.812739961232351e-11,"No",1.0,2.4895740572731505e-26,"No",0.9992383570272872,0.0007616429727165582,"Yes",0.9962259502753066,0.0037740497246901753,"Yes",0.9999999999959073,4.089253544696752e-12,"No",0.9590173737032562,0.0409826262967462,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEt multicenter randomiseret fase III forsøg med peroral LDK378 sammenlignet med standard kemoterapi hos hidtil ubehandlede voksne med ALK positiv ikke-skvamøs ikke-småcellet lungekræft stadium IIIB eller IV","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.342800705989011e-95,3.838476677087085e-07,0.9999996161523255,"2+",7.446810365401634e-19,1.0,"Yes",1.0,2.311018773577302e-18,"No",1.0,8.094539085915578e-34,"No",0.9999634820644815,3.65179355301398e-05,"Yes",0.9999999935011489,6.49884694640967e-09,"Yes",1.0,2.2381970432492855e-17,"No",5.865795078744164e-07,0.9999994134204842,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEstudio de fase III multicéntrico  aleatorizado de LDK378 oral frente a quimioterapia estándar en pacientes adultos con cáncer de pulmón de células no pequeñas no escamoso con reordenamiento de ALK (ALK-positivo) estadio IIIB o IV que no han sido tratados previamente","FR","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.640731140973589e-121,0.9724806215986059,0.02751937840138573,"2+",3.6741059217951764e-22,1.0,"Yes",1.0,4.3293502738834915e-21,"No",1.0,1.2382767100071086e-53,"No",0.9999999968443946,3.1555779527581727e-09,"Yes",0.9999999267511753,7.324880038517643e-08,"Yes",1.0,3.643381533684753e-37,"No",0.9993496058318719,0.0006503941681302638,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEt multicenter randomiseret fase III forsøg med peroral LDK378 sammenlignet med standard kemoterapi hos hidtil ubehandlede voksne med ALK positiv ikke-skvamøs ikke-småcellet lungekræft stadium IIIB eller IV","HU","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.342800705989011e-95,3.838476677087085e-07,0.9999996161523255,"2+",7.446810365401634e-19,1.0,"Yes",1.0,2.311018773577302e-18,"No",1.0,8.094539085915578e-34,"No",0.9999634820644815,3.65179355301398e-05,"Yes",0.9999999935011489,6.49884694640967e-09,"Yes",1.0,2.2381970432492855e-17,"No",5.865795078744164e-07,0.9999994134204842,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancer","NL","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2663905129410137e-67,0.5214695667068513,0.47853043329314393,"2+",2.5783162954913313e-11,0.9999999999742215,"Yes",0.9999999999218687,7.812739961232351e-11,"No",1.0,2.4895740572731505e-26,"No",0.9992383570272872,0.0007616429727165582,"Yes",0.9962259502753066,0.0037740497246901753,"Yes",0.9999999999959073,4.089253544696752e-12,"No",0.9590173737032562,0.0409826262967462,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEstudio de fase III multicéntrico  aleatorizado de LDK378 oral frente a quimioterapia estándar en pacientes adultos con cáncer de pulmón de células no pequeñas no escamoso con reordenamiento de ALK (ALK-positivo) estadio IIIB o IV que no han sido tratados previamente","SE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.640731140973589e-121,0.9724806215986059,0.02751937840138573,"2+",3.6741059217951764e-22,1.0,"Yes",1.0,4.3293502738834915e-21,"No",1.0,1.2382767100071086e-53,"No",0.9999999968443946,3.1555779527581727e-09,"Yes",0.9999999267511753,7.324880038517643e-08,"Yes",1.0,3.643381533684753e-37,"No",0.9993496058318719,0.0006503941681302638,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEt multicenter randomiseret fase III forsøg med peroral LDK378 sammenlignet med standard kemoterapi hos hidtil ubehandlede voksne med ALK positiv ikke-skvamøs ikke-småcellet lungekræft stadium IIIB eller IV","GR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.342800705989011e-95,3.838476677087085e-07,0.9999996161523255,"2+",7.446810365401634e-19,1.0,"Yes",1.0,2.311018773577302e-18,"No",1.0,8.094539085915578e-34,"No",0.9999634820644815,3.65179355301398e-05,"Yes",0.9999999935011489,6.49884694640967e-09,"Yes",1.0,2.2381970432492855e-17,"No",5.865795078744164e-07,0.9999994134204842,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancer","AT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2663905129410137e-67,0.5214695667068513,0.47853043329314393,"2+",2.5783162954913313e-11,0.9999999999742215,"Yes",0.9999999999218687,7.812739961232351e-11,"No",1.0,2.4895740572731505e-26,"No",0.9992383570272872,0.0007616429727165582,"Yes",0.9962259502753066,0.0037740497246901753,"Yes",0.9999999999959073,4.089253544696752e-12,"No",0.9590173737032562,0.0409826262967462,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEstudio de fase III multicéntrico  aleatorizado de LDK378 oral frente a quimioterapia estándar en pacientes adultos con cáncer de pulmón de células no pequeñas no escamoso con reordenamiento de ALK (ALK-positivo) estadio IIIB o IV que no han sido tratados previamente","DK","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.640731140973589e-121,0.9724806215986059,0.02751937840138573,"2+",3.6741059217951764e-22,1.0,"Yes",1.0,4.3293502738834915e-21,"No",1.0,1.2382767100071086e-53,"No",0.9999999968443946,3.1555779527581727e-09,"Yes",0.9999999267511753,7.324880038517643e-08,"Yes",1.0,3.643381533684753e-37,"No",0.9993496058318719,0.0006503941681302638,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancer","PT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2663905129410137e-67,0.5214695667068513,0.47853043329314393,"2+",2.5783162954913313e-11,0.9999999999742215,"Yes",0.9999999999218687,7.812739961232351e-11,"No",1.0,2.4895740572731505e-26,"No",0.9992383570272872,0.0007616429727165582,"Yes",0.9962259502753066,0.0037740497246901753,"Yes",0.9999999999959073,4.089253544696752e-12,"No",0.9590173737032562,0.0409826262967462,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEstudio de fase III multicéntrico  aleatorizado de LDK378 oral frente a quimioterapia estándar en pacientes adultos con cáncer de pulmón de células no pequeñas no escamoso con reordenamiento de ALK (ALK-positivo) estadio IIIB o IV que no han sido tratados previamente","GB","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.640731140973589e-121,0.9724806215986059,0.02751937840138573,"2+",3.6741059217951764e-22,1.0,"Yes",1.0,4.3293502738834915e-21,"No",1.0,1.2382767100071086e-53,"No",0.9999999968443946,3.1555779527581727e-09,"Yes",0.9999999267511753,7.324880038517643e-08,"Yes",1.0,3.643381533684753e-37,"No",0.9993496058318719,0.0006503941681302638,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEstudio de fase III multicéntrico  aleatorizado de LDK378 oral frente a quimioterapia estándar en pacientes adultos con cáncer de pulmón de células no pequeñas no escamoso con reordenamiento de ALK (ALK-positivo) estadio IIIB o IV que no han sido tratados previamente","ES","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.640731140973589e-121,0.9724806215986059,0.02751937840138573,"2+",3.6741059217951764e-22,1.0,"Yes",1.0,4.3293502738834915e-21,"No",1.0,1.2382767100071086e-53,"No",0.9999999968443946,3.1555779527581727e-09,"Yes",0.9999999267511753,7.324880038517643e-08,"Yes",1.0,3.643381533684753e-37,"No",0.9993496058318719,0.0006503941681302638,"Yes"
"2013-000319-26","A phase III multicenter randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive) stage IIIB or IV non-squamous non-small cell lung cancerEstudio de fase III multicéntrico  aleatorizado de LDK378 oral frente a quimioterapia estándar en pacientes adultos con cáncer de pulmón de células no pequeñas no escamoso con reordenamiento de ALK (ALK-positivo) estadio IIIB o IV que no han sido tratados previamente","IE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.640731140973589e-121,0.9724806215986059,0.02751937840138573,"2+",3.6741059217951764e-22,1.0,"Yes",1.0,4.3293502738834915e-21,"No",1.0,1.2382767100071086e-53,"No",0.9999999968443946,3.1555779527581727e-09,"Yes",0.9999999267511753,7.324880038517643e-08,"Yes",1.0,3.643381533684753e-37,"No",0.9993496058318719,0.0006503941681302638,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.745906865576083e-45,7.343263158440285e-07,0.999999265673679,"2+",3.76876425640699e-12,0.9999999999962199,"Yes",0.9999999999933779,6.6328289890030146e-12,"No",1.0,3.2135021281496787e-19,"No",7.016318561385945e-07,0.9999992983681427,"Yes",0.0005509282183442023,0.9994490717816614,"Yes",0.9999999999992895,7.183926938673153e-13,"No",5.39148775842511e-07,0.9999994608512315,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","GR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant efficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.745906865576083e-45,7.343263158440285e-07,0.999999265673679,"2+",3.76876425640699e-12,0.9999999999962199,"Yes",0.9999999999933779,6.6328289890030146e-12,"No",1.0,3.2135021281496787e-19,"No",7.016318561385945e-07,0.9999992983681427,"Yes",0.0005509282183442023,0.9994490717816614,"Yes",0.9999999999992895,7.183926938673153e-13,"No",5.39148775842511e-07,0.9999994608512315,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant efficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.745906865576083e-45,7.343263158440285e-07,0.999999265673679,"2+",3.76876425640699e-12,0.9999999999962199,"Yes",0.9999999999933779,6.6328289890030146e-12,"No",1.0,3.2135021281496787e-19,"No",7.016318561385945e-07,0.9999992983681427,"Yes",0.0005509282183442023,0.9994490717816614,"Yes",0.9999999999992895,7.183926938673153e-13,"No",5.39148775842511e-07,0.9999994608512315,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","HR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant efficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant efficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","BG","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","NO","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.745906865576083e-45,7.343263158440285e-07,0.999999265673679,"2+",3.76876425640699e-12,0.9999999999962199,"Yes",0.9999999999933779,6.6328289890030146e-12,"No",1.0,3.2135021281496787e-19,"No",7.016318561385945e-07,0.9999992983681427,"Yes",0.0005509282183442023,0.9994490717816614,"Yes",0.9999999999992895,7.183926938673153e-13,"No",5.39148775842511e-07,0.9999994608512315,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","SK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.745906865576083e-45,7.343263158440285e-07,0.999999265673679,"2+",3.76876425640699e-12,0.9999999999962199,"Yes",0.9999999999933779,6.6328289890030146e-12,"No",1.0,3.2135021281496787e-19,"No",7.016318561385945e-07,0.9999992983681427,"Yes",0.0005509282183442023,0.9994490717816614,"Yes",0.9999999999992895,7.183926938673153e-13,"No",5.39148775842511e-07,0.9999994608512315,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","SI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.745906865576083e-45,7.343263158440285e-07,0.999999265673679,"2+",3.76876425640699e-12,0.9999999999962199,"Yes",0.9999999999933779,6.6328289890030146e-12,"No",1.0,3.2135021281496787e-19,"No",7.016318561385945e-07,0.9999992983681427,"Yes",0.0005509282183442023,0.9994490717816614,"Yes",0.9999999999992895,7.183926938673153e-13,"No",5.39148775842511e-07,0.9999994608512315,"Yes"
"2013-000322-66","A 24 month multicenter randomized open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy andsafety Outcomes with an eveRolimus-based regiMen (TRANSFORM)","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.402312789708186e-47,1.3630939314387323e-07,0.9999998636905993,"2+",7.734643268684518e-12,0.9999999999922693,"Yes",0.9999999999853061,1.4707060952225356e-11,"No",1.0,9.616787227492654e-21,"No",1.0326034218179804e-07,0.9999998967396718,"Yes",0.0008780560601539741,0.9991219439398372,"Yes",0.9999999999999717,3.40398081254571e-14,"No",6.892885788456447e-08,0.9999999310711327,"Yes"
"2013-000423-14","A Randomised Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cance","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9412199300841144e-47,1.8397539512729845e-10,0.9999999998160263,"2+",0.999999930071655,6.992835271469862e-08,"No",6.377070466757958e-07,0.9999993622929582,"Yes",0.9999999992362518,7.637524972871446e-10,"No",1.050454926474164e-11,0.999999999989484,"Yes",0.4059507461062018,0.594049253893798,"Yes",0.9999527203006348,4.7279699356328836e-05,"No",1.538339813848382e-11,0.9999999999846239,"Yes"
"2013-000423-14","A Randomised Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cance","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9412199300841144e-47,1.8397539512729845e-10,0.9999999998160263,"2+",0.999999930071655,6.992835271469862e-08,"No",6.377070466757958e-07,0.9999993622929582,"Yes",0.9999999992362518,7.637524972871446e-10,"No",1.050454926474164e-11,0.999999999989484,"Yes",0.4059507461062018,0.594049253893798,"Yes",0.9999527203006348,4.7279699356328836e-05,"No",1.538339813848382e-11,0.9999999999846239,"Yes"
"2013-000423-14","A Randomised Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cance","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9412199300841144e-47,1.8397539512729845e-10,0.9999999998160263,"2+",0.999999930071655,6.992835271469862e-08,"No",6.377070466757958e-07,0.9999993622929582,"Yes",0.9999999992362518,7.637524972871446e-10,"No",1.050454926474164e-11,0.999999999989484,"Yes",0.4059507461062018,0.594049253893798,"Yes",0.9999527203006348,4.7279699356328836e-05,"No",1.538339813848382e-11,0.9999999999846239,"Yes"
"2013-000423-14","A Randomised Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cance","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9412199300841144e-47,1.8397539512729845e-10,0.9999999998160263,"2+",0.999999930071655,6.992835271469862e-08,"No",6.377070466757958e-07,0.9999993622929582,"Yes",0.9999999992362518,7.637524972871446e-10,"No",1.050454926474164e-11,0.999999999989484,"Yes",0.4059507461062018,0.594049253893798,"Yes",0.9999527203006348,4.7279699356328836e-05,"No",1.538339813848382e-11,0.9999999999846239,"Yes"
"2013-000423-14","A Randomised Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cance","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.9412199300841144e-47,1.8397539512729845e-10,0.9999999998160263,"2+",0.999999930071655,6.992835271469862e-08,"No",6.377070466757958e-07,0.9999993622929582,"Yes",0.9999999992362518,7.637524972871446e-10,"No",1.050454926474164e-11,0.999999999989484,"Yes",0.4059507461062018,0.594049253893798,"Yes",0.9999527203006348,4.7279699356328836e-05,"No",1.538339813848382e-11,0.9999999999846239,"Yes"
"2013-000508-40","A Phase 3 Multicenter Investigator-blind Randomized Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h and Vancomycin Oral Liquid or Capsules Taken q6h for 10 Days in Pediatric Subjects with Clostridium difficile-associated DiarrheaWieloośrodkowe randomizowane badanie fazy III prowadzone z zaślepieniem badaczy w grupach równoległych w celu zbadania bezpieczeństwa i skuteczności fidaksomycyny w postaci zawiesiny doustnej lub tabletek przyjmowanych co 12 godzin oraz wankomycyny w postaci płynu doustnego lub kapsułek przyjmowanych co 6 godzin przez okres 10 dni wśród pacjentów pediatrycznych z biegunką wywołaną zakażeniem Clostridium difficile","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",7.5686980824318305e-93,6.286783267140838e-30,1.0,"2+",0.9999999727041318,2.7295921293322123e-08,"No",1.3860275755956932e-07,0.9999998613972235,"No",1.0,2.4042987566284412e-29,"Yes",8.861167085261559e-24,1.0,"Yes",6.603526126273886e-17,1.0,"Yes",1.0,3.280129410466376e-27,"No",2.82690660001213e-29,1.0,"Yes"
"2013-000508-40","A Phase 3 Multicenter Investigator-blind Randomized Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h and Vancomycin Oral Liquid or Capsules Taken q6h for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",8.43533864562409e-51,1.1541335101773107e-16,1.0,"2+",0.9999999988433217,1.1566849233230362e-09,"No",8.268659440747233e-09,0.999999991731329,"No",0.9999999994257394,5.742603413140265e-10,"Yes",7.213421098479299e-13,0.9999999999992895,"Yes",1.2391664986286306e-10,0.9999999998760813,"Yes",0.9999999998708802,1.291333283990963e-10,"No",3.012185430650622e-16,1.0,"Yes"
"2013-000508-40","A Phase 3 Multicenter Investigator-blind Randomized Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h and Vancomycin Oral Liquid or Capsules Taken q6h for 10 Days in Pediatric Subjects with Clostridium difficile-associated DiarrheaWieloośrodkowe randomizowane badanie fazy III prowadzone z zaślepieniem badaczy w grupach równoległych w celu zbadania bezpieczeństwa i skuteczności fidaksomycyny w postaci zawiesiny doustnej lub tabletek przyjmowanych co 12 godzin oraz wankomycyny w postaci płynu doustnego lub kapsułek przyjmowanych co 6 godzin przez okres 10 dni wśród pacjentów pediatrycznych z biegunką wywołaną zakażeniem Clostridium difficile","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",7.5686980824318305e-93,6.286783267140838e-30,1.0,"2+",0.9999999727041318,2.7295921293322123e-08,"No",1.3860275755956932e-07,0.9999998613972235,"No",1.0,2.4042987566284412e-29,"Yes",8.861167085261559e-24,1.0,"Yes",6.603526126273886e-17,1.0,"Yes",1.0,3.280129410466376e-27,"No",2.82690660001213e-29,1.0,"Yes"
"2013-000508-40","A Phase 3 Multicenter Investigator-blind Randomized Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h and Vancomycin Oral Liquid or Capsules Taken q6h for 10 Days in Pediatric Subjects with Clostridium difficile-associated DiarrheaWieloośrodkowe randomizowane badanie fazy III prowadzone z zaślepieniem badaczy w grupach równoległych w celu zbadania bezpieczeństwa i skuteczności fidaksomycyny w postaci zawiesiny doustnej lub tabletek przyjmowanych co 12 godzin oraz wankomycyny w postaci płynu doustnego lub kapsułek przyjmowanych co 6 godzin przez okres 10 dni wśród pacjentów pediatrycznych z biegunką wywołaną zakażeniem Clostridium difficile","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",7.5686980824318305e-93,6.286783267140838e-30,1.0,"2+",0.9999999727041318,2.7295921293322123e-08,"No",1.3860275755956932e-07,0.9999998613972235,"No",1.0,2.4042987566284412e-29,"Yes",8.861167085261559e-24,1.0,"Yes",6.603526126273886e-17,1.0,"Yes",1.0,3.280129410466376e-27,"No",2.82690660001213e-29,1.0,"Yes"
"2013-000508-40","A Phase 3 Multicenter Investigator-blind Randomized Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h and Vancomycin Oral Liquid or Capsules Taken q6h for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",8.43533864562409e-51,1.1541335101773107e-16,1.0,"2+",0.9999999988433217,1.1566849233230362e-09,"No",8.268659440747233e-09,0.999999991731329,"No",0.9999999994257394,5.742603413140265e-10,"Yes",7.213421098479299e-13,0.9999999999992895,"Yes",1.2391664986286306e-10,0.9999999998760813,"Yes",0.9999999998708802,1.291333283990963e-10,"No",3.012185430650622e-16,1.0,"Yes"
"2013-000508-40","A Phase 3 Multicenter Investigator-blind Randomized Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h and Vancomycin Oral Liquid or Capsules Taken q6h for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",8.43533864562409e-51,1.1541335101773107e-16,1.0,"2+",0.9999999988433217,1.1566849233230362e-09,"No",8.268659440747233e-09,0.999999991731329,"No",0.9999999994257394,5.742603413140265e-10,"Yes",7.213421098479299e-13,0.9999999999992895,"Yes",1.2391664986286306e-10,0.9999999998760813,"Yes",0.9999999998708802,1.291333283990963e-10,"No",3.012185430650622e-16,1.0,"Yes"
"2013-000508-40","A Phase 3 Multicenter Investigator-blind Randomized Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h and Vancomycin Oral Liquid or Capsules Taken q6h for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",8.43533864562409e-51,1.1541335101773107e-16,1.0,"2+",0.9999999988433217,1.1566849233230362e-09,"No",8.268659440747233e-09,0.999999991731329,"No",0.9999999994257394,5.742603413140265e-10,"Yes",7.213421098479299e-13,0.9999999999992895,"Yes",1.2391664986286306e-10,0.9999999998760813,"Yes",0.9999999998708802,1.291333283990963e-10,"No",3.012185430650622e-16,1.0,"Yes"
"2013-000508-40","A Phase 3 Multicenter Investigator-blind Randomized Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h and Vancomycin Oral Liquid or Capsules Taken q6h for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","Yes","No","Yes","No","Yes","2+","Yes",8.43533864562409e-51,1.1541335101773107e-16,1.0,"2+",0.9999999988433217,1.1566849233230362e-09,"No",8.268659440747233e-09,0.999999991731329,"No",0.9999999994257394,5.742603413140265e-10,"Yes",7.213421098479299e-13,0.9999999999992895,"Yes",1.2391664986286306e-10,0.9999999998760813,"Yes",0.9999999998708802,1.291333283990963e-10,"No",3.012185430650622e-16,1.0,"Yes"
"2013-000516-25","A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",7.622109674612901e-39,0.250624583120018,0.7493754168799809,"2+",0.0003774776820222924,0.9996225223179647,"Yes",0.9996145069993158,0.0003854930006741,"No",1.0,1.4605060131065893e-16,"No",0.13524564782825804,0.864754352171753,"No",0.9690108210591905,0.030989178940816254,"No",0.9999999920607082,7.939279394447557e-09,"No",0.11365717742820368,0.8863428225717921,"No"
"2013-000516-25","A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal ImpairmentEstudio de fase 3 abierto para evaluar la seguridad del tratamiento en un solo comprimido de elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida en pacientes infectados por el VIH 1 con insuficiencia renal leve o moderada","IT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7128031993532187e-69,0.6168569144781978,0.38314308552181564,"2+",7.060899192522722e-10,0.9999999992938912,"Yes",0.9999999987922479,1.2077645700922998e-09,"No",1.0,6.664976432924089e-34,"No",0.5234020160523062,0.4765979839476834,"No",0.9998786188583997,0.00012138114159853239,"No",1.0,1.5091838748291323e-22,"No",0.563976451929316,0.43602354807068877,"No"
"2013-000516-25","A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal ImpairmentEstudio de fase 3 abierto para evaluar la seguridad del tratamiento en un solo comprimido de elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida en pacientes infectados por el VIH 1 con insuficiencia renal leve o moderada","AT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7128031993532187e-69,0.6168569144781978,0.38314308552181564,"2+",7.060899192522722e-10,0.9999999992938912,"Yes",0.9999999987922479,1.2077645700922998e-09,"No",1.0,6.664976432924089e-34,"No",0.5234020160523062,0.4765979839476834,"No",0.9998786188583997,0.00012138114159853239,"No",1.0,1.5091838748291323e-22,"No",0.563976451929316,0.43602354807068877,"No"
"2013-000516-25","A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",7.622109674612901e-39,0.250624583120018,0.7493754168799809,"2+",0.0003774776820222924,0.9996225223179647,"Yes",0.9996145069993158,0.0003854930006741,"No",1.0,1.4605060131065893e-16,"No",0.13524564782825804,0.864754352171753,"No",0.9690108210591905,0.030989178940816254,"No",0.9999999920607082,7.939279394447557e-09,"No",0.11365717742820368,0.8863428225717921,"No"
"2013-000516-25","A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal ImpairmentEstudio de fase 3 abierto para evaluar la seguridad del tratamiento en un solo comprimido de elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida en pacientes infectados por el VIH 1 con insuficiencia renal leve o moderada","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7128031993532187e-69,0.6168569144781978,0.38314308552181564,"2+",7.060899192522722e-10,0.9999999992938912,"Yes",0.9999999987922479,1.2077645700922998e-09,"No",1.0,6.664976432924089e-34,"No",0.5234020160523062,0.4765979839476834,"No",0.9998786188583997,0.00012138114159853239,"No",1.0,1.5091838748291323e-22,"No",0.563976451929316,0.43602354807068877,"No"
"2013-000516-25","A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal ImpairmentEstudio de fase 3 abierto para evaluar la seguridad del tratamiento en un solo comprimido de elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida en pacientes infectados por el VIH 1 con insuficiencia renal leve o moderada","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7128031993532187e-69,0.6168569144781978,0.38314308552181564,"2+",7.060899192522722e-10,0.9999999992938912,"Yes",0.9999999987922479,1.2077645700922998e-09,"No",1.0,6.664976432924089e-34,"No",0.5234020160523062,0.4765979839476834,"No",0.9998786188583997,0.00012138114159853239,"No",1.0,1.5091838748291323e-22,"No",0.563976451929316,0.43602354807068877,"No"
"2013-000516-25","A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal ImpairmentEstudio de fase 3 abierto para evaluar la seguridad del tratamiento en un solo comprimido de elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida en pacientes infectados por el VIH 1 con insuficiencia renal leve o moderada","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7128031993532187e-69,0.6168569144781978,0.38314308552181564,"2+",7.060899192522722e-10,0.9999999992938912,"Yes",0.9999999987922479,1.2077645700922998e-09,"No",1.0,6.664976432924089e-34,"No",0.5234020160523062,0.4765979839476834,"No",0.9998786188583997,0.00012138114159853239,"No",1.0,1.5091838748291323e-22,"No",0.563976451929316,0.43602354807068877,"No"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","AT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","GR","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","PL","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","FR","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","IT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","BE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","BG","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","ES","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","GB","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","CZ","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","IE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000536-10","A Phase 3 Randomized Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)","DE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.734340544610404e-37,0.5871671697418127,0.41283283025819983,"2+",9.949647207088016e-09,0.9999999900503554,"Yes",0.9999999853687599,1.4631245499202624e-08,"No",0.9999999999997442,2.5533100273073793e-13,"No",0.9933140752531989,0.006685924746797805,"Yes",0.996196975338808,0.003803024661181544,"No",0.9999928685021392,7.131497874107595e-06,"No",0.9468637630358006,0.053136236964195345,"Yes"
"2013-000577-77","EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options)Tratamiento oral precoz en bacteriemia de bajo riesgo producida por Staphylococcus aureus Acrónimo: SABATO: (S.Aureus Bacteriemia Antibiotic Treatment Options)","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.66598981631543e-33,2.6544017987537555e-21,1.0,"2+",0.020174087801816138,0.979825912198183,"Yes",0.9608954413754819,0.03910455862449643,"No",1.0,2.1035491163480365e-17,"No",2.7075643961551587e-10,0.9999999997292549,"Yes",0.01291403114432534,0.987085968855691,"Yes",1.0,8.013153291761718e-23,"No",1.507833367571304e-22,1.0,"Yes"
"2013-000577-77","EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options)Tratamiento oral precoz en bacteriemia de bajo riesgo producida por Staphylococcus aureus Acrónimo: SABATO: (S.Aureus Bacteriemia Antibiotic Treatment Options)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.66598981631543e-33,2.6544017987537555e-21,1.0,"2+",0.020174087801816138,0.979825912198183,"Yes",0.9608954413754819,0.03910455862449643,"No",1.0,2.1035491163480365e-17,"No",2.7075643961551587e-10,0.9999999997292549,"Yes",0.01291403114432534,0.987085968855691,"Yes",1.0,8.013153291761718e-23,"No",1.507833367571304e-22,1.0,"Yes"
"2013-000577-77","EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options)Tratamiento oral precoz en bacteriemia de bajo riesgo producida por Staphylococcus aureus Acrónimo: SABATO: (S.Aureus Bacteriemia Antibiotic Treatment Options)","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.66598981631543e-33,2.6544017987537555e-21,1.0,"2+",0.020174087801816138,0.979825912198183,"Yes",0.9608954413754819,0.03910455862449643,"No",1.0,2.1035491163480365e-17,"No",2.7075643961551587e-10,0.9999999997292549,"Yes",0.01291403114432534,0.987085968855691,"Yes",1.0,8.013153291761718e-23,"No",1.507833367571304e-22,1.0,"Yes"
"2013-000860-27","A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera","FR","No","No","Yes","ok","No","Yes","No","No","1","","","Yes","No","No","No","No","No","1","No",3.190262495832661e-14,0.9703076070407296,0.029692392959243988,"-1",0.0059214735639853775,0.9940785264360108,"Yes",0.9915742845812431,0.008425715418760665,"No",0.9999999947444566,5.255538091907169e-09,"No",0.9966594718318533,0.003340528168153833,"No",0.9745922142922496,0.02540778570775449,"No",0.237053126118282,0.7629468738817177,"No",0.9908728150443317,0.009127184955661222,"No"
"2013-000860-27","A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera“Studio in due parti per valutare la sicurezza e l'efficacia preliminare di Givinostat in pazienti JAK2V617F positivi affetti da policitemia vera”","IT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2626362645606453e-37,0.9996500864359095,0.00034991356409575604,"-1",7.24236712857846e-05,0.999927576328724,"Yes",0.9998095496174624,0.0001904503825466664,"No",0.9999999999999717,1.609683274262255e-14,"No",0.9998156170024589,0.00018438299755027586,"No",0.9074480892273326,0.09255191077265537,"No",0.9961220900119075,0.0038779099880834034,"No",0.999525946987064,0.00047405301293835703,"No"
"2013-000860-27","A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera“Studio in due parti per valutare la sicurezza e l'efficacia preliminare di Givinostat in pazienti JAK2V617F positivi affetti da policitemia vera”","PL","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2626362645606453e-37,0.9996500864359095,0.00034991356409575604,"-1",7.24236712857846e-05,0.999927576328724,"Yes",0.9998095496174624,0.0001904503825466664,"No",0.9999999999999717,1.609683274262255e-14,"No",0.9998156170024589,0.00018438299755027586,"No",0.9074480892273326,0.09255191077265537,"No",0.9961220900119075,0.0038779099880834034,"No",0.999525946987064,0.00047405301293835703,"No"
"2013-000860-27","A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera","DE","No","No","Yes","ok","No","Yes","No","No","1","","","Yes","No","No","No","No","No","1","No",3.190262495832661e-14,0.9703076070407296,0.029692392959243988,"-1",0.0059214735639853775,0.9940785264360108,"Yes",0.9915742845812431,0.008425715418760665,"No",0.9999999947444566,5.255538091907169e-09,"No",0.9966594718318533,0.003340528168153833,"No",0.9745922142922496,0.02540778570775449,"No",0.237053126118282,0.7629468738817177,"No",0.9908728150443317,0.009127184955661222,"No"
"2013-000860-27","A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera“Studio in due parti per valutare la sicurezza e l'efficacia preliminare di Givinostat in pazienti JAK2V617F positivi affetti da policitemia vera”","GB","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.2626362645606453e-37,0.9996500864359095,0.00034991356409575604,"-1",7.24236712857846e-05,0.999927576328724,"Yes",0.9998095496174624,0.0001904503825466664,"No",0.9999999999999717,1.609683274262255e-14,"No",0.9998156170024589,0.00018438299755027586,"No",0.9074480892273326,0.09255191077265537,"No",0.9961220900119075,0.0038779099880834034,"No",0.999525946987064,0.00047405301293835703,"No"
"2013-000860-27","A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera","HU","No","No","Yes","ok","No","Yes","No","No","1","","","Yes","No","No","No","No","No","1","No",3.190262495832661e-14,0.9703076070407296,0.029692392959243988,"-1",0.0059214735639853775,0.9940785264360108,"Yes",0.9915742845812431,0.008425715418760665,"No",0.9999999947444566,5.255538091907169e-09,"No",0.9966594718318533,0.003340528168153833,"No",0.9745922142922496,0.02540778570775449,"No",0.237053126118282,0.7629468738817177,"No",0.9908728150443317,0.009127184955661222,"No"
"2013-000895-14","A 52-week double-blind randomised placebo-controlled parallel-groupphase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D).52týdenní dvojitě zaslepená randomizovaná placebem kontrolovaná studie fáze III paralelních skupin s opětovnou randomizací po 25 týdnech k posouzení účinnosti a bezpečnosti perorálního užívání ibodutantu 10 mg jednou denně u pacientek se syndromem dráždivého tračníku s průjmem ","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8632803716713514e-116,2.1309711637205045e-34,1.0,"2+",1.0,1.877309291326747e-33,"No",1.8342364113867968e-32,1.0,"Yes",1.0,2.850417462754873e-43,"No",1.9583300597975086e-36,1.0,"Yes",4.456652797629982e-17,1.0,"Yes",1.0,3.441977393733382e-28,"No",4.407334994780825e-32,1.0,"Yes"
"2013-000895-14","A 52-week double-blind randomised placebo-controlled parallel-groupphase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D).","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3687031500548263e-59,7.705407584050022e-15,1.0,"2+",1.0,7.338976165825449e-17,"No",1.1796214297582167e-15,1.0,"Yes",0.9999999999999432,5.876175945107214e-14,"No",3.2096572619944755e-17,1.0,"Yes",9.45819960515067e-09,0.9999999905417952,"Yes",0.9999999999798206,2.0190570611403357e-11,"No",8.660053541370189e-15,1.0,"Yes"
"2013-000895-14","A 52-week double-blind randomised placebo-controlled parallel-groupphase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D).52týdenní dvojitě zaslepená randomizovaná placebem kontrolovaná studie fáze III paralelních skupin s opětovnou randomizací po 25 týdnech k posouzení účinnosti a bezpečnosti perorálního užívání ibodutantu 10 mg jednou denně u pacientek se syndromem dráždivého tračníku s průjmem ","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8632803716713514e-116,2.1309711637205045e-34,1.0,"2+",1.0,1.877309291326747e-33,"No",1.8342364113867968e-32,1.0,"Yes",1.0,2.850417462754873e-43,"No",1.9583300597975086e-36,1.0,"Yes",4.456652797629982e-17,1.0,"Yes",1.0,3.441977393733382e-28,"No",4.407334994780825e-32,1.0,"Yes"
"2013-000895-14","A 52-week double-blind randomised placebo-controlled parallel-groupphase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D).52týdenní dvojitě zaslepená randomizovaná placebem kontrolovaná studie fáze III paralelních skupin s opětovnou randomizací po 25 týdnech k posouzení účinnosti a bezpečnosti perorálního užívání ibodutantu 10 mg jednou denně u pacientek se syndromem dráždivého tračníku s průjmem ","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8632803716713514e-116,2.1309711637205045e-34,1.0,"2+",1.0,1.877309291326747e-33,"No",1.8342364113867968e-32,1.0,"Yes",1.0,2.850417462754873e-43,"No",1.9583300597975086e-36,1.0,"Yes",4.456652797629982e-17,1.0,"Yes",1.0,3.441977393733382e-28,"No",4.407334994780825e-32,1.0,"Yes"
"2013-000895-14","A 52-week double-blind randomised placebo-controlled parallel-groupphase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D).52týdenní dvojitě zaslepená randomizovaná placebem kontrolovaná studie fáze III paralelních skupin s opětovnou randomizací po 25 týdnech k posouzení účinnosti a bezpečnosti perorálního užívání ibodutantu 10 mg jednou denně u pacientek se syndromem dráždivého tračníku s průjmem ","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8632803716713514e-116,2.1309711637205045e-34,1.0,"2+",1.0,1.877309291326747e-33,"No",1.8342364113867968e-32,1.0,"Yes",1.0,2.850417462754873e-43,"No",1.9583300597975086e-36,1.0,"Yes",4.456652797629982e-17,1.0,"Yes",1.0,3.441977393733382e-28,"No",4.407334994780825e-32,1.0,"Yes"
"2013-000895-14","A 52-week double-blind randomised placebo-controlled parallel-groupphase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D).","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3687031500548263e-59,7.705407584050022e-15,1.0,"2+",1.0,7.338976165825449e-17,"No",1.1796214297582167e-15,1.0,"Yes",0.9999999999999432,5.876175945107214e-14,"No",3.2096572619944755e-17,1.0,"Yes",9.45819960515067e-09,0.9999999905417952,"Yes",0.9999999999798206,2.0190570611403357e-11,"No",8.660053541370189e-15,1.0,"Yes"
"2013-000895-14","A 52-week double-blind randomised placebo-controlled parallel-groupphase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D).","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3687031500548263e-59,7.705407584050022e-15,1.0,"2+",1.0,7.338976165825449e-17,"No",1.1796214297582167e-15,1.0,"Yes",0.9999999999999432,5.876175945107214e-14,"No",3.2096572619944755e-17,1.0,"Yes",9.45819960515067e-09,0.9999999905417952,"Yes",0.9999999999798206,2.0190570611403357e-11,"No",8.660053541370189e-15,1.0,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5395111370365912e-33,2.9802504265135647e-05,0.9999701974957419,"2+",0.03205070488462167,0.9679492951153772,"Yes",0.961281510124421,0.03871848987557558,"No",0.999999893822482,1.0617752250272567e-07,"No",8.184229555675387e-05,0.999918157704449,"Yes",0.00016276002450346425,0.9998372399754945,"No",0.9999131027922911,8.689720770388551e-05,"No",0.0009220692475534893,0.99907793075245,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on DialysisRandomizované otvorené klinické skúšanie vo fáze 3 s aktívnou kontrolou na zhodnotenie účinnosti a bezpečnosti lieku roxadustat pri liečbe anémie u nedialyzovaných pacientov s chronickým renálnym ochorením.","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.506597801818398e-63,9.41297315754785e-12,0.999999999990564,"2+",0.9977819496708833,0.0022180503290963067,"Yes",0.0005538175977551887,0.9994461824022539,"No",1.0,1.3385138730473054e-26,"No",4.639259467146535e-16,1.0,"Yes",4.457417612246275e-08,0.9999999554258362,"No",1.0,1.4540730845196166e-27,"No",1.3254801269722555e-12,0.9999999999986926,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5395111370365912e-33,2.9802504265135647e-05,0.9999701974957419,"2+",0.03205070488462167,0.9679492951153772,"Yes",0.961281510124421,0.03871848987557558,"No",0.999999893822482,1.0617752250272567e-07,"No",8.184229555675387e-05,0.999918157704449,"Yes",0.00016276002450346425,0.9998372399754945,"No",0.9999131027922911,8.689720770388551e-05,"No",0.0009220692475534893,0.99907793075245,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5395111370365912e-33,2.9802504265135647e-05,0.9999701974957419,"2+",0.03205070488462167,0.9679492951153772,"Yes",0.961281510124421,0.03871848987557558,"No",0.999999893822482,1.0617752250272567e-07,"No",8.184229555675387e-05,0.999918157704449,"Yes",0.00016276002450346425,0.9998372399754945,"No",0.9999131027922911,8.689720770388551e-05,"No",0.0009220692475534893,0.99907793075245,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on DialysisRandomizované otvorené klinické skúšanie vo fáze 3 s aktívnou kontrolou na zhodnotenie účinnosti a bezpečnosti lieku roxadustat pri liečbe anémie u nedialyzovaných pacientov s chronickým renálnym ochorením.","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.506597801818398e-63,9.41297315754785e-12,0.999999999990564,"2+",0.9977819496708833,0.0022180503290963067,"Yes",0.0005538175977551887,0.9994461824022539,"No",1.0,1.3385138730473054e-26,"No",4.639259467146535e-16,1.0,"Yes",4.457417612246275e-08,0.9999999554258362,"No",1.0,1.4540730845196166e-27,"No",1.3254801269722555e-12,0.9999999999986926,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on Dialysis","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.325125396840959e-26,6.536686259784253e-06,0.999993463313734,"2+",0.3941645595318077,0.6058354404681886,"Yes",0.5305951280003125,0.46940487199968656,"No",0.9999999894158976,1.0584103414485862e-08,"No",1.0384887082915766e-05,0.9999896151129167,"Yes",2.6564971952764043e-05,0.999973435028053,"No",0.9999971921885928,2.8078114063001424e-06,"No",6.98362973105201e-05,0.999930163702686,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on DialysisRandomizované otvorené klinické skúšanie vo fáze 3 s aktívnou kontrolou na zhodnotenie účinnosti a bezpečnosti lieku roxadustat pri liečbe anémie u nedialyzovaných pacientov s chronickým renálnym ochorením.","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.506597801818398e-63,9.41297315754785e-12,0.999999999990564,"2+",0.9977819496708833,0.0022180503290963067,"Yes",0.0005538175977551887,0.9994461824022539,"No",1.0,1.3385138730473054e-26,"No",4.639259467146535e-16,1.0,"Yes",4.457417612246275e-08,0.9999999554258362,"No",1.0,1.4540730845196166e-27,"No",1.3254801269722555e-12,0.9999999999986926,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on DialysisRandomizované otvorené klinické skúšanie vo fáze 3 s aktívnou kontrolou na zhodnotenie účinnosti a bezpečnosti lieku roxadustat pri liečbe anémie u nedialyzovaných pacientov s chronickým renálnym ochorením.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.506597801818398e-63,9.41297315754785e-12,0.999999999990564,"2+",0.9977819496708833,0.0022180503290963067,"Yes",0.0005538175977551887,0.9994461824022539,"No",1.0,1.3385138730473054e-26,"No",4.639259467146535e-16,1.0,"Yes",4.457417612246275e-08,0.9999999554258362,"No",1.0,1.4540730845196166e-27,"No",1.3254801269722555e-12,0.9999999999986926,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on DialysisRandomizované otvorené klinické skúšanie vo fáze 3 s aktívnou kontrolou na zhodnotenie účinnosti a bezpečnosti lieku roxadustat pri liečbe anémie u nedialyzovaných pacientov s chronickým renálnym ochorením.","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.506597801818398e-63,9.41297315754785e-12,0.999999999990564,"2+",0.9977819496708833,0.0022180503290963067,"Yes",0.0005538175977551887,0.9994461824022539,"No",1.0,1.3385138730473054e-26,"No",4.639259467146535e-16,1.0,"Yes",4.457417612246275e-08,0.9999999554258362,"No",1.0,1.4540730845196166e-27,"No",1.3254801269722555e-12,0.9999999999986926,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis","SI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5395111370365912e-33,2.9802504265135647e-05,0.9999701974957419,"2+",0.03205070488462167,0.9679492951153772,"Yes",0.961281510124421,0.03871848987557558,"No",0.999999893822482,1.0617752250272567e-07,"No",8.184229555675387e-05,0.999918157704449,"Yes",0.00016276002450346425,0.9998372399754945,"No",0.9999131027922911,8.689720770388551e-05,"No",0.0009220692475534893,0.99907793075245,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on Dialysis","FI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.325125396840959e-26,6.536686259784253e-06,0.999993463313734,"2+",0.3941645595318077,0.6058354404681886,"Yes",0.5305951280003125,0.46940487199968656,"No",0.9999999894158976,1.0584103414485862e-08,"No",1.0384887082915766e-05,0.9999896151129167,"Yes",2.6564971952764043e-05,0.999973435028053,"No",0.9999971921885928,2.8078114063001424e-06,"No",6.98362973105201e-05,0.999930163702686,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5395111370365912e-33,2.9802504265135647e-05,0.9999701974957419,"2+",0.03205070488462167,0.9679492951153772,"Yes",0.961281510124421,0.03871848987557558,"No",0.999999893822482,1.0617752250272567e-07,"No",8.184229555675387e-05,0.999918157704449,"Yes",0.00016276002450346425,0.9998372399754945,"No",0.9999131027922911,8.689720770388551e-05,"No",0.0009220692475534893,0.99907793075245,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on Dialysis","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.325125396840959e-26,6.536686259784253e-06,0.999993463313734,"2+",0.3941645595318077,0.6058354404681886,"Yes",0.5305951280003125,0.46940487199968656,"No",0.9999999894158976,1.0584103414485862e-08,"No",1.0384887082915766e-05,0.9999896151129167,"Yes",2.6564971952764043e-05,0.999973435028053,"No",0.9999971921885928,2.8078114063001424e-06,"No",6.98362973105201e-05,0.999930163702686,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on Dialysis","HR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.325125396840959e-26,6.536686259784253e-06,0.999993463313734,"2+",0.3941645595318077,0.6058354404681886,"Yes",0.5305951280003125,0.46940487199968656,"No",0.9999999894158976,1.0584103414485862e-08,"No",1.0384887082915766e-05,0.9999896151129167,"Yes",2.6564971952764043e-05,0.999973435028053,"No",0.9999971921885928,2.8078114063001424e-06,"No",6.98362973105201e-05,0.999930163702686,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on Dialysis","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.325125396840959e-26,6.536686259784253e-06,0.999993463313734,"2+",0.3941645595318077,0.6058354404681886,"Yes",0.5305951280003125,0.46940487199968656,"No",0.9999999894158976,1.0584103414485862e-08,"No",1.0384887082915766e-05,0.9999896151129167,"Yes",2.6564971952764043e-05,0.999973435028053,"No",0.9999971921885928,2.8078114063001424e-06,"No",6.98362973105201e-05,0.999930163702686,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on Dialysis","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.325125396840959e-26,6.536686259784253e-06,0.999993463313734,"2+",0.3941645595318077,0.6058354404681886,"Yes",0.5305951280003125,0.46940487199968656,"No",0.9999999894158976,1.0584103414485862e-08,"No",1.0384887082915766e-05,0.9999896151129167,"Yes",2.6564971952764043e-05,0.999973435028053,"No",0.9999971921885928,2.8078114063001424e-06,"No",6.98362973105201e-05,0.999930163702686,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluatethe Efficacy and Safety of Roxadustat in the Treatment of Anemia in ChronicKidney Disease Patients Not on Dialysis","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.325125396840959e-26,6.536686259784253e-06,0.999993463313734,"2+",0.3941645595318077,0.6058354404681886,"Yes",0.5305951280003125,0.46940487199968656,"No",0.9999999894158976,1.0584103414485862e-08,"No",1.0384887082915766e-05,0.9999896151129167,"Yes",2.6564971952764043e-05,0.999973435028053,"No",0.9999971921885928,2.8078114063001424e-06,"No",6.98362973105201e-05,0.999930163702686,"Yes"
"2013-000951-42","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5395111370365912e-33,2.9802504265135647e-05,0.9999701974957419,"2+",0.03205070488462167,0.9679492951153772,"Yes",0.961281510124421,0.03871848987557558,"No",0.999999893822482,1.0617752250272567e-07,"No",8.184229555675387e-05,0.999918157704449,"Yes",0.00016276002450346425,0.9998372399754945,"No",0.9999131027922911,8.689720770388551e-05,"No",0.0009220692475534893,0.99907793075245,"Yes"
"2013-000999-15","The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M reg Trial","DE","No","No","Yes","","No","No","No","No","2+","","","Yes","No","No","No","No","No","1","No",6.655760552445784e-15,0.4574708237658236,0.5425291762341697,"-1",0.004080145319482572,0.9959198546805115,"Information not present in EudraCT",0.9979132648443974,0.0020867351556008414,"Information not present in EudraCT",0.9999973361405193,2.663859482039371e-06,"Information not present in EudraCT",0.5007918654313457,0.49920813456865926,"No",0.9678294709127816,0.032170529087213635,"",0.9999993409650939,6.590349042516139e-07,"",0.668667392133729,0.33133260786627494,""
"2013-001192-21","A randomized parallel group open-label multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific","IT","No","No","Yes","ok","No","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.511546606803874e-44,3.2089074315915347e-13,0.9999999999996874,"2+",5.976417234826593e-05,0.9999402358276515,"Yes",0.9999250951456151,7.490485438713534e-05,"No",0.9999999999999432,4.512256591122196e-14,"No",1.2558543818626725e-13,0.9999999999998864,"Yes",1.2062481690437973e-07,0.9999998793751745,"No",1.0,1.0396511798282346e-14,"No",0.9969603803738074,0.0030396196261925873,"Yes"
"2013-001192-21","A randomized parallel group open-label multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific","ES","No","No","Yes","ok","No","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.511546606803874e-44,3.2089074315915347e-13,0.9999999999996874,"2+",5.976417234826593e-05,0.9999402358276515,"Yes",0.9999250951456151,7.490485438713534e-05,"No",0.9999999999999432,4.512256591122196e-14,"No",1.2558543818626725e-13,0.9999999999998864,"Yes",1.2062481690437973e-07,0.9999998793751745,"No",1.0,1.0396511798282346e-14,"No",0.9969603803738074,0.0030396196261925873,"Yes"
"2013-001192-21","A randomized parallel group open-label multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific","PL","No","No","Yes","ok","No","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.511546606803874e-44,3.2089074315915347e-13,0.9999999999996874,"2+",5.976417234826593e-05,0.9999402358276515,"Yes",0.9999250951456151,7.490485438713534e-05,"No",0.9999999999999432,4.512256591122196e-14,"No",1.2558543818626725e-13,0.9999999999998864,"Yes",1.2062481690437973e-07,0.9999998793751745,"No",1.0,1.0396511798282346e-14,"No",0.9969603803738074,0.0030396196261925873,"Yes"
"2013-001192-21","A randomized parallel group open-label multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific","HU","No","No","Yes","ok","No","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.511546606803874e-44,3.2089074315915347e-13,0.9999999999996874,"2+",5.976417234826593e-05,0.9999402358276515,"Yes",0.9999250951456151,7.490485438713534e-05,"No",0.9999999999999432,4.512256591122196e-14,"No",1.2558543818626725e-13,0.9999999999998864,"Yes",1.2062481690437973e-07,0.9999998793751745,"No",1.0,1.0396511798282346e-14,"No",0.9969603803738074,0.0030396196261925873,"Yes"
"2013-001192-21","A randomized parallel group open-label multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific","BG","No","No","Yes","ok","No","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.511546606803874e-44,3.2089074315915347e-13,0.9999999999996874,"2+",5.976417234826593e-05,0.9999402358276515,"Yes",0.9999250951456151,7.490485438713534e-05,"No",0.9999999999999432,4.512256591122196e-14,"No",1.2558543818626725e-13,0.9999999999998864,"Yes",1.2062481690437973e-07,0.9999998793751745,"No",1.0,1.0396511798282346e-14,"No",0.9969603803738074,0.0030396196261925873,"Yes"
"2013-001192-21","A randomized parallel group open-label multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific","DE","No","No","Yes","ok","No","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.511546606803874e-44,3.2089074315915347e-13,0.9999999999996874,"2+",5.976417234826593e-05,0.9999402358276515,"Yes",0.9999250951456151,7.490485438713534e-05,"No",0.9999999999999432,4.512256591122196e-14,"No",1.2558543818626725e-13,0.9999999999998864,"Yes",1.2062481690437973e-07,0.9999998793751745,"No",1.0,1.0396511798282346e-14,"No",0.9969603803738074,0.0030396196261925873,"Yes"
"2013-001193-14","A randomized placebo-controlled double-blind parallel group multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85-3934 administered orally in the correction of anemia in erythropoiesis-stimulating agent naïve pre dialysis subjects with chronic kidney disease in Europe and Asia PacificEstudio aleatorizado multicéntrico controlado con placebo doble ciego y de grupos paralelos para investigar la eficacia y seguridad de 5 dosis fijas de BAY 85-3934 administrado por vía oral para corregir antes de la diálisis la anemia de pacientes procedentes de Europa y del Pacífico asiático con nefropatía crónica y que nunca han recibido un fármaco estimulante de la eritropoyesis","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5612284363546377e-131,4.966874421382997e-31,1.0,"2+",0.9999791953383295,2.080466168238601e-05,"No",0.000673100415672816,0.9993268995843764,"Yes",1.0,2.758668076352291e-32,"No",7.873000441603724e-30,1.0,"Yes",6.816016842198004e-14,0.9999999999998864,"Yes",1.0,9.619087755290525e-34,"No",7.182341580428927e-05,0.9999281765842469,"Yes"
"2013-001193-14","randomized placebo-controlled double-blind parallel group multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85- 934 administered orally in the correction of anemia in pre-dialysis subjects with chronic kidney disease not currently treated with erythropoiesis-stimulating agent in Europe and Asia Pacific","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.278093045249478e-65,2.9878449262035657e-13,0.9999999999996874,"2+",0.9999982164196116,1.7835803900373268e-06,"No",1.1948070516408012e-05,0.9999880519294896,"Yes",0.9999999999985221,1.4867617054422391e-12,"No",1.1010738841015669e-13,0.9999999999998864,"Yes",3.050995829654291e-07,0.999999694900414,"Yes",0.999999999999801,1.8920012027733751e-13,"No",2.120630321873595e-05,0.9999787936967678,"Yes"
"2013-001193-14","A randomized placebo-controlled double-blind parallel group multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85- 3934 administered orally in the correction of anemia in pre-dialysis subjects with chronic kidney disease not currently treated with erythropoiesis-stimulating agent in Europe and Asia Pacific","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.398503845488157e-66,6.016476969298521e-14,0.9999999999999432,"2+",0.9999548342293624,4.516577064570022e-05,"No",0.000279680630884033,0.9997203193691322,"Yes",0.9999999999997727,2.123914172689312e-13,"No",1.5556732743374018e-14,1.0,"Yes",4.960845429408351e-08,0.999999950391556,"Yes",0.9999999999999432,2.864853151180448e-14,"No",0.0012718178969250706,0.9987281821031,"Yes"
"2013-001193-14","A randomized placebo-controlled double-blind parallel group multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85-3934 administered orally in the correction of anemia in erythropoiesis-stimulating agent naïve pre dialysis subjects with chronic kidney disease in Europe and Asia PacificEstudio aleatorizado multicéntrico controlado con placebo doble ciego y de grupos paralelos para investigar la eficacia y seguridad de 5 dosis fijas de BAY 85-3934 administrado por vía oral para corregir antes de la diálisis la anemia de pacientes procedentes de Europa y del Pacífico asiático con nefropatía crónica y que nunca han recibido un fármaco estimulante de la eritropoyesis","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5612284363546377e-131,4.966874421382997e-31,1.0,"2+",0.9999791953383295,2.080466168238601e-05,"No",0.000673100415672816,0.9993268995843764,"Yes",1.0,2.758668076352291e-32,"No",7.873000441603724e-30,1.0,"Yes",6.816016842198004e-14,0.9999999999998864,"Yes",1.0,9.619087755290525e-34,"No",7.182341580428927e-05,0.9999281765842469,"Yes"
"2013-001193-14","A randomized placebo-controlled double-blind parallel group multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85- 3934 administered orally in the correction of anemia in pre-dialysis subjects with chronic kidney disease not currently treated with erythropoiesis-stimulating agent in Europe and Asia Pacific","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.398503845488157e-66,6.016476969298521e-14,0.9999999999999432,"2+",0.9999548342293624,4.516577064570022e-05,"No",0.000279680630884033,0.9997203193691322,"Yes",0.9999999999997727,2.123914172689312e-13,"No",1.5556732743374018e-14,1.0,"Yes",4.960845429408351e-08,0.999999950391556,"Yes",0.9999999999999432,2.864853151180448e-14,"No",0.0012718178969250706,0.9987281821031,"Yes"
"2013-001193-14","A randomized placebo-controlled double-blind parallel group multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85-3934 administered orally in the correction of anemia in erythropoiesis-stimulating agent naïve pre dialysis subjects with chronic kidney disease in Europe and Asia PacificEstudio aleatorizado multicéntrico controlado con placebo doble ciego y de grupos paralelos para investigar la eficacia y seguridad de 5 dosis fijas de BAY 85-3934 administrado por vía oral para corregir antes de la diálisis la anemia de pacientes procedentes de Europa y del Pacífico asiático con nefropatía crónica y que nunca han recibido un fármaco estimulante de la eritropoyesis","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5612284363546377e-131,4.966874421382997e-31,1.0,"2+",0.9999791953383295,2.080466168238601e-05,"No",0.000673100415672816,0.9993268995843764,"Yes",1.0,2.758668076352291e-32,"No",7.873000441603724e-30,1.0,"Yes",6.816016842198004e-14,0.9999999999998864,"Yes",1.0,9.619087755290525e-34,"No",7.182341580428927e-05,0.9999281765842469,"Yes"
"2013-001284-23","A randomized phase IIIB open-label two-arm multicenter comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex TEVA) in comparison to pegfilgrastim (Neulasta® Amgen) in elderly patients with aggressive B cell Non-HOdgkin lymphomas at hIgh risk for R-CHOP-21-inDuced neutropenia – AVOID Neutropenia","DE","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.072516888810415e-46,0.33719469958995596,0.6628053004100478,"2+",3.8303890452891437e-10,0.999999999616989,"Yes",0.9999999999127455,8.72350195538654e-11,"No",1.0,1.1551082147745983e-23,"No",0.48154415409418255,0.5184558459058165,"Yes",0.9937913521842072,0.006208647815819565,"Yes",1.0,1.4972684932919586e-19,"No",0.9672912183153607,0.03270878168465938,"Yes"
"2013-001284-23","A randomized phase IIIB open-label two-arm multicenter comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex TEVA) in comparison to pegfilgrastim (Neulasta® Amgen) in elderly patients with aggressive B cell Non-HOdgkin lymphomas at hIgh risk for R-CHOP-21-inDuced neutropenia – AVOID Neutropenia","IT","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.072516888810415e-46,0.33719469958995596,0.6628053004100478,"2+",3.8303890452891437e-10,0.999999999616989,"Yes",0.9999999999127455,8.72350195538654e-11,"No",1.0,1.1551082147745983e-23,"No",0.48154415409418255,0.5184558459058165,"Yes",0.9937913521842072,0.006208647815819565,"Yes",1.0,1.4972684932919586e-19,"No",0.9672912183153607,0.03270878168465938,"Yes"
"2013-001284-23","A randomized phase IIIB open-label two-arm multicenter comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex TEVA) in comparison to pegfilgrastim (Neulasta® Amgen) in elderly patients with aggressive B cell Non-HOdgkin lymphomas at hIgh risk for R-CHOP-21-inDuced neutropenia – AVOID Neutropenia","ES","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.072516888810415e-46,0.33719469958995596,0.6628053004100478,"2+",3.8303890452891437e-10,0.999999999616989,"Yes",0.9999999999127455,8.72350195538654e-11,"No",1.0,1.1551082147745983e-23,"No",0.48154415409418255,0.5184558459058165,"Yes",0.9937913521842072,0.006208647815819565,"Yes",1.0,1.4972684932919586e-19,"No",0.9672912183153607,0.03270878168465938,"Yes"
"2013-001322-26","A randomized open-label three-arm multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.714731097457224e-55,0.0006817499506696041,0.9993182500493295,"2+",4.135213496592025e-09,0.9999999958647835,"Yes",0.9999999928007243,7.1992707652932294e-09,"No",1.0,6.5050233675536496e-15,"No",0.010561384290001972,0.9894386157099868,"Yes",0.8760029534349046,0.12399704656509007,"Yes",0.9999999999996306,3.6992467305372503e-13,"No",0.002486595302878927,0.9975134046971211,"Yes"
"2013-001322-26","A randomized open-label three-arm multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.714731097457224e-55,0.0006817499506696041,0.9993182500493295,"2+",4.135213496592025e-09,0.9999999958647835,"Yes",0.9999999928007243,7.1992707652932294e-09,"No",1.0,6.5050233675536496e-15,"No",0.010561384290001972,0.9894386157099868,"Yes",0.8760029534349046,0.12399704656509007,"Yes",0.9999999999996306,3.6992467305372503e-13,"No",0.002486595302878927,0.9975134046971211,"Yes"
"2013-001322-26","A randomized open-label three-arm multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.714731097457224e-55,0.0006817499506696041,0.9993182500493295,"2+",4.135213496592025e-09,0.9999999958647835,"Yes",0.9999999928007243,7.1992707652932294e-09,"No",1.0,6.5050233675536496e-15,"No",0.010561384290001972,0.9894386157099868,"Yes",0.8760029534349046,0.12399704656509007,"Yes",0.9999999999996306,3.6992467305372503e-13,"No",0.002486595302878927,0.9975134046971211,"Yes"
"2013-001323-38","A randomized open-label parallel group multi-center Phase II clinicaltrial evaluating effect of addition of DCVAC/OvCa to standardchemotherapy (carboplatin and gemcitabine) in women with relapsedplatinum sensitive epithelial ovarian carcinomaRandomizované nezaslepené multicentrické klinické hodnocení fáze II s paralelními skupinami vyhodnocující účinek přídavku DCVAC/OvCa ke standardní chemoterapii (karboplatina a gemcitabin) u žen s recidivujícím epiteliálním ovariálním karcinomem citlivým na platinu","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.722482331370521e-79,5.322003657920804e-17,1.0,"2+",2.0515481817697004e-16,1.0,"Yes",1.0,2.121475914401441e-15,"No",1.0,1.1803444795971832e-43,"No",1.6384310487925114e-18,1.0,"Yes",3.071854151058177e-06,0.9999969281458336,"Yes",1.0,2.9090534776437424e-37,"No",7.328055706068881e-14,0.9999999999999432,"Yes"
"2013-001323-38","A randomized open-label parallel group multi-center Phase II clinicaltrial evaluating effect of addition of DCVAC/OvCa to standardchemotherapy (carboplatin and gemcitabine) in women with relapsedplatinum sensitive epithelial ovarian carcinoma","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5936349241252936e-42,1.7277782341542693e-06,0.9999982722217601,"2+",8.505607929852841e-08,0.999999914943917,"Yes",0.9999998651015949,1.348984024500706e-07,"No",1.0,6.349722650507608e-16,"No",9.237303318554155e-06,0.9999907626966863,"Yes",0.005420894988992135,0.9945791050110137,"Yes",1.0,7.462117262943632e-15,"No",4.842372311545274e-06,0.9999951576276804,"Yes"
"2013-001323-38","A randomized open-label parallel group multi-center Phase II clinicaltrial evaluating effect of addition of DCVAC/OvCa to standardchemotherapy (carboplatin and gemcitabine) in women with relapsedplatinum sensitive epithelial ovarian carcinoma","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5936349241252936e-42,1.7277782341542693e-06,0.9999982722217601,"2+",8.505607929852841e-08,0.999999914943917,"Yes",0.9999998651015949,1.348984024500706e-07,"No",1.0,6.349722650507608e-16,"No",9.237303318554155e-06,0.9999907626966863,"Yes",0.005420894988992135,0.9945791050110137,"Yes",1.0,7.462117262943632e-15,"No",4.842372311545274e-06,0.9999951576276804,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","BG","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","SK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001497-16","A Phase 3 Randomized Open-Label Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis ","HR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9492277286289745e-34,7.458834067095201e-07,0.9999992541165963,"2+",0.170260631462465,0.8297393685375272,"Yes",0.8061620738832452,0.19383792611674946,"No",0.9999999975730135,2.4269923222832287e-09,"No",1.6125022079454286e-06,0.9999983874978041,"Yes",0.00016344270788322735,0.9998365572921104,"No",0.9999902415146744,9.758485325451131e-06,"No",9.598192271577465e-05,0.9999040180772711,"Yes"
"2013-001790-25","An Open-Label Single-Arm Study of the Safety Efficacy and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate CarcinomaOtvorená jednoramenná štúdia bezpečnosti účinnosti a farmakokinetického správania leuprolid mesylátu pre injekčnú suspenziu (LMIS 50 mg) u subjektov s pokročilým karcinómom prostaty","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.436707151846404e-54,1.0,3.1117159171270034e-18,"1",2.897526782562769e-14,0.9999999999999432,"Yes",1.0,2.0547544722877176e-14,"No",1.0,1.2381096838719948e-25,"No",1.0,9.733098335046365e-18,"No",0.9999999999998864,1.1781049325662197e-13,"No",0.9999999999997727,2.0066842342407423e-13,"No",1.0,5.617487384602351e-17,"No"
"2013-001790-25","An Open-Label Single-Arm Study of the Safety Efficacy and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate Carcinoma","AT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.215672391158593e-26,0.9999997520460818,2.4795391159150544e-07,"1",1.5813401928832736e-06,0.9999984186597997,"Yes",0.9999996541843957,3.4581560628592053e-07,"No",0.9999999990415916,9.583958354121124e-10,"No",0.9999996113216315,3.8867836091466524e-07,"No",0.9996396431634009,0.00036035683659410545,"No",0.9996207874216462,0.00037921257836716105,"No",0.9999986270875684,1.372912434584133e-06,"No"
"2013-001790-25","An Open-Label Single-Arm Study of the Safety Efficacy and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate CarcinomaOtvorená jednoramenná štúdia bezpečnosti účinnosti a farmakokinetického správania leuprolid mesylátu pre injekčnú suspenziu (LMIS 50 mg) u subjektov s pokročilým karcinómom prostaty","PL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.436707151846404e-54,1.0,3.1117159171270034e-18,"1",2.897526782562769e-14,0.9999999999999432,"Yes",1.0,2.0547544722877176e-14,"No",1.0,1.2381096838719948e-25,"No",1.0,9.733098335046365e-18,"No",0.9999999999998864,1.1781049325662197e-13,"No",0.9999999999997727,2.0066842342407423e-13,"No",1.0,5.617487384602351e-17,"No"
"2013-001790-25","An Open-Label Single-Arm Study of the Safety Efficacy and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate CarcinomaOtvorená jednoramenná štúdia bezpečnosti účinnosti a farmakokinetického správania leuprolid mesylátu pre injekčnú suspenziu (LMIS 50 mg) u subjektov s pokročilým karcinómom prostaty","LT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.436707151846404e-54,1.0,3.1117159171270034e-18,"1",2.897526782562769e-14,0.9999999999999432,"Yes",1.0,2.0547544722877176e-14,"No",1.0,1.2381096838719948e-25,"No",1.0,9.733098335046365e-18,"No",0.9999999999998864,1.1781049325662197e-13,"No",0.9999999999997727,2.0066842342407423e-13,"No",1.0,5.617487384602351e-17,"No"
"2013-001790-25","An Open-Label Single-Arm Study of the Safety Efficacy and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate CarcinomaOtvorená jednoramenná štúdia bezpečnosti účinnosti a farmakokinetického správania leuprolid mesylátu pre injekčnú suspenziu (LMIS 50 mg) u subjektov s pokročilým karcinómom prostaty","SK","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.436707151846404e-54,1.0,3.1117159171270034e-18,"1",2.897526782562769e-14,0.9999999999999432,"Yes",1.0,2.0547544722877176e-14,"No",1.0,1.2381096838719948e-25,"No",1.0,9.733098335046365e-18,"No",0.9999999999998864,1.1781049325662197e-13,"No",0.9999999999997727,2.0066842342407423e-13,"No",1.0,5.617487384602351e-17,"No"
"2013-001790-25","An Open-Label Single-Arm Study of the Safety Efficacy and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate CarcinomaOtvorená jednoramenná štúdia bezpečnosti účinnosti a farmakokinetického správania leuprolid mesylátu pre injekčnú suspenziu (LMIS 50 mg) u subjektov s pokročilým karcinómom prostaty","CZ","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.436707151846404e-54,1.0,3.1117159171270034e-18,"1",2.897526782562769e-14,0.9999999999999432,"Yes",1.0,2.0547544722877176e-14,"No",1.0,1.2381096838719948e-25,"No",1.0,9.733098335046365e-18,"No",0.9999999999998864,1.1781049325662197e-13,"No",0.9999999999997727,2.0066842342407423e-13,"No",1.0,5.617487384602351e-17,"No"
"2013-001903-36","A PHASE 2 MULTICENTER OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND MODERATE OR SEVERE RENAL IMPAIRMENT INCLUDING SUBJECTS UNDERGOING HEMODIALYSIS","FR","No","No","Yes","","No","No","Yes","No","2+","","","Yes","No","No","No","No","No","1","No",6.245511847686882e-46,0.051374763100936735,0.9486252368990747,"-1",1.8890496362657791e-06,0.999998110950366,"Information not present in EudraCT",0.9999972576375258,2.742362484625348e-06,"Information not present in EudraCT",1.0,3.0078459901755346e-16,"Information not present in EudraCT",0.9794907056461873,0.02050929435381606,"No",0.32155716376129206,0.678442836238718,"",0.9999999933753828,6.624626646841305e-09,"",0.9924169033686894,0.007583096631320701,""
"2013-001903-36","A PHASE 2 MULTICENTER OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND MODERATE OR SEVERE RENAL IMPAIRMENT INCLUDING SUBJECTS UNDERGOING HEMODIALYSISΜία Φάσης ΙΙ Πολυκεντρική Ανοικτής Επισήμανσης Ερευνητικού Προϊόντος Κλινική Μελέτη για τον Προσδιορισμό της Αποτελεσματικότητας και της Ασφάλειας της Πομαλιδομίδης (CC-4047) σε Συνδυασμό με Χαμηλή Δόση Δεξαμεθαζόνης σε Ασθενείς με Υποτροπιάζον ή Ανθεκτικό Πολλαπλούν Μυέλωμα και Μέτρια έως Σοβαρή Νεφρική Ανεπάρκεια Συμπεριλαμβανόμενων Ασθενών Σε Αιμοκάθαρση","GB","No","No","Yes","","No","No","Yes","No","2+","","","Yes","No","No","No","No","No","1","No",7.102010080856511e-48,0.002604965369502593,0.9973950346304975,"-1",2.3621379913242976e-06,0.9999976378620136,"Information not present in EudraCT",0.9999959886019976,4.011397989058554e-06,"Information not present in EudraCT",1.0,4.627085950978264e-19,"Information not present in EudraCT",0.9855851447592692,0.014414855240718573,"No",0.13768480238888922,0.8623151976111029,"",0.9999999999884892,1.1501780486150057e-11,"",0.998270023963195,0.0017299760368046366,""
"2013-001903-36","A PHASE 2 MULTICENTER OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND MODERATE OR SEVERE RENAL IMPAIRMENT INCLUDING SUBJECTS UNDERGOING HEMODIALYSISΜία Φάσης ΙΙ Πολυκεντρική Ανοικτής Επισήμανσης Ερευνητικού Προϊόντος Κλινική Μελέτη για τον Προσδιορισμό της Αποτελεσματικότητας και της Ασφάλειας της Πομαλιδομίδης (CC-4047) σε Συνδυασμό με Χαμηλή Δόση Δεξαμεθαζόνης σε Ασθενείς με Υποτροπιάζον ή Ανθεκτικό Πολλαπλούν Μυέλωμα και Μέτρια έως Σοβαρή Νεφρική Ανεπάρκεια Συμπεριλαμβανόμενων Ασθενών Σε Αιμοκάθαρση","NL","No","No","Yes","","No","No","Yes","No","2+","","","Yes","No","No","No","No","No","1","No",7.102010080856511e-48,0.002604965369502593,0.9973950346304975,"-1",2.3621379913242976e-06,0.9999976378620136,"Information not present in EudraCT",0.9999959886019976,4.011397989058554e-06,"Information not present in EudraCT",1.0,4.627085950978264e-19,"Information not present in EudraCT",0.9855851447592692,0.014414855240718573,"No",0.13768480238888922,0.8623151976111029,"",0.9999999999884892,1.1501780486150057e-11,"",0.998270023963195,0.0017299760368046366,""
"2013-001903-36","A PHASE 2 MULTICENTER OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND MODERATE OR SEVERE RENAL IMPAIRMENT INCLUDING SUBJECTS UNDERGOING HEMODIALYSISΜία Φάσης ΙΙ Πολυκεντρική Ανοικτής Επισήμανσης Ερευνητικού Προϊόντος Κλινική Μελέτη για τον Προσδιορισμό της Αποτελεσματικότητας και της Ασφάλειας της Πομαλιδομίδης (CC-4047) σε Συνδυασμό με Χαμηλή Δόση Δεξαμεθαζόνης σε Ασθενείς με Υποτροπιάζον ή Ανθεκτικό Πολλαπλούν Μυέλωμα και Μέτρια έως Σοβαρή Νεφρική Ανεπάρκεια Συμπεριλαμβανόμενων Ασθενών Σε Αιμοκάθαρση","GR","No","No","Yes","ok","No","No","Yes","No","2+","","","Yes","No","No","No","No","No","1","No",7.102010080856511e-48,0.002604965369502593,0.9973950346304975,"-1",2.3621379913242976e-06,0.9999976378620136,"Yes",0.9999959886019976,4.011397989058554e-06,"No",1.0,4.627085950978264e-19,"No",0.9855851447592692,0.014414855240718573,"No",0.13768480238888922,0.8623151976111029,"",0.9999999999884892,1.1501780486150057e-11,"",0.998270023963195,0.0017299760368046366,""
"2013-001903-36","A PHASE 2 MULTICENTER OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND MODERATE OR SEVERE RENAL IMPAIRMENT INCLUDING SUBJECTS UNDERGOING HEMODIALYSISΜία Φάσης ΙΙ Πολυκεντρική Ανοικτής Επισήμανσης Ερευνητικού Προϊόντος Κλινική Μελέτη για τον Προσδιορισμό της Αποτελεσματικότητας και της Ασφάλειας της Πομαλιδομίδης (CC-4047) σε Συνδυασμό με Χαμηλή Δόση Δεξαμεθαζόνης σε Ασθενείς με Υποτροπιάζον ή Ανθεκτικό Πολλαπλούν Μυέλωμα και Μέτρια έως Σοβαρή Νεφρική Ανεπάρκεια Συμπεριλαμβανόμενων Ασθενών Σε Αιμοκάθαρση","ES","No","No","Yes","","No","No","Yes","No","2+","","","Yes","No","No","No","No","No","1","No",7.102010080856511e-48,0.002604965369502593,0.9973950346304975,"-1",2.3621379913242976e-06,0.9999976378620136,"Information not present in EudraCT",0.9999959886019976,4.011397989058554e-06,"Information not present in EudraCT",1.0,4.627085950978264e-19,"Information not present in EudraCT",0.9855851447592692,0.014414855240718573,"No",0.13768480238888922,0.8623151976111029,"",0.9999999999884892,1.1501780486150057e-11,"",0.998270023963195,0.0017299760368046366,""
"2013-001903-36","A PHASE 2 MULTICENTER OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND MODERATE OR SEVERE RENAL IMPAIRMENT INCLUDING SUBJECTS UNDERGOING HEMODIALYSISΜία Φάσης ΙΙ Πολυκεντρική Ανοικτής Επισήμανσης Ερευνητικού Προϊόντος Κλινική Μελέτη για τον Προσδιορισμό της Αποτελεσματικότητας και της Ασφάλειας της Πομαλιδομίδης (CC-4047) σε Συνδυασμό με Χαμηλή Δόση Δεξαμεθαζόνης σε Ασθενείς με Υποτροπιάζον ή Ανθεκτικό Πολλαπλούν Μυέλωμα και Μέτρια έως Σοβαρή Νεφρική Ανεπάρκεια Συμπεριλαμβανόμενων Ασθενών Σε Αιμοκάθαρση","IT","No","No","Yes","","No","No","Yes","No","2+","","","Yes","No","No","No","No","No","1","No",7.102010080856511e-48,0.002604965369502593,0.9973950346304975,"-1",2.3621379913242976e-06,0.9999976378620136,"Information not present in EudraCT",0.9999959886019976,4.011397989058554e-06,"Information not present in EudraCT",1.0,4.627085950978264e-19,"Information not present in EudraCT",0.9855851447592692,0.014414855240718573,"No",0.13768480238888922,0.8623151976111029,"",0.9999999999884892,1.1501780486150057e-11,"",0.998270023963195,0.0017299760368046366,""
"2013-002053-30","A Multicenter Single Arm Phase Ib/II Study to Evaluate Efficacy Safety and PK ofMSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma withChild Pugh Class A Liver Function Who Have Failed Sorafenib TreatmentEstudio de fase Ib/II multicéntrico de un solo grupo para evaluar la eficacia la seguridad y la FC de MSC2156119J en monoterapia en sujetos con carcinoma hepatocelular avanzado MET+ con función hepática de clase A de Child Pugh que han presentado fracaso durante el tratamiento con sorafenib","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.9759632051779333e-87,0.9999999319715608,6.802845120304967e-08,"1",1.0043979030833867e-16,1.0,"Yes",1.0,1.0398154021351146e-16,"No",1.0,7.222856141953396e-27,"No",0.9999999994256541,5.743220923005816e-10,"No",0.999999999960778,3.9242339611451383e-11,"No",1.0,2.3127740096159597e-28,"No",0.9999999976589606,2.3410241418840913e-09,"No"
"2013-002053-30","A Multicenter Single Arm Phase Ib/II Study to Evaluate Efficacy Safety and PK ofMSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma withChild Pugh Class A Liver Function Who Have Failed Sorafenib TreatmentStudio multicentrico a braccio singolo di Fase Ib/II per valutare l’efficacia la sicurezza e la farmacocinetica (PK) di MSC2156119J in monoterapia in soggetti affetti da carcinoma epatocellulare avanzato MET positivo (MET+) con funzionalità epatica Child Pugh di classe A non responsivi al trattamento con Sorafenib","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.703833255063697e-103,0.9999991129097863,8.870902356022606e-07,"1",2.689655030344894e-15,1.0,"Yes",1.0,1.9677601069153446e-15,"No",1.0,1.1379690931111255e-28,"No",0.9999999999885745,1.1443170060418055e-11,"No",0.9999999995521307,4.4788738445082856e-10,"No",1.0,5.873614695198308e-21,"No",0.999999998817259,1.1827131705792192e-09,"No"
"2013-002053-30","A Multicenter Single Arm Phase Ib/II Study to Evaluate Efficacy Safety and PK ofMSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma withChild Pugh Class A Liver Function Who Have Failed Sorafenib TreatmentEstudio de fase Ib/II multicéntrico de un solo grupo para evaluar la eficacia la seguridad y la FC de MSC2156119J en monoterapia en sujetos con carcinoma hepatocelular avanzado MET+ con función hepática de clase A de Child Pugh que han presentado fracaso durante el tratamiento con sorafenib","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.9759632051779333e-87,0.9999999319715608,6.802845120304967e-08,"1",1.0043979030833867e-16,1.0,"Yes",1.0,1.0398154021351146e-16,"No",1.0,7.222856141953396e-27,"No",0.9999999994256541,5.743220923005816e-10,"No",0.999999999960778,3.9242339611451383e-11,"No",1.0,2.3127740096159597e-28,"No",0.9999999976589606,2.3410241418840913e-09,"No"
"2013-002053-30","A Multicenter Single Arm Phase Ib/II Study to Evaluate Efficacy Safety and PK ofMSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma withChild Pugh Class A Liver Function Who Have Failed Sorafenib TreatmentStudio multicentrico a braccio singolo di Fase Ib/II per valutare l’efficacia la sicurezza e la farmacocinetica (PK) di MSC2156119J in monoterapia in soggetti affetti da carcinoma epatocellulare avanzato MET positivo (MET+) con funzionalità epatica Child Pugh di classe A non responsivi al trattamento con Sorafenib","IT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.703833255063697e-103,0.9999991129097863,8.870902356022606e-07,"1",2.689655030344894e-15,1.0,"Yes",1.0,1.9677601069153446e-15,"No",1.0,1.1379690931111255e-28,"No",0.9999999999885745,1.1443170060418055e-11,"No",0.9999999995521307,4.4788738445082856e-10,"No",1.0,5.873614695198308e-21,"No",0.999999998817259,1.1827131705792192e-09,"No"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMABMulticentrické otevřené randomizované klinické hodnocení fáze III pro pacienty s recidivující/rezistentní chronickou lymfocytární leukémií k vyhodnocení přínosu přípravku GDC-0199 (ABT-199) v kombinaci s rituximabem v porovnání s bendamustinem a rituximabem","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.718105733039227e-96,1.3640399025974862e-09,0.9999999986359853,"2+",3.0832183157642647e-16,1.0,"Yes",1.0,1.3753245616974504e-15,"No",1.0,9.454481675138245e-49,"No",1.2717455384047957e-09,0.9999999987282422,"No",0.7836633484912815,0.21633665150874537,"No",1.0,8.629190241071714e-35,"No",7.35665478130617e-05,0.9999264334521807,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2948266870715255e-49,0.002127729468951681,0.9978722705310533,"2+",2.8208073254731957e-10,0.9999999997179145,"Yes",0.9999999995169447,4.830604402505977e-10,"No",1.0,1.3604458320158446e-22,"No",0.01751209735226255,0.9824879026477271,"No",0.5573914109537973,0.4426085890461957,"No",1.0,8.724488230471478e-19,"No",0.008552509575128058,0.9914474904248797,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMABMulticentrické otevřené randomizované klinické hodnocení fáze III pro pacienty s recidivující/rezistentní chronickou lymfocytární leukémií k vyhodnocení přínosu přípravku GDC-0199 (ABT-199) v kombinaci s rituximabem v porovnání s bendamustinem a rituximabem","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.718105733039227e-96,1.3640399025974862e-09,0.9999999986359853,"2+",3.0832183157642647e-16,1.0,"Yes",1.0,1.3753245616974504e-15,"No",1.0,9.454481675138245e-49,"No",1.2717455384047957e-09,0.9999999987282422,"No",0.7836633484912815,0.21633665150874537,"No",1.0,8.629190241071714e-35,"No",7.35665478130617e-05,0.9999264334521807,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMABMulticentrické otevřené randomizované klinické hodnocení fáze III pro pacienty s recidivující/rezistentní chronickou lymfocytární leukémií k vyhodnocení přínosu přípravku GDC-0199 (ABT-199) v kombinaci s rituximabem v porovnání s bendamustinem a rituximabem","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.718105733039227e-96,1.3640399025974862e-09,0.9999999986359853,"2+",3.0832183157642647e-16,1.0,"Yes",1.0,1.3753245616974504e-15,"No",1.0,9.454481675138245e-49,"No",1.2717455384047957e-09,0.9999999987282422,"No",0.7836633484912815,0.21633665150874537,"No",1.0,8.629190241071714e-35,"No",7.35665478130617e-05,0.9999264334521807,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMABMulticentrické otevřené randomizované klinické hodnocení fáze III pro pacienty s recidivující/rezistentní chronickou lymfocytární leukémií k vyhodnocení přínosu přípravku GDC-0199 (ABT-199) v kombinaci s rituximabem v porovnání s bendamustinem a rituximabem","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.718105733039227e-96,1.3640399025974862e-09,0.9999999986359853,"2+",3.0832183157642647e-16,1.0,"Yes",1.0,1.3753245616974504e-15,"No",1.0,9.454481675138245e-49,"No",1.2717455384047957e-09,0.9999999987282422,"No",0.7836633484912815,0.21633665150874537,"No",1.0,8.629190241071714e-35,"No",7.35665478130617e-05,0.9999264334521807,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMABMulticentrické otevřené randomizované klinické hodnocení fáze III pro pacienty s recidivující/rezistentní chronickou lymfocytární leukémií k vyhodnocení přínosu přípravku GDC-0199 (ABT-199) v kombinaci s rituximabem v porovnání s bendamustinem a rituximabem","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.718105733039227e-96,1.3640399025974862e-09,0.9999999986359853,"2+",3.0832183157642647e-16,1.0,"Yes",1.0,1.3753245616974504e-15,"No",1.0,9.454481675138245e-49,"No",1.2717455384047957e-09,0.9999999987282422,"No",0.7836633484912815,0.21633665150874537,"No",1.0,8.629190241071714e-35,"No",7.35665478130617e-05,0.9999264334521807,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMABMulticentrické otevřené randomizované klinické hodnocení fáze III pro pacienty s recidivující/rezistentní chronickou lymfocytární leukémií k vyhodnocení přínosu přípravku GDC-0199 (ABT-199) v kombinaci s rituximabem v porovnání s bendamustinem a rituximabem","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.718105733039227e-96,1.3640399025974862e-09,0.9999999986359853,"2+",3.0832183157642647e-16,1.0,"Yes",1.0,1.3753245616974504e-15,"No",1.0,9.454481675138245e-49,"No",1.2717455384047957e-09,0.9999999987282422,"No",0.7836633484912815,0.21633665150874537,"No",1.0,8.629190241071714e-35,"No",7.35665478130617e-05,0.9999264334521807,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMABMulticentrické otevřené randomizované klinické hodnocení fáze III pro pacienty s recidivující/rezistentní chronickou lymfocytární leukémií k vyhodnocení přínosu přípravku GDC-0199 (ABT-199) v kombinaci s rituximabem v porovnání s bendamustinem a rituximabem","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.718105733039227e-96,1.3640399025974862e-09,0.9999999986359853,"2+",3.0832183157642647e-16,1.0,"Yes",1.0,1.3753245616974504e-15,"No",1.0,9.454481675138245e-49,"No",1.2717455384047957e-09,0.9999999987282422,"No",0.7836633484912815,0.21633665150874537,"No",1.0,8.629190241071714e-35,"No",7.35665478130617e-05,0.9999264334521807,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2948266870715255e-49,0.002127729468951681,0.9978722705310533,"2+",2.8208073254731957e-10,0.9999999997179145,"Yes",0.9999999995169447,4.830604402505977e-10,"No",1.0,1.3604458320158446e-22,"No",0.01751209735226255,0.9824879026477271,"No",0.5573914109537973,0.4426085890461957,"No",1.0,8.724488230471478e-19,"No",0.008552509575128058,0.9914474904248797,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2948266870715255e-49,0.002127729468951681,0.9978722705310533,"2+",2.8208073254731957e-10,0.9999999997179145,"Yes",0.9999999995169447,4.830604402505977e-10,"No",1.0,1.3604458320158446e-22,"No",0.01751209735226255,0.9824879026477271,"No",0.5573914109537973,0.4426085890461957,"No",1.0,8.724488230471478e-19,"No",0.008552509575128058,0.9914474904248797,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMABMulticentrické otevřené randomizované klinické hodnocení fáze III pro pacienty s recidivující/rezistentní chronickou lymfocytární leukémií k vyhodnocení přínosu přípravku GDC-0199 (ABT-199) v kombinaci s rituximabem v porovnání s bendamustinem a rituximabem","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.718105733039227e-96,1.3640399025974862e-09,0.9999999986359853,"2+",3.0832183157642647e-16,1.0,"Yes",1.0,1.3753245616974504e-15,"No",1.0,9.454481675138245e-49,"No",1.2717455384047957e-09,0.9999999987282422,"No",0.7836633484912815,0.21633665150874537,"No",1.0,8.629190241071714e-35,"No",7.35665478130617e-05,0.9999264334521807,"Yes"
"2013-002110-12","A MULTICENTER PHASE III OPEN-LABEL RANDOMIZED STUDY INRELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199)PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMABMulticentrické otevřené randomizované klinické hodnocení fáze III pro pacienty s recidivující/rezistentní chronickou lymfocytární leukémií k vyhodnocení přínosu přípravku GDC-0199 (ABT-199) v kombinaci s rituximabem v porovnání s bendamustinem a rituximabem","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.718105733039227e-96,1.3640399025974862e-09,0.9999999986359853,"2+",3.0832183157642647e-16,1.0,"Yes",1.0,1.3753245616974504e-15,"No",1.0,9.454481675138245e-49,"No",1.2717455384047957e-09,0.9999999987282422,"No",0.7836633484912815,0.21633665150874537,"No",1.0,8.629190241071714e-35,"No",7.35665478130617e-05,0.9999264334521807,"Yes"
"2013-002271-17","A Multi-center Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.278442993936278e-41,0.9999952880727133,4.711927282084938e-06,"-1",3.610577755161783e-05,0.9999638942224524,"Yes",0.9999559063442156,4.4093655785342296e-05,"No",0.9999999999999717,3.434225118558323e-14,"No",0.9999821914241621,1.7808575837812278e-05,"No",0.9975562713781607,0.0024437286218381765,"No",0.9977087474579361,0.0022912525420588524,"No",0.9999142353244572,8.576467554527064e-05,"No"
"2013-002271-17","A Multi-center Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.278442993936278e-41,0.9999952880727133,4.711927282084938e-06,"-1",3.610577755161783e-05,0.9999638942224524,"Yes",0.9999559063442156,4.4093655785342296e-05,"No",0.9999999999999717,3.434225118558323e-14,"No",0.9999821914241621,1.7808575837812278e-05,"No",0.9975562713781607,0.0024437286218381765,"No",0.9977087474579361,0.0022912525420588524,"No",0.9999142353244572,8.576467554527064e-05,"No"
"2013-002271-17","A Multi-center Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.278442993936278e-41,0.9999952880727133,4.711927282084938e-06,"-1",3.610577755161783e-05,0.9999638942224524,"Yes",0.9999559063442156,4.4093655785342296e-05,"No",0.9999999999999717,3.434225118558323e-14,"No",0.9999821914241621,1.7808575837812278e-05,"No",0.9975562713781607,0.0024437286218381765,"No",0.9977087474579361,0.0022912525420588524,"No",0.9999142353244572,8.576467554527064e-05,"No"
"2013-002271-17","A Multi-center Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate","GB","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.278442993936278e-41,0.9999952880727133,4.711927282084938e-06,"-1",3.610577755161783e-05,0.9999638942224524,"Yes",0.9999559063442156,4.4093655785342296e-05,"No",0.9999999999999717,3.434225118558323e-14,"No",0.9999821914241621,1.7808575837812278e-05,"No",0.9975562713781607,0.0024437286218381765,"No",0.9977087474579361,0.0022912525420588524,"No",0.9999142353244572,8.576467554527064e-05,"No"
"2013-002431-15","A 12-month phase IV randomized open label multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore correlated functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD)","NO","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.702768970119605e-70,0.18563753497246707,0.8143624650275452,"2+",0.028614926062359113,0.9713850739376672,"Yes",0.9991414426420474,0.0008585573579369908,"No",0.9999999654916685,3.4508338319372796e-08,"No",0.001383509564776406,0.9986164904352419,"Yes",0.20897282757885582,0.791027172421137,"Yes",1.0,1.6799144788982374e-19,"No",1.2289688485186248e-06,0.9999987710311465,"Yes"
"2013-002431-15","A 12-month phase IV randomized open label multicenter study to compare efficacy of 0.5 mg ranibizumab PRN versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD)","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.008099500630845e-70,0.06834897211718968,0.9316510278828039,"2+",0.028957914454028573,0.9710420855459541,"Yes",0.9970128325085545,0.002987167491421376,"No",0.9999999993005417,6.994494604104398e-10,"No",0.0003821032132932242,0.9996178967867324,"Yes",0.037835170990877916,0.9621648290091437,"Yes",1.0,2.518196369171584e-19,"No",4.022198687335179e-07,0.9999995977801418,"Yes"
"2013-002431-15","A 12-month phase IV randomized open label multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore correlated functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD)","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.702768970119605e-70,0.18563753497246707,0.8143624650275452,"2+",0.028614926062359113,0.9713850739376672,"Yes",0.9991414426420474,0.0008585573579369908,"No",0.9999999654916685,3.4508338319372796e-08,"No",0.001383509564776406,0.9986164904352419,"Yes",0.20897282757885582,0.791027172421137,"Yes",1.0,1.6799144788982374e-19,"No",1.2289688485186248e-06,0.9999987710311465,"Yes"
"2013-002431-15","A 12-month phase IV randomized open label multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore correlated functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD)","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.702768970119605e-70,0.18563753497246707,0.8143624650275452,"2+",0.028614926062359113,0.9713850739376672,"Yes",0.9991414426420474,0.0008585573579369908,"No",0.9999999654916685,3.4508338319372796e-08,"No",0.001383509564776406,0.9986164904352419,"Yes",0.20897282757885582,0.791027172421137,"Yes",1.0,1.6799144788982374e-19,"No",1.2289688485186248e-06,0.9999987710311465,"Yes"
"2013-002431-15","A 12-month phase IV randomized open label multicenter study to compare efficacy of 0.5 mg ranibizumab PRN versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD)","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.008099500630845e-70,0.06834897211718968,0.9316510278828039,"2+",0.028957914454028573,0.9710420855459541,"Yes",0.9970128325085545,0.002987167491421376,"No",0.9999999993005417,6.994494604104398e-10,"No",0.0003821032132932242,0.9996178967867324,"Yes",0.037835170990877916,0.9621648290091437,"Yes",1.0,2.518196369171584e-19,"No",4.022198687335179e-07,0.9999995977801418,"Yes"
"2013-002431-15","A 12-month phase IV randomized open label multicenter study to compare efficacy of 0.5 mg ranibizumab PRN versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD)","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.008099500630845e-70,0.06834897211718968,0.9316510278828039,"2+",0.028957914454028573,0.9710420855459541,"Yes",0.9970128325085545,0.002987167491421376,"No",0.9999999993005417,6.994494604104398e-10,"No",0.0003821032132932242,0.9996178967867324,"Yes",0.037835170990877916,0.9621648290091437,"Yes",1.0,2.518196369171584e-19,"No",4.022198687335179e-07,0.9999995977801418,"Yes"
"2013-002431-15","A 12-month phase IV randomized open label multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore correlated functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.702768970119605e-70,0.18563753497246707,0.8143624650275452,"2+",0.028614926062359113,0.9713850739376672,"Yes",0.9991414426420474,0.0008585573579369908,"No",0.9999999654916685,3.4508338319372796e-08,"No",0.001383509564776406,0.9986164904352419,"Yes",0.20897282757885582,0.791027172421137,"Yes",1.0,1.6799144788982374e-19,"No",1.2289688485186248e-06,0.9999987710311465,"Yes"
"2013-002431-15","A 12-month phase IV randomized open label multicenter study to compare efficacy of 0.5 mg ranibizumab PRN versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD)","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.008099500630845e-70,0.06834897211718968,0.9316510278828039,"2+",0.028957914454028573,0.9710420855459541,"Yes",0.9970128325085545,0.002987167491421376,"No",0.9999999993005417,6.994494604104398e-10,"No",0.0003821032132932242,0.9996178967867324,"Yes",0.037835170990877916,0.9621648290091437,"Yes",1.0,2.518196369171584e-19,"No",4.022198687335179e-07,0.9999995977801418,"Yes"
"2013-002453-29","A PHASE 3 MULTICENTER RANDOMIZED SINGLE-BLIND DOSE-RANGING CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) FOR THE PREVENTION OF ANGIOEDEMA ATTACKS IN CHILDREN 6 TO 11 YEARS OF AGE WITH HEREDITARY ANGIOEDEMA","RO","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","No","No","Yes","No","Yes","Yes","No","2+","Yes",2.3160099275008528e-57,1.3888902604498923e-05,0.999986111097388,"2+",0.9999258376528745,7.416234711671496e-05,"No",0.0005188958497274699,0.9994811041502597,"No",0.9999999994960548,5.039574040322829e-10,"Yes",0.003602268904115466,0.9963977310958854,"Yes",0.9999997679740019,2.3202598967528283e-07,"No",4.4708109260446725e-05,0.9999552918907448,"Yes",0.3117686772378174,0.6882313227621898,"Yes"
"2013-002453-29","A PHASE 3 MULTICENTER RANDOMIZED SINGLE-BLIND DOSE-RANGING CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) FOR THE PREVENTION OF ANGIOEDEMA ATTACKS IN CHILDREN 6 TO 11 YEARS OF AGE WITH HEREDITARY ANGIOEDEMA","DE","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","No","No","Yes","No","Yes","Yes","No","2+","Yes",2.3160099275008528e-57,1.3888902604498923e-05,0.999986111097388,"2+",0.9999258376528745,7.416234711671496e-05,"No",0.0005188958497274699,0.9994811041502597,"No",0.9999999994960548,5.039574040322829e-10,"Yes",0.003602268904115466,0.9963977310958854,"Yes",0.9999997679740019,2.3202598967528283e-07,"No",4.4708109260446725e-05,0.9999552918907448,"Yes",0.3117686772378174,0.6882313227621898,"Yes"
"2013-002453-29","A PHASE 3 MULTICENTER RANDOMIZED SINGLE-BLIND DOSE-RANGING CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) FOR THE PREVENTION OF ANGIOEDEMA ATTACKS IN CHILDREN 6 TO 11 YEARS OF AGE WITH HEREDITARY ANGIOEDEMA","IT","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","No","No","Yes","No","Yes","Yes","No","2+","Yes",2.3160099275008528e-57,1.3888902604498923e-05,0.999986111097388,"2+",0.9999258376528745,7.416234711671496e-05,"No",0.0005188958497274699,0.9994811041502597,"No",0.9999999994960548,5.039574040322829e-10,"Yes",0.003602268904115466,0.9963977310958854,"Yes",0.9999997679740019,2.3202598967528283e-07,"No",4.4708109260446725e-05,0.9999552918907448,"Yes",0.3117686772378174,0.6882313227621898,"Yes"
"2013-002453-29","A PHASE 3 MULTICENTER RANDOMIZED SINGLE-BLIND DOSE-RANGING CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) FOR THE PREVENTION OF ANGIOEDEMA ATTACKS IN CHILDREN 6 TO 11 YEARS OF AGE WITH HEREDITARY ANGIOEDEMA","GB","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","No","No","Yes","No","Yes","Yes","No","2+","Yes",2.3160099275008528e-57,1.3888902604498923e-05,0.999986111097388,"2+",0.9999258376528745,7.416234711671496e-05,"No",0.0005188958497274699,0.9994811041502597,"No",0.9999999994960548,5.039574040322829e-10,"Yes",0.003602268904115466,0.9963977310958854,"Yes",0.9999997679740019,2.3202598967528283e-07,"No",4.4708109260446725e-05,0.9999552918907448,"Yes",0.3117686772378174,0.6882313227621898,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrična prospektivna randomizirana odprta študija za oceno učinkov serelaksina v primerjavi s standardno oskrbo pri bolnikih z akutnim srčnim popuščanjem (AHF)","SI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.464560275124414e-51,3.957774315047437e-10,0.9999999996041993,"2+",0.9999378621782898,6.213782172157897e-05,"Yes",1.8593824877923087e-05,0.9999814061751019,"No",1.0,2.6180653051309884e-26,"No",5.943571408001271e-13,0.9999999999994316,"Yes",0.18564107265393853,0.8143589273460429,"No",0.9999999999989768,9.954583819783353e-13,"No",1.2498609835097592e-13,0.9999999999998864,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.247281892154404e-31,2.890250390593653e-05,0.9999710974961005,"2+",0.8242840622247489,0.17571593777524444,"Yes",0.1923995308202919,0.8076004691797136,"No",0.9999968690377999,3.130962198175163e-06,"No",5.802730570195715e-06,0.9999941972694263,"Yes",0.034841216902291576,0.9651587830977046,"No",0.9999769644901922,2.3035509802377507e-05,"No",1.475363260226442e-06,0.9999985246367457,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrično prospektivno randomizirano otvoreno ispitivanje procjene učinka serelaksina u usporedbi sa standardnim liječenjem bolesnika s akutnim zatajivanjem srca (AZS)","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.8236692598110925e-45,2.7951880676022965e-13,0.9999999999997159,"2+",0.9274229826576852,0.07257701734228643,"Yes",0.03272079206001381,0.9672792079399963,"No",1.0,4.1790471754157835e-19,"No",2.1697462588729128e-12,0.99999999999784,"Yes",0.0017048113246341404,0.9982951886753723,"No",1.0,3.8257731226095766e-19,"No",1.1889897099324061e-14,1.0,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrično prospektivno randomizirano otvoreno ispitivanje procjene učinka serelaksina u usporedbi sa standardnim liječenjem bolesnika s akutnim zatajivanjem srca (AZS)","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.8236692598110925e-45,2.7951880676022965e-13,0.9999999999997159,"2+",0.9274229826576852,0.07257701734228643,"Yes",0.03272079206001381,0.9672792079399963,"No",1.0,4.1790471754157835e-19,"No",2.1697462588729128e-12,0.99999999999784,"Yes",0.0017048113246341404,0.9982951886753723,"No",1.0,3.8257731226095766e-19,"No",1.1889897099324061e-14,1.0,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrické prospektivní randomizované otevřené klinické hodnocení účinnosti serelaxinu oproti standardní léčbě u pacientů s akutním srdečním selháním.","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.238961208518887e-60,1.8655285960566325e-11,0.9999999999813555,"2+",0.9999314337924364,6.856620756056899e-05,"Yes",3.1087391799742175e-05,0.9999689126082074,"No",1.0,1.1036805945328277e-20,"No",3.971162243613192e-14,0.9999999999999717,"Yes",0.0008505465543968757,0.9991494534456071,"No",1.0,6.715161641999286e-20,"No",1.2803228944992117e-13,0.9999999999998579,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.247281892154404e-31,2.890250390593653e-05,0.9999710974961005,"2+",0.8242840622247489,0.17571593777524444,"Yes",0.1923995308202919,0.8076004691797136,"No",0.9999968690377999,3.130962198175163e-06,"No",5.802730570195715e-06,0.9999941972694263,"Yes",0.034841216902291576,0.9651587830977046,"No",0.9999769644901922,2.3035509802377507e-05,"No",1.475363260226442e-06,0.9999985246367457,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.247281892154404e-31,2.890250390593653e-05,0.9999710974961005,"2+",0.8242840622247489,0.17571593777524444,"Yes",0.1923995308202919,0.8076004691797136,"No",0.9999968690377999,3.130962198175163e-06,"No",5.802730570195715e-06,0.9999941972694263,"Yes",0.034841216902291576,0.9651587830977046,"No",0.9999769644901922,2.3035509802377507e-05,"No",1.475363260226442e-06,0.9999985246367457,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrična prospektivna randomizirana odprta študija za oceno učinkov serelaksina v primerjavi s standardno oskrbo pri bolnikih z akutnim srčnim popuščanjem (AHF)","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.464560275124414e-51,3.957774315047437e-10,0.9999999996041993,"2+",0.9999378621782898,6.213782172157897e-05,"Yes",1.8593824877923087e-05,0.9999814061751019,"No",1.0,2.6180653051309884e-26,"No",5.943571408001271e-13,0.9999999999994316,"Yes",0.18564107265393853,0.8143589273460429,"No",0.9999999999989768,9.954583819783353e-13,"No",1.2498609835097592e-13,0.9999999999998864,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrické prospektivní randomizované otevřené klinické hodnocení účinnosti serelaxinu oproti standardní léčbě u pacientů s akutním srdečním selháním.","EE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.238961208518887e-60,1.8655285960566325e-11,0.9999999999813555,"2+",0.9999314337924364,6.856620756056899e-05,"Yes",3.1087391799742175e-05,0.9999689126082074,"No",1.0,1.1036805945328277e-20,"No",3.971162243613192e-14,0.9999999999999717,"Yes",0.0008505465543968757,0.9991494534456071,"No",1.0,6.715161641999286e-20,"No",1.2803228944992117e-13,0.9999999999998579,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.","IS","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.247281892154404e-31,2.890250390593653e-05,0.9999710974961005,"2+",0.8242840622247489,0.17571593777524444,"Yes",0.1923995308202919,0.8076004691797136,"No",0.9999968690377999,3.130962198175163e-06,"No",5.802730570195715e-06,0.9999941972694263,"Yes",0.034841216902291576,0.9651587830977046,"No",0.9999769644901922,2.3035509802377507e-05,"No",1.475363260226442e-06,0.9999985246367457,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrično prospektivno randomizirano otvoreno ispitivanje procjene učinka serelaksina u usporedbi sa standardnim liječenjem bolesnika s akutnim zatajivanjem srca (AZS)","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.8236692598110925e-45,2.7951880676022965e-13,0.9999999999997159,"2+",0.9274229826576852,0.07257701734228643,"Yes",0.03272079206001381,0.9672792079399963,"No",1.0,4.1790471754157835e-19,"No",2.1697462588729128e-12,0.99999999999784,"Yes",0.0017048113246341404,0.9982951886753723,"No",1.0,3.8257731226095766e-19,"No",1.1889897099324061e-14,1.0,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrické prospektivní randomizované otevřené klinické hodnocení účinnosti serelaxinu oproti standardní léčbě u pacientů s akutním srdečním selháním.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.238961208518887e-60,1.8655285960566325e-11,0.9999999999813555,"2+",0.9999314337924364,6.856620756056899e-05,"Yes",3.1087391799742175e-05,0.9999689126082074,"No",1.0,1.1036805945328277e-20,"No",3.971162243613192e-14,0.9999999999999717,"Yes",0.0008505465543968757,0.9991494534456071,"No",1.0,6.715161641999286e-20,"No",1.2803228944992117e-13,0.9999999999998579,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrično prospektivno randomizirano otvoreno ispitivanje procjene učinka serelaksina u usporedbi sa standardnim liječenjem bolesnika s akutnim zatajivanjem srca (AZS)","HR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.8236692598110925e-45,2.7951880676022965e-13,0.9999999999997159,"2+",0.9274229826576852,0.07257701734228643,"Yes",0.03272079206001381,0.9672792079399963,"No",1.0,4.1790471754157835e-19,"No",2.1697462588729128e-12,0.99999999999784,"Yes",0.0017048113246341404,0.9982951886753723,"No",1.0,3.8257731226095766e-19,"No",1.1889897099324061e-14,1.0,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrično prospektivno randomizirano otvoreno ispitivanje procjene učinka serelaksina u usporedbi sa standardnim liječenjem bolesnika s akutnim zatajivanjem srca (AZS)","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.8236692598110925e-45,2.7951880676022965e-13,0.9999999999997159,"2+",0.9274229826576852,0.07257701734228643,"Yes",0.03272079206001381,0.9672792079399963,"No",1.0,4.1790471754157835e-19,"No",2.1697462588729128e-12,0.99999999999784,"Yes",0.0017048113246341404,0.9982951886753723,"No",1.0,3.8257731226095766e-19,"No",1.1889897099324061e-14,1.0,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.247281892154404e-31,2.890250390593653e-05,0.9999710974961005,"2+",0.8242840622247489,0.17571593777524444,"Yes",0.1923995308202919,0.8076004691797136,"No",0.9999968690377999,3.130962198175163e-06,"No",5.802730570195715e-06,0.9999941972694263,"Yes",0.034841216902291576,0.9651587830977046,"No",0.9999769644901922,2.3035509802377507e-05,"No",1.475363260226442e-06,0.9999985246367457,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrična prospektivna randomizirana odprta študija za oceno učinkov serelaksina v primerjavi s standardno oskrbo pri bolnikih z akutnim srčnim popuščanjem (AHF)","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.464560275124414e-51,3.957774315047437e-10,0.9999999996041993,"2+",0.9999378621782898,6.213782172157897e-05,"Yes",1.8593824877923087e-05,0.9999814061751019,"No",1.0,2.6180653051309884e-26,"No",5.943571408001271e-13,0.9999999999994316,"Yes",0.18564107265393853,0.8143589273460429,"No",0.9999999999989768,9.954583819783353e-13,"No",1.2498609835097592e-13,0.9999999999998864,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.247281892154404e-31,2.890250390593653e-05,0.9999710974961005,"2+",0.8242840622247489,0.17571593777524444,"Yes",0.1923995308202919,0.8076004691797136,"No",0.9999968690377999,3.130962198175163e-06,"No",5.802730570195715e-06,0.9999941972694263,"Yes",0.034841216902291576,0.9651587830977046,"No",0.9999769644901922,2.3035509802377507e-05,"No",1.475363260226442e-06,0.9999985246367457,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrično prospektivno randomizirano otvoreno ispitivanje procjene učinka serelaksina u usporedbi sa standardnim liječenjem bolesnika s akutnim zatajivanjem srca (AZS)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.8236692598110925e-45,2.7951880676022965e-13,0.9999999999997159,"2+",0.9274229826576852,0.07257701734228643,"Yes",0.03272079206001381,0.9672792079399963,"No",1.0,4.1790471754157835e-19,"No",2.1697462588729128e-12,0.99999999999784,"Yes",0.0017048113246341404,0.9982951886753723,"No",1.0,3.8257731226095766e-19,"No",1.1889897099324061e-14,1.0,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrično prospektivno randomizirano otvoreno ispitivanje procjene učinka serelaksina u usporedbi sa standardnim liječenjem bolesnika s akutnim zatajivanjem srca (AZS)","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.8236692598110925e-45,2.7951880676022965e-13,0.9999999999997159,"2+",0.9274229826576852,0.07257701734228643,"Yes",0.03272079206001381,0.9672792079399963,"No",1.0,4.1790471754157835e-19,"No",2.1697462588729128e-12,0.99999999999784,"Yes",0.0017048113246341404,0.9982951886753723,"No",1.0,3.8257731226095766e-19,"No",1.1889897099324061e-14,1.0,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Multicentrična prospektivna randomizirana odprta študija za oceno učinkov serelaksina v primerjavi s standardno oskrbo pri bolnikih z akutnim srčnim popuščanjem (AHF)","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.464560275124414e-51,3.957774315047437e-10,0.9999999996041993,"2+",0.9999378621782898,6.213782172157897e-05,"Yes",1.8593824877923087e-05,0.9999814061751019,"No",1.0,2.6180653051309884e-26,"No",5.943571408001271e-13,0.9999999999994316,"Yes",0.18564107265393853,0.8143589273460429,"No",0.9999999999989768,9.954583819783353e-13,"No",1.2498609835097592e-13,0.9999999999998864,"Yes"
"2013-002513-35","A multicenter prospective randomized open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.247281892154404e-31,2.890250390593653e-05,0.9999710974961005,"2+",0.8242840622247489,0.17571593777524444,"Yes",0.1923995308202919,0.8076004691797136,"No",0.9999968690377999,3.130962198175163e-06,"No",5.802730570195715e-06,0.9999941972694263,"Yes",0.034841216902291576,0.9651587830977046,"No",0.9999769644901922,2.3035509802377507e-05,"No",1.475363260226442e-06,0.9999985246367457,"Yes"
"2013-002522-23","A double blinded placebo controlled study to investigate the safety tolerability pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the partial adenosine A1 receptor agonist BAY 1067197 in patients with chronic systolic heart failure : PARSiFAL-pilot study.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9216016412746576e-51,3.5670834534939346e-10,0.9999999996432791,"2+",0.9999999999928094,7.180766716043644e-12,"No",2.6999480327129454e-10,0.9999999997299938,"Yes",0.9999981561604674,1.8438395308517876e-06,"No",2.0553591496403482e-11,0.9999999999794511,"Yes",3.944621695544692e-05,0.9999605537830472,"Yes",0.9999547636103479,4.523638964318791e-05,"No",1.3043192344455027e-09,0.9999999986956709,"Yes"
"2013-002522-23","A double blinded placebo controlled study to investigate the safety tolerability pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the partial adenosine A1 receptor agonist BAY 1067197 in patients with chronic systolic heart failure : PARSiFAL-pilot study.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9216016412746576e-51,3.5670834534939346e-10,0.9999999996432791,"2+",0.9999999999928094,7.180766716043644e-12,"No",2.6999480327129454e-10,0.9999999997299938,"Yes",0.9999981561604674,1.8438395308517876e-06,"No",2.0553591496403482e-11,0.9999999999794511,"Yes",3.944621695544692e-05,0.9999605537830472,"Yes",0.9999547636103479,4.523638964318791e-05,"No",1.3043192344455027e-09,0.9999999986956709,"Yes"
"2013-002522-23","A double blinded placebo controlled study to investigate the safety tolerability pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the partial adenosine A1 receptor agonist BAY 1067197 in patients with chronic systolic heart failure : PARSiFAL-pilot study.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9216016412746576e-51,3.5670834534939346e-10,0.9999999996432791,"2+",0.9999999999928094,7.180766716043644e-12,"No",2.6999480327129454e-10,0.9999999997299938,"Yes",0.9999981561604674,1.8438395308517876e-06,"No",2.0553591496403482e-11,0.9999999999794511,"Yes",3.944621695544692e-05,0.9999605537830472,"Yes",0.9999547636103479,4.523638964318791e-05,"No",1.3043192344455027e-09,0.9999999986956709,"Yes"
"2013-002539-13","Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg) in infants with retinopathy of prematurity (ROP)Eine multizentrische randomisierte doppelblinde zweiarmige explorative Studie zur vergleichenden Beurteilung der Sicherheit und Wirksamkeit zweier unterschiedlicher Dosen intravitrealer Ranibizumab-Injektionen (012 mg vs. 020 mg) bei Kindern mit Frühgeborenenretinopathie (ROP) ","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.139021240642977e-87,1.5763061418668048e-18,1.0,"2+",0.999994413558995,5.58644098512264e-06,"No",0.0006976988203247028,0.9993023011796742,"Yes",0.9999995107338638,4.89266120932509e-07,"No",1.0469976920449963e-16,1.0,"Yes",0.0007071895923690236,0.9992928104076552,"Yes",0.9999999999999432,3.026526383741799e-14,"No",6.148605003023678e-17,1.0,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","BE","Yes","No","No","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.981880211563061e-51,5.588094442693756e-07,0.9999994411905532,"2+",0.8171049668029188,0.18289503319706946,"No",0.32713746399826316,0.6728625360017326,"Yes",1.0,1.5668611658247055e-16,"No",0.00062542753532969,0.999374572464661,"Yes",0.9999999964978771,3.5021324795056145e-09,"Yes",1.1631846076295311e-11,0.9999999999883755,"No",2.5029507682649403e-05,0.9999749704923111,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","GB","Yes","No","No","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.981880211563061e-51,5.588094442693756e-07,0.9999994411905532,"2+",0.8171049668029188,0.18289503319706946,"No",0.32713746399826316,0.6728625360017326,"Yes",1.0,1.5668611658247055e-16,"No",0.00062542753532969,0.999374572464661,"Yes",0.9999999964978771,3.5021324795056145e-09,"Yes",1.1631846076295311e-11,0.9999999999883755,"No",2.5029507682649403e-05,0.9999749704923111,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","BG","Yes","No","No","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.981880211563061e-51,5.588094442693756e-07,0.9999994411905532,"2+",0.8171049668029188,0.18289503319706946,"No",0.32713746399826316,0.6728625360017326,"Yes",1.0,1.5668611658247055e-16,"No",0.00062542753532969,0.999374572464661,"Yes",0.9999999964978771,3.5021324795056145e-09,"Yes",1.1631846076295311e-11,0.9999999999883755,"No",2.5029507682649403e-05,0.9999749704923111,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","PL","Yes","No","No","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.981880211563061e-51,5.588094442693756e-07,0.9999994411905532,"2+",0.8171049668029188,0.18289503319706946,"No",0.32713746399826316,0.6728625360017326,"Yes",1.0,1.5668611658247055e-16,"No",0.00062542753532969,0.999374572464661,"Yes",0.9999999964978771,3.5021324795056145e-09,"Yes",1.1631846076295311e-11,0.9999999999883755,"No",2.5029507682649403e-05,0.9999749704923111,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Randomizovaná dvojitě zaslepená aktivně kontrolovaná studie fáze 3 hodnotící přípravek Momelitinib proti přípravku Ruxolitinib u subjektů s primární myelofibrózou (PMF) nebo myelofibrózou po polycytemia vera nebo po esenciální trombocytémii (Post-PV/ET MF)","AT","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.205059237353562e-102,1.9165838034775931e-22,1.0,"2+",0.027947445995014086,0.972052554004964,"No",0.9749837839254715,0.025016216074555526,"Yes",1.0,8.606789216125085e-47,"No",1.910994805467869e-16,1.0,"Yes",0.9999999999986359,1.3421776492398005e-12,"Yes",7.423691726246e-07,0.9999992576308527,"No",3.1337252539408206e-16,1.0,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Randomizovaná dvojitě zaslepená aktivně kontrolovaná studie fáze 3 hodnotící přípravek Momelitinib proti přípravku Ruxolitinib u subjektů s primární myelofibrózou (PMF) nebo myelofibrózou po polycytemia vera nebo po esenciální trombocytémii (Post-PV/ET MF)","RO","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.205059237353562e-102,1.9165838034775931e-22,1.0,"2+",0.027947445995014086,0.972052554004964,"No",0.9749837839254715,0.025016216074555526,"Yes",1.0,8.606789216125085e-47,"No",1.910994805467869e-16,1.0,"Yes",0.9999999999986359,1.3421776492398005e-12,"Yes",7.423691726246e-07,0.9999992576308527,"No",3.1337252539408206e-16,1.0,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Randomizovaná dvojitě zaslepená aktivně kontrolovaná studie fáze 3 hodnotící přípravek Momelitinib proti přípravku Ruxolitinib u subjektů s primární myelofibrózou (PMF) nebo myelofibrózou po polycytemia vera nebo po esenciální trombocytémii (Post-PV/ET MF)","DE","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.205059237353562e-102,1.9165838034775931e-22,1.0,"2+",0.027947445995014086,0.972052554004964,"No",0.9749837839254715,0.025016216074555526,"Yes",1.0,8.606789216125085e-47,"No",1.910994805467869e-16,1.0,"Yes",0.9999999999986359,1.3421776492398005e-12,"Yes",7.423691726246e-07,0.9999992576308527,"No",3.1337252539408206e-16,1.0,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","FR","Yes","No","No","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.981880211563061e-51,5.588094442693756e-07,0.9999994411905532,"2+",0.8171049668029188,0.18289503319706946,"No",0.32713746399826316,0.6728625360017326,"Yes",1.0,1.5668611658247055e-16,"No",0.00062542753532969,0.999374572464661,"Yes",0.9999999964978771,3.5021324795056145e-09,"Yes",1.1631846076295311e-11,0.9999999999883755,"No",2.5029507682649403e-05,0.9999749704923111,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","DK","Yes","No","No","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.981880211563061e-51,5.588094442693756e-07,0.9999994411905532,"2+",0.8171049668029188,0.18289503319706946,"No",0.32713746399826316,0.6728625360017326,"Yes",1.0,1.5668611658247055e-16,"No",0.00062542753532969,0.999374572464661,"Yes",0.9999999964978771,3.5021324795056145e-09,"Yes",1.1631846076295311e-11,0.9999999999883755,"No",2.5029507682649403e-05,0.9999749704923111,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Randomizovaná dvojitě zaslepená aktivně kontrolovaná studie fáze 3 hodnotící přípravek Momelitinib proti přípravku Ruxolitinib u subjektů s primární myelofibrózou (PMF) nebo myelofibrózou po polycytemia vera nebo po esenciální trombocytémii (Post-PV/ET MF)","ES","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.205059237353562e-102,1.9165838034775931e-22,1.0,"2+",0.027947445995014086,0.972052554004964,"No",0.9749837839254715,0.025016216074555526,"Yes",1.0,8.606789216125085e-47,"No",1.910994805467869e-16,1.0,"Yes",0.9999999999986359,1.3421776492398005e-12,"Yes",7.423691726246e-07,0.9999992576308527,"No",3.1337252539408206e-16,1.0,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Randomizovaná dvojitě zaslepená aktivně kontrolovaná studie fáze 3 hodnotící přípravek Momelitinib proti přípravku Ruxolitinib u subjektů s primární myelofibrózou (PMF) nebo myelofibrózou po polycytemia vera nebo po esenciální trombocytémii (Post-PV/ET MF)","HU","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.205059237353562e-102,1.9165838034775931e-22,1.0,"2+",0.027947445995014086,0.972052554004964,"No",0.9749837839254715,0.025016216074555526,"Yes",1.0,8.606789216125085e-47,"No",1.910994805467869e-16,1.0,"Yes",0.9999999999986359,1.3421776492398005e-12,"Yes",7.423691726246e-07,0.9999992576308527,"No",3.1337252539408206e-16,1.0,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","SE","Yes","No","No","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.981880211563061e-51,5.588094442693756e-07,0.9999994411905532,"2+",0.8171049668029188,0.18289503319706946,"No",0.32713746399826316,0.6728625360017326,"Yes",1.0,1.5668611658247055e-16,"No",0.00062542753532969,0.999374572464661,"Yes",0.9999999964978771,3.5021324795056145e-09,"Yes",1.1631846076295311e-11,0.9999999999883755,"No",2.5029507682649403e-05,0.9999749704923111,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","CZ","Yes","No","No","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.981880211563061e-51,5.588094442693756e-07,0.9999994411905532,"2+",0.8171049668029188,0.18289503319706946,"No",0.32713746399826316,0.6728625360017326,"Yes",1.0,1.5668611658247055e-16,"No",0.00062542753532969,0.999374572464661,"Yes",0.9999999964978771,3.5021324795056145e-09,"Yes",1.1631846076295311e-11,0.9999999999883755,"No",2.5029507682649403e-05,0.9999749704923111,"Yes"
"2013-002707-33","A Phase 3 Randomized Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Randomizovaná dvojitě zaslepená aktivně kontrolovaná studie fáze 3 hodnotící přípravek Momelitinib proti přípravku Ruxolitinib u subjektů s primární myelofibrózou (PMF) nebo myelofibrózou po polycytemia vera nebo po esenciální trombocytémii (Post-PV/ET MF)","NL","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.205059237353562e-102,1.9165838034775931e-22,1.0,"2+",0.027947445995014086,0.972052554004964,"No",0.9749837839254715,0.025016216074555526,"Yes",1.0,8.606789216125085e-47,"No",1.910994805467869e-16,1.0,"Yes",0.9999999999986359,1.3421776492398005e-12,"Yes",7.423691726246e-07,0.9999992576308527,"No",3.1337252539408206e-16,1.0,"Yes"
"2013-002716-28","A Phase 3 Open-Label Randomized Parallel 2-Arm Multi-Center Study of BMN 673 versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease","FR","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.303324901071562e-65,0.016168970464252592,0.9838310295357511,"2+",9.465867544345468e-14,0.9999999999999147,"Yes",0.9999999999997159,2.913513434090818e-13,"No",1.0,5.266664937289072e-24,"No",0.9892135389462628,0.010786461053730023,"Yes",0.9999913872723306,8.612727673850483e-06,"Yes",1.0,4.580866630247741e-17,"No",0.9976736411931094,0.002326358806879298,"Yes"
"2013-002716-28","A Phase 3 Open-Label Randomized Parallel 2-Arm Multi-Center Study of BMN 673 versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease","IE","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.303324901071562e-65,0.016168970464252592,0.9838310295357511,"2+",9.465867544345468e-14,0.9999999999999147,"Yes",0.9999999999997159,2.913513434090818e-13,"No",1.0,5.266664937289072e-24,"No",0.9892135389462628,0.010786461053730023,"Yes",0.9999913872723306,8.612727673850483e-06,"Yes",1.0,4.580866630247741e-17,"No",0.9976736411931094,0.002326358806879298,"Yes"
"2013-002716-28","A Phase 3 Open-Label Randomized Parallel 2-Arm Multi-Center Study of BMN 673 versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease","GB","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.303324901071562e-65,0.016168970464252592,0.9838310295357511,"2+",9.465867544345468e-14,0.9999999999999147,"Yes",0.9999999999997159,2.913513434090818e-13,"No",1.0,5.266664937289072e-24,"No",0.9892135389462628,0.010786461053730023,"Yes",0.9999913872723306,8.612727673850483e-06,"Yes",1.0,4.580866630247741e-17,"No",0.9976736411931094,0.002326358806879298,"Yes"
"2013-002716-28","A Phase 3 Open-Label Randomized Parallel 2-Arm Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Who Have Received Prior Chemotherapy Regimens for Metastatic Disease","DE","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.554256289967612e-62,0.23493920553005102,0.7650607944699562,"2+",2.7626401322380183e-15,1.0,"Yes",1.0,9.1134879736494e-15,"No",1.0,6.141151578961632e-25,"No",0.9991869420296219,0.0008130579703735257,"Yes",0.9999985478586125,1.4521413895406373e-06,"Yes",1.0,5.0279917944230906e-18,"No",0.9998375642717161,0.0001624357282864284,"Yes"
"2013-002716-28","A Phase 3 Open-Label Randomized Parallel 2-Arm Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Who Have Received Prior Chemotherapy Regimens for Metastatic Disease","IT","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.554256289967612e-62,0.23493920553005102,0.7650607944699562,"2+",2.7626401322380183e-15,1.0,"Yes",1.0,9.1134879736494e-15,"No",1.0,6.141151578961632e-25,"No",0.9991869420296219,0.0008130579703735257,"Yes",0.9999985478586125,1.4521413895406373e-06,"Yes",1.0,5.0279917944230906e-18,"No",0.9998375642717161,0.0001624357282864284,"Yes"
"2013-002716-28","A Phase 3 Open-Label Randomized Parallel 2-Arm Multi-Center Study of BMN 673 versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease","ES","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.303324901071562e-65,0.016168970464252592,0.9838310295357511,"2+",9.465867544345468e-14,0.9999999999999147,"Yes",0.9999999999997159,2.913513434090818e-13,"No",1.0,5.266664937289072e-24,"No",0.9892135389462628,0.010786461053730023,"Yes",0.9999913872723306,8.612727673850483e-06,"Yes",1.0,4.580866630247741e-17,"No",0.9976736411931094,0.002326358806879298,"Yes"
"2013-002716-28","A Phase 3 Open-Label Randomized Parallel 2-Arm Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Who Have Received Prior Chemotherapy Regimens for Metastatic Disease","BE","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.554256289967612e-62,0.23493920553005102,0.7650607944699562,"2+",2.7626401322380183e-15,1.0,"Yes",1.0,9.1134879736494e-15,"No",1.0,6.141151578961632e-25,"No",0.9991869420296219,0.0008130579703735257,"Yes",0.9999985478586125,1.4521413895406373e-06,"Yes",1.0,5.0279917944230906e-18,"No",0.9998375642717161,0.0001624357282864284,"Yes"
"2013-002716-28","A Phase 3 Open-Label Randomized Parallel 2-Arm Multi-Center Study of BMN 673 versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease","PL","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.303324901071562e-65,0.016168970464252592,0.9838310295357511,"2+",9.465867544345468e-14,0.9999999999999147,"Yes",0.9999999999997159,2.913513434090818e-13,"No",1.0,5.266664937289072e-24,"No",0.9892135389462628,0.010786461053730023,"Yes",0.9999913872723306,8.612727673850483e-06,"Yes",1.0,4.580866630247741e-17,"No",0.9976736411931094,0.002326358806879298,"Yes"
"2013-002737-38","A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations ","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.4806180465608498e-20,0.757452537581751,0.24254746241824732,"-1",2.3879216361902463e-06,0.999997612078369,"Yes",0.999995945045733,4.0549542667890815e-06,"No",0.9999999998954934,1.0450352393283315e-10,"No",0.9994645925665826,0.0005354074334207842,"No",0.9994072998939784,0.0005927001060173663,"No",0.9999960914814849,3.9085185157843765e-06,"No",0.9955946036890932,0.00440539631090074,"No"
"2013-002737-38","A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations ","AT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.4806180465608498e-20,0.757452537581751,0.24254746241824732,"-1",2.3879216361902463e-06,0.999997612078369,"Yes",0.999995945045733,4.0549542667890815e-06,"No",0.9999999998954934,1.0450352393283315e-10,"No",0.9994645925665826,0.0005354074334207842,"No",0.9994072998939784,0.0005927001060173663,"No",0.9999960914814849,3.9085185157843765e-06,"No",0.9955946036890932,0.00440539631090074,"No"
"2013-002755-15","A first-in-human dose escalation and dose finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer","BE","No","No","Yes","","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.3097031170991688e-35,0.5764649062078854,0.4235350937921116,"-1",0.021786964139093836,0.9782130358609123,"Information not present in EudraCT",0.9829889102308822,0.017011089769112846,"Information not present in EudraCT",0.9911457485443651,0.008854251455641149,"Information not present in EudraCT",0.9707687973383217,0.029231202661678855,"No",0.9371312115349771,0.06286878846502508,"",0.9999209291789292,7.907082106712244e-05,"",0.9026338097436257,0.09736619025636775,"No"
"2013-002902-29","A phase II multicenter randomized double-blind multiple dose placebo-controlled parallel-group study to evaluate the efficacy pharmacokinetics and safety of BI 655066 an IL-23 p19 antagonist monoclonal antibody in patients with moderately to severely active Crohn's disease who are naïve to or were previously treated with anti-TNF therapy.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8478156948131862e-89,2.271655292136617e-11,0.999999999977291,"2+",0.9999999999961915,3.812574610791012e-12,"No",8.107491905408984e-12,0.9999999999918998,"Yes",1.0,2.4011132023637972e-28,"No",3.479100179012258e-11,0.9999999999652118,"Yes",1.8024599186316973e-05,0.9999819754008151,"Yes",1.0,1.0883113163343178e-14,"No",5.301663197138068e-10,0.9999999994698214,"Yes"
"2013-002902-29","A phase II multicenter randomized double-blind multiple dose placebo-controlled parallel-group study to evaluate the efficacy pharmacokinetics and safety of BI 655066 an IL-23 p19 antagonist monoclonal antibody in patients with moderately to severely active Crohn's disease who are naïve to or were previously treated with anti-TNF therapy.Estudio en fase II multicéntrico aleatorizado doble ciego con dosis múltiples controlado con placebo con grupos paralelos para evaluar la eficacia farmacocinética y seguridad de BI 655066 un anticuerpo monoclonal antagonista de IL-23 p19 en pacientes con enfermedad de Crohn activa de moderada a grave sin tratamiento previo anti-TNF o en pacientes que hayan recibido previamente tratamiento anti-TNF","IE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7620245239801702e-175,9.861430060193295e-18,1.0,"2+",1.0,3.4675962582071094e-20,"No",1.2307006302489708e-19,1.0,"Yes",1.0,3.2230946522584753e-65,"No",1.4314961381182067e-17,1.0,"Yes",5.994913830781456e-09,0.9999999940050658,"Yes",1.0,1.954598871182423e-36,"No",9.831834204030852e-15,1.0,"Yes"
"2013-002902-29","A phase II multicenter randomized double-blind multiple dose placebo-controlled parallel-group study to evaluate the efficacy pharmacokinetics and safety of BI 655066 an IL-23 p19 antagonist monoclonal antibody in patients with moderately to severely active Crohn's disease who are naïve to or were previously treated with anti-TNF therapy.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8478156948131862e-89,2.271655292136617e-11,0.999999999977291,"2+",0.9999999999961915,3.812574610791012e-12,"No",8.107491905408984e-12,0.9999999999918998,"Yes",1.0,2.4011132023637972e-28,"No",3.479100179012258e-11,0.9999999999652118,"Yes",1.8024599186316973e-05,0.9999819754008151,"Yes",1.0,1.0883113163343178e-14,"No",5.301663197138068e-10,0.9999999994698214,"Yes"
"2013-002902-29","A phase II multicenter randomized double-blind multiple dose placebo-controlled parallel-group study to evaluate the efficacy pharmacokinetics and safety of BI 655066 an IL-23 p19 antagonist monoclonal antibody in patients with moderately to severely active Crohn's disease who are naïve to or were previously treated with anti-TNF therapy.Estudio en fase II multicéntrico aleatorizado doble ciego con dosis múltiples controlado con placebo con grupos paralelos para evaluar la eficacia farmacocinética y seguridad de BI 655066 un anticuerpo monoclonal antagonista de IL-23 p19 en pacientes con enfermedad de Crohn activa de moderada a grave sin tratamiento previo anti-TNF o en pacientes que hayan recibido previamente tratamiento anti-TNF","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7620245239801702e-175,9.861430060193295e-18,1.0,"2+",1.0,3.4675962582071094e-20,"No",1.2307006302489708e-19,1.0,"Yes",1.0,3.2230946522584753e-65,"No",1.4314961381182067e-17,1.0,"Yes",5.994913830781456e-09,0.9999999940050658,"Yes",1.0,1.954598871182423e-36,"No",9.831834204030852e-15,1.0,"Yes"
"2013-002902-29","A phase II multicenter randomized double-blind multiple dose placebo-controlled parallel-group study to evaluate the efficacy pharmacokinetics and safety of BI 655066 an IL-23 p19 antagonist monoclonal antibody in patients with moderately to severely active Crohn's disease who are naïve to or were previously treated with anti-TNF therapy.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.8478156948131862e-89,2.271655292136617e-11,0.999999999977291,"2+",0.9999999999961915,3.812574610791012e-12,"No",8.107491905408984e-12,0.9999999999918998,"Yes",1.0,2.4011132023637972e-28,"No",3.479100179012258e-11,0.9999999999652118,"Yes",1.8024599186316973e-05,0.9999819754008151,"Yes",1.0,1.0883113163343178e-14,"No",5.301663197138068e-10,0.9999999994698214,"Yes"
"2013-003022-92","A Multicenter Single-Arm Open-Label Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of SeizureStudio sulla sicurezza post-marketing multicentrico a braccio singolo inaperto volto a valutare il rischio di attacchi convulsivi in soggetti affetti dacarcinoma prostatico metastatico resistente alla castrazione (mCRPC)trattati con enzalutamide che sono a maggiore rischio potenziale diattacchi convulsivi","FI","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.190710464210424e-75,0.9999992647541806,7.35245840227855e-07,"1",1.4056778619087775e-08,0.9999999859432479,"Yes",0.9999999886549064,1.1345115112838886e-08,"No",1.0,3.99690264752591e-31,"No",0.9997882463741783,0.00021175362580878827,"No",0.9998087955441763,0.00019120445581662077,"No",1.0,3.913768995759496e-15,"No",0.9999977541335947,2.2458664135695335e-06,"No"
"2013-003022-92","A Multicenter Single-Arm Open-Label Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of SeizureStudio sulla sicurezza post-marketing multicentrico a braccio singolo inaperto volto a valutare il rischio di attacchi convulsivi in soggetti affetti dacarcinoma prostatico metastatico resistente alla castrazione (mCRPC)trattati con enzalutamide che sono a maggiore rischio potenziale diattacchi convulsivi","CZ","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.190710464210424e-75,0.9999992647541806,7.35245840227855e-07,"1",1.4056778619087775e-08,0.9999999859432479,"Yes",0.9999999886549064,1.1345115112838886e-08,"No",1.0,3.99690264752591e-31,"No",0.9997882463741783,0.00021175362580878827,"No",0.9998087955441763,0.00019120445581662077,"No",1.0,3.913768995759496e-15,"No",0.9999977541335947,2.2458664135695335e-06,"No"
"2013-003022-92","A Multicenter Single-Arm Open-Label Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of SeizureStudio sulla sicurezza post-marketing multicentrico a braccio singolo inaperto volto a valutare il rischio di attacchi convulsivi in soggetti affetti dacarcinoma prostatico metastatico resistente alla castrazione (mCRPC)trattati con enzalutamide che sono a maggiore rischio potenziale diattacchi convulsivi","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.190710464210424e-75,0.9999992647541806,7.35245840227855e-07,"1",1.4056778619087775e-08,0.9999999859432479,"Yes",0.9999999886549064,1.1345115112838886e-08,"No",1.0,3.99690264752591e-31,"No",0.9997882463741783,0.00021175362580878827,"No",0.9998087955441763,0.00019120445581662077,"No",1.0,3.913768995759496e-15,"No",0.9999977541335947,2.2458664135695335e-06,"No"
"2013-003022-92","A Multicenter Single-Arm Open-Label Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure(UPWARD)","SE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.120989488214182e-38,0.9994303859422259,0.0005696140577769271,"1",6.89021559851791e-05,0.9999310978440084,"Yes",0.9999389877281581,6.101227184508869e-05,"No",1.0,7.229393550816348e-15,"No",0.9982655872582787,0.0017344127417228425,"No",0.9996365102238309,0.0003634897761594195,"No",0.9999991499833729,8.500166396538492e-07,"No",0.9974888108100071,0.0025111891900003614,"No"
"2013-003022-92","A Multicenter Single-Arm Open-Label Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of SeizureStudio sulla sicurezza post-marketing multicentrico a braccio singolo inaperto volto a valutare il rischio di attacchi convulsivi in soggetti affetti dacarcinoma prostatico metastatico resistente alla castrazione (mCRPC)trattati con enzalutamide che sono a maggiore rischio potenziale diattacchi convulsivi","HU","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.190710464210424e-75,0.9999992647541806,7.35245840227855e-07,"1",1.4056778619087775e-08,0.9999999859432479,"Yes",0.9999999886549064,1.1345115112838886e-08,"No",1.0,3.99690264752591e-31,"No",0.9997882463741783,0.00021175362580878827,"No",0.9998087955441763,0.00019120445581662077,"No",1.0,3.913768995759496e-15,"No",0.9999977541335947,2.2458664135695335e-06,"No"
"2013-003022-92","A Multicenter Single-Arm Open-Label Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of SeizureStudio sulla sicurezza post-marketing multicentrico a braccio singolo inaperto volto a valutare il rischio di attacchi convulsivi in soggetti affetti dacarcinoma prostatico metastatico resistente alla castrazione (mCRPC)trattati con enzalutamide che sono a maggiore rischio potenziale diattacchi convulsivi","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.190710464210424e-75,0.9999992647541806,7.35245840227855e-07,"1",1.4056778619087775e-08,0.9999999859432479,"Yes",0.9999999886549064,1.1345115112838886e-08,"No",1.0,3.99690264752591e-31,"No",0.9997882463741783,0.00021175362580878827,"No",0.9998087955441763,0.00019120445581662077,"No",1.0,3.913768995759496e-15,"No",0.9999977541335947,2.2458664135695335e-06,"No"
"2013-003022-92","A Multicenter Single-Arm Open-Label Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure (UPWARD)","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.120989488214182e-38,0.9994303859422259,0.0005696140577769271,"1",6.89021559851791e-05,0.9999310978440084,"Yes",0.9999389877281581,6.101227184508869e-05,"No",1.0,7.229393550816348e-15,"No",0.9982655872582787,0.0017344127417228425,"No",0.9996365102238309,0.0003634897761594195,"No",0.9999991499833729,8.500166396538492e-07,"No",0.9974888108100071,0.0025111891900003614,"No"
"2013-003022-92","A Multicenter Single-Arm Open-Label Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of SeizureStudio sulla sicurezza post-marketing multicentrico a braccio singolo inaperto volto a valutare il rischio di attacchi convulsivi in soggetti affetti dacarcinoma prostatico metastatico resistente alla castrazione (mCRPC)trattati con enzalutamide che sono a maggiore rischio potenziale diattacchi convulsivi","IT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",8.190710464210424e-75,0.9999992647541806,7.35245840227855e-07,"1",1.4056778619087775e-08,0.9999999859432479,"Yes",0.9999999886549064,1.1345115112838886e-08,"No",1.0,3.99690264752591e-31,"No",0.9997882463741783,0.00021175362580878827,"No",0.9998087955441763,0.00019120445581662077,"No",1.0,3.913768995759496e-15,"No",0.9999977541335947,2.2458664135695335e-06,"No"
"2013-003022-92","A Multicenter Single-Arm Open-Label Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure (UPWARD)","GR","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.120989488214182e-38,0.9994303859422259,0.0005696140577769271,"1",6.89021559851791e-05,0.9999310978440084,"Yes",0.9999389877281581,6.101227184508869e-05,"No",1.0,7.229393550816348e-15,"No",0.9982655872582787,0.0017344127417228425,"No",0.9996365102238309,0.0003634897761594195,"No",0.9999991499833729,8.500166396538492e-07,"No",0.9974888108100071,0.0025111891900003614,"No"
"2013-003046-17","A re-treatment safety study of radium-223 dichloride in subjects withcastration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeksEstudio de seguridad de la repetición del tratamiento de dicloruro de radio 223 en pacientes con cáncer de próstata resistente a la castración con metástasis ósea que recibieron un ciclo inicial de seis dosis de dicloruro de radio 223 de 50 kBq/kg cada cuatro semanas","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",5.514346939040867e-51,6.027178121258922e-06,0.9999939728218997,"1",0.9812316530699974,0.018768346930024937,"Yes",0.12954924657070002,0.870450753429326,"No",1.0,1.8883563640019533e-34,"No",2.346224548680283e-07,0.9999997653775656,"No",9.086571967408764e-08,0.9999999091342644,"No",1.0,9.541429126969419e-30,"No",4.8676137295008666e-09,0.9999999951323845,"No"
"2013-003046-17","A re-treatment safety study of radium-223 dichloride in subjects withcastration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeksEstudio de seguridad de la repetición del tratamiento de dicloruro de radio 223 en pacientes con cáncer de próstata resistente a la castración con metástasis ósea que recibieron un ciclo inicial de seis dosis de dicloruro de radio 223 de 50 kBq/kg cada cuatro semanas","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",5.514346939040867e-51,6.027178121258922e-06,0.9999939728218997,"1",0.9812316530699974,0.018768346930024937,"Yes",0.12954924657070002,0.870450753429326,"No",1.0,1.8883563640019533e-34,"No",2.346224548680283e-07,0.9999997653775656,"No",9.086571967408764e-08,0.9999999091342644,"No",1.0,9.541429126969419e-30,"No",4.8676137295008666e-09,0.9999999951323845,"No"
"2013-003046-17","A re-treatment safety study of radium-223 dichloride in subjects withcastration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeks","NO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",3.5616355173201617e-26,0.00016104301517185095,0.9998389569848242,"1",0.9994546353055034,0.000545364694497967,"Yes",0.0002512558840491032,0.9997487441159567,"No",1.0,3.4567878019023554e-18,"No",2.0042633663146825e-05,0.9999799573663496,"No",5.076808884276587e-06,0.9999949231911224,"No",0.9999999999907914,9.217885779859641e-12,"No",2.5714865486189437e-06,0.999997428513448,"No"
"2013-003046-17","A re-treatment safety study of radium-223 dichloride in subjects withcastration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeks","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",3.5616355173201617e-26,0.00016104301517185095,0.9998389569848242,"1",0.9994546353055034,0.000545364694497967,"Yes",0.0002512558840491032,0.9997487441159567,"No",1.0,3.4567878019023554e-18,"No",2.0042633663146825e-05,0.9999799573663496,"No",5.076808884276587e-06,0.9999949231911224,"No",0.9999999999907914,9.217885779859641e-12,"No",2.5714865486189437e-06,0.999997428513448,"No"
"2013-003046-17","A re-treatment safety study of radium-223 dichloride in subjects withcastration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeksEstudio de seguridad de la repetición del tratamiento de dicloruro de radio 223 en pacientes con cáncer de próstata resistente a la castración con metástasis ósea que recibieron un ciclo inicial de seis dosis de dicloruro de radio 223 de 50 kBq/kg cada cuatro semanas","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",5.514346939040867e-51,6.027178121258922e-06,0.9999939728218997,"1",0.9812316530699974,0.018768346930024937,"Yes",0.12954924657070002,0.870450753429326,"No",1.0,1.8883563640019533e-34,"No",2.346224548680283e-07,0.9999997653775656,"No",9.086571967408764e-08,0.9999999091342644,"No",1.0,9.541429126969419e-30,"No",4.8676137295008666e-09,0.9999999951323845,"No"
"2013-003046-17","A re-treatment safety study of radium-223 dichloride in subjects withcastration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeks","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",3.5616355173201617e-26,0.00016104301517185095,0.9998389569848242,"1",0.9994546353055034,0.000545364694497967,"Yes",0.0002512558840491032,0.9997487441159567,"No",1.0,3.4567878019023554e-18,"No",2.0042633663146825e-05,0.9999799573663496,"No",5.076808884276587e-06,0.9999949231911224,"No",0.9999999999907914,9.217885779859641e-12,"No",2.5714865486189437e-06,0.999997428513448,"No"
"2013-003046-17","A re-treatment safety study of radium-223 dichloride in subjects withcastration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeks","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",3.5616355173201617e-26,0.00016104301517185095,0.9998389569848242,"1",0.9994546353055034,0.000545364694497967,"Yes",0.0002512558840491032,0.9997487441159567,"No",1.0,3.4567878019023554e-18,"No",2.0042633663146825e-05,0.9999799573663496,"No",5.076808884276587e-06,0.9999949231911224,"No",0.9999999999907914,9.217885779859641e-12,"No",2.5714865486189437e-06,0.999997428513448,"No"
"2013-003050-25","A Randomized Multicenter Double-Blind Parallel Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.001546432405775e-43,3.174840756833109e-14,0.9999999999999717,"2+",0.9999999992232347,7.767705735252195e-10,"No",3.1003097650229556e-09,0.999999996899689,"Yes",0.999999995478433,4.521563138869697e-09,"No",3.971448578874003e-14,0.9999999999999574,"Yes",1.3992143788496974e-06,0.999998600785615,"Yes",0.999586116011314,0.0004138839886820064,"No",1.5084271791824494e-11,0.9999999999849223,"Yes"
"2013-003050-25","A Randomized Multicenter Double-Blind Parallel Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.001546432405775e-43,3.174840756833109e-14,0.9999999999999717,"2+",0.9999999992232347,7.767705735252195e-10,"No",3.1003097650229556e-09,0.999999996899689,"Yes",0.999999995478433,4.521563138869697e-09,"No",3.971448578874003e-14,0.9999999999999574,"Yes",1.3992143788496974e-06,0.999998600785615,"Yes",0.999586116011314,0.0004138839886820064,"No",1.5084271791824494e-11,0.9999999999849223,"Yes"
"2013-003050-25","A Randomized Multicenter Double-Blind Parallel Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.001546432405775e-43,3.174840756833109e-14,0.9999999999999717,"2+",0.9999999992232347,7.767705735252195e-10,"No",3.1003097650229556e-09,0.999999996899689,"Yes",0.999999995478433,4.521563138869697e-09,"No",3.971448578874003e-14,0.9999999999999574,"Yes",1.3992143788496974e-06,0.999998600785615,"Yes",0.999586116011314,0.0004138839886820064,"No",1.5084271791824494e-11,0.9999999999849223,"Yes"
"2013-003050-25","A Randomized Multicenter Double-Blind Parallel Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.001546432405775e-43,3.174840756833109e-14,0.9999999999999717,"2+",0.9999999992232347,7.767705735252195e-10,"No",3.1003097650229556e-09,0.999999996899689,"Yes",0.999999995478433,4.521563138869697e-09,"No",3.971448578874003e-14,0.9999999999999574,"Yes",1.3992143788496974e-06,0.999998600785615,"Yes",0.999586116011314,0.0004138839886820064,"No",1.5084271791824494e-11,0.9999999999849223,"Yes"
"2013-003050-25","A Randomized Multicenter Double-Blind Parallel Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.001546432405775e-43,3.174840756833109e-14,0.9999999999999717,"2+",0.9999999992232347,7.767705735252195e-10,"No",3.1003097650229556e-09,0.999999996899689,"Yes",0.999999995478433,4.521563138869697e-09,"No",3.971448578874003e-14,0.9999999999999574,"Yes",1.3992143788496974e-06,0.999998600785615,"Yes",0.999586116011314,0.0004138839886820064,"No",1.5084271791824494e-11,0.9999999999849223,"Yes"
"2013-003050-25","A Randomized Multicenter Double-Blind Parallel Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.001546432405775e-43,3.174840756833109e-14,0.9999999999999717,"2+",0.9999999992232347,7.767705735252195e-10,"No",3.1003097650229556e-09,0.999999996899689,"Yes",0.999999995478433,4.521563138869697e-09,"No",3.971448578874003e-14,0.9999999999999574,"Yes",1.3992143788496974e-06,0.999998600785615,"Yes",0.999586116011314,0.0004138839886820064,"No",1.5084271791824494e-11,0.9999999999849223,"Yes"
"2013-003050-25","A Randomized Multicenter Double-Blind Parallel Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.001546432405775e-43,3.174840756833109e-14,0.9999999999999717,"2+",0.9999999992232347,7.767705735252195e-10,"No",3.1003097650229556e-09,0.999999996899689,"Yes",0.999999995478433,4.521563138869697e-09,"No",3.971448578874003e-14,0.9999999999999574,"Yes",1.3992143788496974e-06,0.999998600785615,"Yes",0.999586116011314,0.0004138839886820064,"No",1.5084271791824494e-11,0.9999999999849223,"Yes"
"2013-003050-25","A Randomized Multicenter Double-Blind Parallel Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.001546432405775e-43,3.174840756833109e-14,0.9999999999999717,"2+",0.9999999992232347,7.767705735252195e-10,"No",3.1003097650229556e-09,0.999999996899689,"Yes",0.999999995478433,4.521563138869697e-09,"No",3.971448578874003e-14,0.9999999999999574,"Yes",1.3992143788496974e-06,0.999998600785615,"Yes",0.999586116011314,0.0004138839886820064,"No",1.5084271791824494e-11,0.9999999999849223,"Yes"
"2013-003050-25","A Randomized Multicenter Double-Blind Parallel Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.001546432405775e-43,3.174840756833109e-14,0.9999999999999717,"2+",0.9999999992232347,7.767705735252195e-10,"No",3.1003097650229556e-09,0.999999996899689,"Yes",0.999999995478433,4.521563138869697e-09,"No",3.971448578874003e-14,0.9999999999999574,"Yes",1.3992143788496974e-06,0.999998600785615,"Yes",0.999586116011314,0.0004138839886820064,"No",1.5084271791824494e-11,0.9999999999849223,"Yes"
"2013-003118-42","A three arm randomized open-label Phase II study of radium-223 dichloride 50 kBq/kg (55 kBq/kg after implementation of NIST update) versus 80 kBq/kg (88 kBq/kg after implementation of NIST update) and versus 50 kBq/kg (55 kBq/kg after implementation of NIST update) in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.680259665729118e-51,6.201723063410584e-08,0.999999937982752,"2+",1.129869808905192e-05,0.9999887013018977,"Yes",0.9999867343250876,1.326567491002613e-05,"No",1.0,2.310629933735861e-18,"No",3.5455979823545643e-06,0.9999964544020133,"No",0.002614195282172053,0.9973858047178501,"No",0.9999999999970441,2.9732742857216537e-12,"No",8.499633034816498e-07,0.999999150036692,"Yes"
"2013-003118-42","A three arm randomized open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.631576289122013e-44,0.0008510410397609821,0.9991489589602399,"2+",0.0006358340258244763,0.9993641659741733,"Yes",0.9992335851187073,0.0007664148812981257,"No",1.0,2.126770871036084e-15,"No",0.0035207014418229257,0.9964792985581843,"No",0.5302751515570711,0.46972484844292994,"No",0.9999999758839525,2.4116048962564044e-08,"No",0.00046325857524599117,0.9995367414247539,"Yes"
"2013-003118-42","A three arm randomized open-label Phase II study of radium-223 dichloride 50 kBq/kg (55 kBq/kg after implementation of NIST update) versus 80 kBq/kg (88 kBq/kg after implementation of NIST update) and versus 50 kBq/kg (55 kBq/kg after implementation of NIST update) in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone","FI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.680259665729118e-51,6.201723063410584e-08,0.999999937982752,"2+",1.129869808905192e-05,0.9999887013018977,"Yes",0.9999867343250876,1.326567491002613e-05,"No",1.0,2.310629933735861e-18,"No",3.5455979823545643e-06,0.9999964544020133,"No",0.002614195282172053,0.9973858047178501,"No",0.9999999999970441,2.9732742857216537e-12,"No",8.499633034816498e-07,0.999999150036692,"Yes"
"2013-003118-42","A three arm randomized open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.631576289122013e-44,0.0008510410397609821,0.9991489589602399,"2+",0.0006358340258244763,0.9993641659741733,"Yes",0.9992335851187073,0.0007664148812981257,"No",1.0,2.126770871036084e-15,"No",0.0035207014418229257,0.9964792985581843,"No",0.5302751515570711,0.46972484844292994,"No",0.9999999758839525,2.4116048962564044e-08,"No",0.00046325857524599117,0.9995367414247539,"Yes"
"2013-003118-42","A three arm randomized open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.631576289122013e-44,0.0008510410397609821,0.9991489589602399,"2+",0.0006358340258244763,0.9993641659741733,"Yes",0.9992335851187073,0.0007664148812981257,"No",1.0,2.126770871036084e-15,"No",0.0035207014418229257,0.9964792985581843,"No",0.5302751515570711,0.46972484844292994,"No",0.9999999758839525,2.4116048962564044e-08,"No",0.00046325857524599117,0.9995367414247539,"Yes"
"2013-003118-42","A three arm randomized open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.631576289122013e-44,0.0008510410397609821,0.9991489589602399,"2+",0.0006358340258244763,0.9993641659741733,"Yes",0.9992335851187073,0.0007664148812981257,"No",1.0,2.126770871036084e-15,"No",0.0035207014418229257,0.9964792985581843,"No",0.5302751515570711,0.46972484844292994,"No",0.9999999758839525,2.4116048962564044e-08,"No",0.00046325857524599117,0.9995367414247539,"Yes"
"2013-003118-42","A three arm randomized open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.631576289122013e-44,0.0008510410397609821,0.9991489589602399,"2+",0.0006358340258244763,0.9993641659741733,"Yes",0.9992335851187073,0.0007664148812981257,"No",1.0,2.126770871036084e-15,"No",0.0035207014418229257,0.9964792985581843,"No",0.5302751515570711,0.46972484844292994,"No",0.9999999758839525,2.4116048962564044e-08,"No",0.00046325857524599117,0.9995367414247539,"Yes"
"2013-003129-27","Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM)Estudio de fase Ib/II multicéntrico de buparlisib más carboplatino o lomustina en pacientes con glioblastoma multiforme (GBM) recurrente","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","Yes","Yes","No","No","Yes","No","Yes","2+","Yes",1.6993318214699607e-54,2.786257324160611e-09,0.9999999972137347,"2+",9.082882103847533e-06,0.999990917117894,"No",0.9999985402178165,1.4597821844363367e-06,"Yes",0.9999999999965895,3.4050207581644867e-12,"No",7.257936516629113e-08,0.9999999274206486,"Yes",0.9991748029079489,0.000825197092054725,"Yes",1.0,5.082182574418606e-27,"No",0.0033776959452014614,0.9966223040547944,"Yes"
"2013-003156-21","A randomised open-label phase III trial evaluating the addition ofdenosumab to standard first-line anticancer treatment in advancedNSCLC","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5440906536523732e-21,0.0014399860757940092,0.998560013924201,"2+",0.0045411601289380744,0.9954588398710562,"Yes",0.998314656250068,0.0016853437499348039,"No",0.9992866708092946,0.0007133291907010747,"No",0.004769274578576039,0.9952307254214267,"Yes",0.31917888557078306,0.6808211144292157,"Yes",0.999800785958452,0.0001992140415463947,"No",0.0035792834346946205,0.9964207165652984,"Yes"
"2013-003156-21","A randomised open-label phase III trial evaluating the addition ofdenosumab to standard first-line anticancer treatment in advancedNSCLC","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5440906536523732e-21,0.0014399860757940092,0.998560013924201,"2+",0.0045411601289380744,0.9954588398710562,"Yes",0.998314656250068,0.0016853437499348039,"No",0.9992866708092946,0.0007133291907010747,"No",0.004769274578576039,0.9952307254214267,"Yes",0.31917888557078306,0.6808211144292157,"Yes",0.999800785958452,0.0001992140415463947,"No",0.0035792834346946205,0.9964207165652984,"Yes"
"2013-003156-21","A randomised open-label phase III trial evaluating the addition ofdenosumab to standard first-line anticancer treatment in advancedNSCLC","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5440906536523732e-21,0.0014399860757940092,0.998560013924201,"2+",0.0045411601289380744,0.9954588398710562,"Yes",0.998314656250068,0.0016853437499348039,"No",0.9992866708092946,0.0007133291907010747,"No",0.004769274578576039,0.9952307254214267,"Yes",0.31917888557078306,0.6808211144292157,"Yes",0.999800785958452,0.0001992140415463947,"No",0.0035792834346946205,0.9964207165652984,"Yes"
"2013-003156-21","A randomised open-label phase III trial evaluating the addition ofdenosumab to standard first-line anticancer treatment in advancedNSCLC","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5440906536523732e-21,0.0014399860757940092,0.998560013924201,"2+",0.0045411601289380744,0.9954588398710562,"Yes",0.998314656250068,0.0016853437499348039,"No",0.9992866708092946,0.0007133291907010747,"No",0.004769274578576039,0.9952307254214267,"Yes",0.31917888557078306,0.6808211144292157,"Yes",0.999800785958452,0.0001992140415463947,"No",0.0035792834346946205,0.9964207165652984,"Yes"
"2013-003156-21","A randomised open-label phase III trial evaluating the addition ofdenosumab to standard first-line anticancer treatment in advancedNSCLC","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5440906536523732e-21,0.0014399860757940092,0.998560013924201,"2+",0.0045411601289380744,0.9954588398710562,"Yes",0.998314656250068,0.0016853437499348039,"No",0.9992866708092946,0.0007133291907010747,"No",0.004769274578576039,0.9952307254214267,"Yes",0.31917888557078306,0.6808211144292157,"Yes",0.999800785958452,0.0001992140415463947,"No",0.0035792834346946205,0.9964207165652984,"Yes"
"2013-003156-21","A randomised open-label phase III trial evaluating the addition ofdenosumab to standard first-line anticancer treatment in advancedNSCLC","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5440906536523732e-21,0.0014399860757940092,0.998560013924201,"2+",0.0045411601289380744,0.9954588398710562,"Yes",0.998314656250068,0.0016853437499348039,"No",0.9992866708092946,0.0007133291907010747,"No",0.004769274578576039,0.9952307254214267,"Yes",0.31917888557078306,0.6808211144292157,"Yes",0.999800785958452,0.0001992140415463947,"No",0.0035792834346946205,0.9964207165652984,"Yes"
"2013-003156-21","A randomised open-label phase III trial evaluating the addition ofdenosumab to standard first-line anticancer treatment in advancedNSCLC","SI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5440906536523732e-21,0.0014399860757940092,0.998560013924201,"2+",0.0045411601289380744,0.9954588398710562,"Yes",0.998314656250068,0.0016853437499348039,"No",0.9992866708092946,0.0007133291907010747,"No",0.004769274578576039,0.9952307254214267,"Yes",0.31917888557078306,0.6808211144292157,"Yes",0.999800785958452,0.0001992140415463947,"No",0.0035792834346946205,0.9964207165652984,"Yes"
"2013-003156-21","A randomised open-label phase III trial evaluating the addition ofdenosumab to standard first-line anticancer treatment in advancedNSCLC","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5440906536523732e-21,0.0014399860757940092,0.998560013924201,"2+",0.0045411601289380744,0.9954588398710562,"Yes",0.998314656250068,0.0016853437499348039,"No",0.9992866708092946,0.0007133291907010747,"No",0.004769274578576039,0.9952307254214267,"Yes",0.31917888557078306,0.6808211144292157,"Yes",0.999800785958452,0.0001992140415463947,"No",0.0035792834346946205,0.9964207165652984,"Yes"
"2013-003156-21","A randomised open-label phase III trial evaluating the addition ofdenosumab to standard first-line anticancer treatment in advancedNSCLC","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5440906536523732e-21,0.0014399860757940092,0.998560013924201,"2+",0.0045411601289380744,0.9954588398710562,"Yes",0.998314656250068,0.0016853437499348039,"No",0.9992866708092946,0.0007133291907010747,"No",0.004769274578576039,0.9952307254214267,"Yes",0.31917888557078306,0.6808211144292157,"Yes",0.999800785958452,0.0001992140415463947,"No",0.0035792834346946205,0.9964207165652984,"Yes"
"2013-003167-58","A PHASE II RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELLCARCINOMA.","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.510182848699612e-37,0.010072808961184804,0.9899271910388198,"2+",1.5220240305176118e-06,0.9999984779759715,"Yes",0.9999974365717208,2.56342827282256e-06,"No",0.9999999999994601,5.432370272134173e-13,"No",0.001687666063701118,0.9983123339362973,"Yes",0.9707836670545151,0.02921633294548613,"No",0.9994708736047747,0.0005291263952230015,"Yes",0.0067799812939663764,0.99322001870603,"Yes"
"2013-003167-58","A PHASE II RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELLCARCINOMA.","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.150509626504662e-46,0.00405247841296798,0.9959475215870361,"2+",2.5753715547873577e-06,0.9999974246284377,"Yes",0.9999948633976364,5.136602374426091e-06,"No",1.0,9.379162567435435e-19,"No",0.013262284084131644,0.986737715915864,"Yes",0.9236847217749435,0.07631527822506942,"No",0.9999910323289145,8.967671094911468e-06,"Yes",0.011279344947367572,0.9887206550526193,"Yes"
"2013-003167-58","A PHASE II RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELLCARCINOMA.ESTUDIO FASE II ALEATORIZADO DE MPDL3280A ADMINISTRADO COMO MONOTERAPIA O EN COMBINACIÓN CON BEVACIZUMAB FRENTE A SUNITINIB EN PACIENTES CON CARCINOMA AVANZADO DE CÉLULAS RENALES NO TRATADO.","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4217722746582622e-76,0.006671189626692898,0.9933288103732966,"2+",7.972870587626699e-14,0.9999999999999147,"Yes",0.9999999999997442,2.554143669278201e-13,"No",1.0,1.4176911073677709e-30,"No",0.0001438659706192936,0.9998561340294073,"Yes",0.9999368999741657,6.31000258256532e-05,"No",0.9999999999646434,3.5349467464190045e-11,"Yes",0.0007196737764401933,0.9992803262235525,"Yes"
"2013-003167-58","A PHASE II RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELLCARCINOMA.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.510182848699612e-37,0.010072808961184804,0.9899271910388198,"2+",1.5220240305176118e-06,0.9999984779759715,"Yes",0.9999974365717208,2.56342827282256e-06,"No",0.9999999999994601,5.432370272134173e-13,"No",0.001687666063701118,0.9983123339362973,"Yes",0.9707836670545151,0.02921633294548613,"No",0.9994708736047747,0.0005291263952230015,"Yes",0.0067799812939663764,0.99322001870603,"Yes"
"2013-003167-58","A PHASE II RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA.STUDIU FAZA II RANDOMIZAT ASUPRA MPDL3280A ADMINISTRAT CA MONOTERAPIE SAU ÎN COMBINAŢIE CU BEVACIZUMAB FAŢĂ DE SUNITINIB LA PACIENŢII CU CARCINOM CU CELULE RENALE AVANSAT NETRATAT ","RO","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4167695519166877e-56,0.590170389162858,0.4098296108371679,"2+",1.5998176033969775e-08,0.9999999840018179,"Yes",0.999999994524842,5.475173530913162e-09,"No",1.0,2.327416234992081e-25,"No",0.001451834246024242,0.9985481657539691,"Yes",0.9987344450780379,0.0012655549219633972,"No",1.0,8.241780053360512e-19,"Yes",0.027310303321910694,0.9726896966781083,"Yes"
"2013-003167-58","A PHASE II RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA.STUDIU FAZA II RANDOMIZAT ASUPRA MPDL3280A ADMINISTRAT CA MONOTERAPIE SAU ÎN COMBINAŢIE CU BEVACIZUMAB FAŢĂ DE SUNITINIB LA PACIENŢII CU CARCINOM CU CELULE RENALE AVANSAT NETRATAT ","ES","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4167695519166877e-56,0.590170389162858,0.4098296108371679,"2+",1.5998176033969775e-08,0.9999999840018179,"Yes",0.999999994524842,5.475173530913162e-09,"No",1.0,2.327416234992081e-25,"No",0.001451834246024242,0.9985481657539691,"Yes",0.9987344450780379,0.0012655549219633972,"No",1.0,8.241780053360512e-19,"Yes",0.027310303321910694,0.9726896966781083,"Yes"
"2013-003167-58","A PHASE II RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1ANTIBODY) ADMINISTERED AS MONOTHERAPY OR IN COMBINATIONWITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.448620375539808e-41,0.0005571860416968919,0.9994428139583058,"2+",5.612002055480852e-05,0.9999438799794519,"Yes",0.9998881941825242,0.0001118058174728859,"No",1.0,2.925537576600539e-17,"No",0.008779284987299225,0.9912207150127019,"Yes",0.9863568352299419,0.013643164770063668,"No",0.9999991517157457,8.482842608757753e-07,"Yes",0.008301049780484364,0.991698950219517,"Yes"
"2013-003167-58","A PHASE II RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA.STUDIU FAZA II RANDOMIZAT ASUPRA MPDL3280A ADMINISTRAT CA MONOTERAPIE SAU ÎN COMBINAŢIE CU BEVACIZUMAB FAŢĂ DE SUNITINIB LA PACIENŢII CU CARCINOM CU CELULE RENALE AVANSAT NETRATAT ","IT","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4167695519166877e-56,0.590170389162858,0.4098296108371679,"2+",1.5998176033969775e-08,0.9999999840018179,"Yes",0.999999994524842,5.475173530913162e-09,"No",1.0,2.327416234992081e-25,"No",0.001451834246024242,0.9985481657539691,"Yes",0.9987344450780379,0.0012655549219633972,"No",1.0,8.241780053360512e-19,"Yes",0.027310303321910694,0.9726896966781083,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s diseaseA GANTENERUMAB HATÁSOSSÁGÁNAK ÉS BIZTONSÁGOSSÁGÁNAK III. FÁZISÚ RANDOMIZÁLT KETTŐS-VAK PLACEBO-KONTROLLÁLT PÁRHUZAMOS CSOPORTOS MULTICENTRIKUS VIZSGÁLATA ENYHE ALZHEIMER-KÓRBAN SZENVEDŐ BETEGEK ESETÉBEN","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1393266716815044e-79,5.362319986988305e-22,1.0,"2+",1.0,2.3929799605709616e-22,"No",3.606988356570054e-21,1.0,"Yes",1.0,6.262430198271887e-19,"No",1.8392544463356734e-24,1.0,"Yes",3.980475283575136e-06,0.9999960195247223,"Yes",1.0,2.1114910006459802e-19,"No",1.6531704221048804e-20,1.0,"Yes"
"2013-003390-95","A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP MULTICENTER EFFICACY AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER’S DISEASE PART II:  OPEN-LABEL EXTENSION FOR PARTICIPATING PATIENTS","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2490173429327976e-52,1.1207420427866797e-09,0.9999999988792468,"2+",0.999999997777394,2.222596413910991e-09,"No",1.4773331478807354e-07,0.9999998522666939,"Yes",0.9999999989344418,1.0655625188721023e-09,"No",1.9306849192986813e-09,0.9999999980693134,"Yes",0.04005710817890112,0.9599428918210928,"Yes",0.9999999998203465,1.7966170684839267e-10,"No",4.5803821843893886e-08,0.999999954196171,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s disease","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.496366888958254e-45,1.325737387037301e-11,0.9999999999867414,"2+",0.9999999999968595,3.1428342121299254e-12,"No",1.439717911388413e-11,0.9999999999856045,"Yes",0.9999999542870921,4.57129060674974e-08,"No",1.9552990398661348e-11,0.999999999980446,"Yes",0.0045471141616905885,0.9954528858383073,"Yes",0.9999999885265397,1.1473456935259662e-08,"No",4.756499234105113e-10,0.9999999995243485,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s diseaseA GANTENERUMAB HATÁSOSSÁGÁNAK ÉS BIZTONSÁGOSSÁGÁNAK III. FÁZISÚ RANDOMIZÁLT KETTŐS-VAK PLACEBO-KONTROLLÁLT PÁRHUZAMOS CSOPORTOS MULTICENTRIKUS VIZSGÁLATA ENYHE ALZHEIMER-KÓRBAN SZENVEDŐ BETEGEK ESETÉBEN","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1393266716815044e-79,5.362319986988305e-22,1.0,"2+",1.0,2.3929799605709616e-22,"No",3.606988356570054e-21,1.0,"Yes",1.0,6.262430198271887e-19,"No",1.8392544463356734e-24,1.0,"Yes",3.980475283575136e-06,0.9999960195247223,"Yes",1.0,2.1114910006459802e-19,"No",1.6531704221048804e-20,1.0,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s diseaseA GANTENERUMAB HATÁSOSSÁGÁNAK ÉS BIZTONSÁGOSSÁGÁNAK III. FÁZISÚ RANDOMIZÁLT KETTŐS-VAK PLACEBO-KONTROLLÁLT PÁRHUZAMOS CSOPORTOS MULTICENTRIKUS VIZSGÁLATA ENYHE ALZHEIMER-KÓRBAN SZENVEDŐ BETEGEK ESETÉBEN","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1393266716815044e-79,5.362319986988305e-22,1.0,"2+",1.0,2.3929799605709616e-22,"No",3.606988356570054e-21,1.0,"Yes",1.0,6.262430198271887e-19,"No",1.8392544463356734e-24,1.0,"Yes",3.980475283575136e-06,0.9999960195247223,"Yes",1.0,2.1114910006459802e-19,"No",1.6531704221048804e-20,1.0,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s disease","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.496366888958254e-45,1.325737387037301e-11,0.9999999999867414,"2+",0.9999999999968595,3.1428342121299254e-12,"No",1.439717911388413e-11,0.9999999999856045,"Yes",0.9999999542870921,4.57129060674974e-08,"No",1.9552990398661348e-11,0.999999999980446,"Yes",0.0045471141616905885,0.9954528858383073,"Yes",0.9999999885265397,1.1473456935259662e-08,"No",4.756499234105113e-10,0.9999999995243485,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s disease","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.496366888958254e-45,1.325737387037301e-11,0.9999999999867414,"2+",0.9999999999968595,3.1428342121299254e-12,"No",1.439717911388413e-11,0.9999999999856045,"Yes",0.9999999542870921,4.57129060674974e-08,"No",1.9552990398661348e-11,0.999999999980446,"Yes",0.0045471141616905885,0.9954528858383073,"Yes",0.9999999885265397,1.1473456935259662e-08,"No",4.756499234105113e-10,0.9999999995243485,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s diseaseA GANTENERUMAB HATÁSOSSÁGÁNAK ÉS BIZTONSÁGOSSÁGÁNAK III. FÁZISÚ RANDOMIZÁLT KETTŐS-VAK PLACEBO-KONTROLLÁLT PÁRHUZAMOS CSOPORTOS MULTICENTRIKUS VIZSGÁLATA ENYHE ALZHEIMER-KÓRBAN SZENVEDŐ BETEGEK ESETÉBEN","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1393266716815044e-79,5.362319986988305e-22,1.0,"2+",1.0,2.3929799605709616e-22,"No",3.606988356570054e-21,1.0,"Yes",1.0,6.262430198271887e-19,"No",1.8392544463356734e-24,1.0,"Yes",3.980475283575136e-06,0.9999960195247223,"Yes",1.0,2.1114910006459802e-19,"No",1.6531704221048804e-20,1.0,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s disease","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.496366888958254e-45,1.325737387037301e-11,0.9999999999867414,"2+",0.9999999999968595,3.1428342121299254e-12,"No",1.439717911388413e-11,0.9999999999856045,"Yes",0.9999999542870921,4.57129060674974e-08,"No",1.9552990398661348e-11,0.999999999980446,"Yes",0.0045471141616905885,0.9954528858383073,"Yes",0.9999999885265397,1.1473456935259662e-08,"No",4.756499234105113e-10,0.9999999995243485,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s diseaseA GANTENERUMAB HATÁSOSSÁGÁNAK ÉS BIZTONSÁGOSSÁGÁNAK III. FÁZISÚ RANDOMIZÁLT KETTŐS-VAK PLACEBO-KONTROLLÁLT PÁRHUZAMOS CSOPORTOS MULTICENTRIKUS VIZSGÁLATA ENYHE ALZHEIMER-KÓRBAN SZENVEDŐ BETEGEK ESETÉBEN","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1393266716815044e-79,5.362319986988305e-22,1.0,"2+",1.0,2.3929799605709616e-22,"No",3.606988356570054e-21,1.0,"Yes",1.0,6.262430198271887e-19,"No",1.8392544463356734e-24,1.0,"Yes",3.980475283575136e-06,0.9999960195247223,"Yes",1.0,2.1114910006459802e-19,"No",1.6531704221048804e-20,1.0,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s diseaseA GANTENERUMAB HATÁSOSSÁGÁNAK ÉS BIZTONSÁGOSSÁGÁNAK III. FÁZISÚ RANDOMIZÁLT KETTŐS-VAK PLACEBO-KONTROLLÁLT PÁRHUZAMOS CSOPORTOS MULTICENTRIKUS VIZSGÁLATA ENYHE ALZHEIMER-KÓRBAN SZENVEDŐ BETEGEK ESETÉBEN","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1393266716815044e-79,5.362319986988305e-22,1.0,"2+",1.0,2.3929799605709616e-22,"No",3.606988356570054e-21,1.0,"Yes",1.0,6.262430198271887e-19,"No",1.8392544463356734e-24,1.0,"Yes",3.980475283575136e-06,0.9999960195247223,"Yes",1.0,2.1114910006459802e-19,"No",1.6531704221048804e-20,1.0,"Yes"
"2013-003390-95","A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP MULTICENTER EFFICACY AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER’S DISEASE PART II:  OPEN-LABEL EXTENSION FOR PARTICIPATING PATIENTS","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2490173429327976e-52,1.1207420427866797e-09,0.9999999988792468,"2+",0.999999997777394,2.222596413910991e-09,"No",1.4773331478807354e-07,0.9999998522666939,"Yes",0.9999999989344418,1.0655625188721023e-09,"No",1.9306849192986813e-09,0.9999999980693134,"Yes",0.04005710817890112,0.9599428918210928,"Yes",0.9999999998203465,1.7966170684839267e-10,"No",4.5803821843893886e-08,0.999999954196171,"Yes"
"2013-003390-95","A Phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s diseaseA GANTENERUMAB HATÁSOSSÁGÁNAK ÉS BIZTONSÁGOSSÁGÁNAK III. FÁZISÚ RANDOMIZÁLT KETTŐS-VAK PLACEBO-KONTROLLÁLT PÁRHUZAMOS CSOPORTOS MULTICENTRIKUS VIZSGÁLATA ENYHE ALZHEIMER-KÓRBAN SZENVEDŐ BETEGEK ESETÉBEN","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.1393266716815044e-79,5.362319986988305e-22,1.0,"2+",1.0,2.3929799605709616e-22,"No",3.606988356570054e-21,1.0,"Yes",1.0,6.262430198271887e-19,"No",1.8392544463356734e-24,1.0,"Yes",3.980475283575136e-06,0.9999960195247223,"Yes",1.0,2.1114910006459802e-19,"No",1.6531704221048804e-20,1.0,"Yes"
"2013-003397-27","A Randomized Double Blind Double Dummy Placebo Controlled Parallel Group 12 Week Clinical Study to Assess the Efficacy and Safety Of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent AsthmaRandomizált kettős-vak kettős- álcázott adagolási technikával végzett placebokontrollospárhuzamos csoportos 12-hetes klinikai vizsgálat a belégzés általaktivált inhalátorral (BAI) vagy adagolószelepes inhalátorral (MDI) alkalmazottnapi 320 vagy 640 mcgr beklometazon-dipropionát hatásosságának ésbiztonságosságnak értékelésére perzisztáló asztmában szenvedő legalább 12éves serdülőknél és felnőtteknél.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.188243804392745e-111,1.5013600415368733e-41,1.0,"2+",1.0,3.577562412800185e-39,"No",2.4583207115440504e-30,1.0,"Yes",1.0,1.5464484949760478e-18,"No",5.874534016660129e-42,1.0,"Yes",1.171604455402139e-10,0.9999999998827889,"Yes",0.9999999999994316,5.734756444776934e-13,"No",1.4441743708415241e-40,1.0,"Yes"
"2013-003397-27","A Randomized Double Blind Double Dummy Placebo Controlled Parallel Group 12 Week Clinical Study to Assess the Efficacy and Safety Of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma","PL","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7115188841655968e-79,2.1924953877313658e-27,1.0,"2+",1.0,8.624742995763362e-25,"No",4.426862166763507e-19,1.0,"Yes",0.9999999994101927,5.897931439758038e-10,"No",7.576592963694152e-27,1.0,"Yes",0.00013108657392765197,0.9998689134260728,"Yes",0.00043006195509714165,0.9995699380448791,"No",2.7533840718666366e-27,1.0,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","NO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003438-33","A phase III randomized double-blind placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.519888283092734e-60,2.4544888327932285e-12,0.9999999999975557,"2+",0.9999999723917203,2.7608267739457325e-08,"No",3.550910980780066e-08,0.9999999644908832,"Yes",1.0,1.0267146540328833e-25,"No",3.753465217962328e-11,0.9999999999624549,"Yes",0.00018815881374817728,0.9998118411862523,"Yes",0.9999999998881606,1.1184316175784191e-10,"No",1.5946055774263954e-11,0.9999999999840554,"Yes"
"2013-003492-35","Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran after Pulmonary Vein Isolation for Atrial Fibrillation ","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.382834237409152e-18,0.01829961859387357,0.9817003814061219,"2+",0.0016547432245131387,0.99834525677549,"Yes",0.9978599775893198,0.0021400224106802672,"No",0.9999997888501834,2.1114981663612294e-07,"No",0.00028750400739960426,0.9997124959925953,"Yes",0.21447933051237136,0.7855206694876258,"Yes",0.9999997164151869,2.8358480702651237e-07,"No",1.4640507937127543e-06,0.999998535949209,"Yes"
"2013-003714-40","Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group then switch placebo to active drug and STOP randomized controlled in parallel-groupto evaluate the efficacy and safety of hydroxychloroquine (HCQ)Hidroxicloroquina en EPI pediátrica. START aleatorizado controlado de grupos paralelos con cambio de placebo a fármaco activo y STOP aleatorizado controlado de grupos paralelos para evaluar la eficacia y seguridad de hidroxicloroquina (HCQ)","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.227729963764129e-83,4.52386058069695e-27,1.0,"2+",0.9999999999989768,1.0360667723664512e-12,"No",3.34701508123484e-11,0.9999999999665192,"Yes",0.9999999900315971,9.968430674898032e-09,"No",1.4144473314226265e-24,1.0,"Yes",8.743706154205853e-09,0.9999999912562886,"Yes",1.0,1.539731731556021e-29,"No",4.513889288085107e-22,1.0,"Yes"
"2013-003714-40","Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group then switch placebo to active drug and STOP randomized controlled in parallel-groupto evaluate the efficacy and safety of hydroxychloroquine (HCQ)Hidroxicloroquina en EPI pediátrica. START aleatorizado controlado de grupos paralelos con cambio de placebo a fármaco activo y STOP aleatorizado controlado de grupos paralelos para evaluar la eficacia y seguridad de hidroxicloroquina (HCQ)","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.227729963764129e-83,4.52386058069695e-27,1.0,"2+",0.9999999999989768,1.0360667723664512e-12,"No",3.34701508123484e-11,0.9999999999665192,"Yes",0.9999999900315971,9.968430674898032e-09,"No",1.4144473314226265e-24,1.0,"Yes",8.743706154205853e-09,0.9999999912562886,"Yes",1.0,1.539731731556021e-29,"No",4.513889288085107e-22,1.0,"Yes"
"2013-003714-40","Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group then switch placebo to active drug and STOP randomized controlled in parallel-groupto evaluate the efficacy and safety of hydroxychloroquine (HCQ)Hidroxicloroquina en EPI pediátrica. START aleatorizado controlado de grupos paralelos con cambio de placebo a fármaco activo y STOP aleatorizado controlado de grupos paralelos para evaluar la eficacia y seguridad de hidroxicloroquina (HCQ)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.227729963764129e-83,4.52386058069695e-27,1.0,"2+",0.9999999999989768,1.0360667723664512e-12,"No",3.34701508123484e-11,0.9999999999665192,"Yes",0.9999999900315971,9.968430674898032e-09,"No",1.4144473314226265e-24,1.0,"Yes",8.743706154205853e-09,0.9999999912562886,"Yes",1.0,1.539731731556021e-29,"No",4.513889288085107e-22,1.0,"Yes"
"2013-003714-40","Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group then switch placebo to active drug and STOP randomized controlled in parallel-groupto evaluate the efficacy and safety of hydroxychloroquine (HCQ)Hidroxicloroquina en EPI pediátrica. START aleatorizado controlado de grupos paralelos con cambio de placebo a fármaco activo y STOP aleatorizado controlado de grupos paralelos para evaluar la eficacia y seguridad de hidroxicloroquina (HCQ)","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.227729963764129e-83,4.52386058069695e-27,1.0,"2+",0.9999999999989768,1.0360667723664512e-12,"No",3.34701508123484e-11,0.9999999999665192,"Yes",0.9999999900315971,9.968430674898032e-09,"No",1.4144473314226265e-24,1.0,"Yes",8.743706154205853e-09,0.9999999912562886,"Yes",1.0,1.539731731556021e-29,"No",4.513889288085107e-22,1.0,"Yes"
"2013-003763-56","Proof of Concept Study of Eurartesim® in Patients with Imported Uncomplicated Plasmodium Vivax Malaria ","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",5.716833205188531e-09,0.11534769678951556,0.8846522974936518,"-1",0.9864102884425622,0.0135897115574374,"Yes",0.01763905075400595,0.9823609492459923,"No",0.9846283395237645,0.015371660476237893,"No",0.051458130486006635,0.9485418695139927,"No",0.9450121661216206,0.054987833878378745,"No",0.9607981549972028,0.039201845002796706,"No",0.4863280275588895,0.5136719724411076,"No"
"2013-003763-56","Proof of Concept Study of Eurartesim® in Patients with Imported Uncomplicated Plasmodium Vivax Malaria ","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",5.716833205188531e-09,0.11534769678951556,0.8846522974936518,"-1",0.9864102884425622,0.0135897115574374,"Yes",0.01763905075400595,0.9823609492459923,"No",0.9846283395237645,0.015371660476237893,"No",0.051458130486006635,0.9485418695139927,"No",0.9450121661216206,0.054987833878378745,"No",0.9607981549972028,0.039201845002796706,"No",0.4863280275588895,0.5136719724411076,"No"
"2013-003763-56","Proof of Concept Study of Eurartesim® in Patients with Imported Uncomplicated Plasmodium Vivax Malaria ","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",5.716833205188531e-09,0.11534769678951556,0.8846522974936518,"-1",0.9864102884425622,0.0135897115574374,"Yes",0.01763905075400595,0.9823609492459923,"No",0.9846283395237645,0.015371660476237893,"No",0.051458130486006635,0.9485418695139927,"No",0.9450121661216206,0.054987833878378745,"No",0.9607981549972028,0.039201845002796706,"No",0.4863280275588895,0.5136719724411076,"No"
"2013-003763-56","Proof of Concept Study of Eurartesim® in Patients with Imported Uncomplicated Plasmodium Vivax Malaria Estudio Prueba de Concepto de Eurartesim® en pacientes con paludismo importado no complicado debido a Plasmodium vivax ","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",5.853102906979915e-16,0.04258833947632328,0.9574116605236812,"-1",0.9999307658063064,6.923419369508986e-05,"Yes",0.00016750044608441307,0.9998324995539185,"No",0.9996217153727356,0.00037828462726682724,"No",0.0009331225836800759,0.9990668774163218,"No",0.9846455934240594,0.015354406575947529,"No",0.9999931747001947,6.82529980924378e-06,"No",0.0775941210213559,0.922405878978639,"No"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.637052391762984e-41,8.036658481146109e-06,0.9999919633415075,"2+",0.9999910865114064,8.91348860235408e-06,"No",2.0977910718497383e-05,0.9999790220892906,"Yes",0.9999999999999717,1.6168868861565706e-14,"No",1.5210518154130601e-05,0.9999847894818336,"Yes",0.11927536261705128,0.8807246373829408,"Yes",0.9861350882577914,0.013864911742201565,"No",2.3327848826220367e-05,0.9999766721511667,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","PL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.897860021778132e-48,7.389808106030055e-07,0.9999992610192012,"2+",0.9999184857918748,8.151420812410792e-05,"No",0.0002017365086003279,0.9997982634913964,"Yes",1.0,9.49735050299992e-15,"No",0.0001240799848980961,0.9998759200151124,"Yes",0.7630031573894104,0.23699684261058207,"Yes",0.9907693551737978,0.009230644826210267,"No",3.0982534716652647e-06,0.9999969017465239,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.547163177738459e-41,3.18841191226526e-06,0.999996811588086,"2+",0.9998996861091268,0.00010031389086514177,"No",0.00021826039202030905,0.9997817396079672,"Yes",1.0,4.7976995729731015e-15,"No",0.00040896206365230735,0.9995910379363414,"Yes",0.6407594087358512,0.3592405912641395,"Yes",0.9955919919319145,0.004408008068082765,"No",6.93158224873995e-06,0.9999930684177586,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERMezinárodní randomizovaná dvojitě zaslepená placebem kontrolovaná studie fáze III  hodnotící účinnost a bezpečnost přípravku darolutamidu (ODM-201) u mužů ohrožených vysokým rizikem nemetastázujícího kastračně rezistentního karcinomu prostaty.","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.120039652358568e-74,2.334314274081777e-18,1.0,"2+",0.9999999999997727,2.3469325421850267e-13,"No",2.646775104032072e-13,0.9999999999997159,"Yes",1.0,2.628791502656105e-36,"No",2.4802369983352916e-16,1.0,"Yes",0.04276354051296827,0.9572364594870035,"Yes",0.9999999999998864,9.81965251089963e-14,"No",6.562531197103244e-14,0.9999999999999432,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.547163177738459e-41,3.18841191226526e-06,0.999996811588086,"2+",0.9998996861091268,0.00010031389086514177,"No",0.00021826039202030905,0.9997817396079672,"Yes",1.0,4.7976995729731015e-15,"No",0.00040896206365230735,0.9995910379363414,"Yes",0.6407594087358512,0.3592405912641395,"Yes",0.9955919919319145,0.004408008068082765,"No",6.93158224873995e-06,0.9999930684177586,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.4926184017531807e-40,5.031142724188304e-07,0.9999994968857338,"2+",0.9999256329474144,7.436705257524185e-05,"No",0.0001750074815118103,0.9998249925185018,"Yes",0.9999999999999147,8.873353652684131e-14,"No",7.751952149356089e-05,0.9999224804785106,"Yes",0.18472671963910237,0.8152732803609053,"Yes",0.9997894710719175,0.00021052892808239644,"No",1.450854127258847e-06,0.9999985491458867,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.547163177738459e-41,3.18841191226526e-06,0.999996811588086,"2+",0.9998996861091268,0.00010031389086514177,"No",0.00021826039202030905,0.9997817396079672,"Yes",1.0,4.7976995729731015e-15,"No",0.00040896206365230735,0.9995910379363414,"Yes",0.6407594087358512,0.3592405912641395,"Yes",0.9955919919319145,0.004408008068082765,"No",6.93158224873995e-06,0.9999930684177586,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERMezinárodní randomizovaná dvojitě zaslepená placebem kontrolovaná studie fáze III  hodnotící účinnost a bezpečnost přípravku darolutamidu (ODM-201) u mužů ohrožených vysokým rizikem nemetastázujícího kastračně rezistentního karcinomu prostaty.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.120039652358568e-74,2.334314274081777e-18,1.0,"2+",0.9999999999997727,2.3469325421850267e-13,"No",2.646775104032072e-13,0.9999999999997159,"Yes",1.0,2.628791502656105e-36,"No",2.4802369983352916e-16,1.0,"Yes",0.04276354051296827,0.9572364594870035,"Yes",0.9999999999998864,9.81965251089963e-14,"No",6.562531197103244e-14,0.9999999999999432,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERMezinárodní randomizovaná dvojitě zaslepená placebem kontrolovaná studie fáze III  hodnotící účinnost a bezpečnost přípravku darolutamidu (ODM-201) u mužů ohrožených vysokým rizikem nemetastázujícího kastračně rezistentního karcinomu prostaty.","RO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.120039652358568e-74,2.334314274081777e-18,1.0,"2+",0.9999999999997727,2.3469325421850267e-13,"No",2.646775104032072e-13,0.9999999999997159,"Yes",1.0,2.628791502656105e-36,"No",2.4802369983352916e-16,1.0,"Yes",0.04276354051296827,0.9572364594870035,"Yes",0.9999999999998864,9.81965251089963e-14,"No",6.562531197103244e-14,0.9999999999999432,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.547163177738459e-41,3.18841191226526e-06,0.999996811588086,"2+",0.9998996861091268,0.00010031389086514177,"No",0.00021826039202030905,0.9997817396079672,"Yes",1.0,4.7976995729731015e-15,"No",0.00040896206365230735,0.9995910379363414,"Yes",0.6407594087358512,0.3592405912641395,"Yes",0.9955919919319145,0.004408008068082765,"No",6.93158224873995e-06,0.9999930684177586,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","SK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.547163177738459e-41,3.18841191226526e-06,0.999996811588086,"2+",0.9998996861091268,0.00010031389086514177,"No",0.00021826039202030905,0.9997817396079672,"Yes",1.0,4.7976995729731015e-15,"No",0.00040896206365230735,0.9995910379363414,"Yes",0.6407594087358512,0.3592405912641395,"Yes",0.9955919919319145,0.004408008068082765,"No",6.93158224873995e-06,0.9999930684177586,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.637052391762984e-41,8.036658481146109e-06,0.9999919633415075,"2+",0.9999910865114064,8.91348860235408e-06,"No",2.0977910718497383e-05,0.9999790220892906,"Yes",0.9999999999999717,1.6168868861565706e-14,"No",1.5210518154130601e-05,0.9999847894818336,"Yes",0.11927536261705128,0.8807246373829408,"Yes",0.9861350882577914,0.013864911742201565,"No",2.3327848826220367e-05,0.9999766721511667,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","BG","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.547163177738459e-41,3.18841191226526e-06,0.999996811588086,"2+",0.9998996861091268,0.00010031389086514177,"No",0.00021826039202030905,0.9997817396079672,"Yes",1.0,4.7976995729731015e-15,"No",0.00040896206365230735,0.9995910379363414,"Yes",0.6407594087358512,0.3592405912641395,"Yes",0.9955919919319145,0.004408008068082765,"No",6.93158224873995e-06,0.9999930684177586,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","FI","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.897860021778132e-48,7.389808106030055e-07,0.9999992610192012,"2+",0.9999184857918748,8.151420812410792e-05,"No",0.0002017365086003279,0.9997982634913964,"Yes",1.0,9.49735050299992e-15,"No",0.0001240799848980961,0.9998759200151124,"Yes",0.7630031573894104,0.23699684261058207,"Yes",0.9907693551737978,0.009230644826210267,"No",3.0982534716652647e-06,0.9999969017465239,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.547163177738459e-41,3.18841191226526e-06,0.999996811588086,"2+",0.9998996861091268,0.00010031389086514177,"No",0.00021826039202030905,0.9997817396079672,"Yes",1.0,4.7976995729731015e-15,"No",0.00040896206365230735,0.9995910379363414,"Yes",0.6407594087358512,0.3592405912641395,"Yes",0.9955919919319145,0.004408008068082765,"No",6.93158224873995e-06,0.9999930684177586,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","EE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.897860021778132e-48,7.389808106030055e-07,0.9999992610192012,"2+",0.9999184857918748,8.151420812410792e-05,"No",0.0002017365086003279,0.9997982634913964,"Yes",1.0,9.49735050299992e-15,"No",0.0001240799848980961,0.9998759200151124,"Yes",0.7630031573894104,0.23699684261058207,"Yes",0.9907693551737978,0.009230644826210267,"No",3.0982534716652647e-06,0.9999969017465239,"Yes"
"2013-003820-36","A MULTINATIONAL RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLEDPHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.4926184017531807e-40,5.031142724188304e-07,0.9999994968857338,"2+",0.9999256329474144,7.436705257524185e-05,"No",0.0001750074815118103,0.9998249925185018,"Yes",0.9999999999999147,8.873353652684131e-14,"No",7.751952149356089e-05,0.9999224804785106,"Yes",0.18472671963910237,0.8152732803609053,"Yes",0.9997894710719175,0.00021052892808239644,"No",1.450854127258847e-06,0.9999985491458867,"Yes"
"2013-003822-96","A prospective multicenter double-blind randomized placebo-controlled parallel group 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunctionEstudio a 12 semanas prospectivo multicéntrico a doble ciego aleatorizado controlado con placebo de grupos paralelos para evaluar la seguridad y la tolerabilidad de macitentan en sujetos con hipertensión pulmonar combinada postcapilar-precapilar (CpcPH) debida a disfunción ventricular izquierda","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.510253067626001e-98,7.993843934383818e-23,1.0,"2+",1.0,7.913749069791009e-23,"No",8.392749732931959e-21,1.0,"Yes",0.9999999999999432,3.922303159493021e-14,"No",2.87352058360613e-22,1.0,"Yes",5.988092484564881e-11,0.999999999940144,"Yes",1.0,5.728455601650477e-25,"No",5.518066095718788e-21,1.0,"Yes"
"2013-003822-96","A prospective multicenter double-blind randomized placebo-controlled parallel group 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.424845484392162e-56,3.125865105872411e-12,0.9999999999968736,"2+",0.9999999999990052,9.84669135070857e-13,"No",1.5596220779083122e-11,0.9999999999843966,"Yes",0.9998630122004808,0.00013698779951900868,"No",1.577886865605274e-12,0.9999999999984084,"Yes",6.654408770049424e-06,0.9999933455912358,"Yes",0.9999999995735891,4.2640805308923894e-10,"No",8.470030320022967e-12,0.9999999999915304,"Yes"
"2013-003822-96","A prospective multicenter double-blind randomized placebo-controlled parallel group 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.424845484392162e-56,3.125865105872411e-12,0.9999999999968736,"2+",0.9999999999990052,9.84669135070857e-13,"No",1.5596220779083122e-11,0.9999999999843966,"Yes",0.9998630122004808,0.00013698779951900868,"No",1.577886865605274e-12,0.9999999999984084,"Yes",6.654408770049424e-06,0.9999933455912358,"Yes",0.9999999995735891,4.2640805308923894e-10,"No",8.470030320022967e-12,0.9999999999915304,"Yes"
"2013-003822-96","A prospective multicenter double-blind randomized placebo-controlled parallel group 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunctionEstudio a 12 semanas prospectivo multicéntrico a doble ciego aleatorizado controlado con placebo de grupos paralelos para evaluar la seguridad y la tolerabilidad de macitentan en sujetos con hipertensión pulmonar combinada postcapilar-precapilar (CpcPH) debida a disfunción ventricular izquierda","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.510253067626001e-98,7.993843934383818e-23,1.0,"2+",1.0,7.913749069791009e-23,"No",8.392749732931959e-21,1.0,"Yes",0.9999999999999432,3.922303159493021e-14,"No",2.87352058360613e-22,1.0,"Yes",5.988092484564881e-11,0.999999999940144,"Yes",1.0,5.728455601650477e-25,"No",5.518066095718788e-21,1.0,"Yes"
"2013-003822-96","A prospective multicenter double-blind randomized placebo-controlled parallel group 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunctionProspektivní randomizované dvojitě zaslepené placebem kontrolované multicentrické  12 týdenní klinické hodnocení s paralelními skupinami k prokázání bezpečnosti a snášenlivosti macitentanu u pacientů s kombinovanou pre- a post- kapilární plicní hypertenzí ( CpcPH) při dysfunkci levé komory.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.872739453086746e-108,4.2497693463737e-28,1.0,"2+",1.0,2.884759494017054e-26,"No",1.2447768466402308e-25,1.0,"Yes",1.0,6.823454557641669e-35,"No",9.8213866187887e-31,1.0,"Yes",1.6111699446854517e-09,0.9999999983888302,"Yes",1.0,1.532807320001992e-29,"No",3.169713483976977e-24,1.0,"Yes"
"2013-003829-29","Open-label Randomized Controlled Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care Capecitabine 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5735194779417574e-61,2.3050972432936177e-09,0.9999999976949142,"2+",3.4539947156859424e-09,0.999999996545995,"Yes",0.9999999979761469,2.023854753003649e-09,"No",1.0,1.2589485903931524e-22,"No",6.0120863739590587e-05,0.9999398791362588,"Yes",0.971154706090534,0.02884529390946054,"No",0.9999999999999147,8.459000924415052e-14,"No",2.7191667681479166e-08,0.9999999728083258,"Yes"
"2013-003829-29","Open-label Randomized Controlled Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care Capecitabine 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal AntibodiesEnsayo abierto aleatorizado controlado multicéntrico de fase II que investiga 2 dosis de Sym004 frente a la elección del investigador (mejor tratamiento de soporte capecitabina 5-FU) en pacientes con cáncer colorrectal metastático y resistencia adquirida a los anticuerpos monoclonales anti-EGFR","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1421128726201494e-113,3.572781838830477e-15,1.0,"2+",5.428424481138647e-20,1.0,"Yes",1.0,9.642860354312559e-21,"No",1.0,6.626664617077654e-39,"No",4.932856985737821e-11,0.99999999995066,"Yes",0.9995997902332406,0.00040020976678774024,"No",1.0,7.744818942024137e-29,"No",1.9262199233823366e-15,1.0,"Yes"
"2013-003829-29","Open-label Randomized Controlled Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care Capecitabine 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal AntibodiesEnsayo abierto aleatorizado controlado multicéntrico de fase II que investiga 2 dosis de Sym004 frente a la elección del investigador (mejor tratamiento de soporte capecitabina 5-FU) en pacientes con cáncer colorrectal metastático y resistencia adquirida a los anticuerpos monoclonales anti-EGFR","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1421128726201494e-113,3.572781838830477e-15,1.0,"2+",5.428424481138647e-20,1.0,"Yes",1.0,9.642860354312559e-21,"No",1.0,6.626664617077654e-39,"No",4.932856985737821e-11,0.99999999995066,"Yes",0.9995997902332406,0.00040020976678774024,"No",1.0,7.744818942024137e-29,"No",1.9262199233823366e-15,1.0,"Yes"
"2013-003829-29","Open-label Randomized Controlled Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care Capecitabine 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal AntibodiesEnsayo abierto aleatorizado controlado multicéntrico de fase II que investiga 2 dosis de Sym004 frente a la elección del investigador (mejor tratamiento de soporte capecitabina 5-FU) en pacientes con cáncer colorrectal metastático y resistencia adquirida a los anticuerpos monoclonales anti-EGFR","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1421128726201494e-113,3.572781838830477e-15,1.0,"2+",5.428424481138647e-20,1.0,"Yes",1.0,9.642860354312559e-21,"No",1.0,6.626664617077654e-39,"No",4.932856985737821e-11,0.99999999995066,"Yes",0.9995997902332406,0.00040020976678774024,"No",1.0,7.744818942024137e-29,"No",1.9262199233823366e-15,1.0,"Yes"
"2013-003829-29","Open-label Randomized Controlled Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care Capecitabine 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5735194779417574e-61,2.3050972432936177e-09,0.9999999976949142,"2+",3.4539947156859424e-09,0.999999996545995,"Yes",0.9999999979761469,2.023854753003649e-09,"No",1.0,1.2589485903931524e-22,"No",6.0120863739590587e-05,0.9999398791362588,"Yes",0.971154706090534,0.02884529390946054,"No",0.9999999999999147,8.459000924415052e-14,"No",2.7191667681479166e-08,0.9999999728083258,"Yes"
"2013-003829-29","Open-label Randomized Controlled Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care Capecitabine 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5735194779417574e-61,2.3050972432936177e-09,0.9999999976949142,"2+",3.4539947156859424e-09,0.999999996545995,"Yes",0.9999999979761469,2.023854753003649e-09,"No",1.0,1.2589485903931524e-22,"No",6.0120863739590587e-05,0.9999398791362588,"Yes",0.971154706090534,0.02884529390946054,"No",0.9999999999999147,8.459000924415052e-14,"No",2.7191667681479166e-08,0.9999999728083258,"Yes"
"2013-003829-29","Open-label Randomized Controlled Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care Capecitabine 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal AntibodiesSperimentazione di fase II in aperto randomizzata controllata multicentrica volta a valutare 2 dosi di Sym004 rispetto alla scelta dello sperimentatore (miglior terapia di supporto capecitabina 5-FU) in soggetti affetti da carcinoma colorettale metastatico con resistenza acquisita agli anticorpi monoclonali anti-EGFR","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.8450771182070053e-115,3.061843164865054e-12,0.9999999999969305,"2+",3.452793580942996e-17,1.0,"Yes",1.0,1.0016778229726864e-16,"No",1.0,2.0365480628339761e-47,"No",4.872824987471352e-07,0.9999995127175276,"Yes",0.31373140722638865,0.6862685927735916,"No",1.0,1.4021101358755602e-32,"No",1.625663509872787e-11,0.9999999999837428,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","PT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","IS","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","PL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003839-30","A randomised double-blind parallel group placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.521335957051538e-83,3.3692310773549745e-13,0.9999999999996589,"2+",0.9998902936299608,0.0001097063700356158,"No",0.0004367915346581775,0.9995632084653421,"Yes",1.0,3.1967544094305995e-22,"No",1.0253354658985436e-09,0.9999999989746584,"Yes",0.7824446507816691,0.2175553492183334,"Yes",1.0,7.132126563343714e-22,"No",1.540538168863553e-11,0.9999999999845954,"Yes"
"2013-003868-31","A two-part multicentre international phase I and II trial assessing the safety and efficacy of the Hsp90 inhibitor ganetespib in combination with paclitaxel weekly in women with high-grade serous high-grade endometrioid or undifferentiated platinum-resistant epithelial ovarian fallopian tube or primary peritoneal cancerEine zweiteilige multizentrische internationale Phase-I- und Phase-II-Studie zur Überprüfung der Sicherheit und Wirksamkeit des Hsp90-Inhibitors Ganetespib in Kombination mit wöchentlichem Paclitaxel bei Frauen mit mit hochgradig serösem hochgradig endometroidem oder undifferenzierten platinresistentem epithelialem Ovarial- Tuben- oder primärem Peritonealkarzinom ","BE","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7111873118005598e-96,5.1251550792435185e-08,0.999999948748497,"2+",5.7846380013675815e-15,1.0,"Yes",1.0,7.000216241171999e-15,"No",1.0,1.3268632061591826e-18,"No",3.739386219553438e-07,0.9999996260613233,"Yes",0.9999254635111344,7.453648883340222e-05,"Yes",1.0,3.4651909465236815e-22,"No",0.9347713569047791,0.06522864309523846,"Yes"
"2013-003868-31","A two-part multicentre international phase I and II trial assessing the safety and efficacy of the Hsp90 inhibitor ganetespib in combination with paclitaxel weekly in women with high-grade serous high-grade endometrioid or undifferentiated platinum-resistant epithelial ovarian fallopian tube or primary peritoneal cancer ","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.777913605940416e-55,3.130518231064816e-08,0.9999999686948234,"2+",2.269282487788813e-06,0.9999977307175127,"Yes",0.9999952912191096,4.7087809000634185e-06,"No",1.0,4.908238978373111e-15,"No",3.573139406215533e-06,0.9999964268605939,"Yes",0.6430030716155433,0.356996928384451,"Yes",1.0,9.812698871164731e-17,"No",0.00016313027471332185,0.9998368697252756,"Yes"
"2013-003868-31","A two-part multicentre international phase I and II trial assessing the safety and efficacy of the Hsp90 inhibitor ganetespib in combination with paclitaxel weekly in women with high-grade serous high-grade endometrioid or undifferentiated platinum-resistant epithelial ovarian fallopian tube or primary peritoneal cancer ","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.777913605940416e-55,3.130518231064816e-08,0.9999999686948234,"2+",2.269282487788813e-06,0.9999977307175127,"Yes",0.9999952912191096,4.7087809000634185e-06,"No",1.0,4.908238978373111e-15,"No",3.573139406215533e-06,0.9999964268605939,"Yes",0.6430030716155433,0.356996928384451,"Yes",1.0,9.812698871164731e-17,"No",0.00016313027471332185,0.9998368697252756,"Yes"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisStudio di estensione multicentrico a braccio singolo per descrivere la sicurezza a lungo termine di AMG 416 (velcalcetide) nel trattamento dell’iperparatiroidismo secondario nei soggetti con insufficienza renale cronica sottoposti ad emodialisi","DK","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.8784447690509295e-52,0.9999999999975557,2.4393889670785113e-12,"1",1.8335632998277558e-07,0.9999998166436681,"Yes",0.9999999071556588,9.284432817241745e-08,"No",1.0,5.5318830698214674e-21,"No",0.9999999991965751,8.034306175979117e-10,"No",0.9999999857773788,1.4222639530805548e-08,"No",1.0,1.1200218649668874e-24,"No",0.9999999999997727,1.9906468042522526e-13,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisEstudio de extensión multicéntrico y de un solo grupo para describir la seguridad a largo plazo de AMG 416 (velcalcetide) en el tratamiento del hiperparatiroidismo secundario en sujetos con insuficiencia renal crónica sometidos a hemodiálisis","LV","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",9.096108428011405e-44,0.9999999391103548,6.088964480574101e-08,"1",3.8700536302848856e-05,0.9999612994637077,"Yes",0.9999432810695014,5.671893052608754e-05,"No",1.0,1.8392103957709306e-19,"No",0.9999994648796655,5.351203378686709e-07,"No",0.9999999959629805,4.036991314907408e-09,"No",1.0,2.6393839958015064e-23,"No",0.9999999999976126,2.4055685212585027e-12,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisΜία Πολυκεντρική Μελέτη Επέκτασης Ενός Σκέλους για την Περιγραφή της Μακροχρόνιας Ασφάλειας του AMG 416 (Velcalcetide) στη Θεραπεία του Δευτεροπαθούς Υπερπαραθυρεοειδισμού σε Αιμοκαθαιρόμενους Ασθενείς με Χρόνια Νεφρική Νόσο","SE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.0138754393674575e-22,0.9999997589428353,2.410571722020191e-07,"1",0.15972150531924947,0.8402784946807365,"Yes",0.7948475357979395,0.20515246420206432,"No",0.9999999999999717,2.0614162250524394e-14,"No",0.9999990089970162,9.910029839208705e-07,"No",0.9999991970020785,8.02997919834128e-07,"No",0.9999999999977264,2.2836715009817347e-12,"No",0.9999999224329517,7.756703848056764e-08,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisStudio di estensione multicentrico a braccio singolo per descrivere la sicurezza a lungo termine di AMG 416 (velcalcetide) nel trattamento dell’iperparatiroidismo secondario nei soggetti con insufficienza renale cronica sottoposti ad emodialisi","HU","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.8784447690509295e-52,0.9999999999975557,2.4393889670785113e-12,"1",1.8335632998277558e-07,0.9999998166436681,"Yes",0.9999999071556588,9.284432817241745e-08,"No",1.0,5.5318830698214674e-21,"No",0.9999999991965751,8.034306175979117e-10,"No",0.9999999857773788,1.4222639530805548e-08,"No",1.0,1.1200218649668874e-24,"No",0.9999999999997727,1.9906468042522526e-13,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416  in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.31343020038935e-23,0.9999995873312598,4.1266874224300755e-07,"1",0.04287872654743482,0.9571212734525516,"Yes",0.9505687212771416,0.04943127872286582,"No",0.9999999999196802,8.033031524679399e-11,"No",0.999998429662565,1.570337429105888e-06,"No",0.9999713356025909,2.8664397412655334e-05,"No",0.9999999922587507,7.74123636189726e-09,"No",0.9999998103483316,1.896516611841992e-07,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416  in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.31343020038935e-23,0.9999995873312598,4.1266874224300755e-07,"1",0.04287872654743482,0.9571212734525516,"Yes",0.9505687212771416,0.04943127872286582,"No",0.9999999999196802,8.033031524679399e-11,"No",0.999998429662565,1.570337429105888e-06,"No",0.9999713356025909,2.8664397412655334e-05,"No",0.9999999922587507,7.74123636189726e-09,"No",0.9999998103483316,1.896516611841992e-07,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","IT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.31343020038935e-23,0.9999995873312598,4.1266874224300755e-07,"1",0.04287872654743482,0.9571212734525516,"Yes",0.9505687212771416,0.04943127872286582,"No",0.9999999999196802,8.033031524679399e-11,"No",0.999998429662565,1.570337429105888e-06,"No",0.9999713356025909,2.8664397412655334e-05,"No",0.9999999922587507,7.74123636189726e-09,"No",0.9999998103483316,1.896516611841992e-07,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","AT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.31343020038935e-23,0.9999995873312598,4.1266874224300755e-07,"1",0.04287872654743482,0.9571212734525516,"Yes",0.9505687212771416,0.04943127872286582,"No",0.9999999999196802,8.033031524679399e-11,"No",0.999998429662565,1.570337429105888e-06,"No",0.9999713356025909,2.8664397412655334e-05,"No",0.9999999922587507,7.74123636189726e-09,"No",0.9999998103483316,1.896516611841992e-07,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisΜία Πολυκεντρική Μελέτη Επέκτασης Ενός Σκέλους για την Περιγραφή της Μακροχρόνιας Ασφάλειας του AMG 416 (Velcalcetide) στη Θεραπεία του Δευτεροπαθούς Υπερπαραθυρεοειδισμού σε Αιμοκαθαιρόμενους Ασθενείς με Χρόνια Νεφρική Νόσο","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.0138754393674575e-22,0.9999997589428353,2.410571722020191e-07,"1",0.15972150531924947,0.8402784946807365,"Yes",0.7948475357979395,0.20515246420206432,"No",0.9999999999999717,2.0614162250524394e-14,"No",0.9999990089970162,9.910029839208705e-07,"No",0.9999991970020785,8.02997919834128e-07,"No",0.9999999999977264,2.2836715009817347e-12,"No",0.9999999224329517,7.756703848056764e-08,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisStudio di estensione multicentrico a braccio singolo per descrivere la sicurezza a lungo termine di AMG 416 (velcalcetide) nel trattamento dell’iperparatiroidismo secondario nei soggetti con insufficienza renale cronica sottoposti ad emodialisi","LT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.8784447690509295e-52,0.9999999999975557,2.4393889670785113e-12,"1",1.8335632998277558e-07,0.9999998166436681,"Yes",0.9999999071556588,9.284432817241745e-08,"No",1.0,5.5318830698214674e-21,"No",0.9999999991965751,8.034306175979117e-10,"No",0.9999999857773788,1.4222639530805548e-08,"No",1.0,1.1200218649668874e-24,"No",0.9999999999997727,1.9906468042522526e-13,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisEstudio de extensión multicéntrico y de un solo grupo para describir la seguridad a largo plazo de AMG 416 (velcalcetide) en el tratamiento del hiperparatiroidismo secundario en sujetos con insuficiencia renal crónica sometidos a hemodiálisis","PT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",9.096108428011405e-44,0.9999999391103548,6.088964480574101e-08,"1",3.8700536302848856e-05,0.9999612994637077,"Yes",0.9999432810695014,5.671893052608754e-05,"No",1.0,1.8392103957709306e-19,"No",0.9999994648796655,5.351203378686709e-07,"No",0.9999999959629805,4.036991314907408e-09,"No",1.0,2.6393839958015064e-23,"No",0.9999999999976126,2.4055685212585027e-12,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisStudio di estensione multicentrico a braccio singolo per descrivere la sicurezza a lungo termine di AMG 416 (velcalcetide) nel trattamento dell’iperparatiroidismo secondario nei soggetti con insufficienza renale cronica sottoposti ad emodialisi","PL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",2.8784447690509295e-52,0.9999999999975557,2.4393889670785113e-12,"1",1.8335632998277558e-07,0.9999998166436681,"Yes",0.9999999071556588,9.284432817241745e-08,"No",1.0,5.5318830698214674e-21,"No",0.9999999991965751,8.034306175979117e-10,"No",0.9999999857773788,1.4222639530805548e-08,"No",1.0,1.1200218649668874e-24,"No",0.9999999999997727,1.9906468042522526e-13,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisEstudio de extensión multicéntrico y de un solo grupo para describir la seguridad a largo plazo de AMG 416 (velcalcetide) en el tratamiento del hiperparatiroidismo secundario en sujetos con insuficiencia renal crónica sometidos a hemodiálisis","CZ","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",9.096108428011405e-44,0.9999999391103548,6.088964480574101e-08,"1",3.8700536302848856e-05,0.9999612994637077,"Yes",0.9999432810695014,5.671893052608754e-05,"No",1.0,1.8392103957709306e-19,"No",0.9999994648796655,5.351203378686709e-07,"No",0.9999999959629805,4.036991314907408e-09,"No",1.0,2.6393839958015064e-23,"No",0.9999999999976126,2.4055685212585027e-12,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisΜία Πολυκεντρική Μελέτη Επέκτασης Ενός Σκέλους για την Περιγραφή της Μακροχρόνιας Ασφάλειας του AMG 416 (Velcalcetide) στη Θεραπεία του Δευτεροπαθούς Υπερπαραθυρεοειδισμού σε Αιμοκαθαιρόμενους Ασθενείς με Χρόνια Νεφρική Νόσο","GR","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.0138754393674575e-22,0.9999997589428353,2.410571722020191e-07,"1",0.15972150531924947,0.8402784946807365,"Yes",0.7948475357979395,0.20515246420206432,"No",0.9999999999999717,2.0614162250524394e-14,"No",0.9999990089970162,9.910029839208705e-07,"No",0.9999991970020785,8.02997919834128e-07,"No",0.9999999999977264,2.2836715009817347e-12,"No",0.9999999224329517,7.756703848056764e-08,"No"
"2013-004136-30","A Multicenter Single-arm Extension Study to Describe the Long-term Safetyof AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on HemodialysisΜία Πολυκεντρική Μελέτη Επέκτασης Ενός Σκέλους για την Περιγραφή της Μακροχρόνιας Ασφάλειας του AMG 416 (Velcalcetide) στη Θεραπεία του Δευτεροπαθούς Υπερπαραθυρεοειδισμού σε Αιμοκαθαιρόμενους Ασθενείς με Χρόνια Νεφρική Νόσο","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",5.0138754393674575e-22,0.9999997589428353,2.410571722020191e-07,"1",0.15972150531924947,0.8402784946807365,"Yes",0.7948475357979395,0.20515246420206432,"No",0.9999999999999717,2.0614162250524394e-14,"No",0.9999990089970162,9.910029839208705e-07,"No",0.9999991970020785,8.02997919834128e-07,"No",0.9999999999977264,2.2836715009817347e-12,"No",0.9999999224329517,7.756703848056764e-08,"No"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLED MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0828608873942814e-52,1.0284829794340244e-07,0.9999998971517012,"2+",0.9999999967600105,3.2399876521389044e-09,"No",8.547280378307338e-09,0.999999991452711,"Yes",1.0,1.4267493204158344e-21,"No",1.0675493141567836e-05,0.9999893245068543,"Yes",0.009259656061584673,0.9907403439384049,"Yes",0.9999999975210586,2.4789461115886957e-09,"No",4.859608729738035e-07,0.9999995140391365,"Yes"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLED MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0828608873942814e-52,1.0284829794340244e-07,0.9999998971517012,"2+",0.9999999967600105,3.2399876521389044e-09,"No",8.547280378307338e-09,0.999999991452711,"Yes",1.0,1.4267493204158344e-21,"No",1.0675493141567836e-05,0.9999893245068543,"Yes",0.009259656061584673,0.9907403439384049,"Yes",0.9999999975210586,2.4789461115886957e-09,"No",4.859608729738035e-07,0.9999995140391365,"Yes"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLEDMULTICENTER STUDY OF THE EFFICACY AND SAFETY OFETROLIZUMAB DURING INDUCTION AND MAINTENANCE INPATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVECOLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNFINHIBITORS","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.455633306937891e-36,3.4612540367605955e-07,0.9999996538745992,"2+",0.9999999977415541,2.258440408652613e-09,"No",7.372470650523897e-09,0.9999999926275366,"Yes",0.9999999999832597,1.6743059289663694e-11,"No",8.449432205632675e-07,0.9999991550567859,"Yes",0.1204511702202423,0.8795488297797537,"Yes",0.9999999992481605,7.518377508897538e-10,"No",2.168736512009884e-06,0.9999978312634922,"Yes"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLEDMULTICENTER STUDY OF THE EFFICACY AND SAFETY OFETROLIZUMAB DURING INDUCTION AND MAINTENANCE INPATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVECOLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6516547663421643e-38,3.842524628231202e-08,0.9999999615747591,"2+",0.999999988526966,1.147303811050342e-08,"No",3.1607426372047486e-08,0.9999999683925728,"Yes",1.0,7.76792153855681e-17,"No",2.6642000913692185e-06,0.9999973357999145,"Yes",0.028281834879022215,0.9717181651209756,"Yes",0.9999999326486938,6.735130611653556e-08,"No",1.3376889643534987e-07,0.9999998662311019,"Yes"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLEDMULTICENTER STUDY OF THE EFFICACY AND SAFETY OFETROLIZUMAB DURING INDUCTION AND MAINTENANCE INPATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVECOLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6516547663421643e-38,3.842524628231202e-08,0.9999999615747591,"2+",0.999999988526966,1.147303811050342e-08,"No",3.1607426372047486e-08,0.9999999683925728,"Yes",1.0,7.76792153855681e-17,"No",2.6642000913692185e-06,0.9999973357999145,"Yes",0.028281834879022215,0.9717181651209756,"Yes",0.9999999326486938,6.735130611653556e-08,"No",1.3376889643534987e-07,0.9999998662311019,"Yes"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLEDMULTICENTER STUDY OF THE EFFICACY AND SAFETY OFETROLIZUMAB DURING INDUCTION AND MAINTENANCE INPATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVECOLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNFINHIBITORS","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.455633306937891e-36,3.4612540367605955e-07,0.9999996538745992,"2+",0.9999999977415541,2.258440408652613e-09,"No",7.372470650523897e-09,0.9999999926275366,"Yes",0.9999999999832597,1.6743059289663694e-11,"No",8.449432205632675e-07,0.9999991550567859,"Yes",0.1204511702202423,0.8795488297797537,"Yes",0.9999999992481605,7.518377508897538e-10,"No",2.168736512009884e-06,0.9999978312634922,"Yes"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLEDMULTICENTER STUDY OF THE EFFICACY AND SAFETY OFETROLIZUMAB DURING INDUCTION AND MAINTENANCE INPATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVECOLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNFINHIBITORS","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.455633306937891e-36,3.4612540367605955e-07,0.9999996538745992,"2+",0.9999999977415541,2.258440408652613e-09,"No",7.372470650523897e-09,0.9999999926275366,"Yes",0.9999999999832597,1.6743059289663694e-11,"No",8.449432205632675e-07,0.9999991550567859,"Yes",0.1204511702202423,0.8795488297797537,"Yes",0.9999999992481605,7.518377508897538e-10,"No",2.168736512009884e-06,0.9999978312634922,"Yes"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLEDMULTICENTER STUDY OF THE EFFICACY AND SAFETY OFETROLIZUMAB DURING INDUCTION AND MAINTENANCE INPATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVECOLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6516547663421643e-38,3.842524628231202e-08,0.9999999615747591,"2+",0.999999988526966,1.147303811050342e-08,"No",3.1607426372047486e-08,0.9999999683925728,"Yes",1.0,7.76792153855681e-17,"No",2.6642000913692185e-06,0.9999973357999145,"Yes",0.028281834879022215,0.9717181651209756,"Yes",0.9999999326486938,6.735130611653556e-08,"No",1.3376889643534987e-07,0.9999998662311019,"Yes"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLEDMULTICENTER STUDY OF THE EFFICACY AND SAFETY OFETROLIZUMAB DURING INDUCTION AND MAINTENANCE INPATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVECOLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.6516547663421643e-38,3.842524628231202e-08,0.9999999615747591,"2+",0.999999988526966,1.147303811050342e-08,"No",3.1607426372047486e-08,0.9999999683925728,"Yes",1.0,7.76792153855681e-17,"No",2.6642000913692185e-06,0.9999973357999145,"Yes",0.028281834879022215,0.9717181651209756,"Yes",0.9999999326486938,6.735130611653556e-08,"No",1.3376889643534987e-07,0.9999998662311019,"Yes"
"2013-004278-88","PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0828608873942814e-52,1.0284829794340244e-07,0.9999998971517012,"2+",0.9999999967600105,3.2399876521389044e-09,"No",8.547280378307338e-09,0.999999991452711,"Yes",1.0,1.4267493204158344e-21,"No",1.0675493141567836e-05,0.9999893245068543,"Yes",0.009259656061584673,0.9907403439384049,"Yes",0.9999999975210586,2.4789461115886957e-09,"No",4.859608729738035e-07,0.9999995140391365,"Yes"
"2013-004278-88","PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0828608873942814e-52,1.0284829794340244e-07,0.9999998971517012,"2+",0.9999999967600105,3.2399876521389044e-09,"No",8.547280378307338e-09,0.999999991452711,"Yes",1.0,1.4267493204158344e-21,"No",1.0675493141567836e-05,0.9999893245068543,"Yes",0.009259656061584673,0.9907403439384049,"Yes",0.9999999975210586,2.4789461115886957e-09,"No",4.859608729738035e-07,0.9999995140391365,"Yes"
"2013-004278-88","PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0828608873942814e-52,1.0284829794340244e-07,0.9999998971517012,"2+",0.9999999967600105,3.2399876521389044e-09,"No",8.547280378307338e-09,0.999999991452711,"Yes",1.0,1.4267493204158344e-21,"No",1.0675493141567836e-05,0.9999893245068543,"Yes",0.009259656061584673,0.9907403439384049,"Yes",0.9999999975210586,2.4789461115886957e-09,"No",4.859608729738035e-07,0.9999995140391365,"Yes"
"2013-004278-88","PHASE III DOUBLE BLIND PLACEBO-CONTROLLED MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO HAVE BEEN PREVIOUSLY EXPOSED TO TNF INHIBITORS","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0828608873942814e-52,1.0284829794340244e-07,0.9999998971517012,"2+",0.9999999967600105,3.2399876521389044e-09,"No",8.547280378307338e-09,0.999999991452711,"Yes",1.0,1.4267493204158344e-21,"No",1.0675493141567836e-05,0.9999893245068543,"Yes",0.009259656061584673,0.9907403439384049,"Yes",0.9999999975210586,2.4789461115886957e-09,"No",4.859608729738035e-07,0.9999995140391365,"Yes"
"2013-004392-12","Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetesUčinkovitost in varnost semaglutida enkrat na teden v primerjavi z insulinom glargin enkrat na dan kot dodatka k zdravljenju z metforminom s sulfonilsečnino ali brez nje pri bolnikih s sladkorno boleznijo tipa 2 ki se še niso zdravili z insulinom","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.367627498326826e-72,1.4734220516352617e-26,1.0,"2+",0.9999739369709533,2.6063029048821567e-05,"Yes",2.474906381328028e-06,0.9999975250936404,"No",1.0,2.0913962083369386e-41,"No",1.399451396257789e-29,1.0,"Yes",6.476166370993151e-15,1.0,"Yes",1.0,2.7770095566071894e-17,"No",2.4785704371618328e-31,1.0,"Yes"
"2013-004392-12","Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes","HR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.398735930306352e-30,3.9356968224804084e-13,0.9999999999996021,"2+",0.6907628137801514,0.30923718621984614,"Yes",0.188938395120483,0.8110616048795211,"No",0.9999999999996733,3.335506370803218e-13,"No",1.0145211643157374e-12,0.999999999998991,"Yes",1.43802098149725e-08,0.9999999856197946,"Yes",0.9999879200794383,1.2079920554997706e-05,"No",6.817569033695752e-14,0.9999999999999291,"Yes"
"2013-004392-12","Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetesÚčinnosť a bezpečnosť semaglutidu podávaného jedenkrát týždenne v porovnaní s inzulínom glargín podávaným jedenkrát denne pridaným k metformínu so sulfonylureou alebo bez nej u doteraz inzulínom neliečených pacientov s diabetom 2. typu ","DE","Yes","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.25980532814235e-65,9.770592957222044e-23,1.0,"2+",0.32591807814281204,0.6740819218571659,"Yes",0.2103054113536683,0.7896945886463571,"No",1.0,3.518829268639347e-42,"No",2.2945086183754863e-25,1.0,"Yes",8.920033409543512e-16,1.0,"Yes",1.0,9.665889995822134e-32,"No",9.68739804501896e-26,1.0,"Yes"
"2013-004392-12","Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetesÚčinnosť a bezpečnosť semaglutidu podávaného jedenkrát týždenne v porovnaní s inzulínom glargín podávaným jedenkrát denne pridaným k metformínu so sulfonylureou alebo bez nej u doteraz inzulínom neliečených pacientov s diabetom 2. typu ","NL","Yes","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.25980532814235e-65,9.770592957222044e-23,1.0,"2+",0.32591807814281204,0.6740819218571659,"Yes",0.2103054113536683,0.7896945886463571,"No",1.0,3.518829268639347e-42,"No",2.2945086183754863e-25,1.0,"Yes",8.920033409543512e-16,1.0,"Yes",1.0,9.665889995822134e-32,"No",9.68739804501896e-26,1.0,"Yes"
"2013-004392-12","Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetesUčinkovitost in varnost semaglutida enkrat na teden v primerjavi z insulinom glargin enkrat na dan kot dodatka k zdravljenju z metforminom s sulfonilsečnino ali brez nje pri bolnikih s sladkorno boleznijo tipa 2 ki se še niso zdravili z insulinom","RO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.367627498326826e-72,1.4734220516352617e-26,1.0,"2+",0.9999739369709533,2.6063029048821567e-05,"Yes",2.474906381328028e-06,0.9999975250936404,"No",1.0,2.0913962083369386e-41,"No",1.399451396257789e-29,1.0,"Yes",6.476166370993151e-15,1.0,"Yes",1.0,2.7770095566071894e-17,"No",2.4785704371618328e-31,1.0,"Yes"
"2013-004392-12","Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes","SI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.398735930306352e-30,3.9356968224804084e-13,0.9999999999996021,"2+",0.6907628137801514,0.30923718621984614,"Yes",0.188938395120483,0.8110616048795211,"No",0.9999999999996733,3.335506370803218e-13,"No",1.0145211643157374e-12,0.999999999998991,"Yes",1.43802098149725e-08,0.9999999856197946,"Yes",0.9999879200794383,1.2079920554997706e-05,"No",6.817569033695752e-14,0.9999999999999291,"Yes"
"2013-004392-12","Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetesUčinkovitost in varnost semaglutida enkrat na teden v primerjavi z insulinom glargin enkrat na dan kot dodatka k zdravljenju z metforminom s sulfonilsečnino ali brez nje pri bolnikih s sladkorno boleznijo tipa 2 ki se še niso zdravili z insulinom","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.367627498326826e-72,1.4734220516352617e-26,1.0,"2+",0.9999739369709533,2.6063029048821567e-05,"Yes",2.474906381328028e-06,0.9999975250936404,"No",1.0,2.0913962083369386e-41,"No",1.399451396257789e-29,1.0,"Yes",6.476166370993151e-15,1.0,"Yes",1.0,2.7770095566071894e-17,"No",2.4785704371618328e-31,1.0,"Yes"
"2013-004422-29","A Phase 3 Randomized Double-blind Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscular Atrophy","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.2959573689222176e-43,3.238276137096931e-05,0.9999676172386196,"2+",0.9999999873523963,1.2647604217268374e-08,"No",7.919832799633844e-08,0.9999999208016593,"Yes",0.9999996882874516,3.1171256109435577e-07,"No",0.000676479193096153,0.9993235208069063,"Yes",0.9991883537503747,0.0008116462496275009,"No",0.9999999996610711,3.3893765277875677e-10,"No",0.009415746576121875,0.9905842534238644,"Yes"
"2013-004422-29","A Phase 3 Randomized Double-blind Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscular Atrophy","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.2959573689222176e-43,3.238276137096931e-05,0.9999676172386196,"2+",0.9999999873523963,1.2647604217268374e-08,"No",7.919832799633844e-08,0.9999999208016593,"Yes",0.9999996882874516,3.1171256109435577e-07,"No",0.000676479193096153,0.9993235208069063,"Yes",0.9991883537503747,0.0008116462496275009,"No",0.9999999996610711,3.3893765277875677e-10,"No",0.009415746576121875,0.9905842534238644,"Yes"
"2013-004422-29","A Phase 3 Randomized Double-blind Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscular AtrophyEstudio de fase 3 aleatorizado a doble ciego controlado con procedimiento simulado para evaluar la eficacia clínica y la seguridad de ISIS 396443 administrado por vía intratecal en pacientes con atrofia muscular espinal de inicio en edad infantil","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.343684075439213e-78,2.636247049265717e-09,0.9999999973637729,"2+",1.0,1.4659635286515136e-14,"No",6.050622655112263e-13,0.9999999999993748,"Yes",1.0,4.8186479147603565e-17,"No",1.6835650202999814e-06,0.9999983164349789,"Yes",0.9999999960560332,3.943971935585609e-09,"No",1.0,4.552213015770151e-25,"No",0.0005045376171410012,0.9994954623828733,"Yes"
"2013-004422-29","A Phase 3 Randomized Double-blind Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscular AtrophyEstudio de fase 3 aleatorizado a doble ciego controlado con procedimiento simulado para evaluar la eficacia clínica y la seguridad de ISIS 396443 administrado por vía intratecal en pacientes con atrofia muscular espinal de inicio en edad infantil","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.343684075439213e-78,2.636247049265717e-09,0.9999999973637729,"2+",1.0,1.4659635286515136e-14,"No",6.050622655112263e-13,0.9999999999993748,"Yes",1.0,4.8186479147603565e-17,"No",1.6835650202999814e-06,0.9999983164349789,"Yes",0.9999999960560332,3.943971935585609e-09,"No",1.0,4.552213015770151e-25,"No",0.0005045376171410012,0.9994954623828733,"Yes"
"2013-004422-29","A Phase 3 Randomized Double-blind Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscular Atrophy","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.2959573689222176e-43,3.238276137096931e-05,0.9999676172386196,"2+",0.9999999873523963,1.2647604217268374e-08,"No",7.919832799633844e-08,0.9999999208016593,"Yes",0.9999996882874516,3.1171256109435577e-07,"No",0.000676479193096153,0.9993235208069063,"Yes",0.9991883537503747,0.0008116462496275009,"No",0.9999999996610711,3.3893765277875677e-10,"No",0.009415746576121875,0.9905842534238644,"Yes"
"2013-004422-29","A Phase 3 Randomized Double-blind Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscular AtrophyEstudio de fase 3 aleatorizado a doble ciego controlado con procedimiento simulado para evaluar la eficacia clínica y la seguridad de ISIS 396443 administrado por vía intratecal en pacientes con atrofia muscular espinal de inicio en edad infantil","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.343684075439213e-78,2.636247049265717e-09,0.9999999973637729,"2+",1.0,1.4659635286515136e-14,"No",6.050622655112263e-13,0.9999999999993748,"Yes",1.0,4.8186479147603565e-17,"No",1.6835650202999814e-06,0.9999983164349789,"Yes",0.9999999960560332,3.943971935585609e-09,"No",1.0,4.552213015770151e-25,"No",0.0005045376171410012,0.9994954623828733,"Yes"
"2013-004430-15","A Phase 2 Double-Blind Randomized Placebo Controlled Dose Ranging Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8680667412605407e-54,2.1790522358550493e-19,1.0,"2+",1.0,8.558106251371139e-16,"No",2.6637326878666514e-12,0.9999999999973284,"Yes",0.9998364413994013,0.00016355860060344074,"No",2.7967516376302324e-17,1.0,"Yes",3.740241769727705e-07,0.9999996259758308,"Yes",1.0,3.2064514859046297e-16,"No",3.3885750117142245e-13,0.9999999999996589,"Yes"
"2013-004430-15","A Phase 2 Double-Blind Randomized Placebo Controlled Dose Ranging Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)Randomizované dvojitě zaslepené placebem kontrolované klinické hodnocení fáze 2  s paralelními skupinami hodnotící účinnost léčby s různými dávkami přípravku GS-6615 na komorovou arytmii u pacientů s implantabilním kardioverter-defibrilátorem (ICD) nebo s defibrilátorem pro srdeční resynchronizační terapii (CRT D)","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1926143619064194e-119,2.0155335063614087e-38,1.0,"2+",1.0,3.5748002620529833e-28,"No",2.210929645561639e-22,1.0,"Yes",1.0,7.050512156355824e-34,"No",1.7593720261787628e-37,1.0,"Yes",2.2147050980594158e-10,0.9999999997785382,"Yes",1.0,4.583816812601363e-39,"No",4.2852381445399505e-22,1.0,"Yes"
"2013-004430-15","A Phase 2 Double-Blind Randomized Placebo Controlled Dose Ranging Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.8680667412605407e-54,2.1790522358550493e-19,1.0,"2+",1.0,8.558106251371139e-16,"No",2.6637326878666514e-12,0.9999999999973284,"Yes",0.9998364413994013,0.00016355860060344074,"No",2.7967516376302324e-17,1.0,"Yes",3.740241769727705e-07,0.9999996259758308,"Yes",1.0,3.2064514859046297e-16,"No",3.3885750117142245e-13,0.9999999999996589,"Yes"
"2013-004430-15","A Phase 2 Double-Blind Randomized Placebo Controlled Dose Ranging Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)Randomizované dvojitě zaslepené placebem kontrolované klinické hodnocení fáze 2  s paralelními skupinami hodnotící účinnost léčby s různými dávkami přípravku GS-6615 na komorovou arytmii u pacientů s implantabilním kardioverter-defibrilátorem (ICD) nebo s defibrilátorem pro srdeční resynchronizační terapii (CRT D)","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1926143619064194e-119,2.0155335063614087e-38,1.0,"2+",1.0,3.5748002620529833e-28,"No",2.210929645561639e-22,1.0,"Yes",1.0,7.050512156355824e-34,"No",1.7593720261787628e-37,1.0,"Yes",2.2147050980594158e-10,0.9999999997785382,"Yes",1.0,4.583816812601363e-39,"No",4.2852381445399505e-22,1.0,"Yes"
"2013-004430-15","A Phase 2 Double-Blind Randomized Placebo Controlled Dose Ranging Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)Randomizované dvojitě zaslepené placebem kontrolované klinické hodnocení fáze 2  s paralelními skupinami hodnotící účinnost léčby s různými dávkami přípravku GS-6615 na komorovou arytmii u pacientů s implantabilním kardioverter-defibrilátorem (ICD) nebo s defibrilátorem pro srdeční resynchronizační terapii (CRT D)","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.1926143619064194e-119,2.0155335063614087e-38,1.0,"2+",1.0,3.5748002620529833e-28,"No",2.210929645561639e-22,1.0,"Yes",1.0,7.050512156355824e-34,"No",1.7593720261787628e-37,1.0,"Yes",2.2147050980594158e-10,0.9999999997785382,"Yes",1.0,4.583816812601363e-39,"No",4.2852381445399505e-22,1.0,"Yes"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","DK","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIESNEZASLEPENÉ POKRAČOVACÍ KLINICKÉ HODNOCENÍ SE SLEDOVÁNÍM BEZPEČNOSTI U PACIENTŮ S MÍRNOU AŽ TĚŽKOU ULCERÓZNÍ KOLITIDOU KTEŘÍ SE V MINULOSTI ÚČASTNILI KLINICKÝCH HODNOCENÍ ETROLIZUMABU III. FÁZE","PT","Yes","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",1.2023426667083493e-74,0.9999987629895748,1.2370104336480363e-06,"1",0.2940608863748758,0.7059391136251418,"Yes",0.4054498260358768,0.5945501739641426,"No",1.0,1.2896378538585064e-32,"No",0.999989514772156,1.0485227840011007e-05,"No",0.9975124047542528,0.0024875952457447184,"No",1.0,6.4691763046545166e-24,"No",0.9999958673166265,4.132683401867353e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","GB","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","HU","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIESNEZASLEPENÉ POKRAČOVACÍ KLINICKÉ HODNOCENÍ SE SLEDOVÁNÍM BEZPEČNOSTI U PACIENTŮ S MÍRNOU AŽ TĚŽKOU ULCERÓZNÍ KOLITIDOU KTEŘÍ SE V MINULOSTI ÚČASTNILI KLINICKÝCH HODNOCENÍ ETROLIZUMABU III. FÁZE","HR","Yes","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",1.2023426667083493e-74,0.9999987629895748,1.2370104336480363e-06,"1",0.2940608863748758,0.7059391136251418,"Yes",0.4054498260358768,0.5945501739641426,"No",1.0,1.2896378538585064e-32,"No",0.999989514772156,1.0485227840011007e-05,"No",0.9975124047542528,0.0024875952457447184,"No",1.0,6.4691763046545166e-24,"No",0.9999958673166265,4.132683401867353e-06,"No"
"2013-004435-72","AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES","NL","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",3.593731112615898e-33,0.9999969834813408,3.0165186645329216e-06,"1",0.0007876870482035587,0.9992123129518004,"Yes",0.9991322941653903,0.0008677058346164831,"No",0.9999999999999859,1.0555776213165501e-14,"No",0.9999980796841434,1.920315855160349e-06,"No",0.9984173950864623,0.0015826049135325261,"No",0.9999999993507629,6.492399725587581e-10,"No",0.9999973708521169,2.629147876747059e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIESNEZASLEPENÉ POKRAČOVACÍ KLINICKÉ HODNOCENÍ SE SLEDOVÁNÍM BEZPEČNOSTI U PACIENTŮ S MÍRNOU AŽ TĚŽKOU ULCERÓZNÍ KOLITIDOU KTEŘÍ SE V MINULOSTI ÚČASTNILI KLINICKÝCH HODNOCENÍ ETROLIZUMABU III. FÁZE","LV","Yes","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",1.2023426667083493e-74,0.9999987629895748,1.2370104336480363e-06,"1",0.2940608863748758,0.7059391136251418,"Yes",0.4054498260358768,0.5945501739641426,"No",1.0,1.2896378538585064e-32,"No",0.999989514772156,1.0485227840011007e-05,"No",0.9975124047542528,0.0024875952457447184,"No",1.0,6.4691763046545166e-24,"No",0.9999958673166265,4.132683401867353e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","CZ","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","LT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES","NO","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",3.593731112615898e-33,0.9999969834813408,3.0165186645329216e-06,"1",0.0007876870482035587,0.9992123129518004,"Yes",0.9991322941653903,0.0008677058346164831,"No",0.9999999999999859,1.0555776213165501e-14,"No",0.9999980796841434,1.920315855160349e-06,"No",0.9984173950864623,0.0015826049135325261,"No",0.9999999993507629,6.492399725587581e-10,"No",0.9999973708521169,2.629147876747059e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","SK","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","FR","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES","AT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",3.593731112615898e-33,0.9999969834813408,3.0165186645329216e-06,"1",0.0007876870482035587,0.9992123129518004,"Yes",0.9991322941653903,0.0008677058346164831,"No",0.9999999999999859,1.0555776213165501e-14,"No",0.9999980796841434,1.920315855160349e-06,"No",0.9984173950864623,0.0015826049135325261,"No",0.9999999993507629,6.492399725587581e-10,"No",0.9999973708521169,2.629147876747059e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","DE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","ES","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","GR","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIESNEZASLEPENÉ POKRAČOVACÍ KLINICKÉ HODNOCENÍ SE SLEDOVÁNÍM BEZPEČNOSTI U PACIENTŮ S MÍRNOU AŽ TĚŽKOU ULCERÓZNÍ KOLITIDOU KTEŘÍ SE V MINULOSTI ÚČASTNILI KLINICKÝCH HODNOCENÍ ETROLIZUMABU III. FÁZE","BG","Yes","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",1.2023426667083493e-74,0.9999987629895748,1.2370104336480363e-06,"1",0.2940608863748758,0.7059391136251418,"Yes",0.4054498260358768,0.5945501739641426,"No",1.0,1.2896378538585064e-32,"No",0.999989514772156,1.0485227840011007e-05,"No",0.9975124047542528,0.0024875952457447184,"No",1.0,6.4691763046545166e-24,"No",0.9999958673166265,4.132683401867353e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIESNEZASLEPENÉ POKRAČOVACÍ KLINICKÉ HODNOCENÍ SE SLEDOVÁNÍM BEZPEČNOSTI U PACIENTŮ S MÍRNOU AŽ TĚŽKOU ULCERÓZNÍ KOLITIDOU KTEŘÍ SE V MINULOSTI ÚČASTNILI KLINICKÝCH HODNOCENÍ ETROLIZUMABU III. FÁZE","BE","Yes","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",1.2023426667083493e-74,0.9999987629895748,1.2370104336480363e-06,"1",0.2940608863748758,0.7059391136251418,"Yes",0.4054498260358768,0.5945501739641426,"No",1.0,1.2896378538585064e-32,"No",0.999989514772156,1.0485227840011007e-05,"No",0.9975124047542528,0.0024875952457447184,"No",1.0,6.4691763046545166e-24,"No",0.9999958673166265,4.132683401867353e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","IT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","EE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004435-72","AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES","SE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","2+","No",2.581702018877448e-36,0.9999982781032389,1.721896759417895e-06,"1",0.0003547599592109804,0.9996452400407868,"Yes",0.999594987715022,0.00040501228497797373,"No",1.0,5.875582282110167e-15,"No",0.9999992090711631,7.909288371991582e-07,"No",0.9991232725614673,0.0008767274385397263,"No",0.9999999994786748,5.213183246188078e-10,"No",0.9999988294251128,1.1705748846999963e-06,"No"
"2013-004482-14","A phase I/II multicenter open-label study of EGFRmut–TKI EGF816administered orally in adult patients with EGFRmut solid malignancies","IT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","2+","No",8.717645271006368e-23,0.9988032490773225,0.001196750922678795,"2+",7.034962095878301e-05,0.9999296503790385,"Yes",0.9999354844755509,6.451552445552901e-05,"No",0.9999927400486892,7.259951310026107e-06,"No",0.9999770226486316,2.2977351365266618e-05,"No",0.9951465003788663,0.004853499621138467,"No",0.9999172943506277,8.27056493664971e-05,"No",0.9999296477686881,7.035223131220574e-05,"No"
"2013-004482-14","A phase I/II multicenter open-label study of EGFRmut–TKI EGF816administered orally in adult patients with EGFRmut solid malignanciesStudio di Fase I/II multicentrico in aperto con EGFRmut-TKI EGF816 somministrato per via orale in pazienti adulti con tumori solidi con EGFRmut","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","2+","No",2.0188478391879096e-42,0.9885688254530007,0.011431174546998067,"2+",8.434844954971602e-11,0.9999999999156444,"Yes",0.9999999998333352,1.6666459276568453e-10,"No",0.9999999999998295,1.712572507386656e-13,"No",0.9999999976324432,2.3675642808524953e-09,"No",0.9999573779426093,4.2622057394478926e-05,"No",0.9999999998563851,1.436032035510071e-10,"No",0.9999999962900291,3.709963983528523e-09,"No"
"2013-004482-14","A phase I/II multicenter open-label study of EGFRmut–TKI EGF816administered orally in adult patients with EGFRmut solid malignancies","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","2+","No",8.717645271006368e-23,0.9988032490773225,0.001196750922678795,"2+",7.034962095878301e-05,0.9999296503790385,"Yes",0.9999354844755509,6.451552445552901e-05,"No",0.9999927400486892,7.259951310026107e-06,"No",0.9999770226486316,2.2977351365266618e-05,"No",0.9951465003788663,0.004853499621138467,"No",0.9999172943506277,8.27056493664971e-05,"No",0.9999296477686881,7.035223131220574e-05,"No"
"2013-004482-14","A phase I/II multicenter open-label study of EGFRmut?TKI EGF816administered orally in adult patients with EGFRmut solid malignanciesEstudio fase I/II multicéntrico abierto del TKI EGF816-EGFRmut administrado por vía oral a pacientes adultos con tumores sólidos malignos con mutación EGFR","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","2+","No",2.3912411785891e-52,0.999999999713424,2.865878942522001e-10,"2+",1.3114293390319797e-14,1.0,"Yes",0.9999999999999717,2.8316790448682348e-14,"No",1.0,6.369205405475995e-20,"No",0.9999999999999717,2.174437584767272e-14,"No",0.999999999519531,4.804696271989214e-10,"No",1.0,4.541665660636042e-16,"No",0.9999999999999432,6.782486987576304e-14,"No"
"2013-004482-14","A phase I/II multicenter open-label study of EGFRmut–TKI EGF816administered orally in adult patients with EGFRmut solid malignanciesStudio di Fase I/II multicentrico in aperto con EGFRmut-TKI EGF816 somministrato per via orale in pazienti adulti con tumori solidi con EGFRmut","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","2+","No",2.0188478391879096e-42,0.9885688254530007,0.011431174546998067,"2+",8.434844954971602e-11,0.9999999999156444,"Yes",0.9999999998333352,1.6666459276568453e-10,"No",0.9999999999998295,1.712572507386656e-13,"No",0.9999999976324432,2.3675642808524953e-09,"No",0.9999573779426093,4.2622057394478926e-05,"No",0.9999999998563851,1.436032035510071e-10,"No",0.9999999962900291,3.709963983528523e-09,"No"
"2013-004482-14","A phase I/II multicenter open-label study of EGFRmut–TKI EGF816administered orally in adult patients with EGFRmut solid malignanciesStudio di Fase I/II multicentrico in aperto con EGFRmut-TKI EGF816 somministrato per via orale in pazienti adulti con tumori solidi con EGFRmut","FR","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","2+","No",2.0188478391879096e-42,0.9885688254530007,0.011431174546998067,"2+",8.434844954971602e-11,0.9999999999156444,"Yes",0.9999999998333352,1.6666459276568453e-10,"No",0.9999999999998295,1.712572507386656e-13,"No",0.9999999976324432,2.3675642808524953e-09,"No",0.9999573779426093,4.2622057394478926e-05,"No",0.9999999998563851,1.436032035510071e-10,"No",0.9999999962900291,3.709963983528523e-09,"No"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic NephropathyRandomizované dvojitě zaslepené multicentrické klinické hodnocení kontrolované placebem a závislé na počtu příhod posuzující účinek kanagliflozinu na ledvinové funkce a kardiovaskulární onemocnění u pacientů s diabetem mellitus 2. typu a diabetickou nefropatií ","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.166687083761952e-90,1.6229632167793946e-32,1.0,"2+",1.0,9.31794182591539e-23,"No",1.0023545107097951e-22,1.0,"Yes",1.0,8.907167559625303e-45,"No",6.791082421422695e-34,1.0,"Yes",6.047233530556191e-14,0.9999999999999432,"No",1.0,4.756345324403589e-25,"No",1.0251934545758704e-30,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic NephropathyRandomizované dvojito zaslepené udalosťami riadené placebom kontrolované multicentrické skúšanie účinkov kanagliflozínu na renálne a kardiovaskulárne výsledky u účastníkov s diabetes mellitus 2. typu a diabetickou nefropatiou ","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.285487858973861e-79,2.2676206410059076e-32,1.0,"2+",1.0,1.284034342490051e-21,"No",2.4093638088118405e-21,1.0,"Yes",1.0,2.7763648376733394e-35,"No",5.767240833664362e-34,1.0,"Yes",3.131981152181075e-10,0.9999999996867929,"No",1.0,3.978706082539678e-21,"No",6.116680581750024e-31,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.717234452058625e-48,1.1347152714395623e-17,1.0,"2+",0.9999999999749605,2.5025942058080348e-11,"No",7.835869967067078e-11,0.9999999999216413,"Yes",1.0,2.1744364742418524e-17,"No",6.505606796281893e-17,1.0,"Yes",2.7694425805095396e-08,0.9999999723055741,"No",0.9999999972571915,2.742811132283949e-09,"No",2.1723594404992462e-17,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.717234452058625e-48,1.1347152714395623e-17,1.0,"2+",0.9999999999749605,2.5025942058080348e-11,"No",7.835869967067078e-11,0.9999999999216413,"Yes",1.0,2.1744364742418524e-17,"No",6.505606796281893e-17,1.0,"Yes",2.7694425805095396e-08,0.9999999723055741,"No",0.9999999972571915,2.742811132283949e-09,"No",2.1723594404992462e-17,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic NephropathyRandomizované dvojito zaslepené udalosťami riadené placebom kontrolované multicentrické skúšanie účinkov kanagliflozínu na renálne a kardiovaskulárne výsledky u účastníkov s diabetes mellitus 2. typu a diabetickou nefropatiou ","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.285487858973861e-79,2.2676206410059076e-32,1.0,"2+",1.0,1.284034342490051e-21,"No",2.4093638088118405e-21,1.0,"Yes",1.0,2.7763648376733394e-35,"No",5.767240833664362e-34,1.0,"Yes",3.131981152181075e-10,0.9999999996867929,"No",1.0,3.978706082539678e-21,"No",6.116680581750024e-31,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.717234452058625e-48,1.1347152714395623e-17,1.0,"2+",0.9999999999749605,2.5025942058080348e-11,"No",7.835869967067078e-11,0.9999999999216413,"Yes",1.0,2.1744364742418524e-17,"No",6.505606796281893e-17,1.0,"Yes",2.7694425805095396e-08,0.9999999723055741,"No",0.9999999972571915,2.742811132283949e-09,"No",2.1723594404992462e-17,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic NephropathyRandomizované dvojitě zaslepené multicentrické klinické hodnocení kontrolované placebem a závislé na počtu příhod posuzující účinek kanagliflozinu na ledvinové funkce a kardiovaskulární onemocnění u pacientů s diabetem mellitus 2. typu a diabetickou nefropatií ","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.166687083761952e-90,1.6229632167793946e-32,1.0,"2+",1.0,9.31794182591539e-23,"No",1.0023545107097951e-22,1.0,"Yes",1.0,8.907167559625303e-45,"No",6.791082421422695e-34,1.0,"Yes",6.047233530556191e-14,0.9999999999999432,"No",1.0,4.756345324403589e-25,"No",1.0251934545758704e-30,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic NephropathyRandomizované dvojitě zaslepené multicentrické klinické hodnocení kontrolované placebem a závislé na počtu příhod posuzující účinek kanagliflozinu na ledvinové funkce a kardiovaskulární onemocnění u pacientů s diabetem mellitus 2. typu a diabetickou nefropatií ","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.166687083761952e-90,1.6229632167793946e-32,1.0,"2+",1.0,9.31794182591539e-23,"No",1.0023545107097951e-22,1.0,"Yes",1.0,8.907167559625303e-45,"No",6.791082421422695e-34,1.0,"Yes",6.047233530556191e-14,0.9999999999999432,"No",1.0,4.756345324403589e-25,"No",1.0251934545758704e-30,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic NephropathyRandomizované dvojitě zaslepené multicentrické klinické hodnocení kontrolované placebem a závislé na počtu příhod posuzující účinek kanagliflozinu na ledvinové funkce a kardiovaskulární onemocnění u pacientů s diabetem mellitus 2. typu a diabetickou nefropatií ","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.166687083761952e-90,1.6229632167793946e-32,1.0,"2+",1.0,9.31794182591539e-23,"No",1.0023545107097951e-22,1.0,"Yes",1.0,8.907167559625303e-45,"No",6.791082421422695e-34,1.0,"Yes",6.047233530556191e-14,0.9999999999999432,"No",1.0,4.756345324403589e-25,"No",1.0251934545758704e-30,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic NephropathyRandomizované dvojitě zaslepené multicentrické klinické hodnocení kontrolované placebem a závislé na počtu příhod posuzující účinek kanagliflozinu na ledvinové funkce a kardiovaskulární onemocnění u pacientů s diabetem mellitus 2. typu a diabetickou nefropatií ","LT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.166687083761952e-90,1.6229632167793946e-32,1.0,"2+",1.0,9.31794182591539e-23,"No",1.0023545107097951e-22,1.0,"Yes",1.0,8.907167559625303e-45,"No",6.791082421422695e-34,1.0,"Yes",6.047233530556191e-14,0.9999999999999432,"No",1.0,4.756345324403589e-25,"No",1.0251934545758704e-30,1.0,"Yes"
"2013-004494-28","A Randomized Double-blind Event-driven Placebo-controlled Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic NephropathyRandomizované dvojito zaslepené udalosťami riadené placebom kontrolované multicentrické skúšanie účinkov kanagliflozínu na renálne a kardiovaskulárne výsledky u účastníkov s diabetes mellitus 2. typu a diabetickou nefropatiou ","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.285487858973861e-79,2.2676206410059076e-32,1.0,"2+",1.0,1.284034342490051e-21,"No",2.4093638088118405e-21,1.0,"Yes",1.0,2.7763648376733394e-35,"No",5.767240833664362e-34,1.0,"Yes",3.131981152181075e-10,0.9999999996867929,"No",1.0,3.978706082539678e-21,"No",6.116680581750024e-31,1.0,"Yes"
"2013-004654-13","An Open-Label Single-arm Extension Study to Evaluate the Long-termSafety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis","CZ","No","No","No","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7409399885269378e-15,0.9990837892327052,0.0009162107672950378,"-1",0.6387638385920128,0.36123616140799186,"Yes",0.6145013497660681,0.3854986502339272,"No",0.9999999179263347,8.207366463941004e-08,"No",0.9990152791781581,0.0009847208218470927,"No",0.9658708757366381,0.03412912426336241,"No",0.9999986209259493,1.3790740475391499e-06,"No",0.9993127708052592,0.0006872291947451641,"No"
"2013-004654-13","An Open-Label Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid ArthritisESTUDIO ABIERTO DE EXTENSIÓN DE UN SOLO BRAZO PARA EVALUAR LA EFICACIA Y SEGURIDAD A LARGO PLAZO DE ABP 501 EN PACIENTES CON ARTRITIS REUMATOIDE MODERADA O SEVERA","DE","No","No","No","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.5999210558117455e-42,0.9992081269340144,0.0007918730659603017,"-1",0.7691310258906072,0.23086897410940346,"Yes",0.5740253929338843,0.4259746070661392,"No",1.0,1.862370342099525e-23,"No",0.999978630426362,2.136957361404097e-05,"No",0.9999806959823367,1.9304017667094242e-05,"No",1.0,4.063272237126446e-20,"No",0.9999993486364208,6.513635661867898e-07,"No"
"2013-004654-13","An Open-Label Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid ArthritisESTUDIO ABIERTO DE EXTENSIÓN DE UN SOLO BRAZO PARA EVALUAR LA EFICACIA Y SEGURIDAD A LARGO PLAZO DE ABP 501 EN PACIENTES CON ARTRITIS REUMATOIDE MODERADA O SEVERA","RO","No","No","No","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.5999210558117455e-42,0.9992081269340144,0.0007918730659603017,"-1",0.7691310258906072,0.23086897410940346,"Yes",0.5740253929338843,0.4259746070661392,"No",1.0,1.862370342099525e-23,"No",0.999978630426362,2.136957361404097e-05,"No",0.9999806959823367,1.9304017667094242e-05,"No",1.0,4.063272237126446e-20,"No",0.9999993486364208,6.513635661867898e-07,"No"
"2013-004654-13","An Open-Label Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid ArthritisESTUDIO ABIERTO DE EXTENSIÓN DE UN SOLO BRAZO PARA EVALUAR LA EFICACIA Y SEGURIDAD A LARGO PLAZO DE ABP 501 EN PACIENTES CON ARTRITIS REUMATOIDE MODERADA O SEVERA","HU","No","No","No","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.5999210558117455e-42,0.9992081269340144,0.0007918730659603017,"-1",0.7691310258906072,0.23086897410940346,"Yes",0.5740253929338843,0.4259746070661392,"No",1.0,1.862370342099525e-23,"No",0.999978630426362,2.136957361404097e-05,"No",0.9999806959823367,1.9304017667094242e-05,"No",1.0,4.063272237126446e-20,"No",0.9999993486364208,6.513635661867898e-07,"No"
"2013-004654-13","An Open-Label Single-arm Extension Study to Evaluate the Long-termSafety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis","PL","No","No","No","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7409399885269378e-15,0.9990837892327052,0.0009162107672950378,"-1",0.6387638385920128,0.36123616140799186,"Yes",0.6145013497660681,0.3854986502339272,"No",0.9999999179263347,8.207366463941004e-08,"No",0.9990152791781581,0.0009847208218470927,"No",0.9658708757366381,0.03412912426336241,"No",0.9999986209259493,1.3790740475391499e-06,"No",0.9993127708052592,0.0006872291947451641,"No"
"2013-004654-13","An Open-Label Single-arm Extension Study to Evaluate the Long-termSafety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis","ES","No","No","No","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7409399885269378e-15,0.9990837892327052,0.0009162107672950378,"-1",0.6387638385920128,0.36123616140799186,"Yes",0.6145013497660681,0.3854986502339272,"No",0.9999999179263347,8.207366463941004e-08,"No",0.9990152791781581,0.0009847208218470927,"No",0.9658708757366381,0.03412912426336241,"No",0.9999986209259493,1.3790740475391499e-06,"No",0.9993127708052592,0.0006872291947451641,"No"
"2013-004654-13","An Open-Label Single-arm Extension Study to Evaluate the Long-termSafety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis","GB","No","No","No","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7409399885269378e-15,0.9990837892327052,0.0009162107672950378,"-1",0.6387638385920128,0.36123616140799186,"Yes",0.6145013497660681,0.3854986502339272,"No",0.9999999179263347,8.207366463941004e-08,"No",0.9990152791781581,0.0009847208218470927,"No",0.9658708757366381,0.03412912426336241,"No",0.9999986209259493,1.3790740475391499e-06,"No",0.9993127708052592,0.0006872291947451641,"No"
"2013-004654-13","An Open-Label Single-arm Extension Study to Evaluate the Long-termSafety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis","BG","No","No","No","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.7409399885269378e-15,0.9990837892327052,0.0009162107672950378,"-1",0.6387638385920128,0.36123616140799186,"Yes",0.6145013497660681,0.3854986502339272,"No",0.9999999179263347,8.207366463941004e-08,"No",0.9990152791781581,0.0009847208218470927,"No",0.9658708757366381,0.03412912426336241,"No",0.9999986209259493,1.3790740475391499e-06,"No",0.9993127708052592,0.0006872291947451641,"No"
"2013-004659-19","Randomized double-blind placebo-controlled multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis.","LV","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7056596069363245e-69,6.933383077653042e-20,1.0,"2+",1.0,2.68022176783588e-20,"No",1.840435163849766e-18,1.0,"Yes",1.0,3.744382891341818e-17,"No",2.50063477705391e-21,1.0,"Yes",4.235208493090107e-09,0.9999999957647675,"Yes",0.027839246699808994,0.9721607533002018,"No",3.889211547533919e-21,1.0,"Yes"
"2013-004659-19","Randomized double-blind placebo-controlled multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis.","NL","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7056596069363245e-69,6.933383077653042e-20,1.0,"2+",1.0,2.68022176783588e-20,"No",1.840435163849766e-18,1.0,"Yes",1.0,3.744382891341818e-17,"No",2.50063477705391e-21,1.0,"Yes",4.235208493090107e-09,0.9999999957647675,"Yes",0.027839246699808994,0.9721607533002018,"No",3.889211547533919e-21,1.0,"Yes"
"2013-004659-19","Randomized double-blind placebo-controlled multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis.Randomizovaná dvojito zaslepená placebom kontrolovaná multicentrická štúdia porovnávajúca dávku ciprofloxacínu DPI 325 mg dvakrát denne prerušovane podávanú po dobu 28 dní s liečbou/ 28 dní bez liečby alebo po dobu 14 dní s liečbou/ 14 dní bez liečby proti placebu zameraná na vyhodnotenie času do prvej exacerbácie a frekvencie exacerbácií u pacientov s bronchiektáziami bez súvislosti s cystickou fibrózou. ","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.7901398888771083e-136,5.388106639166884e-47,1.0,"2+",1.0,8.027265820829874e-36,"No",6.977998425050538e-34,1.0,"Yes",1.0,6.8954731547639834e-62,"No",8.917849974405818e-48,1.0,"Yes",6.191700760556018e-12,0.9999999999938609,"Yes",1.0,3.2583012070678646e-23,"No",1.614945271766935e-44,1.0,"Yes"
"2013-004659-19","Randomized double-blind placebo-controlled multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis.Randomizovaná dvojito zaslepená placebom kontrolovaná multicentrická štúdia porovnávajúca dávku ciprofloxacínu DPI 325 mg dvakrát denne prerušovane podávanú po dobu 28 dní s liečbou/ 28 dní bez liečby alebo po dobu 14 dní s liečbou/ 14 dní bez liečby proti placebu zameraná na vyhodnotenie času do prvej exacerbácie a frekvencie exacerbácií u pacientov s bronchiektáziami bez súvislosti s cystickou fibrózou. ","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.7901398888771083e-136,5.388106639166884e-47,1.0,"2+",1.0,8.027265820829874e-36,"No",6.977998425050538e-34,1.0,"Yes",1.0,6.8954731547639834e-62,"No",8.917849974405818e-48,1.0,"Yes",6.191700760556018e-12,0.9999999999938609,"Yes",1.0,3.2583012070678646e-23,"No",1.614945271766935e-44,1.0,"Yes"
"2013-004659-19","Randomized double-blind placebo-controlled multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis.","LT","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7056596069363245e-69,6.933383077653042e-20,1.0,"2+",1.0,2.68022176783588e-20,"No",1.840435163849766e-18,1.0,"Yes",1.0,3.744382891341818e-17,"No",2.50063477705391e-21,1.0,"Yes",4.235208493090107e-09,0.9999999957647675,"Yes",0.027839246699808994,0.9721607533002018,"No",3.889211547533919e-21,1.0,"Yes"
"2013-004659-19","Randomized double-blind placebo-controlled multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis.","BG","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7056596069363245e-69,6.933383077653042e-20,1.0,"2+",1.0,2.68022176783588e-20,"No",1.840435163849766e-18,1.0,"Yes",1.0,3.744382891341818e-17,"No",2.50063477705391e-21,1.0,"Yes",4.235208493090107e-09,0.9999999957647675,"Yes",0.027839246699808994,0.9721607533002018,"No",3.889211547533919e-21,1.0,"Yes"
"2013-004659-19","Randomized double-blind placebo-controlled multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis.","PT","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7056596069363245e-69,6.933383077653042e-20,1.0,"2+",1.0,2.68022176783588e-20,"No",1.840435163849766e-18,1.0,"Yes",1.0,3.744382891341818e-17,"No",2.50063477705391e-21,1.0,"Yes",4.235208493090107e-09,0.9999999957647675,"Yes",0.027839246699808994,0.9721607533002018,"No",3.889211547533919e-21,1.0,"Yes"
"2013-004659-19","Randomized double-blind placebo-controlled multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis.","CZ","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.7056596069363245e-69,6.933383077653042e-20,1.0,"2+",1.0,2.68022176783588e-20,"No",1.840435163849766e-18,1.0,"Yes",1.0,3.744382891341818e-17,"No",2.50063477705391e-21,1.0,"Yes",4.235208493090107e-09,0.9999999957647675,"Yes",0.027839246699808994,0.9721607533002018,"No",3.889211547533919e-21,1.0,"Yes"
"2013-004659-19","Randomized double-blind placebo-controlled multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis.Randomizovaná dvojito zaslepená placebom kontrolovaná multicentrická štúdia porovnávajúca dávku ciprofloxacínu DPI 325 mg dvakrát denne prerušovane podávanú po dobu 28 dní s liečbou/ 28 dní bez liečby alebo po dobu 14 dní s liečbou/ 14 dní bez liečby proti placebu zameraná na vyhodnotenie času do prvej exacerbácie a frekvencie exacerbácií u pacientov s bronchiektáziami bez súvislosti s cystickou fibrózou. ","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.7901398888771083e-136,5.388106639166884e-47,1.0,"2+",1.0,8.027265820829874e-36,"No",6.977998425050538e-34,1.0,"Yes",1.0,6.8954731547639834e-62,"No",8.917849974405818e-48,1.0,"Yes",6.191700760556018e-12,0.9999999999938609,"Yes",1.0,3.2583012070678646e-23,"No",1.614945271766935e-44,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","FI","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004674-97","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.042483563810728e-56,3.644573532159589e-17,1.0,"2+",0.9999999999226646,7.733433673410287e-11,"No",2.7776035689623117e-10,0.9999999997222347,"Yes",0.9999999999872672,1.2737886471563997e-11,"No",8.713412860752763e-17,1.0,"Yes",2.041082805401317e-08,0.999999979589177,"Yes",0.9999955689867592,4.431013242557518e-06,"No",1.9358599645723596e-15,1.0,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide inChemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneEstudio de fase IIIb aleatorizado doble ciego controlado con placebo para evaluar la eficacia y seguridad de continuar el tratamiento con enzalutamida en pacientes con cáncer de próstata resistente a la castración metastásico que no han recibido quimioterapia previa que han experimentado progresión al tratamiento con enzalutamida sola tratados con docetaxel más prednisolona","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.371458460911393e-111,6.462992946763273e-15,1.0,"2+",0.996439078262218,0.003560921737766188,"No",0.008576119305802366,0.9914238806942156,"Yes",1.0,3.26206524575938e-47,"No",7.185225173158267e-10,0.9999999992814992,"Yes",0.6091645328512265,0.3908354671487614,"Yes",1.0,2.2228331506610112e-34,"No",5.7620550051345945e-12,0.9999999999942588,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide inChemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneEstudio de fase IIIb aleatorizado doble ciego controlado con placebo para evaluar la eficacia y seguridad de continuar el tratamiento con enzalutamida en pacientes con cáncer de próstata resistente a la castración metastásico que no han recibido quimioterapia previa que han experimentado progresión al tratamiento con enzalutamida sola tratados con docetaxel más prednisolona","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.371458460911393e-111,6.462992946763273e-15,1.0,"2+",0.996439078262218,0.003560921737766188,"No",0.008576119305802366,0.9914238806942156,"Yes",1.0,3.26206524575938e-47,"No",7.185225173158267e-10,0.9999999992814992,"Yes",0.6091645328512265,0.3908354671487614,"Yes",1.0,2.2228331506610112e-34,"No",5.7620550051345945e-12,0.9999999999942588,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneRandomizowane kontrolowane placebo prowadzone na zasadzie podwójnie ślepej próby badanie fazy III b oceniające skuteczność i bezpieczeństwo kontynuowania terapii enzalutamidem u pacjentów z przerzutowym rakiem gruczołu krokowego opornym na terapię kastracyjną niepoddawanych wcześniej chemioterapii leczonych docetakselem i prednizolonem u których doszło do progresji choroby podczas monoterapii enzalutamidem.","PL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5112281935123735e-97,4.201091830370441e-15,1.0,"2+",0.9999999206370408,7.93629686635633e-08,"No",5.8181533980433375e-08,0.9999999418184888,"Yes",1.0,5.5002038159377e-54,"No",2.574519321640168e-15,1.0,"Yes",0.9404255876281061,0.059574412371921945,"Yes",1.0,1.27306522372972e-30,"No",7.257502985148055e-13,0.999999999999261,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneRandomizowane kontrolowane placebo prowadzone na zasadzie podwójnie ślepej próby badanie fazy III b oceniające skuteczność i bezpieczeństwo kontynuowania terapii enzalutamidem u pacjentów z przerzutowym rakiem gruczołu krokowego opornym na terapię kastracyjną niepoddawanych wcześniej chemioterapii leczonych docetakselem i prednizolonem u których doszło do progresji choroby podczas monoterapii enzalutamidem.","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5112281935123735e-97,4.201091830370441e-15,1.0,"2+",0.9999999206370408,7.93629686635633e-08,"No",5.8181533980433375e-08,0.9999999418184888,"Yes",1.0,5.5002038159377e-54,"No",2.574519321640168e-15,1.0,"Yes",0.9404255876281061,0.059574412371921945,"Yes",1.0,1.27306522372972e-30,"No",7.257502985148055e-13,0.999999999999261,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide inChemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneEen gerandomiseerd dubbelblind placebogecontroleerd fase IIIb onderzoek naar de werkzaamheid en veiligheid van het voortzetten van enzalutamide bij patiënten met chemotherapie-naïeve gemetastaseerde castratieresistente prostaatkanker die behandeld worden met docetaxel en prednisolon en die progressie vertoonden bij een behandeling met enkel enzalutamide.","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5281434001206878e-96,2.5558220008580268e-09,0.9999999974442063,"2+",0.15279537107326907,0.8472046289267376,"No",0.9817449084756268,0.01825509152437352,"Yes",1.0,1.2603473550645046e-29,"No",2.938214469968127e-08,0.9999999706178646,"Yes",0.9999999450492412,5.495075344839812e-08,"Yes",1.0,7.799786111483796e-16,"No",7.557437546303377e-05,0.9999244256245161,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide inChemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide Alone","GR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0232419613187663e-53,6.59455558528852e-07,0.9999993405444528,"2+",0.9993450912039317,0.0006549087960789885,"No",0.0011804933266264573,0.9988195066733797,"Yes",1.0,1.0594966140319493e-21,"No",5.8519386003973366e-05,0.9999414806139874,"Yes",0.5440951687966743,0.45590483120332365,"Yes",0.9999999965219787,3.4780315479462817e-09,"No",3.200068819856088e-05,0.9999679993118081,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide inChemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneEstudio de fase IIIb aleatorizado doble ciego controlado con placebo para evaluar la eficacia y seguridad de continuar el tratamiento con enzalutamida en pacientes con cáncer de próstata resistente a la castración metastásico que no han recibido quimioterapia previa que han experimentado progresión al tratamiento con enzalutamida sola tratados con docetaxel más prednisolona","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.371458460911393e-111,6.462992946763273e-15,1.0,"2+",0.996439078262218,0.003560921737766188,"No",0.008576119305802366,0.9914238806942156,"Yes",1.0,3.26206524575938e-47,"No",7.185225173158267e-10,0.9999999992814992,"Yes",0.6091645328512265,0.3908354671487614,"Yes",1.0,2.2228331506610112e-34,"No",5.7620550051345945e-12,0.9999999999942588,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneRandomizowane kontrolowane placebo prowadzone na zasadzie podwójnie ślepej próby badanie fazy III b oceniające skuteczność i bezpieczeństwo kontynuowania terapii enzalutamidem u pacjentów z przerzutowym rakiem gruczołu krokowego opornym na terapię kastracyjną niepoddawanych wcześniej chemioterapii leczonych docetakselem i prednizolonem u których doszło do progresji choroby podczas monoterapii enzalutamidem.","FR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5112281935123735e-97,4.201091830370441e-15,1.0,"2+",0.9999999206370408,7.93629686635633e-08,"No",5.8181533980433375e-08,0.9999999418184888,"Yes",1.0,5.5002038159377e-54,"No",2.574519321640168e-15,1.0,"Yes",0.9404255876281061,0.059574412371921945,"Yes",1.0,1.27306522372972e-30,"No",7.257502985148055e-13,0.999999999999261,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneRandomizowane kontrolowane placebo prowadzone na zasadzie podwójnie ślepej próby badanie fazy III b oceniające skuteczność i bezpieczeństwo kontynuowania terapii enzalutamidem u pacjentów z przerzutowym rakiem gruczołu krokowego opornym na terapię kastracyjną niepoddawanych wcześniej chemioterapii leczonych docetakselem i prednizolonem u których doszło do progresji choroby podczas monoterapii enzalutamidem.","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5112281935123735e-97,4.201091830370441e-15,1.0,"2+",0.9999999206370408,7.93629686635633e-08,"No",5.8181533980433375e-08,0.9999999418184888,"Yes",1.0,5.5002038159377e-54,"No",2.574519321640168e-15,1.0,"Yes",0.9404255876281061,0.059574412371921945,"Yes",1.0,1.27306522372972e-30,"No",7.257502985148055e-13,0.999999999999261,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide inChemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide Alone","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.0232419613187663e-53,6.59455558528852e-07,0.9999993405444528,"2+",0.9993450912039317,0.0006549087960789885,"No",0.0011804933266264573,0.9988195066733797,"Yes",1.0,1.0594966140319493e-21,"No",5.8519386003973366e-05,0.9999414806139874,"Yes",0.5440951687966743,0.45590483120332365,"Yes",0.9999999965219787,3.4780315479462817e-09,"No",3.200068819856088e-05,0.9999679993118081,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneRandomizowane kontrolowane placebo prowadzone na zasadzie podwójnie ślepej próby badanie fazy III b oceniające skuteczność i bezpieczeństwo kontynuowania terapii enzalutamidem u pacjentów z przerzutowym rakiem gruczołu krokowego opornym na terapię kastracyjną niepoddawanych wcześniej chemioterapii leczonych docetakselem i prednizolonem u których doszło do progresji choroby podczas monoterapii enzalutamidem.","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5112281935123735e-97,4.201091830370441e-15,1.0,"2+",0.9999999206370408,7.93629686635633e-08,"No",5.8181533980433375e-08,0.9999999418184888,"Yes",1.0,5.5002038159377e-54,"No",2.574519321640168e-15,1.0,"Yes",0.9404255876281061,0.059574412371921945,"Yes",1.0,1.27306522372972e-30,"No",7.257502985148055e-13,0.999999999999261,"Yes"
"2013-004711-50","A Randomized Double-Blind Placebo-Controlled Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide AloneRandomizowane kontrolowane placebo prowadzone na zasadzie podwójnie ślepej próby badanie fazy III b oceniające skuteczność i bezpieczeństwo kontynuowania terapii enzalutamidem u pacjentów z przerzutowym rakiem gruczołu krokowego opornym na terapię kastracyjną niepoddawanych wcześniej chemioterapii leczonych docetakselem i prednizolonem u których doszło do progresji choroby podczas monoterapii enzalutamidem.","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5112281935123735e-97,4.201091830370441e-15,1.0,"2+",0.9999999206370408,7.93629686635633e-08,"No",5.8181533980433375e-08,0.9999999418184888,"Yes",1.0,5.5002038159377e-54,"No",2.574519321640168e-15,1.0,"Yes",0.9404255876281061,0.059574412371921945,"Yes",1.0,1.27306522372972e-30,"No",7.257502985148055e-13,0.999999999999261,"Yes"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. REVERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","PT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",7.8934223900693195e-59,0.9587387021603311,0.0412612978396903,"1",4.8459676256856456e-08,0.9999999515403045,"Yes",0.999999985238219,1.4761798500776882e-08,"No",1.0,8.176177264833755e-18,"No",0.990850186065748,0.009149813934225707,"No",0.9999637578656507,3.6242134341621645e-05,"No",0.9999999999973852,2.5873100679138158e-12,"No",0.9968820962478615,0.003117903752128482,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. REVERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","EE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.0804021573821302e-54,0.9902342649031389,0.009765735096863565,"1",1.0576172056559475e-08,0.9999999894238273,"Yes",0.9999999961246432,3.875365238727649e-09,"No",1.0,3.565336151815841e-18,"No",0.9974605252220108,0.0025394747779819587,"No",0.9999980969813496,1.9030186402187629e-06,"No",0.9999999999849934,1.4986604002949625e-11,"No",0.9987940818263861,0.001205918173622233,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. REVERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","ES","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.0804021573821302e-54,0.9902342649031389,0.009765735096863565,"1",1.0576172056559475e-08,0.9999999894238273,"Yes",0.9999999961246432,3.875365238727649e-09,"No",1.0,3.565336151815841e-18,"No",0.9974605252220108,0.0025394747779819587,"No",0.9999980969813496,1.9030186402187629e-06,"No",0.9999999999849934,1.4986604002949625e-11,"No",0.9987940818263861,0.001205918173622233,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD ( A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","DE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.4254122184116444e-53,0.9865981965807233,0.013401803419299453,"1",5.048043333872461e-07,0.9999994951956661,"Yes",0.9999998289777214,1.7102227388775087e-07,"No",1.0,1.0261016401517172e-16,"No",0.9971590561180432,0.002840943881973927,"No",0.9999972731843288,2.726815694479317e-06,"No",0.999999999592717,4.072750785709131e-10,"No",0.9985063075893855,0.0014936924105897764,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","LV","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.4254122184116444e-53,0.9865981965807233,0.013401803419299453,"1",5.048043333872461e-07,0.9999994951956661,"Yes",0.9999998289777214,1.7102227388775087e-07,"No",1.0,1.0261016401517172e-16,"No",0.9971590561180432,0.002840943881973927,"No",0.9999972731843288,2.726815694479317e-06,"No",0.999999999592717,4.072750785709131e-10,"No",0.9985063075893855,0.0014936924105897764,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","SK","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.0292183432169388e-57,0.944038631271517,0.05596136872847829,"1",2.3129929365554646e-06,0.9999976870070701,"Yes",0.9999993485529748,6.514470263735703e-07,"No",1.0,2.3530989910569205e-16,"No",0.9897720293120222,0.010227970687956313,"No",0.9999480697930866,5.1930206886618845e-05,"No",0.9999999999296848,7.031258791729725e-11,"No",0.9961398188042271,0.0038601811957812244,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial.","IT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.4254122184116444e-53,0.9865981965807233,0.013401803419299453,"1",5.048043333872461e-07,0.9999994951956661,"Yes",0.9999998289777214,1.7102227388775087e-07,"No",1.0,1.0261016401517172e-16,"No",0.9971590561180432,0.002840943881973927,"No",0.9999972731843288,2.726815694479317e-06,"No",0.999999999592717,4.072750785709131e-10,"No",0.9985063075893855,0.0014936924105897764,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.Studio clinico di fase III a serie di casi sulla reversibilita' dell'effetto anticoagulante di dabigatran mediante somministrazione endovenosa di 5.0 g di idarucizumab (BI 655075) in pazienti in trattamento con dabigatran etexilato che presentino sanguinamento incontrollato o necessitino di procedure o chirurgia d’emergenza.","NL","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.9038222762611574e-103,0.9989510459371498,0.0010489540628706615,"1",4.6825660959203925e-14,0.9999999999999432,"Yes",1.0,1.2607488944925599e-14,"No",1.0,2.0920890503747527e-26,"No",0.9979360540074449,0.0020639459925346194,"No",0.9999998853282999,1.1467169906097649e-07,"No",1.0,3.005903312470735e-17,"No",0.9992743372647526,0.0007256627352570913,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","FR","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.0292183432169388e-57,0.944038631271517,0.05596136872847829,"1",2.3129929365554646e-06,0.9999976870070701,"Yes",0.9999993485529748,6.514470263735703e-07,"No",1.0,2.3530989910569205e-16,"No",0.9897720293120222,0.010227970687956313,"No",0.9999480697930866,5.1930206886618845e-05,"No",0.9999999999296848,7.031258791729725e-11,"No",0.9961398188042271,0.0038601811957812244,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. REVERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","BE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",7.8934223900693195e-59,0.9587387021603311,0.0412612978396903,"1",4.8459676256856456e-08,0.9999999515403045,"Yes",0.999999985238219,1.4761798500776882e-08,"No",1.0,8.176177264833755e-18,"No",0.990850186065748,0.009149813934225707,"No",0.9999637578656507,3.6242134341621645e-05,"No",0.9999999999973852,2.5873100679138158e-12,"No",0.9968820962478615,0.003117903752128482,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. REVERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","DK","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.0804021573821302e-54,0.9902342649031389,0.009765735096863565,"1",1.0576172056559475e-08,0.9999999894238273,"Yes",0.9999999961246432,3.875365238727649e-09,"No",1.0,3.565336151815841e-18,"No",0.9974605252220108,0.0025394747779819587,"No",0.9999980969813496,1.9030186402187629e-06,"No",0.9999999999849934,1.4986604002949625e-11,"No",0.9987940818263861,0.001205918173622233,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.Studio clinico di fase III a serie di casi sulla reversibilita' dell'effetto anticoagulante di dabigatran mediante somministrazione endovenosa di 5.0 g di idarucizumab (BI 655075) in pazienti in trattamento con dabigatran etexilato che presentino sanguinamento incontrollato o necessitino di procedure o chirurgia d’emergenza.","CZ","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.9038222762611574e-103,0.9989510459371498,0.0010489540628706615,"1",4.6825660959203925e-14,0.9999999999999432,"Yes",1.0,1.2607488944925599e-14,"No",1.0,2.0920890503747527e-26,"No",0.9979360540074449,0.0020639459925346194,"No",0.9999998853282999,1.1467169906097649e-07,"No",1.0,3.005903312470735e-17,"No",0.9992743372647526,0.0007256627352570913,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD ( A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","AT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.4254122184116444e-53,0.9865981965807233,0.013401803419299453,"1",5.048043333872461e-07,0.9999994951956661,"Yes",0.9999998289777214,1.7102227388775087e-07,"No",1.0,1.0261016401517172e-16,"No",0.9971590561180432,0.002840943881973927,"No",0.9999972731843288,2.726815694479317e-06,"No",0.999999999592717,4.072750785709131e-10,"No",0.9985063075893855,0.0014936924105897764,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.Studio clinico di fase III a serie di casi sulla reversibilita' dell'effetto anticoagulante di dabigatran mediante somministrazione endovenosa di 5.0 g di idarucizumab (BI 655075) in pazienti in trattamento con dabigatran etexilato che presentino sanguinamento incontrollato o necessitino di procedure o chirurgia d’emergenza.","FI","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.9038222762611574e-103,0.9989510459371498,0.0010489540628706615,"1",4.6825660959203925e-14,0.9999999999999432,"Yes",1.0,1.2607488944925599e-14,"No",1.0,2.0920890503747527e-26,"No",0.9979360540074449,0.0020639459925346194,"No",0.9999998853282999,1.1467169906097649e-07,"No",1.0,3.005903312470735e-17,"No",0.9992743372647526,0.0007256627352570913,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD ( A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","NO","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.4254122184116444e-53,0.9865981965807233,0.013401803419299453,"1",5.048043333872461e-07,0.9999994951956661,"Yes",0.9999998289777214,1.7102227388775087e-07,"No",1.0,1.0261016401517172e-16,"No",0.9971590561180432,0.002840943881973927,"No",0.9999972731843288,2.726815694479317e-06,"No",0.999999999592717,4.072750785709131e-10,"No",0.9985063075893855,0.0014936924105897764,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial","SE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.4254122184116444e-53,0.9865981965807233,0.013401803419299453,"1",5.048043333872461e-07,0.9999994951956661,"Yes",0.9999998289777214,1.7102227388775087e-07,"No",1.0,1.0261016401517172e-16,"No",0.9971590561180432,0.002840943881973927,"No",0.9999972731843288,2.726815694479317e-06,"No",0.999999999592717,4.072750785709131e-10,"No",0.9985063075893855,0.0014936924105897764,"No"
"2013-004813-41","A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.Studio clinico di fase III a serie di casi sulla reversibilita' dell'effetto anticoagulante di dabigatran mediante somministrazione endovenosa di 5.0 g di idarucizumab (BI 655075) in pazienti in trattamento con dabigatran etexilato che presentino sanguinamento incontrollato o necessitino di procedure o chirurgia d’emergenza.","IE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.9038222762611574e-103,0.9989510459371498,0.0010489540628706615,"1",4.6825660959203925e-14,0.9999999999999432,"Yes",1.0,1.2607488944925599e-14,"No",1.0,2.0920890503747527e-26,"No",0.9979360540074449,0.0020639459925346194,"No",0.9999998853282999,1.1467169906097649e-07,"No",1.0,3.005903312470735e-17,"No",0.9992743372647526,0.0007256627352570913,"No"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving DialysisStudio randomizzato controllato in aperto volto a valutare l’efficacia e la sicurezza di cinacalcet HCl nei soggetti pediatrici con iperparatiroidismo secondario e malattia renale cronica sottoposti a dialisi","DE","No","No","Yes","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4754454405381316e-48,0.37858857855696393,0.6214114214430445,"2+",1.2621542404049177e-06,0.9999987378457725,"Yes",0.9999980605315436,1.9394684442279134e-06,"No",1.0,5.593242943706936e-16,"No",0.49017985639248773,0.5098201436075249,"Yes",0.11734452230785239,0.8826554776921588,"No",0.9999999999999432,7.205175341245035e-14,"No",0.9847717843629654,0.015228215637025219,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving Dialysis«Μία Τυχαιοποιημένη Ανοιχτή Ελεγχόμενη Μελέτη για την Αξιολόγηση της Αποτελεσματικότητας και της Ασφάλειας της Υδροχλωρικής Κινακαλσέτης σεΠαιδιατρικούς Ασθενείς με Δευτεροπαθή Υπερπαραθυρεοειδισμό και ΧρόνιαΝεφρική Νόσο που Υποβάλλονται σε Εξωνεφρική Κάθαρση»","ES","No","No","Yes","ok","No","No","Yes","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.646158446903086e-21,0.22824592128456386,0.7717540787154322,"2+",0.0023564861522248604,0.9976435138477768,"Yes",0.9974313838510676,0.002568616148935156,"No",0.9999999945001435,5.499853381264956e-09,"No",0.529824830085096,0.4701751699149039,"Yes",0.49969458955627083,0.5003054104437281,"No",0.9999904715265938,9.52847340766538e-06,"No",0.9140073605054769,0.0859926394945169,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving DialysisStudio randomizzato controllato in aperto volto a valutare l’efficacia e la sicurezza di cinacalcet HCl nei soggetti pediatrici con iperparatiroidismo secondario e malattia renale cronica sottoposti a dialisi","FR","No","No","Yes","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4754454405381316e-48,0.37858857855696393,0.6214114214430445,"2+",1.2621542404049177e-06,0.9999987378457725,"Yes",0.9999980605315436,1.9394684442279134e-06,"No",1.0,5.593242943706936e-16,"No",0.49017985639248773,0.5098201436075249,"Yes",0.11734452230785239,0.8826554776921588,"No",0.9999999999999432,7.205175341245035e-14,"No",0.9847717843629654,0.015228215637025219,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving DialysisEstudio aleatorizado abierto y controlado para evaluar la eficacia y seguridad de cinacalcet HCl en sujetos pediátricos con hiperparatiroidismo secundario e insuficiencia renal crónica sometidos a diálisis","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.23374285970973e-46,2.25194540530066e-06,0.9999977480546026,"2+",5.23939282213976e-05,0.9999476060717829,"Yes",0.9999562900758253,4.370992420105648e-05,"No",0.9999999999674288,3.256974328114273e-11,"No",8.499574365312878e-05,0.9999150042563661,"Yes",0.01729936057415496,0.9827006394258412,"No",1.0,3.1555639316009435e-17,"No",0.05161333106276525,0.9483866689372101,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving Dialysis«Μία Τυχαιοποιημένη Ανοιχτή Ελεγχόμενη Μελέτη για την Αξιολόγηση της Αποτελεσματικότητας και της Ασφάλειας της Υδροχλωρικής Κινακαλσέτης σεΠαιδιατρικούς Ασθενείς με Δευτεροπαθή Υπερπαραθυρεοειδισμό και ΧρόνιαΝεφρική Νόσο που Υποβάλλονται σε Εξωνεφρική Κάθαρση»","BE","No","No","Yes","ok","No","No","Yes","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.646158446903086e-21,0.22824592128456386,0.7717540787154322,"2+",0.0023564861522248604,0.9976435138477768,"Yes",0.9974313838510676,0.002568616148935156,"No",0.9999999945001435,5.499853381264956e-09,"No",0.529824830085096,0.4701751699149039,"Yes",0.49969458955627083,0.5003054104437281,"No",0.9999904715265938,9.52847340766538e-06,"No",0.9140073605054769,0.0859926394945169,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving DialysisStudio randomizzato controllato in aperto volto a valutare l’efficacia e la sicurezza di cinacalcet HCl nei soggetti pediatrici con iperparatiroidismo secondario e malattia renale cronica sottoposti a dialisi","CZ","No","No","Yes","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4754454405381316e-48,0.37858857855696393,0.6214114214430445,"2+",1.2621542404049177e-06,0.9999987378457725,"Yes",0.9999980605315436,1.9394684442279134e-06,"No",1.0,5.593242943706936e-16,"No",0.49017985639248773,0.5098201436075249,"Yes",0.11734452230785239,0.8826554776921588,"No",0.9999999999999432,7.205175341245035e-14,"No",0.9847717843629654,0.015228215637025219,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving Dialysis","SK","No","No","Yes","ok","No","No","Yes","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.646158446903086e-21,0.22824592128456386,0.7717540787154322,"2+",0.0023564861522248604,0.9976435138477768,"Yes",0.9974313838510676,0.002568616148935156,"No",0.9999999945001435,5.499853381264956e-09,"No",0.529824830085096,0.4701751699149039,"Yes",0.49969458955627083,0.5003054104437281,"No",0.9999904715265938,9.52847340766538e-06,"No",0.9140073605054769,0.0859926394945169,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving Dialysis","IT","No","No","Yes","ok","No","No","Yes","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.646158446903086e-21,0.22824592128456386,0.7717540787154322,"2+",0.0023564861522248604,0.9976435138477768,"Yes",0.9974313838510676,0.002568616148935156,"No",0.9999999945001435,5.499853381264956e-09,"No",0.529824830085096,0.4701751699149039,"Yes",0.49969458955627083,0.5003054104437281,"No",0.9999904715265938,9.52847340766538e-06,"No",0.9140073605054769,0.0859926394945169,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving Dialysis","GR","No","No","Yes","ok","No","No","Yes","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.646158446903086e-21,0.22824592128456386,0.7717540787154322,"2+",0.0023564861522248604,0.9976435138477768,"Yes",0.9974313838510676,0.002568616148935156,"No",0.9999999945001435,5.499853381264956e-09,"No",0.529824830085096,0.4701751699149039,"Yes",0.49969458955627083,0.5003054104437281,"No",0.9999904715265938,9.52847340766538e-06,"No",0.9140073605054769,0.0859926394945169,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving DialysisEstudio aleatorizado abierto y controlado para evaluar la eficacia y seguridad de cinacalcet HCl en sujetos pediátricos con hiperparatiroidismo secundario e insuficiencia renal crónica sometidos a diálisis","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.23374285970973e-46,2.25194540530066e-06,0.9999977480546026,"2+",5.23939282213976e-05,0.9999476060717829,"Yes",0.9999562900758253,4.370992420105648e-05,"No",0.9999999999674288,3.256974328114273e-11,"No",8.499574365312878e-05,0.9999150042563661,"Yes",0.01729936057415496,0.9827006394258412,"No",1.0,3.1555639316009435e-17,"No",0.05161333106276525,0.9483866689372101,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving DialysisStudio randomizzato controllato in aperto volto a valutare l’efficacia e la sicurezza di cinacalcet HCl nei soggetti pediatrici con iperparatiroidismo secondario e malattia renale cronica sottoposti a dialisi","LT","No","No","Yes","ok","No","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4754454405381316e-48,0.37858857855696393,0.6214114214430445,"2+",1.2621542404049177e-06,0.9999987378457725,"Yes",0.9999980605315436,1.9394684442279134e-06,"No",1.0,5.593242943706936e-16,"No",0.49017985639248773,0.5098201436075249,"Yes",0.11734452230785239,0.8826554776921588,"No",0.9999999999999432,7.205175341245035e-14,"No",0.9847717843629654,0.015228215637025219,"Yes"
"2013-004958-18","A Randomized Open-label Controlled Study to Assess the Efficacy andSafety of Cinacalcet HCl in Pediatric Subjects With SecondaryHyperparathyroidism and Chronic Kidney Disease Receiving Dialysis«Μία Τυχαιοποιημένη Ανοιχτή Ελεγχόμενη Μελέτη για την Αξιολόγηση της Αποτελεσματικότητας και της Ασφάλειας της Υδροχλωρικής Κινακαλσέτης σεΠαιδιατρικούς Ασθενείς με Δευτεροπαθή Υπερπαραθυρεοειδισμό και ΧρόνιαΝεφρική Νόσο που Υποβάλλονται σε Εξωνεφρική Κάθαρση»","Outside EU/EEA","No","No","Yes","ok","No","No","Yes","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.646158446903086e-21,0.22824592128456386,0.7717540787154322,"2+",0.0023564861522248604,0.9976435138477768,"Yes",0.9974313838510676,0.002568616148935156,"No",0.9999999945001435,5.499853381264956e-09,"No",0.529824830085096,0.4701751699149039,"Yes",0.49969458955627083,0.5003054104437281,"No",0.9999904715265938,9.52847340766538e-06,"No",0.9140073605054769,0.0859926394945169,"Yes"
"2013-005007-13","A Phase 3 Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib","IT","No","No","Yes","ok","Yes","Yes","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.866667649395492e-44,0.09405313761076148,0.9059468623892308,"2+",3.551825161225443e-06,0.9999964481748389,"Yes",0.9999964119740947,3.5880259094071557e-06,"No",1.0,3.5189462354362854e-19,"No",0.9978817429021063,0.002118257097905331,"Yes",0.9999999987826413,1.217350755271301e-09,"Yes",6.949479879340938e-12,0.9999999999930367,"No",0.27548526510069776,0.7245147348992946,"Yes"
"2013-005007-13","A Phase 3 Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib","FR","No","No","Yes","ok","Yes","Yes","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.866667649395492e-44,0.09405313761076148,0.9059468623892308,"2+",3.551825161225443e-06,0.9999964481748389,"Yes",0.9999964119740947,3.5880259094071557e-06,"No",1.0,3.5189462354362854e-19,"No",0.9978817429021063,0.002118257097905331,"Yes",0.9999999987826413,1.217350755271301e-09,"Yes",6.949479879340938e-12,0.9999999999930367,"No",0.27548526510069776,0.7245147348992946,"Yes"
"2013-005007-13","A Phase 3 Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib","GB","No","No","Yes","ok","Yes","Yes","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.866667649395492e-44,0.09405313761076148,0.9059468623892308,"2+",3.551825161225443e-06,0.9999964481748389,"Yes",0.9999964119740947,3.5880259094071557e-06,"No",1.0,3.5189462354362854e-19,"No",0.9978817429021063,0.002118257097905331,"Yes",0.9999999987826413,1.217350755271301e-09,"Yes",6.949479879340938e-12,0.9999999999930367,"No",0.27548526510069776,0.7245147348992946,"Yes"
"2013-005007-13","A Phase 3 Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib","DE","No","No","Yes","ok","Yes","Yes","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.866667649395492e-44,0.09405313761076148,0.9059468623892308,"2+",3.551825161225443e-06,0.9999964481748389,"Yes",0.9999964119740947,3.5880259094071557e-06,"No",1.0,3.5189462354362854e-19,"No",0.9978817429021063,0.002118257097905331,"Yes",0.9999999987826413,1.217350755271301e-09,"Yes",6.949479879340938e-12,0.9999999999930367,"No",0.27548526510069776,0.7245147348992946,"Yes"
"2013-005427-16","A Phase II Non-comparative Open label Multi-centre International Studyof MEDI4736 in Patients with Locally Advanced or Metastatic Non-SmallCell Lung Cancer (Stage IIIB-IV) who have received at least Two PriorSystemic Treatment Regimens Including One Platinum-basedChemotherapy Regimen (ATLANTIC)","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.291782609816193e-56,0.6887621228079681,0.3112378771920254,"-1",4.40668018311283e-10,0.9999999995593214,"Yes",0.9999999988982893,1.1017075484269233e-09,"No",1.0,6.444469476259511e-19,"No",0.9994267408703945,0.0005732591296079855,"No",0.943469729538051,0.056530270461954524,"No",1.0,1.1845970413354895e-15,"No",0.5714529019074436,0.4285470980925691,"No"
"2013-005427-16","A Phase II Non-comparative Open label Multi-centre International Study of MEDI4736 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.0411251905416601e-71,0.9952753128010127,0.0047246871989910285,"-1",1.5213799906581192e-11,0.9999999999847944,"Yes",0.9999999999553211,4.4677583883421484e-11,"No",1.0,4.2158548384670406e-24,"No",0.9999767808308383,2.321916915263767e-05,"No",0.9714702118326193,0.028529788167375794,"No",1.0,2.2194883289569857e-16,"No",0.997164967940407,0.002835032059584652,"No"
"2013-005427-16","A Phase II Non-comparative Open label Multi-centre International Study of MEDI4736 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)","HU","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.0411251905416601e-71,0.9952753128010127,0.0047246871989910285,"-1",1.5213799906581192e-11,0.9999999999847944,"Yes",0.9999999999553211,4.4677583883421484e-11,"No",1.0,4.2158548384670406e-24,"No",0.9999767808308383,2.321916915263767e-05,"No",0.9714702118326193,0.028529788167375794,"No",1.0,2.2194883289569857e-16,"No",0.997164967940407,0.002835032059584652,"No"
"2013-005427-16","A Phase II Non-comparative Open label Multi-centre International Study of MEDI4736 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)","IT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.0411251905416601e-71,0.9952753128010127,0.0047246871989910285,"-1",1.5213799906581192e-11,0.9999999999847944,"Yes",0.9999999999553211,4.4677583883421484e-11,"No",1.0,4.2158548384670406e-24,"No",0.9999767808308383,2.321916915263767e-05,"No",0.9714702118326193,0.028529788167375794,"No",1.0,2.2194883289569857e-16,"No",0.997164967940407,0.002835032059584652,"No"
"2013-005427-16","A Phase II Non-comparative Open label Multi-centre International Studyof MEDI4736 in Patients with Locally Advanced or Metastatic Non-SmallCell Lung Cancer (Stage IIIB-IV) who have received at least Two PriorSystemic Treatment Regimens Including One Platinum-basedChemotherapy Regimen (ATLANTIC)","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.291782609816193e-56,0.6887621228079681,0.3112378771920254,"-1",4.40668018311283e-10,0.9999999995593214,"Yes",0.9999999988982893,1.1017075484269233e-09,"No",1.0,6.444469476259511e-19,"No",0.9994267408703945,0.0005732591296079855,"No",0.943469729538051,0.056530270461954524,"No",1.0,1.1845970413354895e-15,"No",0.5714529019074436,0.4285470980925691,"No"
"2013-005427-16","A Phase II Non-comparative Open label Multi-centre International Studyof MEDI4736 in Patients with Locally Advanced or Metastatic Non-SmallCell Lung Cancer (Stage IIIB-IV) who have received at least Two PriorSystemic Treatment Regimens Including One Platinum-basedChemotherapy Regimen (ATLANTIC)","CZ","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.291782609816193e-56,0.6887621228079681,0.3112378771920254,"-1",4.40668018311283e-10,0.9999999995593214,"Yes",0.9999999988982893,1.1017075484269233e-09,"No",1.0,6.444469476259511e-19,"No",0.9994267408703945,0.0005732591296079855,"No",0.943469729538051,0.056530270461954524,"No",1.0,1.1845970413354895e-15,"No",0.5714529019074436,0.4285470980925691,"No"
"2013-005427-16","A Phase II Non-comparative Open label Multi-centre International Studyof MEDI4736 in Patients with Locally Advanced or Metastatic Non-SmallCell Lung Cancer (Stage IIIB-IV) who have received at least Two PriorSystemic Treatment Regimens Including One Platinum-basedChemotherapy Regimen (ATLANTIC)","PL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.291782609816193e-56,0.6887621228079681,0.3112378771920254,"-1",4.40668018311283e-10,0.9999999995593214,"Yes",0.9999999988982893,1.1017075484269233e-09,"No",1.0,6.444469476259511e-19,"No",0.9994267408703945,0.0005732591296079855,"No",0.943469729538051,0.056530270461954524,"No",1.0,1.1845970413354895e-15,"No",0.5714529019074436,0.4285470980925691,"No"
"2013-005427-16","A Phase II Non-comparative Open label Multi-centre International Studyof MEDI4736 in Patients with Locally Advanced or Metastatic Non-SmallCell Lung Cancer (Stage IIIB-IV) who have received at least Two PriorSystemic Treatment Regimens Including One Platinum-basedChemotherapy Regimen (ATLANTIC)Nekomparativní otevřené multicentrické mezinárodní klinické hodnocení fáze II hodnotící přípravek MEDI4736 u pacientů s místně pokročilým nebo metastazujícím nemalobuněčným karcinomem plic (stádium IIIB-IV) kteří podstoupili minimálně dva předchozí cykly systémové léčby včetně jednoho cyklu chemoterapie na bázi platiny (ATLANTIC)","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",2.5002861395727626e-110,3.811835285428287e-11,0.9999999999619149,"-1",1.440718419484959e-16,1.0,"Yes",1.0,4.866696782748812e-15,"No",1.0,6.730561507162274e-62,"No",2.4232170803643716e-06,0.999997576782883,"No",0.9705633857509678,0.029436614249088,"No",1.0,3.4457772840999744e-45,"No",3.0802060359045948e-12,0.9999999999969305,"No"
"2013-005449-35","An Open-Label Safety and Efficacy Study for Patients with Nonsense Mutation Cystic Fibrosis Previously Treated with Ataluren (PTC124®)Estudio abierto de seguridad y de eficacia en pacientes con fibrosis quística mediada por mutación terminadora tratados previamente con atalurén (PTC124®)","ES","Yes","No","No","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",7.325002849836187e-33,0.49310672856213417,0.5068932714378728,"-1",0.9063731157477176,0.09362688425229296,"Information not present in EudraCT",0.04689515805507441,0.9531048419449223,"Information not present in EudraCT",1.0,1.0348185313078022e-22,"Information not present in EudraCT",0.09602374948296331,0.9039762505170306,"No",0.995458860719975,0.004541139280016968,"",0.9999999997082227,2.917814292672924e-10,"",0.01976436914702726,0.9802356308529799,""
"2013-005449-35","An Open-Label Safety and Efficacy Study for Patients with Nonsense Mutation Cystic Fibrosis Previously Treated with Ataluren (PTC124®)","DE","Yes","No","No","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",4.014316821584338e-15,0.4180722220431544,0.5819277779568396,"-1",0.819291804651069,0.18070819534893193,"Information not present in EudraCT",0.12957317000753613,0.8704268299924685,"Information not present in EudraCT",0.9999999999975273,2.4705633946589835e-12,"Information not present in EudraCT",0.2036878391011551,0.7963121608988407,"No",0.985014252828747,0.014985747171259417,"",0.9960797847733037,0.00392021522670232,"",0.12516770256260654,0.8748322974373867,""
"2013-005449-35","An Open-Label Safety and Efficacy Study for Patients with Nonsense Mutation Cystic Fibrosis Previously Treated with Ataluren (PTC124®)","IT","Yes","No","No","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",4.014316821584338e-15,0.4180722220431544,0.5819277779568396,"-1",0.819291804651069,0.18070819534893193,"Information not present in EudraCT",0.12957317000753613,0.8704268299924685,"Information not present in EudraCT",0.9999999999975273,2.4705633946589835e-12,"Information not present in EudraCT",0.2036878391011551,0.7963121608988407,"No",0.985014252828747,0.014985747171259417,"",0.9960797847733037,0.00392021522670232,"",0.12516770256260654,0.8748322974373867,""
"2013-005449-35","An Open-Label Safety and Efficacy Study for Patients with Nonsense Mutation Cystic Fibrosis Previously Treated with Ataluren (PTC124®)Estudio abierto de seguridad y de eficacia en pacientes con fibrosis quística mediada por mutación terminadora tratados previamente con atalurén (PTC124®)","BE","Yes","No","No","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",7.325002849836187e-33,0.49310672856213417,0.5068932714378728,"-1",0.9063731157477176,0.09362688425229296,"Information not present in EudraCT",0.04689515805507441,0.9531048419449223,"Information not present in EudraCT",1.0,1.0348185313078022e-22,"Information not present in EudraCT",0.09602374948296331,0.9039762505170306,"No",0.995458860719975,0.004541139280016968,"",0.9999999997082227,2.917814292672924e-10,"",0.01976436914702726,0.9802356308529799,""
"2013-005449-35","An Open-Label Safety and Efficacy Study for Patients with Nonsense Mutation Cystic Fibrosis Previously Treated with Ataluren (PTC124®)Estudio abierto de seguridad y de eficacia en pacientes con fibrosis quística mediada por mutación terminadora tratados previamente con atalurén (PTC124®)","SE","Yes","No","No","","Yes","No","No","Yes","2+","","","Yes","No","No","No","No","No","1","No",7.325002849836187e-33,0.49310672856213417,0.5068932714378728,"-1",0.9063731157477176,0.09362688425229296,"Information not present in EudraCT",0.04689515805507441,0.9531048419449223,"Information not present in EudraCT",1.0,1.0348185313078022e-22,"Information not present in EudraCT",0.09602374948296331,0.9039762505170306,"No",0.995458860719975,0.004541139280016968,"",0.9999999997082227,2.917814292672924e-10,"",0.01976436914702726,0.9802356308529799,""
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATIONESTUDIO DE FASE III MULTICÉNTRICO RANDOMIZADO CON DOBLE ENMASCARAMIENTO CONTROLADO CON  SIMULACIÓN PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LAMPALIZUMAB ADMINISTRADO EN INYECCIÓN INTRAVÍTREA A PACIENTES CON ATROFIA GEOGRÁFICA SECUNDARIA A DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD .","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0134111375665547e-79,3.853942179603792e-17,1.0,"2+",1.0,2.2137564033463388e-17,"No",1.3538186075870188e-14,1.0,"Yes",0.9999999996559836,3.440273674535129e-10,"No",1.8698889929528335e-16,1.0,"Yes",2.430593233666754e-06,0.9999975694067852,"Yes",1.0,1.8378287972047506e-17,"No",1.9010682512855608e-20,1.0,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATIONESTUDIO DE FASE III MULTICÉNTRICO RANDOMIZADO CON DOBLE ENMASCARAMIENTO CONTROLADO CON  SIMULACIÓN PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LAMPALIZUMAB ADMINISTRADO EN INYECCIÓN INTRAVÍTREA A PACIENTES CON ATROFIA GEOGRÁFICA SECUNDARIA A DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD .","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0134111375665547e-79,3.853942179603792e-17,1.0,"2+",1.0,2.2137564033463388e-17,"No",1.3538186075870188e-14,1.0,"Yes",0.9999999996559836,3.440273674535129e-10,"No",1.8698889929528335e-16,1.0,"Yes",2.430593233666754e-06,0.9999975694067852,"Yes",1.0,1.8378287972047506e-17,"No",1.9010682512855608e-20,1.0,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATIONESTUDIO DE FASE III MULTICÉNTRICO RANDOMIZADO CON DOBLE ENMASCARAMIENTO CONTROLADO CON  SIMULACIÓN PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LAMPALIZUMAB ADMINISTRADO EN INYECCIÓN INTRAVÍTREA A PACIENTES CON ATROFIA GEOGRÁFICA SECUNDARIA A DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD .","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0134111375665547e-79,3.853942179603792e-17,1.0,"2+",1.0,2.2137564033463388e-17,"No",1.3538186075870188e-14,1.0,"Yes",0.9999999996559836,3.440273674535129e-10,"No",1.8698889929528335e-16,1.0,"Yes",2.430593233666754e-06,0.9999975694067852,"Yes",1.0,1.8378287972047506e-17,"No",1.9010682512855608e-20,1.0,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATIONESTUDIO DE FASE III MULTICÉNTRICO RANDOMIZADO CON DOBLE ENMASCARAMIENTO CONTROLADO CON  SIMULACIÓN PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LAMPALIZUMAB ADMINISTRADO EN INYECCIÓN INTRAVÍTREA A PACIENTES CON ATROFIA GEOGRÁFICA SECUNDARIA A DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD .","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0134111375665547e-79,3.853942179603792e-17,1.0,"2+",1.0,2.2137564033463388e-17,"No",1.3538186075870188e-14,1.0,"Yes",0.9999999996559836,3.440273674535129e-10,"No",1.8698889929528335e-16,1.0,"Yes",2.430593233666754e-06,0.9999975694067852,"Yes",1.0,1.8378287972047506e-17,"No",1.9010682512855608e-20,1.0,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2224450490627177e-44,5.031150840345773e-10,0.999999999496879,"2+",0.9999999999872103,1.2780747216086606e-11,"No",7.316251016484695e-10,0.9999999992683685,"Yes",0.9995502280806607,0.0004497719193426529,"No",2.8211159089480455e-09,0.9999999971788895,"Yes",8.008002077710332e-05,0.9999199199792306,"Yes",0.9999999933534128,6.646596573697492e-09,"No",1.8028416824250917e-10,0.9999999998197211,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATIONESTUDIO DE FASE III MULTICÉNTRICO RANDOMIZADO CON DOBLE ENMASCARAMIENTO CONTROLADO CON  SIMULACIÓN PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LAMPALIZUMAB ADMINISTRADO EN INYECCIÓN INTRAVÍTREA A PACIENTES CON ATROFIA GEOGRÁFICA SECUNDARIA A DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD .","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0134111375665547e-79,3.853942179603792e-17,1.0,"2+",1.0,2.2137564033463388e-17,"No",1.3538186075870188e-14,1.0,"Yes",0.9999999996559836,3.440273674535129e-10,"No",1.8698889929528335e-16,1.0,"Yes",2.430593233666754e-06,0.9999975694067852,"Yes",1.0,1.8378287972047506e-17,"No",1.9010682512855608e-20,1.0,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATIONESTUDIO DE FASE III MULTICÉNTRICO RANDOMIZADO CON DOBLE ENMASCARAMIENTO CONTROLADO CON  SIMULACIÓN PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LAMPALIZUMAB ADMINISTRADO EN INYECCIÓN INTRAVÍTREA A PACIENTES CON ATROFIA GEOGRÁFICA SECUNDARIA A DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD .","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0134111375665547e-79,3.853942179603792e-17,1.0,"2+",1.0,2.2137564033463388e-17,"No",1.3538186075870188e-14,1.0,"Yes",0.9999999996559836,3.440273674535129e-10,"No",1.8698889929528335e-16,1.0,"Yes",2.430593233666754e-06,0.9999975694067852,"Yes",1.0,1.8378287972047506e-17,"No",1.9010682512855608e-20,1.0,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2224450490627177e-44,5.031150840345773e-10,0.999999999496879,"2+",0.9999999999872103,1.2780747216086606e-11,"No",7.316251016484695e-10,0.9999999992683685,"Yes",0.9995502280806607,0.0004497719193426529,"No",2.8211159089480455e-09,0.9999999971788895,"Yes",8.008002077710332e-05,0.9999199199792306,"Yes",0.9999999933534128,6.646596573697492e-09,"No",1.8028416824250917e-10,0.9999999998197211,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2224450490627177e-44,5.031150840345773e-10,0.999999999496879,"2+",0.9999999999872103,1.2780747216086606e-11,"No",7.316251016484695e-10,0.9999999992683685,"Yes",0.9995502280806607,0.0004497719193426529,"No",2.8211159089480455e-09,0.9999999971788895,"Yes",8.008002077710332e-05,0.9999199199792306,"Yes",0.9999999933534128,6.646596573697492e-09,"No",1.8028416824250917e-10,0.9999999998197211,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2224450490627177e-44,5.031150840345773e-10,0.999999999496879,"2+",0.9999999999872103,1.2780747216086606e-11,"No",7.316251016484695e-10,0.9999999992683685,"Yes",0.9995502280806607,0.0004497719193426529,"No",2.8211159089480455e-09,0.9999999971788895,"Yes",8.008002077710332e-05,0.9999199199792306,"Yes",0.9999999933534128,6.646596573697492e-09,"No",1.8028416824250917e-10,0.9999999998197211,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATIONESTUDIO DE FASE III MULTICÉNTRICO RANDOMIZADO CON DOBLE ENMASCARAMIENTO CONTROLADO CON  SIMULACIÓN PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LAMPALIZUMAB ADMINISTRADO EN INYECCIÓN INTRAVÍTREA A PACIENTES CON ATROFIA GEOGRÁFICA SECUNDARIA A DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD .","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0134111375665547e-79,3.853942179603792e-17,1.0,"2+",1.0,2.2137564033463388e-17,"No",1.3538186075870188e-14,1.0,"Yes",0.9999999996559836,3.440273674535129e-10,"No",1.8698889929528335e-16,1.0,"Yes",2.430593233666754e-06,0.9999975694067852,"Yes",1.0,1.8378287972047506e-17,"No",1.9010682512855608e-20,1.0,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATIONESTUDIO DE FASE III MULTICÉNTRICO RANDOMIZADO CON DOBLE ENMASCARAMIENTO CONTROLADO CON  SIMULACIÓN PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LAMPALIZUMAB ADMINISTRADO EN INYECCIÓN INTRAVÍTREA A PACIENTES CON ATROFIA GEOGRÁFICA SECUNDARIA A DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD .","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0134111375665547e-79,3.853942179603792e-17,1.0,"2+",1.0,2.2137564033463388e-17,"No",1.3538186075870188e-14,1.0,"Yes",0.9999999996559836,3.440273674535129e-10,"No",1.8698889929528335e-16,1.0,"Yes",2.430593233666754e-06,0.9999975694067852,"Yes",1.0,1.8378287972047506e-17,"No",1.9010682512855608e-20,1.0,"Yes"
"2014-000106-35","A PHASE III MULTICENTER RANDOMIZED DOUBLE-MASKED SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.2224450490627177e-44,5.031150840345773e-10,0.999999999496879,"2+",0.9999999999872103,1.2780747216086606e-11,"No",7.316251016484695e-10,0.9999999992683685,"Yes",0.9995502280806607,0.0004497719193426529,"No",2.8211159089480455e-09,0.9999999971788895,"Yes",8.008002077710332e-05,0.9999199199792306,"Yes",0.9999999933534128,6.646596573697492e-09,"No",1.8028416824250917e-10,0.9999999998197211,"Yes"
"2014-000222-38","PERMIXON® 160 mg hard capsule versus placebo in the treatment ofsymptomatic lower urinary tract symptoms due to benign prostatichyperplasia.Single-blind placebo run-in period then double-blind randomisedmultinational multicentric placebo-controlled in 3 parallel-group comparative treatment period.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.584621470747407e-60,1.576387593266148e-18,1.0,"2+",1.0,1.8460005714495635e-19,"No",5.413771814828486e-16,1.0,"Yes",0.9998824950513838,0.0001175049486060384,"No",2.3957437451943686e-19,1.0,"Yes",4.602023663157726e-08,0.9999999539797682,"Yes",0.9999999998217676,1.7822725315105512e-10,"No",1.2737387772618935e-17,1.0,"Yes"
"2014-000222-38","PERMIXON® 160 mg hard capsule versus placebo in the treatment ofsymptomatic lower urinary tract symptoms due to benign prostatichyperplasia.Single-blind placebo run-in period then double-blind randomisedmultinational multicentric placebo-controlled in 3 parallel-group comparative treatment period.PERMIXON® 160 mg tvrdá tobolka ve srovnání s placebem v léčbě symptomatického syndromu dolních cest močových na podkladě benigní hyperplazie prostaty.Jednoduše zaslepené skríninkové období dále dvojitě zaslepené randomizované mezinárodní multicentrické placebem kontrolované do 3 paralelních skupin rozdělené srovnávací léčebné období.","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0205123047326178e-105,1.505606063946621e-36,1.0,"2+",1.0,1.8934772395632973e-37,"No",6.62680300612316e-33,1.0,"Yes",1.0,1.5072213959250667e-32,"No",7.508836143648343e-41,1.0,"Yes",2.6821636441782733e-14,1.0,"Yes",1.0,6.060132506223233e-31,"No",3.5864955107571414e-36,1.0,"Yes"
"2014-000222-38","PERMIXON® 160 mg hard capsule versus placebo in the treatment ofsymptomatic lower urinary tract symptoms due to benign prostatichyperplasia.Single-blind placebo run-in period then double-blind randomisedmultinational multicentric placebo-controlled in 3 parallel-group comparative treatment period.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.584621470747407e-60,1.576387593266148e-18,1.0,"2+",1.0,1.8460005714495635e-19,"No",5.413771814828486e-16,1.0,"Yes",0.9998824950513838,0.0001175049486060384,"No",2.3957437451943686e-19,1.0,"Yes",4.602023663157726e-08,0.9999999539797682,"Yes",0.9999999998217676,1.7822725315105512e-10,"No",1.2737387772618935e-17,1.0,"Yes"
"2014-000222-38","PERMIXON® 160 mg hard capsule versus placebo in the treatment ofsymptomatic lower urinary tract symptoms due to benign prostatichyperplasia.Single-blind placebo run-in period then double-blind randomisedmultinational multicentric placebo-controlled in 3 parallel-group comparative treatment period.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.584621470747407e-60,1.576387593266148e-18,1.0,"2+",1.0,1.8460005714495635e-19,"No",5.413771814828486e-16,1.0,"Yes",0.9998824950513838,0.0001175049486060384,"No",2.3957437451943686e-19,1.0,"Yes",4.602023663157726e-08,0.9999999539797682,"Yes",0.9999999998217676,1.7822725315105512e-10,"No",1.2737387772618935e-17,1.0,"Yes"
"2014-000222-38","PERMIXON® 160 mg hard capsule versus placebo in the treatment ofsymptomatic lower urinary tract symptoms due to benign prostatichyperplasia.Single-blind placebo run-in period then double-blind randomisedmultinational multicentric placebo-controlled in 3 parallel-group comparative treatment period.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.584621470747407e-60,1.576387593266148e-18,1.0,"2+",1.0,1.8460005714495635e-19,"No",5.413771814828486e-16,1.0,"Yes",0.9998824950513838,0.0001175049486060384,"No",2.3957437451943686e-19,1.0,"Yes",4.602023663157726e-08,0.9999999539797682,"Yes",0.9999999998217676,1.7822725315105512e-10,"No",1.2737387772618935e-17,1.0,"Yes"
"2014-000255-85","Phase 3 Study Comparing Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple MyelomaStudio di fase 3 sul confronto fra daratumumab bortezomib e desametasone (DVd) verso bortezomib e desametasone (Vd) in soggetti con mieloma multiplo recidivante o refrattario.","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.8184137877365063e-65,2.2756815535230707e-08,0.9999999772431923,"2+",9.306865992991537e-24,1.0,"Yes",1.0,1.9238060877303256e-23,"No",1.0,1.1488498385975147e-30,"No",0.0022566466396329804,0.9977433533603566,"Yes",0.9994467762272236,0.0005532237727637705,"Yes",0.9996421106493805,0.00035788935059173,"No",0.00017034564488241762,0.9998296543551441,"Yes"
"2014-000255-85","Phase 3 Study Comparing Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple MyelomaStudio di fase 3 sul confronto fra daratumumab bortezomib e desametasone (DVd) verso bortezomib e desametasone (Vd) in soggetti con mieloma multiplo recidivante o refrattario.","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.8184137877365063e-65,2.2756815535230707e-08,0.9999999772431923,"2+",9.306865992991537e-24,1.0,"Yes",1.0,1.9238060877303256e-23,"No",1.0,1.1488498385975147e-30,"No",0.0022566466396329804,0.9977433533603566,"Yes",0.9994467762272236,0.0005532237727637705,"Yes",0.9996421106493805,0.00035788935059173,"No",0.00017034564488241762,0.9998296543551441,"Yes"
"2014-000255-85","Phase 3 Study Comparing Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma","HU","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.093181344258715e-31,0.0007233205684265005,0.9992766794315769,"2+",2.537181423523298e-11,0.9999999999746336,"Yes",0.9999999999595134,4.048111139018981e-11,"No",1.0,2.428070723537831e-15,"No",0.2670312243983031,0.7329687756016922,"Yes",0.995670215219372,0.004329784780630547,"Yes",0.0037102489026975853,0.996289751097297,"No",0.01616856379727587,0.9838314362027211,"Yes"
"2014-000255-85","Phase 3 Study Comparing Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma","NL","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.093181344258715e-31,0.0007233205684265005,0.9992766794315769,"2+",2.537181423523298e-11,0.9999999999746336,"Yes",0.9999999999595134,4.048111139018981e-11,"No",1.0,2.428070723537831e-15,"No",0.2670312243983031,0.7329687756016922,"Yes",0.995670215219372,0.004329784780630547,"Yes",0.0037102489026975853,0.996289751097297,"No",0.01616856379727587,0.9838314362027211,"Yes"
"2014-000255-85","Phase 3 Study Comparing Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma","CZ","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.093181344258715e-31,0.0007233205684265005,0.9992766794315769,"2+",2.537181423523298e-11,0.9999999999746336,"Yes",0.9999999999595134,4.048111139018981e-11,"No",1.0,2.428070723537831e-15,"No",0.2670312243983031,0.7329687756016922,"Yes",0.995670215219372,0.004329784780630547,"Yes",0.0037102489026975853,0.996289751097297,"No",0.01616856379727587,0.9838314362027211,"Yes"
"2014-000255-85","Phase 3 Study Comparing Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple MyelomaStudio di fase 3 sul confronto fra daratumumab bortezomib e desametasone (DVd) verso bortezomib e desametasone (Vd) in soggetti con mieloma multiplo recidivante o refrattario.","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.8184137877365063e-65,2.2756815535230707e-08,0.9999999772431923,"2+",9.306865992991537e-24,1.0,"Yes",1.0,1.9238060877303256e-23,"No",1.0,1.1488498385975147e-30,"No",0.0022566466396329804,0.9977433533603566,"Yes",0.9994467762272236,0.0005532237727637705,"Yes",0.9996421106493805,0.00035788935059173,"No",0.00017034564488241762,0.9998296543551441,"Yes"
"2014-000255-85","Phase 3 Study Comparing Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma","IT","No","No","Yes","ok","Yes","Yes","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.093181344258715e-31,0.0007233205684265005,0.9992766794315769,"2+",2.537181423523298e-11,0.9999999999746336,"Yes",0.9999999999595134,4.048111139018981e-11,"No",1.0,2.428070723537831e-15,"No",0.2670312243983031,0.7329687756016922,"Yes",0.995670215219372,0.004329784780630547,"Yes",0.0037102489026975853,0.996289751097297,"No",0.01616856379727587,0.9838314362027211,"Yes"
"2014-000255-85","Phase 3 Study Comparing Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple MyelomaStudio di fase 3 sul confronto fra daratumumab bortezomib e desametasone (DVd) verso bortezomib e desametasone (Vd) in soggetti con mieloma multiplo recidivante o refrattario.","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.8184137877365063e-65,2.2756815535230707e-08,0.9999999772431923,"2+",9.306865992991537e-24,1.0,"Yes",1.0,1.9238060877303256e-23,"No",1.0,1.1488498385975147e-30,"No",0.0022566466396329804,0.9977433533603566,"Yes",0.9994467762272236,0.0005532237727637705,"Yes",0.9996421106493805,0.00035788935059173,"No",0.00017034564488241762,0.9998296543551441,"Yes"
"2014-000331-16","A Phase 2 Multi-Center Randomised Double-Blind Ascending-Dose Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.4107460631786633e-41,3.9123890183886453e-10,0.999999999608761,"2+",0.9999999998650537,1.3494302390299722e-10,"No",7.314700349146537e-10,0.9999999992685247,"Yes",0.9999997959280829,2.040719156951137e-07,"No",1.5005262803805026e-08,0.9999999849947303,"Yes",0.4823546552762822,0.5176453447237132,"Yes",0.9992037242425719,0.0007962757574267886,"No",2.221356468347031e-07,0.9999997778643567,"Yes"
"2014-000331-16","A Phase 2 Multi-Center Randomised Double-Blind Ascending-Dose Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","No","2+","Yes",1.4107460631786633e-41,3.9123890183886453e-10,0.999999999608761,"2+",0.9999999998650537,1.3494302390299722e-10,"No",7.314700349146537e-10,0.9999999992685247,"Yes",0.9999997959280829,2.040719156951137e-07,"No",1.5005262803805026e-08,0.9999999849947303,"Yes",0.4823546552762822,0.5176453447237132,"Yes",0.9992037242425719,0.0007962757574267886,"No",2.221356468347031e-07,0.9999997778643567,"Yes"
"2014-000382-41","A randomized double-blind double-dummy active-comparator multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.906852100309277e-38,6.521400271602984e-14,0.9999999999999291,"2+",0.9999999996091873,3.9081528732978143e-10,"No",4.714339915873029e-09,0.9999999952856627,"Yes",0.9999999985595879,1.44041639360297e-09,"No",7.929761753842452e-14,0.9999999999999147,"Yes",0.0016332944656600153,0.9983667055343429,"Yes",0.9999994536872167,5.463127864757007e-07,"No",2.3377873511803988e-11,0.9999999999766231,"Yes"
"2014-000382-41","A randomized double-blind double-dummy active-comparator multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.906852100309277e-38,6.521400271602984e-14,0.9999999999999291,"2+",0.9999999996091873,3.9081528732978143e-10,"No",4.714339915873029e-09,0.9999999952856627,"Yes",0.9999999985595879,1.44041639360297e-09,"No",7.929761753842452e-14,0.9999999999999147,"Yes",0.0016332944656600153,0.9983667055343429,"Yes",0.9999994536872167,5.463127864757007e-07,"No",2.3377873511803988e-11,0.9999999999766231,"Yes"
"2014-000382-41","A randomized double-blind double-dummy active-comparator multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.906852100309277e-38,6.521400271602984e-14,0.9999999999999291,"2+",0.9999999996091873,3.9081528732978143e-10,"No",4.714339915873029e-09,0.9999999952856627,"Yes",0.9999999985595879,1.44041639360297e-09,"No",7.929761753842452e-14,0.9999999999999147,"Yes",0.0016332944656600153,0.9983667055343429,"Yes",0.9999994536872167,5.463127864757007e-07,"No",2.3377873511803988e-11,0.9999999999766231,"Yes"
"2014-000382-41","A randomized double-blind double-dummy active-comparator multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.906852100309277e-38,6.521400271602984e-14,0.9999999999999291,"2+",0.9999999996091873,3.9081528732978143e-10,"No",4.714339915873029e-09,0.9999999952856627,"Yes",0.9999999985595879,1.44041639360297e-09,"No",7.929761753842452e-14,0.9999999999999147,"Yes",0.0016332944656600153,0.9983667055343429,"Yes",0.9999994536872167,5.463127864757007e-07,"No",2.3377873511803988e-11,0.9999999999766231,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismTöbbcentrumos nyílt aktív kontrollos randomizált vizsgálat az életkor és testtömeg szerint korrigált dózisú rivaroxaban-kezelés hatásosságának és biztonságosságának értékelésére akut vénás tromboembólián átesett gyermekeknél a szokásos kezeléssel összehasonlítva","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.069010135195178e-65,1.3396356674803818e-15,1.0,"2+",0.2624109971112916,0.7375890028886823,"Yes",0.9708143568178391,0.029185643182171685,"No",0.9999999999760689,2.3957063865428328e-11,"No",1.0088416087327391e-17,1.0,"Yes",0.002678167047243458,0.9973218329527297,"No",1.0,1.8967254156876075e-21,"No",1.5986976193230196e-16,1.0,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismTöbbcentrumos nyílt aktív kontrollos randomizált vizsgálat az életkor és testtömeg szerint korrigált dózisú rivaroxaban-kezelés hatásosságának és biztonságosságának értékelésére akut vénás tromboembólián átesett gyermekeknél a szokásos kezeléssel összehasonlítva","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.069010135195178e-65,1.3396356674803818e-15,1.0,"2+",0.2624109971112916,0.7375890028886823,"Yes",0.9708143568178391,0.029185643182171685,"No",0.9999999999760689,2.3957063865428328e-11,"No",1.0088416087327391e-17,1.0,"Yes",0.002678167047243458,0.9973218329527297,"No",1.0,1.8967254156876075e-21,"No",1.5986976193230196e-16,1.0,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1620025583514459e-36,1.7793418933926282e-06,0.9999982206581052,"2+",1.856764949746158e-05,0.9999814323504983,"Yes",0.9999815856027797,1.841439721779349e-05,"No",0.9999999998766215,1.2337172928271383e-10,"No",1.015056382674736e-06,0.9999989849436056,"Yes",0.5459124533566443,0.4540875466433417,"No",0.9999999999997442,2.5117936486219375e-13,"No",5.590854388898349e-07,0.9999994409145501,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism","FI","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1620025583514459e-36,1.7793418933926282e-06,0.9999982206581052,"2+",1.856764949746158e-05,0.9999814323504983,"Yes",0.9999815856027797,1.841439721779349e-05,"No",0.9999999998766215,1.2337172928271383e-10,"No",1.015056382674736e-06,0.9999989849436056,"Yes",0.5459124533566443,0.4540875466433417,"No",0.9999999999997442,2.5117936486219375e-13,"No",5.590854388898349e-07,0.9999994409145501,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1620025583514459e-36,1.7793418933926282e-06,0.9999982206581052,"2+",1.856764949746158e-05,0.9999814323504983,"Yes",0.9999815856027797,1.841439721779349e-05,"No",0.9999999998766215,1.2337172928271383e-10,"No",1.015056382674736e-06,0.9999989849436056,"Yes",0.5459124533566443,0.4540875466433417,"No",0.9999999999997442,2.5117936486219375e-13,"No",5.590854388898349e-07,0.9999994409145501,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismTöbbcentrumos nyílt aktív kontrollos randomizált vizsgálat az életkor és testtömeg szerint korrigált dózisú rivaroxaban-kezelés hatásosságának és biztonságosságának értékelésére akut vénás tromboembólián átesett gyermekeknél a szokásos kezeléssel összehasonlítva","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.069010135195178e-65,1.3396356674803818e-15,1.0,"2+",0.2624109971112916,0.7375890028886823,"Yes",0.9708143568178391,0.029185643182171685,"No",0.9999999999760689,2.3957063865428328e-11,"No",1.0088416087327391e-17,1.0,"Yes",0.002678167047243458,0.9973218329527297,"No",1.0,1.8967254156876075e-21,"No",1.5986976193230196e-16,1.0,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismEnsayo clínico multicéntrico aleatorizado abierto controlado con comparador activo para evaluar la eficacia y la seguridad de rivaroxaban a un régimen de dosis ajustado según la edad y el peso en niños con tromboembolismo venoso agudo","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6480739938326746e-69,4.868792992220638e-15,1.0,"2+",4.517618206100016e-06,0.9999954823818211,"Yes",0.9999990443020599,9.556979223249529e-07,"No",0.9999999999997727,2.0854689706392954e-13,"No",7.242076423825317e-15,1.0,"Yes",0.0018596638212410822,0.9981403361787654,"No",1.0,4.749927820828217e-25,"No",1.557900840416908e-13,0.9999999999998295,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismMulticentrické nezaslepené randomizované klinické skúšanie kontrolované účinnou látkou s cieľom vyhodnotiť účinnosť a bezpečnosť rivaroxabanu podávaného v dávke upravenej podľa veku a telesnej hmotnosti a v porovnaní so štandardnou starostlivosťou u detí s akútnym venóznym tromboembolizmom","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.431891884935691e-75,3.0569631059596615e-19,1.0,"2+",0.9958898542751434,0.004110145724833688,"Yes",0.0010232553021411002,0.9989767446978828,"No",1.0,7.257036798884989e-33,"No",4.889561926885616e-25,1.0,"Yes",0.9582490293223668,0.04175097067763241,"No",1.0,1.4093557177933895e-34,"No",3.076238108208805e-20,1.0,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismEnsaio multicêntrico aberto controlado com substância ativa e aleatorizado para avaliar a eficácia e segurança de um regime de rivaroxabano ajustado à idade e ao peso corporal em comparação com o tratamento padrão em crianças com tromboembolismo venoso agudo.","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.8316613819008104e-74,1.72710841699566e-15,1.0,"2+",6.793859427478922e-07,0.999999320614055,"Yes",0.9999996749091298,3.2509087435061457e-07,"No",1.0,4.6939005288278937e-17,"No",2.640179579144018e-15,1.0,"Yes",9.787413724951143e-05,0.9999021258627365,"No",1.0,5.901508436287748e-21,"No",1.702213863545601e-14,1.0,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismEnsaio multicêntrico aberto controlado com substância ativa e aleatorizado para avaliar a eficácia e segurança de um regime de rivaroxabano ajustado à idade e ao peso corporal em comparação com o tratamento padrão em crianças com tromboembolismo venoso agudo.","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.8316613819008104e-74,1.72710841699566e-15,1.0,"2+",6.793859427478922e-07,0.999999320614055,"Yes",0.9999996749091298,3.2509087435061457e-07,"No",1.0,4.6939005288278937e-17,"No",2.640179579144018e-15,1.0,"Yes",9.787413724951143e-05,0.9999021258627365,"No",1.0,5.901508436287748e-21,"No",1.702213863545601e-14,1.0,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismTöbbcentrumos nyílt aktív kontrollos randomizált vizsgálat az életkor és testtömeg szerint korrigált dózisú rivaroxaban-kezelés hatásosságának és biztonságosságának értékelésére akut vénás tromboembólián átesett gyermekeknél a szokásos kezeléssel összehasonlítva","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.069010135195178e-65,1.3396356674803818e-15,1.0,"2+",0.2624109971112916,0.7375890028886823,"Yes",0.9708143568178391,0.029185643182171685,"No",0.9999999999760689,2.3957063865428328e-11,"No",1.0088416087327391e-17,1.0,"Yes",0.002678167047243458,0.9973218329527297,"No",1.0,1.8967254156876075e-21,"No",1.5986976193230196e-16,1.0,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismTöbbcentrumos nyílt aktív kontrollos randomizált vizsgálat az életkor és testtömeg szerint korrigált dózisú rivaroxaban-kezelés hatásosságának és biztonságosságának értékelésére akut vénás tromboembólián átesett gyermekeknél a szokásos kezeléssel összehasonlítva","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.069010135195178e-65,1.3396356674803818e-15,1.0,"2+",0.2624109971112916,0.7375890028886823,"Yes",0.9708143568178391,0.029185643182171685,"No",0.9999999999760689,2.3957063865428328e-11,"No",1.0088416087327391e-17,1.0,"Yes",0.002678167047243458,0.9973218329527297,"No",1.0,1.8967254156876075e-21,"No",1.5986976193230196e-16,1.0,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismEnsayo clínico multicéntrico aleatorizado abierto controlado con comparador activo para evaluar la eficacia y la seguridad de rivaroxaban a un régimen de dosis ajustado según la edad y el peso en niños con tromboembolismo venoso agudo","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6480739938326746e-69,4.868792992220638e-15,1.0,"2+",4.517618206100016e-06,0.9999954823818211,"Yes",0.9999990443020599,9.556979223249529e-07,"No",0.9999999999997727,2.0854689706392954e-13,"No",7.242076423825317e-15,1.0,"Yes",0.0018596638212410822,0.9981403361787654,"No",1.0,4.749927820828217e-25,"No",1.557900840416908e-13,0.9999999999998295,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolismTöbbcentrumos nyílt aktív kontrollos randomizált vizsgálat az életkor és testtömeg szerint korrigált dózisú rivaroxaban-kezelés hatásosságának és biztonságosságának értékelésére akut vénás tromboembólián átesett gyermekeknél a szokásos kezeléssel összehasonlítva","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.069010135195178e-65,1.3396356674803818e-15,1.0,"2+",0.2624109971112916,0.7375890028886823,"Yes",0.9708143568178391,0.029185643182171685,"No",0.9999999999760689,2.3957063865428328e-11,"No",1.0088416087327391e-17,1.0,"Yes",0.002678167047243458,0.9973218329527297,"No",1.0,1.8967254156876075e-21,"No",1.5986976193230196e-16,1.0,"Yes"
"2014-000565-47","Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism","SK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1620025583514459e-36,1.7793418933926282e-06,0.9999982206581052,"2+",1.856764949746158e-05,0.9999814323504983,"Yes",0.9999815856027797,1.841439721779349e-05,"No",0.9999999998766215,1.2337172928271383e-10,"No",1.015056382674736e-06,0.9999989849436056,"Yes",0.5459124533566443,0.4540875466433417,"No",0.9999999999997442,2.5117936486219375e-13,"No",5.590854388898349e-07,0.9999994409145501,"Yes"
"2014-000566-22","30-day open-label active-controlled randomized study of the safety efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosisEnsayo clínico aleatorizado abierto  controlado con comparador activo  para evaluar la seguridad la eficacia y las propiedades farmacocinéticas y farmacodinámicas de rivaroxaban oral durante 30 días de tratamiento en  niños con manifestaciones diversas de trombosis venosa","FI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",2.1936745076598046e-58,1.9721650788594933e-14,1.0,"2+",3.801890053048307e-05,0.9999619810994613,"Yes",0.9999783499704334,2.1650029549415155e-05,"No",1.0,4.581748870011632e-16,"No",1.4447477249199158e-11,0.9999999999855619,"No",0.009109287077929362,0.9908907129220953,"No",0.9999999999993748,6.105456728537805e-13,"No",2.945771478202527e-11,0.9999999999705552,"No"
"2014-000566-22","30-day single arm study of the safety efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis","IE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.444006136508527e-23,0.001919684976582795,0.9980803150234132,"2+",0.06277340100750643,0.9372265989924936,"Yes",0.9715056133632387,0.02849438663676164,"No",0.9999999573556987,4.2644312882181785e-08,"No",0.016667103848003538,0.9833328961519942,"No",0.9526726525307713,0.0473273474692344,"No",0.9999997237312455,2.762687615845992e-07,"No",0.010927440037975822,0.9890725599620181,"No"
"2014-000566-22","30-day single-arm study of the safety efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.444006136508527e-23,0.001919684976582795,0.9980803150234132,"2+",0.06277340100750643,0.9372265989924936,"Yes",0.9715056133632387,0.02849438663676164,"No",0.9999999573556987,4.2644312882181785e-08,"No",0.016667103848003538,0.9833328961519942,"No",0.9526726525307713,0.0473273474692344,"No",0.9999997237312455,2.762687615845992e-07,"No",0.010927440037975822,0.9890725599620181,"No"
"2014-000566-22","30-day single arm study of the safety efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.444006136508527e-23,0.001919684976582795,0.9980803150234132,"2+",0.06277340100750643,0.9372265989924936,"Yes",0.9715056133632387,0.02849438663676164,"No",0.9999999573556987,4.2644312882181785e-08,"No",0.016667103848003538,0.9833328961519942,"No",0.9526726525307713,0.0473273474692344,"No",0.9999997237312455,2.762687615845992e-07,"No",0.010927440037975822,0.9890725599620181,"No"
"2014-000566-22","30-day open-label active-controlled randomized study of the safety efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosisEnsayo clínico aleatorizado abierto  controlado con comparador activo  para evaluar la seguridad la eficacia y las propiedades farmacocinéticas y farmacodinámicas de rivaroxaban oral durante 30 días de tratamiento en  niños con manifestaciones diversas de trombosis venosa","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",2.1936745076598046e-58,1.9721650788594933e-14,1.0,"2+",3.801890053048307e-05,0.9999619810994613,"Yes",0.9999783499704334,2.1650029549415155e-05,"No",1.0,4.581748870011632e-16,"No",1.4447477249199158e-11,0.9999999999855619,"No",0.009109287077929362,0.9908907129220953,"No",0.9999999999993748,6.105456728537805e-13,"No",2.945771478202527e-11,0.9999999999705552,"No"
"2014-000566-22","30-day single-arm study of the safety efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.444006136508527e-23,0.001919684976582795,0.9980803150234132,"2+",0.06277340100750643,0.9372265989924936,"Yes",0.9715056133632387,0.02849438663676164,"No",0.9999999573556987,4.2644312882181785e-08,"No",0.016667103848003538,0.9833328961519942,"No",0.9526726525307713,0.0473273474692344,"No",0.9999997237312455,2.762687615845992e-07,"No",0.010927440037975822,0.9890725599620181,"No"
"2014-000566-22","30-day single-arm study of the safety efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",1.444006136508527e-23,0.001919684976582795,0.9980803150234132,"2+",0.06277340100750643,0.9372265989924936,"Yes",0.9715056133632387,0.02849438663676164,"No",0.9999999573556987,4.2644312882181785e-08,"No",0.016667103848003538,0.9833328961519942,"No",0.9526726525307713,0.0473273474692344,"No",0.9999997237312455,2.762687615845992e-07,"No",0.010927440037975822,0.9890725599620181,"No"
"2014-000566-22","30-day open-label active-controlled randomized study of the safety efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosisEnsayo clínico aleatorizado abierto  controlado con comparador activo  para evaluar la seguridad la eficacia y las propiedades farmacocinéticas y farmacodinámicas de rivaroxaban oral durante 30 días de tratamiento en  niños con manifestaciones diversas de trombosis venosa","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",2.1936745076598046e-58,1.9721650788594933e-14,1.0,"2+",3.801890053048307e-05,0.9999619810994613,"Yes",0.9999783499704334,2.1650029549415155e-05,"No",1.0,4.581748870011632e-16,"No",1.4447477249199158e-11,0.9999999999855619,"No",0.009109287077929362,0.9908907129220953,"No",0.9999999999993748,6.105456728537805e-13,"No",2.945771478202527e-11,0.9999999999705552,"No"
"2014-000566-22","30-day open-label active-controlled randomized study of the safety efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosisEnsayo clínico aleatorizado abierto  controlado con comparador activo  para evaluar la seguridad la eficacia y las propiedades farmacocinéticas y farmacodinámicas de rivaroxaban oral durante 30 días de tratamiento en  niños con manifestaciones diversas de trombosis venosa","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",2.1936745076598046e-58,1.9721650788594933e-14,1.0,"2+",3.801890053048307e-05,0.9999619810994613,"Yes",0.9999783499704334,2.1650029549415155e-05,"No",1.0,4.581748870011632e-16,"No",1.4447477249199158e-11,0.9999999999855619,"No",0.009109287077929362,0.9908907129220953,"No",0.9999999999993748,6.105456728537805e-13,"No",2.945771478202527e-11,0.9999999999705552,"No"
"2014-000569-35","A prospective open-label multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 maintenance in CLL patients (CLL2-BIG protocol)","DE","No","No","Yes","ok","No","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",3.7134019863323376e-42,0.8699432639217685,0.1300567360782343,"1",2.3488814619896495e-13,0.9999999999997727,"Yes",0.9999999999994601,5.372586234445936e-13,"No",1.0,1.6600940538615952e-20,"No",0.0005251168788286675,0.9994748831211775,"No",0.9941552535896673,0.005844746410338173,"No",1.0,3.618871065183278e-19,"No",0.5615508959102578,0.43844910408975074,"No"
"2014-000907-29","Efficacy and safety of Sinusitis Hevert SL tablets compared to placebo in adult patients with acute uncomplicated rhinosinusitis.A multicenter randomized double-blind placebo-controlled parallel group phase IV study.Wirksamkeit und Sicherheit von Sinusitis Hevert SL Tabletten im Vergleich zu Placebo bei erwachsenen Patienten mit akuter unkomplizierter Rhinosinusitis.Eine multizentrische randomisierte doppelblinde placebo-kontrollierte Parallelgruppen-Phase-IV-Studie.","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.988933174020274e-95,6.0456630489132544e-21,1.0,"2+",1.0,4.044994919379761e-20,"No",2.0711122683958542e-17,1.0,"Yes",0.999999841972807,1.580271754119397e-07,"No",5.834796756290453e-22,1.0,"Yes",0.0005652413615277055,0.9994347586384608,"Yes",0.9999999570689521,4.293104223753587e-08,"No",3.980234231147025e-17,1.0,"Yes"
"2014-000907-29","Efficacy and safety of Sinusitis Hevert SL tablets compared to placebo in adult patients with acute uncomplicated rhinosinusitis.A multicenter randomized double-blind placebo-controlled parallel group phase IV study.Wirksamkeit und Sicherheit von Sinusitis Hevert SL Tabletten im Vergleich zu Placebo bei erwachsenen Patienten mit akuter unkomplizierter Rhinosinusitis.Eine multizentrische randomisierte doppelblinde placebo-kontrollierte Parallelgruppen-Phase-IV-Studie.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.988933174020274e-95,6.0456630489132544e-21,1.0,"2+",1.0,4.044994919379761e-20,"No",2.0711122683958542e-17,1.0,"Yes",0.999999841972807,1.580271754119397e-07,"No",5.834796756290453e-22,1.0,"Yes",0.0005652413615277055,0.9994347586384608,"Yes",0.9999999570689521,4.293104223753587e-08,"No",3.980234231147025e-17,1.0,"Yes"
"2014-001280-13","An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled in Study A536-03","DE","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",9.57791844825807e-32,0.9997383178861875,0.00026168211380562856,"-1",1.2137002135592268e-05,0.9999878629978546,"Yes",0.9999854835603852,1.451643960992804e-05,"No",1.0,3.6208965501769005e-16,"No",0.9995642584128138,0.00043574158717977254,"No",0.11661184058354856,0.8833881594164567,"No",0.9999999999979252,2.078134760551883e-12,"No",0.9998537184665214,0.00014628153348389777,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyCheckMate 172: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 172","HU","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.5140218725173559e-61,0.9999963814200997,3.618579910911007e-06,"1",1.3458692020292487e-13,0.9999999999998579,"Yes",0.9999999999998579,1.508571627689393e-13,"No",1.0,1.506374397633374e-25,"No",0.9999992771979916,7.228020091653828e-07,"No",0.9999575040201812,4.249597981115374e-05,"No",1.0,1.502823188749109e-20,"No",0.9999976884174658,2.3115825249919617e-06,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyStudio clinico multicentrico a braccio singolo in aperto con Nivolumab (BMS-936558) in soggetti con melanoma in stadio III (non resecabile) confermato istologicamente o in stadio IV in progressione dopo un precedente trattamento contenente un anticorpo monoclonale anti-CTLA-4","SE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",7.049680631322265e-95,0.9999986766100282,1.323389978037375e-06,"1",2.390427452532622e-22,1.0,"Yes",1.0,1.8242730782689027e-22,"No",1.0,1.0140521622818364e-42,"No",0.9999998241372778,1.758626998508983e-07,"No",0.9999999533050652,4.669495106154536e-08,"No",1.0,7.407531202941595e-40,"No",0.9999998068964446,1.9310353228795735e-07,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III(unresectable) or Stage IV Melanoma Progressing After Prior TreatmentContaining an Anti-CTLA-4 Monoclonal Antibody","GR","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",2.0544689139014743e-49,0.9992952775613902,0.0007047224386009893,"1",1.2524637328129223e-10,0.9999999998747455,"Yes",0.9999999998305782,1.6943079080382078e-10,"No",1.0,4.9998437853213015e-23,"No",0.9998731226320564,0.00012687736793619818,"No",0.9994220108076961,0.00057798919230463,"No",1.0,1.2749930199061855e-17,"No",0.9996629047129583,0.0003370952870515089,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyCheckMate 172: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 172","NL","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.5140218725173559e-61,0.9999963814200997,3.618579910911007e-06,"1",1.3458692020292487e-13,0.9999999999998579,"Yes",0.9999999999998579,1.508571627689393e-13,"No",1.0,1.506374397633374e-25,"No",0.9999992771979916,7.228020091653828e-07,"No",0.9999575040201812,4.249597981115374e-05,"No",1.0,1.502823188749109e-20,"No",0.9999976884174658,2.3115825249919617e-06,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyCheckMate 172: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 172","AT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.5140218725173559e-61,0.9999963814200997,3.618579910911007e-06,"1",1.3458692020292487e-13,0.9999999999998579,"Yes",0.9999999999998579,1.508571627689393e-13,"No",1.0,1.506374397633374e-25,"No",0.9999992771979916,7.228020091653828e-07,"No",0.9999575040201812,4.249597981115374e-05,"No",1.0,1.502823188749109e-20,"No",0.9999976884174658,2.3115825249919617e-06,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyStudio clinico multicentrico a braccio singolo in aperto con Nivolumab (BMS-936558) in soggetti con melanoma in stadio III (non resecabile) confermato istologicamente o in stadio IV in progressione dopo un precedente trattamento contenente un anticorpo monoclonale anti-CTLA-4","PL","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",7.049680631322265e-95,0.9999986766100282,1.323389978037375e-06,"1",2.390427452532622e-22,1.0,"Yes",1.0,1.8242730782689027e-22,"No",1.0,1.0140521622818364e-42,"No",0.9999998241372778,1.758626998508983e-07,"No",0.9999999533050652,4.669495106154536e-08,"No",1.0,7.407531202941595e-40,"No",0.9999998068964446,1.9310353228795735e-07,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III(unresectable) or Stage IV Melanoma Progressing After Prior TreatmentContaining an Anti-CTLA-4 Monoclonal Antibody","IE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",2.0544689139014743e-49,0.9992952775613902,0.0007047224386009893,"1",1.2524637328129223e-10,0.9999999998747455,"Yes",0.9999999998305782,1.6943079080382078e-10,"No",1.0,4.9998437853213015e-23,"No",0.9998731226320564,0.00012687736793619818,"No",0.9994220108076961,0.00057798919230463,"No",1.0,1.2749930199061855e-17,"No",0.9996629047129583,0.0003370952870515089,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyA nivolumab (BMS-936558) egykaros nyílt multicentrikus klinikai vizsgálata szövettanilag igazolt III-as (nem eltávolítható) vagy IV-es stádiumú anti-CTLA-4 monoklonális antitestet tartalmazó korábbi kezelés után progrediáló melanomában szenvedő betegeken","BE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",2.0172181877373065e-84,0.9999990614966093,9.3850341595972e-07,"1",4.0547454602883705e-18,1.0,"Yes",1.0,4.753927349842879e-18,"No",1.0,1.6785713193935062e-37,"No",0.9999971062909854,2.8937090300716703e-06,"No",0.9999783247576265,2.1675242374759465e-05,"No",1.0,4.3383847922911116e-26,"No",0.9999842492483829,1.575075161601666e-05,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyStudio clinico multicentrico a braccio singolo in aperto con Nivolumab (BMS-936558) in soggetti con melanoma in stadio III (non resecabile) confermato istologicamente o in stadio IV in progressione dopo un precedente trattamento contenente un anticorpo monoclonale anti-CTLA-4","ES","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",7.049680631322265e-95,0.9999986766100282,1.323389978037375e-06,"1",2.390427452532622e-22,1.0,"Yes",1.0,1.8242730782689027e-22,"No",1.0,1.0140521622818364e-42,"No",0.9999998241372778,1.758626998508983e-07,"No",0.9999999533050652,4.669495106154536e-08,"No",1.0,7.407531202941595e-40,"No",0.9999998068964446,1.9310353228795735e-07,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyCheckMate 172: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 172","PT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.5140218725173559e-61,0.9999963814200997,3.618579910911007e-06,"1",1.3458692020292487e-13,0.9999999999998579,"Yes",0.9999999999998579,1.508571627689393e-13,"No",1.0,1.506374397633374e-25,"No",0.9999992771979916,7.228020091653828e-07,"No",0.9999575040201812,4.249597981115374e-05,"No",1.0,1.502823188749109e-20,"No",0.9999976884174658,2.3115825249919617e-06,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyCheckMate 172: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 172","IT","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.5140218725173559e-61,0.9999963814200997,3.618579910911007e-06,"1",1.3458692020292487e-13,0.9999999999998579,"Yes",0.9999999999998579,1.508571627689393e-13,"No",1.0,1.506374397633374e-25,"No",0.9999992771979916,7.228020091653828e-07,"No",0.9999575040201812,4.249597981115374e-05,"No",1.0,1.502823188749109e-20,"No",0.9999976884174658,2.3115825249919617e-06,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyJednoramenné otevřené multicentrické klinické hodnocení s přípravkem nivolumab (BMS-936558) pro pacienty s histologicky potvrzeným melanomem ve stadiu III (neresektabilním) nebo stádiu IV progredujícím po předchozí léčbě obsahující Anti-CTLA-4 monoklonální protilátku.","CZ","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",5.019865133441266e-94,0.9710012288597416,0.028998771140234355,"1",5.809569669429572e-14,0.9999999999999432,"Yes",0.9999999999997727,2.4576449866089837e-13,"No",1.0,6.431361643726519e-50,"No",0.9786242161776126,0.02137578382237327,"No",0.9996706344764018,0.0003293655235717585,"No",1.0,4.200750670876795e-40,"No",0.8775002302066437,0.12249976979336012,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyStudio clinico multicentrico a braccio singolo in aperto con Nivolumab (BMS-936558) in soggetti con melanoma in stadio III (non resecabile) confermato istologicamente o in stadio IV in progressione dopo un precedente trattamento contenente un anticorpo monoclonale anti-CTLA-4","GB","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",7.049680631322265e-95,0.9999986766100282,1.323389978037375e-06,"1",2.390427452532622e-22,1.0,"Yes",1.0,1.8242730782689027e-22,"No",1.0,1.0140521622818364e-42,"No",0.9999998241372778,1.758626998508983e-07,"No",0.9999999533050652,4.669495106154536e-08,"No",1.0,7.407531202941595e-40,"No",0.9999998068964446,1.9310353228795735e-07,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyCheckMate 172: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 172","DE","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.5140218725173559e-61,0.9999963814200997,3.618579910911007e-06,"1",1.3458692020292487e-13,0.9999999999998579,"Yes",0.9999999999998579,1.508571627689393e-13,"No",1.0,1.506374397633374e-25,"No",0.9999992771979916,7.228020091653828e-07,"No",0.9999575040201812,4.249597981115374e-05,"No",1.0,1.502823188749109e-20,"No",0.9999976884174658,2.3115825249919617e-06,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS936558) for Subjects with Histologically Confirmed Stage III(unresectable) or Stage IV Melanoma Progressing After Prior TreatmentContaining an Anti-CTLA-4 Monoclonal Antibody ","DK","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.825834205002123e-45,0.994578093553762,0.00542190644623466,"1",3.0237769438458295e-09,0.9999999969762144,"Yes",0.9999999963677056,3.6323080574262977e-09,"No",1.0,6.795869079966852e-19,"No",0.9986556474755441,0.0013443525244532521,"No",0.9994866890540667,0.0005133109459214211,"No",0.9999999999998579,1.550811025918527e-13,"No",0.9972586202946123,0.0027413797053998713,"No"
"2014-001286-28","A Single-Arm Open-Label Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal AntibodyCheckMate 172: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 172","FI","No","No","Yes","ok","No","No","No","No","1","","","Yes","No","No","No","No","No","1","No",1.5140218725173559e-61,0.9999963814200997,3.618579910911007e-06,"1",1.3458692020292487e-13,0.9999999999998579,"Yes",0.9999999999998579,1.508571627689393e-13,"No",1.0,1.506374397633374e-25,"No",0.9999992771979916,7.228020091653828e-07,"No",0.9999575040201812,4.249597981115374e-05,"No",1.0,1.502823188749109e-20,"No",0.9999976884174658,2.3115825249919617e-06,"No"
"2014-001363-12","autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized EuropeanMCL Network trialProtocolo TRIANGLE del European MCL Network- Estudio Aleatorizado con Régimen de Inducción Combinando Rituximab/Ibrutinib/ara-C seguido de Trasplante Autólogo en Linfoma de Células del Manto Diseminado","SE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.659748093014017e-58,0.9989906911269258,0.0010093088730925971,"2+",3.9404487071879106e-11,0.9999999999606076,"Yes",0.9999999999781153,2.1879647005711656e-11,"No",1.0,1.4514168177000775e-27,"No",0.9783802505992951,0.021619749400726498,"Yes",0.9999999938407315,6.159241960964124e-09,"No",1.0,7.19016200108118e-33,"No",0.9998922982323456,0.00010770176764035756,"Yes"
"2014-001363-12","Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction  in Generalized mantle cell Lymphoma – a randomized European MCL Network trial","PL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3370848731868806e-32,0.9884059078064718,0.011594092193516183,"2+",1.3154435836120567e-05,0.9999868455641708,"Yes",0.9999915023899555,8.497610033955181e-06,"No",1.0,9.246147172219103e-15,"No",0.8140688231906349,0.18593117680935112,"Yes",0.9999928339727944,7.166027200859524e-06,"No",1.0,4.728779096564169e-15,"No",0.989360871100308,0.010639128899689324,"Yes"
"2014-001363-12","Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction  in Generalized mantle cell Lymphoma – a randomized European MCL Network trial","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3370848731868806e-32,0.9884059078064718,0.011594092193516183,"2+",1.3154435836120567e-05,0.9999868455641708,"Yes",0.9999915023899555,8.497610033955181e-06,"No",1.0,9.246147172219103e-15,"No",0.8140688231906349,0.18593117680935112,"Yes",0.9999928339727944,7.166027200859524e-06,"No",1.0,4.728779096564169e-15,"No",0.989360871100308,0.010639128899689324,"Yes"
"2014-001363-12","autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized EuropeanMCL Network trialProtocolo TRIANGLE del European MCL Network- Estudio Aleatorizado con Régimen de Inducción Combinando Rituximab/Ibrutinib/ara-C seguido de Trasplante Autólogo en Linfoma de Células del Manto Diseminado","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.659748093014017e-58,0.9989906911269258,0.0010093088730925971,"2+",3.9404487071879106e-11,0.9999999999606076,"Yes",0.9999999999781153,2.1879647005711656e-11,"No",1.0,1.4514168177000775e-27,"No",0.9783802505992951,0.021619749400726498,"Yes",0.9999999938407315,6.159241960964124e-09,"No",1.0,7.19016200108118e-33,"No",0.9998922982323456,0.00010770176764035756,"Yes"
"2014-001363-12","autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized EuropeanMCL Network trialProtocolo TRIANGLE del European MCL Network- Estudio Aleatorizado con Régimen de Inducción Combinando Rituximab/Ibrutinib/ara-C seguido de Trasplante Autólogo en Linfoma de Células del Manto Diseminado","FI","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.659748093014017e-58,0.9989906911269258,0.0010093088730925971,"2+",3.9404487071879106e-11,0.9999999999606076,"Yes",0.9999999999781153,2.1879647005711656e-11,"No",1.0,1.4514168177000775e-27,"No",0.9783802505992951,0.021619749400726498,"Yes",0.9999999938407315,6.159241960964124e-09,"No",1.0,7.19016200108118e-33,"No",0.9998922982323456,0.00010770176764035756,"Yes"
"2014-001363-12","autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized EuropeanMCL Network trialProtocolo TRIANGLE del European MCL Network- Estudio Aleatorizado con Régimen de Inducción Combinando Rituximab/Ibrutinib/ara-C seguido de Trasplante Autólogo en Linfoma de Células del Manto Diseminado","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.659748093014017e-58,0.9989906911269258,0.0010093088730925971,"2+",3.9404487071879106e-11,0.9999999999606076,"Yes",0.9999999999781153,2.1879647005711656e-11,"No",1.0,1.4514168177000775e-27,"No",0.9783802505992951,0.021619749400726498,"Yes",0.9999999938407315,6.159241960964124e-09,"No",1.0,7.19016200108118e-33,"No",0.9998922982323456,0.00010770176764035756,"Yes"
"2014-001363-12","autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized EuropeanMCL Network trialProtocolo TRIANGLE del European MCL Network- Estudio Aleatorizado con Régimen de Inducción Combinando Rituximab/Ibrutinib/ara-C seguido de Trasplante Autólogo en Linfoma de Células del Manto Diseminado","CZ","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.659748093014017e-58,0.9989906911269258,0.0010093088730925971,"2+",3.9404487071879106e-11,0.9999999999606076,"Yes",0.9999999999781153,2.1879647005711656e-11,"No",1.0,1.4514168177000775e-27,"No",0.9783802505992951,0.021619749400726498,"Yes",0.9999999938407315,6.159241960964124e-09,"No",1.0,7.19016200108118e-33,"No",0.9998922982323456,0.00010770176764035756,"Yes"
"2014-001363-12","autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized EuropeanMCL Network trialProtocolo TRIANGLE del European MCL Network- Estudio Aleatorizado con Régimen de Inducción Combinando Rituximab/Ibrutinib/ara-C seguido de Trasplante Autólogo en Linfoma de Células del Manto Diseminado","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.659748093014017e-58,0.9989906911269258,0.0010093088730925971,"2+",3.9404487071879106e-11,0.9999999999606076,"Yes",0.9999999999781153,2.1879647005711656e-11,"No",1.0,1.4514168177000775e-27,"No",0.9783802505992951,0.021619749400726498,"Yes",0.9999999938407315,6.159241960964124e-09,"No",1.0,7.19016200108118e-33,"No",0.9998922982323456,0.00010770176764035756,"Yes"
"2014-001363-12","Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction  in Generalized mantle cell Lymphoma – a randomized European MCL Network trial","DK","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3370848731868806e-32,0.9884059078064718,0.011594092193516183,"2+",1.3154435836120567e-05,0.9999868455641708,"Yes",0.9999915023899555,8.497610033955181e-06,"No",1.0,9.246147172219103e-15,"No",0.8140688231906349,0.18593117680935112,"Yes",0.9999928339727944,7.166027200859524e-06,"No",1.0,4.728779096564169e-15,"No",0.989360871100308,0.010639128899689324,"Yes"
"2014-001486-27","10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group CELG GIMEMA and German MDS Study Group10 dias de decitabina versus quimioterapia convencional (“3+7”) seguida de alotransplante (aloHCT) em doentes com LMA com idade ≥ 60 anos: um estudo aleatorizado de fase III do Grupo de Leucemia da EORTC CELG GIMEMA e Grupo de Estudo Alemão de SMD.","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1682937257728665e-90,1.0748032946182154e-06,0.9999989251966873,"2+",2.230848127607311e-14,1.0,"Yes",1.0,1.6902518192033429e-15,"No",1.0,2.0438415899041165e-14,"No",9.613042753540998e-18,1.0,"Yes",0.012078659818303679,0.9879213401817066,"Yes",1.0,1.827382624739857e-34,"No",1.5763100111897617e-14,1.0,"Yes"
"2014-001486-27","10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group CELG GIMEMA and German MDS Study Group","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5505329729525783e-50,3.4047293320193256e-05,0.9999659527066924,"2+",2.5009335779648685e-05,0.9999749906642283,"Yes",0.9999923193093941,7.680690604242215e-06,"No",0.9999999836029476,1.6397042566848922e-08,"No",7.837893531434305e-09,0.9999999921621169,"Yes",0.006833870396717577,0.9931661296032693,"Yes",1.0,5.441021205131537e-19,"No",7.872694292699905e-08,0.9999999212730617,"Yes"
"2014-001486-27","10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group CELG GIMEMA and German MDS Study Group10 dias de decitabina versus quimioterapia convencional (“3+7”) seguida de alotransplante (aloHCT) em doentes com LMA com idade ≥ 60 anos: um estudo aleatorizado de fase III do Grupo de Leucemia da EORTC CELG GIMEMA e Grupo de Estudo Alemão de SMD.","SK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1682937257728665e-90,1.0748032946182154e-06,0.9999989251966873,"2+",2.230848127607311e-14,1.0,"Yes",1.0,1.6902518192033429e-15,"No",1.0,2.0438415899041165e-14,"No",9.613042753540998e-18,1.0,"Yes",0.012078659818303679,0.9879213401817066,"Yes",1.0,1.827382624739857e-34,"No",1.5763100111897617e-14,1.0,"Yes"
"2014-001486-27","10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group CELG GIMEMA and German MDS Study Group10 dias de decitabina versus quimioterapia convencional (“3+7”) seguida de alotransplante (aloHCT) em doentes com LMA com idade ≥ 60 anos: um estudo aleatorizado de fase III do Grupo de Leucemia da EORTC CELG GIMEMA e Grupo de Estudo Alemão de SMD.","LT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1682937257728665e-90,1.0748032946182154e-06,0.9999989251966873,"2+",2.230848127607311e-14,1.0,"Yes",1.0,1.6902518192033429e-15,"No",1.0,2.0438415899041165e-14,"No",9.613042753540998e-18,1.0,"Yes",0.012078659818303679,0.9879213401817066,"Yes",1.0,1.827382624739857e-34,"No",1.5763100111897617e-14,1.0,"Yes"
"2014-001486-27","10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group CELG GIMEMA and German MDS Study Group","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5505329729525783e-50,3.4047293320193256e-05,0.9999659527066924,"2+",2.5009335779648685e-05,0.9999749906642283,"Yes",0.9999923193093941,7.680690604242215e-06,"No",0.9999999836029476,1.6397042566848922e-08,"No",7.837893531434305e-09,0.9999999921621169,"Yes",0.006833870396717577,0.9931661296032693,"Yes",1.0,5.441021205131537e-19,"No",7.872694292699905e-08,0.9999999212730617,"Yes"
"2014-001486-27","10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group CELG GIMEMA and German MDS Study Group10 dias de decitabina versus quimioterapia convencional (“3+7”) seguida de alotransplante (aloHCT) em doentes com LMA com idade ≥ 60 anos: um estudo aleatorizado de fase III do Grupo de Leucemia da EORTC CELG GIMEMA e Grupo de Estudo Alemão de SMD.","BG","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1682937257728665e-90,1.0748032946182154e-06,0.9999989251966873,"2+",2.230848127607311e-14,1.0,"Yes",1.0,1.6902518192033429e-15,"No",1.0,2.0438415899041165e-14,"No",9.613042753540998e-18,1.0,"Yes",0.012078659818303679,0.9879213401817066,"Yes",1.0,1.827382624739857e-34,"No",1.5763100111897617e-14,1.0,"Yes"
"2014-001486-27","10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group CELG GIMEMA and German MDS Study Group","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5505329729525783e-50,3.4047293320193256e-05,0.9999659527066924,"2+",2.5009335779648685e-05,0.9999749906642283,"Yes",0.9999923193093941,7.680690604242215e-06,"No",0.9999999836029476,1.6397042566848922e-08,"No",7.837893531434305e-09,0.9999999921621169,"Yes",0.006833870396717577,0.9931661296032693,"Yes",1.0,5.441021205131537e-19,"No",7.872694292699905e-08,0.9999999212730617,"Yes"
"2014-001718-25","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Estudio de fase III aleatorizado controlado con placebo y doble ciego de JNJ-56021927 en combinación con acetato de abiraterona y prednisona en comparación con acetato de abiraterona y prednisona en sujetos con cáncer de próstata metastásico resistente a la castración (CPRCm) que no han recibido nunca quimioterapia","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.916247395325534e-118,5.31969821115174e-20,1.0,"2+",0.9975248846402952,0.002475115359698682,"No",0.004264447466307889,0.9957355525336992,"Yes",1.0,5.7313693141396764e-49,"No",1.1488621468809384e-18,1.0,"Yes",0.019891767715819877,0.9801082322841655,"No",1.0,1.2505072927652944e-30,"No",4.104777814744383e-21,1.0,"Yes"
"2014-001718-25","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Studio di fase 3 randomizzato controllato con placebo in doppio cieco di JNJ-56021927 in combinazione con abiraterone acetato e prednisone rispetto ad abiraterone acetato e prednisone nei soggetti con carcinoma prostatico metastatico resistente alla castrazione (Metastatic Castration-resistant Prostate Cancer mCRPC) mai trattato in precedenza con chemioterapia","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.4191919450291875e-130,4.3546923005162024e-16,1.0,"2+",0.5926272891827769,0.40737271081720894,"No",0.3540643338859444,0.6459356661140508,"Yes",1.0,2.813425000563188e-59,"No",5.374259383154895e-15,1.0,"Yes",0.0007105082513022418,0.9992894917487262,"No",1.0,6.952990580370924e-24,"No",2.5175351753503377e-17,1.0,"Yes"
"2014-001718-25","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Studio di fase 3 randomizzato controllato con placebo in doppio cieco di JNJ-56021927 in combinazione con abiraterone acetato e prednisone rispetto ad abiraterone acetato e prednisone nei soggetti con carcinoma prostatico metastatico resistente alla castrazione (Metastatic Castration-resistant Prostate Cancer mCRPC) mai trattato in precedenza con chemioterapia","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.4191919450291875e-130,4.3546923005162024e-16,1.0,"2+",0.5926272891827769,0.40737271081720894,"No",0.3540643338859444,0.6459356661140508,"Yes",1.0,2.813425000563188e-59,"No",5.374259383154895e-15,1.0,"Yes",0.0007105082513022418,0.9992894917487262,"No",1.0,6.952990580370924e-24,"No",2.5175351753503377e-17,1.0,"Yes"
"2014-001718-25","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.1584256956387707e-58,4.087665483206172e-09,0.999999995912333,"2+",0.9987004471214496,0.0012995528785551185,"No",0.0021458248843621523,0.9978541751156278,"Yes",1.0,6.946727933839013e-25,"No",4.8807581066210406e-08,0.9999999511924228,"Yes",0.5411299243119725,0.45887007568802995,"No",0.9999997098923497,2.9010764774103486e-07,"No",1.026976814283199e-09,0.99999999897301,"Yes"
"2014-001718-25","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Estudio de fase III aleatorizado controlado con placebo y doble ciego de JNJ-56021927 en combinación con acetato de abiraterona y prednisona en comparación con acetato de abiraterona y prednisona en sujetos con cáncer de próstata metastásico resistente a la castración (CPRCm) que no han recibido nunca quimioterapia","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",7.916247395325534e-118,5.31969821115174e-20,1.0,"2+",0.9975248846402952,0.002475115359698682,"No",0.004264447466307889,0.9957355525336992,"Yes",1.0,5.7313693141396764e-49,"No",1.1488621468809384e-18,1.0,"Yes",0.019891767715819877,0.9801082322841655,"No",1.0,1.2505072927652944e-30,"No",4.104777814744383e-21,1.0,"Yes"
"2014-001718-25","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Studio di fase 3 randomizzato controllato con placebo in doppio cieco di JNJ-56021927 in combinazione con abiraterone acetato e prednisone rispetto ad abiraterone acetato e prednisone nei soggetti con carcinoma prostatico metastatico resistente alla castrazione (Metastatic Castration-resistant Prostate Cancer mCRPC) mai trattato in precedenza con chemioterapia","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.4191919450291875e-130,4.3546923005162024e-16,1.0,"2+",0.5926272891827769,0.40737271081720894,"No",0.3540643338859444,0.6459356661140508,"Yes",1.0,2.813425000563188e-59,"No",5.374259383154895e-15,1.0,"Yes",0.0007105082513022418,0.9992894917487262,"No",1.0,6.952990580370924e-24,"No",2.5175351753503377e-17,1.0,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","ES","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.732929470592359e-40,0.2584360383891068,0.7415639616108917,"2+",4.849860610886177e-08,0.9999999515013952,"Yes",0.9999998946049458,1.0539505385864739e-07,"No",1.0,2.2759708844014238e-21,"No",0.2715199766279485,0.7284800233720492,"Yes",0.7990143675229673,0.20098563247702908,"Yes",0.9999999324972487,6.750274618476287e-08,"Yes",0.6362785164779452,0.3637214835220596,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","AT","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.732929470592359e-40,0.2584360383891068,0.7415639616108917,"2+",4.849860610886177e-08,0.9999999515013952,"Yes",0.9999998946049458,1.0539505385864739e-07,"No",1.0,2.2759708844014238e-21,"No",0.2715199766279485,0.7284800233720492,"Yes",0.7990143675229673,0.20098563247702908,"Yes",0.9999999324972487,6.750274618476287e-08,"Yes",0.6362785164779452,0.3637214835220596,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaPharmacogenetics Blood Sample Amendment 01 dated 17-jul-2014 Protocol Amendment 06 sites-specific dated 05-Nov-2014","PL","No","No","Yes","ok","Yes","No","Yes","Yes","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.220380576289158e-63,0.9784057492389188,0.021594250761103984,"2+",1.8867360411818717e-09,0.9999999981132534,"Yes",0.999999995050132,4.949872117448202e-09,"No",1.0,2.937759420235002e-36,"No",0.09716033950488703,0.902839660495123,"Yes",1.4457245572883159e-05,0.9999855427544451,"Yes",1.0,7.536698996247193e-28,"Yes",0.03319498459725018,0.9668050154027558,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaRandomizovaná otevřená studie fáze 3 hodnotící nivolumab v kombinaci s ipilimumabem proti monoterapii sunitinibem u pacientů s dosud neléčeným pokročilým nebo metastatickým renálním karcinomem","FI","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4857096333720252e-78,9.584048245145045e-07,0.9999990415951788,"2+",9.506634369579045e-14,0.9999999999998864,"Yes",0.9999999999993179,6.952145348245505e-13,"No",1.0,5.672867512428295e-45,"No",1.2423912126721361e-05,0.9999875760878877,"Yes",0.0036119785198523947,0.9963880214801465,"Yes",1.0,2.4602551147432602e-21,"Yes",8.797527377078088e-05,0.9999120247262376,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaRandomizovaná otevřená studie fáze 3 hodnotící nivolumab v kombinaci s ipilimumabem proti monoterapii sunitinibem u pacientů s dosud neléčeným pokročilým nebo metastatickým renálním karcinomem","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4857096333720252e-78,9.584048245145045e-07,0.9999990415951788,"2+",9.506634369579045e-14,0.9999999999998864,"Yes",0.9999999999993179,6.952145348245505e-13,"No",1.0,5.672867512428295e-45,"No",1.2423912126721361e-05,0.9999875760878877,"Yes",0.0036119785198523947,0.9963880214801465,"Yes",1.0,2.4602551147432602e-21,"Yes",8.797527377078088e-05,0.9999120247262376,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaPharmacogenetics Blood Sample Amendment 01 dated 17-jul-2014 Protocol Amendment 06 sites-specific dated 05-Nov-2014","SE","No","No","Yes","ok","Yes","No","Yes","Yes","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.220380576289158e-63,0.9784057492389188,0.021594250761103984,"2+",1.8867360411818717e-09,0.9999999981132534,"Yes",0.999999995050132,4.949872117448202e-09,"No",1.0,2.937759420235002e-36,"No",0.09716033950488703,0.902839660495123,"Yes",1.4457245572883159e-05,0.9999855427544451,"Yes",1.0,7.536698996247193e-28,"Yes",0.03319498459725018,0.9668050154027558,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","GB","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.732929470592359e-40,0.2584360383891068,0.7415639616108917,"2+",4.849860610886177e-08,0.9999999515013952,"Yes",0.9999998946049458,1.0539505385864739e-07,"No",1.0,2.2759708844014238e-21,"No",0.2715199766279485,0.7284800233720492,"Yes",0.7990143675229673,0.20098563247702908,"Yes",0.9999999324972487,6.750274618476287e-08,"Yes",0.6362785164779452,0.3637214835220596,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaPharmacogenetics Blood Sample Amendment 01 dated 17-jul-2014 Protocol Amendment 06 sites-specific dated 05-Nov-2014","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.220380576289158e-63,0.9784057492389188,0.021594250761103984,"2+",1.8867360411818717e-09,0.9999999981132534,"Yes",0.999999995050132,4.949872117448202e-09,"No",1.0,2.937759420235002e-36,"No",0.09716033950488703,0.902839660495123,"Yes",1.4457245572883159e-05,0.9999855427544451,"Yes",1.0,7.536698996247193e-28,"Yes",0.03319498459725018,0.9668050154027558,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaRandomizovaná otevřená studie fáze 3 hodnotící nivolumab v kombinaci s ipilimumabem proti monoterapii sunitinibem u pacientů s dosud neléčeným pokročilým nebo metastatickým renálním karcinomem","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4857096333720252e-78,9.584048245145045e-07,0.9999990415951788,"2+",9.506634369579045e-14,0.9999999999998864,"Yes",0.9999999999993179,6.952145348245505e-13,"No",1.0,5.672867512428295e-45,"No",1.2423912126721361e-05,0.9999875760878877,"Yes",0.0036119785198523947,0.9963880214801465,"Yes",1.0,2.4602551147432602e-21,"Yes",8.797527377078088e-05,0.9999120247262376,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaPharmacogenetics Blood Sample Amendment 01 dated 17-jul-2014 Protocol Amendment 06 sites-specific dated 05-Nov-2014","DE","No","No","Yes","ok","Yes","No","Yes","Yes","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.220380576289158e-63,0.9784057492389188,0.021594250761103984,"2+",1.8867360411818717e-09,0.9999999981132534,"Yes",0.999999995050132,4.949872117448202e-09,"No",1.0,2.937759420235002e-36,"No",0.09716033950488703,0.902839660495123,"Yes",1.4457245572883159e-05,0.9999855427544451,"Yes",1.0,7.536698996247193e-28,"Yes",0.03319498459725018,0.9668050154027558,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","DK","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.732929470592359e-40,0.2584360383891068,0.7415639616108917,"2+",4.849860610886177e-08,0.9999999515013952,"Yes",0.9999998946049458,1.0539505385864739e-07,"No",1.0,2.2759708844014238e-21,"No",0.2715199766279485,0.7284800233720492,"Yes",0.7990143675229673,0.20098563247702908,"Yes",0.9999999324972487,6.750274618476287e-08,"Yes",0.6362785164779452,0.3637214835220596,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaRandomizovaná otevřená studie fáze 3 hodnotící nivolumab v kombinaci s ipilimumabem proti monoterapii sunitinibem u pacientů s dosud neléčeným pokročilým nebo metastatickým renálním karcinomem","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.4857096333720252e-78,9.584048245145045e-07,0.9999990415951788,"2+",9.506634369579045e-14,0.9999999999998864,"Yes",0.9999999999993179,6.952145348245505e-13,"No",1.0,5.672867512428295e-45,"No",1.2423912126721361e-05,0.9999875760878877,"Yes",0.0036119785198523947,0.9963880214801465,"Yes",1.0,2.4602551147432602e-21,"Yes",8.797527377078088e-05,0.9999120247262376,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","IT","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.732929470592359e-40,0.2584360383891068,0.7415639616108917,"2+",4.849860610886177e-08,0.9999999515013952,"Yes",0.9999998946049458,1.0539505385864739e-07,"No",1.0,2.2759708844014238e-21,"No",0.2715199766279485,0.7284800233720492,"Yes",0.7990143675229673,0.20098563247702908,"Yes",0.9999999324972487,6.750274618476287e-08,"Yes",0.6362785164779452,0.3637214835220596,"Yes"
"2014-001750-42","A Phase 3 Randomized Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated Advanced or Metastatic Renal Cell CarcinomaPharmacogenetics Blood Sample Amendment 01 dated 17-jul-2014 Protocol Amendment 06 sites-specific dated 05-Nov-2014","HU","No","No","Yes","ok","Yes","No","Yes","Yes","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.220380576289158e-63,0.9784057492389188,0.021594250761103984,"2+",1.8867360411818717e-09,0.9999999981132534,"Yes",0.999999995050132,4.949872117448202e-09,"No",1.0,2.937759420235002e-36,"No",0.09716033950488703,0.902839660495123,"Yes",1.4457245572883159e-05,0.9999855427544451,"Yes",1.0,7.536698996247193e-28,"Yes",0.03319498459725018,0.9668050154027558,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-001824-32","A long term randomised double blind placebo-controlled study to determine the effect of albiglutide when added to standard blood glucose lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus ","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.953584746098114e-50,7.11126272236156e-16,1.0,"2+",0.9999999995786767,4.213248580073131e-10,"No",2.5866557333423437e-09,0.9999999974133403,"Yes",0.999999999999801,2.010738268087599e-13,"No",6.051598223193554e-16,1.0,"Yes",5.090772188968874e-06,0.9999949092278064,"No",0.9999951422094894,4.857790517415014e-06,"No",1.3340486565524144e-14,1.0,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3454307938059566e-42,0.00035801062884382686,0.9996419893711598,"2+",6.004203967656324e-06,0.9999939957960382,"Yes",0.9999901101245058,9.889875491416949e-06,"No",1.0,4.9043871123023e-15,"No",0.004489265651584752,0.9955107343484176,"Yes",0.7308164753031118,0.26918352469689305,"No",0.999999989034663,1.0965331279586103e-08,"Yes",0.00015512090503830335,0.999844879094956,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer","IE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3454307938059566e-42,0.00035801062884382686,0.9996419893711598,"2+",6.004203967656324e-06,0.9999939957960382,"Yes",0.9999901101245058,9.889875491416949e-06,"No",1.0,4.9043871123023e-15,"No",0.004489265651584752,0.9955107343484176,"Yes",0.7308164753031118,0.26918352469689305,"No",0.999999989034663,1.0965331279586103e-08,"Yes",0.00015512090503830335,0.999844879094956,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial CancerEnsayo clínico aleatorizado de fase III de pembrolizumab (MK-3475) frente a paclitaxel docetaxel o vinflunina en sujetos con cáncer urotelial metastásico recidivante o progresivo","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.210197454438382e-79,3.225958357212521e-07,0.9999996774041572,"2+",1.0230175753487611e-11,0.9999999999897683,"Yes",0.9999999999672013,3.2797064488997374e-11,"No",1.0,5.373758256930999e-32,"No",2.8787700147745808e-05,0.9999712122998257,"Yes",0.6577438862360814,0.34225611376392423,"No",1.0,5.321209885553963e-20,"Yes",3.0406052235603086e-08,0.9999999695939442,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial CancerEnsayo clínico aleatorizado de fase III de pembrolizumab (MK-3475) frente a paclitaxel docetaxel o vinflunina en sujetos con cáncer urotelial metastásico recidivante o progresivo","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.210197454438382e-79,3.225958357212521e-07,0.9999996774041572,"2+",1.0230175753487611e-11,0.9999999999897683,"Yes",0.9999999999672013,3.2797064488997374e-11,"No",1.0,5.373758256930999e-32,"No",2.8787700147745808e-05,0.9999712122998257,"Yes",0.6577438862360814,0.34225611376392423,"No",1.0,5.321209885553963e-20,"Yes",3.0406052235603086e-08,0.9999999695939442,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer","PT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3454307938059566e-42,0.00035801062884382686,0.9996419893711598,"2+",6.004203967656324e-06,0.9999939957960382,"Yes",0.9999901101245058,9.889875491416949e-06,"No",1.0,4.9043871123023e-15,"No",0.004489265651584752,0.9955107343484176,"Yes",0.7308164753031118,0.26918352469689305,"No",0.999999989034663,1.0965331279586103e-08,"Yes",0.00015512090503830335,0.999844879094956,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial CancerEnsayo clínico aleatorizado de fase III de pembrolizumab (MK-3475) frente a paclitaxel docetaxel o vinflunina en sujetos con cáncer urotelial metastásico recidivante o progresivo","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.210197454438382e-79,3.225958357212521e-07,0.9999996774041572,"2+",1.0230175753487611e-11,0.9999999999897683,"Yes",0.9999999999672013,3.2797064488997374e-11,"No",1.0,5.373758256930999e-32,"No",2.8787700147745808e-05,0.9999712122998257,"Yes",0.6577438862360814,0.34225611376392423,"No",1.0,5.321209885553963e-20,"Yes",3.0406052235603086e-08,0.9999999695939442,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3454307938059566e-42,0.00035801062884382686,0.9996419893711598,"2+",6.004203967656324e-06,0.9999939957960382,"Yes",0.9999901101245058,9.889875491416949e-06,"No",1.0,4.9043871123023e-15,"No",0.004489265651584752,0.9955107343484176,"Yes",0.7308164753031118,0.26918352469689305,"No",0.999999989034663,1.0965331279586103e-08,"Yes",0.00015512090503830335,0.999844879094956,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3454307938059566e-42,0.00035801062884382686,0.9996419893711598,"2+",6.004203967656324e-06,0.9999939957960382,"Yes",0.9999901101245058,9.889875491416949e-06,"No",1.0,4.9043871123023e-15,"No",0.004489265651584752,0.9955107343484176,"Yes",0.7308164753031118,0.26918352469689305,"No",0.999999989034663,1.0965331279586103e-08,"Yes",0.00015512090503830335,0.999844879094956,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial CancerEnsayo clínico aleatorizado de fase III de pembrolizumab (MK-3475) frente a paclitaxel docetaxel o vinflunina en sujetos con cáncer urotelial metastásico recidivante o progresivo","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.210197454438382e-79,3.225958357212521e-07,0.9999996774041572,"2+",1.0230175753487611e-11,0.9999999999897683,"Yes",0.9999999999672013,3.2797064488997374e-11,"No",1.0,5.373758256930999e-32,"No",2.8787700147745808e-05,0.9999712122998257,"Yes",0.6577438862360814,0.34225611376392423,"No",1.0,5.321209885553963e-20,"Yes",3.0406052235603086e-08,0.9999999695939442,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3454307938059566e-42,0.00035801062884382686,0.9996419893711598,"2+",6.004203967656324e-06,0.9999939957960382,"Yes",0.9999901101245058,9.889875491416949e-06,"No",1.0,4.9043871123023e-15,"No",0.004489265651584752,0.9955107343484176,"Yes",0.7308164753031118,0.26918352469689305,"No",0.999999989034663,1.0965331279586103e-08,"Yes",0.00015512090503830335,0.999844879094956,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3454307938059566e-42,0.00035801062884382686,0.9996419893711598,"2+",6.004203967656324e-06,0.9999939957960382,"Yes",0.9999901101245058,9.889875491416949e-06,"No",1.0,4.9043871123023e-15,"No",0.004489265651584752,0.9955107343484176,"Yes",0.7308164753031118,0.26918352469689305,"No",0.999999989034663,1.0965331279586103e-08,"Yes",0.00015512090503830335,0.999844879094956,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.3454307938059566e-42,0.00035801062884382686,0.9996419893711598,"2+",6.004203967656324e-06,0.9999939957960382,"Yes",0.9999901101245058,9.889875491416949e-06,"No",1.0,4.9043871123023e-15,"No",0.004489265651584752,0.9955107343484176,"Yes",0.7308164753031118,0.26918352469689305,"No",0.999999989034663,1.0965331279586103e-08,"Yes",0.00015512090503830335,0.999844879094956,"Yes"
"2014-002009-40","A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial CancerEnsayo clínico aleatorizado de fase III de pembrolizumab (MK-3475) frente a paclitaxel docetaxel o vinflunina en sujetos con cáncer urotelial metastásico recidivante o progresivo","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.210197454438382e-79,3.225958357212521e-07,0.9999996774041572,"2+",1.0230175753487611e-11,0.9999999999897683,"Yes",0.9999999999672013,3.2797064488997374e-11,"No",1.0,5.373758256930999e-32,"No",2.8787700147745808e-05,0.9999712122998257,"Yes",0.6577438862360814,0.34225611376392423,"No",1.0,5.321209885553963e-20,"Yes",3.0406052235603086e-08,0.9999999695939442,"Yes"
"2014-002249-22","DETECT V/CHEVENDO: A multicenter randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.DETECT V/CHEVENDO: Eine multizentrische randomisierte Phase III-Studie zum Vergleich einer Chemo- versus einer endokrinen Behandlung in Kombination mit einer dualen HER2-gerichteten Herceptin® (Trastuzumab)/ Perjeta® (Pertuzumab)-Therapie plus Kisqali® (Ribociclib) bei Patientinnen mit HER2-positivem und hormonrezeptorpositivem metastasiertem Brustkrebs.","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1667264249915893e-124,0.06658043656925111,0.9334195634308038,"2+",9.865531200422811e-19,1.0,"Yes",1.0,7.300381881602597e-18,"No",1.0,4.947920414193681e-50,"No",0.9022025972497167,0.09779740275025653,"Yes",0.9999999999922693,7.706281258959995e-12,"No",1.0,3.542535793653946e-24,"No",0.19822507253298025,0.8017749274669874,"Yes"
"2014-002273-11","A Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.782065300725966e-41,4.070768288896215e-06,0.9999959292317023,"2+",2.979785404786048e-11,0.999999999970214,"Yes",0.9999999999510011,4.9008098585733437e-11,"No",1.0,4.838959419647792e-22,"No",0.00032218823161973473,0.9996778117683712,"Yes",0.008603099396566628,0.9913969006034423,"Yes",0.9999999999346016,6.539711240409301e-11,"No",6.0493506757915455e-05,0.9999395064932508,"Yes"
"2014-002273-11","A Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.782065300725966e-41,4.070768288896215e-06,0.9999959292317023,"2+",2.979785404786048e-11,0.999999999970214,"Yes",0.9999999999510011,4.9008098585733437e-11,"No",1.0,4.838959419647792e-22,"No",0.00032218823161973473,0.9996778117683712,"Yes",0.008603099396566628,0.9913969006034423,"Yes",0.9999999999346016,6.539711240409301e-11,"No",6.0493506757915455e-05,0.9999395064932508,"Yes"
"2014-002273-11","A Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.782065300725966e-41,4.070768288896215e-06,0.9999959292317023,"2+",2.979785404786048e-11,0.999999999970214,"Yes",0.9999999999510011,4.9008098585733437e-11,"No",1.0,4.838959419647792e-22,"No",0.00032218823161973473,0.9996778117683712,"Yes",0.008603099396566628,0.9913969006034423,"Yes",0.9999999999346016,6.539711240409301e-11,"No",6.0493506757915455e-05,0.9999395064932508,"Yes"
"2014-002273-11","A Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.782065300725966e-41,4.070768288896215e-06,0.9999959292317023,"2+",2.979785404786048e-11,0.999999999970214,"Yes",0.9999999999510011,4.9008098585733437e-11,"No",1.0,4.838959419647792e-22,"No",0.00032218823161973473,0.9996778117683712,"Yes",0.008603099396566628,0.9913969006034423,"Yes",0.9999999999346016,6.539711240409301e-11,"No",6.0493506757915455e-05,0.9999395064932508,"Yes"
"2014-002273-11","A Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.782065300725966e-41,4.070768288896215e-06,0.9999959292317023,"2+",2.979785404786048e-11,0.999999999970214,"Yes",0.9999999999510011,4.9008098585733437e-11,"No",1.0,4.838959419647792e-22,"No",0.00032218823161973473,0.9996778117683712,"Yes",0.008603099396566628,0.9913969006034423,"Yes",0.9999999999346016,6.539711240409301e-11,"No",6.0493506757915455e-05,0.9999395064932508,"Yes"
"2014-002273-11","A Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.782065300725966e-41,4.070768288896215e-06,0.9999959292317023,"2+",2.979785404786048e-11,0.999999999970214,"Yes",0.9999999999510011,4.9008098585733437e-11,"No",1.0,4.838959419647792e-22,"No",0.00032218823161973473,0.9996778117683712,"Yes",0.008603099396566628,0.9913969006034423,"Yes",0.9999999999346016,6.539711240409301e-11,"No",6.0493506757915455e-05,0.9999395064932508,"Yes"
"2014-002273-11","A Phase 3 Study Comparing Daratumumab Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.782065300725966e-41,4.070768288896215e-06,0.9999959292317023,"2+",2.979785404786048e-11,0.999999999970214,"Yes",0.9999999999510011,4.9008098585733437e-11,"No",1.0,4.838959419647792e-22,"No",0.00032218823161973473,0.9996778117683712,"Yes",0.008603099396566628,0.9913969006034423,"Yes",0.9999999999346016,6.539711240409301e-11,"No",6.0493506757915455e-05,0.9999395064932508,"Yes"
"2014-002446-47","Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.Trabectedina en el meningioma de grado II o III recurrente: un estudio aleatorizado de fase II del Grupo de Tumores Cerebrales de la EORTC","NL","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7803030074630177e-56,0.8300970721158933,0.16990292788409625,"2+",6.393963951476032e-14,0.9999999999999432,"Yes",0.9999999999999147,8.554987546210234e-14,"No",0.9999999999126317,8.736700484459127e-11,"No",0.9873700459635484,0.012629954036447502,"Yes",0.9997182454621331,0.00028175453786052966,"Yes",0.9999999999995168,4.824338926210245e-13,"No",0.9680118329125605,0.031988167087442274,"Yes"
"2014-002446-47","Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.Trabectedina en el meningioma de grado II o III recurrente: un estudio aleatorizado de fase II del Grupo de Tumores Cerebrales de la EORTC","BE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7803030074630177e-56,0.8300970721158933,0.16990292788409625,"2+",6.393963951476032e-14,0.9999999999999432,"Yes",0.9999999999999147,8.554987546210234e-14,"No",0.9999999999126317,8.736700484459127e-11,"No",0.9873700459635484,0.012629954036447502,"Yes",0.9997182454621331,0.00028175453786052966,"Yes",0.9999999999995168,4.824338926210245e-13,"No",0.9680118329125605,0.031988167087442274,"Yes"
"2014-002446-47","Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.Trabectedina en el meningioma de grado II o III recurrente: un estudio aleatorizado de fase II del Grupo de Tumores Cerebrales de la EORTC","AT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7803030074630177e-56,0.8300970721158933,0.16990292788409625,"2+",6.393963951476032e-14,0.9999999999999432,"Yes",0.9999999999999147,8.554987546210234e-14,"No",0.9999999999126317,8.736700484459127e-11,"No",0.9873700459635484,0.012629954036447502,"Yes",0.9997182454621331,0.00028175453786052966,"Yes",0.9999999999995168,4.824338926210245e-13,"No",0.9680118329125605,0.031988167087442274,"Yes"
"2014-002446-47","Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.Trabectedina en el meningioma de grado II o III recurrente: un estudio aleatorizado de fase II del Grupo de Tumores Cerebrales de la EORTC","DE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7803030074630177e-56,0.8300970721158933,0.16990292788409625,"2+",6.393963951476032e-14,0.9999999999999432,"Yes",0.9999999999999147,8.554987546210234e-14,"No",0.9999999999126317,8.736700484459127e-11,"No",0.9873700459635484,0.012629954036447502,"Yes",0.9997182454621331,0.00028175453786052966,"Yes",0.9999999999995168,4.824338926210245e-13,"No",0.9680118329125605,0.031988167087442274,"Yes"
"2014-002446-47","Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.Trabectedina en el meningioma de grado II o III recurrente: un estudio aleatorizado de fase II del Grupo de Tumores Cerebrales de la EORTC","ES","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.7803030074630177e-56,0.8300970721158933,0.16990292788409625,"2+",6.393963951476032e-14,0.9999999999999432,"Yes",0.9999999999999147,8.554987546210234e-14,"No",0.9999999999126317,8.736700484459127e-11,"No",0.9873700459635484,0.012629954036447502,"Yes",0.9997182454621331,0.00028175453786052966,"Yes",0.9999999999995168,4.824338926210245e-13,"No",0.9680118329125605,0.031988167087442274,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.986963324963496e-52,0.0018675165857346577,0.998132483414275,"2+",1.485841049645786e-06,0.9999985141589559,"Yes",0.9999981427182174,1.8572817761994857e-06,"No",1.0,1.2426415425295664e-15,"No",0.05785824888139347,0.9421417511185977,"Yes",0.9946522854972204,0.0053477145027891896,"No",0.9999999999997159,2.714929868613651e-13,"No",0.35426521078374074,0.6457347892162459,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Adaptive Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Ensayo adaptativo de fase 3 aleatorizado abierto y controlado para investigar la eficacia seguridad y tolerabilidad del anticuerpo BiTE® blinatumomab como tratamiento de consolidación frente a la quimioterapia de consolidación convencional en sujetos pediátricos con leucemia linfoblástica aguda (LLA) de precursores B en primera recaída de alto riesgo","GR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.926184282160852e-105,4.267021007107124e-12,0.9999999999957369,"2+",1.954977462009871e-10,0.9999999998045155,"Yes",0.9999999998855742,1.144340956348071e-10,"No",1.0,1.7362364749273917e-28,"No",6.503996387442892e-10,0.9999999993495976,"Yes",0.056231556975427345,0.943768443024574,"No",1.0,6.003659438621065e-43,"No",8.14289503370213e-09,0.9999999918571235,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Adaptive Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Ensayo adaptativo de fase 3 aleatorizado abierto y controlado para investigar la eficacia seguridad y tolerabilidad del anticuerpo BiTE® blinatumomab como tratamiento de consolidación frente a la quimioterapia de consolidación convencional en sujetos pediátricos con leucemia linfoblástica aguda (LLA) de precursores B en primera recaída de alto riesgo","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.926184282160852e-105,4.267021007107124e-12,0.9999999999957369,"2+",1.954977462009871e-10,0.9999999998045155,"Yes",0.9999999998855742,1.144340956348071e-10,"No",1.0,1.7362364749273917e-28,"No",6.503996387442892e-10,0.9999999993495976,"Yes",0.056231556975427345,0.943768443024574,"No",1.0,6.003659438621065e-43,"No",8.14289503370213e-09,0.9999999918571235,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.986963324963496e-52,0.0018675165857346577,0.998132483414275,"2+",1.485841049645786e-06,0.9999985141589559,"Yes",0.9999981427182174,1.8572817761994857e-06,"No",1.0,1.2426415425295664e-15,"No",0.05785824888139347,0.9421417511185977,"Yes",0.9946522854972204,0.0053477145027891896,"No",0.9999999999997159,2.714929868613651e-13,"No",0.35426521078374074,0.6457347892162459,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Adaptive Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Ensayo adaptativo de fase 3 aleatorizado abierto y controlado para investigar la eficacia seguridad y tolerabilidad del anticuerpo BiTE® blinatumomab como tratamiento de consolidación frente a la quimioterapia de consolidación convencional en sujetos pediátricos con leucemia linfoblástica aguda (LLA) de precursores B en primera recaída de alto riesgo","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.926184282160852e-105,4.267021007107124e-12,0.9999999999957369,"2+",1.954977462009871e-10,0.9999999998045155,"Yes",0.9999999998855742,1.144340956348071e-10,"No",1.0,1.7362364749273917e-28,"No",6.503996387442892e-10,0.9999999993495976,"Yes",0.056231556975427345,0.943768443024574,"No",1.0,6.003659438621065e-43,"No",8.14289503370213e-09,0.9999999918571235,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Randomizované otevřené kontrolované adaptivní klinické hodnocení fáze 3 hodnotící účinnost bezpečnost a snášenlivost konsolidační léčby BiTE® protilátkou blinatumomabem ve srovnání se standardní konsolidační chemoterapií u pediatrických pacientů s vysoce rizikovou akutní lymfoblastickou leukemii (ALL) z prekurzorů B buněk s prvním relapsem","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1899547480020132e-107,1.7514669262021756e-12,0.999999999998238,"2+",1.069867887993021e-08,0.9999999893013297,"Yes",0.9999999520133555,4.79866487895886e-08,"No",1.0,1.6708405739352222e-41,"No",1.0545792576481242e-13,0.9999999999998864,"Yes",0.9999831266209965,1.687337900615276e-05,"No",1.0,1.3556091462599508e-33,"No",1.4461070497183567e-05,0.9999855389295067,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Adaptive Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Ensayo adaptativo de fase 3 aleatorizado abierto y controlado para investigar la eficacia seguridad y tolerabilidad del anticuerpo BiTE® blinatumomab como tratamiento de consolidación frente a la quimioterapia de consolidación convencional en sujetos pediátricos con leucemia linfoblástica aguda (LLA) de precursores B en primera recaída de alto riesgo","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.926184282160852e-105,4.267021007107124e-12,0.9999999999957369,"2+",1.954977462009871e-10,0.9999999998045155,"Yes",0.9999999998855742,1.144340956348071e-10,"No",1.0,1.7362364749273917e-28,"No",6.503996387442892e-10,0.9999999993495976,"Yes",0.056231556975427345,0.943768443024574,"No",1.0,6.003659438621065e-43,"No",8.14289503370213e-09,0.9999999918571235,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","Outside EU/EEA","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.986963324963496e-52,0.0018675165857346577,0.998132483414275,"2+",1.485841049645786e-06,0.9999985141589559,"Yes",0.9999981427182174,1.8572817761994857e-06,"No",1.0,1.2426415425295664e-15,"No",0.05785824888139347,0.9421417511185977,"Yes",0.9946522854972204,0.0053477145027891896,"No",0.9999999999997159,2.714929868613651e-13,"No",0.35426521078374074,0.6457347892162459,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Adaptive Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Studio Adattativo di Fase 3 Controllato in Aperto Randomizzato per valutare l’Efficacia la Sicurezza e la Tollerabilità dell’Anticorpo BiTE® Blinatumomab come Terapia di Consolidamento Rispetto alla Chemioterapia di Consolidamento Convenzionale in Soggetti Pediatrici con Leucemia Linfoblastica Acuta (LLA) da precursori delle cellule B in Prima Recidiva ad Alto Rischio","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.67181579679335e-117,4.330221718146841e-09,0.9999999956697821,"2+",1.1773016891530119e-13,0.9999999999998864,"Yes",0.9999999999998864,6.29724780271265e-14,"No",1.0,2.550757490328497e-32,"No",1.8387464623879172e-06,0.9999981612535146,"Yes",0.06194915156700135,0.9380508484329895,"No",1.0,1.493885327621277e-37,"No",0.0004061061202745795,0.9995938938796892,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.986963324963496e-52,0.0018675165857346577,0.998132483414275,"2+",1.485841049645786e-06,0.9999985141589559,"Yes",0.9999981427182174,1.8572817761994857e-06,"No",1.0,1.2426415425295664e-15,"No",0.05785824888139347,0.9421417511185977,"Yes",0.9946522854972204,0.0053477145027891896,"No",0.9999999999997159,2.714929868613651e-13,"No",0.35426521078374074,0.6457347892162459,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Adaptive Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Studio Adattativo di Fase 3 Controllato in Aperto Randomizzato per valutare l’Efficacia la Sicurezza e la Tollerabilità dell’Anticorpo BiTE® Blinatumomab come Terapia di Consolidamento Rispetto alla Chemioterapia di Consolidamento Convenzionale in Soggetti Pediatrici con Leucemia Linfoblastica Acuta (LLA) da precursori delle cellule B in Prima Recidiva ad Alto Rischio","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.67181579679335e-117,4.330221718146841e-09,0.9999999956697821,"2+",1.1773016891530119e-13,0.9999999999998864,"Yes",0.9999999999998864,6.29724780271265e-14,"No",1.0,2.550757490328497e-32,"No",1.8387464623879172e-06,0.9999981612535146,"Yes",0.06194915156700135,0.9380508484329895,"No",1.0,1.493885327621277e-37,"No",0.0004061061202745795,0.9995938938796892,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Adaptive Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Studio Adattativo di Fase 3 Controllato in Aperto Randomizzato per valutare l’Efficacia la Sicurezza e la Tollerabilità dell’Anticorpo BiTE® Blinatumomab come Terapia di Consolidamento Rispetto alla Chemioterapia di Consolidamento Convenzionale in Soggetti Pediatrici con Leucemia Linfoblastica Acuta (LLA) da precursori delle cellule B in Prima Recidiva ad Alto Rischio","NO","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.67181579679335e-117,4.330221718146841e-09,0.9999999956697821,"2+",1.1773016891530119e-13,0.9999999999998864,"Yes",0.9999999999998864,6.29724780271265e-14,"No",1.0,2.550757490328497e-32,"No",1.8387464623879172e-06,0.9999981612535146,"Yes",0.06194915156700135,0.9380508484329895,"No",1.0,1.493885327621277e-37,"No",0.0004061061202745795,0.9995938938796892,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Adaptive Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Studio Adattativo di Fase 3 Controllato in Aperto Randomizzato per valutare l’Efficacia la Sicurezza e la Tollerabilità dell’Anticorpo BiTE® Blinatumomab come Terapia di Consolidamento Rispetto alla Chemioterapia di Consolidamento Convenzionale in Soggetti Pediatrici con Leucemia Linfoblastica Acuta (LLA) da precursori delle cellule B in Prima Recidiva ad Alto Rischio","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.67181579679335e-117,4.330221718146841e-09,0.9999999956697821,"2+",1.1773016891530119e-13,0.9999999999998864,"Yes",0.9999999999998864,6.29724780271265e-14,"No",1.0,2.550757490328497e-32,"No",1.8387464623879172e-06,0.9999981612535146,"Yes",0.06194915156700135,0.9380508484329895,"No",1.0,1.493885327621277e-37,"No",0.0004061061202745795,0.9995938938796892,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Randomizované otevřené kontrolované adaptivní klinické hodnocení fáze 3 hodnotící účinnost bezpečnost a snášenlivost konsolidační léčby BiTE® protilátkou blinatumomabem ve srovnání se standardní konsolidační chemoterapií u pediatrických pacientů s vysoce rizikovou akutní lymfoblastickou leukemii (ALL) z prekurzorů B buněk s prvním relapsem","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1899547480020132e-107,1.7514669262021756e-12,0.999999999998238,"2+",1.069867887993021e-08,0.9999999893013297,"Yes",0.9999999520133555,4.79866487895886e-08,"No",1.0,1.6708405739352222e-41,"No",1.0545792576481242e-13,0.9999999999998864,"Yes",0.9999831266209965,1.687337900615276e-05,"No",1.0,1.3556091462599508e-33,"No",1.4461070497183567e-05,0.9999855389295067,"Yes"
"2014-002476-92","A Randomized Open-label Controlled Phase 3 Trial to Investigate the Efficacy Safety and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects with High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)Randomizované otevřené kontrolované adaptivní klinické hodnocení fáze 3 hodnotící účinnost bezpečnost a snášenlivost konsolidační léčby BiTE® protilátkou blinatumomabem ve srovnání se standardní konsolidační chemoterapií u pediatrických pacientů s vysoce rizikovou akutní lymfoblastickou leukemii (ALL) z prekurzorů B buněk s prvním relapsem","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1899547480020132e-107,1.7514669262021756e-12,0.999999999998238,"2+",1.069867887993021e-08,0.9999999893013297,"Yes",0.9999999520133555,4.79866487895886e-08,"No",1.0,1.6708405739352222e-41,"No",1.0545792576481242e-13,0.9999999999998864,"Yes",0.9999831266209965,1.687337900615276e-05,"No",1.0,1.3556091462599508e-33,"No",1.4461070497183567e-05,0.9999855389295067,"Yes"
"2014-002987-34","A Phase 2 Randomized Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally SymptomaticPharmacogenetics Blood Sample Amendment Number 01Estudio Fase 2 aleatorizado doble ciego de ipilimumab administrado a dosis de 3 mg/kg frente a 10 mg/kg en sujetos adultos con cáncer de próstata metastásico resistente a la castración asintomáticos o con mínima sintomatología y no tratados previamente con quimioterapiaEnmienda sobre muestras de sangre para farmacogenética Número 1.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.233547360002417e-125,3.375106520302951e-15,1.0,"2+",0.9999657453185719,3.425468138742094e-05,"No",0.00023502034282738422,0.9997649796571567,"Yes",1.0,8.752652211267637e-35,"No",9.926221320198017e-14,0.9999999999998864,"Yes",0.009630185145429569,0.9903698148545813,"Yes",1.0,3.4588528444233864e-25,"No",1.0781330049732437e-13,0.9999999999998864,"Yes"
"2014-002987-34","A Phase 2 Randomized Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally SymptomaticPharmacogenetics Blood Sample Amendment Number 01Estudio Fase 2 aleatorizado doble ciego de ipilimumab administrado a dosis de 3 mg/kg frente a 10 mg/kg en sujetos adultos con cáncer de próstata metastásico resistente a la castración asintomáticos o con mínima sintomatología y no tratados previamente con quimioterapiaEnmienda sobre muestras de sangre para farmacogenética Número 1.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.233547360002417e-125,3.375106520302951e-15,1.0,"2+",0.9999657453185719,3.425468138742094e-05,"No",0.00023502034282738422,0.9997649796571567,"Yes",1.0,8.752652211267637e-35,"No",9.926221320198017e-14,0.9999999999998864,"Yes",0.009630185145429569,0.9903698148545813,"Yes",1.0,3.4588528444233864e-25,"No",1.0781330049732437e-13,0.9999999999998864,"Yes"
"2014-002987-34","A Phase 2 Randomized Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally SymptomaticPharmacogenetics Blood Sample Amendment Number 01Estudio Fase 2 aleatorizado doble ciego de ipilimumab administrado a dosis de 3 mg/kg frente a 10 mg/kg en sujetos adultos con cáncer de próstata metastásico resistente a la castración asintomáticos o con mínima sintomatología y no tratados previamente con quimioterapiaEnmienda sobre muestras de sangre para farmacogenética Número 1.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.233547360002417e-125,3.375106520302951e-15,1.0,"2+",0.9999657453185719,3.425468138742094e-05,"No",0.00023502034282738422,0.9997649796571567,"Yes",1.0,8.752652211267637e-35,"No",9.926221320198017e-14,0.9999999999998864,"Yes",0.009630185145429569,0.9903698148545813,"Yes",1.0,3.4588528444233864e-25,"No",1.0781330049732437e-13,0.9999999999998864,"Yes"
"2014-002987-34","A Phase 2 Randomized Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally SymptomaticPharmacogenetics Blood Sample Amendment Number 01Estudio Fase 2 aleatorizado doble ciego de ipilimumab administrado a dosis de 3 mg/kg frente a 10 mg/kg en sujetos adultos con cáncer de próstata metastásico resistente a la castración asintomáticos o con mínima sintomatología y no tratados previamente con quimioterapiaEnmienda sobre muestras de sangre para farmacogenética Número 1.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.233547360002417e-125,3.375106520302951e-15,1.0,"2+",0.9999657453185719,3.425468138742094e-05,"No",0.00023502034282738422,0.9997649796571567,"Yes",1.0,8.752652211267637e-35,"No",9.926221320198017e-14,0.9999999999998864,"Yes",0.009630185145429569,0.9903698148545813,"Yes",1.0,3.4588528444233864e-25,"No",1.0781330049732437e-13,0.9999999999998864,"Yes"
"2014-002987-34","A Phase 2 Randomized Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally SymptomaticPharmacogenetics Blood Sample Amendment Number 01Estudio Fase 2 aleatorizado doble ciego de ipilimumab administrado a dosis de 3 mg/kg frente a 10 mg/kg en sujetos adultos con cáncer de próstata metastásico resistente a la castración asintomáticos o con mínima sintomatología y no tratados previamente con quimioterapiaEnmienda sobre muestras de sangre para farmacogenética Número 1.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",5.233547360002417e-125,3.375106520302951e-15,1.0,"2+",0.9999657453185719,3.425468138742094e-05,"No",0.00023502034282738422,0.9997649796571567,"Yes",1.0,8.752652211267637e-35,"No",9.926221320198017e-14,0.9999999999998864,"Yes",0.009630185145429569,0.9903698148545813,"Yes",1.0,3.4588528444233864e-25,"No",1.0781330049732437e-13,0.9999999999998864,"Yes"
"2014-003150-13","A randomized placebo-controlled phase 2 study of decitabine with or without eltrombopag in AML patients ≥65 years of age not eligible for intensive chemotherapyRandomisierte Placebo-kontrollierte Phase-II-Studie zu Decitabin in Kombination mit oder ohne Eltrombopag bei AML-Patienten ≥65 Jahre für die eine intensive Chemotherapie nicht in Frage kommt","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.428940307366127e-69,9.760600808009788e-06,0.9999902393992104,"2+",0.0003342485041460622,0.9996657514958367,"No",0.9999664918199448,3.3508180072891824e-05,"Yes",0.9999938171122414,6.182887740688549e-06,"No",7.312337007494494e-09,0.9999999926876627,"Yes",0.9451197815310656,0.054880218468912376,"Yes",1.0,1.4076461635281648e-20,"No",1.3083099993238107e-06,0.9999986916899989,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","NL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.542245178738264e-44,0.014128996805573639,0.9858710031944179,"2+",2.6086346887761395e-09,0.9999999973913702,"Yes",0.9999999953466842,4.653318426424627e-09,"No",1.0,6.748399655888801e-18,"No",0.9668819696045445,0.03311803039545226,"Yes",0.9958193231277063,0.004180676872306535,"No",0.9999999999957653,4.23199787768589e-12,"No",0.029604150965555576,0.9703958490344466,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","DK","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.542245178738264e-44,0.014128996805573639,0.9858710031944179,"2+",2.6086346887761395e-09,0.9999999973913702,"Yes",0.9999999953466842,4.653318426424627e-09,"No",1.0,6.748399655888801e-18,"No",0.9668819696045445,0.03311803039545226,"Yes",0.9958193231277063,0.004180676872306535,"No",0.9999999999957653,4.23199787768589e-12,"No",0.029604150965555576,0.9703958490344466,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","PL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.198318752039932e-53,0.009911261291286194,0.9900887387087266,"2+",4.717740896542528e-08,0.9999999528225784,"Yes",0.999999912732822,8.726717870875959e-08,"No",1.0,1.4608902736758035e-18,"No",0.9887687755816433,0.011231224418356904,"Yes",0.9993395053086024,0.0006604946913992959,"No",0.9999999999864144,1.3583089639781612e-11,"No",0.03565243474215774,0.96434756525783,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACYAND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1ANTIBODY) COMPARED WITH CHEMOTHERAPY INPATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTERFAILURE WITH PLATINUM-CONTAININGCHEMOTHERAPY","BE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.9291958930405134e-32,0.0051973153942956795,0.9948026846057175,"2+",2.842147015577461e-08,0.9999999715785184,"Yes",0.9999999348966946,6.510330689715356e-08,"No",1.0,7.313750103927095e-18,"No",0.8104745045744745,0.18952549542553915,"Yes",0.9900920052268302,0.00990799477317752,"No",0.9999999999868976,1.3108044740402548e-11,"No",0.019750805324264528,0.9802491946757341,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACYAND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1ANTIBODY) COMPARED WITH CHEMOTHERAPY INPATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTERFAILURE WITH PLATINUM-CONTAININGCHEMOTHERAPY","NO","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.9291958930405134e-32,0.0051973153942956795,0.9948026846057175,"2+",2.842147015577461e-08,0.9999999715785184,"Yes",0.9999999348966946,6.510330689715356e-08,"No",1.0,7.313750103927095e-18,"No",0.8104745045744745,0.18952549542553915,"Yes",0.9900920052268302,0.00990799477317752,"No",0.9999999999868976,1.3108044740402548e-11,"No",0.019750805324264528,0.9802491946757341,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","PT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.198318752039932e-53,0.009911261291286194,0.9900887387087266,"2+",4.717740896542528e-08,0.9999999528225784,"Yes",0.999999912732822,8.726717870875959e-08,"No",1.0,1.4608902736758035e-18,"No",0.9887687755816433,0.011231224418356904,"Yes",0.9993395053086024,0.0006604946913992959,"No",0.9999999999864144,1.3583089639781612e-11,"No",0.03565243474215774,0.96434756525783,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACYAND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1ANTIBODY) COMPARED WITH CHEMOTHERAPY INPATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTERFAILURE WITH PLATINUM-CONTAININGCHEMOTHERAPY","FR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.9291958930405134e-32,0.0051973153942956795,0.9948026846057175,"2+",2.842147015577461e-08,0.9999999715785184,"Yes",0.9999999348966946,6.510330689715356e-08,"No",1.0,7.313750103927095e-18,"No",0.8104745045744745,0.18952549542553915,"Yes",0.9900920052268302,0.00990799477317752,"No",0.9999999999868976,1.3108044740402548e-11,"No",0.019750805324264528,0.9802491946757341,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","GR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.198318752039932e-53,0.009911261291286194,0.9900887387087266,"2+",4.717740896542528e-08,0.9999999528225784,"Yes",0.999999912732822,8.726717870875959e-08,"No",1.0,1.4608902736758035e-18,"No",0.9887687755816433,0.011231224418356904,"Yes",0.9993395053086024,0.0006604946913992959,"No",0.9999999999864144,1.3583089639781612e-11,"No",0.03565243474215774,0.96434756525783,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","RO","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1870647377624477e-52,0.018901676010475123,0.9810983239895389,"2+",5.788182682190174e-10,0.9999999994211919,"Yes",0.9999999989293258,1.0706785378939725e-09,"No",1.0,5.584630219010472e-18,"No",0.9905337599331636,0.009466240066840029,"Yes",0.9999726211320702,2.7378867927849553e-05,"No",0.9999999999463114,5.3701353888135777e-11,"No",0.030317719051990582,0.9696822809480223,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.542245178738264e-44,0.014128996805573639,0.9858710031944179,"2+",2.6086346887761395e-09,0.9999999973913702,"Yes",0.9999999953466842,4.653318426424627e-09,"No",1.0,6.748399655888801e-18,"No",0.9668819696045445,0.03311803039545226,"Yes",0.9958193231277063,0.004180676872306535,"No",0.9999999999957653,4.23199787768589e-12,"No",0.029604150965555576,0.9703958490344466,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACYAND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1ANTIBODY) COMPARED WITH CHEMOTHERAPY INPATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTERFAILURE WITH PLATINUM-CONTAININGCHEMOTHERAPY","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.9291958930405134e-32,0.0051973153942956795,0.9948026846057175,"2+",2.842147015577461e-08,0.9999999715785184,"Yes",0.9999999348966946,6.510330689715356e-08,"No",1.0,7.313750103927095e-18,"No",0.8104745045744745,0.18952549542553915,"Yes",0.9900920052268302,0.00990799477317752,"No",0.9999999999868976,1.3108044740402548e-11,"No",0.019750805324264528,0.9802491946757341,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACYAND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1ANTIBODY) COMPARED WITH CHEMOTHERAPY INPATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTERFAILURE WITH PLATINUM-CONTAININGCHEMOTHERAPY","GB","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.9291958930405134e-32,0.0051973153942956795,0.9948026846057175,"2+",2.842147015577461e-08,0.9999999715785184,"Yes",0.9999999348966946,6.510330689715356e-08,"No",1.0,7.313750103927095e-18,"No",0.8104745045744745,0.18952549542553915,"Yes",0.9900920052268302,0.00990799477317752,"No",0.9999999999868976,1.3108044740402548e-11,"No",0.019750805324264528,0.9802491946757341,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","SI","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1870647377624477e-52,0.018901676010475123,0.9810983239895389,"2+",5.788182682190174e-10,0.9999999994211919,"Yes",0.9999999989293258,1.0706785378939725e-09,"No",1.0,5.584630219010472e-18,"No",0.9905337599331636,0.009466240066840029,"Yes",0.9999726211320702,2.7378867927849553e-05,"No",0.9999999999463114,5.3701353888135777e-11,"No",0.030317719051990582,0.9696822809480223,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","SE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1870647377624477e-52,0.018901676010475123,0.9810983239895389,"2+",5.788182682190174e-10,0.9999999994211919,"Yes",0.9999999989293258,1.0706785378939725e-09,"No",1.0,5.584630219010472e-18,"No",0.9905337599331636,0.009466240066840029,"Yes",0.9999726211320702,2.7378867927849553e-05,"No",0.9999999999463114,5.3701353888135777e-11,"No",0.030317719051990582,0.9696822809480223,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","HU","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.1870647377624477e-52,0.018901676010475123,0.9810983239895389,"2+",5.788182682190174e-10,0.9999999994211919,"Yes",0.9999999989293258,1.0706785378939725e-09,"No",1.0,5.584630219010472e-18,"No",0.9905337599331636,0.009466240066840029,"Yes",0.9999726211320702,2.7378867927849553e-05,"No",0.9999999999463114,5.3701353888135777e-11,"No",0.030317719051990582,0.9696822809480223,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","IT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.542245178738264e-44,0.014128996805573639,0.9858710031944179,"2+",2.6086346887761395e-09,0.9999999973913702,"Yes",0.9999999953466842,4.653318426424627e-09,"No",1.0,6.748399655888801e-18,"No",0.9668819696045445,0.03311803039545226,"Yes",0.9958193231277063,0.004180676872306535,"No",0.9999999999957653,4.23199787768589e-12,"No",0.029604150965555576,0.9703958490344466,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTERRANDOMIZED STUDY TO INVESTIGATE THE EFFICACYAND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1ANTIBODY) COMPARED WITH CHEMOTHERAPY INPATIENTS WITH LOCALLY ADVANCED ORMETASTATIC UROTHELIAL BLADDER CANCER AFTERFAILURE WITH PLATINUM-CONTAININGCHEMOTHERAPY","FI","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.9291958930405134e-32,0.0051973153942956795,0.9948026846057175,"2+",2.842147015577461e-08,0.9999999715785184,"Yes",0.9999999348966946,6.510330689715356e-08,"No",1.0,7.313750103927095e-18,"No",0.8104745045744745,0.18952549542553915,"Yes",0.9900920052268302,0.00990799477317752,"No",0.9999999999868976,1.3108044740402548e-11,"No",0.019750805324264528,0.9802491946757341,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPYMulticentrična randomizirana odprta raziskava faze III za proučitev učinkovitosti in varnosti zdravila MPDL3280A (protitelo anti−PD-L1) v primerjavi s kemoterapijo pri bolnikih z lokalno napredovalim ali metastatskim urotelnim karcinomom sečnega mehurja pri katerih je bolezen napredovala po zdravljenju s kemoterapijo s platino","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.5138371765321863e-96,1.5053639097868908e-13,0.9999999999998295,"2+",1.424862302967897e-05,0.9999857513769729,"Yes",0.9998131015959038,0.00018689840411144817,"No",1.0,4.875403019031762e-51,"No",9.70431870648657e-11,0.9999999999029683,"Yes",0.9999919430637758,8.056936233484492e-06,"No",1.0,5.5043651942533954e-27,"No",1.4941691221841185e-15,1.0,"Yes"
"2014-003231-19","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.198318752039932e-53,0.009911261291286194,0.9900887387087266,"2+",4.717740896542528e-08,0.9999999528225784,"Yes",0.999999912732822,8.726717870875959e-08,"No",1.0,1.4608902736758035e-18,"No",0.9887687755816433,0.011231224418356904,"Yes",0.9993395053086024,0.0006604946913992959,"No",0.9999999999864144,1.3583089639781612e-11,"No",0.03565243474215774,0.96434756525783,"Yes"
"2014-003282-19","An Open Label Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma.","NL","No","No","Yes","ok","Yes","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.602159915596617e-27,0.021788560657422063,0.9782114393425773,"2+",4.2532719574096625e-10,0.9999999995746691,"Yes",0.9999999994277431,5.722599341509729e-10,"No",0.9999999999926672,7.339289789690245e-12,"No",0.6223952880444138,0.37760471195558937,"Yes",0.31214531569422793,0.687854684305772,"Yes",0.9998153479408889,0.00018465205911051178,"No",0.1692712308350501,0.830728769164957,"Yes"
"2014-003282-19","An Open Label Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma.+ Country specific protocol amdt 05 dated 11-May-2016","FR","No","No","Yes","ok","No","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.096142748370352e-37,0.10413086457881741,0.8958691354211861,"2+",2.4231788948312077e-11,0.9999999999757563,"Yes",0.9999999999872956,1.2690611053934327e-11,"No",1.0,1.9103189837956934e-15,"No",0.994494411164172,0.005505588835825255,"Yes",0.02477176577712561,0.975228234222874,"Yes",0.9999999999932642,6.731757473010237e-12,"No",0.8739570896514153,0.12604291034857248,"Yes"
"2014-003282-19","An Open Label Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma.+ Country specific protocol amdt 05 dated 11-May-2016","GR","No","No","Yes","ok","No","No","Yes","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.096142748370352e-37,0.10413086457881741,0.8958691354211861,"2+",2.4231788948312077e-11,0.9999999999757563,"Yes",0.9999999999872956,1.2690611053934327e-11,"No",1.0,1.9103189837956934e-15,"No",0.994494411164172,0.005505588835825255,"Yes",0.02477176577712561,0.975228234222874,"Yes",0.9999999999932642,6.731757473010237e-12,"No",0.8739570896514153,0.12604291034857248,"Yes"
"2014-003282-19","An Open Label Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma.Ensayo fase 2 abierto aleatorizado de Pomalidomida/Dexametasona con o sin Elotuzumab en el mieloma múltiple en recidiva y refractario","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3278469213766373e-53,0.00020952431252106477,0.9997904756874778,"2+",3.9698183941007304e-20,1.0,"Yes",1.0,6.192067916689031e-20,"No",1.0,6.95066349077848e-20,"No",0.1784684567793293,0.8215315432206736,"Yes",0.05437807918468588,0.9456219208153117,"Yes",0.9999999999942588,5.73437107844109e-12,"No",0.0011853992310573002,0.9988146007689346,"Yes"
"2014-003282-19","An Open Label Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma.Ensayo fase 2 abierto aleatorizado de Pomalidomida/Dexametasona con o sin Elotuzumab en el mieloma múltiple en recidiva y refractario","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3278469213766373e-53,0.00020952431252106477,0.9997904756874778,"2+",3.9698183941007304e-20,1.0,"Yes",1.0,6.192067916689031e-20,"No",1.0,6.95066349077848e-20,"No",0.1784684567793293,0.8215315432206736,"Yes",0.05437807918468588,0.9456219208153117,"Yes",0.9999999999942588,5.73437107844109e-12,"No",0.0011853992310573002,0.9988146007689346,"Yes"
"2014-003282-19","An Open Label Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma.Ensayo fase 2 abierto aleatorizado de Pomalidomida/Dexametasona con o sin Elotuzumab en el mieloma múltiple en recidiva y refractario","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.3278469213766373e-53,0.00020952431252106477,0.9997904756874778,"2+",3.9698183941007304e-20,1.0,"Yes",1.0,6.192067916689031e-20,"No",1.0,6.95066349077848e-20,"No",0.1784684567793293,0.8215315432206736,"Yes",0.05437807918468588,0.9456219208153117,"Yes",0.9999999999942588,5.73437107844109e-12,"No",0.0011853992310573002,0.9988146007689346,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","RO","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003626-40","A Phase 3 Randomized Double-blind Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.9280998861660676e-44,5.889923025515009e-08,0.9999999411007696,"2+",0.999836966526647,0.0001630334733529887,"No",0.0005696941634784757,0.999430305836518,"Yes",0.9999999748223164,2.5177682870433612e-08,"No",2.2855677513505256e-05,0.9999771443224854,"Yes",0.100341507977839,0.8996584920221544,"Yes",0.9999979932213662,2.0067786347540785e-06,"No",1.162696719720338e-06,0.9999988373032745,"Yes"
"2014-003655-66","A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.199349497784663e-69,1.5855878743237306e-11,0.9999999999841408,"2+",0.999831047992662,0.00016895200733472494,"No",0.0005649039470815154,0.9994350960529184,"Yes",1.0,2.3544299142912702e-23,"No",1.1473964515936074e-09,0.9999999988526156,"Yes",0.02217979115763693,0.9778202088423625,"Yes",0.9999999999992895,6.9869926698294e-13,"No",1.5146490639958442e-10,0.9999999998485407,"Yes"
"2014-003655-66","A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.199349497784663e-69,1.5855878743237306e-11,0.9999999999841408,"2+",0.999831047992662,0.00016895200733472494,"No",0.0005649039470815154,0.9994350960529184,"Yes",1.0,2.3544299142912702e-23,"No",1.1473964515936074e-09,0.9999999988526156,"Yes",0.02217979115763693,0.9778202088423625,"Yes",0.9999999999992895,6.9869926698294e-13,"No",1.5146490639958442e-10,0.9999999998485407,"Yes"
"2014-003655-66","A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.Estudio de fase 3 aleatorizado doble ciego controlado con placebo en el que se compara ramucirumab y docetaxel con placebo y docetaxel en pacientes con carcinoma urotelial localmente avanzado o irresecable o metastásico que hayan progresado durante o después de un tratamiento basado en platino","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2479744553631589e-142,3.792155256246274e-19,1.0,"2+",0.9998527286708637,0.00014727132914649357,"No",0.000810665920873173,0.9991893340791014,"Yes",1.0,1.4178693294221649e-53,"No",5.360238042122753e-15,1.0,"Yes",0.0004161564497902263,0.9995838435502046,"Yes",1.0,4.063178604612215e-34,"No",3.105961664918084e-17,1.0,"Yes"
"2014-003655-66","A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.Estudio de fase 3 aleatorizado doble ciego controlado con placebo en el que se compara ramucirumab y docetaxel con placebo y docetaxel en pacientes con carcinoma urotelial localmente avanzado o irresecable o metastásico que hayan progresado durante o después de un tratamiento basado en platino","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2479744553631589e-142,3.792155256246274e-19,1.0,"2+",0.9998527286708637,0.00014727132914649357,"No",0.000810665920873173,0.9991893340791014,"Yes",1.0,1.4178693294221649e-53,"No",5.360238042122753e-15,1.0,"Yes",0.0004161564497902263,0.9995838435502046,"Yes",1.0,4.063178604612215e-34,"No",3.105961664918084e-17,1.0,"Yes"
"2014-003655-66","A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.199349497784663e-69,1.5855878743237306e-11,0.9999999999841408,"2+",0.999831047992662,0.00016895200733472494,"No",0.0005649039470815154,0.9994350960529184,"Yes",1.0,2.3544299142912702e-23,"No",1.1473964515936074e-09,0.9999999988526156,"Yes",0.02217979115763693,0.9778202088423625,"Yes",0.9999999999992895,6.9869926698294e-13,"No",1.5146490639958442e-10,0.9999999998485407,"Yes"
"2014-003655-66","A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.199349497784663e-69,1.5855878743237306e-11,0.9999999999841408,"2+",0.999831047992662,0.00016895200733472494,"No",0.0005649039470815154,0.9994350960529184,"Yes",1.0,2.3544299142912702e-23,"No",1.1473964515936074e-09,0.9999999988526156,"Yes",0.02217979115763693,0.9778202088423625,"Yes",0.9999999999992895,6.9869926698294e-13,"No",1.5146490639958442e-10,0.9999999998485407,"Yes"
"2014-003655-66","A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.199349497784663e-69,1.5855878743237306e-11,0.9999999999841408,"2+",0.999831047992662,0.00016895200733472494,"No",0.0005649039470815154,0.9994350960529184,"Yes",1.0,2.3544299142912702e-23,"No",1.1473964515936074e-09,0.9999999988526156,"Yes",0.02217979115763693,0.9778202088423625,"Yes",0.9999999999992895,6.9869926698294e-13,"No",1.5146490639958442e-10,0.9999999998485407,"Yes"
"2014-003655-66","A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.Estudio de fase 3 aleatorizado doble ciego controlado con placebo en el que se compara ramucirumab y docetaxel con placebo y docetaxel en pacientes con carcinoma urotelial localmente avanzado o irresecable o metastásico que hayan progresado durante o después de un tratamiento basado en platino","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2479744553631589e-142,3.792155256246274e-19,1.0,"2+",0.9998527286708637,0.00014727132914649357,"No",0.000810665920873173,0.9991893340791014,"Yes",1.0,1.4178693294221649e-53,"No",5.360238042122753e-15,1.0,"Yes",0.0004161564497902263,0.9995838435502046,"Yes",1.0,4.063178604612215e-34,"No",3.105961664918084e-17,1.0,"Yes"
"2014-003655-66","A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.Estudio de fase 3 aleatorizado doble ciego controlado con placebo en el que se compara ramucirumab y docetaxel con placebo y docetaxel en pacientes con carcinoma urotelial localmente avanzado o irresecable o metastásico que hayan progresado durante o después de un tratamiento basado en platino","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.2479744553631589e-142,3.792155256246274e-19,1.0,"2+",0.9998527286708637,0.00014727132914649357,"No",0.000810665920873173,0.9991893340791014,"Yes",1.0,1.4178693294221649e-53,"No",5.360238042122753e-15,1.0,"Yes",0.0004161564497902263,0.9995838435502046,"Yes",1.0,4.063178604612215e-34,"No",3.105961664918084e-17,1.0,"Yes"
"2014-003850-15","A phase II multicenter three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt) advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease ","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.4587078913972242e-66,0.5632976213467615,0.43670237865323946,"-1",1.2315887277628609e-13,0.9999999999998864,"Yes",0.9999999999994601,5.310273561920643e-13,"No",1.0,9.667080776896055e-30,"No",0.9999960851445343,3.914855460215897e-06,"No",0.9999995110986278,4.889013615234174e-07,"No",0.9999999999997159,2.8465792199751955e-13,"No",0.9968252957785496,0.0031747042214568676,"No"
"2014-003850-15","A phase II multicenter study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt) advanced non-small cell lung cancer (NSCLC)","GB","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","No","No","Yes","2+","No",1.617783060460915e-47,0.004138946982293312,0.995861053017707,"-1",2.0252983392295595e-10,0.9999999997974669,"Yes",0.999999999461636,5.383539008014906e-10,"No",1.0,1.89219206165971e-21,"No",0.991464337094431,0.0085356629055816,"No",0.9999851149299803,1.4885070031514425e-05,"No",0.999999970995106,2.900488391682278e-08,"No",0.4999645103129186,0.500035489687085,"No"
"2014-003850-15","A phase II multicenter study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt) advanced non-small cell lung cancer (NSCLC) ","SE","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","No","No","Yes","2+","No",1.617783060460915e-47,0.004138946982293312,0.995861053017707,"-1",2.0252983392295595e-10,0.9999999997974669,"Yes",0.999999999461636,5.383539008014906e-10,"No",1.0,1.89219206165971e-21,"No",0.991464337094431,0.0085356629055816,"No",0.9999851149299803,1.4885070031514425e-05,"No",0.999999970995106,2.900488391682278e-08,"No",0.4999645103129186,0.500035489687085,"No"
"2014-003850-15","A phase II multicenter study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt) advanced non-small cell lung cancer (NSCLC)","AT","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","No","No","Yes","2+","No",1.617783060460915e-47,0.004138946982293312,0.995861053017707,"-1",2.0252983392295595e-10,0.9999999997974669,"Yes",0.999999999461636,5.383539008014906e-10,"No",1.0,1.89219206165971e-21,"No",0.991464337094431,0.0085356629055816,"No",0.9999851149299803,1.4885070031514425e-05,"No",0.999999970995106,2.900488391682278e-08,"No",0.4999645103129186,0.500035489687085,"No"
"2014-003850-15","A phase II multicenter three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt) advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease ","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.4587078913972242e-66,0.5632976213467615,0.43670237865323946,"-1",1.2315887277628609e-13,0.9999999999998864,"Yes",0.9999999999994601,5.310273561920643e-13,"No",1.0,9.667080776896055e-30,"No",0.9999960851445343,3.914855460215897e-06,"No",0.9999995110986278,4.889013615234174e-07,"No",0.9999999999997159,2.8465792199751955e-13,"No",0.9968252957785496,0.0031747042214568676,"No"
"2014-003850-15","A phase II multicenter three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt) advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease ","BE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.4587078913972242e-66,0.5632976213467615,0.43670237865323946,"-1",1.2315887277628609e-13,0.9999999999998864,"Yes",0.9999999999994601,5.310273561920643e-13,"No",1.0,9.667080776896055e-30,"No",0.9999960851445343,3.914855460215897e-06,"No",0.9999995110986278,4.889013615234174e-07,"No",0.9999999999997159,2.8465792199751955e-13,"No",0.9968252957785496,0.0031747042214568676,"No"
"2014-003850-15","A phase II multicenter three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt) advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease ","FR","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.4587078913972242e-66,0.5632976213467615,0.43670237865323946,"-1",1.2315887277628609e-13,0.9999999999998864,"Yes",0.9999999999994601,5.310273561920643e-13,"No",1.0,9.667080776896055e-30,"No",0.9999960851445343,3.914855460215897e-06,"No",0.9999995110986278,4.889013615234174e-07,"No",0.9999999999997159,2.8465792199751955e-13,"No",0.9968252957785496,0.0031747042214568676,"No"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancerStudio di fase 3 randomizzato in doppio cieco su PF-06439535 in associazione con paclitaxel-carboplatino e bevacizumab in associazione con paclitaxel-carboplatino per il trattamento di prima linea di pazienti affetti da carcinoma polmonare non a piccole cellule non squamoso in stadio avanzato","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.908083312359539e-129,1.4921640524832926e-16,1.0,"2+",0.0012783188721606597,0.9987216811278602,"No",0.9966908625108972,0.0033091374890996685,"Yes",1.0,3.88427636213064e-55,"No",3.4745568542786e-11,0.9999999999652687,"Yes",0.0046414024369125055,0.9953585975630759,"Yes",1.0,4.184880903731103e-34,"No",8.013658609612836e-14,0.9999999999999432,"Yes"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer. RANDOMIZOVANÉ DVOJITO ZASLEPENÉ KLINICKÉ SKÚŠANIE FÁZY 3 POROVNÁVAJÚCE KOMBINÁCIU PF 06439535 PLUS PAKLITAXEL-KARBOPLATINA A BEVACIZUMAB PLUS PAKLITAXEL-KARBOPLATINA AKO PRVOLÍNIOVEJ LIEČBY PACIENTOV S POKROČILOU NESKVAMÓZNOU NEMALOBUNKOVOU RAKOVINOU PĽÚC","HR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.515413309905487e-100,1.2942569488514715e-22,1.0,"2+",0.022623913039573743,0.9773760869604329,"No",0.9363326546122935,0.06366734538767811,"Yes",1.0,5.449176445643241e-53,"No",8.226785064498547e-21,1.0,"Yes",0.830933822440402,0.1690661775596182,"Yes",1.0,2.6186173897746004e-34,"No",8.755795953055837e-22,1.0,"Yes"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer. RANDOMIZOVANÉ DVOJITO ZASLEPENÉ KLINICKÉ SKÚŠANIE FÁZY 3 POROVNÁVAJÚCE KOMBINÁCIU PF 06439535 PLUS PAKLITAXEL-KARBOPLATINA A BEVACIZUMAB PLUS PAKLITAXEL-KARBOPLATINA AKO PRVOLÍNIOVEJ LIEČBY PACIENTOV S POKROČILOU NESKVAMÓZNOU NEMALOBUNKOVOU RAKOVINOU PĽÚC","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.515413309905487e-100,1.2942569488514715e-22,1.0,"2+",0.022623913039573743,0.9773760869604329,"No",0.9363326546122935,0.06366734538767811,"Yes",1.0,5.449176445643241e-53,"No",8.226785064498547e-21,1.0,"Yes",0.830933822440402,0.1690661775596182,"Yes",1.0,2.6186173897746004e-34,"No",8.755795953055837e-22,1.0,"Yes"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancerStudio di fase 3 randomizzato in doppio cieco su PF-06439535 in associazione con paclitaxel-carboplatino e bevacizumab in associazione con paclitaxel-carboplatino per il trattamento di prima linea di pazienti affetti da carcinoma polmonare non a piccole cellule non squamoso in stadio avanzato","SK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.908083312359539e-129,1.4921640524832926e-16,1.0,"2+",0.0012783188721606597,0.9987216811278602,"No",0.9966908625108972,0.0033091374890996685,"Yes",1.0,3.88427636213064e-55,"No",3.4745568542786e-11,0.9999999999652687,"Yes",0.0046414024369125055,0.9953585975630759,"Yes",1.0,4.184880903731103e-34,"No",8.013658609612836e-14,0.9999999999999432,"Yes"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer. ","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.715180739994675e-63,5.83681052478848e-09,0.9999999941631758,"2+",0.5132108316227393,0.4867891683772585,"No",0.49843676373934953,0.501563236260659,"Yes",1.0,3.746304702353928e-26,"No",4.387921476773134e-06,0.9999956120785134,"Yes",0.5944008469090479,0.4055991530909636,"Yes",0.9999999990854178,9.145843508143949e-10,"No",8.977100769190687e-08,0.9999999102289833,"Yes"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancerStudio di fase 3 randomizzato in doppio cieco su PF-06439535 in associazione con paclitaxel-carboplatino e bevacizumab in associazione con paclitaxel-carboplatino per il trattamento di prima linea di pazienti affetti da carcinoma polmonare non a piccole cellule non squamoso in stadio avanzato","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.908083312359539e-129,1.4921640524832926e-16,1.0,"2+",0.0012783188721606597,0.9987216811278602,"No",0.9966908625108972,0.0033091374890996685,"Yes",1.0,3.88427636213064e-55,"No",3.4745568542786e-11,0.9999999999652687,"Yes",0.0046414024369125055,0.9953585975630759,"Yes",1.0,4.184880903731103e-34,"No",8.013658609612836e-14,0.9999999999999432,"Yes"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer. Randomizirano dvostruko slijepo ispitivanje faze III lijeka PF 06439535 u kombinaciji s paklitakselom i karboplatinom  te bevacizumaba u kombinaciji s  paklitakselom i karboplatinom  kao prve linije liječenja u bolesnika s uznapredovalim neskvamoznim karcinomom nemalih stanica pluća ","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.2147636482557538e-102,5.764592224565584e-24,1.0,"2+",0.9999999999126885,8.728824822859812e-11,"No",1.5665590290738172e-11,0.9999999999843112,"Yes",1.0,1.9874136710353772e-54,"No",1.3926736618821323e-21,1.0,"Yes",0.20117078084699688,0.7988292191530127,"Yes",1.0,1.777732002478043e-36,"No",4.6284306324189135e-24,1.0,"Yes"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer. Randomizirano dvostruko slijepo ispitivanje faze III lijeka PF 06439535 u kombinaciji s paklitakselom i karboplatinom  te bevacizumaba u kombinaciji s  paklitakselom i karboplatinom  kao prve linije liječenja u bolesnika s uznapredovalim neskvamoznim karcinomom nemalih stanica pluća ","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",1.2147636482557538e-102,5.764592224565584e-24,1.0,"2+",0.9999999999126885,8.728824822859812e-11,"No",1.5665590290738172e-11,0.9999999999843112,"Yes",1.0,1.9874136710353772e-54,"No",1.3926736618821323e-21,1.0,"Yes",0.20117078084699688,0.7988292191530127,"Yes",1.0,1.777732002478043e-36,"No",4.6284306324189135e-24,1.0,"Yes"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer.ESTUDIO EN FASE III ALEATORIZADO Y DOBLE CIEGO DE PF-06439535 MÁS PACLITAXEL-CARBOPLATINO Y BEVACIZUMAB MÁS PACLITAXEL-CARBOPLATINO PARA EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CÁNCER DE PULMÓN NO ESCAMOCELULAR NO MICROCÍTICO AVANZADO","GR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.504332144828544e-114,1.2647787517073176e-16,1.0,"2+",0.26699542438158697,0.7330045756183984,"No",0.7219039414800577,0.27809605851996166,"Yes",1.0,1.2924093680407143e-48,"No",1.5799126928041213e-11,0.9999999999841975,"Yes",0.24023107298481158,0.7597689270151855,"Yes",1.0,1.6761940320032234e-35,"No",3.406219709894973e-14,0.9999999999999432,"Yes"
"2014-003878-16","A Phase 3 randomized double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer.ESTUDIO EN FASE III ALEATORIZADO Y DOBLE CIEGO DE PF-06439535 MÁS PACLITAXEL-CARBOPLATINO Y BEVACIZUMAB MÁS PACLITAXEL-CARBOPLATINO PARA EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CÁNCER DE PULMÓN NO ESCAMOCELULAR NO MICROCÍTICO AVANZADO","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",3.504332144828544e-114,1.2647787517073176e-16,1.0,"2+",0.26699542438158697,0.7330045756183984,"No",0.7219039414800577,0.27809605851996166,"Yes",1.0,1.2924093680407143e-48,"No",1.5799126928041213e-11,0.9999999999841975,"Yes",0.24023107298481158,0.7597689270151855,"Yes",1.0,1.6761940320032234e-35,"No",3.406219709894973e-14,0.9999999999999432,"Yes"
"2014-004599-49","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus - Study Two","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.475954186852398e-56,4.500852833004402e-17,1.0,"2+",0.9999999999261036,7.39018046409284e-11,"No",2.6051861979153405e-10,0.9999999997394866,"Yes",0.9999999999913882,8.61588882331106e-12,"No",1.1247195363248332e-16,1.0,"Yes",2.153566845125253e-08,0.9999999784643311,"Yes",0.9999957668305868,4.233169411666829e-06,"No",2.4606112002887007e-15,1.0,"Yes"
"2014-004599-49","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus - Study Two","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.475954186852398e-56,4.500852833004402e-17,1.0,"2+",0.9999999999261036,7.39018046409284e-11,"No",2.6051861979153405e-10,0.9999999997394866,"Yes",0.9999999999913882,8.61588882331106e-12,"No",1.1247195363248332e-16,1.0,"Yes",2.153566845125253e-08,0.9999999784643311,"Yes",0.9999957668305868,4.233169411666829e-06,"No",2.4606112002887007e-15,1.0,"Yes"
"2014-004599-49","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus - Study Two","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.475954186852398e-56,4.500852833004402e-17,1.0,"2+",0.9999999999261036,7.39018046409284e-11,"No",2.6051861979153405e-10,0.9999999997394866,"Yes",0.9999999999913882,8.61588882331106e-12,"No",1.1247195363248332e-16,1.0,"Yes",2.153566845125253e-08,0.9999999784643311,"Yes",0.9999957668305868,4.233169411666829e-06,"No",2.4606112002887007e-15,1.0,"Yes"
"2014-004599-49","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus - Study Two","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.475954186852398e-56,4.500852833004402e-17,1.0,"2+",0.9999999999261036,7.39018046409284e-11,"No",2.6051861979153405e-10,0.9999999997394866,"Yes",0.9999999999913882,8.61588882331106e-12,"No",1.1247195363248332e-16,1.0,"Yes",2.153566845125253e-08,0.9999999784643311,"Yes",0.9999957668305868,4.233169411666829e-06,"No",2.4606112002887007e-15,1.0,"Yes"
"2014-004599-49","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus - Study Two","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.475954186852398e-56,4.500852833004402e-17,1.0,"2+",0.9999999999261036,7.39018046409284e-11,"No",2.6051861979153405e-10,0.9999999997394866,"Yes",0.9999999999913882,8.61588882331106e-12,"No",1.1247195363248332e-16,1.0,"Yes",2.153566845125253e-08,0.9999999784643311,"Yes",0.9999957668305868,4.233169411666829e-06,"No",2.4606112002887007e-15,1.0,"Yes"
"2014-004599-49","A Multicenter Randomized Double-Blind Placebo-controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus - Study Two","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.475954186852398e-56,4.500852833004402e-17,1.0,"2+",0.9999999999261036,7.39018046409284e-11,"No",2.6051861979153405e-10,0.9999999997394866,"Yes",0.9999999999913882,8.61588882331106e-12,"No",1.1247195363248332e-16,1.0,"Yes",2.153566845125253e-08,0.9999999784643311,"Yes",0.9999957668305868,4.233169411666829e-06,"No",2.4606112002887007e-15,1.0,"Yes"
"2014-004697-41","AN EARLY-PHASE MULTICENTER OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI−PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.2998876017495982e-37,0.9991271429569483,0.0008728570430592611,"-1",3.9804570692561704e-10,0.9999999996019541,"Yes",0.9999999993117826,6.882246681068741e-10,"No",1.0,5.412541229221212e-16,"No",0.9999999645895066,3.541048938563435e-08,"No",0.999999991293791,8.70621304157129e-09,"No",0.9999989908042982,1.0091957104317944e-06,"No",0.9999953475157723,4.652484225177086e-06,"No"
"2014-004697-41","AN EARLY-PHASE MULTICENTER OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI?PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORSESTUDIO EN FASE TEMPRANA MULTICÉNTRICO ABIERTO DE LA SEGURIDAD Y FARMACOCINÉTICA DEL ANTICUERPO ANTI-PD-L1 (MPDL3280A) EN PACIENTES PEDIÁTRICOS Y ADULTOS JÓVENES CON TUMORES SÓLIDOS PREVIAMENTE TRATADOS","AT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.3598806991042243e-80,0.9999999906625591,9.337432677916427e-09,"-1",4.20156992404522e-21,1.0,"Yes",1.0,7.285908640703022e-21,"No",1.0,1.6328216404887109e-34,"No",1.0,3.320892075585233e-16,"No",1.0,2.9715663381792658e-15,"No",1.0,2.7969556831085107e-17,"No",0.9999999999995453,4.3412022641869003e-13,"No"
"2014-004697-41","AN EARLY-PHASE MULTICENTER OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI?PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORSESTUDIO EN FASE TEMPRANA MULTICÉNTRICO ABIERTO DE LA SEGURIDAD Y FARMACOCINÉTICA DEL ANTICUERPO ANTI-PD-L1 (MPDL3280A) EN PACIENTES PEDIÁTRICOS Y ADULTOS JÓVENES CON TUMORES SÓLIDOS PREVIAMENTE TRATADOS","DK","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.3598806991042243e-80,0.9999999906625591,9.337432677916427e-09,"-1",4.20156992404522e-21,1.0,"Yes",1.0,7.285908640703022e-21,"No",1.0,1.6328216404887109e-34,"No",1.0,3.320892075585233e-16,"No",1.0,2.9715663381792658e-15,"No",1.0,2.7969556831085107e-17,"No",0.9999999999995453,4.3412022641869003e-13,"No"
"2014-004697-41","AN EARLY-PHASE MULTICENTER OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI?PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORSESTUDIO EN FASE TEMPRANA MULTICÉNTRICO ABIERTO DE LA SEGURIDAD Y FARMACOCINÉTICA DEL ANTICUERPO ANTI-PD-L1 (MPDL3280A) EN PACIENTES PEDIÁTRICOS Y ADULTOS JÓVENES CON TUMORES SÓLIDOS PREVIAMENTE TRATADOS","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.3598806991042243e-80,0.9999999906625591,9.337432677916427e-09,"-1",4.20156992404522e-21,1.0,"Yes",1.0,7.285908640703022e-21,"No",1.0,1.6328216404887109e-34,"No",1.0,3.320892075585233e-16,"No",1.0,2.9715663381792658e-15,"No",1.0,2.7969556831085107e-17,"No",0.9999999999995453,4.3412022641869003e-13,"No"
"2014-004697-41","AN EARLY-PHASE MULTICENTER OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI−PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.2998876017495982e-37,0.9991271429569483,0.0008728570430592611,"-1",3.9804570692561704e-10,0.9999999996019541,"Yes",0.9999999993117826,6.882246681068741e-10,"No",1.0,5.412541229221212e-16,"No",0.9999999645895066,3.541048938563435e-08,"No",0.999999991293791,8.70621304157129e-09,"No",0.9999989908042982,1.0091957104317944e-06,"No",0.9999953475157723,4.652484225177086e-06,"No"
"2014-004697-41","AN EARLY-PHASE MULTICENTER OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI−PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS","IE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.2998876017495982e-37,0.9991271429569483,0.0008728570430592611,"-1",3.9804570692561704e-10,0.9999999996019541,"Yes",0.9999999993117826,6.882246681068741e-10,"No",1.0,5.412541229221212e-16,"No",0.9999999645895066,3.541048938563435e-08,"No",0.999999991293791,8.70621304157129e-09,"No",0.9999989908042982,1.0091957104317944e-06,"No",0.9999953475157723,4.652484225177086e-06,"No"
"2014-004697-41","AN EARLY-PHASE MULTICENTER OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI−PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS","IT","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.2998876017495982e-37,0.9991271429569483,0.0008728570430592611,"-1",3.9804570692561704e-10,0.9999999996019541,"Yes",0.9999999993117826,6.882246681068741e-10,"No",1.0,5.412541229221212e-16,"No",0.9999999645895066,3.541048938563435e-08,"No",0.999999991293791,8.70621304157129e-09,"No",0.9999989908042982,1.0091957104317944e-06,"No",0.9999953475157723,4.652484225177086e-06,"No"
"2014-004697-41","AN EARLY-PHASE MULTICENTER OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI?PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORSESTUDIO EN FASE TEMPRANA MULTICÉNTRICO ABIERTO DE LA SEGURIDAD Y FARMACOCINÉTICA DEL ANTICUERPO ANTI-PD-L1 (MPDL3280A) EN PACIENTES PEDIÁTRICOS Y ADULTOS JÓVENES CON TUMORES SÓLIDOS PREVIAMENTE TRATADOS","FR","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",3.3598806991042243e-80,0.9999999906625591,9.337432677916427e-09,"-1",4.20156992404522e-21,1.0,"Yes",1.0,7.285908640703022e-21,"No",1.0,1.6328216404887109e-34,"No",1.0,3.320892075585233e-16,"No",1.0,2.9715663381792658e-15,"No",1.0,2.7969556831085107e-17,"No",0.9999999999995453,4.3412022641869003e-13,"No"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.088238877604061e-70,1.4890717373084584e-11,0.999999999985107,"2+",0.976334964890738,0.02366503510927026,"No",0.05235268740294016,0.9476473125970574,"Yes",1.0,1.456627654994398e-27,"No",4.5452866875756424e-08,0.9999999545471223,"Yes",0.07697842312750765,0.9230215768724878,"No",0.999999999999801,2.0878357018092937e-13,"Yes",6.320196131195607e-10,0.9999999993679864,"Yes"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.Inmunoterapia complementaria con pembrolizumab (MK-3475) un anticuerpo monoclonal anti-PD-1 en comparación con placebo tras resección completa de melanoma en estadio III de alto riesgo: un ensayo en fase III aleatorizado y doble ciego del grupo de melanoma de la EORTC","AT","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5822909567972783e-132,2.9739775057881493e-19,1.0,"2+",0.6898366354300032,0.31016336456998406,"No",0.6409371930742196,0.3590628069257901,"Yes",1.0,1.9559891343454978e-56,"No",1.5131038405447373e-13,0.9999999999998295,"Yes",0.3881111225123857,0.611888877487597,"No",1.0,9.988689296846735e-35,"Yes",8.236740253621535e-18,1.0,"Yes"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.088238877604061e-70,1.4890717373084584e-11,0.999999999985107,"2+",0.976334964890738,0.02366503510927026,"No",0.05235268740294016,0.9476473125970574,"Yes",1.0,1.456627654994398e-27,"No",4.5452866875756424e-08,0.9999999545471223,"Yes",0.07697842312750765,0.9230215768724878,"No",0.999999999999801,2.0878357018092937e-13,"Yes",6.320196131195607e-10,0.9999999993679864,"Yes"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.088238877604061e-70,1.4890717373084584e-11,0.999999999985107,"2+",0.976334964890738,0.02366503510927026,"No",0.05235268740294016,0.9476473125970574,"Yes",1.0,1.456627654994398e-27,"No",4.5452866875756424e-08,0.9999999545471223,"Yes",0.07697842312750765,0.9230215768724878,"No",0.999999999999801,2.0878357018092937e-13,"Yes",6.320196131195607e-10,0.9999999993679864,"Yes"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.088238877604061e-70,1.4890717373084584e-11,0.999999999985107,"2+",0.976334964890738,0.02366503510927026,"No",0.05235268740294016,0.9476473125970574,"Yes",1.0,1.456627654994398e-27,"No",4.5452866875756424e-08,0.9999999545471223,"Yes",0.07697842312750765,0.9230215768724878,"No",0.999999999999801,2.0878357018092937e-13,"Yes",6.320196131195607e-10,0.9999999993679864,"Yes"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.","PT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.088238877604061e-70,1.4890717373084584e-11,0.999999999985107,"2+",0.976334964890738,0.02366503510927026,"No",0.05235268740294016,0.9476473125970574,"Yes",1.0,1.456627654994398e-27,"No",4.5452866875756424e-08,0.9999999545471223,"Yes",0.07697842312750765,0.9230215768724878,"No",0.999999999999801,2.0878357018092937e-13,"Yes",6.320196131195607e-10,0.9999999993679864,"Yes"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.Inmunoterapia complementaria con pembrolizumab (MK-3475) un anticuerpo monoclonal anti-PD-1 en comparación con placebo tras resección completa de melanoma en estadio III de alto riesgo: un ensayo en fase III aleatorizado y doble ciego del grupo de melanoma de la EORTC","BE","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5822909567972783e-132,2.9739775057881493e-19,1.0,"2+",0.6898366354300032,0.31016336456998406,"No",0.6409371930742196,0.3590628069257901,"Yes",1.0,1.9559891343454978e-56,"No",1.5131038405447373e-13,0.9999999999998295,"Yes",0.3881111225123857,0.611888877487597,"No",1.0,9.988689296846735e-35,"Yes",8.236740253621535e-18,1.0,"Yes"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.Inmunoterapia complementaria con pembrolizumab (MK-3475) un anticuerpo monoclonal anti-PD-1 en comparación con placebo tras resección completa de melanoma en estadio III de alto riesgo: un ensayo en fase III aleatorizado y doble ciego del grupo de melanoma de la EORTC","NL","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5822909567972783e-132,2.9739775057881493e-19,1.0,"2+",0.6898366354300032,0.31016336456998406,"No",0.6409371930742196,0.3590628069257901,"Yes",1.0,1.9559891343454978e-56,"No",1.5131038405447373e-13,0.9999999999998295,"Yes",0.3881111225123857,0.611888877487597,"No",1.0,9.988689296846735e-35,"Yes",8.236740253621535e-18,1.0,"Yes"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.Inmunoterapia complementaria con pembrolizumab (MK-3475) un anticuerpo monoclonal anti-PD-1 en comparación con placebo tras resección completa de melanoma en estadio III de alto riesgo: un ensayo en fase III aleatorizado y doble ciego del grupo de melanoma de la EORTC","FI","No","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.5822909567972783e-132,2.9739775057881493e-19,1.0,"2+",0.6898366354300032,0.31016336456998406,"No",0.6409371930742196,0.3590628069257901,"Yes",1.0,1.9559891343454978e-56,"No",1.5131038405447373e-13,0.9999999999998295,"Yes",0.3881111225123857,0.611888877487597,"No",1.0,9.988689296846735e-35,"Yes",8.236740253621535e-18,1.0,"Yes"
"2014-004944-37","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized double-blind Phase 3 trial of the EORTC Melanoma Group.","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.088238877604061e-70,1.4890717373084584e-11,0.999999999985107,"2+",0.976334964890738,0.02366503510927026,"No",0.05235268740294016,0.9476473125970574,"Yes",1.0,1.456627654994398e-27,"No",4.5452866875756424e-08,0.9999999545471223,"Yes",0.07697842312750765,0.9230215768724878,"No",0.999999999999801,2.0878357018092937e-13,"Yes",6.320196131195607e-10,0.9999999993679864,"Yes"
"2014-005199-27","A Multicenter Randomized Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects with 131I Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose But Have a Better Safety Profile","DE","Yes","No","No","","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5392357655797825e-64,2.40084100107786e-07,0.9999997599159092,"2+",0.9998242051091181,0.00017579489089480647,"No",0.0003023086616460654,0.9996976913383621,"Information not present in EudraCT",1.0,4.869893094252779e-16,"No",5.0235060137423584e-08,0.9999999497649426,"Yes",0.9997828967094988,0.00021710329049615947,"No",0.9999999999783427,2.1645884242304853e-11,"No",1.9455017049628538e-06,0.9999980544983086,"Yes"
"2014-005199-27","A Multicenter Randomized Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects with 131I Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose But Have a Better Safety ProfileEnsayo multicéntrico aleatorizado doble ciego de fase 2 de lenvatinib (E7080) en sujetos con cáncer tiroideo diferenciado resistente a 131I para determinar si una dosis oral inicial de 20 mg o 14 mg al día proporciona una eficacia comparable a la de una dosis inicial de 24 mg pero con un mejor perfil de seguridad","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.4023841664455097e-132,1.1609190192655564e-16,1.0,"2+",0.9999999999699868,2.9964874637179405e-11,"No",6.404071659721378e-11,0.9999999999359944,"Yes",1.0,1.5350992747723577e-32,"No",1.4854634400530335e-17,1.0,"Yes",0.9999367809617956,6.321903819535112e-05,"No",1.0,2.1186714883437064e-30,"No",1.8031170717567434e-17,1.0,"Yes"
"2014-005199-27","A Multicenter Randomized Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects with 131I Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose But Have a Better Safety ProfileEnsayo multicéntrico aleatorizado doble ciego de fase 2 de lenvatinib (E7080) en sujetos con cáncer tiroideo diferenciado resistente a 131I para determinar si una dosis oral inicial de 20 mg o 14 mg al día proporciona una eficacia comparable a la de una dosis inicial de 24 mg pero con un mejor perfil de seguridad","DK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.4023841664455097e-132,1.1609190192655564e-16,1.0,"2+",0.9999999999699868,2.9964874637179405e-11,"No",6.404071659721378e-11,0.9999999999359944,"Yes",1.0,1.5350992747723577e-32,"No",1.4854634400530335e-17,1.0,"Yes",0.9999367809617956,6.321903819535112e-05,"No",1.0,2.1186714883437064e-30,"No",1.8031170717567434e-17,1.0,"Yes"
"2014-005199-27","A Multicenter Randomized Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects with 131I Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose But Have a Better Safety ProfileEnsayo multicéntrico aleatorizado doble ciego de fase 2 de lenvatinib (E7080) en sujetos con cáncer tiroideo diferenciado resistente a 131I para determinar si una dosis oral inicial de 20 mg o 14 mg al día proporciona una eficacia comparable a la de una dosis inicial de 24 mg pero con un mejor perfil de seguridad","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",2.4023841664455097e-132,1.1609190192655564e-16,1.0,"2+",0.9999999999699868,2.9964874637179405e-11,"No",6.404071659721378e-11,0.9999999999359944,"Yes",1.0,1.5350992747723577e-32,"No",1.4854634400530335e-17,1.0,"Yes",0.9999367809617956,6.321903819535112e-05,"No",1.0,2.1186714883437064e-30,"No",1.8031170717567434e-17,1.0,"Yes"
"2014-005199-27","A Multicenter Randomized Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects with 131I Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose But Have a Better Safety Profile","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.5392357655797825e-64,2.40084100107786e-07,0.9999997599159092,"2+",0.9998242051091181,0.00017579489089480647,"No",0.0003023086616460654,0.9996976913383621,"Yes",1.0,4.869893094252779e-16,"No",5.0235060137423584e-08,0.9999999497649426,"Yes",0.9997828967094988,0.00021710329049615947,"No",0.9999999999783427,2.1645884242304853e-11,"No",1.9455017049628538e-06,0.9999980544983086,"Yes"
"2014-005330-58","A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",9.003193408653997e-37,0.7439356259179105,0.2560643740820934,"1",6.002761146756533e-07,0.9999993997238715,"Yes",0.9999992513627621,7.486372386766765e-07,"No",0.9999999555646762,4.443532062927905e-08,"No",0.9602777532880767,0.03972224671192231,"No",0.8068023614596816,0.19319763854031513,"No",0.9999999992147082,7.852950729095404e-10,"No",0.634326260820929,0.36567373917907453,"No"
"2014-005330-58","A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",9.003193408653997e-37,0.7439356259179105,0.2560643740820934,"1",6.002761146756533e-07,0.9999993997238715,"Yes",0.9999992513627621,7.486372386766765e-07,"No",0.9999999555646762,4.443532062927905e-08,"No",0.9602777532880767,0.03972224671192231,"No",0.8068023614596816,0.19319763854031513,"No",0.9999999992147082,7.852950729095404e-10,"No",0.634326260820929,0.36567373917907453,"No"
"2014-005486-75","neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive HER2 Negative Breast CancerneoMONARCH: Ensayo de fase 2 de neoadyuvancia en el que se comparan los efectos biológicos de la administración durante 2 semanas de la combinación de abemaciclib (LY2835219) y anastrozol con los de abemaciclib y anastrozol ambos en monoterapia evaluando asimismo la actividad clínica y la seguridad de un tratamiento posterior con abemaciclib y anastrozol en combinación durante 14 semanas en mujeres posmenopáusicas con cáncer de mama receptores hormonales positivos y HER2 negativo","NL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6901385620772774e-144,3.298752328413231e-10,0.9999999996700809,"2+",2.275418277461938e-12,0.9999999999977264,"Yes",0.9999999999946568,5.348145655879278e-12,"No",1.0,3.1423071851855383e-53,"No",0.9995358788565402,0.0004641211434623233,"Yes",0.9998202577240789,0.00017974227595617516,"No",1.0,1.2018030447358257e-46,"Yes",1.5142902342182776e-10,0.9999999998485692,"Yes"
"2014-005486-75","neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive HER2 Negative Breast CancerneoMONARCH: Ensayo de fase 2 de neoadyuvancia en el que se comparan los efectos biológicos de la administración durante 2 semanas de la combinación de abemaciclib (LY2835219) y anastrozol con los de abemaciclib y anastrozol ambos en monoterapia evaluando asimismo la actividad clínica y la seguridad de un tratamiento posterior con abemaciclib y anastrozol en combinación durante 14 semanas en mujeres posmenopáusicas con cáncer de mama receptores hormonales positivos y HER2 negativo","AT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6901385620772774e-144,3.298752328413231e-10,0.9999999996700809,"2+",2.275418277461938e-12,0.9999999999977264,"Yes",0.9999999999946568,5.348145655879278e-12,"No",1.0,3.1423071851855383e-53,"No",0.9995358788565402,0.0004641211434623233,"Yes",0.9998202577240789,0.00017974227595617516,"No",1.0,1.2018030447358257e-46,"Yes",1.5142902342182776e-10,0.9999999998485692,"Yes"
"2014-005486-75","neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive HER2 Negative Breast Cancer","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3479183102265083e-75,1.4024603199689783e-07,0.9999998597539942,"2+",4.527895737825041e-07,0.999999547210439,"Yes",0.999998607190495,1.3928094904180639e-06,"No",1.0,4.7721831477744517e-26,"No",0.1382480705118175,0.8617519294881829,"Yes",0.9819273864796678,0.018072613520311087,"No",1.0,6.010076030745969e-19,"Yes",3.7625750292687147e-07,0.9999996237425106,"Yes"
"2014-005486-75","neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive HER2 Negative Breast CancerneoMONARCH: Ensayo de fase 2 de neoadyuvancia en el que se comparan los efectos biológicos de la administración durante 2 semanas de la combinación de abemaciclib (LY2835219) y anastrozol con los de abemaciclib y anastrozol ambos en monoterapia evaluando asimismo la actividad clínica y la seguridad de un tratamiento posterior con abemaciclib y anastrozol en combinación durante 14 semanas en mujeres posmenopáusicas con cáncer de mama receptores hormonales positivos y HER2 negativo","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6901385620772774e-144,3.298752328413231e-10,0.9999999996700809,"2+",2.275418277461938e-12,0.9999999999977264,"Yes",0.9999999999946568,5.348145655879278e-12,"No",1.0,3.1423071851855383e-53,"No",0.9995358788565402,0.0004641211434623233,"Yes",0.9998202577240789,0.00017974227595617516,"No",1.0,1.2018030447358257e-46,"Yes",1.5142902342182776e-10,0.9999999998485692,"Yes"
"2014-005486-75","neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive HER2 Negative Breast CancerneoMONARCH: Ensayo de fase 2 de neoadyuvancia en el que se comparan los efectos biológicos de la administración durante 2 semanas de la combinación de abemaciclib (LY2835219) y anastrozol con los de abemaciclib y anastrozol ambos en monoterapia evaluando asimismo la actividad clínica y la seguridad de un tratamiento posterior con abemaciclib y anastrozol en combinación durante 14 semanas en mujeres posmenopáusicas con cáncer de mama receptores hormonales positivos y HER2 negativo","BE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6901385620772774e-144,3.298752328413231e-10,0.9999999996700809,"2+",2.275418277461938e-12,0.9999999999977264,"Yes",0.9999999999946568,5.348145655879278e-12,"No",1.0,3.1423071851855383e-53,"No",0.9995358788565402,0.0004641211434623233,"Yes",0.9998202577240789,0.00017974227595617516,"No",1.0,1.2018030447358257e-46,"Yes",1.5142902342182776e-10,0.9999999998485692,"Yes"
"2014-005595-28","Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial. Einleitungstherapie mit Gefitinib gefolgt von einer Taxan-Platin-Chemotherapie mit Verabreichung von Gefitinib bei nicht-kleinzelligem Lungenkarzinom Stadium II-IIIb mit aktivierenden EGFR Mutationen - eine einarmige Phase II Studie","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",1.0632300732336874e-78,0.8525292031706811,0.14747079682929698,"1",1.2577585052460997e-19,1.0,"Yes",1.0,3.657662257926895e-19,"No",1.0,1.5746201752449121e-30,"No",0.9016518644325363,0.09834813556748506,"No",0.999999884529252,1.1547073311366524e-07,"No",1.0,4.996782461931429e-25,"No",0.921038914263025,0.07896108573697118,"No"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED HIGH RISK MUSCLE INVASIVE BLADDER CANCER AFTER CYSTECTOMY","GR","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0838477836385247e-52,0.029979550946416588,0.9700204490535694,"2+",1.1647474722197975e-13,0.9999999999998864,"Yes",0.9999999999997442,2.5877741440803396e-13,"No",1.0,1.4321205030343327e-20,"No",0.9846018949476886,0.015398105052315524,"Yes",0.9999993211135947,6.7888640862344e-07,"No",0.9999999997429825,2.5702029358485773e-10,"No",0.00782172035452328,0.992178279645485,"Yes"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB  (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-POSITIVE HIGH RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION","ES","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.379380287204992e-56,0.02975990751118689,0.9702400924888037,"2+",6.463689872002324e-11,0.9999999999353691,"Yes",0.9999999999128022,8.718933482463754e-11,"No",1.0,5.0830962641588086e-20,"No",0.977013259266915,0.022986740733084012,"Yes",0.9998809234525753,0.00011907654741157105,"No",0.999999999743352,2.5663636475431856e-10,"No",0.0166610000214361,0.9833389999785727,"Yes"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED HIGH RISK MUSCLE INVASIVE BLADDER CANCER AFTER CYSTECTOMY","NL","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0838477836385247e-52,0.029979550946416588,0.9700204490535694,"2+",1.1647474722197975e-13,0.9999999999998864,"Yes",0.9999999999997442,2.5877741440803396e-13,"No",1.0,1.4321205030343327e-20,"No",0.9846018949476886,0.015398105052315524,"Yes",0.9999993211135947,6.7888640862344e-07,"No",0.9999999997429825,2.5702029358485773e-10,"No",0.00782172035452328,0.992178279645485,"Yes"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED HIGH RISK MUSCLE INVASIVE BLADDER CANCER AFTER CYSTECTOMY","FR","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0838477836385247e-52,0.029979550946416588,0.9700204490535694,"2+",1.1647474722197975e-13,0.9999999999998864,"Yes",0.9999999999997442,2.5877741440803396e-13,"No",1.0,1.4321205030343327e-20,"No",0.9846018949476886,0.015398105052315524,"Yes",0.9999993211135947,6.7888640862344e-07,"No",0.9999999997429825,2.5702029358485773e-10,"No",0.00782172035452328,0.992178279645485,"Yes"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED HIGH RISK MUSCLE INVASIVE BLADDER CANCER AFTER CYSTECTOMY","CZ","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.0838477836385247e-52,0.029979550946416588,0.9700204490535694,"2+",1.1647474722197975e-13,0.9999999999998864,"Yes",0.9999999999997442,2.5877741440803396e-13,"No",1.0,1.4321205030343327e-20,"No",0.9846018949476886,0.015398105052315524,"Yes",0.9999993211135947,6.7888640862344e-07,"No",0.9999999997429825,2.5702029358485773e-10,"No",0.00782172035452328,0.992178279645485,"Yes"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED HIGH RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION","BE","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0076983678821164e-46,0.21153473232297246,0.7884652676770253,"2+",2.0901317258968882e-10,0.9999999997909867,"Yes",0.9999999997612292,2.387614800194498e-10,"No",1.0,5.389586248118107e-15,"No",0.9746151270667175,0.025384872933296485,"Yes",0.9999563174462702,4.3682553719335126e-05,"No",0.9999999998829595,1.170389298742899e-10,"No",0.08055189753750971,0.919448102462489,"Yes"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED HIGH RISK MUSCLE INVASIVE BLADDER CANCER AFTER CYSTECTOMYESTUDIO DE FASE III MULTICÉNTRICO ABIERTO RANDOMIZADO DE MPDL3280A (ANTICUERPO ANTI-PD-L1) FRENTE A OBSERVACIÓN COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON CÁNCER DE VEJIGA MÚSCULO-INVASIVO DE ALTO RIESGO SELECCIONADOS POR PD-L1 TRAS CISTECTOMÍA","DE","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.595692555551367e-90,2.828339441819943e-05,0.99997171660559,"2+",5.251990143053952e-26,1.0,"Yes",1.0,1.8204538563029803e-25,"No",1.0,1.6994254534493168e-38,"No",0.960148907284741,0.03985109271528423,"Yes",0.9999999999706688,2.934895228482169e-11,"No",1.0,2.2680551509484035e-23,"No",1.9385038648333768e-08,0.9999999806149733,"Yes"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED HIGH RISK MUSCLE INVASIVE BLADDER CANCER AFTER CYSTECTOMYESTUDIO DE FASE III MULTICÉNTRICO ABIERTO RANDOMIZADO DE MPDL3280A (ANTICUERPO ANTI-PD-L1) FRENTE A OBSERVACIÓN COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON CÁNCER DE VEJIGA MÚSCULO-INVASIVO DE ALTO RIESGO SELECCIONADOS POR PD-L1 TRAS CISTECTOMÍA","GB","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.595692555551367e-90,2.828339441819943e-05,0.99997171660559,"2+",5.251990143053952e-26,1.0,"Yes",1.0,1.8204538563029803e-25,"No",1.0,1.6994254534493168e-38,"No",0.960148907284741,0.03985109271528423,"Yes",0.9999999999706688,2.934895228482169e-11,"No",1.0,2.2680551509484035e-23,"No",1.9385038648333768e-08,0.9999999806149733,"Yes"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION","PL","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.9053817475134175e-50,0.08212850013476869,0.9178714998652324,"2+",2.9608107675488117e-09,0.999999997039197,"Yes",0.9999999967925818,3.2074148790559586e-09,"No",0.9999999999999147,7.820998152535633e-14,"No",0.9074834955393087,0.09251650446068872,"Yes",0.9992460153618095,0.0007539846381910988,"No",0.9999999993382858,6.61704514546399e-10,"No",0.02279351494880306,0.9772064850511868,"Yes"
"2014-005603-25","A PHASE III OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB  (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-POSITIVE HIGH RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION","FI","No","No","Yes","ok","Yes","No","No","No","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.379380287204992e-56,0.02975990751118689,0.9702400924888037,"2+",6.463689872002324e-11,0.9999999999353691,"Yes",0.9999999999128022,8.718933482463754e-11,"No",1.0,5.0830962641588086e-20,"No",0.977013259266915,0.022986740733084012,"Yes",0.9998809234525753,0.00011907654741157105,"No",0.999999999743352,2.5663636475431856e-10,"No",0.0166610000214361,0.9833389999785727,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatmentSOLAR-1: Estudio de fase III aleatorizado doble ciego controlado con placebo de alpelisib en combinación con fulvestrant en hombres y mujeres posmenopáusicas con cáncer de mama avanzado receptor hormonal positivo HER2 negativo que han progresado mientras o después del tratamiento con un inhibidor de la aromatasa","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.957515899862991e-125,6.806542758702456e-16,1.0,"2+",0.999916291009605,8.370899042279084e-05,"No",0.0013104528278924496,0.9986895471721147,"Yes",1.0,5.164397087247817e-50,"No",1.8276377102930928e-06,0.9999981723622899,"Yes",0.999998970480324,1.0295196526280739e-06,"Yes",1.0,2.0699995547780884e-25,"No",6.213886891529915e-08,0.9999999378611071,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment","GR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.76480183370932e-61,4.2760408817975584e-11,0.9999999999572539,"2+",0.9998286866475641,0.0001713133524249008,"No",0.0029410396677049277,0.9970589603323069,"Yes",1.0,2.5027969320868477e-20,"No",1.944763120876545e-05,0.9999805523688007,"Yes",0.9972421175339627,0.0027578824660436287,"Yes",0.9999999985990088,1.401003534043096e-09,"No",1.2537456739232303e-06,0.9999987462543247,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatmentSOLAR-1: Fase III gerandomiseerd dubbelblind placebogecontroleerd onderzoek met alpelisib in combinatie met fulvestrant bij mannen en postmenopauzale vrouwen met hormoongevoelige HER2-negatieve gevorderde borstkanker die verergerd is tijdens of na behandeling met een aromataseremmer","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.513129460765604e-103,4.1959809036939416e-18,1.0,"2+",0.9999993721832805,6.278167222730834e-07,"No",2.0662596229292093e-05,0.9999793374037428,"Yes",1.0,1.1258121365257478e-31,"No",1.650937396479516e-11,0.9999999999835155,"Yes",0.9999107026480017,8.929735197139365e-05,"Yes",0.9999999999999432,2.8595883158748755e-14,"No",5.6161348910005066e-12,0.9999999999943726,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment","PT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.76480183370932e-61,4.2760408817975584e-11,0.9999999999572539,"2+",0.9998286866475641,0.0001713133524249008,"No",0.0029410396677049277,0.9970589603323069,"Yes",1.0,2.5027969320868477e-20,"No",1.944763120876545e-05,0.9999805523688007,"Yes",0.9972421175339627,0.0027578824660436287,"Yes",0.9999999985990088,1.401003534043096e-09,"No",1.2537456739232303e-06,0.9999987462543247,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.005507394484902e-62,8.471914741820827e-11,0.999999999915275,"2+",0.9998281683194142,0.00017183168058610278,"No",0.002728043087463555,0.9972719569125427,"Yes",1.0,2.1045299553562835e-22,"No",3.108414851212341e-05,0.9999689158514784,"Yes",0.9964905473438167,0.0035094526561790526,"Yes",0.9999999991008792,8.991212493202079e-10,"No",1.9583638819942446e-06,0.9999980416361175,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment","BG","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.005507394484902e-62,8.471914741820827e-11,0.999999999915275,"2+",0.9998281683194142,0.00017183168058610278,"No",0.002728043087463555,0.9972719569125427,"Yes",1.0,2.1045299553562835e-22,"No",3.108414851212341e-05,0.9999689158514784,"Yes",0.9964905473438167,0.0035094526561790526,"Yes",0.9999999991008792,8.991212493202079e-10,"No",1.9583638819942446e-06,0.9999980416361175,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatmentSOLAR-1: Estudio de fase III aleatorizado doble ciego controlado con placebo de alpelisib en combinación con fulvestrant en hombres y mujeres posmenopáusicas con cáncer de mama avanzado receptor hormonal positivo HER2 negativo que han progresado mientras o después del tratamiento con un inhibidor de la aromatasa","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.957515899862991e-125,6.806542758702456e-16,1.0,"2+",0.999916291009605,8.370899042279084e-05,"No",0.0013104528278924496,0.9986895471721147,"Yes",1.0,5.164397087247817e-50,"No",1.8276377102930928e-06,0.9999981723622899,"Yes",0.999998970480324,1.0295196526280739e-06,"Yes",1.0,2.0699995547780884e-25,"No",6.213886891529915e-08,0.9999999378611071,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment","DK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.76480183370932e-61,4.2760408817975584e-11,0.9999999999572539,"2+",0.9998286866475641,0.0001713133524249008,"No",0.0029410396677049277,0.9970589603323069,"Yes",1.0,2.5027969320868477e-20,"No",1.944763120876545e-05,0.9999805523688007,"Yes",0.9972421175339627,0.0027578824660436287,"Yes",0.9999999985990088,1.401003534043096e-09,"No",1.2537456739232303e-06,0.9999987462543247,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatmentSOLAR-1: Fase III gerandomiseerd dubbelblind placebogecontroleerd onderzoek met alpelisib in combinatie met fulvestrant bij mannen en postmenopauzale vrouwen met hormoongevoelige HER2-negatieve gevorderde borstkanker die verergerd is tijdens of na behandeling met een aromataseremmer","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.513129460765604e-103,4.1959809036939416e-18,1.0,"2+",0.9999993721832805,6.278167222730834e-07,"No",2.0662596229292093e-05,0.9999793374037428,"Yes",1.0,1.1258121365257478e-31,"No",1.650937396479516e-11,0.9999999999835155,"Yes",0.9999107026480017,8.929735197139365e-05,"Yes",0.9999999999999432,2.8595883158748755e-14,"No",5.6161348910005066e-12,0.9999999999943726,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.005507394484902e-62,8.471914741820827e-11,0.999999999915275,"2+",0.9998281683194142,0.00017183168058610278,"No",0.002728043087463555,0.9972719569125427,"Yes",1.0,2.1045299553562835e-22,"No",3.108414851212341e-05,0.9999689158514784,"Yes",0.9964905473438167,0.0035094526561790526,"Yes",0.9999999991008792,8.991212493202079e-10,"No",1.9583638819942446e-06,0.9999980416361175,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.76480183370932e-61,4.2760408817975584e-11,0.9999999999572539,"2+",0.9998286866475641,0.0001713133524249008,"No",0.0029410396677049277,0.9970589603323069,"Yes",1.0,2.5027969320868477e-20,"No",1.944763120876545e-05,0.9999805523688007,"Yes",0.9972421175339627,0.0027578824660436287,"Yes",0.9999999985990088,1.401003534043096e-09,"No",1.2537456739232303e-06,0.9999987462543247,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatmentSOLAR-1: Fase III gerandomiseerd dubbelblind placebogecontroleerd onderzoek met alpelisib in combinatie met fulvestrant bij mannen en postmenopauzale vrouwen met hormoongevoelige HER2-negatieve gevorderde borstkanker die verergerd is tijdens of na behandeling met een aromataseremmer","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.513129460765604e-103,4.1959809036939416e-18,1.0,"2+",0.9999993721832805,6.278167222730834e-07,"No",2.0662596229292093e-05,0.9999793374037428,"Yes",1.0,1.1258121365257478e-31,"No",1.650937396479516e-11,0.9999999999835155,"Yes",0.9999107026480017,8.929735197139365e-05,"Yes",0.9999999999999432,2.8595883158748755e-14,"No",5.6161348910005066e-12,0.9999999999943726,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.76480183370932e-61,4.2760408817975584e-11,0.9999999999572539,"2+",0.9998286866475641,0.0001713133524249008,"No",0.0029410396677049277,0.9970589603323069,"Yes",1.0,2.5027969320868477e-20,"No",1.944763120876545e-05,0.9999805523688007,"Yes",0.9972421175339627,0.0027578824660436287,"Yes",0.9999999985990088,1.401003534043096e-09,"No",1.2537456739232303e-06,0.9999987462543247,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment","FR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.005507394484902e-62,8.471914741820827e-11,0.999999999915275,"2+",0.9998281683194142,0.00017183168058610278,"No",0.002728043087463555,0.9972719569125427,"Yes",1.0,2.1045299553562835e-22,"No",3.108414851212341e-05,0.9999689158514784,"Yes",0.9964905473438167,0.0035094526561790526,"Yes",0.9999999991008792,8.991212493202079e-10,"No",1.9583638819942446e-06,0.9999980416361175,"Yes"
"2015-000340-42","SOLAR-1: A phase III randomized double-blind placebo controlled study of alpelisib in combination with fulvestrant for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatmentSOLAR-1: Estudio de fase III aleatorizado doble ciego controlado con placebo de alpelisib en combinación con fulvestrant en hombres y mujeres posmenopáusicas con cáncer de mama avanzado receptor hormonal positivo HER2 negativo que han progresado mientras o después del tratamiento con un inhibidor de la aromatasa","AT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.957515899862991e-125,6.806542758702456e-16,1.0,"2+",0.999916291009605,8.370899042279084e-05,"No",0.0013104528278924496,0.9986895471721147,"Yes",1.0,5.164397087247817e-50,"No",1.8276377102930928e-06,0.9999981723622899,"Yes",0.999998970480324,1.0295196526280739e-06,"Yes",1.0,2.0699995547780884e-25,"No",6.213886891529915e-08,0.9999999378611071,"Yes"
"2015-000735-32","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low-volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Estudio fase 3 aleatorizado doble-ciego y controlado con placebo de JNJ-56021927 más terapia de privación de andrógenos (TPA) frente a TPA en sujetos con cáncer de próstata metastásico hormonosensible (CPmHS) de bajacarga tumoral.","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.078144369272844e-94,4.2260654308543593e-19,1.0,"2+",0.9999844116060477,1.5588393962125147e-05,"No",0.0002050106512591907,0.9997949893487293,"Yes",1.0,1.9814472569660949e-26,"No",7.435582361472738e-18,1.0,"Yes",0.9223290494757249,0.07767095052424819,"No",1.0,3.4629393268139523e-22,"No",3.558129676824819e-20,1.0,"Yes"
"2015-000735-32","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low-volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Estudio fase 3 aleatorizado doble-ciego y controlado con placebo de JNJ-56021927 más terapia de privación de andrógenos (TPA) frente a TPA en sujetos con cáncer de próstata metastásico hormonosensible (CPmHS) de bajacarga tumoral.","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.078144369272844e-94,4.2260654308543593e-19,1.0,"2+",0.9999844116060477,1.5588393962125147e-05,"No",0.0002050106512591907,0.9997949893487293,"Yes",1.0,1.9814472569660949e-26,"No",7.435582361472738e-18,1.0,"Yes",0.9223290494757249,0.07767095052424819,"No",1.0,3.4629393268139523e-22,"No",3.558129676824819e-20,1.0,"Yes"
"2015-000735-32","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low-volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Estudio fase 3 aleatorizado doble-ciego y controlado con placebo de JNJ-56021927 más terapia de privación de andrógenos (TPA) frente a TPA en sujetos con cáncer de próstata metastásico hormonosensible (CPmHS) de bajacarga tumoral.","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.078144369272844e-94,4.2260654308543593e-19,1.0,"2+",0.9999844116060477,1.5588393962125147e-05,"No",0.0002050106512591907,0.9997949893487293,"Yes",1.0,1.9814472569660949e-26,"No",7.435582361472738e-18,1.0,"Yes",0.9223290494757249,0.07767095052424819,"No",1.0,3.4629393268139523e-22,"No",3.558129676824819e-20,1.0,"Yes"
"2015-000735-32","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low-volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Estudio fase 3 aleatorizado doble-ciego y controlado con placebo de JNJ-56021927 más terapia de privación de andrógenos (TPA) frente a TPA en sujetos con cáncer de próstata metastásico hormonosensible (CPmHS) de bajacarga tumoral.","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.078144369272844e-94,4.2260654308543593e-19,1.0,"2+",0.9999844116060477,1.5588393962125147e-05,"No",0.0002050106512591907,0.9997949893487293,"Yes",1.0,1.9814472569660949e-26,"No",7.435582361472738e-18,1.0,"Yes",0.9223290494757249,0.07767095052424819,"No",1.0,3.4629393268139523e-22,"No",3.558129676824819e-20,1.0,"Yes"
"2015-000735-32","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low-volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Estudio fase 3 aleatorizado doble-ciego y controlado con placebo de JNJ-56021927 más terapia de privación de andrógenos (TPA) frente a TPA en sujetos con cáncer de próstata metastásico hormonosensible (CPmHS) de bajacarga tumoral.","RO","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.078144369272844e-94,4.2260654308543593e-19,1.0,"2+",0.9999844116060477,1.5588393962125147e-05,"No",0.0002050106512591907,0.9997949893487293,"Yes",1.0,1.9814472569660949e-26,"No",7.435582361472738e-18,1.0,"Yes",0.9223290494757249,0.07767095052424819,"No",1.0,3.4629393268139523e-22,"No",3.558129676824819e-20,1.0,"Yes"
"2015-000735-32","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low-volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Estudio fase 3 aleatorizado doble-ciego y controlado con placebo de JNJ-56021927 más terapia de privación de andrógenos (TPA) frente a TPA en sujetos con cáncer de próstata metastásico hormonosensible (CPmHS) de bajacarga tumoral.","PL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.078144369272844e-94,4.2260654308543593e-19,1.0,"2+",0.9999844116060477,1.5588393962125147e-05,"No",0.0002050106512591907,0.9997949893487293,"Yes",1.0,1.9814472569660949e-26,"No",7.435582361472738e-18,1.0,"Yes",0.9223290494757249,0.07767095052424819,"No",1.0,3.4629393268139523e-22,"No",3.558129676824819e-20,1.0,"Yes"
"2015-000735-32","A Phase 3 Randomized Placebo-controlled Double-blind Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low-volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Estudio fase 3 aleatorizado doble-ciego y controlado con placebo de JNJ-56021927 más terapia de privación de andrógenos (TPA) frente a TPA en sujetos con cáncer de próstata metastásico hormonosensible (CPmHS) de bajacarga tumoral.","HU","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.078144369272844e-94,4.2260654308543593e-19,1.0,"2+",0.9999844116060477,1.5588393962125147e-05,"No",0.0002050106512591907,0.9997949893487293,"Yes",1.0,1.9814472569660949e-26,"No",7.435582361472738e-18,1.0,"Yes",0.9223290494757249,0.07767095052424819,"No",1.0,3.4629393268139523e-22,"No",3.558129676824819e-20,1.0,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.960777328867232e-33,1.8975429005971523e-06,0.9999981024570942,"2+",4.556421755867332e-06,0.9999954435782494,"Yes",0.9999929849808702,7.0150191329601035e-06,"No",0.9999999999896119,1.0394562381459437e-11,"No",5.435270757356672e-06,0.9999945647292411,"Yes",0.23546494619486574,0.7645350538051405,"Yes",0.9999999968388807,3.1611137968785045e-09,"No",0.00026877097217733065,0.9997312290278215,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.960777328867232e-33,1.8975429005971523e-06,0.9999981024570942,"2+",4.556421755867332e-06,0.9999954435782494,"Yes",0.9999929849808702,7.0150191329601035e-06,"No",0.9999999999896119,1.0394562381459437e-11,"No",5.435270757356672e-06,0.9999945647292411,"Yes",0.23546494619486574,0.7645350538051405,"Yes",0.9999999968388807,3.1611137968785045e-09,"No",0.00026877097217733065,0.9997312290278215,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.960777328867232e-33,1.8975429005971523e-06,0.9999981024570942,"2+",4.556421755867332e-06,0.9999954435782494,"Yes",0.9999929849808702,7.0150191329601035e-06,"No",0.9999999999896119,1.0394562381459437e-11,"No",5.435270757356672e-06,0.9999945647292411,"Yes",0.23546494619486574,0.7645350538051405,"Yes",0.9999999968388807,3.1611137968785045e-09,"No",0.00026877097217733065,0.9997312290278215,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertibversus Physician's Choice of Treatment in Patients with MyelodysplasticSyndrome after Failure of a Hypomethylating AgentIII. fázisú nemzetközi randomizált kontrollos vizsgálat a hipometiláló szerrel végzett sikertelen kezelést követően alkalmazott rigoszertib és az orvos által választott kezelés összehasonlítására mielodiszpláziás szindrómában szenvedő betegeknél","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0860724631252418e-53,3.443102358905605e-15,1.0,"2+",0.4982068417492468,0.501793158250753,"Yes",0.896337450046454,0.1036625499535658,"No",0.9999999989811955,1.0187918137843622e-09,"No",5.888625789590845e-16,1.0,"Yes",0.00015482665868344362,0.9998451733412993,"Yes",0.9999999882556382,1.1744357089307763e-08,"No",8.650214469050067e-16,1.0,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertibversus Physician's Choice of Treatment in Patients with MyelodysplasticSyndrome after Failure of a Hypomethylating AgentIII. fázisú nemzetközi randomizált kontrollos vizsgálat a hipometiláló szerrel végzett sikertelen kezelést követően alkalmazott rigoszertib és az orvos által választott kezelés összehasonlítására mielodiszpláziás szindrómában szenvedő betegeknél","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0860724631252418e-53,3.443102358905605e-15,1.0,"2+",0.4982068417492468,0.501793158250753,"Yes",0.896337450046454,0.1036625499535658,"No",0.9999999989811955,1.0187918137843622e-09,"No",5.888625789590845e-16,1.0,"Yes",0.00015482665868344362,0.9998451733412993,"Yes",0.9999999882556382,1.1744357089307763e-08,"No",8.650214469050067e-16,1.0,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.960777328867232e-33,1.8975429005971523e-06,0.9999981024570942,"2+",4.556421755867332e-06,0.9999954435782494,"Yes",0.9999929849808702,7.0150191329601035e-06,"No",0.9999999999896119,1.0394562381459437e-11,"No",5.435270757356672e-06,0.9999945647292411,"Yes",0.23546494619486574,0.7645350538051405,"Yes",0.9999999968388807,3.1611137968785045e-09,"No",0.00026877097217733065,0.9997312290278215,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.960777328867232e-33,1.8975429005971523e-06,0.9999981024570942,"2+",4.556421755867332e-06,0.9999954435782494,"Yes",0.9999929849808702,7.0150191329601035e-06,"No",0.9999999999896119,1.0394562381459437e-11,"No",5.435270757356672e-06,0.9999945647292411,"Yes",0.23546494619486574,0.7645350538051405,"Yes",0.9999999968388807,3.1611137968785045e-09,"No",0.00026877097217733065,0.9997312290278215,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertibversus Physician's Choice of Treatment in Patients with MyelodysplasticSyndrome after Failure of a Hypomethylating AgentIII. fázisú nemzetközi randomizált kontrollos vizsgálat a hipometiláló szerrel végzett sikertelen kezelést követően alkalmazott rigoszertib és az orvos által választott kezelés összehasonlítására mielodiszpláziás szindrómában szenvedő betegeknél","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0860724631252418e-53,3.443102358905605e-15,1.0,"2+",0.4982068417492468,0.501793158250753,"Yes",0.896337450046454,0.1036625499535658,"No",0.9999999989811955,1.0187918137843622e-09,"No",5.888625789590845e-16,1.0,"Yes",0.00015482665868344362,0.9998451733412993,"Yes",0.9999999882556382,1.1744357089307763e-08,"No",8.650214469050067e-16,1.0,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent","HR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.960777328867232e-33,1.8975429005971523e-06,0.9999981024570942,"2+",4.556421755867332e-06,0.9999954435782494,"Yes",0.9999929849808702,7.0150191329601035e-06,"No",0.9999999999896119,1.0394562381459437e-11,"No",5.435270757356672e-06,0.9999945647292411,"Yes",0.23546494619486574,0.7645350538051405,"Yes",0.9999999968388807,3.1611137968785045e-09,"No",0.00026877097217733065,0.9997312290278215,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",2.960777328867232e-33,1.8975429005971523e-06,0.9999981024570942,"2+",4.556421755867332e-06,0.9999954435782494,"Yes",0.9999929849808702,7.0150191329601035e-06,"No",0.9999999999896119,1.0394562381459437e-11,"No",5.435270757356672e-06,0.9999945647292411,"Yes",0.23546494619486574,0.7645350538051405,"Yes",0.9999999968388807,3.1611137968785045e-09,"No",0.00026877097217733065,0.9997312290278215,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertibversus Physician's Choice of Treatment in Patients with MyelodysplasticSyndrome after Failure of a Hypomethylating AgentIII. fázisú nemzetközi randomizált kontrollos vizsgálat a hipometiláló szerrel végzett sikertelen kezelést követően alkalmazott rigoszertib és az orvos által választott kezelés összehasonlítására mielodiszpláziás szindrómában szenvedő betegeknél","IE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0860724631252418e-53,3.443102358905605e-15,1.0,"2+",0.4982068417492468,0.501793158250753,"Yes",0.896337450046454,0.1036625499535658,"No",0.9999999989811955,1.0187918137843622e-09,"No",5.888625789590845e-16,1.0,"Yes",0.00015482665868344362,0.9998451733412993,"Yes",0.9999999882556382,1.1744357089307763e-08,"No",8.650214469050067e-16,1.0,"Yes"
"2015-001476-22","A Phase III International Randomized Controlled Study of Rigosertibversus Physician's Choice of Treatment in Patients with MyelodysplasticSyndrome after Failure of a Hypomethylating AgentIII. fázisú nemzetközi randomizált kontrollos vizsgálat a hipometiláló szerrel végzett sikertelen kezelést követően alkalmazott rigoszertib és az orvos által választott kezelés összehasonlítására mielodiszpláziás szindrómában szenvedő betegeknél","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0860724631252418e-53,3.443102358905605e-15,1.0,"2+",0.4982068417492468,0.501793158250753,"Yes",0.896337450046454,0.1036625499535658,"No",0.9999999989811955,1.0187918137843622e-09,"No",5.888625789590845e-16,1.0,"Yes",0.00015482665868344362,0.9998451733412993,"Yes",0.9999999882556382,1.1744357089307763e-08,"No",8.650214469050067e-16,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)Ensayo clínico de fase III aleatorizado de lurbinectedin (PM01183)/doxorubicina (DOX) en comparación con ciclofosfamida (CTX) doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmón (CMP) en quienes ha fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS)","CZ","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.844806333737581e-104,3.0423534757003944e-21,1.0,"2+",5.122493148222681e-31,1.0,"Yes",1.0,4.2919294693850526e-30,"No",1.0,1.0388524060295024e-46,"No",1.4690110394570158e-18,1.0,"Yes",0.999999941315993,5.8683984867823906e-08,"Yes",1.0,2.7932851534516923e-47,"No",1.0034817598740081e-19,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)Ensayo clínico de fase III aleatorizado de lurbinectedin (PM01183)/doxorubicina (DOX) en comparación con ciclofosfamida (CTX) doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmón (CMP) en quienes ha fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS)","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.844806333737581e-104,3.0423534757003944e-21,1.0,"2+",5.122493148222681e-31,1.0,"Yes",1.0,4.2919294693850526e-30,"No",1.0,1.0388524060295024e-46,"No",1.4690110394570158e-18,1.0,"Yes",0.999999941315993,5.8683984867823906e-08,"Yes",1.0,2.7932851534516923e-47,"No",1.0034817598740081e-19,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)Ensayo clínico de fase III aleatorizado de lurbinectedin (PM01183)/doxorubicina (DOX) en comparación con ciclofosfamida (CTX) doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmón (CMP) en quienes ha fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS)","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.844806333737581e-104,3.0423534757003944e-21,1.0,"2+",5.122493148222681e-31,1.0,"Yes",1.0,4.2919294693850526e-30,"No",1.0,1.0388524060295024e-46,"No",1.4690110394570158e-18,1.0,"Yes",0.999999941315993,5.8683984867823906e-08,"Yes",1.0,2.7932851534516923e-47,"No",1.0034817598740081e-19,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)Ensayo clínico de fase III aleatorizado de lurbinectedin (PM01183)/doxorubicina (DOX) en comparación con ciclofosfamida (CTX) doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmón (CMP) en quienes ha fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS)","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.844806333737581e-104,3.0423534757003944e-21,1.0,"2+",5.122493148222681e-31,1.0,"Yes",1.0,4.2919294693850526e-30,"No",1.0,1.0388524060295024e-46,"No",1.4690110394570158e-18,1.0,"Yes",0.999999941315993,5.8683984867823906e-08,"Yes",1.0,2.7932851534516923e-47,"No",1.0034817598740081e-19,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5732567166515138e-57,1.8666344132476595e-11,0.999999999981327,"2+",1.5631460693901144e-15,1.0,"Yes",1.0,4.8596556066335485e-15,"No",1.0,9.580934782901767e-27,"No",8.838010469384183e-08,0.9999999116198848,"Yes",0.9999509421946283,4.9057805372663804e-05,"Yes",1.0,1.0801039429331069e-19,"No",3.563200402723782e-08,0.9999999643679878,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)","BG","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5732567166515138e-57,1.8666344132476595e-11,0.999999999981327,"2+",1.5631460693901144e-15,1.0,"Yes",1.0,4.8596556066335485e-15,"No",1.0,9.580934782901767e-27,"No",8.838010469384183e-08,0.9999999116198848,"Yes",0.9999509421946283,4.9057805372663804e-05,"Yes",1.0,1.0801039429331069e-19,"No",3.563200402723782e-08,0.9999999643679878,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)Ensayo clínico de fase III aleatorizado de lurbinectedin (PM01183)/doxorubicina (DOX) en comparación con ciclofosfamida (CTX) doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmón (CMP) en quienes ha fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS)","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.844806333737581e-104,3.0423534757003944e-21,1.0,"2+",5.122493148222681e-31,1.0,"Yes",1.0,4.2919294693850526e-30,"No",1.0,1.0388524060295024e-46,"No",1.4690110394570158e-18,1.0,"Yes",0.999999941315993,5.8683984867823906e-08,"Yes",1.0,2.7932851534516923e-47,"No",1.0034817598740081e-19,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)Ensayo clínico de fase III aleatorizado de lurbinectedin (PM01183)/doxorubicina (DOX) en comparación con ciclofosfamida (CTX) doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmón (CMP) en quienes ha fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS)","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.844806333737581e-104,3.0423534757003944e-21,1.0,"2+",5.122493148222681e-31,1.0,"Yes",1.0,4.2919294693850526e-30,"No",1.0,1.0388524060295024e-46,"No",1.4690110394570158e-18,1.0,"Yes",0.999999941315993,5.8683984867823906e-08,"Yes",1.0,2.7932851534516923e-47,"No",1.0034817598740081e-19,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)Ensayo clínico de fase III aleatorizado de lurbinectedin (PM01183)/doxorubicina (DOX) en comparación con ciclofosfamida (CTX) doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmón (CMP) en quienes ha fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS)","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.844806333737581e-104,3.0423534757003944e-21,1.0,"2+",5.122493148222681e-31,1.0,"Yes",1.0,4.2919294693850526e-30,"No",1.0,1.0388524060295024e-46,"No",1.4690110394570158e-18,1.0,"Yes",0.999999941315993,5.8683984867823906e-08,"Yes",1.0,2.7932851534516923e-47,"No",1.0034817598740081e-19,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)Ensayo clínico de fase III aleatorizado de lurbinectedin (PM01183)/doxorubicina (DOX) en comparación con ciclofosfamida (CTX) doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmón (CMP) en quienes ha fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS)","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.844806333737581e-104,3.0423534757003944e-21,1.0,"2+",5.122493148222681e-31,1.0,"Yes",1.0,4.2919294693850526e-30,"No",1.0,1.0388524060295024e-46,"No",1.4690110394570158e-18,1.0,"Yes",0.999999941315993,5.8683984867823906e-08,"Yes",1.0,2.7932851534516923e-47,"No",1.0034817598740081e-19,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)Ensayo clínico de fase III aleatorizado de lurbinectedin (PM01183)/doxorubicina (DOX) en comparación con ciclofosfamida (CTX) doxorubicina (DOX) y vincristina (VCR) (CAV) o topotecán como tratamiento en pacientes con carcinoma microcítico de pulmón (CMP) en quienes ha fracasado una línea de tratamiento anterior con platino (ensayo ATLANTIS)","PT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.844806333737581e-104,3.0423534757003944e-21,1.0,"2+",5.122493148222681e-31,1.0,"Yes",1.0,4.2919294693850526e-30,"No",1.0,1.0388524060295024e-46,"No",1.4690110394570158e-18,1.0,"Yes",0.999999941315993,5.8683984867823906e-08,"Yes",1.0,2.7932851534516923e-47,"No",1.0034817598740081e-19,1.0,"Yes"
"2015-001641-89","Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX) Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)","HU","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5732567166515138e-57,1.8666344132476595e-11,0.999999999981327,"2+",1.5631460693901144e-15,1.0,"Yes",1.0,4.8596556066335485e-15,"No",1.0,9.580934782901767e-27,"No",8.838010469384183e-08,0.9999999116198848,"Yes",0.9999509421946283,4.9057805372663804e-05,"Yes",1.0,1.0801039429331069e-19,"No",3.563200402723782e-08,0.9999999643679878,"Yes"
"2015-001785-26","Prospective Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4).","FR","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.0539465586466813e-23,0.9206108995040796,0.07938910049592686,"-1",0.0011781433931527835,0.9988218566068536,"Yes",0.9991763352731775,0.0008236647268278638,"No",0.9998752121762445,0.00012478782374879746,"No",0.6440926660687181,0.35590733393128754,"No",0.3384848522435525,0.661515147756447,"No",0.9710358719328963,0.028964128067102014,"No",0.8703868953948851,0.1296131046051088,"No"
"2015-001785-26","Prospective Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4).","DE","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.0539465586466813e-23,0.9206108995040796,0.07938910049592686,"-1",0.0011781433931527835,0.9988218566068536,"Yes",0.9991763352731775,0.0008236647268278638,"No",0.9998752121762445,0.00012478782374879746,"No",0.6440926660687181,0.35590733393128754,"No",0.3384848522435525,0.661515147756447,"No",0.9710358719328963,0.028964128067102014,"No",0.8703868953948851,0.1296131046051088,"No"
"2015-001785-26","Prospective Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4).","BE","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.0539465586466813e-23,0.9206108995040796,0.07938910049592686,"-1",0.0011781433931527835,0.9988218566068536,"Yes",0.9991763352731775,0.0008236647268278638,"No",0.9998752121762445,0.00012478782374879746,"No",0.6440926660687181,0.35590733393128754,"No",0.3384848522435525,0.661515147756447,"No",0.9710358719328963,0.028964128067102014,"No",0.8703868953948851,0.1296131046051088,"No"
"2015-001785-26","Prospective Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4).","GB","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.0539465586466813e-23,0.9206108995040796,0.07938910049592686,"-1",0.0011781433931527835,0.9988218566068536,"Yes",0.9991763352731775,0.0008236647268278638,"No",0.9998752121762445,0.00012478782374879746,"No",0.6440926660687181,0.35590733393128754,"No",0.3384848522435525,0.661515147756447,"No",0.9710358719328963,0.028964128067102014,"No",0.8703868953948851,0.1296131046051088,"No"
"2015-001785-26","Prospective Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4).","NL","No","No","Yes","ok","No","No","Yes","No","1","No","No","Yes","No","No","No","No","No","1","No",1.0539465586466813e-23,0.9206108995040796,0.07938910049592686,"-1",0.0011781433931527835,0.9988218566068536,"Yes",0.9991763352731775,0.0008236647268278638,"No",0.9998752121762445,0.00012478782374879746,"No",0.6440926660687181,0.35590733393128754,"No",0.3384848522435525,0.661515147756447,"No",0.9710358719328963,0.028964128067102014,"No",0.8703868953948851,0.1296131046051088,"No"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.766480146973089e-40,6.87243523315535e-16,1.0,"2+",8.071999398405465e-11,0.9999999999192825,"Yes",0.9999999999057252,9.427036310904591e-11,"No",1.0,6.326184545463706e-21,"No",1.993761452266141e-13,0.999999999999801,"Yes",0.0002478750106180208,0.9997521249893884,"Yes",1.0,9.688294312783092e-17,"No",8.484666312837274e-14,0.9999999999999147,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlledstudy comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomesStudio globale multicentrico in aperto randomizzato event-driven a controllo attivo per la comparazione di una strategia antitrombotica a base di rivAroxaban rispetto ad una strategia di anti-aggregazione piastrinica in seguito a sostituzione valvolare aortica transcatetere (TAVR - Transcatheter Aortic Valve Replacement) al fine di ottimizzare gli esiti clinici.","NL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2860581573741866e-83,2.147790685433998e-32,1.0,"2+",1.299392219047505e-19,1.0,"Yes",1.0,2.679391144039488e-19,"No",1.0,1.0337542051234318e-38,"No",1.9623426991550128e-29,1.0,"Yes",8.98049180360983e-11,0.9999999999101875,"Yes",1.0,2.356140527491171e-37,"No",9.774118034912341e-28,1.0,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlledstudy comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomesStudio globale multicentrico in aperto randomizzato event-driven a controllo attivo per la comparazione di una strategia antitrombotica a base di rivAroxaban rispetto ad una strategia di anti-aggregazione piastrinica in seguito a sostituzione valvolare aortica transcatetere (TAVR - Transcatheter Aortic Valve Replacement) al fine di ottimizzare gli esiti clinici.","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2860581573741866e-83,2.147790685433998e-32,1.0,"2+",1.299392219047505e-19,1.0,"Yes",1.0,2.679391144039488e-19,"No",1.0,1.0337542051234318e-38,"No",1.9623426991550128e-29,1.0,"Yes",8.98049180360983e-11,0.9999999999101875,"Yes",1.0,2.356140527491171e-37,"No",9.774118034912341e-28,1.0,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlledstudy comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomesStudio globale multicentrico in aperto randomizzato event-driven a controllo attivo per la comparazione di una strategia antitrombotica a base di rivAroxaban rispetto ad una strategia di anti-aggregazione piastrinica in seguito a sostituzione valvolare aortica transcatetere (TAVR - Transcatheter Aortic Valve Replacement) al fine di ottimizzare gli esiti clinici.","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2860581573741866e-83,2.147790685433998e-32,1.0,"2+",1.299392219047505e-19,1.0,"Yes",1.0,2.679391144039488e-19,"No",1.0,1.0337542051234318e-38,"No",1.9623426991550128e-29,1.0,"Yes",8.98049180360983e-11,0.9999999999101875,"Yes",1.0,2.356140527491171e-37,"No",9.774118034912341e-28,1.0,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlledstudy comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomesStudio globale multicentrico in aperto randomizzato event-driven a controllo attivo per la comparazione di una strategia antitrombotica a base di rivAroxaban rispetto ad una strategia di anti-aggregazione piastrinica in seguito a sostituzione valvolare aortica transcatetere (TAVR - Transcatheter Aortic Valve Replacement) al fine di ottimizzare gli esiti clinici.","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2860581573741866e-83,2.147790685433998e-32,1.0,"2+",1.299392219047505e-19,1.0,"Yes",1.0,2.679391144039488e-19,"No",1.0,1.0337542051234318e-38,"No",1.9623426991550128e-29,1.0,"Yes",8.98049180360983e-11,0.9999999999101875,"Yes",1.0,2.356140527491171e-37,"No",9.774118034912341e-28,1.0,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlledstudy comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomesStudio globale multicentrico in aperto randomizzato event-driven a controllo attivo per la comparazione di una strategia antitrombotica a base di rivAroxaban rispetto ad una strategia di anti-aggregazione piastrinica in seguito a sostituzione valvolare aortica transcatetere (TAVR - Transcatheter Aortic Valve Replacement) al fine di ottimizzare gli esiti clinici.","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2860581573741866e-83,2.147790685433998e-32,1.0,"2+",1.299392219047505e-19,1.0,"Yes",1.0,2.679391144039488e-19,"No",1.0,1.0337542051234318e-38,"No",1.9623426991550128e-29,1.0,"Yes",8.98049180360983e-11,0.9999999999101875,"Yes",1.0,2.356140527491171e-37,"No",9.774118034912341e-28,1.0,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes","NO","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.766480146973089e-40,6.87243523315535e-16,1.0,"2+",8.071999398405465e-11,0.9999999999192825,"Yes",0.9999999999057252,9.427036310904591e-11,"No",1.0,6.326184545463706e-21,"No",1.993761452266141e-13,0.999999999999801,"Yes",0.0002478750106180208,0.9997521249893884,"Yes",1.0,9.688294312783092e-17,"No",8.484666312837274e-14,0.9999999999999147,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlledstudy comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomesStudio globale multicentrico in aperto randomizzato event-driven a controllo attivo per la comparazione di una strategia antitrombotica a base di rivAroxaban rispetto ad una strategia di anti-aggregazione piastrinica in seguito a sostituzione valvolare aortica transcatetere (TAVR - Transcatheter Aortic Valve Replacement) al fine di ottimizzare gli esiti clinici.","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2860581573741866e-83,2.147790685433998e-32,1.0,"2+",1.299392219047505e-19,1.0,"Yes",1.0,2.679391144039488e-19,"No",1.0,1.0337542051234318e-38,"No",1.9623426991550128e-29,1.0,"Yes",8.98049180360983e-11,0.9999999999101875,"Yes",1.0,2.356140527491171e-37,"No",9.774118034912341e-28,1.0,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlledstudy comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomesStudio globale multicentrico in aperto randomizzato event-driven a controllo attivo per la comparazione di una strategia antitrombotica a base di rivAroxaban rispetto ad una strategia di anti-aggregazione piastrinica in seguito a sostituzione valvolare aortica transcatetere (TAVR - Transcatheter Aortic Valve Replacement) al fine di ottimizzare gli esiti clinici.","BE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2860581573741866e-83,2.147790685433998e-32,1.0,"2+",1.299392219047505e-19,1.0,"Yes",1.0,2.679391144039488e-19,"No",1.0,1.0337542051234318e-38,"No",1.9623426991550128e-29,1.0,"Yes",8.98049180360983e-11,0.9999999999101875,"Yes",1.0,2.356140527491171e-37,"No",9.774118034912341e-28,1.0,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes","SE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.766480146973089e-40,6.87243523315535e-16,1.0,"2+",8.071999398405465e-11,0.9999999999192825,"Yes",0.9999999999057252,9.427036310904591e-11,"No",1.0,6.326184545463706e-21,"No",1.993761452266141e-13,0.999999999999801,"Yes",0.0002478750106180208,0.9997521249893884,"Yes",1.0,9.688294312783092e-17,"No",8.484666312837274e-14,0.9999999999999147,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes","IT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.766480146973089e-40,6.87243523315535e-16,1.0,"2+",8.071999398405465e-11,0.9999999999192825,"Yes",0.9999999999057252,9.427036310904591e-11,"No",1.0,6.326184545463706e-21,"No",1.993761452266141e-13,0.999999999999801,"Yes",0.0002478750106180208,0.9997521249893884,"Yes",1.0,9.688294312783092e-17,"No",8.484666312837274e-14,0.9999999999999147,"Yes"
"2015-001975-30","Global multicenter open-label randomized event-driven active-controlledstudy comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomesStudio globale multicentrico in aperto randomizzato event-driven a controllo attivo per la comparazione di una strategia antitrombotica a base di rivAroxaban rispetto ad una strategia di anti-aggregazione piastrinica in seguito a sostituzione valvolare aortica transcatetere (TAVR - Transcatheter Aortic Valve Replacement) al fine di ottimizzare gli esiti clinici.","DK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2860581573741866e-83,2.147790685433998e-32,1.0,"2+",1.299392219047505e-19,1.0,"Yes",1.0,2.679391144039488e-19,"No",1.0,1.0337542051234318e-38,"No",1.9623426991550128e-29,1.0,"Yes",8.98049180360983e-11,0.9999999999101875,"Yes",1.0,2.356140527491171e-37,"No",9.774118034912341e-28,1.0,"Yes"
"2015-002212-32","Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: Amulticentre randomized Trial","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.337608388122095e-25,0.07543291577991111,0.9245670842200863,"2+",0.09230303373459073,0.9076969662654124,"Yes",0.9121840735736761,0.08781592642632773,"No",0.9990438508789963,0.0009561491210082167,"No",0.1046425451941237,0.8953574548058741,"Yes",0.43903455902374017,0.5609654409762664,"Yes",0.9998699674703614,0.00013003252963879593,"No",0.01543279877858199,0.9845672012214249,"Yes"
"2015-002222-40","Randomized Placebo-Controlled Double Blind Phase 2 Study of Patritumab (U3-1287) in Combination with Cetuximab plus Platinum Based Therapy in First Line Setting in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.988910579877266e-60,5.920660190404229e-11,0.9999999999407977,"2+",0.9996352930518563,0.00036470694813508256,"No",0.0008527134736118292,0.9991472865263922,"Yes",1.0,1.5890217285930816e-20,"No",5.4250605352802946e-09,0.9999999945749495,"Yes",0.0006798998662890565,0.9993201001337075,"No",1.0,1.0609110566467778e-18,"No",1.1333106972285395e-09,0.9999999988666844,"Yes"
"2015-002222-40","Randomized Placebo-Controlled Double Blind Phase 2 Study of Patritumab (U3-1287) in Combination with Cetuximab plus Platinum Based Therapy in First Line Setting in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.988910579877266e-60,5.920660190404229e-11,0.9999999999407977,"2+",0.9996352930518563,0.00036470694813508256,"No",0.0008527134736118292,0.9991472865263922,"Yes",1.0,1.5890217285930816e-20,"No",5.4250605352802946e-09,0.9999999945749495,"Yes",0.0006798998662890565,0.9993201001337075,"No",1.0,1.0609110566467778e-18,"No",1.1333106972285395e-09,0.9999999988666844,"Yes"
"2015-002222-40","Randomized Placebo-Controlled Double Blind Phase 2 Study of Patritumab (U3-1287) in Combination with Cetuximab plus Platinum Based Therapy in First Line Setting in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.988910579877266e-60,5.920660190404229e-11,0.9999999999407977,"2+",0.9996352930518563,0.00036470694813508256,"No",0.0008527134736118292,0.9991472865263922,"Yes",1.0,1.5890217285930816e-20,"No",5.4250605352802946e-09,0.9999999945749495,"Yes",0.0006798998662890565,0.9993201001337075,"No",1.0,1.0609110566467778e-18,"No",1.1333106972285395e-09,0.9999999988666844,"Yes"
"2015-002222-40","Randomized Placebo-Controlled Double Blind Phase 2 Study of Patritumab (U3-1287) in Combination with Cetuximab plus Platinum Based Therapy in First Line Setting in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.988910579877266e-60,5.920660190404229e-11,0.9999999999407977,"2+",0.9996352930518563,0.00036470694813508256,"No",0.0008527134736118292,0.9991472865263922,"Yes",1.0,1.5890217285930816e-20,"No",5.4250605352802946e-09,0.9999999945749495,"Yes",0.0006798998662890565,0.9993201001337075,"No",1.0,1.0609110566467778e-18,"No",1.1333106972285395e-09,0.9999999988666844,"Yes"
"2015-002365-34","A RANDOMIZED DOUBLE-BLIND VEHICLE-CONTROLLED PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.034560379541006e-36,2.8242866541844983e-12,0.9999999999971722,"2+",0.9999999999912462,8.759375549980853e-12,"No",2.1514581545368897e-10,0.9999999997848478,"Yes",0.9820434386991606,0.0179565613008412,"No",7.082110678851067e-12,0.999999999992923,"Yes",2.0985130321872373e-05,0.9999790148696741,"Yes",0.9999999992213162,7.786862232434574e-10,"No",4.1385210954523907e-10,0.9999999995861516,"Yes"
"2015-002365-34","A RANDOMIZED DOUBLE-BLIND VEHICLE-CONTROLLED PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.034560379541006e-36,2.8242866541844983e-12,0.9999999999971722,"2+",0.9999999999912462,8.759375549980853e-12,"No",2.1514581545368897e-10,0.9999999997848478,"Yes",0.9820434386991606,0.0179565613008412,"No",7.082110678851067e-12,0.999999999992923,"Yes",2.0985130321872373e-05,0.9999790148696741,"Yes",0.9999999992213162,7.786862232434574e-10,"No",4.1385210954523907e-10,0.9999999995861516,"Yes"
"2015-002365-34","A RANDOMIZED DOUBLE-BLIND VEHICLE-CONTROLLED PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.034560379541006e-36,2.8242866541844983e-12,0.9999999999971722,"2+",0.9999999999912462,8.759375549980853e-12,"No",2.1514581545368897e-10,0.9999999997848478,"Yes",0.9820434386991606,0.0179565613008412,"No",7.082110678851067e-12,0.999999999992923,"Yes",2.0985130321872373e-05,0.9999790148696741,"Yes",0.9999999992213162,7.786862232434574e-10,"No",4.1385210954523907e-10,0.9999999995861516,"Yes"
"2015-002365-34","A RANDOMIZED DOUBLE-BLIND VEHICLE-CONTROLLED PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS","LV","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.034560379541006e-36,2.8242866541844983e-12,0.9999999999971722,"2+",0.9999999999912462,8.759375549980853e-12,"No",2.1514581545368897e-10,0.9999999997848478,"Yes",0.9820434386991606,0.0179565613008412,"No",7.082110678851067e-12,0.999999999992923,"Yes",2.0985130321872373e-05,0.9999790148696741,"Yes",0.9999999992213162,7.786862232434574e-10,"No",4.1385210954523907e-10,0.9999999995861516,"Yes"
"2015-002365-34","A RANDOMIZED DOUBLE-BLIND VEHICLE-CONTROLLED PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.034560379541006e-36,2.8242866541844983e-12,0.9999999999971722,"2+",0.9999999999912462,8.759375549980853e-12,"No",2.1514581545368897e-10,0.9999999997848478,"Yes",0.9820434386991606,0.0179565613008412,"No",7.082110678851067e-12,0.999999999992923,"Yes",2.0985130321872373e-05,0.9999790148696741,"Yes",0.9999999992213162,7.786862232434574e-10,"No",4.1385210954523907e-10,0.9999999995861516,"Yes"
"2015-002365-34","A RANDOMIZED DOUBLE-BLIND VEHICLE-CONTROLLED PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","No","No","No","Yes","Yes","No","Yes","2+","Yes",4.034560379541006e-36,2.8242866541844983e-12,0.9999999999971722,"2+",0.9999999999912462,8.759375549980853e-12,"No",2.1514581545368897e-10,0.9999999997848478,"Yes",0.9820434386991606,0.0179565613008412,"No",7.082110678851067e-12,0.999999999992923,"Yes",2.0985130321872373e-05,0.9999790148696741,"Yes",0.9999999992213162,7.786862232434574e-10,"No",4.1385210954523907e-10,0.9999999995861516,"Yes"
"2015-002505-11","A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety Tolerability and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558 anti-PD-1 Monoclonal Antibody) in Advanced Solid TumorsEstudio fase 1/2a de escalada de dosis y expansión de cohortes sobre la seguridad tolerabilidad y eficacia del anticuerpo monoclonal anti-GITR (BMS-986156) administrado en monoterapia y en combinación con nivolumab (BMS-936558 anticuerpo monoclonal anti-PD-1) en tumores sólidos avanzados.","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.8168873260385652e-115,0.9999999999996021,4.26409446481912e-13,"2+",4.327734688676774e-20,1.0,"Yes",1.0,1.3594475778374749e-19,"No",1.0,7.889726075671018e-53,"No",1.0,1.890692197789734e-22,"No",0.999999999998238,1.7898101035194797e-12,"No",1.0,7.724667743235528e-51,"No",1.0,1.375369454029993e-21,"No"
"2015-002505-11","A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety Tolerability and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558 anti-PD-1 Monoclonal Antibody) in Advanced Solid Tumors","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",3.3891261973437304e-53,0.9999993360504151,6.639495903215078e-07,"2+",3.614589308401264e-08,0.9999999638540948,"Yes",0.9999999438770731,5.61229136783955e-08,"No",1.0,1.6889984729768318e-22,"No",0.9999999990041317,9.958550382074669e-10,"No",0.9999659848077217,3.401519226565448e-05,"No",1.0,2.040392210578363e-21,"No",0.9999999977329992,2.2669879812111876e-09,"No"
"2015-002509-13","A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM) (KEYNOTE 183)Estudio en fase III de pomalidomida y dexametasona en dosis baja con o sin pembrolizumab (MK3475) en el mieloma múltiple resistente o recidivante y resistente (MMrr). (KEYNOTE 183)","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.190583800682948e-71,0.002494943243566,0.997505056756419,"2+",3.003066276656415e-17,1.0,"Yes",1.0,6.88509167323972e-17,"No",1.0,5.474057157339956e-28,"No",0.3160854589461886,0.6839145410538013,"Yes",0.9999992617418795,7.382581096116914e-07,"Yes",0.9999415421796248,5.845782034783668e-05,"No",0.04543033442145358,0.9545696655785249,"Yes"
"2015-002509-13","A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM) (KEYNOTE 183)Studio di fase III su pomalidomide e desametasone a basso dosaggio con o senza pembrolizumab (MK3475) nel mieloma multiplo refrattario oppure recidivante e refrattario (rrMM) (KEYNOTE 183)","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.6335482837135466e-70,3.0112123627907874e-05,0.9999698878763712,"2+",6.626821460567852e-20,1.0,"Yes",1.0,2.067976657400208e-19,"No",1.0,7.986291891756566e-35,"No",0.9295537144826587,0.07044628551732754,"Yes",0.9999974197766369,2.5802233523190547e-06,"Yes",1.0,1.6124374088612382e-14,"No",0.1495614368290342,0.8504385631709878,"Yes"
"2015-002509-13","A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM) (KEYNOTE 183)","ES","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.361343280721175e-32,0.1303386563398893,0.8696613436601072,"2+",8.200861989753885e-09,0.9999999917991432,"Yes",0.9999999872666337,1.2733372736542216e-08,"No",1.0,1.3810263498214612e-15,"No",0.785694295099337,0.21430570490066334,"Yes",0.9995729631278121,0.00042703687218854995,"Yes",0.924253626581577,0.07574637341841846,"No",0.8051860052293349,0.19481399477066058,"Yes"
"2015-002509-13","A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM) (KEYNOTE 183)","FR","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.361343280721175e-32,0.1303386563398893,0.8696613436601072,"2+",8.200861989753885e-09,0.9999999917991432,"Yes",0.9999999872666337,1.2733372736542216e-08,"No",1.0,1.3810263498214612e-15,"No",0.785694295099337,0.21430570490066334,"Yes",0.9995729631278121,0.00042703687218854995,"Yes",0.924253626581577,0.07574637341841846,"No",0.8051860052293349,0.19481399477066058,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer","BE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer ","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer ","SE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer ","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer","PL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer","BG","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer","FI","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002590-38","A randomized double-blind placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer ","CZ","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.4060965170181747e-59,4.279011771738358e-12,0.9999999999957083,"2+",0.9999643572935409,3.564270645104068e-05,"No",0.00012442100105880858,0.999875578998937,"Yes",1.0,1.5170996141900472e-18,"No",3.1515177356282286e-09,0.9999999968484873,"Yes",0.9343540352970694,0.06564596470294325,"No",0.9999999824076442,1.759235503108209e-08,"No",3.4202796335072623e-11,0.9999999999658087,"Yes"
"2015-002894-39","An Open-label Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line treatment of Patients with Stage IIIB/IV NonsmallCell Lung Cancer Tumors with EGFR Activating MutationsStudio di fase 3 randomizzato in aperto sull’efficacia di ASP8273 rispetto a erlotinib o gefitinib nel trattamento di prima linea di pazienti con carcinomi polmonari non a piccole cellule allo stadio IIIB/IV con mutazioni attivanti il recettore del fattore di crescita dell’epidermide (Epidermal Growth Factor Receptor EGFR)","FR","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.20204054069419e-104,0.3003551904167832,0.6996448095832336,"2+",1.8660212004895216e-25,1.0,"Yes",1.0,2.2403411717987475e-24,"No",1.0,8.640285237618125e-39,"No",0.9986163187525774,0.0013836812474313852,"Yes",0.9999996039088263,3.960911855608782e-07,"Yes",1.0,5.035290706239897e-31,"No",0.8053194509020798,0.1946805490979168,"Yes"
"2015-002894-39","An Open-label Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating MutationsEstudio de Fase 3 abierto y aleatorizado de la eficacia de ASP8273 frente a erlotinib o gefitinib como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico y mutaciones de activación del EGFR en estadío IIIB/IV","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1920130992051945e-93,0.004257799133185484,0.9957422008667989,"2+",1.0785973649918797e-20,1.0,"Yes",1.0,5.201515628084986e-20,"No",1.0,2.3691843809976208e-39,"No",0.7675421318510861,0.2324578681489415,"Yes",0.9999994455613265,5.544386751886011e-07,"Yes",1.0,5.756836263185465e-30,"No",0.13749089541715587,0.8625091045828684,"Yes"
"2015-002894-39","An Open-label Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations","GB","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.9560909367279803e-45,0.12875583319330353,0.8712441668067017,"2+",2.8523226005208572e-12,0.9999999999971579,"Yes",0.9999999999922978,7.689480643653246e-12,"No",1.0,4.526242803445907e-22,"No",0.9291736684755155,0.07082633152447375,"Yes",0.9985638485615224,0.0014361514384890425,"Yes",0.9999999999906494,9.337649006163938e-12,"No",0.503398420182338,0.4966015798176514,"Yes"
"2015-002894-39","An Open-label Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating MutationsEstudio de Fase 3 abierto y aleatorizado de la eficacia de ASP8273 frente a erlotinib o gefitinib como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico y mutaciones de activación del EGFR en estadío IIIB/IV","IT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1920130992051945e-93,0.004257799133185484,0.9957422008667989,"2+",1.0785973649918797e-20,1.0,"Yes",1.0,5.201515628084986e-20,"No",1.0,2.3691843809976208e-39,"No",0.7675421318510861,0.2324578681489415,"Yes",0.9999994455613265,5.544386751886011e-07,"Yes",1.0,5.756836263185465e-30,"No",0.13749089541715587,0.8625091045828684,"Yes"
"2015-002894-39","An Open-label Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line treatment of Patients with Stage IIIB/IV NonsmallCell Lung Cancer Tumors with EGFR Activating MutationsStudio di fase 3 randomizzato in aperto sull’efficacia di ASP8273 rispetto a erlotinib o gefitinib nel trattamento di prima linea di pazienti con carcinomi polmonari non a piccole cellule allo stadio IIIB/IV con mutazioni attivanti il recettore del fattore di crescita dell’epidermide (Epidermal Growth Factor Receptor EGFR)","NL","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.20204054069419e-104,0.3003551904167832,0.6996448095832336,"2+",1.8660212004895216e-25,1.0,"Yes",1.0,2.2403411717987475e-24,"No",1.0,8.640285237618125e-39,"No",0.9986163187525774,0.0013836812474313852,"Yes",0.9999996039088263,3.960911855608782e-07,"Yes",1.0,5.035290706239897e-31,"No",0.8053194509020798,0.1946805490979168,"Yes"
"2015-002894-39","An Open-label Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating MutationsEstudio de Fase 3 abierto y aleatorizado de la eficacia de ASP8273 frente a erlotinib o gefitinib como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico y mutaciones de activación del EGFR en estadío IIIB/IV","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1920130992051945e-93,0.004257799133185484,0.9957422008667989,"2+",1.0785973649918797e-20,1.0,"Yes",1.0,5.201515628084986e-20,"No",1.0,2.3691843809976208e-39,"No",0.7675421318510861,0.2324578681489415,"Yes",0.9999994455613265,5.544386751886011e-07,"Yes",1.0,5.756836263185465e-30,"No",0.13749089541715587,0.8625091045828684,"Yes"
"2015-002894-39","An Open-label Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line treatment of Patients with Stage IIIB/IV NonsmallCell Lung Cancer Tumors with EGFR Activating MutationsStudio di fase 3 randomizzato in aperto sull’efficacia di ASP8273 rispetto a erlotinib o gefitinib nel trattamento di prima linea di pazienti con carcinomi polmonari non a piccole cellule allo stadio IIIB/IV con mutazioni attivanti il recettore del fattore di crescita dell’epidermide (Epidermal Growth Factor Receptor EGFR)","HU","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.20204054069419e-104,0.3003551904167832,0.6996448095832336,"2+",1.8660212004895216e-25,1.0,"Yes",1.0,2.2403411717987475e-24,"No",1.0,8.640285237618125e-39,"No",0.9986163187525774,0.0013836812474313852,"Yes",0.9999996039088263,3.960911855608782e-07,"Yes",1.0,5.035290706239897e-31,"No",0.8053194509020798,0.1946805490979168,"Yes"
"2015-002894-39","An Open-label Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating MutationsEstudio de Fase 3 abierto y aleatorizado de la eficacia de ASP8273 frente a erlotinib o gefitinib como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico y mutaciones de activación del EGFR en estadío IIIB/IV","BE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.1920130992051945e-93,0.004257799133185484,0.9957422008667989,"2+",1.0785973649918797e-20,1.0,"Yes",1.0,5.201515628084986e-20,"No",1.0,2.3691843809976208e-39,"No",0.7675421318510861,0.2324578681489415,"Yes",0.9999994455613265,5.544386751886011e-07,"Yes",1.0,5.756836263185465e-30,"No",0.13749089541715587,0.8625091045828684,"Yes"
"2015-002894-39","An Open-label Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line treatment of Patients with Stage IIIB/IV NonsmallCell Lung Cancer Tumors with EGFR Activating MutationsStudio di fase 3 randomizzato in aperto sull’efficacia di ASP8273 rispetto a erlotinib o gefitinib nel trattamento di prima linea di pazienti con carcinomi polmonari non a piccole cellule allo stadio IIIB/IV con mutazioni attivanti il recettore del fattore di crescita dell’epidermide (Epidermal Growth Factor Receptor EGFR)","PT","No","No","Yes","ok","No","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",5.20204054069419e-104,0.3003551904167832,0.6996448095832336,"2+",1.8660212004895216e-25,1.0,"Yes",1.0,2.2403411717987475e-24,"No",1.0,8.640285237618125e-39,"No",0.9986163187525774,0.0013836812474313852,"Yes",0.9999996039088263,3.960911855608782e-07,"Yes",1.0,5.035290706239897e-31,"No",0.8053194509020798,0.1946805490979168,"Yes"
"2015-002901-12","A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185).Studio di fase 3 con Lenalidomide e Desametasone a basso dosaggio con o senza Pembrolizumab (MK3475) in pazienti con mieloma multiplo di nuova diagnosi e non precedentemente trattati (KEYNOTE 185)","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2868436388626057e-72,1.4005678284083761e-07,0.9999998599432259,"2+",4.070129067934137e-11,0.9999999999593001,"Yes",0.999999999875115,1.248700084320875e-10,"No",1.0,9.9232069957838e-33,"No",0.0011368190848773723,0.9988631809151027,"Yes",0.9828998529614201,0.017100147038557792,"No",1.0,2.0944357958874253e-19,"No",0.0006802905761488127,0.9993197094238658,"Yes"
"2015-002901-12","A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185).Studio di fase 3 con Lenalidomide e Desametasone a basso dosaggio con o senza Pembrolizumab (MK3475) in pazienti con mieloma multiplo di nuova diagnosi e non precedentemente trattati (KEYNOTE 185)","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2868436388626057e-72,1.4005678284083761e-07,0.9999998599432259,"2+",4.070129067934137e-11,0.9999999999593001,"Yes",0.999999999875115,1.248700084320875e-10,"No",1.0,9.9232069957838e-33,"No",0.0011368190848773723,0.9988631809151027,"Yes",0.9828998529614201,0.017100147038557792,"No",1.0,2.0944357958874253e-19,"No",0.0006802905761488127,0.9993197094238658,"Yes"
"2015-002901-12","A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185).Studio di fase 3 con Lenalidomide e Desametasone a basso dosaggio con o senza Pembrolizumab (MK3475) in pazienti con mieloma multiplo di nuova diagnosi e non precedentemente trattati (KEYNOTE 185)","IE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2868436388626057e-72,1.4005678284083761e-07,0.9999998599432259,"2+",4.070129067934137e-11,0.9999999999593001,"Yes",0.999999999875115,1.248700084320875e-10,"No",1.0,9.9232069957838e-33,"No",0.0011368190848773723,0.9988631809151027,"Yes",0.9828998529614201,0.017100147038557792,"No",1.0,2.0944357958874253e-19,"No",0.0006802905761488127,0.9993197094238658,"Yes"
"2015-002901-12","A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185).Studio di fase 3 con Lenalidomide e Desametasone a basso dosaggio con o senza Pembrolizumab (MK3475) in pazienti con mieloma multiplo di nuova diagnosi e non precedentemente trattati (KEYNOTE 185)","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2868436388626057e-72,1.4005678284083761e-07,0.9999998599432259,"2+",4.070129067934137e-11,0.9999999999593001,"Yes",0.999999999875115,1.248700084320875e-10,"No",1.0,9.9232069957838e-33,"No",0.0011368190848773723,0.9988631809151027,"Yes",0.9828998529614201,0.017100147038557792,"No",1.0,2.0944357958874253e-19,"No",0.0006802905761488127,0.9993197094238658,"Yes"
"2015-002901-12","A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185).Studio di fase 3 con Lenalidomide e Desametasone a basso dosaggio con o senza Pembrolizumab (MK3475) in pazienti con mieloma multiplo di nuova diagnosi e non precedentemente trattati (KEYNOTE 185)","IT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2868436388626057e-72,1.4005678284083761e-07,0.9999998599432259,"2+",4.070129067934137e-11,0.9999999999593001,"Yes",0.999999999875115,1.248700084320875e-10,"No",1.0,9.9232069957838e-33,"No",0.0011368190848773723,0.9988631809151027,"Yes",0.9828998529614201,0.017100147038557792,"No",1.0,2.0944357958874253e-19,"No",0.0006802905761488127,0.9993197094238658,"Yes"
"2015-003007-38","A Randomized Double-blind Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy","FR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3819535073218779e-49,1.0558931213287664e-08,0.9999999894410793,"2+",0.9999966658485723,3.334151433345325e-06,"No",9.586481242153535e-06,0.999990413518752,"Yes",0.9999999999957653,4.2342329679109025e-12,"No",9.52931748932722e-08,0.9999999047068161,"Yes",0.03263277532358898,0.9673672246764082,"No",0.9999999909104532,9.089556879945397e-09,"No",1.3747196285839719e-08,0.9999999862528172,"Yes"
"2015-003007-38","A Randomized Double-blind Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.912658054819918e-48,1.0334998399196408e-08,0.9999999896649997,"2+",0.9999955773274424,4.422672560821599e-06,"No",1.3753461864819661e-05,0.999986246538135,"Yes",0.9999999994657004,5.342933769166771e-10,"No",8.733960779806966e-08,0.9999999126603892,"Yes",0.04038330448027415,0.9596166955197326,"No",0.999998916731205,1.0832687987053457e-06,"No",1.0674197449824424e-07,0.999999893258027,"Yes"
"2015-003007-38","A Randomized Double-blind Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3819535073218779e-49,1.0558931213287664e-08,0.9999999894410793,"2+",0.9999966658485723,3.334151433345325e-06,"No",9.586481242153535e-06,0.999990413518752,"Yes",0.9999999999957653,4.2342329679109025e-12,"No",9.52931748932722e-08,0.9999999047068161,"Yes",0.03263277532358898,0.9673672246764082,"No",0.9999999909104532,9.089556879945397e-09,"No",1.3747196285839719e-08,0.9999999862528172,"Yes"
"2015-003007-38","A Randomized Double-blind Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.912658054819918e-48,1.0334998399196408e-08,0.9999999896649997,"2+",0.9999955773274424,4.422672560821599e-06,"No",1.3753461864819661e-05,0.999986246538135,"Yes",0.9999999994657004,5.342933769166771e-10,"No",8.733960779806966e-08,0.9999999126603892,"Yes",0.04038330448027415,0.9596166955197326,"No",0.999998916731205,1.0832687987053457e-06,"No",1.0674197449824424e-07,0.999999893258027,"Yes"
"2015-003007-38","A Randomized Double-blind Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation TherapyRandomizowane kontrolowane placebo z zastosowaniem podwójnie ślepej próby badanie kliniczne 3 fazy z zastosowaniem JNJ-56021927 (ARN-509) w leczeniu pacjentów ze zlokalizowanym lub miejscowo zaawansowanym rakiem gruczołu krokowego wysokiego ryzyka poddanych pierwotnej radioterapii.","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.879635240309223e-78,5.828187827554594e-21,1.0,"2+",0.9999999999629949,3.7026880747718026e-11,"No",5.126595500539927e-11,0.9999999999487272,"Yes",1.0,1.5262071492527267e-37,"No",1.2163859407066838e-20,1.0,"Yes",6.038046108691694e-06,0.9999939619539014,"No",1.0,5.7793681077957324e-24,"No",1.4424330190405397e-19,1.0,"Yes"
"2015-003007-38","A Randomized Double-blind Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3819535073218779e-49,1.0558931213287664e-08,0.9999999894410793,"2+",0.9999966658485723,3.334151433345325e-06,"No",9.586481242153535e-06,0.999990413518752,"Yes",0.9999999999957653,4.2342329679109025e-12,"No",9.52931748932722e-08,0.9999999047068161,"Yes",0.03263277532358898,0.9673672246764082,"No",0.9999999909104532,9.089556879945397e-09,"No",1.3747196285839719e-08,0.9999999862528172,"Yes"
"2015-003007-38","A Randomized Double-blind Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation TherapyRandomizowane kontrolowane placebo z zastosowaniem podwójnie ślepej próby badanie kliniczne 3 fazy z zastosowaniem JNJ-56021927 (ARN-509) w leczeniu pacjentów ze zlokalizowanym lub miejscowo zaawansowanym rakiem gruczołu krokowego wysokiego ryzyka poddanych pierwotnej radioterapii.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.879635240309223e-78,5.828187827554594e-21,1.0,"2+",0.9999999999629949,3.7026880747718026e-11,"No",5.126595500539927e-11,0.9999999999487272,"Yes",1.0,1.5262071492527267e-37,"No",1.2163859407066838e-20,1.0,"Yes",6.038046108691694e-06,0.9999939619539014,"No",1.0,5.7793681077957324e-24,"No",1.4424330190405397e-19,1.0,"Yes"
"2015-003007-38","A Randomized Double-blind Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.912658054819918e-48,1.0334998399196408e-08,0.9999999896649997,"2+",0.9999955773274424,4.422672560821599e-06,"No",1.3753461864819661e-05,0.999986246538135,"Yes",0.9999999994657004,5.342933769166771e-10,"No",8.733960779806966e-08,0.9999999126603892,"Yes",0.04038330448027415,0.9596166955197326,"No",0.999998916731205,1.0832687987053457e-06,"No",1.0674197449824424e-07,0.999999893258027,"Yes"
"2015-003007-38","A Randomized Double-blind Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","Yes","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.912658054819918e-48,1.0334998399196408e-08,0.9999999896649997,"2+",0.9999955773274424,4.422672560821599e-06,"No",1.3753461864819661e-05,0.999986246538135,"Yes",0.9999999994657004,5.342933769166771e-10,"No",8.733960779806966e-08,0.9999999126603892,"Yes",0.04038330448027415,0.9596166955197326,"No",0.999998916731205,1.0832687987053457e-06,"No",1.0674197449824424e-07,0.999999893258027,"Yes"
"2015-003400-24","monarcHER: A Phase 2 Randomized Multicenter 3-Arm Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+ HER2+ Locally Advanced or Metastatic Breast CancermonarcHER: Μία Τυχαιοποιημένη Πολυκεντρική 3 Ομάδων Ανοιχτή Μελέτη Φάσης 2 για τη Σύγκριση της Αποτελεσματικότητας του Abemaciclib σε Συνδυασμό με Τραστουζουμάμπη με ή χωρίς Φουλβεστράντη έναντι της Συνήθους Χημειοθεραπείας Επιλογής του Γιατρού σε Συνδυασμό με Τραστουζουμάμπη σε Γυναίκες με HR+ HER2+ Τοπικά Προχωρημένο ή Μεταστατικό Καρκίνο του Μαστού","GR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3656461520913847e-67,1.7351566853856094e-05,0.9999826484331511,"2+",2.1556733032708265e-14,0.9999999999999717,"Yes",0.9999999999999147,7.737958369512486e-14,"No",1.0,5.338484826799822e-32,"No",0.8292669649456734,0.17073303505432882,"Yes",0.9999036852794587,9.631472053504459e-05,"Yes",1.0,2.4666480519159383e-15,"No",0.0035448956982718507,0.9964551043017192,"Yes"
"2015-003400-24","monarcHER: A Phase 2 Randomized Multicenter 3-Arm Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+ HER2+ Locally Advanced or Metastatic Breast CancermonarcHER: Μία Τυχαιοποιημένη Πολυκεντρική 3 Ομάδων Ανοιχτή Μελέτη Φάσης 2 για τη Σύγκριση της Αποτελεσματικότητας του Abemaciclib σε Συνδυασμό με Τραστουζουμάμπη με ή χωρίς Φουλβεστράντη έναντι της Συνήθους Χημειοθεραπείας Επιλογής του Γιατρού σε Συνδυασμό με Τραστουζουμάμπη σε Γυναίκες με HR+ HER2+ Τοπικά Προχωρημένο ή Μεταστατικό Καρκίνο του Μαστού","GB","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3656461520913847e-67,1.7351566853856094e-05,0.9999826484331511,"2+",2.1556733032708265e-14,0.9999999999999717,"Yes",0.9999999999999147,7.737958369512486e-14,"No",1.0,5.338484826799822e-32,"No",0.8292669649456734,0.17073303505432882,"Yes",0.9999036852794587,9.631472053504459e-05,"Yes",1.0,2.4666480519159383e-15,"No",0.0035448956982718507,0.9964551043017192,"Yes"
"2015-003400-24","monarcHER: A Phase 2 Randomized Multicenter 3-Arm Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+ HER2+ Locally Advanced or Metastatic Breast CancermonarcHER: Μία Τυχαιοποιημένη Πολυκεντρική 3 Ομάδων Ανοιχτή Μελέτη Φάσης 2 για τη Σύγκριση της Αποτελεσματικότητας του Abemaciclib σε Συνδυασμό με Τραστουζουμάμπη με ή χωρίς Φουλβεστράντη έναντι της Συνήθους Χημειοθεραπείας Επιλογής του Γιατρού σε Συνδυασμό με Τραστουζουμάμπη σε Γυναίκες με HR+ HER2+ Τοπικά Προχωρημένο ή Μεταστατικό Καρκίνο του Μαστού","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3656461520913847e-67,1.7351566853856094e-05,0.9999826484331511,"2+",2.1556733032708265e-14,0.9999999999999717,"Yes",0.9999999999999147,7.737958369512486e-14,"No",1.0,5.338484826799822e-32,"No",0.8292669649456734,0.17073303505432882,"Yes",0.9999036852794587,9.631472053504459e-05,"Yes",1.0,2.4666480519159383e-15,"No",0.0035448956982718507,0.9964551043017192,"Yes"
"2015-003400-24","monarcHER: A Phase 2 Randomized Multicenter 3-Arm Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+ HER2+ Locally Advanced or Metastatic Breast CancermonarcHER: Μία Τυχαιοποιημένη Πολυκεντρική 3 Ομάδων Ανοιχτή Μελέτη Φάσης 2 για τη Σύγκριση της Αποτελεσματικότητας του Abemaciclib σε Συνδυασμό με Τραστουζουμάμπη με ή χωρίς Φουλβεστράντη έναντι της Συνήθους Χημειοθεραπείας Επιλογής του Γιατρού σε Συνδυασμό με Τραστουζουμάμπη σε Γυναίκες με HR+ HER2+ Τοπικά Προχωρημένο ή Μεταστατικό Καρκίνο του Μαστού","BE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.3656461520913847e-67,1.7351566853856094e-05,0.9999826484331511,"2+",2.1556733032708265e-14,0.9999999999999717,"Yes",0.9999999999999147,7.737958369512486e-14,"No",1.0,5.338484826799822e-32,"No",0.8292669649456734,0.17073303505432882,"Yes",0.9999036852794587,9.631472053504459e-05,"Yes",1.0,2.4666480519159383e-15,"No",0.0035448956982718507,0.9964551043017192,"Yes"
"2015-003482-28","A randomized double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)Randomizovaná dvojitě zaslepená studie fáze 3 zkoumající vadastuximab talirin (SGN-CD33A) ve srovnání s placebem v kombinaci s azacitidinem nebo decitabinem v léčbě starších pacientů s nově diagnostikovanou akutní myeloidní leukémií (AML)","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.615803064704616e-96,1.3002504589815418e-21,1.0,"2+",0.9999051661361209,9.483386387846809e-05,"No",0.00014527146913105747,0.9998547285308613,"Yes",1.0,1.093106601785847e-38,"No",1.6296730391836497e-23,1.0,"Yes",0.05574974010616687,0.9442502598938476,"Yes",1.0,3.827559016661145e-26,"No",1.769782170132062e-15,1.0,"Yes"
"2015-003482-28","A randomized double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)Estudio aleatorizado doble ciego fase 3 de vadastuximab talirine (SGNCD33A) frente a placebo en combinación con azacitidina o decitabina en el tratamiento de pacientes mayores con leucemia mieloide aguda de nuevodiagnóstico.","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.96188877612548e-82,1.3951187990091944e-13,0.9999999999998864,"2+",0.9449923001718917,0.05500769982811159,"No",0.3383359848285106,0.6616640151714867,"Yes",1.0,1.6181450652258577e-27,"No",8.702699826972011e-20,1.0,"Yes",0.03479579859396952,0.9652042014060435,"Yes",1.0,3.8210066264151207e-25,"No",4.7719819764378467e-14,0.9999999999999432,"Yes"
"2015-003482-28","A randomized double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)Estudio aleatorizado doble ciego fase 3 de vadastuximab talirine (SGNCD33A) frente a placebo en combinación con azacitidina o decitabina en el tratamiento de pacientes mayores con leucemia mieloide aguda de nuevodiagnóstico.","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.96188877612548e-82,1.3951187990091944e-13,0.9999999999998864,"2+",0.9449923001718917,0.05500769982811159,"No",0.3383359848285106,0.6616640151714867,"Yes",1.0,1.6181450652258577e-27,"No",8.702699826972011e-20,1.0,"Yes",0.03479579859396952,0.9652042014060435,"Yes",1.0,3.8210066264151207e-25,"No",4.7719819764378467e-14,0.9999999999999432,"Yes"
"2015-003482-28","A randomized double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.960543432481408e-47,1.9809708103167484e-08,0.9999999801902961,"2+",0.492172110842746,0.5078278891572401,"No",0.7143178457349943,0.2856821542649959,"Yes",1.0,8.451696682484242e-17,"No",3.388205810446298e-10,0.9999999996611848,"Yes",0.10227141494973052,0.897728585050282,"Yes",0.9999999999993463,6.499565342521178e-13,"No",2.872261166955245e-07,0.9999997127738838,"Yes"
"2015-003482-28","A randomized double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",9.960543432481408e-47,1.9809708103167484e-08,0.9999999801902961,"2+",0.492172110842746,0.5078278891572401,"No",0.7143178457349943,0.2856821542649959,"Yes",1.0,8.451696682484242e-17,"No",3.388205810446298e-10,0.9999999996611848,"Yes",0.10227141494973052,0.897728585050282,"Yes",0.9999999999993463,6.499565342521178e-13,"No",2.872261166955245e-07,0.9999997127738838,"Yes"
"2015-003482-28","A randomized double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)Randomizovaná dvojitě zaslepená studie fáze 3 zkoumající vadastuximab talirin (SGN-CD33A) ve srovnání s placebem v kombinaci s azacitidinem nebo decitabinem v léčbě starších pacientů s nově diagnostikovanou akutní myeloidní leukémií (AML)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.615803064704616e-96,1.3002504589815418e-21,1.0,"2+",0.9999051661361209,9.483386387846809e-05,"No",0.00014527146913105747,0.9998547285308613,"Yes",1.0,1.093106601785847e-38,"No",1.6296730391836497e-23,1.0,"Yes",0.05574974010616687,0.9442502598938476,"Yes",1.0,3.827559016661145e-26,"No",1.769782170132062e-15,1.0,"Yes"
"2015-003482-28","A randomized double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)Estudio aleatorizado doble ciego fase 3 de vadastuximab talirine (SGNCD33A) frente a placebo en combinación con azacitidina o decitabina en el tratamiento de pacientes mayores con leucemia mieloide aguda de nuevodiagnóstico.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.96188877612548e-82,1.3951187990091944e-13,0.9999999999998864,"2+",0.9449923001718917,0.05500769982811159,"No",0.3383359848285106,0.6616640151714867,"Yes",1.0,1.6181450652258577e-27,"No",8.702699826972011e-20,1.0,"Yes",0.03479579859396952,0.9652042014060435,"Yes",1.0,3.8210066264151207e-25,"No",4.7719819764378467e-14,0.9999999999999432,"Yes"
"2015-003482-28","A randomized double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)Estudio aleatorizado doble ciego fase 3 de vadastuximab talirine (SGNCD33A) frente a placebo en combinación con azacitidina o decitabina en el tratamiento de pacientes mayores con leucemia mieloide aguda de nuevodiagnóstico.","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.96188877612548e-82,1.3951187990091944e-13,0.9999999999998864,"2+",0.9449923001718917,0.05500769982811159,"No",0.3383359848285106,0.6616640151714867,"Yes",1.0,1.6181450652258577e-27,"No",8.702699826972011e-20,1.0,"Yes",0.03479579859396952,0.9652042014060435,"Yes",1.0,3.8210066264151207e-25,"No",4.7719819764378467e-14,0.9999999999999432,"Yes"
"2015-003644-40","Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy","PL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.374384098719027e-35,0.74821220153077,0.25178779846923155,"1",0.00020106319833802905,0.9997989368016609,"Yes",0.9995757103679407,0.0004242896320529227,"No",1.0,3.542275231374444e-18,"No",0.877356192335621,0.12264380766437373,"No",0.9835228537537571,0.016477146246245536,"No",0.9994083479687166,0.0005916520312781817,"No",0.5529817334647276,0.44701826653527865,"No"
"2015-003644-40","Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy","DE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.374384098719027e-35,0.74821220153077,0.25178779846923155,"1",0.00020106319833802905,0.9997989368016609,"Yes",0.9995757103679407,0.0004242896320529227,"No",1.0,3.542275231374444e-18,"No",0.877356192335621,0.12264380766437373,"No",0.9835228537537571,0.016477146246245536,"No",0.9994083479687166,0.0005916520312781817,"No",0.5529817334647276,0.44701826653527865,"No"
"2015-003644-40","Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy","ES","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.374384098719027e-35,0.74821220153077,0.25178779846923155,"1",0.00020106319833802905,0.9997989368016609,"Yes",0.9995757103679407,0.0004242896320529227,"No",1.0,3.542275231374444e-18,"No",0.877356192335621,0.12264380766437373,"No",0.9835228537537571,0.016477146246245536,"No",0.9994083479687166,0.0005916520312781817,"No",0.5529817334647276,0.44701826653527865,"No"
"2015-003644-40","Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy","FI","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.374384098719027e-35,0.74821220153077,0.25178779846923155,"1",0.00020106319833802905,0.9997989368016609,"Yes",0.9995757103679407,0.0004242896320529227,"No",1.0,3.542275231374444e-18,"No",0.877356192335621,0.12264380766437373,"No",0.9835228537537571,0.016477146246245536,"No",0.9994083479687166,0.0005916520312781817,"No",0.5529817334647276,0.44701826653527865,"No"
"2015-003644-40","Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy","FR","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.374384098719027e-35,0.74821220153077,0.25178779846923155,"1",0.00020106319833802905,0.9997989368016609,"Yes",0.9995757103679407,0.0004242896320529227,"No",1.0,3.542275231374444e-18,"No",0.877356192335621,0.12264380766437373,"No",0.9835228537537571,0.016477146246245536,"No",0.9994083479687166,0.0005916520312781817,"No",0.5529817334647276,0.44701826653527865,"No"
"2015-003644-40","Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.374384098719027e-35,0.74821220153077,0.25178779846923155,"1",0.00020106319833802905,0.9997989368016609,"Yes",0.9995757103679407,0.0004242896320529227,"No",1.0,3.542275231374444e-18,"No",0.877356192335621,0.12264380766437373,"No",0.9835228537537571,0.016477146246245536,"No",0.9994083479687166,0.0005916520312781817,"No",0.5529817334647276,0.44701826653527865,"No"
"2015-003644-40","Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy","EE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.374384098719027e-35,0.74821220153077,0.25178779846923155,"1",0.00020106319833802905,0.9997989368016609,"Yes",0.9995757103679407,0.0004242896320529227,"No",1.0,3.542275231374444e-18,"No",0.877356192335621,0.12264380766437373,"No",0.9835228537537571,0.016477146246245536,"No",0.9994083479687166,0.0005916520312781817,"No",0.5529817334647276,0.44701826653527865,"No"
"2015-003644-40","Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy","SE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.374384098719027e-35,0.74821220153077,0.25178779846923155,"1",0.00020106319833802905,0.9997989368016609,"Yes",0.9995757103679407,0.0004242896320529227,"No",1.0,3.542275231374444e-18,"No",0.877356192335621,0.12264380766437373,"No",0.9835228537537571,0.016477146246245536,"No",0.9994083479687166,0.0005916520312781817,"No",0.5529817334647276,0.44701826653527865,"No"
"2015-003644-40","Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy","IE","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","Yes","2+","No",1.374384098719027e-35,0.74821220153077,0.25178779846923155,"1",0.00020106319833802905,0.9997989368016609,"Yes",0.9995757103679407,0.0004242896320529227,"No",1.0,3.542275231374444e-18,"No",0.877356192335621,0.12264380766437373,"No",0.9835228537537571,0.016477146246245536,"No",0.9994083479687166,0.0005916520312781817,"No",0.5529817334647276,0.44701826653527865,"No"
"2015-003739-37","A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methyltransferase) Glioblastoma","AT","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.5033794345793797e-34,0.1788482451167515,0.8211517548832549,"2+",3.699700346743396e-10,0.9999999996300346,"Yes",0.9999999992649009,7.351006927711249e-10,"No",1.0,9.751447621169664e-15,"No",0.001616186370387973,0.9983838136296094,"Yes",0.9885660263970084,0.011433973603004846,"Yes",1.0,2.4559784657200423e-16,"No",0.5752874815361398,0.42471251846384805,"Yes"
"2015-003739-37","A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methyltransferase) Glioblastoma","BE","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.5033794345793797e-34,0.1788482451167515,0.8211517548832549,"2+",3.699700346743396e-10,0.9999999996300346,"Yes",0.9999999992649009,7.351006927711249e-10,"No",1.0,9.751447621169664e-15,"No",0.001616186370387973,0.9983838136296094,"Yes",0.9885660263970084,0.011433973603004846,"Yes",1.0,2.4559784657200423e-16,"No",0.5752874815361398,0.42471251846384805,"Yes"
"2015-003739-37","A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methyltransferase) Glioblastoma","DE","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.5033794345793797e-34,0.1788482451167515,0.8211517548832549,"2+",3.699700346743396e-10,0.9999999996300346,"Yes",0.9999999992649009,7.351006927711249e-10,"No",1.0,9.751447621169664e-15,"No",0.001616186370387973,0.9983838136296094,"Yes",0.9885660263970084,0.011433973603004846,"Yes",1.0,2.4559784657200423e-16,"No",0.5752874815361398,0.42471251846384805,"Yes"
"2015-003739-37","A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methyltransferase) GlioblastomaEstudio fase 3 aleatorizado abierto de nivolumab frente a temozolomida cada uno en combinación con radioterapia en sujetos adultos recién diagnosticados de glioblastoma con MGMT (O-6-metilguanina ADN metiltransferasa tumoral) no metilado","SE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0670665424100845e-63,0.05735531705437607,0.9426446829456243,"2+",3.8659512474749085e-16,1.0,"Yes",1.0,1.5584209139822583e-16,"No",1.0,2.7360490986638727e-22,"No",4.079446209137812e-06,0.9999959205537939,"Yes",0.9999827266066474,1.7273393342237717e-05,"Yes",1.0,2.1111264812108432e-33,"No",0.03398356844395152,0.9660164315560357,"Yes"
"2015-003739-37","A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methyltransferase) Glioblastoma","ES","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.5033794345793797e-34,0.1788482451167515,0.8211517548832549,"2+",3.699700346743396e-10,0.9999999996300346,"Yes",0.9999999992649009,7.351006927711249e-10,"No",1.0,9.751447621169664e-15,"No",0.001616186370387973,0.9983838136296094,"Yes",0.9885660263970084,0.011433973603004846,"Yes",1.0,2.4559784657200423e-16,"No",0.5752874815361398,0.42471251846384805,"Yes"
"2015-003739-37","A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methyltransferase) GlioblastomaEstudio fase 3 aleatorizado abierto de nivolumab frente a temozolomida cada uno en combinación con radioterapia en sujetos adultos recién diagnosticados de glioblastoma con MGMT (O-6-metilguanina ADN metiltransferasa tumoral) no metilado","GB","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0670665424100845e-63,0.05735531705437607,0.9426446829456243,"2+",3.8659512474749085e-16,1.0,"Yes",1.0,1.5584209139822583e-16,"No",1.0,2.7360490986638727e-22,"No",4.079446209137812e-06,0.9999959205537939,"Yes",0.9999827266066474,1.7273393342237717e-05,"Yes",1.0,2.1111264812108432e-33,"No",0.03398356844395152,0.9660164315560357,"Yes"
"2015-003739-37","A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methyltransferase) Glioblastoma","NL","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.5033794345793797e-34,0.1788482451167515,0.8211517548832549,"2+",3.699700346743396e-10,0.9999999996300346,"Yes",0.9999999992649009,7.351006927711249e-10,"No",1.0,9.751447621169664e-15,"No",0.001616186370387973,0.9983838136296094,"Yes",0.9885660263970084,0.011433973603004846,"Yes",1.0,2.4559784657200423e-16,"No",0.5752874815361398,0.42471251846384805,"Yes"
"2015-003739-37","A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methyltransferase) GlioblastomaEstudio fase 3 aleatorizado abierto de nivolumab frente a temozolomida cada uno en combinación con radioterapia en sujetos adultos recién diagnosticados de glioblastoma con MGMT (O-6-metilguanina ADN metiltransferasa tumoral) no metilado","DK","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0670665424100845e-63,0.05735531705437607,0.9426446829456243,"2+",3.8659512474749085e-16,1.0,"Yes",1.0,1.5584209139822583e-16,"No",1.0,2.7360490986638727e-22,"No",4.079446209137812e-06,0.9999959205537939,"Yes",0.9999827266066474,1.7273393342237717e-05,"Yes",1.0,2.1111264812108432e-33,"No",0.03398356844395152,0.9660164315560357,"Yes"
"2015-003739-37","A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methyltransferase) GlioblastomaEstudio fase 3 aleatorizado abierto de nivolumab frente a temozolomida cada uno en combinación con radioterapia en sujetos adultos recién diagnosticados de glioblastoma con MGMT (O-6-metilguanina ADN metiltransferasa tumoral) no metilado","PL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.0670665424100845e-63,0.05735531705437607,0.9426446829456243,"2+",3.8659512474749085e-16,1.0,"Yes",1.0,1.5584209139822583e-16,"No",1.0,2.7360490986638727e-22,"No",4.079446209137812e-06,0.9999959205537939,"Yes",0.9999827266066474,1.7273393342237717e-05,"Yes",1.0,2.1111264812108432e-33,"No",0.03398356844395152,0.9660164315560357,"Yes"
"2015-003869-28","ARCHES: A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).","GB","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.328206477320105e-59,1.8659900631083335e-11,0.999999999981327,"2+",0.9999468509117725,5.3149088217867956e-05,"No",0.0001903442625608031,0.9998096557374453,"Yes",0.9999999999999717,1.8385044634378334e-14,"No",1.1050720584832323e-10,0.9999999998894965,"Yes",0.8424505974227577,0.15754940257723116,"No",0.9999999860970662,1.3902941944869426e-08,"No",8.094473486847612e-11,0.999999999919055,"Yes"
"2015-003869-28","ARCHES: A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).","DK","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.328206477320105e-59,1.8659900631083335e-11,0.999999999981327,"2+",0.9999468509117725,5.3149088217867956e-05,"No",0.0001903442625608031,0.9998096557374453,"Yes",0.9999999999999717,1.8385044634378334e-14,"No",1.1050720584832323e-10,0.9999999998894965,"Yes",0.8424505974227577,0.15754940257723116,"No",0.9999999860970662,1.3902941944869426e-08,"No",8.094473486847612e-11,0.999999999919055,"Yes"
"2015-003869-28","A Multinational Phase 3 Randomized Double-blind Placebo-controlledEfficacy and Safety Study of Enzalutamide Plus Androgen DeprivationTherapy (ADT) Versus Placebo Plus ADT in Patients with MetastaticHormone Sensitive Prostate Cancer (mHSPC). Studio multinazionale di fase 3 randomizzato in doppio cieco controllato con placebo di valutazione dell'efficacia e della sicurezza di enzalutamide associato a terapia di deprivazione androgenica (ADT) rispetto a placebo associato ad ADT in pazienti affetti da carcinoma alla prostata ormone-sensibile metastatico (mHSPC).","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.824919542514867e-116,4.541967620233509e-15,1.0,"2+",0.999989328105459,1.0671894518409831e-05,"No",5.862501290332297e-05,0.9999413749871113,"Yes",1.0,9.681167377838165e-28,"No",2.285759462650578e-16,1.0,"Yes",0.18202209880189588,0.8179779011980762,"No",1.0,6.137475356903012e-19,"No",2.145278862610539e-14,1.0,"Yes"
"2015-003869-28","ARCHES: A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.328206477320105e-59,1.8659900631083335e-11,0.999999999981327,"2+",0.9999468509117725,5.3149088217867956e-05,"No",0.0001903442625608031,0.9998096557374453,"Yes",0.9999999999999717,1.8385044634378334e-14,"No",1.1050720584832323e-10,0.9999999998894965,"Yes",0.8424505974227577,0.15754940257723116,"No",0.9999999860970662,1.3902941944869426e-08,"No",8.094473486847612e-11,0.999999999919055,"Yes"
"2015-003869-28","A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).Estudio de eficacia y seguridad de fase 3 multinacional aleatorizado doble ciego y controlado con placebo de enzalutamida más tratamiento de privación androgénica (TPA) frente a placebo más TPA en pacientes con cáncer de próstata metastásico hormonosensible (CPmHS)","FI","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.624155673488923e-110,1.4385421149081352e-21,1.0,"2+",0.9999999979631299,2.0368563965077663e-09,"No",2.166001063247555e-08,0.9999999783399861,"Yes",1.0,7.389785063238408e-28,"No",1.9523385188031566e-20,1.0,"Yes",0.6156270029401999,0.3843729970597982,"No",1.0,2.5613974942342686e-24,"No",1.8529506125214485e-20,1.0,"Yes"
"2015-003869-28","A Multinational Phase 3 Randomized Double-blind Placebo-controlledEfficacy and Safety Study of Enzalutamide Plus Androgen DeprivationTherapy (ADT) Versus Placebo Plus ADT in Patients with MetastaticHormone Sensitive Prostate Cancer (mHSPC). Studio multinazionale di fase 3 randomizzato in doppio cieco controllato con placebo di valutazione dell'efficacia e della sicurezza di enzalutamide associato a terapia di deprivazione androgenica (ADT) rispetto a placebo associato ad ADT in pazienti affetti da carcinoma alla prostata ormone-sensibile metastatico (mHSPC).","SK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.824919542514867e-116,4.541967620233509e-15,1.0,"2+",0.999989328105459,1.0671894518409831e-05,"No",5.862501290332297e-05,0.9999413749871113,"Yes",1.0,9.681167377838165e-28,"No",2.285759462650578e-16,1.0,"Yes",0.18202209880189588,0.8179779011980762,"No",1.0,6.137475356903012e-19,"No",2.145278862610539e-14,1.0,"Yes"
"2015-003869-28","ARCHES: A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).","FR","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.328206477320105e-59,1.8659900631083335e-11,0.999999999981327,"2+",0.9999468509117725,5.3149088217867956e-05,"No",0.0001903442625608031,0.9998096557374453,"Yes",0.9999999999999717,1.8385044634378334e-14,"No",1.1050720584832323e-10,0.9999999998894965,"Yes",0.8424505974227577,0.15754940257723116,"No",0.9999999860970662,1.3902941944869426e-08,"No",8.094473486847612e-11,0.999999999919055,"Yes"
"2015-003869-28","A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).Estudio de eficacia y seguridad de fase 3 multinacional aleatorizado doble ciego y controlado con placebo de enzalutamida más tratamiento de privación androgénica (TPA) frente a placebo más TPA en pacientes con cáncer de próstata metastásico hormonosensible (CPmHS)","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.624155673488923e-110,1.4385421149081352e-21,1.0,"2+",0.9999999979631299,2.0368563965077663e-09,"No",2.166001063247555e-08,0.9999999783399861,"Yes",1.0,7.389785063238408e-28,"No",1.9523385188031566e-20,1.0,"Yes",0.6156270029401999,0.3843729970597982,"No",1.0,2.5613974942342686e-24,"No",1.8529506125214485e-20,1.0,"Yes"
"2015-003869-28","A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).Estudio de eficacia y seguridad de fase 3 multinacional aleatorizado doble ciego y controlado con placebo de enzalutamida más tratamiento de privación androgénica (TPA) frente a placebo más TPA en pacientes con cáncer de próstata metastásico hormonosensible (CPmHS)","IT","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.624155673488923e-110,1.4385421149081352e-21,1.0,"2+",0.9999999979631299,2.0368563965077663e-09,"No",2.166001063247555e-08,0.9999999783399861,"Yes",1.0,7.389785063238408e-28,"No",1.9523385188031566e-20,1.0,"Yes",0.6156270029401999,0.3843729970597982,"No",1.0,2.5613974942342686e-24,"No",1.8529506125214485e-20,1.0,"Yes"
"2015-003869-28","A Multinational Phase 3 Randomized Double-blind Placebo-controlledEfficacy and Safety Study of Enzalutamide Plus Androgen DeprivationTherapy (ADT) Versus Placebo Plus ADT in Patients with MetastaticHormone Sensitive Prostate Cancer (mHSPC). Studio multinazionale di fase 3 randomizzato in doppio cieco controllato con placebo di valutazione dell'efficacia e della sicurezza di enzalutamide associato a terapia di deprivazione androgenica (ADT) rispetto a placebo associato ad ADT in pazienti affetti da carcinoma alla prostata ormone-sensibile metastatico (mHSPC).","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.824919542514867e-116,4.541967620233509e-15,1.0,"2+",0.999989328105459,1.0671894518409831e-05,"No",5.862501290332297e-05,0.9999413749871113,"Yes",1.0,9.681167377838165e-28,"No",2.285759462650578e-16,1.0,"Yes",0.18202209880189588,0.8179779011980762,"No",1.0,6.137475356903012e-19,"No",2.145278862610539e-14,1.0,"Yes"
"2015-003869-28","ARCHES: A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).","NL","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.328206477320105e-59,1.8659900631083335e-11,0.999999999981327,"2+",0.9999468509117725,5.3149088217867956e-05,"No",0.0001903442625608031,0.9998096557374453,"Yes",0.9999999999999717,1.8385044634378334e-14,"No",1.1050720584832323e-10,0.9999999998894965,"Yes",0.8424505974227577,0.15754940257723116,"No",0.9999999860970662,1.3902941944869426e-08,"No",8.094473486847612e-11,0.999999999919055,"Yes"
"2015-003943-20","HELP Study™: A Multicenter Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study to Evaluate DX 2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)HELP StudyTM: Studio di efficacia e sicurezza multicentrico randomizzato in doppio cieco controllato verso placebo per la valutazione di DX 2930 nella profilassi a lungo termine contro gli attacchi acuti di angioedema ereditario (AEE)","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.0008932005312224e-71,2.3062942484891754e-10,0.9999999997693862,"2+",0.9999999999999432,3.928228066365674e-14,"No",1.3676753145234105e-13,0.9999999999998864,"Yes",1.0,4.536585265931497e-25,"No",3.178083247146788e-10,0.9999999996821886,"Yes",0.00023863369377956538,0.9997613663062093,"Yes",0.9999999687923383,3.120765895098649e-08,"No",5.718889292972831e-05,0.9999428111070945,"Yes"
"2015-003943-20","HELP Study™: A Multicenter Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study to Evaluate DX 2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)","GB","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3779469552546373e-28,1.1008294080548782e-05,0.9999889917059159,"2+",0.9999999477044966,5.2295508473421546e-08,"No",1.6615446539848727e-07,0.9999998338455353,"Yes",0.9999999989472742,1.0527325886463821e-09,"No",9.868774336578693e-05,0.9999013122566349,"Yes",0.8471711316840503,0.15282886831594558,"Yes",0.020703687961959295,0.9792963120380395,"No",0.009161870328294594,0.9908381296717028,"Yes"
"2015-003943-20","HELP Study™: A Multicenter Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study to Evaluate DX 2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)","DE","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.3779469552546373e-28,1.1008294080548782e-05,0.9999889917059159,"2+",0.9999999477044966,5.2295508473421546e-08,"No",1.6615446539848727e-07,0.9999998338455353,"Yes",0.9999999989472742,1.0527325886463821e-09,"No",9.868774336578693e-05,0.9999013122566349,"Yes",0.8471711316840503,0.15282886831594558,"Yes",0.020703687961959295,0.9792963120380395,"No",0.009161870328294594,0.9908381296717028,"Yes"
"2015-004572-30","A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib a Selective SYK Inhibitor in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)","FR","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.4805570580868535e-58,2.3948279118690073e-10,0.9999999997605188,"2+",0.9999983378726427,1.6621273588601394e-06,"No",6.90345235731453e-06,0.9999930965476382,"Yes",0.9999999993366089,6.633928718172741e-10,"No",1.3662853007084148e-09,0.9999999986337117,"Yes",0.10473026690671461,0.8952697330932807,"Yes",0.2824563141187909,0.7175436858812042,"No",1.799662317780969e-09,0.9999999982003375,"Yes"
"2015-004572-30","A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib a Selective SYK Inhibitor in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)Estudio de fase 2 aleatorizado con doble enmascaramiento y controlado con placebo para evaluar la eficacia y la tolerabilidad del Entospletinib un inhibidor selectivo de SYK en combinación con corticoesteroides sistémicos como tratamiento de primera línea en pacientes con enfermedad crónica de injerto contra huésped (EICHc)","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.425707604406713e-113,1.7963264082299856e-16,1.0,"2+",0.9999999997567102,2.43287966276285e-10,"No",2.8028434494289328e-09,0.9999999971971648,"Yes",1.0,7.099173641651855e-21,"No",1.3564904021470015e-13,0.9999999999998864,"Yes",0.025778167228412776,0.9742218327715788,"Yes",1.0,1.1764933231597955e-16,"No",2.0237606025444833e-12,0.9999999999979536,"Yes"
"2015-004572-30","A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib a Selective SYK Inhibitor in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)Etude de phase II randomisée en double aveugle testant l'efficacité et la tolérance  de l'Entospletinb un inhibiteur spécifique de SYK et des corticoïdes contre placebo en association avec des corticoïdes en traitement de première ligne de patients atteints de GVH chronique","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1494660028834252e-104,1.7951098837353004e-13,0.9999999999998295,"2+",0.9957814057933527,0.004218594206645348,"No",0.051914820670163654,0.9480851793298137,"Yes",1.0,1.3806111419465467e-21,"No",2.7244390491388906e-14,1.0,"Yes",0.38999040832126264,0.6100095916787158,"Yes",0.9999997638051066,2.3619490877108243e-07,"No",5.2011319935389906e-14,0.9999999999999432,"Yes"
"2015-004703-23","A Multicenter Randomized Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative PathogensEstudio clínico multicéntrico aleatorizado y abierto de S-649266 o mejor tratamiento disponible para infecciones graves provocadas por patógenos gram negativos resistentes a carbapenemos","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.823058205445618e-51,1.5721901628735687e-11,0.9999999999842544,"2+",2.0789138588195706e-06,0.9999979210861635,"Yes",0.9999956575470531,4.342452955312866e-06,"No",1.0,4.644982599105294e-23,"No",1.991377621179875e-11,0.9999999999801048,"Yes",0.934601290964763,0.06539870903521826,"Yes",1.0,2.489656320337372e-16,"No",6.854732036243063e-14,0.9999999999999432,"Yes"
"2015-004703-23","A Multicenter Randomized Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative PathogensÉtude clinique multicentrique en ouvert randomisée concernant l’administration de S 649266 ou du meilleur traitement disponible contre les infections graves dues aux pathogènes Gram négatif résistants aux carbapénèmes","HR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.551220355405445e-52,6.729224503901037e-07,0.9999993270775454,"2+",7.834625801310395e-11,0.9999999999216698,"Yes",0.9999999999711237,2.885694117767419e-11,"No",1.0,6.709857692540358e-21,"No",0.002885404692669509,0.9971145953073217,"Yes",0.9999999931895333,6.8104722163657794e-09,"Yes",0.9999805119082723,1.948809174809727e-05,"No",3.0445882472402896e-08,0.999999969554097,"Yes"
"2015-004703-23","A Multicenter Randomized Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative PathogensÉtude clinique multicentrique en ouvert randomisée concernant l’administration de S 649266 ou du meilleur traitement disponible contre les infections graves dues aux pathogènes Gram négatif résistants aux carbapénèmes","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.551220355405445e-52,6.729224503901037e-07,0.9999993270775454,"2+",7.834625801310395e-11,0.9999999999216698,"Yes",0.9999999999711237,2.885694117767419e-11,"No",1.0,6.709857692540358e-21,"No",0.002885404692669509,0.9971145953073217,"Yes",0.9999999931895333,6.8104722163657794e-09,"Yes",0.9999805119082723,1.948809174809727e-05,"No",3.0445882472402896e-08,0.999999969554097,"Yes"
"2015-004703-23","A Multicenter Randomized Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative PathogensEstudio clínico multicéntrico aleatorizado y abierto de S-649266 o mejor tratamiento disponible para infecciones graves provocadas por patógenos gram negativos resistentes a carbapenemos","GR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",9.823058205445618e-51,1.5721901628735687e-11,0.9999999999842544,"2+",2.0789138588195706e-06,0.9999979210861635,"Yes",0.9999956575470531,4.342452955312866e-06,"No",1.0,4.644982599105294e-23,"No",1.991377621179875e-11,0.9999999999801048,"Yes",0.934601290964763,0.06539870903521826,"Yes",1.0,2.489656320337372e-16,"No",6.854732036243063e-14,0.9999999999999432,"Yes"
"2015-004703-23","A Multicenter Randomized Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative PathogensÉtude clinique multicentrique en ouvert randomisée concernant l’administration de S 649266 ou du meilleur traitement disponible contre les infections graves dues aux pathogènes Gram négatif résistants aux carbapénèmes","FR","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",6.551220355405445e-52,6.729224503901037e-07,0.9999993270775454,"2+",7.834625801310395e-11,0.9999999999216698,"Yes",0.9999999999711237,2.885694117767419e-11,"No",1.0,6.709857692540358e-21,"No",0.002885404692669509,0.9971145953073217,"Yes",0.9999999931895333,6.8104722163657794e-09,"Yes",0.9999805119082723,1.948809174809727e-05,"No",3.0445882472402896e-08,0.999999969554097,"Yes"
"2015-004722-34","A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) GlioblastomaEstudio fase 2 aleatorizado simple ciego de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado","NL","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.101462923478235e-74,5.815163520460177e-07,0.9999994184836382,"2+",0.0009586682433340754,0.9990413317566926,"No",0.9999997060369743,2.939630292946648e-07,"No",1.0,1.493735748933861e-19,"Yes",4.858820948083122e-12,0.9999999999951684,"Yes",0.9999759552370363,2.404476296093849e-05,"Yes",1.0,5.562718588200546e-34,"No",0.0003011837318215526,0.9996988162681802,"Yes"
"2015-004722-34","A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) GlioblastomaEstudio fase 2 aleatorizado simple ciego de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.101462923478235e-74,5.815163520460177e-07,0.9999994184836382,"2+",0.0009586682433340754,0.9990413317566926,"No",0.9999997060369743,2.939630292946648e-07,"No",1.0,1.493735748933861e-19,"Yes",4.858820948083122e-12,0.9999999999951684,"Yes",0.9999759552370363,2.404476296093849e-05,"Yes",1.0,5.562718588200546e-34,"No",0.0003011837318215526,0.9996988162681802,"Yes"
"2015-004722-34","A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma","DK","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.6077891789131084e-42,0.03841779038877571,0.961582209611231,"2+",0.0003331829432052962,0.9996668170568012,"No",0.9999048124904268,9.51875095742141e-05,"No",0.99999999991104,8.894629196757592e-11,"Yes",2.6288810600668534e-05,0.9999737111894036,"Yes",0.9994000383417334,0.0005999616582540088,"Yes",1.0,2.693401412539195e-15,"No",0.5536403911496411,0.44635960885036213,"Yes"
"2015-004722-34","A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma","ES","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.1951346045640536e-42,0.015943986171256447,0.9840560138287535,"2+",0.00046142577590495813,0.9995385742240859,"No",0.9998702185366383,0.00012978146335732078,"No",0.999999999898563,1.0142654898050357e-10,"Yes",8.503828977663464e-06,0.9999914961710258,"Yes",0.9993687267794474,0.0006312732205473854,"Yes",1.0,2.9411920203707007e-15,"No",0.3577938854680946,0.6422061145318966,"Yes"
"2015-004722-34","A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) GlioblastomaEstudio fase 2 aleatorizado simple ciego de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.101462923478235e-74,5.815163520460177e-07,0.9999994184836382,"2+",0.0009586682433340754,0.9990413317566926,"No",0.9999997060369743,2.939630292946648e-07,"No",1.0,1.493735748933861e-19,"Yes",4.858820948083122e-12,0.9999999999951684,"Yes",0.9999759552370363,2.404476296093849e-05,"Yes",1.0,5.562718588200546e-34,"No",0.0003011837318215526,0.9996988162681802,"Yes"
"2015-004722-34","A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) GlioblastomaEstudio fase 2 aleatorizado simple ciego de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado","AT","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",6.101462923478235e-74,5.815163520460177e-07,0.9999994184836382,"2+",0.0009586682433340754,0.9990413317566926,"No",0.9999997060369743,2.939630292946648e-07,"No",1.0,1.493735748933861e-19,"Yes",4.858820948083122e-12,0.9999999999951684,"Yes",0.9999759552370363,2.404476296093849e-05,"Yes",1.0,5.562718588200546e-34,"No",0.0003011837318215526,0.9996988162681802,"Yes"
"2015-004722-34","A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma","PL","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.6077891789131084e-42,0.03841779038877571,0.961582209611231,"2+",0.0003331829432052962,0.9996668170568012,"No",0.9999048124904268,9.51875095742141e-05,"No",0.99999999991104,8.894629196757592e-11,"Yes",2.6288810600668534e-05,0.9999737111894036,"Yes",0.9994000383417334,0.0005999616582540088,"Yes",1.0,2.693401412539195e-15,"No",0.5536403911496411,0.44635960885036213,"Yes"
"2015-004722-34","A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma","SE","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.6077891789131084e-42,0.03841779038877571,0.961582209611231,"2+",0.0003331829432052962,0.9996668170568012,"No",0.9999048124904268,9.51875095742141e-05,"No",0.99999999991104,8.894629196757592e-11,"Yes",2.6288810600668534e-05,0.9999737111894036,"Yes",0.9994000383417334,0.0005999616582540088,"Yes",1.0,2.693401412539195e-15,"No",0.5536403911496411,0.44635960885036213,"Yes"
"2015-004722-34","A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma","GB","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","No","No","Yes","Yes","No","Yes","2+","Yes",2.6077891789131084e-42,0.03841779038877571,0.961582209611231,"2+",0.0003331829432052962,0.9996668170568012,"No",0.9999048124904268,9.51875095742141e-05,"No",0.99999999991104,8.894629196757592e-11,"Yes",2.6288810600668534e-05,0.9999737111894036,"Yes",0.9994000383417334,0.0005999616582540088,"Yes",1.0,2.693401412539195e-15,"No",0.5536403911496411,0.44635960885036213,"Yes"
"2015-004936-36","A phase 3 multicenter randomized prospective open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus  obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutationEine prospektive offene multizentrische Phase-III-Studie zur Behandlung von körperlich fitten nicht vorbehandelten CLL Patienten ohne  del(17p) oder TP53 Mutationen die eine von vier Kombinationstherapien erhalten:  Standardchemoimmuntherapie (FCR/BR)  Rituximimab und Venetoclax (RVe) Obinutuzumab  und Venetoclax (GVe) oder Obinutuzumab Ibrutinib und Venetoclax (GIVe) ","SE","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.426773374054771e-126,0.9999957541766985,4.2458233243226895e-06,"2+",2.2968891393003747e-37,1.0,"Yes",1.0,6.458405616212901e-37,"No",1.0,6.988281624183514e-50,"No",0.9999991027752391,8.972247156087352e-07,"Yes",1.0,2.915349281419071e-18,"Yes",1.0,5.868521573433053e-47,"No",0.9999999951419342,4.85801501756915e-09,"Yes"
"2015-004936-36","A phase 3 multicenter randomized prospective open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus  obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutationEine prospektive offene multizentrische Phase-III-Studie zur Behandlung von körperlich fitten nicht vorbehandelten CLL Patienten ohne  del(17p) oder TP53 Mutationen die eine von vier Kombinationstherapien erhalten:  Standardchemoimmuntherapie (FCR/BR)  Rituximimab und Venetoclax (RVe) Obinutuzumab  und Venetoclax (GVe) oder Obinutuzumab Ibrutinib und Venetoclax (GIVe) ","DK","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.426773374054771e-126,0.9999957541766985,4.2458233243226895e-06,"2+",2.2968891393003747e-37,1.0,"Yes",1.0,6.458405616212901e-37,"No",1.0,6.988281624183514e-50,"No",0.9999991027752391,8.972247156087352e-07,"Yes",1.0,2.915349281419071e-18,"Yes",1.0,5.868521573433053e-47,"No",0.9999999951419342,4.85801501756915e-09,"Yes"
"2015-004936-36","A phase 3 multicenter randomized prospective open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus  obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation","FI","No","No","Yes","ok","No","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",4.863581227232868e-74,0.02184965879351461,0.9781503412065006,"2+",2.5649052769310187e-23,1.0,"Yes",1.0,8.925170481803381e-23,"No",1.0,1.2427449759292933e-37,"No",0.4519087288892978,0.5480912711106891,"Yes",0.9999998790286855,1.209713192511505e-07,"Yes",1.0,2.400900949771467e-26,"No",0.6531436674901872,0.34685633250980685,"Yes"
"2015-004936-36","A phase 3 multicenter randomized prospective open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus  obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutationEine prospektive offene multizentrische Phase-III-Studie zur Behandlung von körperlich fitten nicht vorbehandelten CLL Patienten ohne  del(17p) oder TP53 Mutationen die eine von vier Kombinationstherapien erhalten:  Standardchemoimmuntherapie (FCR/BR)  Rituximimab und Venetoclax (RVe) Obinutuzumab  und Venetoclax (GVe) oder Obinutuzumab Ibrutinib und Venetoclax (GIVe) ","AT","No","No","Yes","ok","No","No","No","No","1","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.426773374054771e-126,0.9999957541766985,4.2458233243226895e-06,"2+",2.2968891393003747e-37,1.0,"Yes",1.0,6.458405616212901e-37,"No",1.0,6.988281624183514e-50,"No",0.9999991027752391,8.972247156087352e-07,"Yes",1.0,2.915349281419071e-18,"Yes",1.0,5.868521573433053e-47,"No",0.9999999951419342,4.85801501756915e-09,"Yes"
"2015-004936-36","A phase 3 multicenter randomized prospective open-label trial ofstandard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax(RVe) versus obinutuzumab (GA101) plus venetoclax (GVe)versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tientswith previously untreated chronic lymphocytic leukemia (CLL) withoutdel(17p) or TP53 mutationVAIHEEN 3 SATUNNAISTETTU PROSPEKTIIVINEN AVOIN MONIKESKUSTUTKIMUS VAKIINTUNEEN KEMOIMMUNOTERAPIAN (FCR/BR) JA RITUKSIMABIN PLUS VENETOKLAKSIN (RVE) OBINUTUTSUMABIN (GA101) PLUS VENETOKLAKSIN (GVE) TAI OBINUTUTSUMABIN PLUS IBRUTINIBIN PLUS VENETOKLAKSIN (GIVE) KÄYTÖSTÄ HYVÄKUNTOISILLA POTILAILLA JOILLA ON AIEMMIN HOITAMATON KROONINEN LYMFAATTINEN LEUKEMIA (KLL) ILMAN DELEETIOTA (17P) TAI TP53-MUTAATIOTA","BE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6814299131417384e-89,1.2971762702253341e-09,0.9999999987028333,"2+",1.8367579095640147e-26,1.0,"Yes",1.0,1.602740459624089e-25,"No",1.0,8.972643981323133e-53,"No",3.962732115032943e-08,0.9999999603726346,"Yes",0.9999999999946568,5.347496187101729e-12,"Yes",1.0,6.085453618350053e-45,"No",0.00020414039038798274,0.9997958596096685,"Yes"
"2015-004936-36","A phase 3 multicenter randomized prospective open-label trial ofstandard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax(RVe) versus obinutuzumab (GA101) plus venetoclax (GVe)versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tientswith previously untreated chronic lymphocytic leukemia (CLL) withoutdel(17p) or TP53 mutationVAIHEEN 3 SATUNNAISTETTU PROSPEKTIIVINEN AVOIN MONIKESKUSTUTKIMUS VAKIINTUNEEN KEMOIMMUNOTERAPIAN (FCR/BR) JA RITUKSIMABIN PLUS VENETOKLAKSIN (RVE) OBINUTUTSUMABIN (GA101) PLUS VENETOKLAKSIN (GVE) TAI OBINUTUTSUMABIN PLUS IBRUTINIBIN PLUS VENETOKLAKSIN (GIVE) KÄYTÖSTÄ HYVÄKUNTOISILLA POTILAILLA JOILLA ON AIEMMIN HOITAMATON KROONINEN LYMFAATTINEN LEUKEMIA (KLL) ILMAN DELEETIOTA (17P) TAI TP53-MUTAATIOTA","DE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6814299131417384e-89,1.2971762702253341e-09,0.9999999987028333,"2+",1.8367579095640147e-26,1.0,"Yes",1.0,1.602740459624089e-25,"No",1.0,8.972643981323133e-53,"No",3.962732115032943e-08,0.9999999603726346,"Yes",0.9999999999946568,5.347496187101729e-12,"Yes",1.0,6.085453618350053e-45,"No",0.00020414039038798274,0.9997958596096685,"Yes"
"2015-004936-36","A phase 3 multicenter randomized prospective open-label trial ofstandard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax(RVe) versus obinutuzumab (GA101) plus venetoclax (GVe)versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tientswith previously untreated chronic lymphocytic leukemia (CLL) withoutdel(17p) or TP53 mutationVAIHEEN 3 SATUNNAISTETTU PROSPEKTIIVINEN AVOIN MONIKESKUSTUTKIMUS VAKIINTUNEEN KEMOIMMUNOTERAPIAN (FCR/BR) JA RITUKSIMABIN PLUS VENETOKLAKSIN (RVE) OBINUTUTSUMABIN (GA101) PLUS VENETOKLAKSIN (GVE) TAI OBINUTUTSUMABIN PLUS IBRUTINIBIN PLUS VENETOKLAKSIN (GIVE) KÄYTÖSTÄ HYVÄKUNTOISILLA POTILAILLA JOILLA ON AIEMMIN HOITAMATON KROONINEN LYMFAATTINEN LEUKEMIA (KLL) ILMAN DELEETIOTA (17P) TAI TP53-MUTAATIOTA","IE","No","No","Yes","ok","Yes","No","No","Yes","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.6814299131417384e-89,1.2971762702253341e-09,0.9999999987028333,"2+",1.8367579095640147e-26,1.0,"Yes",1.0,1.602740459624089e-25,"No",1.0,8.972643981323133e-53,"No",3.962732115032943e-08,0.9999999603726346,"Yes",0.9999999999946568,5.347496187101729e-12,"Yes",1.0,6.085453618350053e-45,"No",0.00020414039038798274,0.9997958596096685,"Yes"
"2016-000285-28","A phase II randomised double-blinded placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over12 week treatment period in patients with SchizophreniaStudio di fase II a gruppi paralleli randomizzato in doppio cieco e controllato con placebo volto a valutare l'efficacia e la sicurezza di 4 dosi orali di BI 425809 somministrate una volta al giorno per un periodo di trattamento di 12 settimane a pazienti affetti da schizofrenia.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.542003376503359e-132,6.7010032863188306e-21,1.0,"2+",1.0,1.8853214520862698e-18,"No",4.395977798278027e-17,1.0,"Yes",1.0,7.276947641844625e-26,"No",1.9279809199528202e-21,1.0,"Yes",1.51249389755068e-14,1.0,"Yes",1.0,9.989957867013085e-24,"No",1.5184865084435737e-21,1.0,"Yes"
"2016-000285-28","A phase II randomised double-blinded placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over12 week treatment period in patients with Schizophrenia","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.967261520754567e-54,3.4275549178601516e-11,0.9999999999657235,"2+",0.9999999999065778,9.341113505272611e-11,"No",2.605947602093257e-10,0.9999999997394013,"Yes",0.9999999983350278,1.6649707281927225e-09,"No",3.9101157720876344e-11,0.9999999999608917,"Yes",9.594485337852447e-07,0.9999990405514778,"Yes",0.9999916924478254,8.307552183253905e-06,"No",5.571815314058306e-11,0.9999999999442934,"Yes"
"2016-000285-28","A phase II randomised double-blinded placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over12 week treatment period in patients with Schizophrenia","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",7.967261520754567e-54,3.4275549178601516e-11,0.9999999999657235,"2+",0.9999999999065778,9.341113505272611e-11,"No",2.605947602093257e-10,0.9999999997394013,"Yes",0.9999999983350278,1.6649707281927225e-09,"No",3.9101157720876344e-11,0.9999999999608917,"Yes",9.594485337852447e-07,0.9999990405514778,"Yes",0.9999916924478254,8.307552183253905e-06,"No",5.571815314058306e-11,0.9999999999442934,"Yes"
"2016-000285-28","A phase II randomised double-blinded placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over12 week treatment period in patients with SchizophreniaStudio di fase II a gruppi paralleli randomizzato in doppio cieco e controllato con placebo volto a valutare l'efficacia e la sicurezza di 4 dosi orali di BI 425809 somministrate una volta al giorno per un periodo di trattamento di 12 settimane a pazienti affetti da schizofrenia.","IT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.542003376503359e-132,6.7010032863188306e-21,1.0,"2+",1.0,1.8853214520862698e-18,"No",4.395977798278027e-17,1.0,"Yes",1.0,7.276947641844625e-26,"No",1.9279809199528202e-21,1.0,"Yes",1.51249389755068e-14,1.0,"Yes",1.0,9.989957867013085e-24,"No",1.5184865084435737e-21,1.0,"Yes"
"2016-000588-17","A Phase III Randomized Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.260654836661685e-48,0.009666857415143447,0.9903331425848595,"2+",8.361124264603768e-09,0.9999999916388732,"Yes",0.9999999738306262,2.6169383278316554e-08,"No",1.0,2.5398098512842686e-25,"No",0.005179330705153709,0.9948206692948547,"Yes",0.2564418655045072,0.7435581344954934,"Yes",0.9999997293375682,2.706624211290039e-07,"No",0.01793042754897052,0.9820695724510339,"Yes"
"2016-000588-17","A Phase III Randomized Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.260654836661685e-48,0.009666857415143447,0.9903331425848595,"2+",8.361124264603768e-09,0.9999999916388732,"Yes",0.9999999738306262,2.6169383278316554e-08,"No",1.0,2.5398098512842686e-25,"No",0.005179330705153709,0.9948206692948547,"Yes",0.2564418655045072,0.7435581344954934,"Yes",0.9999997293375682,2.706624211290039e-07,"No",0.01793042754897052,0.9820695724510339,"Yes"
"2016-000588-17","A Phase III Randomized Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.260654836661685e-48,0.009666857415143447,0.9903331425848595,"2+",8.361124264603768e-09,0.9999999916388732,"Yes",0.9999999738306262,2.6169383278316554e-08,"No",1.0,2.5398098512842686e-25,"No",0.005179330705153709,0.9948206692948547,"Yes",0.2564418655045072,0.7435581344954934,"Yes",0.9999997293375682,2.706624211290039e-07,"No",0.01793042754897052,0.9820695724510339,"Yes"
"2016-000588-17","A Phase III Randomized Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)Estudio de fase III aleatorizado y abierto para evaluar la eficacia y la seguridad de pembrolizumab (MK-3475) en combinación con axitinib frente a sunitinib en monoterapia como tratamiento de primera línea del carcinoma renal metastásico (CRm) o localmente avanzado (KEYNOTE-426)","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.82627136001761e-105,5.981655241092133e-05,0.9999401834476118,"2+",5.902637733094154e-17,1.0,"Yes",1.0,3.273290790866941e-16,"No",1.0,5.444974864056457e-48,"No",3.080226618534087e-06,0.9999969197733922,"Yes",0.037310275317985864,0.9626897246819915,"Yes",1.0,5.113377182817029e-24,"No",0.00023942536290886128,0.9997605746371034,"Yes"
"2016-000588-17","A Phase III Randomized Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)Estudio de fase III aleatorizado y abierto para evaluar la eficacia y la seguridad de pembrolizumab (MK-3475) en combinación con axitinib frente a sunitinib en monoterapia como tratamiento de primera línea del carcinoma renal metastásico (CRm) o localmente avanzado (KEYNOTE-426)","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.82627136001761e-105,5.981655241092133e-05,0.9999401834476118,"2+",5.902637733094154e-17,1.0,"Yes",1.0,3.273290790866941e-16,"No",1.0,5.444974864056457e-48,"No",3.080226618534087e-06,0.9999969197733922,"Yes",0.037310275317985864,0.9626897246819915,"Yes",1.0,5.113377182817029e-24,"No",0.00023942536290886128,0.9997605746371034,"Yes"
"2016-000588-17","A Phase III Randomized Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",7.260654836661685e-48,0.009666857415143447,0.9903331425848595,"2+",8.361124264603768e-09,0.9999999916388732,"Yes",0.9999999738306262,2.6169383278316554e-08,"No",1.0,2.5398098512842686e-25,"No",0.005179330705153709,0.9948206692948547,"Yes",0.2564418655045072,0.7435581344954934,"Yes",0.9999997293375682,2.706624211290039e-07,"No",0.01793042754897052,0.9820695724510339,"Yes"
"2016-000588-17","A Phase III Randomized Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)Estudio de fase III aleatorizado y abierto para evaluar la eficacia y la seguridad de pembrolizumab (MK-3475) en combinación con axitinib frente a sunitinib en monoterapia como tratamiento de primera línea del carcinoma renal metastásico (CRm) o localmente avanzado (KEYNOTE-426)","FR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",3.82627136001761e-105,5.981655241092133e-05,0.9999401834476118,"2+",5.902637733094154e-17,1.0,"Yes",1.0,3.273290790866941e-16,"No",1.0,5.444974864056457e-48,"No",3.080226618534087e-06,0.9999969197733922,"Yes",0.037310275317985864,0.9626897246819915,"Yes",1.0,5.113377182817029e-24,"No",0.00023942536290886128,0.9997605746371034,"Yes"
"2016-001018-76","A Randomized Multicenter Open-Label Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)","PL","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2979167374010004e-68,8.419495639562241e-08,0.9999999158050663,"2+",1.4330649244383385e-09,0.9999999985669207,"Yes",0.9999999941162515,5.883729080330666e-09,"No",1.0,2.4085368276143794e-37,"No",0.0007624552982495154,0.999237544701745,"No",0.05747395403743249,0.9425260459625576,"No",1.0,6.269177019592806e-24,"No",5.515991281441899e-06,0.9999944840087456,"Yes"
"2016-001018-76","A Randomized Multicenter Open-Label Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerRandomizovaná multicentrická otevřená studie fáze III hodnotící léčbu nivolumabem v kombinaci s ipilimumabem nebo nivolumabem v kombinaci s oxaliplatinou a fluoropyrimidinem oproti léčbě oxaliplatinou a fluoropyrimidinem u pacientů s neléčeným pokročilým nebo metastazujícím karcinomem žaludku nebo gastroezofageální junkce.","PT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.357437449168962e-110,1.0205351681894383e-19,1.0,"2+",2.1715222728690184e-09,0.9999999978284677,"Yes",0.9999999609436835,3.905633759861898e-08,"No",1.0,3.438255138262834e-63,"No",6.212553411455493e-14,0.9999999999999432,"No",4.845298582860163e-07,0.9999995154701689,"No",1.0,7.554898261894081e-39,"No",1.3896902342558595e-15,1.0,"Yes"
"2016-001018-76","A Randomized Multicenter Open-Label Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)","GB","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2979167374010004e-68,8.419495639562241e-08,0.9999999158050663,"2+",1.4330649244383385e-09,0.9999999985669207,"Yes",0.9999999941162515,5.883729080330666e-09,"No",1.0,2.4085368276143794e-37,"No",0.0007624552982495154,0.999237544701745,"No",0.05747395403743249,0.9425260459625576,"No",1.0,6.269177019592806e-24,"No",5.515991281441899e-06,0.9999944840087456,"Yes"
"2016-001018-76","A Randomized Multicenter Open-Label Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerRandomizovaná multicentrická otevřená studie fáze III hodnotící léčbu nivolumabem v kombinaci s ipilimumabem nebo nivolumabem v kombinaci s oxaliplatinou a fluoropyrimidinem oproti léčbě oxaliplatinou a fluoropyrimidinem u pacientů s neléčeným pokročilým nebo metastazujícím karcinomem žaludku nebo gastroezofageální junkce.","ES","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",8.357437449168962e-110,1.0205351681894383e-19,1.0,"2+",2.1715222728690184e-09,0.9999999978284677,"Yes",0.9999999609436835,3.905633759861898e-08,"No",1.0,3.438255138262834e-63,"No",6.212553411455493e-14,0.9999999999999432,"No",4.845298582860163e-07,0.9999995154701689,"No",1.0,7.554898261894081e-39,"No",1.3896902342558595e-15,1.0,"Yes"
"2016-001018-76","A Randomized Multicenter Open-Label Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)","GR","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2979167374010004e-68,8.419495639562241e-08,0.9999999158050663,"2+",1.4330649244383385e-09,0.9999999985669207,"Yes",0.9999999941162515,5.883729080330666e-09,"No",1.0,2.4085368276143794e-37,"No",0.0007624552982495154,0.999237544701745,"No",0.05747395403743249,0.9425260459625576,"No",1.0,6.269177019592806e-24,"No",5.515991281441899e-06,0.9999944840087456,"Yes"
"2016-001018-76","A Randomized Multicenter Open-Label Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2979167374010004e-68,8.419495639562241e-08,0.9999999158050663,"2+",1.4330649244383385e-09,0.9999999985669207,"Yes",0.9999999941162515,5.883729080330666e-09,"No",1.0,2.4085368276143794e-37,"No",0.0007624552982495154,0.999237544701745,"No",0.05747395403743249,0.9425260459625576,"No",1.0,6.269177019592806e-24,"No",5.515991281441899e-06,0.9999944840087456,"Yes"
"2016-001018-76","A Randomized Multicenter Open-Label Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2979167374010004e-68,8.419495639562241e-08,0.9999999158050663,"2+",1.4330649244383385e-09,0.9999999985669207,"Yes",0.9999999941162515,5.883729080330666e-09,"No",1.0,2.4085368276143794e-37,"No",0.0007624552982495154,0.999237544701745,"No",0.05747395403743249,0.9425260459625576,"No",1.0,6.269177019592806e-24,"No",5.515991281441899e-06,0.9999944840087456,"Yes"
"2016-001018-76","A Randomized Multicenter Open-Label Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)","HU","No","No","Yes","ok","Yes","No","Yes","Yes","2+","No","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.2979167374010004e-68,8.419495639562241e-08,0.9999999158050663,"2+",1.4330649244383385e-09,0.9999999985669207,"Yes",0.9999999941162515,5.883729080330666e-09,"No",1.0,2.4085368276143794e-37,"No",0.0007624552982495154,0.999237544701745,"No",0.05747395403743249,0.9425260459625576,"No",1.0,6.269177019592806e-24,"No",5.515991281441899e-06,0.9999944840087456,"Yes"
"2016-001815-19","An open-label single-arm rater-blinded multicenter phase 1/2 study to assess safety and diagnostic accuracy and radiotherapeutic implications of pre-operative Ga-68-PSMA-11 PET/CT imaging in comparison to histopathology in newly-diagnosed prostate cancer (PCA) patients at high risk for metastasis scheduled for radical prostatectomy (RP) with extended pelvic lymph node dissection (EPLND).","AT","No","No","Yes","ok","No","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",5.119329465283783e-55,0.3970929643871343,0.6029070356128842,"1",8.126043340452572e-13,0.9999999999992043,"Yes",1.0,1.0124135238977653e-14,"No",0.9999986102017141,1.3897982680661824e-06,"No",3.4848955355818306e-06,0.9999965151044891,"No",0.9999999999993179,6.813358016722467e-13,"No",1.0,4.603548117267729e-19,"No",0.882001626996878,0.11799837300310202,"No"
"2016-001815-19","An open-label single-arm rater-blinded multicenter phase 1/2 study to assess safety and diagnostic accuracy and radiotherapeutic implications of pre-operative Ga-68-PSMA-11 PET/CT imaging in comparison to histopathology in newly-diagnosed prostate cancer (PCA) patients at high risk for metastasis scheduled for radical prostatectomy (RP) with extended pelvic lymph node dissection (EPLND).","DE","No","No","Yes","ok","No","No","No","Yes","2+","No","No","Yes","No","No","No","No","No","1","No",5.119329465283783e-55,0.3970929643871343,0.6029070356128842,"1",8.126043340452572e-13,0.9999999999992043,"Yes",1.0,1.0124135238977653e-14,"No",0.9999986102017141,1.3897982680661824e-06,"No",3.4848955355818306e-06,0.9999965151044891,"No",0.9999999999993179,6.813358016722467e-13,"No",1.0,4.603548117267729e-19,"No",0.882001626996878,0.11799837300310202,"No"
"2016-001935-12","AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemiaAIEOP-BFM ALL 2017 - Medzinárodný liečebný  protokol pre deti a adolescentov s akútnou lymfoblastovou leukémiou ","AT","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",5.543295217907862e-23,2.5511645506247894e-05,0.9999744883544953,"2+",1.0134400664503232e-07,0.9999998986560054,"Yes",0.9999997925001127,2.074998825894222e-07,"No",0.9999999999878356,1.217702774570563e-11,"No",0.00022804681218071938,0.9997719531878284,"Yes",0.012541523516161711,0.9874584764838334,"Yes",0.9999999999986926,1.306987582148725e-12,"No",4.924847700113284e-06,0.9999950751522899,"Yes"
"2016-001935-12","AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemiaAIEOP-BFM ALL 2017 - Medzinárodný liečebný  protokol pre deti a adolescentov s akútnou lymfoblastovou leukémiou ","SK","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",5.543295217907862e-23,2.5511645506247894e-05,0.9999744883544953,"2+",1.0134400664503232e-07,0.9999998986560054,"Yes",0.9999997925001127,2.074998825894222e-07,"No",0.9999999999878356,1.217702774570563e-11,"No",0.00022804681218071938,0.9997719531878284,"Yes",0.012541523516161711,0.9874584764838334,"Yes",0.9999999999986926,1.306987582148725e-12,"No",4.924847700113284e-06,0.9999950751522899,"Yes"
"2016-001935-12","AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemiaAIEOP-BFM ALL 2017- Mezinárodní léčebný protokol pro léčbu akutní lymfoblastické leukémie u dětí a dospívajících","DE","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",2.3964723573336748e-27,2.12790400496384e-05,0.9999787209599393,"2+",2.7076713057924675e-09,0.9999999972923207,"Yes",0.9999999931054618,6.8945333049421155e-09,"No",1.0,1.0058377038522614e-18,"No",0.00012007328303948478,0.9998799267169514,"Yes",0.051882156104745565,0.9481178438952685,"Yes",0.9999999999998579,1.406264824136974e-13,"No",3.574477770182107e-05,0.9999642552222918,"Yes"
"2016-001935-12","AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemiaAIEOP-BFM ALL 2017 - Medzinárodný liečebný  protokol pre deti a adolescentov s akútnou lymfoblastovou leukémiou ","CZ","No","No","Yes","ok","Yes","No","Yes","Yes","2+","Yes","No","Yes","No","No","Yes","No","No","2+","Yes",5.543295217907862e-23,2.5511645506247894e-05,0.9999744883544953,"2+",1.0134400664503232e-07,0.9999998986560054,"Yes",0.9999997925001127,2.074998825894222e-07,"No",0.9999999999878356,1.217702774570563e-11,"No",0.00022804681218071938,0.9997719531878284,"Yes",0.012541523516161711,0.9874584764838334,"Yes",0.9999999999986926,1.306987582148725e-12,"No",4.924847700113284e-06,0.9999950751522899,"Yes"
"2016-002057-38","A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","FR","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.8373668404424204e-24,0.9866758085249597,0.013324191475040614,"1",4.145149414729123e-05,0.9999585485058502,"Yes",0.9999454142167316,5.458578326453159e-05,"No",0.9999999999337349,6.627201203683278e-11,"No",0.9510510409262177,0.048948959073789315,"No",0.9998226832711972,0.00017731672879956888,"No",0.999997088132621,2.9118673767826214e-06,"No",0.964775211014701,0.03522478898530275,"No"
"2016-002057-38","A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesEstudio fase 2 de eficacia y seguridad de Niraparib en hombres con cáncerde próstata metastásico resistente a castración y anomalías en lareparación de ADN","ES","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",1.640273283073585e-43,0.758496142105663,0.24150385789432585,"1",1.6019668803840563e-07,0.9999998398033214,"Yes",0.9999997006735719,2.9932643109540915e-07,"No",1.0,1.8501690225530612e-19,"No",0.4858788036495244,0.5141211963504825,"No",0.99997176515458,2.8234845424024828e-05,"No",0.9999999999997727,2.2579298198402454e-13,"No",0.13283817076088433,0.8671618292391198,"No"
"2016-002057-38","A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","GB","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.8373668404424204e-24,0.9866758085249597,0.013324191475040614,"1",4.145149414729123e-05,0.9999585485058502,"Yes",0.9999454142167316,5.458578326453159e-05,"No",0.9999999999337349,6.627201203683278e-11,"No",0.9510510409262177,0.048948959073789315,"No",0.9998226832711972,0.00017731672879956888,"No",0.999997088132621,2.9118673767826214e-06,"No",0.964775211014701,0.03522478898530275,"No"
"2016-002057-38","A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesEstudio fase 2 de eficacia y seguridad de Niraparib en hombres con cáncerde próstata metastásico resistente a castración y anomalías en lareparación de ADN","SE","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",1.640273283073585e-43,0.758496142105663,0.24150385789432585,"1",1.6019668803840563e-07,0.9999998398033214,"Yes",0.9999997006735719,2.9932643109540915e-07,"No",1.0,1.8501690225530612e-19,"No",0.4858788036495244,0.5141211963504825,"No",0.99997176515458,2.8234845424024828e-05,"No",0.9999999999997727,2.2579298198402454e-13,"No",0.13283817076088433,0.8671618292391198,"No"
"2016-002057-38","A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","DK","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.8373668404424204e-24,0.9866758085249597,0.013324191475040614,"1",4.145149414729123e-05,0.9999585485058502,"Yes",0.9999454142167316,5.458578326453159e-05,"No",0.9999999999337349,6.627201203683278e-11,"No",0.9510510409262177,0.048948959073789315,"No",0.9998226832711972,0.00017731672879956888,"No",0.999997088132621,2.9118673767826214e-06,"No",0.964775211014701,0.03522478898530275,"No"
"2016-002057-38","A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesEstudio fase 2 de eficacia y seguridad de Niraparib en hombres con cáncerde próstata metastásico resistente a castración y anomalías en lareparación de ADN","BE","No","No","Yes","ok","Yes","No","No","Yes","1","No","No","Yes","No","No","No","No","No","1","No",1.640273283073585e-43,0.758496142105663,0.24150385789432585,"1",1.6019668803840563e-07,0.9999998398033214,"Yes",0.9999997006735719,2.9932643109540915e-07,"No",1.0,1.8501690225530612e-19,"No",0.4858788036495244,0.5141211963504825,"No",0.99997176515458,2.8234845424024828e-05,"No",0.9999999999997727,2.2579298198402454e-13,"No",0.13283817076088433,0.8671618292391198,"No"
"2016-002057-38","A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","NL","No","No","Yes","ok","No","No","No","No","1","No","No","Yes","No","No","No","No","No","1","No",4.8373668404424204e-24,0.9866758085249597,0.013324191475040614,"1",4.145149414729123e-05,0.9999585485058502,"Yes",0.9999454142167316,5.458578326453159e-05,"No",0.9999999999337349,6.627201203683278e-11,"No",0.9510510409262177,0.048948959073789315,"No",0.9998226832711972,0.00017731672879956888,"No",0.999997088132621,2.9118673767826214e-06,"No",0.964775211014701,0.03522478898530275,"No"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","AT","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","HU","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","CZ","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","DE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","ES","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","GR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","BE","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","PL","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","FR","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003092-22","A PHASE III MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF INELIGIBILITY FOR OR REFUSAL OF A TAXANE REGIMEN","DK","No","No","Yes","ok","Yes","No","No","No","2+","Yes","No","Yes","No","No","Yes","No","Yes","2+","Yes",1.5691421218756712e-55,0.06001820590172249,0.9399817940982673,"2+",8.680717309538721e-08,0.9999999131928272,"Yes",0.9999997491860628,2.508139316896734e-07,"No",1.0,4.5669283889839825e-22,"No",0.9618781786487991,0.03812182135119013,"Yes",0.9998738072249121,0.000126192775086595,"Yes",0.9999999999426167,5.737562614971994e-11,"No",0.3103219476487406,0.6896780523512466,"Yes"
"2016-003653-15","A multi-center double-blind placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular diseaseEstudio de fase IIb multicéntrico con doble enmascaramiento y controlado con placebo para evaluar la eficacia y la seguridad de macitentan en pacientes con insuficiencia cardíaca con fracción de eyección preservada y vasculopatía pulmonar.","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.8540029149580803e-85,4.826658684833138e-22,1.0,"2+",1.0,3.51397632102241e-24,"No",2.857045359816722e-23,1.0,"Yes",1.0,3.677318199095752e-24,"No",1.690382005383963e-24,1.0,"Yes",6.961350386750559e-07,0.9999993038649827,"Yes",1.0,2.1335043650094593e-25,"No",7.873390797052109e-20,1.0,"No"
"2016-003653-15","A multi-center double-blind placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular diseaseEstudio de fase IIb multicéntrico con doble enmascaramiento y controlado con placebo para evaluar la eficacia y la seguridad de macitentan en pacientes con insuficiencia cardíaca con fracción de eyección preservada y vasculopatía pulmonar.","AT","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.8540029149580803e-85,4.826658684833138e-22,1.0,"2+",1.0,3.51397632102241e-24,"No",2.857045359816722e-23,1.0,"Yes",1.0,3.677318199095752e-24,"No",1.690382005383963e-24,1.0,"Yes",6.961350386750559e-07,0.9999993038649827,"Yes",1.0,2.1335043650094593e-25,"No",7.873390797052109e-20,1.0,"No"
"2016-003653-15","A multi-center double-blind placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular diseaseEstudio de fase IIb multicéntrico con doble enmascaramiento y controlado con placebo para evaluar la eficacia y la seguridad de macitentan en pacientes con insuficiencia cardíaca con fracción de eyección preservada y vasculopatía pulmonar.","HU","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.8540029149580803e-85,4.826658684833138e-22,1.0,"2+",1.0,3.51397632102241e-24,"No",2.857045359816722e-23,1.0,"Yes",1.0,3.677318199095752e-24,"No",1.690382005383963e-24,1.0,"Yes",6.961350386750559e-07,0.9999993038649827,"Yes",1.0,2.1335043650094593e-25,"No",7.873390797052109e-20,1.0,"No"
"2016-003653-15","A multi-center double-blind placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease","DK","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.359548150892667e-45,7.44987963468835e-12,0.9999999999925536,"2+",0.9999999999999717,4.179844736024975e-14,"No",1.604945258796742e-13,0.9999999999998295,"Yes",0.9999999999992043,8.016431855862445e-13,"No",4.216261391538721e-14,0.9999999999999717,"Yes",6.327540153737436e-05,0.9999367245984602,"Yes",0.9999999999202487,7.976491945992484e-11,"No",3.417968854412508e-11,0.9999999999658087,"No"
"2016-003653-15","A multi-center double-blind placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular diseaseEstudio de fase IIb multicéntrico con doble enmascaramiento y controlado con placebo para evaluar la eficacia y la seguridad de macitentan en pacientes con insuficiencia cardíaca con fracción de eyección preservada y vasculopatía pulmonar.","BG","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.8540029149580803e-85,4.826658684833138e-22,1.0,"2+",1.0,3.51397632102241e-24,"No",2.857045359816722e-23,1.0,"Yes",1.0,3.677318199095752e-24,"No",1.690382005383963e-24,1.0,"Yes",6.961350386750559e-07,0.9999993038649827,"Yes",1.0,2.1335043650094593e-25,"No",7.873390797052109e-20,1.0,"No"
"2016-003653-15","A multi-center double-blind placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease","CZ","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.359548150892667e-45,7.44987963468835e-12,0.9999999999925536,"2+",0.9999999999999717,4.179844736024975e-14,"No",1.604945258796742e-13,0.9999999999998295,"Yes",0.9999999999992043,8.016431855862445e-13,"No",4.216261391538721e-14,0.9999999999999717,"Yes",6.327540153737436e-05,0.9999367245984602,"Yes",0.9999999999202487,7.976491945992484e-11,"No",3.417968854412508e-11,0.9999999999658087,"No"
"2016-003653-15","A multi-center double-blind placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular diseaseEstudio de fase IIb multicéntrico con doble enmascaramiento y controlado con placebo para evaluar la eficacia y la seguridad de macitentan en pacientes con insuficiencia cardíaca con fracción de eyección preservada y vasculopatía pulmonar.","GB","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.8540029149580803e-85,4.826658684833138e-22,1.0,"2+",1.0,3.51397632102241e-24,"No",2.857045359816722e-23,1.0,"Yes",1.0,3.677318199095752e-24,"No",1.690382005383963e-24,1.0,"Yes",6.961350386750559e-07,0.9999993038649827,"Yes",1.0,2.1335043650094593e-25,"No",7.873390797052109e-20,1.0,"No"
"2016-003653-15","A multi-center double-blind placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular diseaseEstudio de fase IIb multicéntrico con doble enmascaramiento y controlado con placebo para evaluar la eficacia y la seguridad de macitentan en pacientes con insuficiencia cardíaca con fracción de eyección preservada y vasculopatía pulmonar.","SE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.8540029149580803e-85,4.826658684833138e-22,1.0,"2+",1.0,3.51397632102241e-24,"No",2.857045359816722e-23,1.0,"Yes",1.0,3.677318199095752e-24,"No",1.690382005383963e-24,1.0,"Yes",6.961350386750559e-07,0.9999993038649827,"Yes",1.0,2.1335043650094593e-25,"No",7.873390797052109e-20,1.0,"No"
"2016-003653-15","A multi-center double-blind placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular diseaseEstudio de fase IIb multicéntrico con doble enmascaramiento y controlado con placebo para evaluar la eficacia y la seguridad de macitentan en pacientes con insuficiencia cardíaca con fracción de eyección preservada y vasculopatía pulmonar.","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",4.8540029149580803e-85,4.826658684833138e-22,1.0,"2+",1.0,3.51397632102241e-24,"No",2.857045359816722e-23,1.0,"Yes",1.0,3.677318199095752e-24,"No",1.690382005383963e-24,1.0,"Yes",6.961350386750559e-07,0.9999993038649827,"Yes",1.0,2.1335043650094593e-25,"No",7.873390797052109e-20,1.0,"No"
"2016-004599-23","A Double-Blind Randomized Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphataseEen dubbelblinde gerandomiseerde placebogecontroleerde klinische studie ter beoordeling van de werkzaamheid en veiligheid van oraal GKT137831 bij patiënten met primaire biliaire cholangitis met een aanhoudend verhoogde alkalische fosfatasewaarde die ursodeoxycholzuur krijgen","BE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.355718963678725e-71,1.7321705895452402e-19,1.0,"2+",1.0,1.7233012356368898e-14,"No",3.206404110137383e-13,0.9999999999996589,"Yes",0.9999999999647571,3.5269292392581324e-11,"No",7.088189769334923e-19,1.0,"Yes",0.4825926089546578,0.5174073910453313,"No",0.9999980850511324,1.91494887212123e-06,"No",4.883519932275943e-12,0.9999999999951116,"Yes"
"2016-004599-23","A Double-Blind Randomized Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphataseEine doppelblinde randomisierte placebokontrollierte klinische Prüfung zur Bewertung der Wirksamkeit und Sicherheit von oral verabreichtem GKT137831 bei Patienten mit primärer biliärer Cholangitis die mit Ursodesoxycholsäure behandelt werden und eine anhaltend erhöhte alkalische Phosphatase haben","DE","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1318898768057622e-80,2.4879115895341553e-18,1.0,"2+",1.0,6.743925503004322e-17,"No",1.2114767741390012e-14,1.0,"Yes",0.9999999402453473,5.975466096958552e-08,"No",9.578386946692002e-18,1.0,"Yes",0.8699507439524636,0.13004925604754652,"No",0.9999999998648832,1.3510000239929222e-10,"No",1.0214107523716828e-11,0.9999999999897683,"Yes"
"2016-004599-23","A Double-Blind Randomized Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphataseEen dubbelblinde gerandomiseerde placebogecontroleerde klinische studie ter beoordeling van de werkzaamheid en veiligheid van oraal GKT137831 bij patiënten met primaire biliaire cholangitis met een aanhoudend verhoogde alkalische fosfatasewaarde die ursodeoxycholzuur krijgen","GR","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",8.355718963678725e-71,1.7321705895452402e-19,1.0,"2+",1.0,1.7233012356368898e-14,"No",3.206404110137383e-13,0.9999999999996589,"Yes",0.9999999999647571,3.5269292392581324e-11,"No",7.088189769334923e-19,1.0,"Yes",0.4825926089546578,0.5174073910453313,"No",0.9999980850511324,1.91494887212123e-06,"No",4.883519932275943e-12,0.9999999999951116,"Yes"
"2016-004599-23","A Double-Blind Randomized Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline PhosphataseEine doppelblinde randomisierte placebokontrollierte klinische Prüfung zur Bewertung der Wirksamkeit und Sicherheit von oral verabreichtem GKT137831 bei Patienten mit primärer biliärer Cholangitis die mit Ursodesoxycholsäure behandelt werden und eine anhaltend erhöhte alkalische Phosphatase haben","ES","Yes","No","No","ok","Yes","No","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.1318898768057622e-80,2.4879115895341553e-18,1.0,"2+",1.0,6.743925503004322e-17,"No",1.2114767741390012e-14,1.0,"Yes",0.9999999402453473,5.975466096958552e-08,"No",9.578386946692002e-18,1.0,"Yes",0.8699507439524636,0.13004925604754652,"No",0.9999999998648832,1.3510000239929222e-10,"No",1.0214107523716828e-11,0.9999999999897683,"Yes"
"2017-000372-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis","DE","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.560433163022269e-41,2.390054941742967e-07,0.9999997609945128,"2+",0.9999999349462336,6.505376947088142e-08,"No",2.4926428905809893e-07,0.9999997507357135,"Yes",0.999999995784009,4.2159846056255515e-09,"No",4.416164579827825e-07,0.999999558383548,"Yes",0.023966019458199032,0.9760339805417941,"Yes",0.9999996266503346,3.7334966775275347e-07,"No",3.2452393485927065e-06,0.9999967547606524,"Yes"
"2017-000372-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis","PL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.560433163022269e-41,2.390054941742967e-07,0.9999997609945128,"2+",0.9999999349462336,6.505376947088142e-08,"No",2.4926428905809893e-07,0.9999997507357135,"Yes",0.999999995784009,4.2159846056255515e-09,"No",4.416164579827825e-07,0.999999558383548,"Yes",0.023966019458199032,0.9760339805417941,"Yes",0.9999996266503346,3.7334966775275347e-07,"No",3.2452393485927065e-06,0.9999967547606524,"Yes"
"2017-000372-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis","ES","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.560433163022269e-41,2.390054941742967e-07,0.9999997609945128,"2+",0.9999999349462336,6.505376947088142e-08,"No",2.4926428905809893e-07,0.9999997507357135,"Yes",0.999999995784009,4.2159846056255515e-09,"No",4.416164579827825e-07,0.999999558383548,"Yes",0.023966019458199032,0.9760339805417941,"Yes",0.9999996266503346,3.7334966775275347e-07,"No",3.2452393485927065e-06,0.9999967547606524,"Yes"
"2017-000372-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis","NL","Yes","No","No","ok","Yes","No","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",1.560433163022269e-41,2.390054941742967e-07,0.9999997609945128,"2+",0.9999999349462336,6.505376947088142e-08,"No",2.4926428905809893e-07,0.9999997507357135,"Yes",0.999999995784009,4.2159846056255515e-09,"No",4.416164579827825e-07,0.999999558383548,"Yes",0.023966019458199032,0.9760339805417941,"Yes",0.9999996266503346,3.7334966775275347e-07,"No",3.2452393485927065e-06,0.9999967547606524,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis","NL","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.991285672181313e-38,5.172805437519265e-08,0.9999999482719503,"2+",0.9999999948164772,5.183521807525332e-09,"No",2.694009732153009e-08,0.9999999730599005,"Yes",0.9994835455405475,0.0005164544594537803,"No",1.9146560577519087e-07,0.9999998085343875,"Yes",0.014024747276560012,0.9859752527234348,"Yes",0.47046385477701924,0.5295361452229748,"No",6.640642357661348e-07,0.999999335935762,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisМногоцентрово рандомизирано двойно-сляпо плацебо-контролирано фаза 2 изпитване за оценка на ефикасността и безопасността на Lenabasum  при кистична фиброза","FR","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.719622272086895e-41,5.726168865513268e-08,0.9999999427383147,"2+",0.9999999943952248,5.6047691787451405e-09,"No",2.8865627041219054e-08,0.9999999711343723,"Yes",0.9995581626012626,0.00044183739874121723,"No",2.700287732743839e-07,0.9999997299712301,"Yes",0.012776099289181482,0.9872239007108223,"Yes",0.4798814605095355,0.520118539490466,"No",7.93489948145618e-07,0.9999992065100565,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisEine multizentrische randomisierte doppelblinde Placebo-kontrollierte Phase-2-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenabasum bei cystischer Fibrose","DE","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.29245281364122e-69,5.309396057145126e-11,0.9999999999469082,"2+",0.999999999999801,1.848563607066029e-13,"No",4.527444141761254e-12,0.999999999995481,"Yes",0.9985403408928268,0.0014596591071595747,"No",5.442296584758354e-10,0.9999999994557812,"Yes",0.5694840981942362,0.4305159018057723,"Yes",0.0003382388434142933,0.9996617611565757,"No",1.2426539765784868e-08,0.9999999875734603,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisМногоцентрово рандомизирано двойно-сляпо плацебо-контролирано фаза 2 изпитване за оценка на ефикасността и безопасността на Lenabasum  при кистична фиброза","ES","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.719622272086895e-41,5.726168865513268e-08,0.9999999427383147,"2+",0.9999999943952248,5.6047691787451405e-09,"No",2.8865627041219054e-08,0.9999999711343723,"Yes",0.9995581626012626,0.00044183739874121723,"No",2.700287732743839e-07,0.9999997299712301,"Yes",0.012776099289181482,0.9872239007108223,"Yes",0.4798814605095355,0.520118539490466,"No",7.93489948145618e-07,0.9999992065100565,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisEine multizentrische randomisierte doppelblinde Placebo-kontrollierte Phase-2-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenabasum bei cystischer Fibrose","HU","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.29245281364122e-69,5.309396057145126e-11,0.9999999999469082,"2+",0.999999999999801,1.848563607066029e-13,"No",4.527444141761254e-12,0.999999999995481,"Yes",0.9985403408928268,0.0014596591071595747,"No",5.442296584758354e-10,0.9999999994557812,"Yes",0.5694840981942362,0.4305159018057723,"Yes",0.0003382388434142933,0.9996617611565757,"No",1.2426539765784868e-08,0.9999999875734603,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis","GR","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",5.991285672181313e-38,5.172805437519265e-08,0.9999999482719503,"2+",0.9999999948164772,5.183521807525332e-09,"No",2.694009732153009e-08,0.9999999730599005,"Yes",0.9994835455405475,0.0005164544594537803,"No",1.9146560577519087e-07,0.9999998085343875,"Yes",0.014024747276560012,0.9859752527234348,"Yes",0.47046385477701924,0.5295361452229748,"No",6.640642357661348e-07,0.999999335935762,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisМногоцентрово рандомизирано двойно-сляпо плацебо-контролирано фаза 2 изпитване за оценка на ефикасността и безопасността на Lenabasum  при кистична фиброза","BE","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.719622272086895e-41,5.726168865513268e-08,0.9999999427383147,"2+",0.9999999943952248,5.6047691787451405e-09,"No",2.8865627041219054e-08,0.9999999711343723,"Yes",0.9995581626012626,0.00044183739874121723,"No",2.700287732743839e-07,0.9999997299712301,"Yes",0.012776099289181482,0.9872239007108223,"Yes",0.4798814605095355,0.520118539490466,"No",7.93489948145618e-07,0.9999992065100565,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisМногоцентрово рандомизирано двойно-сляпо плацебо-контролирано фаза 2 изпитване за оценка на ефикасността и безопасността на Lenabasum  при кистична фиброза","CZ","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.719622272086895e-41,5.726168865513268e-08,0.9999999427383147,"2+",0.9999999943952248,5.6047691787451405e-09,"No",2.8865627041219054e-08,0.9999999711343723,"Yes",0.9995581626012626,0.00044183739874121723,"No",2.700287732743839e-07,0.9999997299712301,"Yes",0.012776099289181482,0.9872239007108223,"Yes",0.4798814605095355,0.520118539490466,"No",7.93489948145618e-07,0.9999992065100565,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisEine multizentrische randomisierte doppelblinde Placebo-kontrollierte Phase-2-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenabasum bei cystischer Fibrose","SE","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.29245281364122e-69,5.309396057145126e-11,0.9999999999469082,"2+",0.999999999999801,1.848563607066029e-13,"No",4.527444141761254e-12,0.999999999995481,"Yes",0.9985403408928268,0.0014596591071595747,"No",5.442296584758354e-10,0.9999999994557812,"Yes",0.5694840981942362,0.4305159018057723,"Yes",0.0003382388434142933,0.9996617611565757,"No",1.2426539765784868e-08,0.9999999875734603,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisМногоцентрово рандомизирано двойно-сляпо плацебо-контролирано фаза 2 изпитване за оценка на ефикасността и безопасността на Lenabasum  при кистична фиброза","SK","Yes","No","No","ok","Yes","Yes","Yes","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",3.719622272086895e-41,5.726168865513268e-08,0.9999999427383147,"2+",0.9999999943952248,5.6047691787451405e-09,"No",2.8865627041219054e-08,0.9999999711343723,"Yes",0.9995581626012626,0.00044183739874121723,"No",2.700287732743839e-07,0.9999997299712301,"Yes",0.012776099289181482,0.9872239007108223,"Yes",0.4798814605095355,0.520118539490466,"No",7.93489948145618e-07,0.9999992065100565,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisEine multizentrische randomisierte doppelblinde Placebo-kontrollierte Phase-2-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenabasum bei cystischer Fibrose","AT","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.29245281364122e-69,5.309396057145126e-11,0.9999999999469082,"2+",0.999999999999801,1.848563607066029e-13,"No",4.527444141761254e-12,0.999999999995481,"Yes",0.9985403408928268,0.0014596591071595747,"No",5.442296584758354e-10,0.9999999994557812,"Yes",0.5694840981942362,0.4305159018057723,"Yes",0.0003382388434142933,0.9996617611565757,"No",1.2426539765784868e-08,0.9999999875734603,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisEine multizentrische randomisierte doppelblinde Placebo-kontrollierte Phase-2-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenabasum bei cystischer Fibrose","PT","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.29245281364122e-69,5.309396057145126e-11,0.9999999999469082,"2+",0.999999999999801,1.848563607066029e-13,"No",4.527444141761254e-12,0.999999999995481,"Yes",0.9985403408928268,0.0014596591071595747,"No",5.442296584758354e-10,0.9999999994557812,"Yes",0.5694840981942362,0.4305159018057723,"Yes",0.0003382388434142933,0.9996617611565757,"No",1.2426539765784868e-08,0.9999999875734603,"Yes"
"2017-003723-29","A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisEine multizentrische randomisierte doppelblinde Placebo-kontrollierte Phase-2-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenabasum bei cystischer Fibrose","BG","Yes","No","No","ok","Yes","Yes","No","Yes","2+","No","Yes","No","No","Yes","Yes","No","Yes","2+","Yes",6.29245281364122e-69,5.309396057145126e-11,0.9999999999469082,"2+",0.999999999999801,1.848563607066029e-13,"No",4.527444141761254e-12,0.999999999995481,"Yes",0.9985403408928268,0.0014596591071595747,"No",5.442296584758354e-10,0.9999999994557812,"Yes",0.5694840981942362,0.4305159018057723,"Yes",0.0003382388434142933,0.9996617611565757,"No",1.2426539765784868e-08,0.9999999875734603,"Yes"
